{"d5ad926afb0860117c4bc646191a47a3d6b23dbc": [["IntroductionPhysiologic aging is a complex, albeit normal process of life that affects many components of vertebrate biology including the immune system.", [["immune system", "ANATOMY", 139, 152], ["immune system", "ANATOMICAL_SYSTEM", 139, 152]]], ["Age-related declines in immune function render the aged more susceptible to infectious diseases resulting in increased morbidity and mortality.", [["infectious diseases", "DISEASE", 76, 95], ["infectious diseases", "PROBLEM", 76, 95], ["increased morbidity", "PROBLEM", 109, 128], ["increased", "OBSERVATION_MODIFIER", 109, 118], ["morbidity", "OBSERVATION", 119, 128]]], ["Furthermore, the efficacy of vaccination is greatly reduced in the elderly, thus limiting preventative prophylaxis.", [["vaccination", "TREATMENT", 29, 40], ["preventative prophylaxis", "TREATMENT", 90, 114], ["greatly", "OBSERVATION_MODIFIER", 44, 51], ["reduced", "OBSERVATION_MODIFIER", 52, 59]]], ["For example, in older (e.g. \u226565 years old) individuals, the yearly influenza vaccine is only 40-60% efficacious [1] .", [["influenza", "DISEASE", 67, 76], ["individuals", "PROBLEM", 43, 54], ["the yearly influenza vaccine", "TREATMENT", 56, 84]]], ["Additionally, reduced immune responses have been observed in elderly individuals vaccinated against tetanus, hepatitis and Streptococcus pneumoniae [2] [3] [4] (also see the article by Sztein et al. in this issue).", [["tetanus", "DISEASE", 100, 107], ["hepatitis", "DISEASE", 109, 118], ["Streptococcus pneumoniae", "ORGANISM", 123, 147], ["Streptococcus pneumoniae", "SPECIES", 123, 147], ["Streptococcus pneumoniae", "SPECIES", 123, 147], ["reduced immune responses", "PROBLEM", 14, 38], ["tetanus", "PROBLEM", 100, 107], ["hepatitis", "PROBLEM", 109, 118], ["Streptococcus pneumoniae", "PROBLEM", 123, 147], ["Streptococcus pneumoniae", "OBSERVATION", 123, 147]]], ["With a substantial percentage of the global population approaching an advanced age, coupled with the threat of emerging diseases that can severely impact the aged, such as pandemic influenza (H5N1), West Nile virus (WNV) and severe acute respiratory syndrome (SARS), it is crucial that we devise means to improve the vaccination of the aged and therapies to increase immunity in this susceptible population.", [["influenza", "DISEASE", 181, 190], ["H5N1", "DISEASE", 192, 196], ["West Nile virus (WNV", "DISEASE", 199, 219], ["acute respiratory syndrome", "DISEASE", 232, 258], ["SARS", "DISEASE", 260, 264], ["pandemic influenza (H5N1", "ORGANISM", 172, 196], ["West Nile virus", "ORGANISM", 199, 214], ["pandemic influenza (H5N1", "SPECIES", 172, 196], ["West Nile virus", "SPECIES", 199, 214], ["West Nile virus", "SPECIES", 199, 214], ["WNV", "SPECIES", 216, 219], ["the global population", "PROBLEM", 33, 54], ["emerging diseases", "PROBLEM", 111, 128], ["pandemic influenza (H5N1", "PROBLEM", 172, 196], ["West Nile virus (WNV", "PROBLEM", 199, 219], ["severe acute respiratory syndrome", "PROBLEM", 225, 258], ["SARS", "PROBLEM", 260, 264], ["therapies", "TREATMENT", 345, 354], ["this susceptible population", "PROBLEM", 379, 406], ["substantial", "OBSERVATION_MODIFIER", 7, 18], ["percentage", "OBSERVATION_MODIFIER", 19, 29], ["global", "OBSERVATION_MODIFIER", 37, 43], ["population", "OBSERVATION", 44, 54], ["diseases", "OBSERVATION", 120, 128], ["severe", "OBSERVATION_MODIFIER", 225, 231], ["acute", "OBSERVATION_MODIFIER", 232, 237], ["respiratory syndrome", "OBSERVATION", 238, 258]]], ["However, to achieve this, a thorough understanding of the mechanisms responsible for age-related declines in immune function is needed.IntroductionIn general, immune-mediated protection from infection is attributable to circulating antibodies and antigen-specific CD8 + T cells, which are elicited as a result of prior infection or vaccination.", [["CD8 + T cells", "ANATOMY", 264, 277], ["infection", "DISEASE", 191, 200], ["infection", "DISEASE", 319, 328], ["antigen", "GENE_OR_GENE_PRODUCT", 247, 254], ["CD8", "GENE_OR_GENE_PRODUCT", 264, 267], ["circulating antibodies", "PROTEIN", 220, 242], ["antigen-specific CD8 + T cells", "CELL_TYPE", 247, 277], ["immune-mediated protection", "TREATMENT", 159, 185], ["infection", "PROBLEM", 191, 200], ["circulating antibodies", "TEST", 220, 242], ["antigen", "TEST", 247, 254], ["T cells", "PROBLEM", 270, 277], ["prior infection", "PROBLEM", 313, 328], ["vaccination", "PROBLEM", 332, 343], ["infection", "OBSERVATION", 191, 200], ["infection", "OBSERVATION", 319, 328]]], ["Antibody responses generated early in life, before the onsetof immunosenescence, persist well into later life, as evidenced by the recent isolation of protective antibodies from survivors of the 1918 influenza epidemic [5] .", [["influenza", "DISEASE", 200, 209], ["protective antibodies", "PROTEIN", 151, 172], ["Antibody responses", "TEST", 0, 18], ["protective antibodies", "PROBLEM", 151, 172]]], ["Likewise, T-cell memory generated during youth generally functions well into old age, whereas immune memory generated later in life (i.e. elderly) functions poorly [6] .", [["T-cell", "ANATOMY", 10, 16], ["T-cell", "CELL", 10, 16]]], ["T-cell functions in the elderly decrease because of the accumulation of age-related defects, thereby limiting effective immune responses [6, 7] .", [["T-cell", "ANATOMY", 0, 6], ["T-cell", "CELL", 0, 6], ["age-related defects", "PROBLEM", 72, 91], ["cell functions", "OBSERVATION", 2, 16], ["defects", "OBSERVATION", 84, 91]]], ["Therefore, it is the generation of 'new' immune responses against annual or novel vaccines in the aged that is of crucial importance.", [["novel vaccines", "TREATMENT", 76, 90]]], ["In this review, we focus on key findings in experimental mouse models of T-cell immunosenescence, discuss age-related factors affecting primary CD4 + and CD8 + T-cell responses and T-cell memory and the impact that these deficiencies in T-cell function have on vaccine efficacy and immunity.Age-related declines in CD4 + T-cell functionIntrinsic defects of immunosenescent CD4 + T cells A hallmark of age-related declines in immunity is reduced humoral responses.", [["T-cell", "ANATOMY", 73, 79], ["primary CD4 + and CD8 + T-cell", "ANATOMY", 136, 166], ["T-cell", "ANATOMY", 181, 187], ["T-cell", "ANATOMY", 237, 243], ["CD4 + T-cell", "ANATOMY", 315, 327], ["immunosenescent CD4 + T cells", "ANATOMY", 357, 386], ["mouse", "ORGANISM", 57, 62], ["T-cell", "CELL", 73, 79], ["CD4", "GENE_OR_GENE_PRODUCT", 144, 147], ["CD8", "GENE_OR_GENE_PRODUCT", 154, 157], ["T-cell", "CELL", 181, 187], ["T-cell", "CELL", 237, 243], ["CD4", "GENE_OR_GENE_PRODUCT", 315, 318], ["CD4", "GENE_OR_GENE_PRODUCT", 373, 376], ["CD4", "PROTEIN", 144, 147], ["CD8", "PROTEIN", 154, 157], ["CD4", "PROTEIN", 315, 318], ["immunosenescent CD4 + T cells", "CELL_TYPE", 357, 386], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 57, 62], ["primary CD4", "TEST", 136, 147], ["CD8", "TEST", 154, 157], ["these deficiencies", "PROBLEM", 215, 233], ["vaccine efficacy", "TREATMENT", 261, 277], ["related declines", "PROBLEM", 295, 311], ["CD4", "TEST", 315, 318], ["Intrinsic defects", "PROBLEM", 336, 353], ["immunosenescent CD4", "PROBLEM", 357, 376], ["T cells", "PROBLEM", 379, 386], ["reduced humoral responses", "PROBLEM", 437, 462], ["declines", "OBSERVATION_MODIFIER", 303, 311]]], ["This has an especially negative impact because the generation of protective antibodies is the goal of many current vaccines.", [["protective antibodies", "PROTEIN", 65, 86], ["protective antibodies", "TREATMENT", 65, 86], ["many current vaccines", "TREATMENT", 102, 123]]], ["Central to the generation of productive B-cell responses is cognate help provided by CD4 + T cells.", [["B-cell", "ANATOMY", 40, 46], ["CD4 + T cells", "ANATOMY", 85, 98], ["B-cell", "CELL", 40, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 85, 88], ["CD4", "PROTEIN", 85, 88], ["T cells", "CELL_TYPE", 91, 98], ["productive", "OBSERVATION_MODIFIER", 29, 39]]], ["It is well established that na\u00efve CD4 + T cells accumulate various intrinsic defects in immune function over time (Table 1 ) (also see the article by Weng et al. in this issue) [6] [7] [8] .", [["CD4 + T cells", "ANATOMY", 34, 47], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 177, 188], ["na\u00efve CD4 + T cells", "CELL_TYPE", 28, 47], ["T cells", "PROBLEM", 40, 47], ["intrinsic defects", "PROBLEM", 67, 84], ["various", "OBSERVATION_MODIFIER", 59, 66], ["intrinsic defects", "OBSERVATION", 67, 84], ["immune function", "OBSERVATION", 88, 103]]], ["The use of T-cell receptor transgenic (TCR Tg) mouse models to study these intrinsic defects has enabled the field to move forward rapidly, because this model eliminates other age-related changes in the T-cell compartment, such as changes in TCR repertoire and increased regulatory functions, which could otherwise complicate the interpretation of results.", [["T-cell", "ANATOMY", 11, 17], ["T-cell compartment", "ANATOMY", 203, 221], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 11, 26], ["mouse", "ORGANISM", 47, 52], ["T-cell", "CELL", 203, 209], ["TCR", "GENE_OR_GENE_PRODUCT", 242, 245], ["TCR repertoire", "PROTEIN", 242, 256], ["mouse", "SPECIES", 47, 52], ["mouse", "SPECIES", 47, 52], ["T-cell receptor transgenic (TCR Tg)", "TREATMENT", 11, 46], ["these intrinsic defects", "PROBLEM", 69, 92], ["changes in TCR repertoire", "PROBLEM", 231, 256], ["increased regulatory functions", "PROBLEM", 261, 291], ["defects", "OBSERVATION", 85, 92], ["cell compartment", "OBSERVATION", 205, 221], ["increased", "OBSERVATION_MODIFIER", 261, 270], ["regulatory functions", "OBSERVATION", 271, 291]]], ["Another benefit is that the identification of na\u00efve cells in the TCR Tg models is more straightforward, because they can be specifically identified by TCR expression.", [["cells", "ANATOMY", 52, 57], ["TCR", "CHEMICAL", 65, 68], ["na\u00efve cells", "CELL", 46, 57], ["TCR", "GENE_OR_GENE_PRODUCT", 151, 154], ["na\u00efve cells", "CELL_TYPE", 46, 57], ["TCR", "PROTEIN", 65, 68], ["TCR", "PROTEIN", 151, 154], ["na\u00efve cells", "PROBLEM", 46, 57]]], ["Therefore, starting populations are unambiguously na\u00efve cells, which is usually not the case in studies with aged wild-type mice.", [["cells", "ANATOMY", 56, 61], ["na\u00efve cells", "CELL", 50, 61], ["mice", "ORGANISM", 124, 128], ["na\u00efve cells", "CELL_TYPE", 50, 61], ["mice", "SPECIES", 124, 128], ["mice", "SPECIES", 124, 128], ["unambiguously na\u00efve cells", "PROBLEM", 36, 61], ["na\u00efve cells", "OBSERVATION", 50, 61]]], ["Activation of na\u00efve T cells requires their recognition of cognate antigen presented by professional antigenpresenting cells (APCs) in the context of an immunologic synapse.", [["na\u00efve T cells", "ANATOMY", 14, 27], ["antigenpresenting cells", "ANATOMY", 100, 123], ["APCs", "ANATOMY", 125, 129], ["na\u00efve T cells", "CELL", 14, 27], ["professional antigenpresenting cells", "CELL", 87, 123], ["APCs", "CELL", 125, 129], ["na\u00efve T cells", "CELL_TYPE", 14, 27], ["cognate antigen", "PROTEIN", 58, 73], ["professional antigenpresenting cells", "CELL_TYPE", 87, 123], ["APCs", "CELL_TYPE", 125, 129], ["Activation of na\u00efve T cells", "TREATMENT", 0, 27], ["an immunologic synapse", "PROBLEM", 149, 171], ["immunologic synapse", "OBSERVATION", 152, 171]]], ["It has been demonstrated that na\u00efve CD4 + T cells from aged TCR Tg mice do not form immunologic synapses as efficiently as do cells from young mice in vitro [9, 10] .", [["CD4 + T cells", "ANATOMY", 36, 49], ["cells", "ANATOMY", 126, 131], ["CD4", "GENE_OR_GENE_PRODUCT", 36, 39], ["TCR Tg mice", "ORGANISM", 60, 71], ["cells", "CELL", 126, 131], ["mice", "ORGANISM", 143, 147], ["na\u00efve CD4 + T cells", "CELL_TYPE", 30, 49], ["TCR", "PROTEIN", 60, 63], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 67, 71], ["mice", "SPECIES", 143, 147], ["T cells", "PROBLEM", 42, 49], ["immunologic synapses", "PROBLEM", 84, 104]]], ["In addition, there was a reduction of 50% in recruitment of signaling molecules (e.g. Lck, ZAP-70, Fyn, LAT, Grb2 and Vav) to these synapses in aged CD4 + T cells compared with young cells [10] .", [["synapses", "ANATOMY", 132, 140], ["CD4 + T cells", "ANATOMY", 149, 162], ["cells", "ANATOMY", 183, 188], ["Lck", "GENE_OR_GENE_PRODUCT", 86, 89], ["ZAP-70", "GENE_OR_GENE_PRODUCT", 91, 97], ["Fyn", "GENE_OR_GENE_PRODUCT", 99, 102], ["LAT", "GENE_OR_GENE_PRODUCT", 104, 107], ["Grb2", "GENE_OR_GENE_PRODUCT", 109, 113], ["Vav", "GENE_OR_GENE_PRODUCT", 118, 121], ["CD4", "GENE_OR_GENE_PRODUCT", 149, 152], ["cells", "CELL", 183, 188], ["signaling molecules", "PROTEIN", 60, 79], ["Lck", "PROTEIN", 86, 89], ["ZAP", "PROTEIN", 91, 94], ["Fyn", "PROTEIN", 99, 102], ["LAT", "PROTEIN", 104, 107], ["Grb2", "PROTEIN", 109, 113], ["Vav", "PROTEIN", 118, 121], ["aged CD4 + T cells", "CELL_TYPE", 144, 162], ["young cells", "CELL_TYPE", 177, 188], ["a reduction", "TEST", 23, 34], ["signaling molecules", "PROBLEM", 60, 79], ["Lck", "TEST", 86, 89], ["ZAP", "TEST", 91, 94], ["Fyn", "TEST", 99, 102], ["LAT", "TEST", 104, 107], ["Grb2", "TEST", 109, 113], ["these synapses", "TEST", 126, 140], ["reduction", "OBSERVATION_MODIFIER", 25, 34], ["Vav", "ANATOMY", 118, 121]]], ["Significant alterations in cytoskeletal rearrangement [11] , cell surface glycosylation [12] and phosphorylation of key signaling molecules [13] [14] [15] contributing to reduced function were also noted in na\u00efve CD4 + T cells from aged mice.", [["cytoskeletal", "ANATOMY", 27, 39], ["cell surface", "ANATOMY", 61, 73], ["CD4 + T cells", "ANATOMY", 213, 226], ["cytoskeletal", "CELLULAR_COMPONENT", 27, 39], ["cell surface", "CELLULAR_COMPONENT", 61, 73], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 140, 154], ["CD4", "GENE_OR_GENE_PRODUCT", 213, 216], ["mice", "ORGANISM", 237, 241], ["na\u00efve CD4 + T cells", "CELL_TYPE", 207, 226], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 237, 241], ["Significant alterations in cytoskeletal rearrangement", "PROBLEM", 0, 53], ["cell surface glycosylation", "TREATMENT", 61, 87], ["phosphorylation of key signaling molecules", "TREATMENT", 97, 139], ["reduced function", "PROBLEM", 171, 187], ["cytoskeletal rearrangement", "OBSERVATION", 27, 53]]], ["Taken together, these changes negatively influence the intensity of TCR signaling in na\u00efve CD4 + T cells taken from aged mice, contributing to other observed defects downstream of the initial priming event.Age-related declines in CD4 + T-cell functionBecause of defects in TCR signaling and activation, effector CD4 + T cells generated from aged na\u00efve cells function poorly compared with effectors derived from young cells both in vitro and in vivo [6] .", [["CD4 + T cells", "ANATOMY", 91, 104], ["CD4 + T-cell", "ANATOMY", 230, 242], ["CD4 + T cells", "ANATOMY", 312, 325], ["cells", "ANATOMY", 352, 357], ["cells", "ANATOMY", 417, 422], ["TCR", "CHEMICAL", 68, 71], ["TCR", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD4", "GENE_OR_GENE_PRODUCT", 91, 94], ["mice", "ORGANISM", 121, 125], ["CD4", "GENE_OR_GENE_PRODUCT", 230, 233], ["TCR", "GENE_OR_GENE_PRODUCT", 273, 276], ["CD4", "GENE_OR_GENE_PRODUCT", 312, 315], ["cells", "CELL", 352, 357], ["cells", "CELL", 417, 422], ["TCR", "PROTEIN", 68, 71], ["na\u00efve CD4 + T cells", "CELL_TYPE", 85, 104], ["CD4", "PROTEIN", 230, 233], ["TCR", "PROTEIN", 273, 276], ["effector CD4 + T cells", "CELL_TYPE", 303, 325], ["aged na\u00efve cells", "CELL_TYPE", 341, 357], ["young cells", "CELL_TYPE", 411, 422], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 121, 125], ["TCR signaling", "PROBLEM", 68, 81], ["T cells", "PROBLEM", 97, 104], ["other observed defects downstream", "PROBLEM", 143, 176], ["related declines", "PROBLEM", 210, 226], ["CD4", "TEST", 230, 233], ["defects in TCR signaling", "PROBLEM", 262, 286], ["activation", "PROBLEM", 291, 301], ["effector CD4", "TEST", 303, 315], ["T cells", "PROBLEM", 318, 325], ["defects", "OBSERVATION", 158, 165], ["defects", "OBSERVATION", 262, 269], ["TCR signaling", "OBSERVATION", 273, 286]]], ["Results from in vitro studies demonstrate that na\u00efve TCR Tg CD4 + T cells from aged mice exhibit reduced expansion over a 4-d culture period [16] .", [["TCR Tg CD4 + T cells", "ANATOMY", 53, 73], ["TCR", "CHEMICAL", 53, 56], ["TCR", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["mice", "ORGANISM", 84, 88], ["na\u00efve TCR Tg CD4 + T cells", "CELL_TYPE", 47, 73], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["vitro studies", "TEST", 16, 29], ["na\u00efve", "TEST", 47, 52], ["TCR", "TEST", 53, 56], ["CD4", "TEST", 60, 63], ["reduced expansion", "PROBLEM", 97, 114], ["reduced", "OBSERVATION_MODIFIER", 97, 104], ["expansion", "OBSERVATION_MODIFIER", 105, 114]]], ["Na\u00efve CD4 + T cells from young mice expanded 12-fold, whereas those from aged mice only expanded 5fold [17] .", [["CD4 + T cells", "ANATOMY", 6, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 6, 9], ["mice", "ORGANISM", 31, 35], ["mice", "ORGANISM", 78, 82], ["Na\u00efve CD4 + T cells", "CELL_TYPE", 0, 19], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 78, 82], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 78, 82], ["Na\u00efve", "TEST", 0, 5]]], ["In addition, the aged cells had fewer cell divisions compared with CD4 + T cells from young mice.", [["cells", "ANATOMY", 22, 27], ["cell", "ANATOMY", 38, 42], ["CD4 + T cells", "ANATOMY", 67, 80], ["cells", "CELL", 22, 27], ["cell", "CELL", 38, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 67, 70], ["mice", "ORGANISM", 92, 96], ["aged cells", "CELL_TYPE", 17, 27], ["CD4", "PROTEIN", 67, 70], ["T cells", "CELL_TYPE", 73, 80], ["mice", "SPECIES", 92, 96], ["mice", "SPECIES", 92, 96], ["fewer cell divisions", "PROBLEM", 32, 52], ["fewer cell divisions", "OBSERVATION", 32, 52]]], ["Aged CD4 + effector cells did not down-regulate expression of CD62L (Lselectin) or increase surface CD25 expression.", [["CD4 + effector cells", "ANATOMY", 5, 25], ["surface", "ANATOMY", 92, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 5, 8], ["CD62L", "GENE_OR_GENE_PRODUCT", 62, 67], ["Lselectin", "GENE_OR_GENE_PRODUCT", 69, 78], ["CD25", "GENE_OR_GENE_PRODUCT", 100, 104], ["Aged CD4 + effector cells", "CELL_TYPE", 0, 25], ["CD62L", "PROTEIN", 62, 67], ["Lselectin", "PROTEIN", 69, 78], ["CD25", "PROTEIN", 100, 104], ["effector cells", "PROBLEM", 11, 25], ["effector cells", "OBSERVATION", 11, 25]]], ["Furthermore, aged effector cells cultured under Th1 or Th2 polarizing conditions did not polarize as readily without the addition of interleukin-2 (IL-2) compared with young cells [17] .", [["effector cells", "ANATOMY", 18, 32], ["cells", "ANATOMY", 174, 179], ["effector cells", "CELL", 18, 32], ["Th1", "CELL", 48, 51], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 133, 146], ["IL-2", "GENE_OR_GENE_PRODUCT", 148, 152], ["cells", "CELL", 174, 179], ["aged effector cells", "CELL_TYPE", 13, 32], ["interleukin-2 (IL-2", "PROTEIN", 133, 152], ["aged effector cells", "PROBLEM", 13, 32], ["interleukin", "TEST", 133, 144]]], ["The aged CD4 + effectors also have defects in cytokine production after restimulation, with a significantly reduced production of IL-2 compared with young cells [17] .", [["cells", "ANATOMY", 155, 160], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["IL-2", "GENE_OR_GENE_PRODUCT", 130, 134], ["cells", "CELL", 155, 160], ["CD4", "PROTEIN", 9, 12], ["cytokine", "PROTEIN", 46, 54], ["IL", "PROTEIN", 130, 132], ["defects in cytokine production", "PROBLEM", 35, 65], ["a significantly reduced production of IL", "PROBLEM", 92, 132], ["cytokine production", "OBSERVATION", 46, 65]]], ["The defective expansion and differentiation of aged na\u00efve cells during effector generation could be reversed by the addition of exogenous IL-2, indicating they are defective in IL-2 production but not responsiveness to IL-2.", [["cells", "ANATOMY", 58, 63], ["na\u00efve cells", "CELL", 52, 63], ["IL-2", "GENE_OR_GENE_PRODUCT", 138, 142], ["IL-2", "GENE_OR_GENE_PRODUCT", 177, 181], ["IL-2", "GENE_OR_GENE_PRODUCT", 219, 223], ["aged na\u00efve cells", "CELL_LINE", 47, 63], ["IL", "PROTEIN", 138, 140], ["IL", "PROTEIN", 219, 221], ["The defective expansion", "PROBLEM", 0, 23], ["aged na\u00efve cells", "TREATMENT", 47, 63], ["exogenous IL", "TREATMENT", 128, 140], ["defective in IL", "PROBLEM", 164, 179], ["defective", "OBSERVATION_MODIFIER", 4, 13], ["expansion", "OBSERVATION_MODIFIER", 14, 23], ["differentiation", "OBSERVATION_MODIFIER", 28, 43], ["na\u00efve cells", "OBSERVATION", 52, 63], ["defective", "OBSERVATION", 164, 173]]], ["Similarly, when equal numbers of na\u00efve aged or young TCR Tg CD4 + cells were transferred into young hosts and immunized with antigen, donor cells from aged mice did not expand as well as their young counterparts [18] .", [["CD4 + cells", "ANATOMY", 60, 71], ["donor cells", "ANATOMY", 134, 145], ["TCR", "CHEMICAL", 53, 56], ["TCR", "GENE_OR_GENE_PRODUCT", 53, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 60, 63], ["donor cells", "CELL", 134, 145], ["mice", "ORGANISM", 156, 160], ["TCR Tg CD4 + cells", "CELL_TYPE", 53, 71], ["donor cells", "CELL_TYPE", 134, 145], ["mice", "SPECIES", 156, 160], ["mice", "SPECIES", 156, 160]]], ["Additionally, when these cells were stimulated ex vivo, intracellular cytokine staining revealed that aged CD4 + cells produced significantly less IL-2 than young CD4 + T cells.", [["cells", "ANATOMY", 25, 30], ["intracellular", "ANATOMY", 56, 69], ["CD4 + cells", "ANATOMY", 107, 118], ["CD4 + T cells", "ANATOMY", 163, 176], ["cells", "CELL", 25, 30], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 69], ["CD4", "GENE_OR_GENE_PRODUCT", 107, 110], ["IL-2", "GENE_OR_GENE_PRODUCT", 147, 151], ["CD4", "GENE_OR_GENE_PRODUCT", 163, 166], ["cytokine", "PROTEIN", 70, 78], ["aged CD4 + cells", "CELL_TYPE", 102, 118], ["IL", "PROTEIN", 147, 149], ["CD4 + T cells", "CELL_TYPE", 163, 176], ["these cells", "PROBLEM", 19, 30], ["intracellular cytokine staining", "TEST", 56, 87], ["CD4 + cells", "PROBLEM", 107, 118], ["IL", "TEST", 147, 149], ["T cells", "OBSERVATION", 169, 176]]], ["Collectively, these results indicate that there are intrinsic defects in the na\u00efve CD4 T cells from aged mice, although these data do not completely rule out the influence of an aged 'environment'.Age-related declines in CD4 + T-cell functionThe reduced capacity of na\u00efve aged CD4 + T cells to become activated, expand and differentiate extends to having a negative impact on the ability of these cells to provide cognate help to B cells.", [["CD4 T cells", "ANATOMY", 83, 94], ["CD4 + T-cell", "ANATOMY", 221, 233], ["CD4 + T cells", "ANATOMY", 277, 290], ["cells", "ANATOMY", 397, 402], ["B cells", "ANATOMY", 430, 437], ["CD4 T cells", "CELL", 83, 94], ["mice", "ORGANISM", 105, 109], ["CD4", "GENE_OR_GENE_PRODUCT", 221, 224], ["CD4", "GENE_OR_GENE_PRODUCT", 277, 280], ["cells", "CELL", 397, 402], ["B cells", "CELL", 430, 437], ["na\u00efve CD4 T cells", "CELL_TYPE", 77, 94], ["CD4", "PROTEIN", 221, 224], ["na\u00efve aged CD4 + T cells", "CELL_TYPE", 266, 290], ["B cells", "CELL_TYPE", 430, 437], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["intrinsic defects", "PROBLEM", 52, 69], ["these data", "TEST", 120, 130], ["related declines", "PROBLEM", 201, 217], ["CD4", "TEST", 221, 224], ["The reduced capacity", "PROBLEM", 242, 262], ["T cells", "PROBLEM", 283, 290], ["these cells", "TREATMENT", 391, 402], ["intrinsic", "OBSERVATION_MODIFIER", 52, 61], ["defects", "OBSERVATION", 62, 69], ["reduced", "OBSERVATION_MODIFIER", 246, 253], ["capacity", "OBSERVATION_MODIFIER", 254, 262]]], ["After transfer of equal numbers of either young or aged na\u00efve TCR Tg CD4 + cells into young hosts, there were significant reductions in antigen-specific B-cell expansion, antibody production and progression toward a germinal center (GC) phenotype after immunization in mice receiving aged cells [18] .", [["CD4 + cells", "ANATOMY", 69, 80], ["B-cell", "ANATOMY", 153, 159], ["germinal center", "ANATOMY", 216, 231], ["GC", "ANATOMY", 233, 235], ["cells", "ANATOMY", 289, 294], ["TCR", "CHEMICAL", 62, 65], ["TCR", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 69, 72], ["antigen", "GENE_OR_GENE_PRODUCT", 136, 143], ["B-cell", "CELL", 153, 159], ["germinal center", "CELL", 216, 231], ["GC", "CELL", 233, 235], ["mice", "ORGANISM", 269, 273], ["cells", "CELL", 289, 294], ["na\u00efve TCR Tg CD4 + cells", "CELL_TYPE", 56, 80], ["mice", "SPECIES", 269, 273], ["mice", "SPECIES", 269, 273], ["significant reductions in antigen", "PROBLEM", 110, 143], ["cell expansion", "PROBLEM", 155, 169], ["antibody production", "PROBLEM", 171, 190], ["immunization", "TREATMENT", 253, 265], ["significant", "OBSERVATION_MODIFIER", 110, 121], ["reductions", "OBSERVATION_MODIFIER", 122, 132], ["cell expansion", "OBSERVATION", 155, 169]]], ["Although there was no defect in the ability of aged CD4 + T cells to migrate into the GC, their ability to provide cognate help once they arrived was dramatically impaired.", [["CD4 + T cells", "ANATOMY", 52, 65], ["GC", "ANATOMY", 86, 88], ["CD4", "GENE_OR_GENE_PRODUCT", 52, 55], ["aged CD4 + T cells", "CELL_TYPE", 47, 65], ["defect", "PROBLEM", 22, 28], ["T cells", "PROBLEM", 58, 65], ["dramatically impaired", "PROBLEM", 150, 171], ["no", "UNCERTAINTY", 19, 21], ["defect", "OBSERVATION", 22, 28]]], ["Interestingly, although there were significantly more young TCR Tg CD4 + cells in mice receiving young cells at day 7 after immunization, by day 14, the numbers of young and aged donor cells were equivalent; thus, differences in the numbers of helper T cells at this time point could not account for these results, suggesting differences in the ability to provide cognate help to B cells between young and aged CD4 + cells.Ontogeny of age-related declines in CD4 + T-cell functionMany age-related defects in T-cell function have been described, but what is the underlying cause of these defects?", [["TCR Tg CD4 + cells", "ANATOMY", 60, 78], ["cells", "ANATOMY", 103, 108], ["cells", "ANATOMY", 185, 190], ["helper T cells", "ANATOMY", 244, 258], ["B cells", "ANATOMY", 380, 387], ["CD4 + cells", "ANATOMY", 411, 422], ["CD4 + T-cell", "ANATOMY", 459, 471], ["T-cell", "ANATOMY", 508, 514], ["TCR", "GENE_OR_GENE_PRODUCT", 60, 63], ["CD4", "GENE_OR_GENE_PRODUCT", 67, 70], ["mice", "ORGANISM", 82, 86], ["cells", "CELL", 103, 108], ["cells", "CELL", 185, 190], ["helper T cells", "CELL", 244, 258], ["B cells", "CELL", 380, 387], ["CD4 + cells", "CELL", 411, 422], ["CD4", "GENE_OR_GENE_PRODUCT", 459, 462], ["T-cell", "CELL", 508, 514], ["TCR Tg CD4 + cells", "CELL_TYPE", 60, 78], ["young cells", "CELL_TYPE", 97, 108], ["helper T cells", "CELL_TYPE", 244, 258], ["B cells", "CELL_TYPE", 380, 387], ["young and aged CD4 + cells", "CELL_TYPE", 396, 422], ["CD4", "PROTEIN", 459, 462], ["mice", "SPECIES", 82, 86], ["mice", "SPECIES", 82, 86], ["immunization", "TREATMENT", 124, 136], ["related declines", "PROBLEM", 439, 455], ["CD4", "TEST", 459, 462], ["related defects in T-cell function", "PROBLEM", 489, 523], ["these defects", "PROBLEM", 581, 594], ["defects", "OBSERVATION", 497, 504], ["T-cell", "OBSERVATION_MODIFIER", 508, 514], ["defects", "OBSERVATION", 587, 594]]], ["Arguably the most important factor contributing to the onset of immunosenescence is thymic involution that in mammals seems to progress gradually not long after birth (see article by Lynch et al. also in this issue).", [["thymic", "ANATOMY", 84, 90], ["immunosenescence", "DISEASE", 64, 80], ["thymic", "ORGAN", 84, 90], ["thymic involution", "PROBLEM", 84, 101], ["thymic involution", "OBSERVATION", 84, 101]]], ["After involution, the thymus exhibits a greatly reduced output of na\u00efve T cells.", [["thymus", "ANATOMY", 22, 28], ["na\u00efve T cells", "ANATOMY", 66, 79], ["thymus", "ORGAN", 22, 28], ["na\u00efve T cells", "CELL", 66, 79], ["na\u00efve T cells", "CELL_TYPE", 66, 79], ["involution", "PROBLEM", 6, 16], ["a greatly reduced output of na\u00efve T cells", "PROBLEM", 38, 79], ["involution", "OBSERVATION", 6, 16], ["thymus", "ANATOMY", 22, 28], ["greatly", "OBSERVATION_MODIFIER", 40, 47], ["reduced", "OBSERVATION_MODIFIER", 48, 55], ["output", "OBSERVATION_MODIFIER", 56, 62], ["na\u00efve T cells", "OBSERVATION", 66, 79]]], ["An elegant study by Hale et al. [19] demonstrated in the mouse that the number of recent thymic emigrants (RTEs) in the periphery peaks at 6 weeks of age and declines thereafter.", [["thymic emigrants", "ANATOMY", 89, 105], ["mouse", "ORGANISM", 57, 62], ["thymic emigrants", "MULTI-TISSUE_STRUCTURE", 89, 105], ["thymic emigrants", "CELL_TYPE", 89, 105], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 57, 62], ["An elegant study", "TEST", 0, 16], ["thymic emigrants", "OBSERVATION", 89, 105], ["periphery", "ANATOMY_MODIFIER", 120, 129]]], ["Without a continuous stream of new T cells to replenish the peripheral T-cell compartment, it is probable that the resident cells have increased longevity to compensate for reduced output (see article by Dowling and Hodgkin also in this issue).", [["T cells", "ANATOMY", 35, 42], ["peripheral T-cell compartment", "ANATOMY", 60, 89], ["cells", "ANATOMY", 124, 129], ["T cells", "CELL", 35, 42], ["peripheral T-cell", "CELL", 60, 77], ["cells", "CELL", 124, 129], ["T cells", "CELL_TYPE", 35, 42], ["peripheral T-cell compartment", "CELL_TYPE", 60, 89], ["resident cells", "CELL_TYPE", 115, 129], ["new T cells", "PROBLEM", 31, 42], ["reduced output", "PROBLEM", 173, 187], ["peripheral", "ANATOMY_MODIFIER", 60, 70], ["cell compartment", "OBSERVATION", 73, 89], ["is probable", "UNCERTAINTY", 94, 105]]], ["Several studies support the hypothesis that increased postthymic longevity of CD4 + T cells is sufficient for the accumulation of age-related defects in CD4 T-cell function.", [["postthymic", "ANATOMY", 54, 64], ["CD4 + T cells", "ANATOMY", 78, 91], ["CD4 T-cell", "ANATOMY", 153, 163], ["CD4", "GENE_OR_GENE_PRODUCT", 78, 81], ["CD4", "GENE_OR_GENE_PRODUCT", 153, 156], ["CD4", "PROTEIN", 78, 81], ["T cells", "CELL_TYPE", 84, 91], ["CD4", "PROTEIN", 153, 156], ["Several studies", "TEST", 0, 15], ["the hypothesis", "PROBLEM", 24, 38], ["CD4 + T cells", "PROBLEM", 78, 91], ["related defects", "PROBLEM", 134, 149], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["defects", "OBSERVATION", 142, 149]]], ["A recent study using OT-II (V\u03b12 V\u03b25) TCR Tg mice found that aged CD4 + TCR Tg-expressing cells were subject to superantigen-mediated deletion in the periphery.", [["CD4 + TCR Tg-expressing cells", "ANATOMY", 65, 94], ["periphery", "ANATOMY", 149, 158], ["OT-II", "GENE_OR_GENE_PRODUCT", 21, 26], ["V\u03b12 V\u03b25", "GENE_OR_GENE_PRODUCT", 28, 35], ["TCR", "GENE_OR_GENE_PRODUCT", 37, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["TCR", "GENE_OR_GENE_PRODUCT", 71, 74], ["superantigen", "GENE_OR_GENE_PRODUCT", 111, 123], ["OT-II (V\u03b12 V\u03b25", "CELL_LINE", 21, 35], ["TCR", "PROTEIN", 37, 40], ["CD4", "PROTEIN", 65, 68], ["TCR Tg-expressing cells", "CELL_TYPE", 71, 94], ["superantigen", "PROTEIN", 111, 123], ["mice", "SPECIES", 44, 48], ["A recent study", "TEST", 0, 14], ["OT", "TEST", 21, 23], ["TCR Tg mice", "TEST", 37, 48], ["CD4", "TEST", 65, 68], ["TCR Tg", "TEST", 71, 77], ["expressing cells", "PROBLEM", 78, 94], ["superantigen-mediated deletion in the periphery", "PROBLEM", 111, 158], ["deletion", "OBSERVATION", 133, 141], ["periphery", "ANATOMY_MODIFIER", 149, 158]]], ["Previously, it was demonstrated that, in C57BL/6 mice, CD4 + T cells bearing V\u03b25 TCRs are chronically deleted by an endogenous super-antigen encoded by mouse mammary tumor viruses-8 and -9 [20] .", [["CD4 + T cells", "ANATOMY", 55, 68], ["mammary tumor", "ANATOMY", 158, 171], ["mammary tumor", "DISEASE", 158, 171], ["C57BL/6 mice", "ORGANISM", 41, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 55, 58], ["V\u03b25 TCRs", "GENE_OR_GENE_PRODUCT", 77, 85], ["super-antigen", "GENE_OR_GENE_PRODUCT", 127, 140], ["mouse", "ORGANISM", 152, 157], ["mammary tumor", "CANCER", 158, 171], ["viruses-8", "ORGANISM", 172, 181], ["CD4", "PROTEIN", 55, 58], ["T cells", "CELL_TYPE", 61, 68], ["V\u03b25 TCRs", "PROTEIN", 77, 85], ["endogenous super-antigen", "PROTEIN", 116, 140], ["mice", "SPECIES", 49, 53], ["mouse", "SPECIES", 152, 157], ["mice", "SPECIES", 49, 53], ["mouse", "SPECIES", 152, 157], ["CD4", "TEST", 55, 58], ["mouse mammary tumor viruses", "PROBLEM", 152, 179], ["mammary", "ANATOMY", 158, 165], ["tumor", "OBSERVATION", 166, 171]]], ["Thus, the OT-II TCR Tg + cells found in these aged animals were actually of a younger post-thymic age (i.e. more recent thymic emigrants) compared with other non-V\u03b25 TCR Tg models [21] .", [["OT-II TCR Tg + cells", "ANATOMY", 10, 30], ["thymic", "ANATOMY", 91, 97], ["thymic emigrants", "ANATOMY", 120, 136], ["TCR", "CHEMICAL", 16, 19], ["OT-II TCR", "GENE_OR_GENE_PRODUCT", 10, 19], ["animals", "ORGANISM", 51, 58], ["thymic", "ORGAN", 91, 97], ["OT-II TCR Tg + cells", "CELL_LINE", 10, 30], ["TCR", "PROTEIN", 166, 169], ["the OT-II TCR Tg", "TEST", 6, 22], ["thymic", "ANATOMY", 91, 97], ["thymic emigrants", "OBSERVATION", 120, 136]]], ["Importantly, when compared against age-matched na\u00efve TCR Tg cells not subject to deletion, na\u00efve aged OT-II (V\u03b12 V\u03b25) TCR Tg CD4 + T cells in this model produced more IL-2 and exhibited greater expansion after stimulation.", [["cells", "ANATOMY", 60, 65], ["CD4 + T cells", "ANATOMY", 125, 138], ["TCR Tg cells", "CELL", 53, 65], ["OT-II", "GENE_OR_GENE_PRODUCT", 102, 107], ["TCR", "GENE_OR_GENE_PRODUCT", 118, 121], ["IL-2", "GENE_OR_GENE_PRODUCT", 167, 171], ["na\u00efve TCR Tg cells", "CELL_LINE", 47, 65], ["OT-II (V\u03b12 V\u03b25", "CELL_LINE", 102, 116], ["TCR Tg CD4 + T cells", "CELL_LINE", 118, 138], ["IL", "PROTEIN", 167, 169], ["deletion", "TEST", 81, 89], ["na\u00efve", "TEST", 91, 96], ["OT", "TEST", 102, 104], ["V", "TEST", 109, 110], ["\u03b2", "TEST", 114, 115], ["TCR Tg CD4", "TEST", 118, 128], ["this model", "TEST", 142, 152], ["greater", "OBSERVATION_MODIFIER", 186, 193], ["expansion", "OBSERVATION", 194, 203]]], ["Further support for the role of thymic involution in the acquisition of agerelated declines in CD4 + T-cell function is evident when young mice are thymectomized [22] .", [["thymic", "ANATOMY", 32, 38], ["CD4 + T-cell", "ANATOMY", 95, 107], ["thymic", "ORGAN", 32, 38], ["CD4", "GENE_OR_GENE_PRODUCT", 95, 98], ["mice", "ORGANISM", 139, 143], ["CD4", "PROTEIN", 95, 98], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 139, 143], ["Further support", "TREATMENT", 0, 15], ["thymic involution", "PROBLEM", 32, 49], ["agerelated declines", "PROBLEM", 72, 91], ["CD4", "TEST", 95, 98], ["thymic", "ANATOMY", 32, 38], ["involution", "OBSERVATION", 39, 49]]], ["Eight months after surgical ablation of the thymus, TCR Tg CD4 + T cells possessed significant defects in IL-2 production and CD25 expression following stimulation with peptide-pulsed APC compared with cells from mock-treated mice.", [["thymus", "ANATOMY", 44, 50], ["TCR Tg CD4 + T cells", "ANATOMY", 52, 72], ["cells", "ANATOMY", 202, 207], ["TCR", "CHEMICAL", 52, 55], ["thymus", "ORGAN", 44, 50], ["TCR", "GENE_OR_GENE_PRODUCT", 52, 55], ["IL-2", "GENE_OR_GENE_PRODUCT", 106, 110], ["CD25", "GENE_OR_GENE_PRODUCT", 126, 130], ["APC", "GENE_OR_GENE_PRODUCT", 184, 187], ["cells", "CELL", 202, 207], ["mice", "ORGANISM", 226, 230], ["TCR Tg CD4 + T cells", "CELL_TYPE", 52, 72], ["CD25", "PROTEIN", 126, 130], ["APC", "CELL_TYPE", 184, 187], ["mice", "SPECIES", 226, 230], ["mice", "SPECIES", 226, 230], ["surgical ablation of the thymus", "TREATMENT", 19, 50], ["TCR", "TEST", 52, 55], ["T cells", "PROBLEM", 65, 72], ["significant defects in IL", "PROBLEM", 83, 108], ["stimulation with peptide", "TREATMENT", 152, 176], ["pulsed APC", "PROBLEM", 177, 187], ["thymus", "ANATOMY", 44, 50], ["significant", "OBSERVATION_MODIFIER", 83, 94], ["defects", "OBSERVATION", 95, 102], ["IL", "OBSERVATION_MODIFIER", 106, 108]]], ["Thus, the amount of time a T cell has spent in the periphery has an impact on its ability to respond to stimulation.Ontogeny of age-related declines in CD4 + T-cell functionWhile there is a clear correlation between reduced thymic output and diminished na\u00efve CD4 + T-cell function, there are also data indicating that RTEs generated in the aged possess intrinsic defects.", [["T cell", "ANATOMY", 27, 33], ["CD4 + T-cell", "ANATOMY", 152, 164], ["thymic", "ANATOMY", 224, 230], ["CD4 + T-cell", "ANATOMY", 259, 271], ["T cell", "CELL", 27, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 152, 155], ["thymic", "ORGAN", 224, 230], ["CD4", "GENE_OR_GENE_PRODUCT", 259, 262], ["RTEs", "GENE_OR_GENE_PRODUCT", 318, 322], ["T cell", "CELL_TYPE", 27, 33], ["CD4", "PROTEIN", 152, 155], ["CD4", "PROTEIN", 259, 262], ["RTEs", "PROTEIN", 318, 322], ["related declines", "PROBLEM", 132, 148], ["CD4", "TEST", 152, 155], ["reduced thymic output", "PROBLEM", 216, 237], ["RTEs", "TEST", 318, 322], ["intrinsic defects", "PROBLEM", 353, 370], ["amount", "OBSERVATION_MODIFIER", 10, 16], ["clear", "OBSERVATION", 190, 195], ["reduced", "OBSERVATION_MODIFIER", 216, 223], ["thymic output", "OBSERVATION", 224, 237], ["diminished", "OBSERVATION_MODIFIER", 242, 252], ["na\u00efve CD4", "OBSERVATION", 253, 262], ["defects", "OBSERVATION", 363, 370]]], ["RTEs from aged mice have been shown to produce less IL-2 and expand poorly after stimulation compared with RTEs from their young counterparts [19, 22, 23] .", [["mice", "ORGANISM", 15, 19], ["IL-2", "GENE_OR_GENE_PRODUCT", 52, 56], ["IL", "PROTEIN", 52, 54], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19]]], ["In addition, RTE from aged mice possess defects in Ca 2+ mobilization following TCR ligation [23] .", [["Ca", "CHEMICAL", 51, 53], ["TCR", "CHEMICAL", 80, 83], ["Ca 2+", "CHEMICAL", 51, 56], ["mice", "ORGANISM", 27, 31], ["Ca 2+", "SIMPLE_CHEMICAL", 51, 56], ["TCR", "GENE_OR_GENE_PRODUCT", 80, 83], ["RTE", "DNA", 13, 16], ["TCR", "PROTEIN", 80, 83], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["defects in Ca", "PROBLEM", 40, 53], ["mobilization following TCR ligation", "TREATMENT", 57, 92]]], ["Although these defects in RTE generated in aged mice are well documented, new CD4 + T cells generated from aged bone marrow stem cells (BMSCs) in young hosts are highly functional [24] .", [["CD4 + T cells", "ANATOMY", 78, 91], ["bone marrow stem cells", "ANATOMY", 112, 134], ["BMSCs", "ANATOMY", 136, 141], ["mice", "ORGANISM", 48, 52], ["CD4", "GENE_OR_GENE_PRODUCT", 78, 81], ["bone marrow stem cells", "CELL", 112, 134], ["BMSCs", "CELL", 136, 141], ["RTE", "DNA", 26, 29], ["CD4 + T cells", "CELL_TYPE", 78, 91], ["aged bone marrow stem cells", "CELL_TYPE", 107, 134], ["BMSCs", "CELL_TYPE", 136, 141], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["these defects in RTE", "PROBLEM", 9, 29], ["new CD4 + T cells", "PROBLEM", 74, 91], ["defects", "OBSERVATION", 15, 22], ["bone", "ANATOMY", 112, 116], ["marrow stem cells", "OBSERVATION", 117, 134]]], ["These newly generated CD4 + T cells exhibit robust responses in both primary and memory assays and function well to help humoral responses after vaccination.", [["CD4 + T cells", "ANATOMY", 22, 35], ["CD4", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD4 + T cells", "CELL_TYPE", 22, 35], ["T cells", "PROBLEM", 28, 35], ["vaccination", "TREATMENT", 145, 156]]], ["Thus, these data imply that, even though aged BMSCs remain functional, the aged thymus microenvironment plays an important role in producing defective T cells.Impact of progressive aging on CD8 + T-cell responsesSimilar to CD4 + T cells, with increasing age there is a decline in CD8 + T-cell responsiveness to newly encountered antigens (Table 1 ).", [["BMSCs", "ANATOMY", 46, 51], ["thymus", "ANATOMY", 80, 86], ["T cells", "ANATOMY", 151, 158], ["CD8 + T-cell", "ANATOMY", 190, 202], ["CD4 + T cells", "ANATOMY", 223, 236], ["CD8 + T-cell", "ANATOMY", 280, 292], ["BMSCs", "CELL", 46, 51], ["thymus", "ORGAN", 80, 86], ["T cells", "CELL", 151, 158], ["CD8", "GENE_OR_GENE_PRODUCT", 190, 193], ["CD4", "GENE_OR_GENE_PRODUCT", 223, 226], ["CD8", "GENE_OR_GENE_PRODUCT", 280, 283], ["BMSCs", "CELL_TYPE", 46, 51], ["T cells", "CELL_TYPE", 151, 158], ["CD8", "PROTEIN", 190, 193], ["CD4", "PROTEIN", 223, 226], ["T cells", "CELL_TYPE", 229, 236], ["CD8", "PROTEIN", 280, 283], ["antigens", "PROTEIN", 329, 337], ["defective T cells", "PROBLEM", 141, 158], ["progressive aging", "PROBLEM", 169, 186], ["CD8", "TEST", 190, 193], ["CD4 + T cells", "PROBLEM", 223, 236], ["a decline", "PROBLEM", 267, 276], ["CD8", "TEST", 280, 283], ["progressive", "OBSERVATION_MODIFIER", 169, 180]]], ["This has been demonstrated in models of viral infection in which sublethal infection of aged mice results in delayed clearance of virus [25] .", [["viral infection", "DISEASE", 40, 55], ["infection", "DISEASE", 75, 84], ["mice", "ORGANISM", 93, 97], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["viral infection", "PROBLEM", 40, 55], ["sublethal infection", "PROBLEM", 65, 84], ["delayed clearance of virus", "PROBLEM", 109, 135], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["infection", "OBSERVATION", 46, 55]]], ["Following infection of young or aged mice with lymphocytic choriomeningitis virus (LCMV), aged mice exhibit a lower percentage of LCMV-specific CD8 + T cells than young animals [26] .", [["CD8 + T cells", "ANATOMY", 144, 157], ["infection", "DISEASE", 10, 19], ["lymphocytic choriomeningitis virus", "DISEASE", 47, 81], ["mice", "ORGANISM", 37, 41], ["lymphocytic choriomeningitis virus", "ORGANISM", 47, 81], ["LCMV", "ORGANISM", 83, 87], ["mice", "ORGANISM", 95, 99], ["LCMV", "ORGANISM", 130, 134], ["CD8", "GENE_OR_GENE_PRODUCT", 144, 147], ["LCMV-specific CD8 + T cells", "CELL_TYPE", 130, 157], ["mice", "SPECIES", 37, 41], ["lymphocytic choriomeningitis virus", "SPECIES", 47, 81], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 37, 41], ["lymphocytic choriomeningitis virus", "SPECIES", 47, 81], ["LCMV", "SPECIES", 83, 87], ["mice", "SPECIES", 95, 99], ["LCMV", "SPECIES", 130, 134], ["infection", "PROBLEM", 10, 19], ["lymphocytic choriomeningitis virus", "PROBLEM", 47, 81], ["LCMV", "TEST", 130, 134], ["infection", "OBSERVATION", 10, 19], ["lymphocytic choriomeningitis", "OBSERVATION", 47, 75], ["LCMV", "OBSERVATION", 130, 134]]], ["In addition, the frequency of CD8 + T cells capable of producing interferon-gamma (IFN-\u03b3) in response to LCMV peptides was reduced in aged mice.", [["CD8 + T cells", "ANATOMY", 30, 43], ["CD8", "GENE_OR_GENE_PRODUCT", 30, 33], ["interferon-gamma", "GENE_OR_GENE_PRODUCT", 65, 81], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 83, 88], ["LCMV", "ORGANISM", 105, 109], ["mice", "ORGANISM", 139, 143], ["CD8", "PROTEIN", 30, 33], ["T cells", "CELL_TYPE", 36, 43], ["interferon-gamma", "PROTEIN", 65, 81], ["IFN", "PROTEIN", 83, 86], ["\u03b3", "PROTEIN", 87, 88], ["mice", "SPECIES", 139, 143], ["LCMV", "SPECIES", 105, 109], ["mice", "SPECIES", 139, 143], ["LCMV peptides", "TREATMENT", 105, 118], ["LCMV peptides", "OBSERVATION", 105, 118]]], ["Similarly, in a mouse model of influenza infection, the magnitude of the aged CD8 + T-cell response directed against the immunodominant nucleoprotein (NP) epitope is reduced [27] .", [["CD8 + T-cell", "ANATOMY", 78, 90], ["influenza infection", "DISEASE", 31, 50], ["mouse", "ORGANISM", 16, 21], ["influenza", "ORGANISM", 31, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["CD8", "PROTEIN", 78, 81], ["immunodominant nucleoprotein (NP) epitope", "PROTEIN", 121, 162], ["mouse", "SPECIES", 16, 21], ["mouse", "SPECIES", 16, 21], ["influenza infection", "PROBLEM", 31, 50], ["the immunodominant nucleoprotein (NP) epitope", "TREATMENT", 117, 162], ["influenza", "OBSERVATION_MODIFIER", 31, 40], ["infection", "OBSERVATION", 41, 50]]], ["There was also a delay in the peak of the CD8 + T-cell response detected in aged mice compared with young counterparts.", [["CD8 + T-cell", "ANATOMY", 42, 54], ["CD8", "GENE_OR_GENE_PRODUCT", 42, 45], ["mice", "ORGANISM", 81, 85], ["CD8", "PROTEIN", 42, 45], ["mice", "SPECIES", 81, 85], ["mice", "SPECIES", 81, 85], ["a delay", "PROBLEM", 15, 22], ["the CD8", "TEST", 38, 45], ["delay", "OBSERVATION_MODIFIER", 17, 22]]], ["Therefore, it is clear that progressive aging affects CD8 + T-cell responses; however, it remains unclear whether the reported deficiencies in CD8 + Tcell function result from a reduction in the number of CD8 + T cells elicited during an immune response, represent functional defects intrinsic to aged T cells or are a consequence of functionally defective CD4 + T cells that are unable to provide effective cognate help to the CD8 + T cells.Effect of decline in CD8 + T-cell repertoire diversityMaintenance of a diverse T-cell repertoire is essential to mount effective T-cell responses against new pathogens and vaccines [28, 29] .", [["CD8 + T-cell", "ANATOMY", 54, 66], ["CD8 + Tcell", "ANATOMY", 143, 154], ["CD8 + T cells", "ANATOMY", 205, 218], ["T cells", "ANATOMY", 302, 309], ["CD4 + T cells", "ANATOMY", 357, 370], ["CD8 + T cells", "ANATOMY", 428, 441], ["CD8 + T-cell", "ANATOMY", 463, 475], ["T-cell", "ANATOMY", 521, 527], ["T-cell", "ANATOMY", 571, 577], ["CD8", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 143, 146], ["CD8", "GENE_OR_GENE_PRODUCT", 205, 208], ["T cells", "CELL", 302, 309], ["CD4", "GENE_OR_GENE_PRODUCT", 357, 360], ["CD8", "GENE_OR_GENE_PRODUCT", 428, 431], ["CD8", "GENE_OR_GENE_PRODUCT", 463, 466], ["T-cell", "CELL", 521, 527], ["T-cell", "CELL", 571, 577], ["CD8", "PROTEIN", 54, 57], ["CD8", "PROTEIN", 143, 146], ["CD8 + T cells", "CELL_TYPE", 205, 218], ["aged T cells", "CELL_TYPE", 297, 309], ["CD4 + T cells", "CELL_TYPE", 357, 370], ["CD8 + T cells", "CELL_TYPE", 428, 441], ["CD8", "PROTEIN", 463, 466], ["the reported deficiencies in CD8 + Tcell function", "PROBLEM", 114, 163], ["a reduction", "PROBLEM", 176, 187], ["CD8 + T cells", "PROBLEM", 205, 218], ["functional defects", "PROBLEM", 265, 283], ["functionally defective CD4 + T cells", "PROBLEM", 334, 370], ["decline", "PROBLEM", 452, 459], ["CD8", "TEST", 463, 466], ["a diverse T-cell repertoire", "TREATMENT", 511, 538], ["new pathogens", "PROBLEM", 596, 609], ["progressive", "OBSERVATION_MODIFIER", 28, 39], ["reduction", "OBSERVATION_MODIFIER", 178, 187], ["functional defects", "OBSERVATION", 265, 283], ["defective CD4", "OBSERVATION", 347, 360], ["decline", "OBSERVATION_MODIFIER", 452, 459]]], ["It has been proposed that age-related declines in CD8 + T-cell repertoire diversity provides an explanation for the increased susceptibility to infectious disease and reduced vaccine efficacy observed in the aged.", [["CD8 + T-cell", "ANATOMY", 50, 62], ["infectious disease", "DISEASE", 144, 162], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["CD8", "PROTEIN", 50, 53], ["CD8", "TEST", 50, 53], ["the increased susceptibility to infectious disease", "PROBLEM", 112, 162], ["reduced vaccine efficacy", "PROBLEM", 167, 191], ["infectious", "OBSERVATION", 144, 154]]], ["Detrimental reductions in the size and diversity of the aged CD8 + T-cell repertoire probably represent the coalescence of three events associated with progressive age in mice and humans: (i) thymic involution, (ii) steady increases in the proportion of antigen-experienced memory CD8 + T cells and (iii) the appearance of CD8 + T-cell clonal expansions.Effect of decline in CD8 + T-cell repertoire diversityThe generation of T-cell receptor diversity is entirely dependent on the production of new T cells by the thymus [30] .", [["CD8 + T-cell", "ANATOMY", 61, 73], ["thymic", "ANATOMY", 192, 198], ["memory CD8 + T cells", "ANATOMY", 274, 294], ["CD8 + T-cell", "ANATOMY", 323, 335], ["CD8 + T-cell", "ANATOMY", 375, 387], ["T-cell", "ANATOMY", 426, 432], ["T cells", "ANATOMY", 499, 506], ["thymus", "ANATOMY", 514, 520], ["CD8", "GENE_OR_GENE_PRODUCT", 61, 64], ["mice", "ORGANISM", 171, 175], ["humans", "ORGANISM", 180, 186], ["thymic", "ORGAN", 192, 198], ["antigen", "GENE_OR_GENE_PRODUCT", 254, 261], ["CD8", "GENE_OR_GENE_PRODUCT", 281, 284], ["CD8", "GENE_OR_GENE_PRODUCT", 323, 326], ["CD8", "GENE_OR_GENE_PRODUCT", 375, 378], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 426, 441], ["T cells", "CELL", 499, 506], ["thymus", "ORGAN", 514, 520], ["CD8", "PROTEIN", 61, 64], ["memory CD8 + T cells", "CELL_TYPE", 274, 294], ["CD8", "PROTEIN", 323, 326], ["CD8", "PROTEIN", 375, 378], ["T cells", "CELL_TYPE", 499, 506], ["mice", "SPECIES", 171, 175], ["humans", "SPECIES", 180, 186], ["mice", "SPECIES", 171, 175], ["humans", "SPECIES", 180, 186], ["Detrimental reductions in the size", "PROBLEM", 0, 34], ["thymic involution", "PROBLEM", 192, 209], ["CD8", "TEST", 323, 326], ["T-cell clonal expansions", "PROBLEM", 329, 353], ["decline", "PROBLEM", 364, 371], ["CD8", "TEST", 375, 378], ["reductions", "OBSERVATION_MODIFIER", 12, 22], ["size", "OBSERVATION_MODIFIER", 30, 34], ["probably represent", "UNCERTAINTY", 85, 103], ["progressive", "OBSERVATION_MODIFIER", 152, 163], ["thymic", "ANATOMY", 192, 198], ["involution", "OBSERVATION", 199, 209], ["cell", "OBSERVATION", 331, 335], ["clonal expansions", "OBSERVATION", 336, 353], ["dependent", "OBSERVATION_MODIFIER", 464, 473], ["thymus", "ANATOMY", 514, 520]]], ["The aged thymus is still capable of contributing new na\u00efve cells to the peripheral T-cell pool, although the output of new T cells is severely reduced by thymic involution.", [["thymus", "ANATOMY", 9, 15], ["na\u00efve cells", "ANATOMY", 53, 64], ["peripheral T-cell", "ANATOMY", 72, 89], ["T cells", "ANATOMY", 123, 130], ["thymic", "ANATOMY", 154, 160], ["thymus", "ORGAN", 9, 15], ["na\u00efve cells", "CELL", 53, 64], ["peripheral T-cell", "CELL", 72, 89], ["T cells", "CELL", 123, 130], ["thymic", "ORGAN", 154, 160], ["na\u00efve cells", "CELL_TYPE", 53, 64], ["peripheral T-cell pool", "CELL_TYPE", 72, 94], ["T cells", "CELL_TYPE", 123, 130], ["new na\u00efve cells", "PROBLEM", 49, 64], ["the output", "TEST", 105, 115], ["new T cells", "PROBLEM", 119, 130], ["thymic involution", "PROBLEM", 154, 171], ["thymus", "ANATOMY", 9, 15], ["new", "OBSERVATION_MODIFIER", 49, 52], ["na\u00efve cells", "OBSERVATION", 53, 64], ["peripheral", "ANATOMY_MODIFIER", 72, 82], ["cell pool", "OBSERVATION", 85, 94], ["output", "OBSERVATION_MODIFIER", 109, 115], ["new", "OBSERVATION_MODIFIER", 119, 122], ["T cells", "OBSERVATION", 123, 130], ["severely", "OBSERVATION_MODIFIER", 134, 142], ["reduced", "OBSERVATION_MODIFIER", 143, 150], ["thymic involution", "OBSERVATION", 154, 171]]], ["Further evidence of the importance of the thymus in maintaining CD8 + T-cell repertoire diversity is demonstrated by mice that have been subjected to thymectomy.", [["thymus", "ANATOMY", 42, 48], ["CD8 + T-cell", "ANATOMY", 64, 76], ["thymus", "ORGAN", 42, 48], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["mice", "ORGANISM", 117, 121], ["CD8", "PROTEIN", 64, 67], ["mice", "SPECIES", 117, 121], ["mice", "SPECIES", 117, 121], ["thymectomy", "TREATMENT", 150, 160], ["thymus", "ANATOMY", 42, 48], ["cell", "OBSERVATION", 72, 76], ["repertoire diversity", "OBSERVATION", 77, 97], ["thymectomy", "OBSERVATION", 150, 160]]], ["Mice thymectomized at 6 weeks of age exhibit increased frequencies of expanded T-cell clonotypes compared with intact animals at 18 months of age [31] .", [["T-cell", "ANATOMY", 79, 85], ["Mice", "ORGANISM", 0, 4], ["T-cell clonotypes", "CELL", 79, 96], ["expanded T-cell clonotypes", "CELL_TYPE", 70, 96], ["Mice", "SPECIES", 0, 4], ["increased frequencies", "PROBLEM", 45, 66], ["expanded T-cell clonotypes", "PROBLEM", 70, 96], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["cell clonotypes", "OBSERVATION", 81, 96]]], ["In addition, thymectomy of young mice was shown to result in the loss of reactivity to influenza NP peptide, highlighting the role of the thymus in maintaining repertoire diversity [32] .Effect of decline in CD8 + T-cell repertoire diversitySeveral recent studies have indicated that, in the face of decreasing thymic export, maintenance of the na\u00efve T-cell pool in the aged becomes increasingly dependent on peripheral homeostatic proliferation [33] [34] [35] .", [["thymus", "ANATOMY", 138, 144], ["CD8 + T-cell", "ANATOMY", 208, 220], ["thymic", "ANATOMY", 311, 317], ["T-cell", "ANATOMY", 351, 357], ["mice", "ORGANISM", 33, 37], ["thymus", "ORGAN", 138, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 208, 211], ["thymic", "ORGAN", 311, 317], ["T-cell", "CELL", 351, 357], ["CD8", "PROTEIN", 208, 211], ["na\u00efve T-cell pool", "CELL_TYPE", 345, 362], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["thymectomy", "TREATMENT", 13, 23], ["the loss of reactivity", "PROBLEM", 61, 83], ["influenza NP peptide", "TREATMENT", 87, 107], ["decline", "PROBLEM", 197, 204], ["CD8", "TEST", 208, 211], ["Several recent studies", "TEST", 241, 263], ["decreasing thymic export", "PROBLEM", 300, 324], ["increasingly dependent", "PROBLEM", 383, 405], ["peripheral homeostatic proliferation", "TEST", 409, 445], ["thymectomy", "OBSERVATION", 13, 23], ["thymus", "ANATOMY", 138, 144], ["decreasing", "OBSERVATION_MODIFIER", 300, 310], ["thymic export", "OBSERVATION", 311, 324], ["peripheral homeostatic proliferation", "OBSERVATION", 409, 445]]], ["Although T-cell maturation occurs predominantly in the thymus, thymic emigrants can undergo further maturation in the periphery following low-affinity interactions with self-peptide-major histocompatibility complex (MHC) complexes [36, 37] .", [["T-cell", "ANATOMY", 9, 15], ["thymus", "ANATOMY", 55, 61], ["thymic emigrants", "ANATOMY", 63, 79], ["T-cell", "CELL", 9, 15], ["thymus", "ORGAN", 55, 61], ["thymic emigrants", "CELL", 63, 79], ["thymic emigrants", "CELL_TYPE", 63, 79], ["major histocompatibility complex (MHC) complexes", "PROTEIN", 182, 230], ["self-peptide", "TREATMENT", 169, 181], ["cell maturation", "OBSERVATION", 11, 26], ["thymus", "ANATOMY", 55, 61], ["thymic", "ANATOMY", 63, 69]]], ["Some have speculated that, although homeostatic proliferation is able to maintain the number of peripheral na\u00efve T cells in aged mice, the overall T-cell repertoire diversity is compromised as the maintenance of individual T-cell clones differs based on TCR avidity and the availability of selecting ligands.", [["peripheral na\u00efve T cells", "ANATOMY", 96, 120], ["T-cell", "ANATOMY", 147, 153], ["T-cell clones", "ANATOMY", 223, 236], ["peripheral na\u00efve T cells", "CELL", 96, 120], ["mice", "ORGANISM", 129, 133], ["T-cell", "CELL", 147, 153], ["T-cell clones", "CELL", 223, 236], ["TCR", "GENE_OR_GENE_PRODUCT", 254, 257], ["peripheral na\u00efve T cells", "CELL_TYPE", 96, 120], ["T-cell clones", "CELL_LINE", 223, 236], ["TCR", "PROTEIN", 254, 257], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 129, 133], ["homeostatic proliferation", "PROBLEM", 36, 61], ["individual T-cell clones", "TREATMENT", 212, 236], ["proliferation", "OBSERVATION", 48, 61]]], ["To examine this idea further, isolated populations of na\u00efve CD8 + T cells from individual aged mice were subjected to DNA spectratype and sequence analyses to determine TCR diversity [38] .", [["CD8 + T cells", "ANATOMY", 60, 73], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["mice", "ORGANISM", 95, 99], ["DNA", "CELLULAR_COMPONENT", 118, 121], ["TCR", "GENE_OR_GENE_PRODUCT", 169, 172], ["na\u00efve CD8 + T cells", "CELL_TYPE", 54, 73], ["TCR", "PROTEIN", 169, 172], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["T cells", "PROBLEM", 66, 73], ["DNA spectratype", "TEST", 118, 133], ["sequence analyses", "TEST", 138, 155]]], ["In contrast to the diverse na\u00efve repertoire present in younger mice, naive CD8 + T cells isolated from individual aged mice showed extensive perturbations in the normally gaussian TCR V\u03b2 spectratype profiles, indicative of oligoclonal expansions and an overall reduction in repertoire diversity.", [["CD8 + T cells", "ANATOMY", 75, 88], ["mice", "ORGANISM", 63, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 75, 78], ["mice", "ORGANISM", 119, 123], ["TCR", "GENE_OR_GENE_PRODUCT", 180, 183], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 184, 186], ["naive CD8 + T cells", "CELL_TYPE", 69, 88], ["TCR", "PROTEIN", 180, 183], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 119, 123], ["mice", "SPECIES", 63, 67], ["mice", "SPECIES", 119, 123], ["T cells", "TEST", 81, 88], ["extensive perturbations", "PROBLEM", 131, 154], ["oligoclonal expansions", "PROBLEM", 223, 245], ["extensive", "OBSERVATION_MODIFIER", 131, 140], ["perturbations", "OBSERVATION", 141, 154], ["gaussian TCR", "OBSERVATION", 171, 183], ["indicative of", "UNCERTAINTY", 209, 222], ["oligoclonal expansions", "OBSERVATION", 223, 245], ["overall", "OBSERVATION_MODIFIER", 253, 260], ["reduction", "OBSERVATION_MODIFIER", 261, 270], ["repertoire diversity", "OBSERVATION", 274, 294]]], ["Subsequent DNA sequence analyses led to the novel observation that clonally expanded populations of na\u00efve CD8 + T cells exist in aged mice.", [["CD8 + T cells", "ANATOMY", 106, 119], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["CD8", "GENE_OR_GENE_PRODUCT", 106, 109], ["mice", "ORGANISM", 134, 138], ["na\u00efve CD8 + T cells", "CELL_TYPE", 100, 119], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 134, 138], ["Subsequent DNA sequence analyses", "TEST", 0, 32], ["the novel observation", "TEST", 40, 61]]], ["Thus, these data suggest that, along with a decrease in thymic export, pressure to maintain the size of the na\u00efve T-cell pool in aged mice through homeostatic proliferation also results in a reduction in the level of repertoire diversity through the selective outgrowth of specific clonotypes.Effect of decline in CD8 + T-cell repertoire diversityThese age-related changes are important and can have dramatic impacts on the response to an infectious pathogen.", [["thymic", "ANATOMY", 56, 62], ["T-cell", "ANATOMY", 114, 120], ["CD8 + T-cell", "ANATOMY", 314, 326], ["thymic", "ORGAN", 56, 62], ["T-cell", "CELL", 114, 120], ["mice", "ORGANISM", 134, 138], ["CD8", "GENE_OR_GENE_PRODUCT", 314, 317], ["CD8", "PROTEIN", 314, 317], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 134, 138], ["these data", "TEST", 6, 16], ["a decrease in thymic export", "PROBLEM", 42, 69], ["homeostatic proliferation", "PROBLEM", 147, 172], ["a reduction", "TREATMENT", 189, 200], ["repertoire diversity", "TREATMENT", 217, 237], ["decline", "PROBLEM", 303, 310], ["CD8", "TEST", 314, 317], ["an infectious pathogen", "PROBLEM", 436, 458], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["thymic export", "OBSERVATION", 56, 69], ["size", "OBSERVATION_MODIFIER", 96, 100], ["homeostatic proliferation", "OBSERVATION", 147, 172], ["reduction", "OBSERVATION_MODIFIER", 191, 200], ["selective", "OBSERVATION_MODIFIER", 250, 259], ["outgrowth", "OBSERVATION_MODIFIER", 260, 269], ["infectious", "OBSERVATION", 439, 449]]], ["A recent study demonstrated that the age-associated decline in repertoire diversity negatively impacts the capacity of aged CD8 + T cells to respond to influenza infection [32] .", [["CD8 + T cells", "ANATOMY", 124, 137], ["influenza infection", "DISEASE", 152, 171], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["aged CD8 + T cells", "CELL_TYPE", 119, 137], ["A recent study", "TEST", 0, 14], ["T cells", "PROBLEM", 130, 137], ["influenza infection", "PROBLEM", 152, 171]]], ["The repertoire of CD8 + T cells responding to immunodominant influenza virus epitopes after primary influenza virus infection has been well characterized, with the responses to NP and acid polymer-ase (PA) being dominant [39] .", [["CD8 + T cells", "ANATOMY", 18, 31], ["influenza virus infection", "DISEASE", 100, 125], ["acid polymer-ase", "CHEMICAL", 184, 200], ["CD8", "GENE_OR_GENE_PRODUCT", 18, 21], ["immunodominant influenza virus", "ORGANISM", 46, 76], ["primary influenza virus", "ORGANISM", 92, 115], ["acid polymer-ase", "SIMPLE_CHEMICAL", 184, 200], ["PA", "SIMPLE_CHEMICAL", 202, 204], ["CD8 + T cells", "CELL_TYPE", 18, 31], ["influenza virus", "SPECIES", 61, 76], ["influenza virus", "SPECIES", 100, 115], ["influenza virus", "SPECIES", 100, 115], ["T cells", "PROBLEM", 24, 31], ["immunodominant influenza virus epitopes", "PROBLEM", 46, 85], ["primary influenza virus infection", "PROBLEM", 92, 125], ["NP", "TREATMENT", 177, 179], ["acid polymer", "TEST", 184, 196], ["influenza virus", "OBSERVATION", 61, 76]]], ["After primary influenza infection, the absolute numbers of CD8 + T cells elicited in young and aged mice were similar, but aged mice exhibited a fivefold reduction in the CD8 T-cell response to NP compared with young mice, both in terms of frequencies and absolute numbers of NPspecific T cells detected in the lung airways [32] .", [["CD8 + T cells", "ANATOMY", 59, 72], ["CD8 T-cell", "ANATOMY", 171, 181], ["NPspecific T cells", "ANATOMY", 276, 294], ["lung airways", "ANATOMY", 311, 323], ["influenza infection", "DISEASE", 14, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 59, 62], ["mice", "ORGANISM", 100, 104], ["mice", "ORGANISM", 128, 132], ["CD8", "GENE_OR_GENE_PRODUCT", 171, 174], ["mice", "ORGANISM", 217, 221], ["NPspecific T cells", "CELL", 276, 294], ["lung airways", "MULTI-TISSUE_STRUCTURE", 311, 323], ["CD8 + T cells", "CELL_TYPE", 59, 72], ["NPspecific T cells", "CELL_TYPE", 276, 294], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 217, 221], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 128, 132], ["mice", "SPECIES", 217, 221], ["primary influenza infection", "PROBLEM", 6, 33], ["T cells", "PROBLEM", 65, 72], ["a fivefold reduction", "PROBLEM", 143, 163], ["NPspecific T cells", "PROBLEM", 276, 294], ["influenza infection", "OBSERVATION", 14, 33], ["reduction", "OBSERVATION_MODIFIER", 154, 163], ["lung", "ANATOMY", 311, 315], ["airways", "ANATOMY", 316, 323]]], ["Analysis of TCR V\u03b2 use by spectratype and flow cytometric analyses revealed that the repertoire of NP-specific CD8 + T cells elicited in infected aged mice was often less diverse compared with the population of NPspecific CD8 + T cells generated in young mice.", [["CD8 + T cells", "ANATOMY", 111, 124], ["NPspecific CD8 + T cells", "ANATOMY", 211, 235], ["TCR V\u03b2", "GENE_OR_GENE_PRODUCT", 12, 18], ["NP", "GENE_OR_GENE_PRODUCT", 99, 101], ["CD8", "GENE_OR_GENE_PRODUCT", 111, 114], ["mice", "ORGANISM", 151, 155], ["CD8", "GENE_OR_GENE_PRODUCT", 222, 225], ["mice", "ORGANISM", 255, 259], ["TCR V\u03b2", "PROTEIN", 12, 18], ["NP-specific CD8 + T cells", "CELL_TYPE", 99, 124], ["NPspecific CD8 + T cells", "CELL_TYPE", 211, 235], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 255, 259], ["mice", "SPECIES", 151, 155], ["mice", "SPECIES", 255, 259], ["flow cytometric analyses", "TEST", 42, 66], ["NP", "TEST", 99, 101], ["T cells", "PROBLEM", 117, 124]]], ["Consequently, a reduction in NP reactivity and repertoire diversity with aging was associated with a decline in heterosubtypic (i.e. cross-protective) immunity against a secondary influenza infection.", [["influenza infection", "DISEASE", 180, 199], ["a reduction in NP reactivity", "PROBLEM", 14, 42], ["a decline", "PROBLEM", 99, 108], ["a secondary influenza infection", "PROBLEM", 168, 199], ["reduction", "OBSERVATION_MODIFIER", 16, 25], ["NP reactivity", "OBSERVATION", 29, 42], ["diversity", "OBSERVATION_MODIFIER", 58, 67], ["secondary", "OBSERVATION_MODIFIER", 170, 179], ["influenza infection", "OBSERVATION", 180, 199]]], ["Thus, contractions in size and diversity of the na\u00efve CD8 + T cell repertoire caused by aging can result in a preferential decline in reactivity to an immunodominant viral epitope crucial for host protection.CD8 + T-cell clonal expansionsPerturbations in the aged CD8 + T-cell repertoire can also be attributed to the nonmalignant expansion of individual CD8 + T-cell clones.", [["CD8 + T cell", "ANATOMY", 54, 66], ["CD8 + T-cell", "ANATOMY", 208, 220], ["CD8 + T-cell", "ANATOMY", 264, 276], ["nonmalignant", "ANATOMY", 318, 330], ["CD8 + T-cell clones", "ANATOMY", 355, 374], ["CD8", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 208, 211], ["CD8", "GENE_OR_GENE_PRODUCT", 264, 267], ["CD8", "GENE_OR_GENE_PRODUCT", 355, 358], ["CD8", "PROTEIN", 54, 57], ["immunodominant viral epitope", "PROTEIN", 151, 179], ["CD8", "PROTEIN", 208, 211], ["CD8", "PROTEIN", 264, 267], ["CD8 + T-cell clones", "CELL_LINE", 355, 374], ["contractions in size", "PROBLEM", 6, 26], ["the na\u00efve CD8", "TEST", 44, 57], ["a preferential decline in reactivity", "PROBLEM", 108, 144], ["an immunodominant viral epitope", "TREATMENT", 148, 179], ["host protection", "TREATMENT", 192, 207], ["CD8", "TEST", 208, 211], ["T-cell clonal expansionsPerturbations", "PROBLEM", 214, 251], ["the nonmalignant expansion", "PROBLEM", 314, 340], ["T-cell clones", "PROBLEM", 361, 374], ["contractions", "OBSERVATION", 6, 18], ["size", "OBSERVATION_MODIFIER", 22, 26], ["diversity", "OBSERVATION_MODIFIER", 31, 40], ["preferential", "OBSERVATION_MODIFIER", 110, 122], ["decline", "OBSERVATION", 123, 130], ["viral epitope", "OBSERVATION", 166, 179], ["T-cell", "OBSERVATION", 214, 220], ["clonal", "OBSERVATION_MODIFIER", 221, 227], ["expansions", "OBSERVATION_MODIFIER", 228, 238], ["Perturbations", "OBSERVATION_MODIFIER", 238, 251], ["nonmalignant", "OBSERVATION_MODIFIER", 318, 330], ["cell clones", "OBSERVATION", 363, 374]]], ["In mice up to 12 months of age, the percentages of CD8 + T cells bearing polyclonal V\u03b2 expression patterns remain constant [31] .", [["CD8 + T cells", "ANATOMY", 51, 64], ["mice", "ORGANISM", 3, 7], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["V\u03b2", "GENE_OR_GENE_PRODUCT", 84, 86], ["CD8", "PROTEIN", 51, 54], ["T cells", "CELL_TYPE", 57, 64], ["V\u03b2", "PROTEIN", 84, 86], ["mice", "SPECIES", 3, 7], ["mice", "SPECIES", 3, 7], ["the percentages", "TEST", 32, 47], ["CD8", "TEST", 51, 54], ["T cells", "PROBLEM", 57, 64], ["polyclonal V\u03b2 expression patterns", "PROBLEM", 73, 106]]], ["However, after 18 months of age, the frequency of expanded T-cell clones increases rapidly.", [["T-cell clones", "ANATOMY", 59, 72], ["T-cell clones", "CELL", 59, 72], ["expanded T-cell clones", "CELL_LINE", 50, 72], ["expanded T-cell clones", "PROBLEM", 50, 72], ["cell clones", "OBSERVATION", 61, 72]]], ["T-cell clonal expansions (TCEs) can dominate as much as 50% of the peripheral CD8 + T-cell repertoire in aged humans and up to 80% of the repertoire in aged mice, severely constraining the repertoire of cells able to respond to new infections or vaccination [40] [41] [42] [43] .CD8 + T-cell clonal expansionsMost TCEs identified in mice and humans are believed to arise from the dysregulated outgrowth of T-cell clones in response to persistent antigenic stimulation during chronic infections.", [["T-cell", "ANATOMY", 0, 6], ["TCEs", "ANATOMY", 26, 30], ["peripheral CD8 + T-cell", "ANATOMY", 67, 90], ["cells", "ANATOMY", 203, 208], [".CD8 + T-cell", "ANATOMY", 278, 291], ["T-cell clones", "ANATOMY", 406, 419], ["infections", "DISEASE", 232, 242], ["chronic infections", "DISEASE", 475, 493], ["T-cell clonal", "CELL", 0, 13], ["CD8", "GENE_OR_GENE_PRODUCT", 78, 81], ["humans", "ORGANISM", 110, 116], ["mice", "ORGANISM", 157, 161], ["cells", "CELL", 203, 208], ["T-cell", "CELL", 285, 291], ["TCEs", "GENE_OR_GENE_PRODUCT", 314, 318], ["mice", "ORGANISM", 333, 337], ["humans", "ORGANISM", 342, 348], ["T-cell clones", "CELL", 406, 419], ["CD8", "PROTEIN", 78, 81], ["TCEs", "PROTEIN", 314, 318], ["T-cell clones", "CELL_LINE", 406, 419], ["humans", "SPECIES", 110, 116], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 333, 337], ["humans", "SPECIES", 342, 348], ["humans", "SPECIES", 110, 116], ["mice", "SPECIES", 157, 161], ["mice", "SPECIES", 333, 337], ["humans", "SPECIES", 342, 348], ["T-cell clonal expansions", "PROBLEM", 0, 24], ["the peripheral CD8", "TEST", 63, 81], ["new infections", "PROBLEM", 228, 242], ["T", "TEST", 285, 286], ["cell clonal expansions", "PROBLEM", 287, 309], ["persistent antigenic stimulation", "PROBLEM", 435, 467], ["chronic infections", "PROBLEM", 475, 493], ["cell", "OBSERVATION", 2, 6], ["clonal expansions", "OBSERVATION", 7, 24], ["peripheral CD8", "ANATOMY", 67, 81], ["clonal expansions", "OBSERVATION", 292, 309], ["cell clones", "OBSERVATION", 408, 419], ["persistent", "OBSERVATION_MODIFIER", 435, 445], ["antigenic stimulation", "OBSERVATION", 446, 467], ["chronic", "OBSERVATION_MODIFIER", 475, 482], ["infections", "OBSERVATION", 483, 493]]], ["However, a recent report showed that antigen-specific TCE can also develop from the pool of conventional memory CD8 + T cells generated after infection by a nonpersistent virus [44] .", [["memory CD8 + T cells", "ANATOMY", 105, 125], ["TCE", "CHEMICAL", 54, 57], ["infection", "DISEASE", 142, 151], ["TCE", "CHEMICAL", 54, 57], ["antigen", "GENE_OR_GENE_PRODUCT", 37, 44], ["TCE", "SIMPLE_CHEMICAL", 54, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 112, 115], ["memory CD8 + T cells", "CELL_TYPE", 105, 125], ["antigen", "TEST", 37, 44], ["T cells", "PROBLEM", 118, 125], ["infection", "PROBLEM", 142, 151], ["a nonpersistent virus", "PROBLEM", 155, 176]]], ["A proportion of aged mice was shown to have an increased frequency of peripheral memory CD8 + T cells specific for an immunodominant epitope 19-20 months after intranasal Sendai virus infection.", [["peripheral memory CD8 + T cells", "ANATOMY", 70, 101], ["Sendai virus infection", "DISEASE", 171, 193], ["mice", "ORGANISM", 21, 25], ["CD8", "GENE_OR_GENE_PRODUCT", 88, 91], ["Sendai virus", "ORGANISM", 171, 183], ["peripheral memory CD8 + T cells", "CELL_TYPE", 70, 101], ["mice", "SPECIES", 21, 25], ["Sendai virus", "SPECIES", 171, 183], ["mice", "SPECIES", 21, 25], ["Sendai virus", "SPECIES", 171, 183], ["T cells", "PROBLEM", 94, 101], ["an immunodominant epitope", "TEST", 115, 140], ["intranasal Sendai virus infection", "PROBLEM", 160, 193], ["increased", "OBSERVATION_MODIFIER", 47, 56], ["peripheral", "ANATOMY_MODIFIER", 70, 80], ["memory CD8", "OBSERVATION", 81, 91], ["Sendai virus infection", "OBSERVATION", 171, 193]]], ["Consistent with other identified TCEs, Sendai-virus specific TCEs expressed elevated levels of CD122 and CD127, molecules comprising the receptors for the homeostatic cytokines IL-15 and IL-7, respectively [42, 44] .", [["TCEs", "GENE_OR_GENE_PRODUCT", 33, 37], ["Sendai-virus", "ORGANISM", 39, 51], ["TCEs", "GENE_OR_GENE_PRODUCT", 61, 65], ["CD122", "GENE_OR_GENE_PRODUCT", 95, 100], ["CD127", "GENE_OR_GENE_PRODUCT", 105, 110], ["IL-15", "GENE_OR_GENE_PRODUCT", 177, 182], ["IL-7", "GENE_OR_GENE_PRODUCT", 187, 191], ["Sendai-virus specific TCEs", "PROTEIN", 39, 65], ["CD122", "PROTEIN", 95, 100], ["CD127", "PROTEIN", 105, 110], ["cytokines", "PROTEIN", 167, 176], ["IL-15", "PROTEIN", 177, 182], ["IL", "PROTEIN", 187, 189], ["Sendai-virus", "SPECIES", 39, 51], ["TCEs", "TEST", 33, 37], ["Sendai-virus specific TCEs", "TEST", 39, 65], ["elevated levels of CD122", "PROBLEM", 76, 100], ["CD127", "TEST", 105, 110], ["the homeostatic cytokines IL", "TEST", 151, 179]]], ["Although TCEs generated during chronic infections are found to be functionally impaired, these virus-specific TCEs were shown to both produce cytokines in response to antigenic stimulation and exhibit functional TCR avidities similar to those of normal virus-specific memory T cells present in younger mice [44] .", [["memory T cells", "ANATOMY", 268, 282], ["infections", "DISEASE", 39, 49], ["TCEs", "GENE_OR_GENE_PRODUCT", 9, 13], ["TCEs", "GENE_OR_GENE_PRODUCT", 110, 114], ["TCR", "GENE_OR_GENE_PRODUCT", 212, 215], ["normal virus", "ORGANISM", 246, 258], ["memory T cells", "CELL", 268, 282], ["mice", "ORGANISM", 302, 306], ["TCEs", "PROTEIN", 110, 114], ["cytokines", "PROTEIN", 142, 151], ["TCR", "PROTEIN", 212, 215], ["normal virus-specific memory T cells", "CELL_TYPE", 246, 282], ["mice", "SPECIES", 302, 306], ["mice", "SPECIES", 302, 306], ["chronic infections", "PROBLEM", 31, 49], ["functionally impaired", "PROBLEM", 66, 87], ["these virus", "PROBLEM", 89, 100], ["antigenic stimulation", "TREATMENT", 167, 188], ["functional TCR avidities", "PROBLEM", 201, 225], ["chronic", "OBSERVATION_MODIFIER", 31, 38], ["infections", "OBSERVATION", 39, 49], ["impaired", "OBSERVATION", 79, 87]]], ["These data would suggest that TCEs are a natural outcome of the long-term homeostatic proliferation of the memory T-cell pool.", [["memory T-cell", "ANATOMY", 107, 120], ["TCEs", "SIMPLE_CHEMICAL", 30, 34], ["memory T-cell", "CELL", 107, 120], ["memory T-cell pool", "CELL_TYPE", 107, 125], ["long-term homeostatic", "OBSERVATION_MODIFIER", 64, 85], ["proliferation", "OBSERVATION_MODIFIER", 86, 99]]], ["Although functional and probably able to mediate protective immunity against a secondary viral challenge, the presence of these TCEs still severely compromises the overall size and diversity of the T-cell pool, substantially reducing responsiveness to newly encountered pathogens.Effect of aging on established CD8 + T-cell memoryIt has been shown that robust and long-lasting CD8 + T-cell memory is not generated after infection of aged mice [26] .", [["T-cell", "ANATOMY", 198, 204], ["CD8 + T-cell", "ANATOMY", 311, 323], ["CD8 + T-cell", "ANATOMY", 377, 389], ["infection", "DISEASE", 420, 429], ["TCEs", "GENE_OR_GENE_PRODUCT", 128, 132], ["T-cell", "CELL", 198, 204], ["CD8", "GENE_OR_GENE_PRODUCT", 311, 314], ["CD8", "GENE_OR_GENE_PRODUCT", 377, 380], ["mice", "ORGANISM", 438, 442], ["CD8", "PROTEIN", 311, 314], ["CD8", "PROTEIN", 377, 380], ["mice", "SPECIES", 438, 442], ["mice", "SPECIES", 438, 442], ["a secondary viral challenge", "TREATMENT", 77, 104], ["these TCEs", "PROBLEM", 122, 132], ["newly encountered pathogens", "PROBLEM", 252, 279], ["CD8", "TEST", 311, 314], ["overall", "OBSERVATION_MODIFIER", 164, 171], ["size", "OBSERVATION_MODIFIER", 172, 176], ["robust", "OBSERVATION_MODIFIER", 353, 359]]], ["This is probably a direct consequence of a defective primary immune response in aged mice, perhaps a consequence of impaired function or reduced diversity in the CD8 + T-cell repertoire.", [["CD8 + T-cell", "ANATOMY", 162, 174], ["mice", "ORGANISM", 85, 89], ["CD8", "GENE_OR_GENE_PRODUCT", 162, 165], ["CD8", "PROTEIN", 162, 165], ["mice", "SPECIES", 85, 89], ["mice", "SPECIES", 85, 89], ["a defective primary immune response", "PROBLEM", 41, 76], ["impaired function", "PROBLEM", 116, 133], ["reduced diversity", "PROBLEM", 137, 154], ["defective", "OBSERVATION_MODIFIER", 43, 52], ["primary immune response", "OBSERVATION", 53, 76], ["reduced", "OBSERVATION_MODIFIER", 137, 144], ["diversity", "OBSERVATION_MODIFIER", 145, 154]]], ["For example, the number of memory CD8 + T cells specific for an immunodominant influenza virus epitope, NP, was reduced after infection of aged mice, and the absence of this response correlated with poor viral clearance after a recall response [32] .", [["memory CD8 + T cells", "ANATOMY", 27, 47], ["infection", "DISEASE", 126, 135], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["mice", "ORGANISM", 144, 148], ["memory CD8 + T cells", "CELL_TYPE", 27, 47], ["influenza virus", "SPECIES", 79, 94], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 144, 148], ["T cells", "PROBLEM", 40, 47], ["an immunodominant influenza virus epitope", "PROBLEM", 61, 102], ["poor viral clearance", "PROBLEM", 199, 219], ["influenza virus", "OBSERVATION", 79, 94]]], ["Importantly, even if an adequate primary response to infection is generated, CD8 memory generation is deficient.", [["infection", "DISEASE", 53, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 77, 80], ["CD8", "PROTEIN", 77, 80], ["infection", "PROBLEM", 53, 62], ["infection", "OBSERVATION", 53, 62]]], ["The mechanisms underlying this are not well characterized and might be a consequence of several factors, including poor CD4 help because of impaired function of CD4 + T cells in aged mice.Effect of aging on established CD8 + T-cell memorySimilar to CD4 + T-cell memory, it has generally been shown that CD8 + T-cell memory generated when young is maintained long term and remains functional [26] .", [["CD4 + T cells", "ANATOMY", 161, 174], ["CD8 + T-cell", "ANATOMY", 219, 231], ["CD4 + T-cell", "ANATOMY", 249, 261], ["CD8 + T-cell", "ANATOMY", 303, 315], ["CD4", "GENE_OR_GENE_PRODUCT", 120, 123], ["CD4", "GENE_OR_GENE_PRODUCT", 161, 164], ["mice", "ORGANISM", 183, 187], ["CD8", "GENE_OR_GENE_PRODUCT", 219, 222], ["CD4", "GENE_OR_GENE_PRODUCT", 249, 252], ["CD8", "GENE_OR_GENE_PRODUCT", 303, 306], ["CD4", "PROTEIN", 120, 123], ["CD4", "PROTEIN", 161, 164], ["T cells", "CELL_TYPE", 167, 174], ["CD8", "PROTEIN", 219, 222], ["CD4", "PROTEIN", 249, 252], ["CD8", "PROTEIN", 303, 306], ["mice", "SPECIES", 183, 187], ["mice", "SPECIES", 183, 187], ["CD8", "TEST", 219, 222], ["T", "TEST", 225, 226], ["CD4", "TEST", 249, 252], ["CD8", "TEST", 303, 306], ["cell memory", "OBSERVATION", 257, 268]]], ["However, there are significant changes in the nature of peripheral and systemic memory over time.", [["peripheral", "TISSUE", 56, 66], ["significant changes", "PROBLEM", 19, 38], ["significant", "OBSERVATION_MODIFIER", 19, 30], ["changes", "OBSERVATION", 31, 38], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["systemic memory", "OBSERVATION", 71, 86]]], ["For example, after a respiratory virus infection, the number of memory cells in the airways (peripheral memory) declines, whereas the numbers of memory cells in the spleen (systemic memory) remain stable over time [45] [46] [47] .", [["memory cells", "ANATOMY", 64, 76], ["airways", "ANATOMY", 84, 91], ["memory cells", "ANATOMY", 145, 157], ["spleen", "ANATOMY", 165, 171], ["respiratory virus infection", "DISEASE", 21, 48], ["memory cells", "CELL", 64, 76], ["airways", "MULTI-TISSUE_STRUCTURE", 84, 91], ["memory cells", "CELL", 145, 157], ["spleen", "ORGAN", 165, 171], ["memory cells", "CELL_TYPE", 64, 76], ["memory cells", "CELL_TYPE", 145, 157], ["a respiratory virus infection", "PROBLEM", 19, 48], ["respiratory virus", "OBSERVATION", 21, 38], ["memory cells", "OBSERVATION", 64, 76], ["airways", "ANATOMY", 84, 91], ["peripheral", "ANATOMY_MODIFIER", 93, 103], ["memory cells", "OBSERVATION", 145, 157], ["spleen", "ANATOMY", 165, 171], ["stable", "OBSERVATION_MODIFIER", 197, 203]]], ["Interestingly, dual adoptive transfer experiments directly comparing the function of newly generated and aged CD8 + memory T cells have shown that the recall function of virus-specific memory CD8 + T cells in the spleen actually improves with age on a per cell basis [48] .", [["CD8 + memory T cells", "ANATOMY", 110, 130], ["memory CD8 + T cells", "ANATOMY", 185, 205], ["spleen", "ANATOMY", 213, 219], ["cell", "ANATOMY", 256, 260], ["CD8", "GENE_OR_GENE_PRODUCT", 110, 113], ["CD8", "GENE_OR_GENE_PRODUCT", 192, 195], ["spleen", "ORGAN", 213, 219], ["cell", "CELL", 256, 260], ["CD8 + memory T cells", "CELL_TYPE", 110, 130], ["memory CD8 + T cells", "CELL_TYPE", 185, 205], ["dual adoptive transfer experiments", "TREATMENT", 15, 49], ["virus", "TEST", 170, 175], ["T cells in the spleen", "PROBLEM", 198, 219], ["spleen", "ANATOMY", 213, 219]]], ["The data show that there are substantial phenotypic changes in memory cells over time, and the overall improvement might be explained by the progressive loss of senescent cells.Effect of aging on established CD8 + T-cell memoryWith very advanced age, there is also a dysregulation of memory CD8 + T cells manifested by the development of large clonal expansions, as discussed above.", [["memory cells", "ANATOMY", 63, 75], ["cells", "ANATOMY", 171, 176], ["CD8 + T-cell", "ANATOMY", 208, 220], ["memory CD8 + T cells", "ANATOMY", 284, 304], ["memory cells", "CELL", 63, 75], ["cells", "CELL", 171, 176], ["CD8", "GENE_OR_GENE_PRODUCT", 208, 211], ["CD8", "GENE_OR_GENE_PRODUCT", 291, 294], ["memory cells", "CELL_TYPE", 63, 75], ["senescent cells", "CELL_TYPE", 161, 176], ["CD8", "PROTEIN", 208, 211], ["memory CD8 + T cells", "CELL_TYPE", 284, 304], ["The data", "TEST", 0, 8], ["substantial phenotypic changes in memory cells", "PROBLEM", 29, 75], ["the progressive loss of senescent cells", "PROBLEM", 137, 176], ["T cells", "PROBLEM", 297, 304], ["large clonal expansions", "PROBLEM", 338, 361], ["substantial", "OBSERVATION_MODIFIER", 29, 40], ["phenotypic", "OBSERVATION_MODIFIER", 41, 51], ["changes", "OBSERVATION", 52, 59], ["memory cells", "OBSERVATION", 63, 75], ["might be explained", "UNCERTAINTY", 115, 133], ["progressive", "OBSERVATION_MODIFIER", 141, 152], ["loss", "OBSERVATION_MODIFIER", 153, 157], ["senescent cells", "OBSERVATION", 161, 176], ["memory CD8", "OBSERVATION", 284, 294], ["large", "OBSERVATION_MODIFIER", 338, 343], ["clonal expansions", "OBSERVATION", 344, 361]]], ["In many cases this is thought to be the consequence of persistent activation by ubiquitous chronic viral infections such as cytomegalovirus (CMV) observed in humans.", [["viral infections such as cytomegalovirus (CMV)", "DISEASE", 99, 145], ["cytomegalovirus", "ORGANISM", 124, 139], ["CMV", "ORGANISM", 141, 144], ["humans", "ORGANISM", 158, 164], ["humans", "SPECIES", 158, 164], ["CMV", "SPECIES", 141, 144], ["humans", "SPECIES", 158, 164], ["persistent activation", "PROBLEM", 55, 76], ["ubiquitous chronic viral infections", "PROBLEM", 80, 115], ["cytomegalovirus (CMV", "PROBLEM", 124, 144], ["thought to be", "UNCERTAINTY", 22, 35], ["persistent", "OBSERVATION_MODIFIER", 55, 65], ["activation", "OBSERVATION", 66, 76], ["ubiquitous", "OBSERVATION_MODIFIER", 80, 90], ["chronic", "OBSERVATION_MODIFIER", 91, 98], ["viral infections", "OBSERVATION", 99, 115], ["cytomegalovirus", "OBSERVATION", 124, 139]]], ["Although these cells are nonmalignant, they are functionally impaired.", [["cells", "ANATOMY", 15, 20], ["nonmalignant", "ANATOMY", 25, 37], ["cells", "CELL", 15, 20], ["nonmalignant", "CANCER", 25, 37], ["cells", "OBSERVATION", 15, 20], ["nonmalignant", "OBSERVATION_MODIFIER", 25, 37], ["functionally", "OBSERVATION_MODIFIER", 48, 60], ["impaired", "OBSERVATION", 61, 69]]], ["More recently, it has been shown in mice that clonal expansions can also arise from conventional CD8 + memory T cells [44] , probably through homeostatic mechanisms.", [["CD8 + memory T cells", "ANATOMY", 97, 117], ["mice", "ORGANISM", 36, 40], ["clonal", "CELL", 46, 52], ["CD8", "GENE_OR_GENE_PRODUCT", 97, 100], ["CD8", "PROTEIN", 97, 100], ["memory T cells", "CELL_TYPE", 103, 117], ["mice", "SPECIES", 36, 40], ["mice", "SPECIES", 36, 40], ["clonal expansions", "PROBLEM", 46, 63]]], ["These cells can be considered part of the memory T-cell pool, because they retain the ability to respond to antigen.ConclusionsBy using experimental mouse models, it has been demonstrated that significant defects in CD4 + and CD8 + T-cell responses occur with increasing age.", [["cells", "ANATOMY", 6, 11], ["memory T-cell", "ANATOMY", 42, 55], ["CD4 +", "ANATOMY", 216, 221], ["CD8 + T-cell", "ANATOMY", 226, 238], ["cells", "CELL", 6, 11], ["memory T-cell", "CELL", 42, 55], ["mouse", "ORGANISM", 149, 154], ["CD4", "GENE_OR_GENE_PRODUCT", 216, 219], ["CD8", "GENE_OR_GENE_PRODUCT", 226, 229], ["memory T-cell pool", "CELL_TYPE", 42, 60], ["CD4", "PROTEIN", 216, 219], ["CD8", "PROTEIN", 226, 229], ["mouse", "SPECIES", 149, 154], ["mouse", "SPECIES", 149, 154], ["experimental mouse models", "TEST", 136, 161], ["significant defects", "PROBLEM", 193, 212], ["CD4", "TEST", 216, 219], ["CD8", "TEST", 226, 229], ["significant", "OBSERVATION_MODIFIER", 193, 204], ["defects", "OBSERVATION", 205, 212], ["CD4", "OBSERVATION", 216, 219], ["increasing", "OBSERVATION_MODIFIER", 260, 270]]], ["Intrinsic defects of aged na\u00efve CD4 + T cells limit the initial priming event, which has dramatic effects on expansion, differentiation and the ability to provide cognate help to B cells.", [["CD4 + T cells", "ANATOMY", 32, 45], ["B cells", "ANATOMY", 179, 186], ["CD4", "GENE_OR_GENE_PRODUCT", 32, 35], ["B cells", "CELL", 179, 186], ["aged na\u00efve CD4 + T cells", "CELL_TYPE", 21, 45], ["B cells", "CELL_TYPE", 179, 186], ["Intrinsic defects", "PROBLEM", 0, 17], ["T cells", "PROBLEM", 38, 45], ["defects", "OBSERVATION", 10, 17], ["dramatic", "OBSERVATION_MODIFIER", 89, 97]]], ["Consequently, antibody responses in the aged are diminished.", [["antibody responses", "TEST", 14, 32], ["diminished", "PROBLEM", 49, 59], ["diminished", "OBSERVATION", 49, 59]]], ["In CD8 + T cells, age-associated declines in repertoire diversity can severely limit the initiation of effective immune responses.", [["CD8 + T cells", "ANATOMY", 3, 16], ["CD8", "GENE_OR_GENE_PRODUCT", 3, 6], ["CD8 + T cells", "CELL_TYPE", 3, 16]]], ["In addition, aging significantly impacts the generation of CD8 + T-cell memory and recall responses in the aged.", [["CD8 + T-cell", "ANATOMY", 59, 71], ["CD8", "GENE_OR_GENE_PRODUCT", 59, 62], ["CD8", "PROTEIN", 59, 62]]], ["Clearly, the effects of thymic involution are implicated in the acquisition of agerelated defects in T-cell function.", [["thymic", "ANATOMY", 24, 30], ["T-cell", "ANATOMY", 101, 107], ["thymic", "ORGAN", 24, 30], ["T-cell", "CELL", 101, 107], ["thymic involution", "PROBLEM", 24, 41], ["agerelated defects", "PROBLEM", 79, 97], ["thymic involution", "OBSERVATION", 24, 41], ["defects", "OBSERVATION", 90, 97], ["cell function", "OBSERVATION", 103, 116]]], ["Thus, as T cells age in the periphery, these defects accumulate and contribute significantly to reduced immune function in older individuals.", [["T cells", "ANATOMY", 9, 16], ["T cells", "CELL", 9, 16], ["T cells", "CELL_TYPE", 9, 16], ["these defects", "PROBLEM", 39, 52], ["periphery", "ANATOMY_MODIFIER", 28, 37], ["defects", "OBSERVATION", 45, 52], ["reduced", "OBSERVATION_MODIFIER", 96, 103], ["immune function", "OBSERVATION", 104, 119]]], ["Approaches that can overcome these defects can include enhancing the production of new T cells in the aged or the use of more potent adjuvants to overcome intrinsic defects in T cells.", [["T cells", "ANATOMY", 87, 94], ["T cells", "ANATOMY", 176, 183], ["T cells", "CELL", 87, 94], ["T cells", "CELL", 176, 183], ["T cells", "CELL_TYPE", 87, 94], ["T cells", "CELL_TYPE", 176, 183], ["these defects", "PROBLEM", 29, 42], ["new T cells", "PROBLEM", 83, 94], ["more potent adjuvants", "TREATMENT", 121, 142], ["intrinsic defects in T cells", "PROBLEM", 155, 183], ["defects", "OBSERVATION", 35, 42], ["enhancing", "OBSERVATION_MODIFIER", 55, 64], ["new", "OBSERVATION_MODIFIER", 83, 86], ["defects", "OBSERVATION", 165, 172], ["T cells", "OBSERVATION", 176, 183]]], ["Such approaches could serve to increase the efficacy of vaccination and immunity to infection in the aged.", [["infection", "DISEASE", 84, 93], ["vaccination", "TREATMENT", 56, 67], ["infection", "PROBLEM", 84, 93]]]], "68de54421b8809597e9e4ea01feb31e73cbe0012": [["IntroductionThe novel coronavirus disease 2019 (COVID-19) has triggered a public health emergency of international concern.", [["coronavirus disease", "DISEASE", 22, 41], ["COVID-19", "CHEMICAL", 48, 56], ["coronavirus", "ORGANISM", 22, 33], ["The novel coronavirus disease", "PROBLEM", 12, 41], ["COVID", "TEST", 48, 53], ["coronavirus disease", "OBSERVATION", 22, 41]]], ["Within a period of six months, the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has spread to more than 200 countries/territories, infected more than ten million people worldwide, and claimed over half a million lives.", [["Acute Respiratory Syndrome", "DISEASE", 42, 68], ["SARS-CoV-2", "CHEMICAL", 84, 94], ["SARS-CoV-2", "ORGANISM", 84, 94], ["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184], ["Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2", "SPECIES", 35, 94], ["the Severe Acute Respiratory Syndrome Coronavirus", "PROBLEM", 31, 80], ["SARS", "TEST", 84, 88], ["CoV", "TEST", 89, 92], ["Severe", "OBSERVATION_MODIFIER", 35, 41], ["Acute", "OBSERVATION_MODIFIER", 42, 47], ["Respiratory Syndrome Coronavirus", "OBSERVATION", 48, 80]]], ["The COVID-19 causes a plethora of clinical manifestations, and the severity and outcomes may vary depending on the underlying comorbidities (diabetes, heart diseases, hypertension, COPD), age, sex, and geographic locations (1) .", [["heart", "ANATOMY", 151, 156], ["diabetes", "DISEASE", 141, 149], ["heart diseases", "DISEASE", 151, 165], ["hypertension", "DISEASE", 167, 179], ["COPD", "DISEASE", 181, 185], ["heart", "ORGAN", 151, 156], ["COVID-19", "DNA", 4, 12], ["The COVID", "TEST", 0, 9], ["clinical manifestations", "PROBLEM", 34, 57], ["the underlying comorbidities", "PROBLEM", 111, 139], ["diabetes", "PROBLEM", 141, 149], ["heart diseases", "PROBLEM", 151, 165], ["hypertension", "PROBLEM", 167, 179], ["COPD", "PROBLEM", 181, 185], ["plethora", "OBSERVATION_MODIFIER", 22, 30], ["heart", "ANATOMY", 151, 156], ["diseases", "OBSERVATION", 157, 165], ["hypertension", "OBSERVATION", 167, 179], ["COPD", "OBSERVATION", 181, 185]]], ["In South Asia, despite implementing various public health measures, the overall situation of the COVID-19 pandemic has been worsening and there is no sign of expected epidemic growth curve to be flattened.", [["COVID-19", "ORGANISM", 97, 105], ["various public health measures", "TREATMENT", 36, 66], ["the COVID", "TEST", 93, 102], ["pandemic", "PROBLEM", 106, 114], ["expected epidemic growth curve", "PROBLEM", 158, 188], ["worsening", "OBSERVATION_MODIFIER", 124, 133], ["no sign of", "UNCERTAINTY", 147, 157]]], ["As of 12 July 2020, over one million cases and 31,688 deaths have been reported in the South Asia, and hence created an alarming situation as one-third of the world's population (~1.7 billion) with similar socio-economic characteristics live in these densely populated and resourcelimited regions.", [["deaths", "DISEASE", 54, 60], ["densely", "OBSERVATION_MODIFIER", 251, 258], ["populated", "OBSERVATION", 259, 268]]], ["In this regard, Bangladesh could be an interesting setting to understand the characteristic of the COVID-19 pandemic from the South Asian perspective.IntroductionWith a population of over 160 million, Bangladesh is one of the most densely populated (1265 per square km) countries in the world.", [["population", "OBSERVATION_MODIFIER", 169, 179]]], ["The care-home facility is virtually non-existent and the extended family structure combines the aged with the young in the same household, Because of economic prosperity, the country has been experiencing an increasing trend of unplanned urbanization, and currently, more than 32% of people live in urban areas.", [["people", "ORGANISM", 284, 290], ["people", "SPECIES", 284, 290], ["increasing", "OBSERVATION_MODIFIER", 208, 218]]], ["Bangladesh is also undergoing nutrition and epidemiologic transition with a higher burden of noncommunicable diseases (NCDs).", [["noncommunicable diseases", "DISEASE", 93, 117], ["NCDs", "DISEASE", 119, 123], ["noncommunicable diseases", "PROBLEM", 93, 117], ["noncommunicable diseases", "OBSERVATION", 93, 117]]], ["A recent metaanalysis has shown that overall prevalence for metabolic syndrome (a cluster of health problems including high blood pressure, abdominal fat, high triglycerides, high blood sugar, and low HDL cholesterol) is higher in Bangladesh compared to the estimated world prevalence (30% versus 20-25%) (3) .", [["blood", "ANATOMY", 124, 129], ["abdominal fat", "ANATOMY", 140, 153], ["blood", "ANATOMY", 180, 185], ["metabolic syndrome", "DISEASE", 60, 78], ["cholesterol", "CHEMICAL", 205, 216], ["triglycerides", "CHEMICAL", 160, 173], ["sugar", "CHEMICAL", 186, 191], ["cholesterol", "CHEMICAL", 205, 216], ["blood", "ORGANISM_SUBSTANCE", 124, 129], ["abdominal", "ORGANISM_SUBDIVISION", 140, 149], ["fat", "TISSUE", 150, 153], ["triglycerides", "SIMPLE_CHEMICAL", 160, 173], ["blood", "ORGANISM_SUBSTANCE", 180, 185], ["sugar", "SIMPLE_CHEMICAL", 186, 191], ["HDL", "SIMPLE_CHEMICAL", 201, 204], ["A recent metaanalysis", "TEST", 0, 21], ["metabolic syndrome", "PROBLEM", 60, 78], ["health problems", "PROBLEM", 93, 108], ["high blood pressure", "PROBLEM", 119, 138], ["abdominal fat", "PROBLEM", 140, 153], ["high triglycerides", "PROBLEM", 155, 173], ["high blood sugar", "PROBLEM", 175, 191], ["low HDL cholesterol)", "PROBLEM", 197, 217], ["metabolic syndrome", "OBSERVATION", 60, 78], ["abdominal fat", "ANATOMY", 140, 153], ["higher", "OBSERVATION_MODIFIER", 221, 227]]], ["Besides, approximately 34% of adults are overweight and NCDs account for 67% of deaths in Bangladesh (4, 5) .IntroductionThe capital Dhaka city has a population of nearly 20 million, and currently it is the epicenter of COVID-19 outbreak in Bangladesh.", [["overweight", "DISEASE", 41, 51], ["NCDs", "DISEASE", 56, 60], ["deaths", "DISEASE", 80, 86], ["adults", "ORGANISM", 30, 36], ["capital", "OBSERVATION_MODIFIER", 125, 132]]], ["The first three official COVID-19 cases were reported on March 8, 2020, which included two men returning from Italy.", [["men", "ORGANISM", 91, 94], ["men", "SPECIES", 91, 94]]], ["Amid the upsurges of unofficial deaths of people with COVID-19 like symptoms, the first official death was confirmed on 18 March 2020.", [["deaths", "DISEASE", 32, 38], ["COVID", "DISEASE", 54, 59], ["death", "DISEASE", 97, 102], ["people", "ORGANISM", 42, 48], ["people", "SPECIES", 42, 48], ["COVID-19 like symptoms", "PROBLEM", 54, 76]]], ["The city hosts more than 1 million slum dwellers and marginal communities who live in close proximity and are deprived of adequate facilities for maintaining personal hygiene as bathroom/toilets and water reservoirs are shared between several families (6, 7) .IntroductionInformation on in-depth epidemiological features of the COVID-19 pandemic is lacking from the setting of developing countries, particularly from South Asia.", [["water reservoirs", "TREATMENT", 199, 215], ["the COVID", "TEST", 324, 333], ["pandemic", "PROBLEM", 337, 345]]], ["In this context, we aim to (1) understand the gaps in public health preparedness, and (2) analyze the epidemiological characteristics including incidence, mortality, and geospatial distribution of the COVID-19 pandemic in Bangladesh.", [["the COVID", "TEST", 197, 206]]], ["Moreover, comparative epidemiological trends were analyzed between Bangladesh and other countries with significant incidences of the disease.Trends analysis and modelingData from the Johns Hopkins University Coronavirus Resource Centre was used to analyze the current trend of Bangladesh compared to South Asian countries (India, Pakistan, and Nepal) and other countries with higher incidence (Saudi Arabia, Brazil, UK, USA, and Italy) (18) .", [["the disease", "PROBLEM", 129, 140], ["Trends analysis", "TEST", 141, 156], ["disease", "OBSERVATION", 133, 140]]], ["For SIR models (Bangladesh, India, Pakistan, and Nepal) COVID-19 data from the above-mentioned source and population data were obtained from Our World in Data.Statistical analysisDescriptive statistics were used to report incidence, mortality, age, and gender-specific attributes.", [["COVID", "TEST", 56, 61], ["population data", "TEST", 106, 121]]], ["To model the COVID-19 infection dynamics, a simple SIR model was used, which is particularly suitable to deal with a large population.", [["infection", "DISEASE", 22, 31], ["COVID", "DNA", 13, 18], ["the COVID", "TEST", 9, 18], ["infection dynamics", "PROBLEM", 22, 40], ["a simple SIR model", "TEST", 42, 60], ["a large population", "PROBLEM", 115, 133], ["infection", "OBSERVATION", 22, 31], ["large", "OBSERVATION_MODIFIER", 117, 122], ["population", "OBSERVATION", 123, 133]]], ["The initial model considers the N number of populations to be classified into three categories: the susceptible (S), the infected (I), and the recovered (R).", [["infected", "OBSERVATION", 121, 129]]], ["The rate of transition from susceptible to infected is denoted by or the transmission rate; and the rate of transition from infected to recovered is by or the recovery rate.", [["the transmission rate", "TEST", 69, 90], ["infected", "OBSERVATION", 43, 51], ["infected", "OBSERVATION", 124, 132]]], ["We assumed that the population in our study was closed and individuals mixed uniformly in the community.", [["our study", "TEST", 34, 43], ["population", "OBSERVATION_MODIFIER", 20, 30]]], ["Following Britton and Giardina, we also assumed that all individuals were equally susceptible to the disease and equally infectious if they get infected (19) .", [["the disease", "PROBLEM", 97, 108]]], ["We fitted the SIR model for each country considered in this study.", [["this study", "TEST", 55, 65]]], ["We used L-Broyden-Fletcher-Goldfarb-Shanno algorithm (L-BFGS) to optimize the and parameters of the SIR model while 0.5 was considered as the initial value for each of the parameters.", [["L-Broyden-Fletcher", "TREATMENT", 8, 26], ["Goldfarb-Shanno algorithm", "TREATMENT", 27, 52], ["L-BFGS)", "TREATMENT", 54, 61], ["the SIR model", "TEST", 96, 109]]], ["The L-BFGS was a limited-memory version of BFGS and generated the optimized and parameters using the COVID-19 observed incidences.Statistical analysisThe following equations were used in the SIR model:Major events, the trend of infection and deaths in the first four months of COVID-19 outbreakFigure1 represents an overall timeline of COVID-19 related major events in the first four months in Bangladesh.", [["infection", "DISEASE", 228, 237], ["deaths", "DISEASE", 242, 248], ["L-BFGS", "DNA", 4, 10], ["The L-BFGS", "TEST", 0, 10], ["BFGS", "TEST", 43, 47], ["the COVID", "TREATMENT", 97, 106], ["Statistical analysis", "TEST", 130, 150], ["Major events", "PROBLEM", 201, 213], ["infection", "PROBLEM", 228, 237], ["COVID", "TEST", 277, 282], ["infection", "OBSERVATION", 228, 237]]], ["Bangladesh officially started imposing intervention measures to tackle COVID-19 in March 2020.", [["intervention measures", "TREATMENT", 39, 60]]], ["After the first case was reported, flights were limited, educational institutions were closed, and health screening was imposed at all the port of entries.", [["health screening", "TEST", 99, 115]]], ["During this period, all offices remain closed, public transportation was shut, gatherings and all sorts of inter-district travels were suspended, prayers in places of worship were suspended, and mandatory stay at home order was imposed.", [["inter-district travels", "TREATMENT", 107, 129]]], ["The lockdown was relaxed after 66 days at which point the total COVID-19 cases reached 47,153 with a death toll of 650.", [["death", "DISEASE", 101, 106], ["the total COVID", "TEST", 54, 69]]], ["Within a week, reporting of new cases increased by roughly 50%.", [["new", "OBSERVATION_MODIFIER", 28, 31], ["increased", "OBSERVATION_MODIFIER", 38, 47]]], ["After three months into the pandemic, the total cases reached 68,508; among them, 14,560 (21.25%) were recovered and 930 (1.36%) were deceased.Major events, the trend of infection and deaths in the first four months of COVID-19 outbreakAll rights reserved.", [["infection", "DISEASE", 170, 179], ["deaths", "DISEASE", 184, 190], ["the total cases", "TEST", 38, 53], ["Major events", "PROBLEM", 143, 155], ["infection", "PROBLEM", 170, 179], ["COVID", "TEST", 219, 224], ["infection", "OBSERVATION", 170, 179]]], ["No reuse allowed without permission.Major events, the trend of infection and deaths in the first four months of COVID-19 outbreak(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Major events, the trend of infection and deaths in the first four months of COVID-19 outbreakThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprintDemographic characteristics of COVID-19 cases and mortalityMore than 50% of patients infected with SARS-CoV-2 were aged between 21 and 40 years ( Figure 2A ).", [["infection", "DISEASE", 63, 72], ["deaths", "DISEASE", 77, 83], ["infection", "DISEASE", 291, 300], ["deaths", "DISEASE", 305, 311], ["SARS", "DISEASE", 598, 602], ["patients", "ORGANISM", 575, 583], ["SARS-CoV-2", "ORGANISM", 598, 608], ["patients", "SPECIES", 575, 583], ["SARS-CoV", "SPECIES", 598, 606], ["Major events", "PROBLEM", 36, 48], ["infection", "PROBLEM", 63, 72], ["Major events", "PROBLEM", 264, 276], ["infection", "PROBLEM", 291, 300], ["COVID", "TEST", 340, 345], ["The copyright holder", "TREATMENT", 357, 377], ["medRxiv", "TREATMENT", 483, 490], ["COVID", "TEST", 530, 535], ["SARS", "PROBLEM", 598, 602], ["infection", "OBSERVATION", 63, 72], ["med", "ANATOMY", 208, 211], ["infection", "OBSERVATION", 291, 300]]], ["Children and elderly people belong to the least infected group.", [["Children", "ORGANISM", 0, 8], ["people", "ORGANISM", 21, 27], ["Children", "SPECIES", 0, 8], ["people", "SPECIES", 21, 27], ["infected", "OBSERVATION", 48, 56]]], ["Deaths due to COVID-19 in Bangladesh increased with the age of patients ( Figure 2B ).", [["COVID-19", "CHEMICAL", 14, 22], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["COVID", "TEST", 14, 19]]], ["Males were infected (71%) and died (77%) in a higher proportion than females.", [["infected", "OBSERVATION_MODIFIER", 11, 19]]], ["Overall case fatality rate (CFR) in Bangladesh was 1.27% while CFR for males was higher than females (1.38% vs 1.01%).Demographic characteristics of COVID-19 cases and mortalityAs of 12 July 2020, over 20,000 frontline health workers (5483), law enforcement officers, and journalists were infected (Table 1) .", [["CFR", "TEST", 63, 66], ["COVID", "TEST", 149, 154]]], ["A high CFR (3.34%) was recorded for frontline physicians.", [["A high CFR", "TEST", 0, 10], ["high CFR", "OBSERVATION_MODIFIER", 2, 10]]], ["A total of 1500 unofficial deaths (as of 2 July 2020) with COVID-19 like symptoms were reported ( Figure 3 ).", [["deaths", "DISEASE", 27, 33], ["COVID", "TEST", 59, 64], ["symptoms", "PROBLEM", 73, 81]]], ["In the first three weeks of April, the unofficial death of COVID-19 suspects increased rapidly in the All rights reserved.", [["death", "DISEASE", 50, 55], ["COVID", "TEST", 59, 64], ["increased", "OBSERVATION_MODIFIER", 77, 86], ["rapidly", "OBSERVATION_MODIFIER", 87, 94]]], ["No reuse allowed without permission.Demographic characteristics of COVID-19 cases and mortality(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Demographic characteristics of COVID-19 cases and mortalityThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint Dhaka division while deaths increased alarmingly in Chattogram division after June 7, 2020, and now most deaths reported from this division with a death toll of 451.", [["deaths", "DISEASE", 453, 459], ["deaths", "DISEASE", 537, 543], ["death", "DISEASE", 579, 584], ["COVID", "TEST", 67, 72], ["COVID", "TEST", 261, 266], ["The copyright holder", "TREATMENT", 289, 309], ["med", "ANATOMY", 174, 177]]], ["The trend of an increase in the number of deaths was slow in Barishal, Rangpur, Mymensingh, Sylhet, Khulna, and Rajshahi as compared to Dhaka and Chattogram.Demographic characteristics of COVID-19 cases and mortalityThe testing facility was minimal in the first month of the outbreak (March 2020) and later increased to 66 laboratories nationwide.", [["deaths", "DISEASE", 42, 48], ["Chattogram", "TEST", 146, 156], ["COVID", "TEST", 188, 193], ["trend", "OBSERVATION_MODIFIER", 4, 9], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["number", "OBSERVATION_MODIFIER", 32, 38], ["slow", "OBSERVATION_MODIFIER", 53, 57], ["Khulna", "ANATOMY", 100, 106]]], ["Albeit the overall testing rate was still only 4.7 tests per 1000 people and was below the rate of India, Pakistan, Sri Lanka, and other South Asian countries (Suppl.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72], ["the overall testing rate", "TEST", 7, 31]]], ["Figure 1 ).Figure 2:Demography of reported COVID-19 cases and deaths in Bangladesh (8 march 2020-30 June 2020).", [["deaths", "DISEASE", 62, 68], ["COVID", "TEST", 43, 48]]], ["A) Age group specific cases B) Age group specific deaths C) Sex specific cases D) Sex specific deaths.The district-wise burden of COVID-19 in BangladeshDistrict-wise data for active COVID-19 cases (excluding recovered and deceased cases) were retrieved on two-time points (June 7, 2020, and June 30, 2020).", [["deaths", "DISEASE", 50, 56], ["deaths", "DISEASE", 95, 101], ["COVID", "TEST", 130, 135], ["active COVID", "TEST", 175, 187]]], ["The infection rate rose to 521 cases per million on June 30 from 275 cases per million on June 7 th , nearly a 90% increase over three weeks ( Figure 4 ).", [["infection", "DISEASE", 4, 13], ["The infection rate", "TEST", 0, 18], ["infection", "OBSERVATION", 4, 13]]], ["This may suggest that the disease spread over the country except for the epicenter Dhaka.", [["the disease", "PROBLEM", 22, 33], ["may suggest", "UNCERTAINTY", 5, 16], ["disease", "OBSERVATION", 26, 33]]], ["The rapid spread of the disease was observed in Tangail (from 15 cases per million to 168 cases) and Khulna (from 66 cases to 742 cases per million).", [["the disease", "PROBLEM", 20, 31], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["spread", "OBSERVATION_MODIFIER", 10, 16], ["disease", "OBSERVATION", 24, 31]]], ["Twelve districts out of 64 reported a 4 to 10-fold increase of COVID-19 incidences.Trends of cumulative incidence and mortality of Bangladesh compared to other countriesThe trends of incidence and mortality in Bangladesh were compared with some South Asian and other countries with significant COVID-19 infections.", [["infections", "DISEASE", 303, 313], ["Twelve districts", "TEST", 0, 16], ["COVID", "TEST", 63, 68], ["significant COVID-19 infections", "PROBLEM", 282, 313], ["infections", "OBSERVATION", 303, 313]]], ["No reuse allowed without permission.Trends of cumulative incidence and mortality of Bangladesh compared to other countries(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Trends of cumulative incidence and mortality of Bangladesh compared to other countriesThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint in Bangladesh and other South Asian countries slowed down compared to Brazil, the USA, and European countries.", [["The copyright holder", "TREATMENT", 343, 363], ["med", "ANATOMY", 201, 204]]], ["As for mortality, the South Asian countries had significantly fewer deaths over time compared to the other countries in the EU and the USA.", [["deaths", "DISEASE", 68, 74]]], ["Interestingly, both incidence and deaths in Nepal started to pick up after more than one and a half months since the first confirmed case. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Trends of cumulative incidence and mortality of Bangladesh compared to other countriesThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Trends of cumulative incidence and mortality of Bangladesh compared to other countriesThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprintInfection dynamics via SIR modelsGiven predictions obtained by the SIR model till June 28, with the same settings, Bangladesh was expected to reach the peak by the end of July (Table 2, Figure 6 ).", [["deaths", "DISEASE", 34, 40], ["The copyright holder", "TREATMENT", 360, 380], ["The copyright holder", "TREATMENT", 724, 744], ["medRxiv", "TREATMENT", 850, 857], ["med", "ANATOMY", 218, 221], ["med", "ANATOMY", 582, 585]]], ["About 852,525 people would be infected by then, which translates to about 170,505 severe cases who would need hospital admissions and over 34,100 persons in need of intensive care and up to 10,753 deaths (assuming a 1.26% fatality rate, as found in Bangladesh as of 28 June 2020.", [["deaths", "DISEASE", 197, 203], ["people", "ORGANISM", 14, 20], ["people", "SPECIES", 14, 20], ["persons", "SPECIES", 146, 153]]], ["The peak in India, Pakistan, and Nepal were expected to be reached on July 23, August 10, and August 5 respectively (Table 2 ).DiscussionThe COVID-19 pandemic has appeared as a daunting disaster for Bangladesh as the country now transitions towards its highest peak in the number of positive cases.", [["peak", "OBSERVATION_MODIFIER", 4, 8], ["positive cases", "OBSERVATION", 283, 297]]], ["This article is the first attempt to describe the public health preparedness and epidemiological characteristics of the first wave of COVID-19 pandemic in Bangladesh.Ineffective public health crisis communication and countermeasuresAfter the official announcement of COVID-19 cases in Dhaka, the Government took a number of initiatives to revamp the testing facility, medical equipment supply, and nationwide surveillance.", [["COVID", "TEST", 134, 139], ["nationwide surveillance", "TEST", 398, 421]]], ["The lockdown measures with the deployment of police and armed forces were routed to enforce the law.", [["The lockdown measures", "TREATMENT", 0, 21]]], ["However, our study shows that public health countermeasures were not up to the mark to flatten the curve as the country has been witnessing a steep rise in the number of confirmed cases.", [["our study", "TEST", 9, 18]]], ["A series of events such as the mobilization of 11 million mobile users from city to rural areas, local violence, massive gathering for Janaza prayer (funeral), and purposive rule-breaking indicated that people, by and large, failed to take into account the importance of maintaining social distancing.", [["people", "ORGANISM", 203, 209], ["people", "SPECIES", 203, 209], ["Janaza prayer", "TREATMENT", 135, 148]]], ["While strict lockdown policy has shown success in China, New Zealand, Italy, and largely in the developed All rights reserved.", [["New", "OBSERVATION_MODIFIER", 57, 60], ["Zealand", "OBSERVATION_MODIFIER", 61, 68]]], ["No reuse allowed without permission.Ineffective public health crisis communication and countermeasures(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Ineffective public health crisis communication and countermeasuresThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint countries, a similar approach did not achieve success in Bangladesh, for which the underlying socioeconomic and demographic factors were at fault.", [["The copyright holder", "TREATMENT", 303, 323], ["the underlying socioeconomic and demographic factors", "PROBLEM", 525, 577], ["med", "ANATOMY", 181, 184]]], ["A similar trend was also observed in India and Pakistan where the early lockdown measures might have helped in the preparation of medical logistics but ultimately failed to contain the viral spread.Ineffective public health crisis communication and countermeasuresOne recent study in Bangladesh has shown that people were confused about the \"english\" terms such as \"stay at home,\" \"social distancing,\" \"quarantine,\" and \"lockdown\" (20) .", [["people", "ORGANISM", 310, 316], ["people", "SPECIES", 310, 316], ["the early lockdown measures", "TREATMENT", 62, 89], ["medical logistics", "TREATMENT", 130, 147], ["the viral spread", "PROBLEM", 181, 197], ["One recent study", "TEST", 264, 280], ["confused", "PROBLEM", 322, 330], ["viral spread", "OBSERVATION", 185, 197]]], ["The upward trajectory of positive cases despite an extended period of nationwide lockdown and restrictions indicate the inefficiency of public health risk communication.", [["positive cases", "PROBLEM", 25, 39], ["nationwide lockdown", "TREATMENT", 70, 89], ["upward", "OBSERVATION_MODIFIER", 4, 10], ["trajectory", "OBSERVATION_MODIFIER", 11, 21], ["positive cases", "OBSERVATION", 25, 39]]], ["The gap in the public health preparedness in battling COVID-19 can be minimized by taking into account the nuances of geographical & cultural contexts and devising specific strategies.", [["gap", "OBSERVATION_MODIFIER", 4, 7]]], ["Significant investment and support are required to generate sufficient data for improving the efficiency of public health decisions.Gender disparity and spatial distribution of infectionIn Bangladesh, the proportion of men catching the virus was 2.5 times more than women, although studies around the world suggest that both men and women are equally susceptible to the virus (15, 21) .", [["men", "ORGANISM", 219, 222], ["women", "ORGANISM", 266, 271], ["men", "ORGANISM", 325, 328], ["women", "ORGANISM", 333, 338], ["men", "SPECIES", 219, 222], ["women", "SPECIES", 266, 271], ["men", "SPECIES", 325, 328], ["women", "SPECIES", 333, 338], ["Gender disparity", "PROBLEM", 132, 148], ["the virus", "PROBLEM", 232, 241], ["studies", "TEST", 282, 289], ["the virus", "PROBLEM", 366, 375], ["spatial", "OBSERVATION_MODIFIER", 153, 160], ["distribution", "OBSERVATION_MODIFIER", 161, 173], ["virus", "OBSERVATION", 370, 375]]], ["A similar observation was noted in India and Pakistan where men comprised about 65% and 70% of confirmed cases, respectively (22, 23) .", [["men", "ORGANISM", 60, 63], ["men", "SPECIES", 60, 63]]], ["This disparity in susceptibility might be due to cultural aspects since men dominate the outdoor activities and are less careful towards keeping up with personal hygiene.", [["men", "ORGANISM", 72, 75], ["men", "SPECIES", 72, 75], ["might be due to", "UNCERTAINTY", 33, 48]]], ["Also, the percentage of susceptibility might vary since COVID-19 is more fatal for men, causing them to seek medical care and subject to testing (24) .", [["men", "ORGANISM", 83, 86], ["men", "SPECIES", 83, 86], ["COVID", "TEST", 56, 61], ["testing", "TEST", 137, 144], ["susceptibility", "OBSERVATION", 24, 38]]], ["The death rate among males was found higher in various studies around the world.", [["death", "DISEASE", 4, 9], ["The death rate", "TEST", 0, 14], ["higher", "OBSERVATION_MODIFIER", 37, 43]]], ["Studies showed that men over 60 years of age are twice as likely to die of COVID-19 than women (24, 25) .", [["men", "ORGANISM", 20, 23], ["women", "ORGANISM", 89, 94], ["men", "SPECIES", 20, 23], ["women", "SPECIES", 89, 94], ["Studies", "TEST", 0, 7], ["COVID", "TEST", 75, 80]]], ["This could partly be explained by the presence of higher comorbidity and the smoking habit in men, although the exact reason remains to be elucidated (26) .", [["men", "ORGANISM", 94, 97], ["men", "SPECIES", 94, 97], ["higher comorbidity", "PROBLEM", 50, 68], ["higher", "OBSERVATION_MODIFIER", 50, 56], ["comorbidity", "OBSERVATION", 57, 68]]], ["However, women in India had a higher case fatality rate compared to males (CFR: 2.9% versus 3.3%) which contrasts the scenario of Bangladesh (CFR: 1.4% versus 1.01%) (21, 22) .", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["CFR", "TEST", 75, 78], ["CFR", "TEST", 142, 145]]], ["Future studies are warranted to understand the disparity in sex-specific mortality risk in South Asia.Gender disparity and spatial distribution of infectionIn Bangladesh, the existing data suggest that the infection rate in people from urban areas is higher than in rural villages.", [["infection", "DISEASE", 206, 215], ["people", "ORGANISM", 224, 230], ["people", "SPECIES", 224, 230], ["Future studies", "TEST", 0, 14], ["Gender disparity", "PROBLEM", 102, 118], ["the infection rate", "PROBLEM", 202, 220], ["spatial", "OBSERVATION_MODIFIER", 123, 130], ["distribution", "OBSERVATION_MODIFIER", 131, 143], ["infection", "OBSERVATION", 206, 215], ["higher", "OBSERVATION_MODIFIER", 251, 257]]], ["This is unsurprising because urban settings offer a higher chance of catching the virus.", [["urban settings", "TREATMENT", 29, 43], ["catching the virus", "PROBLEM", 69, 87]]], ["For instance, the Dhaka or Chittagong city relies heavily on congested infrastructures where the population density is the highest, and the citizens receive reduced sunlight exposure.", [["congested infrastructures", "PROBLEM", 61, 86], ["congested", "OBSERVATION", 61, 70], ["population", "OBSERVATION_MODIFIER", 97, 107], ["density", "OBSERVATION", 108, 115], ["highest", "OBSERVATION_MODIFIER", 123, 130]]], ["Vitamin D deficiency in city areas is well documented, and some early studies indicated that vitamin D deficiency could be a risk factor for COVID-19 adversity (27, 28) .Gender disparity and spatial distribution of infectionOn the flip side, the rural remote regions of the country suffer from a lack of proper medical support.", [["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 93, 102], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 93, 102], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["vitamin D", "SIMPLE_CHEMICAL", 93, 102], ["Vitamin D deficiency", "PROBLEM", 0, 20], ["some early studies", "TEST", 59, 77], ["vitamin D deficiency", "PROBLEM", 93, 113], ["COVID", "TEST", 141, 146], ["Gender disparity", "PROBLEM", 170, 186], ["infectionOn the flip side", "PROBLEM", 215, 240], ["proper medical support", "TREATMENT", 304, 326], ["deficiency", "OBSERVATION", 10, 20], ["spatial", "OBSERVATION_MODIFIER", 191, 198], ["distribution", "OBSERVATION_MODIFIER", 199, 211]]], ["Out of 64 districts, almost half of the districts have over 100,000 people who are aged above 65 years, and data show that the proportion of the elderly is higher in rural areas (29, 30) .", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["higher", "OBSERVATION_MODIFIER", 156, 162]]], ["As hospital facilities and medical assistance are more centered towards urban residents, about 3 million people from 50 tribal and ethnic minor communities living in remote areas remain vulnerable to COVID-19 (29) .", [["COVID-19", "CHEMICAL", 200, 208], ["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["COVID", "TEST", 200, 205]]], ["In Brazil, around 9.1% of indigenous people infected with the disease died, and the rate of infection is soaring in distant communities (31).", [["infection", "DISEASE", 92, 101], ["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43], ["the disease", "PROBLEM", 58, 69], ["infection", "PROBLEM", 92, 101], ["disease", "OBSERVATION", 62, 69], ["infection", "OBSERVATION", 92, 101]]], ["Correspondingly, the Rohingya refugee forcibly displaced from Myanmar are living in crowded quarters in Cox's Bazar area, Bangladesh, where they are subject to several health issues such as malnutrition, limited medical access, food-and water-borne diseases, reproductive health, and communicable diseases.", [["malnutrition", "DISEASE", 190, 202], ["communicable diseases", "DISEASE", 284, 305], ["malnutrition", "PROBLEM", 190, 202], ["communicable diseases", "PROBLEM", 284, 305], ["displaced", "OBSERVATION_MODIFIER", 47, 56]]], ["In addition to Bangladesh Government's support, the All rights reserved.", [["Bangladesh Government's support", "TREATMENT", 15, 46]]], ["No reuse allowed without permission.Gender disparity and spatial distribution of infection(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Gender disparity and spatial distribution of infectionThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint UN initiative to mobilize women in spreading awareness regarding COVID-19 in Rohingya camps might lessen the disease burden; however, additional international aid is necessary to cope up with the challenges (32).Low fatality rate as compared to other countriesInterestingly, despite the official numbers jumping above 186,000 (as of 12 July 2020) cases, the death rate remained fairly low (1.27%) in Bangladesh and close to the other South Asian countries such as Afghanistan (2.93%), India (2.64%) and Pakistan (2.09%).", [["infection", "DISEASE", 81, 90], ["infection", "DISEASE", 270, 279], ["death", "DISEASE", 780, 785], ["women", "ORGANISM", 448, 453], ["women", "SPECIES", 448, 453], ["Gender disparity", "PROBLEM", 36, 52], ["infection", "PROBLEM", 81, 90], ["Gender disparity", "PROBLEM", 225, 241], ["infection", "PROBLEM", 270, 279], ["The copyright holder", "TREATMENT", 279, 299], ["COVID", "TEST", 487, 492], ["the disease burden", "PROBLEM", 527, 545], ["Low fatality rate", "PROBLEM", 634, 651], ["the death rate", "TEST", 776, 790], ["spatial", "OBSERVATION_MODIFIER", 57, 64], ["distribution", "OBSERVATION_MODIFIER", 65, 77], ["infection", "OBSERVATION", 81, 90], ["med", "ANATOMY", 169, 172], ["spatial", "OBSERVATION_MODIFIER", 246, 253], ["distribution", "OBSERVATION_MODIFIER", 254, 266], ["infection", "OBSERVATION", 270, 279], ["disease", "OBSERVATION", 531, 538]]], ["This trend contrasts strongly to the other countries such as France (14.5%), Italy (14.3%), the UK (13.9%), Spain (10.4%), USA (4.07%), China (5.54%), Japan (4.39%) and Iran (4.99%) (33).", [["the UK", "TEST", 92, 98], ["Spain", "TEST", 108, 113], ["USA", "TEST", 123, 126], ["Iran", "TEST", 169, 173]]], ["The lower mortality rate in the developing countries may be due to the fact that the overall life expectancy is within 64 to 72 years, leaving out the overly elder population; and there is a higher proportion of young populations in Afghanistan, Pakistan, India, and Bangladesh.", [["The lower mortality rate", "PROBLEM", 0, 24], ["lower", "OBSERVATION_MODIFIER", 4, 9]]], ["By comparison, the proportion of people aged over 70 years is much higher in the European and American settings (34) .Low fatality rate as compared to other countriesSpeculations regarding the low death rate in developing countries questioned the under-reporting of actual death cases as testing facilities were very limited.", [["death", "DISEASE", 197, 202], ["death", "DISEASE", 273, 278], ["people", "ORGANISM", 33, 39], ["people", "SPECIES", 33, 39], ["Low fatality rate", "PROBLEM", 118, 135], ["the low death rate", "PROBLEM", 189, 207]]], ["The unofficial sources indicated that a slightly higher number of deaths (n=1500) occurred in Bangladesh during the initial phase of the outbreak.", [["deaths", "DISEASE", 66, 72], ["slightly", "OBSERVATION_MODIFIER", 40, 48], ["higher", "OBSERVATION_MODIFIER", 49, 55]]], ["Over the last four months, the Bangladesh Government has increased its testing capacity nationwide, yet the combined overall mortality rate remains surprisingly lower than what has been observed in the western world.", [["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["As opposed, the rapid spread of the infection among the elderly in care homes contributed to half of the total deaths in the western world.", [["infection", "DISEASE", 36, 45], ["deaths", "DISEASE", 111, 117], ["the infection", "PROBLEM", 32, 45], ["rapid", "OBSERVATION_MODIFIER", 16, 21], ["spread", "OBSERVATION_MODIFIER", 22, 28], ["infection", "OBSERVATION", 36, 45]]], ["In France, the deaths linked to care homes were 51%, and in Canada, as many as 82% of COVID-19 deaths occurred among care home residents (35).Slow progression of COVID-19 pandemic in South Asian countriesDespite higher population density and low awareness of personal hygiene, the South Asian countries have witnessed a rather noticeable slow progression.", [["deaths", "DISEASE", 15, 21], ["deaths", "DISEASE", 95, 101], ["COVID", "DISEASE", 162, 167], ["Slow progression of COVID", "PROBLEM", 142, 167], ["higher population density", "PROBLEM", 212, 237], ["a rather noticeable slow progression", "PROBLEM", 318, 354], ["progression", "OBSERVATION_MODIFIER", 147, 158], ["low", "OBSERVATION_MODIFIER", 242, 245]]], ["Our model also demonstrated a similar scenario where the peak infection is coming much later than any of the western countries although South Asian countries are closer to and have strong economic relations with China.", [["infection", "DISEASE", 62, 71], ["the peak infection", "PROBLEM", 53, 71], ["similar", "OBSERVATION_MODIFIER", 30, 37], ["scenario", "OBSERVATION", 38, 46], ["peak", "OBSERVATION_MODIFIER", 57, 61], ["infection", "OBSERVATION", 62, 71]]], ["Of note, the first COVID-19 positive case was identified on January 30 in India, February 26 in Pakistan, and March 8 in Bangladesh.", [["the first COVID", "TEST", 9, 24]]], ["Despite such early detection, the subsequent numbers of infection and mortality continued to rise slowly.", [["infection", "DISEASE", 56, 65], ["infection", "PROBLEM", 56, 65], ["mortality", "PROBLEM", 70, 79], ["infection", "OBSERVATION", 56, 65]]], ["Several factors might influence the disease progression such as the wide-scale adaptation of facemask, tropical climate, or cross-immunity from other viruses as the region is under the high burden of disease (36, 37) .", [["the disease progression", "PROBLEM", 32, 55], ["facemask", "TREATMENT", 93, 101], ["tropical climate", "PROBLEM", 103, 119], ["cross-immunity", "PROBLEM", 124, 138], ["other viruses", "PROBLEM", 144, 157], ["the high burden of disease", "PROBLEM", 181, 207], ["disease", "OBSERVATION", 36, 43], ["high", "OBSERVATION_MODIFIER", 185, 189], ["burden", "OBSERVATION_MODIFIER", 190, 196], ["disease", "OBSERVATION", 200, 207]]], ["However, the most probable reason is that, unlike China that locked down Wuhan city, the South Asian countries went for a nationwide total lockdown.", [["most probable", "UNCERTAINTY", 13, 26]]], ["Such actions had a tremendous impact on the daily lives of people, especially the daily wage earners but the measures turned out to be unsustainable.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["Now that countries are easing down on lockdown measures, the numbers are soaring up.", [["lockdown measures", "TREATMENT", 38, 55]]], ["In Bangladesh, the post-lockdown COVID-19 infection is dispersing quickly from the cities towards the peripheral districts, and a dramatic shift in the percent-change of disease transmission is observed.", [["infection", "DISEASE", 42, 51], ["COVID-19", "ORGANISM", 33, 41], ["COVID-19", "SPECIES", 33, 41], ["the post-lockdown COVID", "TEST", 15, 38], ["infection", "PROBLEM", 42, 51], ["a dramatic shift", "PROBLEM", 128, 144], ["disease transmission", "PROBLEM", 170, 190], ["infection", "OBSERVATION", 42, 51], ["peripheral", "ANATOMY_MODIFIER", 102, 112], ["districts", "OBSERVATION", 113, 122], ["dramatic", "OBSERVATION_MODIFIER", 130, 138], ["shift", "OBSERVATION_MODIFIER", 139, 144], ["percent", "OBSERVATION_MODIFIER", 152, 159], ["disease", "OBSERVATION", 170, 177]]], ["This underpins the fact that relaxing social distancing measures might bring about similar consequences for developing countries.Slow progression of COVID-19 pandemic in South Asian countriesAll rights reserved.", [["COVID", "DISEASE", 149, 154], ["Slow progression of COVID", "PROBLEM", 129, 154]]], ["No reuse allowed without permission.Slow progression of COVID-19 pandemic in South Asian countries(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Slow progression of COVID-19 pandemic in South Asian countriesThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Slow progression of COVID-19 pandemic in South Asian countriesThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint 4.5 Overburden of healthcare system: higher fatality rate among medical doctors, limited testing, and ICU beds A significant number of medical personnel and law enforcement workers were infected during the first wave of the COVID-19 epidemic.", [["COVID", "DISEASE", 56, 61], ["COVID", "DISEASE", 253, 258], ["COVID", "DISEASE", 593, 598], ["Slow progression of COVID", "PROBLEM", 36, 61], ["Slow progression of COVID", "PROBLEM", 233, 258], ["The copyright holder", "TREATMENT", 295, 315], ["Slow progression of COVID", "PROBLEM", 573, 598], ["The copyright holder", "TREATMENT", 635, 655], ["limited testing", "TEST", 859, 874], ["the COVID", "TEST", 998, 1007], ["epidemic", "PROBLEM", 1011, 1019], ["progression", "OBSERVATION_MODIFIER", 41, 52], ["med", "ANATOMY", 177, 180], ["med", "ANATOMY", 517, 520]]], ["In particular, the fatality rate among the doctors in Bangladesh (3.34%) was higher than the healthcare workers in Pakistan (1.01%) and India (3.30%) and slightly lower than Afghanistan (3.75%) (38).", [["Afghanistan", "TEST", 174, 185]]], ["The higher proportion of frontliners contracting the virus implies the lack of personal safety and inconsistency in management.", [["the virus", "PROBLEM", 49, 58], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["virus", "OBSERVATION", 53, 58]]], ["The quality of personal protective equipment (PPE) and its training of proper handling remains in doubt.", [["personal protective equipment (PPE)", "TREATMENT", 15, 50], ["its training", "TREATMENT", 55, 67]]], ["With only 733 ICU beds in government hospitals, the healthcare has crumbled as COVID-19 infection rate increases in torrent (39) .", [["infection", "DISEASE", 88, 97], ["COVID", "TEST", 79, 84], ["infection rate", "TEST", 88, 102]]], ["It is surmised that the number of deaths in the age range of 60-70 could be subverted if proper ICU and medical support were provided.", [["deaths", "DISEASE", 34, 40], ["medical support", "TREATMENT", 104, 119]]], ["Our model implied that the number of hospitalized and ICU patients will drastically increase during the peak period of infection which will overload the medical capacity.", [["infection", "DISEASE", 119, 128], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["infection", "PROBLEM", 119, 128], ["overload the medical capacity", "PROBLEM", 140, 169], ["infection", "OBSERVATION", 119, 128]]], ["This underscores the need for urgent investment and remodeling of the healthcare sector.Slow progression of COVID-19 pandemic in South Asian countriesUndoubtedly, the biggest problem with social distancing in Bangladesh lies in the population density and city-based centralized facilities.", [["COVID", "DISEASE", 108, 113], ["urgent investment", "TREATMENT", 30, 47], ["Slow progression of COVID", "PROBLEM", 88, 113], ["progression", "OBSERVATION_MODIFIER", 93, 104], ["biggest", "OBSERVATION_MODIFIER", 167, 174], ["population", "OBSERVATION_MODIFIER", 232, 242], ["density", "OBSERVATION", 243, 250]]], ["The disaster of COVID-19 pandemic thus points out the fragility of the existing system and urges to prioritize the decentralization of healthcare facilities.", [["COVID", "TEST", 16, 21], ["pandemic", "PROBLEM", 25, 33]]], ["The establishment of universal health care should also be directed as a long-term goal.Slow progression of COVID-19 pandemic in South Asian countriesThe abrupt onset of critical patients at the hospitals has strained medical resources; and expensive PCR based testing facilities and related workforce remained in pestilence to meet the demand.", [["COVID", "DISEASE", 107, 112], ["patients", "ORGANISM", 178, 186], ["patients", "SPECIES", 178, 186], ["universal health care", "TREATMENT", 21, 42], ["a long-term goal", "TREATMENT", 70, 86], ["Slow progression of COVID", "PROBLEM", 87, 112], ["expensive PCR", "TEST", 240, 253], ["abrupt", "OBSERVATION_MODIFIER", 153, 159], ["onset", "OBSERVATION_MODIFIER", 160, 165]]], ["Despite the upscaling of testing labs, Bangladesh is lagging behind the race in regard to tests per 1000 people.", [["people", "ORGANISM", 105, 111], ["people", "SPECIES", 105, 111], ["testing labs", "TEST", 25, 37], ["tests", "TEST", 90, 95]]], ["Interestingly, Japan has tested fewer than Bangladesh and still maintains a very low infection and mortality rate.", [["infection", "DISEASE", 85, 94], ["a very low infection", "PROBLEM", 74, 94], ["mortality rate", "TEST", 99, 113], ["very", "OBSERVATION_MODIFIER", 76, 80], ["low", "OBSERVATION_MODIFIER", 81, 84], ["infection", "OBSERVATION", 85, 94]]], ["This indicates that proper contact tracing and quarantining is equally important.", [["proper contact tracing", "TEST", 20, 42]]], ["Since public health measures in the developing countries are constrained by resources both in terms of financial support and trained workforce, it is essential to devise a strategy that is most suitable for such settings.", [["public health measures", "TREATMENT", 6, 28]]], ["It is recommended that instead of depending on RT-PCR based tests that are costly and timeconsuming, the low-middle income countries could focus on syndromic diagnosis based on the constellation of symptoms and signs of COVID-19 in a disease afflicted area (40) .", [["RT-PCR based tests", "TEST", 47, 65], ["symptoms", "PROBLEM", 198, 206], ["COVID", "TEST", 220, 225], ["a disease afflicted area", "PROBLEM", 232, 256]]], ["This way, the burden of expensive testing could be largely reduced, the suspected patients identified earlier, and the investment channeled out into rebuilding healthcare facilities.", [["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["expensive testing", "TEST", 24, 41]]], ["Moreover, patients who were denied hospital admittance because of the absence of COVID-19 test report will also receive early medical support.Slow progression of COVID-19 pandemic in South Asian countriesIn the last four months, the Bangladesh government has scaled up the testing facility across the country as 66 labs are now providing RT-PCR based COVID-19 detection tests.", [["COVID", "DISEASE", 162, 167], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["COVID", "TEST", 81, 86], ["early medical support", "TREATMENT", 120, 141], ["Slow progression of COVID", "PROBLEM", 142, 167], ["RT-PCR", "TEST", 338, 344], ["COVID", "TEST", 351, 356], ["detection tests", "TEST", 360, 375]]], ["Although the situation is not going to be under control any time soon, by the time COVID-19 ends, the testing labs should be converted into regional surveillance centers instead of dissolving them.", [["the testing labs", "TEST", 98, 114]]], ["A nationwide sustainable monitoring and coordination system will help in swift action in case of future outbreaks. developed on the assumption that lockdown and social distancing did not restrict the movements of people, therefore people had an equal chance of contact with every other person among the population irrespective of space or distance.", [["people", "ORGANISM", 213, 219], ["people", "ORGANISM", 231, 237], ["people", "SPECIES", 213, 219], ["people", "SPECIES", 231, 237], ["person", "SPECIES", 286, 292]]], ["Third, unofficial death counts with COVID-19 like symptoms (not confirmed by the test) were extracted from well-established national news media and thus, these should be considered as probable death cases.", [["death", "DISEASE", 18, 23], ["death", "DISEASE", 193, 198], ["unofficial death counts", "TEST", 7, 30], ["COVID", "TEST", 36, 41], ["symptoms", "PROBLEM", 50, 58]]], ["But, Due to limited healthcare infrastructure and testing facilities, it was not possible to confirm all suspected deaths.ConclusionWe found that despite imposing a number of public health measures to 'flatten the curve; the outbreak continued to grow and spread across Bangladesh.", [["deaths", "DISEASE", 115, 121], ["public health measures", "TREATMENT", 175, 197], ["the outbreak", "PROBLEM", 221, 233]]], ["Males were disproportionately infected and died at a higher percentage.", [["disproportionately", "OBSERVATION_MODIFIER", 11, 29], ["infected", "OBSERVATION", 30, 38]]], ["South Asian countries including Bangladesh had significantly fewer deaths over time compared to the other western countries.", [["deaths", "DISEASE", 67, 73]]], ["Our finding on gaps in public health preparedness and communication, and epidemiological characteristics would contribute to better public health decisions for managing current and future pandemic like COVID-19 in Bangladesh and other similar settings elsewhere in the world, particularly in South Asia.Supplementary materialsA.", [["COVID-19", "CHEMICAL", 202, 210]]], ["Test per 1,000 people All rights reserved.", [["people", "SPECIES", 15, 21], ["Test", "TEST", 0, 4]]], ["No reuse allowed without permission.Supplementary materials(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Supplementary materialsThe copyright holder for this preprint this version posted August 6, 2020. . https://doi.org/10.1101/2020.08.05.20168674 doi: medRxiv preprint", [["Supplementary materials", "TREATMENT", 194, 217], ["The copyright holder", "TREATMENT", 217, 237], ["medRxiv", "TREATMENT", 343, 350], ["med", "ANATOMY", 138, 141]]]], "e5d54917d149ed87572748aafa6b0847668ce5a6": [["A 30-year-old female with systemic lupus erythematosusis recovering from a fracture of the right femur and right radius following a motor vehicle accident.", [["right femur", "ANATOMY", 91, 102], ["right radius", "ANATOMY", 107, 119], ["systemic lupus erythematosusis", "DISEASE", 26, 56], ["fracture", "DISEASE", 75, 83], ["motor vehicle accident", "DISEASE", 132, 154], ["female", "ORGANISM", 14, 20], ["femur", "ORGAN", 97, 102], ["systemic lupus erythematosusis", "PROBLEM", 26, 56], ["a fracture of the right femur and right radius", "PROBLEM", 73, 119], ["30-", "OBSERVATION_MODIFIER", 2, 5], ["systemic", "OBSERVATION_MODIFIER", 26, 34], ["lupus erythematosusis", "OBSERVATION", 35, 56], ["fracture", "OBSERVATION", 75, 83], ["right", "ANATOMY_MODIFIER", 91, 96], ["femur", "ANATOMY", 97, 102], ["right", "ANATOMY_MODIFIER", 107, 112], ["radius", "ANATOMY", 113, 119], ["motor vehicle", "OBSERVATION", 132, 145]]], ["She has a temperature spike of 39.0 \u00b0C (102.2 \u00b0F).", [["a temperature spike", "PROBLEM", 8, 27]]], ["Blood cultures are drawn which grow yeast, species to be identifi ed.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["yeast", "SPECIES", 36, 41], ["yeast", "SPECIES", 36, 41], ["Blood cultures", "TEST", 0, 14], ["yeast", "PROBLEM", 36, 41]]], ["She does not appear ill or toxic.", [["toxic", "PROBLEM", 27, 32], ["not appear", "UNCERTAINTY", 9, 19], ["ill", "OBSERVATION", 20, 23], ["toxic", "OBSERVATION_MODIFIER", 27, 32]]], ["No obvious source of infection is found.", [["infection", "DISEASE", 21, 30], ["infection", "PROBLEM", 21, 30], ["obvious source of", "UNCERTAINTY", 3, 20], ["infection", "OBSERVATION", 21, 30]]], ["The patient has an indwelling central catheter.A 30-year-old female with systemic lupus erythematosusIn addition to changing the patient's central line, which of the following do you recommend?", [["systemic lupus erythematosus", "DISEASE", 73, 101], ["patient", "ORGANISM", 4, 11], ["female", "ORGANISM", 61, 67], ["patient", "ORGANISM", 129, 136], ["central line", "CELL", 139, 151], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 129, 136], ["an indwelling central catheter", "TREATMENT", 16, 46], ["systemic lupus erythematosus", "PROBLEM", 73, 101], ["the patient's central line", "TREATMENT", 125, 151], ["indwelling", "OBSERVATION", 19, 29], ["central catheter", "OBSERVATION", 30, 46], ["systemic", "ANATOMY", 73, 81], ["lupus erythematosus", "OBSERVATION", 82, 101], ["central line", "OBSERVATION", 139, 151]]], ["B) Computed tomography of the chest and abdomen.", [["chest", "ANATOMY", 30, 35], ["abdomen", "ANATOMY", 40, 47], ["chest", "ORGAN", 30, 35], ["abdomen", "ORGAN", 40, 47], ["Computed tomography of the chest and abdomen", "TEST", 3, 47], ["chest", "ANATOMY", 30, 35], ["abdomen", "ANATOMY", 40, 47]]], ["C) Start fl uconazole.", [["uconazole", "CHEMICAL", 12, 21], ["uconazole", "CHEMICAL", 12, 21], ["Start fl uconazole", "SIMPLE_CHEMICAL", 3, 21], ["fl uconazole", "TREATMENT", 9, 21]]], ["D) Start liposomal amphotericin B. E) Repeat blood cultures and treat if positive.A 30-year-old female with systemic lupus erythematosusAnswer: C Candida is an increasingly common pathogen found due to line infections.", [["blood cultures", "ANATOMY", 45, 59], ["amphotericin", "CHEMICAL", 19, 31], ["systemic lupus erythematosus", "DISEASE", 108, 136], ["infections", "DISEASE", 207, 217], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["female", "ORGANISM", 96, 102], ["C Candida", "ORGANISM", 144, 153], ["liposomal amphotericin B.", "TREATMENT", 9, 34], ["Repeat blood cultures", "TEST", 38, 59], ["positive", "PROBLEM", 73, 81], ["systemic lupus erythematosus", "PROBLEM", 108, 136], ["C Candida", "PROBLEM", 144, 153], ["an increasingly common pathogen", "PROBLEM", 157, 188], ["line infections", "PROBLEM", 202, 217], ["systemic", "ANATOMY", 108, 116], ["lupus erythematosus", "OBSERVATION", 117, 136], ["infections", "OBSERVATION", 207, 217]]], ["It is currently the fourth leading bloodstream pathogen.", [["bloodstream", "ANATOMY", 35, 46], ["the fourth leading bloodstream pathogen", "PROBLEM", 16, 55], ["bloodstream", "OBSERVATION_MODIFIER", 35, 46], ["pathogen", "OBSERVATION", 47, 55]]], ["In this particular case, despite the patient not appearing ill, treatment directed toward Candida should be initiated.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["treatment", "TREATMENT", 64, 73], ["Candida", "TREATMENT", 90, 97]]], ["The most common antifungal agents used for the treatment of candidemia are fl uconazole and the echinocandins.", [["candidemia", "DISEASE", 60, 70], ["fl uconazole", "CHEMICAL", 75, 87], ["echinocandins", "CHEMICAL", 96, 109], ["uconazole", "CHEMICAL", 78, 87], ["echinocandins", "CHEMICAL", 96, 109], ["fl uconazole", "SIMPLE_CHEMICAL", 75, 87], ["echinocandins", "SIMPLE_CHEMICAL", 96, 109], ["The most common antifungal agents", "TREATMENT", 0, 33], ["candidemia", "PROBLEM", 60, 70], ["fl uconazole", "TREATMENT", 75, 87], ["the echinocandins", "TREATMENT", 92, 109], ["candidemia", "OBSERVATION", 60, 70]]], ["These include caspofungin, micafungin, and anidulafungin.", [["caspofungin", "CHEMICAL", 14, 25], ["micafungin", "CHEMICAL", 27, 37], ["anidulafungin", "CHEMICAL", 43, 56], ["caspofungin", "CHEMICAL", 14, 25], ["micafungin", "CHEMICAL", 27, 37], ["anidulafungin", "CHEMICAL", 43, 56], ["caspofungin", "SIMPLE_CHEMICAL", 14, 25], ["micafungin", "SIMPLE_CHEMICAL", 27, 37], ["anidulafungin", "SIMPLE_CHEMICAL", 43, 56], ["caspofungin", "TREATMENT", 14, 25], ["micafungin", "TREATMENT", 27, 37], ["anidulafungin", "TREATMENT", 43, 56], ["caspofungin", "OBSERVATION", 14, 25]]], ["Amphotericin B is given less often due to the risk of nephrotoxicity.", [["Amphotericin B", "CHEMICAL", 0, 14], ["nephrotoxicity", "DISEASE", 54, 68], ["Amphotericin B", "CHEMICAL", 0, 14], ["Amphotericin B", "SIMPLE_CHEMICAL", 0, 14], ["Amphotericin B", "TREATMENT", 0, 14], ["nephrotoxicity", "PROBLEM", 54, 68], ["nephrotoxicity", "OBSERVATION", 54, 68]]], ["Both the echinocandins and the azoles are better tolerated than amphotericin B formulations.", [["echinocandins", "CHEMICAL", 9, 22], ["azoles", "CHEMICAL", 31, 37], ["amphotericin B", "CHEMICAL", 64, 78], ["echinocandins", "CHEMICAL", 9, 22], ["azoles", "CHEMICAL", 31, 37], ["amphotericin B", "CHEMICAL", 64, 78], ["echinocandins", "SIMPLE_CHEMICAL", 9, 22], ["azoles", "SIMPLE_CHEMICAL", 31, 37], ["amphotericin B", "SIMPLE_CHEMICAL", 64, 78], ["the echinocandins", "TREATMENT", 5, 22], ["the azoles", "TREATMENT", 27, 37], ["amphotericin B formulations", "TREATMENT", 64, 91], ["echinocandins", "OBSERVATION", 9, 22]]], ["Candidemia requires treatment with antifungal agents.", [["Candidemia", "DISEASE", 0, 10], ["Candidemia", "PROBLEM", 0, 10], ["treatment", "TREATMENT", 20, 29], ["antifungal agents", "TREATMENT", 35, 52]]], ["Catheter removal alone is not adequate therapy for candidemia.", [["Catheter", "ANATOMY", 0, 8], ["candidemia", "DISEASE", 51, 61], ["Catheter removal", "TREATMENT", 0, 16], ["candidemia", "PROBLEM", 51, 61], ["candidemia", "OBSERVATION", 51, 61]]], ["Several studies have noted the high mortality rates associated with candidemia.", [["candidemia", "DISEASE", 68, 78], ["Several studies", "TEST", 0, 15], ["the high mortality rates", "PROBLEM", 27, 51], ["candidemia", "PROBLEM", 68, 78], ["candidemia", "OBSERVATION", 68, 78]]], ["Furthermore, prompt initiation of therapy is crucial.", [["therapy", "TREATMENT", 34, 41]]], ["A 41-year-old male presented to the emergency room with shortness of breath and chest pain.", [["chest", "ANATOMY", 80, 85], ["shortness of breath", "DISEASE", 56, 75], ["chest pain", "DISEASE", 80, 90], ["male", "ORGANISM", 14, 18], ["chest", "ORGANISM_SUBDIVISION", 80, 85], ["shortness of breath", "PROBLEM", 56, 75], ["chest pain", "PROBLEM", 80, 90], ["chest", "ANATOMY", 80, 85]]], ["Imaging reveals a pulmonary embolus.", [["pulmonary embolus", "ANATOMY", 18, 35], ["pulmonary embolus", "DISEASE", 18, 35], ["pulmonary embolus", "PATHOLOGICAL_FORMATION", 18, 35], ["Imaging", "TEST", 0, 7], ["a pulmonary embolus", "PROBLEM", 16, 35], ["pulmonary", "ANATOMY", 18, 27], ["embolus", "OBSERVATION", 28, 35]]], ["He is started on enoxaparin 1 mg/kg SQ BID and warfarin 5 mg PO daily.", [["enoxaparin", "CHEMICAL", 17, 27], ["warfarin", "CHEMICAL", 47, 55], ["enoxaparin", "CHEMICAL", 17, 27], ["BID", "CHEMICAL", 39, 42], ["warfarin", "CHEMICAL", 47, 55], ["enoxaparin", "SIMPLE_CHEMICAL", 17, 27], ["BID", "SIMPLE_CHEMICAL", 39, 42], ["warfarin", "SIMPLE_CHEMICAL", 47, 55], ["PO", "SIMPLE_CHEMICAL", 61, 63], ["enoxaparin", "TREATMENT", 17, 27], ["warfarin", "TREATMENT", 47, 55]]], ["Nursing staff reports to perform enoxaparin teaching in preparation for his discharge the following day; however, he reports that he is terrifi ed of needles and feels as if twice daily injections will not be possible (weight = 77 kg, CrCl = 89 ml/min).", [["enoxaparin", "CHEMICAL", 33, 43], ["enoxaparin", "CHEMICAL", 33, 43], ["enoxaparin", "SIMPLE_CHEMICAL", 33, 43], ["enoxaparin teaching", "TREATMENT", 33, 52], ["needles", "TREATMENT", 150, 157], ["weight", "TEST", 219, 225], ["CrCl", "TEST", 235, 239]]], ["Are there any other options to decrease the number of injections for this patient?", [["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["injections", "TREATMENT", 54, 64]]], ["A) Enoxaparin 1 mg/kg SQ daily B) Enoxaparin 0.5 mg/kg SQ daily C) Enoxaparin 1.5 mg/kg SQ daily D) Both A and C Answer: C Enoxaparin 1 mg/kg SQ daily would be used if a patient had a CrCl < 30 ml/min.", [["Enoxaparin", "CHEMICAL", 3, 13], ["Enoxaparin", "CHEMICAL", 34, 44], ["Enoxaparin", "CHEMICAL", 67, 77], ["Enoxaparin", "CHEMICAL", 123, 133], ["Enoxaparin", "CHEMICAL", 3, 13], ["Enoxaparin", "CHEMICAL", 34, 44], ["Enoxaparin", "CHEMICAL", 67, 77], ["Enoxaparin", "SIMPLE_CHEMICAL", 3, 13], ["Enoxaparin", "SIMPLE_CHEMICAL", 34, 44], ["Enoxaparin", "SIMPLE_CHEMICAL", 67, 77], ["C Enoxaparin", "SIMPLE_CHEMICAL", 121, 133], ["SQ", "SIMPLE_CHEMICAL", 142, 144], ["patient", "ORGANISM", 170, 177], ["CrCl", "SIMPLE_CHEMICAL", 184, 188], ["patient", "SPECIES", 170, 177], ["Enoxaparin", "TREATMENT", 3, 13], ["Enoxaparin", "TREATMENT", 34, 44], ["Enoxaparin", "TREATMENT", 67, 77], ["Enoxaparin", "TREATMENT", 123, 133], ["a CrCl", "TEST", 182, 188]]], ["Enoxaparin 0.5 mg/kg SQ is the indicated dose for infants >2 months and children </=18 years of age for thromboembolism prophylaxis and would be dosed BID, not daily.", [["Enoxaparin", "CHEMICAL", 0, 10], ["SQ", "CHEMICAL", 21, 23], ["thromboembolism", "DISEASE", 104, 119], ["Enoxaparin", "CHEMICAL", 0, 10], ["BID", "CHEMICAL", 151, 154], ["Enoxaparin", "SIMPLE_CHEMICAL", 0, 10], ["infants", "ORGANISM", 50, 57], ["children", "ORGANISM", 72, 80], ["BID", "SIMPLE_CHEMICAL", 151, 154], ["infants", "SPECIES", 50, 57], ["children", "SPECIES", 72, 80], ["Enoxaparin", "TREATMENT", 0, 10], ["thromboembolism prophylaxis", "TREATMENT", 104, 131]]], ["Enoxaparin 1.5 mg/kg SQ daily is an appropriate outpatient dosing regimen for patients with a CrCl > 30 ml/min for treatment.Reference3.", [["Enoxaparin", "CHEMICAL", 0, 10], ["SQ", "CHEMICAL", 21, 23], ["Enoxaparin", "CHEMICAL", 0, 10], ["Enoxaparin", "SIMPLE_CHEMICAL", 0, 10], ["SQ", "SIMPLE_CHEMICAL", 21, 23], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["Enoxaparin", "TREATMENT", 0, 10], ["an appropriate outpatient dosing regimen", "TREATMENT", 33, 73], ["a CrCl", "TREATMENT", 92, 98], ["treatment", "TREATMENT", 115, 124]]], ["A 39-year-old female presents to the emergency room with progressive worsening of imbalance and vertigo accompanied by recent falls.", [["vertigo", "DISEASE", 96, 103], ["female", "ORGANISM", 14, 20], ["progressive worsening of imbalance", "PROBLEM", 57, 91], ["vertigo", "PROBLEM", 96, 103], ["recent falls", "PROBLEM", 119, 131], ["progressive", "OBSERVATION_MODIFIER", 57, 68], ["worsening", "OBSERVATION_MODIFIER", 69, 78], ["imbalance", "OBSERVATION", 82, 91], ["vertigo", "OBSERVATION", 96, 103], ["falls", "OBSERVATION", 126, 131]]], ["She has a 5-year history of multiple sclerosis.", [["multiple sclerosis", "DISEASE", 28, 46], ["multiple sclerosis", "PROBLEM", 28, 46], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["sclerosis", "OBSERVATION", 37, 46]]], ["Her last admit for a multiple sclerosis fl air was 6 months ago.", [["a multiple sclerosis fl air", "PROBLEM", 19, 46], ["multiple", "OBSERVATION_MODIFIER", 21, 29], ["sclerosis", "OBSERVATION", 30, 39], ["fl air", "OBSERVATION", 40, 46]]], ["Medications are currently interferon beta-1a and gabapentin for neuropathic pain.", [["interferon beta-1a", "CHEMICAL", 26, 44], ["gabapentin", "CHEMICAL", 49, 59], ["neuropathic pain", "DISEASE", 64, 80], ["gabapentin", "CHEMICAL", 49, 59], ["interferon beta-1a", "GENE_OR_GENE_PRODUCT", 26, 44], ["gabapentin", "SIMPLE_CHEMICAL", 49, 59], ["interferon beta", "PROTEIN", 26, 41], ["Medications", "TREATMENT", 0, 11], ["interferon beta", "TREATMENT", 26, 41], ["gabapentin", "TREATMENT", 49, 59], ["neuropathic pain", "PROBLEM", 64, 80], ["neuropathic", "OBSERVATION_MODIFIER", 64, 75], ["pain", "OBSERVATION", 76, 80]]], ["On physical examination, she is afebrile.", [["physical examination", "TEST", 3, 23], ["afebrile", "PROBLEM", 32, 40], ["afebrile", "OBSERVATION", 32, 40]]], ["Blood pressure is 120/66 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Heart rate is 60 bpm.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["Heart rate", "TEST", 0, 10], ["60 bpm", "OBSERVATION", 14, 20]]], ["Internuclear ophthalmoplegia is noted on the left.", [["Internuclear ophthalmoplegia", "DISEASE", 0, 28], ["Internuclear ophthalmoplegia", "PROBLEM", 0, 28], ["ophthalmoplegia", "OBSERVATION", 13, 28], ["left", "ANATOMY_MODIFIER", 45, 49]]], ["Gait testing shows imbalance when she walks, which is markedly worse from baseline.", [["Gait testing", "TEST", 0, 12], ["imbalance", "PROBLEM", 19, 28], ["imbalance", "OBSERVATION", 19, 28], ["markedly", "OBSERVATION_MODIFIER", 54, 62], ["worse", "OBSERVATION_MODIFIER", 63, 68]]], ["An MRI is scheduled for the morning.ReferenceWhich of the following is the most appropriate fi rstline treatment?", [["An MRI", "TEST", 0, 6], ["appropriate fi rstline treatment", "TREATMENT", 80, 112]]], ["A) Oral prednisone 60 mg daily B) Intravenous methylprednisolone 1 g daily administration C) Methylprednisolone 125 mg Q 6 h D) Increase gabapentin dosage E) Plasmapheresis F) B and E Answer: F Intravenous methylprednisolone with a suggested dose of 1 g/day for 3-5 days has been the traditional treatment for acute exacerbations of multiple sclerosis.", [["Oral", "ANATOMY", 3, 7], ["prednisone", "CHEMICAL", 8, 18], ["methylprednisolone", "CHEMICAL", 46, 64], ["Methylprednisolone", "CHEMICAL", 93, 111], ["gabapentin", "CHEMICAL", 137, 147], ["methylprednisolone", "CHEMICAL", 206, 224], ["multiple sclerosis", "DISEASE", 333, 351], ["prednisone", "CHEMICAL", 8, 18], ["methylprednisolone", "CHEMICAL", 46, 64], ["Methylprednisolone", "CHEMICAL", 93, 111], ["gabapentin", "CHEMICAL", 137, 147], ["methylprednisolone", "CHEMICAL", 206, 224], ["prednisone", "SIMPLE_CHEMICAL", 8, 18], ["Methylprednisolone", "SIMPLE_CHEMICAL", 93, 111], ["gabapentin", "SIMPLE_CHEMICAL", 137, 147], ["methylprednisolone", "SIMPLE_CHEMICAL", 206, 224], ["A) Oral prednisone", "TREATMENT", 0, 18], ["Intravenous methylprednisolone", "TREATMENT", 34, 64], ["Methylprednisolone", "TREATMENT", 93, 111], ["Increase gabapentin dosage E", "TREATMENT", 128, 156], ["Intravenous methylprednisolone", "TREATMENT", 194, 224], ["the traditional treatment", "TREATMENT", 280, 305], ["acute exacerbations", "PROBLEM", 310, 329], ["multiple sclerosis", "PROBLEM", 333, 351], ["acute", "OBSERVATION_MODIFIER", 310, 315], ["exacerbations", "OBSERVATION", 316, 329], ["multiple", "OBSERVATION_MODIFIER", 333, 341], ["sclerosis", "OBSERVATION", 342, 351]]], ["This patient is experiencing an acute exacerbation or relapse of her underlying multiple sclerosis.", [["multiple sclerosis", "DISEASE", 80, 98], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["an acute exacerbation", "PROBLEM", 29, 50], ["her underlying multiple sclerosis", "PROBLEM", 65, 98], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["exacerbation", "OBSERVATION", 38, 50], ["multiple", "OBSERVATION_MODIFIER", 80, 88], ["sclerosis", "OBSERVATION", 89, 98]]], ["The data supports the use of high-dose intravenous corticosteroids.", [["intravenous", "ANATOMY", 39, 50], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["high-dose intravenous corticosteroids", "TREATMENT", 29, 66]]], ["This treatment regimen has been demonstrated to speed the recovery from a multiple sclerosis attacks; however, it is uncertain whether this impacts long-term disability.", [["multiple sclerosis attacks", "DISEASE", 74, 100], ["This treatment regimen", "TREATMENT", 0, 22], ["a multiple sclerosis attacks", "PROBLEM", 72, 100], ["multiple", "OBSERVATION_MODIFIER", 74, 82], ["sclerosis", "OBSERVATION", 83, 92]]], ["The 2011 American Academy of Neurology (AAN) Plasmapheresis Guideline Update states that plasmapheresis is effective and may be considered in fulminant demyelinating CNS disease as a fi rst-line agent.", [["CNS", "ANATOMY", 166, 169], ["fulminant demyelinating CNS disease", "DISEASE", 142, 177], ["CNS", "ANATOMICAL_SYSTEM", 166, 169], ["plasmapheresis", "TREATMENT", 89, 103], ["fulminant demyelinating CNS disease", "PROBLEM", 142, 177], ["a fi rst-line agent", "TREATMENT", 181, 200], ["fulminant", "OBSERVATION_MODIFIER", 142, 151], ["demyelinating", "OBSERVATION", 152, 165]]], ["Plasmapheresis can also be considered in cases resistant to corticosteroid therapy, and clinical improvement should be followed closely.", [["Plasmapheresis", "TREATMENT", 0, 14], ["corticosteroid therapy", "TREATMENT", 60, 82]]], ["Previous clinical trials have demonstrated that oral prednisone is inferior to high-dose intravenous corticosteroids.", [["oral", "ANATOMY", 48, 52], ["intravenous", "ANATOMY", 89, 100], ["prednisone", "CHEMICAL", 53, 63], ["prednisone", "CHEMICAL", 53, 63], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["prednisone", "SIMPLE_CHEMICAL", 53, 63], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 89, 100], ["oral prednisone", "TREATMENT", 48, 63], ["high-dose intravenous corticosteroids", "TREATMENT", 79, 116]]], ["A change in this patient's chronic disease-modifying therapy may be considered in consultation with a multiple sclerosis specialist, but would be of no benefi t in the acute multiple sclerosis fl air.ReferenceRodriguez M, Karnes WE, Bartleson JD, Pineda AA.", [["multiple sclerosis", "DISEASE", 102, 120], ["acute multiple sclerosis", "DISEASE", 168, 192], ["AA", "CHEMICAL", 254, 256], ["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["A change", "PROBLEM", 0, 8], ["this patient's chronic disease", "PROBLEM", 12, 42], ["modifying therapy", "TREATMENT", 43, 60], ["the acute multiple sclerosis fl air", "PROBLEM", 164, 199], ["change", "OBSERVATION_MODIFIER", 2, 8], ["chronic", "OBSERVATION_MODIFIER", 27, 34], ["disease", "OBSERVATION", 35, 42], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["multiple", "OBSERVATION_MODIFIER", 174, 182], ["sclerosis", "OBSERVATION", 183, 192], ["fl air", "OBSERVATION", 193, 199]]], ["Plasmapheresis in acute episodes of fulminant CNS infl ammatory demyelination.", [["CNS", "ANATOMY", 46, 49], ["demyelination", "DISEASE", 64, 77], ["Plasmapheresis", "TREATMENT", 0, 14], ["fulminant CNS infl ammatory demyelination", "PROBLEM", 36, 77], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["fulminant", "OBSERVATION_MODIFIER", 36, 45], ["CNS", "ANATOMY", 46, 49], ["infl ammatory demyelination", "OBSERVATION", 50, 77]]], ["1993; 43(6) :1100-4.4.A 65-year-old woman presents complaining of severe dizziness.", [["dizziness", "DISEASE", 73, 82], ["woman", "ORGANISM", 36, 41], ["woman", "SPECIES", 36, 41], ["severe dizziness", "PROBLEM", 66, 82], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["dizziness", "OBSERVATION", 73, 82]]], ["Some mild nausea with eating is reported as well.", [["nausea", "DISEASE", 10, 16], ["Some mild nausea", "PROBLEM", 0, 16], ["mild", "OBSERVATION_MODIFIER", 5, 9], ["nausea", "OBSERVATION", 10, 16]]], ["She has had an episode of this before which resolved without medical care.", [["medical care", "TREATMENT", 61, 73]]], ["She is currently unable to take care of herself at home and is admitted for further workup and intravenous fl uids.", [["intravenous", "ANATOMY", 95, 106], ["intravenous fl uids", "SIMPLE_CHEMICAL", 95, 114], ["further workup", "TEST", 76, 90], ["intravenous fl uids", "TREATMENT", 95, 114]]], ["On physical exam, you ask the patient to sit on the bedside with her head turned approximately 45\u00b0 to the right.", [["head", "ANATOMY", 69, 73], ["patient", "ORGANISM", 30, 37], ["head", "ORGANISM_SUBDIVISION", 69, 73], ["patient", "SPECIES", 30, 37], ["physical exam", "TEST", 3, 16], ["right", "ANATOMY_MODIFIER", 106, 111]]], ["You slowly lower the patient to the supine position and extend her head backward 20\u00b0.", [["head", "ANATOMY", 67, 71], ["patient", "ORGANISM", 21, 28], ["head", "ORGANISM_SUBDIVISION", 67, 71], ["patient", "SPECIES", 21, 28], ["head", "ANATOMY", 67, 71]]], ["This maneuver immediately reproduces the patient's dizziness, and you note increased nystagmus.4.What is the appropriate management in the evaluation and treatment of this patient?", [["dizziness", "DISEASE", 51, 60], ["nystagmus", "DISEASE", 85, 94], ["patient", "ORGANISM", 41, 48], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 41, 48], ["patient", "SPECIES", 172, 179], ["This maneuver", "TREATMENT", 0, 13], ["the patient's dizziness", "PROBLEM", 37, 60], ["increased nystagmus", "PROBLEM", 75, 94], ["the evaluation", "TEST", 135, 149], ["treatment", "TREATMENT", 154, 163], ["increased", "OBSERVATION_MODIFIER", 75, 84], ["nystagmus", "OBSERVATION", 85, 94]]], ["A) MRI of her cerebellum B) Methylprednisolone taper beginning at 60 mg daily C) Repositioning (Epley) maneuvers D) Rizatriptan 10 mg orally once E) Valacyclovir 1000 mg three times daily for 10 days Answer: C The symptoms and physical examination of this patient are typical of benign paroxysmal positional vertigo (BPPV).", [["cerebellum", "ANATOMY", 14, 24], ["Methylprednisolone", "CHEMICAL", 28, 46], ["Rizatriptan", "CHEMICAL", 116, 127], ["Valacyclovir", "CHEMICAL", 149, 161], ["paroxysmal positional vertigo", "DISEASE", 286, 315], ["BPPV", "DISEASE", 317, 321], ["Methylprednisolone", "CHEMICAL", 28, 46], ["Valacyclovir", "CHEMICAL", 149, 161], ["Methylprednisolone", "SIMPLE_CHEMICAL", 28, 46], ["Valacyclovir", "SIMPLE_CHEMICAL", 149, 161], ["patient", "ORGANISM", 256, 263], ["patient", "SPECIES", 256, 263], ["MRI", "TEST", 3, 6], ["her cerebellum B) Methylprednisolone taper", "TREATMENT", 10, 52], ["Repositioning (Epley) maneuvers D", "TREATMENT", 81, 114], ["Rizatriptan", "TREATMENT", 116, 127], ["Valacyclovir", "TREATMENT", 149, 161], ["The symptoms", "PROBLEM", 210, 222], ["physical examination", "TEST", 227, 247], ["benign paroxysmal positional vertigo (BPPV)", "PROBLEM", 279, 322], ["benign", "OBSERVATION_MODIFIER", 279, 285], ["positional vertigo", "OBSERVATION", 297, 315]]], ["Referral to ENT or physical therapy for repositioning maneuvers is the best treatment.", [["physical therapy", "TREATMENT", 19, 35], ["repositioning maneuvers", "TREATMENT", 40, 63]]], ["BPPV is a common cause of vertigo.", [["BPPV", "DISEASE", 0, 4], ["vertigo", "DISEASE", 26, 33], ["BPPV", "PROBLEM", 0, 4], ["vertigo", "PROBLEM", 26, 33], ["vertigo", "OBSERVATION", 26, 33]]], ["Episodes of BPPV are typically brief, lasting no more than 1 min.", [["BPPV", "DISEASE", 12, 16], ["BPPV", "PROBLEM", 12, 16], ["BPPV", "OBSERVATION", 12, 16]]], ["Typical reported movements that elicit vertigo are lying down, rolling over in bed, rising from bed, sitting up and tilting the head to look upward.", [["head", "ANATOMY", 128, 132], ["vertigo", "DISEASE", 39, 46], ["head", "ORGANISM_SUBDIVISION", 128, 132], ["vertigo", "PROBLEM", 39, 46], ["movements", "OBSERVATION", 17, 26], ["head", "ANATOMY", 128, 132]]], ["Vertigo is often accompanied by nystagmus that beats upward and torsionally toward the affected ear.", [["ear", "ANATOMY", 96, 99], ["Vertigo", "DISEASE", 0, 7], ["nystagmus", "DISEASE", 32, 41], ["ear", "ORGAN", 96, 99], ["Vertigo", "PROBLEM", 0, 7], ["nystagmus", "PROBLEM", 32, 41], ["nystagmus", "OBSERVATION", 32, 41], ["ear", "ANATOMY", 96, 99]]], ["This can be elicited by the Dix-Hallpike maneuver which was performed on physical exam.", [["physical exam", "TEST", 73, 86]]], ["The history and physical examination are not consistent with a central cause of vertigo.", [["vertigo", "DISEASE", 80, 87], ["physical examination", "TEST", 16, 36], ["vertigo", "PROBLEM", 80, 87], ["not consistent with", "UNCERTAINTY", 41, 60], ["vertigo", "OBSERVATION", 80, 87]]], ["An MRI can probably be avoided.", [["An MRI", "TEST", 0, 6]]], ["Methylprednisolone is the primary treatment of acute vestibular neuritis.", [["vestibular", "ANATOMY", 53, 63], ["Methylprednisolone", "CHEMICAL", 0, 18], ["acute vestibular neuritis", "DISEASE", 47, 72], ["Methylprednisolone", "CHEMICAL", 0, 18], ["Methylprednisolone", "SIMPLE_CHEMICAL", 0, 18], ["Methylprednisolone", "TREATMENT", 0, 18], ["acute vestibular neuritis", "PROBLEM", 47, 72], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["vestibular neuritis", "OBSERVATION", 53, 72]]], ["It is of benefi t if used within the fi rst 3 days of symptoms.", [["symptoms", "PROBLEM", 54, 62]]], ["Vestibular neuritis often presents with more prolonged and persistent symptoms.", [["Vestibular neuritis", "DISEASE", 0, 19], ["Vestibular neuritis", "PROBLEM", 0, 19], ["persistent symptoms", "PROBLEM", 59, 78], ["neuritis", "OBSERVATION", 11, 19], ["persistent", "OBSERVATION_MODIFIER", 59, 69], ["symptoms", "OBSERVATION", 70, 78]]], ["Most patients recover spontaneously, but when used early, methylprednisolone will decrease the duration of symptoms.", [["methylprednisolone", "CHEMICAL", 58, 76], ["methylprednisolone", "CHEMICAL", 58, 76], ["patients", "ORGANISM", 5, 13], ["methylprednisolone", "SIMPLE_CHEMICAL", 58, 76], ["patients", "SPECIES", 5, 13], ["methylprednisolone", "TREATMENT", 58, 76], ["symptoms", "PROBLEM", 107, 115]]], ["Antiviral therapy is not indicated unless there is an obvious herpes zoster infection.", [["herpes zoster infection", "DISEASE", 62, 85], ["herpes zoster", "ORGANISM", 62, 75], ["herpes zoster", "SPECIES", 62, 75], ["Antiviral therapy", "TREATMENT", 0, 17], ["an obvious herpes zoster infection", "PROBLEM", 51, 85], ["obvious", "OBSERVATION_MODIFIER", 54, 61], ["herpes", "OBSERVATION_MODIFIER", 62, 68], ["zoster", "OBSERVATION_MODIFIER", 69, 75], ["infection", "OBSERVATION", 76, 85]]], ["Likewise, the symptoms are not consistent with migrainous vertigo, which would be persistent for hours and not be affected by positional changes.ReferenceEpley JM.", [["migrainous vertigo", "DISEASE", 47, 65], ["the symptoms", "PROBLEM", 10, 22], ["migrainous vertigo", "PROBLEM", 47, 65], ["not consistent with", "UNCERTAINTY", 27, 46], ["migrainous", "OBSERVATION_MODIFIER", 47, 57], ["vertigo", "OBSERVATION", 58, 65], ["persistent", "OBSERVATION_MODIFIER", 82, 92]]], ["The canalith repositioning procedure: for treatment of benign paroxysmal positional vertigo.", [["paroxysmal positional vertigo", "DISEASE", 62, 91], ["The canalith repositioning procedure", "TREATMENT", 0, 36], ["treatment", "TREATMENT", 42, 51], ["benign paroxysmal positional vertigo", "PROBLEM", 55, 91], ["benign", "OBSERVATION_MODIFIER", 55, 61], ["paroxysmal", "OBSERVATION_MODIFIER", 62, 72], ["positional vertigo", "OBSERVATION", 73, 91]]], ["Otolaryngol Head Neck Surg. 1992;107(3):399-404.5.A 26-year-old woman presents to the emergency department with shortness of breath as her primary complaint, which has been progressively increasing for several days since starting her menstrual period.", [["shortness of breath", "DISEASE", 112, 131], ["woman", "ORGANISM", 64, 69], ["woman", "SPECIES", 64, 69], ["Otolaryngol Head Neck Surg.", "TEST", 0, 27], ["shortness of breath", "PROBLEM", 112, 131], ["Neck", "ANATOMY", 17, 21], ["26-", "OBSERVATION_MODIFIER", 52, 55], ["progressively", "OBSERVATION_MODIFIER", 173, 186], ["increasing", "OBSERVATION_MODIFIER", 187, 197]]], ["She has also been experiencing increasing weakness during the past week as well.", [["increasing weakness", "PROBLEM", 31, 50], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["weakness", "OBSERVATION", 42, 50]]], ["She notes a worsening of her symptoms at the end of the day, and she has noticed weakness while brushing her hair.", [["hair", "ANATOMY", 109, 113], ["weakness", "DISEASE", 81, 89], ["hair", "ORGAN", 109, 113], ["her symptoms", "PROBLEM", 25, 37], ["weakness", "PROBLEM", 81, 89], ["worsening", "OBSERVATION_MODIFIER", 12, 21], ["weakness", "OBSERVATION", 81, 89]]], ["Occasionally she reports blurry vision or difficulty with reading.", [["blurry vision", "DISEASE", 25, 38], ["blurry vision", "PROBLEM", 25, 38], ["difficulty with reading", "PROBLEM", 42, 65]]], ["On physical exam, no specifi c weakness is noted.", [["physical exam", "TEST", 3, 16], ["specifi c weakness", "PROBLEM", 21, 39], ["no", "UNCERTAINTY", 18, 20], ["weakness", "OBSERVATION", 31, 39]]], ["She seems fatigued in general and has a depressed affect.", [["depressed", "DISEASE", 40, 49], ["fatigued", "PROBLEM", 10, 18], ["a depressed affect", "PROBLEM", 38, 56], ["fatigued", "OBSERVATION", 10, 18], ["depressed", "OBSERVATION", 40, 49]]], ["Pulmonary exam is normal.", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary exam", "TEST", 0, 14], ["normal", "OBSERVATION", 18, 24]]], ["All labs are within normal range.", [["All labs", "TEST", 0, 8], ["normal range", "OBSERVATION", 20, 32]]], ["Which of the following neuromuscular disorders is most likely the cause of this patient's symptoms?", [["neuromuscular", "ANATOMY", 23, 36], ["neuromuscular disorders", "DISEASE", 23, 46], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["neuromuscular disorders", "PROBLEM", 23, 46], ["this patient's symptoms", "PROBLEM", 75, 98], ["most likely the cause", "UNCERTAINTY", 50, 71]]], ["A) Guillain-Barr\u00e9 syndrome B) Bilateral diaphragmatic paralysis C) Myasthenia gravis D) Duchenne muscular dystrophy E) Amyotrophic lateral sclerosis (ALS) Answer: C Multiple neuromuscular disorders may affect respiratory function.", [["diaphragmatic", "ANATOMY", 40, 53], ["neuromuscular", "ANATOMY", 174, 187], ["respiratory", "ANATOMY", 209, 220], ["Guillain-Barr\u00e9 syndrome B", "DISEASE", 3, 28], ["diaphragmatic paralysis", "DISEASE", 40, 63], ["Myasthenia gravis", "DISEASE", 67, 84], ["Duchenne muscular dystrophy", "DISEASE", 88, 115], ["Amyotrophic lateral sclerosis", "DISEASE", 119, 148], ["ALS", "DISEASE", 150, 153], ["neuromuscular disorders", "DISEASE", 174, 197], ["Guillain-Barr\u00e9", "ORGANISM", 3, 17], ["diaphragmatic", "ORGAN", 40, 53], ["A) Guillain-Barr\u00e9 syndrome", "PROBLEM", 0, 26], ["Bilateral diaphragmatic paralysis C", "PROBLEM", 30, 65], ["Myasthenia gravis D)", "PROBLEM", 67, 87], ["Duchenne muscular dystrophy E", "PROBLEM", 88, 117], ["Amyotrophic lateral sclerosis (ALS)", "PROBLEM", 119, 154], ["Multiple neuromuscular disorders", "PROBLEM", 165, 197], ["respiratory function", "PROBLEM", 209, 229], ["Bilateral", "ANATOMY_MODIFIER", 30, 39], ["diaphragmatic", "ANATOMY", 40, 53], ["paralysis", "OBSERVATION", 54, 63], ["muscular dystrophy", "OBSERVATION", 97, 115], ["Amyotrophic", "OBSERVATION_MODIFIER", 119, 130], ["lateral", "OBSERVATION_MODIFIER", 131, 138], ["sclerosis", "OBSERVATION", 139, 148], ["neuromuscular", "ANATOMY", 174, 187]]], ["Guillain-Barr\u00e9 syndrome usually presents as an ascending paralysis with respiratory symptoms occurring later and rarely as a presenting symptom.", [["respiratory", "ANATOMY", 72, 83], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 0, 23], ["paralysis", "DISEASE", 57, 66], ["respiratory symptoms", "DISEASE", 72, 92], ["Guillain-Barr\u00e9", "ORGANISM", 0, 14], ["Barr\u00e9 syndrome", "PROBLEM", 9, 23], ["an ascending paralysis", "PROBLEM", 44, 66], ["respiratory symptoms", "PROBLEM", 72, 92], ["a presenting symptom", "PROBLEM", 123, 143], ["Barr\u00e9 syndrome", "OBSERVATION", 9, 23], ["ascending", "ANATOMY_MODIFIER", 47, 56], ["paralysis", "OBSERVATION", 57, 66]]], ["Although bilateral diaphragmatic paralysis would explain this patient's shortness of breath, the proximal muscle weakness and ocular symptoms would remain unexplained.", [["diaphragmatic", "ANATOMY", 19, 32], ["muscle", "ANATOMY", 106, 112], ["ocular", "ANATOMY", 126, 132], ["diaphragmatic paralysis", "DISEASE", 19, 42], ["shortness of breath", "DISEASE", 72, 91], ["muscle weakness", "DISEASE", 106, 121], ["ocular symptoms", "DISEASE", 126, 141], ["diaphragmatic", "ORGAN", 19, 32], ["patient", "ORGANISM", 62, 69], ["muscle", "ORGAN", 106, 112], ["ocular", "ORGAN", 126, 132], ["patient", "SPECIES", 62, 69], ["bilateral diaphragmatic paralysis", "PROBLEM", 9, 42], ["this patient's shortness of breath", "PROBLEM", 57, 91], ["the proximal muscle weakness", "PROBLEM", 93, 121], ["ocular symptoms", "PROBLEM", 126, 141], ["unexplained", "PROBLEM", 155, 166], ["bilateral", "ANATOMY_MODIFIER", 9, 18], ["diaphragmatic", "ANATOMY", 19, 32], ["paralysis", "OBSERVATION", 33, 42], ["proximal", "ANATOMY_MODIFIER", 97, 105], ["muscle", "ANATOMY", 106, 112], ["weakness", "OBSERVATION", 113, 121], ["ocular", "ANATOMY", 126, 132]]], ["Duchenne muscular dystrophy is an X-linked disorder that exclusively affects males that presents by 12 years of age.", [["Duchenne muscular dystrophy", "ANATOMY", 0, 27], ["Duchenne muscular dystrophy", "DISEASE", 0, 27], ["Duchenne muscular dystrophy", "PROBLEM", 0, 27], ["an X-linked disorder", "PROBLEM", 31, 51], ["muscular", "ANATOMY", 9, 17], ["dystrophy", "OBSERVATION", 18, 27], ["X-linked", "OBSERVATION_MODIFIER", 34, 42]]], ["The majority of patients with ALS present clinically with progressive asymmetrical weakness, fasciculations, and prominent muscle atrophy.", [["muscle", "ANATOMY", 123, 129], ["ALS", "DISEASE", 30, 33], ["weakness", "DISEASE", 83, 91], ["fasciculations", "DISEASE", 93, 107], ["muscle atrophy", "DISEASE", 123, 137], ["patients", "ORGANISM", 16, 24], ["muscle", "ORGAN", 123, 129], ["patients", "SPECIES", 16, 24], ["progressive asymmetrical weakness", "PROBLEM", 58, 91], ["fasciculations", "PROBLEM", 93, 107], ["prominent muscle atrophy", "PROBLEM", 113, 137], ["progressive", "OBSERVATION_MODIFIER", 58, 69], ["asymmetrical", "OBSERVATION_MODIFIER", 70, 82], ["weakness", "OBSERVATION", 83, 91], ["fasciculations", "OBSERVATION", 93, 107], ["prominent", "OBSERVATION_MODIFIER", 113, 122], ["muscle", "ANATOMY", 123, 129], ["atrophy", "OBSERVATION", 130, 137]]], ["The distal musculature is primarily involved.", [["distal musculature", "ANATOMY", 4, 22], ["distal musculature", "MULTI-TISSUE_STRUCTURE", 4, 22], ["distal", "ANATOMY_MODIFIER", 4, 10], ["musculature", "ANATOMY", 11, 22]]], ["Myasthenia gravis is an autoimmune disorder that interferes with the postsynaptic acetylcholine receptor.", [["postsynaptic", "ANATOMY", 69, 81], ["Myasthenia gravis", "DISEASE", 0, 17], ["autoimmune disorder", "DISEASE", 24, 43], ["acetylcholine", "CHEMICAL", 82, 95], ["acetylcholine", "CHEMICAL", 82, 95], ["acetylcholine receptor", "GENE_OR_GENE_PRODUCT", 82, 104], ["postsynaptic acetylcholine receptor", "PROTEIN", 69, 104], ["Myasthenia gravis", "PROBLEM", 0, 17], ["an autoimmune disorder", "PROBLEM", 21, 43], ["the postsynaptic acetylcholine receptor", "TREATMENT", 65, 104], ["autoimmune disorder", "OBSERVATION", 24, 43]]], ["Patients usually present with intermittent symptoms that are usually worse at the end of the day.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["intermittent symptoms", "PROBLEM", 30, 51]]], ["Respiratory symptoms may be the presenting symptom.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory symptoms", "DISEASE", 0, 20], ["Respiratory symptoms", "PROBLEM", 0, 20], ["the presenting symptom", "PROBLEM", 28, 50]]], ["The most common severe symptom of myasthenia gravis is respiratory failure.", [["respiratory", "ANATOMY", 55, 66], ["myasthenia gravis", "DISEASE", 34, 51], ["respiratory failure", "DISEASE", 55, 74], ["myasthenia gravis", "PROBLEM", 34, 51], ["respiratory failure", "PROBLEM", 55, 74], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["severe", "OBSERVATION_MODIFIER", 16, 22], ["myasthenia gravis", "OBSERVATION", 34, 51], ["respiratory failure", "OBSERVATION", 55, 74]]], ["Exposure to bright sunlight, surgery, immunization, emotional stress, menstruation, infection and physical factors might trigger or worsen exacerbations.ReferenceKeesey JC.", [["infection", "DISEASE", 84, 93], ["surgery", "TREATMENT", 29, 36], ["immunization", "TREATMENT", 38, 50], ["emotional stress", "PROBLEM", 52, 68], ["menstruation", "PROBLEM", 70, 82], ["infection", "PROBLEM", 84, 93], ["physical factors", "PROBLEM", 98, 114], ["worsen exacerbations", "PROBLEM", 132, 152]]], ["Clinical evaluation and management of myasthenia gravis.", [["myasthenia gravis", "DISEASE", 38, 55], ["Clinical evaluation", "TEST", 0, 19], ["management", "TREATMENT", 24, 34], ["myasthenia gravis", "PROBLEM", 38, 55], ["myasthenia gravis", "OBSERVATION", 38, 55]]], ["Muscle Nerve.", [["Muscle", "ANATOMY", 0, 6], ["Muscle Nerve", "TISSUE", 0, 12], ["Nerve", "ANATOMY", 7, 12]]], ["A 57-year-old white man is admitted with exertional shortness of breath.", [["exertional shortness of breath", "DISEASE", 41, 71], ["man", "ORGANISM", 20, 23], ["man", "SPECIES", 20, 23], ["exertional shortness of breath", "PROBLEM", 41, 71]]], ["His symptom began several months ago and has gotten progressively worse over time.", [["His symptom", "PROBLEM", 0, 11], ["progressively", "OBSERVATION_MODIFIER", 52, 65], ["worse", "OBSERVATION_MODIFIER", 66, 71]]], ["He reports occasional upper respiratory complaints, some fatigue, and a nonpainful, nonpruritic rash on his lower extremities.", [["respiratory", "ANATOMY", 28, 39], ["lower extremities", "ANATOMY", 108, 125], ["upper respiratory complaints", "DISEASE", 22, 50], ["fatigue", "DISEASE", 57, 64], ["rash", "DISEASE", 96, 100], ["upper respiratory", "ORGANISM_SUBDIVISION", 22, 39], ["lower extremities", "ORGANISM_SUBDIVISION", 108, 125], ["occasional upper respiratory complaints", "PROBLEM", 11, 50], ["some fatigue", "PROBLEM", 52, 64], ["a nonpainful, nonpruritic rash on his lower extremities", "PROBLEM", 70, 125], ["occasional", "OBSERVATION_MODIFIER", 11, 21], ["upper", "ANATOMY_MODIFIER", 22, 27], ["respiratory", "ANATOMY", 28, 39], ["complaints", "OBSERVATION", 40, 50], ["fatigue", "OBSERVATION", 57, 64], ["nonpainful", "OBSERVATION_MODIFIER", 72, 82], ["nonpruritic", "OBSERVATION_MODIFIER", 84, 95], ["rash", "OBSERVATION", 96, 100], ["lower extremities", "ANATOMY", 108, 125]]], ["His medical history is signifi cant only for diabetes.", [["diabetes", "DISEASE", 45, 53], ["diabetes", "PROBLEM", 45, 53], ["diabetes", "OBSERVATION", 45, 53]]], ["On physical exam, you note a mildly erythematous, papular rash with a few nodules on his lower extremities.ReferenceHis pulmonary examination is notable for bilateral crackles.", [["papular", "ANATOMY", 50, 57], ["nodules", "ANATOMY", 74, 81], ["lower extremities", "ANATOMY", 89, 106], ["pulmonary", "ANATOMY", 120, 129], ["rash", "DISEASE", 58, 62], ["nodules", "CANCER", 74, 81], ["lower extremities", "ORGANISM_SUBDIVISION", 89, 106], ["pulmonary", "ORGAN", 120, 129], ["physical exam", "TEST", 3, 16], ["a mildly erythematous, papular rash", "PROBLEM", 27, 62], ["a few nodules on his lower extremities", "PROBLEM", 68, 106], ["ReferenceHis pulmonary examination", "TEST", 107, 141], ["bilateral crackles", "PROBLEM", 157, 175], ["mildly", "OBSERVATION_MODIFIER", 29, 35], ["erythematous", "OBSERVATION_MODIFIER", 36, 48], ["papular", "OBSERVATION_MODIFIER", 50, 57], ["rash", "OBSERVATION", 58, 62], ["few", "OBSERVATION_MODIFIER", 70, 73], ["nodules", "OBSERVATION", 74, 81], ["lower extremities", "ANATOMY", 89, 106], ["pulmonary", "ANATOMY", 120, 129], ["bilateral", "ANATOMY_MODIFIER", 157, 166], ["crackles", "OBSERVATION", 167, 175]]], ["Initial workup is unrevealing.", [["Initial workup", "TEST", 0, 14]]], ["A chest radiograph reveals interstitial abnormalities bilaterally.", [["chest", "ANATOMY", 2, 7], ["interstitial", "ANATOMY", 27, 39], ["interstitial abnormalities", "DISEASE", 27, 53], ["interstitial", "PATHOLOGICAL_FORMATION", 27, 39], ["A chest radiograph", "TEST", 0, 18], ["interstitial abnormalities bilaterally", "PROBLEM", 27, 65], ["chest", "ANATOMY", 2, 7], ["interstitial", "ANATOMY_MODIFIER", 27, 39], ["abnormalities", "OBSERVATION", 40, 53], ["bilaterally", "ANATOMY_MODIFIER", 54, 65]]], ["Urine dipstick testing reveals proteinuria and hematuria.", [["Urine", "ANATOMY", 0, 5], ["proteinuria", "DISEASE", 31, 42], ["hematuria", "DISEASE", 47, 56], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine dipstick testing", "TEST", 0, 22], ["proteinuria", "PROBLEM", 31, 42], ["hematuria", "PROBLEM", 47, 56], ["proteinuria", "OBSERVATION", 31, 42], ["hematuria", "OBSERVATION", 47, 56]]], ["A blood test for cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA) is pending.", [["blood", "ANATOMY", 2, 7], ["cytoplasmic", "ANATOMY", 17, 28], ["blood", "ORGANISM_SUBSTANCE", 2, 7], ["cytoplasmic", "ORGANISM_SUBSTANCE", 17, 28], ["antineutrophil cytoplasmic antibodies", "GENE_OR_GENE_PRODUCT", 29, 66], ["c-ANCA", "GENE_OR_GENE_PRODUCT", 68, 74], ["cytoplasmic antineutrophil cytoplasmic antibodies", "PROTEIN", 17, 66], ["c", "PROTEIN", 68, 69], ["ANCA", "PROTEIN", 70, 74], ["A blood test", "TEST", 0, 12], ["cytoplasmic antineutrophil cytoplasmic antibodies", "TEST", 17, 66], ["c-ANCA)", "TEST", 68, 75]]], ["A subsequent biopsy reveals a necrotizing granulomatous vasculitis.ReferenceThis patient's fi ndings are most consistent with which of the following diagnoses?", [["vasculitis", "DISEASE", 56, 66], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["A subsequent biopsy", "TEST", 0, 19], ["a necrotizing granulomatous vasculitis", "PROBLEM", 28, 66], ["necrotizing", "OBSERVATION_MODIFIER", 30, 41], ["granulomatous", "OBSERVATION_MODIFIER", 42, 55], ["vasculitis", "OBSERVATION", 56, 66], ["most consistent with", "UNCERTAINTY", 105, 125]]], ["A) Lymphomatoid granulomatosis B) Systemic lupus erythematosus (SLE) C) Granulomatosis with polyangiitis (GPA) D) Churg-Strauss syndrome E) Goodpasture disease Answer: C This patient has granulomatosis with polyangiitis (GPA), which was formerly known as Wegener's disease.", [["Lymphomatoid granulomatosis B", "DISEASE", 3, 32], ["Systemic lupus erythematosus", "DISEASE", 34, 62], ["SLE", "DISEASE", 64, 67], ["Granulomatosis with polyangiitis", "DISEASE", 72, 104], ["Churg-Strauss syndrome", "DISEASE", 114, 136], ["Goodpasture disease", "DISEASE", 140, 159], ["granulomatosis with polyangiitis", "DISEASE", 187, 219], ["GPA", "DISEASE", 221, 224], ["Wegener's disease", "DISEASE", 255, 272], ["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 175, 182], ["A) Lymphomatoid granulomatosis", "PROBLEM", 0, 30], ["Systemic lupus erythematosus (SLE) C) Granulomatosis", "PROBLEM", 34, 86], ["polyangiitis (GPA) D) Churg-Strauss syndrome", "PROBLEM", 92, 136], ["Goodpasture disease", "PROBLEM", 140, 159], ["granulomatosis", "PROBLEM", 187, 201], ["polyangiitis", "PROBLEM", 207, 219], ["Wegener's disease", "PROBLEM", 255, 272], ["Lymphomatoid granulomatosis", "OBSERVATION", 3, 30], ["Systemic", "OBSERVATION_MODIFIER", 34, 42], ["lupus erythematosus", "OBSERVATION", 43, 62], ["Granulomatosis", "OBSERVATION", 72, 86], ["polyangiitis", "OBSERVATION", 92, 104], ["Strauss syndrome", "OBSERVATION", 120, 136], ["granulomatosis", "OBSERVATION", 187, 201], ["polyangiitis", "OBSERVATION", 207, 219], ["Wegener", "OBSERVATION", 255, 262]]], ["It is associated with both distinctive and nonspecifi c mucocutaneous signs.", [["both distinctive and nonspecifi c mucocutaneous signs", "PROBLEM", 22, 75], ["mucocutaneous signs", "OBSERVATION", 56, 75]]], ["Palpable purpura suggestive of vasculitis is one of the most common skin fi ndings.", [["skin", "ANATOMY", 68, 72], ["purpura", "DISEASE", 9, 16], ["vasculitis", "DISEASE", 31, 41], ["skin", "ORGAN", 68, 72], ["Palpable purpura", "PROBLEM", 0, 16], ["vasculitis", "PROBLEM", 31, 41], ["purpura", "OBSERVATION", 9, 16], ["suggestive of", "UNCERTAINTY", 17, 30], ["vasculitis", "OBSERVATION", 31, 41]]], ["A variety of other dermatologic conditions have been reported including ulcers, papules, and nodules.", [["ulcers", "ANATOMY", 72, 78], ["papules", "ANATOMY", 80, 87], ["nodules", "ANATOMY", 93, 100], ["ulcers", "DISEASE", 72, 78], ["papules", "DISEASE", 80, 87], ["ulcers", "PATHOLOGICAL_FORMATION", 72, 78], ["papules", "PATHOLOGICAL_FORMATION", 80, 87], ["nodules", "PATHOLOGICAL_FORMATION", 93, 100], ["A variety of other dermatologic conditions", "PROBLEM", 0, 42], ["ulcers", "PROBLEM", 72, 78], ["papules", "PROBLEM", 80, 87], ["nodules", "PROBLEM", 93, 100], ["variety", "OBSERVATION_MODIFIER", 2, 9], ["ulcers", "OBSERVATION", 72, 78], ["papules", "OBSERVATION", 80, 87], ["nodules", "OBSERVATION", 93, 100]]], ["In addition to upper and lower pulmonary symptoms, nasal ulcerations and septal perforation should suggest the diagnosis.", [["lower pulmonary", "ANATOMY", 25, 40], ["nasal", "ANATOMY", 51, 56], ["septal", "ANATOMY", 73, 79], ["nasal ulcerations", "DISEASE", 51, 68], ["septal perforation", "DISEASE", 73, 91], ["upper", "ORGANISM_SUBDIVISION", 15, 20], ["pulmonary", "ORGAN", 31, 40], ["nasal ulcerations", "PATHOLOGICAL_FORMATION", 51, 68], ["septal perforation", "PATHOLOGICAL_FORMATION", 73, 91], ["upper and lower pulmonary symptoms", "PROBLEM", 15, 49], ["nasal ulcerations", "PROBLEM", 51, 68], ["septal perforation", "PROBLEM", 73, 91], ["upper", "ANATOMY_MODIFIER", 15, 20], ["lower", "ANATOMY_MODIFIER", 25, 30], ["pulmonary", "ANATOMY", 31, 40], ["symptoms", "OBSERVATION", 41, 49], ["nasal", "ANATOMY", 51, 56], ["ulcerations", "OBSERVATION", 57, 68], ["septal", "ANATOMY_MODIFIER", 73, 79], ["perforation", "OBSERVATION", 80, 91]]], ["Biopsy is required.", [["Biopsy", "TEST", 0, 6]]], ["Diagnosis is made by the demonstration of a necrotizing granulomatous vasculitis in a patient with upper and lower respiratory tract disease and glomerulonephritis.", [["lower respiratory tract", "ANATOMY", 109, 132], ["vasculitis", "DISEASE", 70, 80], ["upper and lower respiratory tract disease", "DISEASE", 99, 140], ["glomerulonephritis", "DISEASE", 145, 163], ["patient", "ORGANISM", 86, 93], ["upper", "ORGANISM_SUBDIVISION", 99, 104], ["tract", "ORGANISM_SUBDIVISION", 127, 132], ["patient", "SPECIES", 86, 93], ["a necrotizing granulomatous vasculitis", "PROBLEM", 42, 80], ["upper and lower respiratory tract disease", "PROBLEM", 99, 140], ["glomerulonephritis", "PROBLEM", 145, 163], ["necrotizing", "OBSERVATION_MODIFIER", 44, 55], ["granulomatous", "OBSERVATION_MODIFIER", 56, 69], ["vasculitis", "OBSERVATION", 70, 80], ["upper", "ANATOMY_MODIFIER", 99, 104], ["lower", "ANATOMY_MODIFIER", 109, 114], ["respiratory tract", "ANATOMY", 115, 132], ["disease", "OBSERVATION", 133, 140], ["glomerulonephritis", "OBSERVATION", 145, 163]]], ["C-ANCA autoantibodies make several autoimmune diseases less likely.", [["autoimmune diseases", "DISEASE", 35, 54], ["C-ANCA", "GENE_OR_GENE_PRODUCT", 0, 6], ["ANCA autoantibodies", "PROTEIN", 2, 21], ["C", "TEST", 0, 1], ["ANCA autoantibodies", "PROBLEM", 2, 21], ["several autoimmune diseases", "PROBLEM", 27, 54], ["ANCA autoantibodies", "OBSERVATION", 2, 21], ["several", "OBSERVATION_MODIFIER", 27, 34], ["autoimmune diseases", "OBSERVATION", 35, 54]]], ["The absence of asthma makes the diagnosis of Churg-Strauss syndrome unlikely.", [["asthma", "DISEASE", 15, 21], ["Churg-Strauss syndrome", "DISEASE", 45, 67], ["asthma", "PROBLEM", 15, 21], ["Churg", "PROBLEM", 45, 50], ["Strauss syndrome", "PROBLEM", 51, 67], ["asthma", "OBSERVATION", 15, 21], ["Strauss syndrome", "OBSERVATION", 51, 67]]], ["Patients with lymphomatoid granulomatosis present with a predominance of pulmonary and nervous system manifestations, and tests for ANCA autoantibodies are usually negative.ReferenceCartin-Ceba R, Peikert T, Specks U. Pathogenesis of ANCAassociated vasculitis.", [["pulmonary", "ANATOMY", 73, 82], ["nervous system", "ANATOMY", 87, 101], ["lymphomatoid granulomatosis", "DISEASE", 14, 41], ["pulmonary and nervous system manifestations", "DISEASE", 73, 116], ["ANCAassociated vasculitis", "DISEASE", 234, 259], ["Patients", "ORGANISM", 0, 8], ["pulmonary", "ORGAN", 73, 82], ["nervous", "ANATOMICAL_SYSTEM", 87, 94], ["system", "ANATOMICAL_SYSTEM", 95, 101], ["ANCA", "GENE_OR_GENE_PRODUCT", 132, 136], ["ANCA autoantibodies", "PROTEIN", 132, 151], ["Patients", "SPECIES", 0, 8], ["lymphomatoid granulomatosis", "PROBLEM", 14, 41], ["pulmonary and nervous system manifestations", "PROBLEM", 73, 116], ["tests", "TEST", 122, 127], ["ANCA autoantibodies", "TEST", 132, 151], ["ReferenceCartin", "TEST", 173, 188], ["ANCAassociated vasculitis", "PROBLEM", 234, 259], ["lymphomatoid granulomatosis", "OBSERVATION", 14, 41], ["pulmonary", "ANATOMY", 73, 82], ["nervous system", "ANATOMY", 87, 101], ["ANCAassociated", "OBSERVATION_MODIFIER", 234, 248], ["vasculitis", "OBSERVATION", 249, 259]]], ["A 68-year-old male was admitted to the hospital for pneumonia.", [["pneumonia", "DISEASE", 52, 61], ["male", "ORGANISM", 14, 18], ["pneumonia", "PROBLEM", 52, 61], ["pneumonia", "OBSERVATION", 52, 61]]], ["He had a chest X-ray done that reveals a left lung infi ltrate and pleural effusion.", [["left lung", "ANATOMY", 41, 50], ["pleural effusion", "ANATOMY", 67, 83], ["pleural effusion", "DISEASE", 67, 83], ["lung", "ORGAN", 46, 50], ["pleural effusion", "CANCER", 67, 83], ["a chest X-ray", "TEST", 7, 20], ["a left lung infi ltrate", "PROBLEM", 39, 62], ["pleural effusion", "PROBLEM", 67, 83], ["chest", "ANATOMY", 9, 14], ["left", "ANATOMY_MODIFIER", 41, 45], ["lung", "ANATOMY", 46, 50], ["infi", "ANATOMY_MODIFIER", 51, 55], ["ltrate", "OBSERVATION", 56, 62], ["pleural", "ANATOMY", 67, 74], ["effusion", "OBSERVATION", 75, 83]]], ["He underwent a thoracentesis that revealed an exudative effusion.", [["effusion", "DISEASE", 56, 64], ["a thoracentesis", "TEST", 13, 28], ["an exudative effusion", "PROBLEM", 43, 64], ["thoracentesis", "OBSERVATION", 15, 28], ["exudative", "OBSERVATION_MODIFIER", 46, 55], ["effusion", "OBSERVATION", 56, 64]]], ["With no resolution of the effusion, a repeat thoracentesis and chest tube was placed 2 days later.", [["chest tube", "ANATOMY", 63, 73], ["effusion", "DISEASE", 26, 34], ["chest tube", "MULTI-TISSUE_STRUCTURE", 63, 73], ["the effusion", "PROBLEM", 22, 34], ["a repeat thoracentesis", "TREATMENT", 36, 58], ["chest tube", "TREATMENT", 63, 73], ["no", "UNCERTAINTY", 5, 7], ["resolution", "OBSERVATION_MODIFIER", 8, 18], ["effusion", "OBSERVATION", 26, 34], ["thoracentesis", "OBSERVATION", 45, 58], ["chest", "ANATOMY", 63, 68], ["tube", "OBSERVATION", 69, 73]]], ["Three days later, he is spiking temperatures to 103 \u00b0F. Repeat chest X-ray reveals a worsening effusion on the left.", [["effusion", "DISEASE", 95, 103], ["spiking temperatures", "PROBLEM", 24, 44], ["Repeat chest X-ray", "TEST", 56, 74], ["a worsening effusion on the left", "PROBLEM", 83, 115], ["chest", "ANATOMY", 63, 68], ["worsening", "OBSERVATION_MODIFIER", 85, 94], ["effusion", "OBSERVATION", 95, 103], ["left", "ANATOMY_MODIFIER", 111, 115]]], ["Which of the following is the best option in management at this time?", [["management", "TREATMENT", 45, 55]]], ["A) Expand antibiotic coverage B) Repeat chest tube placement C) Change antibiotics and continue with chest tube drainage D) Perform video-assisted thoracic surgery (VATS) E) No change required at this time Answer: D Patients with pneumonia and exudative effusion resistant to drainage should be considered for video-assisted thoracoscopic surgery (VATS).", [["chest tube", "ANATOMY", 40, 50], ["thoracic", "ANATOMY", 147, 155], ["pneumonia", "DISEASE", 230, 239], ["exudative effusion", "DISEASE", 244, 262], ["Patients", "ORGANISM", 216, 224], ["Patients", "SPECIES", 216, 224], ["A) Expand antibiotic coverage B", "TREATMENT", 0, 31], ["Repeat chest tube placement C", "TREATMENT", 33, 62], ["Change antibiotics", "TREATMENT", 64, 82], ["chest tube drainage", "TREATMENT", 101, 120], ["video-assisted thoracic surgery", "TREATMENT", 132, 163], ["pneumonia", "PROBLEM", 230, 239], ["exudative effusion", "PROBLEM", 244, 262], ["drainage", "TREATMENT", 276, 284], ["video-assisted thoracoscopic surgery", "TREATMENT", 310, 346], ["VATS", "TREATMENT", 348, 352], ["chest", "ANATOMY", 40, 45], ["chest", "ANATOMY", 101, 106], ["thoracic", "ANATOMY", 147, 155], ["pneumonia", "OBSERVATION", 230, 239], ["exudative", "OBSERVATION_MODIFIER", 244, 253], ["effusion", "OBSERVATION", 254, 262]]], ["Approximately 15-40% of patients with exudative effusion require surgical drainage of the infected pleural space.", [["pleural space", "ANATOMY", 99, 112], ["exudative effusion", "DISEASE", 38, 56], ["patients", "ORGANISM", 24, 32], ["pleural space", "MULTI-TISSUE_STRUCTURE", 99, 112], ["patients", "SPECIES", 24, 32], ["exudative effusion", "PROBLEM", 38, 56], ["surgical drainage", "TREATMENT", 65, 82], ["the infected pleural space", "PROBLEM", 86, 112], ["15-40", "OBSERVATION_MODIFIER", 14, 19], ["exudative", "OBSERVATION_MODIFIER", 38, 47], ["effusion", "OBSERVATION", 48, 56], ["surgical drainage", "OBSERVATION", 65, 82], ["infected", "OBSERVATION_MODIFIER", 90, 98], ["pleural", "ANATOMY", 99, 106], ["space", "ANATOMY_MODIFIER", 107, 112]]], ["Chest tubes often become clogged or effusions become loculated.", [["Chest tubes", "ANATOMY", 0, 11], ["effusions", "ANATOMY", 36, 45], ["effusions", "DISEASE", 36, 45], ["Chest tubes", "CANCER", 0, 11], ["Chest tubes", "TREATMENT", 0, 11], ["effusions", "PROBLEM", 36, 45], ["loculated", "PROBLEM", 53, 62], ["tubes", "OBSERVATION", 6, 11], ["clogged", "OBSERVATION", 25, 32], ["effusions", "OBSERVATION", 36, 45], ["loculated", "OBSERVATION", 53, 62]]], ["Patients should be considered for surgery if they have ongoing signs of sepsis in association with a persistent pleural collection.", [["pleural", "ANATOMY", 112, 119], ["sepsis", "DISEASE", 72, 78], ["Patients", "ORGANISM", 0, 8], ["pleural", "ORGAN", 112, 119], ["Patients", "SPECIES", 0, 8], ["surgery", "TREATMENT", 34, 41], ["sepsis", "PROBLEM", 72, 78], ["a persistent pleural collection", "PROBLEM", 99, 130], ["sepsis", "OBSERVATION", 72, 78], ["persistent", "OBSERVATION_MODIFIER", 101, 111], ["pleural", "ANATOMY", 112, 119], ["collection", "OBSERVATION", 120, 130]]], ["VATS is used as a fi rst-line therapy in many hospitals if cardiothoracic surgery support is available.", [["VATS", "TREATMENT", 0, 4], ["a fi rst-line therapy", "TREATMENT", 16, 37], ["cardiothoracic surgery support", "TREATMENT", 59, 89]]], ["Open thoracic drainage remains a frequently used alternative technique.ReferenceFerguson AD, Prescott RJ, Selkon JB, Watson D, Swinburn CR.", [["thoracic", "ANATOMY", 5, 13], ["thoracic", "MULTI-TISSUE_STRUCTURE", 5, 13], ["Open thoracic drainage", "TREATMENT", 0, 22], ["alternative technique", "TREATMENT", 49, 70], ["thoracic", "ANATOMY", 5, 13], ["drainage", "OBSERVATION", 14, 22], ["Selkon JB", "ANATOMY", 106, 115]]], ["The clinical course and management of thoracic empyema.", [["thoracic empyema", "ANATOMY", 38, 54], ["thoracic empyema", "DISEASE", 38, 54], ["thoracic empyema", "PATHOLOGICAL_FORMATION", 38, 54], ["management", "TREATMENT", 24, 34], ["thoracic empyema", "PROBLEM", 38, 54], ["thoracic", "ANATOMY", 38, 46], ["empyema", "OBSERVATION", 47, 54]]], ["You are called to see a patient on the fl oor for acute obtundation.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["acute obtundation", "PROBLEM", 50, 67]]], ["She has been admitted for chronic abdominal pain and possible pancreatitis.", [["abdominal", "ANATOMY", 34, 43], ["chronic abdominal pain", "DISEASE", 26, 48], ["pancreatitis", "DISEASE", 62, 74], ["abdominal", "ORGANISM_SUBDIVISION", 34, 43], ["chronic abdominal pain", "PROBLEM", 26, 48], ["pancreatitis", "PROBLEM", 62, 74], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["abdominal", "ANATOMY", 34, 43], ["pain", "OBSERVATION", 44, 48], ["possible", "UNCERTAINTY", 53, 61], ["pancreatitis", "OBSERVATION", 62, 74]]], ["She has been in the hospital for 6 h and has received several doses of narcotics.", [["narcotics", "SIMPLE_CHEMICAL", 71, 80], ["narcotics", "TREATMENT", 71, 80]]], ["Her last dose was 4 mg of hydromorphone 15 min ago.", [["hydromorphone", "CHEMICAL", 26, 39], ["hydromorphone", "CHEMICAL", 26, 39], ["hydromorphone", "SIMPLE_CHEMICAL", 26, 39], ["hydromorphone", "TREATMENT", 26, 39]]], ["She has been on hydromorphone every 4 h.", [["hydromorphone", "CHEMICAL", 16, 29], ["hydromorphone", "CHEMICAL", 16, 29], ["hydromorphone", "SIMPLE_CHEMICAL", 16, 29], ["hydromorphone", "TREATMENT", 16, 29]]], ["After you assess the patient, you administer a dose of naloxone.", [["naloxone", "CHEMICAL", 55, 63], ["naloxone", "CHEMICAL", 55, 63], ["patient", "ORGANISM", 21, 28], ["naloxone", "SIMPLE_CHEMICAL", 55, 63], ["patient", "SPECIES", 21, 28], ["naloxone", "TREATMENT", 55, 63]]], ["The patient has an immediate improvement of her symptoms.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["her symptoms", "PROBLEM", 44, 56], ["immediate", "OBSERVATION_MODIFIER", 19, 28], ["improvement", "OBSERVATION_MODIFIER", 29, 40]]], ["One hour later, you are called again to see the patient, who has become somnolent again.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["somnolent", "PROBLEM", 72, 81]]], ["The most likely cause of patient's worsening mental status is: A) Worsening CO 2 retention B) Diminishing effects of naloxone C) Further narcotic use D) Sepsis E) Delirium secondary to pancreatitis Answer: B Naloxone has an extremely rapid onset of action.", [["naloxone", "CHEMICAL", 117, 125], ["Sepsis", "DISEASE", 153, 159], ["Delirium", "DISEASE", 163, 171], ["pancreatitis", "DISEASE", 185, 197], ["Naloxone", "CHEMICAL", 208, 216], ["CO 2", "CHEMICAL", 76, 80], ["naloxone C", "CHEMICAL", 117, 127], ["Naloxone", "CHEMICAL", 208, 216], ["patient", "ORGANISM", 25, 32], ["naloxone C", "SIMPLE_CHEMICAL", 117, 127], ["patient", "SPECIES", 25, 32], ["patient's worsening mental status", "PROBLEM", 25, 58], ["Worsening CO 2 retention", "PROBLEM", 66, 90], ["naloxone C", "TREATMENT", 117, 127], ["Sepsis E", "PROBLEM", 153, 161], ["Delirium", "PROBLEM", 163, 171], ["pancreatitis", "PROBLEM", 185, 197], ["Naloxone", "TREATMENT", 208, 216], ["most likely", "UNCERTAINTY", 4, 15], ["pancreatitis", "OBSERVATION", 185, 197]]], ["The duration of naloxone is no greater than 1-2 h.", [["naloxone", "CHEMICAL", 16, 24], ["naloxone", "CHEMICAL", 16, 24], ["naloxone", "SIMPLE_CHEMICAL", 16, 24], ["naloxone", "TREATMENT", 16, 24]]], ["This is of importance as patients who have received a one-time dose may have a return of intoxication symptoms.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["intoxication symptoms", "PROBLEM", 89, 110]]], ["All opiates have a longer duration of action than naloxone.", [["naloxone", "CHEMICAL", 50, 58], ["naloxone", "CHEMICAL", 50, 58], ["opiates", "SIMPLE_CHEMICAL", 4, 11], ["naloxone", "SIMPLE_CHEMICAL", 50, 58], ["All opiates", "TREATMENT", 0, 11], ["naloxone", "TREATMENT", 50, 58], ["opiates", "OBSERVATION", 4, 11]]], ["All patients with opiate overdose symptoms both in the emergency room and on the fl oor should be monitored for a return of symptoms after naloxone has been given.", [["overdose", "DISEASE", 25, 33], ["naloxone", "CHEMICAL", 139, 147], ["naloxone", "CHEMICAL", 139, 147], ["patients", "ORGANISM", 4, 12], ["naloxone", "SIMPLE_CHEMICAL", 139, 147], ["patients", "SPECIES", 4, 12], ["opiate overdose symptoms", "PROBLEM", 18, 42], ["symptoms", "PROBLEM", 124, 132], ["naloxone", "TREATMENT", 139, 147]]], ["Naloxone is most commonly injected intravenously for fastest action, which usually causes the drug to act within a minute.", [["intravenously", "ANATOMY", 35, 48], ["Naloxone", "CHEMICAL", 0, 8], ["Naloxone", "CHEMICAL", 0, 8], ["Naloxone", "SIMPLE_CHEMICAL", 0, 8], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 48], ["Naloxone", "TREATMENT", 0, 8]]], ["When IV access is not available, it can also be administered via intramuscular or subcutaneous injection.", [["intramuscular", "ANATOMY", 65, 78], ["subcutaneous", "ANATOMY", 82, 94], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 65, 78], ["IV access", "TREATMENT", 5, 14], ["intramuscular or subcutaneous injection", "TREATMENT", 65, 104]]], ["In emergency circumstances, it can be administered intranasally.ReferenceOrman JS, Keating GM.", [["GM", "CHEMICAL", 91, 93]]], ["Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.", [["Buprenorphine", "CHEMICAL", 0, 13], ["naloxone", "CHEMICAL", 14, 22], ["Buprenorphine", "CHEMICAL", 0, 13], ["naloxone", "CHEMICAL", 14, 22], ["Buprenorphine", "SIMPLE_CHEMICAL", 0, 13], ["naloxone", "SIMPLE_CHEMICAL", 14, 22], ["Buprenorphine", "TREATMENT", 0, 13], ["naloxone", "TREATMENT", 14, 22], ["opioid dependence", "PROBLEM", 64, 81], ["opioid dependence", "OBSERVATION", 64, 81]]], ["Drugs.", [["Drugs", "TREATMENT", 0, 5]]], ["A 55-year-old female presents with an the inability to close her left eye, mild numbness, and tingling of the left cheek.", [["left eye", "ANATOMY", 65, 73], ["left cheek", "ANATOMY", 110, 120], ["numbness", "DISEASE", 80, 88], ["tingling of the left cheek", "DISEASE", 94, 120], ["female", "ORGANISM", 14, 20], ["eye", "ORGAN", 70, 73], ["cheek", "ORGAN", 115, 120], ["mild numbness", "PROBLEM", 75, 88], ["tingling of the left cheek", "PROBLEM", 94, 120], ["left", "ANATOMY_MODIFIER", 65, 69], ["eye", "ANATOMY", 70, 73], ["mild", "OBSERVATION_MODIFIER", 75, 79], ["numbness", "OBSERVATION", 80, 88], ["tingling", "OBSERVATION", 94, 102], ["left", "ANATOMY_MODIFIER", 110, 114], ["cheek", "ANATOMY", 115, 120]]], ["She has a history of hypertension.", [["hypertension", "DISEASE", 21, 33], ["hypertension", "PROBLEM", 21, 33], ["hypertension", "OBSERVATION", 21, 33]]], ["You are consulted by the emergency room to admit the patient for probable stroke.", [["stroke", "DISEASE", 74, 80], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["stroke", "PROBLEM", 74, 80], ["stroke", "OBSERVATION", 74, 80]]], ["On physical examination, vital signs are normal.", [["physical examination", "TEST", 3, 23], ["vital signs", "TEST", 25, 36], ["normal", "OBSERVATION", 41, 47]]], ["No lesions of the skin or mucous membranes are noted.", [["lesions", "ANATOMY", 3, 10], ["skin", "ANATOMY", 18, 22], ["mucous membranes", "ANATOMY", 26, 42], ["lesions", "PATHOLOGICAL_FORMATION", 3, 10], ["skin", "ORGAN", 18, 22], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 26, 42], ["lesions of the skin or mucous membranes", "PROBLEM", 3, 42], ["lesions", "OBSERVATION", 3, 10], ["skin", "ANATOMY", 18, 22], ["mucous membranes", "ANATOMY", 26, 42]]], ["Neurologic examination reveals a weakness of the left upper and lower facial muscles and an inability to close the left eye.", [["left upper", "ANATOMY", 49, 59], ["lower facial muscles", "ANATOMY", 64, 84], ["left eye", "ANATOMY", 115, 123], ["upper", "ORGANISM_SUBDIVISION", 54, 59], ["lower", "ORGANISM_SUBDIVISION", 64, 69], ["facial muscles", "ORGAN", 70, 84], ["eye", "ORGAN", 120, 123], ["Neurologic examination", "TEST", 0, 22], ["a weakness of the left upper and lower facial muscles", "PROBLEM", 31, 84], ["weakness", "OBSERVATION", 33, 41], ["left", "ANATOMY_MODIFIER", 49, 53], ["upper", "ANATOMY_MODIFIER", 54, 59], ["lower", "ANATOMY_MODIFIER", 64, 69], ["facial muscles", "ANATOMY", 70, 84], ["left", "ANATOMY_MODIFIER", 115, 119], ["eye", "ANATOMY", 120, 123]]], ["Sensory examination reveals the facial sensation is normal bilaterally.ReferenceCT scan is performed which reveals no signifi cant abnormalities.", [["facial", "ANATOMY", 32, 38], ["facial", "ORGAN", 32, 38], ["Sensory examination", "TEST", 0, 19], ["ReferenceCT scan", "TEST", 71, 87], ["signifi cant abnormalities", "PROBLEM", 118, 144], ["facial", "ANATOMY", 32, 38], ["normal", "OBSERVATION", 52, 58], ["bilaterally", "ANATOMY_MODIFIER", 59, 70], ["no", "UNCERTAINTY", 115, 117], ["abnormalities", "OBSERVATION", 131, 144]]], ["Other labs are within normal limits.ReferenceWhich of the following is the most appropriate treatment?", [["Other labs", "TEST", 0, 10], ["within normal limits", "OBSERVATION", 15, 35]]], ["A) Acyclovir B) Intravenous methylprednisolone C) Aspirin D) Sumatriptan E) PrednisoneReferenceAnswer: E This patient has an acute onset of Bell's palsy.", [["Acyclovir B", "CHEMICAL", 3, 14], ["methylprednisolone", "CHEMICAL", 28, 46], ["Aspirin", "CHEMICAL", 50, 57], ["Bell's palsy", "DISEASE", 140, 152], ["Acyclovir B", "CHEMICAL", 3, 14], ["methylprednisolone C", "CHEMICAL", 28, 48], ["Aspirin D", "CHEMICAL", 50, 59], ["Sumatriptan E", "CHEMICAL", 61, 74], ["Acyclovir B", "SIMPLE_CHEMICAL", 3, 14], ["Intravenous methylprednisolone C", "SIMPLE_CHEMICAL", 16, 48], ["Aspirin D", "SIMPLE_CHEMICAL", 50, 59], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 110, 117], ["A) Acyclovir B) Intravenous methylprednisolone C) Aspirin D) Sumatriptan E)", "TREATMENT", 0, 75], ["Bell's palsy", "PROBLEM", 140, 152], ["acute", "OBSERVATION_MODIFIER", 125, 130], ["Bell's palsy", "OBSERVATION", 140, 152]]], ["The current treatment of choice is prednisone.", [["prednisone", "CHEMICAL", 35, 45], ["prednisone", "CHEMICAL", 35, 45], ["prednisone", "SIMPLE_CHEMICAL", 35, 45], ["prednisone", "TREATMENT", 35, 45]]], ["Mounting evidence suggests that Bell's palsy is due to human herpes virus 1.", [["Bell's palsy", "DISEASE", 32, 44], ["human", "ORGANISM", 55, 60], ["herpes virus 1", "ORGANISM", 61, 75], ["human", "SPECIES", 55, 60], ["herpes virus", "SPECIES", 61, 73], ["human herpes virus 1", "SPECIES", 55, 75], ["Bell's palsy", "PROBLEM", 32, 44], ["human herpes virus", "PROBLEM", 55, 73]]], ["It is often is seen after a viral prodrome.", [["viral prodrome", "DISEASE", 28, 42], ["a viral prodrome", "PROBLEM", 26, 42], ["viral", "OBSERVATION", 28, 33]]], ["Physical examination reveals paralysis of both the upper and lower facial motor neurons which distinguishes it from a cerebrovascular accident.", [["upper", "ANATOMY", 51, 56], ["lower facial motor neurons", "ANATOMY", 61, 87], ["cerebrovascular", "ANATOMY", 118, 133], ["paralysis", "DISEASE", 29, 38], ["cerebrovascular accident", "DISEASE", 118, 142], ["upper", "ORGANISM_SUBDIVISION", 51, 56], ["upper and lower facial motor neurons", "CELL_TYPE", 51, 87], ["Physical examination", "TEST", 0, 20], ["paralysis of both the upper and lower facial motor neurons", "PROBLEM", 29, 87], ["a cerebrovascular accident", "PROBLEM", 116, 142], ["paralysis", "OBSERVATION", 29, 38], ["both", "ANATOMY_MODIFIER", 42, 46], ["upper", "ANATOMY_MODIFIER", 51, 56], ["lower", "ANATOMY_MODIFIER", 61, 66], ["facial motor neurons", "ANATOMY", 67, 87], ["cerebrovascular", "ANATOMY", 118, 133], ["accident", "OBSERVATION", 134, 142]]], ["The patient may also report dry mouth, impaired taste, and pain and numbness in the ear.", [["mouth", "ANATOMY", 32, 37], ["ear", "ANATOMY", 84, 87], ["dry mouth", "DISEASE", 28, 37], ["impaired taste", "DISEASE", 39, 53], ["pain", "DISEASE", 59, 63], ["numbness", "DISEASE", 68, 76], ["patient", "ORGANISM", 4, 11], ["mouth", "ORGANISM_SUBDIVISION", 32, 37], ["ear", "ORGAN", 84, 87], ["patient", "SPECIES", 4, 11], ["dry mouth", "PROBLEM", 28, 37], ["impaired taste", "PROBLEM", 39, 53], ["pain", "PROBLEM", 59, 63], ["numbness in the ear", "PROBLEM", 68, 87], ["impaired", "OBSERVATION", 39, 47], ["numbness", "OBSERVATION", 68, 76], ["ear", "ANATOMY", 84, 87]]], ["Abrupt onset of symptoms usually occurs over 1-2 days.", [["Abrupt onset of symptoms", "PROBLEM", 0, 24], ["symptoms", "OBSERVATION", 16, 24]]], ["The most appropriate treatment is oral prednisone 40 mg per day, started within the fi rst 72 h.", [["oral", "ANATOMY", 34, 38], ["prednisone", "CHEMICAL", 39, 49], ["prednisone", "CHEMICAL", 39, 49], ["oral", "ORGANISM_SUBDIVISION", 34, 38], ["prednisone", "SIMPLE_CHEMICAL", 39, 49], ["oral prednisone", "TREATMENT", 34, 49]]], ["Antiviral agents have been used in the past.", [["Antiviral agents", "TREATMENT", 0, 16]]], ["There is no evidence to date that anti-herpes virus agents, such as acyclovir, as monotherapy for Bell's palsy are of benefi t.", [["acyclovir", "CHEMICAL", 68, 77], ["Bell's palsy", "DISEASE", 98, 110], ["acyclovir", "CHEMICAL", 68, 77], ["anti-herpes virus", "ORGANISM", 34, 51], ["acyclovir", "SIMPLE_CHEMICAL", 68, 77], ["anti-herpes virus", "SPECIES", 34, 51], ["anti-herpes virus agents", "TREATMENT", 34, 58], ["acyclovir", "TREATMENT", 68, 77], ["monotherapy", "TREATMENT", 82, 93], ["Bell's palsy", "PROBLEM", 98, 110], ["no evidence to", "UNCERTAINTY", 9, 23]]], ["High-dose intravenous corticosteroids are not indicated for the treatment of Bell's palsy.", [["intravenous", "ANATOMY", 10, 21], ["Bell's palsy", "DISEASE", 77, 89], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 10, 21], ["High-dose intravenous corticosteroids", "TREATMENT", 0, 37], ["Bell's palsy", "PROBLEM", 77, 89], ["palsy", "OBSERVATION", 84, 89]]], ["A 23-year-old female is brought to the emergency room by her roommate with the chief complaint of increasing agitation, which began this morning.", [["agitation", "DISEASE", 109, 118], ["female", "ORGANISM", 14, 20], ["increasing agitation", "PROBLEM", 98, 118], ["23-", "OBSERVATION_MODIFIER", 2, 5], ["increasing", "OBSERVATION_MODIFIER", 98, 108], ["agitation", "OBSERVATION", 109, 118]]], ["All history is obtained from the roommate who reports that the patient has been out for the past two days and has been acting strange and paranoid since returning home.", [["paranoid", "DISEASE", 138, 146], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["paranoid", "PROBLEM", 138, 146]]], ["Nothing is known about what the patient may have ingested.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39]]], ["On physical exam, she is diaphoretic, alert, and agitated.", [["physical exam", "TEST", 3, 16], ["diaphoretic", "PROBLEM", 25, 36], ["agitated", "PROBLEM", 49, 57]]], ["She exhibits some unusual behaviors, such as picking at her legs.", [["legs", "ANATOMY", 60, 64], ["legs", "ORGANISM_SUBDIVISION", 60, 64], ["some unusual behaviors", "PROBLEM", 13, 35], ["picking at her legs", "PROBLEM", 45, 64], ["legs", "ANATOMY", 60, 64]]], ["Her temperature is 38.3 \u00b0C (101.0 \u00b0F), heart rate is 120 bpm, and respirations are 26 per minute.", [["heart", "ANATOMY", 39, 44], ["heart", "ORGAN", 39, 44], ["Her temperature", "TEST", 0, 15], ["\u00b0C", "TEST", 24, 26], ["heart rate", "TEST", 39, 49], ["respirations", "TEST", 66, 78], ["heart", "ANATOMY", 39, 44]]], ["Her blood pressure is 165/100 mmHg.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["Her blood pressure", "TEST", 0, 18], ["pressure", "OBSERVATION_MODIFIER", 10, 18]]], ["On physical exam, it is noted that she has poor dentition.", [["physical exam", "TEST", 3, 16], ["poor dentition", "PROBLEM", 43, 57], ["poor dentition", "OBSERVATION", 43, 57]]], ["A few pustules and scabs are noted on the face.", [["pustules", "ANATOMY", 6, 14], ["scabs", "ANATOMY", 19, 24], ["pustules", "DISEASE", 6, 14], ["pustules", "PATHOLOGICAL_FORMATION", 6, 14], ["scabs", "CANCER", 19, 24], ["A few pustules", "PROBLEM", 0, 14], ["scabs", "PROBLEM", 19, 24], ["few", "OBSERVATION_MODIFIER", 2, 5], ["pustules", "OBSERVATION", 6, 14], ["scabs", "OBSERVATION", 19, 24], ["face", "ANATOMY", 42, 46]]], ["Cardiopulmonary and abdominal exams are normal.", [["abdominal", "ANATOMY", 20, 29], ["abdominal", "ORGAN", 20, 29], ["Cardiopulmonary and abdominal exams", "TEST", 0, 35], ["abdominal", "ANATOMY", 20, 29], ["normal", "OBSERVATION", 40, 46]]], ["She is slightly hyperrefl exic.", [["slightly hyperrefl exic", "PROBLEM", 7, 30], ["slightly", "OBSERVATION_MODIFIER", 7, 15], ["hyperrefl", "OBSERVATION", 16, 25]]], ["Laboratory examination reveals normal liver enzymes and a normal basic metabolic profi le.ReferenceWhich of the following substances is the most likely cause of the patient's clinical picture?", [["liver", "ANATOMY", 38, 43], ["liver", "ORGAN", 38, 43], ["patient", "ORGANISM", 165, 172], ["liver enzymes", "PROTEIN", 38, 51], ["patient", "SPECIES", 165, 172], ["Laboratory examination", "TEST", 0, 22], ["the patient's clinical picture", "PROBLEM", 161, 191], ["normal", "OBSERVATION", 31, 37], ["liver", "ANATOMY", 38, 43], ["metabolic profi", "OBSERVATION", 71, 86], ["most likely", "UNCERTAINTY", 140, 151]]], ["A) Cocaine B) Benocyclidine C) Methamphetamine (Crystal Meth) D) MDMA (ecstasy) E) LSD Answer: C Methamphetamine, which has multiple street names including crystal or crystal meth, presents with hypertension, tachycardia, hyperthermia, and often with poor dentition and evidence of skin excoriations.", [["skin", "ANATOMY", 282, 286], ["Cocaine", "CHEMICAL", 3, 10], ["Benocyclidine", "CHEMICAL", 14, 27], ["Methamphetamine", "CHEMICAL", 31, 46], ["MDMA", "CHEMICAL", 65, 69], ["ecstasy", "CHEMICAL", 71, 78], ["Methamphetamine", "CHEMICAL", 97, 112], ["hypertension", "DISEASE", 195, 207], ["tachycardia", "DISEASE", 209, 220], ["hyperthermia", "DISEASE", 222, 234], ["Cocaine B", "CHEMICAL", 3, 12], ["Benocyclidine C", "CHEMICAL", 14, 29], ["Methamphetamine", "CHEMICAL", 31, 46], ["Crystal Meth) D", "CHEMICAL", 48, 63], ["MDMA", "CHEMICAL", 65, 69], ["ecstasy", "CHEMICAL", 71, 78], ["Methamphetamine", "CHEMICAL", 97, 112], ["Cocaine B) Benocyclidine C", "SIMPLE_CHEMICAL", 3, 29], ["Methamphetamine", "SIMPLE_CHEMICAL", 31, 46], ["Crystal Meth) D", "SIMPLE_CHEMICAL", 48, 63], ["MDMA", "SIMPLE_CHEMICAL", 65, 69], ["C Methamphetamine", "SIMPLE_CHEMICAL", 95, 112], ["skin", "ORGAN", 282, 286], ["A) Cocaine B) Benocyclidine C) Methamphetamine (Crystal Meth)", "TREATMENT", 0, 61], ["crystal or crystal meth", "TREATMENT", 156, 179], ["hypertension", "PROBLEM", 195, 207], ["tachycardia", "PROBLEM", 209, 220], ["hyperthermia", "PROBLEM", 222, 234], ["poor dentition", "PROBLEM", 251, 265], ["skin excoriations", "PROBLEM", 282, 299], ["hypertension", "OBSERVATION", 195, 207], ["tachycardia", "OBSERVATION", 209, 220], ["hyperthermia", "OBSERVATION", 222, 234], ["skin", "ANATOMY", 282, 286], ["excoriations", "OBSERVATION", 287, 299]]], ["Other common symptoms are paranoia and diaphoresis.", [["paranoia", "DISEASE", 26, 34], ["diaphoresis", "DISEASE", 39, 50], ["Other common symptoms", "PROBLEM", 0, 21], ["paranoia", "PROBLEM", 26, 34], ["diaphoresis", "PROBLEM", 39, 50], ["paranoia", "OBSERVATION", 26, 34]]], ["Methamphetamine ingestion is commonly seen in both urban and rural settings.", [["Methamphetamine", "CHEMICAL", 0, 15], ["Methamphetamine", "CHEMICAL", 0, 15], ["Methamphetamine", "SIMPLE_CHEMICAL", 0, 15], ["Methamphetamine ingestion", "TREATMENT", 0, 25]]], ["Methamphetamine users and addicts may lose their teeth abnormally quickly.", [["teeth", "ANATOMY", 49, 54], ["Methamphetamine", "CHEMICAL", 0, 15], ["Methamphetamine", "CHEMICAL", 0, 15], ["Methamphetamine", "SIMPLE_CHEMICAL", 0, 15], ["teeth", "ORGAN", 49, 54], ["Methamphetamine users", "TREATMENT", 0, 21]]], ["This may be due to several factors that lead to dry mouth as well as specifi c behaviors that are induced by the drug.", [["mouth", "ANATOMY", 52, 57], ["dry mouth", "DISEASE", 48, 57], ["mouth", "ORGANISM_SUBDIVISION", 52, 57], ["dry mouth", "PROBLEM", 48, 57], ["specifi c behaviors", "PROBLEM", 69, 88], ["may be due to", "UNCERTAINTY", 5, 18]]], ["Antipsychotic medications may effectively resolve the symptoms of acute amphetamine psychosis.", [["amphetamine", "CHEMICAL", 72, 83], ["psychosis", "DISEASE", 84, 93], ["amphetamine", "CHEMICAL", 72, 83], ["Antipsychotic medications", "TREATMENT", 0, 25], ["the symptoms", "PROBLEM", 50, 62], ["acute amphetamine psychosis", "PROBLEM", 66, 93], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["amphetamine psychosis", "OBSERVATION", 72, 93]]], ["A 28-year-old white male presents to ED with a large swollen left arm and severe left arm pain and redness.ReferenceHe believes the only signifi cant event that happened prior to the swelling was picking up a propane tank with his left arm.", [["left arm", "ANATOMY", 61, 69], ["left arm", "ANATOMY", 81, 89], ["left arm", "ANATOMY", 231, 239], ["left arm pain", "DISEASE", 81, 94], ["redness", "DISEASE", 99, 106], ["swelling", "DISEASE", 183, 191], ["propane", "CHEMICAL", 209, 216], ["male", "ORGANISM", 20, 24], ["arm", "ORGANISM_SUBDIVISION", 66, 69], ["arm", "ORGANISM_SUBDIVISION", 86, 89], ["arm", "ORGANISM_SUBDIVISION", 236, 239], ["a large swollen left arm", "PROBLEM", 45, 69], ["severe left arm pain", "PROBLEM", 74, 94], ["redness", "PROBLEM", 99, 106], ["the swelling", "PROBLEM", 179, 191], ["large", "OBSERVATION_MODIFIER", 47, 52], ["swollen", "OBSERVATION", 53, 60], ["left", "ANATOMY_MODIFIER", 61, 65], ["arm", "ANATOMY", 66, 69], ["severe", "OBSERVATION_MODIFIER", 74, 80], ["left", "ANATOMY_MODIFIER", 81, 85], ["arm", "ANATOMY", 86, 89], ["pain", "OBSERVATION", 90, 94], ["redness", "OBSERVATION", 99, 106], ["swelling", "OBSERVATION", 183, 191], ["left", "ANATOMY_MODIFIER", 231, 235], ["arm", "ANATOMY", 236, 239]]], ["After initial workup and imaging, a DVT is confi rmed in the upper extremity.", [["upper extremity", "ANATOMY", 61, 76], ["DVT", "DISEASE", 36, 39], ["upper extremity", "ORGANISM_SUBDIVISION", 61, 76], ["initial workup", "TEST", 6, 20], ["imaging", "TEST", 25, 32], ["a DVT", "PROBLEM", 34, 39], ["DVT", "OBSERVATION", 36, 39], ["upper extremity", "ANATOMY", 61, 76]]], ["What would be an appropriate therapy to start?", [["an appropriate therapy", "TREATMENT", 14, 36]]], ["A) Rivaroxaban B) Warfarin plus Enoxaparin 1 mg/kg SQ BID x minimum 5 days C) Warfarin alone D) Enoxaparin 1 mg/kg for 2 weeks alone E) A or BReferenceAnswer: E Rivaroxaban may be a great choice for this patient due to his age and work lifestyle.", [["Rivaroxaban B", "CHEMICAL", 3, 16], ["Warfarin", "CHEMICAL", 18, 26], ["Enoxaparin", "CHEMICAL", 32, 42], ["Warfarin", "CHEMICAL", 78, 86], ["Enoxaparin", "CHEMICAL", 96, 106], ["Rivaroxaban", "CHEMICAL", 161, 172], ["Rivaroxaban B", "CHEMICAL", 3, 16], ["Warfarin", "CHEMICAL", 18, 26], ["Enoxaparin", "CHEMICAL", 32, 42], ["Warfarin", "CHEMICAL", 78, 86], ["Enoxaparin", "CHEMICAL", 96, 106], ["Rivaroxaban", "CHEMICAL", 161, 172], ["Warfarin", "SIMPLE_CHEMICAL", 18, 26], ["Enoxaparin", "SIMPLE_CHEMICAL", 32, 42], ["Warfarin", "SIMPLE_CHEMICAL", 78, 86], ["E Rivaroxaban", "SIMPLE_CHEMICAL", 159, 172], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["A) Rivaroxaban B) Warfarin", "TREATMENT", 0, 26], ["Enoxaparin", "TREATMENT", 32, 42], ["Warfarin alone D", "TREATMENT", 78, 94], ["Enoxaparin", "TREATMENT", 96, 106], ["Rivaroxaban", "TREATMENT", 161, 172]]], ["It can be started without the need for bridging therapy.", [["bridging therapy", "TREATMENT", 39, 55]]], ["Coumadin monitoring can be problematic and leads to a great deal of noncompliance.", [["Coumadin", "CHEMICAL", 0, 8], ["Coumadin", "CHEMICAL", 0, 8], ["Coumadin", "SIMPLE_CHEMICAL", 0, 8], ["Coumadin monitoring", "TREATMENT", 0, 19], ["noncompliance", "PROBLEM", 68, 81], ["noncompliance", "OBSERVATION", 68, 81]]], ["If agreeable to the patient, warfarin plus enoxaparin is also an acceptable option.", [["warfarin", "CHEMICAL", 29, 37], ["enoxaparin", "CHEMICAL", 43, 53], ["warfarin", "CHEMICAL", 29, 37], ["enoxaparin", "CHEMICAL", 43, 53], ["patient", "ORGANISM", 20, 27], ["warfarin", "SIMPLE_CHEMICAL", 29, 37], ["enoxaparin", "SIMPLE_CHEMICAL", 43, 53], ["patient", "SPECIES", 20, 27], ["warfarin", "TREATMENT", 29, 37], ["enoxaparin", "TREATMENT", 43, 53]]], ["This dosing regimen is well established and validated.", [["This dosing regimen", "TREATMENT", 0, 19]]], ["Current guidelines recommend that patients with upper extremity DVTs require treatment similar to lower extremity DVT.", [["lower extremity DVT", "ANATOMY", 98, 117], ["DVTs", "DISEASE", 64, 68], ["DVT", "DISEASE", 114, 117], ["patients", "ORGANISM", 34, 42], ["upper extremity", "ORGANISM_SUBDIVISION", 48, 63], ["lower extremity", "ORGANISM_SUBDIVISION", 98, 113], ["patients", "SPECIES", 34, 42], ["upper extremity DVTs", "PROBLEM", 48, 68], ["treatment", "TREATMENT", 77, 86], ["lower extremity DVT", "PROBLEM", 98, 117], ["upper", "ANATOMY_MODIFIER", 48, 53], ["extremity", "ANATOMY", 54, 63], ["DVTs", "OBSERVATION", 64, 68], ["lower", "ANATOMY_MODIFIER", 98, 103], ["extremity", "ANATOMY", 104, 113], ["DVT", "OBSERVATION", 114, 117]]], ["Option C is incorrect because of the lack of bridging required initially for this disease state.", [["this disease state", "PROBLEM", 77, 95], ["bridging", "OBSERVATION", 45, 53]]], ["A 38-year-old female patient with a history of end-stage renal disease on home peritoneal dialysis presents with a chief complaint of new onset abdominal pain.", [["renal", "ANATOMY", 57, 62], ["peritoneal", "ANATOMY", 79, 89], ["abdominal", "ANATOMY", 144, 153], ["end-stage renal disease", "DISEASE", 47, 70], ["abdominal pain", "DISEASE", 144, 158], ["female", "ORGANISM", 14, 20], ["patient", "ORGANISM", 21, 28], ["renal", "ORGAN", 57, 62], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 79, 89], ["abdominal", "ORGANISM_SUBDIVISION", 144, 153], ["patient", "SPECIES", 21, 28], ["end-stage renal disease", "PROBLEM", 47, 70], ["home peritoneal dialysis", "TREATMENT", 74, 98], ["new onset abdominal pain", "PROBLEM", 134, 158], ["stage", "OBSERVATION_MODIFIER", 51, 56], ["renal", "ANATOMY", 57, 62], ["disease", "OBSERVATION", 63, 70], ["peritoneal", "ANATOMY", 79, 89], ["dialysis", "OBSERVATION", 90, 98], ["new", "OBSERVATION_MODIFIER", 134, 137], ["abdominal", "ANATOMY", 144, 153], ["pain", "OBSERVATION", 154, 158]]], ["A peritoneal catheter was placed 6 months ago and since that time has had no complications.", [["peritoneal", "ANATOMY", 2, 12], ["peritoneal catheter", "MULTI-TISSUE_STRUCTURE", 2, 21], ["A peritoneal catheter", "TREATMENT", 0, 21], ["complications", "PROBLEM", 77, 90], ["peritoneal", "ANATOMY", 2, 12], ["catheter", "OBSERVATION", 13, 21], ["no", "UNCERTAINTY", 74, 76], ["complications", "OBSERVATION", 77, 90]]], ["On physical exam, the abdomen is diffusely tender.", [["abdomen", "ANATOMY", 22, 29], ["abdomen", "ORGAN", 22, 29], ["physical exam", "TEST", 3, 16], ["diffusely tender", "PROBLEM", 33, 49], ["abdomen", "ANATOMY", 22, 29], ["diffusely", "OBSERVATION_MODIFIER", 33, 42], ["tender", "OBSERVATION", 43, 49]]], ["She is afebrile.", [["afebrile", "PROBLEM", 7, 15], ["afebrile", "OBSERVATION", 7, 15]]], ["Serum WBC count is 15,000/\u03bcL.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum WBC count", "TEST", 0, 15]]], ["Initial therapy for treatment of suspected peritoneal dialysis-induced peritonitis would include which of the following?", [["peritoneal", "ANATOMY", 43, 53], ["peritonitis", "DISEASE", 71, 82], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["Initial therapy", "TREATMENT", 0, 15], ["treatment", "TREATMENT", 20, 29], ["suspected peritoneal dialysis", "TREATMENT", 33, 62], ["peritonitis", "PROBLEM", 71, 82], ["peritoneal", "ANATOMY", 43, 53], ["dialysis", "OBSERVATION", 54, 62], ["peritonitis", "OBSERVATION", 71, 82]]], ["A) Ceftriaxone B) Vancomycin plus ceftriaxone C) Vancomycin, ceftriaxone, and difl ucan D) Vancomycin E) Ceftriaxone and catheter removal Answer: B Peritonitis is a common complication seen in peritoneal dialysis patients.", [["peritoneal", "ANATOMY", 193, 203], ["Ceftriaxone B", "CHEMICAL", 3, 16], ["Vancomycin", "CHEMICAL", 18, 28], ["ceftriaxone", "CHEMICAL", 34, 45], ["Vancomycin", "CHEMICAL", 49, 59], ["ceftriaxone", "CHEMICAL", 61, 72], ["difl ucan D", "CHEMICAL", 78, 89], ["Vancomycin E", "CHEMICAL", 91, 103], ["Ceftriaxone", "CHEMICAL", 105, 116], ["Peritonitis", "DISEASE", 148, 159], ["Ceftriaxone B", "CHEMICAL", 3, 16], ["Vancomycin", "CHEMICAL", 18, 28], ["ceftriaxone C", "CHEMICAL", 34, 47], ["Vancomycin", "CHEMICAL", 49, 59], ["ceftriaxone", "CHEMICAL", 61, 72], ["difl ucan D", "CHEMICAL", 78, 89], ["Vancomycin E", "CHEMICAL", 91, 103], ["Ceftriaxone", "CHEMICAL", 105, 116], ["Ceftriaxone B", "SIMPLE_CHEMICAL", 3, 16], ["Vancomycin", "SIMPLE_CHEMICAL", 18, 28], ["ceftriaxone C", "SIMPLE_CHEMICAL", 34, 47], ["Vancomycin", "SIMPLE_CHEMICAL", 49, 59], ["ceftriaxone", "SIMPLE_CHEMICAL", 61, 72], ["difl ucan D", "SIMPLE_CHEMICAL", 78, 89], ["Vancomycin E", "SIMPLE_CHEMICAL", 91, 103], ["Ceftriaxone", "SIMPLE_CHEMICAL", 105, 116], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 193, 203], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["A) Ceftriaxone B)", "TREATMENT", 0, 17], ["Vancomycin", "TREATMENT", 18, 28], ["ceftriaxone C", "TREATMENT", 34, 47], ["Vancomycin", "TREATMENT", 49, 59], ["ceftriaxone", "TREATMENT", 61, 72], ["difl ucan D", "TREATMENT", 78, 89], ["Vancomycin E", "TREATMENT", 91, 103], ["Ceftriaxone", "TREATMENT", 105, 116], ["catheter removal", "TREATMENT", 121, 137], ["B Peritonitis", "PROBLEM", 146, 159], ["a common complication", "PROBLEM", 163, 184], ["peritoneal dialysis patients", "TREATMENT", 193, 221], ["Peritonitis", "OBSERVATION", 148, 159], ["peritoneal", "ANATOMY", 193, 203], ["dialysis", "OBSERVATION", 204, 212]]], ["Unlike peritonitis seen in end-stage liver disease, the majority of infections are gram-positive bacteria.", [["liver", "ANATOMY", 37, 42], ["peritonitis", "DISEASE", 7, 18], ["end-stage liver disease", "DISEASE", 27, 50], ["infections", "DISEASE", 68, 78], ["liver", "ORGAN", 37, 42], ["peritonitis", "PROBLEM", 7, 18], ["end-stage liver disease", "PROBLEM", 27, 50], ["infections", "PROBLEM", 68, 78], ["gram", "TEST", 83, 87], ["positive bacteria", "PROBLEM", 88, 105], ["peritonitis", "OBSERVATION", 7, 18], ["end", "OBSERVATION_MODIFIER", 27, 30], ["-stage", "OBSERVATION_MODIFIER", 30, 36], ["liver", "ANATOMY", 37, 42], ["disease", "OBSERVATION", 43, 50], ["majority", "OBSERVATION_MODIFIER", 56, 64], ["infections", "OBSERVATION", 68, 78], ["positive bacteria", "OBSERVATION", 88, 105]]], ["For this reason, vancomycin or other MRSAcovering antibiotic should be included in the initial therapy.", [["vancomycin", "CHEMICAL", 17, 27], ["vancomycin", "CHEMICAL", 17, 27], ["vancomycin", "SIMPLE_CHEMICAL", 17, 27], ["vancomycin", "TREATMENT", 17, 27], ["other MRSAcovering antibiotic", "TREATMENT", 31, 60], ["the initial therapy", "TREATMENT", 83, 102]]], ["Antifungal therapy should be initiated only if the gram stain reveals yeast.", [["yeast", "SPECIES", 70, 75], ["yeast", "SPECIES", 70, 75], ["Antifungal therapy", "TREATMENT", 0, 18], ["the gram stain", "TEST", 47, 61], ["yeast", "PROBLEM", 70, 75], ["yeast", "OBSERVATION", 70, 75]]], ["Catheter removal should be considered in certain circumstances but is not necessarily indicated with every infection.", [["Catheter", "ANATOMY", 0, 8], ["infection", "DISEASE", 107, 116], ["Catheter removal", "TREATMENT", 0, 16], ["every infection", "PROBLEM", 101, 116], ["infection", "OBSERVATION", 107, 116]]], ["Indications for removal of catheter include a repeat infection after 4 weeks of antibiotic therapy, infection not responding to antibiotics, fungal peritonitis, or other resistant causes of peritonitis.", [["infection", "DISEASE", 53, 62], ["infection", "DISEASE", 100, 109], ["fungal peritonitis", "DISEASE", 141, 159], ["peritonitis", "DISEASE", 190, 201], ["removal of catheter", "TREATMENT", 16, 35], ["a repeat infection", "PROBLEM", 44, 62], ["antibiotic therapy", "TREATMENT", 80, 98], ["infection", "PROBLEM", 100, 109], ["antibiotics", "TREATMENT", 128, 139], ["fungal peritonitis", "PROBLEM", 141, 159], ["peritonitis", "PROBLEM", 190, 201], ["catheter", "OBSERVATION", 27, 35], ["infection", "OBSERVATION", 53, 62], ["peritonitis", "OBSERVATION", 148, 159], ["peritonitis", "OBSERVATION", 190, 201]]], ["A 65-year-old man with a history of hepatitis C and progressive liver disease presents to the hospital with increasing low-grade fever, abdominal pain, and distension.", [["liver", "ANATOMY", 64, 69], ["abdominal", "ANATOMY", 136, 145], ["hepatitis C", "DISEASE", 36, 47], ["liver disease", "DISEASE", 64, 77], ["fever", "DISEASE", 129, 134], ["abdominal pain", "DISEASE", 136, 150], ["man", "ORGANISM", 14, 17], ["liver", "ORGAN", 64, 69], ["abdominal", "ORGANISM_SUBDIVISION", 136, 145], ["man", "SPECIES", 14, 17], ["hepatitis C", "PROBLEM", 36, 47], ["progressive liver disease", "PROBLEM", 52, 77], ["increasing low-grade fever", "PROBLEM", 108, 134], ["abdominal pain", "PROBLEM", 136, 150], ["distension", "PROBLEM", 156, 166], ["hepatitis", "OBSERVATION", 36, 45], ["progressive", "OBSERVATION_MODIFIER", 52, 63], ["liver", "ANATOMY", 64, 69], ["disease", "OBSERVATION", 70, 77], ["increasing", "OBSERVATION_MODIFIER", 108, 118], ["low-grade", "OBSERVATION_MODIFIER", 119, 128], ["fever", "OBSERVATION", 129, 134], ["abdominal", "ANATOMY", 136, 145], ["pain", "OBSERVATION", 146, 150], ["distension", "OBSERVATION", 156, 166]]], ["He is currently on furosemide, spironolactone, and nadolol.", [["furosemide", "CHEMICAL", 19, 29], ["spironolactone", "CHEMICAL", 31, 45], ["nadolol", "CHEMICAL", 51, 58], ["furosemide", "CHEMICAL", 19, 29], ["spironolactone", "CHEMICAL", 31, 45], ["nadolol", "CHEMICAL", 51, 58], ["furosemide", "SIMPLE_CHEMICAL", 19, 29], ["spironolactone", "SIMPLE_CHEMICAL", 31, 45], ["nadolol", "SIMPLE_CHEMICAL", 51, 58], ["furosemide", "TREATMENT", 19, 29], ["spironolactone", "TREATMENT", 31, 45], ["nadolol", "TREATMENT", 51, 58]]], ["On physical examination, his temperature is 37.5 \u00b0C(99.5 \u00b0F), blood pressure is 100/50 mmHg.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["physical examination", "TEST", 3, 23], ["his temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 62, 76]]], ["Abdominal examination reveals distended abdomen and marked ascites.", [["Abdominal", "ANATOMY", 0, 9], ["abdomen", "ANATOMY", 40, 47], ["ascites", "ANATOMY", 59, 66], ["ascites", "DISEASE", 59, 66], ["abdomen", "ORGAN", 40, 47], ["Abdominal examination", "TEST", 0, 21], ["distended abdomen", "PROBLEM", 30, 47], ["marked ascites", "PROBLEM", 52, 66], ["distended", "OBSERVATION", 30, 39], ["abdomen", "ANATOMY", 40, 47], ["marked", "OBSERVATION_MODIFIER", 52, 58], ["ascites", "OBSERVATION", 59, 66]]], ["The abdomen is mildly tender upon palpation.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["mildly tender", "PROBLEM", 15, 28], ["palpation", "TEST", 34, 43], ["abdomen", "ANATOMY", 4, 11], ["mildly", "OBSERVATION_MODIFIER", 15, 21], ["tender", "OBSERVATION", 22, 28], ["palpation", "OBSERVATION", 34, 43]]], ["Creatinine is 0.8 mg/dl and total bilirubin is 2.1 mg/dl.ReferenceAbdominal ultrasound is consistent with cirrhosis, splenomegaly, and large volume of ascites.", [["ascites", "ANATOMY", 151, 158], ["Creatinine", "CHEMICAL", 0, 10], ["bilirubin", "CHEMICAL", 34, 43], ["cirrhosis", "DISEASE", 106, 115], ["splenomegaly", "DISEASE", 117, 129], ["ascites", "DISEASE", 151, 158], ["Creatinine", "CHEMICAL", 0, 10], ["bilirubin", "CHEMICAL", 34, 43], ["Creatinine", "SIMPLE_CHEMICAL", 0, 10], ["bilirubin", "GENE_OR_GENE_PRODUCT", 34, 43], ["Creatinine", "TEST", 0, 10], ["total bilirubin", "TEST", 28, 43], ["ReferenceAbdominal ultrasound", "TEST", 57, 86], ["cirrhosis", "PROBLEM", 106, 115], ["splenomegaly", "PROBLEM", 117, 129], ["large volume of ascites", "PROBLEM", 135, 158], ["consistent with", "UNCERTAINTY", 90, 105], ["cirrhosis", "OBSERVATION", 106, 115], ["splenomegaly", "OBSERVATION", 117, 129], ["large", "OBSERVATION_MODIFIER", 135, 140], ["volume", "OBSERVATION_MODIFIER", 141, 147], ["ascites", "OBSERVATION", 151, 158]]], ["Diagnostic paracentesis is scheduled.ReferenceThe most appropriate initial treatment is?", [["Diagnostic paracentesis", "TREATMENT", 0, 23]]], ["A) Cefotaxime B) Cefotaxime and albumin C) Furosemide and spironolactone D) Large volume paracentesis Answer: A Spontaneous bacterial peritonitis (SBP) is a common complication of end-stage liver disease.", [["liver", "ANATOMY", 190, 195], ["Cefotaxime B", "CHEMICAL", 3, 15], ["Cefotaxime", "CHEMICAL", 17, 27], ["Furosemide", "CHEMICAL", 43, 53], ["spironolactone", "CHEMICAL", 58, 72], ["Spontaneous bacterial peritonitis", "DISEASE", 112, 145], ["end-stage liver disease", "DISEASE", 180, 203], ["Cefotaxime B", "CHEMICAL", 3, 15], ["Cefotaxime", "CHEMICAL", 17, 27], ["Furosemide", "CHEMICAL", 43, 53], ["spironolactone D", "CHEMICAL", 58, 74], ["Cefotaxime B", "SIMPLE_CHEMICAL", 3, 15], ["Cefotaxime", "SIMPLE_CHEMICAL", 17, 27], ["albumin C", "SIMPLE_CHEMICAL", 32, 41], ["Furosemide", "SIMPLE_CHEMICAL", 43, 53], ["spironolactone D", "SIMPLE_CHEMICAL", 58, 74], ["liver", "ORGAN", 190, 195], ["A) Cefotaxime B) Cefotaxime", "TREATMENT", 0, 27], ["albumin C", "TREATMENT", 32, 41], ["Furosemide", "TREATMENT", 43, 53], ["spironolactone D", "TREATMENT", 58, 74], ["Large volume paracentesis", "TREATMENT", 76, 101], ["A Spontaneous bacterial peritonitis", "PROBLEM", 110, 145], ["a common complication", "PROBLEM", 155, 176], ["end-stage liver disease", "PROBLEM", 180, 203], ["bacterial", "OBSERVATION_MODIFIER", 124, 133], ["peritonitis", "OBSERVATION", 134, 145], ["stage", "OBSERVATION_MODIFIER", 184, 189], ["liver", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203]]], ["Initial treatment consists of antibiotics that have coverage of gram-negative bacteria.", [["antibiotics", "TREATMENT", 30, 41], ["gram-negative bacteria", "PROBLEM", 64, 86], ["negative bacteria", "OBSERVATION", 69, 86]]], ["Common isolates are Escherichia coli and Klebsiella pneumonia .", [["Klebsiella pneumonia", "DISEASE", 41, 61], ["Escherichia coli", "ORGANISM", 20, 36], ["Klebsiella pneumonia", "ORGANISM", 41, 61], ["Escherichia coli", "SPECIES", 20, 36], ["Escherichia coli", "SPECIES", 20, 36], ["Klebsiella pneumonia", "SPECIES", 41, 61], ["Common isolates", "PROBLEM", 0, 15], ["Escherichia coli", "PROBLEM", 20, 36], ["Klebsiella pneumonia", "PROBLEM", 41, 61], ["Escherichia coli", "OBSERVATION", 20, 36], ["Klebsiella", "OBSERVATION_MODIFIER", 41, 51], ["pneumonia", "OBSERVATION", 52, 61]]], ["There is no evidence that large volume paracentesis improves outcomes in patients with spontaneous bacterial peritonitis.", [["bacterial peritonitis", "DISEASE", 99, 120], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["large volume paracentesis", "TREATMENT", 26, 51], ["spontaneous bacterial peritonitis", "PROBLEM", 87, 120], ["no evidence that", "UNCERTAINTY", 9, 25], ["large", "OBSERVATION_MODIFIER", 26, 31], ["volume", "OBSERVATION_MODIFIER", 32, 38], ["paracentesis", "OBSERVATION", 39, 51], ["bacterial peritonitis", "OBSERVATION", 99, 120]]], ["Diagnostic paracentesis should be undertaken to confi rm the diagnosis.", [["Diagnostic paracentesis", "TREATMENT", 0, 23]]], ["SBP is confi rmed when a WBC count of >250 per microliter is found.", [["WBC", "ANATOMY", 25, 28], ["SBP", "TEST", 0, 3], ["a WBC count", "TEST", 23, 34]]], ["Additional paracentesis can be considered to determine the effi cacy of treatment or to relieve symptoms.ReferenceReference Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ.", [["Kontou-Kastellanou C", "CELL", 182, 202], ["Archimandritis AJ", "CELL", 204, 221], ["Additional paracentesis", "TREATMENT", 0, 23], ["treatment", "TREATMENT", 72, 81], ["symptoms", "PROBLEM", 96, 104], ["Cholongitas", "TEST", 124, 135], ["paracentesis", "OBSERVATION", 11, 23]]], ["Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis.", [["bacterial peritonitis", "DISEASE", 62, 83], ["Gram-", "GENE_OR_GENE_PRODUCT", 24, 29], ["Gram-positive bacteria", "PROBLEM", 24, 46], ["spontaneous bacterial peritonitis", "PROBLEM", 50, 83], ["Gram-positive bacteria", "OBSERVATION", 24, 46], ["spontaneous bacterial peritonitis", "OBSERVATION", 50, 83]]], ["Liver Int.", [["Liver", "ANATOMY", 0, 5], ["Liver", "ORGAN", 0, 5], ["Int.", "OBSERVATION", 6, 10]]], ["2005; 25 (1):57-61.Reference14.", [["Reference14", "PROTEIN", 19, 30]]], ["A 45-year-old woman is being admitted for continued fever.", [["fever", "DISEASE", 52, 57], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["continued fever", "PROBLEM", 42, 57], ["45-", "OBSERVATION_MODIFIER", 2, 5], ["fever", "OBSERVATION", 52, 57]]], ["Her symptoms started fi ve weeks ago with the onset of low-grade daily fever.", [["fever", "DISEASE", 71, 76], ["Her symptoms", "PROBLEM", 0, 12], ["low-grade daily fever", "PROBLEM", 55, 76], ["low-grade", "OBSERVATION_MODIFIER", 55, 64], ["fever", "OBSERVATION", 71, 76]]], ["Over the past 2 weeks, she has developed erythematous rash, fatigue, and weight loss.", [["rash", "DISEASE", 54, 58], ["fatigue", "DISEASE", 60, 67], ["weight loss", "DISEASE", 73, 84], ["erythematous rash", "PROBLEM", 41, 58], ["fatigue", "PROBLEM", 60, 67], ["weight loss", "PROBLEM", 73, 84], ["erythematous", "OBSERVATION_MODIFIER", 41, 53], ["rash", "OBSERVATION", 54, 58], ["fatigue", "OBSERVATION", 60, 67], ["weight loss", "OBSERVATION", 73, 84]]], ["Limited workup has been unrevealing.", [["Limited workup", "TEST", 0, 14]]], ["Her medical history is only signifi cant for hypertension.", [["hypertension", "DISEASE", 45, 57], ["hypertension", "PROBLEM", 45, 57], ["hypertension", "OBSERVATION", 45, 57]]], ["She takes lisinopril.", [["lisinopril", "CHEMICAL", 10, 20], ["lisinopril", "CHEMICAL", 10, 20], ["lisinopril", "SIMPLE_CHEMICAL", 10, 20], ["lisinopril", "TREATMENT", 10, 20]]], ["On physical exam, the patient's temperature is found to be 38.3 \u00b0C (101.0 \u00b0F), a 2/6 murmur is heard in the mitral area of the chest, and an erythematous rash is noted on both legs.", [["mitral area", "ANATOMY", 108, 119], ["chest", "ANATOMY", 127, 132], ["legs", "ANATOMY", 176, 180], ["rash", "DISEASE", 154, 158], ["patient", "ORGANISM", 22, 29], ["mitral area", "MULTI-TISSUE_STRUCTURE", 108, 119], ["chest", "ORGAN", 127, 132], ["legs", "ORGANISM_SUBDIVISION", 176, 180], ["patient", "SPECIES", 22, 29], ["physical exam", "TEST", 3, 16], ["the patient's temperature", "TEST", 18, 43], ["\u00b0C", "TEST", 64, 66], ["a 2/6 murmur", "PROBLEM", 79, 91], ["an erythematous rash", "PROBLEM", 138, 158], ["murmur", "OBSERVATION", 85, 91], ["mitral", "ANATOMY", 108, 114], ["area", "ANATOMY_MODIFIER", 115, 119], ["chest", "ANATOMY", 127, 132], ["erythematous", "OBSERVATION_MODIFIER", 141, 153], ["rash", "OBSERVATION", 154, 158], ["both", "ANATOMY_MODIFIER", 171, 175], ["legs", "ANATOMY", 176, 180]]], ["A complete blood count shows anemia.", [["blood", "ANATOMY", 11, 16], ["anemia", "DISEASE", 29, 35], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["A complete blood count", "TEST", 0, 22], ["anemia", "PROBLEM", 29, 35], ["anemia", "OBSERVATION", 29, 35]]], ["The patient's erythrocyte sedimentation rate (ESR) is elevated at 80 mm/h.", [["erythrocyte", "ANATOMY", 14, 25], ["patient", "ORGANISM", 4, 11], ["erythrocyte", "CELL", 14, 25], ["patient", "SPECIES", 4, 11], ["The patient's erythrocyte sedimentation rate", "TEST", 0, 44], ["ESR", "TEST", 46, 49], ["elevated", "PROBLEM", 54, 62]]], ["A transthoracic echocardiogram shows a 2 cm pedunculated mass in the left atrium.ReferenceWhich of the following is the most likely diagnosis?", [["pedunculated mass", "ANATOMY", 44, 61], ["left atrium", "ANATOMY", 69, 80], ["atrium", "MULTI-TISSUE_STRUCTURE", 74, 80], ["A transthoracic echocardiogram", "TEST", 0, 30], ["a 2 cm pedunculated mass in the left atrium", "PROBLEM", 37, 80], ["2 cm", "OBSERVATION_MODIFIER", 39, 43], ["pedunculated", "OBSERVATION_MODIFIER", 44, 56], ["mass", "OBSERVATION", 57, 61], ["left atrium", "ANATOMY", 69, 80], ["most likely", "UNCERTAINTY", 120, 131]]], ["A) Metastatic colon adenocarcinoma B) Cardiac rhabdomyosarcoma C) Papillary fi broelastoma D) Cardiac myxoma E) Endocarditis Answer: D This patient has an atrial myxoma.", [["Metastatic colon adenocarcinoma B", "ANATOMY", 3, 36], ["Cardiac rhabdomyosarcoma C) Papillary fi broelastoma", "ANATOMY", 38, 90], ["atrial myxoma", "ANATOMY", 155, 168], ["Metastatic colon adenocarcinoma B", "DISEASE", 3, 36], ["Cardiac rhabdomyosarcoma", "DISEASE", 38, 62], ["Cardiac myxoma", "DISEASE", 94, 108], ["Endocarditis", "DISEASE", 112, 124], ["atrial myxoma", "DISEASE", 155, 168], ["D", "CHEMICAL", 133, 134], ["Metastatic colon adenocarcinoma B", "CANCER", 3, 36], ["Cardiac rhabdomyosarcoma C", "CANCER", 38, 64], ["Papillary fi broelastoma D", "CANCER", 66, 92], ["patient", "ORGANISM", 140, 147], ["atrial myxoma", "CANCER", 155, 168], ["patient", "SPECIES", 140, 147], ["A) Metastatic colon adenocarcinoma", "PROBLEM", 0, 34], ["Cardiac rhabdomyosarcoma C", "PROBLEM", 38, 64], ["Papillary fi broelastoma D)", "PROBLEM", 66, 93], ["Cardiac myxoma E", "PROBLEM", 94, 110], ["Endocarditis", "PROBLEM", 112, 124], ["an atrial myxoma", "PROBLEM", 152, 168], ["Metastatic", "OBSERVATION_MODIFIER", 3, 13], ["colon", "ANATOMY", 14, 19], ["adenocarcinoma", "OBSERVATION", 20, 34], ["Cardiac", "ANATOMY", 38, 45], ["rhabdomyosarcoma", "OBSERVATION", 46, 62], ["Papillary fi", "ANATOMY", 66, 78], ["Cardiac", "ANATOMY", 94, 101], ["myxoma", "OBSERVATION", 102, 108], ["Endocarditis", "OBSERVATION", 112, 124], ["atrial", "ANATOMY", 155, 161], ["myxoma", "OBSERVATION", 162, 168]]], ["Myxomas consist of benign scattered stellate cells embedded in a mucinous matrix.", [["Myxomas", "ANATOMY", 0, 7], ["stellate cells", "ANATOMY", 36, 50], ["mucinous matrix", "ANATOMY", 65, 80], ["Myxomas", "DISEASE", 0, 7], ["stellate cells", "CELL", 36, 50], ["mucinous matrix", "TISSUE", 65, 80], ["benign scattered stellate cells", "CELL_TYPE", 19, 50], ["Myxomas", "PROBLEM", 0, 7], ["benign scattered stellate cells", "PROBLEM", 19, 50], ["a mucinous matrix", "PROBLEM", 63, 80], ["benign", "OBSERVATION_MODIFIER", 19, 25], ["scattered", "OBSERVATION_MODIFIER", 26, 35], ["stellate cells", "OBSERVATION", 36, 50], ["mucinous matrix", "OBSERVATION", 65, 80]]], ["About 70 % of myxomas are in the left atrium.", [["myxomas", "ANATOMY", 14, 21], ["left atrium", "ANATOMY", 33, 44], ["myxomas", "DISEASE", 14, 21], ["myxomas", "CANCER", 14, 21], ["left atrium", "MULTI-TISSUE_STRUCTURE", 33, 44], ["myxomas", "PROBLEM", 14, 21], ["myxomas", "OBSERVATION", 14, 21], ["left atrium", "ANATOMY", 33, 44]]], ["Myxomas often present clinically with mechanical hemodynamic effects, which often simulate mitral or tricuspid stenoses or regurgitation.", [["mitral", "ANATOMY", 91, 97], ["tricuspid", "ANATOMY", 101, 110], ["Myxomas", "DISEASE", 0, 7], ["mitral or tricuspid stenoses", "DISEASE", 91, 119], ["mitral", "MULTI-TISSUE_STRUCTURE", 91, 97], ["tricuspid", "PATHOLOGICAL_FORMATION", 101, 110], ["Myxomas", "PROBLEM", 0, 7], ["mechanical hemodynamic effects", "PROBLEM", 38, 68], ["mitral or tricuspid stenoses", "PROBLEM", 91, 119], ["regurgitation", "PROBLEM", 123, 136], ["hemodynamic effects", "OBSERVATION", 49, 68], ["mitral", "OBSERVATION", 91, 97], ["tricuspid", "ANATOMY", 101, 110], ["stenoses", "OBSERVATION", 111, 119], ["regurgitation", "OBSERVATION", 123, 136]]], ["Systemic symptoms include fatigue, fever, erythematous rash, myalgias, and weight loss, accompanied by anemia and an increased ESR.", [["erythematous", "ANATOMY", 42, 54], ["fatigue", "DISEASE", 26, 33], ["fever", "DISEASE", 35, 40], ["rash", "DISEASE", 55, 59], ["myalgias", "DISEASE", 61, 69], ["weight loss", "DISEASE", 75, 86], ["anemia", "DISEASE", 103, 109], ["ESR", "PROTEIN", 127, 130], ["Systemic symptoms", "PROBLEM", 0, 17], ["fatigue", "PROBLEM", 26, 33], ["fever", "PROBLEM", 35, 40], ["erythematous rash", "PROBLEM", 42, 59], ["myalgias", "PROBLEM", 61, 69], ["weight loss", "PROBLEM", 75, 86], ["anemia", "PROBLEM", 103, 109], ["an increased ESR", "PROBLEM", 114, 130], ["fatigue", "OBSERVATION", 26, 33], ["fever", "OBSERVATION_MODIFIER", 35, 40], ["erythematous", "OBSERVATION_MODIFIER", 42, 54], ["rash", "OBSERVATION", 55, 59], ["myalgias", "OBSERVATION", 61, 69], ["weight loss", "OBSERVATION_MODIFIER", 75, 86], ["anemia", "OBSERVATION", 103, 109], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["ESR", "OBSERVATION", 127, 130]]], ["These symptoms may mimic endocarditis.", [["endocarditis", "DISEASE", 25, 37], ["These symptoms", "PROBLEM", 0, 14], ["endocarditis", "PROBLEM", 25, 37], ["endocarditis", "OBSERVATION", 25, 37]]], ["About 10 % of myxomas are genetic.", [["myxomas", "ANATOMY", 14, 21], ["myxomas", "DISEASE", 14, 21], ["myxomas", "CANCER", 14, 21], ["myxomas", "PROBLEM", 14, 21], ["myxomas", "OBSERVATION", 14, 21]]], ["Surgery is the primary treatment.", [["Surgery", "TREATMENT", 0, 7], ["the primary treatment", "TREATMENT", 11, 32]]], ["Cardiac tumors are usually metastatic.", [["Cardiac tumors", "ANATOMY", 0, 14], ["Cardiac tumors", "DISEASE", 0, 14], ["Cardiac tumors", "CANCER", 0, 14], ["Cardiac tumors", "PROBLEM", 0, 14], ["metastatic", "PROBLEM", 27, 37], ["tumors", "OBSERVATION", 8, 14], ["metastatic", "OBSERVATION", 27, 37]]], ["Metastatic cardiac involvement occurs 20-40 times more frequently than primary tumors.", [["Metastatic cardiac", "ANATOMY", 0, 18], ["primary tumors", "ANATOMY", 71, 85], ["primary tumors", "DISEASE", 71, 85], ["cardiac", "ORGAN", 11, 18], ["tumors", "CANCER", 79, 85], ["Metastatic cardiac involvement", "PROBLEM", 0, 30], ["primary tumors", "PROBLEM", 71, 85], ["involvement", "OBSERVATION", 19, 30], ["20-40 times", "OBSERVATION_MODIFIER", 38, 49], ["tumors", "OBSERVATION", 79, 85]]], ["Eighty percent of all primary cardiac tumors are benign.", [["primary cardiac tumors", "ANATOMY", 22, 44], ["cardiac tumors", "DISEASE", 30, 44], ["cardiac tumors", "CANCER", 30, 44], ["all primary cardiac tumors", "PROBLEM", 18, 44], ["all", "OBSERVATION_MODIFIER", 18, 21], ["primary", "OBSERVATION_MODIFIER", 22, 29], ["cardiac", "ANATOMY", 30, 37], ["tumors", "OBSERVATION", 38, 44], ["benign", "OBSERVATION_MODIFIER", 49, 55]]], ["Myxomas account for more than half of these in adults.ReferenceLarsson S, Lepore V, Kennergren C. Atrial myxomas: results of 25 years' experience and review of the literature.", [["Atrial myxomas", "ANATOMY", 98, 112], ["Myxomas", "DISEASE", 0, 7], ["Atrial myxomas", "DISEASE", 98, 112], ["Myxomas", "CANCER", 0, 7], ["Atrial myxomas", "CANCER", 98, 112], ["Myxomas", "PROBLEM", 0, 7], ["Atrial myxomas", "PROBLEM", 98, 112], ["Atrial", "ANATOMY", 98, 104], ["myxomas", "OBSERVATION", 105, 112]]], ["Surgery.", [["Surgery", "TREATMENT", 0, 7]]], ["You are asked to admit a 40-year-old man with atypical chest pain.", [["chest", "ANATOMY", 55, 60], ["chest pain", "DISEASE", 55, 65], ["man", "ORGANISM", 37, 40], ["chest", "ORGANISM_SUBDIVISION", 55, 60], ["man", "SPECIES", 37, 40], ["atypical chest pain", "PROBLEM", 46, 65], ["atypical", "OBSERVATION_MODIFIER", 46, 54], ["chest", "ANATOMY", 55, 60], ["pain", "OBSERVATION", 61, 65]]], ["He reports the abrupt onset of an exertional type of pain.", [["pain", "DISEASE", 53, 57], ["an exertional type of pain", "PROBLEM", 31, 57], ["abrupt", "OBSERVATION_MODIFIER", 15, 21]]], ["The emergency room staff is concerned that the pain may be angina.", [["pain", "DISEASE", 47, 51], ["angina", "DISEASE", 59, 65], ["the pain", "PROBLEM", 43, 51], ["angina", "PROBLEM", 59, 65], ["angina", "OBSERVATION", 59, 65]]], ["On further questioning by you, he reports a constant pain of 4 days duration.", [["pain", "DISEASE", 53, 57], ["a constant pain", "PROBLEM", 42, 57]]], ["The pain is worse with inspiration and is positional.", [["pain", "DISEASE", 4, 8], ["The pain", "PROBLEM", 0, 8], ["pain", "OBSERVATION", 4, 8], ["worse", "OBSERVATION_MODIFIER", 12, 17], ["positional", "OBSERVATION_MODIFIER", 42, 52]]], ["He also reports recent fever.", [["fever", "DISEASE", 23, 28], ["recent fever", "PROBLEM", 16, 28], ["fever", "OBSERVATION", 23, 28]]], ["On physical exam, he has diffuse mild chest wall tenderness but is primarily positional in nature.", [["chest wall", "ANATOMY", 38, 48], ["chest wall tenderness", "DISEASE", 38, 59], ["chest wall", "PATHOLOGICAL_FORMATION", 38, 48], ["physical exam", "TEST", 3, 16], ["diffuse mild chest wall tenderness", "PROBLEM", 25, 59], ["diffuse", "OBSERVATION_MODIFIER", 25, 32], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["chest", "ANATOMY", 38, 43], ["wall", "ANATOMY_MODIFIER", 44, 48], ["tenderness", "OBSERVATION", 49, 59], ["positional", "OBSERVATION_MODIFIER", 77, 87]]], ["An ECG shows 2 mm elevation ST elevation in the precordial leads, without reciprocal changes and with PR segment depression in lead 2.", [["depression", "DISEASE", 113, 123], ["PR", "PROTEIN", 102, 104], ["An ECG", "TEST", 0, 6], ["2 mm elevation ST elevation in the precordial leads", "PROBLEM", 13, 64], ["reciprocal changes", "PROBLEM", 74, 92], ["PR segment depression in lead 2", "PROBLEM", 102, 133], ["2 mm", "OBSERVATION_MODIFIER", 13, 17], ["elevation", "OBSERVATION", 18, 27], ["elevation", "OBSERVATION_MODIFIER", 31, 40], ["precordial", "ANATOMY_MODIFIER", 48, 58], ["without", "UNCERTAINTY", 66, 73], ["reciprocal changes", "OBSERVATION", 74, 92], ["segment depression", "OBSERVATION", 105, 123]]], ["An echocardiogram performed in the emergency room is normal.", [["An echocardiogram", "TEST", 0, 17], ["normal", "OBSERVATION", 53, 59]]], ["A CT angiogram of the chest is pending.ReferenceWhat is the most likely diagnosis and treatment for this patient?", [["chest", "ANATOMY", 22, 27], ["chest", "ORGAN", 22, 27], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["A CT angiogram of the chest", "TEST", 0, 27], ["treatment", "TREATMENT", 86, 95], ["chest", "ANATOMY", 22, 27], ["most likely", "UNCERTAINTY", 60, 71]]], ["A) Acute pericarditis; nonsteroidal anti-infl ammatory drug (NSAID) are indicated B) Acute pericarditis; start prednisone C) Acute pericarditis; echocardiogram in 1 week to confi rm diagnosis D) Musculoskeletal strain; observation alone E) Pulmonary embolism Answer: A The patient has acute pericarditis.", [["pericarditis", "DISEASE", 9, 21], ["pericarditis", "DISEASE", 91, 103], ["prednisone", "CHEMICAL", 111, 121], ["pericarditis", "DISEASE", 131, 143], ["Pulmonary embolism", "DISEASE", 240, 258], ["pericarditis", "DISEASE", 291, 303], ["prednisone C", "CHEMICAL", 111, 123], ["NSAID", "SIMPLE_CHEMICAL", 61, 66], ["patient", "ORGANISM", 273, 280], ["patient", "SPECIES", 273, 280], ["Acute pericarditis", "PROBLEM", 3, 21], ["nonsteroidal anti-infl ammatory drug (NSAID", "TREATMENT", 23, 66], ["Acute pericarditis", "PROBLEM", 85, 103], ["prednisone C", "TREATMENT", 111, 123], ["Acute pericarditis", "PROBLEM", 125, 143], ["echocardiogram", "TEST", 145, 159], ["Musculoskeletal strain", "PROBLEM", 195, 217], ["Pulmonary embolism", "PROBLEM", 240, 258], ["acute pericarditis", "PROBLEM", 285, 303], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["pericarditis", "OBSERVATION", 9, 21], ["Acute", "OBSERVATION_MODIFIER", 85, 90], ["pericarditis", "OBSERVATION", 91, 103], ["Acute", "OBSERVATION_MODIFIER", 125, 130], ["pericarditis", "OBSERVATION", 131, 143], ["Musculoskeletal", "ANATOMY", 195, 210], ["Pulmonary", "ANATOMY", 240, 249], ["embolism", "OBSERVATION", 250, 258], ["acute", "OBSERVATION_MODIFIER", 285, 290], ["pericarditis", "OBSERVATION", 291, 303]]], ["The chest pain of acute pericarditis is sudden and severe.", [["chest", "ANATOMY", 4, 9], ["chest pain", "DISEASE", 4, 14], ["pericarditis", "DISEASE", 24, 36], ["chest", "ORGANISM_SUBDIVISION", 4, 9], ["The chest pain", "PROBLEM", 0, 14], ["acute pericarditis", "PROBLEM", 18, 36], ["chest", "ANATOMY", 4, 9], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["pericarditis", "OBSERVATION", 24, 36], ["severe", "OBSERVATION_MODIFIER", 51, 57]]], ["It is constant over the anterior chest.", [["anterior chest", "ANATOMY", 24, 38], ["anterior chest", "MULTI-TISSUE_STRUCTURE", 24, 38], ["constant", "OBSERVATION_MODIFIER", 6, 14], ["anterior", "ANATOMY_MODIFIER", 24, 32], ["chest", "ANATOMY", 33, 38]]], ["In acute pericarditis, the pain worsens with inspiration and is reliably positional.", [["pericarditis", "DISEASE", 9, 21], ["pain", "DISEASE", 27, 31], ["acute pericarditis", "PROBLEM", 3, 21], ["the pain", "PROBLEM", 23, 31], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["pericarditis", "OBSERVATION", 9, 21], ["positional", "OBSERVATION_MODIFIER", 73, 83]]], ["The absence of a signifi cant effusion on echocardiography is not evidence against acute pericarditis.", [["effusion", "DISEASE", 30, 38], ["pericarditis", "DISEASE", 89, 101], ["a signifi cant effusion", "PROBLEM", 15, 38], ["echocardiography", "TEST", 42, 58], ["acute pericarditis", "PROBLEM", 83, 101], ["effusion", "OBSERVATION", 30, 38], ["not evidence against", "UNCERTAINTY", 62, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["pericarditis", "OBSERVATION", 89, 101]]], ["Salicylates or NSAIDs are the fi rst-line agents for treatment.", [["Salicylates", "CHEMICAL", 0, 11], ["NSAIDs", "CHEMICAL", 15, 21], ["Salicylates", "CHEMICAL", 0, 11], ["Salicylates", "SIMPLE_CHEMICAL", 0, 11], ["NSAIDs", "SIMPLE_CHEMICAL", 15, 21], ["Salicylates", "TREATMENT", 0, 11], ["NSAIDs", "TREATMENT", 15, 21], ["the fi rst-line agents", "TREATMENT", 26, 48], ["treatment", "TREATMENT", 53, 62]]], ["Corticosteroids should be reserved for severe cases that are unresponsive to initial therapy.", [["Corticosteroids", "TREATMENT", 0, 15], ["severe cases", "PROBLEM", 39, 51], ["initial therapy", "TREATMENT", 77, 92]]], ["Symptoms may recur after steroid withdrawal, making their use problematic.", [["steroid", "CHEMICAL", 25, 32], ["steroid", "CHEMICAL", 25, 32], ["Symptoms", "PROBLEM", 0, 8], ["steroid withdrawal", "PROBLEM", 25, 43]]], ["Low-grade fever and sinus tachycardia may be present.", [["sinus", "ANATOMY", 20, 25], ["fever", "DISEASE", 10, 15], ["sinus tachycardia", "DISEASE", 20, 37], ["Low-grade fever", "PROBLEM", 0, 15], ["sinus tachycardia", "PROBLEM", 20, 37], ["-grade", "OBSERVATION_MODIFIER", 3, 9], ["fever", "OBSERVATION", 10, 15], ["sinus", "ANATOMY", 20, 25], ["tachycardia", "OBSERVATION", 26, 37], ["may be", "UNCERTAINTY", 38, 44]]], ["If carefully auscultated, a pericardial friction rub can be detected in most patients when symptoms are acute.", [["pericardial", "ANATOMY", 28, 39], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["a pericardial friction rub", "TREATMENT", 26, 52], ["symptoms", "PROBLEM", 91, 99], ["acute", "PROBLEM", 104, 109], ["pericardial", "ANATOMY", 28, 39], ["friction", "OBSERVATION", 40, 48], ["acute", "OBSERVATION_MODIFIER", 104, 109]]], ["Electrocardiographic changes are common in infectious pericarditis and can occur with other etiologies as well.", [["infectious pericarditis", "DISEASE", 43, 66], ["Electrocardiographic changes", "PROBLEM", 0, 28], ["infectious pericarditis", "PROBLEM", 43, 66], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["pericarditis", "OBSERVATION", 54, 66]]], ["The characteristic change is an elevation in the ST segment in all leads.", [["ST segment", "DNA", 49, 59], ["an elevation in the ST segment in all leads", "PROBLEM", 29, 72], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["change", "OBSERVATION", 19, 25], ["elevation", "OBSERVATION", 32, 41], ["ST segment", "ANATOMY_MODIFIER", 49, 59], ["all leads", "ANATOMY_MODIFIER", 63, 72]]], ["The absence of reciprocal ST segment depression distinguishes this characteristic pattern of acute pericarditis from acute myocardial infarction.", [["myocardial", "ANATOMY", 123, 133], ["depression", "DISEASE", 37, 47], ["pericarditis", "DISEASE", 99, 111], ["acute myocardial infarction", "DISEASE", 117, 144], ["myocardial", "MULTI-TISSUE_STRUCTURE", 123, 133], ["reciprocal ST segment depression", "PROBLEM", 15, 47], ["acute pericarditis", "PROBLEM", 93, 111], ["acute myocardial infarction", "PROBLEM", 117, 144], ["segment depression", "OBSERVATION", 29, 47], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["pericarditis", "OBSERVATION", 99, 111], ["acute", "OBSERVATION_MODIFIER", 117, 122], ["myocardial", "ANATOMY", 123, 133], ["infarction", "OBSERVATION", 134, 144]]], ["Depression of the PR interval, which is not as obvious, is often the earliest electrocardiographic manifestation.ReferenceMaisch B, Seferovic PM, Ristic AD, Erbel R, Rienm\u00fcller R, Adler Y, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; the Task force on the diagnosis and management of pericardial diseases of the European society of cardiology.", [["pericardial", "ANATOMY", 242, 253], ["pericardial", "ANATOMY", 332, 343], ["Depression", "DISEASE", 0, 10], ["pericardial diseases", "DISEASE", 242, 262], ["pericardial diseases", "DISEASE", 332, 352], ["pericardial", "ORGAN", 242, 253], ["pericardial", "ORGAN", 332, 343], ["PR", "PROTEIN", 18, 20], ["Depression of the PR interval", "PROBLEM", 0, 29], ["Ristic", "TEST", 146, 152], ["management", "TREATMENT", 228, 238], ["pericardial diseases", "PROBLEM", 242, 262], ["management", "TREATMENT", 318, 328], ["pericardial diseases", "PROBLEM", 332, 352], ["not as obvious", "UNCERTAINTY", 40, 54], ["pericardial", "ANATOMY", 242, 253], ["diseases", "OBSERVATION", 254, 262], ["pericardial", "ANATOMY", 332, 343], ["diseases", "OBSERVATION", 344, 352]]], ["Eur Heart J. 2004;25 (7):587-610.", [["Heart", "ANATOMY", 4, 9]]], ["A 45-year-old-man is brought to the emergency department by his family for lethargy, altered mental status, and abdominal discomfort.", [["abdominal", "ANATOMY", 112, 121], ["lethargy", "DISEASE", 75, 83], ["abdominal discomfort", "DISEASE", 112, 132], ["man", "ORGANISM", 14, 17], ["abdominal", "ORGANISM_SUBDIVISION", 112, 121], ["man", "SPECIES", 14, 17], ["lethargy", "PROBLEM", 75, 83], ["altered mental status", "PROBLEM", 85, 106], ["abdominal discomfort", "PROBLEM", 112, 132], ["abdominal", "ANATOMY", 112, 121], ["discomfort", "OBSERVATION", 122, 132]]], ["His past medical history includes combined diastolic and systolic heart disease with EF of 30 %, diabetes mellitus 2 with a HgA1c of 11 %, and a baseline creatinine of 1.8 units/L checked last week in clinic.", [["heart", "ANATOMY", 66, 71], ["diastolic and systolic heart disease", "DISEASE", 43, 79], ["diabetes mellitus", "DISEASE", 97, 114], ["creatinine", "CHEMICAL", 154, 164], ["creatinine", "CHEMICAL", 154, 164], ["heart", "ORGAN", 66, 71], ["combined diastolic and systolic heart disease", "PROBLEM", 34, 79], ["EF", "TEST", 85, 87], ["diabetes mellitus", "PROBLEM", 97, 114], ["a HgA1c", "TEST", 122, 129], ["a baseline creatinine", "TEST", 143, 164], ["diastolic", "OBSERVATION", 43, 52], ["systolic", "ANATOMY_MODIFIER", 57, 65], ["heart", "ANATOMY", 66, 71], ["disease", "OBSERVATION", 72, 79]]], ["However, the patient is not currently taking any medications for diabetic management.", [["diabetic", "DISEASE", 65, 73], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["any medications", "TREATMENT", 45, 60], ["diabetic management", "TREATMENT", 65, 84]]], ["His glucose on admission was 450 mg/dL with negative serum ketones.", [["serum", "ANATOMY", 53, 58], ["glucose", "CHEMICAL", 4, 11], ["ketones", "CHEMICAL", 59, 66], ["glucose", "CHEMICAL", 4, 11], ["ketones", "CHEMICAL", 59, 66], ["glucose", "SIMPLE_CHEMICAL", 4, 11], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["ketones", "SIMPLE_CHEMICAL", 59, 66], ["His glucose", "TEST", 0, 11], ["serum ketones", "TEST", 53, 66]]], ["A diagnosis of hyperosmolar nonketotic acidosis was made.", [["hyperosmolar nonketotic acidosis", "DISEASE", 15, 47], ["hyperosmolar nonketotic acidosis", "PROBLEM", 15, 47], ["hyperosmolar", "OBSERVATION", 15, 27], ["nonketotic acidosis", "OBSERVATION", 28, 47]]], ["The patient was treated with an intensive insulin drip and fl uids with resolution of symptoms.", [["patient", "ORGANISM", 4, 11], ["insulin", "GENE_OR_GENE_PRODUCT", 42, 49], ["patient", "SPECIES", 4, 11], ["an intensive insulin drip", "TREATMENT", 29, 54], ["fl uids", "TREATMENT", 59, 66], ["symptoms", "PROBLEM", 86, 94]]], ["A successful transition to basal-prandial insulin regimen is made the next day.", [["insulin", "GENE_OR_GENE_PRODUCT", 42, 49], ["basal-prandial insulin regimen", "TREATMENT", 27, 57], ["prandial insulin", "OBSERVATION", 33, 49]]], ["What is the best diabetic regimen to discharge your patient home on?", [["diabetic", "DISEASE", 17, 25], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59]]], ["A) Metformin BID plus lantus 10U SQ nightly B) Levemir SQ nightly with prandial novolog with meals C) Glyburide 5 mg daily and insulin sliding scale D) Dual oral therapy with metformin and rosiglitazone Answer: B The patient presented with hyperosmolar nonketotic acidosis and a hemoglobin A1c of 11 % meeting requirements to begin a basal-prandial insulin regimen.", [["oral", "ANATOMY", 157, 161], ["Metformin", "CHEMICAL", 3, 12], ["Glyburide", "CHEMICAL", 102, 111], ["metformin", "CHEMICAL", 175, 184], ["rosiglitazone", "CHEMICAL", 189, 202], ["hyperosmolar nonketotic acidosis", "DISEASE", 240, 272], ["Metformin", "CHEMICAL", 3, 12], ["metformin", "CHEMICAL", 175, 184], ["rosiglitazone", "CHEMICAL", 189, 202], ["Metformin", "SIMPLE_CHEMICAL", 3, 12], ["BID", "SIMPLE_CHEMICAL", 13, 16], ["Glyburide", "SIMPLE_CHEMICAL", 102, 111], ["insulin", "GENE_OR_GENE_PRODUCT", 127, 134], ["oral", "ORGANISM_SUBDIVISION", 157, 161], ["metformin", "SIMPLE_CHEMICAL", 175, 184], ["rosiglitazone", "SIMPLE_CHEMICAL", 189, 202], ["patient", "ORGANISM", 217, 224], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 279, 289], ["insulin", "GENE_OR_GENE_PRODUCT", 349, 356], ["hemoglobin", "PROTEIN", 279, 289], ["patient", "SPECIES", 217, 224], ["Metformin", "TREATMENT", 3, 12], ["lantus", "TREATMENT", 22, 28], ["Levemir SQ", "TREATMENT", 47, 57], ["prandial novolog", "TREATMENT", 71, 87], ["Glyburide", "TREATMENT", 102, 111], ["insulin sliding scale D", "TREATMENT", 127, 150], ["Dual oral therapy", "TREATMENT", 152, 169], ["metformin", "TREATMENT", 175, 184], ["rosiglitazone", "TREATMENT", 189, 202], ["hyperosmolar nonketotic acidosis", "PROBLEM", 240, 272], ["a hemoglobin A1c", "TEST", 277, 293], ["a basal-prandial insulin regimen", "TREATMENT", 332, 364], ["nonketotic acidosis", "OBSERVATION", 253, 272]]], ["In patients with consistent extreme hyperglycemia greater than 300 mg/ dl, hgbA1c greater than 10 %, insulin should be started immediately.", [["hyperglycemia", "DISEASE", 36, 49], ["patients", "ORGANISM", 3, 11], ["insulin", "GENE_OR_GENE_PRODUCT", 101, 108], ["patients", "SPECIES", 3, 11], ["consistent extreme hyperglycemia", "PROBLEM", 17, 49], ["hgbA1c", "TEST", 75, 81], ["insulin", "TREATMENT", 101, 108], ["extreme", "OBSERVATION_MODIFIER", 28, 35], ["hyperglycemia", "OBSERVATION", 36, 49]]], ["Metformin is contraindicated in men with a creatinine >1.5 mg/dL and women with creatinine >1.4 mg/dL.", [["Metformin", "CHEMICAL", 0, 9], ["creatinine", "CHEMICAL", 43, 53], ["creatinine", "CHEMICAL", 80, 90], ["Metformin", "CHEMICAL", 0, 9], ["creatinine", "CHEMICAL", 43, 53], ["creatinine", "CHEMICAL", 80, 90], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["men", "ORGANISM", 32, 35], ["creatinine", "SIMPLE_CHEMICAL", 43, 53], ["women", "ORGANISM", 69, 74], ["creatinine", "SIMPLE_CHEMICAL", 80, 90], ["men", "SPECIES", 32, 35], ["women", "SPECIES", 69, 74], ["Metformin", "TREATMENT", 0, 9], ["a creatinine", "TEST", 41, 53], ["creatinine", "TEST", 80, 90]]], ["The glitazones are typically not recommended for diabetics in the setting of severe uncontrolled hyperglycemia.", [["glitazones", "CHEMICAL", 4, 14], ["hyperglycemia", "DISEASE", 97, 110], ["glitazones", "CHEMICAL", 4, 14], ["glitazones", "SIMPLE_CHEMICAL", 4, 14], ["The glitazones", "TREATMENT", 0, 14], ["diabetics", "PROBLEM", 49, 58], ["severe uncontrolled hyperglycemia", "PROBLEM", 77, 110], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["uncontrolled", "OBSERVATION_MODIFIER", 84, 96], ["hyperglycemia", "OBSERVATION", 97, 110]]], ["A 27-year-old male is brought to the emergency room after being found down in the parking lot of a grocery store.", [["male", "ORGANISM", 14, 18], ["27-", "OBSERVATION_MODIFIER", 2, 5]]], ["While in the emergency room, he awakens and reports chest pain.", [["chest", "ANATOMY", 52, 57], ["chest pain", "DISEASE", 52, 62], ["chest", "ORGANISM_SUBDIVISION", 52, 57], ["chest pain", "PROBLEM", 52, 62], ["chest", "ANATOMY", 52, 57]]], ["An ECG reveals a 4 mm ST segment elevation in leads II, III, and aVF.", [["aVF", "PROTEIN", 65, 68], ["An ECG", "TEST", 0, 6], ["a 4 mm ST segment elevation in leads II, III, and aVF", "PROBLEM", 15, 68], ["segment", "ANATOMY_MODIFIER", 25, 32], ["elevation", "OBSERVATION", 33, 42], ["leads II", "ANATOMY_MODIFIER", 46, 54], ["aVF", "ANATOMY", 65, 68]]], ["Rapid drug screen is positive for cocaine.", [["cocaine", "CHEMICAL", 34, 41], ["cocaine", "CHEMICAL", 34, 41], ["cocaine", "SIMPLE_CHEMICAL", 34, 41], ["Rapid drug screen", "TEST", 0, 17], ["cocaine", "PROBLEM", 34, 41]]], ["The emergency room staff administers aspirin, Ativan, and sublingual nitroglycerin.", [["sublingual", "ANATOMY", 58, 68], ["aspirin", "CHEMICAL", 37, 44], ["Ativan", "CHEMICAL", 46, 52], ["nitroglycerin", "CHEMICAL", 69, 82], ["aspirin", "CHEMICAL", 37, 44], ["nitroglycerin", "CHEMICAL", 69, 82], ["aspirin", "SIMPLE_CHEMICAL", 37, 44], ["Ativan", "SIMPLE_CHEMICAL", 46, 52], ["sublingual nitroglycerin", "SIMPLE_CHEMICAL", 58, 82], ["aspirin", "TREATMENT", 37, 44], ["Ativan", "TREATMENT", 46, 52], ["sublingual nitroglycerin", "TREATMENT", 58, 82]]], ["His heart rate is 120 beats per minute.", [["heart", "ANATOMY", 4, 9], ["heart", "ORGAN", 4, 9], ["His heart rate", "TEST", 0, 14], ["heart", "ANATOMY", 4, 9]]], ["After 5 min, chest pain is not alleviated by nitroglycerin.ReferenceWhich of the following is the most appropriate treatment?", [["chest", "ANATOMY", 13, 18], ["chest pain", "DISEASE", 13, 23], ["nitroglycerin", "CHEMICAL", 45, 58], ["nitroglycerin", "CHEMICAL", 45, 58], ["chest", "ORGANISM_SUBDIVISION", 13, 18], ["nitroglycerin", "SIMPLE_CHEMICAL", 45, 58], ["chest pain", "PROBLEM", 13, 23], ["nitroglycerin", "TREATMENT", 45, 58], ["chest", "ANATOMY", 13, 18]]], ["A) Enoxaparin B) Repeat lorazepam C) IV metoprolol D) Nitroprusside E) Urgent coronary arteriography Answer: E Cocaine often induces vascular syndromes due to increased platelet aggregation and endothelial dysfunction.", [["coronary", "ANATOMY", 78, 86], ["vascular", "ANATOMY", 133, 141], ["platelet", "ANATOMY", 169, 177], ["endothelial", "ANATOMY", 194, 205], ["Enoxaparin B", "CHEMICAL", 3, 15], ["lorazepam", "CHEMICAL", 24, 33], ["metoprolol", "CHEMICAL", 40, 50], ["Nitroprusside E", "CHEMICAL", 54, 69], ["Cocaine", "CHEMICAL", 111, 118], ["vascular syndromes", "DISEASE", 133, 151], ["platelet aggregation", "DISEASE", 169, 189], ["endothelial dysfunction", "DISEASE", 194, 217], ["Enoxaparin B", "CHEMICAL", 3, 15], ["lorazepam C", "CHEMICAL", 24, 35], ["metoprolol D", "CHEMICAL", 40, 52], ["Nitroprusside E", "CHEMICAL", 54, 69], ["Cocaine", "CHEMICAL", 111, 118], ["Enoxaparin B", "SIMPLE_CHEMICAL", 3, 15], ["lorazepam C) IV metoprolol D) Nitroprusside E", "SIMPLE_CHEMICAL", 24, 69], ["coronary", "MULTI-TISSUE_STRUCTURE", 78, 86], ["E Cocaine", "SIMPLE_CHEMICAL", 109, 118], ["vascular", "MULTI-TISSUE_STRUCTURE", 133, 141], ["platelet", "CELL", 169, 177], ["endothelial", "TISSUE", 194, 205], ["A) Enoxaparin B", "TREATMENT", 0, 15], ["Repeat lorazepam C) IV metoprolol D) Nitroprusside E", "TREATMENT", 17, 69], ["Urgent coronary arteriography", "TEST", 71, 100], ["vascular syndromes", "PROBLEM", 133, 151], ["increased platelet aggregation", "PROBLEM", 159, 189], ["endothelial dysfunction", "PROBLEM", 194, 217], ["coronary", "ANATOMY", 78, 86], ["vascular", "ANATOMY", 133, 141], ["increased platelet aggregation", "OBSERVATION", 159, 189], ["endothelial dysfunction", "OBSERVATION", 194, 217]]], ["In this particular case, the patient is suffering an acute myocardial infarction due to cocaine.", [["myocardial", "ANATOMY", 59, 69], ["acute myocardial infarction", "DISEASE", 53, 80], ["cocaine", "CHEMICAL", 88, 95], ["cocaine", "CHEMICAL", 88, 95], ["patient", "ORGANISM", 29, 36], ["myocardial", "MULTI-TISSUE_STRUCTURE", 59, 69], ["cocaine", "SIMPLE_CHEMICAL", 88, 95], ["patient", "SPECIES", 29, 36], ["an acute myocardial infarction", "PROBLEM", 50, 80], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["myocardial", "ANATOMY", 59, 69], ["infarction", "OBSERVATION", 70, 80]]], ["Urgent coronary arteriography, if available, is recommended.", [["coronary", "ANATOMY", 7, 15], ["coronary", "MULTI-TISSUE_STRUCTURE", 7, 15], ["Urgent coronary arteriography", "TEST", 0, 29], ["coronary", "ANATOMY", 7, 15]]], ["Avoidance of beta-blockers acutely after cocaine use is currently a part of the American Heart Association guidelines.", [["cocaine", "CHEMICAL", 41, 48], ["cocaine", "CHEMICAL", 41, 48], ["beta-blockers", "GENE_OR_GENE_PRODUCT", 13, 26], ["cocaine", "SIMPLE_CHEMICAL", 41, 48], ["beta-blockers", "TREATMENT", 13, 26]]], ["This is due to the possibility that beta-blockers may lead to unopposed alpha-adrenergic stimulation with subsequent worsening coronary vasospasm.", [["coronary", "ANATOMY", 127, 135], ["coronary vasospasm", "DISEASE", 127, 145], ["beta-blockers", "GENE_OR_GENE_PRODUCT", 36, 49], ["coronary", "MULTI-TISSUE_STRUCTURE", 127, 135], ["beta-blockers", "TREATMENT", 36, 49], ["unopposed alpha-adrenergic stimulation", "PROBLEM", 62, 100], ["subsequent worsening coronary vasospasm", "PROBLEM", 106, 145], ["worsening", "OBSERVATION_MODIFIER", 117, 126], ["coronary", "ANATOMY", 127, 135], ["vasospasm", "OBSERVATION", 136, 145]]], ["There have been no controlled trials on this issue yet.", [["no", "UNCERTAINTY", 16, 18], ["controlled", "OBSERVATION_MODIFIER", 19, 29], ["trials", "OBSERVATION", 30, 36]]], ["It is important to recognize that cocaine can induce myocardial infarctions and other thrombotic events in a low-incidence population such as the case here.ReferenceHiestand BC, Smith SW.", [["myocardial", "ANATOMY", 53, 63], ["cocaine", "CHEMICAL", 34, 41], ["myocardial infarctions", "DISEASE", 53, 75], ["thrombotic", "DISEASE", 86, 96], ["cocaine", "CHEMICAL", 34, 41], ["cocaine", "SIMPLE_CHEMICAL", 34, 41], ["myocardial", "MULTI-TISSUE_STRUCTURE", 53, 63], ["myocardial infarctions", "PROBLEM", 53, 75], ["other thrombotic events", "PROBLEM", 80, 103], ["myocardial", "ANATOMY", 53, 63], ["infarctions", "OBSERVATION", 64, 75], ["thrombotic", "OBSERVATION", 86, 96]]], ["Cocaine chest pain: between a (crack) rock and a hard place.", [["chest", "ANATOMY", 8, 13], ["Cocaine", "CHEMICAL", 0, 7], ["chest pain", "DISEASE", 8, 18], ["Cocaine", "CHEMICAL", 0, 7], ["Cocaine chest pain", "PROBLEM", 0, 18], ["chest", "ANATOMY", 8, 13]]], ["2011;18(1):68-71.Reference18.", [["Reference18", "PROTEIN", 17, 28]]], ["A 65-year-old man with acute respiratory distress is transferred to the intensive care unit.", [["respiratory", "ANATOMY", 29, 40], ["respiratory distress", "DISEASE", 29, 49], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["acute respiratory distress", "PROBLEM", 23, 49], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory distress", "OBSERVATION", 29, 49]]], ["He has just been intubated and placed on mechanical ventilation for respiratory failure secondary to aspiration pneumonia.", [["respiratory", "ANATOMY", 68, 79], ["respiratory failure", "DISEASE", 68, 87], ["aspiration pneumonia", "DISEASE", 101, 121], ["He", "ORGANISM", 0, 2], ["intubated", "TREATMENT", 17, 26], ["mechanical ventilation", "TREATMENT", 41, 63], ["respiratory failure", "PROBLEM", 68, 87], ["aspiration pneumonia", "PROBLEM", 101, 121], ["respiratory failure", "OBSERVATION", 68, 87], ["aspiration", "OBSERVATION_MODIFIER", 101, 111], ["pneumonia", "OBSERVATION", 112, 121]]], ["Before intubation, his oxygen saturation was 81 % breathing 100 % oxygen with a nonrebreather mask.", [["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "CHEMICAL", 23, 29], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "SIMPLE_CHEMICAL", 23, 29], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["intubation", "TREATMENT", 7, 17], ["his oxygen saturation", "TEST", 19, 40], ["a nonrebreather mask", "TREATMENT", 78, 98]]], ["On physical examination, temperature is 37.0 \u00b0C (98.6 \u00b0F), blood pressure is 145/85 mmHg, and pulse rate is 110 bpm.", [["blood", "ANATOMY", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["\u00b0C", "TEST", 45, 47], ["blood pressure", "TEST", 59, 73], ["pulse rate", "TEST", 94, 104]]], ["His height is 150 cm (59 in) and his weight is 78.0 kg (154.3 lb).", [["His height", "TEST", 0, 10], ["his weight", "TEST", 33, 43], ["150 cm", "OBSERVATION_MODIFIER", 14, 20]]], ["Ideal body weight is calculated to be 50.0 kg (114.6 lb).", [["body", "ANATOMY", 6, 10], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["Ideal body weight", "TEST", 0, 17]]], ["Central venous pressure is 9 cm H 2 O. Cardiac examination reveals normal heart sounds, no murmurs, and no rubs.", [["venous", "ANATOMY", 8, 14], ["Cardiac", "ANATOMY", 39, 46], ["heart", "ANATOMY", 74, 79], ["venous", "MULTI-TISSUE_STRUCTURE", 8, 14], ["heart", "ORGAN", 74, 79], ["Central venous pressure", "TEST", 0, 23], ["Cardiac examination", "TEST", 39, 58], ["murmurs", "PROBLEM", 91, 98], ["rubs", "PROBLEM", 107, 111], ["venous", "ANATOMY", 8, 14], ["pressure", "OBSERVATION_MODIFIER", 15, 23], ["9 cm", "OBSERVATION_MODIFIER", 27, 31], ["normal", "OBSERVATION", 67, 73], ["heart", "ANATOMY", 74, 79], ["sounds", "OBSERVATION", 80, 86], ["no", "UNCERTAINTY", 88, 90], ["murmurs", "OBSERVATION", 91, 98], ["no", "UNCERTAINTY", 104, 106], ["rubs", "OBSERVATION", 107, 111]]], ["Crackles are auscultated in the right and left lung fi elds.", [["right", "ANATOMY", 32, 37], ["left lung", "ANATOMY", 42, 51], ["lung", "ORGAN", 47, 51], ["Crackles", "PROBLEM", 0, 8], ["auscultated", "OBSERVATION", 13, 24], ["right", "ANATOMY_MODIFIER", 32, 37], ["left", "ANATOMY_MODIFIER", 42, 46], ["lung", "ANATOMY", 47, 51], ["fi", "ANATOMY_MODIFIER", 52, 54], ["elds", "OBSERVATION", 55, 59]]], ["The patient is sedated.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["sedated", "TREATMENT", 15, 22]]], ["Neurologic examination is nonfocal.ReferenceMechanical ventilation is set on the assist/control mode at a rate of 16/min.", [["Neurologic examination", "TEST", 0, 22], ["ReferenceMechanical ventilation", "TREATMENT", 35, 66], ["a rate", "TEST", 104, 110], ["nonfocal", "OBSERVATION", 26, 34]]], ["Positive end-expiratory pressure is 8 cm H 2 O, and FIO 2 is 1.0.ReferenceWhich of the following is the correct tidal volume?", [["H 2 O", "CHEMICAL", 41, 46], ["end-expiratory pressure", "TEST", 9, 32], ["FIO", "TEST", 52, 55], ["tidal volume", "TEST", 112, 124], ["end", "OBSERVATION_MODIFIER", 9, 12], ["expiratory pressure", "OBSERVATION", 13, 32], ["8 cm", "OBSERVATION_MODIFIER", 36, 40], ["tidal volume", "OBSERVATION", 112, 124]]], ["A) 300 mL B) 450 mL C) 700 mL D) 840 mL Answer: A This patient's presentation is consistent with acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 103, 114], ["acute respiratory distress syndrome", "DISEASE", 97, 132], ["ARDS", "DISEASE", 134, 138], ["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["acute respiratory distress syndrome", "PROBLEM", 97, 132], ["ARDS", "PROBLEM", 134, 138], ["consistent with", "UNCERTAINTY", 81, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory distress syndrome", "OBSERVATION", 103, 132], ["ARDS", "OBSERVATION", 134, 138]]], ["The most appropriate tidal volume is 300 mL.", [["tidal volume", "OBSERVATION", 21, 33]]], ["Survival in ARDS is improved when patients are ventilated with a tidal volume of 6 mL/kg of ideal body weight (IBW).", [["body", "ANATOMY", 98, 102], ["ARDS", "DISEASE", 12, 16], ["patients", "ORGANISM", 34, 42], ["body", "ORGANISM_SUBDIVISION", 98, 102], ["patients", "SPECIES", 34, 42], ["ARDS", "PROBLEM", 12, 16], ["a tidal volume", "TEST", 63, 77], ["ARDS", "OBSERVATION", 12, 16], ["improved", "OBSERVATION_MODIFIER", 20, 28]]], ["A low tidal volume mechanical ventilation strategy is now the standard of care for ARDS.", [["ARDS", "DISEASE", 83, 87], ["A low tidal volume mechanical ventilation strategy", "TREATMENT", 0, 50], ["ARDS", "PROBLEM", 83, 87], ["low", "OBSERVATION_MODIFIER", 2, 5], ["tidal volume", "OBSERVATION", 6, 18], ["mechanical ventilation", "OBSERVATION", 19, 41], ["ARDS", "OBSERVATION", 83, 87]]], ["Lung injury is presumed to arise from repetitive opening and closing of alveoli.", [["Lung", "ANATOMY", 0, 4], ["alveoli", "ANATOMY", 72, 79], ["Lung injury", "DISEASE", 0, 11], ["Lung", "ORGAN", 0, 4], ["alveoli", "MULTI-TISSUE_STRUCTURE", 72, 79], ["Lung injury", "PROBLEM", 0, 11], ["repetitive opening", "PROBLEM", 38, 56], ["closing of alveoli", "PROBLEM", 61, 79], ["injury", "OBSERVATION", 5, 11], ["presumed to arise", "UNCERTAINTY", 15, 32], ["repetitive", "OBSERVATION_MODIFIER", 38, 48], ["opening", "OBSERVATION", 49, 56], ["alveoli", "ANATOMY", 72, 79]]], ["Barotrauma may be limited by low tidal volumes.", [["Barotrauma", "DISEASE", 0, 10], ["tidal", "ORGANISM_SUBDIVISION", 33, 38], ["Barotrauma", "TREATMENT", 0, 10], ["low tidal volumes", "PROBLEM", 29, 46], ["low", "OBSERVATION_MODIFIER", 29, 32], ["tidal volumes", "OBSERVATION", 33, 46]]], ["This can be achieved by delivering limited size tidal volumes, minimizing plateau pressure, optimizing PEEP, and reducing FIO 2 to less than 0.6.", [["plateau pressure", "TREATMENT", 74, 90], ["optimizing PEEP", "TREATMENT", 92, 107], ["FIO", "TEST", 122, 125], ["size", "OBSERVATION_MODIFIER", 43, 47], ["tidal volumes", "OBSERVATION", 48, 61], ["plateau pressure", "OBSERVATION", 74, 90]]], ["Ideal body weight rather than actual body weight should be used.", [["body", "ANATOMY", 6, 10], ["body", "ANATOMY", 37, 41], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["actual body weight", "TREATMENT", 30, 48]]], ["Use caution in patients who are overweight or edematous.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["caution", "TREATMENT", 4, 11], ["edematous", "PROBLEM", 46, 55], ["edematous", "OBSERVATION", 46, 55]]], ["Calculating actual body weight will typically result in inappropriately large tidal volumes.ReferenceThe Acute Respiratory Distress Syndrome Network.", [["body", "ANATOMY", 19, 23], ["Acute Respiratory Distress Syndrome", "DISEASE", 105, 140], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["Calculating actual body weight", "TEST", 0, 30], ["inappropriately large tidal volumes", "PROBLEM", 56, 91], ["The Acute Respiratory Distress Syndrome", "PROBLEM", 101, 140], ["large", "OBSERVATION_MODIFIER", 72, 77], ["tidal volumes", "OBSERVATION", 78, 91], ["Acute", "OBSERVATION_MODIFIER", 105, 110], ["Respiratory Distress Syndrome", "OBSERVATION", 111, 140]]], ["Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.", [["lung", "ANATOMY", 90, 94], ["respiratory", "ANATOMY", 116, 127], ["acute lung injury", "DISEASE", 84, 101], ["acute respiratory distress syndrome", "DISEASE", 110, 145], ["lung", "ORGAN", 90, 94], ["Ventilation", "TREATMENT", 0, 11], ["lower tidal volumes", "PROBLEM", 17, 36], ["traditional tidal volumes", "TEST", 54, 79], ["acute lung injury", "PROBLEM", 84, 101], ["the acute respiratory distress syndrome", "PROBLEM", 106, 145], ["lower", "OBSERVATION_MODIFIER", 17, 22], ["tidal volumes", "OBSERVATION", 23, 36], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["lung", "ANATOMY", 90, 94], ["injury", "OBSERVATION", 95, 101], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["respiratory distress syndrome", "OBSERVATION", 116, 145]]], ["A 75 year old Vietnamese male presents with a one month history of bilateral hand swelling and recurrent ulcerations.", [["hand", "ANATOMY", 77, 81], ["swelling", "DISEASE", 82, 90], ["ulcerations", "DISEASE", 105, 116], ["male", "ORGANISM", 25, 29], ["hand", "ORGANISM_SUBDIVISION", 77, 81], ["ulcerations", "PATHOLOGICAL_FORMATION", 105, 116], ["bilateral hand swelling", "PROBLEM", 67, 90], ["recurrent ulcerations", "PROBLEM", 95, 116], ["bilateral", "ANATOMY_MODIFIER", 67, 76], ["hand", "ANATOMY", 77, 81], ["swelling", "OBSERVATION", 82, 90], ["recurrent", "OBSERVATION_MODIFIER", 95, 104], ["ulcerations", "OBSERVATION", 105, 116]]], ["Over that time period he has been treated with several course of oral antibiotics for presumed cellulitis with no improvement.", [["oral", "ANATOMY", 65, 69], ["cellulitis", "DISEASE", 95, 105], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["oral antibiotics", "TREATMENT", 65, 81], ["cellulitis", "PROBLEM", 95, 105], ["cellulitis", "OBSERVATION", 95, 105], ["no", "UNCERTAINTY", 111, 113], ["improvement", "OBSERVATION_MODIFIER", 114, 125]]], ["The family reports that he has had several ulcerations on his fi ngers develop in the past month that have resolved.", [["ulcerations", "DISEASE", 43, 54], ["ulcerations", "PATHOLOGICAL_FORMATION", 43, 54], ["several ulcerations", "PROBLEM", 35, 54], ["several", "OBSERVATION_MODIFIER", 35, 42], ["ulcerations", "OBSERVATION", 43, 54], ["resolved", "OBSERVATION_MODIFIER", 107, 115]]], ["He is an active gardener and spends several hours per day tending to his plants.", [["He", "ORGANISM", 0, 2], ["active", "OBSERVATION_MODIFIER", 9, 15], ["gardener", "OBSERVATION", 16, 24]]], ["He has no other past medical history.ReferenceOn physical exam one 3x 3cm superative ulceration is noted distally on his right fi fth fi nger.", [["ulceration", "DISEASE", 85, 95], ["right fi fth fi nger", "DNA", 121, 141], ["ReferenceOn physical exam", "TEST", 37, 62], ["3cm superative ulceration", "PROBLEM", 70, 95], ["no", "UNCERTAINTY", 7, 9], ["one 3x 3cm", "OBSERVATION_MODIFIER", 63, 73], ["superative", "OBSERVATION_MODIFIER", 74, 84], ["ulceration", "OBSERVATION", 85, 95], ["distally", "ANATOMY_MODIFIER", 105, 113], ["right", "ANATOMY_MODIFIER", 121, 126]]], ["Some erythema around the ulceration is noted.", [["erythema", "DISEASE", 5, 13], ["ulceration", "DISEASE", 25, 35], ["erythema", "PATHOLOGICAL_FORMATION", 5, 13], ["ulceration", "PATHOLOGICAL_FORMATION", 25, 35], ["Some erythema", "PROBLEM", 0, 13], ["the ulceration", "PROBLEM", 21, 35], ["erythema", "OBSERVATION", 5, 13], ["ulceration", "OBSERVATION", 25, 35]]], ["Both hands are markedly swollen.", [["hands", "ORGANISM_SUBDIVISION", 5, 10], ["markedly swollen", "PROBLEM", 15, 31], ["hands", "ANATOMY", 5, 10], ["markedly", "OBSERVATION_MODIFIER", 15, 23], ["swollen", "OBSERVATION", 24, 31]]], ["He is admitted and started on IV vancomycin.", [["vancomycin", "CHEMICAL", 33, 43], ["vancomycin", "CHEMICAL", 33, 43], ["He", "ORGANISM", 0, 2], ["vancomycin", "SIMPLE_CHEMICAL", 33, 43], ["IV vancomycin", "TREATMENT", 30, 43]]], ["After three days no improvement is seen.", [["improvement", "OBSERVATION_MODIFIER", 20, 31]]], ["No fever or elevation in WBC is noted.ReferenceOn day three, one new lesion similar to the previous lesion develops on the dorsum of his hand.", [["WBC", "ANATOMY", 25, 28], ["lesion", "ANATOMY", 69, 75], ["lesion", "ANATOMY", 100, 106], ["dorsum", "ANATOMY", 123, 129], ["hand", "ANATOMY", 137, 141], ["fever", "DISEASE", 3, 8], ["WBC", "CELL", 25, 28], ["lesion", "CANCER", 69, 75], ["lesion", "CANCER", 100, 106], ["dorsum", "ORGANISM_SUBDIVISION", 123, 129], ["hand", "ORGANISM_SUBDIVISION", 137, 141], ["WBC", "CELL_TYPE", 25, 28], ["fever", "PROBLEM", 3, 8], ["elevation in WBC", "PROBLEM", 12, 28], ["one new lesion", "PROBLEM", 61, 75], ["the previous lesion", "PROBLEM", 87, 106], ["fever", "OBSERVATION", 3, 8], ["elevation", "OBSERVATION_MODIFIER", 12, 21], ["WBC", "OBSERVATION", 25, 28], ["new", "OBSERVATION_MODIFIER", 65, 68], ["lesion", "OBSERVATION", 69, 75], ["lesion", "OBSERVATION", 100, 106], ["dorsum", "ANATOMY_MODIFIER", 123, 129], ["hand", "ANATOMY", 137, 141]]], ["On day four another lesion develops proximally on the forearm.ReferenceWhich of the following is the most likely diagnosis?", [["lesion", "ANATOMY", 20, 26], ["forearm", "ANATOMY", 54, 61], ["forearm", "ORGANISM_SUBDIVISION", 54, 61], ["another lesion", "PROBLEM", 12, 26], ["lesion", "OBSERVATION", 20, 26], ["proximally", "ANATOMY_MODIFIER", 36, 46], ["forearm", "ANATOMY", 54, 61], ["most likely", "UNCERTAINTY", 101, 112]]], ["A) Rheumatoid arthritis B) Cutaneous Sporotrichosis C) Mycobacterium Marinum D) Hypersensitivity Reaction E) Small Vessel Vasculitis Answer: B A non healing cellulitis with ulceration is suugestive of an atypical bacterial or fungal infection.", [["Rheumatoid arthritis B", "DISEASE", 3, 25], ["Hypersensitivity", "DISEASE", 80, 96], ["Vasculitis", "DISEASE", 122, 132], ["cellulitis", "DISEASE", 157, 167], ["ulceration", "DISEASE", 173, 183], ["fungal infection", "DISEASE", 226, 242], ["A) Rheumatoid arthritis", "PROBLEM", 0, 23], ["Cutaneous Sporotrichosis C", "PROBLEM", 27, 53], ["Mycobacterium Marinum D)", "PROBLEM", 55, 79], ["Hypersensitivity Reaction", "PROBLEM", 80, 105], ["Small Vessel Vasculitis", "PROBLEM", 109, 132], ["A non healing cellulitis", "PROBLEM", 143, 167], ["ulceration", "PROBLEM", 173, 183], ["an atypical bacterial or fungal infection", "PROBLEM", 201, 242], ["Rheumatoid", "OBSERVATION_MODIFIER", 3, 13], ["arthritis", "OBSERVATION", 14, 23], ["Cutaneous", "ANATOMY", 27, 36], ["Sporotrichosis", "OBSERVATION", 37, 51], ["Mycobacterium Marinum", "OBSERVATION", 55, 76], ["Small", "OBSERVATION_MODIFIER", 109, 114], ["Vessel", "ANATOMY", 115, 121], ["Vasculitis", "OBSERVATION", 122, 132], ["healing", "OBSERVATION_MODIFIER", 149, 156], ["cellulitis", "OBSERVATION", 157, 167], ["ulceration", "OBSERVATION", 173, 183], ["atypical", "OBSERVATION_MODIFIER", 204, 212], ["bacterial", "OBSERVATION_MODIFIER", 213, 222], ["fungal", "OBSERVATION_MODIFIER", 226, 232], ["infection", "OBSERVATION", 233, 242]]], ["In this patient with signifi cant environmental exposure and classic lymphatic spread, Sporotrichosis is the likely diagnosis.", [["lymphatic", "ANATOMY", 69, 78], ["Sporotrichosis", "DISEASE", 87, 101], ["patient", "ORGANISM", 8, 15], ["lymphatic", "ORGAN", 69, 78], ["patient", "SPECIES", 8, 15], ["signifi cant environmental exposure", "PROBLEM", 21, 56], ["classic lymphatic spread", "PROBLEM", 61, 85], ["Sporotrichosis", "PROBLEM", 87, 101], ["environmental exposure", "OBSERVATION", 34, 56], ["classic", "OBSERVATION_MODIFIER", 61, 68], ["lymphatic spread", "OBSERVATION", 69, 85], ["Sporotrichosis", "OBSERVATION", 87, 101]]], ["Sporotrichosis is a subacute infection caused by the saprophytic dimorphic fungus Sporothrix schenckii .", [["Sporotrichosis", "DISEASE", 0, 14], ["infection", "DISEASE", 29, 38], ["fungus Sporothrix schenckii", "ORGANISM", 75, 102], ["Sporothrix schenckii", "SPECIES", 82, 102], ["Sporothrix schenckii", "SPECIES", 82, 102], ["Sporotrichosis", "PROBLEM", 0, 14], ["a subacute infection", "PROBLEM", 18, 38], ["the saprophytic dimorphic fungus Sporothrix schenckii", "PROBLEM", 49, 102], ["subacute", "OBSERVATION_MODIFIER", 20, 28], ["infection", "OBSERVATION", 29, 38], ["saprophytic", "OBSERVATION_MODIFIER", 53, 64], ["dimorphic", "OBSERVATION_MODIFIER", 65, 74], ["fungus", "OBSERVATION_MODIFIER", 75, 81], ["Sporothrix schenckii", "OBSERVATION", 82, 102]]], ["The characteristic infection involves ulcerative subcutaneous nodules that progress proximally along lymphatic channels.", [["ulcerative subcutaneous nodules", "ANATOMY", 38, 69], ["lymphatic", "ANATOMY", 101, 110], ["infection", "DISEASE", 19, 28], ["ulcerative subcutaneous nodules", "PATHOLOGICAL_FORMATION", 38, 69], ["lymphatic", "ORGAN", 101, 110], ["The characteristic infection", "PROBLEM", 0, 28], ["ulcerative subcutaneous nodules", "PROBLEM", 38, 69], ["characteristic", "OBSERVATION_MODIFIER", 4, 18], ["infection", "OBSERVATION", 19, 28], ["ulcerative", "OBSERVATION_MODIFIER", 38, 48], ["subcutaneous", "ANATOMY", 49, 61], ["nodules", "OBSERVATION", 62, 69], ["proximally", "ANATOMY_MODIFIER", 84, 94], ["lymphatic channels", "OBSERVATION", 101, 119]]], ["The primary lesion develops at the site of cutaneous inoculation, typically in the distal upper extremities.", [["primary lesion", "ANATOMY", 4, 18], ["cutaneous", "ANATOMY", 43, 52], ["distal upper extremities", "ANATOMY", 83, 107], ["lesion", "CANCER", 12, 18], ["cutaneous", "ORGANISM_SUBDIVISION", 43, 52], ["upper extremities", "ORGANISM_SUBDIVISION", 90, 107], ["The primary lesion", "PROBLEM", 0, 18], ["cutaneous inoculation", "PROBLEM", 43, 64], ["primary", "OBSERVATION_MODIFIER", 4, 11], ["lesion", "OBSERVATION", 12, 18], ["site", "OBSERVATION_MODIFIER", 35, 39], ["cutaneous", "OBSERVATION_MODIFIER", 43, 52], ["inoculation", "OBSERVATION", 53, 64], ["distal", "ANATOMY_MODIFIER", 83, 89], ["upper", "ANATOMY_MODIFIER", 90, 95], ["extremities", "ANATOMY", 96, 107]]], ["After several weeks, new lesions appear along the lymphatic tracts.", [["lesions", "ANATOMY", 25, 32], ["lymphatic tracts", "ANATOMY", 50, 66], ["lesions", "PATHOLOGICAL_FORMATION", 25, 32], ["lymphatic tracts", "MULTI-TISSUE_STRUCTURE", 50, 66], ["new lesions", "PROBLEM", 21, 32], ["new", "OBSERVATION_MODIFIER", 21, 24], ["lesions", "OBSERVATION", 25, 32], ["lymphatic tracts", "ANATOMY", 50, 66]]], ["Patients are typically afebrile and not systemically ill.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["afebrile", "PROBLEM", 23, 31], ["afebrile", "OBSERVATION", 23, 31]]], ["The lesions usually cause minimal pain.", [["lesions", "ANATOMY", 4, 11], ["pain", "DISEASE", 34, 38], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["The lesions", "PROBLEM", 0, 11], ["minimal pain", "PROBLEM", 26, 38], ["lesions", "OBSERVATION", 4, 11], ["minimal", "OBSERVATION_MODIFIER", 26, 33], ["pain", "OBSERVATION", 34, 38]]], ["Many affected patients have received one or more courses of antibacterial therapy without benefi t.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["antibacterial therapy", "TREATMENT", 60, 81], ["benefi", "PROBLEM", 90, 96]]], ["Sporotrichosis may involve other organs, including the eye, prostate oral mucosa, paranasal sinuses, larynx and joints.", [["organs", "ANATOMY", 33, 39], ["eye", "ANATOMY", 55, 58], ["prostate oral mucosa", "ANATOMY", 60, 80], ["paranasal sinuses", "ANATOMY", 82, 99], ["larynx", "ANATOMY", 101, 107], ["joints", "ANATOMY", 112, 118], ["Sporotrichosis", "DISEASE", 0, 14], ["organs", "ORGAN", 33, 39], ["eye", "ORGAN", 55, 58], ["prostate oral mucosa", "MULTI-TISSUE_STRUCTURE", 60, 80], ["paranasal sinuses", "MULTI-TISSUE_STRUCTURE", 82, 99], ["larynx", "ORGAN", 101, 107], ["joints", "MULTI-TISSUE_STRUCTURE", 112, 118], ["Sporotrichosis", "PROBLEM", 0, 14], ["other organs, including the eye, prostate oral mucosa, paranasal sinuses, larynx and joints", "PROBLEM", 27, 118], ["eye", "ANATOMY", 55, 58], ["prostate", "ANATOMY", 60, 68], ["oral mucosa", "ANATOMY", 69, 80], ["paranasal sinuses", "ANATOMY", 82, 99], ["larynx", "ANATOMY", 101, 107], ["joints", "ANATOMY", 112, 118]]], ["In such patients, the clinical manifestations depend on the organs involved.ReferenceSoil, plants, moss and other organic material are common sources.", [["organs", "ANATOMY", 60, 66], ["patients", "ORGANISM", 8, 16], ["organs", "ORGAN", 60, 66], ["patients", "SPECIES", 8, 16], ["moss and other organic material", "PROBLEM", 99, 130]]], ["Sporotrichosis occurs worldwide, with focal areas of hyperendemicity, such as Peru and China.", [["Sporotrichosis", "DISEASE", 0, 14], ["hyperendemicity", "DISEASE", 53, 68], ["Sporotrichosis", "PROBLEM", 0, 14], ["hyperendemicity", "PROBLEM", 53, 68], ["worldwide", "OBSERVATION_MODIFIER", 22, 31], ["focal", "OBSERVATION_MODIFIER", 38, 43], ["areas", "OBSERVATION_MODIFIER", 44, 49], ["hyperendemicity", "OBSERVATION", 53, 68]]], ["Treatment can be lengthy.", [["Treatment", "TREATMENT", 0, 9], ["lengthy", "OBSERVATION_MODIFIER", 17, 24]]], ["One recent guideline recommends oral itraconazole 200 mg/d until 2-4 weeks after all lesions have resolved, usually for a total of 3-6 months.ReferenceReference Barros MB, de Almeida Paes R, Schubach AO.", [["oral", "ANATOMY", 32, 36], ["lesions", "ANATOMY", 85, 92], ["itraconazole", "CHEMICAL", 37, 49], ["itraconazole", "CHEMICAL", 37, 49], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["itraconazole", "SIMPLE_CHEMICAL", 37, 49], ["lesions", "PATHOLOGICAL_FORMATION", 85, 92], ["oral itraconazole", "TREATMENT", 32, 49], ["all lesions", "PROBLEM", 81, 92], ["lesions", "OBSERVATION", 85, 92]]], ["Sporothrix schenckii and Sporotrichosis.", [["Sporotrichosis", "CHEMICAL", 25, 39], ["Sporothrix schenckii", "ORGANISM", 0, 20], ["Sporothrix schenckii", "SPECIES", 0, 20], ["Sporothrix schenckii", "SPECIES", 0, 20], ["Sporothrix schenckii", "PROBLEM", 0, 20], ["Sporotrichosis", "PROBLEM", 25, 39], ["schenckii", "OBSERVATION", 11, 20], ["Sporotrichosis", "OBSERVATION", 25, 39]]], ["Clin Micro Rev .", [["Rev", "PROTEIN", 11, 14]]], ["A 24 year-old presents with rash, hypotension, and fever.", [["rash", "DISEASE", 28, 32], ["hypotension", "DISEASE", 34, 45], ["fever", "DISEASE", 51, 56], ["rash", "PROBLEM", 28, 32], ["hypotension", "PROBLEM", 34, 45], ["fever", "PROBLEM", 51, 56], ["rash", "OBSERVATION", 28, 32], ["hypotension", "OBSERVATION", 34, 45], ["fever", "OBSERVATION", 51, 56]]], ["One week ago she was involved in a biking accident, where she sustained a laceration to the leg.", [["leg", "ANATOMY", 92, 95], ["laceration to the leg", "DISEASE", 74, 95], ["leg", "ORGANISM_SUBDIVISION", 92, 95], ["a laceration to the leg", "PROBLEM", 72, 95], ["laceration", "OBSERVATION", 74, 84], ["leg", "ANATOMY", 92, 95]]], ["It did not require sutures.", [["sutures", "TREATMENT", 19, 26], ["not require", "UNCERTAINTY", 7, 18], ["sutures", "OBSERVATION", 19, 26]]], ["She has had no recent travel, gardening exposure, or exposure to pets.", [["no", "UNCERTAINTY", 12, 14]]], ["She does not use IV drugs.", [["IV drugs", "TREATMENT", 17, 25]]], ["On examination her heart rate is 120 bpm, blood pressure is 87/58.", [["heart", "ANATOMY", 19, 24], ["blood", "ANATOMY", 42, 47], ["heart", "ORGAN", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["examination", "TEST", 3, 14], ["her heart rate", "TEST", 15, 29], ["blood pressure", "TEST", 42, 56], ["heart", "ANATOMY", 19, 24]]], ["The leg laceration looks clean with a wellgranulated base and no erythema, warmth, or pustular discharge.", [["leg", "ANATOMY", 4, 7], ["pustular", "ANATOMY", 86, 94], ["erythema", "DISEASE", 65, 73], ["pustular", "DISEASE", 86, 94], ["leg", "ORGANISM_SUBDIVISION", 4, 7], ["The leg laceration", "PROBLEM", 0, 18], ["a wellgranulated base", "PROBLEM", 36, 57], ["erythema", "PROBLEM", 65, 73], ["warmth", "PROBLEM", 75, 81], ["pustular discharge", "PROBLEM", 86, 104], ["leg", "ANATOMY", 4, 7], ["laceration", "OBSERVATION", 8, 18], ["clean", "OBSERVATION", 25, 30], ["no", "UNCERTAINTY", 62, 64], ["erythema", "OBSERVATION", 65, 73], ["warmth", "OBSERVATION_MODIFIER", 75, 81], ["pustular", "OBSERVATION_MODIFIER", 86, 94]]], ["She does have diffuse erythema that is prominent on her palms, conjunctiva, and oral mucosa.", [["palms", "ANATOMY", 56, 61], ["conjunctiva", "ANATOMY", 63, 74], ["oral mucosa", "ANATOMY", 80, 91], ["erythema", "DISEASE", 22, 30], ["erythema", "PATHOLOGICAL_FORMATION", 22, 30], ["palms", "ORGANISM_SUBDIVISION", 56, 61], ["conjunctiva", "ORGAN", 63, 74], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 80, 91], ["diffuse erythema", "PROBLEM", 14, 30], ["diffuse", "OBSERVATION_MODIFIER", 14, 21], ["erythema", "OBSERVATION", 22, 30], ["prominent", "OBSERVATION_MODIFIER", 39, 48], ["conjunctiva", "ANATOMY", 63, 74], ["oral mucosa", "ANATOMY", 80, 91]]], ["There is some mild desquamation noted on her fi ngertips.ReferenceLaboratory results are notable for a creatinine of 3.0 mg/dL, aspartate aminotransferase of 289 U/L, alanine aminotransferase of 372 U/L, total bilirubin of 2.8 mg/dL, INR of 1.5, and platelets at 82,000/\u03bcL.", [["platelets", "ANATOMY", 250, 259], ["creatinine", "CHEMICAL", 103, 113], ["aspartate", "CHEMICAL", 128, 137], ["alanine", "CHEMICAL", 167, 174], ["bilirubin", "CHEMICAL", 210, 219], ["creatinine", "CHEMICAL", 103, 113], ["aspartate", "CHEMICAL", 128, 137], ["alanine", "CHEMICAL", 167, 174], ["bilirubin", "CHEMICAL", 210, 219], ["creatinine", "SIMPLE_CHEMICAL", 103, 113], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 128, 154], ["alanine", "AMINO_ACID", 167, 174], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 175, 191], ["bilirubin", "GENE_OR_GENE_PRODUCT", 210, 219], ["platelets", "CELL", 250, 259], ["aspartate aminotransferase", "PROTEIN", 128, 154], ["alanine aminotransferase", "PROTEIN", 167, 191], ["platelets", "CELL_TYPE", 250, 259], ["some mild desquamation", "PROBLEM", 9, 31], ["a creatinine", "TEST", 101, 113], ["aspartate aminotransferase", "TEST", 128, 154], ["U/L", "TEST", 162, 165], ["alanine aminotransferase", "TEST", 167, 191], ["U/L", "TEST", 199, 202], ["total bilirubin", "TEST", 204, 219], ["INR", "TEST", 234, 237], ["platelets", "TEST", 250, 259], ["some", "OBSERVATION_MODIFIER", 9, 13], ["mild", "OBSERVATION_MODIFIER", 14, 18], ["desquamation", "OBSERVATION", 19, 31]]], ["She is started on broad-spectrum antibiotics and IV fl uids.ReferenceWhat is the most likely diagnosis?", [["IV fl uids", "SIMPLE_CHEMICAL", 49, 59], ["broad-spectrum antibiotics", "TREATMENT", 18, 44], ["IV fl uids", "TREATMENT", 49, 59], ["most likely", "UNCERTAINTY", 81, 92]]], ["A) Sepsis B) Leptospirosis C) Staphylococcal toxic shock syndrome D) Streptococcal toxic shock syndrome E) Drug reaction Answer: C She has toxic shock syndrome.", [["Sepsis", "DISEASE", 3, 9], ["Leptospirosis", "DISEASE", 13, 26], ["Staphylococcal toxic shock syndrome", "DISEASE", 30, 65], ["Streptococcal toxic shock syndrome", "DISEASE", 69, 103], ["toxic shock syndrome", "DISEASE", 139, 159], ["A) Sepsis B) Leptospirosis C) Staphylococcal toxic shock syndrome D", "PROBLEM", 0, 67], ["Streptococcal toxic shock syndrome", "PROBLEM", 69, 103], ["Drug reaction", "PROBLEM", 107, 120], ["toxic shock syndrome", "PROBLEM", 139, 159], ["Sepsis", "OBSERVATION", 3, 9], ["toxic shock syndrome", "OBSERVATION", 45, 65], ["toxic shock syndrome", "OBSERVATION", 83, 103], ["toxic", "OBSERVATION_MODIFIER", 139, 144], ["shock syndrome", "OBSERVATION", 145, 159]]], ["The characteristic diffuse rash and systemic symptoms make Staphylococcus the most likely inciting agent.", [["rash", "DISEASE", 27, 31], ["The characteristic diffuse rash", "PROBLEM", 0, 31], ["systemic symptoms", "PROBLEM", 36, 53], ["Staphylococcus", "PROBLEM", 59, 73], ["diffuse", "OBSERVATION_MODIFIER", 19, 26], ["rash", "OBSERVATION", 27, 31], ["most likely", "UNCERTAINTY", 78, 89]]], ["Antibiotic treatment should cover both the leading causes, S. pyogenes and S. aureus .", [["S. pyogenes and S. aureus", "DISEASE", 59, 84], ["S. pyogenes", "ORGANISM", 59, 70], ["S. aureus", "ORGANISM", 75, 84], ["S. pyogenes", "SPECIES", 59, 70], ["S. aureus", "SPECIES", 75, 84], ["S. pyogenes", "SPECIES", 59, 70], ["S. aureus", "SPECIES", 75, 84], ["Antibiotic treatment", "TREATMENT", 0, 20], ["S. pyogenes", "PROBLEM", 59, 70], ["S. aureus", "PROBLEM", 75, 84], ["aureus", "OBSERVATION", 78, 84]]], ["This may include a combination of cephalosporins, vancomycin, or drugs effective against MRSA.", [["cephalosporins", "CHEMICAL", 34, 48], ["vancomycin", "CHEMICAL", 50, 60], ["MRSA", "DISEASE", 89, 93], ["cephalosporins", "CHEMICAL", 34, 48], ["vancomycin", "CHEMICAL", 50, 60], ["cephalosporins", "SIMPLE_CHEMICAL", 34, 48], ["vancomycin", "SIMPLE_CHEMICAL", 50, 60], ["MRSA", "SPECIES", 89, 93], ["MRSA", "SPECIES", 89, 93], ["cephalosporins", "TREATMENT", 34, 48], ["vancomycin", "TREATMENT", 50, 60], ["drugs", "TREATMENT", 65, 70], ["MRSA", "PROBLEM", 89, 93]]], ["The addition of clindamycin may reduce toxin production and mortality.", [["clindamycin", "CHEMICAL", 16, 27], ["clindamycin", "CHEMICAL", 16, 27], ["clindamycin", "SIMPLE_CHEMICAL", 16, 27], ["toxin", "SIMPLE_CHEMICAL", 39, 44], ["clindamycin", "TREATMENT", 16, 27], ["toxin production", "PROBLEM", 39, 55]]], ["Toxic shock usually has a prominent primary site of infection or source.", [["site", "ANATOMY", 44, 48], ["shock", "DISEASE", 6, 11], ["infection", "DISEASE", 52, 61], ["Toxic shock", "PROBLEM", 0, 11], ["infection", "PROBLEM", 52, 61], ["shock", "OBSERVATION", 6, 11], ["prominent", "OBSERVATION_MODIFIER", 26, 35], ["primary", "OBSERVATION_MODIFIER", 36, 43], ["infection", "OBSERVATION", 52, 61]]], ["Staphylococcal toxic shock can be associated with immunosuppression, surgical wounds, or retained tampons.", [["wounds", "ANATOMY", 78, 84], ["Staphylococcal toxic shock", "DISEASE", 0, 26], ["wounds", "PATHOLOGICAL_FORMATION", 78, 84], ["Staphylococcal toxic shock", "PROBLEM", 0, 26], ["immunosuppression", "TREATMENT", 50, 67], ["surgical wounds", "PROBLEM", 69, 84], ["retained tampons", "PROBLEM", 89, 105], ["toxic shock", "OBSERVATION", 15, 26], ["can be associated with", "UNCERTAINTY", 27, 49], ["immunosuppression", "OBSERVATION", 50, 67], ["surgical wounds", "OBSERVATION", 69, 84], ["tampons", "OBSERVATION", 98, 105]]], ["Staphylococcus aureus colonization can incite toxic shock.", [["Staphylococcus aureus", "DISEASE", 0, 21], ["shock", "DISEASE", 52, 57], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Staphylococcus aureus colonization", "PROBLEM", 0, 34], ["toxic shock", "PROBLEM", 46, 57], ["aureus", "OBSERVATION", 15, 21], ["toxic shock", "OBSERVATION", 46, 57]]], ["In certain circumstances and loca-tion, it has been suggested that Rocky Mountain spotted fever and leptospirosis which can have a similar presentation be ruled out serologically to confirm the diagnosis.", [["fever", "DISEASE", 90, 95], ["leptospirosis", "DISEASE", 100, 113], ["Rocky Mountain spotted fever", "SPECIES", 67, 95], ["fever", "PROBLEM", 90, 95], ["leptospirosis", "PROBLEM", 100, 113]]], ["This patient is at very low risk for these diagnoses.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12]]], ["On physical examinations, she has an erythematous oropharynx and cervical lymphadenopathy.", [["erythematous oropharynx", "ANATOMY", 37, 60], ["cervical", "ANATOMY", 65, 73], ["cervical lymphadenopathy", "DISEASE", 65, 89], ["oropharynx", "ORGAN", 50, 60], ["cervical lymphadenopathy", "CANCER", 65, 89], ["physical examinations", "TEST", 3, 24], ["an erythematous oropharynx", "PROBLEM", 34, 60], ["cervical lymphadenopathy", "PROBLEM", 65, 89], ["erythematous", "OBSERVATION_MODIFIER", 37, 49], ["oropharynx", "ANATOMY", 50, 60], ["cervical", "ANATOMY", 65, 73], ["lymphadenopathy", "OBSERVATION", 74, 89]]], ["The patient has no known history of drug allergy.", [["drug allergy", "DISEASE", 36, 48], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["drug allergy", "PROBLEM", 36, 48], ["no", "UNCERTAINTY", 16, 18], ["drug allergy", "OBSERVATION", 36, 48]]], ["She is started on an empirical regimen of amoxicillin for streptococcal pharyngitis.ReferencesThe next day she developed an erythematous maculopapular rash on several areas.", [["maculopapular", "ANATOMY", 137, 150], ["amoxicillin", "CHEMICAL", 42, 53], ["streptococcal pharyngitis", "DISEASE", 58, 83], ["rash", "DISEASE", 151, 155], ["amoxicillin", "CHEMICAL", 42, 53], ["amoxicillin", "SIMPLE_CHEMICAL", 42, 53], ["an empirical regimen", "TREATMENT", 18, 38], ["amoxicillin", "TREATMENT", 42, 53], ["streptococcal pharyngitis", "PROBLEM", 58, 83], ["an erythematous maculopapular rash", "PROBLEM", 121, 155], ["pharyngitis", "OBSERVATION", 72, 83], ["erythematous", "OBSERVATION_MODIFIER", 124, 136], ["maculopapular", "OBSERVATION_MODIFIER", 137, 150], ["rash", "OBSERVATION", 151, 155]]], ["The mono spot test comes back positive.ReferencesWhich of the following statements regarding this patient's exanthematous drug eruption is true?", [["drug eruption", "DISEASE", 122, 135], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["The mono spot test", "TEST", 0, 18], ["positive", "PROBLEM", 30, 38], ["this patient's exanthematous drug eruption", "PROBLEM", 93, 135]]], ["A) Fever is common in viral-related exanthematous eruptions.", [["Fever", "DISEASE", 3, 8], ["Fever", "PROBLEM", 3, 8], ["exanthematous eruptions", "PROBLEM", 36, 59], ["Fever", "OBSERVATION", 3, 8], ["viral", "OBSERVATION", 22, 27], ["exanthematous", "OBSERVATION_MODIFIER", 36, 49], ["eruptions", "OBSERVATION", 50, 59]]], ["B) Systemic corticosteroids are required to treat this drug eruption.", [["Systemic corticosteroids", "TREATMENT", 3, 27], ["this drug eruption", "PROBLEM", 50, 68], ["Systemic", "ANATOMY", 3, 11], ["corticosteroids", "OBSERVATION", 12, 27]]], ["C) In the future she will be able to tolerate all \u03b2-lactam antibiotics, including ampicillin.", [["\u03b2-lactam", "CHEMICAL", 50, 58], ["ampicillin", "CHEMICAL", 82, 92], ["\u03b2-lactam", "CHEMICAL", 50, 58], ["ampicillin", "CHEMICAL", 82, 92], ["\u03b2-lactam", "SIMPLE_CHEMICAL", 50, 58], ["ampicillin", "SIMPLE_CHEMICAL", 82, 92], ["all \u03b2-lactam antibiotics", "TREATMENT", 46, 70], ["ampicillin", "TREATMENT", 82, 92]]], ["D) The mechanism of exanthematous eruption caused by ampicillin is mast cell degranulation.", [["mast cell", "ANATOMY", 67, 76], ["exanthematous eruption", "DISEASE", 20, 42], ["ampicillin", "CHEMICAL", 53, 63], ["ampicillin", "CHEMICAL", 53, 63], ["ampicillin", "SIMPLE_CHEMICAL", 53, 63], ["mast cell", "CELL", 67, 76], ["exanthematous eruption", "PROBLEM", 20, 42], ["ampicillin", "TREATMENT", 53, 63], ["mast cell degranulation", "PROBLEM", 67, 90], ["mechanism of", "UNCERTAINTY", 7, 19], ["exanthematous", "OBSERVATION_MODIFIER", 20, 33], ["eruption", "OBSERVATION", 34, 42], ["mast cell degranulation", "OBSERVATION", 67, 90]]], ["E) This patient's rash can be expected to be severe.ReferencesAnswer: C This patient has ampicillin-or amoxicillin-related exanthematous eruption that can frequently occur with mononucleosis.", [["rash", "DISEASE", 18, 22], ["ampicillin", "CHEMICAL", 89, 99], ["amoxicillin", "CHEMICAL", 103, 114], ["exanthematous eruption", "DISEASE", 123, 145], ["mononucleosis", "DISEASE", 177, 190], ["ampicillin", "CHEMICAL", 89, 99], ["amoxicillin", "CHEMICAL", 103, 114], ["patient", "ORGANISM", 8, 15], ["patient", "ORGANISM", 77, 84], ["ampicillin", "SIMPLE_CHEMICAL", 89, 99], ["amoxicillin", "SIMPLE_CHEMICAL", 103, 114], ["patient", "SPECIES", 8, 15], ["patient", "SPECIES", 77, 84], ["This patient's rash", "PROBLEM", 3, 22], ["ampicillin", "TREATMENT", 89, 99], ["amoxicillin", "TREATMENT", 103, 114], ["exanthematous eruption", "PROBLEM", 123, 145], ["mononucleosis", "PROBLEM", 177, 190], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["exanthematous", "OBSERVATION_MODIFIER", 123, 136], ["eruption", "OBSERVATION", 137, 145], ["mononucleosis", "OBSERVATION", 177, 190]]], ["This does not appear to be IgE mediated and is not a penicillin allergy.", [["penicillin", "CHEMICAL", 53, 63], ["allergy", "DISEASE", 64, 71], ["penicillin", "CHEMICAL", 53, 63], ["IgE", "GENE_OR_GENE_PRODUCT", 27, 30], ["penicillin", "SIMPLE_CHEMICAL", 53, 63], ["IgE", "PROTEIN", 27, 30], ["a penicillin allergy", "PROBLEM", 51, 71]]], ["Patients may receive penicillins in the future.", [["penicillins", "CHEMICAL", 21, 32], ["penicillins", "CHEMICAL", 21, 32], ["Patients", "ORGANISM", 0, 8], ["penicillins", "SIMPLE_CHEMICAL", 21, 32], ["Patients", "SPECIES", 0, 8], ["penicillins", "TREATMENT", 21, 32]]], ["The etiology of the ampicillin rash that occurs in association with a viral infection is unknown.", [["ampicillin", "CHEMICAL", 20, 30], ["rash", "DISEASE", 31, 35], ["viral infection", "DISEASE", 70, 85], ["ampicillin", "CHEMICAL", 20, 30], ["ampicillin", "SIMPLE_CHEMICAL", 20, 30], ["the ampicillin rash", "PROBLEM", 16, 35], ["a viral infection", "PROBLEM", 68, 85], ["ampicillin rash", "OBSERVATION", 20, 35], ["viral", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 76, 85]]], ["Fever is not associated with simple exanthematous eruptions.", [["Fever", "DISEASE", 0, 5], ["Fever", "PROBLEM", 0, 5], ["simple exanthematous eruptions", "PROBLEM", 29, 59], ["not associated with", "UNCERTAINTY", 9, 28], ["simple", "OBSERVATION_MODIFIER", 29, 35], ["exanthematous", "OBSERVATION_MODIFIER", 36, 49], ["eruptions", "OBSERVATION", 50, 59]]], ["These eruptions usually occur within 1 week after the beginning of therapy and generally resolve within 7-14 days.", [["These eruptions", "PROBLEM", 0, 15], ["therapy", "TREATMENT", 67, 74]]], ["Scaling or desquamation may follow resolution.", [["Scaling", "PROBLEM", 0, 7], ["desquamation", "PROBLEM", 11, 23], ["desquamation", "OBSERVATION", 11, 23]]], ["On physical exam, she has a temperature of 37.9 \u00b0C (100.3 \u00b0F), active bowel sounds are heard, and she has right lower quadrant tenderness.ReferencesWhich of the following statements is true for this patient?ReferencesA) The anemia is probably caused by folate defi ciency.", [["bowel", "ANATOMY", 70, 75], ["right lower quadrant", "ANATOMY", 106, 126], ["tenderness", "DISEASE", 127, 137], ["anemia", "DISEASE", 224, 230], ["folate", "CHEMICAL", 253, 259], ["folate", "CHEMICAL", 253, 259], ["bowel", "ORGAN", 70, 75], ["patient", "ORGANISM", 199, 206], ["folate", "SIMPLE_CHEMICAL", 253, 259], ["patient", "SPECIES", 199, 206], ["physical exam", "TEST", 3, 16], ["a temperature", "TEST", 26, 39], ["\u00b0C", "TEST", 48, 50], ["right lower quadrant tenderness", "PROBLEM", 106, 137], ["The anemia", "PROBLEM", 220, 230], ["folate defi ciency", "PROBLEM", 253, 271], ["bowel", "ANATOMY", 70, 75], ["sounds", "OBSERVATION", 76, 82], ["right", "ANATOMY_MODIFIER", 106, 111], ["lower", "ANATOMY_MODIFIER", 112, 117], ["quadrant", "ANATOMY", 118, 126], ["tenderness", "OBSERVATION", 127, 137], ["anemia", "OBSERVATION", 224, 230], ["probably caused", "UNCERTAINTY", 234, 249], ["folate defi", "OBSERVATION", 253, 264]]], ["B) Sulfasalazine is the fi rst-line therapy.", [["Sulfasalazine", "CHEMICAL", 3, 16], ["Sulfasalazine", "CHEMICAL", 3, 16], ["Sulfasalazine", "SIMPLE_CHEMICAL", 3, 16], ["Sulfasalazine", "TREATMENT", 3, 16], ["the fi rst-line therapy", "TREATMENT", 20, 43], ["line therapy", "OBSERVATION", 31, 43]]], ["C) An aminosalicylate (5-ASA) will be required to control this fl are.", [["aminosalicylate", "CHEMICAL", 6, 21], ["5-ASA", "CHEMICAL", 23, 28], ["aminosalicylate", "CHEMICAL", 6, 21], ["5-ASA", "CHEMICAL", 23, 28], ["aminosalicylate", "SIMPLE_CHEMICAL", 6, 21], ["5-ASA", "SIMPLE_CHEMICAL", 23, 28], ["An aminosalicylate (5-ASA)", "TREATMENT", 3, 29]]], ["D) Corticosteroids will be necessary to control her symptoms.", [["Corticosteroids", "TREATMENT", 3, 18], ["her symptoms", "PROBLEM", 48, 60]]], ["E) She should be hospitalized and given infl iximab.ReferencesAnswer: D This patient has moderate to severe Crohn's disease.", [["Crohn's disease", "DISEASE", 108, 123], ["She", "ORGANISM", 3, 6], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["infl iximab", "TREATMENT", 40, 51], ["moderate to severe Crohn's disease", "PROBLEM", 89, 123], ["moderate", "OBSERVATION_MODIFIER", 89, 97], ["severe", "OBSERVATION_MODIFIER", 101, 107], ["Crohn", "OBSERVATION", 108, 113], ["'s disease", "OBSERVATION", 113, 123]]], ["This is based on her symptoms of fever, weight loss, abdominal pain without obstruction, and ability to continue oral intake.", [["abdominal", "ANATOMY", 53, 62], ["oral", "ANATOMY", 113, 117], ["fever", "DISEASE", 33, 38], ["weight loss", "DISEASE", 40, 51], ["abdominal pain", "DISEASE", 53, 67], ["obstruction", "DISEASE", 76, 87], ["abdominal", "ORGANISM_SUBDIVISION", 53, 62], ["oral", "ORGANISM_SUBDIVISION", 113, 117], ["her symptoms", "PROBLEM", 17, 29], ["fever", "PROBLEM", 33, 38], ["weight loss", "PROBLEM", 40, 51], ["abdominal pain", "PROBLEM", 53, 67], ["obstruction", "PROBLEM", 76, 87], ["fever", "OBSERVATION", 33, 38], ["abdominal", "ANATOMY", 53, 62], ["pain", "OBSERVATION", 63, 67], ["obstruction", "OBSERVATION", 76, 87]]], ["For the treatment of moderate to severe Crohn's disease, the current recommendations include the \"top-down\" approach.", [["Crohn's disease", "DISEASE", 40, 55], ["moderate to severe Crohn's disease", "PROBLEM", 21, 55], ["the \"top-down\" approach", "TREATMENT", 93, 116], ["moderate", "OBSERVATION_MODIFIER", 21, 29], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["Crohn's disease", "OBSERVATION", 40, 55]]], ["For symptoms of this severity, corticosteroids will be necessary.", [["corticosteroids", "CHEMICAL", 31, 46], ["corticosteroids", "SIMPLE_CHEMICAL", 31, 46], ["symptoms", "PROBLEM", 4, 12], ["this severity", "PROBLEM", 16, 29], ["corticosteroids", "TREATMENT", 31, 46]]], ["The use of 5-ASA for the treatment of Crohn's disease is limited.", [["5-ASA", "CHEMICAL", 11, 16], ["Crohn's disease", "DISEASE", 38, 53], ["5-ASA", "CHEMICAL", 11, 16], ["5-ASA", "SIMPLE_CHEMICAL", 11, 16], ["ASA", "TREATMENT", 13, 16], ["Crohn's disease", "PROBLEM", 38, 53], ["Crohn", "OBSERVATION", 38, 43]]], ["In studies, only a small subset of patients have benefi tted from this agent.ReferencesInfl iximab may be used in patients who are not responsive to salicylates, antibiotics, or steroids.", [["steroids", "CHEMICAL", 178, 186], ["salicylates", "CHEMICAL", 149, 160], ["steroids", "CHEMICAL", 178, 186], ["patients", "ORGANISM", 35, 43], ["Infl iximab", "SIMPLE_CHEMICAL", 87, 98], ["patients", "ORGANISM", 114, 122], ["salicylates", "SIMPLE_CHEMICAL", 149, 160], ["steroids", "SIMPLE_CHEMICAL", 178, 186], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 114, 122], ["this agent", "TREATMENT", 66, 76], ["salicylates", "TREATMENT", 149, 160], ["antibiotics", "TREATMENT", 162, 173], ["steroids", "TREATMENT", 178, 186], ["small", "OBSERVATION_MODIFIER", 19, 24]]], ["Unless the small bowel mucosal disease is very extensive, the macrocytic anemia is most likely caused by a defi ciency of vitamin B12, which is absorbed in the terminal ileum.", [["bowel mucosal", "ANATOMY", 17, 30], ["terminal ileum", "ANATOMY", 160, 174], ["bowel mucosal disease", "DISEASE", 17, 38], ["macrocytic anemia", "DISEASE", 62, 79], ["vitamin B12", "CHEMICAL", 122, 133], ["vitamin B12", "CHEMICAL", 122, 133], ["bowel mucosal", "MULTI-TISSUE_STRUCTURE", 17, 30], ["vitamin B12", "SIMPLE_CHEMICAL", 122, 133], ["ileum", "MULTI-TISSUE_STRUCTURE", 169, 174], ["the small bowel mucosal disease", "PROBLEM", 7, 38], ["the macrocytic anemia", "PROBLEM", 58, 79], ["vitamin B12", "TREATMENT", 122, 133], ["small", "OBSERVATION_MODIFIER", 11, 16], ["bowel mucosal", "ANATOMY", 17, 30], ["disease", "OBSERVATION", 31, 38], ["very", "OBSERVATION_MODIFIER", 42, 46], ["extensive", "OBSERVATION_MODIFIER", 47, 56], ["macrocytic", "OBSERVATION_MODIFIER", 62, 72], ["anemia", "OBSERVATION", 73, 79], ["most likely", "UNCERTAINTY", 83, 94], ["terminal", "ANATOMY_MODIFIER", 160, 168], ["ileum", "ANATOMY", 169, 174]]], ["On physical exam she appears to be euvolemic.", [["physical exam", "TEST", 3, 16], ["euvolemic", "OBSERVATION", 35, 44]]], ["The most appropriate initial therapy includes: A) Slow correction of her sodium with normal saline B) Free water restriction C) 3 % saline administration with close monitoring D) Demeclocycline E) Dexamethasone Answer: C In a setting of signifi cant hyponatremia with neurologic symptoms, consideration must be given to administering hypertonic saline.", [["neurologic", "ANATOMY", 268, 278], ["sodium", "CHEMICAL", 73, 79], ["hyponatremia", "DISEASE", 250, 262], ["neurologic symptoms", "DISEASE", 268, 287], ["sodium", "CHEMICAL", 73, 79], ["Demeclocycline E", "CHEMICAL", 179, 195], ["Dexamethasone", "CHEMICAL", 197, 210], ["sodium", "SIMPLE_CHEMICAL", 73, 79], ["saline", "SIMPLE_CHEMICAL", 132, 138], ["Demeclocycline E", "SIMPLE_CHEMICAL", 179, 195], ["Dexamethasone", "SIMPLE_CHEMICAL", 197, 210], ["hypertonic saline", "SIMPLE_CHEMICAL", 334, 351], ["her sodium", "TREATMENT", 69, 79], ["normal saline B", "TREATMENT", 85, 100], ["Free water restriction C)", "TREATMENT", 102, 127], ["3 % saline administration", "TREATMENT", 128, 153], ["Demeclocycline E) Dexamethasone", "TREATMENT", 179, 210], ["signifi cant hyponatremia", "PROBLEM", 237, 262], ["neurologic symptoms", "PROBLEM", 268, 287], ["hypertonic saline", "TREATMENT", 334, 351], ["hyponatremia", "OBSERVATION", 250, 262]]], ["This patient's condition is almost certainly due to syndrome of inappropriate antidiuretic hormone (SIADH) due to her small cell lung cancer.", [["small cell lung cancer", "ANATOMY", 118, 140], ["inappropriate antidiuretic hormone", "DISEASE", 64, 98], ["SIADH", "DISEASE", 100, 105], ["lung cancer", "DISEASE", 129, 140], ["patient", "ORGANISM", 5, 12], ["antidiuretic hormone", "GENE_OR_GENE_PRODUCT", 78, 98], ["small cell lung cancer", "CANCER", 118, 140], ["patient", "SPECIES", 5, 12], ["syndrome", "PROBLEM", 52, 60], ["inappropriate antidiuretic hormone", "PROBLEM", 64, 98], ["SIADH", "PROBLEM", 100, 105], ["her small cell lung cancer", "PROBLEM", 114, 140], ["antidiuretic hormone", "OBSERVATION", 78, 98], ["small cell", "OBSERVATION", 118, 128], ["lung", "ANATOMY", 129, 133], ["cancer", "OBSERVATION", 134, 140]]], ["Isotonic normal saline would probably worsen the hyponatremia by the mechanism of water retention and sodium excretion.", [["hyponatremia", "DISEASE", 49, 61], ["sodium", "CHEMICAL", 102, 108], ["sodium", "CHEMICAL", 102, 108], ["saline", "SIMPLE_CHEMICAL", 16, 22], ["water", "SIMPLE_CHEMICAL", 82, 87], ["sodium", "SIMPLE_CHEMICAL", 102, 108], ["Isotonic normal saline", "TREATMENT", 0, 22], ["the hyponatremia", "PROBLEM", 45, 61], ["water retention", "PROBLEM", 82, 97], ["sodium excretion", "TEST", 102, 118], ["normal saline", "OBSERVATION", 9, 22], ["hyponatremia", "OBSERVATION", 49, 61], ["water retention", "OBSERVATION", 82, 97]]], ["When hypertonic saline is administered, careful monitoring of her sodium levels should be done to prevent central pontine myelinolysis, which can occur with rapid correction.", [["pontine", "ANATOMY", 114, 121], ["sodium", "CHEMICAL", 66, 72], ["myelinolysis", "DISEASE", 122, 134], ["sodium", "CHEMICAL", 66, 72], ["saline", "SIMPLE_CHEMICAL", 16, 22], ["sodium", "SIMPLE_CHEMICAL", 66, 72], ["pontine", "ORGANISM_SUBDIVISION", 114, 121], ["hypertonic saline", "TREATMENT", 5, 22], ["careful monitoring of her sodium levels", "TEST", 40, 79], ["central pontine myelinolysis", "PROBLEM", 106, 134], ["rapid correction", "TREATMENT", 157, 173], ["central", "ANATOMY_MODIFIER", 106, 113], ["pontine", "ANATOMY", 114, 121], ["myelinolysis", "OBSERVATION", 122, 134]]], ["In less severe cases with no neurologic fi ndings, water restriction would be the fi rst line of treatment.32.A 54-year-old man is admitted with abdominal pain.", [["neurologic", "ANATOMY", 29, 39], ["abdominal", "ANATOMY", 145, 154], ["abdominal pain", "DISEASE", 145, 159], ["man", "ORGANISM", 124, 127], ["abdominal", "ORGANISM_SUBDIVISION", 145, 154], ["man", "SPECIES", 124, 127], ["neurologic fi ndings", "PROBLEM", 29, 49], ["water restriction", "TREATMENT", 51, 68], ["the fi rst line of treatment", "TREATMENT", 78, 106], ["abdominal pain", "PROBLEM", 145, 159], ["less severe", "OBSERVATION_MODIFIER", 3, 14], ["no", "UNCERTAINTY", 26, 28], ["abdominal", "ANATOMY", 145, 154], ["pain", "OBSERVATION", 155, 159]]], ["He had a similar episode 6 months ago for which he was seen in the emergency room several days after the onset of pain and was discharged home without a defi nitive diagnosis.", [["pain", "DISEASE", 114, 118], ["pain", "PROBLEM", 114, 118]]], ["He has a history of poorly controlled diabetes mellitus.", [["diabetes mellitus", "DISEASE", 38, 55], ["poorly controlled diabetes mellitus", "PROBLEM", 20, 55], ["poorly controlled", "OBSERVATION_MODIFIER", 20, 37], ["diabetes mellitus", "OBSERVATION", 38, 55]]], ["He has pain for the past 3 days.", [["pain", "DISEASE", 7, 11], ["He", "ORGANISM", 0, 2], ["pain", "PROBLEM", 7, 11], ["pain", "OBSERVATION", 7, 11]]], ["He denies any alcohol use, which is confi rmed by family members.", [["alcohol", "CHEMICAL", 14, 21], ["alcohol", "CHEMICAL", 14, 21]]], ["On physical exam, he is tachycardic and has diminished bowel sounds and epigastric tenderness.", [["bowel", "ANATOMY", 55, 60], ["epigastric", "ANATOMY", 72, 82], ["epigastric tenderness", "DISEASE", 72, 93], ["bowel", "ORGAN", 55, 60], ["epigastric", "ORGANISM_SUBDIVISION", 72, 82], ["physical exam", "TEST", 3, 16], ["tachycardic", "PROBLEM", 24, 35], ["diminished bowel sounds", "PROBLEM", 44, 67], ["epigastric tenderness", "PROBLEM", 72, 93], ["tachycardic", "OBSERVATION", 24, 35], ["diminished", "OBSERVATION_MODIFIER", 44, 54], ["bowel", "ANATOMY", 55, 60], ["sounds", "OBSERVATION", 61, 67], ["epigastric", "ANATOMY", 72, 82], ["tenderness", "OBSERVATION", 83, 93]]], ["He has a papular rash on his knees.32.Initial laboratory studies are signifi cant for the following: leukocytes, 16,000 cells/mm 3 ; blood glucose level of 400 mg/dl.", [["papular", "ANATOMY", 9, 16], ["knees", "ANATOMY", 29, 34], ["leukocytes", "ANATOMY", 101, 111], ["cells", "ANATOMY", 120, 125], ["blood", "ANATOMY", 133, 138], ["rash", "DISEASE", 17, 21], ["glucose", "CHEMICAL", 139, 146], ["glucose", "CHEMICAL", 139, 146], ["He", "ORGANISM", 0, 2], ["knees", "ORGANISM_SUBDIVISION", 29, 34], ["leukocytes", "CELL", 101, 111], ["cells", "CELL", 120, 125], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["glucose", "SIMPLE_CHEMICAL", 139, 146], ["leukocytes", "CELL_TYPE", 101, 111], ["a papular rash on his knees", "PROBLEM", 7, 34], ["Initial laboratory studies", "TEST", 38, 64], ["leukocytes", "TEST", 101, 111], ["cells", "TEST", 120, 125], ["mm", "TEST", 126, 128], ["blood glucose level", "TEST", 133, 152], ["papular", "OBSERVATION_MODIFIER", 9, 16], ["rash", "OBSERVATION", 17, 21], ["knees", "ANATOMY", 29, 34]]], ["An amylase level is normal.32.Which of the following is the most likely diagnosis for this patient?", [["amylase", "GENE_OR_GENE_PRODUCT", 3, 10], ["patient", "ORGANISM", 91, 98], ["amylase", "PROTEIN", 3, 10], ["patient", "SPECIES", 91, 98], ["An amylase level", "TEST", 0, 16], ["amylase", "ANATOMY", 3, 10], ["normal", "OBSERVATION", 20, 26]]], ["A) Acute or chronic idiopathic pancreatitis B) Gallstone pancreatitis C) Alcoholic pancreatitis D) Pancreatitis secondary to hypertriglyceridemia E) Malignancy-induced pancreatitis Answer: D This patient has triglyceride induced pancreatitis.", [["idiopathic pancreatitis B", "DISEASE", 20, 45], ["Gallstone pancreatitis", "DISEASE", 47, 69], ["Alcoholic pancreatitis", "DISEASE", 73, 95], ["Pancreatitis", "DISEASE", 99, 111], ["hypertriglyceridemia", "DISEASE", 125, 145], ["Malignancy", "DISEASE", 149, 159], ["pancreatitis", "DISEASE", 168, 180], ["triglyceride", "CHEMICAL", 208, 220], ["pancreatitis", "DISEASE", 229, 241], ["D", "CHEMICAL", 189, 190], ["triglyceride", "CHEMICAL", 208, 220], ["patient", "ORGANISM", 196, 203], ["triglyceride", "SIMPLE_CHEMICAL", 208, 220], ["patient", "SPECIES", 196, 203], ["Acute or chronic idiopathic pancreatitis", "PROBLEM", 3, 43], ["Gallstone pancreatitis", "PROBLEM", 47, 69], ["Alcoholic pancreatitis D)", "PROBLEM", 73, 98], ["Pancreatitis", "PROBLEM", 99, 111], ["hypertriglyceridemia E) Malignancy", "PROBLEM", 125, 159], ["pancreatitis", "PROBLEM", 168, 180], ["triglyceride induced pancreatitis", "PROBLEM", 208, 241], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["chronic", "OBSERVATION_MODIFIER", 12, 19], ["idiopathic", "OBSERVATION_MODIFIER", 20, 30], ["pancreatitis", "OBSERVATION", 31, 43], ["Gallstone", "OBSERVATION", 47, 56], ["Alcoholic", "OBSERVATION_MODIFIER", 73, 82], ["pancreatitis", "OBSERVATION", 83, 95], ["Pancreatitis", "OBSERVATION", 99, 111], ["hypertriglyceridemia", "OBSERVATION", 125, 145], ["Malignancy", "OBSERVATION", 149, 159], ["pancreatitis", "OBSERVATION", 168, 180], ["pancreatitis", "OBSERVATION", 229, 241]]], ["The serum amylase level may be normal in some patients with acute pancreatitis associated with high triglycerides as marked elevations in the triglyceride level can interfere with the laboratory assay for amylase.", [["serum", "ANATOMY", 4, 9], ["pancreatitis", "DISEASE", 66, 78], ["triglyceride", "CHEMICAL", 142, 154], ["triglycerides", "CHEMICAL", 100, 113], ["triglyceride", "CHEMICAL", 142, 154], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["amylase", "GENE_OR_GENE_PRODUCT", 10, 17], ["patients", "ORGANISM", 46, 54], ["triglycerides", "SIMPLE_CHEMICAL", 100, 113], ["triglyceride", "SIMPLE_CHEMICAL", 142, 154], ["amylase", "GENE_OR_GENE_PRODUCT", 205, 212], ["serum amylase", "PROTEIN", 4, 17], ["amylase", "PROTEIN", 205, 212], ["patients", "SPECIES", 46, 54], ["The serum amylase level", "TEST", 0, 23], ["acute pancreatitis", "PROBLEM", 60, 78], ["high triglycerides", "PROBLEM", 95, 113], ["marked elevations in the triglyceride level", "PROBLEM", 117, 160], ["the laboratory assay", "TEST", 180, 200], ["amylase", "TEST", 205, 212], ["normal", "OBSERVATION", 31, 37], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["pancreatitis", "OBSERVATION", 66, 78], ["marked", "OBSERVATION_MODIFIER", 117, 123], ["elevations", "OBSERVATION_MODIFIER", 124, 134]]], ["The presence of a papular rash on this patient is consistent with eruptive xanthomas due to hypertriglyceridemia.", [["papular", "ANATOMY", 18, 25], ["rash", "DISEASE", 26, 30], ["xanthomas", "DISEASE", 75, 84], ["hypertriglyceridemia", "DISEASE", 92, 112], ["patient", "ORGANISM", 39, 46], ["xanthomas", "PATHOLOGICAL_FORMATION", 75, 84], ["patient", "SPECIES", 39, 46], ["a papular rash", "PROBLEM", 16, 30], ["eruptive xanthomas", "PROBLEM", 66, 84], ["hypertriglyceridemia", "PROBLEM", 92, 112], ["papular", "OBSERVATION_MODIFIER", 18, 25], ["rash", "OBSERVATION", 26, 30], ["consistent with", "UNCERTAINTY", 50, 65], ["hypertriglyceridemia", "OBSERVATION", 92, 112]]], ["In the acute phase, the initial treatment of hypertriglyceridemia-induced acute pancreatitis focuses on good hydration and analgesia and is similar to the management of acute pancreatitis due to any etiology.", [["hypertriglyceridemia", "DISEASE", 45, 65], ["pancreatitis", "DISEASE", 80, 92], ["pancreatitis", "DISEASE", 175, 187], ["hypertriglyceridemia", "PROBLEM", 45, 65], ["acute pancreatitis", "PROBLEM", 74, 92], ["analgesia", "TREATMENT", 123, 132], ["acute pancreatitis", "PROBLEM", 169, 187], ["acute phase", "OBSERVATION_MODIFIER", 7, 18], ["hypertriglyceridemia", "OBSERVATION", 45, 65], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["pancreatitis", "OBSERVATION", 80, 92], ["acute", "OBSERVATION_MODIFIER", 169, 174], ["pancreatitis", "OBSERVATION", 175, 187]]], ["The triglyceride levels usually rapidly decrease within 48 h of the onset of acute pancreatitis.", [["triglyceride", "CHEMICAL", 4, 16], ["pancreatitis", "DISEASE", 83, 95], ["triglyceride", "CHEMICAL", 4, 16], ["triglyceride", "SIMPLE_CHEMICAL", 4, 16], ["The triglyceride levels", "TEST", 0, 23], ["acute pancreatitis", "PROBLEM", 77, 95], ["rapidly", "OBSERVATION_MODIFIER", 32, 39], ["decrease", "OBSERVATION_MODIFIER", 40, 48], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["pancreatitis", "OBSERVATION", 83, 95]]], ["Gallstones and alcohol abuse combined account for 70-80 % of all cases of acute pancreatitis.", [["Gallstones", "DISEASE", 0, 10], ["alcohol abuse", "DISEASE", 15, 28], ["pancreatitis", "DISEASE", 80, 92], ["alcohol", "CHEMICAL", 15, 22], ["Gallstones", "PROBLEM", 0, 10], ["acute pancreatitis", "PROBLEM", 74, 92], ["alcohol abuse", "OBSERVATION", 15, 28], ["acute", "OBSERVATION_MODIFIER", 74, 79], ["pancreatitis", "OBSERVATION", 80, 92]]], ["Other etiologies include sphincter of Oddi dysfunction, strictures of the pancreatic duct, congenital anatomic abnormalities and genetic disorders, drugs, toxins, trauma, infections, and metabolic causes.", [["sphincter", "ANATOMY", 25, 34], ["pancreatic duct", "ANATOMY", 74, 89], ["sphincter of Oddi dysfunction", "DISEASE", 25, 54], ["strictures of the pancreatic duct", "DISEASE", 56, 89], ["congenital anatomic abnormalities", "DISEASE", 91, 124], ["genetic disorders", "DISEASE", 129, 146], ["trauma", "DISEASE", 163, 169], ["infections", "DISEASE", 171, 181], ["sphincter", "ORGAN", 25, 34], ["strictures", "PATHOLOGICAL_FORMATION", 56, 66], ["pancreatic duct", "MULTI-TISSUE_STRUCTURE", 74, 89], ["sphincter of Oddi dysfunction", "PROBLEM", 25, 54], ["strictures of the pancreatic duct", "PROBLEM", 56, 89], ["congenital anatomic abnormalities", "PROBLEM", 91, 124], ["genetic disorders", "PROBLEM", 129, 146], ["drugs", "TREATMENT", 148, 153], ["toxins", "PROBLEM", 155, 161], ["trauma", "PROBLEM", 163, 169], ["infections", "PROBLEM", 171, 181], ["metabolic causes", "PROBLEM", 187, 203], ["sphincter", "ANATOMY_MODIFIER", 25, 34], ["Oddi", "ANATOMY", 38, 42], ["dysfunction", "OBSERVATION", 43, 54], ["strictures", "OBSERVATION", 56, 66], ["pancreatic duct", "ANATOMY", 74, 89], ["congenital", "OBSERVATION_MODIFIER", 91, 101], ["anatomic abnormalities", "OBSERVATION", 102, 124], ["infections", "OBSERVATION", 171, 181], ["metabolic causes", "OBSERVATION", 187, 203]]], ["Some cases are idiopathic.", [["idiopathic", "PROBLEM", 15, 25], ["idiopathic", "OBSERVATION", 15, 25]]], ["Metabolic causes of acute pancreatitis include not only hypertriglyceridemia but hypercalcemias well.", [["pancreatitis", "DISEASE", 26, 38], ["hypertriglyceridemia", "DISEASE", 56, 76], ["hypercalcemias", "DISEASE", 81, 95], ["acute pancreatitis", "PROBLEM", 20, 38], ["hypertriglyceridemia", "PROBLEM", 56, 76], ["hypercalcemias", "PROBLEM", 81, 95], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["pancreatitis", "OBSERVATION", 26, 38], ["hypertriglyceridemia", "OBSERVATION", 56, 76], ["hypercalcemias", "OBSERVATION", 81, 95]]], ["Serum triglycerides generally need to be in excess of 1,000 mg/ dl to produce acute pancreatitis.", [["Serum", "ANATOMY", 0, 5], ["pancreatitis", "DISEASE", 84, 96], ["triglycerides", "CHEMICAL", 6, 19], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["triglycerides", "SIMPLE_CHEMICAL", 6, 19], ["Serum triglycerides", "TEST", 0, 19], ["acute pancreatitis", "PROBLEM", 78, 96], ["acute", "OBSERVATION_MODIFIER", 78, 83], ["pancreatitis", "OBSERVATION", 84, 96]]], ["This is most commonly seen in type V hyperlipoproteinemia and is usually associated with diabetes mellitus.", [["hyperlipoproteinemia", "DISEASE", 37, 57], ["diabetes mellitus", "DISEASE", 89, 106], ["type V hyperlipoproteinemia", "PROBLEM", 30, 57], ["diabetes mellitus", "PROBLEM", 89, 106], ["most commonly", "OBSERVATION_MODIFIER", 8, 21], ["type V", "OBSERVATION_MODIFIER", 30, 36], ["hyperlipoproteinemia", "OBSERVATION", 37, 57], ["usually associated with", "UNCERTAINTY", 65, 88], ["diabetes", "OBSERVATION", 89, 97]]], ["Acute pancreatitis can itself raise triglyceride levels, but not to this degree.", [["pancreatitis", "DISEASE", 6, 18], ["triglyceride", "CHEMICAL", 36, 48], ["triglyceride", "CHEMICAL", 36, 48], ["triglyceride", "SIMPLE_CHEMICAL", 36, 48], ["Acute pancreatitis", "PROBLEM", 0, 18], ["triglyceride levels", "TEST", 36, 55], ["pancreatitis", "OBSERVATION", 6, 18]]], ["An 80-year-old man has been admitted with a urinary tract infection.", [["urinary tract", "ANATOMY", 44, 57], ["urinary tract infection", "DISEASE", 44, 67], ["man", "ORGANISM", 15, 18], ["urinary tract", "ORGANISM_SUBDIVISION", 44, 57], ["man", "SPECIES", 15, 18], ["a urinary tract infection", "PROBLEM", 42, 67], ["urinary tract", "ANATOMY", 44, 57], ["infection", "OBSERVATION", 58, 67]]], ["On the third day from his admission, he develops the acute onset of chest pain of 30 min duration.", [["chest", "ANATOMY", 68, 73], ["chest pain", "DISEASE", 68, 78], ["chest", "ORGANISM_SUBDIVISION", 68, 73], ["chest pain", "PROBLEM", 68, 78], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["chest", "ANATOMY", 68, 73]]], ["He has a history of an inferior myocardial infarction 3 years ago.", [["myocardial", "ANATOMY", 32, 42], ["inferior myocardial infarction", "DISEASE", 23, 53], ["myocardial", "MULTI-TISSUE_STRUCTURE", 32, 42], ["an inferior myocardial infarction", "PROBLEM", 20, 53], ["inferior", "ANATOMY_MODIFIER", 23, 31], ["myocardial", "ANATOMY", 32, 42], ["infarction", "OBSERVATION", 43, 53]]], ["His medical history is remarkable for hypertension and an ischemic stroke 8 years ago.", [["hypertension", "DISEASE", 38, 50], ["ischemic stroke", "DISEASE", 58, 73], ["hypertension", "PROBLEM", 38, 50], ["an ischemic stroke", "PROBLEM", 55, 73], ["remarkable for", "UNCERTAINTY", 23, 37], ["hypertension", "OBSERVATION", 38, 50], ["ischemic", "OBSERVATION_MODIFIER", 58, 66], ["stroke", "OBSERVATION", 67, 73]]], ["Current medications include atenolol and aspirin.", [["atenolol", "CHEMICAL", 28, 36], ["aspirin", "CHEMICAL", 41, 48], ["atenolol", "CHEMICAL", 28, 36], ["aspirin", "CHEMICAL", 41, 48], ["atenolol", "SIMPLE_CHEMICAL", 28, 36], ["aspirin", "SIMPLE_CHEMICAL", 41, 48], ["Current medications", "TREATMENT", 0, 19], ["atenolol", "TREATMENT", 28, 36], ["aspirin", "TREATMENT", 41, 48]]], ["On physical exam, the patient is afebrile, his blood pressure is 170/100 mmHg, his pulse is 90 beats/min, and his respiratory rate is 20 breaths/min.", [["blood", "ANATOMY", 47, 52], ["respiratory", "ANATOMY", 114, 125], ["patient", "ORGANISM", 22, 29], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["patient", "SPECIES", 22, 29], ["physical exam", "TEST", 3, 16], ["afebrile", "PROBLEM", 33, 41], ["his blood pressure", "TEST", 43, 61], ["his pulse", "TEST", 79, 88], ["his respiratory rate", "TEST", 110, 130]]], ["He is diaphoretic and in apparent pain.", [["pain", "DISEASE", 34, 38], ["diaphoretic", "PROBLEM", 6, 17], ["apparent pain", "PROBLEM", 25, 38], ["diaphoretic", "OBSERVATION", 6, 17], ["pain", "OBSERVATION", 34, 38]]], ["ECG reveals 0.2 mm elevations in leads V2-V6.ReferencesWhich of the following features, in this case, would be an absolute contraindication to thrombolytic therapy?", [["V6", "PROTEIN", 42, 44], ["ECG", "TEST", 0, 3], ["0.2 mm elevations in leads V2", "PROBLEM", 12, 41], ["thrombolytic therapy", "TREATMENT", 143, 163], ["0.2 mm", "OBSERVATION_MODIFIER", 12, 18], ["elevations", "OBSERVATION", 19, 29], ["V2", "ANATOMY_MODIFIER", 39, 41]]], ["A) Failure to meet ECG criteria.", [["ECG criteria", "TEST", 19, 31], ["Failure", "OBSERVATION", 3, 10]]], ["C) History of stroke.", [["stroke", "DISEASE", 14, 20], ["stroke", "PROBLEM", 14, 20], ["stroke", "OBSERVATION", 14, 20]]], ["D) Elevated blood pressure.", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["Elevated blood pressure", "PROBLEM", 3, 26], ["Elevated", "OBSERVATION", 3, 11], ["blood pressure", "OBSERVATION", 12, 26]]], ["E) There are no absolute contraindications.ReferencesAnswer: E In this case, there are no absolute contraindications to thrombolytic therapy.", [["absolute contraindications", "PROBLEM", 16, 42], ["thrombolytic therapy", "TREATMENT", 120, 140], ["no", "UNCERTAINTY", 13, 15], ["absolute", "OBSERVATION_MODIFIER", 16, 24], ["no", "UNCERTAINTY", 87, 89]]], ["The patient meets ECG criteria for the administration of thrombolytic therapy.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["ECG criteria", "TEST", 18, 30], ["thrombolytic therapy", "TREATMENT", 57, 77]]], ["This includes ST segment elevation greater than 0.1 mm in two contiguous leads.", [["ST segment elevation", "PROBLEM", 14, 34], ["segment", "ANATOMY_MODIFIER", 17, 24], ["elevation", "OBSERVATION", 25, 34]]], ["Age greater than 75 years is not a contraindication to thrombolysis.", [["thrombolysis", "TREATMENT", 55, 67]]], ["In patients older than 75 years, there is an increased risk of hemorrhagic stroke.", [["hemorrhagic stroke", "DISEASE", 63, 81], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["hemorrhagic stroke", "PROBLEM", 63, 81], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["hemorrhagic", "OBSERVATION_MODIFIER", 63, 74], ["stroke", "OBSERVATION", 75, 81]]], ["Overall mortality is reduced in such patients without other contraindications.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["mortality", "OBSERVATION", 8, 17], ["reduced", "OBSERVATION_MODIFIER", 21, 28]]], ["A prior history of hemorrhagic stroke is an absolute contraindication to thrombolytic.", [["hemorrhagic stroke", "DISEASE", 19, 37], ["hemorrhagic stroke", "PROBLEM", 19, 37], ["thrombolytic", "TREATMENT", 73, 85], ["hemorrhagic", "OBSERVATION_MODIFIER", 19, 30], ["stroke", "OBSERVATION", 31, 37]]], ["A history of an ischemic stroke less than 1 year is an absolute contraindication.", [["ischemic stroke", "DISEASE", 16, 31], ["an ischemic stroke", "PROBLEM", 13, 31], ["ischemic", "OBSERVATION_MODIFIER", 16, 24], ["stroke", "OBSERVATION", 25, 31]]], ["A stroke more than 1 year before presentation is a relative contraindication.", [["stroke", "DISEASE", 2, 8], ["A stroke", "PROBLEM", 0, 8], ["stroke", "OBSERVATION", 2, 8]]], ["Blood pressure >180/110 mmHg is a relative contraindication to thrombolytic therapy.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["thrombolytic therapy", "TREATMENT", 63, 83], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Magnetic resonance imaging of the brain reveals a 1 cm tumor in the left cerebral cortex, which is consistent with metastatic disease.", [["brain", "ANATOMY", 34, 39], ["tumor", "ANATOMY", 55, 60], ["left cerebral cortex", "ANATOMY", 68, 88], ["metastatic disease", "ANATOMY", 115, 133], ["tumor", "DISEASE", 55, 60], ["brain", "ORGAN", 34, 39], ["tumor", "CANCER", 55, 60], ["cerebral cortex", "CANCER", 73, 88], ["metastatic disease", "CANCER", 115, 133], ["Magnetic resonance imaging of the brain", "TEST", 0, 39], ["a 1 cm tumor in the left cerebral cortex", "PROBLEM", 48, 88], ["metastatic disease", "PROBLEM", 115, 133], ["brain", "ANATOMY", 34, 39], ["1 cm", "OBSERVATION_MODIFIER", 50, 54], ["tumor", "OBSERVATION", 55, 60], ["left cerebral cortex", "ANATOMY", 68, 88], ["consistent with", "UNCERTAINTY", 99, 114], ["metastatic", "OBSERVATION", 115, 125]]], ["The patient has no history of seizures or syncope.", [["seizures", "DISEASE", 30, 38], ["syncope", "DISEASE", 42, 49], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["seizures", "PROBLEM", 30, 38], ["syncope", "PROBLEM", 42, 49], ["no history of", "UNCERTAINTY", 16, 29], ["seizures", "OBSERVATION", 30, 38], ["syncope", "OBSERVATION", 42, 49]]], ["The patient is referred to outpatient therapy in the hematology/oncology service as well as follow-up with radiation oncology.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The patient is ready for discharge.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Which of the following would be the most appropriate therapy for primary seizure prevention?", [["seizure", "DISEASE", 73, 80], ["primary seizure prevention", "TREATMENT", 65, 91]]], ["A) Seizure prophylaxis is not indicated.", [["Seizure", "DISEASE", 3, 10], ["A) Seizure prophylaxis", "TREATMENT", 0, 22]]], ["B) Valproate.", [["Valproate", "CHEMICAL", 3, 12], ["Valproate", "CHEMICAL", 3, 12], ["Valproate", "SIMPLE_CHEMICAL", 3, 12], ["Valproate", "TREATMENT", 3, 12]]], ["C) Phenytoin.", [["Phenytoin", "CHEMICAL", 3, 12], ["Phenytoin", "CHEMICAL", 3, 12], ["Phenytoin", "SIMPLE_CHEMICAL", 3, 12], ["Phenytoin", "TREATMENT", 3, 12]]], ["D) Phenobarbital.", [["Phenobarbital", "CHEMICAL", 3, 16], ["Phenobarbital", "CHEMICAL", 3, 16], ["Phenobarbital", "SIMPLE_CHEMICAL", 3, 16], ["Phenobarbital", "TREATMENT", 3, 16]]], ["E) Oral prednisone 40 mg daily.ReferencesAnswer: A There is no indication for antiepileptic therapy for primary prevention in patients who have brain metastasis who have not undergone resection.", [["brain", "ANATOMY", 144, 149], ["prednisone", "CHEMICAL", 8, 18], ["brain metastasis", "DISEASE", 144, 160], ["prednisone", "CHEMICAL", 8, 18], ["prednisone", "SIMPLE_CHEMICAL", 8, 18], ["patients", "ORGANISM", 126, 134], ["brain", "ORGAN", 144, 149], ["patients", "SPECIES", 126, 134], ["Oral prednisone", "TREATMENT", 3, 18], ["antiepileptic therapy", "TREATMENT", 78, 99], ["primary prevention", "TREATMENT", 104, 122], ["brain metastasis", "PROBLEM", 144, 160], ["resection", "TREATMENT", 184, 193], ["no indication for", "UNCERTAINTY", 60, 77], ["brain", "ANATOMY", 144, 149], ["metastasis", "OBSERVATION", 150, 160], ["resection", "OBSERVATION", 184, 193]]], ["Past studies have revealed no difference in seizure rates between placebo and antiepileptic therapy in patients who have brain tumors.", [["brain tumors", "ANATOMY", 121, 133], ["seizure", "DISEASE", 44, 51], ["brain tumors", "DISEASE", 121, 133], ["patients", "ORGANISM", 103, 111], ["brain tumors", "CANCER", 121, 133], ["patients", "SPECIES", 103, 111], ["Past studies", "TEST", 0, 12], ["difference in seizure rates", "PROBLEM", 30, 57], ["placebo", "TREATMENT", 66, 73], ["antiepileptic therapy", "TREATMENT", 78, 99], ["brain tumors", "PROBLEM", 121, 133], ["no", "UNCERTAINTY", 27, 29], ["brain", "ANATOMY", 121, 126], ["tumors", "OBSERVATION", 127, 133]]], ["Antiepileptic therapy has high rates of adverse reactions and caution should be used in their use.", [["Antiepileptic therapy", "TREATMENT", 0, 21], ["adverse reactions", "PROBLEM", 40, 57], ["caution", "TREATMENT", 62, 69]]], ["On physical exam, his temperature is 39.5 \u00b0C (103.1 \u00b0F), pulse is 72, and respiratory rate is 30.", [["physical exam", "TEST", 3, 16], ["his temperature", "TEST", 18, 33], ["\u00b0C", "TEST", 42, 44], ["pulse", "TEST", 57, 62], ["respiratory rate", "TEST", 74, 90]]], ["He is in moderate respiratory distress.", [["respiratory", "ANATOMY", 18, 29], ["respiratory distress", "DISEASE", 18, 38], ["moderate respiratory distress", "PROBLEM", 9, 38], ["moderate", "OBSERVATION_MODIFIER", 9, 17], ["respiratory distress", "OBSERVATION", 18, 38]]], ["Oxygen saturation is 95 % on 2 l of oxygen.", [["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 36, 42], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 36, 42], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 36, 42], ["Oxygen saturation", "TEST", 0, 17], ["oxygen", "TREATMENT", 36, 42]]], ["He has moderate abdominal pain.ReferencesLaboratory data is signifi cant for mild elevation of his transaminases and a sodium of 128.", [["abdominal", "ANATOMY", 16, 25], ["abdominal pain", "DISEASE", 16, 30], ["sodium", "CHEMICAL", 119, 125], ["sodium", "CHEMICAL", 119, 125], ["abdominal", "ORGANISM_SUBDIVISION", 16, 25], ["sodium", "SIMPLE_CHEMICAL", 119, 125], ["moderate abdominal pain", "PROBLEM", 7, 30], ["ReferencesLaboratory data", "TEST", 31, 56], ["mild elevation", "PROBLEM", 77, 91], ["his transaminases", "TEST", 95, 112], ["a sodium", "TEST", 117, 125], ["moderate", "OBSERVATION_MODIFIER", 7, 15], ["abdominal", "ANATOMY", 16, 25], ["pain", "OBSERVATION", 26, 30], ["mild", "OBSERVATION_MODIFIER", 77, 81], ["elevation", "OBSERVATION", 82, 91]]], ["Chest radiograph reveals bilateral infi ltrates.ReferencesThe most appropriate antibiotics and treatment are: A) Vancomycin 1 g q12 and piperacillin/sulbactam 4.gms q 8 B) Ceftriaxone 1 g q 12 and azithromycin 500 mg q8 C) Vancomycin 1 g q12/gentamicin D) Ceftriaxone 1 g q12/Prednisone 40 mg QD E) Bactrim Answer: B This patient has legionella pneumonia, which should be treated with a quinolone or macrolide antibiotic.", [["Vancomycin", "CHEMICAL", 113, 123], ["q12", "CHEMICAL", 128, 131], ["piperacillin", "CHEMICAL", 136, 148], ["sulbactam", "CHEMICAL", 149, 158], ["4.gms q 8 B", "CHEMICAL", 159, 170], ["Ceftriaxone", "CHEMICAL", 172, 183], ["azithromycin", "CHEMICAL", 197, 209], ["Vancomycin", "CHEMICAL", 223, 233], ["gentamicin", "CHEMICAL", 242, 252], ["Ceftriaxone", "CHEMICAL", 256, 267], ["Prednisone", "CHEMICAL", 276, 286], ["pneumonia", "DISEASE", 345, 354], ["quinolone", "CHEMICAL", 387, 396], ["macrolide", "CHEMICAL", 400, 409], ["Vancomycin", "CHEMICAL", 113, 123], ["piperacillin", "CHEMICAL", 136, 148], ["sulbactam", "CHEMICAL", 149, 158], ["Ceftriaxone", "CHEMICAL", 172, 183], ["azithromycin", "CHEMICAL", 197, 209], ["Vancomycin", "CHEMICAL", 223, 233], ["gentamicin D", "CHEMICAL", 242, 254], ["Ceftriaxone", "CHEMICAL", 256, 267], ["Prednisone", "CHEMICAL", 276, 286], ["quinolone", "CHEMICAL", 387, 396], ["macrolide", "CHEMICAL", 400, 409], ["Vancomycin", "SIMPLE_CHEMICAL", 113, 123], ["q12", "SIMPLE_CHEMICAL", 128, 131], ["piperacillin", "SIMPLE_CHEMICAL", 136, 148], ["sulbactam", "SIMPLE_CHEMICAL", 149, 158], ["azithromycin", "SIMPLE_CHEMICAL", 197, 209], ["gentamicin D", "SIMPLE_CHEMICAL", 242, 254], ["Prednisone", "SIMPLE_CHEMICAL", 276, 286], ["patient", "ORGANISM", 322, 329], ["legionella", "ORGANISM", 334, 344], ["quinolone", "SIMPLE_CHEMICAL", 387, 396], ["macrolide", "SIMPLE_CHEMICAL", 400, 409], ["patient", "SPECIES", 322, 329], ["Chest radiograph", "TEST", 0, 16], ["bilateral infi ltrates", "PROBLEM", 25, 47], ["appropriate antibiotics", "TREATMENT", 67, 90], ["A) Vancomycin", "TREATMENT", 110, 123], ["piperacillin", "TREATMENT", 136, 148], ["sulbactam", "TREATMENT", 149, 158], ["Ceftriaxone", "TREATMENT", 172, 183], ["azithromycin", "TREATMENT", 197, 209], ["Vancomycin", "TREATMENT", 223, 233], ["gentamicin D", "TREATMENT", 242, 254], ["Ceftriaxone", "TREATMENT", 256, 267], ["Prednisone", "TREATMENT", 276, 286], ["Bactrim", "TREATMENT", 299, 306], ["legionella pneumonia", "PROBLEM", 334, 354], ["a quinolone", "TREATMENT", 385, 396], ["macrolide antibiotic", "TREATMENT", 400, 420], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["legionella", "OBSERVATION_MODIFIER", 334, 344], ["pneumonia", "OBSERVATION", 345, 354]]], ["Legionella pneumonia presents with the common symptoms of fever, chills, and cough.", [["Legionella pneumonia", "DISEASE", 0, 20], ["fever", "DISEASE", 58, 63], ["chills", "DISEASE", 65, 71], ["cough", "DISEASE", 77, 82], ["Legionella pneumonia", "PROBLEM", 0, 20], ["the common symptoms", "PROBLEM", 35, 54], ["fever", "PROBLEM", 58, 63], ["chills", "PROBLEM", 65, 71], ["cough", "PROBLEM", 77, 82], ["pneumonia", "OBSERVATION", 11, 20], ["fever", "OBSERVATION", 58, 63], ["chills", "OBSERVATION", 65, 71], ["cough", "OBSERVATION", 77, 82]]], ["Distinguishing features are loss of appetite, loss of coordination, and occasionally diarrhea and vomiting.", [["loss of appetite", "DISEASE", 28, 44], ["loss of coordination", "DISEASE", 46, 66], ["diarrhea", "DISEASE", 85, 93], ["vomiting", "DISEASE", 98, 106], ["loss of appetite", "PROBLEM", 28, 44], ["loss of coordination", "PROBLEM", 46, 66], ["occasionally diarrhea", "PROBLEM", 72, 93], ["vomiting", "PROBLEM", 98, 106], ["loss", "OBSERVATION_MODIFIER", 28, 32], ["occasionally", "OBSERVATION_MODIFIER", 72, 84], ["diarrhea", "OBSERVATION", 85, 93]]], ["Relative bradycardia has traditionally been considered a symptom.", [["bradycardia", "DISEASE", 9, 20], ["Relative bradycardia", "PROBLEM", 0, 20], ["a symptom", "PROBLEM", 55, 64], ["bradycardia", "OBSERVATION", 9, 20]]], ["Laboratory tests may show signifi cant changes in renal functions, liver functions, and electrolytes.", [["renal", "ANATOMY", 50, 55], ["liver", "ANATOMY", 67, 72], ["renal", "ORGAN", 50, 55], ["liver", "ORGAN", 67, 72], ["Laboratory tests", "TEST", 0, 16], ["signifi cant changes in renal functions", "PROBLEM", 26, 65], ["liver functions", "TEST", 67, 82], ["electrolytes", "TEST", 88, 100], ["renal", "ANATOMY", 50, 55], ["liver", "ANATOMY", 67, 72]]], ["This can include marked hyponatremia.", [["hyponatremia", "DISEASE", 24, 36], ["marked hyponatremia", "PROBLEM", 17, 36], ["marked", "OBSERVATION_MODIFIER", 17, 23], ["hyponatremia", "OBSERVATION", 24, 36]]], ["Chest X-rays often show bi-basal consolidation.", [["Chest X-rays", "TEST", 0, 12], ["bi-basal consolidation", "PROBLEM", 24, 46], ["bi-basal", "OBSERVATION_MODIFIER", 24, 32], ["consolidation", "OBSERVATION", 33, 46]]], ["It is diffi cult to distinguish Legionnaires' disease from other types of pneumonia by symptoms alone.", [["Legionnaires' disease", "DISEASE", 32, 53], ["pneumonia", "DISEASE", 74, 83], ["Legionnaires' disease", "PROBLEM", 32, 53], ["pneumonia", "PROBLEM", 74, 83], ["symptoms", "PROBLEM", 87, 95], ["pneumonia", "OBSERVATION", 74, 83]]], ["Serology is often required for diagnosis.", [["Serology", "TEST", 0, 8]]], ["Many hospitals utilize the urinary antigen test for initial detection when legionella pneumonia is suspected.", [["urinary", "ANATOMY", 27, 34], ["pneumonia", "DISEASE", 86, 95], ["urinary", "ORGANISM_SUBSTANCE", 27, 34], ["the urinary antigen test", "TEST", 23, 47], ["initial detection", "TEST", 52, 69], ["legionella pneumonia", "PROBLEM", 75, 95], ["pneumonia", "OBSERVATION", 86, 95]]], ["It is not spread from person to person, but rather often through exposure to aerosolized cool water, such is the case here.", [["person", "SPECIES", 22, 28], ["person", "SPECIES", 32, 38], ["not", "UNCERTAINTY", 6, 9], ["spread", "OBSERVATION_MODIFIER", 10, 16]]], ["It acquired its name after a July 1976 outbreak of a then unrecognized disease, which affl icted 221 persons, resulting in 34 deaths.", [["deaths", "DISEASE", 126, 132], ["persons", "ORGANISM", 101, 108], ["persons", "SPECIES", 101, 108], ["a then unrecognized disease", "PROBLEM", 51, 78], ["disease", "OBSERVATION", 71, 78]]], ["The outbreak was fi rst noticed among people attending a convention the American Legion.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["You are called to the fl oor to see a 77-year-old man who has recently passed a large amount of red and maroon blood per rectum.", [["blood", "ANATOMY", 111, 116], ["rectum", "ANATOMY", 121, 127], ["man", "ORGANISM", 50, 53], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["rectum", "ORGAN", 121, 127], ["man", "SPECIES", 50, 53], ["red and maroon blood per rectum", "PROBLEM", 96, 127], ["large", "OBSERVATION_MODIFIER", 80, 85], ["amount", "OBSERVATION_MODIFIER", 86, 92], ["red", "OBSERVATION", 96, 99], ["maroon blood", "OBSERVATION", 104, 116], ["rectum", "ANATOMY", 121, 127]]], ["He was admitted 2 days ago for a urinary tract infection.", [["urinary tract", "ANATOMY", 33, 46], ["urinary tract infection", "DISEASE", 33, 56], ["He", "ORGANISM", 0, 2], ["urinary tract", "ORGANISM_SUBDIVISION", 33, 46], ["a urinary tract infection", "PROBLEM", 31, 56], ["urinary tract", "ANATOMY", 33, 46], ["infection", "OBSERVATION", 47, 56]]], ["After this episode, the patient feels dizzy but is conscious and able to converse.", [["dizzy", "DISEASE", 38, 43], ["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["dizzy", "PROBLEM", 38, 43]]], ["On physical exam, his blood pressure is 100/60 mmHg and the pulse rate is 110/min.", [["blood", "ANATOMY", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["physical exam", "TEST", 3, 16], ["his blood pressure", "TEST", 18, 36], ["the pulse rate", "TEST", 56, 70]]], ["He has no abdominal pain, nausea, vomiting, fever, or weight loss.", [["abdominal", "ANATOMY", 10, 19], ["abdominal pain", "DISEASE", 10, 24], ["nausea", "DISEASE", 26, 32], ["vomiting", "DISEASE", 34, 42], ["fever", "DISEASE", 44, 49], ["weight loss", "DISEASE", 54, 65], ["abdominal", "ORGANISM_SUBDIVISION", 10, 19], ["abdominal pain", "PROBLEM", 10, 24], ["nausea", "PROBLEM", 26, 32], ["vomiting", "PROBLEM", 34, 42], ["fever", "PROBLEM", 44, 49], ["weight loss", "PROBLEM", 54, 65], ["no", "UNCERTAINTY", 7, 9], ["abdominal", "ANATOMY", 10, 19], ["pain", "OBSERVATION", 20, 24], ["nausea", "OBSERVATION", 26, 32], ["fever", "OBSERVATION", 44, 49]]], ["He had a colonoscopy 1 year ago that showed a benign polyp and extensive diverticulosis.", [["benign polyp", "ANATOMY", 46, 58], ["polyp", "DISEASE", 53, 58], ["diverticulosis", "DISEASE", 73, 87], ["polyp", "PATHOLOGICAL_FORMATION", 53, 58], ["diverticulosis", "PATHOLOGICAL_FORMATION", 73, 87], ["a colonoscopy", "TEST", 7, 20], ["a benign polyp", "PROBLEM", 44, 58], ["extensive diverticulosis", "PROBLEM", 63, 87], ["benign", "OBSERVATION_MODIFIER", 46, 52], ["polyp", "OBSERVATION", 53, 58], ["extensive", "OBSERVATION_MODIFIER", 63, 72], ["diverticulosis", "OBSERVATION", 73, 87]]], ["He has a single 22 g IV access.ReferencesStat laboratory studies reveal a hemoglobin of 7.5 g/ dL.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 74, 84], ["hemoglobin", "PROTEIN", 74, 84], ["a single 22 g IV access", "TREATMENT", 7, 30], ["a hemoglobin", "TEST", 72, 84]]], ["The leukocyte count is 5600/\u03bcL.", [["leukocyte", "ANATOMY", 4, 13], ["leukocyte", "CELL", 4, 13], ["The leukocyte count", "TEST", 0, 19], ["leukocyte count", "OBSERVATION", 4, 19]]], ["Prothrombin time and activated partial thromboplastin times are normal.ReferencesWhich of the following is the most appropriate next step in the management of this patient?", [["Prothrombin", "GENE_OR_GENE_PRODUCT", 0, 11], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 39, 53], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["Prothrombin time", "TEST", 0, 16], ["activated partial thromboplastin times", "TEST", 21, 59], ["partial thromboplastin", "OBSERVATION", 31, 53], ["normal", "OBSERVATION", 64, 70]]], ["A) Colonoscopy B) Esophagogastroduodenoscopy C) Increased intravenous access D) Placement of a nasogastric tube with lavage E) Technetium-labeled red blood cell scan Answer: C This patient is volume depleted and not hemodynamically stable.", [["intravenous", "ANATOMY", 58, 69], ["red blood cell", "ANATOMY", 146, 160], ["Technetium", "CHEMICAL", 127, 137], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 58, 69], ["red blood cell", "CELL", 146, 160], ["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188], ["Colonoscopy", "TEST", 3, 14], ["Increased intravenous access D", "TREATMENT", 48, 78], ["a nasogastric tube", "TREATMENT", 93, 111], ["lavage E", "TREATMENT", 117, 125], ["Technetium", "TEST", 127, 137], ["red blood cell scan", "TEST", 146, 165], ["volume depleted", "PROBLEM", 192, 207], ["nasogastric", "ANATOMY", 95, 106], ["tube", "OBSERVATION", 107, 111], ["volume depleted", "OBSERVATION", 192, 207], ["stable", "OBSERVATION_MODIFIER", 232, 238]]], ["Two large-bore peripheral catheters or a central line for volume repletion is urgently required.", [["central line", "ANATOMY", 41, 53], ["peripheral catheters", "MULTI-TISSUE_STRUCTURE", 15, 35], ["Two large-bore peripheral catheters", "TREATMENT", 0, 35], ["a central line", "TREATMENT", 39, 53], ["volume repletion", "TREATMENT", 58, 74], ["large", "OBSERVATION_MODIFIER", 4, 9], ["-bore", "OBSERVATION_MODIFIER", 9, 14], ["peripheral", "ANATOMY_MODIFIER", 15, 25], ["catheters", "OBSERVATION", 26, 35], ["central line", "OBSERVATION", 41, 53]]], ["Fluid resuscitation should be started as well as an urgent type and match for blood transfusion.", [["blood", "ANATOMY", 78, 83], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["Fluid resuscitation", "TREATMENT", 0, 19], ["blood transfusion", "TREATMENT", 78, 95]]], ["Although rapid diagnosis may be of benefi t, early resuscitation measures should not be delayed by diagnostic workup.", [["early resuscitation measures", "TREATMENT", 45, 73], ["diagnostic workup", "TEST", 99, 116], ["may be", "UNCERTAINTY", 25, 31]]], ["A nasogastric tube may be considered after volume resuscitation, if an upper source of gastrointestinal bleeding is likely.", [["nasogastric tube", "ANATOMY", 2, 18], ["gastrointestinal", "ANATOMY", 87, 103], ["gastrointestinal bleeding", "DISEASE", 87, 112], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 2, 18], ["upper", "ORGANISM_SUBDIVISION", 71, 76], ["gastrointestinal", "ORGANISM_SUBDIVISION", 87, 103], ["A nasogastric tube", "TREATMENT", 0, 18], ["volume resuscitation", "TREATMENT", 43, 63], ["gastrointestinal bleeding", "PROBLEM", 87, 112], ["nasogastric tube", "OBSERVATION", 2, 18], ["may be considered", "UNCERTAINTY", 19, 36], ["gastrointestinal", "ANATOMY", 87, 103], ["bleeding", "OBSERVATION", 104, 112]]], ["Regardless of the source of bleeding at this point in the management, the fi rst rule is to achieve hemodynamic stability.", [["bleeding", "DISEASE", 28, 36], ["bleeding", "PROBLEM", 28, 36], ["the management", "TREATMENT", 54, 68], ["the fi rst rule", "TEST", 70, 85], ["bleeding", "OBSERVATION", 28, 36]]], ["Although a colonoscopy is the diagnostic test of choice to evaluate for sources of lower gastrointestinal bleeding, this should not occur before volume resuscitation.", [["lower gastrointestinal", "ANATOMY", 83, 105], ["lower gastrointestinal bleeding", "DISEASE", 83, 114], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 83, 105], ["a colonoscopy", "TEST", 9, 22], ["the diagnostic test", "TEST", 26, 45], ["lower gastrointestinal bleeding", "PROBLEM", 83, 114], ["volume resuscitation", "TREATMENT", 145, 165], ["lower", "ANATOMY_MODIFIER", 83, 88], ["gastrointestinal", "ANATOMY", 89, 105], ["bleeding", "OBSERVATION", 106, 114]]], ["A bleeding scan may be indicated if an endoscopic evaluation is not immediately possible or if an endoscopic evaluation has been non-revealing.", [["bleeding", "DISEASE", 2, 10], ["A bleeding scan", "TEST", 0, 15], ["an endoscopic evaluation", "TEST", 36, 60], ["an endoscopic evaluation", "TEST", 95, 119], ["bleeding", "OBSERVATION", 2, 10]]], ["Diverticular bleed is certainly a possibility in this case.", [["Diverticular", "ANATOMY", 0, 12], ["Diverticular bleed", "DISEASE", 0, 18], ["Diverticular bleed", "PROBLEM", 0, 18], ["bleed", "OBSERVATION", 13, 18], ["certainly a possibility", "UNCERTAINTY", 22, 45]]], ["If a bleeding diverticulum is detected on colonoscopy, it can be treated with thermal coagulation or epinephrine injection.", [["bleeding diverticulum", "ANATOMY", 5, 26], ["bleeding diverticulum", "DISEASE", 5, 26], ["epinephrine", "CHEMICAL", 101, 112], ["epinephrine", "CHEMICAL", 101, 112], ["bleeding diverticulum", "PATHOLOGICAL_FORMATION", 5, 26], ["epinephrine", "SIMPLE_CHEMICAL", 101, 112], ["a bleeding diverticulum", "PROBLEM", 3, 26], ["colonoscopy", "TEST", 42, 53], ["thermal coagulation", "TREATMENT", 78, 97], ["epinephrine injection", "TREATMENT", 101, 122], ["bleeding", "OBSERVATION_MODIFIER", 5, 13], ["diverticulum", "OBSERVATION", 14, 26]]], ["Up to 90 % of diverticular bleeding resolves without intervention.", [["diverticular", "ANATOMY", 14, 26], ["diverticular bleeding", "DISEASE", 14, 35], ["diverticular bleeding", "PATHOLOGICAL_FORMATION", 14, 35], ["diverticular bleeding", "PROBLEM", 14, 35], ["intervention", "TREATMENT", 53, 65], ["diverticular", "OBSERVATION_MODIFIER", 14, 26], ["bleeding", "OBSERVATION", 27, 35]]], ["On physical examination, the temperature is 39.0 \u00b0C (102.2 \u00b0F).", [["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51]]], ["Blood pressure is 120/75 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["There is no evidence of mucositis.", [["mucositis", "DISEASE", 24, 33], ["mucositis", "PATHOLOGICAL_FORMATION", 24, 33], ["mucositis", "PROBLEM", 24, 33], ["no evidence of", "UNCERTAINTY", 9, 23], ["mucositis", "OBSERVATION", 24, 33]]], ["Chest exam is normal.", [["Chest exam", "TEST", 0, 10], ["normal", "OBSERVATION", 14, 20]]], ["Heart examination is normal as well.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["Heart examination", "TEST", 0, 17], ["normal", "OBSERVATION", 21, 27]]], ["Abdominal exam reveals normal bowel sounds and is nontender.", [["Abdominal", "ANATOMY", 0, 9], ["bowel", "ANATOMY", 30, 35], ["bowel", "ORGAN", 30, 35], ["Abdominal exam", "TEST", 0, 14], ["nontender", "PROBLEM", 50, 59], ["normal", "OBSERVATION", 23, 29], ["bowel", "ANATOMY", 30, 35], ["sounds", "OBSERVATION", 36, 42], ["nontender", "OBSERVATION", 50, 59]]], ["Laboratory data shows a hemoglobin of 10.8 g/dL and leukocyte count of 600/mcL.", [["leukocyte", "ANATOMY", 52, 61], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 24, 34], ["leukocyte", "CELL", 52, 61], ["hemoglobin", "PROTEIN", 24, 34], ["Laboratory data", "TEST", 0, 15], ["a hemoglobin", "TEST", 22, 34], ["dL", "TEST", 45, 47], ["leukocyte count", "TEST", 52, 67], ["mcL", "TEST", 75, 78]]], ["The differential is 10 % neutrophils and 90 % lymphocytes.", [["neutrophils", "ANATOMY", 25, 36], ["lymphocytes", "ANATOMY", 46, 57], ["neutrophils", "CELL", 25, 36], ["lymphocytes", "CELL", 46, 57], ["neutrophils", "CELL_TYPE", 25, 36], ["lymphocytes", "CELL_TYPE", 46, 57], ["The differential", "TEST", 0, 16], ["neutrophils", "TEST", 25, 36], ["lymphocytes", "TEST", 46, 57], ["10 %", "OBSERVATION_MODIFIER", 20, 24]]], ["Chest X-ray is normal.", [["Chest X-ray", "TEST", 0, 11], ["normal", "OBSERVATION", 15, 21]]], ["Blood and urine cultures are pending.ReferencesWhich is the most appropriate treatment course?", [["Blood", "ANATOMY", 0, 5], ["urine cultures", "ANATOMY", 10, 24], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 10, 15], ["Blood and urine cultures", "TEST", 0, 24], ["urine", "ANATOMY", 10, 15]]], ["A) Begin vancomycin.", [["vancomycin", "CHEMICAL", 9, 19], ["vancomycin", "CHEMICAL", 9, 19], ["vancomycin", "SIMPLE_CHEMICAL", 9, 19], ["vancomycin", "TREATMENT", 9, 19]]], ["B) Await blood cultures and urine cultures.", [["blood cultures", "ANATOMY", 9, 23], ["urine cultures", "ANATOMY", 28, 42], ["B", "CELL", 0, 1], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["cultures", "CELL", 15, 23], ["urine", "ORGANISM_SUBSTANCE", 28, 33], ["Await blood cultures", "CELL_LINE", 3, 23], ["blood cultures", "TEST", 9, 23], ["urine cultures", "TEST", 28, 42]]], ["C) Begin vancomycin, amphotericin, and acyclovir.", [["vancomycin", "CHEMICAL", 9, 19], ["amphotericin", "CHEMICAL", 21, 33], ["acyclovir", "CHEMICAL", 39, 48], ["vancomycin", "CHEMICAL", 9, 19], ["amphotericin", "CHEMICAL", 21, 33], ["acyclovir", "CHEMICAL", 39, 48], ["vancomycin", "SIMPLE_CHEMICAL", 9, 19], ["amphotericin", "SIMPLE_CHEMICAL", 21, 33], ["acyclovir", "SIMPLE_CHEMICAL", 39, 48], ["vancomycin", "TREATMENT", 9, 19], ["amphotericin", "TREATMENT", 21, 33], ["acyclovir", "TREATMENT", 39, 48]]], ["D) Begin piperacillin/tazobactam.", [["piperacillin/tazobactam", "CHEMICAL", 9, 32], ["piperacillin", "CHEMICAL", 9, 21], ["tazobactam", "CHEMICAL", 22, 32], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 9, 32], ["piperacillin", "TREATMENT", 9, 21], ["tazobactam", "TREATMENT", 22, 32]]], ["E) Begin vancomycin, amphotericin, acyclovir, and difl ucan.ReferencesAnswer: D This patient is neutropenic and febrile and warrants rapid initiation of antibiotics.", [["vancomycin", "CHEMICAL", 9, 19], ["amphotericin", "CHEMICAL", 21, 33], ["acyclovir", "CHEMICAL", 35, 44], ["difl ucan", "CHEMICAL", 50, 59], ["neutropenic", "DISEASE", 96, 107], ["febrile", "DISEASE", 112, 119], ["vancomycin", "CHEMICAL", 9, 19], ["amphotericin", "CHEMICAL", 21, 33], ["acyclovir", "CHEMICAL", 35, 44], ["difl ucan", "CHEMICAL", 50, 59], ["vancomycin", "SIMPLE_CHEMICAL", 9, 19], ["amphotericin", "SIMPLE_CHEMICAL", 21, 33], ["acyclovir", "SIMPLE_CHEMICAL", 35, 44], ["difl ucan", "SIMPLE_CHEMICAL", 50, 59], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["vancomycin", "TREATMENT", 9, 19], ["amphotericin", "TREATMENT", 21, 33], ["acyclovir", "TREATMENT", 35, 44], ["difl ucan", "TREATMENT", 50, 59], ["neutropenic", "PROBLEM", 96, 107], ["febrile", "PROBLEM", 112, 119], ["antibiotics", "TREATMENT", 153, 164], ["neutropenic", "OBSERVATION", 96, 107]]], ["A stepwise and logical approach is needed for the selection of antibiotics.", [["A stepwise", "TREATMENT", 0, 10], ["logical approach", "TREATMENT", 15, 31], ["antibiotics", "TREATMENT", 63, 74]]], ["Febrile neutropenia is a medical emergency.", [["Febrile neutropenia", "DISEASE", 0, 19], ["Febrile neutropenia", "PROBLEM", 0, 19], ["neutropenia", "OBSERVATION", 8, 19]]], ["Patients may not present with overt signs of infection.", [["infection", "DISEASE", 45, 54], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infection", "PROBLEM", 45, 54], ["infection", "OBSERVATION", 45, 54]]], ["However, septic shock and death can occur within hours of presentation.", [["septic shock", "DISEASE", 9, 21], ["death", "DISEASE", 26, 31], ["septic shock", "PROBLEM", 9, 21], ["death", "PROBLEM", 26, 31], ["septic shock", "OBSERVATION", 9, 21]]], ["Initial antibiotic choices may include a third-generation cephalosporin, penicillin with beta-lactamase inhibitor, or cefepime.", [["cephalosporin", "CHEMICAL", 58, 71], ["penicillin", "CHEMICAL", 73, 83], ["cefepime", "CHEMICAL", 118, 126], ["cephalosporin", "CHEMICAL", 58, 71], ["penicillin", "CHEMICAL", 73, 83], ["cefepime", "CHEMICAL", 118, 126], ["cephalosporin", "SIMPLE_CHEMICAL", 58, 71], ["penicillin", "SIMPLE_CHEMICAL", 73, 83], ["beta-lactamase", "GENE_OR_GENE_PRODUCT", 89, 103], ["cefepime", "SIMPLE_CHEMICAL", 118, 126], ["Initial antibiotic choices", "TREATMENT", 0, 26], ["a third-generation cephalosporin", "TREATMENT", 39, 71], ["penicillin", "TREATMENT", 73, 83], ["beta-lactamase inhibitor", "TREATMENT", 89, 113], ["cefepime", "TREATMENT", 118, 126]]], ["Endogenous fl ora from the gastrointestinal tract is the probable cause for most cases of febrile neutropenia.", [["gastrointestinal tract", "ANATOMY", 27, 49], ["gastrointestinal tract", "DISEASE", 27, 49], ["neutropenia", "DISEASE", 98, 109], ["fl ora", "GENE_OR_GENE_PRODUCT", 11, 17], ["gastrointestinal tract", "ORGAN", 27, 49], ["Endogenous fl ora", "PROTEIN", 0, 17], ["Endogenous fl ora from the gastrointestinal tract", "PROBLEM", 0, 49], ["febrile neutropenia", "PROBLEM", 90, 109], ["fl ora", "OBSERVATION", 11, 17], ["gastrointestinal tract", "ANATOMY", 27, 49], ["febrile", "OBSERVATION_MODIFIER", 90, 97], ["neutropenia", "OBSERVATION", 98, 109]]], ["Vancomycin may be considered but alone would not be suffi cient coverage for this patient.", [["Vancomycin", "CHEMICAL", 0, 10], ["Vancomycin", "CHEMICAL", 0, 10], ["Vancomycin", "SIMPLE_CHEMICAL", 0, 10], ["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 82, 89], ["Vancomycin", "TREATMENT", 0, 10], ["suffi cient coverage", "TREATMENT", 52, 72]]], ["Empiric antifungal therapy is usually reserved for patients who are febrile after the source of infection is not found following 4-7 days of broad-spectrum antimicrobial therapy.", [["febrile", "DISEASE", 68, 75], ["infection", "DISEASE", 96, 105], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["Empiric antifungal therapy", "TREATMENT", 0, 26], ["febrile", "PROBLEM", 68, 75], ["infection", "PROBLEM", 96, 105], ["broad-spectrum antimicrobial therapy", "TREATMENT", 141, 177], ["antifungal therapy", "OBSERVATION", 8, 26], ["infection", "OBSERVATION", 96, 105], ["antimicrobial therapy", "OBSERVATION", 156, 177]]], ["Viral infections are not common, and empiric therapy with antiviral agents such as acyclovir is not warranted.", [["Viral infections", "DISEASE", 0, 16], ["acyclovir", "CHEMICAL", 83, 92], ["acyclovir", "CHEMICAL", 83, 92], ["Viral", "ORGANISM", 0, 5], ["acyclovir", "SIMPLE_CHEMICAL", 83, 92], ["Viral infections", "PROBLEM", 0, 16], ["empiric therapy", "TREATMENT", 37, 52], ["antiviral agents", "TREATMENT", 58, 74], ["acyclovir", "TREATMENT", 83, 92], ["infections", "OBSERVATION", 6, 16]]], ["An 82-year-old female presents to the emergency department complaining nausea and vomiting.", [["nausea", "DISEASE", 71, 77], ["vomiting", "DISEASE", 82, 90], ["female", "ORGANISM", 15, 21], ["nausea", "PROBLEM", 71, 77], ["vomiting", "PROBLEM", 82, 90]]], ["She is admitted for dehydration due to probable viral gastroenteritis.", [["dehydration", "DISEASE", 20, 31], ["viral gastroenteritis", "DISEASE", 48, 69], ["dehydration", "PROBLEM", 20, 31], ["viral gastroenteritis", "PROBLEM", 48, 69], ["probable", "UNCERTAINTY", 39, 47], ["viral gastroenteritis", "OBSERVATION", 48, 69]]], ["On admission her serum creatinine is noted to be 3.0 mg/dL, her baseline is 1.2 mg/dl.", [["serum", "ANATOMY", 17, 22], ["creatinine", "CHEMICAL", 23, 33], ["creatinine", "CHEMICAL", 23, 33], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["creatinine", "SIMPLE_CHEMICAL", 23, 33], ["her serum creatinine", "TEST", 13, 33]]], ["After transfer to the fl oor, she acutely develops dizziness with a heart rate of 34/min.", [["heart", "ANATOMY", 68, 73], ["dizziness", "DISEASE", 51, 60], ["heart", "ORGAN", 68, 73], ["dizziness", "PROBLEM", 51, 60], ["a heart rate", "TEST", 66, 78], ["dizziness", "OBSERVATION", 51, 60], ["heart", "ANATOMY", 68, 73]]], ["12-lead ECG shows marked sinus bradycardia without any ST segment changes.", [["sinus", "ANATOMY", 25, 30], ["sinus bradycardia", "DISEASE", 25, 42], ["sinus", "MULTI-TISSUE_STRUCTURE", 25, 30], ["lead ECG", "TEST", 3, 11], ["marked sinus bradycardia", "PROBLEM", 18, 42], ["any ST segment changes", "PROBLEM", 51, 73], ["marked", "OBSERVATION_MODIFIER", 18, 24], ["sinus bradycardia", "OBSERVATION", 25, 42]]], ["Stat glucose is 95 mg/dl.", [["glucose", "CHEMICAL", 5, 12], ["glucose", "CHEMICAL", 5, 12], ["Stat", "GENE_OR_GENE_PRODUCT", 0, 4], ["glucose", "SIMPLE_CHEMICAL", 5, 12], ["Stat glucose", "TEST", 0, 12]]], ["Home medications include atenolol 100 mg daily and hydrochlorothiazide 25 mg daily.", [["atenolol", "CHEMICAL", 25, 33], ["hydrochlorothiazide", "CHEMICAL", 51, 70], ["atenolol", "CHEMICAL", 25, 33], ["hydrochlorothiazide", "CHEMICAL", 51, 70], ["atenolol", "SIMPLE_CHEMICAL", 25, 33], ["hydrochlorothiazide", "SIMPLE_CHEMICAL", 51, 70], ["Home medications", "TREATMENT", 0, 16], ["atenolol", "TREATMENT", 25, 33], ["hydrochlorothiazide", "TREATMENT", 51, 70]]], ["Blood pressure is 85/68 mmHg.ReferenceWhich of the following medications is the most appropriate to administer next?", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["the following medications", "TREATMENT", 47, 72], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["A) Intravenous 50 % dextrose solution and insulin B) Intravenous glucagon C) Intravenous calcium gluconate D) Intravenous magnesium sulfate E) Intravenous atropine F) B or E Answer: F This patient has bradycardia and hypotension from betablocker toxicity.", [["dextrose", "CHEMICAL", 20, 28], ["insulin B", "CHEMICAL", 42, 51], ["glucagon C", "CHEMICAL", 65, 75], ["calcium gluconate", "CHEMICAL", 89, 106], ["magnesium sulfate", "CHEMICAL", 122, 139], ["atropine", "CHEMICAL", 155, 163], ["bradycardia", "DISEASE", 201, 212], ["hypotension", "DISEASE", 217, 228], ["toxicity", "DISEASE", 246, 254], ["dextrose", "CHEMICAL", 20, 28], ["calcium gluconate D", "CHEMICAL", 89, 108], ["magnesium sulfate E", "CHEMICAL", 122, 141], ["atropine F", "CHEMICAL", 155, 165], ["dextrose", "SIMPLE_CHEMICAL", 20, 28], ["insulin B", "SIMPLE_CHEMICAL", 42, 51], ["glucagon C", "SIMPLE_CHEMICAL", 65, 75], ["Intravenous calcium gluconate D", "SIMPLE_CHEMICAL", 77, 108], ["magnesium sulfate E", "SIMPLE_CHEMICAL", 122, 141], ["patient", "ORGANISM", 189, 196], ["patient", "SPECIES", 189, 196], ["F", "SPECIES", 182, 183], ["A) Intravenous 50 % dextrose solution", "TREATMENT", 0, 37], ["insulin B) Intravenous glucagon C) Intravenous calcium gluconate D) Intravenous magnesium sulfate E", "TREATMENT", 42, 141], ["Intravenous atropine", "TREATMENT", 143, 163], ["bradycardia", "PROBLEM", 201, 212], ["hypotension", "PROBLEM", 217, 228], ["betablocker toxicity", "PROBLEM", 234, 254], ["bradycardia", "OBSERVATION", 201, 212], ["hypotension", "OBSERVATION", 217, 228], ["betablocker toxicity", "OBSERVATION", 234, 254]]], ["This is caused by a reduced clearance of atenolol, which is renally excreted and impaired because of her prerenal kidney failure.", [["kidney", "ANATOMY", 114, 120], ["atenolol", "CHEMICAL", 41, 49], ["kidney failure", "DISEASE", 114, 128], ["atenolol", "CHEMICAL", 41, 49], ["atenolol", "SIMPLE_CHEMICAL", 41, 49], ["renally", "SIMPLE_CHEMICAL", 60, 67], ["kidney", "ORGAN", 114, 120], ["atenolol", "TREATMENT", 41, 49], ["her prerenal kidney failure", "PROBLEM", 101, 128], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["prerenal", "OBSERVATION", 105, 113], ["kidney", "ANATOMY", 114, 120], ["failure", "OBSERVATION", 121, 128]]], ["Glucagon is used to reverse beta-blocker toxicity and is often used as a fi rst-line agent when beta-blocker toxicity is the confi rmed issue.", [["Glucagon", "CHEMICAL", 0, 8], ["toxicity", "DISEASE", 41, 49], ["toxicity", "DISEASE", 109, 117], ["Glucagon", "SIMPLE_CHEMICAL", 0, 8], ["beta-blocker", "SIMPLE_CHEMICAL", 28, 40], ["beta-blocker", "SIMPLE_CHEMICAL", 96, 108], ["Glucagon", "TREATMENT", 0, 8], ["beta-blocker toxicity", "TREATMENT", 28, 49], ["a fi rst-line agent", "TREATMENT", 71, 90], ["beta-blocker toxicity", "TREATMENT", 96, 117]]], ["Atropine may be used according protocols as well.", [["Atropine", "CHEMICAL", 0, 8], ["Atropine", "CHEMICAL", 0, 8], ["Atropine", "SIMPLE_CHEMICAL", 0, 8], ["Atropine", "TREATMENT", 0, 8]]], ["She should also receive fl uid resuscitation with intravenous normal saline solution.", [["intravenous", "ANATOMY", 50, 61], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 61], ["fl uid resuscitation", "TREATMENT", 24, 44], ["intravenous normal saline solution", "TREATMENT", 50, 84]]], ["If she does not improve with glucagon and IV fl uids, external pacemaker or transvenous pacemaker can also be used.", [["glucagon", "CHEMICAL", 29, 37], ["glucagon", "SIMPLE_CHEMICAL", 29, 37], ["IV fl uids", "SIMPLE_CHEMICAL", 42, 52], ["glucagon", "TREATMENT", 29, 37], ["IV fl uids", "TREATMENT", 42, 52], ["external pacemaker", "TREATMENT", 54, 72], ["transvenous pacemaker", "TREATMENT", 76, 97], ["pacemaker", "OBSERVATION", 63, 72], ["transvenous pacemaker", "OBSERVATION", 76, 97]]], ["On examination, the foot appears atypical for cellulitis.", [["foot", "ANATOMY", 20, 24], ["cellulitis", "DISEASE", 46, 56], ["foot", "ORGANISM_SUBDIVISION", 20, 24], ["examination", "TEST", 3, 14], ["cellulitis", "PROBLEM", 46, 56], ["foot", "ANATOMY", 20, 24], ["atypical", "OBSERVATION", 33, 41], ["cellulitis", "OBSERVATION", 46, 56]]], ["It has hemorrhagic vesicles distributed throughout the foot distal to the ankle.", [["hemorrhagic vesicles", "ANATOMY", 7, 27], ["foot distal", "ANATOMY", 55, 66], ["ankle", "ANATOMY", 74, 79], ["hemorrhagic", "DISEASE", 7, 18], ["foot", "ORGANISM_SUBDIVISION", 55, 59], ["ankle", "ORGANISM_SUBDIVISION", 74, 79], ["hemorrhagic vesicles", "PROBLEM", 7, 27], ["hemorrhagic", "OBSERVATION_MODIFIER", 7, 18], ["vesicles", "OBSERVATION", 19, 27], ["foot", "ANATOMY", 55, 59], ["distal", "ANATOMY_MODIFIER", 60, 66], ["ankle", "ANATOMY", 74, 79]]], ["The left foot is cool and has no sensation to pain or temperature.", [["left foot", "ANATOMY", 4, 13], ["pain", "DISEASE", 46, 50], ["foot", "ORGANISM_SUBDIVISION", 9, 13], ["sensation to pain", "PROBLEM", 33, 50], ["left", "ANATOMY_MODIFIER", 4, 8], ["foot", "ANATOMY", 9, 13], ["cool", "OBSERVATION", 17, 21], ["no", "UNCERTAINTY", 30, 32]]], ["The right foot is hyperemic but does not have vesicles and has normal sensation.", [["right foot", "ANATOMY", 4, 14], ["vesicles", "ANATOMY", 46, 54], ["foot", "ORGANISM_SUBDIVISION", 10, 14], ["vesicles", "CELLULAR_COMPONENT", 46, 54], ["hyperemic", "PROBLEM", 18, 27], ["right", "ANATOMY_MODIFIER", 4, 9], ["foot", "ANATOMY", 10, 14], ["hyperemic", "OBSERVATION", 18, 27], ["normal", "OBSERVATION", 63, 69], ["sensation", "OBSERVATION_MODIFIER", 70, 79]]], ["The remainders of the physical examination fi ndings are normal.", [["the physical examination fi ndings", "TEST", 18, 52], ["remainders", "OBSERVATION_MODIFIER", 4, 14], ["normal", "OBSERVATION", 57, 63]]], ["He is started on antibiotics, and further therapy is considered.ReferenceWhich of the following statements regarding the management of his foot is true?", [["foot", "ORGANISM_SUBDIVISION", 139, 143], ["antibiotics", "TREATMENT", 17, 28], ["further therapy", "TREATMENT", 34, 49], ["foot", "ANATOMY", 139, 143]]], ["A) Rewarming should not be attempted.", [["Rewarming", "TREATMENT", 3, 12]]], ["B) Heparin has been shown to improve outcomes.", [["Heparin", "CHEMICAL", 3, 10], ["Heparin", "GENE_OR_GENE_PRODUCT", 3, 10], ["Heparin", "TREATMENT", 3, 10]]], ["C) Surgical consultation and debridement are indicated.", [["Surgical consultation", "TEST", 3, 24], ["debridement", "TREATMENT", 29, 40], ["debridement", "OBSERVATION", 29, 40]]], ["D) Normal sensation is likely to return with rewarming.", [["rewarming", "TREATMENT", 45, 54], ["Normal", "OBSERVATION", 3, 9]]], ["E) Antibiotics improves limb survival.", [["limb", "ANATOMY", 24, 28], ["limb", "ORGANISM_SUBDIVISION", 24, 28], ["Antibiotics", "TREATMENT", 3, 14], ["limb survival", "OBSERVATION", 24, 37]]], ["F) During the period of rewarming, intense pain will occur.ReferenceAnswer: F This patient presents with frostbite of the left foot.", [["left foot", "ANATOMY", 122, 131], ["pain", "DISEASE", 43, 47], ["frostbite of the left foot", "DISEASE", 105, 131], ["patient", "ORGANISM", 83, 90], ["foot", "ORGANISM_SUBDIVISION", 127, 131], ["patient", "SPECIES", 83, 90], ["F", "SPECIES", 76, 77], ["rewarming", "TREATMENT", 24, 33], ["intense pain", "PROBLEM", 35, 47], ["frostbite of the left foot", "PROBLEM", 105, 131], ["frostbite", "OBSERVATION", 105, 114], ["left", "ANATOMY_MODIFIER", 122, 126], ["foot", "ANATOMY", 127, 131]]], ["One of the common presenting symptoms of this is sensory changes that affect both pain and temperature reception.", [["pain", "DISEASE", 82, 86], ["the common presenting symptoms", "PROBLEM", 7, 37], ["sensory changes", "PROBLEM", 49, 64], ["both pain", "PROBLEM", 77, 86], ["common", "OBSERVATION_MODIFIER", 11, 17], ["symptoms", "OBSERVATION", 29, 37], ["sensory changes", "OBSERVATION", 49, 64]]], ["Hemorrhagic vesicles are caused by injury to the vasculature.", [["Hemorrhagic vesicles", "ANATOMY", 0, 20], ["vasculature", "ANATOMY", 49, 60], ["Hemorrhagic vesicles", "DISEASE", 0, 20], ["injury to the vasculature", "DISEASE", 35, 60], ["vasculature", "MULTI-TISSUE_STRUCTURE", 49, 60], ["Hemorrhagic vesicles", "PROBLEM", 0, 20], ["injury to the vasculature", "PROBLEM", 35, 60], ["vesicles", "OBSERVATION", 12, 20], ["injury", "OBSERVATION", 35, 41], ["vasculature", "ANATOMY", 49, 60]]], ["The prognosis is more favorable when the presenting area has a rapid return to normal temperature and color returns as well.", [["more favorable", "OBSERVATION_MODIFIER", 17, 31], ["rapid", "OBSERVATION_MODIFIER", 63, 68], ["normal temperature", "OBSERVATION_MODIFIER", 79, 97]]], ["Treatment of extremities is with rapid rewarming, which usually is accomplished with a 37-40 \u00b0C (98.6-104 \u00b0F) water bath.", [["extremities", "ANATOMY", 13, 24], ["extremities", "DISEASE", 13, 24], ["extremities", "ORGANISM_SUBDIVISION", 13, 24], ["rapid rewarming", "TREATMENT", 33, 48], ["water bath", "TREATMENT", 110, 120], ["extremities", "ANATOMY", 13, 24], ["rapid", "OBSERVATION_MODIFIER", 33, 38], ["rewarming", "OBSERVATION", 39, 48]]], ["The period of rewarming can be intensely painful for the patient, and often narcotic analgesia is warranted and should be anticipated to improve compliance.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["rewarming", "TREATMENT", 14, 23], ["intensely painful", "PROBLEM", 31, 48], ["narcotic analgesia", "TREATMENT", 76, 94]]], ["If the pain is intolerable, the temperature of the water bath may be lowered slightly.", [["pain", "DISEASE", 7, 11], ["the pain", "PROBLEM", 3, 11], ["the water bath", "TREATMENT", 47, 61]]], ["An 18-year-old female is admitted for observation after sustaining a head-to-head blow during a high school soccer game.", [["head", "ANATOMY", 69, 73], ["female", "ORGANISM", 15, 21], ["head", "ORGANISM_SUBDIVISION", 69, 73], ["head blow", "PROBLEM", 77, 86], ["head", "ANATOMY", 69, 73], ["head", "ANATOMY", 77, 81]]], ["Physical examination in the morning is within normal range.", [["Physical examination", "TEST", 0, 20], ["normal range", "OBSERVATION", 46, 58]]], ["Neurologic examination is within normal limits as well.ReferenceWhich of the following is the most appropriate next step in management?", [["Neurologic examination", "TEST", 0, 22], ["within normal limits", "OBSERVATION", 26, 46]]], ["A) CT of the head and return to competition if normal B) Observation for 24 more hours C) Exclusion from competition for 1 week D) Clearance for return to competition E) Funduscopic examination Answer: C This patient has a grade 3 concussion.", [["head", "ANATOMY", 13, 17], ["concussion", "DISEASE", 231, 241], ["head", "ORGANISM_SUBDIVISION", 13, 17], ["patient", "ORGANISM", 209, 216], ["patient", "SPECIES", 209, 216], ["A) CT of the head", "TEST", 0, 17], ["Funduscopic examination", "TEST", 170, 193], ["a grade 3 concussion", "PROBLEM", 221, 241], ["head", "ANATOMY", 13, 17]]], ["A concussion is defi ned as trauma-induced alteration in mental status that may be associated with transient loss of consciousness.", [["concussion", "DISEASE", 2, 12], ["trauma", "DISEASE", 28, 34], ["loss of consciousness", "DISEASE", 109, 130], ["A concussion", "PROBLEM", 0, 12], ["trauma", "PROBLEM", 28, 34], ["alteration in mental status", "PROBLEM", 43, 70], ["transient loss of consciousness", "PROBLEM", 99, 130]]], ["Neither a grade 1 nor a grade 2 concussion involves a loss of consciousness.", [["concussion", "DISEASE", 32, 42], ["loss of consciousness", "DISEASE", 54, 75], ["a grade 2 concussion", "PROBLEM", 22, 42], ["a loss of consciousness", "PROBLEM", 52, 75]]], ["A grade I concussion, or mild bruising of brain tissue, is the most common form of head injury.", [["brain tissue", "ANATOMY", 42, 54], ["head", "ANATOMY", 83, 87], ["concussion", "DISEASE", 10, 20], ["bruising of brain tissue", "DISEASE", 30, 54], ["head injury", "DISEASE", 83, 94], ["brain tissue", "TISSUE", 42, 54], ["head", "ORGANISM_SUBDIVISION", 83, 87], ["A grade I concussion", "PROBLEM", 0, 20], ["mild bruising of brain tissue", "PROBLEM", 25, 54], ["head injury", "PROBLEM", 83, 94], ["grade I", "OBSERVATION_MODIFIER", 2, 9], ["concussion", "OBSERVATION", 10, 20], ["mild", "OBSERVATION_MODIFIER", 25, 29], ["bruising", "OBSERVATION", 30, 38], ["brain tissue", "ANATOMY", 42, 54], ["most common", "OBSERVATION_MODIFIER", 63, 74], ["head", "ANATOMY", 83, 87], ["injury", "OBSERVATION", 88, 94]]], ["The athlete may briefl y appear or act confused; however, he or she is able to remember all events following the impact.", [["confused", "PROBLEM", 39, 47]]], ["The difference between a grade II and a grade I concussion is the presence of post-traumatic amnesia.", [["concussion", "DISEASE", 48, 58], ["post-traumatic amnesia", "DISEASE", 78, 100], ["a grade II and a grade I concussion", "PROBLEM", 23, 58], ["post-traumatic amnesia", "PROBLEM", 78, 100], ["grade II", "OBSERVATION_MODIFIER", 25, 33], ["post-traumatic", "OBSERVATION_MODIFIER", 78, 92], ["amnesia", "OBSERVATION", 93, 100]]], ["A grade 3 concussion, such as is seen in this patient, is defi ned by a brief or prolonged loss of consciousness.", [["concussion", "DISEASE", 10, 20], ["loss of consciousness", "DISEASE", 91, 112], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["A grade 3 concussion", "PROBLEM", 0, 20], ["prolonged loss of consciousness", "PROBLEM", 81, 112], ["grade 3", "OBSERVATION_MODIFIER", 2, 9], ["concussion", "OBSERVATION", 10, 20]]], ["Current recommendations state that a grade 1 concussion are permitted to return to the contest on the same day as the injury.", [["concussion", "DISEASE", 45, 55], ["a grade 1 concussion", "PROBLEM", 35, 55], ["the injury", "PROBLEM", 114, 124], ["injury", "OBSERVATION", 118, 124]]], ["Those with grade 2 or grade 3 concussions are prohibited from returning that day.", [["concussions", "DISEASE", 30, 41], ["grade 2 or grade 3 concussions", "PROBLEM", 11, 41], ["grade 3", "OBSERVATION_MODIFIER", 22, 29], ["concussions", "OBSERVATION", 30, 41]]], ["Grade 3 concussions are prohibited from returning to competition until the athlete is asymptomatic for 1 week.", [["concussions", "DISEASE", 8, 19], ["Grade 3 concussions", "PROBLEM", 0, 19], ["concussions", "OBSERVATION", 8, 19]]], ["Hospitalization is indicated in the presence of traumatic fi ndings, abnormal neuroimaging studies, or with persistent abnormalities seen on physical examination.47.A 31-year-old woman presented to the emergency room with a history of low-grade intermittent fever and reported joint pain, swelling, and rapid onset of decreased mental status over the past 2 days.", [["joint", "ANATOMY", 277, 282], ["fever", "DISEASE", 258, 263], ["joint pain", "DISEASE", 277, 287], ["swelling", "DISEASE", 289, 297], ["woman", "ORGANISM", 179, 184], ["joint", "ORGANISM_SUBDIVISION", 277, 282], ["woman", "SPECIES", 179, 184], ["traumatic fi ndings", "PROBLEM", 48, 67], ["abnormal neuroimaging studies", "PROBLEM", 69, 98], ["persistent abnormalities", "PROBLEM", 108, 132], ["physical examination", "TEST", 141, 161], ["low-grade intermittent fever", "PROBLEM", 235, 263], ["joint pain", "PROBLEM", 277, 287], ["swelling", "PROBLEM", 289, 297], ["decreased mental status", "PROBLEM", 318, 341], ["traumatic", "OBSERVATION", 48, 57], ["persistent", "OBSERVATION_MODIFIER", 108, 118], ["abnormalities", "OBSERVATION", 119, 132], ["low-grade", "OBSERVATION_MODIFIER", 235, 244], ["intermittent", "OBSERVATION_MODIFIER", 245, 257], ["fever", "OBSERVATION", 258, 263], ["joint", "ANATOMY", 277, 282], ["pain", "OBSERVATION", 283, 287], ["swelling", "OBSERVATION", 289, 297], ["rapid", "OBSERVATION_MODIFIER", 303, 308], ["onset", "OBSERVATION_MODIFIER", 309, 314], ["decreased", "OBSERVATION_MODIFIER", 318, 327], ["mental status", "OBSERVATION", 328, 341]]], ["Per family, the joint pains have developed gradually over the past 4 months.", [["joint", "ANATOMY", 16, 21], ["pains", "DISEASE", 22, 27], ["the joint pains", "PROBLEM", 12, 27], ["joint", "ANATOMY", 16, 21], ["pains", "OBSERVATION", 22, 27]]], ["In the past 36 h, she fi rst developed profound personality changes that included agitation and mild visual hallucinations.", [["agitation", "DISEASE", 82, 91], ["visual hallucinations", "DISEASE", 101, 122], ["profound personality changes", "PROBLEM", 39, 67], ["agitation", "PROBLEM", 82, 91], ["mild visual hallucinations", "PROBLEM", 96, 122], ["profound", "OBSERVATION_MODIFIER", 39, 47], ["personality", "OBSERVATION", 48, 59], ["mild", "OBSERVATION_MODIFIER", 96, 100], ["visual hallucinations", "OBSERVATION", 101, 122]]], ["Increasing lethargy followed this.", [["lethargy", "DISEASE", 11, 19], ["Increasing lethargy", "PROBLEM", 0, 19], ["lethargy", "OBSERVATION", 11, 19]]], ["On physical exam she appears obtunded.", [["physical exam", "TEST", 3, 16], ["obtunded", "PROBLEM", 29, 37], ["obtunded", "OBSERVATION", 29, 37]]], ["Joint tenderness is diffi cult to assess due to decreased mental status.", [["tenderness", "DISEASE", 6, 16], ["Joint", "MULTI-TISSUE_STRUCTURE", 0, 5], ["Joint tenderness", "PROBLEM", 0, 16], ["decreased mental status", "PROBLEM", 48, 71], ["tenderness", "OBSERVATION", 6, 16]]], ["Mild swelling is noted in several joints.47.A CT scan of the brain reveals possible diffuse mild cerebral edema.47.Magnetic resonance imaging reveals diffuse microinfarcts.", [["joints", "ANATOMY", 34, 40], ["brain", "ANATOMY", 61, 66], ["cerebral", "ANATOMY", 97, 105], ["swelling", "DISEASE", 5, 13], ["cerebral edema", "DISEASE", 97, 111], ["microinfarcts", "DISEASE", 158, 171], ["joints", "MULTI-TISSUE_STRUCTURE", 34, 40], ["brain", "ORGAN", 61, 66], ["cerebral edema", "PATHOLOGICAL_FORMATION", 97, 111], ["Mild swelling", "PROBLEM", 0, 13], ["A CT scan of the brain", "TEST", 44, 66], ["diffuse mild cerebral edema", "PROBLEM", 84, 111], ["Magnetic resonance imaging", "TEST", 115, 141], ["diffuse microinfarcts", "PROBLEM", 150, 171], ["swelling", "OBSERVATION", 5, 13], ["several", "ANATOMY_MODIFIER", 26, 33], ["joints", "ANATOMY", 34, 40], ["brain", "ANATOMY", 61, 66], ["possible", "UNCERTAINTY", 75, 83], ["diffuse", "OBSERVATION_MODIFIER", 84, 91], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["cerebral", "ANATOMY", 97, 105], ["edema", "OBSERVATION", 106, 111], ["diffuse", "OBSERVATION_MODIFIER", 150, 157], ["microinfarcts", "OBSERVATION", 158, 171]]], ["Hemoglobin, WBC, and platelet counts are within normal range.", [["WBC", "ANATOMY", 12, 15], ["platelet", "ANATOMY", 21, 29], ["Hemoglobin", "GENE_OR_GENE_PRODUCT", 0, 10], ["WBC", "CELL", 12, 15], ["platelet", "CELL", 21, 29], ["Hemoglobin", "PROTEIN", 0, 10], ["WBC", "CELL_TYPE", 12, 15], ["platelet", "CELL_TYPE", 21, 29], ["Hemoglobin", "TEST", 0, 10], ["WBC", "TEST", 12, 15], ["platelet counts", "TEST", 21, 36], ["platelet counts", "OBSERVATION", 21, 36], ["normal range", "OBSERVATION", 48, 60]]], ["The CSF report 110 lymphocytes and an elevated protein.47.The A) Moderate to severe initial episode: vancomycin 125 mg QID for a total of 10-14 days B) Severe initial episode complicated with shock and megacolon: vancomycin 125 mg po QID plus metronidazole 500 mg Q8 h IV.", [["lymphocytes", "ANATOMY", 19, 30], ["vancomycin", "CHEMICAL", 101, 111], ["shock", "DISEASE", 192, 197], ["megacolon", "DISEASE", 202, 211], ["vancomycin", "CHEMICAL", 213, 223], ["QID", "CHEMICAL", 234, 237], ["metronidazole", "CHEMICAL", 243, 256], ["vancomycin", "CHEMICAL", 101, 111], ["vancomycin", "CHEMICAL", 213, 223], ["metronidazole", "CHEMICAL", 243, 256], ["CSF", "GENE_OR_GENE_PRODUCT", 4, 7], ["lymphocytes", "CELL", 19, 30], ["vancomycin", "SIMPLE_CHEMICAL", 101, 111], ["vancomycin", "SIMPLE_CHEMICAL", 213, 223], ["metronidazole", "SIMPLE_CHEMICAL", 243, 256], ["CSF", "PROTEIN", 4, 7], ["lymphocytes", "CELL_TYPE", 19, 30], ["The CSF report", "TEST", 0, 14], ["lymphocytes", "TEST", 19, 30], ["an elevated protein", "PROBLEM", 35, 54], ["Moderate to severe initial episode", "PROBLEM", 65, 99], ["vancomycin", "TREATMENT", 101, 111], ["Severe initial episode", "PROBLEM", 152, 174], ["shock", "PROBLEM", 192, 197], ["megacolon", "PROBLEM", 202, 211], ["vancomycin", "TREATMENT", 213, 223], ["metronidazole", "TREATMENT", 243, 256], ["elevated protein", "OBSERVATION", 38, 54], ["Moderate", "OBSERVATION_MODIFIER", 65, 73], ["severe", "OBSERVATION_MODIFIER", 77, 83]]], ["C) Severe initial episode but with a complete ileus: consider rectal instillation of vancomycin D) None of the above E) All of the above Answer: E The following are 2010 guidelines for the treatment of the fi rst episode of Clostridium diffi cile colitis: First episode with mild or moderate leukocytosis with a white blood cell count of 15,000 cells/mL or lower and a serum creatinine level less than 1.5 times the premorbid level -metronidazole 500 mg 3 times per day by mouth for 10-14 days First episode, severe and leukocytosis with a white blood cell count of 15,000 cells/mL or higher or a serum creatinine level greater than or equal to 1.5 times the premorbid level -vancomycin 125 mg 4 times per day by mouth for 10-14 days First episode, severe and complicated by hypotension or shock, ileus, megacolon -vancomycin 500 mg 4 times per day by mouth or by nasogastric tube, plus metronidazole 500 mg every 8 h intravenously If complete ileus, consider adding rectal instillation of vancomycin.49.A 52-year-old man is evaluated in the emergency department for a 2-week history of fatigue and nonspecifi c arthralgia.", [["rectal", "ANATOMY", 62, 68], ["white blood cell", "ANATOMY", 312, 328], ["cells", "ANATOMY", 345, 350], ["serum", "ANATOMY", 369, 374], ["mouth", "ANATOMY", 473, 478], ["white blood cell", "ANATOMY", 540, 556], ["cells", "ANATOMY", 573, 578], ["serum", "ANATOMY", 597, 602], ["mouth", "ANATOMY", 713, 718], ["mouth", "ANATOMY", 852, 857], ["rectal", "ANATOMY", 967, 973], ["ileus", "DISEASE", 46, 51], ["vancomycin", "CHEMICAL", 85, 95], ["Clostridium diffi cile colitis", "DISEASE", 224, 254], ["leukocytosis", "DISEASE", 292, 304], ["creatinine", "CHEMICAL", 375, 385], ["metronidazole", "CHEMICAL", 433, 446], ["leukocytosis", "DISEASE", 520, 532], ["creatinine", "CHEMICAL", 603, 613], ["-vancomycin", "CHEMICAL", 675, 686], ["hypotension", "DISEASE", 775, 786], ["shock", "DISEASE", 790, 795], ["ileus", "DISEASE", 797, 802], ["megacolon", "DISEASE", 804, 813], ["-vancomycin", "CHEMICAL", 814, 825], ["metronidazole", "CHEMICAL", 887, 900], ["ileus", "DISEASE", 944, 949], ["vancomycin", "CHEMICAL", 990, 1000], ["fatigue", "DISEASE", 1087, 1094], ["arthralgia", "DISEASE", 1112, 1122], ["vancomycin D)", "CHEMICAL", 85, 98], ["creatinine", "CHEMICAL", 375, 385], ["metronidazole", "CHEMICAL", 433, 446], ["creatinine", "CHEMICAL", 603, 613], ["metronidazole", "CHEMICAL", 887, 900], ["vancomycin", "CHEMICAL", 990, 1000], ["rectal", "ORGANISM_SUBDIVISION", 62, 68], ["vancomycin D", "SIMPLE_CHEMICAL", 85, 97], ["blood cell", "CELL", 318, 328], ["serum", "ORGANISM_SUBSTANCE", 369, 374], ["creatinine", "SIMPLE_CHEMICAL", 375, 385], ["metronidazole", "SIMPLE_CHEMICAL", 433, 446], ["mouth", "ORGANISM_SUBDIVISION", 473, 478], ["blood cell", "CELL", 546, 556], ["serum", "ORGANISM_SUBSTANCE", 597, 602], ["creatinine", "SIMPLE_CHEMICAL", 603, 613], ["mouth", "ORGANISM_SUBDIVISION", 713, 718], ["mouth", "ORGANISM_SUBDIVISION", 852, 857], ["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 864, 880], ["metronidazole", "SIMPLE_CHEMICAL", 887, 900], ["rectal", "ORGANISM_SUBDIVISION", 967, 973], ["vancomycin", "SIMPLE_CHEMICAL", 990, 1000], ["man", "ORGANISM", 1018, 1021], ["man", "SPECIES", 1018, 1021], ["Clostridium diffi cile", "SPECIES", 224, 246], ["Severe initial episode", "PROBLEM", 3, 25], ["a complete ileus", "PROBLEM", 35, 51], ["rectal instillation of vancomycin D", "TREATMENT", 62, 97], ["the treatment", "TREATMENT", 185, 198], ["Clostridium diffi cile colitis", "PROBLEM", 224, 254], ["First episode", "PROBLEM", 256, 269], ["mild or moderate leukocytosis", "PROBLEM", 275, 304], ["a white blood cell count", "TEST", 310, 334], ["cells/mL", "TEST", 345, 353], ["a serum creatinine level", "TEST", 367, 391], ["metronidazole", "TREATMENT", 433, 446], ["severe and leukocytosis", "PROBLEM", 509, 532], ["a white blood cell count", "TEST", 538, 562], ["a serum creatinine level", "TEST", 595, 619], ["the premorbid level -vancomycin", "TREATMENT", 655, 686], ["hypotension", "PROBLEM", 775, 786], ["shock", "PROBLEM", 790, 795], ["ileus", "PROBLEM", 797, 802], ["megacolon -vancomycin", "TREATMENT", 804, 825], ["nasogastric tube", "TREATMENT", 864, 880], ["metronidazole", "TREATMENT", 887, 900], ["complete ileus", "PROBLEM", 935, 949], ["rectal instillation of vancomycin", "TREATMENT", 967, 1000], ["fatigue", "PROBLEM", 1087, 1094], ["nonspecifi c arthralgia", "PROBLEM", 1099, 1122], ["Severe", "OBSERVATION_MODIFIER", 3, 9], ["ileus", "OBSERVATION", 46, 51], ["rectal", "ANATOMY", 62, 68], ["Clostridium diffi", "OBSERVATION", 224, 241], ["cile colitis", "OBSERVATION", 242, 254], ["mild", "OBSERVATION_MODIFIER", 275, 279], ["moderate", "OBSERVATION_MODIFIER", 283, 291], ["leukocytosis", "OBSERVATION", 292, 304], ["severe", "OBSERVATION_MODIFIER", 509, 515], ["leukocytosis", "OBSERVATION", 520, 532], ["hypotension", "OBSERVATION", 775, 786], ["ileus", "OBSERVATION", 944, 949], ["arthralgia", "OBSERVATION", 1112, 1122]]], ["He reports some increasing shortness of breath over the past few days and now has some pleuritic chest pain.", [["chest", "ANATOMY", 97, 102], ["shortness of breath", "DISEASE", 27, 46], ["chest pain", "DISEASE", 97, 107], ["chest", "ORGANISM_SUBDIVISION", 97, 102], ["some increasing shortness of breath", "PROBLEM", 11, 46], ["some pleuritic chest pain", "PROBLEM", 82, 107], ["some", "OBSERVATION_MODIFIER", 11, 15], ["increasing", "OBSERVATION_MODIFIER", 16, 26], ["shortness", "OBSERVATION", 27, 36], ["some", "OBSERVATION_MODIFIER", 82, 86], ["pleuritic", "OBSERVATION_MODIFIER", 87, 96], ["chest", "ANATOMY", 97, 102], ["pain", "OBSERVATION", 103, 107]]], ["He has a history of coronary artery disease and hypertension.", [["coronary artery", "ANATOMY", 20, 35], ["coronary artery disease", "DISEASE", 20, 43], ["hypertension", "DISEASE", 48, 60], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 20, 35], ["coronary artery disease", "PROBLEM", 20, 43], ["hypertension", "PROBLEM", 48, 60], ["coronary artery", "ANATOMY", 20, 35], ["disease", "OBSERVATION", 36, 43], ["hypertension", "OBSERVATION", 48, 60]]], ["His medications include diltiazem, hydralazine, aspirin, and isosorbide dinitrate.", [["diltiazem", "CHEMICAL", 24, 33], ["hydralazine", "CHEMICAL", 35, 46], ["aspirin", "CHEMICAL", 48, 55], ["isosorbide dinitrate", "CHEMICAL", 61, 81], ["diltiazem", "CHEMICAL", 24, 33], ["hydralazine", "CHEMICAL", 35, 46], ["aspirin", "CHEMICAL", 48, 55], ["isosorbide dinitrate", "CHEMICAL", 61, 81], ["diltiazem", "SIMPLE_CHEMICAL", 24, 33], ["hydralazine", "SIMPLE_CHEMICAL", 35, 46], ["aspirin", "SIMPLE_CHEMICAL", 48, 55], ["isosorbide dinitrate", "SIMPLE_CHEMICAL", 61, 81], ["His medications", "TREATMENT", 0, 15], ["diltiazem", "TREATMENT", 24, 33], ["hydralazine", "TREATMENT", 35, 46], ["aspirin", "TREATMENT", 48, 55], ["isosorbide dinitrate", "TREATMENT", 61, 81]]], ["On physical examination, his temperature is 37.2 \u00b0C (99 \u00b0F), blood pressure is 145/90 mmHg, pulse rate is 80 bpm, and respiration rate is 24/min.", [["blood", "ANATOMY", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 61, 66], ["physical examination", "TEST", 3, 23], ["his temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 61, 75], ["pulse rate", "TEST", 92, 102], ["respiration rate", "TEST", 118, 134]]], ["Cardiac examination is normal.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac", "ORGAN", 0, 7], ["Cardiac examination", "TEST", 0, 19], ["normal", "OBSERVATION", 23, 29]]], ["Pulmonary examination reveals a mild left pleural friction rub.", [["Pulmonary", "ANATOMY", 0, 9], ["left pleural", "ANATOMY", 37, 49], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary examination", "TEST", 0, 21], ["a mild left pleural friction rub", "PROBLEM", 30, 62], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["left", "ANATOMY_MODIFIER", 37, 41], ["pleural", "ANATOMY", 42, 49], ["friction rub", "OBSERVATION", 50, 62]]], ["There are small bilateral knee effusions.", [["knee", "ANATOMY", 26, 30], ["effusions", "DISEASE", 31, 40], ["knee", "ORGANISM_SUBDIVISION", 26, 30], ["small bilateral knee effusions", "PROBLEM", 10, 40], ["small", "OBSERVATION_MODIFIER", 10, 15], ["bilateral", "ANATOMY_MODIFIER", 16, 25], ["knee", "ANATOMY", 26, 30], ["effusions", "OBSERVATION", 31, 40]]], ["A nonblanching purpuric rash is noted over the distal upper and lower extremities.49.Laboratory studies show hemoglobin of 7.9 g/dL, leukocyte count 2,200/\u03bcL, platelet count 124,000/\u03bcL, and erythrocyte sedimentation rate 88 mm/h.", [["purpuric", "ANATOMY", 15, 23], ["distal upper", "ANATOMY", 47, 59], ["lower extremities", "ANATOMY", 64, 81], ["leukocyte", "ANATOMY", 133, 142], ["platelet", "ANATOMY", 159, 167], ["erythrocyte", "ANATOMY", 190, 201], ["rash", "DISEASE", 24, 28], ["distal upper", "ORGANISM_SUBDIVISION", 47, 59], ["lower extremities", "ORGANISM_SUBDIVISION", 64, 81], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 109, 119], ["leukocyte", "CELL", 133, 142], ["platelet", "CELL", 159, 167], ["erythrocyte", "CELL", 190, 201], ["hemoglobin", "PROTEIN", 109, 119], ["A nonblanching purpuric rash", "PROBLEM", 0, 28], ["Laboratory studies", "TEST", 85, 103], ["hemoglobin", "TEST", 109, 119], ["dL", "TEST", 129, 131], ["leukocyte count", "TEST", 133, 148], ["\u03bcL", "TEST", 155, 157], ["platelet count", "TEST", 159, 173], ["\u03bcL", "TEST", 182, 184], ["erythrocyte sedimentation rate", "TEST", 190, 220], ["nonblanching", "OBSERVATION_MODIFIER", 2, 14], ["purpuric", "OBSERVATION_MODIFIER", 15, 23], ["rash", "OBSERVATION", 24, 28], ["distal", "ANATOMY_MODIFIER", 47, 53], ["upper", "ANATOMY_MODIFIER", 54, 59], ["lower extremities", "ANATOMY", 64, 81]]], ["Urinalysis reveals 1+ protein, 2-5 erythrocytes/hpf, and 5-10 leukocytes/hpf.49.Chest radiograph reveals small bilateral effusions.", [["erythrocytes", "ANATOMY", 35, 47], ["leukocytes", "ANATOMY", 62, 72], ["effusions", "ANATOMY", 121, 130], ["effusions", "DISEASE", 121, 130], ["1+ protein", "GENE_OR_GENE_PRODUCT", 19, 29], ["erythrocytes", "CELL", 35, 47], ["hpf", "CELL", 48, 51], ["leukocytes", "CELL", 62, 72], ["hpf", "CELL", 73, 76], ["leukocytes", "CELL_TYPE", 62, 72], ["Urinalysis", "TEST", 0, 10], ["protein", "TEST", 22, 29], ["erythrocytes", "TEST", 35, 47], ["hpf", "TEST", 48, 51], ["leukocytes", "TEST", 62, 72], ["hpf", "TEST", 73, 76], ["Chest radiograph", "TEST", 80, 96], ["small bilateral effusions", "PROBLEM", 105, 130], ["hpf", "ANATOMY", 48, 51], ["small", "OBSERVATION_MODIFIER", 105, 110], ["bilateral", "ANATOMY_MODIFIER", 111, 120], ["effusions", "OBSERVATION", 121, 130]]], ["A) Serum and urine electrophoresis B) Bone marrow aspiration and biopsy C) CT of the chest, abdomen, and pelvis D) Rheumatoid factor and anti-cyclic citrullinated peptide antibody E) Antinuclear antibody and anti-double-strand DNA antibody assay49.Answer: E This patient has drug-induced lupus erythematosus (DILE).", [["Serum", "ANATOMY", 3, 8], ["urine", "ANATOMY", 13, 18], ["Bone marrow", "ANATOMY", 38, 49], ["chest", "ANATOMY", 85, 90], ["abdomen", "ANATOMY", 92, 99], ["drug-induced lupus erythematosus", "DISEASE", 275, 307], ["DILE", "DISEASE", 309, 313], ["Serum", "ORGANISM_SUBSTANCE", 3, 8], ["urine", "ORGANISM_SUBSTANCE", 13, 18], ["Bone marrow", "MULTI-TISSUE_STRUCTURE", 38, 49], ["chest", "ORGAN", 85, 90], ["abdomen", "ORGAN", 92, 99], ["anti-cyclic citrullinated peptide antibody E", "GENE_OR_GENE_PRODUCT", 137, 181], ["patient", "ORGANISM", 263, 270], ["chest, abdomen, and pelvis D) Rheumatoid factor", "PROTEIN", 85, 132], ["anti-cyclic citrullinated peptide antibody E", "PROTEIN", 137, 181], ["Antinuclear antibody", "PROTEIN", 183, 203], ["anti-double-strand DNA antibody assay49", "PROTEIN", 208, 247], ["patient", "SPECIES", 263, 270], ["A) Serum and urine electrophoresis", "TEST", 0, 34], ["Bone marrow aspiration", "TEST", 38, 60], ["biopsy C", "TEST", 65, 73], ["CT of the chest, abdomen, and pelvis D)", "TEST", 75, 114], ["Rheumatoid factor", "PROBLEM", 115, 132], ["anti-cyclic citrullinated peptide antibody", "TEST", 137, 179], ["E", "TEST", 180, 181], ["Antinuclear antibody", "TEST", 183, 203], ["anti-double", "TEST", 208, 219], ["strand DNA antibody assay49", "TEST", 220, 247], ["lupus erythematosus", "PROBLEM", 288, 307], ["Bone", "ANATOMY", 38, 42], ["chest", "ANATOMY", 85, 90], ["abdomen", "ANATOMY", 92, 99], ["pelvis", "ANATOMY", 105, 111], ["Rheumatoid", "ANATOMY", 115, 125], ["lupus erythematosus", "OBSERVATION", 288, 307]]], ["The most common drugs that cause DILE are hydralazine, procainamide, quinidine, isoniazid, diltiazem, and minocycline.", [["DILE", "DISEASE", 33, 37], ["hydralazine", "CHEMICAL", 42, 53], ["procainamide", "CHEMICAL", 55, 67], ["quinidine", "CHEMICAL", 69, 78], ["isoniazid", "CHEMICAL", 80, 89], ["diltiazem", "CHEMICAL", 91, 100], ["minocycline", "CHEMICAL", 106, 117], ["DILE", "CHEMICAL", 33, 37], ["hydralazine", "CHEMICAL", 42, 53], ["procainamide", "CHEMICAL", 55, 67], ["quinidine", "CHEMICAL", 69, 78], ["isoniazid", "CHEMICAL", 80, 89], ["diltiazem", "CHEMICAL", 91, 100], ["minocycline", "CHEMICAL", 106, 117], ["DILE", "SIMPLE_CHEMICAL", 33, 37], ["hydralazine", "SIMPLE_CHEMICAL", 42, 53], ["procainamide", "SIMPLE_CHEMICAL", 55, 67], ["quinidine", "SIMPLE_CHEMICAL", 69, 78], ["isoniazid", "SIMPLE_CHEMICAL", 80, 89], ["diltiazem", "SIMPLE_CHEMICAL", 91, 100], ["minocycline", "SIMPLE_CHEMICAL", 106, 117], ["DILE", "TREATMENT", 33, 37], ["hydralazine", "TREATMENT", 42, 53], ["procainamide", "TREATMENT", 55, 67], ["quinidine", "TREATMENT", 69, 78], ["isoniazid", "TREATMENT", 80, 89], ["diltiazem", "TREATMENT", 91, 100], ["minocycline", "TREATMENT", 106, 117]]], ["He has new-onset fever, arthralgia, myalgia, nonblanching purpuric rash, pleuritis, pancytopenia, and proteinuria with active urine sediment.", [["purpuric", "ANATOMY", 58, 66], ["urine sediment", "ANATOMY", 126, 140], ["fever", "DISEASE", 17, 22], ["arthralgia", "DISEASE", 24, 34], ["myalgia", "DISEASE", 36, 43], ["purpuric rash", "DISEASE", 58, 71], ["pleuritis", "DISEASE", 73, 82], ["pancytopenia", "DISEASE", 84, 96], ["proteinuria", "DISEASE", 102, 113], ["urine", "ORGANISM_SUBSTANCE", 126, 131], ["fever", "PROBLEM", 17, 22], ["arthralgia", "PROBLEM", 24, 34], ["myalgia", "PROBLEM", 36, 43], ["nonblanching purpuric rash", "PROBLEM", 45, 71], ["pleuritis", "PROBLEM", 73, 82], ["pancytopenia", "PROBLEM", 84, 96], ["proteinuria", "PROBLEM", 102, 113], ["active urine sediment", "PROBLEM", 119, 140], ["new", "OBSERVATION_MODIFIER", 7, 10], ["-onset", "OBSERVATION_MODIFIER", 10, 16], ["fever", "OBSERVATION", 17, 22], ["arthralgia", "OBSERVATION", 24, 34], ["myalgia", "ANATOMY", 36, 43], ["purpuric", "OBSERVATION_MODIFIER", 58, 66], ["rash", "OBSERVATION", 67, 71], ["pleuritis", "OBSERVATION", 73, 82], ["pancytopenia", "OBSERVATION", 84, 96], ["proteinuria", "OBSERVATION", 102, 113], ["active", "OBSERVATION_MODIFIER", 119, 125], ["urine sediment", "OBSERVATION", 126, 140]]], ["Testing for antinuclear antibodies (ANA), as well as antidouble-stranded DNA antibodies and complement levels, is indicated.", [["antinuclear antibodies", "GENE_OR_GENE_PRODUCT", 12, 34], ["ANA", "GENE_OR_GENE_PRODUCT", 36, 39], ["antidouble-stranded", "GENE_OR_GENE_PRODUCT", 53, 72], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["antinuclear antibodies", "PROTEIN", 12, 34], ["ANA", "PROTEIN", 36, 39], ["antidouble-stranded DNA antibodies", "PROTEIN", 53, 87], ["Testing", "TEST", 0, 7], ["antinuclear antibodies", "TEST", 12, 34], ["antidouble-stranded DNA antibodies", "TEST", 53, 87], ["complement levels", "TEST", 92, 109]]], ["This multiorgan pattern is suggestive of an autoimmune disorder, in particular of systemic lupus erythematosus (SLE).", [["multiorgan", "ANATOMY", 5, 15], ["autoimmune disorder", "DISEASE", 44, 63], ["systemic lupus erythematosus", "DISEASE", 82, 110], ["SLE", "DISEASE", 112, 115], ["an autoimmune disorder", "PROBLEM", 41, 63], ["systemic lupus erythematosus", "PROBLEM", 82, 110], ["suggestive of", "UNCERTAINTY", 27, 40], ["autoimmune", "OBSERVATION", 44, 54], ["systemic", "OBSERVATION_MODIFIER", 82, 90], ["lupus erythematosus", "OBSERVATION", 91, 110]]], ["No specifi c criteria establish the diagnosis of DILE.", [["DILE", "DISEASE", 49, 53], ["DILE", "CANCER", 49, 53], ["DILE", "PROBLEM", 49, 53]]], ["Excluding other underlying autoimmune diseases must fi rst be done.", [["autoimmune diseases", "DISEASE", 27, 46], ["other underlying autoimmune diseases", "PROBLEM", 10, 46], ["autoimmune", "OBSERVATION", 27, 37]]], ["SLE is typically ruled out fi rst.", [["SLE", "DISEASE", 0, 3]]], ["Drugs that cause DILE may take months to years before the associated symptoms occur.", [["DILE", "DISEASE", 17, 21], ["Drugs", "TREATMENT", 0, 5], ["the associated symptoms", "PROBLEM", 54, 77]]], ["In addition similar drugs can also induce fl airs of SLE.", [["SLE", "DISEASE", 53, 56], ["similar drugs", "TREATMENT", 12, 25], ["SLE", "PROBLEM", 53, 56]]], ["She is noted to have spontaneous eye opening and is able to track an object visually at times.", [["eye", "ANATOMY", 33, 36], ["eye", "ORGAN", 33, 36], ["spontaneous eye opening", "PROBLEM", 21, 44], ["eye", "ANATOMY", 33, 36], ["opening", "OBSERVATION", 37, 44]]], ["She in intubated but is fed through a gastrostomy tube.", [["intubated", "TREATMENT", 7, 16], ["a gastrostomy tube", "TREATMENT", 36, 54], ["gastrostomy tube", "OBSERVATION", 38, 54]]], ["She moves extremities spontaneously but without purposeful movement.ReferencesWhat term best describes this patient's condition? 51.", [["extremities", "ANATOMY", 10, 21], ["extremities", "ORGANISM_SUBDIVISION", 10, 21], ["patient", "ORGANISM", 108, 115], ["patient", "SPECIES", 108, 115], ["without", "UNCERTAINTY", 40, 47]]], ["An 87-year-old female was admitted to the hospital for a heart failure exacerbation.", [["heart", "ANATOMY", 57, 62], ["heart failure", "DISEASE", 57, 70], ["female", "ORGANISM", 15, 21], ["heart", "ORGAN", 57, 62], ["a heart failure exacerbation", "PROBLEM", 55, 83], ["heart", "ANATOMY", 57, 62], ["failure", "OBSERVATION", 63, 70]]], ["She has ischemic cardiomyopathy, coronary artery disease, hypertension, and hyperlipidemia.", [["coronary artery", "ANATOMY", 33, 48], ["ischemic cardiomyopathy", "DISEASE", 8, 31], ["coronary artery disease", "DISEASE", 33, 56], ["hypertension", "DISEASE", 58, 70], ["hyperlipidemia", "DISEASE", 76, 90], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 33, 48], ["ischemic cardiomyopathy", "PROBLEM", 8, 31], ["coronary artery disease", "PROBLEM", 33, 56], ["hypertension", "PROBLEM", 58, 70], ["hyperlipidemia", "PROBLEM", 76, 90], ["ischemic", "OBSERVATION_MODIFIER", 8, 16], ["cardiomyopathy", "OBSERVATION", 17, 31], ["coronary artery", "ANATOMY", 33, 48], ["disease", "OBSERVATION", 49, 56], ["hypertension", "OBSERVATION", 58, 70], ["hyperlipidemia", "OBSERVATION", 76, 90]]], ["Current medications are furosemide, lisinopril, metoprolol, aspirin, atorvastatin, and heparin given subcutaneously twice daily for deep venous thrombosis prophylaxis.", [["subcutaneously", "ANATOMY", 101, 115], ["venous", "ANATOMY", 137, 143], ["furosemide", "CHEMICAL", 24, 34], ["lisinopril", "CHEMICAL", 36, 46], ["metoprolol", "CHEMICAL", 48, 58], ["aspirin", "CHEMICAL", 60, 67], ["atorvastatin", "CHEMICAL", 69, 81], ["heparin", "CHEMICAL", 87, 94], ["venous thrombosis", "DISEASE", 137, 154], ["furosemide", "CHEMICAL", 24, 34], ["lisinopril", "CHEMICAL", 36, 46], ["metoprolol", "CHEMICAL", 48, 58], ["aspirin", "CHEMICAL", 60, 67], ["atorvastatin", "CHEMICAL", 69, 81], ["furosemide", "SIMPLE_CHEMICAL", 24, 34], ["lisinopril", "SIMPLE_CHEMICAL", 36, 46], ["metoprolol", "SIMPLE_CHEMICAL", 48, 58], ["aspirin", "SIMPLE_CHEMICAL", 60, 67], ["atorvastatin", "SIMPLE_CHEMICAL", 69, 81], ["heparin", "SIMPLE_CHEMICAL", 87, 94], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 137, 143], ["Current medications", "TREATMENT", 0, 19], ["furosemide", "TREATMENT", 24, 34], ["lisinopril", "TREATMENT", 36, 46], ["metoprolol", "TREATMENT", 48, 58], ["aspirin", "TREATMENT", 60, 67], ["atorvastatin", "TREATMENT", 69, 81], ["heparin", "TREATMENT", 87, 94], ["deep venous thrombosis prophylaxis", "TREATMENT", 132, 166], ["deep", "ANATOMY_MODIFIER", 132, 136], ["venous", "ANATOMY", 137, 143], ["thrombosis", "OBSERVATION", 144, 154]]], ["Since admission, the patient has expressed her concern about receiving heparin injections.", [["heparin", "CHEMICAL", 71, 78], ["patient", "ORGANISM", 21, 28], ["heparin", "SIMPLE_CHEMICAL", 71, 78], ["patient", "SPECIES", 21, 28], ["heparin injections", "TREATMENT", 71, 89]]], ["She has had a moderate amount of bruising on her abdomen, which is painful.", [["abdomen", "ANATOMY", 49, 56], ["bruising", "DISEASE", 33, 41], ["abdomen", "ORGANISM_SUBDIVISION", 49, 56], ["bruising on her abdomen", "PROBLEM", 33, 56], ["painful", "PROBLEM", 67, 74], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["amount", "OBSERVATION_MODIFIER", 23, 29], ["bruising", "OBSERVATION", 33, 41], ["abdomen", "ANATOMY", 49, 56], ["painful", "OBSERVATION", 67, 74]]], ["She has asked her nurse several times if she really needs \"those shots,\" and the nurse has relayed her concerns to you.ReferencesOn physical examination, heart rate is 82 beats per minute and blood pressure is 120/65 mmHg.", [["heart", "ANATOMY", 154, 159], ["blood", "ANATOMY", 192, 197], ["heart", "ORGAN", 154, 159], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["ReferencesOn physical examination", "TEST", 119, 152], ["heart rate", "TEST", 154, 164], ["blood pressure", "TEST", 192, 206], ["heart", "ANATOMY", 154, 159]]], ["Crackles are still heard a third the way up in both lung fi elds.", [["lung", "ANATOMY", 52, 56], ["lung", "ORGAN", 52, 56], ["Crackles", "PROBLEM", 0, 8], ["both", "ANATOMY_MODIFIER", 47, 51], ["lung", "ANATOMY", 52, 56], ["fi", "ANATOMY_MODIFIER", 57, 59], ["elds", "OBSERVATION", 60, 64]]], ["Ecchymosis are seen on the abdomen.", [["abdomen", "ANATOMY", 27, 34], ["Ecchymosis", "DISEASE", 0, 10], ["abdomen", "ORGAN", 27, 34], ["Ecchymosis", "PROBLEM", 0, 10], ["abdomen", "ANATOMY", 27, 34]]], ["There is edema (1+) extending to the knees.", [["edema", "ANATOMY", 9, 14], ["knees", "ANATOMY", 37, 42], ["edema", "DISEASE", 9, 14], ["edema", "PATHOLOGICAL_FORMATION", 9, 14], ["knees", "PATHOLOGICAL_FORMATION", 37, 42], ["edema", "PROBLEM", 9, 14], ["edema", "OBSERVATION", 9, 14], ["knees", "ANATOMY", 37, 42]]], ["She can walk slowly but safely with a walker or assistance.ReferencesWhat is the best treatment?", [["a walker", "TREATMENT", 36, 44]]], ["A) Continue the heparin, and explain its necessity to the patient.", [["heparin", "CHEMICAL", 16, 23], ["heparin", "SIMPLE_CHEMICAL", 16, 23], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["the heparin", "TREATMENT", 12, 23]]], ["B) Stop the heparin, and start enoxaparin daily.", [["heparin", "CHEMICAL", 12, 19], ["enoxaparin", "CHEMICAL", 31, 41], ["enoxaparin", "CHEMICAL", 31, 41], ["heparin", "SIMPLE_CHEMICAL", 12, 19], ["enoxaparin", "SIMPLE_CHEMICAL", 31, 41], ["the heparin", "TREATMENT", 8, 19], ["enoxaparin", "TREATMENT", 31, 41]]], ["C) Stop the heparin, and start venous foot pumps.", [["venous", "ANATOMY", 31, 37], ["heparin", "CHEMICAL", 12, 19], ["heparin", "SIMPLE_CHEMICAL", 12, 19], ["the heparin", "TREATMENT", 8, 19], ["venous foot pumps", "TREATMENT", 31, 48], ["venous foot", "ANATOMY", 31, 42]]], ["D) Start Coumadin.", [["Coumadin", "CHEMICAL", 9, 17], ["Coumadin", "TREATMENT", 9, 17]]], ["E) Stop the heparin and encourage the patient to walk with her family.ReferencesAnswer: E The current guidelines recommend that adults older than age 40 who are hospitalized for medical reasons and are expected to be less mobile for 3 days or more be given some form of deep venous thrombosis (DVT) prophylaxis.", [["venous", "ANATOMY", 275, 281], ["heparin", "CHEMICAL", 12, 19], ["venous thrombosis", "DISEASE", 275, 292], ["DVT", "DISEASE", 294, 297], ["heparin", "SIMPLE_CHEMICAL", 12, 19], ["patient", "ORGANISM", 38, 45], ["deep venous", "MULTI-TISSUE_STRUCTURE", 270, 281], ["patient", "SPECIES", 38, 45], ["the heparin", "TREATMENT", 8, 19], ["deep venous thrombosis", "PROBLEM", 270, 292], ["DVT) prophylaxis", "TREATMENT", 294, 310], ["deep", "ANATOMY_MODIFIER", 270, 274], ["venous", "ANATOMY", 275, 281], ["thrombosis", "OBSERVATION", 282, 292], ["DVT", "OBSERVATION", 294, 297]]], ["This is based on several randomized controlled trials.", [["several randomized controlled trials", "TREATMENT", 17, 53]]], ["A systematic review and meta-analysis examined the evidence for harm and efficacy of pharmacologic prophylaxis of DVT in older adults.", [["DVT", "DISEASE", 114, 117], ["A systematic review", "TEST", 0, 19], ["meta-analysis", "TEST", 24, 37], ["harm", "PROBLEM", 64, 68], ["pharmacologic prophylaxis", "TREATMENT", 85, 110], ["DVT", "PROBLEM", 114, 117], ["DVT", "OBSERVATION", 114, 117]]], ["For the most part older adults with comorbidities have been excluded from studies.", [["comorbidities", "PROBLEM", 36, 49], ["comorbidities", "OBSERVATION", 36, 49]]], ["The majority of events prevented in studies are asymptomatic DVTs.", [["DVTs", "DISEASE", 61, 65], ["DVTs", "PATHOLOGICAL_FORMATION", 61, 65], ["asymptomatic DVTs", "PROBLEM", 48, 65], ["asymptomatic", "OBSERVATION_MODIFIER", 48, 60], ["DVTs", "OBSERVATION", 61, 65]]], ["There is no consistent reduction in fatal pulmonary embolism or mortality.", [["pulmonary", "ANATOMY", 42, 51], ["pulmonary embolism", "DISEASE", 42, 60], ["pulmonary", "ORGAN", 42, 51], ["fatal pulmonary embolism", "PROBLEM", 36, 60], ["mortality", "PROBLEM", 64, 73], ["no consistent", "UNCERTAINTY", 9, 22], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["fatal", "OBSERVATION_MODIFIER", 36, 41], ["pulmonary", "ANATOMY", 42, 51], ["embolism", "OBSERVATION", 52, 60], ["mortality", "OBSERVATION", 64, 73]]], ["When data from the three trials with patients older than age 75 are pooled, a similar reduction in endpoints to other trials is seen.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["a similar reduction", "TREATMENT", 76, 95], ["similar", "OBSERVATION_MODIFIER", 78, 85], ["reduction", "OBSERVATION_MODIFIER", 86, 95]]], ["However, two-thirds of these events are asymptomatic DVTs.", [["DVTs", "DISEASE", 53, 57], ["DVTs", "PATHOLOGICAL_FORMATION", 53, 57], ["asymptomatic DVTs", "PROBLEM", 40, 57], ["asymptomatic", "OBSERVATION_MODIFIER", 40, 52], ["DVTs", "OBSERVATION", 53, 57]]], ["In the general population, the absolute bleeding risk is generally increased by 2 % in the heparin treatment group.", [["bleeding", "DISEASE", 40, 48], ["heparin", "CHEMICAL", 91, 98], ["heparin", "SIMPLE_CHEMICAL", 91, 98], ["the absolute bleeding risk", "PROBLEM", 27, 53], ["the heparin treatment group", "TREATMENT", 87, 114], ["absolute", "OBSERVATION_MODIFIER", 31, 39], ["bleeding", "OBSERVATION", 40, 48], ["generally", "OBSERVATION_MODIFIER", 57, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76]]], ["Older age with its comorbidities may increase this risk.", [["its comorbidities", "PROBLEM", 15, 32]]], ["The current data suggest that this patient would gain a very small absolute risk reduction for symptomatic DVTs and an even smaller risk for pulmonary embolism.", [["pulmonary", "ANATOMY", 141, 150], ["DVTs", "DISEASE", 107, 111], ["pulmonary embolism", "DISEASE", 141, 159], ["patient", "ORGANISM", 35, 42], ["pulmonary", "ORGAN", 141, 150], ["patient", "SPECIES", 35, 42], ["a very small absolute risk reduction", "TREATMENT", 54, 90], ["symptomatic DVTs", "PROBLEM", 95, 111], ["pulmonary embolism", "PROBLEM", 141, 159], ["symptomatic", "OBSERVATION_MODIFIER", 95, 106], ["DVTs", "OBSERVATION", 107, 111], ["smaller", "OBSERVATION_MODIFIER", 124, 131], ["pulmonary", "ANATOMY", 141, 150], ["embolism", "OBSERVATION", 151, 159]]], ["Given her wishes, it is reasonable to stop heparin and encourage ambulation.", [["heparin", "CHEMICAL", 43, 50], ["heparin", "SIMPLE_CHEMICAL", 43, 50], ["heparin", "TREATMENT", 43, 50]]], ["In methadone patients, an ECG should be obtained on admission.", [["methadone", "CHEMICAL", 3, 12], ["methadone", "CHEMICAL", 3, 12], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["methadone", "TREATMENT", 3, 12], ["an ECG", "TEST", 23, 29]]], ["QT prolongation may predict subsequent malignant arrhythmias and possible need to alter methadone treatment.", [["QT prolongation", "DISEASE", 0, 15], ["malignant arrhythmias", "DISEASE", 39, 60], ["methadone", "CHEMICAL", 88, 97], ["methadone", "CHEMICAL", 88, 97], ["methadone", "SIMPLE_CHEMICAL", 88, 97], ["QT prolongation", "PROBLEM", 0, 15], ["subsequent malignant arrhythmias", "PROBLEM", 28, 60], ["methadone treatment", "TREATMENT", 88, 107], ["malignant", "OBSERVATION_MODIFIER", 39, 48]]], ["Methadone has been used to treat heroin addicts for nearly 50 years, but little is known about its long-term side effects.ReferenceJusto D, Gal-Oz A, Paran Y et al. Methadone-associated torsades de pointes (polymorphic ventricular tachycardia) in opioid-dependent patients.", [["ventricular", "ANATOMY", 219, 230], ["Methadone", "CHEMICAL", 0, 9], ["heroin", "CHEMICAL", 33, 39], ["Methadone", "CHEMICAL", 165, 174], ["torsades de pointes", "DISEASE", 186, 205], ["ventricular tachycardia", "DISEASE", 219, 242], ["Methadone", "CHEMICAL", 0, 9], ["heroin", "CHEMICAL", 33, 39], ["Methadone", "CHEMICAL", 165, 174], ["ventricular", "ORGAN", 219, 230], ["patients", "ORGANISM", 264, 272], ["patients", "SPECIES", 264, 272], ["Methadone", "TREATMENT", 0, 9], ["Methadone", "TREATMENT", 165, 174], ["torsades de pointes", "PROBLEM", 186, 205], ["polymorphic ventricular tachycardia", "PROBLEM", 207, 242], ["long-term side", "OBSERVATION_MODIFIER", 99, 113]]], ["A 38-year-old man is admitted with atypical chest pain of 3 h duration.", [["chest", "ANATOMY", 44, 49], ["chest pain", "DISEASE", 44, 54], ["man", "ORGANISM", 14, 17], ["chest", "ORGANISM_SUBDIVISION", 44, 49], ["man", "SPECIES", 14, 17], ["atypical chest pain", "PROBLEM", 35, 54], ["atypical", "OBSERVATION_MODIFIER", 35, 43], ["chest", "ANATOMY", 44, 49], ["pain", "OBSERVATION", 50, 54]]], ["While waiting to be seen, his pain resolves.", [["pain", "DISEASE", 30, 34], ["his pain", "PROBLEM", 26, 34]]], ["He reports that he has been smoking marijuana extensively and denies any other ingestions or substances.", [["marijuana", "CHEMICAL", 36, 45]]], ["He reports no past medical history and is not on any meds.", [["any meds", "TREATMENT", 49, 57], ["no", "UNCERTAINTY", 11, 13]]], ["He is not sure but may have chest pain prior to this admission.ReferenceOn physical exam, his heart rate is 110, temperature is 37 \u00b0C (98.6 \u00b0F), and blood pressure is 180/90.", [["chest", "ANATOMY", 28, 33], ["heart", "ANATOMY", 94, 99], ["blood", "ANATOMY", 149, 154], ["chest pain", "DISEASE", 28, 38], ["chest", "ORGANISM_SUBDIVISION", 28, 33], ["heart", "ORGAN", 94, 99], ["blood", "ORGANISM_SUBSTANCE", 149, 154], ["chest pain", "PROBLEM", 28, 38], ["ReferenceOn physical exam", "TEST", 63, 88], ["his heart rate", "TEST", 90, 104], ["temperature", "TEST", 113, 124], ["blood pressure", "TEST", 149, 163], ["chest", "ANATOMY", 28, 33], ["heart", "ANATOMY", 94, 99]]], ["He is agitated, tachycardic, and diaphoretic.", [["agitated", "PROBLEM", 6, 14], ["tachycardic", "PROBLEM", 16, 27], ["diaphoretic", "PROBLEM", 33, 44], ["agitated", "OBSERVATION", 6, 14]]], ["His electrocardiogram reveals slight ST depressions in leads V3 through V5.", [["depressions", "DISEASE", 40, 51], ["V5", "PROTEIN", 72, 74], ["His electrocardiogram", "TEST", 0, 21], ["slight ST depressions in leads V3 through V5", "PROBLEM", 30, 74], ["slight", "OBSERVATION_MODIFIER", 30, 36], ["ST depressions", "OBSERVATION", 37, 51], ["V3", "ANATOMY_MODIFIER", 61, 63]]], ["Initial troponin level is 0.1 mg/mL.", [["troponin", "GENE_OR_GENE_PRODUCT", 8, 16], ["troponin", "PROTEIN", 8, 16], ["Initial troponin level", "TEST", 0, 22]]], ["Toxicology screen is pending.ReferenceInitial therapy should include the following: A) Tissue plasminogen activator (TPA) B) Percutaneous transluminal coronary angioplasty (PTCA) C) Aspirin D) Abciximab E) Metoprolol Answer: C This patient is exhibiting a sympathomimetic presentation probably due to crack cocaine ingestion.", [["coronary", "ANATOMY", 151, 159], ["Aspirin", "CHEMICAL", 182, 189], ["Metoprolol", "CHEMICAL", 206, 216], ["cocaine", "CHEMICAL", 307, 314], ["Aspirin D", "CHEMICAL", 182, 191], ["Abciximab E", "CHEMICAL", 193, 204], ["Metoprolol", "CHEMICAL", 206, 216], ["C", "CHEMICAL", 225, 226], ["cocaine", "CHEMICAL", 307, 314], ["Tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 87, 115], ["TPA", "SIMPLE_CHEMICAL", 117, 120], ["coronary", "MULTI-TISSUE_STRUCTURE", 151, 159], ["Aspirin D", "SIMPLE_CHEMICAL", 182, 191], ["Abciximab E", "SIMPLE_CHEMICAL", 193, 204], ["Metoprolol", "SIMPLE_CHEMICAL", 206, 216], ["patient", "ORGANISM", 232, 239], ["patient", "SPECIES", 232, 239], ["Toxicology screen", "TEST", 0, 17], ["ReferenceInitial therapy", "TREATMENT", 29, 53], ["A) Tissue plasminogen activator (TPA) B) Percutaneous transluminal coronary angioplasty (PTCA) C", "TREATMENT", 84, 180], ["Aspirin D) Abciximab E", "TREATMENT", 182, 204], ["Metoprolol", "TREATMENT", 206, 216], ["a sympathomimetic presentation", "PROBLEM", 254, 284], ["crack cocaine ingestion", "PROBLEM", 301, 324], ["coronary", "ANATOMY", 151, 159], ["angioplasty", "OBSERVATION", 160, 171], ["probably due to", "UNCERTAINTY", 285, 300], ["crack cocaine", "OBSERVATION", 301, 314]]], ["This should be considered as an additive in someone with a history of smoking marijuana.", [["marijuana", "CHEMICAL", 78, 87]]], ["His possible myocardial ischemia is due to endothelial dysfunction as well as aggregation of platelets.", [["myocardial", "ANATOMY", 13, 23], ["endothelial", "ANATOMY", 43, 54], ["platelets", "ANATOMY", 93, 102], ["myocardial ischemia", "DISEASE", 13, 32], ["endothelial dysfunction", "DISEASE", 43, 66], ["myocardial", "MULTI-TISSUE_STRUCTURE", 13, 23], ["endothelial", "CELL", 43, 54], ["platelets", "CELL", 93, 102], ["platelets", "CELL_TYPE", 93, 102], ["myocardial ischemia", "PROBLEM", 13, 32], ["endothelial dysfunction", "PROBLEM", 43, 66], ["aggregation of platelets", "TREATMENT", 78, 102], ["possible", "UNCERTAINTY", 4, 12], ["myocardial", "ANATOMY", 13, 23], ["ischemia", "OBSERVATION", 24, 32], ["is due to", "UNCERTAINTY", 33, 42], ["endothelial dysfunction", "OBSERVATION", 43, 66]]], ["In this particular scenario, there is no evidence of segment elevation myocardial infarction, so PTCA, tPA, and GP IIb/IIIa are not indicated.", [["myocardial", "ANATOMY", 71, 81], ["myocardial infarction", "DISEASE", 71, 92], ["myocardial", "MULTI-TISSUE_STRUCTURE", 71, 81], ["tPA", "GENE_OR_GENE_PRODUCT", 103, 106], ["GP IIb/IIIa", "GENE_OR_GENE_PRODUCT", 112, 123], ["tPA", "PROTEIN", 103, 106], ["GP IIb/IIIa", "PROTEIN", 112, 123], ["segment elevation myocardial infarction", "PROBLEM", 53, 92], ["PTCA", "TREATMENT", 97, 101], ["tPA", "TREATMENT", 103, 106], ["GP IIb/IIIa", "TREATMENT", 112, 123], ["no evidence of", "UNCERTAINTY", 38, 52], ["segment", "ANATOMY_MODIFIER", 53, 60], ["elevation", "OBSERVATION", 61, 70], ["myocardial", "ANATOMY", 71, 81], ["infarction", "OBSERVATION", 82, 92], ["IIIa", "OBSERVATION", 119, 123]]], ["A reasonable approach would be an aspirin with further cardiovascular workup considered.", [["cardiovascular", "ANATOMY", 55, 69], ["aspirin", "CHEMICAL", 34, 41], ["aspirin", "CHEMICAL", 34, 41], ["aspirin", "SIMPLE_CHEMICAL", 34, 41], ["an aspirin", "TREATMENT", 31, 41], ["further cardiovascular workup", "TEST", 47, 76]]], ["Beta-blockers are relatively contraindicated in cocaine-induced chest pain as there is a possible risk of increased peripheral vascular resistance.", [["chest", "ANATOMY", 64, 69], ["peripheral vascular", "ANATOMY", 116, 135], ["cocaine", "CHEMICAL", 48, 55], ["chest pain", "DISEASE", 64, 74], ["cocaine", "CHEMICAL", 48, 55], ["Beta-blockers", "GENE_OR_GENE_PRODUCT", 0, 13], ["cocaine", "SIMPLE_CHEMICAL", 48, 55], ["chest", "ORGANISM_SUBDIVISION", 64, 69], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 116, 135], ["Beta-blockers", "TREATMENT", 0, 13], ["chest pain", "PROBLEM", 64, 74], ["increased peripheral vascular resistance", "PROBLEM", 106, 146], ["chest", "ANATOMY", 64, 69], ["possible risk of", "UNCERTAINTY", 89, 105], ["increased", "OBSERVATION_MODIFIER", 106, 115], ["peripheral", "ANATOMY_MODIFIER", 116, 126], ["vascular", "ANATOMY", 127, 135], ["resistance", "OBSERVATION", 136, 146]]], ["Blood cultures drawn on day 1 started growing enterococci on day 3.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14], ["growing enterococci", "PROBLEM", 38, 57], ["enterococci", "OBSERVATION", 46, 57]]], ["He was also diagnosed with an infective endocarditis and was started on gentamicin and aqueous penicillin G. His labs at the time of admission showed a BUN of 32 mg/dL and serum creatinine of 0.8 mg/dL.", [["serum", "ANATOMY", 172, 177], ["infective endocarditis", "DISEASE", 30, 52], ["gentamicin", "CHEMICAL", 72, 82], ["penicillin", "CHEMICAL", 95, 105], ["creatinine", "CHEMICAL", 178, 188], ["gentamicin", "CHEMICAL", 72, 82], ["penicillin", "CHEMICAL", 95, 105], ["creatinine", "CHEMICAL", 178, 188], ["He", "ORGANISM", 0, 2], ["gentamicin", "SIMPLE_CHEMICAL", 72, 82], ["BUN", "SIMPLE_CHEMICAL", 152, 155], ["serum", "ORGANISM_SUBSTANCE", 172, 177], ["creatinine", "SIMPLE_CHEMICAL", 178, 188], ["an infective endocarditis", "PROBLEM", 27, 52], ["gentamicin", "TREATMENT", 72, 82], ["aqueous penicillin", "TREATMENT", 87, 105], ["His labs", "TEST", 109, 117], ["a BUN", "TEST", 150, 155], ["serum creatinine", "TEST", 172, 188], ["infective", "OBSERVATION_MODIFIER", 30, 39], ["endocarditis", "OBSERVATION", 40, 52]]], ["He started complaining of worsening shortness of breath on the next day, and a CT angiogram of the chest was obtained and pulmonary embolism was ruled out.", [["chest", "ANATOMY", 99, 104], ["pulmonary", "ANATOMY", 122, 131], ["shortness of breath", "DISEASE", 36, 55], ["pulmonary embolism", "DISEASE", 122, 140], ["chest", "ORGAN", 99, 104], ["pulmonary", "ORGAN", 122, 131], ["worsening shortness of breath", "PROBLEM", 26, 55], ["a CT angiogram of the chest", "TEST", 77, 104], ["pulmonary embolism", "PROBLEM", 122, 140], ["worsening", "OBSERVATION_MODIFIER", 26, 35], ["chest", "ANATOMY", 99, 104], ["pulmonary", "ANATOMY", 122, 131], ["embolism", "OBSERVATION", 132, 140]]], ["His BUN on day 7 was 53 mg/dL with a serum creatinine of 2.8 mg/ dL.", [["serum", "ANATOMY", 37, 42], ["creatinine", "CHEMICAL", 43, 53], ["creatinine", "CHEMICAL", 43, 53], ["BUN", "SIMPLE_CHEMICAL", 4, 7], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["creatinine", "SIMPLE_CHEMICAL", 43, 53], ["BUN", "PROTEIN", 4, 7], ["His BUN", "TEST", 0, 7], ["a serum creatinine", "TEST", 35, 53]]], ["Urine output dropped to 600 cc in 24 h.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine output", "TEST", 0, 12], ["output", "OBSERVATION_MODIFIER", 6, 12], ["dropped", "OBSERVATION_MODIFIER", 13, 20]]], ["His vital signs and urinalysis were normal.ReferenceWhat is the reason for this acute renal failure?", [["renal", "ANATOMY", 86, 91], ["acute renal failure", "DISEASE", 80, 99], ["renal", "ORGAN", 86, 91], ["His vital signs", "TEST", 0, 15], ["urinalysis", "TEST", 20, 30], ["this acute renal failure", "PROBLEM", 75, 99], ["normal", "OBSERVATION", 36, 42], ["renal", "ANATOMY", 86, 91], ["failure", "OBSERVATION", 92, 99]]], ["A) Aminoglycoside toxicity B) Drug-induced interstitial nephritis C) Acute glomerulonephritis D) Diabetic nephropathy E) Contrast-induced nephropathy Answer: E This patient has developed acute renal failure secondary to contrast-induced nephropathy.", [["interstitial", "ANATOMY", 43, 55], ["renal", "ANATOMY", 193, 198], ["Aminoglycoside", "CHEMICAL", 3, 17], ["toxicity", "DISEASE", 18, 26], ["interstitial nephritis", "DISEASE", 43, 65], ["glomerulonephritis", "DISEASE", 75, 93], ["Diabetic nephropathy", "DISEASE", 97, 117], ["nephropathy", "DISEASE", 138, 149], ["acute renal failure", "DISEASE", 187, 206], ["nephropathy", "DISEASE", 237, 248], ["Aminoglycoside", "CHEMICAL", 3, 17], ["Aminoglycoside", "SIMPLE_CHEMICAL", 3, 17], ["patient", "ORGANISM", 165, 172], ["renal", "ORGAN", 193, 198], ["patient", "SPECIES", 165, 172], ["A) Aminoglycoside toxicity", "TREATMENT", 0, 26], ["interstitial nephritis C", "PROBLEM", 43, 67], ["Acute glomerulonephritis D", "PROBLEM", 69, 95], ["Diabetic nephropathy E", "PROBLEM", 97, 119], ["Contrast-induced nephropathy", "PROBLEM", 121, 149], ["acute renal failure", "PROBLEM", 187, 206], ["contrast-induced nephropathy", "PROBLEM", 220, 248], ["interstitial", "ANATOMY", 43, 55], ["nephritis", "OBSERVATION", 56, 65], ["Acute", "OBSERVATION_MODIFIER", 69, 74], ["glomerulonephritis", "OBSERVATION", 75, 93], ["Diabetic", "OBSERVATION_MODIFIER", 97, 105], ["nephropathy", "OBSERVATION", 106, 117], ["nephropathy", "OBSERVATION", 138, 149], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["renal", "ANATOMY", 193, 198], ["failure", "OBSERVATION", 199, 206], ["contrast-induced", "OBSERVATION_MODIFIER", 220, 236], ["nephropathy", "OBSERVATION", 237, 248]]], ["Several causes of renal failure are possible.", [["renal", "ANATOMY", 18, 23], ["renal failure", "DISEASE", 18, 31], ["renal", "ORGAN", 18, 23], ["renal failure", "PROBLEM", 18, 31], ["renal", "ANATOMY", 18, 23], ["failure", "OBSERVATION", 24, 31]]], ["They include interstitial nephritis secondary to penicillin and infective endocarditis.", [["interstitial", "ANATOMY", 13, 25], ["interstitial nephritis", "DISEASE", 13, 35], ["penicillin", "CHEMICAL", 49, 59], ["infective endocarditis", "DISEASE", 64, 86], ["penicillin", "CHEMICAL", 49, 59], ["penicillin", "SIMPLE_CHEMICAL", 49, 59], ["interstitial nephritis", "PROBLEM", 13, 35], ["penicillin", "TREATMENT", 49, 59], ["infective endocarditis", "PROBLEM", 64, 86], ["interstitial", "ANATOMY_MODIFIER", 13, 25], ["nephritis", "OBSERVATION", 26, 35], ["penicillin", "OBSERVATION", 49, 59], ["infective", "OBSERVATION_MODIFIER", 64, 73], ["endocarditis", "OBSERVATION", 74, 86]]], ["Aminoglycoside toxicity should also be considered.", [["Aminoglycoside", "CHEMICAL", 0, 14], ["toxicity", "DISEASE", 15, 23], ["Aminoglycoside", "CHEMICAL", 0, 14], ["Aminoglycoside", "SIMPLE_CHEMICAL", 0, 14], ["Aminoglycoside toxicity", "PROBLEM", 0, 23], ["should also be considered", "UNCERTAINTY", 24, 49]]], ["Normal complement levels (C2,3,4) and rapid onset point toward contrast-induced nephropathy.", [["nephropathy", "DISEASE", 80, 91], ["contrast-induced nephropathy", "PROBLEM", 63, 91], ["levels", "OBSERVATION_MODIFIER", 18, 24], ["nephropathy", "OBSERVATION", 80, 91]]], ["Aminoglycoside toxicity usually happens 4-5 days after the therapy.ReferenceMurphy SW, Barrett BJ, Parfrey PS.", [["Aminoglycoside", "CHEMICAL", 0, 14], ["toxicity", "DISEASE", 15, 23], ["Aminoglycoside", "CHEMICAL", 0, 14], ["Aminoglycoside", "SIMPLE_CHEMICAL", 0, 14], ["Aminoglycoside toxicity", "PROBLEM", 0, 23], ["the therapy", "TREATMENT", 55, 66], ["Barrett BJ", "OBSERVATION", 87, 97]]], ["Contrast nephropathy.", [["Contrast nephropathy", "DISEASE", 0, 20], ["Contrast nephropathy", "PROBLEM", 0, 20], ["nephropathy", "OBSERVATION", 9, 20]]], ["J Am Soc Nephrol.", [["Nephrol", "TREATMENT", 9, 16]]], ["A 75-year-old female was admitted to the hospital 3 days prior for community-acquired pneumonia.", [["pneumonia", "DISEASE", 86, 95], ["female", "ORGANISM", 14, 20], ["community-acquired pneumonia", "PROBLEM", 67, 95], ["pneumonia", "OBSERVATION", 86, 95]]], ["She has a history of hypertension, hyperlipidemia, and peripheral vascular disease.", [["peripheral vascular", "ANATOMY", 55, 74], ["hypertension", "DISEASE", 21, 33], ["hyperlipidemia", "DISEASE", 35, 49], ["peripheral vascular disease", "DISEASE", 55, 82], ["peripheral vascular", "MULTI-TISSUE_STRUCTURE", 55, 74], ["hypertension", "PROBLEM", 21, 33], ["hyperlipidemia", "PROBLEM", 35, 49], ["peripheral vascular disease", "PROBLEM", 55, 82], ["hypertension", "OBSERVATION", 21, 33], ["hyperlipidemia", "OBSERVATION", 35, 49], ["peripheral", "ANATOMY_MODIFIER", 55, 65], ["vascular", "ANATOMY", 66, 74], ["disease", "OBSERVATION", 75, 82]]], ["Medications on admission are lisinopril, metoprolol, hydrochlorothiazide, pravastatin, and aspirin.", [["lisinopril", "CHEMICAL", 29, 39], ["metoprolol", "CHEMICAL", 41, 51], ["hydrochlorothiazide", "CHEMICAL", 53, 72], ["pravastatin", "CHEMICAL", 74, 85], ["aspirin", "CHEMICAL", 91, 98], ["lisinopril", "CHEMICAL", 29, 39], ["metoprolol", "CHEMICAL", 41, 51], ["hydrochlorothiazide", "CHEMICAL", 53, 72], ["pravastatin", "CHEMICAL", 74, 85], ["aspirin", "CHEMICAL", 91, 98], ["lisinopril", "SIMPLE_CHEMICAL", 29, 39], ["metoprolol", "SIMPLE_CHEMICAL", 41, 51], ["hydrochlorothiazide", "SIMPLE_CHEMICAL", 53, 72], ["pravastatin", "SIMPLE_CHEMICAL", 74, 85], ["aspirin", "SIMPLE_CHEMICAL", 91, 98], ["Medications", "TREATMENT", 0, 11], ["lisinopril", "TREATMENT", 29, 39], ["metoprolol", "TREATMENT", 41, 51], ["hydrochlorothiazide", "TREATMENT", 53, 72], ["pravastatin", "TREATMENT", 74, 85], ["aspirin", "TREATMENT", 91, 98]]], ["On admission, Zosyn and vancomycin were initiated.", [["Zosyn", "CHEMICAL", 14, 19], ["vancomycin", "CHEMICAL", 24, 34], ["Zosyn", "CHEMICAL", 14, 19], ["vancomycin", "CHEMICAL", 24, 34], ["Zosyn", "SIMPLE_CHEMICAL", 14, 19], ["vancomycin", "SIMPLE_CHEMICAL", 24, 34], ["Zosyn", "TREATMENT", 14, 19], ["vancomycin", "TREATMENT", 24, 34]]], ["She underwent a CT angiogram to rule out pulmonary embolism.", [["pulmonary", "ANATOMY", 41, 50], ["pulmonary embolism", "DISEASE", 41, 59], ["pulmonary", "ORGAN", 41, 50], ["a CT angiogram", "TEST", 14, 28], ["pulmonary embolism", "PROBLEM", 41, 59], ["pulmonary", "ANATOMY", 41, 50], ["embolism", "OBSERVATION", 51, 59]]], ["She is now afebrile.", [["afebrile", "PROBLEM", 11, 19], ["afebrile", "OBSERVATION", 11, 19]]], ["Her blood pressure is 110/55 mmHg.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["Her blood pressure", "TEST", 0, 18]]], ["She has no evidence of orthostasis.", [["orthostasis", "PROBLEM", 23, 34], ["no evidence of", "UNCERTAINTY", 8, 22], ["orthostasis", "OBSERVATION", 23, 34]]], ["Since admission, her respiratory status has improved and her creatinine level has increased from a baseline of 1.5-3.2 mg/dL.", [["respiratory", "ANATOMY", 21, 32], ["creatinine", "CHEMICAL", 61, 71], ["creatinine", "CHEMICAL", 61, 71], ["creatinine", "GENE_OR_GENE_PRODUCT", 61, 71], ["her respiratory status", "PROBLEM", 17, 39], ["her creatinine level", "TEST", 57, 77], ["respiratory", "ANATOMY", 21, 32], ["improved", "OBSERVATION_MODIFIER", 44, 52]]], ["Laboratory studies reveal a urine sodium of 44 mEq.", [["urine", "ANATOMY", 28, 33], ["sodium", "CHEMICAL", 34, 40], ["sodium", "CHEMICAL", 34, 40], ["urine", "ORGANISM_SUBSTANCE", 28, 33], ["Laboratory studies", "TEST", 0, 18], ["urine sodium", "TEST", 28, 40]]], ["Her fractional excretion of sodium is 2 %, and her fractional excretion of urea is 50 %.", [["sodium", "CHEMICAL", 28, 34], ["urea", "CHEMICAL", 75, 79], ["sodium", "CHEMICAL", 28, 34], ["urea", "CHEMICAL", 75, 79], ["sodium", "SIMPLE_CHEMICAL", 28, 34], ["urea", "SIMPLE_CHEMICAL", 75, 79], ["Her fractional excretion of sodium", "TEST", 0, 34], ["her fractional excretion of urea", "TEST", 47, 79]]], ["Which of the following is the most likely cause of this patient's acute renal injury?", [["renal", "ANATOMY", 72, 77], ["acute renal injury", "DISEASE", 66, 84], ["patient", "ORGANISM", 56, 63], ["renal", "ORGAN", 72, 77], ["patient", "SPECIES", 56, 63], ["this patient's acute renal injury", "PROBLEM", 51, 84], ["most likely", "UNCERTAINTY", 30, 41], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["renal", "ANATOMY", 72, 77], ["injury", "OBSERVATION", 78, 84]]], ["A) Cholesterol emboli B) Acute interstitial nephritis C) Prerenal azotemia D) Normotensive ischemic acute kidney injury E) Contrast dye-induced kidney injury Answer: D This patient has normotensive ischemic kidney injury.", [["kidney", "ANATOMY", 106, 112], ["kidney", "ANATOMY", 144, 150], ["kidney", "ANATOMY", 207, 213], ["interstitial nephritis", "DISEASE", 31, 53], ["azotemia", "DISEASE", 66, 74], ["ischemic acute kidney injury", "DISEASE", 91, 119], ["kidney injury", "DISEASE", 144, 157], ["ischemic kidney injury", "DISEASE", 198, 220], ["Cholesterol", "CHEMICAL", 3, 14], ["D", "CHEMICAL", 166, 167], ["kidney", "ORGAN", 106, 112], ["kidney", "ORGAN", 144, 150], ["patient", "ORGANISM", 173, 180], ["kidney", "ORGAN", 207, 213], ["patient", "SPECIES", 173, 180], ["A) Cholesterol emboli B", "PROBLEM", 0, 23], ["Acute interstitial nephritis C", "PROBLEM", 25, 55], ["Prerenal azotemia D", "PROBLEM", 57, 76], ["Normotensive ischemic acute kidney injury E", "PROBLEM", 78, 121], ["Contrast dye-induced kidney injury", "PROBLEM", 123, 157], ["normotensive ischemic kidney injury", "PROBLEM", 185, 220], ["Cholesterol emboli", "OBSERVATION", 3, 21], ["Acute", "OBSERVATION_MODIFIER", 25, 30], ["interstitial", "ANATOMY_MODIFIER", 31, 43], ["nephritis", "OBSERVATION", 44, 53], ["Prerenal", "OBSERVATION_MODIFIER", 57, 65], ["azotemia", "OBSERVATION", 66, 74], ["ischemic", "OBSERVATION_MODIFIER", 91, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["kidney", "ANATOMY", 106, 112], ["injury", "OBSERVATION", 113, 119], ["kidney", "ANATOMY", 144, 150], ["injury", "OBSERVATION", 151, 157], ["normotensive", "OBSERVATION_MODIFIER", 185, 197], ["ischemic", "OBSERVATION_MODIFIER", 198, 206], ["kidney", "ANATOMY", 207, 213], ["injury", "OBSERVATION", 214, 220]]], ["The fi ndings of elevated fractional excretion of sodium, fractional excretion of urea, and granular casts seen on urinalysis are all consistent with this diagnosis.", [["sodium", "CHEMICAL", 50, 56], ["urea", "CHEMICAL", 82, 86], ["sodium", "CHEMICAL", 50, 56], ["urea", "CHEMICAL", 82, 86], ["sodium", "SIMPLE_CHEMICAL", 50, 56], ["urea", "SIMPLE_CHEMICAL", 82, 86], ["elevated fractional excretion of sodium", "PROBLEM", 17, 56], ["fractional excretion of urea", "TEST", 58, 86], ["granular casts", "PROBLEM", 92, 106], ["urinalysis", "TEST", 115, 125], ["elevated", "OBSERVATION_MODIFIER", 17, 25], ["fractional excretion", "OBSERVATION", 26, 46], ["urea", "OBSERVATION_MODIFIER", 82, 86], ["granular casts", "OBSERVATION", 92, 106], ["consistent with", "UNCERTAINTY", 134, 149]]], ["The patient's medical history reveals evidence of an underlying chronic kidney disease possibly due to vascular disease.", [["kidney", "ANATOMY", 72, 78], ["vascular", "ANATOMY", 103, 111], ["chronic kidney disease", "DISEASE", 64, 86], ["vascular disease", "DISEASE", 103, 119], ["patient", "ORGANISM", 4, 11], ["kidney", "ORGAN", 72, 78], ["vascular", "MULTI-TISSUE_STRUCTURE", 103, 111], ["patient", "SPECIES", 4, 11], ["an underlying chronic kidney disease", "PROBLEM", 50, 86], ["vascular disease", "PROBLEM", 103, 119], ["chronic", "OBSERVATION_MODIFIER", 64, 71], ["kidney", "ANATOMY", 72, 78], ["disease", "OBSERVATION", 79, 86], ["possibly due to", "UNCERTAINTY", 87, 102], ["vascular", "ANATOMY", 103, 111], ["disease", "OBSERVATION", 112, 119]]], ["This places the patient at increased risk for normotensive ischemic injury.", [["normotensive ischemic injury", "DISEASE", 46, 74], ["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["normotensive ischemic injury", "PROBLEM", 46, 74], ["normotensive", "OBSERVATION_MODIFIER", 46, 58], ["ischemic", "OBSERVATION_MODIFIER", 59, 67], ["injury", "OBSERVATION", 68, 74]]], ["The patient's lower blood pressure during hospitalization may be the result of a variety of factors, including infection, better medicine compliance, and the low-salt diet typically seen during a hospitalization.", [["blood", "ANATOMY", 20, 25], ["infection", "DISEASE", 111, 120], ["patient", "ORGANISM", 4, 11], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["patient", "SPECIES", 4, 11], ["The patient's lower blood pressure", "TEST", 0, 34], ["infection", "PROBLEM", 111, 120], ["the low-salt diet", "TREATMENT", 154, 171], ["infection", "OBSERVATION", 111, 120]]], ["Acute interstitial nephritis, which is often caused by a hypersensitive reaction to medication, is a possibility.", [["interstitial", "ANATOMY", 6, 18], ["interstitial nephritis", "DISEASE", 6, 28], ["Acute interstitial nephritis", "PROBLEM", 0, 28], ["a hypersensitive reaction", "PROBLEM", 55, 80], ["medication", "TREATMENT", 84, 94], ["interstitial", "ANATOMY_MODIFIER", 6, 18], ["nephritis", "OBSERVATION", 19, 28], ["hypersensitive reaction", "OBSERVATION", 57, 80]]], ["However, the patient's lack of fever, rash, and leukocytes on her urinalysis argues against this diagnosis.", [["leukocytes", "ANATOMY", 48, 58], ["fever", "DISEASE", 31, 36], ["rash", "DISEASE", 38, 42], ["patient", "ORGANISM", 13, 20], ["leukocytes", "CELL", 48, 58], ["leukocytes", "CELL_TYPE", 48, 58], ["patient", "SPECIES", 13, 20], ["fever", "PROBLEM", 31, 36], ["rash", "PROBLEM", 38, 42], ["leukocytes", "PROBLEM", 48, 58], ["her urinalysis", "TEST", 62, 76], ["fever", "OBSERVATION", 31, 36]]], ["Prerenal azotemia is common in the consideration of this patient's differential diagnosis.", [["azotemia", "DISEASE", 9, 17], ["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64], ["Prerenal azotemia", "PROBLEM", 0, 17], ["azotemia", "OBSERVATION", 9, 17]]], ["The patient's fractional excretion of sodium of 2 % and fractional excretion of urea of 50 % argues against this.", [["sodium", "CHEMICAL", 38, 44], ["urea", "CHEMICAL", 80, 84], ["sodium", "CHEMICAL", 38, 44], ["urea", "CHEMICAL", 80, 84], ["patient", "ORGANISM", 4, 11], ["sodium", "SIMPLE_CHEMICAL", 38, 44], ["urea", "SIMPLE_CHEMICAL", 80, 84], ["patient", "SPECIES", 4, 11], ["The patient's fractional excretion of sodium", "TEST", 0, 44], ["fractional excretion of urea", "TEST", 56, 84]]], ["The fractional excretion of urea is a more sensitive test for patients on diuretics.", [["urea", "CHEMICAL", 28, 32], ["urea", "CHEMICAL", 28, 32], ["urea", "SIMPLE_CHEMICAL", 28, 32], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["The fractional excretion of urea", "TEST", 0, 32], ["diuretics", "TREATMENT", 74, 83]]], ["UA is positive with 3+ leukocytes and many bacteria.", [["3+ leukocytes", "ANATOMY", 20, 33], ["UA", "CHEMICAL", 0, 2], ["UA", "SIMPLE_CHEMICAL", 0, 2], ["leukocytes", "CELL", 23, 33], ["leukocytes", "CELL_TYPE", 23, 33], ["UA", "TEST", 0, 2], ["leukocytes", "TEST", 23, 33], ["many bacteria", "PROBLEM", 38, 51], ["positive", "OBSERVATION", 6, 14], ["3+ leukocytes", "OBSERVATION_MODIFIER", 20, 33], ["many", "OBSERVATION_MODIFIER", 38, 42], ["bacteria", "OBSERVATION", 43, 51]]], ["The admitting physician empirically started moxifl oxacin 400 mg IV daily.", [["moxifl oxacin", "CHEMICAL", 44, 57], ["moxifl oxacin", "CHEMICAL", 44, 57], ["moxifl oxacin", "SIMPLE_CHEMICAL", 44, 57], ["moxifl oxacin", "TREATMENT", 44, 57]]], ["Her vital signs are stable, and she seems in no distress.ReferenceWhat would be the next best step?", [["Her vital signs", "TEST", 0, 15], ["distress", "PROBLEM", 48, 56], ["stable", "OBSERVATION_MODIFIER", 20, 26], ["no", "UNCERTAINTY", 45, 47], ["distress", "OBSERVATION", 48, 56]]], ["A) Continue current regimen.", [["current regimen", "TREATMENT", 12, 27]]], ["B) Discontinue moxifl oxacin and start ceftriaxone.", [["moxifl oxacin", "CHEMICAL", 15, 28], ["ceftriaxone", "CHEMICAL", 39, 50], ["moxifl oxacin", "CHEMICAL", 15, 28], ["ceftriaxone", "CHEMICAL", 39, 50], ["moxifl oxacin", "SIMPLE_CHEMICAL", 15, 28], ["ceftriaxone", "SIMPLE_CHEMICAL", 39, 50], ["moxifl oxacin", "TREATMENT", 15, 28], ["ceftriaxone", "TREATMENT", 39, 50]]], ["C) Continue moxifl oxacin but change to PO.", [["moxifl oxacin", "CHEMICAL", 12, 25], ["moxifl oxacin", "CHEMICAL", 12, 25], ["moxifl oxacin", "SIMPLE_CHEMICAL", 12, 25], ["moxifl oxacin", "TREATMENT", 12, 25]]], ["D) None of the above.ReferenceAnswer: B Moxifl oxacin is a quinolone antibiotic that does not achieve adequate concentration in the urine, thereby eliminating its use in the treatment of urinary tract infections.", [["urine", "ANATOMY", 132, 137], ["urinary tract", "ANATOMY", 187, 200], ["Moxifl oxacin", "CHEMICAL", 40, 53], ["quinolone", "CHEMICAL", 59, 68], ["urinary tract infections", "DISEASE", 187, 211], ["quinolone", "CHEMICAL", 59, 68], ["B Moxifl oxacin", "SIMPLE_CHEMICAL", 38, 53], ["quinolone", "SIMPLE_CHEMICAL", 59, 68], ["urine", "ORGANISM_SUBSTANCE", 132, 137], ["urinary tract", "ORGANISM_SUBDIVISION", 187, 200], ["B Moxifl oxacin", "TREATMENT", 38, 53], ["a quinolone antibiotic", "TREATMENT", 57, 79], ["urinary tract infections", "PROBLEM", 187, 211], ["urinary tract", "ANATOMY", 187, 200], ["infections", "OBSERVATION", 201, 211]]], ["It does not matter whether moxifl oxacin is given either oral or IV -the bioavailability of the oral is 100 % and the IV formulation has no ability to concentrate in urine.", [["oral", "ANATOMY", 57, 61], ["oral", "ANATOMY", 96, 100], ["urine", "ANATOMY", 166, 171], ["moxifl oxacin", "CHEMICAL", 27, 40], ["moxifl oxacin", "CHEMICAL", 27, 40], ["moxifl oxacin", "SIMPLE_CHEMICAL", 27, 40], ["oral", "ORGANISM_SUBDIVISION", 57, 61], ["oral", "ORGANISM_SUBDIVISION", 96, 100], ["urine", "ORGANISM_SUBSTANCE", 166, 171], ["moxifl oxacin", "TREATMENT", 27, 40], ["IV", "TREATMENT", 65, 67], ["the IV formulation", "TREATMENT", 114, 132]]], ["You are called in consultation to see a 35-year-old male who was in a motor vehicle accident and underwent surgical repair of a right femur fracture.", [["right femur", "ANATOMY", 128, 139], ["motor vehicle accident", "DISEASE", 70, 92], ["right femur fracture", "DISEASE", 128, 148], ["male", "ORGANISM", 52, 56], ["femur", "ORGAN", 134, 139], ["surgical repair", "TREATMENT", 107, 122], ["a right femur fracture", "PROBLEM", 126, 148], ["surgical repair", "OBSERVATION", 107, 122], ["right", "ANATOMY_MODIFIER", 128, 133], ["femur", "ANATOMY", 134, 139], ["fracture", "OBSERVATION", 140, 148]]], ["Postoperatively, the patient has received acetaminophen and scheduled doses of oral morphine.", [["oral", "ANATOMY", 79, 83], ["acetaminophen", "CHEMICAL", 42, 55], ["morphine", "CHEMICAL", 84, 92], ["acetaminophen", "CHEMICAL", 42, 55], ["morphine", "CHEMICAL", 84, 92], ["patient", "ORGANISM", 21, 28], ["acetaminophen", "SIMPLE_CHEMICAL", 42, 55], ["oral", "ORGANISM_SUBDIVISION", 79, 83], ["morphine", "SIMPLE_CHEMICAL", 84, 92], ["patient", "SPECIES", 21, 28], ["acetaminophen", "TREATMENT", 42, 55], ["oral morphine", "TREATMENT", 79, 92]]], ["He has become acutely agitated and is oriented only to person.", [["person", "SPECIES", 55, 61], ["acutely agitated", "PROBLEM", 14, 30], ["acutely", "OBSERVATION_MODIFIER", 14, 21], ["agitated", "OBSERVATION", 22, 30]]], ["The only admission labs were a complete blood count and a basic metabolic panel, which are normal.", [["blood", "ANATOMY", 40, 45], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["admission labs", "TEST", 9, 23], ["a complete blood count", "TEST", 29, 51], ["a basic metabolic panel", "TEST", 56, 79], ["metabolic panel", "OBSERVATION", 64, 79], ["normal", "OBSERVATION", 91, 97]]], ["On physical examination, his temperature is 39.0 \u00b0C (102.1\u00b0), pulse rate is 110 beats per minute, and respirations are 18 per minute.", [["physical examination", "TEST", 3, 23], ["his temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["pulse rate", "TEST", 62, 72], ["respirations", "TEST", 102, 114]]], ["Blood pressure is 180/90 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["The lungs are clear upon auscultation.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["auscultation", "TEST", 25, 37], ["lungs", "ANATOMY", 4, 9], ["clear", "OBSERVATION", 14, 19], ["auscultation", "OBSERVATION", 25, 37]]], ["There are no signs of infection noted.", [["infection", "DISEASE", 22, 31], ["infection", "PROBLEM", 22, 31], ["no signs of", "UNCERTAINTY", 10, 21], ["infection", "OBSERVATION", 22, 31]]], ["The patient seems agitated with a mild tremor.", [["tremor", "DISEASE", 39, 45], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["agitated", "PROBLEM", 18, 26], ["a mild tremor", "PROBLEM", 32, 45], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["tremor", "OBSERVATION", 39, 45]]], ["He is diaphoretic.ReferenceWhich of the following is the most likely diagnosis?", [["diaphoretic", "PROBLEM", 6, 17], ["diaphoretic", "OBSERVATION", 6, 17], ["most likely", "UNCERTAINTY", 57, 68]]], ["A) Drug-induced delirium from morphine B) Fat emboli C) Alcohol withdrawal D) Pneumonia E) Deep wound infection Answer: C Alcohol use disorders are common and can complicate postoperative recovery.", [["wound", "ANATOMY", 96, 101], ["delirium", "DISEASE", 16, 24], ["morphine", "CHEMICAL", 30, 38], ["Pneumonia", "DISEASE", 78, 87], ["wound infection", "DISEASE", 96, 111], ["Alcohol use disorders", "DISEASE", 122, 143], ["morphine B", "CHEMICAL", 30, 40], ["Drug", "SIMPLE_CHEMICAL", 3, 7], ["morphine B", "SIMPLE_CHEMICAL", 30, 40], ["wound", "PATHOLOGICAL_FORMATION", 96, 101], ["A) Drug-induced delirium", "PROBLEM", 0, 24], ["morphine", "TREATMENT", 30, 38], ["Fat emboli C", "PROBLEM", 42, 54], ["Alcohol withdrawal D) Pneumonia E", "PROBLEM", 56, 89], ["Deep wound infection", "PROBLEM", 91, 111], ["emboli", "OBSERVATION", 46, 52], ["Pneumonia", "OBSERVATION", 78, 87], ["Deep", "ANATOMY_MODIFIER", 91, 95], ["wound", "ANATOMY", 96, 101], ["infection", "OBSERVATION", 102, 111]]], ["In this particular case, the fever, tachycardia, hypertension, and tremor are suggestive of alcohol withdrawal.", [["fever", "DISEASE", 29, 34], ["tachycardia", "DISEASE", 36, 47], ["hypertension", "DISEASE", 49, 61], ["tremor", "DISEASE", 67, 73], ["alcohol", "CHEMICAL", 92, 99], ["alcohol", "CHEMICAL", 92, 99], ["alcohol", "SIMPLE_CHEMICAL", 92, 99], ["the fever", "PROBLEM", 25, 34], ["tachycardia", "PROBLEM", 36, 47], ["hypertension", "PROBLEM", 49, 61], ["tremor", "PROBLEM", 67, 73], ["alcohol withdrawal", "PROBLEM", 92, 110], ["fever", "OBSERVATION", 29, 34], ["hypertension", "OBSERVATION", 49, 61], ["suggestive of", "UNCERTAINTY", 78, 91], ["alcohol withdrawal", "OBSERVATION", 92, 110]]], ["The alcohol level in trauma patients should be checked on admission, as withdrawal is a common source of delirium in this population.", [["alcohol", "CHEMICAL", 4, 11], ["trauma", "DISEASE", 21, 27], ["delirium", "DISEASE", 105, 113], ["alcohol", "CHEMICAL", 4, 11], ["alcohol", "SIMPLE_CHEMICAL", 4, 11], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["The alcohol level", "TEST", 0, 17], ["withdrawal", "PROBLEM", 72, 82], ["delirium", "PROBLEM", 105, 113]]], ["About 9 % of US adults meet the criteria for an alcohol use disorder.", [["alcohol use disorder", "DISEASE", 48, 68], ["alcohol", "CHEMICAL", 48, 55], ["adults", "ORGANISM", 16, 22], ["alcohol", "ORGANISM_SUBDIVISION", 48, 55], ["disorder", "PROBLEM", 60, 68]]], ["Less than 50 % of alcohol-dependent persons develop any signifi cant withdrawal symptoms that require pharmacologic treatment upon cessation of alcohol intake.", [["alcohol", "CHEMICAL", 18, 25], ["alcohol", "CHEMICAL", 144, 151], ["alcohol", "CHEMICAL", 18, 25], ["alcohol", "CHEMICAL", 144, 151], ["alcohol", "SIMPLE_CHEMICAL", 18, 25], ["persons", "ORGANISM", 36, 43], ["alcohol", "SIMPLE_CHEMICAL", 144, 151], ["persons", "SPECIES", 36, 43], ["any signifi cant withdrawal symptoms", "PROBLEM", 52, 88], ["pharmacologic treatment", "TREATMENT", 102, 125]]], ["Minor withdrawal occurs within 6-24 h following the patient's last drink and is characterized by tremor, anxiety, nausea, vomiting, and insomnia.", [["tremor", "DISEASE", 97, 103], ["anxiety", "DISEASE", 105, 112], ["nausea", "DISEASE", 114, 120], ["vomiting", "DISEASE", 122, 130], ["insomnia", "DISEASE", 136, 144], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Minor withdrawal", "PROBLEM", 0, 16], ["tremor", "PROBLEM", 97, 103], ["anxiety", "PROBLEM", 105, 112], ["nausea", "PROBLEM", 114, 120], ["vomiting", "PROBLEM", 122, 130], ["insomnia", "PROBLEM", 136, 144], ["withdrawal", "OBSERVATION", 6, 16], ["tremor", "OBSERVATION", 97, 103]]], ["Major withdrawal occurs 10-72 h after the last drink.", [["Major withdrawal", "PROBLEM", 0, 16], ["withdrawal", "OBSERVATION", 6, 16]]], ["The signs and symptoms include visual and auditory hallucinations, whole body tremor, vomiting, diaphoresis, and hypertension.", [["body", "ANATOMY", 73, 77], ["visual and auditory hallucinations", "DISEASE", 31, 65], ["tremor", "DISEASE", 78, 84], ["vomiting", "DISEASE", 86, 94], ["diaphoresis", "DISEASE", 96, 107], ["hypertension", "DISEASE", 113, 125], ["body", "ORGANISM_SUBDIVISION", 73, 77], ["The signs and symptoms", "PROBLEM", 0, 22], ["visual and auditory hallucinations", "PROBLEM", 31, 65], ["whole body tremor", "PROBLEM", 67, 84], ["vomiting", "PROBLEM", 86, 94], ["diaphoresis", "PROBLEM", 96, 107], ["hypertension", "PROBLEM", 113, 125], ["hypertension", "OBSERVATION", 113, 125]]], ["The most objective and best-validated tool to assess the severity of alcohol withdrawal is the Clinical Institute Withdrawal Assessment for Alcohol.61.A 57-year-old man is admitted for recent onset of fatigue and weakness.", [["alcohol", "CHEMICAL", 69, 76], ["Alcohol", "CHEMICAL", 140, 147], ["fatigue", "DISEASE", 201, 208], ["weakness", "DISEASE", 213, 221], ["alcohol", "CHEMICAL", 69, 76], ["alcohol", "SIMPLE_CHEMICAL", 69, 76], ["man", "ORGANISM", 165, 168], ["man", "SPECIES", 165, 168], ["alcohol withdrawal", "PROBLEM", 69, 87], ["fatigue", "PROBLEM", 201, 208], ["weakness", "PROBLEM", 213, 221], ["fatigue", "OBSERVATION", 201, 208], ["weakness", "OBSERVATION", 213, 221]]], ["He has been seen twice in the past 2 months as an outpatient for similar symptoms with no diagnoses made.", [["similar symptoms", "PROBLEM", 65, 81]]], ["The patient further reports nocturia, polyuria, and weight loss over the past 3 months.", [["nocturia", "DISEASE", 28, 36], ["polyuria", "DISEASE", 38, 46], ["weight loss", "DISEASE", 52, 63], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["nocturia", "PROBLEM", 28, 36], ["polyuria", "PROBLEM", 38, 46], ["weight loss", "PROBLEM", 52, 63], ["nocturia", "OBSERVATION", 28, 36], ["polyuria", "OBSERVATION", 38, 46], ["weight loss", "OBSERVATION_MODIFIER", 52, 63]]], ["He has COPD and a 58-pack-year smoking history.61.On physical examination, the temperature is 36.4 \u00b0C (97.5 \u00b0F), blood pressure is 178/97 mmHg, pulse rate is 86/min, and respiration rate is 24/min.", [["blood", "ANATOMY", 113, 118], ["COPD", "DISEASE", 7, 11], ["blood", "ORGANISM_SUBSTANCE", 113, 118], ["COPD", "PROBLEM", 7, 11], ["physical examination", "TEST", 53, 73], ["the temperature", "TEST", 75, 90], ["\u00b0C", "TEST", 99, 101], ["blood pressure", "TEST", 113, 127], ["pulse rate", "TEST", 144, 154], ["respiration rate", "TEST", 170, 186], ["COPD", "OBSERVATION", 7, 11]]], ["Proximal muscle weakness is noted in the upper and lower extremities.", [["muscle", "ANATOMY", 9, 15], ["upper", "ANATOMY", 41, 46], ["lower extremities", "ANATOMY", 51, 68], ["muscle weakness", "DISEASE", 9, 24], ["muscle", "ORGAN", 9, 15], ["upper", "ORGANISM_SUBDIVISION", 41, 46], ["lower extremities", "ORGANISM_SUBDIVISION", 51, 68], ["Proximal muscle weakness", "PROBLEM", 0, 24], ["muscle", "ANATOMY", 9, 15], ["weakness", "OBSERVATION", 16, 24], ["upper", "ANATOMY_MODIFIER", 41, 46], ["lower extremities", "ANATOMY", 51, 68]]], ["Hyperpigmented mucous membranes are noted.61.Laboratory studies are as follows: creatinine is 1.4 mg/dL, sodium is 149 mEq/L, glucose is 273, urine cortisol is 472ug per 24 h, and ACTH is 257 pg/ml.61.Chest radiographs show hyperinfl ated lung fi elds but no masses.61.Which of the following is the most likely cause of this patient's fi ndings?", [["mucous membranes", "ANATOMY", 15, 31], ["urine", "ANATOMY", 142, 147], ["lung", "ANATOMY", 239, 243], ["masses", "ANATOMY", 259, 265], ["creatinine", "CHEMICAL", 80, 90], ["sodium", "CHEMICAL", 105, 111], ["glucose", "CHEMICAL", 126, 133], ["cortisol", "CHEMICAL", 148, 156], ["creatinine", "CHEMICAL", 80, 90], ["sodium", "CHEMICAL", 105, 111], ["glucose", "CHEMICAL", 126, 133], ["cortisol", "CHEMICAL", 148, 156], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 15, 31], ["creatinine", "SIMPLE_CHEMICAL", 80, 90], ["sodium", "SIMPLE_CHEMICAL", 105, 111], ["glucose", "SIMPLE_CHEMICAL", 126, 133], ["urine", "ORGANISM_SUBSTANCE", 142, 147], ["cortisol", "SIMPLE_CHEMICAL", 148, 156], ["ACTH", "GENE_OR_GENE_PRODUCT", 180, 184], ["lung fi elds", "CANCER", 239, 251], ["masses", "CANCER", 259, 265], ["patient", "ORGANISM", 325, 332], ["patient", "SPECIES", 325, 332], ["Hyperpigmented mucous membranes", "PROBLEM", 0, 31], ["Laboratory studies", "TEST", 45, 63], ["creatinine", "TEST", 80, 90], ["sodium", "TEST", 105, 111], ["glucose", "TEST", 126, 133], ["urine cortisol", "TEST", 142, 156], ["ACTH", "TEST", 180, 184], ["Chest radiographs", "TEST", 201, 218], ["hyperinfl ated lung fi elds", "PROBLEM", 224, 251], ["masses", "PROBLEM", 259, 265], ["mucous membranes", "OBSERVATION", 15, 31], ["hyperinfl", "OBSERVATION", 224, 233], ["lung", "ANATOMY", 239, 243], ["elds", "OBSERVATION", 247, 251], ["no", "UNCERTAINTY", 256, 258], ["masses", "OBSERVATION", 259, 265], ["most likely", "UNCERTAINTY", 299, 310]]], ["A) Adrenal adenoma B) Adrenal carcinoma C) Ectopic ACTH secretion D) Pituitary adenoma E) New onset diabetes Answer: C This patient has Cushing syndrome due to excessive ACTH production.", [["Adrenal adenoma B) Adrenal carcinoma", "ANATOMY", 3, 39], ["Pituitary adenoma", "ANATOMY", 69, 86], ["Adrenal adenoma B", "DISEASE", 3, 20], ["Adrenal carcinoma", "DISEASE", 22, 39], ["Pituitary adenoma", "DISEASE", 69, 86], ["diabetes", "DISEASE", 100, 108], ["Cushing syndrome", "DISEASE", 136, 152], ["Adrenal adenoma B", "CANCER", 3, 20], ["Adrenal carcinoma C", "CANCER", 22, 41], ["patient", "ORGANISM", 124, 131], ["ACTH", "GENE_OR_GENE_PRODUCT", 170, 174], ["patient", "SPECIES", 124, 131], ["A) Adrenal adenoma", "PROBLEM", 0, 18], ["Adrenal carcinoma C", "PROBLEM", 22, 41], ["Ectopic ACTH secretion D)", "PROBLEM", 43, 68], ["Pituitary adenoma E", "PROBLEM", 69, 88], ["New onset diabetes", "PROBLEM", 90, 108], ["Cushing syndrome", "PROBLEM", 136, 152], ["excessive ACTH production", "PROBLEM", 160, 185], ["Adrenal", "ANATOMY", 3, 10], ["adenoma", "OBSERVATION", 11, 18], ["Adrenal", "ANATOMY", 22, 29], ["carcinoma", "OBSERVATION", 30, 39], ["Pituitary", "ANATOMY", 69, 78], ["adenoma", "OBSERVATION", 79, 86]]], ["This is almost certainly due to underlying malignancy such as lung cancer which is the case here.61.Approximately half of all cases of ectopic ACTH secretion are due to small cell lung cancer, which has a long list of paraneoplastic syndromes associated with it.", [["malignancy", "ANATOMY", 43, 53], ["lung cancer", "ANATOMY", 62, 73], ["small cell lung cancer", "ANATOMY", 169, 191], ["malignancy", "DISEASE", 43, 53], ["lung cancer", "DISEASE", 62, 73], ["small cell lung cancer", "DISEASE", 169, 191], ["paraneoplastic syndromes", "DISEASE", 218, 242], ["malignancy", "CANCER", 43, 53], ["lung cancer", "CANCER", 62, 73], ["ACTH", "GENE_OR_GENE_PRODUCT", 143, 147], ["small cell lung cancer", "CANCER", 169, 191], ["underlying malignancy", "PROBLEM", 32, 53], ["lung cancer", "PROBLEM", 62, 73], ["ectopic ACTH secretion", "PROBLEM", 135, 157], ["small cell lung cancer", "PROBLEM", 169, 191], ["paraneoplastic syndromes", "PROBLEM", 218, 242], ["almost certainly due to", "UNCERTAINTY", 8, 31], ["malignancy", "OBSERVATION", 43, 53], ["lung", "ANATOMY", 62, 66], ["cancer", "OBSERVATION", 67, 73], ["ectopic ACTH secretion", "OBSERVATION", 135, 157], ["small", "OBSERVATION_MODIFIER", 169, 174], ["cell", "OBSERVATION", 175, 179], ["lung", "ANATOMY", 180, 184], ["cancer", "OBSERVATION", 185, 191], ["paraneoplastic syndromes", "OBSERVATION", 218, 242]]], ["Adrenal adenomas can be associated with hypercortisolism, but the features tend to cause a mild Cushing syndrome.61.Adrenal adenomas are associated with suppressed ACTH levels.", [["Adrenal adenomas", "ANATOMY", 0, 16], ["Adrenal adenomas", "ANATOMY", 116, 132], ["Adrenal adenomas", "DISEASE", 0, 16], ["hypercortisolism", "DISEASE", 40, 56], ["Cushing syndrome", "DISEASE", 96, 112], ["Adrenal adenomas", "DISEASE", 116, 132], ["Adrenal adenomas", "CANCER", 0, 16], ["Adrenal adenomas", "CANCER", 116, 132], ["ACTH", "GENE_OR_GENE_PRODUCT", 164, 168], ["Adrenal adenomas", "PROBLEM", 0, 16], ["hypercortisolism", "PROBLEM", 40, 56], ["a mild Cushing syndrome", "PROBLEM", 89, 112], ["Adrenal adenomas", "PROBLEM", 116, 132], ["suppressed ACTH levels", "PROBLEM", 153, 175], ["adenomas", "OBSERVATION", 8, 16], ["hypercortisolism", "OBSERVATION", 40, 56], ["mild", "OBSERVATION_MODIFIER", 91, 95], ["Cushing syndrome", "OBSERVATION", 96, 112], ["adenomas", "OBSERVATION", 124, 132], ["suppressed", "OBSERVATION_MODIFIER", 153, 163], ["ACTH levels", "OBSERVATION", 164, 175]]], ["Hyperpigmentation suggests excessive ACTH production.", [["Hyperpigmentation", "DISEASE", 0, 17], ["ACTH", "GENE_OR_GENE_PRODUCT", 37, 41], ["Hyperpigmentation", "PROBLEM", 0, 17], ["excessive ACTH production", "PROBLEM", 27, 52], ["excessive", "OBSERVATION_MODIFIER", 27, 36], ["ACTH production", "OBSERVATION", 37, 52]]], ["A chest radiograph does not rule out the possibility of a lung malignancy and computed topography of the chest is needed.62.A 67-year-old female is admitted to the hospital service with an unexpected syncopal episode.", [["chest", "ANATOMY", 2, 7], ["lung", "ANATOMY", 58, 62], ["chest", "ANATOMY", 105, 110], ["malignancy", "DISEASE", 63, 73], ["syncopal", "DISEASE", 200, 208], ["lung", "ORGAN", 58, 62], ["chest", "ORGAN", 105, 110], ["female", "ORGANISM", 138, 144], ["A chest radiograph", "TEST", 0, 18], ["a lung malignancy", "PROBLEM", 56, 73], ["computed topography of the chest", "TEST", 78, 110], ["an unexpected syncopal episode", "PROBLEM", 186, 216], ["chest", "ANATOMY", 2, 7], ["lung", "ANATOMY", 58, 62], ["malignancy", "OBSERVATION", 63, 73], ["chest", "ANATOMY", 105, 110], ["syncopal episode", "OBSERVATION", 200, 216]]], ["There are no factors to suggest a vasovagal episode.", [["vasovagal", "DISEASE", 34, 43], ["a vasovagal episode", "PROBLEM", 32, 51], ["no factors to suggest", "UNCERTAINTY", 10, 31], ["vasovagal episode", "OBSERVATION", 34, 51]]], ["She reports worsening shortness of breath with exertion over the past 3 months.", [["shortness of breath", "DISEASE", 22, 41], ["worsening shortness of breath", "PROBLEM", 12, 41], ["worsening", "OBSERVATION_MODIFIER", 12, 21]]], ["Physical exam is pertinent for a 3/6 systolic crescendo-decrescendo murmur at the left sternal border with radiation to the carotids.", [["left sternal border", "ANATOMY", 82, 101], ["carotids", "ANATOMY", 124, 132], ["carotids", "CANCER", 124, 132], ["Physical exam", "TEST", 0, 13], ["decrescendo murmur at the left sternal border", "PROBLEM", 56, 101], ["crescendo", "OBSERVATION", 46, 55], ["decrescendo murmur", "OBSERVATION", 56, 74], ["left", "ANATOMY_MODIFIER", 82, 86], ["sternal", "ANATOMY", 87, 94], ["border", "ANATOMY_MODIFIER", 95, 101], ["radiation", "OBSERVATION", 107, 116], ["carotids", "ANATOMY", 124, 132]]], ["You suspect aortic stenosis as the cause of the syncope and order a 2D cardiac echo with color fl ow Doppler.", [["aortic", "ANATOMY", 12, 18], ["cardiac", "ANATOMY", 71, 78], ["aortic stenosis", "DISEASE", 12, 27], ["syncope", "DISEASE", 48, 55], ["aortic", "MULTI-TISSUE_STRUCTURE", 12, 18], ["aortic stenosis", "PROBLEM", 12, 27], ["the syncope", "PROBLEM", 44, 55], ["a 2D cardiac echo", "TEST", 66, 83], ["color fl ow Doppler", "TEST", 89, 108], ["aortic", "ANATOMY", 12, 18], ["stenosis", "OBSERVATION", 19, 27]]], ["Results of the 2D echo indicate aortic stenosis.62.Which of the following are indications to refer your patient for evaluation for aortic valve replacement?", [["aortic", "ANATOMY", 32, 38], ["aortic valve", "ANATOMY", 131, 143], ["aortic stenosis", "DISEASE", 32, 47], ["aortic", "MULTI-TISSUE_STRUCTURE", 32, 38], ["patient", "ORGANISM", 104, 111], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 131, 143], ["patient", "SPECIES", 104, 111], ["the 2D echo", "TEST", 11, 22], ["aortic stenosis", "PROBLEM", 32, 47], ["evaluation", "TEST", 116, 126], ["aortic valve replacement", "TREATMENT", 131, 155], ["aortic", "ANATOMY", 32, 38], ["stenosis", "OBSERVATION", 39, 47], ["aortic valve", "ANATOMY", 131, 143], ["replacement", "OBSERVATION", 144, 155]]], ["A) Exertional dyspnea B) Aortic valve mean pressure gradient of 40 mmHg or higher C) Aortic stenosis in the setting of LVEF less than 50 % D) All of the above E) A and B Answer: D Aortic valve replacement is recommended for symptomatic patients with severe aortic stenosis.", [["Aortic valve", "ANATOMY", 25, 37], ["Aortic", "ANATOMY", 85, 91], ["Aortic valve", "ANATOMY", 180, 192], ["aortic", "ANATOMY", 257, 263], ["dyspnea", "DISEASE", 14, 21], ["Aortic stenosis", "DISEASE", 85, 100], ["aortic stenosis", "DISEASE", 257, 272], ["Aortic", "MULTI-TISSUE_STRUCTURE", 85, 91], ["valve", "MULTI-TISSUE_STRUCTURE", 187, 192], ["patients", "ORGANISM", 236, 244], ["aortic", "MULTI-TISSUE_STRUCTURE", 257, 263], ["patients", "SPECIES", 236, 244], ["A) Exertional dyspnea", "PROBLEM", 0, 21], ["Aortic valve mean pressure gradient", "TEST", 25, 60], ["higher C) Aortic stenosis", "PROBLEM", 75, 100], ["LVEF", "TEST", 119, 123], ["D Aortic valve replacement", "TREATMENT", 178, 204], ["severe aortic stenosis", "PROBLEM", 250, 272], ["Exertional", "OBSERVATION_MODIFIER", 3, 13], ["dyspnea", "OBSERVATION", 14, 21], ["Aortic valve", "ANATOMY", 25, 37], ["Aortic", "ANATOMY", 85, 91], ["stenosis", "OBSERVATION", 92, 100], ["Aortic valve", "ANATOMY", 180, 192], ["replacement", "OBSERVATION", 193, 204], ["severe", "OBSERVATION_MODIFIER", 250, 256], ["aortic", "ANATOMY", 257, 263], ["stenosis", "OBSERVATION", 264, 272]]], ["Severe aortic stenosis is defi ned as an aortic velocity 4.0 m per second or greater or by a mean pressure gradient 40 mmHg or higher.", [["aortic", "ANATOMY", 7, 13], ["aortic", "ANATOMY", 41, 47], ["aortic stenosis", "DISEASE", 7, 22], ["aortic", "MULTI-TISSUE_STRUCTURE", 7, 13], ["aortic", "MULTI-TISSUE_STRUCTURE", 41, 47], ["Severe aortic stenosis", "PROBLEM", 0, 22], ["an aortic velocity", "TEST", 38, 56], ["a mean pressure gradient", "TEST", 91, 115], ["aortic", "ANATOMY", 7, 13], ["stenosis", "OBSERVATION", 14, 22], ["aortic", "ANATOMY", 41, 47], ["velocity", "OBSERVATION_MODIFIER", 48, 56], ["greater", "OBSERVATION_MODIFIER", 77, 84], ["higher", "OBSERVATION_MODIFIER", 127, 133]]], ["Symptoms of heart failure, syncope, exertional dyspnea, angina, or presyncope by history or on exercise testing are also indications.", [["heart", "ANATOMY", 12, 17], ["heart failure", "DISEASE", 12, 25], ["syncope", "DISEASE", 27, 34], ["exertional dyspnea", "DISEASE", 36, 54], ["angina", "DISEASE", 56, 62], ["presyncope", "DISEASE", 67, 77], ["heart", "ORGAN", 12, 17], ["Symptoms", "PROBLEM", 0, 8], ["heart failure", "PROBLEM", 12, 25], ["syncope", "PROBLEM", 27, 34], ["exertional dyspnea", "PROBLEM", 36, 54], ["angina", "PROBLEM", 56, 62], ["presyncope", "PROBLEM", 67, 77], ["exercise testing", "TEST", 95, 111], ["heart", "ANATOMY", 12, 17], ["failure", "OBSERVATION", 18, 25], ["exertional", "OBSERVATION_MODIFIER", 36, 46], ["dyspnea", "OBSERVATION", 47, 54], ["angina", "OBSERVATION", 56, 62]]], ["Hemoglobin concentration is 10.5 g/dL, leukocyte count is 15,600/\u03bcL, and urinalysis reveals 50-75 leukocytes/hpf and many bacteria/hpf.", [["leukocyte", "ANATOMY", 39, 48], ["leukocytes", "ANATOMY", 98, 108], ["Hemoglobin", "GENE_OR_GENE_PRODUCT", 0, 10], ["leukocyte", "CELL", 39, 48], ["leukocytes", "CELL", 98, 108], ["Hemoglobin", "PROTEIN", 0, 10], ["leukocytes", "CELL_TYPE", 98, 108], ["Hemoglobin concentration", "TEST", 0, 24], ["leukocyte count", "TEST", 39, 54], ["urinalysis", "TEST", 73, 83], ["leukocytes", "TEST", 98, 108], ["hpf", "TEST", 109, 112], ["many bacteria/hpf", "PROBLEM", 117, 134], ["many", "OBSERVATION_MODIFIER", 117, 121], ["bacteria", "OBSERVATION", 122, 130]]], ["The patient has an increase anion gap metabolic acidosis.", [["acidosis", "DISEASE", 48, 56], ["patient", "ORGANISM", 4, 11], ["anion", "SIMPLE_CHEMICAL", 28, 33], ["patient", "SPECIES", 4, 11], ["an increase anion gap metabolic acidosis", "PROBLEM", 16, 56], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["anion gap", "OBSERVATION", 28, 37], ["metabolic acidosis", "OBSERVATION", 38, 56]]], ["The patient is admitted to the intensive care unit and antibiotic therapy is started.ReferenceWhich of the following in the next goal of therapy?", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["antibiotic therapy", "TREATMENT", 55, 73], ["therapy", "TREATMENT", 137, 144]]], ["A) Aggressive fl uid resuscitation B) Hemodynamic monitoring with a pulmonary artery catheter C) Maintaining hemoglobin concentration above 12 g/ dL (120 g/L) D) Maintaining PCO 2 below 50 mmHg E) Vasopressor therapy Answer: A The patient has severe sepsis from pyelonephritis.", [["pulmonary artery", "ANATOMY", 68, 84], ["sepsis", "DISEASE", 250, 256], ["pyelonephritis", "DISEASE", 262, 276], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 68, 84], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 109, 119], ["patient", "ORGANISM", 231, 238], ["hemoglobin", "PROTEIN", 109, 119], ["patient", "SPECIES", 231, 238], ["Aggressive fl uid resuscitation", "TREATMENT", 3, 34], ["Hemodynamic monitoring", "TEST", 38, 60], ["a pulmonary artery catheter C", "TREATMENT", 66, 95], ["hemoglobin concentration", "TEST", 109, 133], ["PCO", "TEST", 174, 177], ["Vasopressor therapy", "TREATMENT", 197, 216], ["severe sepsis", "PROBLEM", 243, 256], ["pyelonephritis", "PROBLEM", 262, 276], ["pulmonary artery", "ANATOMY", 68, 84], ["catheter", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 243, 249], ["sepsis", "OBSERVATION", 250, 256], ["pyelonephritis", "OBSERVATION", 262, 276]]], ["Aggressive fl uid resuscitation is indicated.", [["Aggressive fl uid resuscitation", "TREATMENT", 0, 31]]], ["Resolution of lactic acidosis within 6 h will have a benefi cial effect on this patient's survival.", [["lactic acidosis", "DISEASE", 14, 29], ["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["lactic acidosis", "PROBLEM", 14, 29], ["a benefi cial effect", "TREATMENT", 51, 71], ["this patient's survival", "TREATMENT", 75, 98], ["lactic acidosis", "OBSERVATION", 14, 29]]], ["Resuscitation of the circulation should target a central venous oxygen saturation or mixed venous oxygen saturation of at least 70 %.", [["venous", "ANATOMY", 57, 63], ["venous", "ANATOMY", 91, 97], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 98, 104], ["venous", "MULTI-TISSUE_STRUCTURE", 57, 63], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["Resuscitation", "TREATMENT", 0, 13], ["a central venous oxygen saturation", "TEST", 47, 81], ["mixed venous oxygen saturation", "TEST", 85, 115], ["central", "ANATOMY_MODIFIER", 49, 56], ["venous", "ANATOMY", 57, 63], ["oxygen saturation", "OBSERVATION", 64, 81], ["venous", "ANATOMY", 91, 97], ["oxygen saturation", "OBSERVATION", 98, 115]]], ["Other goals include a central venous pressure of 8-12 mmHg, a mean arterial pressure of at least 65 mmHg, and a urine output of at least 0.5 mL/kg/h.", [["venous", "ANATOMY", 30, 36], ["arterial", "ANATOMY", 67, 75], ["urine", "ANATOMY", 112, 117], ["venous", "MULTI-TISSUE_STRUCTURE", 30, 36], ["arterial", "MULTI-TISSUE_STRUCTURE", 67, 75], ["urine", "ORGANISM_SUBSTANCE", 112, 117], ["a central venous pressure", "TEST", 20, 45], ["a mean arterial pressure", "TEST", 60, 84], ["a urine output", "TEST", 110, 124], ["central", "ANATOMY_MODIFIER", 22, 29], ["venous", "ANATOMY", 30, 36], ["pressure", "OBSERVATION_MODIFIER", 37, 45], ["urine output", "OBSERVATION", 112, 124]]], ["Fluid requirements are often as much as 5-6 L of fl uid.", [["Fluid requirements", "TEST", 0, 18]]], ["Early goal-directed therapy sees the most benefi ts within the fi rst 6 h.", [["Early goal-directed therapy", "TREATMENT", 0, 27]]], ["End points that improve survival include maintaining a SCVO 2 of greater than 70 % and resolution of lactic acidosis.", [["lactic acidosis", "DISEASE", 101, 116], ["a SCVO", "TEST", 53, 59], ["lactic acidosis", "PROBLEM", 101, 116], ["lactic acidosis", "OBSERVATION", 101, 116]]], ["Blood transfusion may be part of resuscitation for anemic patients in shock.", [["Blood", "ANATOMY", 0, 5], ["anemic", "DISEASE", 51, 57], ["shock", "DISEASE", 70, 75], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Blood transfusion", "TREATMENT", 0, 17], ["resuscitation", "TREATMENT", 33, 46], ["anemic patients", "PROBLEM", 51, 66], ["shock", "PROBLEM", 70, 75], ["shock", "OBSERVATION", 70, 75]]], ["In stable patients who have not had major blood loss or further blood loss is anticipated, a transfusion threshold of 7 g/dL is an acceptable approach.", [["blood", "ANATOMY", 42, 47], ["blood", "ANATOMY", 64, 69], ["blood loss", "DISEASE", 42, 52], ["blood loss", "DISEASE", 64, 74], ["patients", "ORGANISM", 10, 18], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["patients", "SPECIES", 10, 18], ["major blood loss", "PROBLEM", 36, 52], ["further blood loss", "PROBLEM", 56, 74], ["a transfusion threshold", "TREATMENT", 91, 114], ["stable", "OBSERVATION_MODIFIER", 3, 9]]], ["There are no data to support that maintaining a lower PCO 2 is of any benefi t.", [["PCO", "DISEASE", 54, 57], ["no", "UNCERTAINTY", 10, 12]]], ["In addition placement of a pulmonary artery catheter would help to increase survival in this patient.", [["pulmonary artery", "ANATOMY", 27, 43], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 27, 43], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["a pulmonary artery catheter", "TREATMENT", 25, 52], ["pulmonary artery", "ANATOMY", 27, 43], ["catheter", "OBSERVATION", 44, 52]]], ["Which of the following statements regarding neurally mediated syncope is TRUE?", [["syncope", "DISEASE", 62, 69], ["neurally mediated syncope", "PROBLEM", 44, 69]]], ["A) Neurally mediated syncope occurs when there are abnormalities of the autonomic nervous system.", [["autonomic nervous system", "ANATOMY", 72, 96], ["syncope", "DISEASE", 21, 28], ["abnormalities of the autonomic nervous system", "DISEASE", 51, 96], ["autonomic nervous system", "ANATOMICAL_SYSTEM", 72, 96], ["Neurally mediated syncope", "PROBLEM", 3, 28], ["abnormalities of the autonomic nervous system", "PROBLEM", 51, 96], ["syncope", "OBSERVATION", 21, 28], ["autonomic nervous", "ANATOMY", 72, 89]]], ["B) Myoclonus does not occur during neurally mediated syncope.", [["syncope", "DISEASE", 53, 60], ["Myoclonus", "PROBLEM", 3, 12], ["neurally mediated syncope", "PROBLEM", 35, 60], ["Myoclonus", "OBSERVATION", 3, 12], ["syncope", "OBSERVATION", 53, 60]]], ["C) The fi nal pathway of neurally mediated syncope results in a surge of the sympathetic nervous system with inhibition of the parasympathetic nervous system.", [["sympathetic nervous system", "ANATOMY", 77, 103], ["parasympathetic nervous system", "ANATOMY", 127, 157], ["syncope", "DISEASE", 43, 50], ["fi nal", "GENE_OR_GENE_PRODUCT", 7, 13], ["sympathetic nervous system", "ANATOMICAL_SYSTEM", 77, 103], ["parasympathetic nervous system", "ANATOMICAL_SYSTEM", 127, 157], ["neurally mediated syncope", "PROBLEM", 25, 50], ["the parasympathetic nervous system", "PROBLEM", 123, 157], ["sympathetic nervous", "ANATOMY", 77, 96], ["parasympathetic nervous", "ANATOMY", 127, 150]]], ["D) The usual fi nding with cardiovascular monitoring is hypotension and tachycardia.", [["cardiovascular", "ANATOMY", 27, 41], ["hypotension", "DISEASE", 56, 67], ["tachycardia", "DISEASE", 72, 83], ["cardiovascular", "MULTI-TISSUE_STRUCTURE", 27, 41], ["cardiovascular monitoring", "TEST", 27, 52], ["hypotension", "PROBLEM", 56, 67], ["tachycardia", "PROBLEM", 72, 83], ["hypotension", "OBSERVATION", 56, 67]]], ["E) The primary therapy for neurally mediated syncope is reassurance, avoidance of triggers, and plasma volume expansion.ReferenceAnswer: E Syncope accounts for 3 % of all emergency department visits and 1 % of all hospitalizations.", [["plasma", "ANATOMY", 96, 102], ["syncope", "DISEASE", 45, 52], ["Syncope", "DISEASE", 139, 146], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["The primary therapy", "TREATMENT", 3, 22], ["neurally mediated syncope", "PROBLEM", 27, 52], ["plasma volume expansion", "TEST", 96, 119], ["Syncope", "PROBLEM", 139, 146]]], ["Additionally, it is estimated that 35 % of all individuals will experience at least one syncopal event in their lifetime.", [["syncopal", "DISEASE", 88, 96]]], ["Currently, no specifi c testing has suffi cient power to be recommended for evaluation of syncope.", [["syncope", "DISEASE", 90, 97], ["specifi c testing", "TEST", 14, 31], ["evaluation", "TEST", 76, 86], ["syncope", "PROBLEM", 90, 97], ["no", "UNCERTAINTY", 11, 13], ["syncope", "OBSERVATION", 90, 97]]], ["Syncope occurs when blood fl ow to the brain suddenly drops.ReferenceVasovagal syncope is one category without a clearly defi ned mechanism but can occur with intense emotions, strong odors, or orthostatic factors.", [["blood", "ANATOMY", 20, 25], ["brain", "ANATOMY", 39, 44], ["Syncope", "DISEASE", 0, 7], ["syncope", "DISEASE", 79, 86], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["brain", "ORGAN", 39, 44], ["orthostatic factors", "PROTEIN", 194, 213], ["Syncope", "PROBLEM", 0, 7], ["blood fl", "TEST", 20, 28], ["ReferenceVasovagal syncope", "PROBLEM", 60, 86], ["strong odors", "PROBLEM", 177, 189], ["orthostatic factors", "PROBLEM", 194, 213], ["brain", "ANATOMY", 39, 44]]], ["Neurally mediated syncope can be brought about by specifi c mechanical events such as cough, micturition, swallowing, or carotid sensitivity.", [["carotid", "ANATOMY", 121, 128], ["syncope", "DISEASE", 18, 25], ["cough", "DISEASE", 86, 91], ["carotid", "MULTI-TISSUE_STRUCTURE", 121, 128], ["Neurally mediated syncope", "PROBLEM", 0, 25], ["mechanical events", "PROBLEM", 60, 77], ["cough, micturition, swallowing", "PROBLEM", 86, 116], ["carotid sensitivity", "PROBLEM", 121, 140], ["syncope", "OBSERVATION", 18, 25], ["carotid", "ANATOMY", 121, 128]]], ["Reassurance and avoidance of triggers are the primary treatments.", [["Reassurance", "TREATMENT", 0, 11], ["the primary treatments", "TREATMENT", 42, 64]]], ["Liberal intake of fl uids and salt and prevention of dehydration are protective against all forms of syncopal events.", [["fl uids", "CHEMICAL", 18, 25], ["salt", "CHEMICAL", 30, 34], ["dehydration", "DISEASE", 53, 64], ["syncopal", "DISEASE", 101, 109], ["salt", "SIMPLE_CHEMICAL", 30, 34], ["fl uids", "TREATMENT", 18, 25], ["salt", "TREATMENT", 30, 34], ["dehydration", "PROBLEM", 53, 64], ["syncopal events", "PROBLEM", 101, 116]]], ["In randomized controlled trials, isometric counterpressure maneuvers are also protective.", [["randomized controlled trials", "TREATMENT", 3, 31], ["isometric counterpressure maneuvers", "TREATMENT", 33, 68]]], ["In patients with refractory syncope, fl udrocortisone, beta-blockers, and other vasoconstricting agents have been used with limited success.", [["syncope", "DISEASE", 28, 35], ["udrocortisone", "CHEMICAL", 40, 53], ["beta-blockers", "CHEMICAL", 55, 68], ["udrocortisone", "CHEMICAL", 40, 53], ["patients", "ORGANISM", 3, 11], ["fl udrocortisone", "SIMPLE_CHEMICAL", 37, 53], ["beta-blockers", "SIMPLE_CHEMICAL", 55, 68], ["patients", "SPECIES", 3, 11], ["refractory syncope", "PROBLEM", 17, 35], ["fl udrocortisone", "TREATMENT", 37, 53], ["beta-blockers", "TREATMENT", 55, 68], ["other vasoconstricting agents", "TREATMENT", 74, 103], ["refractory", "OBSERVATION_MODIFIER", 17, 27], ["syncope", "OBSERVATION", 28, 35]]], ["However, there are no clinical trial data to support their use.65.A 56-year-old woman who is listed for liver transplantation due to hepatitis C and portal hypertension is admitted for worsening ascites.", [["liver", "ANATOMY", 104, 109], ["ascites", "ANATOMY", 195, 202], ["hepatitis C", "DISEASE", 133, 144], ["portal hypertension", "DISEASE", 149, 168], ["ascites", "DISEASE", 195, 202], ["woman", "ORGANISM", 80, 85], ["liver", "ORGAN", 104, 109], ["portal", "MULTI-TISSUE_STRUCTURE", 149, 155], ["woman", "SPECIES", 80, 85], ["liver transplantation", "TREATMENT", 104, 125], ["hepatitis C", "PROBLEM", 133, 144], ["portal hypertension", "PROBLEM", 149, 168], ["worsening ascites", "PROBLEM", 185, 202], ["no", "UNCERTAINTY", 19, 21], ["liver", "ANATOMY", 104, 109], ["transplantation", "OBSERVATION", 110, 125], ["hepatitis", "OBSERVATION", 133, 142], ["portal", "ANATOMY", 149, 155], ["hypertension", "OBSERVATION", 156, 168], ["worsening", "OBSERVATION_MODIFIER", 185, 194], ["ascites", "OBSERVATION", 195, 202]]], ["She has had required one uncomplicated, large-volume paracentesis during the past 5 months.", [["large-volume paracentesis", "TREATMENT", 40, 65], ["large", "OBSERVATION_MODIFIER", 40, 45], ["-volume", "OBSERVATION_MODIFIER", 45, 52], ["paracentesis", "OBSERVATION", 53, 65]]], ["Her current medications are furosemide 40 mg daily and spironolactone 100 mg daily.", [["furosemide", "CHEMICAL", 28, 38], ["spironolactone", "CHEMICAL", 55, 69], ["furosemide", "CHEMICAL", 28, 38], ["spironolactone", "CHEMICAL", 55, 69], ["furosemide", "SIMPLE_CHEMICAL", 28, 38], ["spironolactone", "SIMPLE_CHEMICAL", 55, 69], ["Her current medications", "TREATMENT", 0, 23], ["furosemide", "TREATMENT", 28, 38], ["spironolactone", "TREATMENT", 55, 69]]], ["She adheres to a daily diet containing less than 2000 mg of sodium and 2 L of free water.", [["sodium", "CHEMICAL", 60, 66], ["sodium", "CHEMICAL", 60, 66], ["She", "ORGANISM", 0, 3], ["sodium", "SIMPLE_CHEMICAL", 60, 66], ["sodium", "TREATMENT", 60, 66], ["free water", "TREATMENT", 78, 88]]], ["On physical exam, her blood pressure is 115/78 mmHg.", [["blood", "ANATOMY", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["physical exam", "TEST", 3, 16], ["her blood pressure", "TEST", 18, 36]]], ["She has mild muscle wasting.", [["muscle", "ANATOMY", 13, 19], ["muscle wasting", "DISEASE", 13, 27], ["muscle", "ORGAN", 13, 19], ["mild muscle wasting", "PROBLEM", 8, 27], ["mild", "OBSERVATION_MODIFIER", 8, 12], ["muscle", "ANATOMY", 13, 19], ["wasting", "OBSERVATION", 20, 27]]], ["A prominent second heart sound is noted on cardiac auscultation.", [["heart", "ANATOMY", 19, 24], ["cardiac", "ANATOMY", 43, 50], ["heart", "ORGAN", 19, 24], ["cardiac", "ORGAN", 43, 50], ["A prominent second heart sound", "PROBLEM", 0, 30], ["cardiac auscultation", "TEST", 43, 63], ["prominent", "OBSERVATION_MODIFIER", 2, 11], ["second", "OBSERVATION_MODIFIER", 12, 18], ["heart", "ANATOMY", 19, 24], ["sound", "OBSERVATION", 25, 30], ["cardiac", "ANATOMY", 43, 50], ["auscultation", "OBSERVATION", 51, 63]]], ["The abdomen is protuberant with moderate ascites.", [["abdomen", "ANATOMY", 4, 11], ["ascites", "ANATOMY", 41, 48], ["ascites", "DISEASE", 41, 48], ["abdomen", "ORGAN", 4, 11], ["protuberant", "PROBLEM", 15, 26], ["moderate ascites", "PROBLEM", 32, 48], ["abdomen", "ANATOMY", 4, 11], ["protuberant", "OBSERVATION", 15, 26], ["moderate", "OBSERVATION_MODIFIER", 32, 40], ["ascites", "OBSERVATION", 41, 48]]], ["No tenderness is noted.", [["tenderness", "DISEASE", 3, 13], ["tenderness", "PROBLEM", 3, 13], ["tenderness", "OBSERVATION", 3, 13]]], ["No lower extremity edema is evident, and the patient exhibits no confusion or asterixis.65.Her sodium is 132 mmol/L, creatinine is 1.4 mg/dl.", [["lower extremity edema", "ANATOMY", 3, 24], ["edema", "DISEASE", 19, 24], ["confusion", "DISEASE", 65, 74], ["asterixis", "DISEASE", 78, 87], ["sodium", "CHEMICAL", 95, 101], ["creatinine", "CHEMICAL", 117, 127], ["sodium", "CHEMICAL", 95, 101], ["creatinine", "CHEMICAL", 117, 127], ["lower extremity", "ORGANISM_SUBDIVISION", 3, 18], ["edema", "PATHOLOGICAL_FORMATION", 19, 24], ["patient", "ORGANISM", 45, 52], ["sodium", "SIMPLE_CHEMICAL", 95, 101], ["creatinine", "SIMPLE_CHEMICAL", 117, 127], ["patient", "SPECIES", 45, 52], ["lower extremity edema", "PROBLEM", 3, 24], ["confusion", "PROBLEM", 65, 74], ["asterixis", "PROBLEM", 78, 87], ["Her sodium", "TEST", 91, 101], ["creatinine", "TEST", 117, 127], ["lower", "ANATOMY_MODIFIER", 3, 8], ["extremity", "ANATOMY", 9, 18], ["edema", "OBSERVATION", 19, 24], ["no", "UNCERTAINTY", 62, 64], ["confusion", "OBSERVATION", 65, 74], ["asterixis", "OBSERVATION", 78, 87]]], ["Which of the following is the correct approach to treat this patients worsening ascites?", [["ascites", "ANATOMY", 80, 87], ["ascites", "DISEASE", 80, 87], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["this patients worsening ascites", "PROBLEM", 56, 87], ["worsening", "OBSERVATION_MODIFIER", 70, 79], ["ascites", "OBSERVATION", 80, 87]]], ["A) Adjust fl uid restriction to 1.5 L daily B) Antibiotics for possible bacterial peritonitis C) Continue serial paracenteses with albumin infusions D) Refer for transjugular intrahepatic portosystemic shunt E) Increase furosemide and spironolactone65.Answer: E It would be reasonable to try an increased diuretic dose in this patient.", [["peritonitis", "DISEASE", 82, 93], ["furosemide", "CHEMICAL", 220, 230], ["spironolactone65", "CHEMICAL", 235, 251], ["furosemide", "CHEMICAL", 220, 230], ["spironolactone65", "CHEMICAL", 235, 251], ["albumin", "SIMPLE_CHEMICAL", 131, 138], ["furosemide", "SIMPLE_CHEMICAL", 220, 230], ["spironolactone65", "SIMPLE_CHEMICAL", 235, 251], ["patient", "ORGANISM", 327, 334], ["patient", "SPECIES", 327, 334], ["A) Adjust fl uid restriction", "TREATMENT", 0, 28], ["Antibiotics", "TREATMENT", 47, 58], ["bacterial peritonitis", "PROBLEM", 72, 93], ["serial paracenteses", "TREATMENT", 106, 125], ["albumin infusions D", "TREATMENT", 131, 150], ["transjugular intrahepatic portosystemic shunt E", "TREATMENT", 162, 209], ["furosemide", "TREATMENT", 220, 230], ["spironolactone65", "TREATMENT", 235, 251], ["an increased diuretic dose", "TREATMENT", 292, 318], ["peritonitis", "OBSERVATION", 82, 93], ["intrahepatic", "ANATOMY_MODIFIER", 175, 187]]], ["The recommended initial regimen is furosemide 40 mg plus spironolactone 100 mg daily.", [["furosemide", "CHEMICAL", 35, 45], ["spironolactone", "CHEMICAL", 57, 71], ["furosemide", "CHEMICAL", 35, 45], ["spironolactone", "CHEMICAL", 57, 71], ["furosemide", "SIMPLE_CHEMICAL", 35, 45], ["spironolactone", "SIMPLE_CHEMICAL", 57, 71], ["initial regimen", "TREATMENT", 16, 31], ["furosemide", "TREATMENT", 35, 45], ["spironolactone", "TREATMENT", 57, 71]]], ["This patient is not at the maximum diuretic dose.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["the maximum diuretic dose", "TREATMENT", 23, 48]]], ["Diuretics can be increased every 3-5 days, while maintaining the 40:100 mg ratio.", [["Diuretics", "TREATMENT", 0, 9]]], ["In ascites due to end-stage liver disease, the maximum dose for furosemide is 160 mg daily and for spironolactone it is 400 mg daily.", [["ascites", "ANATOMY", 3, 10], ["liver", "ANATOMY", 28, 33], ["ascites", "DISEASE", 3, 10], ["end-stage liver disease", "DISEASE", 18, 41], ["furosemide", "CHEMICAL", 64, 74], ["spironolactone", "CHEMICAL", 99, 113], ["furosemide", "CHEMICAL", 64, 74], ["spironolactone", "CHEMICAL", 99, 113], ["liver", "ORGAN", 28, 33], ["furosemide", "SIMPLE_CHEMICAL", 64, 74], ["spironolactone", "SIMPLE_CHEMICAL", 99, 113], ["ascites", "PROBLEM", 3, 10], ["end-stage liver disease", "PROBLEM", 18, 41], ["furosemide", "TREATMENT", 64, 74], ["spironolactone", "TREATMENT", 99, 113], ["ascites", "OBSERVATION", 3, 10], ["end", "OBSERVATION_MODIFIER", 18, 21], ["-stage", "OBSERVATION_MODIFIER", 21, 27], ["liver", "ANATOMY", 28, 33], ["disease", "OBSERVATION", 34, 41]]], ["At the higher doses, decreasing effi cacy will be seen.", [["decreasing effi cacy", "PROBLEM", 21, 41], ["decreasing", "OBSERVATION_MODIFIER", 21, 31]]], ["As the total diuretic dose is increased, it can be given once daily or divided as twice daily dosing.", [["the total diuretic dose", "TREATMENT", 3, 26]]], ["Serum electrolytes and renal function tests should be carefully monitored as dose adjustments are made.", [["Serum", "ANATOMY", 0, 5], ["renal", "ANATOMY", 23, 28], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["renal", "ORGAN", 23, 28], ["Serum electrolytes", "TEST", 0, 18], ["renal function tests", "TEST", 23, 43], ["renal", "ANATOMY", 23, 28]]], ["The patient should discontinue diuretic therapy if the serum sodium decreases to less than 120 mmol/L, uncontrolled or recurrent encephalopathy develops, or the serum creatinine exceeds 2.0 mg/dL.", [["serum", "ANATOMY", 55, 60], ["serum", "ANATOMY", 161, 166], ["sodium", "CHEMICAL", 61, 67], ["encephalopathy", "DISEASE", 129, 143], ["creatinine", "CHEMICAL", 167, 177], ["sodium", "CHEMICAL", 61, 67], ["creatinine", "CHEMICAL", 167, 177], ["patient", "ORGANISM", 4, 11], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["sodium", "SIMPLE_CHEMICAL", 61, 67], ["serum", "ORGANISM_SUBSTANCE", 161, 166], ["creatinine", "SIMPLE_CHEMICAL", 167, 177], ["patient", "SPECIES", 4, 11], ["diuretic therapy", "TREATMENT", 31, 47], ["the serum sodium", "TEST", 51, 67], ["recurrent encephalopathy", "PROBLEM", 119, 143], ["the serum creatinine", "TEST", 157, 177], ["recurrent", "OBSERVATION_MODIFIER", 119, 128], ["encephalopathy", "OBSERVATION", 129, 143]]], ["She has a history of prior dementia.", [["dementia", "DISEASE", 27, 35], ["prior dementia", "PROBLEM", 21, 35], ["dementia", "OBSERVATION", 27, 35]]], ["On her previous admissions, she has had episodes of delirium, which have resulted in prolonged hospitalization.", [["delirium", "DISEASE", 52, 60], ["delirium", "PROBLEM", 52, 60], ["delirium", "OBSERVATION", 52, 60]]], ["On admission she is on no sedatives or antipsychotic meds.", [["sedatives", "TREATMENT", 26, 35], ["antipsychotic meds", "TREATMENT", 39, 57]]], ["The family is concerned about the possibility of hospitalinduced delirium and would like efforts be made to prevent this.ReferenceIn an effort to reduce the incidence of delirium in this patient, which of the following should you undertake?", [["delirium", "DISEASE", 65, 73], ["delirium", "DISEASE", 170, 178], ["patient", "ORGANISM", 187, 194], ["patient", "SPECIES", 187, 194], ["hospitalinduced delirium", "PROBLEM", 49, 73], ["delirium", "PROBLEM", 170, 178], ["delirium", "OBSERVATION", 170, 178]]], ["A) Nighttime use of melatonin B) Mobilizing patient to the chair early C) Prophylactic use of rivastigmine D) Maintaining lights on for visual stimulation Answer: B Delirium is a common problem in the hospitalized patient, especially with a history of underlying dementia or psychiatric disease.", [["melatonin B", "CHEMICAL", 20, 31], ["rivastigmine", "CHEMICAL", 94, 106], ["Delirium", "DISEASE", 165, 173], ["dementia", "DISEASE", 263, 271], ["psychiatric disease", "DISEASE", 275, 294], ["melatonin B", "CHEMICAL", 20, 31], ["rivastigmine D", "CHEMICAL", 94, 108], ["patient", "ORGANISM", 44, 51], ["rivastigmine D", "SIMPLE_CHEMICAL", 94, 108], ["patient", "ORGANISM", 214, 221], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 214, 221], ["melatonin B)", "TREATMENT", 20, 32], ["rivastigmine D", "TREATMENT", 94, 108], ["visual stimulation", "TREATMENT", 136, 154], ["Delirium", "PROBLEM", 165, 173], ["underlying dementia", "PROBLEM", 252, 271], ["psychiatric disease", "PROBLEM", 275, 294], ["dementia", "OBSERVATION", 263, 271], ["psychiatric disease", "OBSERVATION", 275, 294]]], ["So far, only simple interventions focused on maintaining normal environmental issues have been proven to be of any benefi t.", [["simple interventions", "TREATMENT", 13, 33]]], ["These include promoting sleep by decreasing nighttime stimuli, use of hearing aids and eyeglasses, and minimizing restraints.", [["decreasing nighttime stimuli", "TREATMENT", 33, 61], ["hearing aids", "TREATMENT", 70, 82], ["eyeglasses", "TREATMENT", 87, 97], ["restraints", "TREATMENT", 114, 124]]], ["One study showed a reduction of sound during the night by using earplugs in patients in the ICU setting resulted in a decreased risk of delirium by 53 %.", [["delirium", "DISEASE", 136, 144], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["One study", "TEST", 0, 9], ["a reduction of sound", "PROBLEM", 17, 37], ["earplugs", "TREATMENT", 64, 72], ["a decreased risk of delirium", "PROBLEM", 116, 144], ["reduction", "OBSERVATION_MODIFIER", 19, 28], ["sound", "OBSERVATION_MODIFIER", 32, 37]]], ["Family can play a role in decreasing delirium.", [["delirium", "DISEASE", 37, 45], ["decreasing delirium", "PROBLEM", 26, 45]]], ["They can assist in orienting and reassuring the patient.", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["There are no defi nitive studies that demonstrate the use of any prophylactic medicines, such as haloperidol or risperidone, provides any benefi t.", [["haloperidol", "CHEMICAL", 97, 108], ["risperidone", "CHEMICAL", 112, 123], ["haloperidol", "CHEMICAL", 97, 108], ["risperidone", "CHEMICAL", 112, 123], ["haloperidol", "SIMPLE_CHEMICAL", 97, 108], ["risperidone", "SIMPLE_CHEMICAL", 112, 123], ["defi nitive studies", "TEST", 13, 32], ["any prophylactic medicines", "TREATMENT", 61, 87], ["haloperidol", "TREATMENT", 97, 108], ["risperidone", "TREATMENT", 112, 123], ["no", "UNCERTAINTY", 10, 12]]], ["The use of these and other sedatives should be minimized.", [["these and other sedatives", "TREATMENT", 11, 36]]], ["Pain can contribute to delirium as well as the excessive use of narcotics.", [["Pain", "DISEASE", 0, 4], ["delirium", "DISEASE", 23, 31], ["narcotics", "SIMPLE_CHEMICAL", 64, 73], ["Pain", "PROBLEM", 0, 4], ["delirium", "PROBLEM", 23, 31], ["narcotics", "TREATMENT", 64, 73], ["delirium", "OBSERVATION", 23, 31]]], ["Rivastigmine has been shown to worsen delirium in the hospitalized patient.", [["Rivastigmine", "CHEMICAL", 0, 12], ["delirium", "DISEASE", 38, 46], ["Rivastigmine", "CHEMICAL", 0, 12], ["Rivastigmine", "SIMPLE_CHEMICAL", 0, 12], ["patient", "ORGANISM", 67, 74], ["patient", "SPECIES", 67, 74], ["Rivastigmine", "TREATMENT", 0, 12], ["delirium", "PROBLEM", 38, 46]]], ["Melatonin has had no clear clinical benefi t in reduction of delirium.", [["Melatonin", "CHEMICAL", 0, 9], ["delirium", "DISEASE", 61, 69], ["Melatonin", "CHEMICAL", 0, 9], ["Melatonin", "SIMPLE_CHEMICAL", 0, 9], ["Melatonin", "TREATMENT", 0, 9], ["delirium", "PROBLEM", 61, 69], ["no", "UNCERTAINTY", 18, 20], ["delirium", "OBSERVATION", 61, 69]]], ["Early physical and occupational therapy may also be of some benefi t.ReferenceInouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients.", [["delirium", "DISEASE", 166, 174], ["patients", "ORGANISM", 197, 205], ["patients", "SPECIES", 197, 205], ["occupational therapy", "TREATMENT", 19, 39], ["A multicomponent intervention", "TREATMENT", 125, 154], ["delirium", "PROBLEM", 166, 174]]], ["A 62-year-old male has been admitted for diabetic foot ulcer and associated cellulitis for the past 4 weeks.", [["foot ulcer", "ANATOMY", 50, 60], ["diabetic foot ulcer", "DISEASE", 41, 60], ["cellulitis", "DISEASE", 76, 86], ["male", "ORGANISM", 14, 18], ["foot", "ORGANISM_SUBDIVISION", 50, 54], ["ulcer", "PATHOLOGICAL_FORMATION", 55, 60], ["diabetic foot ulcer", "PROBLEM", 41, 60], ["associated cellulitis", "PROBLEM", 65, 86], ["diabetic", "OBSERVATION_MODIFIER", 41, 49], ["foot", "ANATOMY", 50, 54], ["ulcer", "OBSERVATION", 55, 60], ["cellulitis", "OBSERVATION", 76, 86]]], ["He has chronic diabetic kidney disease, hypertension, and type 1 diabetes mellitus.", [["kidney", "ANATOMY", 24, 30], ["diabetic kidney disease", "DISEASE", 15, 38], ["hypertension", "DISEASE", 40, 52], ["type 1 diabetes mellitus", "DISEASE", 58, 82], ["kidney", "ORGAN", 24, 30], ["chronic diabetic kidney disease", "PROBLEM", 7, 38], ["hypertension", "PROBLEM", 40, 52], ["type 1 diabetes mellitus", "PROBLEM", 58, 82], ["chronic", "OBSERVATION_MODIFIER", 7, 14], ["diabetic", "OBSERVATION", 15, 23], ["kidney", "ANATOMY", 24, 30], ["disease", "OBSERVATION", 31, 38], ["hypertension", "OBSERVATION", 40, 52], ["diabetes mellitus", "OBSERVATION", 65, 82]]], ["Medications are metformin, insulin, and lisinopril.", [["metformin", "CHEMICAL", 16, 25], ["lisinopril", "CHEMICAL", 40, 50], ["metformin", "CHEMICAL", 16, 25], ["lisinopril", "CHEMICAL", 40, 50], ["metformin", "SIMPLE_CHEMICAL", 16, 25], ["insulin", "GENE_OR_GENE_PRODUCT", 27, 34], ["lisinopril", "SIMPLE_CHEMICAL", 40, 50], ["Medications", "TREATMENT", 0, 11], ["metformin", "TREATMENT", 16, 25], ["insulin", "TREATMENT", 27, 34], ["lisinopril", "TREATMENT", 40, 50]]], ["He is started on vancomycin and ciprofl oxacin.", [["vancomycin", "CHEMICAL", 17, 27], ["ciprofl oxacin", "CHEMICAL", 32, 46], ["vancomycin", "CHEMICAL", 17, 27], ["ciprofl oxacin", "CHEMICAL", 32, 46], ["vancomycin", "SIMPLE_CHEMICAL", 17, 27], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 32, 46], ["vancomycin", "TREATMENT", 17, 27], ["ciprofl oxacin", "TREATMENT", 32, 46]]], ["On physical examination, blood pressure is 145/90 mmHg.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["physical examination", "TEST", 3, 23], ["blood pressure", "TEST", 25, 39]]], ["An area of erythema extends about 3 cm around a 3 \u00d7 3 cm ulcer on the right great toe.", [["ulcer", "ANATOMY", 57, 62], ["right great toe", "ANATOMY", 70, 85], ["erythema", "DISEASE", 11, 19], ["ulcer", "DISEASE", 57, 62], ["erythema", "PATHOLOGICAL_FORMATION", 11, 19], ["ulcer", "PATHOLOGICAL_FORMATION", 57, 62], ["toe", "ORGANISM_SUBDIVISION", 82, 85], ["erythema", "PROBLEM", 11, 19], ["a 3 \u00d7 3 cm ulcer on the right great toe", "PROBLEM", 46, 85], ["area", "OBSERVATION_MODIFIER", 3, 7], ["erythema", "OBSERVATION", 11, 19], ["3 cm", "OBSERVATION_MODIFIER", 34, 38], ["3 \u00d7 3 cm", "OBSERVATION_MODIFIER", 48, 56], ["ulcer", "OBSERVATION", 57, 62], ["right", "ANATOMY_MODIFIER", 70, 75], ["great toe", "ANATOMY", 76, 85]]], ["The area involved is tender warm and fl uctuant.ReferenceLaboratory studies reveal an albumin of 2.9 g/dL, and a serum creatinine of 4.1 mg/dL.", [["area", "ANATOMY", 4, 8], ["serum", "ANATOMY", 113, 118], ["creatinine", "CHEMICAL", 119, 129], ["creatinine", "CHEMICAL", 119, 129], ["albumin", "GENE_OR_GENE_PRODUCT", 86, 93], ["serum", "ORGANISM_SUBSTANCE", 113, 118], ["creatinine", "SIMPLE_CHEMICAL", 119, 129], ["tender", "PROBLEM", 21, 27], ["ReferenceLaboratory studies", "TEST", 48, 75], ["an albumin", "TEST", 83, 93], ["a serum creatinine", "TEST", 111, 129], ["tender", "OBSERVATION_MODIFIER", 21, 27], ["warm", "OBSERVATION", 28, 32], ["fl uctuant", "OBSERVATION", 37, 47], ["albumin", "OBSERVATION", 86, 93]]], ["For acute renal failure, complement levels are checked and they are low.", [["renal", "ANATOMY", 10, 15], ["acute renal failure", "DISEASE", 4, 23], ["renal", "ORGAN", 10, 15], ["acute renal failure", "PROBLEM", 4, 23], ["complement levels", "TEST", 25, 42], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["renal", "ANATOMY", 10, 15], ["failure", "OBSERVATION", 16, 23], ["low", "OBSERVATION_MODIFIER", 68, 71]]], ["Urine studies show a urine sodium of 15 mEq/L. Urinalysis reveals 25 erythrocytes per HPF and 1-2 erythrocyte casts.ReferenceWhich of the following is the most likely cause of this patient's acute kidney injury?", [["Urine", "ANATOMY", 0, 5], ["urine", "ANATOMY", 21, 26], ["erythrocytes", "ANATOMY", 69, 81], ["erythrocyte", "ANATOMY", 98, 109], ["kidney", "ANATOMY", 197, 203], ["sodium", "CHEMICAL", 27, 33], ["acute kidney injury", "DISEASE", 191, 210], ["sodium", "CHEMICAL", 27, 33], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 21, 26], ["sodium", "SIMPLE_CHEMICAL", 27, 33], ["erythrocytes", "CELL", 69, 81], ["erythrocyte", "CELL", 98, 109], ["patient", "ORGANISM", 181, 188], ["kidney", "ORGAN", 197, 203], ["patient", "SPECIES", 181, 188], ["Urine studies", "TEST", 0, 13], ["a urine sodium", "TEST", 19, 33], ["Urinalysis", "TEST", 47, 57], ["erythrocytes", "TEST", 69, 81], ["HPF", "TEST", 86, 89], ["erythrocyte casts", "TEST", 98, 115], ["this patient's acute kidney injury", "PROBLEM", 176, 210], ["25 erythrocytes", "OBSERVATION_MODIFIER", 66, 81], ["erythrocyte casts", "OBSERVATION", 98, 115], ["most likely", "UNCERTAINTY", 155, 166], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["kidney", "ANATOMY", 197, 203], ["injury", "OBSERVATION", 204, 210]]], ["A) Diabetic nephropathy B) IgA nephropathy C) Post-infectious glomerulonephritis D) Membranous glomerulonephritis E) Drug-induced acute renal failure Answer: C This patient has post-infectious glomerulonephritis (PIGN).ReferencePIGN presents as an acute nephritic syndrome characterized by rapid onset of edema, hypertension, oliguria, and erythrocyte casts seen in the urine sediment.", [["renal", "ANATOMY", 136, 141], ["edema", "ANATOMY", 305, 310], ["erythrocyte", "ANATOMY", 340, 351], ["urine sediment", "ANATOMY", 370, 384], ["Diabetic nephropathy B", "DISEASE", 3, 25], ["nephropathy", "DISEASE", 31, 42], ["glomerulonephritis", "DISEASE", 62, 80], ["glomerulonephritis", "DISEASE", 95, 113], ["acute renal failure", "DISEASE", 130, 149], ["glomerulonephritis", "DISEASE", 193, 211], ["PIGN", "DISEASE", 213, 217], ["nephritic syndrome", "DISEASE", 254, 272], ["edema", "DISEASE", 305, 310], ["hypertension", "DISEASE", 312, 324], ["oliguria", "DISEASE", 326, 334], ["renal", "ORGAN", 136, 141], ["patient", "ORGANISM", 165, 172], ["PIGN", "CANCER", 213, 217], ["edema", "PATHOLOGICAL_FORMATION", 305, 310], ["erythrocyte", "CELL", 340, 351], ["urine sediment", "ORGANISM_SUBSTANCE", 370, 384], ["patient", "SPECIES", 165, 172], ["A) Diabetic nephropathy", "PROBLEM", 0, 23], ["IgA nephropathy C", "PROBLEM", 27, 44], ["Post-infectious glomerulonephritis D", "PROBLEM", 46, 82], ["Membranous glomerulonephritis E", "PROBLEM", 84, 115], ["acute renal failure", "PROBLEM", 130, 149], ["post-infectious glomerulonephritis", "PROBLEM", 177, 211], ["an acute nephritic syndrome", "PROBLEM", 245, 272], ["edema", "PROBLEM", 305, 310], ["hypertension", "PROBLEM", 312, 324], ["oliguria", "PROBLEM", 326, 334], ["erythrocyte casts", "PROBLEM", 340, 357], ["the urine sediment", "PROBLEM", 366, 384], ["Diabetic", "OBSERVATION_MODIFIER", 3, 11], ["nephropathy", "OBSERVATION", 12, 23], ["infectious", "OBSERVATION_MODIFIER", 51, 61], ["glomerulonephritis", "OBSERVATION", 62, 80], ["Membranous", "OBSERVATION_MODIFIER", 84, 94], ["glomerulonephritis", "OBSERVATION", 95, 113], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["renal", "ANATOMY", 136, 141], ["failure", "OBSERVATION", 142, 149], ["post-infectious", "OBSERVATION_MODIFIER", 177, 192], ["glomerulonephritis", "OBSERVATION", 193, 211], ["acute", "OBSERVATION_MODIFIER", 248, 253], ["nephritic", "OBSERVATION", 254, 263], ["rapid", "OBSERVATION_MODIFIER", 290, 295], ["onset", "OBSERVATION_MODIFIER", 296, 301], ["edema", "OBSERVATION", 305, 310], ["hypertension", "OBSERVATION", 312, 324], ["oliguria", "OBSERVATION", 326, 334], ["erythrocyte casts", "OBSERVATION", 340, 357], ["urine sediment", "OBSERVATION", 370, 384]]], ["Low complement levels further suggest the exudative proliferative glomerulonephritis patterns can be seen by light microscopy on biopsy specimens.", [["biopsy specimens", "ANATOMY", 129, 145], ["glomerulonephritis", "DISEASE", 66, 84], ["biopsy specimens", "CANCER", 129, 145], ["Low complement levels", "PROBLEM", 0, 21], ["the exudative proliferative glomerulonephritis patterns", "PROBLEM", 38, 93], ["light microscopy", "TEST", 109, 125], ["biopsy specimens", "TEST", 129, 145], ["exudative", "OBSERVATION_MODIFIER", 42, 51], ["proliferative", "OBSERVATION_MODIFIER", 52, 65], ["glomerulonephritis", "OBSERVATION", 66, 84]]], ["Diabetic nephropathy does not explain the onset of this patient's acute kidney injury.", [["kidney", "ANATOMY", 72, 78], ["Diabetic nephropathy", "DISEASE", 0, 20], ["acute kidney injury", "DISEASE", 66, 85], ["patient", "ORGANISM", 56, 63], ["kidney", "ORGAN", 72, 78], ["patient", "SPECIES", 56, 63], ["Diabetic nephropathy", "PROBLEM", 0, 20], ["this patient's acute kidney injury", "PROBLEM", 51, 85], ["nephropathy", "OBSERVATION", 9, 20], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["kidney", "ANATOMY", 72, 78], ["injury", "OBSERVATION", 79, 85]]], ["The decline of the glomerular fi ltration is predictable and usually no greater than 12-16 mL/min/1.73 m 2 per year.", [["glomerular", "ANATOMY", 19, 29], ["glomerular", "TISSUE", 19, 29], ["the glomerular fi ltration", "TEST", 15, 41], ["glomerular fi", "ANATOMY", 19, 32], ["predictable", "OBSERVATION_MODIFIER", 45, 56]]], ["Patients with IgA nephropathy may present with an episode of acute renal injury precipitated by infection.", [["renal", "ANATOMY", 67, 72], ["IgA nephropathy", "DISEASE", 14, 29], ["acute renal injury", "DISEASE", 61, 79], ["infection", "DISEASE", 96, 105], ["Patients", "ORGANISM", 0, 8], ["IgA", "GENE_OR_GENE_PRODUCT", 14, 17], ["renal", "ORGAN", 67, 72], ["Patients", "SPECIES", 0, 8], ["IgA nephropathy", "PROBLEM", 14, 29], ["acute renal injury", "PROBLEM", 61, 79], ["infection", "PROBLEM", 96, 105], ["IgA nephropathy", "OBSERVATION", 14, 29], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["renal", "ANATOMY", 67, 72], ["injury", "OBSERVATION", 73, 79], ["infection", "OBSERVATION", 96, 105]]], ["Gross hematuria is often seen.", [["hematuria", "DISEASE", 6, 15], ["Gross hematuria", "PROBLEM", 0, 15], ["hematuria", "OBSERVATION", 6, 15]]], ["Adult patients with primary membranous glomerulonephritis frequently present with a nephritic picture.", [["primary membranous glomerulonephritis", "DISEASE", 20, 57], ["nephritic", "DISEASE", 84, 93], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["primary membranous glomerulonephritis", "PROBLEM", 20, 57], ["a nephritic picture", "PROBLEM", 82, 101], ["primary", "OBSERVATION_MODIFIER", 20, 27], ["membranous", "OBSERVATION_MODIFIER", 28, 38], ["glomerulonephritis", "OBSERVATION", 39, 57], ["nephritic", "OBSERVATION", 84, 93]]], ["In these patients, the urine sediment can be active and reveal granular casts.", [["urine sediment", "ANATOMY", 23, 37], ["patients", "ORGANISM", 9, 17], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["patients", "SPECIES", 9, 17], ["the urine sediment", "TEST", 19, 37], ["granular casts", "PROBLEM", 63, 77], ["sediment", "OBSERVATION", 29, 37], ["granular casts", "OBSERVATION", 63, 77]]], ["Erythrocyte casts are not seen.", [["Erythrocyte", "ANATOMY", 0, 11], ["Erythrocyte", "CELL", 0, 11], ["Erythrocyte casts", "TEST", 0, 17], ["casts", "OBSERVATION", 12, 17], ["not seen", "UNCERTAINTY", 22, 30]]], ["In addition, complement levels are normal.", [["complement levels", "TEST", 13, 30], ["normal", "OBSERVATION", 35, 41]]], ["It has been suggested that PIGN was the cause of death of the composer Wolfgang Amadeus Mozart.", [["death", "DISEASE", 49, 54], ["PIGN", "GENE_OR_GENE_PRODUCT", 27, 31], ["PIGN", "TREATMENT", 27, 31], ["death", "PROBLEM", 49, 54]]], ["A 60-year-old male with end-stage liver disease was admitted for shortness of breath.", [["liver", "ANATOMY", 34, 39], ["end-stage liver disease", "DISEASE", 24, 47], ["shortness of breath", "DISEASE", 65, 84], ["male", "ORGANISM", 14, 18], ["liver", "ORGAN", 34, 39], ["end-stage liver disease", "PROBLEM", 24, 47], ["shortness of breath", "PROBLEM", 65, 84], ["-stage", "OBSERVATION_MODIFIER", 27, 33], ["liver", "ANATOMY", 34, 39], ["disease", "OBSERVATION", 40, 47]]], ["He reports progressive ascites over the past few weeks and a low-grade temperature.", [["ascites", "ANATOMY", 23, 30], ["ascites", "DISEASE", 23, 30], ["progressive ascites", "PROBLEM", 11, 30], ["a low-grade temperature", "PROBLEM", 59, 82], ["progressive", "OBSERVATION_MODIFIER", 11, 22], ["ascites", "OBSERVATION", 23, 30], ["low-grade", "OBSERVATION_MODIFIER", 61, 70], ["temperature", "OBSERVATION_MODIFIER", 71, 82]]], ["On physical exam, his lungs are clear upon auscultation.", [["lungs", "ANATOMY", 22, 27], ["lungs", "ORGAN", 22, 27], ["physical exam", "TEST", 3, 16], ["auscultation", "TEST", 43, 55], ["lungs", "ANATOMY", 22, 27], ["clear", "OBSERVATION", 32, 37]]], ["The abdomen is tender and distended.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["tender", "PROBLEM", 15, 21], ["distended", "PROBLEM", 26, 35], ["abdomen", "ANATOMY", 4, 11], ["tender", "OBSERVATION", 15, 21], ["distended", "OBSERVATION", 26, 35]]], ["Oxygenation is 84 % by pulse oximetry, which improves slightly to 87 % with 5 l of oxygen.", [["oxygen", "CHEMICAL", 83, 89], ["oxygen", "CHEMICAL", 83, 89], ["oxygen", "SIMPLE_CHEMICAL", 83, 89], ["Oxygenation", "TEST", 0, 11], ["pulse oximetry", "TEST", 23, 37], ["oxygen", "TREATMENT", 83, 89], ["slightly", "OBSERVATION_MODIFIER", 54, 62]]], ["Chest X-ray reveals lung fi elds without infi ltrate or pleural effusions.", [["lung", "ANATOMY", 20, 24], ["pleural effusions", "ANATOMY", 56, 73], ["pleural effusions", "DISEASE", 56, 73], ["lung fi elds", "CANCER", 20, 32], ["pleural effusions", "CANCER", 56, 73], ["Chest X-ray", "TEST", 0, 11], ["lung fi elds", "PROBLEM", 20, 32], ["infi ltrate", "PROBLEM", 41, 52], ["pleural effusions", "PROBLEM", 56, 73], ["lung", "ANATOMY", 20, 24], ["without", "UNCERTAINTY", 33, 40], ["pleural", "ANATOMY", 56, 63], ["effusions", "OBSERVATION", 64, 73]]], ["Computed tomography reveals no evidence of pulmonary embolism.ReferencesParacentesis is performed which reveals a white blood cell count of 1,500 WBCs, of which 58 are neutrophils.", [["pulmonary", "ANATOMY", 43, 52], ["white blood cell", "ANATOMY", 114, 130], ["WBCs", "ANATOMY", 146, 150], ["neutrophils", "ANATOMY", 168, 179], ["pulmonary embolism", "DISEASE", 43, 61], ["pulmonary", "ORGAN", 43, 52], ["blood cell", "CELL", 120, 130], ["WBCs", "CELL", 146, 150], ["neutrophils", "CELL", 168, 179], ["neutrophils", "CELL_TYPE", 168, 179], ["Computed tomography", "TEST", 0, 19], ["pulmonary embolism", "PROBLEM", 43, 61], ["Paracentesis", "TREATMENT", 72, 84], ["a white blood cell count", "TEST", 112, 136], ["WBCs", "TEST", 146, 150], ["neutrophils", "TEST", 168, 179], ["no evidence of", "UNCERTAINTY", 28, 42], ["pulmonary", "ANATOMY", 43, 52], ["embolism", "OBSERVATION", 53, 61]]], ["The patient is started on antibiotics.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["antibiotics", "TREATMENT", 26, 37]]], ["Two days later, the patient continues with shortness of breath and marked hypoxia.", [["shortness of breath", "DISEASE", 43, 62], ["hypoxia", "DISEASE", 74, 81], ["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["shortness of breath", "PROBLEM", 43, 62], ["marked hypoxia", "PROBLEM", 67, 81], ["marked", "OBSERVATION_MODIFIER", 67, 73], ["hypoxia", "OBSERVATION", 74, 81]]], ["Pulse oximetry is 93 % when supine but decreases to 84 % when sitting.ReferencesWhich of the following studies is most likely to confi rm patient's cause of hypoxia?", [["hypoxia", "DISEASE", 157, 164], ["patient", "ORGANISM", 138, 145], ["patient", "SPECIES", 138, 145], ["Pulse oximetry", "TEST", 0, 14], ["the following studies", "TEST", 89, 110], ["hypoxia", "PROBLEM", 157, 164], ["most likely", "UNCERTAINTY", 114, 125], ["hypoxia", "OBSERVATION", 157, 164]]], ["A) Ventilation perfusion scan of the lungs B) High contrast CT scan of the chest C) Pulmonary arteriography D) Lung biopsies E) Echocardiography with saline bubble contrast Answer: E This patient has hepatopulmonary syndrome.", [["lungs", "ANATOMY", 37, 42], ["chest", "ANATOMY", 75, 80], ["Pulmonary", "ANATOMY", 84, 93], ["Lung", "ANATOMY", 111, 115], ["hepatopulmonary", "ANATOMY", 200, 215], ["hepatopulmonary syndrome", "DISEASE", 200, 224], ["patient", "ORGANISM", 188, 195], ["patient", "SPECIES", 188, 195], ["A) Ventilation perfusion scan of the lungs", "TEST", 0, 42], ["High contrast CT scan of the chest C", "TEST", 46, 82], ["Pulmonary arteriography", "TEST", 84, 107], ["Lung biopsies E", "TEST", 111, 126], ["Echocardiography with saline bubble contrast", "TEST", 128, 172], ["hepatopulmonary syndrome", "PROBLEM", 200, 224], ["lungs", "ANATOMY", 37, 42], ["chest", "ANATOMY", 75, 80], ["Pulmonary", "ANATOMY", 84, 93], ["Lung", "ANATOMY", 111, 115], ["hepatopulmonary", "ANATOMY", 200, 215], ["syndrome", "OBSERVATION", 216, 224]]], ["In these cases, contrast-or bubble-enhanced echocardiography will reveal a intrapulmonary shunt.", [["intrapulmonary", "ANATOMY", 75, 89], ["contrast", "TEST", 16, 24], ["bubble-enhanced echocardiography", "TEST", 28, 60], ["a intrapulmonary shunt", "TREATMENT", 73, 95], ["intrapulmonary", "ANATOMY", 75, 89], ["shunt", "OBSERVATION", 90, 95]]], ["Hepatopulmonary syndrome is associated with platypnea, which is increased dyspnea in the upright position, and orthodeoxia, which is increased hypoxia when transitioning from the lying to the standing position.", [["platypnea", "ANATOMY", 44, 53], ["Hepatopulmonary syndrome", "DISEASE", 0, 24], ["platypnea", "DISEASE", 44, 53], ["dyspnea", "DISEASE", 74, 81], ["orthodeoxia", "DISEASE", 111, 122], ["hypoxia", "DISEASE", 143, 150], ["Hepatopulmonary syndrome", "PROBLEM", 0, 24], ["platypnea", "PROBLEM", 44, 53], ["increased dyspnea", "PROBLEM", 64, 81], ["orthodeoxia", "PROBLEM", 111, 122], ["increased hypoxia", "PROBLEM", 133, 150], ["syndrome", "OBSERVATION", 16, 24], ["associated with", "UNCERTAINTY", 28, 43], ["platypnea", "OBSERVATION", 44, 53], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["dyspnea", "OBSERVATION", 74, 81], ["upright position", "OBSERVATION_MODIFIER", 89, 105], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["hypoxia", "OBSERVATION", 143, 150]]], ["Hypoxemia, in this case due to intrapulmonary shunt, is not signifi cantly affected by an increase in inhaled O 2 concentration.", [["intrapulmonary", "ANATOMY", 31, 45], ["Hypoxemia", "DISEASE", 0, 9], ["O 2", "CHEMICAL", 110, 113], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 31, 45], ["inhaled O 2", "SIMPLE_CHEMICAL", 102, 113], ["Hypoxemia", "PROBLEM", 0, 9], ["intrapulmonary shunt", "TREATMENT", 31, 51], ["intrapulmonary", "ANATOMY", 31, 45], ["shunt", "OBSERVATION", 46, 51], ["increase", "OBSERVATION_MODIFIER", 90, 98]]], ["This syndrome may resolve with liver transplantation and does not exclude the patient from being considered for transplant.ReferenceRodriguez-Roisin R, Krowka MJ.", [["liver", "ANATOMY", 31, 36], ["liver", "ORGAN", 31, 36], ["patient", "ORGANISM", 78, 85], ["patient", "SPECIES", 78, 85], ["This syndrome", "PROBLEM", 0, 13], ["liver transplantation", "TREATMENT", 31, 52], ["transplant", "TREATMENT", 112, 122], ["ReferenceRodriguez", "TEST", 123, 141], ["liver", "ANATOMY", 31, 36], ["transplantation", "OBSERVATION", 37, 52]]], ["Hepatopulmonary syndrome -a liver-induced lung vascular disorder.", [["liver", "ANATOMY", 28, 33], ["lung vascular", "ANATOMY", 42, 55], ["Hepatopulmonary syndrome", "DISEASE", 0, 24], ["lung vascular disorder", "DISEASE", 42, 64], ["liver", "ORGAN", 28, 33], ["lung vascular", "MULTI-TISSUE_STRUCTURE", 42, 55], ["Hepatopulmonary syndrome", "PROBLEM", 0, 24], ["a liver-induced lung vascular disorder", "PROBLEM", 26, 64], ["syndrome", "OBSERVATION", 16, 24], ["liver", "ANATOMY", 28, 33], ["lung", "ANATOMY", 42, 46], ["vascular", "ANATOMY", 47, 55], ["disorder", "OBSERVATION", 56, 64]]], ["You have just admitted a 28-year-old man with a witnessed seizure.", [["seizure", "DISEASE", 58, 65], ["man", "ORGANISM", 37, 40], ["man", "SPECIES", 37, 40], ["a witnessed seizure", "PROBLEM", 46, 65], ["seizure", "OBSERVATION", 58, 65]]], ["He has a prior history of seizure disorder.", [["seizure disorder", "DISEASE", 26, 42], ["seizure disorder", "PROBLEM", 26, 42], ["seizure", "OBSERVATION", 26, 33]]], ["His family describes movement of his right hand that spread to involve the entire arm.", [["right hand", "ANATOMY", 37, 47], ["hand", "ORGANISM_SUBDIVISION", 43, 47], ["arm", "ORGANISM_SUBDIVISION", 82, 85], ["right", "ANATOMY_MODIFIER", 37, 42], ["hand", "ANATOMY", 43, 47], ["entire", "ANATOMY_MODIFIER", 75, 81], ["arm", "ANATOMY", 82, 85]]], ["He did not lose consciousness.ReferenceOn physical examination, sensation is intact in the affected limb, but his strength is 0 out of 5 in the musculature of the right hand. .", [["limb", "ANATOMY", 100, 104], ["musculature", "ANATOMY", 144, 155], ["right hand", "ANATOMY", 163, 173], ["limb", "ORGANISM_SUBDIVISION", 100, 104], ["musculature", "ORGANISM_SUBDIVISION", 144, 155], ["hand", "ORGANISM_SUBDIVISION", 169, 173], ["ReferenceOn physical examination", "TEST", 30, 62], ["intact", "OBSERVATION", 77, 83], ["limb", "ANATOMY", 100, 104], ["musculature", "ANATOMY", 144, 155], ["right", "ANATOMY_MODIFIER", 163, 168], ["hand", "ANATOMY", 169, 173]]], ["His electrolytes and complete blood count are within normal limits.", [["blood", "ANATOMY", 30, 35], ["His", "CHEMICAL", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["His electrolytes", "TEST", 0, 16], ["complete blood count", "TEST", 21, 41], ["within normal limits", "OBSERVATION", 46, 66]]], ["A toxicology screen is normal.", [["A toxicology screen", "TEST", 0, 19], ["normal", "OBSERVATION", 23, 29]]], ["A noncontrast CT scan of his head is unremarkable.ReferenceWhat is the best course of action at this time?", [["head", "ANATOMY", 29, 33], ["head", "ORGAN", 29, 33], ["A noncontrast CT scan of his head", "TEST", 0, 33], ["head", "ANATOMY", 29, 33], ["unremarkable", "OBSERVATION", 37, 49]]], ["A) Cerebral angiogram B) Magnetic resonance angiogram C) Reassess in a few hours D) Psychiatric evaluation E) Lumbar puncture Answer: C The patient has Todd's paralysis, which may take minutes to many hours to return to normal.", [["Cerebral", "ANATOMY", 3, 11], ["paralysis", "DISEASE", 159, 168], ["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 140, 147], ["A) Cerebral angiogram", "TEST", 0, 21], ["Magnetic resonance angiogram C", "TEST", 25, 55], ["Psychiatric evaluation", "TEST", 84, 106], ["Todd's paralysis", "TREATMENT", 152, 168], ["Cerebral", "ANATOMY", 3, 11], ["Lumbar", "ANATOMY", 110, 116], ["paralysis", "OBSERVATION", 159, 168], ["normal", "OBSERVATION", 220, 226]]], ["The abnormal motor movements that begin in a restricted area and then progress to involve a larger area are termed Jacksonian march.", [["abnormal motor movements", "DISEASE", 4, 28], ["The abnormal motor movements", "PROBLEM", 0, 28], ["abnormal", "OBSERVATION_MODIFIER", 4, 12], ["motor movements", "OBSERVATION", 13, 28], ["Jacksonian march", "OBSERVATION", 115, 131]]], ["If his symptoms were to persist beyond several hours, it would be reasonable to investigate a different etiology of his hand weakness with imaging studies.", [["hand", "ANATOMY", 120, 124], ["hand", "ORGANISM_SUBDIVISION", 120, 124], ["his symptoms", "PROBLEM", 3, 15], ["his hand weakness", "PROBLEM", 116, 133], ["imaging studies", "TEST", 139, 154], ["hand", "ANATOMY", 120, 124], ["weakness", "OBSERVATION", 125, 133]]], ["The symptoms are too lim-ited to suggest conversion disorder.", [["The symptoms", "PROBLEM", 0, 12], ["conversion disorder", "PROBLEM", 41, 60], ["conversion disorder", "OBSERVATION", 41, 60]]], ["Magnetic resonance angiogram or cerebral angiogram may be useful to evaluate for cerebrovascular disorders, if symptoms persist.ReferenceGallmetzer P, Leutmezer F, Serles W, Assem-Hilger E, Spatt J, Baumgartner C. Postictal paresis in focal epilepsiesincidence, duration, and causes: a video-EEG monitoring study.", [["cerebral", "ANATOMY", 32, 40], ["cerebrovascular", "ANATOMY", 81, 96], ["cerebrovascular disorders", "DISEASE", 81, 106], ["Postictal paresis", "DISEASE", 214, 231], ["cerebral", "ORGAN", 32, 40], ["cerebrovascular", "ANATOMICAL_SYSTEM", 81, 96], ["Magnetic resonance angiogram", "TEST", 0, 28], ["cerebral angiogram", "TEST", 32, 50], ["cerebrovascular disorders", "PROBLEM", 81, 106], ["symptoms", "PROBLEM", 111, 119], ["ReferenceGallmetzer", "TEST", 128, 147], ["Assem", "TEST", 174, 179], ["Postictal paresis", "PROBLEM", 214, 231], ["focal epilepsiesincidence", "PROBLEM", 235, 260], ["a video", "TEST", 284, 291], ["EEG monitoring study", "TEST", 292, 312], ["Postictal paresis", "OBSERVATION", 214, 231], ["focal", "OBSERVATION_MODIFIER", 235, 240]]], ["2004;62 (12):2160-4.70.A 22-year-old woman is admitted with fatigue of 1 week's duration.", [["fatigue", "DISEASE", 60, 67], ["woman", "ORGANISM", 37, 42], ["woman", "SPECIES", 37, 42], ["fatigue", "PROBLEM", 60, 67], ["22-", "OBSERVATION_MODIFIER", 25, 28]]], ["She reports that she had a febrile illness 3 weeks ago, during which she experienced a transient rash and joint pain.", [["joint", "ANATOMY", 106, 111], ["febrile illness", "DISEASE", 27, 42], ["rash", "DISEASE", 97, 101], ["joint pain", "DISEASE", 106, 116], ["joint", "ORGANISM_SUBDIVISION", 106, 111], ["a febrile illness", "PROBLEM", 25, 42], ["a transient rash", "PROBLEM", 85, 101], ["joint pain", "PROBLEM", 106, 116], ["transient", "OBSERVATION_MODIFIER", 87, 96], ["rash", "OBSERVATION", 97, 101], ["joint", "ANATOMY", 106, 111], ["pain", "OBSERVATION", 112, 116]]], ["She was treated for a possible urinary tract infection with ciprofl oxacin.", [["urinary tract", "ANATOMY", 31, 44], ["urinary tract infection", "DISEASE", 31, 54], ["ciprofl oxacin", "CHEMICAL", 60, 74], ["ciprofl oxacin", "CHEMICAL", 60, 74], ["urinary tract", "ORGANISM_SUBDIVISION", 31, 44], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 60, 74], ["urinary tract infection", "PROBLEM", 31, 54], ["ciprofl oxacin", "TREATMENT", 60, 74], ["possible", "UNCERTAINTY", 22, 30], ["urinary tract", "ANATOMY", 31, 44], ["infection", "OBSERVATION", 45, 54]]], ["She works in a day care facility, where there has been an outbreak of a febrile illness with a rash during the past few weeks.", [["febrile illness", "DISEASE", 72, 87], ["rash", "DISEASE", 95, 99], ["a febrile illness", "PROBLEM", 70, 87], ["a rash", "PROBLEM", 93, 99]]], ["The patient has a history of hereditary spherocytosis.", [["hereditary spherocytosis", "DISEASE", 29, 53], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["hereditary spherocytosis", "PROBLEM", 29, 53], ["hereditary", "OBSERVATION_MODIFIER", 29, 39], ["spherocytosis", "OBSERVATION", 40, 53]]], ["On physical examination, she is pale, somewhat lethargic, but otherwise there are no signifi cant fi ndings.", [["physical examination", "TEST", 3, 23], ["somewhat lethargic", "PROBLEM", 38, 56], ["signifi cant fi ndings", "PROBLEM", 85, 107], ["pale", "OBSERVATION", 32, 36], ["no", "UNCERTAINTY", 82, 84]]], ["Her laboratory tests show a hematocrit of 22 %, the reticulocyte count is 0.5 %.70.Which of the following is the most likely diagnosis for this patient?", [["reticulocyte", "ANATOMY", 52, 64], ["reticulocyte", "CELL", 52, 64], ["patient", "ORGANISM", 144, 151], ["patient", "SPECIES", 144, 151], ["Her laboratory tests", "TEST", 0, 20], ["a hematocrit", "TEST", 26, 38], ["the reticulocyte count", "TEST", 48, 70]]], ["A) Acute leukemia B) Glucose-6-phosphate dehydrogenase (G6PD) defi ciency C) Systemic lupus erythematosus D) Hereditary spherocytosis in hemolytic crisis E) Aplastic crisis caused by parvovirus B1970.Answer: E This patient has a parvovirus B19 infection.", [["Acute leukemia", "ANATOMY", 3, 17], ["Acute leukemia B", "DISEASE", 3, 19], ["Glucose-6-phosphate", "CHEMICAL", 21, 40], ["Systemic lupus erythematosus", "DISEASE", 77, 105], ["Hereditary spherocytosis", "DISEASE", 109, 133], ["hemolytic crisis", "DISEASE", 137, 153], ["Aplastic crisis", "DISEASE", 157, 172], ["parvovirus B1970", "DISEASE", 183, 199], ["parvovirus B19 infection", "DISEASE", 229, 253], ["Glucose-6-phosphate", "CHEMICAL", 21, 40], ["Acute leukemia B", "CANCER", 3, 19], ["Glucose-6-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 21, 54], ["parvovirus B1970", "ORGANISM", 183, 199], ["patient", "ORGANISM", 215, 222], ["parvovirus B19", "ORGANISM", 229, 243], ["Glucose-6-phosphate dehydrogenase", "PROTEIN", 21, 54], ["G6PD", "PROTEIN", 56, 60], ["patient", "SPECIES", 215, 222], ["parvovirus B19", "SPECIES", 229, 243], ["parvovirus B19", "SPECIES", 229, 243], ["A) Acute leukemia", "PROBLEM", 0, 17], ["Glucose", "TEST", 21, 28], ["phosphate dehydrogenase (G6PD) defi ciency C", "PROBLEM", 31, 75], ["Systemic lupus erythematosus D", "PROBLEM", 77, 107], ["Hereditary spherocytosis", "PROBLEM", 109, 133], ["hemolytic crisis", "PROBLEM", 137, 153], ["Aplastic crisis", "PROBLEM", 157, 172], ["parvovirus", "PROBLEM", 183, 193], ["a parvovirus B19 infection", "PROBLEM", 227, 253], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["leukemia", "OBSERVATION", 9, 17], ["Systemic", "ANATOMY", 77, 85], ["lupus erythematosus", "OBSERVATION", 86, 105], ["Hereditary spherocytosis", "OBSERVATION", 109, 133], ["hemolytic", "OBSERVATION_MODIFIER", 137, 146], ["Aplastic crisis", "OBSERVATION", 157, 172], ["parvovirus B19 infection", "OBSERVATION", 229, 253]]], ["This is the virus that causes the common childhood disease known as erythema infectiosum or fi fth disease.", [["erythema infectiosum", "ANATOMY", 68, 88], ["erythema infectiosum", "DISEASE", 68, 88], ["erythema infectiosum", "CANCER", 68, 88], ["the virus", "PROBLEM", 8, 17], ["the common childhood disease", "PROBLEM", 30, 58], ["erythema infectiosum", "PROBLEM", 68, 88], ["fi fth disease", "PROBLEM", 92, 106], ["virus", "OBSERVATION", 12, 17], ["common", "OBSERVATION_MODIFIER", 34, 40], ["childhood", "OBSERVATION_MODIFIER", 41, 50], ["disease", "OBSERVATION", 51, 58], ["erythema", "OBSERVATION", 68, 76], ["fi", "OBSERVATION_MODIFIER", 92, 94], ["fth disease", "OBSERVATION", 95, 106]]], ["It can cause aplastic crises in persons with hemolytic disorders, chronic anemia in immunocompromised hosts, and fetal loss in pregnant women.", [["fetal", "ANATOMY", 113, 118], ["aplastic crises", "DISEASE", 13, 28], ["hemolytic disorders", "DISEASE", 45, 64], ["anemia", "DISEASE", 74, 80], ["fetal loss", "DISEASE", 113, 123], ["persons", "ORGANISM", 32, 39], ["fetal", "ORGANISM_SUBDIVISION", 113, 118], ["women", "ORGANISM", 136, 141], ["persons", "SPECIES", 32, 39], ["women", "SPECIES", 136, 141], ["aplastic crises", "PROBLEM", 13, 28], ["hemolytic disorders", "PROBLEM", 45, 64], ["chronic anemia", "PROBLEM", 66, 80], ["immunocompromised hosts", "PROBLEM", 84, 107], ["fetal loss in pregnant women", "PROBLEM", 113, 141], ["aplastic crises", "OBSERVATION", 13, 28], ["hemolytic", "OBSERVATION_MODIFIER", 45, 54], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["anemia", "OBSERVATION", 74, 80], ["immunocompromised hosts", "OBSERVATION", 84, 107], ["fetal loss", "OBSERVATION", 113, 123]]], ["The rash of erythema infectiosum usually appears without prodromal symptoms after an incubation period of 4-14 days.", [["erythema infectiosum", "ANATOMY", 12, 32], ["rash", "DISEASE", 4, 8], ["erythema infectiosum", "DISEASE", 12, 32], ["The rash of erythema infectiosum", "PROBLEM", 0, 32], ["prodromal symptoms", "PROBLEM", 57, 75], ["rash", "OBSERVATION_MODIFIER", 4, 8], ["erythema", "OBSERVATION", 12, 20], ["appears without", "UNCERTAINTY", 41, 56]]], ["The rash starts as a fi ery-red rash on both cheeks.", [["cheeks", "ANATOMY", 45, 51], ["rash", "DISEASE", 4, 8], ["rash", "DISEASE", 32, 36], ["cheeks", "ORGANISM_SUBDIVISION", 45, 51], ["The rash", "PROBLEM", 0, 8], ["red rash on both cheeks", "PROBLEM", 28, 51], ["rash", "OBSERVATION", 4, 8], ["red rash", "OBSERVATION", 28, 36], ["both", "ANATOMY_MODIFIER", 40, 44], ["cheeks", "ANATOMY", 45, 51]]], ["It then extends as an erythematous maculopapular eruption on the proximal extremities and trunk in a reticular pattern.", [["maculopapular", "ANATOMY", 35, 48], ["extremities", "ANATOMY", 74, 85], ["trunk", "ANATOMY", 90, 95], ["reticular", "ANATOMY", 101, 110], ["extremities", "ORGANISM_SUBDIVISION", 74, 85], ["trunk", "ORGANISM_SUBDIVISION", 90, 95], ["an erythematous maculopapular eruption", "PROBLEM", 19, 57], ["erythematous", "OBSERVATION_MODIFIER", 22, 34], ["maculopapular", "OBSERVATION_MODIFIER", 35, 48], ["eruption", "OBSERVATION", 49, 57], ["proximal", "ANATOMY_MODIFIER", 65, 73], ["extremities", "ANATOMY", 74, 85], ["trunk", "ANATOMY", 90, 95], ["reticular", "ANATOMY_MODIFIER", 101, 110]]], ["The rash may wax and wane for several weeks.", [["rash", "DISEASE", 4, 8], ["The rash", "PROBLEM", 0, 8], ["rash", "OBSERVATION", 4, 8]]], ["Arthralgia and arthritis are seen in up to 80 % of infected adults.", [["Arthralgia", "DISEASE", 0, 10], ["arthritis", "DISEASE", 15, 24], ["adults", "ORGANISM", 60, 66], ["Arthralgia", "PROBLEM", 0, 10], ["arthritis", "PROBLEM", 15, 24], ["arthritis", "OBSERVATION", 15, 24], ["infected", "OBSERVATION", 51, 59]]], ["Parvovirus B19 can cause an aplastic crises in patients who have sickle cell anemia, hereditary spherocytosis, thalassemia, and various other hemolytic anemias.", [["sickle cell", "ANATOMY", 65, 76], ["Parvovirus B19", "DISEASE", 0, 14], ["aplastic crises", "DISEASE", 28, 43], ["sickle cell anemia", "DISEASE", 65, 83], ["hereditary spherocytosis", "DISEASE", 85, 109], ["thalassemia", "DISEASE", 111, 122], ["hemolytic anemias", "DISEASE", 142, 159], ["Parvovirus B19", "ORGANISM", 0, 14], ["patients", "ORGANISM", 47, 55], ["sickle cell", "CELL", 65, 76], ["Parvovirus B19", "SPECIES", 0, 14], ["patients", "SPECIES", 47, 55], ["Parvovirus B19", "SPECIES", 0, 14], ["Parvovirus B19", "PROBLEM", 0, 14], ["an aplastic crises", "PROBLEM", 25, 43], ["sickle cell anemia", "PROBLEM", 65, 83], ["hereditary spherocytosis", "PROBLEM", 85, 109], ["thalassemia", "PROBLEM", 111, 122], ["various other hemolytic anemias", "PROBLEM", 128, 159], ["aplastic", "OBSERVATION", 28, 36], ["sickle cell anemia", "OBSERVATION", 65, 83], ["hereditary", "OBSERVATION_MODIFIER", 85, 95], ["spherocytosis", "OBSERVATION", 96, 109], ["thalassemia", "OBSERVATION", 111, 122], ["hemolytic", "OBSERVATION_MODIFIER", 142, 151], ["anemias", "OBSERVATION", 152, 159]]], ["These aplastic crises are abrupt in onset and are associated with giant pronormoblasts in the bone marrow.", [["pronormoblasts", "ANATOMY", 72, 86], ["bone marrow", "ANATOMY", 94, 105], ["aplastic crises", "DISEASE", 6, 21], ["pronormoblasts", "CANCER", 72, 86], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 94, 105], ["These aplastic crises", "PROBLEM", 0, 21], ["giant pronormoblasts in the bone marrow", "PROBLEM", 66, 105], ["aplastic", "OBSERVATION", 6, 14], ["abrupt", "OBSERVATION_MODIFIER", 26, 32], ["giant", "OBSERVATION_MODIFIER", 66, 71], ["pronormoblasts", "OBSERVATION", 72, 86], ["bone marrow", "ANATOMY", 94, 105]]], ["In immunocompromised patients, acute infection may lead to viral per-sistence and chronic bone marrow suppression.", [["bone marrow", "ANATOMY", 90, 101], ["infection", "DISEASE", 37, 46], ["bone marrow suppression", "DISEASE", 90, 113], ["patients", "ORGANISM", 21, 29], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 90, 101], ["patients", "SPECIES", 21, 29], ["acute infection", "PROBLEM", 31, 46], ["viral per-sistence", "PROBLEM", 59, 77], ["chronic bone marrow suppression", "PROBLEM", 82, 113], ["immunocompromised", "OBSERVATION", 3, 20], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["infection", "OBSERVATION", 37, 46], ["chronic", "OBSERVATION_MODIFIER", 82, 89], ["bone", "ANATOMY", 90, 94], ["marrow suppression", "OBSERVATION", 95, 113]]], ["In this patient, the anemia with a low reticulocyte count suggests a transient aplastic process and not a hemolytic crisis.71.A 55-year-old woman is admitted with epigastric abdominal pain.", [["reticulocyte", "ANATOMY", 39, 51], ["epigastric abdominal", "ANATOMY", 163, 183], ["anemia", "DISEASE", 21, 27], ["aplastic process", "DISEASE", 79, 95], ["hemolytic crisis", "DISEASE", 106, 122], ["epigastric abdominal pain", "DISEASE", 163, 188], ["patient", "ORGANISM", 8, 15], ["reticulocyte", "CELL", 39, 51], ["woman", "ORGANISM", 140, 145], ["abdominal", "ORGANISM_SUBDIVISION", 174, 183], ["patient", "SPECIES", 8, 15], ["woman", "SPECIES", 140, 145], ["the anemia", "PROBLEM", 17, 27], ["a low reticulocyte count", "PROBLEM", 33, 57], ["a transient aplastic process", "PROBLEM", 67, 95], ["a hemolytic crisis", "PROBLEM", 104, 122], ["epigastric abdominal pain", "PROBLEM", 163, 188], ["anemia", "OBSERVATION", 21, 27], ["low reticulocyte count", "OBSERVATION", 35, 57], ["transient", "OBSERVATION_MODIFIER", 69, 78], ["aplastic process", "OBSERVATION", 79, 95], ["hemolytic", "OBSERVATION_MODIFIER", 106, 115], ["crisis", "OBSERVATION", 116, 122], ["epigastric", "ANATOMY_MODIFIER", 163, 173], ["abdominal", "ANATOMY", 174, 183], ["pain", "OBSERVATION", 184, 188]]], ["Initial clinical exam and laboratory fi ndings are consistent with acute pancreatitis.", [["pancreatitis", "DISEASE", 73, 85], ["Initial clinical exam", "TEST", 0, 21], ["laboratory fi ndings", "TEST", 26, 46], ["acute pancreatitis", "PROBLEM", 67, 85], ["consistent with", "UNCERTAINTY", 51, 66], ["acute", "OBSERVATION_MODIFIER", 67, 72], ["pancreatitis", "OBSERVATION", 73, 85]]], ["She is admitted for aggressive hydration and observation.", [["aggressive hydration", "TREATMENT", 20, 40]]], ["Lipase and amylase have decreased.", [["Lipase", "GENE_OR_GENE_PRODUCT", 0, 6], ["amylase", "GENE_OR_GENE_PRODUCT", 11, 18], ["Lipase", "PROTEIN", 0, 6], ["amylase", "PROTEIN", 11, 18], ["Lipase", "TEST", 0, 6], ["amylase", "TEST", 11, 18], ["amylase", "ANATOMY", 11, 18], ["decreased", "OBSERVATION_MODIFIER", 24, 33]]], ["Four days later she is doing better but pain and nausea still persist.", [["pain", "DISEASE", 40, 44], ["nausea", "DISEASE", 49, 55], ["pain", "PROBLEM", 40, 44], ["nausea", "PROBLEM", 49, 55]]], ["A CT scan with contrast reveals necrotizing pancreatitis.", [["pancreatitis", "DISEASE", 44, 56], ["A CT scan with contrast", "TEST", 0, 23], ["necrotizing pancreatitis", "PROBLEM", 32, 56], ["necrotizing", "OBSERVATION_MODIFIER", 32, 43], ["pancreatitis", "OBSERVATION", 44, 56]]], ["The patient is hemodynamically stable, afebrile, with WBC of 11,000.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["afebrile", "PROBLEM", 39, 47], ["WBC", "TEST", 54, 57], ["hemodynamically", "OBSERVATION_MODIFIER", 15, 30], ["stable", "OBSERVATION_MODIFIER", 31, 37]]], ["A) CT-guided aspiration for culture and gram stain B) Repeat CT scan in 48 h C) Immediate initiation of broad-spectrum antibiotics D) Referral to general surgery for immediate debridement E) Continued observation and hydration71.Answer: E The current recommendations do not support the use of prophylactic antibiotics to prevent pancreatic infection among patients with necrotizing pancreatitis.", [["pancreatic", "ANATOMY", 329, 339], ["pancreatic infection", "DISEASE", 329, 349], ["necrotizing pancreatitis", "DISEASE", 370, 394], ["pancreatic", "ORGAN", 329, 339], ["patients", "ORGANISM", 356, 364], ["patients", "SPECIES", 356, 364], ["A) CT-guided aspiration", "TEST", 0, 23], ["culture", "TEST", 28, 35], ["gram stain", "TEST", 40, 50], ["Repeat CT scan", "TEST", 54, 68], ["broad-spectrum antibiotics D", "TREATMENT", 104, 132], ["general surgery", "TREATMENT", 146, 161], ["immediate debridement E", "TREATMENT", 166, 189], ["hydration", "TREATMENT", 217, 226], ["prophylactic antibiotics", "TREATMENT", 293, 317], ["pancreatic infection", "PROBLEM", 329, 349], ["necrotizing pancreatitis", "PROBLEM", 370, 394], ["pancreatic", "ANATOMY", 329, 339], ["infection", "OBSERVATION", 340, 349], ["necrotizing", "OBSERVATION_MODIFIER", 370, 381], ["pancreatitis", "OBSERVATION", 382, 394]]], ["Some studies suggest that the use of potent antibiotics may lead to a superimposed fungal infection.", [["fungal infection", "DISEASE", 83, 99], ["Some studies", "TEST", 0, 12], ["potent antibiotics", "TREATMENT", 37, 55], ["a superimposed fungal infection", "PROBLEM", 68, 99], ["superimposed", "OBSERVATION_MODIFIER", 70, 82], ["fungal", "OBSERVATION_MODIFIER", 83, 89], ["infection", "OBSERVATION", 90, 99]]], ["The current guidelines recommend medical management during the fi rst 2-3 weeks.", [["medical management", "TREATMENT", 33, 51]]], ["After 3 weeks, if symptoms persist or clinical condition deteriorates, a surgical debridement should be considered.", [["symptoms", "PROBLEM", 18, 26], ["clinical condition", "PROBLEM", 38, 56], ["a surgical debridement", "TREATMENT", 71, 93]]], ["If symptoms worsen or fail to improve, repeat imaging or biopsy can be considered.", [["symptoms", "PROBLEM", 3, 11], ["repeat imaging", "TEST", 39, 53], ["biopsy", "TEST", 57, 63]]], ["You are asked to admit a 49-year-old female with the acute onset of fever and severe headache.", [["fever", "DISEASE", 68, 73], ["headache", "DISEASE", 85, 93], ["female", "ORGANISM", 37, 43], ["fever", "PROBLEM", 68, 73], ["severe headache", "PROBLEM", 78, 93], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["fever", "OBSERVATION", 68, 73], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["headache", "OBSERVATION", 85, 93]]], ["Her past medical history is signifi cant for renal transplant due to diabetes mellitus type 1.", [["renal", "ANATOMY", 45, 50], ["diabetes mellitus", "DISEASE", 69, 86], ["renal", "ORGAN", 45, 50], ["renal transplant", "TREATMENT", 45, 61], ["diabetes mellitus type 1", "PROBLEM", 69, 93], ["renal", "ANATOMY", 45, 50], ["transplant", "OBSERVATION", 51, 61], ["diabetes", "OBSERVATION", 69, 77]]], ["While in the emergency room, she develops chills, photophobia, and stiffness of her neck.", [["neck", "ANATOMY", 84, 88], ["chills", "DISEASE", 42, 48], ["photophobia", "DISEASE", 50, 61], ["stiffness", "DISEASE", 67, 76], ["neck", "ORGANISM_SUBDIVISION", 84, 88], ["chills", "PROBLEM", 42, 48], ["photophobia", "PROBLEM", 50, 61], ["stiffness of her neck", "PROBLEM", 67, 88], ["chills", "OBSERVATION", 42, 48], ["photophobia", "OBSERVATION", 50, 61], ["neck", "ANATOMY", 84, 88]]], ["On physical exam, temperature is 38.6 \u00b0C (101.2 \u00b0F), heart rate is 90, and blood pressure is 120/68 mmHg You have signifi cant concern for meningitis.ReferencesWhich of the following is NOT an appropriate next step in the patient's management?", [["heart", "ANATOMY", 53, 58], ["blood", "ANATOMY", 75, 80], ["meningitis", "DISEASE", 139, 149], ["heart", "ORGAN", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 75, 80], ["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229], ["physical exam", "TEST", 3, 16], ["temperature", "TEST", 18, 29], ["\u00b0C", "TEST", 38, 40], ["heart rate", "TEST", 53, 63], ["blood pressure", "TEST", 75, 89], ["meningitis", "PROBLEM", 139, 149], ["the patient's management", "TREATMENT", 218, 242], ["concern for", "UNCERTAINTY", 127, 138], ["meningitis", "OBSERVATION", 139, 149]]], ["A) Draw stat blood cultures while placing the orders for empiric antibiotics.", [["blood cultures", "ANATOMY", 13, 27], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["stat blood cultures", "TEST", 8, 27], ["empiric antibiotics", "TREATMENT", 57, 76]]], ["B) Perform stat lumbar puncture while waiting for MRI.", [["lumbar", "ANATOMY", 16, 22], ["stat lumbar puncture", "TEST", 11, 31], ["MRI", "TEST", 50, 53], ["lumbar", "ANATOMY", 16, 22]]], ["C) Check CT scan of brain without contrast before lumbar puncture.", [["brain", "ANATOMY", 20, 25], ["lumbar", "ANATOMY", 50, 56], ["brain", "ORGAN", 20, 25], ["Check CT scan of brain without contrast", "TEST", 3, 42], ["lumbar puncture", "TEST", 50, 65], ["brain", "ANATOMY", 20, 25], ["lumbar", "ANATOMY", 50, 56]]], ["D) Give dexamethasone with fi rst dose of antibiotics.", [["dexamethasone", "CHEMICAL", 8, 21], ["dexamethasone", "CHEMICAL", 8, 21], ["dexamethasone", "SIMPLE_CHEMICAL", 8, 21], ["fi rst", "SIMPLE_CHEMICAL", 27, 33], ["dexamethasone", "TREATMENT", 8, 21], ["fi rst dose of antibiotics", "TREATMENT", 27, 53]]], ["E) A than D Answer: E It is important to recognize the treatment sequence in the management of suspected bacterial meningitis.", [["bacterial meningitis", "DISEASE", 105, 125], ["the treatment sequence", "TREATMENT", 51, 73], ["the management", "TREATMENT", 77, 91], ["bacterial meningitis", "PROBLEM", 105, 125], ["bacterial", "OBSERVATION_MODIFIER", 105, 114], ["meningitis", "OBSERVATION", 115, 125]]], ["Imaging and lumbar puncture should not delay empiric antibiotic coverage and steroids.", [["lumbar", "ANATOMY", 12, 18], ["steroids", "CHEMICAL", 77, 85], ["steroids", "CHEMICAL", 77, 85], ["steroids", "SIMPLE_CHEMICAL", 77, 85], ["Imaging", "TEST", 0, 7], ["lumbar puncture", "TEST", 12, 27], ["empiric antibiotic coverage", "TREATMENT", 45, 72], ["steroids", "TREATMENT", 77, 85], ["lumbar", "ANATOMY", 12, 18]]], ["The necessity of a CT scan prior to a lumbar puncture in all instances has been debated.73.A 68-year-old female with metastatic breast cancer involving the lungs is admitted for increasing agitation.", [["lumbar", "ANATOMY", 38, 44], ["metastatic breast cancer", "ANATOMY", 117, 141], ["lungs", "ANATOMY", 156, 161], ["breast cancer", "DISEASE", 128, 141], ["agitation", "DISEASE", 189, 198], ["female", "ORGANISM", 105, 111], ["breast cancer", "CANCER", 128, 141], ["lungs", "ORGAN", 156, 161], ["a CT scan", "TEST", 17, 26], ["a lumbar puncture", "TEST", 36, 53], ["metastatic breast cancer", "PROBLEM", 117, 141], ["increasing agitation", "PROBLEM", 178, 198], ["lumbar", "ANATOMY", 38, 44], ["metastatic", "OBSERVATION_MODIFIER", 117, 127], ["breast", "ANATOMY", 128, 134], ["cancer", "OBSERVATION", 135, 141], ["lungs", "ANATOMY", 156, 161], ["increasing", "OBSERVATION_MODIFIER", 178, 188], ["agitation", "OBSERVATION", 189, 198]]], ["She has been enrolled in home hospice for the past 4 weeks.", [["home hospice", "TREATMENT", 25, 37]]], ["She has diffuse back pain, which is moderately well controlled with transdermal fentanyl and oral hydromorphone.", [["back", "ANATOMY", 16, 20], ["oral", "ANATOMY", 93, 97], ["back pain", "DISEASE", 16, 25], ["fentanyl", "CHEMICAL", 80, 88], ["hydromorphone", "CHEMICAL", 98, 111], ["fentanyl", "CHEMICAL", 80, 88], ["hydromorphone", "CHEMICAL", 98, 111], ["fentanyl", "SIMPLE_CHEMICAL", 80, 88], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["hydromorphone", "SIMPLE_CHEMICAL", 98, 111], ["diffuse back pain", "PROBLEM", 8, 25], ["transdermal fentanyl", "TREATMENT", 68, 88], ["oral hydromorphone", "TREATMENT", 93, 111], ["diffuse", "OBSERVATION_MODIFIER", 8, 15], ["back", "ANATOMY", 16, 20], ["pain", "OBSERVATION", 21, 25], ["moderately", "OBSERVATION_MODIFIER", 36, 46]]], ["On physical exam, the patient is frail and cachectic.", [["cachectic", "DISEASE", 43, 52], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["physical exam", "TEST", 3, 16], ["frail", "PROBLEM", 33, 38], ["cachectic", "PROBLEM", 43, 52], ["frail", "OBSERVATION", 33, 38], ["cachectic", "OBSERVATION", 43, 52]]], ["Tachycardia is noted.", [["Tachycardia", "DISEASE", 0, 11], ["Tachycardia", "PROBLEM", 0, 11]]], ["She is neurologically intact as well as alert and oriented.", [["intact", "OBSERVATION", 22, 28]]], ["Her daughter tells you that she produces a small amount of concentrated urine a few times daily and that she eats occasional small meals but is often nauseated.", [["urine", "ANATOMY", 72, 77], ["urine", "ORGANISM_SUBSTANCE", 72, 77], ["concentrated urine", "PROBLEM", 59, 77], ["nauseated", "PROBLEM", 150, 159], ["small", "OBSERVATION_MODIFIER", 43, 48]]], ["Her daughter notes that she becomes agitated just before dawn if she is still awake.", [["agitated", "PROBLEM", 36, 44]]], ["The daughter would like to take the patient home if the behavior can be controlled.73.Which of the following should you do to decrease this patient's agitation?", [["agitation", "DISEASE", 150, 159], ["patient", "ORGANISM", 36, 43], ["patient", "ORGANISM", 140, 147], ["patient", "SPECIES", 36, 43], ["patient", "SPECIES", 140, 147], ["this patient's agitation", "PROBLEM", 135, 159]]], ["A) Prescribe lorazepam on an as-needed basis.", [["lorazepam", "CHEMICAL", 13, 22], ["lorazepam", "CHEMICAL", 13, 22], ["lorazepam", "SIMPLE_CHEMICAL", 13, 22], ["lorazepam", "TREATMENT", 13, 22], ["an as-needed basis", "TREATMENT", 26, 44]]], ["B) Prescribe zolpidem at bedtime.", [["zolpidem", "CHEMICAL", 13, 21], ["zolpidem", "CHEMICAL", 13, 21], ["zolpidem", "SIMPLE_CHEMICAL", 13, 21], ["zolpidem", "TREATMENT", 13, 21]]], ["C) Prescribe an evening dose of quetiapine.", [["quetiapine", "CHEMICAL", 32, 42], ["quetiapine", "CHEMICAL", 32, 42], ["quetiapine", "SIMPLE_CHEMICAL", 32, 42], ["quetiapine", "TREATMENT", 32, 42]]], ["D) Request that the hospice social worker meets with the patient to address her fears and worries.", [["patient", "ORGANISM", 57, 64], ["patient", "SPECIES", 57, 64]]], ["E) Admit to inpatient hospice.73.Answer: C Quetiapine can be used for agitation in critically ill patients.73.In a prospective, randomized, double-blind, placebocontrolled study conducted on 36 adult critically ill patients with delirium, quetiapine in escalating doses was shown to be effective in palliating agitation.", [["Quetiapine", "CHEMICAL", 43, 53], ["agitation", "DISEASE", 70, 79], ["critically ill", "DISEASE", 83, 97], ["critically ill", "DISEASE", 200, 214], ["delirium", "DISEASE", 229, 237], ["quetiapine", "CHEMICAL", 239, 249], ["agitation", "DISEASE", 310, 319], ["Quetiapine", "CHEMICAL", 43, 53], ["quetiapine", "CHEMICAL", 239, 249], ["Quetiapine", "SIMPLE_CHEMICAL", 43, 53], ["patients", "ORGANISM", 98, 106], ["patients", "ORGANISM", 215, 223], ["quetiapine", "SIMPLE_CHEMICAL", 239, 249], ["patients", "SPECIES", 98, 106], ["patients", "SPECIES", 215, 223], ["Quetiapine", "TREATMENT", 43, 53], ["agitation", "PROBLEM", 70, 79], ["placebocontrolled study", "TEST", 154, 177], ["delirium", "PROBLEM", 229, 237], ["quetiapine", "TREATMENT", 239, 249], ["escalating doses", "TREATMENT", 253, 269], ["palliating agitation", "PROBLEM", 299, 319]]], ["The use of lorazepam may worsen her agitation in her medically fragile state.", [["lorazepam", "CHEMICAL", 11, 20], ["agitation", "DISEASE", 36, 45], ["lorazepam", "CHEMICAL", 11, 20], ["lorazepam", "SIMPLE_CHEMICAL", 11, 20], ["lorazepam", "TREATMENT", 11, 20], ["her agitation", "PROBLEM", 32, 45], ["her medically fragile state", "PROBLEM", 49, 76]]], ["The use of zolpidem will address this patient's disrupted sleep but may increase her agitation.", [["zolpidem", "CHEMICAL", 11, 19], ["agitation", "DISEASE", 85, 94], ["zolpidem", "CHEMICAL", 11, 19], ["zolpidem", "SIMPLE_CHEMICAL", 11, 19], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["zolpidem", "TREATMENT", 11, 19], ["her agitation", "PROBLEM", 81, 94]]], ["Supporting the family with rapid control of behavior issues is needed.", [["behavior issues", "PROBLEM", 44, 59]]], ["While inclusion of psychosocial support is helpful, this patient is rapidly declining and medication can provide immediate benefi t.74.A 34-year-old female is admitted with a 2-day history of right eye redness and pain, photophobia, and decreased visual acuity.", [["right eye", "ANATOMY", 192, 201], ["right eye redness", "DISEASE", 192, 209], ["pain", "DISEASE", 214, 218], ["photophobia", "DISEASE", 220, 231], ["decreased visual acuity", "DISEASE", 237, 260], ["patient", "ORGANISM", 57, 64], ["female", "ORGANISM", 149, 155], ["eye", "ORGAN", 198, 201], ["patient", "SPECIES", 57, 64], ["psychosocial support", "TREATMENT", 19, 39], ["medication", "TREATMENT", 90, 100], ["right eye redness", "PROBLEM", 192, 209], ["pain", "PROBLEM", 214, 218], ["photophobia", "PROBLEM", 220, 231], ["decreased visual acuity", "PROBLEM", 237, 260], ["34-", "OBSERVATION_MODIFIER", 137, 140], ["right", "ANATOMY_MODIFIER", 192, 197], ["eye", "ANATOMY", 198, 201], ["redness", "OBSERVATION", 202, 209], ["pain", "OBSERVATION", 214, 218], ["photophobia", "OBSERVATION", 220, 231], ["decreased", "OBSERVATION_MODIFIER", 237, 246], ["visual acuity", "OBSERVATION", 247, 260]]], ["She has a 2-year history of recurrent oral ulcerations and tender nodules on her shins.", [["oral", "ANATOMY", 38, 42], ["tender nodules", "ANATOMY", 59, 73], ["ulcerations", "DISEASE", 43, 54], ["oral ulcerations", "PATHOLOGICAL_FORMATION", 38, 54], ["tender nodules", "PATHOLOGICAL_FORMATION", 59, 73], ["recurrent oral ulcerations", "PROBLEM", 28, 54], ["tender nodules on her shins", "PROBLEM", 59, 86], ["recurrent", "OBSERVATION_MODIFIER", 28, 37], ["oral", "ANATOMY", 38, 42], ["ulcerations", "OBSERVATION", 43, 54], ["tender", "OBSERVATION_MODIFIER", 59, 65], ["nodules", "OBSERVATION", 66, 73], ["shins", "ANATOMY", 81, 86]]], ["She has had mild rotating joint tenderness for the past 4 months.", [["joint", "ANATOMY", 26, 31], ["tenderness", "DISEASE", 32, 42], ["joint", "ORGANISM_SUBDIVISION", 26, 31], ["mild rotating joint tenderness", "PROBLEM", 12, 42], ["mild", "OBSERVATION_MODIFIER", 12, 16], ["rotating", "OBSERVATION_MODIFIER", 17, 25], ["joint", "ANATOMY", 26, 31], ["tenderness", "OBSERVATION", 32, 42]]], ["Her only medication is ibuprofen.", [["ibuprofen", "CHEMICAL", 23, 32], ["ibuprofen", "CHEMICAL", 23, 32], ["ibuprofen", "SIMPLE_CHEMICAL", 23, 32], ["ibuprofen", "TREATMENT", 23, 32]]], ["She has been treated for genital herpes in the past.", [["genital herpes", "DISEASE", 25, 39], ["genital herpes", "ORGANISM", 25, 39], ["genital herpes", "PROBLEM", 25, 39], ["genital", "ANATOMY", 25, 32], ["herpes", "OBSERVATION", 33, 39]]], ["On physical examination, the temperature is 37.4 \u00b0C (99.3 \u00b0F), blood pressure is 130/80 mmHg, pulse rate is 110/min, and respiration rate is 16/min.", [["blood", "ANATOMY", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 63, 77], ["pulse rate", "TEST", 94, 104], ["respiration rate", "TEST", 121, 137]]], ["Oral ulcerations are noted on the inner cheek, palate, and tongue.", [["Oral", "ANATOMY", 0, 4], ["inner cheek", "ANATOMY", 34, 45], ["palate", "ANATOMY", 47, 53], ["tongue", "ANATOMY", 59, 65], ["ulcerations", "DISEASE", 5, 16], ["Oral ulcerations", "PATHOLOGICAL_FORMATION", 0, 16], ["inner cheek", "ORGAN", 34, 45], ["palate", "ORGAN", 47, 53], ["tongue", "ORGAN", 59, 65], ["Oral ulcerations", "PROBLEM", 0, 16], ["ulcerations", "OBSERVATION", 5, 16], ["inner", "ANATOMY_MODIFIER", 34, 39], ["cheek", "ANATOMY", 40, 45], ["palate", "ANATOMY", 47, 53], ["tongue", "ANATOMY", 59, 65]]], ["The lungs are clear.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["lungs", "ANATOMY", 4, 9], ["clear", "OBSERVATION", 14, 19]]], ["The abdomen is nontender.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["nontender", "PROBLEM", 15, 24], ["abdomen", "ANATOMY", 4, 11], ["nontender", "OBSERVATION", 15, 24]]], ["No bruits are noted.", [["bruits", "PROBLEM", 3, 9], ["bruits", "OBSERVATION", 3, 9]]], ["The right knee and right ankle are swollen.", [["right knee", "ANATOMY", 4, 14], ["right ankle", "ANATOMY", 19, 30], ["knee", "ORGANISM_SUBDIVISION", 10, 14], ["ankle", "ORGANISM_SUBDIVISION", 25, 30], ["swollen", "PROBLEM", 35, 42], ["right", "ANATOMY_MODIFIER", 4, 9], ["knee", "ANATOMY", 10, 14], ["right", "ANATOMY_MODIFIER", 19, 24], ["ankle", "ANATOMY", 25, 30], ["swollen", "OBSERVATION", 35, 42]]], ["Peripheral pulses are normal.", [["Peripheral pulses", "TEST", 0, 17], ["pulses", "ANATOMY_MODIFIER", 11, 17], ["normal", "OBSERVATION", 22, 28]]], ["An ophthalmology consultation reveals anterior and posterior uveitis.74.Complete blood count and the basic metabolic panel and INR are within normal limits.", [["anterior", "ANATOMY", 38, 46], ["blood", "ANATOMY", 81, 86], ["uveitis", "DISEASE", 61, 68], ["anterior", "MULTI-TISSUE_STRUCTURE", 38, 46], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["INR", "PROTEIN", 127, 130], ["An ophthalmology consultation", "TEST", 0, 29], ["anterior and posterior uveitis", "PROBLEM", 38, 68], ["Complete blood count", "TEST", 72, 92], ["the basic metabolic panel", "TEST", 97, 122], ["INR", "TEST", 127, 130], ["anterior", "ANATOMY_MODIFIER", 38, 46], ["posterior", "ANATOMY_MODIFIER", 51, 60], ["uveitis", "OBSERVATION", 61, 68], ["within normal limits", "OBSERVATION", 135, 155]]], ["Chest X-ray reveals a prominent right pulmonary artery.", [["right pulmonary artery", "ANATOMY", 32, 54], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 38, 54], ["Chest X-ray", "TEST", 0, 11], ["a prominent right pulmonary artery", "PROBLEM", 20, 54], ["prominent", "OBSERVATION", 22, 31], ["right", "ANATOMY_MODIFIER", 32, 37], ["pulmonary artery", "ANATOMY", 38, 54]]], ["CT of the chest demonstrates an aneurysm of the right pulmonary artery.74.Which of the following is the most likely diagnosis?", [["chest", "ANATOMY", 10, 15], ["aneurysm", "ANATOMY", 32, 40], ["right pulmonary artery", "ANATOMY", 48, 70], ["aneurysm of the right pulmonary artery", "DISEASE", 32, 70], ["chest", "ORGAN", 10, 15], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 54, 70], ["CT of the chest", "TEST", 0, 15], ["an aneurysm of the right pulmonary artery", "PROBLEM", 29, 70], ["chest", "ANATOMY", 10, 15], ["aneurysm", "OBSERVATION", 32, 40], ["right pulmonary artery", "ANATOMY", 48, 70], ["most likely", "UNCERTAINTY", 104, 115]]], ["A) Beh\u00e7et disease B) Granulomatosis with polyangiitis C) Polyarteritis nodosa D) Gonococcal arthritis E) Reiter's syndrome Answer: A This patient has Beh\u00e7et disease.", [["Beh\u00e7et disease B", "DISEASE", 3, 19], ["Granulomatosis", "DISEASE", 21, 35], ["polyangiitis", "DISEASE", 41, 53], ["Polyarteritis nodosa", "DISEASE", 57, 77], ["Gonococcal arthritis", "DISEASE", 81, 101], ["Reiter's syndrome", "DISEASE", 105, 122], ["Beh\u00e7et disease", "DISEASE", 150, 164], ["Beh\u00e7et disease B", "CANCER", 3, 19], ["patient", "ORGANISM", 138, 145], ["Beh\u00e7et disease", "CANCER", 150, 164], ["patient", "SPECIES", 138, 145], ["A) Beh\u00e7et disease B) Granulomatosis", "PROBLEM", 0, 35], ["polyangiitis C)", "PROBLEM", 41, 56], ["Polyarteritis nodosa D", "PROBLEM", 57, 79], ["Gonococcal arthritis", "PROBLEM", 81, 101], ["Reiter's syndrome", "PROBLEM", 105, 122], ["Beh\u00e7et disease", "PROBLEM", 150, 164], ["Granulomatosis", "OBSERVATION", 21, 35], ["polyangiitis", "OBSERVATION", 41, 53], ["Polyarteritis", "OBSERVATION_MODIFIER", 57, 70], ["nodosa", "OBSERVATION", 71, 77], ["Gonococcal", "OBSERVATION_MODIFIER", 81, 91], ["arthritis", "OBSERVATION", 92, 101], ["disease", "OBSERVATION", 157, 164]]], ["Beh\u00e7et disease is characterized by the triad of recurrent oral aphthous ulcers, genital ulcers, and uveitis.", [["oral", "ANATOMY", 58, 62], ["genital ulcers", "ANATOMY", 80, 94], ["Beh\u00e7et disease", "DISEASE", 0, 14], ["oral aphthous ulcers", "DISEASE", 58, 78], ["genital ulcers", "DISEASE", 80, 94], ["uveitis", "DISEASE", 100, 107], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["aphthous ulcers", "PATHOLOGICAL_FORMATION", 63, 78], ["genital ulcers", "PATHOLOGICAL_FORMATION", 80, 94], ["Beh\u00e7et disease", "PROBLEM", 0, 14], ["recurrent oral aphthous ulcers", "PROBLEM", 48, 78], ["genital ulcers", "PROBLEM", 80, 94], ["uveitis", "PROBLEM", 100, 107], ["disease", "OBSERVATION", 7, 14], ["recurrent", "OBSERVATION_MODIFIER", 48, 57], ["oral", "OBSERVATION_MODIFIER", 58, 62], ["aphthous", "OBSERVATION_MODIFIER", 63, 71], ["ulcers", "OBSERVATION", 72, 78], ["genital", "ANATOMY", 80, 87], ["ulcers", "OBSERVATION", 88, 94], ["uveitis", "OBSERVATION", 100, 107]]], ["Beh\u00e7et disease is a systemic disorder characterized by vasculitis and multiple organ involvement.", [["organ", "ANATOMY", 79, 84], ["Beh\u00e7et disease", "DISEASE", 0, 14], ["systemic disorder", "DISEASE", 20, 37], ["vasculitis", "DISEASE", 55, 65], ["organ", "ORGAN", 79, 84], ["Beh\u00e7et disease", "PROBLEM", 0, 14], ["a systemic disorder", "PROBLEM", 18, 37], ["vasculitis", "PROBLEM", 55, 65], ["multiple organ involvement", "PROBLEM", 70, 96], ["disease", "OBSERVATION", 7, 14], ["systemic disorder", "OBSERVATION", 20, 37], ["vasculitis", "OBSERVATION", 55, 65], ["multiple", "OBSERVATION_MODIFIER", 70, 78], ["organ", "ANATOMY", 79, 84], ["involvement", "OBSERVATION", 85, 96]]], ["The diagnostic clues are intermittent mucous membrane ulcerations and ocular involvement.", [["mucous membrane", "ANATOMY", 38, 53], ["ocular", "ANATOMY", 70, 76], ["ulcerations", "DISEASE", 54, 65], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 38, 53], ["ulcerations", "PATHOLOGICAL_FORMATION", 54, 65], ["ocular", "ORGAN", 70, 76], ["intermittent mucous membrane ulcerations", "PROBLEM", 25, 65], ["ocular involvement", "PROBLEM", 70, 88], ["intermittent", "OBSERVATION_MODIFIER", 25, 37], ["mucous membrane ulcerations", "OBSERVATION", 38, 65], ["ocular", "ANATOMY", 70, 76]]], ["Gastrointestinal, pulmonary, musculoskeletal, and neurologic manifestations may be present.", [["Gastrointestinal", "ANATOMY", 0, 16], ["pulmonary", "ANATOMY", 18, 27], ["neurologic", "ANATOMY", 50, 60], ["Gastrointestinal, pulmonary, musculoskeletal, and neurologic manifestations", "DISEASE", 0, 75], ["Gastrointestinal", "ORGAN", 0, 16], ["pulmonary", "ORGAN", 18, 27], ["neurologic manifestations", "PROBLEM", 50, 75], ["pulmonary", "ANATOMY", 18, 27], ["musculoskeletal", "ANATOMY", 29, 44]]], ["This patient has a 2-year history of recurrent oral ulcerations.", [["oral", "ANATOMY", 47, 51], ["oral ulcerations", "DISEASE", 47, 63], ["patient", "ORGANISM", 5, 12], ["oral ulcerations", "PATHOLOGICAL_FORMATION", 47, 63], ["patient", "SPECIES", 5, 12], ["recurrent oral ulcerations", "PROBLEM", 37, 63], ["recurrent", "OBSERVATION_MODIFIER", 37, 46], ["oral", "ANATOMY", 47, 51], ["ulcerations", "OBSERVATION", 52, 63]]], ["The skin lesions are erythema nodosum.", [["skin lesions", "ANATOMY", 4, 16], ["erythema nodosum", "ANATOMY", 21, 37], ["erythema nodosum", "DISEASE", 21, 37], ["skin lesions", "PATHOLOGICAL_FORMATION", 4, 16], ["The skin lesions", "PROBLEM", 0, 16], ["erythema nodosum", "PROBLEM", 21, 37], ["skin", "ANATOMY", 4, 8], ["lesions", "OBSERVATION", 9, 16], ["erythema", "OBSERVATION_MODIFIER", 21, 29], ["nodosum", "OBSERVATION", 30, 37]]], ["She now presents with panuveitis.", [["panuveitis", "DISEASE", 22, 32], ["panuveitis", "PROBLEM", 22, 32], ["panuveitis", "OBSERVATION", 22, 32]]], ["Pulmonary artery aneurysm also strongly suggests Beh\u00e7et disease.", [["Pulmonary artery aneurysm", "ANATOMY", 0, 25], ["Pulmonary artery aneurysm", "DISEASE", 0, 25], ["Beh\u00e7et disease", "DISEASE", 49, 63], ["Pulmonary artery", "MULTI-TISSUE_STRUCTURE", 0, 16], ["Pulmonary artery aneurysm", "PROBLEM", 0, 25], ["Beh\u00e7et disease", "PROBLEM", 49, 63], ["artery", "ANATOMY", 10, 16], ["aneurysm", "OBSERVATION", 17, 25], ["strongly suggests", "UNCERTAINTY", 31, 48], ["Beh\u00e7et disease", "OBSERVATION", 49, 63]]], ["Exposure to an infectious agent may trigger a cross-reactive immune response.", [["an infectious agent", "TREATMENT", 12, 31], ["a cross-reactive immune response", "PROBLEM", 44, 76], ["infectious", "OBSERVATION", 15, 25], ["cross-reactive immune response", "OBSERVATION", 46, 76]]], ["Proposed infectious agents have included herpes simplex virus, Streptococcus species, Staphylococcus species, and Escherichia coli .", [["herpes simplex virus", "DISEASE", 41, 61], ["herpes simplex virus", "ORGANISM", 41, 61], ["Streptococcus species", "ORGANISM", 63, 84], ["Staphylococcus species", "ORGANISM", 86, 108], ["Escherichia coli", "ORGANISM", 114, 130], ["herpes simplex virus", "SPECIES", 41, 61], ["Streptococcus species", "SPECIES", 63, 84], ["Staphylococcus species", "SPECIES", 86, 108], ["Escherichia coli", "SPECIES", 114, 130], ["herpes simplex virus", "SPECIES", 41, 61], ["Escherichia coli", "SPECIES", 114, 130], ["Proposed infectious agents", "PROBLEM", 0, 26], ["herpes simplex virus", "PROBLEM", 41, 61], ["Streptococcus species", "PROBLEM", 63, 84], ["Staphylococcus species", "PROBLEM", 86, 108], ["Escherichia coli", "PROBLEM", 114, 130], ["infectious", "OBSERVATION", 9, 19], ["Streptococcus species", "OBSERVATION", 63, 84], ["Staphylococcus species", "OBSERVATION", 86, 108], ["Escherichia coli", "OBSERVATION", 114, 130]]], ["There may be relationship to fl ora of the mouth.", [["mouth", "ANATOMY", 43, 48], ["fl ora", "GENE_OR_GENE_PRODUCT", 29, 35], ["mouth", "ORGAN", 43, 48], ["mouth", "ANATOMY", 43, 48]]], ["The treatment approach depends on the severity of the disease and major organ involvement.", [["organ", "ANATOMY", 72, 77], ["organ", "ORGAN", 72, 77], ["The treatment approach", "TREATMENT", 0, 22], ["the disease", "PROBLEM", 50, 61], ["major organ involvement", "PROBLEM", 66, 89], ["disease", "OBSERVATION", 54, 61]]], ["This may include systemic corticosteroids, azathioprine, pentoxifylline, dapsone, interferon-alfa, colchicine, and thalidomide.", [["azathioprine", "CHEMICAL", 43, 55], ["pentoxifylline", "CHEMICAL", 57, 71], ["dapsone", "CHEMICAL", 73, 80], ["interferon-alfa,", "CHEMICAL", 82, 98], ["colchicine", "CHEMICAL", 99, 109], ["thalidomide", "CHEMICAL", 115, 126], ["corticosteroids", "CHEMICAL", 26, 41], ["azathioprine", "CHEMICAL", 43, 55], ["pentoxifylline", "CHEMICAL", 57, 71], ["dapsone", "CHEMICAL", 73, 80], ["colchicine", "CHEMICAL", 99, 109], ["thalidomide", "CHEMICAL", 115, 126], ["azathioprine", "SIMPLE_CHEMICAL", 43, 55], ["pentoxifylline", "SIMPLE_CHEMICAL", 57, 71], ["dapsone", "SIMPLE_CHEMICAL", 73, 80], ["interferon-alfa", "SIMPLE_CHEMICAL", 82, 97], ["colchicine", "SIMPLE_CHEMICAL", 99, 109], ["thalidomide", "SIMPLE_CHEMICAL", 115, 126], ["interferon", "PROTEIN", 82, 92], ["systemic corticosteroids", "TREATMENT", 17, 41], ["azathioprine", "TREATMENT", 43, 55], ["pentoxifylline", "TREATMENT", 57, 71], ["dapsone", "TREATMENT", 73, 80], ["interferon", "TREATMENT", 82, 92], ["alfa", "TREATMENT", 93, 97], ["colchicine", "TREATMENT", 99, 109], ["thalidomide", "TREATMENT", 115, 126], ["may include", "UNCERTAINTY", 5, 16], ["systemic corticosteroids", "OBSERVATION", 17, 41]]], ["A 28-year-old male is admitted with acute agitation.", [["agitation", "DISEASE", 42, 51], ["male", "ORGANISM", 14, 18], ["acute agitation", "PROBLEM", 36, 51], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["agitation", "OBSERVATION", 42, 51]]], ["He was found on the roof of his house.", [["He", "ORGANISM", 0, 2]]], ["On physical exam, he is actively hallucinating, diaphoretic, and is nonresponsive to painful stimuli.", [["physical exam", "TEST", 3, 16], ["actively hallucinating", "PROBLEM", 24, 46], ["diaphoretic", "PROBLEM", 48, 59], ["painful stimuli", "TEST", 85, 100], ["hallucinating", "OBSERVATION", 33, 46]]], ["Drug screen is negative.", [["Drug screen", "TEST", 0, 11], ["negative", "OBSERVATION", 15, 23]]], ["Computed tomography of his head is not possible due to agitation.", [["head", "ANATOMY", 27, 31], ["agitation", "DISEASE", 55, 64], ["head", "ORGAN", 27, 31], ["Computed tomography of his head", "TEST", 0, 31], ["agitation", "PROBLEM", 55, 64], ["head", "ANATOMY", 27, 31]]], ["Over the course of next 2 days, he requires large doses of benzodiazepines and haloperidol for management and sedation.", [["benzodiazepines", "CHEMICAL", 59, 74], ["haloperidol", "CHEMICAL", 79, 90], ["benzodiazepines", "CHEMICAL", 59, 74], ["haloperidol", "CHEMICAL", 79, 90], ["benzodiazepines", "SIMPLE_CHEMICAL", 59, 74], ["haloperidol", "SIMPLE_CHEMICAL", 79, 90], ["benzodiazepines", "TREATMENT", 59, 74], ["haloperidol", "TREATMENT", 79, 90], ["management", "TREATMENT", 95, 105], ["sedation", "TREATMENT", 110, 118]]], ["In addition he requires physical restraints.", [["physical restraints", "TREATMENT", 24, 43]]], ["He gradually returns to his usual functional status in 5 days with little recollection of the event.ReferencesThe most likely ingested substance was: A) Synthetic cathinones \"bath salts\" B) Hallucinogenic mushrooms C) Heroin D) Cocaine E) Ecstasy Answer: A Synthetic cathinones, drugs known as \"bath salts,\" were fi rst described in the United States in 2010.", [["cathinones", "CHEMICAL", 163, 173], ["Heroin", "CHEMICAL", 218, 224], ["Cocaine", "CHEMICAL", 228, 235], ["Ecstasy", "CHEMICAL", 239, 246], ["cathinones", "CHEMICAL", 267, 277], ["cathinones", "CHEMICAL", 163, 173], ["Cocaine E", "CHEMICAL", 228, 237], ["Ecstasy", "CHEMICAL", 239, 246], ["cathinones", "CHEMICAL", 267, 277], ["He", "ORGANISM", 0, 2], ["cathinones", "SIMPLE_CHEMICAL", 163, 173], ["Heroin D", "SIMPLE_CHEMICAL", 218, 226], ["Cocaine E", "SIMPLE_CHEMICAL", 228, 237], ["cathinones", "SIMPLE_CHEMICAL", 267, 277], ["most likely", "UNCERTAINTY", 114, 125]]], ["Users of bath salts experience vivid disturbing hallucinations, agitation, paranoia, and extreme pain intolerance.", [["hallucinations", "DISEASE", 48, 62], ["agitation", "DISEASE", 64, 73], ["paranoia", "DISEASE", 75, 83], ["pain", "DISEASE", 97, 101], ["hallucinations", "PROBLEM", 48, 62], ["agitation", "PROBLEM", 64, 73], ["paranoia", "PROBLEM", 75, 83], ["extreme pain intolerance", "PROBLEM", 89, 113]]], ["They are more potent as compared to other hallucinogens.", [["more potent", "OBSERVATION_MODIFIER", 9, 20]]], ["Episodes of intoxication are unpredictable and are often prolonged lasting several days.", [["intoxication", "PROBLEM", 12, 24], ["intoxication", "OBSERVATION", 12, 24], ["unpredictable", "OBSERVATION_MODIFIER", 29, 42]]], ["Large dose of sedatives are often required as well as careful use of physical restraints.ReferencesDecreased pain sensation makes physical restraint difficult and reports of injury during sedation are common.ReferenceCoppola M, Mondola R. Synthetic cathinones: Chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as \"bath salts\" or \"plant food\".", [["pain", "DISEASE", 109, 113], ["cathinones", "CHEMICAL", 249, 259], ["cathinones", "CHEMICAL", 249, 259], ["sedatives", "TREATMENT", 14, 23], ["physical restraints", "TREATMENT", 69, 88], ["Decreased pain sensation", "PROBLEM", 99, 123], ["physical restraint", "TREATMENT", 130, 148], ["injury", "PROBLEM", 174, 180], ["sedation", "TREATMENT", 188, 196], ["injury", "OBSERVATION", 174, 180]]], ["2012;211(2):144-9. doi: 10.1016/j.toxlet.2012.03.009 .", [[":144-9", "CHEMICAL", 11, 17]]], ["PMID 22459606.77.A 22-year-old male college student is admitted for having a witnessed generalized tonic-clonic seizure.", [["PMID 22459606.77", "CHEMICAL", 0, 16], ["tonic-clonic seizure", "DISEASE", 99, 119], ["a witnessed generalized tonic-clonic seizure", "PROBLEM", 75, 119]]], ["The patient reports that he was out late the night before and drank more than usual over the course of the evening.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["He reports having sudden jerks of his arms this morning before the generalized seizure was witnessed.", [["jerks", "DISEASE", 25, 30], ["seizure", "DISEASE", 79, 86], ["sudden jerks of his arms", "PROBLEM", 18, 42], ["the generalized seizure", "PROBLEM", 63, 86], ["jerks", "OBSERVATION", 25, 30], ["arms", "ANATOMY", 38, 42], ["generalized", "OBSERVATION_MODIFIER", 67, 78], ["seizure", "OBSERVATION", 79, 86]]], ["He has had similar muscular jerks in the previous mornings.", [["muscular", "ANATOMY", 19, 27], ["muscular jerks", "DISEASE", 19, 33], ["He", "ORGANISM", 0, 2], ["muscular", "ORGANISM_SUBDIVISION", 19, 27], ["similar muscular jerks", "PROBLEM", 11, 33], ["similar", "OBSERVATION_MODIFIER", 11, 18], ["muscular jerks", "OBSERVATION", 19, 33]]], ["He reports no history of excessive alcohol use or illicit substance abuse.", [["alcohol", "CHEMICAL", 35, 42], ["substance abuse", "DISEASE", 58, 73], ["alcohol", "CHEMICAL", 35, 42], ["alcohol", "ORGANISM_SUBDIVISION", 35, 42]]], ["He takes no medications.77.Neurologic examination is normal.", [["medications", "TREATMENT", 12, 23], ["Neurologic examination", "TEST", 27, 49], ["normal", "OBSERVATION", 53, 59]]], ["He is oriented and feeling well the day after admission.77.Results of laboratory studies are normal.", [["laboratory studies", "TEST", 70, 88], ["normal", "OBSERVATION", 93, 99]]], ["A CT scan of the head shows no abnormalities.77.Which of the following is the most likely diagnosis?", [["head", "ANATOMY", 17, 21], ["head", "ORGAN", 17, 21], ["A CT scan of the head", "TEST", 0, 21], ["abnormalities", "PROBLEM", 31, 44], ["head", "ANATOMY", 17, 21], ["no", "UNCERTAINTY", 28, 30], ["abnormalities", "OBSERVATION", 31, 44], ["most likely", "UNCERTAINTY", 78, 89]]], ["A) Alcohol withdrawal seizure B) Benign rolandic epilepsy C) Illicit drug-induced seizure D) Temporal lobe epilepsy E) Juvenile myoclonic epilepsy Answer: E This patient has juvenile myoclonic epilepsy.", [["Alcohol withdrawal seizure B", "DISEASE", 3, 31], ["rolandic epilepsy", "DISEASE", 40, 57], ["seizure", "DISEASE", 82, 89], ["Temporal lobe epilepsy", "DISEASE", 93, 115], ["Juvenile myoclonic epilepsy", "DISEASE", 119, 146], ["juvenile myoclonic epilepsy", "DISEASE", 174, 201], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["Alcohol withdrawal seizure B", "PROBLEM", 3, 31], ["Benign rolandic epilepsy C", "PROBLEM", 33, 59], ["seizure D", "PROBLEM", 82, 91], ["Temporal lobe epilepsy E", "PROBLEM", 93, 117], ["Juvenile myoclonic epilepsy", "PROBLEM", 119, 146], ["juvenile myoclonic epilepsy", "PROBLEM", 174, 201], ["Temporal lobe", "ANATOMY", 93, 106], ["juvenile", "OBSERVATION_MODIFIER", 174, 182], ["myoclonic epilepsy", "OBSERVATION", 183, 201]]], ["A history of rapid, unprovoked jerks and generalized tonic-clonic seizures on awakening is a common presentation.", [["jerks", "DISEASE", 31, 36], ["tonic-clonic seizures", "DISEASE", 53, 74], ["rapid, unprovoked jerks", "PROBLEM", 13, 36], ["generalized tonic-clonic seizures", "PROBLEM", 41, 74], ["rapid", "OBSERVATION_MODIFIER", 13, 18], ["generalized", "OBSERVATION_MODIFIER", 41, 52], ["tonic", "OBSERVATION_MODIFIER", 53, 58]]], ["Juvenile myoclonic epilepsy may affect 5-10 % of all patients with epilepsy.", [["Juvenile myoclonic epilepsy", "DISEASE", 0, 27], ["epilepsy", "DISEASE", 67, 75], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["Juvenile myoclonic epilepsy", "PROBLEM", 0, 27], ["epilepsy", "PROBLEM", 67, 75], ["myoclonic", "OBSERVATION_MODIFIER", 9, 18], ["epilepsy", "OBSERVATION", 19, 27], ["epilepsy", "OBSERVATION", 67, 75]]], ["Seizures are often provoked by sleep deprivation, alcohol, video games, or exposure to fl ickering lights.", [["Seizures", "DISEASE", 0, 8], ["alcohol", "CHEMICAL", 50, 57], ["alcohol", "CHEMICAL", 50, 57], ["alcohol", "SIMPLE_CHEMICAL", 50, 57], ["Seizures", "PROBLEM", 0, 8], ["fl ickering lights", "TREATMENT", 87, 105]]], ["Recognizing the specifi c epilepsy syndrome affecting a patient is important in selecting the appropriate therapy.", [["epilepsy syndrome", "DISEASE", 26, 43], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["the specifi c epilepsy syndrome", "PROBLEM", 12, 43], ["the appropriate therapy", "TREATMENT", 90, 113], ["epilepsy syndrome", "OBSERVATION", 26, 43]]], ["Alcohol withdrawal seizures develop in chronic users of alcohol.", [["Alcohol", "DISEASE", 0, 7], ["withdrawal seizures", "DISEASE", 8, 27], ["alcohol", "CHEMICAL", 56, 63], ["alcohol", "CHEMICAL", 56, 63], ["alcohol", "SIMPLE_CHEMICAL", 56, 63], ["Alcohol withdrawal seizures", "PROBLEM", 0, 27], ["chronic", "OBSERVATION_MODIFIER", 39, 46]]], ["It is generally seen in combination with other signs and symptoms of alcohol withdrawal, such as delirium, tremor, tachycardia, and diaphoresis.", [["alcohol", "CHEMICAL", 69, 76], ["delirium", "DISEASE", 97, 105], ["tremor", "DISEASE", 107, 113], ["tachycardia", "DISEASE", 115, 126], ["diaphoresis", "DISEASE", 132, 143], ["alcohol", "CHEMICAL", 69, 76], ["alcohol", "SIMPLE_CHEMICAL", 69, 76], ["other signs and symptoms", "PROBLEM", 41, 65], ["alcohol withdrawal", "PROBLEM", 69, 87], ["delirium", "PROBLEM", 97, 105], ["tremor", "PROBLEM", 107, 113], ["tachycardia", "PROBLEM", 115, 126], ["diaphoresis", "PROBLEM", 132, 143], ["alcohol withdrawal", "OBSERVATION", 69, 87]]], ["Benign rolandic epilepsy is a syndrome seen in younger children who have seizures, usually during sleep.", [["rolandic epilepsy", "DISEASE", 7, 24], ["seizures", "DISEASE", 73, 81], ["children", "ORGANISM", 55, 63], ["children", "SPECIES", 55, 63], ["Benign rolandic epilepsy", "PROBLEM", 0, 24], ["a syndrome", "PROBLEM", 28, 38], ["seizures", "PROBLEM", 73, 81], ["rolandic", "OBSERVATION_MODIFIER", 7, 15], ["epilepsy", "OBSERVATION", 16, 24]]], ["Temporal lobe epilepsy is the most common of the localizationrelated epilepsies.", [["Temporal lobe", "ANATOMY", 0, 13], ["Temporal lobe epilepsy", "DISEASE", 0, 22], ["epilepsies", "DISEASE", 69, 79], ["lobe", "MULTI-TISSUE_STRUCTURE", 9, 13], ["epilepsies", "CANCER", 69, 79], ["Temporal lobe epilepsy", "PROBLEM", 0, 22], ["the localizationrelated epilepsies", "PROBLEM", 45, 79], ["lobe", "ANATOMY", 9, 13], ["epilepsy", "OBSERVATION", 14, 22], ["most common", "OBSERVATION_MODIFIER", 30, 41], ["epilepsies", "OBSERVATION", 69, 79]]], ["This often is due to a specifi c brain malformation, such as trauma, infarct, or congenital.", [["brain", "ANATOMY", 33, 38], ["brain malformation", "DISEASE", 33, 51], ["trauma", "DISEASE", 61, 67], ["infarct", "DISEASE", 69, 76], ["brain", "ORGAN", 33, 38], ["a specifi c brain malformation", "PROBLEM", 21, 51], ["trauma", "PROBLEM", 61, 67], ["infarct", "PROBLEM", 69, 76], ["congenital", "PROBLEM", 81, 91], ["brain", "ANATOMY", 33, 38], ["malformation", "OBSERVATION", 39, 51], ["infarct", "OBSERVATION", 69, 76], ["congenital", "OBSERVATION", 81, 91]]], ["The most common seizure occurring with temporal lobe epi-lepsy is complex partial seizure.", [["temporal lobe", "ANATOMY", 39, 52], ["seizure", "DISEASE", 16, 23], ["temporal lobe epi-lepsy", "DISEASE", 39, 62], ["seizure", "DISEASE", 82, 89], ["temporal lobe", "MULTI-TISSUE_STRUCTURE", 39, 52], ["The most common seizure", "PROBLEM", 0, 23], ["temporal lobe epi-lepsy", "PROBLEM", 39, 62], ["complex partial seizure", "PROBLEM", 66, 89], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["seizure", "OBSERVATION", 16, 23], ["temporal lobe", "ANATOMY", 39, 52], ["complex", "OBSERVATION_MODIFIER", 66, 73], ["partial", "OBSERVATION_MODIFIER", 74, 81], ["seizure", "OBSERVATION", 82, 89]]], ["Patients with complex partial seizures are awake but exhibit altered awareness, such as unresponsiveness or staring.", [["seizures", "DISEASE", 30, 38], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["complex partial seizures", "PROBLEM", 14, 38], ["altered awareness", "PROBLEM", 61, 78], ["unresponsiveness", "PROBLEM", 88, 104], ["staring", "PROBLEM", 108, 115], ["complex", "OBSERVATION_MODIFIER", 14, 21], ["partial", "OBSERVATION_MODIFIER", 22, 29], ["seizures", "OBSERVATION", 30, 38]]], ["A 38-year-old female is admitted to the hospital for a 2-day history of fever and abdominal pain.", [["abdominal", "ANATOMY", 82, 91], ["fever", "DISEASE", 72, 77], ["abdominal pain", "DISEASE", 82, 96], ["female", "ORGANISM", 14, 20], ["abdominal", "ORGANISM_SUBDIVISION", 82, 91], ["fever", "PROBLEM", 72, 77], ["abdominal pain", "PROBLEM", 82, 96], ["fever", "OBSERVATION", 72, 77], ["abdominal", "ANATOMY", 82, 91], ["pain", "OBSERVATION", 92, 96]]], ["Her medical history is notable for cirrhosis due to chronic hepatitis C, esophageal varices, and ascites.", [["esophageal varices", "ANATOMY", 73, 91], ["ascites", "ANATOMY", 97, 104], ["cirrhosis", "DISEASE", 35, 44], ["chronic hepatitis C", "DISEASE", 52, 71], ["esophageal varices", "DISEASE", 73, 91], ["ascites", "DISEASE", 97, 104], ["esophageal varices", "PATHOLOGICAL_FORMATION", 73, 91], ["cirrhosis", "PROBLEM", 35, 44], ["chronic hepatitis C", "PROBLEM", 52, 71], ["esophageal varices", "PROBLEM", 73, 91], ["ascites", "PROBLEM", 97, 104], ["cirrhosis", "OBSERVATION", 35, 44], ["chronic", "OBSERVATION_MODIFIER", 52, 59], ["hepatitis", "OBSERVATION", 60, 69], ["esophageal", "ANATOMY", 73, 83], ["varices", "OBSERVATION", 84, 91], ["ascites", "OBSERVATION", 97, 104]]], ["Her medications are furosemide, spironolactone, nadolol, and lactulose.", [["furosemide", "CHEMICAL", 20, 30], ["spironolactone", "CHEMICAL", 32, 46], ["nadolol", "CHEMICAL", 48, 55], ["lactulose", "CHEMICAL", 61, 70], ["furosemide", "CHEMICAL", 20, 30], ["spironolactone", "CHEMICAL", 32, 46], ["nadolol", "CHEMICAL", 48, 55], ["lactulose", "CHEMICAL", 61, 70], ["furosemide", "SIMPLE_CHEMICAL", 20, 30], ["spironolactone", "SIMPLE_CHEMICAL", 32, 46], ["nadolol", "SIMPLE_CHEMICAL", 48, 55], ["lactulose", "SIMPLE_CHEMICAL", 61, 70], ["Her medications", "TREATMENT", 0, 15], ["furosemide", "TREATMENT", 20, 30], ["spironolactone", "TREATMENT", 32, 46], ["nadolol", "TREATMENT", 48, 55], ["lactulose", "TREATMENT", 61, 70]]], ["On physical examination, the temperature is 36.5 \u00b0C (97.7 \u00b0F), blood pressure is 110/60 mmHg, pulse rate is 90/min, and respiration rate is 20/min.", [["blood", "ANATOMY", 63, 68], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 63, 77], ["pulse rate", "TEST", 94, 104], ["respiration rate", "TEST", 120, 136]]], ["Abdominal examination discloses distention.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal examination", "TEST", 0, 21], ["distention", "PROBLEM", 32, 42], ["distention", "OBSERVATION", 32, 42]]], ["The abdomen is mildly tender upon palpation.ReferencesLaboratory studies show hemoglobin of 9 g/dL, leukocyte count 3,700/\u03bcL platelet count 82,000/\u03bcL, INR 1.6, albumin 2.3 g/dL, alkaline phosphatase 162 units/L, alanine aminotransferase 27 units/L, aspartate aminotransferase 32 units/L, total bilirubin 3.8 mg/dL, and creatinine 2.4 mg/dL.", [["abdomen", "ANATOMY", 4, 11], ["leukocyte", "ANATOMY", 100, 109], ["platelet", "ANATOMY", 125, 133], ["alanine", "CHEMICAL", 212, 219], ["aspartate", "CHEMICAL", 249, 258], ["bilirubin", "CHEMICAL", 294, 303], ["creatinine", "CHEMICAL", 319, 329], ["alanine", "CHEMICAL", 212, 219], ["aspartate", "CHEMICAL", 249, 258], ["bilirubin", "CHEMICAL", 294, 303], ["creatinine", "CHEMICAL", 319, 329], ["abdomen", "ORGAN", 4, 11], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 78, 88], ["leukocyte", "CELL", 100, 109], ["platelet", "CELL", 125, 133], ["albumin", "GENE_OR_GENE_PRODUCT", 160, 167], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 178, 198], ["alanine", "AMINO_ACID", 212, 219], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 220, 236], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 249, 275], ["bilirubin", "SIMPLE_CHEMICAL", 294, 303], ["creatinine", "SIMPLE_CHEMICAL", 319, 329], ["hemoglobin", "PROTEIN", 78, 88], ["INR", "PROTEIN", 151, 154], ["albumin", "PROTEIN", 160, 167], ["alkaline phosphatase", "PROTEIN", 178, 198], ["alanine aminotransferase", "PROTEIN", 212, 236], ["aspartate aminotransferase", "PROTEIN", 249, 275], ["mildly tender", "PROBLEM", 15, 28], ["palpation", "TEST", 34, 43], ["ReferencesLaboratory studies", "TEST", 44, 72], ["hemoglobin", "TEST", 78, 88], ["leukocyte count", "TEST", 100, 115], ["platelet count", "TEST", 125, 139], ["\u03bcL", "TEST", 147, 149], ["INR", "TEST", 151, 154], ["albumin", "TEST", 160, 167], ["dL", "TEST", 174, 176], ["alkaline phosphatase", "TEST", 178, 198], ["alanine aminotransferase", "TEST", 212, 236], ["aspartate aminotransferase", "TEST", 249, 275], ["total bilirubin", "TEST", 288, 303], ["creatinine", "TEST", 319, 329], ["abdomen", "ANATOMY", 4, 11], ["mildly", "OBSERVATION_MODIFIER", 15, 21], ["tender", "OBSERVATION", 22, 28], ["palpation", "OBSERVATION", 34, 43]]], ["Abdominal ultrasound reveals cirrhosis, splenomegaly, and ascites.", [["Abdominal", "ANATOMY", 0, 9], ["ascites", "ANATOMY", 58, 65], ["cirrhosis", "DISEASE", 29, 38], ["splenomegaly", "DISEASE", 40, 52], ["ascites", "DISEASE", 58, 65], ["Abdominal ultrasound", "TEST", 0, 20], ["cirrhosis", "PROBLEM", 29, 38], ["splenomegaly", "PROBLEM", 40, 52], ["ascites", "PROBLEM", 58, 65], ["cirrhosis", "OBSERVATION", 29, 38], ["splenomegaly", "OBSERVATION", 40, 52], ["ascites", "OBSERVATION", 58, 65]]], ["Diagnostic paracentesis discloses a cell count of 1,700/\u03bcL with 20 % neutrophils, a total protein level of 1.2 g/dL, and an albumin level of 0.7 g/dL.ReferencesWhich of the following is the most appropriate treatment?", [["cell", "ANATOMY", 36, 40], ["neutrophils", "ANATOMY", 69, 80], ["cell", "CELL", 36, 40], ["neutrophils", "CELL", 69, 80], ["albumin", "GENE_OR_GENE_PRODUCT", 124, 131], ["neutrophils", "CELL_TYPE", 69, 80], ["albumin", "PROTEIN", 124, 131], ["Diagnostic paracentesis", "TEST", 0, 23], ["a cell count", "TEST", 34, 46], ["neutrophils", "TEST", 69, 80], ["a total protein level", "TEST", 82, 103], ["an albumin level", "TEST", 121, 137]]], ["A) Cefotaxime B) Cefotaxime and albumin C) Furosemide and spironolactone D) Large-volume paracentesis E) Vancomycin and cefotaxime F) Ciprofl oxacin Answer: B This patient has spontaneous bacterial peritonitis and acute kidney injury .", [["kidney", "ANATOMY", 220, 226], ["Cefotaxime B", "CHEMICAL", 3, 15], ["Cefotaxime", "CHEMICAL", 17, 27], ["Furosemide", "CHEMICAL", 43, 53], ["spironolactone", "CHEMICAL", 58, 72], ["Vancomycin", "CHEMICAL", 105, 115], ["cefotaxime", "CHEMICAL", 120, 130], ["bacterial peritonitis", "DISEASE", 188, 209], ["acute kidney injury", "DISEASE", 214, 233], ["Cefotaxime B", "CHEMICAL", 3, 15], ["Cefotaxime", "CHEMICAL", 17, 27], ["Furosemide", "CHEMICAL", 43, 53], ["spironolactone D", "CHEMICAL", 58, 74], ["Vancomycin", "CHEMICAL", 105, 115], ["cefotaxime F", "CHEMICAL", 120, 132], ["Ciprofl oxacin", "CHEMICAL", 134, 148], ["Cefotaxime B", "SIMPLE_CHEMICAL", 3, 15], ["Cefotaxime", "SIMPLE_CHEMICAL", 17, 27], ["albumin C", "SIMPLE_CHEMICAL", 32, 41], ["Furosemide", "SIMPLE_CHEMICAL", 43, 53], ["spironolactone D", "SIMPLE_CHEMICAL", 58, 74], ["Vancomycin", "SIMPLE_CHEMICAL", 105, 115], ["cefotaxime F", "SIMPLE_CHEMICAL", 120, 132], ["Ciprofl oxacin", "SIMPLE_CHEMICAL", 134, 148], ["patient", "ORGANISM", 164, 171], ["kidney", "ORGAN", 220, 226], ["patient", "SPECIES", 164, 171], ["A) Cefotaxime B)", "TREATMENT", 0, 16], ["Cefotaxime", "TREATMENT", 17, 27], ["albumin C", "TREATMENT", 32, 41], ["Furosemide", "TREATMENT", 43, 53], ["spironolactone D", "TREATMENT", 58, 74], ["Large-volume paracentesis E", "TREATMENT", 76, 103], ["Vancomycin", "TREATMENT", 105, 115], ["cefotaxime F", "TREATMENT", 120, 132], ["Ciprofl oxacin", "TREATMENT", 134, 148], ["spontaneous bacterial peritonitis", "PROBLEM", 176, 209], ["acute kidney injury", "PROBLEM", 214, 233], ["bacterial", "OBSERVATION_MODIFIER", 188, 197], ["peritonitis", "OBSERVATION", 198, 209], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["kidney", "ANATOMY", 220, 226], ["injury", "OBSERVATION", 227, 233]]], ["The diagnosis of spontaneous bacterial peritonitis (SBP) is made in the setting of an elevated ascitic fl uid absolute polymorphonuclear (PMN) cell count of greater than 250/\u03bcl without evidence of secondary causes of peritonitis.", [["polymorphonuclear (PMN) cell", "ANATOMY", 119, 147], ["bacterial peritonitis", "DISEASE", 29, 50], ["peritonitis", "DISEASE", 217, 228], ["polymorphonuclear (PMN) cell", "CELL", 119, 147], ["PMN", "CELL_TYPE", 138, 141], ["spontaneous bacterial peritonitis", "PROBLEM", 17, 50], ["SBP", "TEST", 52, 55], ["an elevated ascitic fl uid", "PROBLEM", 83, 109], ["polymorphonuclear (PMN", "TEST", 119, 141], ["cell count", "TEST", 143, 153], ["secondary causes", "PROBLEM", 197, 213], ["peritonitis", "PROBLEM", 217, 228], ["spontaneous", "OBSERVATION_MODIFIER", 17, 28], ["bacterial", "OBSERVATION_MODIFIER", 29, 38], ["peritonitis", "OBSERVATION", 39, 50], ["elevated", "OBSERVATION_MODIFIER", 86, 94], ["ascitic fl", "OBSERVATION", 95, 105], ["without evidence of", "UNCERTAINTY", 177, 196], ["peritonitis", "OBSERVATION", 217, 228]]], ["A positive bacterial culture of the ascitic fl uid is not needed.", [["ascitic fl uid", "ANATOMY", 36, 50], ["A positive bacterial culture", "TEST", 0, 28], ["the ascitic fl uid", "TEST", 32, 50], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["bacterial culture", "OBSERVATION", 11, 28], ["ascitic fl uid", "OBSERVATION", 36, 50]]], ["Intravenous cefotaxime or a similar third-generation cephalosporin is the treatment of choice for SBP.", [["cefotaxime", "CHEMICAL", 12, 22], ["cephalosporin", "CHEMICAL", 53, 66], ["cefotaxime", "CHEMICAL", 12, 22], ["cephalosporin", "CHEMICAL", 53, 66], ["cefotaxime", "SIMPLE_CHEMICAL", 12, 22], ["cephalosporin", "SIMPLE_CHEMICAL", 53, 66], ["Intravenous cefotaxime", "TREATMENT", 0, 22], ["a similar third-generation cephalosporin", "TREATMENT", 26, 66], ["SBP", "PROBLEM", 98, 101]]], ["However per Cochrane review, this class has not been shown to be superior to other classes of antibiotics.", [["antibiotics", "TREATMENT", 94, 105]]], ["Most common isolates are Escherichia coli , Klebsiella pneumoniae , and pneumococci.", [["Klebsiella pneumoniae", "DISEASE", 44, 65], ["Escherichia coli", "ORGANISM", 25, 41], ["Klebsiella pneumoniae", "ORGANISM", 44, 65], ["pneumococci", "CANCER", 72, 83], ["Escherichia coli", "SPECIES", 25, 41], ["Klebsiella pneumoniae", "SPECIES", 44, 65], ["Escherichia coli", "SPECIES", 25, 41], ["Klebsiella pneumoniae", "SPECIES", 44, 65], ["Escherichia coli", "PROBLEM", 25, 41], ["Klebsiella pneumoniae", "PROBLEM", 44, 65], ["pneumococci", "PROBLEM", 72, 83], ["Escherichia coli", "OBSERVATION", 25, 41], ["Klebsiella pneumoniae", "OBSERVATION", 44, 65], ["pneumococci", "OBSERVATION", 72, 83]]], ["Vancomycin is not needed for initial treatment.", [["Vancomycin", "CHEMICAL", 0, 10], ["Vancomycin", "CHEMICAL", 0, 10], ["Vancomycin", "SIMPLE_CHEMICAL", 0, 10], ["Vancomycin", "TREATMENT", 0, 10], ["initial treatment", "TREATMENT", 29, 46]]], ["Oral fl uoroquinolone treatment may be indicated in mild cases treated as an outpatient.", [["Oral", "ANATOMY", 0, 4], ["fl uoroquinolone", "CHEMICAL", 5, 21], ["uoroquinolone", "CHEMICAL", 8, 21], ["Oral fl uoroquinolone", "SIMPLE_CHEMICAL", 0, 21], ["Oral fl uoroquinolone treatment", "TREATMENT", 0, 31]]], ["Several strategies may be employed to improve renal vascular fl ow in the setting of SBP.", [["renal vascular", "ANATOMY", 46, 60], ["renal vascular", "MULTI-TISSUE_STRUCTURE", 46, 60], ["SBP", "PROBLEM", 85, 88], ["vascular", "ANATOMY", 52, 60], ["fl", "OBSERVATION", 61, 63]]], ["Intravenous albumin is the most widely used.", [["albumin", "GENE_OR_GENE_PRODUCT", 12, 19], ["Intravenous albumin", "TREATMENT", 0, 19], ["albumin", "OBSERVATION", 12, 19], ["most widely", "OBSERVATION_MODIFIER", 27, 38]]], ["The use of cefotaxime plus intravenous albumin at 1.5 g/kg on day 3 has been shown to decrease in-hospital mortality by 20 % in patients with serum creatinine values of 1.5 mg/dL or greater.", [["intravenous", "ANATOMY", 27, 38], ["serum", "ANATOMY", 142, 147], ["cefotaxime", "CHEMICAL", 11, 21], ["creatinine", "CHEMICAL", 148, 158], ["cefotaxime", "CHEMICAL", 11, 21], ["creatinine", "CHEMICAL", 148, 158], ["cefotaxime", "SIMPLE_CHEMICAL", 11, 21], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 38], ["albumin", "SIMPLE_CHEMICAL", 39, 46], ["patients", "ORGANISM", 128, 136], ["serum", "ORGANISM_SUBSTANCE", 142, 147], ["creatinine", "SIMPLE_CHEMICAL", 148, 158], ["patients", "SPECIES", 128, 136], ["cefotaxime", "TREATMENT", 11, 21], ["intravenous albumin", "TREATMENT", 27, 46], ["serum creatinine values", "TEST", 142, 165], ["greater", "OBSERVATION_MODIFIER", 182, 189]]], ["There is no evidence that largevolume paracentesis improves outcomes in patients with SBP and should be done with caution.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["largevolume paracentesis", "TREATMENT", 26, 50], ["SBP", "TEST", 86, 89], ["no evidence that", "UNCERTAINTY", 9, 25], ["largevolume", "OBSERVATION_MODIFIER", 26, 37], ["paracentesis", "OBSERVATION", 38, 50]]], ["Excessive fl uid shifts may worsen kidney function.ReferencesChavez- Tapia 79.", [["kidney", "ANATOMY", 35, 41], ["kidney", "ORGAN", 35, 41], ["Excessive fl uid shifts", "PROBLEM", 0, 23], ["fl uid", "OBSERVATION", 10, 16], ["kidney", "ANATOMY", 35, 41]]], ["A 55-year-old female presents to the emergency department 5 h after the onset of left hemiplegia and right gaze deviation.", [["left hemiplegia", "DISEASE", 81, 96], ["female", "ORGANISM", 14, 20], ["left hemiplegia", "PROBLEM", 81, 96], ["right gaze deviation", "PROBLEM", 101, 121], ["left", "ANATOMY_MODIFIER", 81, 85], ["hemiplegia", "OBSERVATION", 86, 96], ["right", "ANATOMY_MODIFIER", 101, 106], ["gaze deviation", "OBSERVATION", 107, 121]]], ["CT scan reveals an early large infarct.", [["infarct", "DISEASE", 31, 38], ["CT scan", "TEST", 0, 7], ["an early large infarct", "PROBLEM", 16, 38], ["early", "OBSERVATION_MODIFIER", 19, 24], ["large", "OBSERVATION_MODIFIER", 25, 30], ["infarct", "OBSERVATION", 31, 38]]], ["Her airway appears to be intact and she is arousable.", [["airway", "ANATOMY", 4, 10], ["Her", "ORGANISM", 0, 3], ["airway", "MULTI-TISSUE_STRUCTURE", 4, 10], ["airway", "ANATOMY", 4, 10], ["appears to be", "UNCERTAINTY", 11, 24], ["intact", "OBSERVATION", 25, 31]]], ["Ten hours later, the patient becomes somnolent.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["somnolent", "PROBLEM", 37, 46], ["somnolent", "OBSERVATION", 37, 46]]], ["On repeat examination, she is no longer responsive to voice and has minimal withdrawal to pain.", [["pain", "DISEASE", 90, 94], ["repeat examination", "TEST", 3, 21], ["longer responsive", "PROBLEM", 33, 50], ["minimal withdrawal to pain", "PROBLEM", 68, 94], ["no longer", "UNCERTAINTY", 30, 39], ["minimal", "OBSERVATION_MODIFIER", 68, 75], ["withdrawal", "OBSERVATION", 76, 86]]], ["The right pupil is large, irregular, and unresponsive.", [["right pupil", "ANATOMY", 4, 15], ["pupil", "ORGAN", 10, 15], ["unresponsive", "PROBLEM", 41, 53], ["right", "ANATOMY_MODIFIER", 4, 9], ["pupil", "ANATOMY", 10, 15], ["large", "OBSERVATION", 19, 24], ["irregular", "OBSERVATION_MODIFIER", 26, 35], ["unresponsive", "OBSERVATION", 41, 53]]], ["Repeat CT scan of the head reveals a 10 mm midline shift as well as the evolution of a well-demarcated right middle cerebral artery infarction.ReferencesWhich of the following is the most appropriate next step in her treatment and management?", [["head", "ANATOMY", 22, 26], ["right middle cerebral artery", "ANATOMY", 103, 131], ["cerebral artery infarction", "DISEASE", 116, 142], ["head", "ORGAN", 22, 26], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 116, 131], ["Repeat CT scan of the head", "TEST", 0, 26], ["a 10 mm midline shift", "PROBLEM", 35, 56], ["a well-demarcated right middle cerebral artery infarction", "PROBLEM", 85, 142], ["her treatment", "TREATMENT", 213, 226], ["management", "TREATMENT", 231, 241], ["head", "ANATOMY", 22, 26], ["10 mm", "OBSERVATION_MODIFIER", 37, 42], ["midline", "ANATOMY_MODIFIER", 43, 50], ["shift", "OBSERVATION", 51, 56], ["demarcated", "OBSERVATION_MODIFIER", 92, 102], ["right middle cerebral artery", "ANATOMY", 103, 131], ["infarction", "OBSERVATION", 132, 142]]], ["A) Neurosurgical consultation for possible hemicraniectomy B) Dexamethasone intravenously C) Transfer to the intensive care unit for intracranial pressure monitoring D) Aspirin E) Bedside intubation Answer: A Patients who have a large territory infarcts are at risk for herniation and should have frequent neurologic checks to follow for signs of deterioration.", [["intracranial", "ANATOMY", 133, 145], ["neurologic", "ANATOMY", 306, 316], ["Dexamethasone", "CHEMICAL", 62, 75], ["Aspirin", "CHEMICAL", 169, 176], ["infarcts", "DISEASE", 245, 253], ["herniation", "DISEASE", 270, 280], ["Dexamethasone", "CHEMICAL", 62, 75], ["Aspirin E", "CHEMICAL", 169, 178], ["Dexamethasone", "SIMPLE_CHEMICAL", 62, 75], ["Patients", "ORGANISM", 209, 217], ["Patients", "SPECIES", 209, 217], ["Neurosurgical consultation", "TEST", 3, 29], ["hemicraniectomy B) Dexamethasone", "TREATMENT", 43, 75], ["intracranial pressure monitoring", "TREATMENT", 133, 165], ["Aspirin E)", "TREATMENT", 169, 179], ["Bedside intubation", "TREATMENT", 180, 198], ["a large territory infarcts", "PROBLEM", 227, 253], ["herniation", "PROBLEM", 270, 280], ["frequent neurologic checks", "TEST", 297, 323], ["deterioration", "PROBLEM", 347, 360], ["large", "OBSERVATION_MODIFIER", 229, 234], ["territory", "OBSERVATION_MODIFIER", 235, 244], ["infarcts", "OBSERVATION", 245, 253], ["herniation", "OBSERVATION", 270, 280]]], ["Early repeat imaging and neurosurgical consult is warranted with signifi cant clinical decline.", [["Early repeat imaging", "TEST", 0, 20], ["signifi cant clinical decline", "PROBLEM", 65, 94]]], ["Three separate European studies reveal that hemicraniectomy reduces mortality and severe disability in patients with malignant middle cerebral artery infarction.", [["malignant middle cerebral artery", "ANATOMY", 117, 149], ["hemicraniectomy", "DISEASE", 44, 59], ["disability", "DISEASE", 89, 99], ["malignant middle cerebral artery infarction", "DISEASE", 117, 160], ["patients", "ORGANISM", 103, 111], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 134, 149], ["patients", "SPECIES", 103, 111], ["Three separate European studies", "TEST", 0, 31], ["hemicraniectomy reduces mortality", "PROBLEM", 44, 77], ["severe disability", "PROBLEM", 82, 99], ["malignant middle cerebral artery infarction", "PROBLEM", 117, 160], ["hemicraniectomy", "OBSERVATION", 44, 59], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["malignant", "OBSERVATION", 117, 126], ["middle cerebral artery", "ANATOMY", 127, 149], ["infarction", "OBSERVATION", 150, 160]]], ["This benefi t is greatest if performed within the fi rst 48 h after stroke and optimally before clinical herniation has occurred.", [["stroke", "DISEASE", 68, 74], ["herniation", "DISEASE", 105, 115], ["stroke", "PROBLEM", 68, 74], ["clinical herniation", "PROBLEM", 96, 115], ["herniation", "OBSERVATION", 105, 115]]], ["This patient has evidence of elevated clinical intracranial pressure, and urgent neurosurgical consultation is needed as well as repeat imaging.", [["intracranial", "ANATOMY", 47, 59], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["elevated clinical intracranial pressure", "PROBLEM", 29, 68], ["urgent neurosurgical consultation", "TEST", 74, 107], ["repeat imaging", "TEST", 129, 143], ["evidence of", "UNCERTAINTY", 17, 28], ["elevated", "OBSERVATION_MODIFIER", 29, 37], ["intracranial pressure", "OBSERVATION", 47, 68]]], ["The neurosurgical consult should come fi rst while arranging for imaging, intensive care unit transfer, and further supportive measures.ReferenceGupta R, Connolly ES, Mayer S, Elkind MSV.", [["Elkind MSV", "ORGANISM", 176, 186], ["imaging", "TEST", 65, 72], ["further supportive measures", "TREATMENT", 108, 135]]], ["Hemicraniectomy for massive middle cerebral artery territory infarction: a systematic review.", [["middle cerebral artery", "ANATOMY", 28, 50], ["Hemicraniectomy", "DISEASE", 0, 15], ["middle cerebral artery territory infarction", "DISEASE", 28, 71], ["cerebral artery", "MULTI-TISSUE_STRUCTURE", 35, 50], ["Hemicraniectomy", "TREATMENT", 0, 15], ["massive middle cerebral artery territory infarction", "PROBLEM", 20, 71], ["a systematic review", "TEST", 73, 92], ["massive", "OBSERVATION_MODIFIER", 20, 27], ["middle cerebral artery", "ANATOMY", 28, 50], ["territory", "OBSERVATION_MODIFIER", 51, 60], ["infarction", "OBSERVATION", 61, 71]]], ["Stroke.", [["Stroke", "DISEASE", 0, 6], ["Stroke", "PROBLEM", 0, 6]]], ["A 54-year-old male is admitted for observation after suffering a concussion in a syncopal episode and suffering a laceration of the head.", [["head", "ANATOMY", 132, 136], ["concussion", "DISEASE", 65, 75], ["syncopal", "DISEASE", 81, 89], ["laceration of the head", "DISEASE", 114, 136], ["male", "ORGANISM", 14, 18], ["head", "ORGANISM_SUBDIVISION", 132, 136], ["a concussion", "PROBLEM", 63, 75], ["a syncopal episode", "PROBLEM", 79, 97], ["a laceration of the head", "PROBLEM", 112, 136], ["laceration", "OBSERVATION", 114, 124], ["head", "ANATOMY", 132, 136]]], ["On presentation he continues to feel slightly dizzy and is noted to be dehydrated.", [["dizzy", "DISEASE", 46, 51], ["slightly dizzy", "PROBLEM", 37, 51], ["dehydrated", "PROBLEM", 71, 81], ["dehydrated", "OBSERVATION", 71, 81]]], ["He has no past medical history and no meds.", [["meds", "TREATMENT", 38, 42], ["no", "UNCERTAINTY", 7, 9]]], ["He also reports increased thirst and urination for the past month.", [["increased thirst and urination", "DISEASE", 16, 46], ["increased thirst and urination", "PROBLEM", 16, 46], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["thirst", "OBSERVATION", 26, 32]]], ["Urinalysis reveals 2+ glucose.", [["glucose", "CHEMICAL", 22, 29], ["glucose", "CHEMICAL", 22, 29], ["2+ glucose", "SIMPLE_CHEMICAL", 19, 29], ["Urinalysis", "TEST", 0, 10], ["glucose", "TEST", 22, 29]]], ["His blood sugar is 305 mg/dl.", [["blood", "ANATOMY", 4, 9], ["sugar", "CHEMICAL", 10, 15], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["sugar", "SIMPLE_CHEMICAL", 10, 15], ["His blood sugar", "TEST", 0, 15]]], ["His hemoglobin A1C is 11 %.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 4, 14], ["hemoglobin", "PROTEIN", 4, 14], ["His hemoglobin A1C", "TEST", 0, 18]]], ["He is started on intravenous fl uids in the emergency room.ReferenceWhat is an appropriate initial diabetic regimen for this patient?", [["intravenous", "ANATOMY", 17, 28], ["diabetic", "DISEASE", 99, 107], ["patient", "ORGANISM", 125, 132], ["patient", "SPECIES", 125, 132], ["intravenous fl uids", "TREATMENT", 17, 36], ["an appropriate initial diabetic regimen", "TREATMENT", 76, 115]]], ["A) Metformin 500 mg PO BID B) Insulin C) Januvia 100 mg PO daily D) Metformin 500 mg PO BID and glipizide 5 mg PO daily Answer: B Initial diabetic therapy is guided by hemoglobin A1C and symptoms.", [["Metformin", "CHEMICAL", 3, 12], ["Januvia", "CHEMICAL", 41, 48], ["Metformin", "CHEMICAL", 68, 77], ["glipizide", "CHEMICAL", 96, 105], ["diabetic", "DISEASE", 138, 146], ["Metformin", "CHEMICAL", 3, 12], ["BID B", "CHEMICAL", 23, 28], ["Metformin", "CHEMICAL", 68, 77], ["BID", "CHEMICAL", 88, 91], ["glipizide", "CHEMICAL", 96, 105], ["Metformin", "SIMPLE_CHEMICAL", 3, 12], ["Insulin C", "SIMPLE_CHEMICAL", 30, 39], ["Metformin", "SIMPLE_CHEMICAL", 68, 77], ["BID", "SIMPLE_CHEMICAL", 88, 91], ["glipizide", "SIMPLE_CHEMICAL", 96, 105], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 168, 178], ["hemoglobin", "PROTEIN", 168, 178], ["Metformin", "TREATMENT", 3, 12], ["Insulin C)", "TREATMENT", 30, 40], ["Januvia", "TREATMENT", 41, 48], ["Metformin", "TREATMENT", 68, 77], ["glipizide", "TREATMENT", 96, 105], ["Initial diabetic therapy", "TREATMENT", 130, 154], ["hemoglobin A1C", "TEST", 168, 182], ["symptoms", "PROBLEM", 187, 195]]], ["According to the American Diabetes Association (ADA), the recommended goal A1C for this patient is less than 7 %.", [["Diabetes", "DISEASE", 26, 34], ["patient", "ORGANISM", 88, 95], ["patient", "SPECIES", 88, 95], ["A1C", "TEST", 75, 78]]], ["Metformin as monotherapy, if not contraindicated, may be fi rst-line therapy.", [["Metformin", "CHEMICAL", 0, 9], ["Metformin", "CHEMICAL", 0, 9], ["Metformin", "SIMPLE_CHEMICAL", 0, 9], ["Metformin", "TREATMENT", 0, 9], ["monotherapy", "TREATMENT", 13, 24], ["fi rst-line therapy", "TREATMENT", 57, 76], ["line therapy", "OBSERVATION", 64, 76]]], ["However, in newly diagnosed type 2 diabetics with marked symptoms and/or highly elevated blood glucose or A1C, insulin therapy is indicated.", [["blood", "ANATOMY", 89, 94], ["diabetics", "DISEASE", 35, 44], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 95, 102], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["A1C", "SIMPLE_CHEMICAL", 106, 109], ["insulin", "GENE_OR_GENE_PRODUCT", 111, 118], ["type 2 diabetics", "PROBLEM", 28, 44], ["marked symptoms", "PROBLEM", 50, 65], ["highly elevated blood glucose", "PROBLEM", 73, 102], ["A1C", "TEST", 106, 109], ["insulin therapy", "TREATMENT", 111, 126]]], ["The American Association of Clinical Endocrinology has more specifi c guidelines with respect to initiating therapy.", [["therapy", "TREATMENT", 108, 115]]], ["Specifi cally, when the entry level A1C is greater than 9 % and/or the patient is symptomatic (urinalysis 2+ glucose, polydipsia, polyuria), insulin plus or minus other agents is recommended.", [["glucose", "CHEMICAL", 109, 116], ["polydipsia", "DISEASE", 118, 128], ["polyuria", "DISEASE", 130, 138], ["insulin", "CHEMICAL", 141, 148], ["glucose", "CHEMICAL", 109, 116], ["patient", "ORGANISM", 71, 78], ["glucose", "SIMPLE_CHEMICAL", 109, 116], ["insulin", "GENE_OR_GENE_PRODUCT", 141, 148], ["patient", "SPECIES", 71, 78], ["the entry level A1C", "TEST", 20, 39], ["symptomatic", "PROBLEM", 82, 93], ["urinalysis", "TEST", 95, 105], ["glucose", "TEST", 109, 116], ["polydipsia", "PROBLEM", 118, 128], ["polyuria", "PROBLEM", 130, 138], ["insulin", "TREATMENT", 141, 148], ["minus other agents", "TREATMENT", 157, 175]]], ["Monotherapy is recommended when the entry A1C is less than 7.5 %.", [["Monotherapy", "TREATMENT", 0, 11], ["the entry A1C", "TEST", 32, 45]]], ["Similarly, dual therapy is recommended when the entry level A1C is greater than or equal to 7.5 %, but less than 9 %.", [["A1C", "PROTEIN", 60, 63], ["dual therapy", "TREATMENT", 11, 23], ["the entry level A1C", "TEST", 44, 63]]], ["Additionally, the oral agents will drop the A1C by approximately 1-2 % (not all oral agents); therefore, this would not be an adequate decrease for a patient with an A1C of 9 % or greater.81.A 50-year-old male is admitted due to observation for chest pain and the possibility of myocardial ischemia.", [["oral", "ANATOMY", 18, 22], ["oral", "ANATOMY", 80, 84], ["chest", "ANATOMY", 245, 250], ["myocardial", "ANATOMY", 279, 289], ["chest pain", "DISEASE", 245, 255], ["myocardial ischemia", "DISEASE", 279, 298], ["oral", "ORGANISM_SUBDIVISION", 18, 22], ["oral", "ORGANISM_SUBDIVISION", 80, 84], ["patient", "ORGANISM", 150, 157], ["male", "ORGANISM", 205, 209], ["chest", "ORGANISM_SUBDIVISION", 245, 250], ["myocardial", "MULTI-TISSUE_STRUCTURE", 279, 289], ["patient", "SPECIES", 150, 157], ["the oral agents", "TREATMENT", 14, 29], ["the A1C", "TEST", 40, 47], ["an A1C", "TEST", 163, 169], ["chest pain", "PROBLEM", 245, 255], ["myocardial ischemia", "PROBLEM", 279, 298], ["adequate", "OBSERVATION_MODIFIER", 126, 134], ["decrease", "OBSERVATION", 135, 143], ["greater", "OBSERVATION_MODIFIER", 180, 187], ["chest", "ANATOMY", 245, 250], ["myocardial", "ANATOMY", 279, 289], ["ischemia", "OBSERVATION", 290, 298]]], ["On presentation, he reported a brief episode of burning chest pain that occurred with maximal exertion.", [["chest", "ANATOMY", 56, 61], ["chest pain", "DISEASE", 56, 66], ["chest", "ORGANISM_SUBDIVISION", 56, 61], ["burning chest pain", "PROBLEM", 48, 66], ["chest", "ANATOMY", 56, 61], ["pain", "OBSERVATION", 62, 66]]], ["The pain lasted less than a minute.", [["pain", "DISEASE", 4, 8], ["The pain", "PROBLEM", 0, 8], ["pain", "OBSERVATION", 4, 8]]], ["Since admission, he has had no further chest pain.", [["chest", "ANATOMY", 39, 44], ["chest pain", "DISEASE", 39, 49], ["chest", "ORGANISM_SUBDIVISION", 39, 44], ["further chest pain", "PROBLEM", 31, 49], ["no", "UNCERTAINTY", 28, 30], ["chest", "ANATOMY", 39, 44], ["pain", "OBSERVATION", 45, 49]]], ["He has a positive family history for coronary artery disease.", [["coronary artery", "ANATOMY", 37, 52], ["coronary artery disease", "DISEASE", 37, 60], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 37, 52], ["coronary artery disease", "PROBLEM", 37, 60], ["positive", "OBSERVATION", 9, 17], ["coronary artery", "ANATOMY", 37, 52], ["disease", "OBSERVATION", 53, 60]]], ["On the fi rst day of admission, blood pressure is noted to be 180/100.81.Which of the following is the most appropriate medicine for the treatment of his hypertension?81.Answer: B Beta-blockers are the best initial antihypertensive agent to use when the possibility of cardiac ischemia is present.", [["blood", "ANATOMY", 32, 37], ["cardiac", "ANATOMY", 269, 276], ["hypertension", "DISEASE", 154, 166], ["cardiac ischemia", "DISEASE", 269, 285], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["cardiac", "ORGAN", 269, 276], ["blood pressure", "TEST", 32, 46], ["his hypertension", "PROBLEM", 150, 166], ["B Beta-blockers", "TREATMENT", 178, 193], ["initial antihypertensive agent", "TREATMENT", 207, 237], ["cardiac ischemia", "PROBLEM", 269, 285], ["hypertension", "OBSERVATION", 154, 166], ["cardiac", "ANATOMY", 269, 276], ["ischemia", "OBSERVATION", 277, 285]]], ["This would be a reasonable fi rst-line choice until the possibility of coronary artery disease is explored.", [["coronary artery", "ANATOMY", 71, 86], ["coronary artery disease", "DISEASE", 71, 94], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 71, 86], ["a reasonable fi rst-line choice", "TREATMENT", 14, 45], ["coronary artery disease", "PROBLEM", 71, 94], ["coronary artery", "ANATOMY", 71, 86], ["disease", "OBSERVATION", 87, 94]]], ["A-65-year-old male with a past medical history of hypertension is admitted with the diagnosis of a pulmonary embolism and is started on intravenous heparin.", [["pulmonary", "ANATOMY", 99, 108], ["intravenous", "ANATOMY", 136, 147], ["hypertension", "DISEASE", 50, 62], ["pulmonary embolism", "DISEASE", 99, 117], ["heparin", "CHEMICAL", 148, 155], ["male", "ORGANISM", 14, 18], ["pulmonary", "ORGAN", 99, 108], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 147], ["heparin", "SIMPLE_CHEMICAL", 148, 155], ["hypertension", "PROBLEM", 50, 62], ["a pulmonary embolism", "PROBLEM", 97, 117], ["intravenous heparin", "TREATMENT", 136, 155], ["hypertension", "OBSERVATION", 50, 62], ["pulmonary", "ANATOMY", 99, 108], ["embolism", "OBSERVATION", 109, 117]]], ["After being transported to his room, his heart rate increases to 130 bmp with a blood pressure of 100/60 mmHg.", [["heart", "ANATOMY", 41, 46], ["blood", "ANATOMY", 80, 85], ["heart", "ORGAN", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["his heart rate", "TEST", 37, 51], ["a blood pressure", "TEST", 78, 94], ["heart", "ANATOMY", 41, 46]]], ["An ECG reveals atrial fi brillation with rapid ventricular response.", [["atrial", "ANATOMY", 15, 21], ["ventricular", "ANATOMY", 47, 58], ["ventricular", "MULTI-TISSUE_STRUCTURE", 47, 58], ["An ECG", "TEST", 0, 6], ["atrial fi brillation", "PROBLEM", 15, 35], ["rapid ventricular response", "PROBLEM", 41, 67], ["atrial", "ANATOMY", 15, 21], ["fi brillation", "OBSERVATION", 22, 35], ["rapid ventricular response", "OBSERVATION", 41, 67]]], ["Rate control is attempted with three doses of IV 5 mg Lopressor, but failed to decrease heart rate.", [["heart", "ANATOMY", 88, 93], ["heart", "ORGAN", 88, 93], ["Rate control", "TREATMENT", 0, 12], ["IV 5 mg Lopressor", "TREATMENT", 46, 63], ["heart rate", "TEST", 88, 98], ["heart", "ANATOMY", 88, 93]]], ["A Cardizem drip is started.ReferenceWhile at the bedside the patient's heart rate increases to 150 bpm and he begins to complain of chest pain.", [["heart", "ANATOMY", 71, 76], ["chest", "ANATOMY", 132, 137], ["chest pain", "DISEASE", 132, 142], ["patient", "ORGANISM", 61, 68], ["heart", "ORGAN", 71, 76], ["chest", "ORGANISM_SUBDIVISION", 132, 137], ["patient", "SPECIES", 61, 68], ["A Cardizem drip", "TREATMENT", 0, 15], ["the patient's heart rate", "TEST", 57, 81], ["chest pain", "PROBLEM", 132, 142], ["heart", "ANATOMY", 71, 76], ["chest", "ANATOMY", 132, 137]]], ["A repeat blood pressure is checked and noted to be 80/40.", [["blood", "ANATOMY", 9, 14], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["A repeat blood pressure", "TEST", 0, 23]]], ["You begin a 500 cc bolus of normal saline but the patient experiences a syncopal episode while sitting in bed.", [["syncopal", "DISEASE", 72, 80], ["saline", "SIMPLE_CHEMICAL", 35, 41], ["patient", "ORGANISM", 50, 57], ["patient", "SPECIES", 50, 57], ["a 500 cc bolus", "TREATMENT", 10, 24], ["normal saline", "TREATMENT", 28, 41], ["a syncopal episode", "PROBLEM", 70, 88]]], ["Pulses are faintly palpable and respirations remain intact.", [["Pulses", "TEST", 0, 6], ["faintly", "OBSERVATION_MODIFIER", 11, 18], ["palpable", "OBSERVATION", 19, 27], ["intact", "OBSERVATION", 52, 58]]], ["A cardiac code is called.ReferenceWhat is the most appropriate next step in acute management after activating the emergency response team?", [["cardiac", "ANATOMY", 2, 9], ["cardiac", "ORGAN", 2, 9], ["acute management", "TREATMENT", 76, 92], ["cardiac", "ANATOMY", 2, 9], ["acute", "OBSERVATION_MODIFIER", 76, 81]]], ["A) Place the patient in reverse Trendelenburg.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20]]], ["B) Begin chest compressions at a rate of 30:2.", [["chest", "ANATOMY", 9, 14], ["chest", "ORGAN", 9, 14], ["chest compressions", "TREATMENT", 9, 27], ["a rate", "TEST", 31, 37], ["chest", "ANATOMY", 9, 14]]], ["C) Push Lopressor 5 mg IV \u00d7 1 dose.", [["Push Lopressor", "TREATMENT", 3, 17]]], ["D) Immediate R-wave synchronized direct-current cardioversion.ReferenceAnswer: D When a rapid ventricular response does not respond promptly to pharmacologic measures for patients with atrial fi brillation with ongoing myocardial ischemia, symptomatic hypotension, angina, or heart failure, immediate R-wave synchronized direct-current cardioversion is recommended.83.A 75-year-old man was admitted to the hospital for diarrhea and hypotension.", [["ventricular", "ANATOMY", 94, 105], ["atrial", "ANATOMY", 185, 191], ["myocardial", "ANATOMY", 219, 229], ["heart", "ANATOMY", 276, 281], ["atrial fi brillation", "DISEASE", 185, 205], ["myocardial ischemia", "DISEASE", 219, 238], ["hypotension", "DISEASE", 252, 263], ["angina", "DISEASE", 265, 271], ["heart failure", "DISEASE", 276, 289], ["diarrhea", "DISEASE", 419, 427], ["hypotension", "DISEASE", 432, 443], ["ventricular", "MULTI-TISSUE_STRUCTURE", 94, 105], ["patients", "ORGANISM", 171, 179], ["myocardial", "MULTI-TISSUE_STRUCTURE", 219, 229], ["heart", "ORGAN", 276, 281], ["man", "ORGANISM", 382, 385], ["patients", "SPECIES", 171, 179], ["man", "SPECIES", 382, 385], ["Immediate R-wave synchronized direct", "TREATMENT", 3, 39], ["current cardioversion", "TREATMENT", 40, 61], ["a rapid ventricular response", "PROBLEM", 86, 114], ["pharmacologic measures", "TREATMENT", 144, 166], ["atrial fi brillation", "PROBLEM", 185, 205], ["ongoing myocardial ischemia", "PROBLEM", 211, 238], ["symptomatic hypotension", "PROBLEM", 240, 263], ["angina", "PROBLEM", 265, 271], ["heart failure", "PROBLEM", 276, 289], ["current cardioversion", "TREATMENT", 328, 349], ["diarrhea", "PROBLEM", 419, 427], ["hypotension", "PROBLEM", 432, 443], ["atrial fi", "ANATOMY", 185, 194], ["myocardial", "ANATOMY", 219, 229], ["ischemia", "OBSERVATION", 230, 238], ["symptomatic", "OBSERVATION_MODIFIER", 240, 251], ["hypotension", "OBSERVATION", 252, 263], ["angina", "OBSERVATION", 265, 271], ["heart", "ANATOMY", 276, 281], ["failure", "OBSERVATION", 282, 289], ["diarrhea", "OBSERVATION", 419, 427], ["hypotension", "OBSERVATION", 432, 443]]], ["During the past year, he has had four prior admissions because of similar problems.", [["similar problems", "PROBLEM", 66, 82]]], ["Polymerase chain reaction assay comes back positive for Clostridium diffi cile infection.", [["infection", "DISEASE", 79, 88], ["Clostridium diffi cile", "ORGANISM", 56, 78], ["Clostridium diffi", "SPECIES", 56, 73], ["Clostridium diffi cile", "SPECIES", 56, 78], ["Polymerase chain reaction assay", "TEST", 0, 31], ["Clostridium diffi cile infection", "PROBLEM", 56, 88], ["infection", "OBSERVATION", 79, 88]]], ["This is his third confi rmed Clostridium diffi cile infection documented by stool polymerase chain reaction assay.", [["infection", "DISEASE", 52, 61], ["Clostridium diffi", "SPECIES", 29, 46], ["Clostridium diffi cile", "SPECIES", 29, 51], ["his third confi rmed Clostridium diffi cile infection", "PROBLEM", 8, 61], ["stool polymerase chain reaction assay", "PROBLEM", 76, 113]]], ["On physical exam, the patient's blood pressure is 80/40 mmHg.", [["blood", "ANATOMY", 32, 37], ["patient", "ORGANISM", 22, 29], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["patient", "SPECIES", 22, 29], ["physical exam", "TEST", 3, 16], ["the patient's blood pressure", "TEST", 18, 46]]], ["The abdomen has diffuse tenderness without peritoneal signs.", [["abdomen", "ANATOMY", 4, 11], ["peritoneal", "ANATOMY", 43, 53], ["tenderness", "DISEASE", 24, 34], ["abdomen", "ORGAN", 4, 11], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 43, 53], ["diffuse tenderness", "PROBLEM", 16, 34], ["peritoneal signs", "PROBLEM", 43, 59], ["abdomen", "ANATOMY", 4, 11], ["diffuse", "OBSERVATION_MODIFIER", 16, 23], ["tenderness", "OBSERVATION", 24, 34], ["without", "UNCERTAINTY", 35, 42], ["peritoneal", "ANATOMY", 43, 53], ["signs", "OBSERVATION", 54, 59]]], ["Computed tomography scan of the abdomen did not show any bowel dilation.", [["abdomen", "ANATOMY", 32, 39], ["bowel", "ANATOMY", 57, 62], ["abdomen", "ORGAN", 32, 39], ["bowel", "ORGAN", 57, 62], ["Computed tomography scan of the abdomen", "TEST", 0, 39], ["any bowel dilation", "PROBLEM", 53, 71], ["abdomen", "ANATOMY", 32, 39], ["bowel", "ANATOMY", 57, 62], ["dilation", "OBSERVATION", 63, 71]]], ["He is started on oral vancomycin and IV Flagyl.83.Since admission, his hemodynamic profi le has rapidly stabilized with additional fl uid administration.83.Which of the following should be considered now?", [["oral", "ANATOMY", 17, 21], ["vancomycin", "CHEMICAL", 22, 32], ["Flagyl", "CHEMICAL", 40, 46], ["vancomycin", "CHEMICAL", 22, 32], ["Flagyl", "CHEMICAL", 40, 46], ["oral", "ORGANISM_SUBDIVISION", 17, 21], ["vancomycin", "SIMPLE_CHEMICAL", 22, 32], ["IV Flagyl", "SIMPLE_CHEMICAL", 37, 46], ["oral vancomycin", "TREATMENT", 17, 32], ["IV Flagyl", "TREATMENT", 37, 46], ["his hemodynamic profi", "TEST", 67, 88], ["additional fl uid administration", "TREATMENT", 120, 152]]], ["On physical exam, his blood pressure is 137/75 mm/ Hg.", [["blood", "ANATOMY", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["physical exam", "TEST", 3, 16], ["his blood pressure", "TEST", 18, 36]]], ["His renal function is at baseline.", [["renal", "ANATOMY", 4, 9], ["renal", "ORGAN", 4, 9], ["renal", "ANATOMY", 4, 9], ["function", "OBSERVATION", 10, 18]]], ["The procedure is due to begin in 2 h, and you would like to prevent or reduce the risk of contrast nephropathy.83.Which agent will best reduce the risk of contrast nephropathy?83.Answer: E Of the other measures mentioned here, only sodium bicarbonate or N-acetylcysteine is recommended for clinical use to reduce the risk of contrast nephropathy.", [["nephropathy", "DISEASE", 99, 110], ["nephropathy", "DISEASE", 164, 175], ["sodium bicarbonate", "CHEMICAL", 232, 250], ["N-acetylcysteine", "CHEMICAL", 254, 270], ["nephropathy", "DISEASE", 334, 345], ["sodium bicarbonate", "CHEMICAL", 232, 250], ["N-acetylcysteine", "CHEMICAL", 254, 270], ["sodium bicarbonate", "SIMPLE_CHEMICAL", 232, 250], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 254, 270], ["The procedure", "TREATMENT", 0, 13], ["contrast nephropathy", "PROBLEM", 90, 110], ["contrast nephropathy", "PROBLEM", 155, 175], ["sodium bicarbonate", "TREATMENT", 232, 250], ["N-acetylcysteine", "TREATMENT", 254, 270], ["contrast nephropathy", "PROBLEM", 325, 345], ["contrast nephropathy", "OBSERVATION", 90, 110], ["contrast nephropathy", "OBSERVATION", 155, 175], ["contrast nephropathy", "OBSERVATION", 325, 345]]], ["Sodium bicarbonate begun within 1 h of the procedure has shown a signifi cant benefi t in randomized controlled trials.", [["Sodium bicarbonate", "CHEMICAL", 0, 18], ["Sodium bicarbonate", "CHEMICAL", 0, 18], ["Sodium bicarbonate", "SIMPLE_CHEMICAL", 0, 18], ["Sodium bicarbonate", "TREATMENT", 0, 18], ["the procedure", "TREATMENT", 39, 52], ["randomized controlled trials", "TREATMENT", 90, 118]]], ["Patients with chronic kidney disease, diabetes mellitus, heart failure, multiple myeloma, and volume depletion are at the highest risk of contrast-induced nephropathy.", [["kidney", "ANATOMY", 22, 28], ["heart", "ANATOMY", 57, 62], ["myeloma", "ANATOMY", 81, 88], ["chronic kidney disease", "DISEASE", 14, 36], ["diabetes mellitus", "DISEASE", 38, 55], ["heart failure", "DISEASE", 57, 70], ["multiple myeloma", "DISEASE", 72, 88], ["nephropathy", "DISEASE", 155, 166], ["Patients", "ORGANISM", 0, 8], ["kidney", "ORGAN", 22, 28], ["heart", "ORGAN", 57, 62], ["myeloma", "CANCER", 81, 88], ["Patients", "SPECIES", 0, 8], ["chronic kidney disease", "PROBLEM", 14, 36], ["diabetes mellitus", "PROBLEM", 38, 55], ["heart failure", "PROBLEM", 57, 70], ["multiple myeloma", "PROBLEM", 72, 88], ["volume depletion", "PROBLEM", 94, 110], ["contrast-induced nephropathy", "PROBLEM", 138, 166], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["kidney", "ANATOMY", 22, 28], ["disease", "OBSERVATION", 29, 36], ["diabetes mellitus", "OBSERVATION", 38, 55], ["heart", "ANATOMY", 57, 62], ["failure", "OBSERVATION", 63, 70], ["multiple", "OBSERVATION_MODIFIER", 72, 80], ["myeloma", "OBSERVATION", 81, 88], ["volume depletion", "OBSERVATION", 94, 110], ["contrast", "OBSERVATION", 138, 146], ["nephropathy", "OBSERVATION", 155, 166]]], ["Hydration with normal saline is an effective measure to prevent contrast nephropathy.", [["nephropathy", "DISEASE", 73, 84], ["saline", "SIMPLE_CHEMICAL", 22, 28], ["Hydration", "TREATMENT", 0, 9], ["normal saline", "TREATMENT", 15, 28], ["contrast nephropathy", "PROBLEM", 64, 84], ["contrast nephropathy", "OBSERVATION", 64, 84]]], ["Dopamine and fenoldopam have been proven an ineffective agent to prevent contrast nephropathy.", [["Dopamine", "CHEMICAL", 0, 8], ["fenoldopam", "CHEMICAL", 13, 23], ["nephropathy", "DISEASE", 82, 93], ["Dopamine", "CHEMICAL", 0, 8], ["fenoldopam", "CHEMICAL", 13, 23], ["Dopamine", "SIMPLE_CHEMICAL", 0, 8], ["fenoldopam", "SIMPLE_CHEMICAL", 13, 23], ["Dopamine", "TREATMENT", 0, 8], ["fenoldopam", "TREATMENT", 13, 23], ["an ineffective agent", "TREATMENT", 41, 61], ["contrast nephropathy", "PROBLEM", 73, 93], ["contrast nephropathy", "OBSERVATION", 73, 93]]], ["Although several small clinical studies have suggested a clinical benefi t to the use of N-acetylcysteine, a meta-analysis has been inconclusive.", [["N-acetylcysteine", "CHEMICAL", 89, 105], ["N-acetylcysteine", "CHEMICAL", 89, 105], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 89, 105], ["several small clinical studies", "TEST", 9, 39], ["N-acetylcysteine", "TREATMENT", 89, 105], ["a meta-analysis", "TEST", 107, 122], ["small", "OBSERVATION_MODIFIER", 17, 22]]], ["In addition, N-acetylcysteine should be given well in advance of 4 h as is needed here.86.A 72-year-old man is admitted to the hospital because of worsening shortness of breath during the past 2 days due to an exacerbation of chronic obstructive pulmonary disease.", [["pulmonary", "ANATOMY", 246, 255], ["N-acetylcysteine", "CHEMICAL", 13, 29], ["shortness of breath", "DISEASE", 157, 176], ["chronic obstructive pulmonary disease", "DISEASE", 226, 263], ["N-acetylcysteine", "CHEMICAL", 13, 29], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 13, 29], ["man", "ORGANISM", 104, 107], ["pulmonary", "ORGAN", 246, 255], ["man", "SPECIES", 104, 107], ["N-acetylcysteine", "TREATMENT", 13, 29], ["worsening shortness of breath", "PROBLEM", 147, 176], ["an exacerbation", "PROBLEM", 207, 222], ["chronic obstructive pulmonary disease", "PROBLEM", 226, 263], ["worsening", "OBSERVATION_MODIFIER", 147, 156], ["exacerbation", "OBSERVATION", 210, 222], ["chronic", "OBSERVATION_MODIFIER", 226, 233], ["obstructive", "OBSERVATION_MODIFIER", 234, 245], ["pulmonary", "ANATOMY", 246, 255], ["disease", "OBSERVATION", 256, 263]]], ["He has not had an increased in temperature but reports increased sputum production.", [["sputum", "ANATOMY", 65, 71], ["He", "ORGANISM", 0, 2], ["sputum", "ORGANISM_SUBSTANCE", 65, 71], ["an increased in temperature", "PROBLEM", 15, 42], ["increased sputum production", "PROBLEM", 55, 82], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["sputum", "OBSERVATION", 65, 71]]], ["He initially responds to breathing treatments, but after arriving on the fl oor, you are called to see him for shortness of breath.", [["shortness of breath", "DISEASE", 111, 130], ["breathing treatments", "TREATMENT", 25, 45], ["shortness of breath", "PROBLEM", 111, 130]]], ["On physical exam, the patient is in respiratory distress with some accessory muscle usage.", [["respiratory", "ANATOMY", 36, 47], ["muscle", "ANATOMY", 77, 83], ["respiratory distress", "DISEASE", 36, 56], ["patient", "ORGANISM", 22, 29], ["muscle", "ORGAN", 77, 83], ["patient", "SPECIES", 22, 29], ["physical exam", "TEST", 3, 16], ["respiratory distress", "PROBLEM", 36, 56], ["respiratory distress", "OBSERVATION", 36, 56], ["accessory muscle usage", "OBSERVATION", 67, 89]]], ["Temperature is 37.1 C (98.8 F), pulse rate is 100 per minute, respirations are 20 per minute, and blood pressure is 120/82 mmHg.", [["blood", "ANATOMY", 98, 103], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["Temperature", "TEST", 0, 11], ["pulse rate", "TEST", 32, 42], ["respirations", "TEST", 62, 74], ["blood pressure", "TEST", 98, 112]]], ["There is minimal air movement.", [["minimal air movement", "PROBLEM", 9, 29], ["minimal", "OBSERVATION_MODIFIER", 9, 16], ["air movement", "OBSERVATION", 17, 29]]], ["No crackles are heard.", [["crackles", "PROBLEM", 3, 11], ["crackles", "OBSERVATION", 3, 11]]], ["Arterial blood studies on 6 L/min oxygen by nasal cannula are pH of 7.34 PCO 2 , of 78 mmHg, and PO2 of 72 mmHg.", [["Arterial blood", "ANATOMY", 0, 14], ["nasal", "ANATOMY", 44, 49], ["oxygen", "CHEMICAL", 34, 40], ["PO2", "CHEMICAL", 97, 100], ["oxygen", "CHEMICAL", 34, 40], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 44, 57], ["Arterial blood studies", "TEST", 0, 22], ["6 L/min oxygen", "TREATMENT", 26, 40], ["nasal cannula", "TEST", 44, 57], ["pH", "TEST", 62, 64], ["PCO", "TEST", 73, 76], ["mmHg", "TEST", 87, 91], ["PO2", "TEST", 97, 100], ["nasal cannula", "ANATOMY", 44, 57]]], ["Repeat chest X-ray is clear.", [["Repeat chest X-ray", "TEST", 0, 18], ["chest", "ANATOMY", 7, 12], ["clear", "OBSERVATION", 22, 27]]], ["Antibiotics and intravenous corticosteroids have been started.", [["intravenous", "ANATOMY", 16, 27], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 16, 27], ["corticosteroids", "SIMPLE_CHEMICAL", 28, 43], ["Antibiotics", "TREATMENT", 0, 11], ["intravenous corticosteroids", "TREATMENT", 16, 43]]], ["Which of the following is indicated for managing this patient's respiratory status?", [["respiratory", "ANATOMY", 64, 75], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61]]], ["A) Continued monitoring on 6 L/min oxygen by nasal cannula B) 50 % oxygen via facemask C) Invasive mechanical ventilation D) 100 % Nonrebreathing mask E) Noninvasive mechanical ventilation (NPPV)86.Answer: E This patient is in respiratory distress.", [["nasal", "ANATOMY", 45, 50], ["respiratory", "ANATOMY", 227, 238], ["oxygen", "CHEMICAL", 35, 41], ["oxygen", "CHEMICAL", 67, 73], ["respiratory distress", "DISEASE", 227, 247], ["oxygen", "CHEMICAL", 35, 41], ["oxygen", "CHEMICAL", 67, 73], ["oxygen", "SIMPLE_CHEMICAL", 35, 41], ["oxygen", "SIMPLE_CHEMICAL", 67, 73], ["patient", "ORGANISM", 213, 220], ["patient", "SPECIES", 213, 220], ["oxygen", "TREATMENT", 35, 41], ["nasal cannula B)", "TREATMENT", 45, 61], ["oxygen via facemask C", "TREATMENT", 67, 88], ["Invasive mechanical ventilation D)", "TREATMENT", 90, 124], ["Nonrebreathing mask E", "TREATMENT", 131, 152], ["Noninvasive mechanical ventilation (NPPV", "TREATMENT", 154, 194], ["respiratory distress", "PROBLEM", 227, 247], ["respiratory distress", "OBSERVATION", 227, 247]]], ["Continued current oxygen via nasal cannula or nonrebreathing mask is not appropriate.", [["nasal", "ANATOMY", 29, 34], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "SIMPLE_CHEMICAL", 18, 24], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 29, 42], ["current oxygen", "TREATMENT", 10, 24], ["nasal cannula", "TREATMENT", 29, 42], ["nonrebreathing mask", "TREATMENT", 46, 65], ["oxygen", "OBSERVATION_MODIFIER", 18, 24]]], ["It is unlikely that increasing delivered oxygen will resolve this patient's ventilation issues.", [["oxygen", "CHEMICAL", 41, 47], ["oxygen", "CHEMICAL", 41, 47], ["oxygen", "SIMPLE_CHEMICAL", 41, 47], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["oxygen", "TREATMENT", 41, 47], ["unlikely", "UNCERTAINTY", 6, 14], ["increasing", "OBSERVATION_MODIFIER", 20, 30]]], ["Avoidance of intubation is desired as well.", [["intubation", "TREATMENT", 13, 23], ["intubation", "OBSERVATION", 13, 23]]], ["This patient has several factors that make NPPV the best option.", [["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["NPPV", "TREATMENT", 43, 47]]], ["In patients who have severe exacerbations of COPD defi ned as PCO 2 > 45 mmHg, use of NPPV resulted in decreased mortality, decreased need for intubation, and reduction in treatment failure compared to standard therapy.", [["COPD", "DISEASE", 45, 49], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["severe exacerbations", "PROBLEM", 21, 41], ["COPD defi", "PROBLEM", 45, 54], ["PCO", "TEST", 62, 65], ["NPPV", "TREATMENT", 86, 90], ["decreased mortality", "PROBLEM", 103, 122], ["intubation", "TREATMENT", 143, 153], ["reduction", "TREATMENT", 159, 168], ["treatment failure", "PROBLEM", 172, 189], ["standard therapy", "TREATMENT", 202, 218], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["exacerbations", "OBSERVATION", 28, 41], ["COPD", "OBSERVATION", 45, 49], ["decreased", "OBSERVATION_MODIFIER", 103, 112], ["mortality", "OBSERVATION", 113, 122], ["decreased", "OBSERVATION_MODIFIER", 124, 133], ["failure", "OBSERVATION", 182, 189]]], ["Factors that predict success with NPPV include higher pH, lower PaCO 2 , and higher FVC.", [["NPPV", "TREATMENT", 34, 38], ["higher pH", "TREATMENT", 47, 56], ["lower PaCO", "TEST", 58, 68], ["higher FVC", "OBSERVATION", 77, 87]]], ["Poor outcomes were associated with a diagnosis of pneumonia, decreased compliance with the apparatus, and severe accessory muscle use.", [["muscle", "ANATOMY", 123, 129], ["pneumonia", "DISEASE", 50, 59], ["muscle", "ORGAN", 123, 129], ["pneumonia", "PROBLEM", 50, 59], ["the apparatus", "TREATMENT", 87, 100], ["severe accessory muscle use", "PROBLEM", 106, 133], ["pneumonia", "OBSERVATION", 50, 59], ["decreased", "OBSERVATION_MODIFIER", 61, 70], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["accessory muscle use", "OBSERVATION", 113, 133]]], ["There is no guarantee that NPPV will resolve the respiratory distress.", [["respiratory", "ANATOMY", 49, 60], ["respiratory distress", "DISEASE", 49, 69], ["NPPV", "TREATMENT", 27, 31], ["the respiratory distress", "PROBLEM", 45, 69], ["no guarantee", "UNCERTAINTY", 9, 21], ["NPPV", "OBSERVATION", 27, 31], ["respiratory distress", "OBSERVATION", 49, 69]]], ["On physical examination, the temperature is 38.6 \u00b0C (101.5 \u00b0F), blood pressure is 110/80 mmHg, and respiration rate is 90 bpm.", [["blood", "ANATOMY", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 64, 78], ["respiration rate", "TEST", 99, 115]]], ["She is noted to have right fl ank pain.", [["pain", "DISEASE", 34, 38], ["right fl ank pain", "PROBLEM", 21, 38], ["right", "ANATOMY_MODIFIER", 21, 26], ["fl", "ANATOMY_MODIFIER", 27, 29], ["ank", "ANATOMY", 30, 33], ["pain", "OBSERVATION", 34, 38]]], ["Otherwise, physical exam is within normal limits.ReferencesLaboratory studies reveal blood urea nitrogen is 40 mg/dL, creatinine is 1.9 mg/dL, sodium is 135 mEq/L, potassium is 5.0 mEq/L, chloride is 105 mEq/L, bicarbonate is 16 mmol/L, and glucose is 258 mg/dL.", [["blood", "ANATOMY", 85, 90], ["blood urea nitrogen", "CHEMICAL", 85, 104], ["creatinine", "CHEMICAL", 118, 128], ["sodium", "CHEMICAL", 143, 149], ["potassium", "CHEMICAL", 164, 173], ["chloride", "CHEMICAL", 188, 196], ["bicarbonate", "CHEMICAL", 211, 222], ["glucose", "CHEMICAL", 241, 248], ["urea", "CHEMICAL", 91, 95], ["nitrogen", "CHEMICAL", 96, 104], ["creatinine", "CHEMICAL", 118, 128], ["sodium", "CHEMICAL", 143, 149], ["potassium", "CHEMICAL", 164, 173], ["chloride", "CHEMICAL", 188, 196], ["bicarbonate", "CHEMICAL", 211, 222], ["glucose", "CHEMICAL", 241, 248], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["urea", "SIMPLE_CHEMICAL", 91, 95], ["creatinine", "SIMPLE_CHEMICAL", 118, 128], ["sodium", "SIMPLE_CHEMICAL", 143, 149], ["potassium", "SIMPLE_CHEMICAL", 164, 173], ["chloride", "SIMPLE_CHEMICAL", 188, 196], ["bicarbonate", "SIMPLE_CHEMICAL", 211, 222], ["glucose", "SIMPLE_CHEMICAL", 241, 248], ["physical exam", "TEST", 11, 24], ["ReferencesLaboratory studies", "TEST", 49, 77], ["blood urea nitrogen", "TEST", 85, 104], ["creatinine", "TEST", 118, 128], ["sodium", "TEST", 143, 149], ["potassium", "TEST", 164, 173], ["chloride", "TEST", 188, 196], ["bicarbonate", "TREATMENT", 211, 222], ["glucose", "TEST", 241, 248], ["within normal limits", "OBSERVATION", 28, 48]]], ["Her urine is noted to be positive for ketones.ReferencesShe is admitted for a urinary tract infection.", [["urine", "ANATOMY", 4, 9], ["urinary tract", "ANATOMY", 78, 91], ["ketones", "CHEMICAL", 38, 45], ["urinary tract infection", "DISEASE", 78, 101], ["ketones", "CHEMICAL", 38, 45], ["urine", "ORGANISM_SUBSTANCE", 4, 9], ["ketones", "SIMPLE_CHEMICAL", 38, 45], ["urinary tract", "ORGANISM_SUBDIVISION", 78, 91], ["Her urine", "TEST", 0, 9], ["ketones", "TEST", 38, 45], ["a urinary tract infection", "PROBLEM", 76, 101], ["ketones", "OBSERVATION", 38, 45], ["urinary tract", "ANATOMY", 78, 91], ["infection", "OBSERVATION", 92, 101]]], ["Prior to admission, she was on an insulin pump, which was discontinued in the emergency room.", [["insulin", "GENE_OR_GENE_PRODUCT", 34, 41], ["an insulin pump", "TREATMENT", 31, 46]]], ["A 52-year-old female is transferred from a rural hospital for new onset abdominal pain and right leg weakness.", [["abdominal", "ANATOMY", 72, 81], ["right leg", "ANATOMY", 91, 100], ["abdominal pain", "DISEASE", 72, 86], ["right leg weakness", "DISEASE", 91, 109], ["female", "ORGANISM", 14, 20], ["abdominal", "ORGANISM_SUBDIVISION", 72, 81], ["leg", "ORGANISM_SUBDIVISION", 97, 100], ["new onset abdominal pain", "PROBLEM", 62, 86], ["right leg weakness", "PROBLEM", 91, 109], ["abdominal", "ANATOMY", 72, 81], ["pain", "OBSERVATION", 82, 86], ["right", "ANATOMY_MODIFIER", 91, 96], ["leg", "ANATOMY", 97, 100], ["weakness", "OBSERVATION", 101, 109]]], ["In the initial workup there has been non-diagnostic including a CT scan of abdomen, head, and spine.", [["abdomen", "ANATOMY", 75, 82], ["head", "ANATOMY", 84, 88], ["spine", "ANATOMY", 94, 99], ["abdomen", "ORGAN", 75, 82], ["head", "ORGANISM_SUBDIVISION", 84, 88], ["spine", "ORGAN", 94, 99], ["the initial workup", "TEST", 3, 21], ["a CT scan of abdomen, head, and spine", "TEST", 62, 99], ["abdomen", "ANATOMY", 75, 82], ["head", "ANATOMY", 84, 88], ["spine", "ANATOMY", 94, 99]]], ["On physical examination, she is awake, alert, and speaking in full sentences.", [["physical examination", "TEST", 3, 23]]], ["Temperature is 37.2 \u00b0C (99.0 \u00b0F).", [["Temperature", "TEST", 0, 11], ["\u00b0C", "TEST", 20, 22]]], ["The lungs are clear upon auscultation.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["auscultation", "TEST", 25, 37], ["lungs", "ANATOMY", 4, 9], ["clear", "OBSERVATION", 14, 19], ["auscultation", "OBSERVATION", 25, 37]]], ["She is using accessory muscles, and breath sounds are decreased at the lung bases.", [["accessory muscles", "ANATOMY", 13, 30], ["lung", "ANATOMY", 71, 75], ["muscles", "ORGAN", 23, 30], ["lung", "ORGAN", 71, 75], ["breath sounds", "TEST", 36, 49], ["accessory muscles", "ANATOMY", 13, 30], ["decreased", "OBSERVATION", 54, 63], ["lung", "ANATOMY", 71, 75], ["bases", "ANATOMY_MODIFIER", 76, 81]]], ["Diffuse symmetrical weakness is noted throughout her lower extremities.", [["lower extremities", "ANATOMY", 53, 70], ["lower extremities", "ORGANISM_SUBDIVISION", 53, 70], ["Diffuse symmetrical weakness", "PROBLEM", 0, 28], ["symmetrical", "OBSERVATION_MODIFIER", 8, 19], ["weakness", "OBSERVATION", 20, 28], ["lower extremities", "ANATOMY", 53, 70]]], ["A diagnosis of Guillain-Barr\u00e9 is suspected, and the patient is transferred to the intensive care unit for close monitoring of her respiratory status.", [["respiratory", "ANATOMY", 130, 141], ["Guillain-Barr\u00e9", "DISEASE", 15, 29], ["Guillain-Barr\u00e9", "ORGANISM", 15, 29], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["Guillain-Barr\u00e9", "PROBLEM", 15, 29], ["close monitoring", "TEST", 106, 122], ["Barr\u00e9", "OBSERVATION", 24, 29], ["respiratory", "ANATOMY", 130, 141]]], ["Routine measurements of patient's bedside vital capacity are initiated.ReferencesWhich of the following is the best management strategy to prevent respiratory failure in this patient?", [["respiratory", "ANATOMY", 147, 158], ["respiratory failure", "DISEASE", 147, 166], ["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 175, 182], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 175, 182], ["Routine measurements", "TEST", 0, 20], ["patient's bedside vital capacity", "TEST", 24, 56], ["the best management strategy", "TREATMENT", 107, 135], ["respiratory failure", "PROBLEM", 147, 166], ["respiratory", "ANATOMY", 147, 158], ["failure", "OBSERVATION", 159, 166]]], ["A) Continuous positive airway pressure.", [["airway", "ANATOMY", 23, 29], ["airway", "MULTI-TISSUE_STRUCTURE", 23, 29], ["Continuous positive airway pressure", "TREATMENT", 3, 38], ["airway pressure", "OBSERVATION", 23, 38]]], ["B) Bilateral transcutaneous phrenic nerve pacing.", [["phrenic nerve", "ANATOMY", 28, 41], ["phrenic nerve", "MULTI-TISSUE_STRUCTURE", 28, 41], ["Bilateral transcutaneous phrenic nerve pacing", "TREATMENT", 3, 48], ["Bilateral", "ANATOMY_MODIFIER", 3, 12], ["transcutaneous", "ANATOMY_MODIFIER", 13, 27], ["phrenic nerve", "ANATOMY", 28, 41], ["pacing", "OBSERVATION", 42, 48]]], ["C) Plasma exchange.", [["Plasma", "ORGANISM_SUBSTANCE", 3, 9], ["Plasma exchange", "TREATMENT", 3, 18]]], ["D) Methylprednisolone.", [["Methylprednisolone", "CHEMICAL", 3, 21], ["Methylprednisolone", "CHEMICAL", 3, 21], ["Methylprednisolone", "SIMPLE_CHEMICAL", 3, 21], ["Methylprednisolone", "TREATMENT", 3, 21]]], ["E) Ciprofl oxacin.ReferencesAnswer: C Plasma exchange and intravenous immunoglobulin (IVIG) are the recommended treatment options for Guillain-Barr\u00e9.", [["intravenous", "ANATOMY", 58, 69], ["Ciprofl oxacin", "CHEMICAL", 3, 17], ["Ciprofl oxacin", "CHEMICAL", 3, 17], ["Ciprofl oxacin", "SIMPLE_CHEMICAL", 3, 17], ["intravenous immunoglobulin", "SIMPLE_CHEMICAL", 58, 84], ["IVIG", "SIMPLE_CHEMICAL", 86, 90], ["intravenous immunoglobulin", "PROTEIN", 58, 84], ["Ciprofl oxacin", "TREATMENT", 3, 17], ["C Plasma exchange", "TREATMENT", 36, 53], ["intravenous immunoglobulin (IVIG", "TREATMENT", 58, 90], ["treatment options", "TREATMENT", 112, 129], ["Guillain-Barr\u00e9", "TREATMENT", 134, 148]]], ["Trials have demonstrated that plasma exchange and IVIG reduce the incidence and duration of mechanical ventilation in patients with Guillain-Barr\u00e9 syndrome as opposed to supportive care.", [["plasma", "ANATOMY", 30, 36], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 132, 155], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["IVIG", "SIMPLE_CHEMICAL", 50, 54], ["patients", "ORGANISM", 118, 126], ["Guillain-Barr\u00e9", "ORGANISM", 132, 146], ["patients", "SPECIES", 118, 126], ["plasma exchange", "TREATMENT", 30, 45], ["IVIG", "TREATMENT", 50, 54], ["mechanical ventilation", "TREATMENT", 92, 114], ["Guillain", "TREATMENT", 132, 140], ["Barr\u00e9 syndrome", "PROBLEM", 141, 155], ["supportive care", "TREATMENT", 170, 185], ["mechanical ventilation", "OBSERVATION", 92, 114], ["Barr\u00e9 syndrome", "OBSERVATION", 141, 155]]], ["The effi cacy of plasmapheresis and IVIGs appears to be about equal in shortening the average duration of disease.", [["IVIGs", "SIMPLE_CHEMICAL", 36, 41], ["plasmapheresis", "TREATMENT", 17, 31], ["IVIGs", "TREATMENT", 36, 41], ["disease", "PROBLEM", 106, 113], ["disease", "OBSERVATION", 106, 113]]], ["Combined treatment has not been shown to produce an additional reduction in disability.", [["disability", "DISEASE", 76, 86], ["Combined treatment", "TREATMENT", 0, 18], ["an additional reduction in disability", "PROBLEM", 49, 86], ["reduction", "OBSERVATION_MODIFIER", 63, 72]]], ["Systemic corticosteroids by themselves or in conjunction with immunoglobulin are no longer indicated based upon previous trials that demonstrated no benefi t.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 62, 76], ["immunoglobulin", "PROTEIN", 62, 76], ["Systemic corticosteroids", "TREATMENT", 0, 24], ["immunoglobulin", "TREATMENT", 62, 76], ["previous trials", "TEST", 112, 127], ["benefi", "PROBLEM", 149, 155], ["corticosteroids", "OBSERVATION", 9, 24], ["no", "UNCERTAINTY", 146, 148]]], ["This patient is at a high risk for respiratory failure.ReferencesApproximately one-third of patients require admission to an ICU, primarily because of respiratory failure.", [["respiratory", "ANATOMY", 35, 46], ["respiratory", "ANATOMY", 151, 162], ["respiratory failure", "DISEASE", 35, 54], ["respiratory failure", "DISEASE", 151, 170], ["patient", "ORGANISM", 5, 12], ["patients", "ORGANISM", 92, 100], ["patient", "SPECIES", 5, 12], ["patients", "SPECIES", 92, 100], ["respiratory failure", "PROBLEM", 35, 54], ["respiratory failure", "PROBLEM", 151, 170], ["respiratory", "ANATOMY", 35, 46], ["failure", "OBSERVATION", 47, 54], ["respiratory", "ANATOMY", 151, 162], ["failure", "OBSERVATION", 163, 170]]], ["Her vital capacity and ability to maintain adequate oxygenation indicate that mechanical ventilation is not currently needed but should be closely followed.", [["Her vital capacity", "TEST", 0, 18], ["mechanical ventilation", "TREATMENT", 78, 100], ["mechanical ventilation", "OBSERVATION", 78, 100]]], ["Stool culture for Salmonella may be considered as well.91.A 47-year-old man with chronic obstructive pulmonary disease (COPD) presents with shortness of breath, purulent sputum, fever, and dyspnea increasing over the past 5 days.", [["pulmonary", "ANATOMY", 101, 110], ["purulent sputum", "ANATOMY", 161, 176], ["chronic obstructive pulmonary disease", "DISEASE", 81, 118], ["COPD", "DISEASE", 120, 124], ["shortness of breath", "DISEASE", 140, 159], ["purulent sputum", "DISEASE", 161, 176], ["fever", "DISEASE", 178, 183], ["dyspnea", "DISEASE", 189, 196], ["man", "ORGANISM", 72, 75], ["pulmonary", "ORGAN", 101, 110], ["man", "SPECIES", 72, 75], ["Salmonella", "SPECIES", 18, 28], ["Stool culture", "TEST", 0, 13], ["Salmonella", "PROBLEM", 18, 28], ["chronic obstructive pulmonary disease", "PROBLEM", 81, 118], ["COPD", "PROBLEM", 120, 124], ["shortness of breath", "PROBLEM", 140, 159], ["purulent sputum", "PROBLEM", 161, 176], ["fever", "PROBLEM", 178, 183], ["dyspnea", "PROBLEM", 189, 196], ["chronic", "OBSERVATION_MODIFIER", 81, 88], ["obstructive", "OBSERVATION_MODIFIER", 89, 100], ["pulmonary", "ANATOMY", 101, 110], ["disease", "OBSERVATION", 111, 118], ["COPD", "OBSERVATION", 120, 124], ["purulent", "OBSERVATION_MODIFIER", 161, 169], ["sputum", "OBSERVATION", 170, 176], ["fever", "OBSERVATION", 178, 183], ["dyspnea", "OBSERVATION", 189, 196], ["increasing", "OBSERVATION_MODIFIER", 197, 207]]], ["He has had multiple COPD exacerbations.", [["COPD", "DISEASE", 20, 24], ["He", "ORGANISM", 0, 2], ["multiple COPD exacerbations", "PROBLEM", 11, 38], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["COPD", "OBSERVATION", 20, 24]]], ["On physical examination, he appears moderately ill.", [["physical examination", "TEST", 3, 23], ["moderately ill", "PROBLEM", 36, 50], ["moderately", "OBSERVATION_MODIFIER", 36, 46], ["ill", "OBSERVATION", 47, 50]]], ["He can speak in full sentences without signifi cant shortness of breath.", [["shortness of breath", "DISEASE", 52, 71], ["He", "ORGANISM", 0, 2], ["signifi cant shortness of breath", "PROBLEM", 39, 71]]], ["His pulse rate is 90 per minute, temperature is 37.5 \u00b0C(99.4 \u00b0F), respirations are 22 per minute, and oxygen saturation is 86 % on room air.", [["oxygen", "CHEMICAL", 102, 108], ["oxygen", "CHEMICAL", 102, 108], ["oxygen", "SIMPLE_CHEMICAL", 102, 108], ["His pulse rate", "TEST", 0, 14], ["temperature", "TEST", 33, 44], ["respirations", "TEST", 66, 78], ["oxygen saturation", "TEST", 102, 119]]], ["He is placed on 3 l nasal cannula, and oxygenation improves to 92 %.91.Chest X-ray reveals no signifi cant infi ltrates.", [["nasal", "ANATOMY", 20, 25], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 20, 33], ["3 l nasal cannula", "TREATMENT", 16, 33], ["oxygenation", "TEST", 39, 50], ["Chest X-ray", "TEST", 71, 82], ["signifi cant infi ltrates", "PROBLEM", 94, 119], ["nasal cannula", "ANATOMY", 20, 33], ["no", "UNCERTAINTY", 91, 93]]], ["Laboratory studies: leukocyte count is 11,000; basic metabolic panel is within normal limits; hemoglobin is 14.0 g/dl.", [["leukocyte", "ANATOMY", 20, 29], ["leukocyte", "CELL", 20, 29], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 94, 104], ["hemoglobin", "PROTEIN", 94, 104], ["Laboratory studies", "TEST", 0, 18], ["leukocyte count", "TEST", 20, 35], ["basic metabolic panel", "TEST", 47, 68], ["hemoglobin", "TEST", 94, 104]]], ["He is admitted and placed on bronchodilators and corticosteroids.", [["corticosteroids", "CHEMICAL", 49, 64], ["corticosteroids", "SIMPLE_CHEMICAL", 49, 64], ["bronchodilators", "TREATMENT", 29, 44], ["corticosteroids", "TREATMENT", 49, 64]]], ["Which of the following approach is best in this patient?", [["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55]]], ["A) Observation without antibiotic therapy B) Doxycycline or azithromycin for 5 days C) Doxycycline or azithromycin for 14 days D) Zosyn (piperacillin and tazobactam) and vancomycin 93.", [["Doxycycline", "CHEMICAL", 45, 56], ["azithromycin", "CHEMICAL", 60, 72], ["Doxycycline", "CHEMICAL", 87, 98], ["azithromycin", "CHEMICAL", 102, 114], ["Zosyn", "CHEMICAL", 130, 135], ["piperacillin", "CHEMICAL", 137, 149], ["tazobactam", "CHEMICAL", 154, 164], ["vancomycin", "CHEMICAL", 170, 180], ["Doxycycline", "CHEMICAL", 45, 56], ["azithromycin", "CHEMICAL", 60, 72], ["Doxycycline", "CHEMICAL", 87, 98], ["azithromycin", "CHEMICAL", 102, 114], ["Zosyn", "CHEMICAL", 130, 135], ["piperacillin", "CHEMICAL", 137, 149], ["tazobactam", "CHEMICAL", 154, 164], ["vancomycin", "CHEMICAL", 170, 180], ["Doxycycline", "SIMPLE_CHEMICAL", 45, 56], ["azithromycin", "SIMPLE_CHEMICAL", 60, 72], ["Doxycycline", "SIMPLE_CHEMICAL", 87, 98], ["azithromycin", "SIMPLE_CHEMICAL", 102, 114], ["Zosyn", "SIMPLE_CHEMICAL", 130, 135], ["piperacillin", "SIMPLE_CHEMICAL", 137, 149], ["tazobactam", "SIMPLE_CHEMICAL", 154, 164], ["vancomycin 93", "SIMPLE_CHEMICAL", 170, 183], ["antibiotic therapy", "TREATMENT", 23, 41], ["Doxycycline", "TREATMENT", 45, 56], ["azithromycin", "TREATMENT", 60, 72], ["Doxycycline", "TREATMENT", 87, 98], ["azithromycin", "TREATMENT", 102, 114], ["Zosyn", "TREATMENT", 130, 135], ["piperacillin", "TREATMENT", 137, 149], ["tazobactam", "TREATMENT", 154, 164], ["vancomycin", "TREATMENT", 170, 180]]], ["A 18-year-old high school football player presents with a chief complaint of erythema to his right thigh which he has had for the past 3 days.", [["right thigh", "ANATOMY", 93, 104], ["erythema", "DISEASE", 77, 85], ["erythema", "PATHOLOGICAL_FORMATION", 77, 85], ["thigh", "ORGANISM_SUBDIVISION", 99, 104], ["erythema to his right thigh", "PROBLEM", 77, 104], ["erythema", "OBSERVATION", 77, 85], ["right", "ANATOMY_MODIFIER", 93, 98], ["thigh", "ANATOMY", 99, 104]]], ["He denies any puncture wounds to the area but does report the usual trauma associated with football practice.", [["wounds", "ANATOMY", 23, 29], ["trauma", "DISEASE", 68, 74], ["wounds", "PATHOLOGICAL_FORMATION", 23, 29], ["any puncture wounds", "PROBLEM", 10, 29], ["the usual trauma", "PROBLEM", 58, 74], ["wounds", "OBSERVATION", 23, 29]]], ["On physical examination, the thigh appears moderately swollen.", [["thigh", "ANATOMY", 29, 34], ["thigh", "ORGANISM_SUBDIVISION", 29, 34], ["physical examination", "TEST", 3, 23], ["moderately swollen", "PROBLEM", 43, 61], ["thigh", "ANATOMY", 29, 34], ["moderately", "OBSERVATION_MODIFIER", 43, 53], ["swollen", "OBSERVATION", 54, 61]]], ["He has a fever of 102.1 \u00b0F. His pulse rate is 110 beats per minute.", [["fever", "DISEASE", 9, 14], ["He", "ORGANISM", 0, 2], ["a fever", "PROBLEM", 7, 14], ["His pulse rate", "TEST", 28, 42], ["fever", "OBSERVATION", 9, 14]]], ["His blood pressure is 95/68.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["His blood pressure", "TEST", 0, 18], ["pressure", "OBSERVATION_MODIFIER", 10, 18]]], ["Some mild lymphangitic spread is noted on the right surface of the thigh extending down to the posterior aspect of his calf.", [["right surface", "ANATOMY", 46, 59], ["thigh", "ANATOMY", 67, 72], ["calf", "ANATOMY", 119, 123], ["thigh", "ORGANISM_SUBDIVISION", 67, 72], ["calf", "ORGANISM_SUBDIVISION", 119, 123], ["calf", "SPECIES", 119, 123], ["Some mild lymphangitic spread", "PROBLEM", 0, 29], ["mild", "OBSERVATION_MODIFIER", 5, 9], ["lymphangitic spread", "OBSERVATION", 10, 29], ["right", "ANATOMY_MODIFIER", 46, 51], ["surface", "ANATOMY_MODIFIER", 52, 59], ["thigh", "ANATOMY", 67, 72], ["posterior", "ANATOMY_MODIFIER", 95, 104], ["calf", "ANATOMY", 119, 123]]], ["In the emergency room, 1 g of ceftriaxone has been administered, and you are consulted for admission.91.Which of the following is the most appropriate for this patient now?", [["ceftriaxone", "CHEMICAL", 30, 41], ["ceftriaxone", "CHEMICAL", 30, 41], ["ceftriaxone", "SIMPLE_CHEMICAL", 30, 41], ["patient", "ORGANISM", 160, 167], ["patient", "SPECIES", 160, 167], ["ceftriaxone", "TREATMENT", 30, 41]]], ["A) Intravenous vancomycin, 1 g every 12 h B) IV clindamycin C) Consultation to surgery for urgent incision and drainage, followed by intravenous vancomycin D) IV ceftriaxone 1 g every 12 h91.Answer: C This patient has cellulitis with evidence of sepsis.", [["intravenous", "ANATOMY", 133, 144], ["vancomycin", "CHEMICAL", 15, 25], ["clindamycin", "CHEMICAL", 48, 59], ["vancomycin", "CHEMICAL", 145, 155], ["ceftriaxone", "CHEMICAL", 162, 173], ["cellulitis", "DISEASE", 218, 228], ["sepsis", "DISEASE", 246, 252], ["vancomycin", "CHEMICAL", 15, 25], ["clindamycin C", "CHEMICAL", 48, 61], ["vancomycin D", "CHEMICAL", 145, 157], ["ceftriaxone", "CHEMICAL", 162, 173], ["vancomycin", "SIMPLE_CHEMICAL", 15, 25], ["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213], ["A) Intravenous vancomycin", "TREATMENT", 0, 25], ["IV clindamycin C", "TREATMENT", 45, 61], ["surgery", "TREATMENT", 79, 86], ["urgent incision", "TREATMENT", 91, 106], ["drainage", "TREATMENT", 111, 119], ["intravenous vancomycin D", "TREATMENT", 133, 157], ["IV ceftriaxone", "TREATMENT", 159, 173], ["cellulitis", "PROBLEM", 218, 228], ["sepsis", "PROBLEM", 246, 252], ["incision", "OBSERVATION", 98, 106], ["cellulitis", "OBSERVATION", 218, 228], ["evidence of", "UNCERTAINTY", 234, 245], ["sepsis", "OBSERVATION", 246, 252]]], ["In this particular case, community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is probable.", [["methicillin", "CHEMICAL", 44, 55], ["Staphylococcus aureus", "DISEASE", 66, 87], ["methicillin", "CHEMICAL", 44, 55], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 44, 87], ["CA-MRSA", "ORGANISM", 89, 96], ["Staphylococcus aureus", "SPECIES", 66, 87], ["MRSA", "SPECIES", 92, 96], ["Staphylococcus aureus", "SPECIES", 66, 87], ["acquired methicillin-resistant Staphylococcus aureus", "PROBLEM", 35, 87], ["MRSA", "PROBLEM", 92, 96]]], ["CA-MRSA is an emerging cause of necrotizing fasciitis.", [["necrotizing fasciitis", "DISEASE", 32, 53], ["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["necrotizing fasciitis", "PATHOLOGICAL_FORMATION", 32, 53], ["MRSA", "SPECIES", 3, 7], ["CA", "TEST", 0, 2], ["MRSA", "PROBLEM", 3, 7], ["necrotizing fasciitis", "PROBLEM", 32, 53], ["MRSA", "OBSERVATION", 3, 7], ["necrotizing", "OBSERVATION_MODIFIER", 32, 43], ["fasciitis", "OBSERVATION", 44, 53]]], ["CA-MRSA infections have become more common in athletes.", [["infections", "DISEASE", 8, 18], ["CA", "GENE_OR_GENE_PRODUCT", 0, 2], ["MRSA", "SPECIES", 3, 7], ["CA", "TEST", 0, 2], ["MRSA infections", "PROBLEM", 3, 18], ["MRSA", "OBSERVATION_MODIFIER", 3, 7], ["infections", "OBSERVATION", 8, 18], ["more common", "OBSERVATION_MODIFIER", 31, 42]]], ["It is important that urgent surgical consultation be obtained in cases where there is suspicion of an underlying fasciitis, as in this case.", [["fasciitis", "DISEASE", 113, 122], ["urgent surgical consultation", "TEST", 21, 49], ["an underlying fasciitis", "PROBLEM", 99, 122], ["suspicion of", "UNCERTAINTY", 86, 98], ["underlying", "OBSERVATION_MODIFIER", 102, 112], ["fasciitis", "OBSERVATION", 113, 122]]], ["The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score can be utilized to risk stratify people having signs of cellulitis to determine the likelihood of necrotizing fasciitis being present.", [["Necrotizing Fasciitis", "DISEASE", 34, 55], ["cellulitis", "DISEASE", 127, 137], ["necrotizing fasciitis", "DISEASE", 169, 190], ["people", "ORGANISM", 104, 110], ["people", "SPECIES", 104, 110], ["Necrotizing Fasciitis (LRINEC) score", "PROBLEM", 34, 70], ["cellulitis", "PROBLEM", 127, 137], ["necrotizing fasciitis", "PROBLEM", 169, 190], ["Necrotizing", "OBSERVATION_MODIFIER", 34, 45], ["Fasciitis", "OBSERVATION", 46, 55], ["cellulitis", "OBSERVATION", 127, 137], ["necrotizing", "OBSERVATION_MODIFIER", 169, 180], ["fasciitis", "OBSERVATION", 181, 190]]], ["It uses six serologic measures: C-reactive protein, total white blood cell count, hemoglobin, sodium, creatinine, and glucose.", [["white blood cell", "ANATOMY", 58, 74], ["sodium", "CHEMICAL", 94, 100], ["creatinine", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 118, 125], ["sodium", "CHEMICAL", 94, 100], ["creatinine", "CHEMICAL", 102, 112], ["glucose", "CHEMICAL", 118, 125], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 32, 50], ["white blood cell", "CELL", 58, 74], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 82, 92], ["sodium", "SIMPLE_CHEMICAL", 94, 100], ["creatinine", "SIMPLE_CHEMICAL", 102, 112], ["glucose", "SIMPLE_CHEMICAL", 118, 125], ["C-reactive protein", "PROTEIN", 32, 50], ["hemoglobin", "PROTEIN", 82, 92], ["six serologic measures", "TEST", 8, 30], ["C-reactive protein", "TEST", 32, 50], ["total white blood cell count", "TEST", 52, 80], ["hemoglobin", "TEST", 82, 92], ["sodium", "TEST", 94, 100], ["creatinine", "TEST", 102, 112], ["glucose", "TEST", 118, 125]]], ["A score greater than or equal to 6 indicates that necrotizing fasciitis should be seriously considered.", [["necrotizing fasciitis", "DISEASE", 50, 71], ["A score", "TEST", 0, 7], ["necrotizing fasciitis", "PROBLEM", 50, 71], ["necrotizing", "OBSERVATION_MODIFIER", 50, 61], ["fasciitis", "OBSERVATION", 62, 71]]], ["Many patients with necrotizing fasciitis who undergone debridement should return to the operating room 24-36 h after the fi rst debridement and then daily thereafter until the surgical team fi nds no further need for debridement.", [["necrotizing fasciitis", "DISEASE", 19, 40], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["necrotizing fasciitis", "PROBLEM", 19, 40], ["debridement", "TREATMENT", 55, 66], ["the fi rst debridement", "TREATMENT", 117, 139], ["debridement", "TREATMENT", 217, 228], ["necrotizing", "OBSERVATION_MODIFIER", 19, 30], ["fasciitis", "OBSERVATION", 31, 40], ["debridement", "OBSERVATION", 55, 66], ["debridement", "OBSERVATION", 128, 139], ["debridement", "OBSERVATION", 217, 228]]], ["Antibiotics, such as vancomycin, should be administered.ReferencesBenjamin HJ, Nikore V, Takagishi J. What is the most appropriate next step in management?", [["vancomycin", "CHEMICAL", 21, 31], ["vancomycin", "CHEMICAL", 21, 31], ["vancomycin", "SIMPLE_CHEMICAL", 21, 31], ["Antibiotics", "TREATMENT", 0, 11], ["vancomycin", "TREATMENT", 21, 31]]], ["A) Stop prednisolone, start pentoxifylline.", [["prednisolone", "CHEMICAL", 8, 20], ["pentoxifylline", "CHEMICAL", 28, 42], ["prednisolone", "CHEMICAL", 8, 20], ["pentoxifylline", "CHEMICAL", 28, 42], ["prednisolone", "SIMPLE_CHEMICAL", 8, 20], ["pentoxifylline", "SIMPLE_CHEMICAL", 28, 42], ["prednisolone", "TREATMENT", 8, 20], ["pentoxifylline", "TREATMENT", 28, 42]]], ["C) Continue prednisolone, start octreotide.", [["prednisolone", "CHEMICAL", 12, 24], ["octreotide", "CHEMICAL", 32, 42], ["prednisolone", "CHEMICAL", 12, 24], ["octreotide", "CHEMICAL", 32, 42], ["prednisolone", "SIMPLE_CHEMICAL", 12, 24], ["octreotide", "SIMPLE_CHEMICAL", 32, 42], ["prednisolone", "TREATMENT", 12, 24], ["octreotide", "TREATMENT", 32, 42]]], ["D) Continue prednisolone, refer to liver transplantation.", [["liver", "ANATOMY", 35, 40], ["prednisolone", "CHEMICAL", 12, 24], ["prednisolone", "CHEMICAL", 12, 24], ["prednisolone", "SIMPLE_CHEMICAL", 12, 24], ["liver", "ORGAN", 35, 40], ["prednisolone", "TREATMENT", 12, 24], ["liver transplantation", "TREATMENT", 35, 56], ["liver", "ANATOMY", 35, 40], ["transplantation", "OBSERVATION", 41, 56]]], ["E) Continue prednisolone, start plasmapheresis.ReferencesThe Lille score is a predictor of response to therapy in acute alcoholic hepatitis.", [["prednisolone", "CHEMICAL", 12, 24], ["acute alcoholic hepatitis", "DISEASE", 114, 139], ["prednisolone", "CHEMICAL", 12, 24], ["prednisolone", "SIMPLE_CHEMICAL", 12, 24], ["prednisolone", "TREATMENT", 12, 24], ["plasmapheresis", "TREATMENT", 32, 46], ["therapy", "TREATMENT", 103, 110], ["acute alcoholic hepatitis", "PROBLEM", 114, 139], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["alcoholic hepatitis", "OBSERVATION", 120, 139]]], ["This patient is a nonresponder as determined by Lille score and there is little clinical benefi t for continuing prednisolone.", [["prednisolone", "CHEMICAL", 113, 125], ["prednisolone", "CHEMICAL", 113, 125], ["patient", "ORGANISM", 5, 12], ["prednisolone", "SIMPLE_CHEMICAL", 113, 125], ["patient", "SPECIES", 5, 12], ["continuing prednisolone", "TREATMENT", 102, 125]]], ["Her prognosis is poor given that she is a nonresponder to corticosteroids and it is reasonable to involve palliative care.", [["corticosteroids", "CHEMICAL", 58, 73], ["corticosteroids", "TREATMENT", 58, 73], ["palliative care", "TREATMENT", 106, 121]]], ["Switching to pentoxifylline has been evaluated in a prospective randomized trial and has no proven clinical benefi t.", [["pentoxifylline", "CHEMICAL", 13, 27], ["pentoxifylline", "CHEMICAL", 13, 27], ["pentoxifylline", "SIMPLE_CHEMICAL", 13, 27], ["pentoxifylline", "TREATMENT", 13, 27], ["a prospective randomized trial", "TREATMENT", 50, 80], ["no proven", "UNCERTAINTY", 89, 98]]], ["The overall 30-day mortality rate in patients hospitalized with alcoholic hepatitis is approximately 15 %.", [["alcoholic hepatitis", "DISEASE", 64, 83], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["alcoholic hepatitis", "PROBLEM", 64, 83], ["alcoholic hepatitis", "OBSERVATION", 64, 83]]], ["In patients with severe chronic liver disease, the rate approaches or exceeds 50 %.", [["liver", "ANATOMY", 32, 37], ["chronic liver disease", "DISEASE", 24, 45], ["patients", "ORGANISM", 3, 11], ["liver", "ORGAN", 32, 37], ["patients", "SPECIES", 3, 11], ["severe chronic liver disease", "PROBLEM", 17, 45], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["chronic", "OBSERVATION_MODIFIER", 24, 31], ["liver", "ANATOMY", 32, 37], ["disease", "OBSERVATION", 38, 45]]], ["Liver transplantation would not be an option in the United States for fulminant alcoholic hepatitis given his recent alcohol use.", [["Liver", "ANATOMY", 0, 5], ["fulminant alcoholic hepatitis", "DISEASE", 70, 99], ["alcohol", "CHEMICAL", 117, 124], ["alcohol", "CHEMICAL", 117, 124], ["Liver", "ORGAN", 0, 5], ["alcohol", "SIMPLE_CHEMICAL", 117, 124], ["Liver transplantation", "TREATMENT", 0, 21], ["fulminant alcoholic hepatitis", "PROBLEM", 70, 99], ["transplantation", "OBSERVATION", 6, 21], ["fulminant", "OBSERVATION_MODIFIER", 70, 79], ["alcoholic hepatitis", "OBSERVATION", 80, 99]]], ["A consultation with the liver transplant service may be needed to review and communicate these issues.", [["liver", "ANATOMY", 24, 29], ["liver", "ORGAN", 24, 29], ["liver", "ANATOMY", 24, 29]]], ["On physical examination, temperature is normal, blood pressure is 130/65 mmHg, pulse rate is 60/min, and respiration rate is 22.", [["blood", "ANATOMY", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["blood pressure", "TEST", 48, 62], ["pulse rate", "TEST", 79, 89], ["respiration rate", "TEST", 105, 121], ["normal", "OBSERVATION", 40, 46]]], ["Cardiopulmonary examination discloses normal heart sounds without murmur and symmetric breath sounds.", [["heart", "ANATOMY", 45, 50], ["heart", "ORGAN", 45, 50], ["Cardiopulmonary examination", "TEST", 0, 27], ["murmur", "PROBLEM", 66, 72], ["normal", "OBSERVATION", 38, 44], ["heart", "ANATOMY", 45, 50], ["sounds", "OBSERVATION", 51, 57], ["without", "UNCERTAINTY", 58, 65], ["murmur", "OBSERVATION", 66, 72], ["symmetric", "OBSERVATION_MODIFIER", 77, 86], ["breath sounds", "OBSERVATION", 87, 100]]], ["She has 2+ pitting edema of the lower extremities.", [["lower extremities", "ANATOMY", 32, 49], ["edema", "DISEASE", 19, 24], ["lower extremities", "ORGANISM_SUBDIVISION", 32, 49], ["pitting edema of the lower extremities", "PROBLEM", 11, 49], ["2+", "OBSERVATION_MODIFIER", 8, 10], ["pitting", "OBSERVATION_MODIFIER", 11, 18], ["edema", "OBSERVATION", 19, 24], ["lower extremities", "ANATOMY", 32, 49]]], ["Abdominal distension is noted.", [["Abdominal", "ANATOMY", 0, 9], ["Abdominal distension", "DISEASE", 0, 20], ["Abdominal distension", "PROBLEM", 0, 20], ["distension", "OBSERVATION", 10, 20]]], ["Laboratory studies show hematocrit of 47 %, leukocyte count 10,000/\u03bcL, platelet count 1,125,000/ \u03bcL L, and total bilirubin 6.0 mg/dL.", [["leukocyte", "ANATOMY", 44, 53], ["platelet", "ANATOMY", 71, 79], ["bilirubin", "CHEMICAL", 113, 122], ["bilirubin", "CHEMICAL", 113, 122], ["leukocyte", "CELL", 44, 53], ["platelet", "CELL", 71, 79], ["bilirubin", "SIMPLE_CHEMICAL", 113, 122], ["Laboratory studies", "TEST", 0, 18], ["hematocrit", "TEST", 24, 34], ["leukocyte count", "TEST", 44, 59], ["\u03bcL", "TEST", 67, 69], ["platelet count", "TEST", 71, 85], ["\u03bcL L", "TEST", 97, 101], ["total bilirubin", "TEST", 107, 122]]], ["A Doppler ultrasound of the abdomen shows occlusion of the hepatic veins.ReferenceWhich of the following is the most appropriate next step in the evaluation of this patient?", [["abdomen", "ANATOMY", 28, 35], ["hepatic veins", "ANATOMY", 59, 72], ["abdomen", "ORGAN", 28, 35], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 59, 72], ["patient", "ORGANISM", 165, 172], ["patient", "SPECIES", 165, 172], ["A Doppler ultrasound of the abdomen", "TEST", 0, 35], ["occlusion of the hepatic veins", "PROBLEM", 42, 72], ["the evaluation", "TEST", 142, 156], ["abdomen", "ANATOMY", 28, 35], ["occlusion", "OBSERVATION", 42, 51], ["hepatic veins", "ANATOMY", 59, 72]]], ["A) Antiphospholipid antibody assay B) Antithrombin activity assay C) Flow cytometry for paroxysmal nocturnal hemoglobinuria D) JAK2 V617F mutational analysis E) Protein C activity assay Answer: D This patient has Budd-Chiari syndrome, which is characterized by thrombosis of the hepatic veins, upper quadrant pain, and hepatomegaly.", [["hepatic veins", "ANATOMY", 279, 292], ["upper quadrant", "ANATOMY", 294, 308], ["paroxysmal nocturnal hemoglobinuria", "DISEASE", 88, 123], ["Budd-Chiari syndrome", "DISEASE", 213, 233], ["thrombosis of the hepatic veins", "DISEASE", 261, 292], ["upper quadrant pain", "DISEASE", 294, 313], ["hepatomegaly", "DISEASE", 319, 331], ["Antiphospholipid antibody assay B) Antithrombin", "GENE_OR_GENE_PRODUCT", 3, 50], ["JAK2", "GENE_OR_GENE_PRODUCT", 127, 131], ["Protein C", "GENE_OR_GENE_PRODUCT", 161, 170], ["patient", "ORGANISM", 201, 208], ["hepatic veins", "MULTI-TISSUE_STRUCTURE", 279, 292], ["upper quadrant", "ORGANISM_SUBDIVISION", 294, 308], ["Antiphospholipid antibody assay B", "PROTEIN", 3, 36], ["Antithrombin", "PROTEIN", 38, 50], ["JAK2", "PROTEIN", 127, 131], ["Protein C", "PROTEIN", 161, 170], ["patient", "SPECIES", 201, 208], ["A) Antiphospholipid antibody assay", "TEST", 0, 34], ["Antithrombin activity assay C", "TEST", 38, 67], ["Flow cytometry", "TEST", 69, 83], ["paroxysmal nocturnal hemoglobinuria D)", "PROBLEM", 88, 126], ["mutational analysis", "TEST", 138, 157], ["Protein C activity assay", "TEST", 161, 185], ["Budd-Chiari syndrome", "PROBLEM", 213, 233], ["thrombosis of the hepatic veins", "PROBLEM", 261, 292], ["upper quadrant pain", "PROBLEM", 294, 313], ["hepatomegaly", "PROBLEM", 319, 331], ["Chiari syndrome", "OBSERVATION", 218, 233], ["thrombosis", "OBSERVATION", 261, 271], ["hepatic veins", "ANATOMY", 279, 292], ["upper", "ANATOMY_MODIFIER", 294, 299], ["quadrant", "ANATOMY", 300, 308], ["pain", "OBSERVATION", 309, 313], ["hepatomegaly", "OBSERVATION", 319, 331]]], ["Rapid development of jaundice and ascites often occur.", [["ascites", "ANATOMY", 34, 41], ["jaundice", "DISEASE", 21, 29], ["ascites", "DISEASE", 34, 41], ["jaundice", "PROBLEM", 21, 29], ["ascites", "PROBLEM", 34, 41], ["jaundice", "OBSERVATION", 21, 29], ["ascites", "OBSERVATION", 34, 41]]], ["Sixty percent of patients with this syndrome have or eventually will be diagnosed with a myeloproliferative disorder.", [["myeloproliferative disorder", "DISEASE", 89, 116], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["this syndrome", "PROBLEM", 31, 44], ["a myeloproliferative disorder", "PROBLEM", 87, 116], ["myeloproliferative disorder", "OBSERVATION", 89, 116]]], ["Polycythemia vera and essential thrombocytosis are the two most common underlying disorders.", [["Polycythemia vera", "DISEASE", 0, 17], ["essential thrombocytosis", "DISEASE", 22, 46], ["Polycythemia vera", "PROBLEM", 0, 17], ["essential thrombocytosis", "PROBLEM", 22, 46], ["underlying disorders", "PROBLEM", 71, 91], ["essential", "OBSERVATION_MODIFIER", 22, 31], ["thrombocytosis", "OBSERVATION", 32, 46], ["two most common", "OBSERVATION_MODIFIER", 55, 70], ["disorders", "OBSERVATION", 82, 91]]], ["The JAK2 V617F gene mutation is present in 97 % of patients with polycythemia vera and in 50 % of those with essential thrombocythemia.", [["polycythemia vera", "DISEASE", 65, 82], ["essential thrombocythemia", "DISEASE", 109, 134], ["JAK2", "GENE_OR_GENE_PRODUCT", 4, 8], ["patients", "ORGANISM", 51, 59], ["JAK2 V617F gene", "DNA", 4, 19], ["patients", "SPECIES", 51, 59], ["The JAK2 V617F gene mutation", "TEST", 0, 28], ["polycythemia vera", "PROBLEM", 65, 82], ["essential thrombocythemia", "PROBLEM", 109, 134], ["JAK2 V617F", "OBSERVATION", 4, 14], ["polycythemia", "OBSERVATION", 65, 77], ["thrombocythemia", "OBSERVATION", 119, 134]]], ["It should be measured in all patients with Budd-Chiari syndrome.", [["Budd-Chiari syndrome", "DISEASE", 43, 63], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["Budd-Chiari syndrome", "PROBLEM", 43, 63], ["Chiari syndrome", "OBSERVATION", 48, 63]]], ["Positive fi ndings indicate a myeloproliferative disorder and suggest the need for cytoreductive therapy.", [["myeloproliferative disorder", "DISEASE", 30, 57], ["a myeloproliferative disorder", "PROBLEM", 28, 57], ["cytoreductive therapy", "TREATMENT", 83, 104], ["myeloproliferative disorder", "OBSERVATION", 30, 57]]], ["There are several options in the treatment of Budd-Chiari including anticoagulation, thrombolytics, and surgery.", [["Budd-Chiari", "DISEASE", 46, 57], ["the treatment", "TREATMENT", 29, 42], ["Budd-Chiari", "TREATMENT", 46, 57], ["anticoagulation", "TREATMENT", 68, 83], ["thrombolytics", "TREATMENT", 85, 98], ["surgery", "TREATMENT", 104, 111], ["Chiari", "ANATOMY", 51, 57]]], ["Consultation with hepatology for the management, guidance, and possible need for transplantation should be fi rst undertaken.", [["the management", "TREATMENT", 33, 47], ["transplantation", "TREATMENT", 81, 96]]], ["The patient was then treated with pentamidine, but this medication was also discontinued because of the development of abdominal pain with elevations in serum amylase and lipase levels.", [["abdominal", "ANATOMY", 119, 128], ["serum", "ANATOMY", 153, 158], ["pentamidine", "CHEMICAL", 34, 45], ["abdominal pain", "DISEASE", 119, 133], ["pentamidine", "CHEMICAL", 34, 45], ["patient", "ORGANISM", 4, 11], ["pentamidine", "SIMPLE_CHEMICAL", 34, 45], ["abdominal", "ORGANISM_SUBDIVISION", 119, 128], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["amylase", "GENE_OR_GENE_PRODUCT", 159, 166], ["lipase", "GENE_OR_GENE_PRODUCT", 171, 177], ["serum amylase", "PROTEIN", 153, 166], ["lipase", "PROTEIN", 171, 177], ["patient", "SPECIES", 4, 11], ["pentamidine", "TREATMENT", 34, 45], ["this medication", "TREATMENT", 51, 66], ["abdominal pain", "PROBLEM", 119, 133], ["elevations in serum amylase", "PROBLEM", 139, 166], ["lipase levels", "TEST", 171, 184], ["abdominal", "ANATOMY", 119, 128], ["pain", "OBSERVATION", 129, 133]]], ["Clindamycin-primaquine was then started.", [["Clindamycin", "CHEMICAL", 0, 11], ["primaquine", "CHEMICAL", 12, 22], ["Clindamycin", "CHEMICAL", 0, 11], ["primaquine", "CHEMICAL", 12, 22], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["primaquine", "SIMPLE_CHEMICAL", 12, 22], ["Clindamycin", "TREATMENT", 0, 11], ["primaquine", "TREATMENT", 12, 22]]], ["On the third day of treatment, he developed jaundice and dark urine.ReferenceWhich of the following tests would most likely provide the etiology of this patient's syndrome?", [["urine", "ANATOMY", 62, 67], ["jaundice", "DISEASE", 44, 52], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["treatment", "TREATMENT", 20, 29], ["jaundice", "PROBLEM", 44, 52], ["dark urine", "PROBLEM", 57, 67], ["the following tests", "TEST", 86, 105], ["this patient's syndrome", "PROBLEM", 148, 171], ["jaundice", "OBSERVATION", 44, 52], ["dark urine", "OBSERVATION", 57, 67]]], ["A) Serum indirect bilirubin B) Serum lactate dehydrogenase C) Blood glucose-6-phosphate dehydrogenase D) Serum trypsin Answer: C Side effects of treatment regimens are often seen in the primary treatment of Pneumocystis jiroveci pneumonia.", [["Serum", "ANATOMY", 3, 8], ["bilirubin", "CHEMICAL", 18, 27], ["lactate", "CHEMICAL", 37, 44], ["glucose-6-phosphate", "CHEMICAL", 68, 87], ["Pneumocystis jiroveci pneumonia", "DISEASE", 207, 238], ["bilirubin B", "CHEMICAL", 18, 29], ["lactate", "CHEMICAL", 37, 44], ["glucose-6-phosphate", "CHEMICAL", 68, 87], ["Serum", "ORGANISM_SUBSTANCE", 3, 8], ["bilirubin B", "GENE_OR_GENE_PRODUCT", 18, 29], ["Serum", "ORGANISM_SUBSTANCE", 31, 36], ["lactate dehydrogenase C", "GENE_OR_GENE_PRODUCT", 37, 60], ["Blood", "ORGANISM_SUBSTANCE", 62, 67], ["glucose-6-phosphate dehydrogenase D", "SIMPLE_CHEMICAL", 68, 103], ["Serum", "ORGANISM_SUBSTANCE", 105, 110], ["Pneumocystis jiroveci", "ORGANISM", 207, 228], ["Serum indirect bilirubin B", "PROTEIN", 3, 29], ["Serum lactate dehydrogenase C", "PROTEIN", 31, 60], ["Blood glucose-6-phosphate dehydrogenase D", "PROTEIN", 62, 103], ["Pneumocystis jiroveci", "SPECIES", 207, 228], ["Pneumocystis jiroveci", "SPECIES", 207, 228], ["A) Serum indirect bilirubin B", "TEST", 0, 29], ["Serum lactate", "TEST", 31, 44], ["dehydrogenase C", "TEST", 45, 60], ["Blood glucose", "TEST", 62, 75], ["phosphate dehydrogenase D) Serum trypsin Answer", "PROBLEM", 78, 125], ["treatment regimens", "TREATMENT", 145, 163], ["Pneumocystis jiroveci pneumonia", "PROBLEM", 207, 238], ["Pneumocystis jiroveci", "OBSERVATION", 207, 228]]], ["Second-line salvage treatment also has high incidences of side effects.", [["Second-line salvage treatment", "TREATMENT", 0, 29], ["side effects", "PROBLEM", 58, 70], ["line salvage", "OBSERVATION", 7, 19]]], ["This patient has fi rst developed a rash and fever due to trimethoprim-sulfamethoxazole.", [["rash", "DISEASE", 36, 40], ["fever", "DISEASE", 45, 50], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 58, 87], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 58, 87], ["patient", "ORGANISM", 5, 12], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 58, 87], ["patient", "SPECIES", 5, 12], ["a rash", "PROBLEM", 34, 40], ["fever", "PROBLEM", 45, 50], ["trimethoprim", "TREATMENT", 58, 70], ["sulfamethoxazole", "TREATMENT", 71, 87], ["rash", "OBSERVATION", 36, 40]]], ["He then developed pancreatitis due to pentamidine.", [["pancreatitis", "DISEASE", 18, 30], ["pentamidine", "CHEMICAL", 38, 49], ["pentamidine", "CHEMICAL", 38, 49], ["He", "ORGANISM", 0, 2], ["pentamidine", "SIMPLE_CHEMICAL", 38, 49], ["pancreatitis", "PROBLEM", 18, 30], ["pentamidine", "TREATMENT", 38, 49], ["pancreatitis", "OBSERVATION", 18, 30], ["pentamidine", "OBSERVATION", 38, 49]]], ["Primaquine can cause hemolytic anemia in patients with G6PD defi ciency, and patients should be tested when possible prior to starting treatment.", [["Primaquine", "CHEMICAL", 0, 10], ["hemolytic anemia", "DISEASE", 21, 37], ["Primaquine", "CHEMICAL", 0, 10], ["Primaquine", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 77, 85], ["Primaquine", "TREATMENT", 0, 10], ["hemolytic anemia", "PROBLEM", 21, 37], ["G6PD defi ciency", "PROBLEM", 55, 71], ["treatment", "TREATMENT", 135, 144], ["hemolytic", "OBSERVATION_MODIFIER", 21, 30]]], ["The patient has developed clinical evidence of hemolysis, and although bilirubin, erythropoietin, and LDH assessment would suggest the diagnosis, actual measurement of G6PD level is indicated.", [["hemolysis", "DISEASE", 47, 56], ["bilirubin", "CHEMICAL", 71, 80], ["bilirubin", "CHEMICAL", 71, 80], ["patient", "ORGANISM", 4, 11], ["bilirubin", "GENE_OR_GENE_PRODUCT", 71, 80], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 82, 96], ["LDH", "SIMPLE_CHEMICAL", 102, 105], ["G6PD", "GENE_OR_GENE_PRODUCT", 168, 172], ["bilirubin", "PROTEIN", 71, 80], ["erythropoietin", "PROTEIN", 82, 96], ["G6PD", "PROTEIN", 168, 172], ["patient", "SPECIES", 4, 11], ["hemolysis", "PROBLEM", 47, 56], ["bilirubin", "TEST", 71, 80], ["erythropoietin", "TEST", 82, 96], ["LDH assessment", "TEST", 102, 116], ["G6PD level", "TEST", 168, 178], ["evidence of", "UNCERTAINTY", 35, 46], ["hemolysis", "OBSERVATION", 47, 56]]], ["A 37-year-old male is admitted for acute alcohol intoxication and the desire to seek help for his alcohol dependency.", [["alcohol", "CHEMICAL", 41, 48], ["alcohol", "CHEMICAL", 98, 105], ["alcohol", "CHEMICAL", 41, 48], ["alcohol", "CHEMICAL", 98, 105], ["male", "ORGANISM", 14, 18], ["alcohol", "SIMPLE_CHEMICAL", 98, 105], ["acute alcohol intoxication", "PROBLEM", 35, 61], ["his alcohol dependency", "PROBLEM", 94, 116]]], ["He denies any history of delirium tremens.", [["delirium", "DISEASE", 25, 33], ["tremens", "DISEASE", 34, 41], ["delirium tremens", "PROBLEM", 25, 41], ["delirium", "OBSERVATION", 25, 33]]], ["However, he states that he has attempted to quit drinking several times in the past, which results in prolonged withdrawal symptoms requiring sedation.", [["prolonged withdrawal symptoms", "PROBLEM", 102, 131], ["sedation", "TREATMENT", 142, 150]]], ["He denies any other past medical history, and he is on no medications.", [["medications", "TREATMENT", 58, 69]]], ["On physical examination, he appears alert and slightly diaphoretic.", [["physical examination", "TEST", 3, 23], ["slightly diaphoretic", "PROBLEM", 46, 66]]], ["He is oriented to person, place, and time.", [["person", "SPECIES", 18, 24]]], ["His temperature is 37.6 \u00b0C (99.6 \u00b0F), pulse rate is 100 per minute, and respirations are 12 per minute.", [["His temperature", "TEST", 0, 15], ["\u00b0C", "TEST", 24, 26], ["pulse rate", "TEST", 38, 48], ["respirations", "TEST", 72, 84]]], ["Blood pressure is 138/74.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Lungs are clear upon auscultation.", [["Lungs", "ANATOMY", 0, 5], ["Lungs", "ORGAN", 0, 5], ["auscultation", "TEST", 21, 33], ["clear", "OBSERVATION", 10, 15], ["auscultation", "OBSERVATION", 21, 33]]], ["He has a mild tremor.", [["tremor", "DISEASE", 14, 20], ["a mild tremor", "PROBLEM", 7, 20], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["tremor", "OBSERVATION", 14, 20]]], ["Laboratory data is within normal range.", [["Laboratory data", "TEST", 0, 15], ["normal range", "OBSERVATION", 26, 38]]], ["He is admitted for acute intoxication and consultation with a substance abuse service is ordered.ReferencesWhich of the following is the most appropriate treatment for the patient's alcohol withdrawal?", [["substance abuse", "DISEASE", 62, 77], ["alcohol", "CHEMICAL", 182, 189], ["alcohol", "CHEMICAL", 182, 189], ["patient", "ORGANISM", 172, 179], ["alcohol", "SIMPLE_CHEMICAL", 182, 189], ["patient", "SPECIES", 172, 179], ["acute intoxication", "PROBLEM", 19, 37], ["the patient's alcohol withdrawal", "PROBLEM", 168, 200]]], ["A) Schedule diazepam 10 mg every 4 h B) Oral chlordiazepoxide 50 mg every 6 h C) Oral chlordiazepoxide 50 mg every 6 h and lorazepam 2 mg every 4 h based on symptoms D) Oral chlordiazepoxide 50 mg every 6 h and Haldol 2.5 mg every 4 h as needed for symptoms E) Oral diazepam 10 mg every 4 h based on symptoms Answer: E This patient demonstrates no symptoms of delirium tremens and is experiencing moderate withdrawal symptoms from alcohol.", [["Oral", "ANATOMY", 261, 265], ["diazepam", "CHEMICAL", 12, 20], ["chlordiazepoxide", "CHEMICAL", 45, 61], ["chlordiazepoxide", "CHEMICAL", 86, 102], ["lorazepam", "CHEMICAL", 123, 132], ["chlordiazepoxide", "CHEMICAL", 174, 190], ["Haldol", "CHEMICAL", 211, 217], ["diazepam", "CHEMICAL", 266, 274], ["delirium", "DISEASE", 360, 368], ["tremens", "DISEASE", 369, 376], ["alcohol", "CHEMICAL", 431, 438], ["diazepam", "CHEMICAL", 12, 20], ["chlordiazepoxide", "CHEMICAL", 45, 61], ["chlordiazepoxide", "CHEMICAL", 86, 102], ["lorazepam", "CHEMICAL", 123, 132], ["chlordiazepoxide", "CHEMICAL", 174, 190], ["Haldol", "CHEMICAL", 211, 217], ["diazepam", "CHEMICAL", 266, 274], ["alcohol", "CHEMICAL", 431, 438], ["diazepam", "SIMPLE_CHEMICAL", 12, 20], ["lorazepam", "SIMPLE_CHEMICAL", 123, 132], ["Haldol", "SIMPLE_CHEMICAL", 211, 217], ["patient", "ORGANISM", 324, 331], ["alcohol", "SIMPLE_CHEMICAL", 431, 438], ["patient", "SPECIES", 324, 331], ["A) Schedule diazepam", "TREATMENT", 0, 20], ["Oral chlordiazepoxide", "TREATMENT", 40, 61], ["Oral chlordiazepoxide", "TREATMENT", 81, 102], ["lorazepam", "TREATMENT", 123, 132], ["symptoms", "PROBLEM", 157, 165], ["Oral chlordiazepoxide", "TREATMENT", 169, 190], ["Haldol", "TREATMENT", 211, 217], ["symptoms", "PROBLEM", 249, 257], ["Oral diazepam", "TREATMENT", 261, 274], ["symptoms", "PROBLEM", 300, 308], ["symptoms", "PROBLEM", 348, 356], ["delirium tremens", "PROBLEM", 360, 376], ["moderate withdrawal symptoms", "PROBLEM", 397, 425], ["no", "UNCERTAINTY", 345, 347], ["moderate", "OBSERVATION_MODIFIER", 397, 405], ["withdrawal", "OBSERVATION", 406, 416]]], ["Symptom-triggered therapy as opposed to fi xed dose is appropriate.", [["fi xed", "SIMPLE_CHEMICAL", 40, 46], ["Symptom", "PROBLEM", 0, 7], ["therapy", "TREATMENT", 18, 25]]], ["The most objective and best-validated tool to assess the severity of alcohol withdrawal is the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar).", [["alcohol", "CHEMICAL", 69, 76], ["Alcohol", "CHEMICAL", 140, 147], ["alcohol", "CHEMICAL", 69, 76], ["alcohol", "SIMPLE_CHEMICAL", 69, 76], ["alcohol withdrawal", "PROBLEM", 69, 87], ["CIWA", "TEST", 158, 162]]], ["Therapy is based upon the score.", [["Therapy", "TREATMENT", 0, 7]]], ["The CIWA-Ar scale has its limitations and is not universally used.", [["The CIWA", "TEST", 0, 8]]], ["It has not been validated in complex medical patients, postsurgical patients, and critically ill patients.", [["critically ill", "DISEASE", 82, 96], ["patients", "ORGANISM", 45, 53], ["patients", "ORGANISM", 68, 76], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 68, 76], ["patients", "SPECIES", 97, 105]]], ["Fixed dose therapy can be instituted if symptoms are not controlled, erratic, or escalate despite symptom-based therapy.", [["Fixed dose therapy", "TREATMENT", 0, 18], ["symptoms", "PROBLEM", 40, 48], ["symptom", "PROBLEM", 98, 105], ["based therapy", "TREATMENT", 106, 119]]], ["Haloperidol is not recommended in alcohol withdrawal in the absence of hallucinations.", [["Haloperidol", "CHEMICAL", 0, 11], ["alcohol", "CHEMICAL", 34, 41], ["hallucinations", "DISEASE", 71, 85], ["Haloperidol", "CHEMICAL", 0, 11], ["alcohol", "CHEMICAL", 34, 41], ["Haloperidol", "SIMPLE_CHEMICAL", 0, 11], ["alcohol", "SIMPLE_CHEMICAL", 34, 41], ["Haloperidol", "TREATMENT", 0, 11], ["alcohol withdrawal", "PROBLEM", 34, 52], ["hallucinations", "PROBLEM", 71, 85]]], ["It may be used in psychosis or agitation nonresponsive to benzodiazepines.", [["psychosis", "DISEASE", 18, 27], ["agitation", "DISEASE", 31, 40], ["benzodiazepines", "CHEMICAL", 58, 73], ["benzodiazepines", "CHEMICAL", 58, 73], ["psychosis", "PROBLEM", 18, 27], ["agitation", "PROBLEM", 31, 40], ["benzodiazepines", "TREATMENT", 58, 73]]], ["A 56-year-old male is admitted for a COPD exacerbation.", [["COPD", "DISEASE", 37, 41], ["male", "ORGANISM", 14, 18], ["a COPD exacerbation", "PROBLEM", 35, 54], ["COPD", "OBSERVATION", 37, 41]]], ["He complains of shortness of breath, \"coughing up yellow stuff,\" and fatigue.", [["shortness of breath", "DISEASE", 16, 35], ["coughing", "DISEASE", 38, 46], ["fatigue", "DISEASE", 69, 76], ["shortness of breath", "PROBLEM", 16, 35], ["coughing up yellow stuff", "PROBLEM", 38, 62], ["fatigue", "PROBLEM", 69, 76], ["fatigue", "OBSERVATION", 69, 76]]], ["He has a past medical history of COPD, diabetes mellitus II, hypertension, and dyslipidemia.", [["COPD", "DISEASE", 33, 37], ["diabetes mellitus II", "DISEASE", 39, 59], ["hypertension", "DISEASE", 61, 73], ["dyslipidemia", "DISEASE", 79, 91], ["COPD", "PROBLEM", 33, 37], ["diabetes mellitus II", "PROBLEM", 39, 59], ["hypertension", "PROBLEM", 61, 73], ["dyslipidemia", "PROBLEM", 79, 91], ["COPD", "OBSERVATION", 33, 37], ["diabetes mellitus", "OBSERVATION", 39, 56], ["hypertension", "OBSERVATION", 61, 73], ["dyslipidemia", "OBSERVATION", 79, 91]]], ["He smokes \u00bd pack per day and drinks 1-2 beers nightly.", [["He", "ORGANISM", 0, 2]]], ["He is on the following medications at home: Insulin detemir 25 units SQ BID, insulin aspart 3 units SQ with meals, tiotropium 18 mcg 2 puffs once daily, fl uticasone/ salmeterol 250/50, 1 inhalation BID, albuterol HFA 90 mcg 2 puffs every 4-6 h as needed for SOB, lisinopril 5 mg PO daily, rosuvastatin 20 mg PO daily, hydrochlorothiazide 12.5 mg PO daily, and gabapentin 300 mg PO TID.", [["tiotropium", "CHEMICAL", 115, 125], ["uticasone", "CHEMICAL", 156, 165], ["salmeterol", "CHEMICAL", 167, 177], ["albuterol", "CHEMICAL", 204, 213], ["SOB", "CHEMICAL", 259, 262], ["lisinopril", "CHEMICAL", 264, 274], ["rosuvastatin", "CHEMICAL", 290, 302], ["hydrochlorothiazide", "CHEMICAL", 319, 338], ["gabapentin", "CHEMICAL", 361, 371], ["TID", "CHEMICAL", 382, 385], ["tiotropium", "CHEMICAL", 115, 125], ["salmeterol", "CHEMICAL", 167, 177], ["BID", "CHEMICAL", 199, 202], ["albuterol", "CHEMICAL", 204, 213], ["lisinopril", "CHEMICAL", 264, 274], ["rosuvastatin", "CHEMICAL", 290, 302], ["hydrochlorothiazide", "CHEMICAL", 319, 338], ["gabapentin", "CHEMICAL", 361, 371], ["Insulin", "GENE_OR_GENE_PRODUCT", 44, 51], ["insulin", "GENE_OR_GENE_PRODUCT", 77, 84], ["salmeterol", "SIMPLE_CHEMICAL", 167, 177], ["BID", "SIMPLE_CHEMICAL", 199, 202], ["albuterol", "SIMPLE_CHEMICAL", 204, 213], ["SOB", "SIMPLE_CHEMICAL", 259, 262], ["lisinopril", "SIMPLE_CHEMICAL", 264, 274], ["PO", "SIMPLE_CHEMICAL", 280, 282], ["rosuvastatin", "SIMPLE_CHEMICAL", 290, 302], ["PO", "SIMPLE_CHEMICAL", 309, 311], ["hydrochlorothiazide", "SIMPLE_CHEMICAL", 319, 338], ["gabapentin", "SIMPLE_CHEMICAL", 361, 371], ["the following medications", "TREATMENT", 9, 34], ["Insulin detemir", "TREATMENT", 44, 59], ["insulin aspart", "TREATMENT", 77, 91], ["tiotropium", "TREATMENT", 115, 125], ["fl uticasone", "TREATMENT", 153, 165], ["salmeterol", "TREATMENT", 167, 177], ["albuterol HFA", "TREATMENT", 204, 217], ["SOB", "PROBLEM", 259, 262], ["lisinopril", "TREATMENT", 264, 274], ["rosuvastatin", "TREATMENT", 290, 302], ["hydrochlorothiazide", "TREATMENT", 319, 338], ["gabapentin", "TREATMENT", 361, 371]]], ["He is started on moxifl oxacin 400 mg PO daily and prednisone 40 mg PO daily during admission.", [["moxifl oxacin", "CHEMICAL", 17, 30], ["prednisone", "CHEMICAL", 51, 61], ["moxifl oxacin", "CHEMICAL", 17, 30], ["prednisone", "CHEMICAL", 51, 61], ["moxifl oxacin", "SIMPLE_CHEMICAL", 17, 30], ["PO", "SIMPLE_CHEMICAL", 38, 40], ["prednisone", "SIMPLE_CHEMICAL", 51, 61], ["PO", "SIMPLE_CHEMICAL", 68, 70], ["moxifl oxacin", "TREATMENT", 17, 30], ["prednisone", "TREATMENT", 51, 61]]], ["He continued on his home insulin dose.", [["insulin", "GENE_OR_GENE_PRODUCT", 25, 32], ["his home insulin dose", "TREATMENT", 16, 37]]], ["On the day following his admission, his accu-check readings are as follows: 0600: 130, 0900: 220, 1230: 245, 1730: 251, 2100: 139.ReferencesWhat medication adjustments would you make after seeing these readings?", [["his accu-check readings", "TEST", 36, 59]]], ["A) Increase meal-time insulin B) Increase basal insulin C) Increase both meal-time and basal insulin D) No change Answer: A Glucocorticoid use is associated with the risk of hyperglycemia.", [["hyperglycemia", "DISEASE", 174, 187], ["insulin B", "GENE_OR_GENE_PRODUCT", 22, 31], ["insulin C", "GENE_OR_GENE_PRODUCT", 48, 57], ["insulin", "GENE_OR_GENE_PRODUCT", 93, 100], ["Glucocorticoid", "SIMPLE_CHEMICAL", 124, 138], ["insulin B", "PROTEIN", 22, 31], ["A) Increase meal-time insulin B", "TREATMENT", 0, 31], ["basal insulin C) Increase both meal", "TREATMENT", 42, 77], ["basal insulin D", "TREATMENT", 87, 102], ["hyperglycemia", "PROBLEM", 174, 187], ["change", "OBSERVATION", 107, 113], ["hyperglycemia", "OBSERVATION", 174, 187]]], ["Effects are greater in the fed rather than fasting state.", [["greater", "OBSERVATION_MODIFIER", 12, 19]]], ["Insulin regimens need to take into account that glucocorticoids typically have greater effects on postprandial glucose levels rather than on fasting levels.", [["glucose", "CHEMICAL", 111, 118], ["glucose", "CHEMICAL", 111, 118], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["glucocorticoids", "SIMPLE_CHEMICAL", 48, 63], ["postprandial", "ORGANISM_SUBDIVISION", 98, 110], ["glucose", "SIMPLE_CHEMICAL", 111, 118], ["Insulin regimens", "TREATMENT", 0, 16], ["glucocorticoids", "TREATMENT", 48, 63], ["postprandial glucose levels", "TEST", 98, 125], ["fasting levels", "TEST", 141, 155]]], ["Thus, the patient's initiation of prednisone is likely the culprit of those increased accu-check readings.", [["prednisone", "CHEMICAL", 34, 44], ["prednisone", "CHEMICAL", 34, 44], ["patient", "ORGANISM", 10, 17], ["prednisone", "SIMPLE_CHEMICAL", 34, 44], ["patient", "SPECIES", 10, 17], ["prednisone", "TREATMENT", 34, 44]]], ["B is incorrect because the target blood glucose goal in the non-critical patient in the hospital is typically 100-140 mg/dl and 140-180 mg/dl in critically ill patients.", [["blood", "ANATOMY", 34, 39], ["glucose", "CHEMICAL", 40, 47], ["critically ill", "DISEASE", 145, 159], ["glucose", "CHEMICAL", 40, 47], ["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["glucose", "SIMPLE_CHEMICAL", 40, 47], ["patient", "ORGANISM", 73, 80], ["patients", "ORGANISM", 160, 168], ["patient", "SPECIES", 73, 80], ["patients", "SPECIES", 160, 168], ["the target blood glucose", "TEST", 23, 47]]], ["Thus, the fasting level of 130 mg/dl is appropriate and does not require dose adjustment.", [["the fasting level", "TEST", 6, 23], ["dose adjustment", "TREATMENT", 73, 88]]], ["C is incorrect as referenced above -no basal adjustments are needed.", [["basal adjustments", "TREATMENT", 39, 56]]], ["Lastly, D is incorrect because a change is required for the meal-time dosing regimen as the values range from 220 to 251 mg/dl.", [["D", "SIMPLE_CHEMICAL", 8, 9], ["the meal-time dosing regimen", "TREATMENT", 56, 84]]], ["A 57-year-old male presents with a chief complaint of an acute onset of chest pain that began approximately 20 min prior to presentation.", [["chest", "ANATOMY", 72, 77], ["chest pain", "DISEASE", 72, 82], ["male", "ORGANISM", 14, 18], ["chest", "ORGANISM_SUBDIVISION", 72, 77], ["chest pain", "PROBLEM", 72, 82], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["chest", "ANATOMY", 72, 77], ["pain", "OBSERVATION", 78, 82]]], ["ECG reveals acute elevations in the anterior leads consistent with an evolving anterior myocardial infarction.", [["anterior", "ANATOMY", 36, 44], ["myocardial", "ANATOMY", 88, 98], ["anterior myocardial infarction", "DISEASE", 79, 109], ["anterior", "ORGAN", 36, 44], ["myocardial", "MULTI-TISSUE_STRUCTURE", 88, 98], ["ECG", "TEST", 0, 3], ["acute elevations in the anterior leads", "PROBLEM", 12, 50], ["an evolving anterior myocardial infarction", "PROBLEM", 67, 109], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["elevations", "OBSERVATION", 18, 28], ["anterior", "ANATOMY_MODIFIER", 36, 44], ["consistent with", "UNCERTAINTY", 51, 66], ["evolving", "OBSERVATION_MODIFIER", 70, 78], ["anterior", "ANATOMY_MODIFIER", 79, 87], ["myocardial", "ANATOMY", 88, 98], ["infarction", "OBSERVATION", 99, 109]]], ["He has a history of peptic ulcer disease for which he was admitted to the hospital 1 month ago, at which time he underwent an EGD which revealed gastritis with no active bleeding sites.ReferencesOn physical examination, he is afebrile.", [["peptic ulcer", "ANATOMY", 20, 32], ["peptic ulcer disease", "DISEASE", 20, 40], ["gastritis", "DISEASE", 145, 154], ["bleeding", "DISEASE", 170, 178], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 20, 32], ["gastritis", "PATHOLOGICAL_FORMATION", 145, 154], ["peptic ulcer disease", "PROBLEM", 20, 40], ["an EGD", "TEST", 123, 129], ["gastritis", "PROBLEM", 145, 154], ["active bleeding sites", "PROBLEM", 163, 184], ["ReferencesOn physical examination", "TEST", 185, 218], ["afebrile", "PROBLEM", 226, 234], ["peptic", "OBSERVATION_MODIFIER", 20, 26], ["ulcer disease", "OBSERVATION", 27, 40], ["gastritis", "OBSERVATION", 145, 154], ["no", "UNCERTAINTY", 160, 162], ["active", "OBSERVATION_MODIFIER", 163, 169], ["bleeding", "OBSERVATION", 170, 178]]], ["Blood pressure is 140/70.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Heart rate is 90.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["Heart rate", "TEST", 0, 10]]], ["Respiration rate is 18.", [["Respiration rate", "TEST", 0, 16]]], ["Cardiovascular examination reveals normal S1 and S2 without an S3.ReferencesSerum troponin is pending.", [["Cardiovascular", "ANATOMY", 0, 14], ["troponin", "GENE_OR_GENE_PRODUCT", 82, 90], ["S2", "PROTEIN", 49, 51], ["S3", "PROTEIN", 63, 65], ["troponin", "PROTEIN", 82, 90], ["Cardiovascular examination", "TEST", 0, 26], ["ReferencesSerum troponin", "TEST", 66, 90], ["normal", "OBSERVATION", 35, 41], ["S1", "ANATOMY", 42, 44], ["S2", "ANATOMY", 49, 51], ["without", "UNCERTAINTY", 52, 59], ["S3", "OBSERVATION", 63, 65]]], ["The hematocrit is 44 %.", [["The hematocrit", "TEST", 0, 14], ["hematocrit", "OBSERVATION_MODIFIER", 4, 14]]], ["A) Thrombolytic therapy.", [["A) Thrombolytic therapy", "TREATMENT", 0, 23], ["Thrombolytic therapy", "OBSERVATION", 3, 23]]], ["C) Antiplatelet therapy.", [["Antiplatelet therapy", "TREATMENT", 3, 23], ["Antiplatelet therapy", "OBSERVATION", 3, 23]]], ["D) Consult cardiology for urgent cardiac catheterization(PCI) and intervention.ReferencesAnswer: D Treatment options include percutaneous coronary intervention, thrombolytic therapy, and medical management.", [["cardiac", "ANATOMY", 33, 40], ["percutaneous", "ANATOMY", 125, 137], ["coronary", "ANATOMY", 138, 146], ["cardiac", "ORGAN", 33, 40], ["coronary", "MULTI-TISSUE_STRUCTURE", 138, 146], ["urgent cardiac catheterization", "TEST", 26, 56], ["PCI", "TREATMENT", 57, 60], ["intervention", "TREATMENT", 66, 78], ["D Treatment options", "TREATMENT", 97, 116], ["percutaneous coronary intervention", "TREATMENT", 125, 159], ["thrombolytic therapy", "TREATMENT", 161, 181], ["medical management", "TREATMENT", 187, 205], ["cardiac", "ANATOMY", 33, 40], ["catheterization", "OBSERVATION", 41, 56], ["coronary", "ANATOMY", 138, 146]]], ["If available, the patient should undergo urgent percutaneous coronary intervention.", [["percutaneous", "ANATOMY", 48, 60], ["coronary", "ANATOMY", 61, 69], ["patient", "ORGANISM", 18, 25], ["coronary", "MULTI-TISSUE_STRUCTURE", 61, 69], ["patient", "SPECIES", 18, 25], ["urgent percutaneous coronary intervention", "TREATMENT", 41, 82], ["coronary", "ANATOMY", 61, 69]]], ["PCI performed within 90 min of a patient's arrival is superior to fi brinolysis with respect to combined endpoints of death, stroke, and reinfarction.", [["death", "DISEASE", 118, 123], ["stroke", "DISEASE", 125, 131], ["reinfarction", "DISEASE", 137, 149], ["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["PCI", "TREATMENT", 0, 3], ["fi brinolysis", "TREATMENT", 66, 79], ["death", "PROBLEM", 118, 123], ["stroke", "PROBLEM", 125, 131], ["reinfarction", "PROBLEM", 137, 149], ["stroke", "OBSERVATION", 125, 131], ["reinfarction", "OBSERVATION", 137, 149]]], ["He has an ECG consistent with acute anterior myocardial infarction.", [["myocardial", "ANATOMY", 45, 55], ["anterior myocardial infarction", "DISEASE", 36, 66], ["myocardial", "MULTI-TISSUE_STRUCTURE", 45, 55], ["an ECG", "TEST", 7, 13], ["acute anterior myocardial infarction", "PROBLEM", 30, 66], ["consistent with", "UNCERTAINTY", 14, 29], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["anterior", "ANATOMY_MODIFIER", 36, 44], ["myocardial", "ANATOMY", 45, 55], ["infarction", "OBSERVATION", 56, 66]]], ["Therapy for an acute MI presenting with 12 h of symptoms should be thrombolytic therapy or percutaneous intervention.", [["percutaneous", "ANATOMY", 91, 103], ["MI", "DISEASE", 21, 23], ["Therapy", "TREATMENT", 0, 7], ["an acute MI", "PROBLEM", 12, 23], ["symptoms", "PROBLEM", 48, 56], ["thrombolytic therapy", "TREATMENT", 67, 87], ["percutaneous intervention", "TREATMENT", 91, 116], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["MI", "OBSERVATION", 21, 23]]], ["This patient has a relative contraindication to thrombolytic therapy with his history of recent peptic ulcer disease.", [["peptic ulcer", "ANATOMY", 96, 108], ["peptic ulcer disease", "DISEASE", 96, 116], ["patient", "ORGANISM", 5, 12], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 96, 108], ["patient", "SPECIES", 5, 12], ["thrombolytic therapy", "TREATMENT", 48, 68], ["recent peptic ulcer disease", "PROBLEM", 89, 116], ["peptic", "OBSERVATION_MODIFIER", 96, 102], ["ulcer disease", "OBSERVATION", 103, 116]]], ["Absolute contraindications to thrombolytic therapy include any history of cerebrovascular hemorrhage, known cerebrovascular lesion, an ischemic stroke within 3 months, signifi cant facial trauma or closed head injury within 3 months.", [["cerebrovascular", "ANATOMY", 74, 89], ["cerebrovascular lesion", "ANATOMY", 108, 130], ["facial", "ANATOMY", 181, 187], ["head", "ANATOMY", 205, 209], ["cerebrovascular hemorrhage", "DISEASE", 74, 100], ["cerebrovascular lesion", "DISEASE", 108, 130], ["ischemic stroke", "DISEASE", 135, 150], ["trauma", "DISEASE", 188, 194], ["cerebrovascular", "ANATOMICAL_SYSTEM", 74, 89], ["cerebrovascular lesion", "PATHOLOGICAL_FORMATION", 108, 130], ["head", "ORGANISM_SUBDIVISION", 205, 209], ["thrombolytic therapy", "TREATMENT", 30, 50], ["cerebrovascular hemorrhage", "PROBLEM", 74, 100], ["known cerebrovascular lesion", "PROBLEM", 102, 130], ["an ischemic stroke", "PROBLEM", 132, 150], ["signifi cant facial trauma", "PROBLEM", 168, 194], ["closed head injury", "PROBLEM", 198, 216], ["cerebrovascular", "ANATOMY", 74, 89], ["hemorrhage", "OBSERVATION", 90, 100], ["cerebrovascular", "ANATOMY", 108, 123], ["lesion", "OBSERVATION", 124, 130], ["ischemic", "OBSERVATION_MODIFIER", 135, 143], ["stroke", "OBSERVATION", 144, 150], ["facial", "ANATOMY", 181, 187], ["trauma", "OBSERVATION", 188, 194], ["head", "ANATOMY", 205, 209], ["injury", "OBSERVATION", 210, 216]]], ["Relative contraindications are poorly controlled hypertension.", [["hypertension", "DISEASE", 49, 61], ["poorly controlled hypertension", "PROBLEM", 31, 61], ["poorly controlled", "OBSERVATION_MODIFIER", 31, 48], ["hypertension", "OBSERVATION", 49, 61]]], ["Medical management of the patient including aggressive anticoagulation should be delayed until defi nitive percutaneous coronary intervention.", [["coronary", "ANATOMY", 120, 128], ["patient", "ORGANISM", 26, 33], ["coronary", "MULTI-TISSUE_STRUCTURE", 120, 128], ["patient", "SPECIES", 26, 33], ["Medical management", "TREATMENT", 0, 18], ["aggressive anticoagulation", "TREATMENT", 44, 70], ["defi nitive percutaneous coronary intervention", "TREATMENT", 95, 141], ["coronary", "ANATOMY", 120, 128]]], ["You are asked to see a 60-year-old man in the emergency department for shaking chills, cough, and productive sputum.", [["sputum", "ANATOMY", 109, 115], ["chills", "DISEASE", 79, 85], ["cough", "DISEASE", 87, 92], ["man", "ORGANISM", 35, 38], ["man", "SPECIES", 35, 38], ["shaking", "PROBLEM", 71, 78], ["chills", "PROBLEM", 79, 85], ["cough", "PROBLEM", 87, 92], ["productive sputum", "PROBLEM", 98, 115], ["productive", "OBSERVATION_MODIFIER", 98, 108], ["sputum", "OBSERVATION", 109, 115]]], ["He has a 37-pack-year history of cigarette smoking but has no other signifi cant medical history.ReferenceOn physical examination, the temperature is 38.6 \u00b0C (101.5 \u00b0F), the blood pressure is 160/90 mmHg, the heart rate is 115 bpm and regular, and the respiration rate is 27/min.", [["blood", "ANATOMY", 174, 179], ["heart", "ANATOMY", 209, 214], ["smoking", "CHEMICAL", 43, 50], ["cigarette", "ORGANISM", 33, 42], ["blood", "ORGANISM_SUBSTANCE", 174, 179], ["heart", "ORGAN", 209, 214], ["physical examination", "TEST", 109, 129], ["the temperature", "TEST", 131, 146], ["\u00b0C", "TEST", 155, 157], ["the blood pressure", "TEST", 170, 188], ["the heart rate", "TEST", 205, 219], ["the respiration rate", "TEST", 248, 268], ["heart", "ANATOMY", 209, 214], ["115 bpm", "OBSERVATION", 223, 230]]], ["There is increased dullness upon percussion at the right base, crackles in the right mid-lung fi eld, and diffuse anterior wheezes.ReferenceChest radiograph shows a right lower lobe posterior infi ltrate and a moderate-sized pleural effusion.", [["right base", "ANATOMY", 51, 61], ["crackles", "ANATOMY", 63, 71], ["right mid-lung fi eld", "ANATOMY", 79, 100], ["right lower lobe", "ANATOMY", 165, 181], ["pleural", "ANATOMY", 225, 232], ["pleural effusion", "DISEASE", 225, 241], ["pleural effusion", "PATHOLOGICAL_FORMATION", 225, 241], ["increased dullness", "PROBLEM", 9, 27], ["percussion", "TEST", 33, 43], ["crackles in the right mid-lung fi eld", "PROBLEM", 63, 100], ["diffuse anterior wheezes", "PROBLEM", 106, 130], ["ReferenceChest radiograph", "TEST", 131, 156], ["a right lower lobe posterior infi ltrate", "PROBLEM", 163, 203], ["a moderate-sized pleural effusion", "PROBLEM", 208, 241], ["increased", "OBSERVATION_MODIFIER", 9, 18], ["dullness", "OBSERVATION", 19, 27], ["percussion", "OBSERVATION_MODIFIER", 33, 43], ["right", "ANATOMY_MODIFIER", 51, 56], ["base", "ANATOMY_MODIFIER", 57, 61], ["crackles", "OBSERVATION", 63, 71], ["right", "ANATOMY_MODIFIER", 79, 84], ["mid-lung", "ANATOMY", 85, 93], ["eld", "OBSERVATION_MODIFIER", 97, 100], ["diffuse", "OBSERVATION_MODIFIER", 106, 113], ["anterior", "OBSERVATION_MODIFIER", 114, 122], ["wheezes", "OBSERVATION", 123, 130], ["right lower lobe", "ANATOMY", 165, 181], ["posterior", "ANATOMY_MODIFIER", 182, 191], ["infi ltrate", "OBSERVATION", 192, 203], ["moderate", "OBSERVATION_MODIFIER", 210, 218], ["sized", "OBSERVATION_MODIFIER", 219, 224], ["pleural", "ANATOMY", 225, 232], ["effusion", "OBSERVATION", 233, 241]]], ["Therapy with ceftriaxone, azithromycin, and inhaled bronchodilators is started in the emergency room.ReferenceWhat is the most appropriate treatment?", [["ceftriaxone", "CHEMICAL", 13, 24], ["azithromycin", "CHEMICAL", 26, 38], ["ceftriaxone", "CHEMICAL", 13, 24], ["azithromycin", "CHEMICAL", 26, 38], ["ceftriaxone", "SIMPLE_CHEMICAL", 13, 24], ["azithromycin", "SIMPLE_CHEMICAL", 26, 38], ["Therapy", "TREATMENT", 0, 7], ["ceftriaxone", "TREATMENT", 13, 24], ["azithromycin", "TREATMENT", 26, 38], ["inhaled bronchodilators", "TREATMENT", 44, 67]]], ["A) Admit and perform pleural cavity drainage.", [["pleural cavity", "ANATOMY", 21, 35], ["pleural cavity", "MULTI-TISSUE_STRUCTURE", 21, 35], ["pleural cavity drainage", "TREATMENT", 21, 44], ["pleural", "ANATOMY", 21, 28], ["cavity", "ANATOMY_MODIFIER", 29, 35], ["drainage", "OBSERVATION", 36, 44]]], ["B) Admit and repeat chest radiograph in 2 days.", [["chest", "ANATOMY", 20, 25], ["repeat chest radiograph", "TEST", 13, 36], ["chest", "ANATOMY", 20, 25]]], ["C) Admit for video-assisted thoracoscopic surgery (VATS).", [["video-assisted thoracoscopic surgery", "TREATMENT", 13, 49], ["VATS", "TREATMENT", 51, 55], ["thoracoscopic", "OBSERVATION", 28, 41]]], ["CT scan of the abdomen is consistent with partial small bowel obstruction.", [["abdomen", "ANATOMY", 15, 22], ["bowel", "ANATOMY", 56, 61], ["bowel obstruction", "DISEASE", 56, 73], ["abdomen", "ORGAN", 15, 22], ["bowel", "ORGAN", 56, 61], ["CT scan of the abdomen", "TEST", 0, 22], ["partial small bowel obstruction", "PROBLEM", 42, 73], ["abdomen", "ANATOMY", 15, 22], ["consistent with", "UNCERTAINTY", 26, 41], ["partial", "OBSERVATION_MODIFIER", 42, 49], ["small", "OBSERVATION_MODIFIER", 50, 55], ["bowel", "ANATOMY", 56, 61], ["obstruction", "OBSERVATION", 62, 73]]], ["Therapy should include the following: A) Surgical consultation for open laparotomy B) NG tube placement and fl uid resuscitation C) Gastrografi n enema D) NG tube placement with clamping Answer: B Conservative therapy will lead to resolution of partial small bowel obstruction in 90 % of cases.", [["bowel", "ANATOMY", 259, 264], ["NG", "CHEMICAL", 86, 88], ["NG", "CHEMICAL", 155, 157], ["bowel obstruction", "DISEASE", 259, 276], ["tube", "TISSUE", 89, 93], ["bowel", "ORGAN", 259, 264], ["Therapy", "TREATMENT", 0, 7], ["open laparotomy B", "TREATMENT", 67, 84], ["NG tube placement", "TREATMENT", 86, 103], ["fl uid resuscitation C", "TREATMENT", 108, 130], ["Gastrografi n enema D", "TREATMENT", 132, 153], ["NG tube placement", "TREATMENT", 155, 172], ["Conservative therapy", "TREATMENT", 197, 217], ["partial small bowel obstruction", "PROBLEM", 245, 276], ["partial", "OBSERVATION_MODIFIER", 245, 252], ["small", "OBSERVATION_MODIFIER", 253, 258], ["bowel", "ANATOMY", 259, 264], ["obstruction", "OBSERVATION", 265, 276]]], ["The leading cause of SBO in industrialized countries is postoperative adhesions.", [["adhesions", "ANATOMY", 70, 79], ["SBO", "DISEASE", 21, 24], ["SBO", "PROBLEM", 21, 24], ["postoperative adhesions", "PROBLEM", 56, 79], ["SBO", "OBSERVATION", 21, 24], ["postoperative adhesions", "OBSERVATION", 56, 79]]], ["Patients without alarming symptoms can be managed conservatively.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["alarming symptoms", "PROBLEM", 17, 34]]], ["Surgery consultation is usually required on admission and is of benefi t as surgery may be indicated at some point during the hospitalization.ReferenceHaving surgery following may decrease the lag time when surgery is indicated.", [["surgery", "TREATMENT", 76, 83], ["surgery", "TREATMENT", 158, 165], ["surgery", "TREATMENT", 207, 214]]], ["Alarming symptoms where surgery is required emergently include complete obstruction, peritonitis, pneumatosis intestinalis, or strangulation.", [["obstruction", "DISEASE", 72, 83], ["peritonitis", "DISEASE", 85, 96], ["pneumatosis intestinalis", "DISEASE", 98, 122], ["strangulation", "DISEASE", 127, 140], ["Alarming symptoms", "PROBLEM", 0, 17], ["surgery", "TREATMENT", 24, 31], ["complete obstruction", "PROBLEM", 63, 83], ["peritonitis", "PROBLEM", 85, 96], ["pneumatosis intestinalis", "PROBLEM", 98, 122], ["strangulation", "PROBLEM", 127, 140], ["obstruction", "OBSERVATION", 72, 83], ["peritonitis", "OBSERVATION", 85, 96], ["pneumatosis", "OBSERVATION", 98, 109], ["strangulation", "OBSERVATION", 127, 140]]], ["Laboratory studies on admission reveal a hematocrit of 30 %, a serum creatinine of 1.9, and a serum lactate level of 3.7 mm/l.", [["serum", "ANATOMY", 63, 68], ["serum", "ANATOMY", 94, 99], ["creatinine", "CHEMICAL", 69, 79], ["lactate", "CHEMICAL", 100, 107], ["creatinine", "CHEMICAL", 69, 79], ["lactate", "CHEMICAL", 100, 107], ["serum", "ORGANISM_SUBSTANCE", 63, 68], ["creatinine", "SIMPLE_CHEMICAL", 69, 79], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["lactate", "SIMPLE_CHEMICAL", 100, 107], ["a hematocrit", "TEST", 39, 51], ["a serum creatinine", "TEST", 61, 79], ["a serum lactate level", "TEST", 92, 113]]], ["A serum albumin is 2.7 g/dL.", [["serum", "ANATOMY", 2, 7], ["serum", "ORGANISM_SUBSTANCE", 2, 7], ["albumin", "GENE_OR_GENE_PRODUCT", 8, 15], ["serum albumin", "PROTEIN", 2, 15], ["A serum albumin", "TEST", 0, 15]]], ["Her blood pressure is noted to be 90/50 with decreased urine output.ReferenceWhich of the following should be selected for ongoing volume resuscitation?", [["blood", "ANATOMY", 4, 9], ["urine", "ANATOMY", 55, 60], ["decreased urine output", "DISEASE", 45, 67], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["urine", "ORGANISM_SUBSTANCE", 55, 60], ["Her blood pressure", "TEST", 0, 18], ["decreased urine output", "PROBLEM", 45, 67], ["ongoing volume resuscitation", "TREATMENT", 123, 151], ["urine output", "OBSERVATION", 55, 67]]], ["A) 0.9 % saline B) 6 % hydroxyethyl starch (HES) solution C) Packed red blood cells D) Normal saline with 5 % albumin infusion E) D5 1/2 normal saline Answer: A Several studies have looked at fl uid resuscitation in sepsis.ReferenceAmong ICU patients, 90-day mortality was observed between patients resuscitated with 0.9 % saline and with 6 % hydroxyethyl starch (HES) solution.", [["red blood cells", "ANATOMY", 68, 83], ["hydroxyethyl starch", "CHEMICAL", 23, 42], ["sepsis", "DISEASE", 216, 222], ["hydroxyethyl starch", "CHEMICAL", 343, 362], ["HES", "CHEMICAL", 364, 367], ["hydroxyethyl", "CHEMICAL", 23, 35], ["hydroxyethyl", "CHEMICAL", 343, 355], ["saline B", "SIMPLE_CHEMICAL", 9, 17], ["hydroxyethyl starch", "SIMPLE_CHEMICAL", 23, 42], ["saline", "SIMPLE_CHEMICAL", 94, 100], ["albumin", "SIMPLE_CHEMICAL", 110, 117], ["patients", "ORGANISM", 242, 250], ["patients", "ORGANISM", 290, 298], ["saline", "SIMPLE_CHEMICAL", 323, 329], ["hydroxyethyl starch", "SIMPLE_CHEMICAL", 343, 362], ["HES", "SIMPLE_CHEMICAL", 364, 367], ["patients", "SPECIES", 242, 250], ["patients", "SPECIES", 290, 298], ["A) 0.9 % saline B)", "TREATMENT", 0, 18], ["hydroxyethyl starch (HES) solution C", "TREATMENT", 23, 59], ["Packed red blood cells D", "TREATMENT", 61, 85], ["Normal saline", "TREATMENT", 87, 100], ["5 % albumin infusion E", "TREATMENT", 106, 128], ["fl uid resuscitation", "TREATMENT", 192, 212], ["sepsis", "PROBLEM", 216, 222], ["0.9 % saline", "TREATMENT", 317, 329], ["6 % hydroxyethyl starch (HES) solution", "TREATMENT", 339, 377], ["sepsis", "OBSERVATION", 216, 222]]], ["In the study, no signifi cant difference was noted.", [["the study", "TEST", 3, 12], ["signifi cant difference", "PROBLEM", 17, 40], ["no", "UNCERTAINTY", 14, 16]]], ["Other studies have looked at crystalloid and albumin for fl uid resuscitation and have found no benefi t as compared to 0.9 % saline.", [["crystalloid", "ORGANISM_SUBSTANCE", 29, 40], ["albumin", "GENE_OR_GENE_PRODUCT", 45, 52], ["saline", "SIMPLE_CHEMICAL", 126, 132], ["Other studies", "TEST", 0, 13], ["crystalloid", "TREATMENT", 29, 40], ["albumin", "TREATMENT", 45, 52], ["fl uid resuscitation", "TREATMENT", 57, 77], ["0.9 % saline", "TREATMENT", 120, 132], ["no", "UNCERTAINTY", 93, 95]]], ["In this particular case, blood products should not be employed for volume expansion unless there is a specifi c need.", [["blood", "ANATOMY", 25, 30], ["blood", "ORGANISM_SUBSTANCE", 25, 30], ["blood products", "TREATMENT", 25, 39], ["volume expansion", "TEST", 67, 83]]], ["An 80-year-old female presents to the emergency room with a one-week history of weakness, fatigue, nausea, and anorexia.", [["weakness", "DISEASE", 80, 88], ["fatigue", "DISEASE", 90, 97], ["nausea", "DISEASE", 99, 105], ["anorexia", "DISEASE", 111, 119], ["female", "ORGANISM", 15, 21], ["weakness", "PROBLEM", 80, 88], ["fatigue", "PROBLEM", 90, 97], ["nausea", "PROBLEM", 99, 105], ["anorexia", "PROBLEM", 111, 119], ["weakness", "OBSERVATION", 80, 88], ["fatigue", "OBSERVATION", 90, 97], ["nausea", "OBSERVATION", 99, 105], ["anorexia", "OBSERVATION", 111, 119]]], ["Past medical history is signifi cant for metastatic squamous cell carcinoma of the lung, which has been treated with chemotherapy.", [["metastatic squamous cell carcinoma", "ANATOMY", 41, 75], ["lung", "ANATOMY", 83, 87], ["squamous cell carcinoma of the lung", "DISEASE", 52, 87], ["squamous cell carcinoma", "CANCER", 52, 75], ["lung", "ORGAN", 83, 87], ["metastatic squamous cell carcinoma of the lung", "PROBLEM", 41, 87], ["chemotherapy", "TREATMENT", 117, 129], ["metastatic", "OBSERVATION_MODIFIER", 41, 51], ["squamous cell carcinoma", "OBSERVATION", 52, 75], ["lung", "ANATOMY", 83, 87]]], ["On physical examination, temperature is 38.2 \u00b0C (100.8 \u00b0F), blood pressure is 100/70, and pulse rate is 125 per minute.", [["blood", "ANATOMY", 60, 65], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["\u00b0C", "TEST", 45, 47], ["blood pressure", "TEST", 60, 74], ["pulse rate", "TEST", 90, 100]]], ["Laboratory studies reveal blood urea nitrogen of 52 mg/dL, calcium level of 14.4 mg/dL, creatinine of 1.9 mg/dL, and phosphorus of 2.2 mg/dL.ReferenceWhich of the following is the most appropriate therapy?", [["blood", "ANATOMY", 26, 31], ["blood urea nitrogen", "CHEMICAL", 26, 45], ["calcium", "CHEMICAL", 59, 66], ["creatinine", "CHEMICAL", 88, 98], ["phosphorus", "CHEMICAL", 117, 127], ["urea", "CHEMICAL", 32, 36], ["nitrogen", "CHEMICAL", 37, 45], ["calcium", "CHEMICAL", 59, 66], ["creatinine", "CHEMICAL", 88, 98], ["phosphorus", "CHEMICAL", 117, 127], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["urea", "SIMPLE_CHEMICAL", 32, 36], ["calcium", "SIMPLE_CHEMICAL", 59, 66], ["creatinine", "SIMPLE_CHEMICAL", 88, 98], ["phosphorus", "SIMPLE_CHEMICAL", 117, 127], ["Laboratory studies", "TEST", 0, 18], ["blood urea nitrogen", "TEST", 26, 45], ["calcium level", "TEST", 59, 72], ["creatinine", "TEST", 88, 98], ["phosphorus", "TEST", 117, 127], ["dL", "ANATOMY", 55, 57]]], ["A) 0.5 % saline infusion with furosemide B) 0.9 % saline infusion C) 0.9 % saline infusion with furosemide D) 0.45 % saline infusionReferenceAnswer: B This patient should receive volume replacement with 0.9 % saline.", [["furosemide B", "CHEMICAL", 30, 42], ["furosemide", "CHEMICAL", 96, 106], ["furosemide B", "CHEMICAL", 30, 42], ["furosemide D", "CHEMICAL", 96, 108], ["saline", "SIMPLE_CHEMICAL", 9, 15], ["furosemide", "SIMPLE_CHEMICAL", 30, 40], ["saline", "SIMPLE_CHEMICAL", 50, 56], ["saline", "SIMPLE_CHEMICAL", 75, 81], ["furosemide D", "SIMPLE_CHEMICAL", 96, 108], ["patient", "ORGANISM", 156, 163], ["saline", "SIMPLE_CHEMICAL", 209, 215], ["patient", "SPECIES", 156, 163], ["A) 0.5 % saline infusion", "TREATMENT", 0, 24], ["furosemide B)", "TREATMENT", 30, 43], ["furosemide D)", "TREATMENT", 96, 109], ["volume replacement", "TREATMENT", 179, 197], ["0.9 % saline", "TREATMENT", 203, 215]]], ["In the treatment of acute hypercalcemia, aggressive volume expansion with an intravenous normal saline is the fi rst step.", [["intravenous", "ANATOMY", 77, 88], ["hypercalcemia", "DISEASE", 26, 39], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 88], ["acute hypercalcemia", "PROBLEM", 20, 39], ["aggressive volume expansion", "TREATMENT", 41, 68], ["an intravenous normal saline", "TREATMENT", 74, 102], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["hypercalcemia", "OBSERVATION", 26, 39], ["aggressive", "OBSERVATION_MODIFIER", 41, 51], ["volume expansion", "OBSERVATION", 52, 68]]], ["Normal saline, as opposed to 0.5 % saline or saline, with furosemide, is the current recommended treatment.", [["furosemide", "CHEMICAL", 58, 68], ["furosemide", "CHEMICAL", 58, 68], ["saline", "SIMPLE_CHEMICAL", 7, 13], ["saline", "SIMPLE_CHEMICAL", 35, 41], ["saline", "SIMPLE_CHEMICAL", 45, 51], ["furosemide", "SIMPLE_CHEMICAL", 58, 68], ["Normal saline", "TREATMENT", 0, 13], ["0.5 % saline", "TREATMENT", 29, 41], ["saline", "TREATMENT", 45, 51], ["furosemide", "TREATMENT", 58, 68], ["treatment", "TREATMENT", 97, 106], ["saline", "OBSERVATION", 7, 13]]], ["Increased excretion of calcium can be achieved by inhibition of proximal tubular and loop sodium reabsorption, which is best achieved by aggressive volume expansion.", [["tubular", "ANATOMY", 73, 80], ["calcium", "CHEMICAL", 23, 30], ["sodium", "CHEMICAL", 90, 96], ["calcium", "CHEMICAL", 23, 30], ["sodium", "CHEMICAL", 90, 96], ["calcium", "SIMPLE_CHEMICAL", 23, 30], ["tubular", "MULTI-TISSUE_STRUCTURE", 73, 80], ["sodium", "SIMPLE_CHEMICAL", 90, 96], ["Increased excretion of calcium", "PROBLEM", 0, 30], ["proximal tubular and loop sodium reabsorption", "TREATMENT", 64, 109], ["aggressive volume expansion", "TREATMENT", 137, 164], ["excretion", "OBSERVATION", 10, 19], ["proximal", "ANATOMY_MODIFIER", 64, 72], ["tubular", "ANATOMY_MODIFIER", 73, 80], ["loop sodium reabsorption", "OBSERVATION", 85, 109], ["aggressive", "OBSERVATION_MODIFIER", 137, 147], ["volume expansion", "OBSERVATION", 148, 164]]], ["A 58-year-old woman who has COPD was admitted for an acute exacerbation.", [["COPD", "DISEASE", 28, 32], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["COPD", "PROBLEM", 28, 32], ["an acute exacerbation", "PROBLEM", 50, 71], ["COPD", "OBSERVATION", 28, 32], ["acute", "OBSERVATION_MODIFIER", 53, 58], ["exacerbation", "OBSERVATION", 59, 71]]], ["The patient has smoked one pack of cigarettes daily for 30 years.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["The patient is physically active, and she has no other medical problems.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["other medical problems", "PROBLEM", 49, 71], ["physically", "OBSERVATION_MODIFIER", 15, 25], ["active", "OBSERVATION", 26, 32]]], ["Her COPD symptoms have been well controlled with inhaled tiotropium.", [["COPD", "DISEASE", 4, 8], ["tiotropium", "CHEMICAL", 57, 67], ["tiotropium", "CHEMICAL", 57, 67], ["tiotropium", "SIMPLE_CHEMICAL", 57, 67], ["Her COPD symptoms", "PROBLEM", 0, 17], ["inhaled tiotropium", "TREATMENT", 49, 67], ["COPD", "OBSERVATION", 4, 8]]], ["One year ago, FEV1 was 60 % of predicted, and FVC was 80 % of predicted.ReferenceWhich of the following should you recommend for smoking cessation?", [["FEV1", "TEST", 14, 18], ["FVC", "TEST", 46, 49]]], ["A) Recommend she try to quit \"cold turkey.\"", [["turkey", "SPECIES", 35, 41]]], ["B) Recommend that she try nonprescription nicotine replacement and use a telephone quit line.", [["nicotine", "CHEMICAL", 42, 50], ["nicotine", "CHEMICAL", 42, 50], ["nicotine", "SIMPLE_CHEMICAL", 42, 50], ["nonprescription nicotine replacement", "TREATMENT", 26, 62]]], ["D) Prescribe varenicline and recommend that the patient try to set a quit date sometime between one and fi ve weeks, scheduling a return visit to the offi ce a week after her quit.ReferenceAnswer: D A hospitalization is an excellent opportunity to address a variety of lifestyle interventions.", [["varenicline", "CHEMICAL", 13, 24], ["varenicline", "CHEMICAL", 13, 24], ["varenicline", "SIMPLE_CHEMICAL", 13, 24], ["patient", "ORGANISM", 48, 55], ["patient", "SPECIES", 48, 55], ["varenicline", "TREATMENT", 13, 24], ["lifestyle interventions", "TREATMENT", 269, 292]]], ["The patient has time and possibly new motivation to undertake this endeavor.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["An opportunity exists while the patient is in the hospital to clean the house of triggers of smoking as well as bring in family members to support the decision.", [["smoking", "CHEMICAL", 93, 100], ["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39]]], ["In general, this may require pharmacotherapy combined with counseling support.", [["pharmacotherapy", "TREATMENT", 29, 44], ["counseling support", "TREATMENT", 59, 77]]], ["Varenicline has greater efficacy than either nicotine replacement or bupropion.", [["Varenicline", "CHEMICAL", 0, 11], ["nicotine", "CHEMICAL", 45, 53], ["bupropion", "CHEMICAL", 69, 78], ["Varenicline", "CHEMICAL", 0, 11], ["nicotine", "CHEMICAL", 45, 53], ["bupropion", "CHEMICAL", 69, 78], ["Varenicline", "SIMPLE_CHEMICAL", 0, 11], ["nicotine", "SIMPLE_CHEMICAL", 45, 53], ["bupropion", "SIMPLE_CHEMICAL", 69, 78], ["Varenicline", "TREATMENT", 0, 11], ["nicotine replacement", "TREATMENT", 45, 65], ["bupropion", "TREATMENT", 69, 78]]], ["A variable stop date strategy has been studied with varenicline with favorable results.", [["varenicline", "CHEMICAL", 52, 63], ["varenicline", "CHEMICAL", 52, 63], ["varenicline", "SIMPLE_CHEMICAL", 52, 63], ["varenicline", "TREATMENT", 52, 63]]], ["A 20-year-old college student presents to the emergency room with a chief complaint of diarrhea, nausea, vomiting, abdominal pain, fever, and chills.", [["abdominal", "ANATOMY", 115, 124], ["diarrhea", "DISEASE", 87, 95], ["nausea", "DISEASE", 97, 103], ["vomiting", "DISEASE", 105, 113], ["abdominal pain", "DISEASE", 115, 129], ["fever", "DISEASE", 131, 136], ["chills", "DISEASE", 142, 148], ["abdominal", "ORGANISM_SUBDIVISION", 115, 124], ["diarrhea", "PROBLEM", 87, 95], ["nausea", "PROBLEM", 97, 103], ["vomiting", "PROBLEM", 105, 113], ["abdominal pain", "PROBLEM", 115, 129], ["fever", "PROBLEM", 131, 136], ["chills", "PROBLEM", 142, 148], ["diarrhea", "OBSERVATION", 87, 95], ["abdominal", "ANATOMY", 115, 124], ["pain", "OBSERVATION", 125, 129], ["fever", "OBSERVATION", 131, 136], ["chills", "OBSERVATION", 142, 148]]], ["He also reports decreased urine output.", [["urine", "ANATOMY", 26, 31], ["decreased urine output", "DISEASE", 16, 38], ["urine", "ORGANISM_SUBSTANCE", 26, 31], ["decreased urine output", "PROBLEM", 16, 38], ["decreased", "OBSERVATION_MODIFIER", 16, 25], ["urine output", "OBSERVATION", 26, 38]]], ["He recently returned from Central America where he has been taking an archaeology course.", [["an archaeology course", "TREATMENT", 67, 88], ["Central", "ANATOMY_MODIFIER", 26, 33]]], ["On physical examination, his temperature is 38.3 \u00b0C,(101 \u00b0F), blood pressure is 120/80, and pulse rate is 120.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["physical examination", "TEST", 3, 23], ["his temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 62, 76], ["pulse rate", "TEST", 92, 102]]], ["Oral mucosa is dry.", [["Oral mucosa", "ANATOMY", 0, 11], ["Oral mucosa", "MULTI-TISSUE_STRUCTURE", 0, 11], ["mucosa", "ANATOMY", 5, 11], ["dry", "OBSERVATION", 15, 18]]], ["He has diffuse abdominal pain with mild guarding.ReferenceLaboratory studies reveal hemoglobin of 8.5 g/dL, leukocyte count of 16,000 \u03bcl, and a platelet count of 38,000 \u03bcl.", [["abdominal", "ANATOMY", 15, 24], ["leukocyte", "ANATOMY", 108, 117], ["platelet", "ANATOMY", 144, 152], ["abdominal pain", "DISEASE", 15, 29], ["abdominal", "ORGANISM_SUBDIVISION", 15, 24], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 84, 94], ["leukocyte", "CELL", 108, 117], ["platelet", "CELL", 144, 152], ["hemoglobin", "PROTEIN", 84, 94], ["diffuse abdominal pain", "PROBLEM", 7, 29], ["mild guarding", "PROBLEM", 35, 48], ["ReferenceLaboratory studies", "TEST", 49, 76], ["hemoglobin", "TEST", 84, 94], ["leukocyte count", "TEST", 108, 123], ["a platelet count", "TEST", 142, 158], ["diffuse", "OBSERVATION_MODIFIER", 7, 14], ["abdominal", "ANATOMY", 15, 24], ["pain", "OBSERVATION", 25, 29], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["guarding", "OBSERVATION", 40, 48], ["hemoglobin", "OBSERVATION_MODIFIER", 84, 94], ["leukocyte count", "OBSERVATION_MODIFIER", 108, 123], ["platelet count", "OBSERVATION_MODIFIER", 144, 158]]], ["Peripheral blood smear reveals many schistocytes.", [["Peripheral blood smear", "ANATOMY", 0, 22], ["schistocytes", "ANATOMY", 36, 48], ["Peripheral blood smear", "ORGANISM_SUBSTANCE", 0, 22], ["schistocytes", "CANCER", 36, 48], ["Peripheral blood smear", "TEST", 0, 22], ["many schistocytes", "PROBLEM", 31, 48], ["blood", "ANATOMY", 11, 16], ["many", "OBSERVATION_MODIFIER", 31, 35], ["schistocytes", "OBSERVATION", 36, 48]]], ["Urinalysis reveals many erythrocytes and erythrocyte casts.", [["erythrocytes", "ANATOMY", 24, 36], ["erythrocyte", "ANATOMY", 41, 52], ["erythrocytes", "CELL", 24, 36], ["erythrocyte", "CELL", 41, 52], ["erythrocytes", "CELL_TYPE", 24, 36], ["Urinalysis", "TEST", 0, 10], ["many erythrocytes", "PROBLEM", 19, 36], ["erythrocyte casts", "TEST", 41, 58], ["many erythrocytes", "OBSERVATION", 19, 36], ["erythrocyte casts", "OBSERVATION", 41, 58]]], ["Urine protein-to-creatinine ratio is 0.6.", [["Urine", "ANATOMY", 0, 5], ["creatinine", "CHEMICAL", 17, 27], ["creatinine", "CHEMICAL", 17, 27], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["creatinine", "SIMPLE_CHEMICAL", 17, 27], ["Urine protein", "PROTEIN", 0, 13], ["Urine protein", "TEST", 0, 13], ["creatinine ratio", "TEST", 17, 33]]], ["Which of the following is the most likely cause of the patient's acute kidney injury?", [["kidney", "ANATOMY", 71, 77], ["acute kidney injury", "DISEASE", 65, 84], ["patient", "ORGANISM", 55, 62], ["kidney", "ORGAN", 71, 77], ["patient", "SPECIES", 55, 62], ["the patient's acute kidney injury", "PROBLEM", 51, 84], ["most likely", "UNCERTAINTY", 30, 41], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["kidney", "ANATOMY", 71, 77], ["injury", "OBSERVATION", 78, 84]]], ["A) Hemolytic uremic syndrome B) Acute tubular necrosis C) Post-infectious glomerulonephritis D) Scleroderma renal crisis E) Sepsis Answer: A This patient has hemolytic uremic syndrome.", [["tubular", "ANATOMY", 38, 45], ["renal", "ANATOMY", 108, 113], ["Hemolytic uremic syndrome B", "DISEASE", 3, 30], ["Acute tubular necrosis", "DISEASE", 32, 54], ["glomerulonephritis", "DISEASE", 74, 92], ["Scleroderma renal crisis", "DISEASE", 96, 120], ["Sepsis", "DISEASE", 124, 130], ["hemolytic uremic syndrome", "DISEASE", 158, 183], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["A) Hemolytic uremic syndrome", "PROBLEM", 0, 28], ["Acute tubular necrosis C", "PROBLEM", 32, 56], ["Post-infectious glomerulonephritis D", "PROBLEM", 58, 94], ["Scleroderma renal crisis", "PROBLEM", 96, 120], ["Sepsis", "PROBLEM", 124, 130], ["hemolytic uremic syndrome", "PROBLEM", 158, 183], ["Hemolytic", "OBSERVATION_MODIFIER", 3, 12], ["uremic syndrome", "OBSERVATION", 13, 28], ["Acute", "OBSERVATION_MODIFIER", 32, 37], ["tubular", "ANATOMY_MODIFIER", 38, 45], ["necrosis", "OBSERVATION", 46, 54], ["infectious", "OBSERVATION_MODIFIER", 63, 73], ["glomerulonephritis", "OBSERVATION", 74, 92], ["Scleroderma", "OBSERVATION", 96, 107], ["renal", "ANATOMY", 108, 113], ["crisis", "OBSERVATION", 114, 120], ["Sepsis", "OBSERVATION", 124, 130], ["hemolytic", "OBSERVATION_MODIFIER", 158, 167], ["uremic syndrome", "OBSERVATION", 168, 183]]], ["It was probably caused by Escherichia coli , in particular the O157: H7 strain.", [["Escherichia coli", "ORGANISM", 26, 42], ["O157: H7 strain", "ORGANISM", 63, 78], ["Escherichia coli", "SPECIES", 26, 42], ["Escherichia coli", "SPECIES", 26, 42], ["O157: H7", "SPECIES", 63, 71], ["Escherichia coli", "PROBLEM", 26, 42], ["H7 strain", "PROBLEM", 69, 78], ["probably caused", "UNCERTAINTY", 7, 22], ["Escherichia coli", "OBSERVATION", 26, 42], ["H7 strain", "OBSERVATION", 69, 78]]], ["This strain produces a Shigella -like toxin that is effective against small blood vessels, like those found in the digestive tract and kidneys.", [["blood vessels", "ANATOMY", 76, 89], ["digestive tract", "ANATOMY", 115, 130], ["kidneys", "ANATOMY", 135, 142], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 76, 89], ["digestive tract", "ORGAN", 115, 130], ["kidneys", "ORGAN", 135, 142], ["This strain", "PROBLEM", 0, 11], ["a Shigella -like toxin", "PROBLEM", 21, 43], ["small blood vessels", "PROBLEM", 70, 89], ["Shigella", "OBSERVATION", 23, 31], ["blood vessels", "ANATOMY", 76, 89], ["digestive tract", "ANATOMY", 115, 130], ["kidneys", "ANATOMY", 135, 142]]], ["In developing countries, infections usually develop after ingesting contaminated food or water.", [["infections", "DISEASE", 25, 35], ["infections", "PROBLEM", 25, 35], ["infections", "OBSERVATION", 25, 35]]], ["This patient has the triad of microangiopathic hemolytic anemia, schistocytes, and thrombocytopenia.", [["schistocytes", "ANATOMY", 65, 77], ["microangiopathic hemolytic anemia", "DISEASE", 30, 63], ["schistocytes", "DISEASE", 65, 77], ["thrombocytopenia", "DISEASE", 83, 99], ["patient", "ORGANISM", 5, 12], ["schistocytes", "CANCER", 65, 77], ["patient", "SPECIES", 5, 12], ["microangiopathic hemolytic anemia", "PROBLEM", 30, 63], ["schistocytes", "PROBLEM", 65, 77], ["thrombocytopenia", "PROBLEM", 83, 99], ["microangiopathic", "OBSERVATION_MODIFIER", 30, 46], ["hemolytic", "OBSERVATION_MODIFIER", 47, 56], ["anemia", "OBSERVATION", 57, 63], ["schistocytes", "OBSERVATION", 65, 77], ["thrombocytopenia", "OBSERVATION", 83, 99]]], ["Patients with acute tubular necrosis are more likely to present with muddy brown casts.", [["tubular", "ANATOMY", 20, 27], ["acute tubular necrosis", "DISEASE", 14, 36], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["acute tubular necrosis", "PROBLEM", 14, 36], ["muddy brown casts", "PROBLEM", 69, 86], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["tubular", "ANATOMY_MODIFIER", 20, 27], ["necrosis", "OBSERVATION", 28, 36], ["more likely", "UNCERTAINTY", 41, 52], ["muddy", "OBSERVATION_MODIFIER", 69, 74], ["brown casts", "OBSERVATION", 75, 86]]], ["Post-infectious glomerulonephritis commonly occurs after Streptococcal and Staphylococcal infections.", [["glomerulonephritis", "DISEASE", 16, 34], ["Streptococcal and Staphylococcal infections", "DISEASE", 57, 100], ["infectious glomerulonephritis", "PROBLEM", 5, 34], ["Streptococcal", "PROBLEM", 57, 70], ["Staphylococcal infections", "PROBLEM", 75, 100], ["infectious", "OBSERVATION_MODIFIER", 5, 15], ["glomerulonephritis", "OBSERVATION", 16, 34], ["Staphylococcal", "OBSERVATION_MODIFIER", 75, 89], ["infections", "OBSERVATION", 90, 100]]], ["Scleroderma renal crisis is characterized by an acute onset of hypertension, kidney failure, and microangiopathic hemolytic anemia.", [["renal", "ANATOMY", 12, 17], ["kidney", "ANATOMY", 77, 83], ["Scleroderma renal crisis", "DISEASE", 0, 24], ["hypertension", "DISEASE", 63, 75], ["kidney failure", "DISEASE", 77, 91], ["microangiopathic hemolytic anemia", "DISEASE", 97, 130], ["renal", "ORGAN", 12, 17], ["kidney", "ORGAN", 77, 83], ["Scleroderma renal crisis", "PROBLEM", 0, 24], ["hypertension", "PROBLEM", 63, 75], ["kidney failure", "PROBLEM", 77, 91], ["microangiopathic hemolytic anemia", "PROBLEM", 97, 130], ["renal", "ANATOMY", 12, 17], ["crisis", "OBSERVATION", 18, 24], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["hypertension", "OBSERVATION", 63, 75], ["kidney", "ANATOMY", 77, 83], ["failure", "OBSERVATION", 84, 91], ["microangiopathic", "OBSERVATION_MODIFIER", 97, 113], ["hemolytic", "OBSERVATION_MODIFIER", 114, 123]]], ["Scleroderma renal crisis is not associated with bloody diarrhea.", [["renal", "ANATOMY", 12, 17], ["Scleroderma renal crisis", "DISEASE", 0, 24], ["diarrhea", "DISEASE", 55, 63], ["renal", "ORGAN", 12, 17], ["Scleroderma renal crisis", "PROBLEM", 0, 24], ["bloody diarrhea", "PROBLEM", 48, 63], ["renal", "ANATOMY", 12, 17], ["crisis", "OBSERVATION", 18, 24], ["not associated with", "UNCERTAINTY", 28, 47], ["diarrhea", "OBSERVATION", 55, 63]]], ["In addition, the absence of skin fi ndings makes this diagnosis unlikely.", [["skin", "ANATOMY", 28, 32], ["skin", "ORGAN", 28, 32], ["skin", "ANATOMY", 28, 32]]], ["A 74-year-old man with a history of cirrhosis and ascites presents with spiking fevers, abdominal pain, and progressive abdominal distention over the last week.", [["ascites", "ANATOMY", 50, 57], ["abdominal", "ANATOMY", 88, 97], ["abdominal", "ANATOMY", 120, 129], ["cirrhosis", "DISEASE", 36, 45], ["ascites", "DISEASE", 50, 57], ["fevers", "DISEASE", 80, 86], ["abdominal pain", "DISEASE", 88, 102], ["abdominal distention", "DISEASE", 120, 140], ["man", "ORGANISM", 14, 17], ["cirrhosis", "CANCER", 36, 45], ["abdominal", "ORGANISM_SUBDIVISION", 88, 97], ["abdominal", "ORGANISM_SUBDIVISION", 120, 129], ["man", "SPECIES", 14, 17], ["cirrhosis", "PROBLEM", 36, 45], ["ascites", "PROBLEM", 50, 57], ["spiking fevers", "PROBLEM", 72, 86], ["abdominal pain", "PROBLEM", 88, 102], ["progressive abdominal distention", "PROBLEM", 108, 140], ["cirrhosis", "OBSERVATION", 36, 45], ["ascites", "OBSERVATION", 50, 57], ["spiking", "OBSERVATION_MODIFIER", 72, 79], ["fevers", "OBSERVATION", 80, 86], ["abdominal", "ANATOMY", 88, 97], ["pain", "OBSERVATION", 98, 102], ["progressive", "OBSERVATION_MODIFIER", 108, 119], ["abdominal", "ANATOMY", 120, 129], ["distention", "OBSERVATION", 130, 140]]], ["He is immediately started on broad-spectrum antibiotics and albumin for possible spontaneous bacterial peritonitis (SBP).", [["bacterial peritonitis", "DISEASE", 93, 114], ["albumin", "GENE_OR_GENE_PRODUCT", 60, 67], ["broad-spectrum antibiotics", "TREATMENT", 29, 55], ["albumin", "TREATMENT", 60, 67], ["spontaneous bacterial peritonitis", "PROBLEM", 81, 114], ["SBP", "TEST", 116, 119], ["bacterial", "OBSERVATION_MODIFIER", 93, 102], ["peritonitis", "OBSERVATION", 103, 114]]], ["What is the demonstrated benefi t of adjuvant albumin treatment in this patient?", [["albumin", "SIMPLE_CHEMICAL", 46, 53], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["adjuvant albumin treatment", "TREATMENT", 37, 63]]], ["A) Improvement in underlying cirrhosis B) No published data to support benefi t C) Prevention of worsening renal failure and D) Improvement in 1 and 3-month survival E) C and D Answer: E Current guidelines call for adjuvant albumin therapy in the treatment of SBP.", [["renal", "ANATOMY", 107, 112], ["cirrhosis", "DISEASE", 29, 38], ["worsening renal failure", "DISEASE", 97, 120], ["renal", "ORGAN", 107, 112], ["albumin", "SIMPLE_CHEMICAL", 224, 231], ["underlying cirrhosis", "PROBLEM", 18, 38], ["worsening renal failure", "PROBLEM", 97, 120], ["adjuvant albumin therapy", "TREATMENT", 215, 239], ["SBP", "PROBLEM", 260, 263], ["Improvement", "OBSERVATION_MODIFIER", 3, 14], ["cirrhosis", "OBSERVATION", 29, 38], ["worsening", "OBSERVATION_MODIFIER", 97, 106], ["renal", "ANATOMY", 107, 112], ["failure", "OBSERVATION", 113, 120]]], ["Based on a large prospective randomized trial, albumin infusion (1.5 g/kg on day 1 and 1 g/kg on day 3) along with antibiotics prevented worsening renal failure with 1 and 3-month survival advantage.", [["renal", "ANATOMY", 147, 152], ["renal failure", "DISEASE", 147, 160], ["albumin", "SIMPLE_CHEMICAL", 47, 54], ["renal", "ORGAN", 147, 152], ["a large prospective randomized trial", "TREATMENT", 9, 45], ["albumin infusion", "TREATMENT", 47, 63], ["antibiotics", "TREATMENT", 115, 126], ["worsening renal failure", "PROBLEM", 137, 160], ["large", "OBSERVATION_MODIFIER", 11, 16], ["worsening", "OBSERVATION_MODIFIER", 137, 146], ["renal", "ANATOMY", 147, 152], ["failure", "OBSERVATION", 153, 160]]], ["Respiration rate is 25.", [["Respiration rate", "TEST", 0, 16]]], ["Oxygen saturation is 90 %.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17]]], ["Cardiac auscultation reveals a regular, tachycardic rhythm.", [["Cardiac", "ANATOMY", 0, 7], ["Cardiac", "ORGAN", 0, 7], ["Cardiac auscultation", "TEST", 0, 20], ["tachycardic rhythm", "PROBLEM", 40, 58], ["auscultation", "OBSERVATION", 8, 20], ["tachycardic rhythm", "OBSERVATION", 40, 58]]], ["Mild expiratory wheezes are heard throughout her lung fi elds.ReferenceWhich of the following is the most appropriate acute treatment?ReferenceAnswer: A The patient presents with a supraventricular tachycardia that may or may not be atrial fi brillation.", [["lung", "ANATOMY", 49, 53], ["supraventricular", "ANATOMY", 181, 197], ["atrial", "ANATOMY", 233, 239], ["supraventricular tachycardia", "DISEASE", 181, 209], ["atrial fi brillation", "DISEASE", 233, 253], ["lung", "ORGAN", 49, 53], ["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["Mild expiratory wheezes", "PROBLEM", 0, 23], ["a supraventricular tachycardia", "PROBLEM", 179, 209], ["atrial fi brillation", "PROBLEM", 233, 253], ["expiratory", "OBSERVATION_MODIFIER", 5, 15], ["wheezes", "OBSERVATION", 16, 23], ["lung", "ANATOMY", 49, 53], ["tachycardia", "OBSERVATION", 198, 209], ["may not be", "UNCERTAINTY", 222, 232], ["fi brillation", "OBSERVATION", 240, 253]]], ["She is hemodynamically stable but requires semi-urgent conversion to normal sinus rhythm.", [["sinus", "ANATOMY", 76, 81], ["sinus", "ORGAN", 76, 81], ["hemodynamically", "OBSERVATION_MODIFIER", 7, 22], ["stable", "OBSERVATION", 23, 29], ["sinus rhythm", "OBSERVATION", 76, 88]]], ["Considerations would include betablockers, but as she is currently experiencing a moderate degree of reactive airway disease.", [["airway", "ANATOMY", 110, 116], ["airway disease", "DISEASE", 110, 124], ["airway", "MULTI-TISSUE_STRUCTURE", 110, 116], ["betablockers", "TREATMENT", 29, 41], ["reactive airway disease", "PROBLEM", 101, 124], ["moderate degree", "OBSERVATION_MODIFIER", 82, 97], ["reactive airway disease", "OBSERVATION", 101, 124]]], ["Beta-blockers may not be the best option.", [["Beta-blockers", "SIMPLE_CHEMICAL", 0, 13], ["Beta-blockers", "TREATMENT", 0, 13]]], ["Adenosine may be useful for diagnosing and treating supraventricular tachycardia.", [["supraventricular", "ANATOMY", 52, 68], ["Adenosine", "CHEMICAL", 0, 9], ["supraventricular tachycardia", "DISEASE", 52, 80], ["Adenosine", "CHEMICAL", 0, 9], ["Adenosine", "SIMPLE_CHEMICAL", 0, 9], ["Adenosine", "TREATMENT", 0, 9], ["diagnosing", "TEST", 28, 38], ["supraventricular tachycardia", "PROBLEM", 52, 80]]], ["It can treat atrioventricular node-dependent tachycardias such as atrioventricular reentrant tachycardia.", [["atrioventricular node", "ANATOMY", 13, 34], ["atrioventricular", "ANATOMY", 66, 82], ["tachycardias", "DISEASE", 45, 57], ["atrioventricular reentrant tachycardia", "DISEASE", 66, 104], ["atrioventricular node", "MULTI-TISSUE_STRUCTURE", 13, 34], ["atrioventricular node", "PROBLEM", 13, 34], ["dependent tachycardias", "PROBLEM", 35, 57], ["atrioventricular reentrant tachycardia", "PROBLEM", 66, 104], ["atrioventricular node", "OBSERVATION", 13, 34], ["dependent", "OBSERVATION_MODIFIER", 35, 44], ["tachycardias", "OBSERVATION", 45, 57], ["atrioventricular reentrant tachycardia", "OBSERVATION", 66, 104]]], ["It is not useful in the treatment of atrial fi brillation.", [["atrial", "ANATOMY", 37, 43], ["atrial fi brillation", "DISEASE", 37, 57], ["atrial fi brillation", "PROBLEM", 37, 57], ["not useful", "UNCERTAINTY", 6, 16], ["atrial fi", "ANATOMY", 37, 46], ["brillation", "OBSERVATION", 47, 57]]], ["Urgent electrocardioversion may be considered if needed urgently, but this must be weighed against the risk of a thrombotic event occurring in a patient who is not anticoagulated.", [["thrombotic", "DISEASE", 113, 123], ["patient", "ORGANISM", 145, 152], ["patient", "SPECIES", 145, 152], ["Urgent electrocardioversion", "TREATMENT", 0, 27], ["a thrombotic event", "PROBLEM", 111, 129], ["may be considered", "UNCERTAINTY", 28, 45], ["thrombotic", "OBSERVATION", 113, 123]]], ["Diltiazem could be considered; however, this may lower her blood pressure.", [["blood", "ANATOMY", 59, 64], ["Diltiazem", "CHEMICAL", 0, 9], ["Diltiazem", "CHEMICAL", 0, 9], ["Diltiazem", "SIMPLE_CHEMICAL", 0, 9], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["Diltiazem", "TREATMENT", 0, 9], ["her blood pressure", "TEST", 55, 73]]], ["Adenosine may control her rate or reveal atrial fi brillation and is an appropriate choice in this situation.", [["atrial", "ANATOMY", 41, 47], ["Adenosine", "CHEMICAL", 0, 9], ["Adenosine", "CHEMICAL", 0, 9], ["Adenosine", "SIMPLE_CHEMICAL", 0, 9], ["Adenosine", "TREATMENT", 0, 9], ["her rate", "TEST", 22, 30], ["atrial fi brillation", "PROBLEM", 41, 61], ["atrial fi", "ANATOMY", 41, 50], ["brillation", "OBSERVATION", 51, 61]]], ["In patients who fail to convert to normal sinus rhythm, the dose may be increased to 12.0 mg.", [["sinus", "ANATOMY", 42, 47], ["patients", "ORGANISM", 3, 11], ["sinus", "ORGAN", 42, 47], ["patients", "SPECIES", 3, 11]]], ["He has a history of mild dementia but has been living independently.", [["dementia", "DISEASE", 25, 33], ["mild dementia", "PROBLEM", 20, 33], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["dementia", "OBSERVATION", 25, 33]]], ["Family members report that his mild memory loss has been stable for the past two years until now.", [["memory loss", "DISEASE", 36, 47], ["his mild memory loss", "PROBLEM", 27, 47], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["memory loss", "OBSERVATION", 36, 47], ["stable", "OBSERVATION_MODIFIER", 57, 63]]], ["He has been in the hospital for one week and despite extensive workup including computed tomography of the head, EEG, and cerebrospinal fl uid analysis, no defi nitive diagnosis has been found.", [["head", "ANATOMY", 107, 111], ["head", "ORGANISM_SUBDIVISION", 107, 111], ["extensive workup", "TEST", 53, 69], ["computed tomography of the head", "TEST", 80, 111], ["EEG", "TEST", 113, 116], ["cerebrospinal fl uid analysis", "TEST", 122, 151], ["defi nitive diagnosis", "PROBLEM", 156, 177], ["head", "ANATOMY", 107, 111], ["cerebrospinal fl", "ANATOMY", 122, 138]]], ["Myoclonus not present on admission is now seen in his right arm.ReferenceThe most likely diagnosis is: A) Creutzfeldt-Jakob disease (CJD) B) Multi-infarct dementia C) Recurrent seizure disorder D) Catatonic depression E) Herpes simplex encephalitis Answer: A The differential diagnosis of a rapidly progressive dementia is limited.", [["right arm", "ANATOMY", 54, 63], ["Myoclonus", "DISEASE", 0, 9], ["Creutzfeldt-Jakob disease", "DISEASE", 106, 131], ["CJD", "DISEASE", 133, 136], ["dementia", "DISEASE", 155, 163], ["seizure disorder", "DISEASE", 177, 193], ["Catatonic depression", "DISEASE", 197, 217], ["Herpes simplex encephalitis", "DISEASE", 221, 248], ["dementia", "DISEASE", 311, 319], ["arm", "ORGANISM_SUBDIVISION", 60, 63], ["Myoclonus", "PROBLEM", 0, 9], ["Jakob disease (CJD)", "PROBLEM", 118, 137], ["Multi-infarct dementia C", "PROBLEM", 141, 165], ["Recurrent seizure disorder D)", "PROBLEM", 167, 196], ["Catatonic depression E", "PROBLEM", 197, 219], ["Herpes simplex encephalitis", "PROBLEM", 221, 248], ["a rapidly progressive dementia", "PROBLEM", 289, 319], ["right", "ANATOMY_MODIFIER", 54, 59], ["arm", "ANATOMY", 60, 63], ["most likely", "UNCERTAINTY", 77, 88], ["rapidly", "OBSERVATION_MODIFIER", 291, 298], ["progressive", "OBSERVATION_MODIFIER", 299, 310], ["dementia", "OBSERVATION", 311, 319]]], ["The clues to CJD in this patient are the relatively normal head imaging, the unexplained rapid onset of dementia, and the eventual appearance of myoclonus.", [["head", "ANATOMY", 59, 63], ["CJD", "DISEASE", 13, 16], ["dementia", "DISEASE", 104, 112], ["myoclonus", "DISEASE", 145, 154], ["patient", "ORGANISM", 25, 32], ["head", "ORGANISM_SUBDIVISION", 59, 63], ["patient", "SPECIES", 25, 32], ["CJD", "PROBLEM", 13, 16], ["dementia", "PROBLEM", 104, 112], ["myoclonus", "PROBLEM", 145, 154], ["rapid", "OBSERVATION_MODIFIER", 89, 94], ["onset", "OBSERVATION_MODIFIER", 95, 100], ["dementia", "OBSERVATION", 104, 112], ["myoclonus", "OBSERVATION", 145, 154]]], ["Initially, individuals experience problems with muscular coordination; personality changes, including impaired memory, judgment, and thinking; and impaired vision.", [["muscular", "ANATOMY", 48, 56], ["muscular coordination", "DISEASE", 48, 69], ["impaired memory, judgment, and thinking", "DISEASE", 102, 141], ["impaired vision", "DISEASE", 147, 162], ["muscular", "ORGANISM_SUBDIVISION", 48, 56], ["muscular coordination", "PROBLEM", 48, 69], ["personality changes", "PROBLEM", 71, 90], ["impaired memory", "PROBLEM", 102, 117], ["impaired vision", "PROBLEM", 147, 162]]], ["EEG, which may initially be normal, but often demonstrates a typical triphasic spike pattern.", [["EEG", "TEST", 0, 3], ["a typical triphasic spike pattern", "PROBLEM", 59, 92], ["may initially be", "UNCERTAINTY", 11, 27], ["normal", "OBSERVATION", 28, 34], ["typical", "OBSERVATION_MODIFIER", 61, 68], ["triphasic", "OBSERVATION_MODIFIER", 69, 78], ["spike pattern", "OBSERVATION", 79, 92]]], ["A confi rmatory protein can be measured in cerebrospinal fl uid.", [["cerebrospinal fl uid", "ANATOMY", 43, 63], ["confi", "GENE_OR_GENE_PRODUCT", 2, 7], ["cerebrospinal fl uid", "CANCER", 43, 63], ["confi rmatory protein", "PROTEIN", 2, 23], ["A confi rmatory protein", "TEST", 0, 23], ["cerebrospinal fl", "ANATOMY", 43, 59]]], ["CJD remains a diagnostic challenge with an average of seven months passing before initial symptoms and confi rmation of a diagnosis.", [["CJD", "DISEASE", 0, 3], ["initial symptoms", "PROBLEM", 82, 98]]], ["Imaging studies are emerging as valuable tools in diagnosing CJD, with evidence that diffusion-weighted imaging (DWI) and magnetic resonance imaging (MRI) sequences are more useful than electroencephalography.", [["CJD", "DISEASE", 61, 64], ["Imaging studies", "TEST", 0, 15], ["CJD", "PROBLEM", 61, 64], ["diffusion-weighted imaging", "TEST", 85, 111], ["DWI", "TEST", 113, 116], ["magnetic resonance imaging (MRI) sequences", "TEST", 122, 164], ["electroencephalography", "TEST", 186, 208]]], ["Paraneoplastic syndromes which can cause a rapid diffuse encephalopathy can present in a similar picture.", [["Paraneoplastic syndromes", "DISEASE", 0, 24], ["encephalopathy", "DISEASE", 57, 71], ["Paraneoplastic syndromes", "PROBLEM", 0, 24], ["a rapid diffuse encephalopathy", "PROBLEM", 41, 71], ["rapid", "OBSERVATION_MODIFIER", 43, 48], ["diffuse", "OBSERVATION_MODIFIER", 49, 56], ["encephalopathy", "OBSERVATION", 57, 71]]], ["A focused workup for malignancy would be warranted in this case as well.", [["malignancy", "DISEASE", 21, 31], ["malignancy", "CANCER", 21, 31], ["A focused workup", "TEST", 0, 16], ["malignancy", "PROBLEM", 21, 31], ["malignancy", "OBSERVATION", 21, 31]]], ["There are investigational therapies available, but treatment is primarily supportive.", [["investigational therapies", "TREATMENT", 10, 35], ["treatment", "TREATMENT", 51, 60]]], ["Rapid progression of the disease and death are the usual outcome.ReferenceTakada LT, Geschwind MD.", [["death", "DISEASE", 37, 42], ["the disease", "PROBLEM", 21, 32], ["death", "PROBLEM", 37, 42], ["progression", "OBSERVATION_MODIFIER", 6, 17], ["disease", "OBSERVATION", 25, 32]]], ["Prion diseases.", [["Prion diseases", "DISEASE", 0, 14], ["Prion diseases", "PROBLEM", 0, 14]]], ["A 38-year-old female with a history of heroin addiction is admitted for withdrawal symptoms consisting of diarrhea, nausea, and vomiting.", [["heroin addiction", "DISEASE", 39, 55], ["diarrhea", "DISEASE", 106, 114], ["nausea", "DISEASE", 116, 122], ["vomiting", "DISEASE", 128, 136], ["heroin", "CHEMICAL", 39, 45], ["female", "ORGANISM", 14, 20], ["withdrawal symptoms", "PROBLEM", 72, 91], ["diarrhea", "PROBLEM", 106, 114], ["nausea", "PROBLEM", 116, 122], ["vomiting", "PROBLEM", 128, 136], ["diarrhea", "OBSERVATION", 106, 114], ["nausea", "OBSERVATION", 116, 122]]], ["On admission, her pulse is 120 beats per minute, respirations are 20 per minute, and blood pressure is 120/70.", [["blood", "ANATOMY", 85, 90], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["her pulse", "TEST", 14, 23], ["respirations", "TEST", 49, 61], ["blood pressure", "TEST", 85, 99]]], ["Oxygen saturation is 94 %.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17]]], ["She is mildly agitated.", [["mildly agitated", "PROBLEM", 7, 22], ["mildly", "OBSERVATION_MODIFIER", 7, 13], ["agitated", "OBSERVATION", 14, 22]]], ["Her agitation and mild psychosis is treated with benzodiazepines and haloperidol.", [["agitation", "DISEASE", 4, 13], ["psychosis", "DISEASE", 23, 32], ["benzodiazepines", "CHEMICAL", 49, 64], ["haloperidol", "CHEMICAL", 69, 80], ["benzodiazepines", "CHEMICAL", 49, 64], ["haloperidol", "CHEMICAL", 69, 80], ["haloperidol", "SIMPLE_CHEMICAL", 69, 80], ["Her agitation", "PROBLEM", 0, 13], ["mild psychosis", "PROBLEM", 18, 32], ["benzodiazepines", "TREATMENT", 49, 64], ["haloperidol", "TREATMENT", 69, 80], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["psychosis", "OBSERVATION", 23, 32]]], ["Her nausea is treated with Phenergan.ReferenceOn her second day of hospitalization, you are urgently called to her bedside.", [["nausea", "DISEASE", 4, 10], ["Phenergan", "CHEMICAL", 27, 36], ["Her nausea", "PROBLEM", 0, 10], ["Phenergan", "TREATMENT", 27, 36], ["nausea", "OBSERVATION", 4, 10]]], ["On physical examination, the patient has marked increased muscle tone.", [["muscle", "ANATOMY", 58, 64], ["patient", "ORGANISM", 29, 36], ["muscle", "ORGAN", 58, 64], ["patient", "SPECIES", 29, 36], ["physical examination", "TEST", 3, 23], ["marked increased muscle tone", "PROBLEM", 41, 69], ["marked", "OBSERVATION_MODIFIER", 41, 47], ["increased", "OBSERVATION_MODIFIER", 48, 57], ["muscle tone", "OBSERVATION", 58, 69]]], ["Her eyes are deviated superiorly, and she states that she has diffi culty moving them.", [["eyes", "ANATOMY", 4, 8], ["eyes", "ORGAN", 4, 8], ["eyes", "ANATOMY", 4, 8], ["deviated", "OBSERVATION", 13, 21], ["superiorly", "OBSERVATION_MODIFIER", 22, 32]]], ["She appears distressed but can follow commands.ReferenceWhich of the following treatments is most appropriate?", [["distressed", "PROBLEM", 12, 22], ["distressed", "OBSERVATION", 12, 22]]], ["A) Lorazepam B) Benztropine C) Naloxone D) Phenytoin load Answer: B This patient is likely experiencing an acute dystonic reaction.", [["Benztropine", "CHEMICAL", 16, 27], ["Naloxone", "CHEMICAL", 31, 39], ["Phenytoin", "CHEMICAL", 43, 52], ["Lorazepam B", "CHEMICAL", 3, 14], ["Benztropine C", "CHEMICAL", 16, 29], ["Naloxone D", "CHEMICAL", 31, 41], ["Phenytoin", "CHEMICAL", 43, 52], ["Benztropine C", "SIMPLE_CHEMICAL", 16, 29], ["Naloxone D", "SIMPLE_CHEMICAL", 31, 41], ["Phenytoin", "SIMPLE_CHEMICAL", 43, 52], ["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["A) Lorazepam B) Benztropine C) Naloxone D) Phenytoin load", "TREATMENT", 0, 57], ["an acute dystonic reaction", "PROBLEM", 104, 130], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["dystonic", "OBSERVATION", 113, 121]]], ["Acute drug-induced dystonia can be treated with anticholinergic agents such as benztropine or diphenhydramine.", [["dystonia", "DISEASE", 19, 27], ["benztropine", "CHEMICAL", 79, 90], ["diphenhydramine", "CHEMICAL", 94, 109], ["benztropine", "CHEMICAL", 79, 90], ["diphenhydramine", "CHEMICAL", 94, 109], ["benztropine", "SIMPLE_CHEMICAL", 79, 90], ["diphenhydramine", "SIMPLE_CHEMICAL", 94, 109], ["Acute drug-induced dystonia", "PROBLEM", 0, 27], ["anticholinergic agents", "TREATMENT", 48, 70], ["benztropine", "TREATMENT", 79, 90], ["diphenhydramine", "TREATMENT", 94, 109]]], ["It is unlikely that this patient is experiencing a seizure.", [["seizure", "DISEASE", 51, 58], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["a seizure", "PROBLEM", 49, 58], ["unlikely", "UNCERTAINTY", 6, 14], ["seizure", "OBSERVATION", 51, 58]]], ["Acute dystonic reactions can include ocular dystonia with eye deviation.", [["ocular", "ANATOMY", 37, 43], ["eye", "ANATOMY", 58, 61], ["dystonic reactions", "DISEASE", 6, 24], ["ocular dystonia", "DISEASE", 37, 52], ["eye deviation", "DISEASE", 58, 71], ["eye", "ORGAN", 58, 61], ["Acute dystonic reactions", "PROBLEM", 0, 24], ["ocular dystonia", "PROBLEM", 37, 52], ["eye deviation", "PROBLEM", 58, 71], ["dystonic", "OBSERVATION", 6, 14], ["ocular", "ANATOMY", 37, 43], ["dystonia", "OBSERVATION", 44, 52], ["eye", "ANATOMY", 58, 61]]], ["Typically, this is superior.", [["superior", "OBSERVATION_MODIFIER", 19, 27]]], ["Dystonic reactions are rarely life threatening but the adverse effects often cause distress for patients and families.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Dystonic reactions", "PROBLEM", 0, 18], ["distress", "PROBLEM", 83, 91]]], ["Medical treatment is usually rapidly effective.", [["Medical treatment", "TREATMENT", 0, 17]]], ["Motor disturbances resolve within minutes, but they can reoccur over subsequent days.", [["Motor disturbances", "PROBLEM", 0, 18]]], ["On physical examination, she appears ill and disheveled.", [["physical examination", "TEST", 3, 23], ["ill", "PROBLEM", 37, 40]]], ["Heart rate is 126 beats/min, blood pressure 92/56 mmHg, respiratory rate 22 bpm, temperature 38.4 \u00b0C (101.1 \u00b0F), and oxygen saturation 94 % on room air.", [["Heart", "ANATOMY", 0, 5], ["blood", "ANATOMY", 29, 34], ["respiratory", "ANATOMY", 56, 67], ["oxygen", "CHEMICAL", 117, 123], ["oxygen", "CHEMICAL", 117, 123], ["Heart", "ORGAN", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["oxygen", "SIMPLE_CHEMICAL", 117, 123], ["Heart rate", "TEST", 0, 10], ["blood pressure", "TEST", 29, 43], ["respiratory rate", "TEST", 56, 72], ["temperature", "TEST", 81, 92], ["\u00b0C", "TEST", 98, 100], ["oxygen saturation", "TEST", 117, 134]]], ["She has scleral icterus, and spider angiomata are present on the trunk.", [["scleral icterus", "ANATOMY", 8, 23], ["angiomata", "ANATOMY", 36, 45], ["trunk", "ANATOMY", 65, 70], ["scleral icterus", "DISEASE", 8, 23], ["spider angiomata", "DISEASE", 29, 45], ["spider angiomata", "CANCER", 29, 45], ["trunk", "ORGANISM_SUBDIVISION", 65, 70], ["scleral icterus", "PROBLEM", 8, 23], ["spider angiomata", "PROBLEM", 29, 45], ["scleral", "ANATOMY", 8, 15], ["icterus", "OBSERVATION", 16, 23], ["spider angiomata", "OBSERVATION", 29, 45], ["trunk", "ANATOMY", 65, 70]]], ["There is a fullness in the right upper quadrant.", [["right upper quadrant", "ANATOMY", 27, 47], ["upper", "ORGANISM_SUBDIVISION", 33, 38], ["a fullness in the right upper quadrant", "PROBLEM", 9, 47], ["fullness", "OBSERVATION", 11, 19], ["right", "ANATOMY_MODIFIER", 27, 32], ["upper", "ANATOMY_MODIFIER", 33, 38], ["quadrant", "ANATOMY", 39, 47]]], ["It is smooth and tender upon palpation.", [["tender", "PROBLEM", 17, 23], ["palpation", "TEST", 29, 38], ["smooth", "OBSERVATION_MODIFIER", 6, 12], ["tender", "OBSERVATION_MODIFIER", 17, 23]]], ["The spleen is not palpable.ReferenceLaboratory studies demonstrate an AST of 543U/L, ALT of 215 U/L, bilirubin of 8.7 mg/dL, alkaline phosphatase of 217U/L, and lipase of 38U/L. Total protein is 4.9 g/dL, and albumin is 2.7 g/dL.", [["spleen", "ANATOMY", 4, 10], ["bilirubin", "CHEMICAL", 101, 110], ["bilirubin", "CHEMICAL", 101, 110], ["spleen", "ORGAN", 4, 10], ["bilirubin", "SIMPLE_CHEMICAL", 101, 110], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 125, 145], ["lipase", "GENE_OR_GENE_PRODUCT", 161, 167], ["albumin", "GENE_OR_GENE_PRODUCT", 209, 216], ["AST", "PROTEIN", 70, 73], ["ALT", "PROTEIN", 85, 88], ["alkaline phosphatase", "PROTEIN", 125, 145], ["lipase", "PROTEIN", 161, 167], ["ReferenceLaboratory studies", "TEST", 27, 54], ["an AST", "TEST", 67, 73], ["ALT", "TEST", 85, 88], ["U/L", "TEST", 96, 99], ["bilirubin", "TEST", 101, 110], ["alkaline phosphatase", "TEST", 125, 145], ["lipase", "TEST", 161, 167], ["Total protein", "TEST", 178, 191], ["albumin", "TEST", 209, 216], ["spleen", "ANATOMY", 4, 10], ["not", "UNCERTAINTY", 14, 17], ["palpable", "OBSERVATION", 18, 26]]], ["The prothrombin time is 30.2 (control is 11) seconds.", [["prothrombin", "GENE_OR_GENE_PRODUCT", 4, 15], ["The prothrombin time", "TEST", 0, 20]]], ["What is the best approach to the treatment of this patient?", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["A) Administer IV fl uids, thiamine, and folate, and observe for improvement in liver function studies.", [["liver", "ANATOMY", 79, 84], ["thiamine", "CHEMICAL", 26, 34], ["folate", "CHEMICAL", 40, 46], ["thiamine", "CHEMICAL", 26, 34], ["folate", "CHEMICAL", 40, 46], ["IV fl uids", "SIMPLE_CHEMICAL", 14, 24], ["thiamine", "SIMPLE_CHEMICAL", 26, 34], ["folate", "SIMPLE_CHEMICAL", 40, 46], ["liver", "ORGAN", 79, 84], ["IV fl uids", "TREATMENT", 14, 24], ["thiamine", "TREATMENT", 26, 34], ["folate", "TREATMENT", 40, 46], ["liver function studies", "TEST", 79, 101], ["liver", "ANATOMY", 79, 84]]], ["B) Administer IV fl uids, thiamine, folate, and broadspectrum antibiotics.", [["thiamine", "CHEMICAL", 26, 34], ["folate", "CHEMICAL", 36, 42], ["broadspectrum", "CHEMICAL", 48, 61], ["thiamine", "CHEMICAL", 26, 34], ["folate", "CHEMICAL", 36, 42], ["IV fl uids", "SIMPLE_CHEMICAL", 14, 24], ["thiamine", "SIMPLE_CHEMICAL", 26, 34], ["folate", "SIMPLE_CHEMICAL", 36, 42], ["broadspectrum antibiotics", "SIMPLE_CHEMICAL", 48, 73], ["IV fl uids", "TREATMENT", 14, 24], ["thiamine", "TREATMENT", 26, 34], ["folate", "TREATMENT", 36, 42], ["broadspectrum antibiotics", "TREATMENT", 48, 73]]], ["C) Administer prednisone 40 mg daily for 4 weeks.", [["prednisone", "CHEMICAL", 14, 24], ["prednisone", "CHEMICAL", 14, 24], ["prednisone", "SIMPLE_CHEMICAL", 14, 24], ["prednisone", "TREATMENT", 14, 24]]], ["D) Perform abdominal ultrasound.", [["abdominal", "ANATOMY", 11, 20], ["abdominal", "ORGANISM_SUBDIVISION", 11, 20], ["abdominal ultrasound", "TEST", 11, 31], ["abdominal", "ANATOMY", 11, 20]]], ["E) Perform an abdominal CT with IV contrast to assess for necrotizing pancreatitis.ReferenceAnswer: C This patient has severe acute alcoholic hepatitis.", [["abdominal", "ANATOMY", 14, 23], ["pancreatitis", "DISEASE", 70, 82], ["acute alcoholic hepatitis", "DISEASE", 126, 151], ["abdominal", "ORGAN", 14, 23], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["an abdominal CT with IV contrast", "TEST", 11, 43], ["necrotizing pancreatitis", "PROBLEM", 58, 82], ["severe acute alcoholic hepatitis", "PROBLEM", 119, 151], ["abdominal", "ANATOMY", 14, 23], ["necrotizing", "OBSERVATION_MODIFIER", 58, 69], ["pancreatitis", "OBSERVATION", 70, 82], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["alcoholic hepatitis", "OBSERVATION", 132, 151]]], ["Treatment with prednisone 40 mg daily for four weeks should be initiated.", [["prednisone", "CHEMICAL", 15, 25], ["prednisone", "CHEMICAL", 15, 25], ["prednisone", "SIMPLE_CHEMICAL", 15, 25], ["prednisone", "TREATMENT", 15, 25]]], ["If steroids are contraindicated, pentoxifylline 400 mg three times daily for four weeks can also be used.", [["steroids", "CHEMICAL", 3, 11], ["pentoxifylline", "CHEMICAL", 33, 47], ["steroids", "CHEMICAL", 3, 11], ["pentoxifylline", "CHEMICAL", 33, 47], ["steroids", "SIMPLE_CHEMICAL", 3, 11], ["pentoxifylline", "SIMPLE_CHEMICAL", 33, 47], ["steroids", "TREATMENT", 3, 11], ["pentoxifylline", "TREATMENT", 33, 47]]], ["A discriminate function (DF) can be calculated as (4.6 \u00d7 the prolongation of prothrombin time above control) + serum bilirubin.", [["serum", "ANATOMY", 111, 116], ["bilirubin", "CHEMICAL", 117, 126], ["bilirubin", "CHEMICAL", 117, 126], ["prothrombin", "GENE_OR_GENE_PRODUCT", 77, 88], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["bilirubin", "SIMPLE_CHEMICAL", 117, 126], ["prothrombin", "PROTEIN", 77, 88], ["prothrombin time", "TEST", 77, 93], ["serum bilirubin", "TEST", 111, 126]]], ["A DF greater than 32 is associated with a poor prognosis and is an indication for treatment with steroids.", [["DF", "DISEASE", 2, 4], ["steroids", "CHEMICAL", 97, 105], ["steroids", "CHEMICAL", 97, 105], ["steroids", "SIMPLE_CHEMICAL", 97, 105], ["treatment", "TREATMENT", 82, 91], ["steroids", "TREATMENT", 97, 105]]], ["The Model for End-Stage Liver Disease (MELD) score can also be used in acute alcoholic hepatitis, with a score greater than 21 being an indication for treatment as well.", [["Liver", "ANATOMY", 24, 29], ["acute alcoholic hepatitis", "DISEASE", 71, 96], ["Liver", "ORGAN", 24, 29], ["End-Stage Liver Disease (MELD) score", "PROBLEM", 14, 50], ["acute alcoholic hepatitis", "PROBLEM", 71, 96], ["treatment", "TREATMENT", 151, 160], ["Stage", "OBSERVATION_MODIFIER", 18, 23], ["Liver", "ANATOMY", 24, 29], ["Disease", "OBSERVATION", 30, 37], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["alcoholic hepatitis", "OBSERVATION", 77, 96]]], ["He develops an unexplained elevated heart rate.", [["heart", "ANATOMY", 36, 41], ["heart", "ORGAN", 36, 41], ["an unexplained elevated heart rate", "PROBLEM", 12, 46], ["unexplained", "OBSERVATION_MODIFIER", 15, 26], ["elevated", "OBSERVATION", 27, 35], ["heart rate", "OBSERVATION", 36, 46]]], ["Thyroid function is ordered.", [["Thyroid", "ANATOMY", 0, 7], ["Thyroid", "ORGAN", 0, 7], ["Thyroid function", "TEST", 0, 16]]], ["After his TSH is 0.2 mU/L, and the total T4 level is normal.", [["TSH", "GENE_OR_GENE_PRODUCT", 10, 13], ["T4", "GENE_OR_GENE_PRODUCT", 41, 43], ["his TSH", "TEST", 6, 13], ["the total T4 level", "TEST", 31, 49], ["total", "ANATOMY_MODIFIER", 35, 40], ["T4", "ANATOMY", 41, 43], ["normal", "OBSERVATION", 53, 59]]], ["T3 is 0.7 \u03bcg/dL.ReferencesWhat is the most appropriate next management step?", [["T3", "SIMPLE_CHEMICAL", 0, 2], ["T3", "TEST", 0, 2]]], ["A) Initiation of levothyroxine B) Initiation of prednisone C) Observation D) Radioiodine uptake scan E) Thyroid ultrasound F) Stress dose steroids Answer: C This patient has euthyroid sick syndrome.", [["levothyroxine B", "CHEMICAL", 17, 32], ["prednisone", "CHEMICAL", 48, 58], ["steroids", "CHEMICAL", 138, 146], ["euthyroid sick syndrome", "DISEASE", 174, 197], ["levothyroxine B", "CHEMICAL", 17, 32], ["prednisone C", "CHEMICAL", 48, 60], ["steroids", "CHEMICAL", 138, 146], ["levothyroxine B", "SIMPLE_CHEMICAL", 17, 32], ["prednisone", "SIMPLE_CHEMICAL", 48, 58], ["Radioiodine", "SIMPLE_CHEMICAL", 77, 88], ["patient", "ORGANISM", 162, 169], ["patient", "SPECIES", 162, 169], ["levothyroxine B)", "TREATMENT", 17, 33], ["prednisone C", "TREATMENT", 48, 60], ["Observation D) Radioiodine uptake scan E", "TEST", 62, 102], ["Thyroid ultrasound", "TEST", 104, 122], ["Stress dose steroids", "TREATMENT", 126, 146], ["euthyroid sick syndrome", "PROBLEM", 174, 197], ["Thyroid", "ANATOMY", 104, 111], ["sick syndrome", "OBSERVATION", 184, 197]]], ["Euthyroid sick syndrome is defi ned as abnormal fi ndings on thyroid function tests that occur in the setting of a nonthyroidal illness.", [["thyroid", "ANATOMY", 61, 68], ["Euthyroid sick syndrome", "DISEASE", 0, 23], ["nonthyroidal illness", "DISEASE", 115, 135], ["thyroid", "ORGAN", 61, 68], ["Euthyroid sick syndrome", "PROBLEM", 0, 23], ["abnormal fi ndings", "PROBLEM", 39, 57], ["thyroid function tests", "TEST", 61, 83], ["a nonthyroidal illness", "PROBLEM", 113, 135], ["sick syndrome", "OBSERVATION", 10, 23], ["thyroid", "ANATOMY", 61, 68], ["nonthyroidal", "ANATOMY", 115, 127], ["illness", "OBSERVATION", 128, 135]]], ["This can commonly occur in the setting of any severe illness.", [["any severe illness", "PROBLEM", 42, 60], ["severe", "OBSERVATION_MODIFIER", 46, 52], ["illness", "OBSERVATION", 53, 60]]], ["The most common hormone pattern is a decrease in total and unbound T3 levels as a peripheral conversion of T4 to T3 is impaired.", [["T3", "SIMPLE_CHEMICAL", 67, 69], ["T4", "GENE_OR_GENE_PRODUCT", 107, 109], ["T3", "SIMPLE_CHEMICAL", 113, 115], ["a decrease in total and unbound T3 levels", "PROBLEM", 35, 76], ["a peripheral conversion of T4 to T3", "PROBLEM", 80, 115], ["most", "ANATOMY_MODIFIER", 4, 8], ["common hormone", "ANATOMY", 9, 23], ["decrease", "OBSERVATION_MODIFIER", 37, 45], ["total", "OBSERVATION_MODIFIER", 49, 54], ["peripheral", "ANATOMY_MODIFIER", 82, 92], ["T4", "ANATOMY", 107, 109], ["T3", "ANATOMY", 113, 115], ["impaired", "OBSERVATION_MODIFIER", 119, 127]]], ["Replacement therapy in critically ill patients has been studied with variable results.", [["critically ill", "DISEASE", 23, 37], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Replacement therapy", "TREATMENT", 0, 19]]], ["Very sick patients may have a decrease in T4 levels.", [["patients", "ORGANISM", 10, 18], ["T4", "SIMPLE_CHEMICAL", 42, 44], ["patients", "SPECIES", 10, 18], ["a decrease in T4 levels", "PROBLEM", 28, 51], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["T4", "ANATOMY", 42, 44]]], ["This patient has abnormal thyroid function tests as a result of his injuries from an accident.", [["thyroid", "ANATOMY", 26, 33], ["abnormal thyroid function", "DISEASE", 17, 42], ["injuries", "DISEASE", 68, 76], ["patient", "ORGANISM", 5, 12], ["thyroid", "ORGAN", 26, 33], ["patient", "SPECIES", 5, 12], ["abnormal thyroid function tests", "PROBLEM", 17, 48], ["his injuries", "PROBLEM", 64, 76], ["thyroid", "ANATOMY", 26, 33]]], ["Traditionally no thyroid replacement is recommended.", [["thyroid", "ANATOMY", 17, 24], ["thyroid", "ORGAN", 17, 24], ["thyroid replacement", "TREATMENT", 17, 36], ["no", "UNCERTAINTY", 14, 16], ["thyroid", "ANATOMY", 17, 24], ["replacement", "OBSERVATION", 25, 36]]], ["Replacement therapy has not been shown to be of benefi t in the vast majority of critically ill patients.", [["critically ill", "DISEASE", 81, 95], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["Replacement therapy", "TREATMENT", 0, 19]]], ["However, this is an area of active research .", [["area", "OBSERVATION_MODIFIER", 20, 24], ["active", "OBSERVATION_MODIFIER", 28, 34], ["research", "OBSERVATION", 35, 43]]], ["There is no prospec- She has no cough, chest pain, joint aches, or rash.", [["chest", "ANATOMY", 39, 44], ["joint", "ANATOMY", 51, 56], ["cough", "DISEASE", 32, 37], ["chest pain", "DISEASE", 39, 49], ["joint aches", "DISEASE", 51, 62], ["rash", "DISEASE", 67, 71], ["chest", "ORGANISM_SUBDIVISION", 39, 44], ["prospec", "PROBLEM", 12, 19], ["cough", "PROBLEM", 32, 37], ["chest pain", "PROBLEM", 39, 49], ["joint aches", "PROBLEM", 51, 62], ["rash", "PROBLEM", 67, 71], ["no", "UNCERTAINTY", 9, 11], ["no", "UNCERTAINTY", 29, 31], ["cough", "OBSERVATION", 32, 37], ["chest", "ANATOMY", 39, 44], ["joint", "ANATOMY", 51, 56], ["rash", "OBSERVATION", 67, 71]]], ["She does note anorexia and occasional loose stools.", [["anorexia", "DISEASE", 14, 22], ["stools", "ORGANISM_SUBSTANCE", 44, 50], ["anorexia", "PROBLEM", 14, 22], ["occasional loose stools", "PROBLEM", 27, 50], ["anorexia", "OBSERVATION", 14, 22], ["occasional", "OBSERVATION_MODIFIER", 27, 37], ["loose stools", "OBSERVATION", 38, 50]]], ["She has lost 25 lbs.", [["25 lbs", "OBSERVATION_MODIFIER", 13, 19]]], ["She has never lived or worked in an institutionalized setting.ReferencesWhich clinical feature is most useful in narrowing the differential diagnosis?", [["narrowing", "OBSERVATION", 113, 122]]], ["A) Weight loss B) Loose bowel movements C) Pattern of fever D) Eating fresh fruit E) Anxiety Answer: C Fever patterns can assist in the diagnosis in fevers of unknown origin.", [["bowel", "ANATOMY", 24, 29], ["fever", "DISEASE", 54, 59], ["fevers", "DISEASE", 149, 155], ["bowel", "ORGAN", 24, 29], ["Weight loss B", "PROBLEM", 3, 16], ["Loose bowel movements C", "PROBLEM", 18, 41], ["fever D", "PROBLEM", 54, 61], ["Anxiety", "PROBLEM", 85, 92], ["Fever patterns", "PROBLEM", 103, 117], ["fevers", "PROBLEM", 149, 155], ["bowel", "ANATOMY", 24, 29]]], ["Of the symptoms listed, it may be the most helpful in narrowing the diagnosis.", [["the symptoms", "PROBLEM", 3, 15], ["narrowing", "OBSERVATION", 54, 63]]], ["This patient has fever of unknown origin -a fever that lasts three weeks or longer with temperatures exceeding 100.9 \u00b0F with no clear diagnosis despite 1 week of clinical investigation.", [["fever", "DISEASE", 17, 22], ["fever", "DISEASE", 44, 49], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["fever", "PROBLEM", 17, 22], ["a fever", "PROBLEM", 42, 49], ["temperatures", "TEST", 88, 100], ["clinical investigation", "TEST", 162, 184], ["fever", "OBSERVATION", 17, 22], ["unknown origin", "OBSERVATION_MODIFIER", 26, 40], ["fever", "OBSERVATION", 44, 49]]], ["Fever lasting 3-10 days followed by afebrile periods of 3-10 days (Pel-Ebstein pattern) is seen in some lymphoma patients.", [["lymphoma", "ANATOMY", 104, 112], ["Fever", "DISEASE", 0, 5], ["lymphoma", "DISEASE", 104, 112], ["lymphoma", "CANCER", 104, 112], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["Fever", "PROBLEM", 0, 5], ["afebrile periods", "PROBLEM", 36, 52], ["Pel-Ebstein pattern", "PROBLEM", 67, 86], ["some lymphoma", "PROBLEM", 99, 112], ["Ebstein pattern", "OBSERVATION_MODIFIER", 71, 86], ["some", "OBSERVATION_MODIFIER", 99, 103], ["lymphoma", "OBSERVATION", 104, 112]]], ["In addition, sixteen percent of patients with Hodgkin's disease present with this cyclic.", [["Hodgkin's disease", "DISEASE", 46, 63], ["patients", "ORGANISM", 32, 40], ["Hodgkin's disease", "CANCER", 46, 63], ["patients", "SPECIES", 32, 40], ["Hodgkin's disease", "PROBLEM", 46, 63], ["this cyclic", "PROBLEM", 77, 88], ["Hodgkin's disease", "OBSERVATION", 46, 63]]], ["A shaking chill and fever lasting a few hours, improving with profuse sweating and coming every other day or every three days strongly suggests malaria.", [["fever", "DISEASE", 20, 25], ["malaria", "DISEASE", 144, 151], ["A shaking chill", "PROBLEM", 0, 15], ["fever", "PROBLEM", 20, 25], ["profuse sweating", "PROBLEM", 62, 78], ["malaria", "PROBLEM", 144, 151], ["shaking chill", "OBSERVATION_MODIFIER", 2, 15], ["fever", "OBSERVATION", 20, 25], ["malaria", "OBSERVATION", 144, 151]]], ["She also has several other symptoms that suggest malignancy or chronic infl ammation including weight loss and sweats, but these are nonspecifi c.", [["malignancy", "DISEASE", 49, 59], ["weight loss", "DISEASE", 95, 106], ["sweats", "DISEASE", 111, 117], ["several other symptoms", "PROBLEM", 13, 35], ["malignancy", "PROBLEM", 49, 59], ["chronic infl ammation", "PROBLEM", 63, 84], ["weight loss", "PROBLEM", 95, 106], ["sweats", "PROBLEM", 111, 117], ["suggest", "UNCERTAINTY", 41, 48], ["malignancy", "OBSERVATION", 49, 59], ["chronic", "OBSERVATION_MODIFIER", 63, 70]]], ["A 67-year-old female is admitted to the hospital for progressive weakness over the past two months.", [["weakness", "DISEASE", 65, 73], ["female", "ORGANISM", 14, 20], ["progressive weakness", "PROBLEM", 53, 73], ["progressive", "OBSERVATION_MODIFIER", 53, 64], ["weakness", "OBSERVATION", 65, 73]]], ["She states she has been feeling depressed lately and is having a diffi cult time adjusting to the cold weather.", [["depressed", "DISEASE", 32, 41], ["depressed", "PROBLEM", 32, 41]]], ["She has no bowel movements for the past week.", [["bowel", "ANATOMY", 11, 16], ["bowel movements", "DISEASE", 11, 26], ["bowel", "ORGAN", 11, 16], ["bowel movements", "PROBLEM", 11, 26], ["no", "UNCERTAINTY", 8, 10], ["bowel", "ANATOMY", 11, 16], ["movements", "OBSERVATION", 17, 26]]], ["On physical exam, her blood pressure is 94/60 mmHg.", [["blood", "ANATOMY", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["physical exam", "TEST", 3, 16], ["her blood pressure", "TEST", 18, 36]]], ["She is thin.", [["thin", "OBSERVATION_MODIFIER", 7, 11]]], ["Her skin appears smooth and tan.", [["skin", "ANATOMY", 4, 8], ["skin", "ORGAN", 4, 8], ["skin", "ANATOMY", 4, 8], ["appears", "UNCERTAINTY", 9, 16], ["smooth", "OBSERVATION_MODIFIER", 17, 23], ["tan", "OBSERVATION", 28, 31]]], ["Her mood is depressed, but she denies suicidal thoughts.ReferencesHer sodium is 134 mEq/L, potassium 5.9 mEq/L, chloride 106 mEq/L, bicarbonate 19 mEq/L, BUN 10 mg/dL, creatinine 1.0 mg/dL, glucose 54 mg/ dL,TSH 18 \u03bcU/mL, and free T4 0.1 ng/dL.", [["depressed", "DISEASE", 12, 21], ["suicidal thoughts", "DISEASE", 38, 55], ["sodium", "CHEMICAL", 70, 76], ["potassium", "CHEMICAL", 91, 100], ["chloride", "CHEMICAL", 112, 120], ["bicarbonate", "CHEMICAL", 132, 143], ["creatinine", "CHEMICAL", 168, 178], ["glucose", "CHEMICAL", 190, 197], ["sodium", "CHEMICAL", 70, 76], ["potassium", "CHEMICAL", 91, 100], ["chloride", "CHEMICAL", 112, 120], ["bicarbonate", "CHEMICAL", 132, 143], ["creatinine", "CHEMICAL", 168, 178], ["glucose", "CHEMICAL", 190, 197], ["sodium", "SIMPLE_CHEMICAL", 70, 76], ["potassium", "SIMPLE_CHEMICAL", 91, 100], ["chloride", "SIMPLE_CHEMICAL", 112, 120], ["bicarbonate", "SIMPLE_CHEMICAL", 132, 143], ["BUN", "SIMPLE_CHEMICAL", 154, 157], ["creatinine", "SIMPLE_CHEMICAL", 168, 178], ["glucose", "SIMPLE_CHEMICAL", 190, 197], ["depressed", "PROBLEM", 12, 21], ["suicidal thoughts", "PROBLEM", 38, 55], ["Her sodium", "TEST", 66, 76], ["potassium", "TEST", 91, 100], ["chloride", "TEST", 112, 120], ["bicarbonate", "TEST", 132, 143], ["BUN", "TEST", 154, 157], ["dL", "TEST", 164, 166], ["creatinine", "TEST", 168, 178], ["glucose", "TEST", 190, 197], ["TSH", "TEST", 208, 211], ["free T4", "TEST", 226, 233]]], ["A) Refer her to a psychiatrist for her depression.", [["depression", "DISEASE", 39, 49], ["her depression", "PROBLEM", 35, 49]]], ["B) Start dexamethasone, and then oral levothyroxine, and perform a cosyntropin stimulation test.", [["oral", "ANATOMY", 33, 37], ["dexamethasone", "CHEMICAL", 9, 22], ["levothyroxine", "CHEMICAL", 38, 51], ["dexamethasone", "CHEMICAL", 9, 22], ["levothyroxine", "CHEMICAL", 38, 51], ["dexamethasone", "SIMPLE_CHEMICAL", 9, 22], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["levothyroxine", "SIMPLE_CHEMICAL", 38, 51], ["dexamethasone", "TREATMENT", 9, 22], ["oral levothyroxine", "TREATMENT", 33, 51], ["a cosyntropin stimulation test", "TEST", 65, 95]]], ["C) Start hydrocortisone, and then oral levothyroxine, and perform a cosyntropin stimulation test.", [["oral", "ANATOMY", 34, 38], ["hydrocortisone", "CHEMICAL", 9, 23], ["levothyroxine", "CHEMICAL", 39, 52], ["hydrocortisone", "CHEMICAL", 9, 23], ["levothyroxine", "CHEMICAL", 39, 52], ["hydrocortisone", "SIMPLE_CHEMICAL", 9, 23], ["oral", "ORGANISM_SUBDIVISION", 34, 38], ["levothyroxine", "SIMPLE_CHEMICAL", 39, 52], ["hydrocortisone", "TREATMENT", 9, 23], ["oral levothyroxine", "TREATMENT", 34, 52], ["a cosyntropin stimulation test", "TEST", 66, 96]]], ["D) Check cosyntropin stimulation test and start levothyroxine.ReferencesAnswer: B This patient has polyendocrine failure.", [["polyendocrine", "ANATOMY", 99, 112], ["levothyroxine", "CHEMICAL", 48, 61], ["polyendocrine failure", "DISEASE", 99, 120], ["levothyroxine", "CHEMICAL", 48, 61], ["levothyroxine", "SIMPLE_CHEMICAL", 48, 61], ["patient", "ORGANISM", 87, 94], ["polyendocrine", "CANCER", 99, 112], ["patient", "SPECIES", 87, 94], ["Check cosyntropin stimulation test", "TEST", 3, 37], ["levothyroxine", "TREATMENT", 48, 61], ["polyendocrine failure", "PROBLEM", 99, 120], ["failure", "OBSERVATION", 113, 120]]], ["This is likely Schmidt's syndrome, which is also known as autoimmune polyendocrine syndrome.", [["Schmidt's syndrome", "DISEASE", 15, 33], ["autoimmune polyendocrine syndrome", "DISEASE", 58, 91], ["Schmidt's syndrome", "PROBLEM", 15, 33], ["autoimmune polyendocrine syndrome", "PROBLEM", 58, 91], ["likely", "UNCERTAINTY", 8, 14], ["Schmidt's syndrome", "OBSERVATION", 15, 33], ["autoimmune polyendocrine syndrome", "OBSERVATION", 58, 91]]], ["Her labs are consistent with hypothyroidism and adrenal insuffi ciency.", [["adrenal", "ANATOMY", 48, 55], ["hypothyroidism", "DISEASE", 29, 43], ["adrenal insuffi ciency", "DISEASE", 48, 70], ["adrenal", "ORGAN", 48, 55], ["Her labs", "TEST", 0, 8], ["hypothyroidism", "PROBLEM", 29, 43], ["adrenal insuffi ciency", "PROBLEM", 48, 70], ["consistent with", "UNCERTAINTY", 13, 28], ["hypothyroidism", "OBSERVATION", 29, 43], ["adrenal", "ANATOMY", 48, 55], ["insuffi", "OBSERVATION", 56, 63]]], ["Hypothyroidism is indicated by labs showing an elevated TSH and decreased free T4.", [["Hypothyroidism", "DISEASE", 0, 14], ["TSH", "GENE_OR_GENE_PRODUCT", 56, 59], ["T4", "SIMPLE_CHEMICAL", 79, 81], ["Hypothyroidism", "PROBLEM", 0, 14], ["labs", "TEST", 31, 35], ["an elevated TSH", "PROBLEM", 44, 59], ["decreased free T4", "PROBLEM", 64, 81], ["elevated", "OBSERVATION", 47, 55], ["decreased", "OBSERVATION_MODIFIER", 64, 73], ["free T4", "OBSERVATION", 74, 81]]], ["Adrenal insuffi ciency is presenting with a thin body habitus hyperkalemia, hypoglycemia, metabolic acidosis, and hyperpigmentation.", [["Adrenal", "ANATOMY", 0, 7], ["body", "ANATOMY", 49, 53], ["hyperkalemia", "DISEASE", 62, 74], ["hypoglycemia", "DISEASE", 76, 88], ["metabolic acidosis", "DISEASE", 90, 108], ["hyperpigmentation", "DISEASE", 114, 131], ["Adrenal", "ORGAN", 0, 7], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["Adrenal insuffi ciency", "PROBLEM", 0, 22], ["a thin body habitus hyperkalemia", "PROBLEM", 42, 74], ["hypoglycemia", "PROBLEM", 76, 88], ["metabolic acidosis", "PROBLEM", 90, 108], ["hyperpigmentation", "PROBLEM", 114, 131], ["hyperkalemia", "OBSERVATION", 62, 74], ["hypoglycemia", "OBSERVATION", 76, 88], ["metabolic acidosis", "OBSERVATION", 90, 108], ["hyperpigmentation", "OBSERVATION", 114, 131]]], ["Adrenal insuffi ciency should be treated urgently before thyroid replacement.", [["Adrenal", "ANATOMY", 0, 7], ["thyroid", "ANATOMY", 57, 64], ["Adrenal", "ORGAN", 0, 7], ["thyroid", "ORGAN", 57, 64], ["Adrenal insuffi ciency", "PROBLEM", 0, 22], ["thyroid replacement", "TREATMENT", 57, 76]]], ["Dexamethasone will not interfere with the cosyntropin stimulation test.", [["Dexamethasone", "CHEMICAL", 0, 13], ["Dexamethasone", "CHEMICAL", 0, 13], ["Dexamethasone", "SIMPLE_CHEMICAL", 0, 13], ["cosyntropin", "SIMPLE_CHEMICAL", 42, 53], ["cosyntropin", "PROTEIN", 42, 53], ["Dexamethasone", "TREATMENT", 0, 13], ["the cosyntropin stimulation test", "TEST", 38, 70]]], ["After starting dexamethasone, levothyroxine will help correct the patient's hypothyroidism.", [["dexamethasone", "CHEMICAL", 15, 28], ["levothyroxine", "CHEMICAL", 30, 43], ["hypothyroidism", "DISEASE", 76, 90], ["dexamethasone", "CHEMICAL", 15, 28], ["levothyroxine", "CHEMICAL", 30, 43], ["dexamethasone", "SIMPLE_CHEMICAL", 15, 28], ["levothyroxine", "SIMPLE_CHEMICAL", 30, 43], ["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["dexamethasone", "TREATMENT", 15, 28], ["levothyroxine", "TREATMENT", 30, 43], ["the patient's hypothyroidism", "PROBLEM", 62, 90], ["hypothyroidism", "OBSERVATION", 76, 90]]], ["Then a cosyntropin stimulation test should be done to confi rm the patient has adrenal insuffi ciency.", [["adrenal", "ANATOMY", 79, 86], ["cosyntropin", "SIMPLE_CHEMICAL", 7, 18], ["patient", "ORGANISM", 67, 74], ["adrenal", "ORGAN", 79, 86], ["patient", "SPECIES", 67, 74], ["a cosyntropin stimulation test", "TEST", 5, 35], ["adrenal insuffi ciency", "PROBLEM", 79, 101], ["adrenal", "ANATOMY", 79, 86], ["insuffi", "OBSERVATION", 87, 94]]], ["If the test indicates that the patient does have adrenal insuffi ciency, then it would be appropriate to start replacement therapy with hydrocortisone.ReferenceBetterle C, Zanchetta R Update on autoimmune polyendocrine syndromes (APS).", [["adrenal", "ANATOMY", 49, 56], ["adrenal insuffi ciency", "DISEASE", 49, 71], ["hydrocortisone", "CHEMICAL", 136, 150], ["autoimmune polyendocrine syndromes", "DISEASE", 194, 228], ["APS", "DISEASE", 230, 233], ["hydrocortisone", "CHEMICAL", 136, 150], ["patient", "ORGANISM", 31, 38], ["adrenal", "ORGAN", 49, 56], ["hydrocortisone", "SIMPLE_CHEMICAL", 136, 150], ["patient", "SPECIES", 31, 38], ["the test", "TEST", 3, 11], ["adrenal insuffi ciency", "PROBLEM", 49, 71], ["replacement therapy", "TREATMENT", 111, 130], ["hydrocortisone", "TREATMENT", 136, 150], ["autoimmune polyendocrine syndromes", "PROBLEM", 194, 228], ["adrenal", "ANATOMY", 49, 56]]], ["An 89-year-old woman is admitted to the hospital for the evaluation of atypical chest pain.", [["chest", "ANATOMY", 80, 85], ["chest pain", "DISEASE", 80, 90], ["woman", "ORGANISM", 15, 20], ["chest", "ORGANISM_SUBDIVISION", 80, 85], ["woman", "SPECIES", 15, 20], ["the evaluation", "TEST", 53, 67], ["atypical chest pain", "PROBLEM", 71, 90], ["atypical", "OBSERVATION_MODIFIER", 71, 79], ["chest", "ANATOMY", 80, 85], ["pain", "OBSERVATION", 86, 90]]], ["She describes the pain as pressure within the middle of her chest with radiation to the neck.", [["chest", "ANATOMY", 60, 65], ["neck", "ANATOMY", 88, 92], ["pain", "DISEASE", 18, 22], ["chest", "ORGANISM_SUBDIVISION", 60, 65], ["neck", "ORGAN", 88, 92], ["the pain", "PROBLEM", 14, 22], ["pain", "OBSERVATION", 18, 22], ["middle", "ANATOMY_MODIFIER", 46, 52], ["chest", "ANATOMY", 60, 65], ["radiation", "OBSERVATION", 71, 80], ["neck", "ANATOMY", 88, 92]]], ["During the past week, she has had several episodes with exertion and rest.", [["several", "OBSERVATION_MODIFIER", 34, 41], ["episodes", "OBSERVATION", 42, 50]]], ["Two episodes occurred in the last 24 h for which she took aspirin.", [["aspirin", "CHEMICAL", 58, 65], ["aspirin", "CHEMICAL", 58, 65], ["aspirin", "SIMPLE_CHEMICAL", 58, 65], ["Two episodes", "PROBLEM", 0, 12], ["aspirin", "TREATMENT", 58, 65]]], ["ECG on admission was signifi cant for ischemia, but is now normal.", [["ischemia", "DISEASE", 38, 46], ["ECG", "TEST", 0, 3], ["ischemia", "PROBLEM", 38, 46], ["ischemia", "OBSERVATION", 38, 46], ["normal", "OBSERVATION", 59, 65]]], ["She is currently free of pain.", [["pain", "DISEASE", 25, 29], ["pain", "PROBLEM", 25, 29], ["free", "OBSERVATION_MODIFIER", 17, 21], ["pain", "OBSERVATION", 25, 29]]], ["She and her family request no further invasive cardiac procedures, including a left heart catheterization.", [["cardiac", "ANATOMY", 47, 54], ["left heart", "ANATOMY", 79, 89], ["cardiac", "ORGAN", 47, 54], ["heart", "ORGAN", 84, 89], ["further invasive cardiac procedures", "TREATMENT", 30, 65], ["a left heart catheterization", "TEST", 77, 105], ["left", "ANATOMY_MODIFIER", 79, 83], ["heart", "ANATOMY", 84, 89], ["catheterization", "OBSERVATION", 90, 105]]], ["They would like to maximize medical therapy.", [["medical therapy", "TREATMENT", 28, 43]]], ["Her medications are aspirin, a multivitamin, and docusate.ReferenceOn physical examination, temperature is normal, blood pressure is 135/80 mmHg, pulse rate is 70/min, and respiration rate is 15 bpm.ReferenceIn addition to aspirin and low-molecular-weight heparin, which of the following is the most appropriate treatment?", [["blood", "ANATOMY", 115, 120], ["aspirin", "CHEMICAL", 20, 27], ["multivitamin", "CHEMICAL", 31, 43], ["docusate", "CHEMICAL", 49, 57], ["aspirin", "CHEMICAL", 223, 230], ["heparin", "CHEMICAL", 256, 263], ["aspirin", "CHEMICAL", 20, 27], ["multivitamin", "CHEMICAL", 31, 43], ["docusate", "CHEMICAL", 49, 57], ["aspirin", "CHEMICAL", 223, 230], ["aspirin", "SIMPLE_CHEMICAL", 20, 27], ["multivitamin", "SIMPLE_CHEMICAL", 31, 43], ["docusate", "SIMPLE_CHEMICAL", 49, 57], ["blood", "ORGANISM_SUBSTANCE", 115, 120], ["aspirin", "SIMPLE_CHEMICAL", 223, 230], ["low-molecular-weight heparin", "SIMPLE_CHEMICAL", 235, 263], ["Her medications", "TREATMENT", 0, 15], ["aspirin", "TREATMENT", 20, 27], ["a multivitamin", "TREATMENT", 29, 43], ["docusate", "TREATMENT", 49, 57], ["ReferenceOn physical examination", "TEST", 58, 90], ["temperature", "TEST", 92, 103], ["blood pressure", "TEST", 115, 129], ["pulse rate", "TEST", 146, 156], ["respiration rate", "TEST", 172, 188], ["aspirin", "TREATMENT", 223, 230], ["low-molecular-weight heparin", "TREATMENT", 235, 263], ["normal", "OBSERVATION", 107, 113]]], ["A) Diltiazem B) Diltiazem, clopidogrel C) Metoprolol D) Metoprolol, atorvastatin, and clopidogrel E) No additional therapy Answer: D Current American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend the use of statin therapy before hospital discharge for all patients with acute coronary syndrome (ACS) regardless of the baseline low-density lipoprotein.", [["coronary", "ANATOMY", 310, 318], ["Diltiazem B", "CHEMICAL", 3, 14], ["Diltiazem", "CHEMICAL", 16, 25], ["clopidogrel", "CHEMICAL", 27, 38], ["Metoprolol", "CHEMICAL", 42, 52], ["Metoprolol", "CHEMICAL", 56, 66], ["atorvastatin", "CHEMICAL", 68, 80], ["clopidogrel", "CHEMICAL", 86, 97], ["statin", "CHEMICAL", 241, 247], ["acute coronary syndrome", "DISEASE", 304, 327], ["ACS", "DISEASE", 329, 332], ["Diltiazem B", "CHEMICAL", 3, 14], ["Diltiazem", "CHEMICAL", 16, 25], ["clopidogrel C", "CHEMICAL", 27, 40], ["Metoprolol D", "CHEMICAL", 42, 54], ["Metoprolol", "CHEMICAL", 56, 66], ["atorvastatin", "CHEMICAL", 68, 80], ["clopidogrel E", "CHEMICAL", 86, 99], ["statin", "CHEMICAL", 241, 247], ["Diltiazem B", "SIMPLE_CHEMICAL", 3, 14], ["Diltiazem", "SIMPLE_CHEMICAL", 16, 25], ["clopidogrel C", "SIMPLE_CHEMICAL", 27, 40], ["Metoprolol D", "SIMPLE_CHEMICAL", 42, 54], ["Metoprolol", "SIMPLE_CHEMICAL", 56, 66], ["atorvastatin", "SIMPLE_CHEMICAL", 68, 80], ["clopidogrel E", "SIMPLE_CHEMICAL", 86, 99], ["patients", "ORGANISM", 290, 298], ["low-density lipoprotein", "PROTEIN", 361, 384], ["patients", "SPECIES", 290, 298], ["A) Diltiazem B)", "TREATMENT", 0, 15], ["Diltiazem", "TREATMENT", 16, 25], ["clopidogrel C", "TREATMENT", 27, 40], ["Metoprolol D", "TREATMENT", 42, 54], ["Metoprolol", "TREATMENT", 56, 66], ["atorvastatin", "TREATMENT", 68, 80], ["clopidogrel E", "TREATMENT", 86, 99], ["statin therapy", "TREATMENT", 241, 255], ["acute coronary syndrome", "PROBLEM", 304, 327], ["ACS", "PROBLEM", 329, 332], ["Heart", "ANATOMY", 181, 186], ["coronary", "ANATOMY", 310, 318], ["syndrome", "OBSERVATION", 319, 327]]], ["Recent fi ndings suggested that the earlier the treatment is started after the diagnosis of ACS, the greater the expected benefi t.", [["ACS", "DISEASE", 92, 95], ["ACS", "PROBLEM", 92, 95], ["ACS", "OBSERVATION", 92, 95], ["greater", "OBSERVATION_MODIFIER", 101, 108]]], ["Despite the non-aggressive approach in this elderly patient here, beta-blockers, statins, and additional and platelet therapy are probably of benefi t in this patient and should be well tolerated.ReferenceReference Angeli, F., Reboldi, G., Garofoli, M., Ramundo, E. and Verdecchia, P. Very early initiation of statin therapy and mortality in patients with acute coronary syndrome.", [["platelet", "ANATOMY", 109, 117], ["coronary", "ANATOMY", 362, 370], ["statins", "CHEMICAL", 81, 88], ["statin", "CHEMICAL", 310, 316], ["acute coronary syndrome", "DISEASE", 356, 379], ["statins", "CHEMICAL", 81, 88], ["statin", "CHEMICAL", 310, 316], ["patient", "ORGANISM", 52, 59], ["beta-blockers", "SIMPLE_CHEMICAL", 66, 79], ["statins", "SIMPLE_CHEMICAL", 81, 88], ["platelet", "CELL", 109, 117], ["benefi", "SIMPLE_CHEMICAL", 142, 148], ["patient", "ORGANISM", 159, 166], ["patients", "ORGANISM", 342, 350], ["patient", "SPECIES", 52, 59], ["patient", "SPECIES", 159, 166], ["patients", "SPECIES", 342, 350], ["the non-aggressive approach", "TREATMENT", 8, 35], ["beta-blockers", "TREATMENT", 66, 79], ["statins", "TREATMENT", 81, 88], ["platelet therapy", "TREATMENT", 109, 125], ["statin therapy", "TREATMENT", 310, 324], ["mortality", "TREATMENT", 329, 338], ["acute coronary syndrome", "PROBLEM", 356, 379], ["Garofoli", "ANATOMY", 240, 248], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["coronary", "ANATOMY", 362, 370], ["syndrome", "OBSERVATION", 371, 379]]], ["2012; 14: 34-39.130.A 32-year-old female with chronic lower back pain on naproxen therapy presents to the emergency department following one episode of bright red hematemesis.", [["chronic lower back pain", "DISEASE", 46, 69], ["naproxen", "CHEMICAL", 73, 81], ["hematemesis", "DISEASE", 163, 174], ["naproxen", "CHEMICAL", 73, 81], ["female", "ORGANISM", 34, 40], ["naproxen", "SIMPLE_CHEMICAL", 73, 81], ["chronic lower back pain", "PROBLEM", 46, 69], ["naproxen therapy", "TREATMENT", 73, 89], ["bright red hematemesis", "PROBLEM", 152, 174], ["chronic", "OBSERVATION_MODIFIER", 46, 53], ["lower", "ANATOMY_MODIFIER", 54, 59], ["back", "ANATOMY", 60, 64], ["pain", "OBSERVATION", 65, 69], ["hematemesis", "OBSERVATION", 163, 174]]], ["In addition, she reports a 3-day history of dark, tarry stools.", [["dark, tarry stools", "PROBLEM", 44, 62]]], ["Following stabilization of the patient, gastroenterology was consulted and performed an EGD.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["an EGD", "TEST", 85, 91]]], ["The procedure report is pertinent for an ulcer.", [["ulcer", "ANATOMY", 41, 46], ["ulcer", "DISEASE", 41, 46], ["ulcer", "PATHOLOGICAL_FORMATION", 41, 46], ["The procedure", "TREATMENT", 0, 13], ["an ulcer", "PROBLEM", 38, 46], ["ulcer", "OBSERVATION", 41, 46]]], ["Which of the following is the lowest-risk stigmata for possible re-bleeding?", [["re-bleeding", "DISEASE", 64, 75], ["re-bleeding", "PROBLEM", 64, 75], ["possible", "UNCERTAINTY", 55, 63], ["re-bleeding", "OBSERVATION", 64, 75]]], ["A) A visible but non-bleeding vessel B) A clean base ulcer located in the duodenum C) An adherent clot D) Active oozing from the site of ulceration E) Non-bleeding clot 131.", [["vessel", "ANATOMY", 30, 36], ["ulcer", "ANATOMY", 53, 58], ["duodenum", "ANATOMY", 74, 82], ["clot", "ANATOMY", 98, 102], ["site", "ANATOMY", 129, 133], ["ulcer", "DISEASE", 53, 58], ["vessel B", "CANCER", 30, 38], ["ulcer", "PATHOLOGICAL_FORMATION", 53, 58], ["duodenum", "ORGAN", 74, 82], ["A visible but non-bleeding vessel B", "PROBLEM", 3, 38], ["A clean base ulcer", "PROBLEM", 40, 58], ["An adherent clot D", "PROBLEM", 86, 104], ["Active oozing", "PROBLEM", 106, 119], ["ulceration E", "PROBLEM", 137, 149], ["Non-bleeding clot", "PROBLEM", 151, 168], ["non-bleeding", "OBSERVATION", 17, 29], ["vessel", "ANATOMY", 30, 36], ["clean", "OBSERVATION_MODIFIER", 42, 47], ["base", "OBSERVATION_MODIFIER", 48, 52], ["ulcer", "OBSERVATION", 53, 58], ["duodenum", "ANATOMY", 74, 82], ["adherent", "OBSERVATION_MODIFIER", 89, 97], ["clot", "OBSERVATION", 98, 102], ["Active", "OBSERVATION_MODIFIER", 106, 112], ["oozing", "OBSERVATION", 113, 119], ["ulceration", "OBSERVATION", 137, 147], ["Non-bleeding", "OBSERVATION_MODIFIER", 151, 163], ["clot", "OBSERVATION", 164, 168]]], ["A 63-year-old male with end-stage liver disease is admitted with spontaneous bacterial peritonitis and possible sepsis.", [["liver", "ANATOMY", 34, 39], ["end-stage liver disease", "DISEASE", 24, 47], ["bacterial peritonitis", "DISEASE", 77, 98], ["sepsis", "DISEASE", 112, 118], ["male", "ORGANISM", 14, 18], ["liver", "ORGAN", 34, 39], ["end-stage liver disease", "PROBLEM", 24, 47], ["spontaneous bacterial peritonitis", "PROBLEM", 65, 98], ["sepsis", "PROBLEM", 112, 118], ["-stage", "OBSERVATION_MODIFIER", 27, 33], ["liver", "ANATOMY", 34, 39], ["disease", "OBSERVATION", 40, 47], ["spontaneous", "OBSERVATION_MODIFIER", 65, 76], ["bacterial", "OBSERVATION_MODIFIER", 77, 86], ["peritonitis", "OBSERVATION", 87, 98], ["possible", "UNCERTAINTY", 103, 111], ["sepsis", "OBSERVATION", 112, 118]]], ["He is started on broad-spectrum antibiotics.", [["broad-spectrum antibiotics", "TREATMENT", 17, 43], ["antibiotics", "OBSERVATION", 32, 43]]], ["Twelve hours after admission, he is noted to be oozing from venipuncture sites.", [["venipuncture sites", "MULTI-TISSUE_STRUCTURE", 60, 78], ["oozing from venipuncture sites", "PROBLEM", 48, 78], ["oozing", "OBSERVATION", 48, 54]]], ["Platelet count is 35,000/\u03bcL, international normalized ratio is 2.9, hemoglobin is 6.1 mg/dL, and D-dimer is elevated to 4.8.", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 68, 78], ["D-dimer", "GENE_OR_GENE_PRODUCT", 97, 104], ["hemoglobin", "PROTEIN", 68, 78], ["Platelet count", "TEST", 0, 14], ["international normalized ratio", "TEST", 29, 59], ["hemoglobin", "TEST", 68, 78], ["D-dimer", "TEST", 97, 104], ["elevated", "PROBLEM", 108, 116]]], ["DIC and his underlying liver disease are considered as possible source of his bleeding.130.What is the best way to distinguish between newonset DIC and his underlying chronic liver disease?", [["liver", "ANATOMY", 23, 28], ["liver", "ANATOMY", 175, 180], ["DIC", "DISEASE", 0, 3], ["liver disease", "DISEASE", 23, 36], ["bleeding", "DISEASE", 78, 86], ["DIC", "DISEASE", 144, 147], ["chronic liver disease", "DISEASE", 167, 188], ["liver", "ORGAN", 23, 28], ["liver", "ORGAN", 175, 180], ["DIC", "PROBLEM", 0, 3], ["his underlying liver disease", "PROBLEM", 8, 36], ["his bleeding", "PROBLEM", 74, 86], ["newonset DIC", "PROBLEM", 135, 147], ["his underlying chronic liver disease", "PROBLEM", 152, 188], ["liver", "ANATOMY", 23, 28], ["disease", "OBSERVATION", 29, 36], ["bleeding", "OBSERVATION", 78, 86], ["chronic", "OBSERVATION_MODIFIER", 167, 174], ["liver", "ANATOMY", 175, 180], ["disease", "OBSERVATION", 181, 188]]], ["A) Blood culture B) Elevated fi brinogen degradation products C) Prolonged aPTT D) Serial laboratory analysis E) Reduced platelet count Answer: D Liver disease and disseminated intravascular coagulation (DIC) can present with similar coagulation profi les.", [["Blood culture", "ANATOMY", 3, 16], ["platelet", "ANATOMY", 121, 129], ["Liver", "ANATOMY", 146, 151], ["intravascular", "ANATOMY", 177, 190], ["Liver disease", "DISEASE", 146, 159], ["disseminated intravascular coagulation", "DISEASE", 164, 202], ["DIC", "DISEASE", 204, 207], ["platelet", "CELL", 121, 129], ["Liver", "ORGAN", 146, 151], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 190], ["A) Blood culture B", "TEST", 0, 18], ["Elevated fi brinogen degradation products", "PROBLEM", 20, 61], ["Prolonged aPTT D", "PROBLEM", 65, 81], ["Serial laboratory analysis", "TEST", 83, 109], ["Reduced platelet count", "PROBLEM", 113, 135], ["D Liver disease", "PROBLEM", 144, 159], ["disseminated intravascular coagulation", "PROBLEM", 164, 202], ["Liver", "ANATOMY", 146, 151], ["disease", "OBSERVATION", 152, 159], ["disseminated", "OBSERVATION_MODIFIER", 164, 176], ["intravascular coagulation", "OBSERVATION", 177, 202]]], ["Both entities may present with elevated fi brinogen degradation products, prolonged activated partial thromboplastin time and prothrombin time, anemia, and thrombocytopenia.", [["anemia", "DISEASE", 144, 150], ["thrombocytopenia", "DISEASE", 156, 172], ["brinogen", "SIMPLE_CHEMICAL", 43, 51], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 102, 116], ["prothrombin", "GENE_OR_GENE_PRODUCT", 126, 137], ["prothrombin", "PROTEIN", 126, 137], ["elevated fi brinogen degradation products", "PROBLEM", 31, 72], ["prolonged activated partial thromboplastin time", "PROBLEM", 74, 121], ["prothrombin time", "PROBLEM", 126, 142], ["anemia", "PROBLEM", 144, 150], ["thrombocytopenia", "PROBLEM", 156, 172], ["partial thromboplastin", "OBSERVATION", 94, 116], ["anemia", "OBSERVATION", 144, 150], ["thrombocytopenia", "OBSERVATION", 156, 172]]], ["Both may cause spontaneous bleeding.", [["bleeding", "DISEASE", 27, 35], ["spontaneous bleeding", "PROBLEM", 15, 35], ["may cause", "UNCERTAINTY", 5, 14], ["spontaneous", "OBSERVATION_MODIFIER", 15, 26], ["bleeding", "OBSERVATION", 27, 35]]], ["When suspecting DIC, these tests should be repeated over a period of 6 h.", [["DIC", "DISEASE", 16, 19], ["DIC", "PROBLEM", 16, 19], ["these tests", "TEST", 21, 32]]], ["Abnormalities may change in patients with severe DIC.", [["DIC", "DISEASE", 49, 52], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["Abnormalities", "PROBLEM", 0, 13], ["severe DIC", "PROBLEM", 42, 52], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["DIC", "OBSERVATION", 49, 52]]], ["In chronic liver disease, coagulation profi les would remain relatively stable.", [["liver", "ANATOMY", 11, 16], ["chronic liver disease", "DISEASE", 3, 24], ["liver", "ORGAN", 11, 16], ["chronic liver disease", "PROBLEM", 3, 24], ["coagulation profi les", "TEST", 26, 47], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["liver", "ANATOMY", 11, 16], ["disease", "OBSERVATION", 17, 24], ["relatively", "OBSERVATION_MODIFIER", 61, 71], ["stable", "OBSERVATION_MODIFIER", 72, 78]]], ["A 32-year-old female presents to the emergency room with severe pain in her upper back and knees for the past 12 h.", [["upper back", "ANATOMY", 76, 86], ["knees", "ANATOMY", 91, 96], ["pain", "DISEASE", 64, 68], ["female", "ORGANISM", 14, 20], ["upper back", "ORGANISM_SUBDIVISION", 76, 86], ["knees", "ORGANISM_SUBDIVISION", 91, 96], ["severe pain in her upper back and knees", "PROBLEM", 57, 96], ["32-", "OBSERVATION_MODIFIER", 2, 5], ["severe", "OBSERVATION_MODIFIER", 57, 63], ["pain", "OBSERVATION", 64, 68], ["upper", "ANATOMY_MODIFIER", 76, 81], ["back", "ANATOMY", 82, 86], ["knees", "ANATOMY", 91, 96]]], ["She reports that this is typical for her usual sickle cell attacks.", [["sickle cell", "ANATOMY", 47, 58], ["sickle cell attacks", "DISEASE", 47, 66], ["sickle cell", "CELL", 47, 58], ["her usual sickle cell attacks", "PROBLEM", 37, 66], ["sickle cell attacks", "OBSERVATION", 47, 66]]], ["She also reports a mild productive cough and moderate shortness of breath.", [["cough", "DISEASE", 35, 40], ["shortness of breath", "DISEASE", 54, 73], ["a mild productive cough", "PROBLEM", 17, 40], ["moderate shortness of breath", "PROBLEM", 45, 73], ["mild", "OBSERVATION_MODIFIER", 19, 23], ["productive", "OBSERVATION_MODIFIER", 24, 34], ["cough", "OBSERVATION", 35, 40], ["moderate", "OBSERVATION_MODIFIER", 45, 53]]], ["On physical examination, her temperature is 39.1 \u00b0C (102.4 \u00b0F), pulse rate is 100 beats per minute, and respirations are 26 per minute.", [["physical examination", "TEST", 3, 23], ["her temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["pulse rate", "TEST", 64, 74], ["respirations", "TEST", 104, 116]]], ["Her blood pressure is 150/68.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["Her blood pressure", "TEST", 0, 18], ["pressure", "OBSERVATION_MODIFIER", 10, 18]]], ["Oxygen saturation is 86 % by pulse oximetry.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17], ["pulse oximetry", "TEST", 29, 43]]], ["The lungs have diffuse moderate wheezes.", [["lungs", "ANATOMY", 4, 9], ["wheezes", "DISEASE", 32, 39], ["lungs", "ORGAN", 4, 9], ["diffuse moderate wheezes", "PROBLEM", 15, 39], ["lungs", "ANATOMY", 4, 9], ["diffuse", "OBSERVATION_MODIFIER", 15, 22], ["moderate", "OBSERVATION_MODIFIER", 23, 31], ["wheezes", "OBSERVATION", 32, 39]]], ["No joint infi ltration or edema is noted.", [["joint", "ANATOMY", 3, 8], ["edema", "ANATOMY", 26, 31], ["edema", "DISEASE", 26, 31], ["edema", "PATHOLOGICAL_FORMATION", 26, 31], ["joint infi ltration", "PROBLEM", 3, 22], ["edema", "PROBLEM", 26, 31], ["joint", "ANATOMY", 3, 8], ["infi", "OBSERVATION", 9, 13], ["edema", "OBSERVATION", 26, 31]]], ["Chest radiograph reveals a right middle lobe opacity.", [["right middle lobe", "ANATOMY", 27, 44], ["right middle lobe opacity", "DISEASE", 27, 52], ["Chest radiograph", "TEST", 0, 16], ["a right middle lobe opacity", "PROBLEM", 25, 52], ["right middle lobe", "ANATOMY", 27, 44], ["opacity", "OBSERVATION", 45, 52]]], ["Laboratory studies are as follows: hematocrit is 22 %; hemoglobin is 6; leukocyte count is 12,800; and platelet count is 170,000.ReferenceIn addition to intravenous fl uids and pain management, which of the following is the next appropriate treatment?", [["leukocyte", "ANATOMY", 72, 81], ["platelet", "ANATOMY", 103, 111], ["pain", "DISEASE", 177, 181], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 55, 65], ["leukocyte", "CELL", 72, 81], ["platelet", "CELL", 103, 111], ["hemoglobin", "PROTEIN", 55, 65], ["Laboratory studies", "TEST", 0, 18], ["hematocrit", "TEST", 35, 45], ["hemoglobin", "TEST", 55, 65], ["leukocyte count", "TEST", 72, 87], ["platelet count", "TEST", 103, 117], ["intravenous fl uids", "TREATMENT", 153, 172], ["pain management", "TREATMENT", 177, 192], ["appropriate treatment", "TREATMENT", 229, 250]]], ["A) Hydroxyurea B) Exchange transfusion C) Packed red blood cells D) Ceftriaxone and erythromycin E) Bronchodilators F) D and E Answer: D This patient possibly has acute chest syndrome.", [["red blood cells", "ANATOMY", 49, 64], ["chest", "ANATOMY", 169, 174], ["Hydroxyurea B", "CHEMICAL", 3, 16], ["Ceftriaxone", "CHEMICAL", 68, 79], ["erythromycin", "CHEMICAL", 84, 96], ["acute chest syndrome", "DISEASE", 163, 183], ["Hydroxyurea B", "CHEMICAL", 3, 16], ["Ceftriaxone", "CHEMICAL", 68, 79], ["erythromycin E", "CHEMICAL", 84, 98], ["Bronchodilators F) D and E", "CHEMICAL", 100, 126], ["D", "CHEMICAL", 135, 136], ["Hydroxyurea B", "SIMPLE_CHEMICAL", 3, 16], ["Ceftriaxone", "SIMPLE_CHEMICAL", 68, 79], ["erythromycin E", "SIMPLE_CHEMICAL", 84, 98], ["D", "SIMPLE_CHEMICAL", 135, 136], ["patient", "ORGANISM", 142, 149], ["chest", "ORGANISM_SUBDIVISION", 169, 174], ["patient", "SPECIES", 142, 149], ["A) Hydroxyurea B) Exchange transfusion C", "TREATMENT", 0, 40], ["Packed red blood cells D", "TREATMENT", 42, 66], ["Ceftriaxone", "TREATMENT", 68, 79], ["erythromycin E) Bronchodilators", "TREATMENT", 84, 115], ["acute chest syndrome", "PROBLEM", 163, 183], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["chest", "ANATOMY", 169, 174], ["syndrome", "OBSERVATION", 175, 183]]], ["This is an urgent and lethal complication of sickle cell disease and should be considered when a sickle cell patient is admitted with marked hypoxia.", [["sickle cell", "ANATOMY", 45, 56], ["sickle cell", "ANATOMY", 97, 108], ["sickle cell disease", "DISEASE", 45, 64], ["sickle", "DISEASE", 97, 103], ["hypoxia", "DISEASE", 141, 148], ["sickle cell", "CELL", 45, 56], ["sickle cell", "CELL", 97, 108], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["sickle cell disease", "PROBLEM", 45, 64], ["a sickle cell", "PROBLEM", 95, 108], ["marked hypoxia", "PROBLEM", 134, 148], ["sickle cell disease", "OBSERVATION", 45, 64], ["sickle cell", "OBSERVATION", 97, 108], ["marked", "OBSERVATION_MODIFIER", 134, 140], ["hypoxia", "OBSERVATION", 141, 148]]], ["Treatment of acute chest syndrome consists of oxygen, antibiotics, incentive spirometry, simple transfusion, and bronchodilators.", [["chest", "ANATOMY", 19, 24], ["acute chest syndrome", "DISEASE", 13, 33], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["chest", "ORGANISM_SUBDIVISION", 19, 24], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["acute chest syndrome", "PROBLEM", 13, 33], ["oxygen", "TREATMENT", 46, 52], ["antibiotics", "TREATMENT", 54, 65], ["incentive spirometry", "TREATMENT", 67, 87], ["simple transfusion", "TREATMENT", 89, 107], ["bronchodilators", "TREATMENT", 113, 128], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["chest", "ANATOMY", 19, 24], ["syndrome", "OBSERVATION", 25, 33], ["oxygen", "OBSERVATION_MODIFIER", 46, 52]]], ["Patients are immunocompromised due to the lack of a functional spleen.", [["spleen", "ANATOMY", 63, 69], ["Patients", "ORGANISM", 0, 8], ["spleen", "ORGAN", 63, 69], ["Patients", "SPECIES", 0, 8], ["immunocompromised", "PROBLEM", 13, 30], ["immunocompromised", "OBSERVATION", 13, 30], ["spleen", "ANATOMY", 63, 69]]], ["In this particular case, antibiotics against S. pneumonia and empiric addition of a macrolide antibiotic, because chlamydial and mycoplasmal infections are common, should be urgently given.", [["S. pneumonia", "DISEASE", 45, 57], ["macrolide", "CHEMICAL", 84, 93], ["mycoplasmal infections", "DISEASE", 129, 151], ["macrolide", "CHEMICAL", 84, 93], ["macrolide", "SIMPLE_CHEMICAL", 84, 93], ["S. pneumonia", "SPECIES", 45, 57], ["antibiotics", "TREATMENT", 25, 36], ["S. pneumonia", "PROBLEM", 45, 57], ["a macrolide antibiotic", "TREATMENT", 82, 104], ["chlamydial", "PROBLEM", 114, 124], ["mycoplasmal infections", "PROBLEM", 129, 151], ["pneumonia", "OBSERVATION", 48, 57], ["mycoplasmal infections", "OBSERVATION", 129, 151]]], ["Bronchodilators, which may be of some benefi t, should be started as well.ReferenceThe role of corticosteroids in nonasthmatic patients with acute chest syndrome remains a topic of clinical research.", [["corticosteroids", "CHEMICAL", 95, 110], ["nonasthmatic", "DISEASE", 114, 126], ["acute chest syndrome", "DISEASE", 141, 161], ["corticosteroids", "CHEMICAL", 95, 110], ["corticosteroids", "SIMPLE_CHEMICAL", 95, 110], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135], ["Bronchodilators", "TREATMENT", 0, 15], ["corticosteroids", "TREATMENT", 95, 110], ["acute chest syndrome", "PROBLEM", 141, 161], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["chest", "ANATOMY", 147, 152], ["syndrome", "OBSERVATION", 153, 161]]], ["Exchange transfusions for the treatment of acute chest syndrome should be considered after antibiotics have been administered.", [["chest", "ANATOMY", 49, 54], ["acute chest syndrome", "DISEASE", 43, 63], ["Exchange transfusions", "TREATMENT", 0, 21], ["acute chest syndrome", "PROBLEM", 43, 63], ["antibiotics", "TREATMENT", 91, 102], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["chest", "ANATOMY", 49, 54], ["syndrome", "OBSERVATION", 55, 63]]], ["This, however, is not the fi rst line of treatment.", [["treatment", "TREATMENT", 41, 50]]], ["Hydroxyurea is often given for chronic treatment of sickle cell disease but has no benefi t in the acute setting.", [["sickle cell", "ANATOMY", 52, 63], ["Hydroxyurea", "CHEMICAL", 0, 11], ["sickle cell disease", "DISEASE", 52, 71], ["Hydroxyurea", "CHEMICAL", 0, 11], ["Hydroxyurea", "SIMPLE_CHEMICAL", 0, 11], ["sickle cell", "CELL", 52, 63], ["Hydroxyurea", "TREATMENT", 0, 11], ["sickle cell disease", "PROBLEM", 52, 71], ["sickle cell disease", "OBSERVATION", 52, 71], ["no", "UNCERTAINTY", 80, 82]]], ["Transfusion greater than baseline will have no benefi t as well.", [["Transfusion", "TREATMENT", 0, 11]]], ["A 65-year-old male with a history of COPD is admitted with a chief complaint of dyspnea, increased cough, and green sputum.", [["sputum", "ANATOMY", 116, 122], ["COPD", "DISEASE", 37, 41], ["dyspnea", "DISEASE", 80, 87], ["cough", "DISEASE", 99, 104], ["male", "ORGANISM", 14, 18], ["COPD", "PROBLEM", 37, 41], ["dyspnea", "PROBLEM", 80, 87], ["increased cough", "PROBLEM", 89, 104], ["green sputum", "PROBLEM", 110, 122], ["COPD", "OBSERVATION", 37, 41], ["dyspnea", "OBSERVATION", 80, 87], ["increased", "OBSERVATION_MODIFIER", 89, 98], ["cough", "OBSERVATION", 99, 104], ["green", "OBSERVATION_MODIFIER", 110, 115], ["sputum", "OBSERVATION", 116, 122]]], ["The patient states he is on 2 l of oxygen at home.", [["oxygen", "CHEMICAL", 35, 41], ["oxygen", "CHEMICAL", 35, 41], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 35, 41], ["patient", "SPECIES", 4, 11], ["oxygen", "TREATMENT", 35, 41]]], ["On the fi rst night of admission, you are called to the patient's room where you fi nd him illappearing and short of breath.", [["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["short of breath", "PROBLEM", 108, 123]]], ["This is a decline from his admission status twelve hours ago.ReferencesOn physical exam, he has course wheezes.", [["ReferencesOn physical exam", "TEST", 61, 87], ["course wheezes", "PROBLEM", 96, 110], ["decline", "OBSERVATION_MODIFIER", 10, 17], ["course", "OBSERVATION_MODIFIER", 96, 102], ["wheezes", "OBSERVATION", 103, 110]]], ["He is in moderate distress.", [["moderate distress", "PROBLEM", 9, 26], ["moderate", "OBSERVATION_MODIFIER", 9, 17], ["distress", "OBSERVATION", 18, 26]]], ["O2 saturation is 85 % on 2 L of oxygen.ReferencesThe most correct initial action is: A) Immediate intubation.", [["oxygen", "CHEMICAL", 32, 38], ["O2", "CHEMICAL", 0, 2], ["oxygen", "CHEMICAL", 32, 38], ["O2", "SIMPLE_CHEMICAL", 0, 2], ["oxygen", "SIMPLE_CHEMICAL", 32, 38], ["O2 saturation", "TEST", 0, 13], ["oxygen", "TREATMENT", 32, 38], ["Immediate intubation", "TREATMENT", 88, 108]]], ["B) Decrease the oxygen to 2 l.", [["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["the oxygen", "TREATMENT", 12, 22], ["Decrease", "OBSERVATION_MODIFIER", 3, 11], ["oxygen", "OBSERVATION_MODIFIER", 16, 22]]], ["C) Increase the oxygen to 6 l.", [["oxygen", "CHEMICAL", 16, 22], ["oxygen", "CHEMICAL", 16, 22], ["oxygen", "SIMPLE_CHEMICAL", 16, 22], ["Increase the oxygen", "TREATMENT", 3, 22], ["Increase", "OBSERVATION_MODIFIER", 3, 11], ["oxygen", "OBSERVATION_MODIFIER", 16, 22]]], ["D) Perform an arterial blood gas (ABG).", [["arterial blood", "ANATOMY", 14, 28], ["arterial", "MULTI-TISSUE_STRUCTURE", 14, 22], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["an arterial blood gas", "TEST", 11, 32], ["ABG", "TEST", 34, 37]]], ["E) Continue the O2 at 4 l and order a stat respiratory treatment.ReferencesAnswer: C Hypoxemia is the most immediate threat to life in patients with a declining COPD exacerbation.", [["Hypoxemia", "DISEASE", 85, 94], ["COPD", "DISEASE", 161, 165], ["O2", "CHEMICAL", 16, 18], ["O2", "SIMPLE_CHEMICAL", 16, 18], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["the O2", "TREATMENT", 12, 18], ["a stat respiratory treatment", "TREATMENT", 36, 64], ["Hypoxemia", "PROBLEM", 85, 94], ["a declining COPD exacerbation", "PROBLEM", 149, 178], ["declining", "OBSERVATION_MODIFIER", 151, 160], ["COPD", "OBSERVATION", 161, 165]]], ["This patient's pulse oximetry of 85 % along with increased respiratory rate indicates severe hypoxemia.", [["respiratory", "ANATOMY", 59, 70], ["hypoxemia", "DISEASE", 93, 102], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["This patient's pulse oximetry", "TEST", 0, 29], ["increased respiratory rate", "PROBLEM", 49, 75], ["severe hypoxemia", "PROBLEM", 86, 102], ["respiratory rate", "OBSERVATION", 59, 75], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["hypoxemia", "OBSERVATION", 93, 102]]], ["Although there is a concern for CO2 retention in patients with COPD, it should not stop the immediate goal of improving oxygenation.", [["CO2", "CHEMICAL", 32, 35], ["COPD", "DISEASE", 63, 67], ["CO2", "CHEMICAL", 32, 35], ["CO2", "SIMPLE_CHEMICAL", 32, 35], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["CO2 retention", "PROBLEM", 32, 45], ["COPD", "PROBLEM", 63, 67], ["concern for", "UNCERTAINTY", 20, 31], ["CO2 retention", "OBSERVATION", 32, 45], ["COPD", "OBSERVATION", 63, 67], ["improving", "OBSERVATION_MODIFIER", 110, 119], ["oxygenation", "OBSERVATION", 120, 131]]], ["This patient's oxygen should be immediately raised while considering further options.", [["oxygen", "CHEMICAL", 15, 21], ["oxygen", "CHEMICAL", 15, 21], ["patient", "ORGANISM", 5, 12], ["oxygen", "SIMPLE_CHEMICAL", 15, 21], ["patient", "SPECIES", 5, 12], ["This patient's oxygen", "TREATMENT", 0, 21]]], ["A reasonable goal of titrating oxygen is 90 % with continued direct observation.", [["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["titrating oxygen", "TREATMENT", 21, 37], ["continued direct observation", "TEST", 51, 79]]], ["Several other modalities may be urgently considered after the oxygen has been increased.", [["oxygen", "CHEMICAL", 62, 68], ["oxygen", "CHEMICAL", 62, 68], ["oxygen", "SIMPLE_CHEMICAL", 62, 68], ["the oxygen", "TREATMENT", 58, 68], ["increased", "OBSERVATION_MODIFIER", 78, 87]]], ["This includes noninvasive measures such as BiPAP and endotracheal intubation.", [["endotracheal", "ANATOMY", 53, 65], ["BiPAP", "SIMPLE_CHEMICAL", 43, 48], ["noninvasive measures", "TREATMENT", 14, 34], ["BiPAP", "TREATMENT", 43, 48], ["endotracheal intubation", "TREATMENT", 53, 76], ["endotracheal intubation", "OBSERVATION", 53, 76]]], ["A 62-year-old man is admitted to the hospital for palpitations and paroxysmal episodes of atrial fi brillation.", [["atrial", "ANATOMY", 90, 96], ["palpitations", "DISEASE", 50, 62], ["atrial fi brillation", "DISEASE", 90, 110], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["palpitations", "PROBLEM", 50, 62], ["paroxysmal episodes of atrial fi brillation", "PROBLEM", 67, 110], ["atrial fi", "ANATOMY", 90, 99], ["brillation", "OBSERVATION", 100, 110]]], ["Five days ago, he was discharged after an acute myocardial infarction.", [["myocardial", "ANATOMY", 48, 58], ["myocardial infarction", "DISEASE", 48, 69], ["myocardial", "MULTI-TISSUE_STRUCTURE", 48, 58], ["an acute myocardial infarction", "PROBLEM", 39, 69], ["acute", "OBSERVATION_MODIFIER", 42, 47], ["myocardial", "ANATOMY", 48, 58], ["infarction", "OBSERVATION", 59, 69]]], ["At that time, he received a drugeluting stent in the left anterior descending coronary artery.", [["left anterior descending coronary artery", "ANATOMY", 53, 93], ["anterior descending coronary artery", "MULTI-TISSUE_STRUCTURE", 58, 93], ["a drugeluting stent in the left anterior descending coronary artery", "TREATMENT", 26, 93], ["stent", "OBSERVATION", 40, 45], ["left anterior descending coronary artery", "ANATOMY", 53, 93]]], ["Medications are lisinopril, digoxin, furosemide, aspirin, clopidogrel, eplerenone, simvastatin, and unfractionated heparin.", [["lisinopril", "CHEMICAL", 16, 26], ["digoxin", "CHEMICAL", 28, 35], ["furosemide", "CHEMICAL", 37, 47], ["aspirin", "CHEMICAL", 49, 56], ["clopidogrel", "CHEMICAL", 58, 69], ["eplerenone", "CHEMICAL", 71, 81], ["simvastatin", "CHEMICAL", 83, 94], ["heparin", "CHEMICAL", 115, 122], ["lisinopril", "CHEMICAL", 16, 26], ["digoxin", "CHEMICAL", 28, 35], ["furosemide", "CHEMICAL", 37, 47], ["aspirin", "CHEMICAL", 49, 56], ["clopidogrel", "CHEMICAL", 58, 69], ["eplerenone", "CHEMICAL", 71, 81], ["simvastatin", "CHEMICAL", 83, 94], ["lisinopril", "SIMPLE_CHEMICAL", 16, 26], ["digoxin", "SIMPLE_CHEMICAL", 28, 35], ["furosemide", "SIMPLE_CHEMICAL", 37, 47], ["aspirin", "SIMPLE_CHEMICAL", 49, 56], ["clopidogrel", "SIMPLE_CHEMICAL", 58, 69], ["eplerenone", "SIMPLE_CHEMICAL", 71, 81], ["simvastatin", "SIMPLE_CHEMICAL", 83, 94], ["unfractionated heparin", "SIMPLE_CHEMICAL", 100, 122], ["Medications", "TREATMENT", 0, 11], ["lisinopril", "TREATMENT", 16, 26], ["digoxin", "TREATMENT", 28, 35], ["furosemide", "TREATMENT", 37, 47], ["aspirin", "TREATMENT", 49, 56], ["clopidogrel", "TREATMENT", 58, 69], ["eplerenone", "TREATMENT", 71, 81], ["simvastatin", "TREATMENT", 83, 94], ["unfractionated heparin", "TREATMENT", 100, 122]]], ["On physical examination, the patient is afebrile, blood pressure is 105/65 mmHg, and pulse rate is 83 min.", [["blood", "ANATOMY", 50, 55], ["patient", "ORGANISM", 29, 36], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["patient", "SPECIES", 29, 36], ["physical examination", "TEST", 3, 23], ["afebrile", "PROBLEM", 40, 48], ["blood pressure", "TEST", 50, 64], ["pulse rate", "TEST", 85, 95]]], ["He is in atrial fi brillation.", [["atrial", "ANATOMY", 9, 15], ["atrial fi brillation", "PROBLEM", 9, 29], ["atrial fi", "ANATOMY", 9, 18], ["brillation", "OBSERVATION", 19, 29]]], ["Mild crackles are heard at the base of his lungs.", [["lungs", "ANATOMY", 43, 48], ["lungs", "ORGAN", 43, 48], ["Mild crackles", "PROBLEM", 0, 13], ["crackles", "OBSERVATION", 5, 13], ["base", "ANATOMY_MODIFIER", 31, 35], ["lungs", "ANATOMY", 43, 48]]], ["CXR reveals evidence of mild fl uid overload.", [["CXR", "PROTEIN", 0, 3], ["CXR", "TEST", 0, 3], ["mild fl uid overload", "PROBLEM", 24, 44], ["evidence of", "UNCERTAINTY", 12, 23], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["fl uid overload", "OBSERVATION", 29, 44]]], ["Transthoracic echocardiogram shows left ventricular ejection fraction of 30 %.ReferenceWhich of the following is the most appropriate treatment for this patient's atrial fi brillation?", [["left ventricular", "ANATOMY", 35, 51], ["atrial", "ANATOMY", 163, 169], ["atrial fi brillation", "DISEASE", 163, 183], ["ventricular", "MULTI-TISSUE_STRUCTURE", 40, 51], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["Transthoracic echocardiogram", "TEST", 0, 28], ["left ventricular ejection fraction", "TEST", 35, 69], ["this patient's atrial fi brillation", "PROBLEM", 148, 183], ["left ventricular", "ANATOMY", 35, 51], ["ejection fraction", "OBSERVATION", 52, 69], ["atrial", "ANATOMY", 163, 169]]], ["A) Amiodarone B) Disopyramide C) Dronedarone D) Flecainide E) Sotalol Answer: A Amiodarone is the best option for managing symptomatic atrial fi brillation in the setting of congestive heart failure (CHF).", [["atrial", "ANATOMY", 135, 141], ["heart", "ANATOMY", 185, 190], ["Amiodarone", "CHEMICAL", 3, 13], ["Disopyramide", "CHEMICAL", 17, 29], ["Amiodarone", "CHEMICAL", 80, 90], ["atrial fi brillation", "DISEASE", 135, 155], ["congestive heart failure", "DISEASE", 174, 198], ["CHF", "DISEASE", 200, 203], ["Amiodarone B", "CHEMICAL", 3, 15], ["Disopyramide C", "CHEMICAL", 17, 31], ["Dronedarone D", "CHEMICAL", 33, 46], ["Flecainide E", "CHEMICAL", 48, 60], ["Amiodarone", "CHEMICAL", 80, 90], ["Amiodarone B) Disopyramide C) Dronedarone D) Flecainide E", "SIMPLE_CHEMICAL", 3, 60], ["Sotalol", "SIMPLE_CHEMICAL", 62, 69], ["Amiodarone", "SIMPLE_CHEMICAL", 80, 90], ["heart", "ORGAN", 185, 190], ["A) Amiodarone B)", "TREATMENT", 0, 16], ["Disopyramide C) Dronedarone D) Flecainide E) Sotalol", "TREATMENT", 17, 69], ["A Amiodarone", "TREATMENT", 78, 90], ["managing symptomatic atrial fi brillation", "PROBLEM", 114, 155], ["congestive heart failure", "PROBLEM", 174, 198], ["CHF", "PROBLEM", 200, 203], ["atrial fi", "ANATOMY", 135, 144], ["brillation", "OBSERVATION", 145, 155], ["congestive", "OBSERVATION", 174, 184], ["heart", "ANATOMY", 185, 190], ["failure", "OBSERVATION", 191, 198], ["CHF", "OBSERVATION", 200, 203]]], ["Patients with heart failure and myocardial infarction are at an increased risk of developing atrial fi brillation.", [["heart", "ANATOMY", 14, 19], ["myocardial", "ANATOMY", 32, 42], ["atrial", "ANATOMY", 93, 99], ["heart failure", "DISEASE", 14, 27], ["myocardial infarction", "DISEASE", 32, 53], ["atrial fi brillation", "DISEASE", 93, 113], ["Patients", "ORGANISM", 0, 8], ["heart", "ORGAN", 14, 19], ["myocardial", "MULTI-TISSUE_STRUCTURE", 32, 42], ["Patients", "SPECIES", 0, 8], ["heart failure", "PROBLEM", 14, 27], ["myocardial infarction", "PROBLEM", 32, 53], ["developing atrial fi brillation", "PROBLEM", 82, 113], ["heart", "ANATOMY", 14, 19], ["failure", "OBSERVATION", 20, 27], ["myocardial", "ANATOMY", 32, 42], ["infarction", "OBSERVATION", 43, 53], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["atrial fi brillation", "OBSERVATION", 93, 113]]], ["Amiodarone has \u03b2-blocking properties that can help with rate control.", [["Amiodarone", "CHEMICAL", 0, 10], ["Amiodarone", "CHEMICAL", 0, 10], ["Amiodarone", "SIMPLE_CHEMICAL", 0, 10], ["Amiodarone", "TREATMENT", 0, 10], ["\u03b2-blocking properties", "TREATMENT", 15, 36], ["rate control", "TREATMENT", 56, 68]]], ["Amiodarone has a class IIa recommendation from the American College of Cardiology for use as a rate-controlling agent for patients who are intolerant to other agents.", [["Amiodarone", "CHEMICAL", 0, 10], ["Amiodarone", "CHEMICAL", 0, 10], ["Amiodarone", "SIMPLE_CHEMICAL", 0, 10], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["Amiodarone", "TREATMENT", 0, 10], ["a rate-controlling agent", "TREATMENT", 93, 117], ["other agents", "TREATMENT", 153, 165]]], ["Patients with CHF may not tolerate diltiazem or metoprolol.", [["CHF", "DISEASE", 14, 17], ["diltiazem", "CHEMICAL", 35, 44], ["metoprolol", "CHEMICAL", 48, 58], ["diltiazem", "CHEMICAL", 35, 44], ["metoprolol", "CHEMICAL", 48, 58], ["Patients", "ORGANISM", 0, 8], ["diltiazem", "SIMPLE_CHEMICAL", 35, 44], ["metoprolol", "SIMPLE_CHEMICAL", 48, 58], ["Patients", "SPECIES", 0, 8], ["CHF", "PROBLEM", 14, 17], ["diltiazem", "TREATMENT", 35, 44], ["metoprolol", "TREATMENT", 48, 58], ["CHF", "OBSERVATION", 14, 17]]], ["Caution should be exercised in those who are not receiving anticoagulation, as amiodarone can promote cardioversion.", [["amiodarone", "CHEMICAL", 79, 89], ["amiodarone", "CHEMICAL", 79, 89], ["amiodarone", "SIMPLE_CHEMICAL", 79, 89], ["anticoagulation", "TREATMENT", 59, 74], ["amiodarone", "TREATMENT", 79, 89], ["cardioversion", "TREATMENT", 102, 115]]], ["Flecainide is contraindicated after a myocardial infarction because it increases the risk of polymorphic ventricular tachycardia.", [["myocardial", "ANATOMY", 38, 48], ["ventricular", "ANATOMY", 105, 116], ["Flecainide", "CHEMICAL", 0, 10], ["myocardial infarction", "DISEASE", 38, 59], ["ventricular tachycardia", "DISEASE", 105, 128], ["Flecainide", "CHEMICAL", 0, 10], ["Flecainide", "SIMPLE_CHEMICAL", 0, 10], ["myocardial", "MULTI-TISSUE_STRUCTURE", 38, 48], ["ventricular", "ORGAN", 105, 116], ["Flecainide", "TREATMENT", 0, 10], ["a myocardial infarction", "PROBLEM", 36, 59], ["polymorphic ventricular tachycardia", "PROBLEM", 93, 128], ["myocardial", "ANATOMY", 38, 48], ["infarction", "OBSERVATION", 49, 59], ["ventricular tachycardia", "OBSERVATION", 105, 128]]], ["Disopyramide has negative inotropic effects, which would detrimental in the setting of reduced left ventricular function and heart failure.", [["left ventricular", "ANATOMY", 95, 111], ["heart", "ANATOMY", 125, 130], ["Disopyramide", "CHEMICAL", 0, 12], ["heart failure", "DISEASE", 125, 138], ["Disopyramide", "CHEMICAL", 0, 12], ["Disopyramide", "SIMPLE_CHEMICAL", 0, 12], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 95, 111], ["heart", "ORGAN", 125, 130], ["Disopyramide", "TREATMENT", 0, 12], ["reduced left ventricular function", "PROBLEM", 87, 120], ["heart failure", "PROBLEM", 125, 138], ["negative", "OBSERVATION_MODIFIER", 17, 25], ["inotropic effects", "OBSERVATION", 26, 43], ["reduced", "OBSERVATION", 87, 94], ["left ventricular", "ANATOMY", 95, 111], ["function", "OBSERVATION", 112, 120], ["heart", "ANATOMY", 125, 130], ["failure", "OBSERVATION", 131, 138]]], ["Lab work is pertinent for elevated WBC of 16,500/ \u03bcL predominantly with neutrophils, lipase of 600 units/L, AST 150 units/L, ALT 165 units/L, and a bilirubin of 4.0 \u03bcmol/L.ReferencesWhich is the following is the least appropriate next step?", [["neutrophils", "ANATOMY", 72, 83], ["bilirubin", "CHEMICAL", 148, 157], ["bilirubin", "CHEMICAL", 148, 157], ["neutrophils", "CELL", 72, 83], ["lipase", "GENE_OR_GENE_PRODUCT", 85, 91], ["bilirubin", "SIMPLE_CHEMICAL", 148, 157], ["neutrophils", "CELL_TYPE", 72, 83], ["lipase", "PROTEIN", 85, 91], ["AST", "PROTEIN", 108, 111], ["ALT", "PROTEIN", 125, 128], ["Lab work", "TEST", 0, 8], ["elevated WBC", "PROBLEM", 26, 38], ["neutrophils", "TEST", 72, 83], ["lipase", "TEST", 85, 91], ["AST", "TEST", 108, 111], ["ALT", "TEST", 125, 128], ["a bilirubin", "TEST", 146, 157]]], ["A) Aggressive hydration with 250-500 ml per hour of isotonic crystalloid solution.B) Stat trans abdominal ultrasound C) MRCP D) Empiric antibiotics E) Nasogastric suctionAnswer: C The diagnosis of acute pancreatitis is established by the presence of two of the three following criteria: abdominal pain consistent with the disease, serum amylase and/or lipase greater than three times the upper limit of normal, and/or characteristic fi ndings from abdominal imaging.", [["abdominal", "ANATOMY", 287, 296], ["serum", "ANATOMY", 331, 336], ["abdominal", "ANATOMY", 448, 457], ["pancreatitis", "DISEASE", 203, 215], ["abdominal pain", "DISEASE", 287, 301], ["abdominal", "ORGANISM_SUBDIVISION", 287, 296], ["serum", "ORGANISM_SUBSTANCE", 331, 336], ["amylase", "GENE_OR_GENE_PRODUCT", 337, 344], ["lipase", "GENE_OR_GENE_PRODUCT", 352, 358], ["abdominal", "ORGANISM_SUBDIVISION", 448, 457], ["serum amylase", "PROTEIN", 331, 344], ["lipase", "PROTEIN", 352, 358], ["Aggressive hydration", "TREATMENT", 3, 23], ["isotonic crystalloid solution", "TREATMENT", 52, 81], ["Stat trans abdominal ultrasound C", "TEST", 85, 118], ["MRCP", "TEST", 120, 124], ["Empiric antibiotics E", "TREATMENT", 128, 149], ["acute pancreatitis", "PROBLEM", 197, 215], ["abdominal pain", "PROBLEM", 287, 301], ["the disease", "PROBLEM", 318, 329], ["serum amylase", "TEST", 331, 344], ["lipase", "TEST", 352, 358], ["abdominal imaging", "TEST", 448, 465], ["abdominal", "ANATOMY", 96, 105], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["pancreatitis", "OBSERVATION", 203, 215], ["abdominal", "ANATOMY", 287, 296], ["pain", "OBSERVATION", 297, 301], ["disease", "OBSERVATION", 322, 329], ["upper limit", "OBSERVATION_MODIFIER", 388, 399], ["normal", "OBSERVATION", 403, 409], ["abdominal", "ANATOMY", 448, 457]]], ["On physical examination, she appears ill.", [["physical examination", "TEST", 3, 23], ["ill", "PROBLEM", 37, 40], ["ill", "OBSERVATION", 37, 40]]], ["Her temperature is 39.9 \u00b0C, blood pressure is 127/878, and pulse rate is 120 per minute.", [["blood", "ANATOMY", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 28, 33], ["Her temperature", "TEST", 0, 15], ["blood pressure", "TEST", 28, 42], ["pulse rate", "TEST", 59, 69]]], ["Laboratory studies reveal a leukocyte count of 23,000 with 87 % neutrophils.", [["leukocyte", "ANATOMY", 28, 37], ["neutrophils", "ANATOMY", 64, 75], ["leukocyte", "CELL", 28, 37], ["neutrophils", "CELL", 64, 75], ["neutrophils", "CELL_TYPE", 64, 75], ["Laboratory studies", "TEST", 0, 18], ["a leukocyte count", "TEST", 26, 43], ["neutrophils", "TEST", 64, 75], ["leukocyte count", "OBSERVATION", 28, 43]]], ["Urinalysis demonstrates >68 leukocytes/hpf and has a positive leukocyte esterase.", [["leukocytes", "ANATOMY", 28, 38], ["leukocyte", "ANATOMY", 62, 71], ["leukocytes", "CELL", 28, 38], ["leukocyte esterase", "GENE_OR_GENE_PRODUCT", 62, 80], ["leukocytes", "CELL_TYPE", 28, 38], ["positive leukocyte esterase", "PROTEIN", 53, 80], ["Urinalysis", "TEST", 0, 10], ["leukocytes", "TEST", 28, 38], ["hpf", "TEST", 39, 42], ["a positive leukocyte esterase", "PROBLEM", 51, 80], ["68 leukocytes", "OBSERVATION_MODIFIER", 25, 38], ["positive leukocyte esterase", "OBSERVATION", 53, 80]]], ["Gram-negative rods are seen upon microscopic examination.B) Stat trans abdominal ultrasound C) MRCP D) Empiric antibiotics E) Nasogastric suctionShe is admitted to the hospital with a diagnosis of probable urinary tract infection.", [["urinary tract", "ANATOMY", 206, 219], ["urinary tract infection", "DISEASE", 206, 229], ["Gram-", "GENE_OR_GENE_PRODUCT", 0, 5], ["urinary tract", "ORGANISM_SUBDIVISION", 206, 219], ["Gram-negative rods", "PROBLEM", 0, 18], ["microscopic examination", "TEST", 33, 56], ["Stat trans abdominal ultrasound", "TEST", 60, 91], ["MRCP", "TEST", 95, 99], ["Empiric antibiotics E", "TREATMENT", 103, 124], ["Nasogastric suction", "TREATMENT", 126, 145], ["urinary tract infection", "PROBLEM", 206, 229], ["negative rods", "OBSERVATION", 5, 18], ["abdominal", "ANATOMY", 71, 80], ["probable", "UNCERTAINTY", 197, 205], ["urinary tract", "ANATOMY", 206, 219], ["infection", "OBSERVATION", 220, 229]]], ["On the second day of her hospitalization, her urine and blood cultures are positive for Escherichia coli , susceptible to piperacillin/tazobactam, ciprofl oxacin, imipenem, ampicillin, and ceftriaxone.B) Stat trans abdominal ultrasound C) MRCP D) Empiric antibiotics E) Nasogastric suctionWhich of the following is the most appropriate management?", [["urine", "ANATOMY", 46, 51], ["blood cultures", "ANATOMY", 56, 70], ["piperacillin/tazobactam", "CHEMICAL", 122, 145], ["ciprofl oxacin", "CHEMICAL", 147, 161], ["imipenem", "CHEMICAL", 163, 171], ["ampicillin", "CHEMICAL", 173, 183], ["ceftriaxone", "CHEMICAL", 189, 200], ["piperacillin", "CHEMICAL", 122, 134], ["tazobactam", "CHEMICAL", 135, 145], ["ciprofl oxacin", "CHEMICAL", 147, 161], ["imipenem", "CHEMICAL", 163, 171], ["ampicillin", "CHEMICAL", 173, 183], ["ceftriaxone", "CHEMICAL", 189, 200], ["urine", "ORGANISM_SUBSTANCE", 46, 51], ["blood cultures", "ORGANISM_SUBSTANCE", 56, 70], ["Escherichia coli", "ORGANISM", 88, 104], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 122, 145], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 147, 161], ["imipenem", "SIMPLE_CHEMICAL", 163, 171], ["ampicillin", "SIMPLE_CHEMICAL", 173, 183], ["ceftriaxone", "SIMPLE_CHEMICAL", 189, 200], ["Escherichia coli", "SPECIES", 88, 104], ["Escherichia coli", "SPECIES", 88, 104], ["her urine", "TEST", 42, 51], ["blood cultures", "TEST", 56, 70], ["Escherichia coli", "PROBLEM", 88, 104], ["piperacillin", "TREATMENT", 122, 134], ["tazobactam", "TREATMENT", 135, 145], ["ciprofl oxacin", "TREATMENT", 147, 161], ["imipenem", "TREATMENT", 163, 171], ["ampicillin", "TREATMENT", 173, 183], ["ceftriaxone", "TREATMENT", 189, 200], ["Stat trans abdominal ultrasound", "TEST", 204, 235], ["MRCP", "TEST", 239, 243], ["Empiric antibiotics E", "TREATMENT", 247, 268], ["Nasogastric suctionWhich", "TREATMENT", 270, 294], ["Escherichia coli", "OBSERVATION", 88, 104], ["abdominal", "ANATOMY", 215, 224]]], ["A) Continue piperacillin/tazobactam.", [["piperacillin/tazobactam", "CHEMICAL", 12, 35], ["piperacillin", "CHEMICAL", 12, 24], ["tazobactam", "CHEMICAL", 25, 35], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 12, 35], ["piperacillin", "TREATMENT", 12, 24], ["tazobactam", "TREATMENT", 25, 35]]], ["B) Discontinue piperacillin/tazobactam and begin ampicillin.", [["piperacillin/tazobactam", "CHEMICAL", 15, 38], ["ampicillin", "CHEMICAL", 49, 59], ["piperacillin", "CHEMICAL", 15, 27], ["tazobactam", "CHEMICAL", 28, 38], ["ampicillin", "CHEMICAL", 49, 59], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 15, 38], ["ampicillin", "SIMPLE_CHEMICAL", 49, 59], ["piperacillin", "TREATMENT", 15, 27], ["tazobactam", "TREATMENT", 28, 38], ["ampicillin", "TREATMENT", 49, 59]]], ["C) Discontinue piperacillin/tazobactam and begin ciprofl oxacin.", [["piperacillin/tazobactam", "CHEMICAL", 15, 38], ["ciprofl oxacin", "CHEMICAL", 49, 63], ["piperacillin", "CHEMICAL", 15, 27], ["tazobactam", "CHEMICAL", 28, 38], ["ciprofl oxacin", "CHEMICAL", 49, 63], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 15, 38], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 49, 63], ["piperacillin", "TREATMENT", 15, 27], ["tazobactam", "TREATMENT", 28, 38], ["ciprofl oxacin", "TREATMENT", 49, 63]]], ["D) Discontinue piperacillin/tazobactam and begin ceftriaxone.B) Stat trans abdominal ultrasound C) MRCP D) Empiric antibiotics E) Nasogastric suctionAnswer: B In this patient, broad-spectrum antibiotics on presentation are indicated.", [["piperacillin/tazobactam", "CHEMICAL", 15, 38], ["ceftriaxone", "CHEMICAL", 49, 60], ["piperacillin", "CHEMICAL", 15, 27], ["tazobactam", "CHEMICAL", 28, 38], ["ceftriaxone", "CHEMICAL", 49, 60], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 15, 38], ["ceftriaxone", "SIMPLE_CHEMICAL", 49, 60], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 167, 174], ["piperacillin", "TREATMENT", 15, 27], ["tazobactam", "TREATMENT", 28, 38], ["ceftriaxone", "TREATMENT", 49, 60], ["Stat trans abdominal ultrasound C", "TEST", 64, 97], ["MRCP", "TEST", 99, 103], ["Empiric antibiotics E", "TREATMENT", 107, 128], ["broad-spectrum antibiotics", "TREATMENT", 176, 202], ["abdominal", "ANATOMY", 75, 84]]], ["However, once the specifi c organism is isolated and sensitivities are known, it is benefi cial to de-escalate therapy to a limited-spectrum antibiotic.", [["specifi c", "GENE_OR_GENE_PRODUCT", 18, 27], ["the specifi c organism", "PROBLEM", 14, 36], ["de-escalate therapy", "TREATMENT", 99, 118], ["a limited-spectrum antibiotic", "TREATMENT", 122, 151]]], ["De-escalation strategies involve not only changing antibiotics but can reduce dosage as well.", [["De-escalation strategies", "TREATMENT", 0, 24], ["changing antibiotics", "TREATMENT", 42, 62]]], ["This may present as a challenge in a situation where a patient has responded well to a broad-spectrum antibiotic.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["a broad-spectrum antibiotic", "TREATMENT", 85, 112]]], ["However, failure to do so places the patient at additional risk for antibiotic-induced complications.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44], ["failure", "PROBLEM", 9, 16], ["antibiotic", "TREATMENT", 68, 78], ["induced complications", "PROBLEM", 79, 100], ["failure", "OBSERVATION", 9, 16]]], ["Ciprofl oxacin may be considered, but it provides unnecessarily broadspectrum coverage.", [["Ciprofl oxacin", "CHEMICAL", 0, 14], ["Ciprofl oxacin", "CHEMICAL", 0, 14], ["Ciprofl oxacin", "SIMPLE_CHEMICAL", 0, 14], ["Ciprofl oxacin", "TREATMENT", 0, 14], ["unnecessarily broadspectrum coverage", "TREATMENT", 50, 86]]], ["Studies have shown that appropriate de-escalation improves outcomes in cases of sepsis and ventilator-related pneumonia.", [["sepsis", "DISEASE", 80, 86], ["pneumonia", "DISEASE", 110, 119], ["Studies", "TEST", 0, 7], ["sepsis", "PROBLEM", 80, 86], ["ventilator", "TREATMENT", 91, 101], ["related pneumonia", "PROBLEM", 102, 119], ["sepsis", "OBSERVATION", 80, 86], ["pneumonia", "OBSERVATION", 110, 119]]], ["On physical examination, the patient is alert and oriented.", [["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["physical examination", "TEST", 3, 23]]], ["Temperature is 36.2 \u00b0C (97.2 \u00b0F), blood pressure is 110/58 mmHg, pulse rate is 64/min, and respiration rate is 18/min.", [["blood", "ANATOMY", 34, 39], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["Temperature", "TEST", 0, 11], ["\u00b0C", "TEST", 20, 22], ["blood pressure", "TEST", 34, 48], ["pulse rate", "TEST", 65, 75], ["respiration rate", "TEST", 91, 107]]], ["There are no focal neurologic defi cits.", [["neurologic", "ANATOMY", 19, 29], ["focal neurologic defi cits", "PROBLEM", 13, 39], ["no", "UNCERTAINTY", 10, 12], ["focal", "OBSERVATION_MODIFIER", 13, 18], ["neurologic defi cits", "OBSERVATION", 19, 39]]], ["There is no asterixis.", [["asterixis", "PROBLEM", 12, 21], ["no", "UNCERTAINTY", 9, 11], ["asterixis", "OBSERVATION", 12, 21]]], ["Abdominal examination reveals shifting abdominal dullness.", [["Abdominal", "ANATOMY", 0, 9], ["abdominal", "ANATOMY", 39, 48], ["abdominal dullness", "DISEASE", 39, 57], ["abdominal", "ORGANISM_SUBDIVISION", 39, 48], ["Abdominal examination", "TEST", 0, 21], ["shifting abdominal dullness", "PROBLEM", 30, 57], ["shifting", "OBSERVATION_MODIFIER", 30, 38], ["abdominal", "ANATOMY", 39, 48], ["dullness", "OBSERVATION", 49, 57]]], ["There is 1+ lower extremity edema.ReferencesLaboratory studies show albumin 1.8 g/dL, blood urea nitrogen 8 mg/dL, serum creatinine 1.6 mg/dL (141 \u03bcmol/L), sodium 119 mEq/L. Her last recorded sodium one month ago was 121 mEq/L.ReferencesWhich of the following is the most appropriate management for this patient's hyponatremia?", [["lower extremity edema", "ANATOMY", 12, 33], ["blood", "ANATOMY", 86, 91], ["serum", "ANATOMY", 115, 120], ["edema", "DISEASE", 28, 33], ["blood urea nitrogen", "CHEMICAL", 86, 105], ["creatinine", "CHEMICAL", 121, 131], ["sodium", "CHEMICAL", 156, 162], ["sodium", "CHEMICAL", 192, 198], ["hyponatremia", "DISEASE", 314, 326], ["urea", "CHEMICAL", 92, 96], ["nitrogen", "CHEMICAL", 97, 105], ["creatinine", "CHEMICAL", 121, 131], ["sodium", "CHEMICAL", 156, 162], ["sodium", "CHEMICAL", 192, 198], ["edema", "PATHOLOGICAL_FORMATION", 28, 33], ["albumin", "GENE_OR_GENE_PRODUCT", 68, 75], ["blood", "ORGANISM_SUBSTANCE", 86, 91], ["urea", "SIMPLE_CHEMICAL", 92, 96], ["serum", "ORGANISM_SUBSTANCE", 115, 120], ["creatinine", "SIMPLE_CHEMICAL", 121, 131], ["sodium", "SIMPLE_CHEMICAL", 156, 162], ["sodium", "SIMPLE_CHEMICAL", 192, 198], ["patient", "ORGANISM", 304, 311], ["albumin", "PROTEIN", 68, 75], ["patient", "SPECIES", 304, 311], ["lower extremity edema", "PROBLEM", 12, 33], ["ReferencesLaboratory studies", "TEST", 34, 62], ["albumin", "TEST", 68, 75], ["dL", "TEST", 82, 84], ["blood urea nitrogen", "TEST", 86, 105], ["serum creatinine", "TEST", 115, 131], ["dL", "TEST", 139, 141], ["sodium", "TEST", 156, 162], ["Her last recorded sodium", "TEST", 174, 198], ["this patient's hyponatremia", "PROBLEM", 299, 326], ["1+", "OBSERVATION_MODIFIER", 9, 11], ["lower", "ANATOMY_MODIFIER", 12, 17], ["extremity", "ANATOMY", 18, 27], ["edema", "OBSERVATION", 28, 33], ["dL", "ANATOMY", 111, 113]]], ["A) 3 % saline B) Conivaptan C) Demeclocycline D) Fluid restriction Answer: D Hyponatremia is common in end-stage liver disease patients.ReferencesAsymptomatic hyponatremia in patients with cirrhosis is a poor prognostic marker.", [["liver", "ANATOMY", 113, 118], ["Conivaptan", "CHEMICAL", 17, 27], ["Demeclocycline", "CHEMICAL", 31, 45], ["Hyponatremia", "DISEASE", 77, 89], ["end-stage liver disease", "DISEASE", 103, 126], ["hyponatremia", "DISEASE", 159, 171], ["cirrhosis", "DISEASE", 189, 198], ["Conivaptan C", "CHEMICAL", 17, 29], ["Demeclocycline D", "CHEMICAL", 31, 47], ["saline B) Conivaptan C", "SIMPLE_CHEMICAL", 7, 29], ["Demeclocycline D", "SIMPLE_CHEMICAL", 31, 47], ["liver", "ORGAN", 113, 118], ["patients", "ORGANISM", 127, 135], ["patients", "ORGANISM", 175, 183], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 175, 183], ["A) 3 % saline B) Conivaptan C) Demeclocycline D) Fluid restriction", "TREATMENT", 0, 66], ["D Hyponatremia", "PROBLEM", 75, 89], ["end-stage liver disease", "PROBLEM", 103, 126], ["ReferencesAsymptomatic hyponatremia", "PROBLEM", 136, 171], ["cirrhosis", "PROBLEM", 189, 198], ["Hyponatremia", "OBSERVATION", 77, 89], ["stage", "OBSERVATION_MODIFIER", 107, 112], ["liver", "ANATOMY", 113, 118], ["disease", "OBSERVATION", 119, 126], ["hyponatremia", "OBSERVATION", 159, 171], ["cirrhosis", "OBSERVATION", 189, 198]]], ["Several studies have shown that hyponatremia is a strong predictor of early mortality, independent of MELD score.", [["hyponatremia", "DISEASE", 32, 44], ["Several studies", "TEST", 0, 15], ["hyponatremia", "PROBLEM", 32, 44], ["MELD score", "TEST", 102, 112], ["hyponatremia", "OBSERVATION", 32, 44]]], ["In the absence of neurologic symptoms, rapid correction of sodium is not indicated.", [["neurologic", "ANATOMY", 18, 28], ["neurologic symptoms", "DISEASE", 18, 37], ["sodium", "CHEMICAL", 59, 65], ["sodium", "CHEMICAL", 59, 65], ["sodium", "SIMPLE_CHEMICAL", 59, 65], ["neurologic symptoms", "PROBLEM", 18, 37], ["sodium", "TEST", 59, 65]]], ["Fluid restriction and following sodium concentration are the correct initial treatment options.", [["sodium", "CHEMICAL", 32, 38], ["sodium", "CHEMICAL", 32, 38], ["sodium", "SIMPLE_CHEMICAL", 32, 38], ["Fluid restriction", "TREATMENT", 0, 17], ["sodium concentration", "TREATMENT", 32, 52], ["initial treatment options", "TREATMENT", 69, 94]]], ["Some degree of hyponatremia can be allowed.", [["hyponatremia", "DISEASE", 15, 27], ["hyponatremia", "PROBLEM", 15, 27], ["degree", "OBSERVATION_MODIFIER", 5, 11], ["hyponatremia", "OBSERVATION", 15, 27]]], ["Several guidelines recommend implementing fl uid restriction only when the serum sodium level is less than 120 mEq/L. On physical exam, her temperature is 38.9 C (102.0 F), pulse rate is 90 per minute, respirations are 21 per minute, and blood pressure is 110/85 mmHg.", [["serum", "ANATOMY", 75, 80], ["blood", "ANATOMY", 238, 243], ["sodium", "CHEMICAL", 81, 87], ["sodium", "CHEMICAL", 81, 87], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["sodium", "SIMPLE_CHEMICAL", 81, 87], ["blood", "ORGANISM_SUBSTANCE", 238, 243], ["fl uid restriction", "TREATMENT", 42, 60], ["the serum sodium level", "TEST", 71, 93], ["physical exam", "TEST", 121, 134], ["her temperature", "TEST", 136, 151], ["pulse rate", "TEST", 173, 183], ["respirations", "TEST", 202, 214], ["blood pressure", "TEST", 238, 252]]], ["Thrush is still present.", [["Thrush", "PROBLEM", 0, 6]]], ["Breath sounds are decreased in the left upper lung.", [["left upper lung", "ANATOMY", 35, 50], ["upper lung", "ORGAN", 40, 50], ["Breath sounds", "TEST", 0, 13], ["sounds", "OBSERVATION", 7, 13], ["decreased", "OBSERVATION", 18, 27], ["left", "ANATOMY_MODIFIER", 35, 39], ["upper", "ANATOMY_MODIFIER", 40, 45], ["lung", "ANATOMY", 46, 50]]], ["HIV antibodies are positive, CD4 lymphocyte count is 65/\u03bcL .", [["CD4 lymphocyte", "ANATOMY", 29, 43], ["HIV", "ORGANISM", 0, 3], ["CD4 lymphocyte", "CELL", 29, 43], ["HIV antibodies", "PROTEIN", 0, 14], ["CD4", "PROTEIN", 29, 32], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV antibodies", "TEST", 0, 14], ["CD4 lymphocyte count", "TEST", 29, 49], ["CD4 lymphocyte count", "OBSERVATION", 29, 49]]], ["Two of three acid-fast bacilli (AFB) smears are positive.", [["three acid-fast bacilli (AFB) smears", "TEST", 7, 43], ["positive", "OBSERVATION", 48, 56]]], ["Chest radiograph reveals an opacity and early cavitation in right upper lung.ReferencesThe patient is treated with fl uconazole for thrush.", [["right upper lung", "ANATOMY", 60, 76], ["uconazole", "CHEMICAL", 118, 127], ["thrush", "DISEASE", 132, 138], ["uconazole", "CHEMICAL", 118, 127], ["upper", "ORGANISM_SUBDIVISION", 66, 71], ["lung", "ORGAN", 72, 76], ["patient", "ORGANISM", 91, 98], ["fl uconazole", "SIMPLE_CHEMICAL", 115, 127], ["patient", "SPECIES", 91, 98], ["Chest radiograph", "TEST", 0, 16], ["an opacity", "PROBLEM", 25, 35], ["early cavitation in right upper lung", "PROBLEM", 40, 76], ["fl uconazole", "TREATMENT", 115, 127], ["thrush", "PROBLEM", 132, 138], ["opacity", "OBSERVATION", 28, 35], ["early", "OBSERVATION_MODIFIER", 40, 45], ["cavitation", "OBSERVATION", 46, 56], ["right", "ANATOMY_MODIFIER", 60, 65], ["upper", "ANATOMY_MODIFIER", 66, 71], ["lung", "ANATOMY", 72, 76], ["thrush", "OBSERVATION", 132, 138]]], ["Four-drug antituberculous therapy is started after the sputum results are reviewed.", [["sputum", "ANATOMY", 55, 61], ["drug antituberculous therapy", "TREATMENT", 5, 33], ["the sputum results", "TEST", 51, 69], ["antituberculous therapy", "OBSERVATION", 10, 33]]], ["Arrangements are being made for appropriate follow-up and surveillance of her tuberculosis medicines.ReferencesWhen should antiretroviral therapy be started?", [["tuberculosis", "DISEASE", 78, 90], ["her tuberculosis medicines", "TREATMENT", 74, 100], ["antiretroviral therapy", "TREATMENT", 123, 145], ["tuberculosis", "OBSERVATION", 78, 90]]], ["A) Immediately B) Four weeks after completing antituberculous therapy C) Eight weeks after initiating antituberculous therapy D) Three to six months after completing antituberculous therapyReferencesAnswer: A There is often some confusion as to when to start antiretroviral therapy in patients presenting with infections and a new HIV diagnosis.", [["confusion", "DISEASE", 229, 238], ["infections", "DISEASE", 310, 320], ["patients", "ORGANISM", 285, 293], ["patients", "SPECIES", 285, 293], ["HIV", "SPECIES", 331, 334], ["antituberculous therapy", "TREATMENT", 46, 69], ["antituberculous therapy D", "TREATMENT", 102, 127], ["antituberculous therapy", "TREATMENT", 166, 189], ["some confusion", "PROBLEM", 224, 238], ["antiretroviral therapy", "TREATMENT", 259, 281], ["infections", "PROBLEM", 310, 320], ["a new HIV diagnosis", "PROBLEM", 325, 344], ["antituberculous therapy", "OBSERVATION", 102, 125], ["antituberculous therapy", "OBSERVATION", 166, 189]]], ["It may be dependent on the type of infection.", [["infection", "DISEASE", 35, 44], ["infection", "PROBLEM", 35, 44], ["may be", "UNCERTAINTY", 3, 9], ["dependent", "OBSERVATION_MODIFIER", 10, 19], ["infection", "OBSERVATION", 35, 44]]], ["Often the recommendation is to start therapy after the cause of infection is resolved.", [["infection", "DISEASE", 64, 73], ["therapy", "TREATMENT", 37, 44], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["Two studies comparing early and delayed antiretroviral therapy suggest that starting within two to four weeks of initiating therapy for tuberculosis improves survival.", [["tuberculosis", "DISEASE", 136, 148], ["Two studies", "TEST", 0, 11], ["delayed antiretroviral therapy", "TREATMENT", 32, 62], ["therapy", "TREATMENT", 124, 131], ["tuberculosis", "PROBLEM", 136, 148], ["tuberculosis", "OBSERVATION", 136, 148]]], ["This is important for hospitalists who may be tempted to wait to start antiviral therapy until the patient sees an infectious disease specialist several weeks later.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["antiviral therapy", "TREATMENT", 71, 88]]], ["A 68-year-old male is admitted with melena and coffee-ground emesis for the past two days.", [["melena", "DISEASE", 36, 42], ["coffee-ground emesis", "DISEASE", 47, 67], ["male", "ORGANISM", 14, 18], ["melena", "PATHOLOGICAL_FORMATION", 36, 42], ["melena", "PROBLEM", 36, 42], ["coffee-ground emesis", "PROBLEM", 47, 67], ["melena", "OBSERVATION", 36, 42], ["coffee-ground emesis", "OBSERVATION", 47, 67]]], ["He has a history of rheumatoid arthritis, for which he takes ibuprofen 400 mg 2-3 times daily.", [["rheumatoid arthritis", "DISEASE", 20, 40], ["ibuprofen", "CHEMICAL", 61, 70], ["ibuprofen", "CHEMICAL", 61, 70], ["ibuprofen", "SIMPLE_CHEMICAL", 61, 70], ["rheumatoid arthritis", "PROBLEM", 20, 40], ["ibuprofen", "TREATMENT", 61, 70], ["rheumatoid", "OBSERVATION_MODIFIER", 20, 30], ["arthritis", "OBSERVATION", 31, 40]]], ["He reports that he has increased his intake of this medicine over the past week due to an increase in his joint pains.", [["joint", "ANATOMY", 106, 111], ["pains", "DISEASE", 112, 117], ["joint", "ORGANISM_SUBDIVISION", 106, 111], ["this medicine", "TREATMENT", 47, 60], ["his joint pains", "PROBLEM", 102, 117], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["joint", "ANATOMY", 106, 111], ["pains", "OBSERVATION", 112, 117]]], ["On physical examination, his heart rate is 90 beats per minute, the temperature is 36.0 \u00b0 C (98.6 \u00b0F), and respirations are 17 per minute.", [["heart", "ANATOMY", 29, 34], ["heart", "ORGAN", 29, 34], ["physical examination", "TEST", 3, 23], ["his heart rate", "TEST", 25, 39], ["the temperature", "TEST", 64, 79], ["C", "TEST", 90, 91], ["respirations", "TEST", 107, 119], ["heart", "ANATOMY", 29, 34]]], ["His blood pressure is 115/73 mmHg.", [["blood", "ANATOMY", 4, 9], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["His blood pressure", "TEST", 0, 18]]], ["He is originally started on intravenous pantoprazole 8 mg/h.", [["intravenous", "ANATOMY", 28, 39], ["pantoprazole", "CHEMICAL", 40, 52], ["pantoprazole", "CHEMICAL", 40, 52], ["He", "ORGANISM", 0, 2], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 28, 39], ["pantoprazole", "SIMPLE_CHEMICAL", 40, 52], ["intravenous pantoprazole", "TREATMENT", 28, 52]]], ["The next morning he undergoes endoscopy that shows an active ulcer that has some slight oozing.ReferencesWhich of the following is the most appropriate therapy for this patient?", [["ulcer", "ANATOMY", 61, 66], ["ulcer", "DISEASE", 61, 66], ["ulcer", "PATHOLOGICAL_FORMATION", 61, 66], ["oozing", "PATHOLOGICAL_FORMATION", 88, 94], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["endoscopy", "TEST", 30, 39], ["an active ulcer", "PROBLEM", 51, 66], ["some slight oozing", "PROBLEM", 76, 94], ["active", "OBSERVATION_MODIFIER", 54, 60], ["ulcer", "OBSERVATION", 61, 66], ["slight", "OBSERVATION_MODIFIER", 81, 87], ["oozing", "OBSERVATION", 88, 94]]], ["A) Oral ranitidine 150 mg twice daily B) Octreotide infusion for 48 h C) Oral pantoprazole 40 mg by mouth every 12 h D) Continue with an 8 mg/h pantoprazole infusion Answer: C Although IV pantoprazole is often initiated, oral pantoprazole has nearly 100 % bioavailability and may be utilized when the patient is able to take pills, and there is a low risk of rebleeding, as in this case.", [["Oral", "ANATOMY", 3, 7], ["mouth", "ANATOMY", 100, 105], ["oral", "ANATOMY", 221, 225], ["ranitidine", "CHEMICAL", 8, 18], ["Octreotide", "CHEMICAL", 41, 51], ["pantoprazole", "CHEMICAL", 78, 90], ["pantoprazole", "CHEMICAL", 144, 156], ["pantoprazole", "CHEMICAL", 188, 200], ["pantoprazole", "CHEMICAL", 226, 238], ["rebleeding", "DISEASE", 359, 369], ["ranitidine", "CHEMICAL", 8, 18], ["Octreotide", "CHEMICAL", 41, 51], ["pantoprazole", "CHEMICAL", 78, 90], ["pantoprazole", "CHEMICAL", 144, 156], ["pantoprazole", "CHEMICAL", 188, 200], ["pantoprazole", "CHEMICAL", 226, 238], ["ranitidine", "SIMPLE_CHEMICAL", 8, 18], ["Octreotide", "SIMPLE_CHEMICAL", 41, 51], ["pantoprazole", "SIMPLE_CHEMICAL", 144, 156], ["pantoprazole", "SIMPLE_CHEMICAL", 188, 200], ["oral", "ORGANISM_SUBDIVISION", 221, 225], ["pantoprazole", "SIMPLE_CHEMICAL", 226, 238], ["patient", "ORGANISM", 301, 308], ["patient", "SPECIES", 301, 308], ["A) Oral ranitidine", "TREATMENT", 0, 18], ["Octreotide infusion", "TREATMENT", 41, 60], ["Oral pantoprazole", "TREATMENT", 73, 90], ["pantoprazole infusion", "TREATMENT", 144, 165], ["IV pantoprazole", "TREATMENT", 185, 200], ["oral pantoprazole", "TREATMENT", 221, 238], ["rebleeding", "PROBLEM", 359, 369], ["rebleeding", "OBSERVATION", 359, 369]]], ["Investigators compared 30-day rebleeding rates in patients randomized to receive intravenous (IV) versus oral high-dose PPI treatment after successful endoscopic therapy for bleeding peptic ulcers.", [["intravenous", "ANATOMY", 81, 92], ["oral", "ANATOMY", 105, 109], ["peptic", "ANATOMY", 183, 189], ["rebleeding", "DISEASE", 30, 40], ["bleeding peptic ulcers", "DISEASE", 174, 196], ["patients", "ORGANISM", 50, 58], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 92], ["oral", "ORGANISM_SUBDIVISION", 105, 109], ["peptic ulcers", "PATHOLOGICAL_FORMATION", 183, 196], ["patients", "SPECIES", 50, 58], ["rebleeding rates", "TEST", 30, 46], ["intravenous (IV)", "TREATMENT", 81, 97], ["oral high-dose PPI treatment", "TREATMENT", 105, 133], ["successful endoscopic therapy", "TREATMENT", 140, 169], ["bleeding peptic ulcers", "PROBLEM", 174, 196], ["peptic ulcers", "OBSERVATION", 183, 196]]], ["Rebleeding rates were similar in the IV-PPI and oral-PPI groups at 72 h 7 days and 30 days.", [["oral", "ANATOMY", 48, 52], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["Rebleeding rates", "PROBLEM", 0, 16], ["the IV-PPI", "TREATMENT", 33, 43], ["oral-PPI groups", "TREATMENT", 48, 63]]], ["Octreotide is benefi cial in acute variceal bleeding and may have a role in severe peptic ulcer disease when endoscopy is deferred or not available.", [["variceal", "ANATOMY", 35, 43], ["peptic ulcer", "ANATOMY", 83, 95], ["Octreotide", "CHEMICAL", 0, 10], ["acute variceal bleeding", "DISEASE", 29, 52], ["peptic ulcer disease", "DISEASE", 83, 103], ["Octreotide", "CHEMICAL", 0, 10], ["Octreotide", "SIMPLE_CHEMICAL", 0, 10], ["peptic ulcer", "PATHOLOGICAL_FORMATION", 83, 95], ["Octreotide", "TREATMENT", 0, 10], ["acute variceal bleeding", "PROBLEM", 29, 52], ["severe peptic ulcer disease", "PROBLEM", 76, 103], ["endoscopy", "TEST", 109, 118], ["acute", "OBSERVATION_MODIFIER", 29, 34], ["variceal bleeding", "OBSERVATION", 35, 52], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["peptic", "OBSERVATION_MODIFIER", 83, 89], ["ulcer disease", "OBSERVATION", 90, 103]]], ["H2-receptor antagonists are inferior to proton-pump inhibitors in the management of acute gastrointestinal bleeds.", [["gastrointestinal", "ANATOMY", 90, 106], ["acute gastrointestinal bleeds", "DISEASE", 84, 113], ["H2", "CHEMICAL", 0, 2], ["H2-receptor antagonists", "GENE_OR_GENE_PRODUCT", 0, 23], ["gastrointestinal bleeds", "PATHOLOGICAL_FORMATION", 90, 113], ["H2-receptor antagonists", "TREATMENT", 0, 23], ["proton-pump inhibitors", "TREATMENT", 40, 62], ["the management", "TREATMENT", 66, 80], ["acute gastrointestinal bleeds", "PROBLEM", 84, 113], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["gastrointestinal", "ANATOMY", 90, 106], ["bleeds", "OBSERVATION", 107, 113]]], ["CMV typically presents with distal esophageal ulceration.", [["esophageal", "ANATOMY", 35, 45], ["distal esophageal ulceration", "DISEASE", 28, 56], ["CMV", "ORGANISM", 0, 3], ["esophageal ulceration", "PATHOLOGICAL_FORMATION", 35, 56], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["distal esophageal ulceration", "PROBLEM", 28, 56], ["distal", "ANATOMY_MODIFIER", 28, 34], ["esophageal", "ANATOMY", 35, 45], ["ulceration", "OBSERVATION", 46, 56]]], ["HSV infection presents with multiple vesiculation and ulcerations.", [["HSV infection", "DISEASE", 0, 13], ["ulcerations", "DISEASE", 54, 65], ["HSV", "ORGANISM", 0, 3], ["ulcerations", "PATHOLOGICAL_FORMATION", 54, 65], ["HSV", "SPECIES", 0, 3], ["HSV infection", "PROBLEM", 0, 13], ["multiple vesiculation", "PROBLEM", 28, 49], ["ulcerations", "PROBLEM", 54, 65], ["infection", "OBSERVATION", 4, 13], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["vesiculation", "OBSERVATION_MODIFIER", 37, 49], ["ulcerations", "OBSERVATION", 54, 65]]], ["The lesions are round, multiple, well circumscribed, uniform, and smaller than those in CMV disease.", [["lesions", "ANATOMY", 4, 11], ["CMV disease", "DISEASE", 88, 99], ["lesions", "PATHOLOGICAL_FORMATION", 4, 11], ["CMV", "ORGANISM", 88, 91], ["CMV", "SPECIES", 88, 91], ["The lesions", "PROBLEM", 0, 11], ["multiple, well circumscribed, uniform, and smaller than those in CMV disease", "PROBLEM", 23, 99], ["lesions", "OBSERVATION", 4, 11], ["round", "OBSERVATION_MODIFIER", 16, 21], ["multiple", "OBSERVATION_MODIFIER", 23, 31], ["well", "OBSERVATION_MODIFIER", 33, 37], ["circumscribed", "OBSERVATION_MODIFIER", 38, 51], ["uniform", "OBSERVATION_MODIFIER", 53, 60], ["smaller", "OBSERVATION_MODIFIER", 66, 73], ["CMV disease", "OBSERVATION", 88, 99]]], ["CMV is the most common cause of intraocular infection in patients with AIDS and should be considered with any visual complaint.", [["intraocular", "ANATOMY", 32, 43], ["intraocular infection", "DISEASE", 32, 53], ["AIDS", "DISEASE", 71, 75], ["CMV", "ORGANISM", 0, 3], ["intraocular", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 43], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["CMV", "SPECIES", 0, 3], ["CMV", "PROBLEM", 0, 3], ["intraocular infection", "PROBLEM", 32, 53], ["AIDS", "PROBLEM", 71, 75], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["intraocular", "OBSERVATION_MODIFIER", 32, 43], ["infection", "OBSERVATION", 44, 53]]], ["This disease represents a reactivation of latent CMV infection.", [["CMV infection", "DISEASE", 49, 62], ["CMV", "ORGANISM", 49, 52], ["CMV", "SPECIES", 49, 52], ["This disease", "PROBLEM", 0, 12], ["latent CMV infection", "PROBLEM", 42, 62], ["disease", "OBSERVATION", 5, 12], ["reactivation", "OBSERVATION_MODIFIER", 26, 38], ["latent", "OBSERVATION_MODIFIER", 42, 48], ["CMV", "OBSERVATION_MODIFIER", 49, 52], ["infection", "OBSERVATION", 53, 62]]], ["Before the advent of highly active antiretroviral therapy (HAART), CMV was the most common opportunistic infection in AIDS patients with a CD4+ cell count below 50/mL.", [["CD4+ cell", "ANATOMY", 139, 148], ["opportunistic infection", "DISEASE", 91, 114], ["AIDS", "DISEASE", 118, 122], ["CMV", "ORGANISM", 67, 70], ["patients", "ORGANISM", 123, 131], ["CD4", "PROTEIN", 139, 142], ["patients", "SPECIES", 123, 131], ["CMV", "SPECIES", 67, 70], ["highly active antiretroviral therapy", "TREATMENT", 21, 57], ["HAART)", "TREATMENT", 59, 65], ["CMV", "PROBLEM", 67, 70], ["a CD4+ cell count", "TEST", 137, 154], ["active", "OBSERVATION_MODIFIER", 28, 34], ["antiretroviral therapy", "OBSERVATION", 35, 57], ["most common", "OBSERVATION_MODIFIER", 79, 90], ["opportunistic", "OBSERVATION_MODIFIER", 91, 104], ["infection", "OBSERVATION", 105, 114]]], ["A 28-year-old female presents to the emergency room with a chief complaint of new-onset bruises to her thighs and some mild bleeding of her gums.", [["thighs", "ANATOMY", 103, 109], ["bruises", "DISEASE", 88, 95], ["bleeding", "DISEASE", 124, 132], ["female", "ORGANISM", 14, 20], ["thighs", "ORGANISM_SUBDIVISION", 103, 109], ["gums", "ORGANISM_SUBDIVISION", 140, 144], ["new-onset bruises to her thighs", "PROBLEM", 78, 109], ["some mild bleeding of her gums", "PROBLEM", 114, 144], ["new", "OBSERVATION_MODIFIER", 78, 81], ["bruises", "OBSERVATION", 88, 95], ["thighs", "ANATOMY", 103, 109], ["mild", "OBSERVATION_MODIFIER", 119, 123], ["bleeding", "OBSERVATION", 124, 132], ["gums", "ANATOMY", 140, 144]]], ["Her menstrual periods are reported to be normal.", [["normal", "OBSERVATION", 41, 47]]], ["She reports taking no medications.", [["medications", "TREATMENT", 22, 33]]], ["On physical exam, she appears well except for the reported bruises on her lower legs and arms.", [["lower legs", "ANATOMY", 74, 84], ["bruises", "DISEASE", 59, 66], ["lower", "ORGANISM_SUBDIVISION", 74, 79], ["legs", "ORGANISM_SUBDIVISION", 80, 84], ["physical exam", "TEST", 3, 16], ["bruises on her lower legs and arms", "PROBLEM", 59, 93], ["bruises", "OBSERVATION", 59, 66], ["lower", "ANATOMY_MODIFIER", 74, 79], ["legs", "ANATOMY", 80, 84], ["arms", "ANATOMY", 89, 93]]], ["Some petechial is noted in her gums.", [["petechial", "ANATOMY", 5, 14], ["petechial", "DISEASE", 5, 14], ["gums", "ORGANISM_SUBDIVISION", 31, 35], ["Some petechial", "PROBLEM", 0, 14], ["petechial", "OBSERVATION", 5, 14], ["gums", "ANATOMY", 31, 35]]], ["Laboratory studies revealed a hemoglobin of 13, a leukocyte count of 6,500/\u03bcL, and a platelet count of 14,000/\u03bcL.", [["leukocyte", "ANATOMY", 50, 59], ["platelet", "ANATOMY", 85, 93], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 30, 40], ["leukocyte", "CELL", 50, 59], ["platelet", "CELL", 85, 93], ["hemoglobin", "PROTEIN", 30, 40], ["Laboratory studies", "TEST", 0, 18], ["a hemoglobin", "TEST", 28, 40], ["a leukocyte count", "TEST", 48, 65], ["a platelet count", "TEST", 83, 99], ["platelet count", "OBSERVATION_MODIFIER", 85, 99]]], ["A peripheral blood smear is normal.", [["peripheral blood", "ANATOMY", 2, 18], ["peripheral blood", "ORGANISM_SUBSTANCE", 2, 18], ["A peripheral blood smear", "TEST", 0, 24], ["peripheral", "ANATOMY_MODIFIER", 2, 12], ["blood", "ANATOMY", 13, 18], ["smear", "OBSERVATION", 19, 24], ["normal", "OBSERVATION", 28, 34]]], ["Rapid HIV screening is normal.ReferenceWhich of the following is the most appropriate management?", [["HIV", "SPECIES", 6, 9], ["HIV", "SPECIES", 6, 9], ["Rapid HIV screening", "TEST", 0, 19], ["HIV", "OBSERVATION", 6, 9], ["normal", "OBSERVATION", 23, 29]]], ["A) Platelet transfusions B) Prednisone 1 mg/kg daily C) Plasmapheresis D) Rituximab E) Immunoglobulin Answer: B This patient has idiopathic thrombocytopenic purpura (ITP).ReferenceITP often occurs in an otherwise healthy person.", [["Platelet", "ANATOMY", 3, 11], ["Prednisone", "CHEMICAL", 28, 38], ["idiopathic thrombocytopenic purpura", "DISEASE", 129, 164], ["ITP", "DISEASE", 166, 169], ["Prednisone", "CHEMICAL", 28, 38], ["Platelet", "CELL", 3, 11], ["Prednisone", "SIMPLE_CHEMICAL", 28, 38], ["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["person", "SPECIES", 221, 227], ["A) Platelet transfusions B", "TREATMENT", 0, 26], ["Prednisone", "TREATMENT", 28, 38], ["Plasmapheresis D) Rituximab E)", "TREATMENT", 56, 86], ["idiopathic thrombocytopenic purpura", "PROBLEM", 129, 164], ["ITP", "PROBLEM", 166, 169], ["idiopathic", "OBSERVATION_MODIFIER", 129, 139], ["thrombocytopenic purpura", "OBSERVATION", 140, 164]]], ["On complete blood cell count, isolated thrombocytopenia is the hallmark of ITP.", [["blood cell", "ANATOMY", 12, 22], ["thrombocytopenia", "DISEASE", 39, 55], ["ITP", "DISEASE", 75, 78], ["blood cell", "CELL", 12, 22], ["complete blood cell count", "TEST", 3, 28], ["isolated thrombocytopenia", "PROBLEM", 30, 55], ["ITP", "PROBLEM", 75, 78], ["thrombocytopenia", "OBSERVATION", 39, 55], ["ITP", "OBSERVATION", 75, 78]]], ["Anemia or neutropenia may indicate other diseases.", [["Anemia", "DISEASE", 0, 6], ["neutropenia", "DISEASE", 10, 21], ["Anemia", "PROBLEM", 0, 6], ["neutropenia", "PROBLEM", 10, 21], ["other diseases", "PROBLEM", 35, 49], ["neutropenia", "OBSERVATION", 10, 21], ["diseases", "OBSERVATION", 41, 49]]], ["ITP has no cure, and relapses may occur years after successful initial medical or surgical management.", [["ITP", "DISEASE", 0, 3], ["ITP", "PROBLEM", 0, 3], ["surgical management", "TREATMENT", 82, 101], ["no", "UNCERTAINTY", 8, 10], ["cure", "OBSERVATION", 11, 15]]], ["The most frequent cause of death in association with ITP is spontaneous or accidental trauma-induced intracranial bleeding.", [["intracranial", "ANATOMY", 101, 113], ["death", "DISEASE", 27, 32], ["ITP", "DISEASE", 53, 56], ["trauma", "DISEASE", 86, 92], ["intracranial bleeding", "DISEASE", 101, 122], ["intracranial bleeding", "PATHOLOGICAL_FORMATION", 101, 122], ["death", "PROBLEM", 27, 32], ["ITP", "PROBLEM", 53, 56], ["accidental trauma", "PROBLEM", 75, 92], ["intracranial bleeding", "PROBLEM", 101, 122], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["death", "OBSERVATION", 27, 32], ["ITP", "OBSERVATION", 53, 56], ["intracranial", "ANATOMY", 101, 113], ["bleeding", "OBSERVATION", 114, 122]]], ["Most adult cases are diagnosed in women aged 30-40 years, although it may be seen in a wide age distribution in adults.", [["women", "ORGANISM", 34, 39], ["women", "SPECIES", 34, 39], ["may be seen", "UNCERTAINTY", 70, 81]]], ["Onset in a patient older than 60 years is uncommon, and a search for other causes of thrombocytopenia is warranted.", [["thrombocytopenia", "DISEASE", 85, 101], ["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["thrombocytopenia", "PROBLEM", 85, 101], ["thrombocytopenia", "OBSERVATION", 85, 101]]], ["The primary treatment for this is oral prednisone and it is usually responsive.", [["oral", "ANATOMY", 34, 38], ["prednisone", "CHEMICAL", 39, 49], ["prednisone", "CHEMICAL", 39, 49], ["oral", "ORGANISM_SUBDIVISION", 34, 38], ["prednisone", "SIMPLE_CHEMICAL", 39, 49], ["The primary treatment", "TREATMENT", 0, 21], ["oral prednisone", "TREATMENT", 34, 49]]], ["Platelet transfusion is reserved for incidences of life- 143.", [["Platelet", "ANATOMY", 0, 8], ["Platelet", "CELL", 0, 8], ["Platelet transfusion", "TREATMENT", 0, 20]]], ["A 56-year-old woman is admitted with worsening confusion.", [["confusion", "DISEASE", 47, 56], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["worsening confusion", "PROBLEM", 37, 56], ["worsening", "OBSERVATION_MODIFIER", 37, 46], ["confusion", "OBSERVATION", 47, 56]]], ["She has a history of hepatitis C virus infection.", [["hepatitis C virus infection", "DISEASE", 21, 48], ["hepatitis C virus", "ORGANISM", 21, 38], ["hepatitis C virus", "SPECIES", 21, 38], ["hepatitis C virus", "SPECIES", 21, 38], ["hepatitis C virus infection", "PROBLEM", 21, 48], ["hepatitis", "OBSERVATION", 21, 30], ["virus infection", "OBSERVATION", 33, 48]]], ["She currently takes phenytoin 100 mg TID for seizure disorder.", [["phenytoin", "CHEMICAL", 20, 29], ["TID", "CHEMICAL", 37, 40], ["seizure disorder", "DISEASE", 45, 61], ["phenytoin", "CHEMICAL", 20, 29], ["TID", "CHEMICAL", 37, 40], ["phenytoin", "SIMPLE_CHEMICAL", 20, 29], ["TID", "SIMPLE_CHEMICAL", 37, 40], ["phenytoin", "TREATMENT", 20, 29], ["seizure disorder", "PROBLEM", 45, 61]]], ["Lactulose 30 g TID and spironolactone 25 mg daily are taken for her liver disease.", [["liver", "ANATOMY", 68, 73], ["Lactulose", "CHEMICAL", 0, 9], ["TID", "CHEMICAL", 15, 18], ["spironolactone", "CHEMICAL", 23, 37], ["liver disease", "DISEASE", 68, 81], ["Lactulose", "CHEMICAL", 0, 9], ["TID", "CHEMICAL", 15, 18], ["spironolactone", "CHEMICAL", 23, 37], ["Lactulose", "SIMPLE_CHEMICAL", 0, 9], ["TID", "SIMPLE_CHEMICAL", 15, 18], ["spironolactone", "SIMPLE_CHEMICAL", 23, 37], ["liver", "ORGAN", 68, 73], ["Lactulose", "TREATMENT", 0, 9], ["spironolactone", "TREATMENT", 23, 37], ["her liver disease", "PROBLEM", 64, 81], ["liver", "ANATOMY", 68, 73], ["disease", "OBSERVATION", 74, 81]]], ["On physical examination, her blood pressure is 110/65 mmHg, heart rate is 87 beats/min, respiratory rate is 22 breaths/min, and oxygen saturation is 97 % on room air.", [["blood", "ANATOMY", 29, 34], ["heart", "ANATOMY", 60, 65], ["respiratory", "ANATOMY", 88, 99], ["oxygen", "CHEMICAL", 128, 134], ["oxygen", "CHEMICAL", 128, 134], ["blood", "ORGANISM_SUBSTANCE", 29, 34], ["heart", "ORGAN", 60, 65], ["oxygen", "SIMPLE_CHEMICAL", 128, 134], ["physical examination", "TEST", 3, 23], ["her blood pressure", "TEST", 25, 43], ["heart rate", "TEST", 60, 70], ["respiratory rate", "TEST", 88, 104], ["oxygen saturation", "TEST", 128, 145]]], ["She is afebrile.", [["afebrile", "PROBLEM", 7, 15], ["afebrile", "OBSERVATION", 7, 15]]], ["She is minimally responsive to voice and follows no commands.", [["minimally responsive", "PROBLEM", 7, 27], ["minimally", "OBSERVATION_MODIFIER", 7, 16], ["responsive", "OBSERVATION", 17, 27]]], ["Her abdomen is distended with a positive fl uid wave but without tenderness.", [["abdomen", "ANATOMY", 4, 11], ["tenderness", "DISEASE", 65, 75], ["abdomen", "ORGAN", 4, 11], ["distended", "PROBLEM", 15, 24], ["tenderness", "PROBLEM", 65, 75], ["abdomen", "ANATOMY", 4, 11], ["distended", "OBSERVATION", 15, 24], ["positive", "OBSERVATION_MODIFIER", 32, 40], ["fl", "OBSERVATION", 41, 43], ["without", "UNCERTAINTY", 57, 64], ["tenderness", "OBSERVATION", 65, 75]]], ["She does not appear to have asterixis.", [["asterixis", "DISEASE", 28, 37], ["She", "ORGANISM", 0, 3], ["asterixis", "PROBLEM", 28, 37], ["asterixis", "OBSERVATION", 28, 37]]], ["She has a horizontal nystagmus on examination.", [["nystagmus", "DISEASE", 21, 30], ["a horizontal nystagmus", "PROBLEM", 8, 30], ["examination", "TEST", 34, 45], ["horizontal", "OBSERVATION_MODIFIER", 10, 20], ["nystagmus", "OBSERVATION", 21, 30]]], ["The white blood cell count is 12,000/\u03bcL with a normal differential.", [["white blood cell", "ANATOMY", 4, 20], ["white blood cell", "CELL", 4, 20], ["The white blood cell count", "TEST", 0, 26], ["normal differential", "OBSERVATION_MODIFIER", 47, 66]]], ["Her liver function tests are unchanged from baseline with the exception of an albumin that is now 2.1 g/dL compared with three months ago when her level was 2.9 g/dL.", [["liver", "ANATOMY", 4, 9], ["liver", "ORGAN", 4, 9], ["albumin", "GENE_OR_GENE_PRODUCT", 78, 85], ["Her liver function tests", "TEST", 0, 24], ["an albumin", "TEST", 75, 85], ["her level", "TEST", 143, 152], ["liver", "ANATOMY", 4, 9], ["unchanged", "OBSERVATION_MODIFIER", 29, 38], ["albumin", "OBSERVATION", 78, 85]]], ["The ammonia level is 15 \u03bcmol/L, and her phenytoin level is 17 mg/L. A paracentesis shows a white blood cell count of 90/\u03bcL.", [["white blood cell", "ANATOMY", 91, 107], ["ammonia", "CHEMICAL", 4, 11], ["phenytoin", "CHEMICAL", 40, 49], ["ammonia", "CHEMICAL", 4, 11], ["phenytoin", "CHEMICAL", 40, 49], ["ammonia", "SIMPLE_CHEMICAL", 4, 11], ["phenytoin", "SIMPLE_CHEMICAL", 40, 49], ["blood cell", "CELL", 97, 107], ["The ammonia level", "TEST", 0, 17], ["her phenytoin level", "TEST", 36, 55], ["A paracentesis", "TREATMENT", 68, 82], ["a white blood cell count", "TEST", 89, 113], ["paracentesis", "OBSERVATION", 70, 82]]], ["What test would be most likely to demonstrate the cause of the patient's change in mental status?", [["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["the patient's change in mental status", "PROBLEM", 59, 96]]], ["A) CT scan of the head B) Free phenytoin level C) Electroencephalogram (EEG)) D) Gram stain of ascites fl uid E) Gram stain of cerebrospinal fl uid (CSF) Answer: B This patient has phenytoin toxicity due to her chronic liver disease.", [["head", "ANATOMY", 18, 22], ["ascites", "ANATOMY", 95, 102], ["liver", "ANATOMY", 219, 224], ["phenytoin", "CHEMICAL", 31, 40], ["ascites", "DISEASE", 95, 102], ["phenytoin", "CHEMICAL", 181, 190], ["toxicity", "DISEASE", 191, 199], ["chronic liver disease", "DISEASE", 211, 232], ["phenytoin", "CHEMICAL", 31, 40], ["phenytoin", "CHEMICAL", 181, 190], ["phenytoin", "SIMPLE_CHEMICAL", 31, 40], ["patient", "ORGANISM", 169, 176], ["phenytoin", "SIMPLE_CHEMICAL", 181, 190], ["liver", "ORGAN", 219, 224], ["CSF", "PROTEIN", 149, 152], ["patient", "SPECIES", 169, 176], ["A) CT scan of the head", "TEST", 0, 22], ["Free phenytoin level C", "TEST", 26, 48], ["Electroencephalogram (EEG)", "TEST", 50, 76], ["Gram stain", "TEST", 81, 91], ["ascites", "PROBLEM", 95, 102], ["Gram stain", "TEST", 113, 123], ["cerebrospinal fl uid", "TEST", 127, 147], ["phenytoin toxicity", "PROBLEM", 181, 199], ["her chronic liver disease", "PROBLEM", 207, 232], ["head", "ANATOMY", 18, 22], ["ascites", "OBSERVATION", 95, 102], ["cerebrospinal fl", "ANATOMY", 127, 143], ["phenytoin toxicity", "OBSERVATION", 181, 199], ["chronic", "OBSERVATION_MODIFIER", 211, 218], ["liver", "ANATOMY", 219, 224], ["disease", "OBSERVATION", 225, 232]]], ["Signs and symptoms of phenytoin toxicity include slurred speech, horizontal nystagmus, and altered mental status that can progress to obtundation and coma.", [["phenytoin", "CHEMICAL", 22, 31], ["toxicity", "DISEASE", 32, 40], ["nystagmus", "DISEASE", 76, 85], ["obtundation", "DISEASE", 134, 145], ["coma", "DISEASE", 150, 154], ["phenytoin", "CHEMICAL", 22, 31], ["phenytoin", "SIMPLE_CHEMICAL", 22, 31], ["Signs and symptoms", "PROBLEM", 0, 18], ["phenytoin toxicity", "PROBLEM", 22, 40], ["slurred speech", "PROBLEM", 49, 63], ["horizontal nystagmus", "PROBLEM", 65, 85], ["altered mental status", "PROBLEM", 91, 112], ["obtundation", "PROBLEM", 134, 145], ["coma", "PROBLEM", 150, 154]]], ["Worsening hypoalbuminemia can lead to increased free levels of drugs that are more highly protein bound.", [["hypoalbuminemia", "DISEASE", 10, 25], ["Worsening hypoalbuminemia", "PROBLEM", 0, 25], ["increased free levels of drugs", "PROBLEM", 38, 68], ["hypoalbuminemia", "OBSERVATION", 10, 25], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["free levels", "OBSERVATION", 48, 59], ["more highly protein bound", "OBSERVATION_MODIFIER", 78, 103]]], ["This can lead to drug toxicity at total drug levels that are not typically considered toxic.", [["toxicity", "DISEASE", 22, 30], ["drug toxicity", "PROBLEM", 17, 30], ["total drug levels", "TEST", 34, 51], ["not typically considered", "UNCERTAINTY", 61, 85], ["toxic", "OBSERVATION_MODIFIER", 86, 91]]], ["Medications that are bound to plasma proteins include phenytoin, warfarin, valproic acid, and amiodarone.", [["plasma", "ANATOMY", 30, 36], ["phenytoin", "CHEMICAL", 54, 63], ["warfarin", "CHEMICAL", 65, 73], ["valproic acid", "CHEMICAL", 75, 88], ["amiodarone", "CHEMICAL", 94, 104], ["phenytoin", "CHEMICAL", 54, 63], ["warfarin", "CHEMICAL", 65, 73], ["valproic acid", "CHEMICAL", 75, 88], ["amiodarone", "CHEMICAL", 94, 104], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["phenytoin", "SIMPLE_CHEMICAL", 54, 63], ["warfarin", "SIMPLE_CHEMICAL", 65, 73], ["valproic acid", "SIMPLE_CHEMICAL", 75, 88], ["amiodarone", "SIMPLE_CHEMICAL", 94, 104], ["plasma proteins", "PROTEIN", 30, 45], ["Medications", "TREATMENT", 0, 11], ["plasma proteins", "TREATMENT", 30, 45], ["phenytoin", "TREATMENT", 54, 63], ["warfarin", "TREATMENT", 65, 73], ["valproic acid", "TREATMENT", 75, 88], ["amiodarone", "TREATMENT", 94, 104]]], ["Although phenytoin is not contraindicated in those with mild liver disease, it should be discontinued in individuals with evidence of cirrhosis.", [["liver", "ANATOMY", 61, 66], ["phenytoin", "CHEMICAL", 9, 18], ["liver disease", "DISEASE", 61, 74], ["cirrhosis", "DISEASE", 134, 143], ["phenytoin", "CHEMICAL", 9, 18], ["phenytoin", "SIMPLE_CHEMICAL", 9, 18], ["liver", "ORGAN", 61, 66], ["phenytoin", "TREATMENT", 9, 18], ["mild liver disease", "PROBLEM", 56, 74], ["cirrhosis", "PROBLEM", 134, 143], ["mild", "OBSERVATION_MODIFIER", 56, 60], ["liver", "ANATOMY", 61, 66], ["disease", "OBSERVATION", 67, 74], ["cirrhosis", "OBSERVATION", 134, 143]]], ["A 55-year-old female not on any medication presents with a 3-month history of worsening rash, fever to 38.2 \u00b0C (100.8 \u00b0F), weight loss, and worsening loss of sensation in her feet.", [["feet", "ANATOMY", 175, 179], ["rash", "DISEASE", 88, 92], ["fever", "DISEASE", 94, 99], ["weight loss", "DISEASE", 123, 134], ["loss of sensation", "DISEASE", 150, 167], ["female", "ORGANISM", 14, 20], ["feet", "ORGANISM_SUBDIVISION", 175, 179], ["any medication", "TREATMENT", 28, 42], ["worsening rash", "PROBLEM", 78, 92], ["fever", "PROBLEM", 94, 99], ["\u00b0C", "PROBLEM", 108, 110], ["weight loss", "PROBLEM", 123, 134], ["worsening loss of sensation in her feet", "PROBLEM", 140, 179], ["worsening", "OBSERVATION_MODIFIER", 78, 87], ["rash", "OBSERVATION", 88, 92], ["worsening", "OBSERVATION_MODIFIER", 140, 149], ["loss", "OBSERVATION_MODIFIER", 150, 154], ["feet", "ANATOMY", 175, 179]]], ["On physical examination, you note tender palpable purpura of the bilateral lower leg.", [["lower leg", "ANATOMY", 75, 84], ["purpura", "DISEASE", 50, 57], ["lower leg", "ORGANISM_SUBDIVISION", 75, 84], ["physical examination", "TEST", 3, 23], ["tender palpable purpura of the bilateral lower leg", "PROBLEM", 34, 84], ["purpura", "OBSERVATION", 50, 57], ["bilateral", "ANATOMY_MODIFIER", 65, 74], ["lower", "ANATOMY_MODIFIER", 75, 80], ["leg", "ANATOMY", 81, 84]]], ["In addition, tract marks on the arms are present.", [["tract", "ANATOMY", 13, 18], ["tract marks on the arms", "PROBLEM", 13, 36], ["tract marks", "OBSERVATION", 13, 24], ["arms", "ANATOMY", 32, 36]]], ["Her laboratories indicate a Hg of 9.5 g/L and a creatinine of 2.5 mg/ dL.", [["Hg", "CHEMICAL", 28, 30], ["creatinine", "CHEMICAL", 48, 58], ["Hg", "CHEMICAL", 28, 30], ["creatinine", "CHEMICAL", 48, 58], ["creatinine", "SIMPLE_CHEMICAL", 48, 58], ["Her laboratories", "TEST", 0, 16], ["a Hg", "TEST", 26, 30], ["a creatinine", "TEST", 46, 58]]], ["Gross proteinuria is noted on urinalysis.", [["proteinuria", "DISEASE", 6, 17], ["Gross proteinuria", "PROBLEM", 0, 17], ["urinalysis", "TEST", 30, 40], ["proteinuria", "OBSERVATION", 6, 17]]], ["Baseline creatinine is 1.2 mg/dL from 6 months ago.ReferenceWhich lab abnormality would you expect?", [["creatinine", "CHEMICAL", 9, 19], ["creatinine", "CHEMICAL", 9, 19], ["creatinine", "SIMPLE_CHEMICAL", 9, 19], ["Baseline creatinine", "TEST", 0, 19], ["lab abnormality", "PROBLEM", 66, 81]]], ["A) Positive hepatitis B surface antigen B) Positive anti-SSA and SSB C) Positive antihistone antibody D) Elevated TSH and low ferritin E) Positive P-ANCA Answer: A The patient's clinical scenario is consistent with a systemic vasculitis.", [["vasculitis", "DISEASE", 226, 236], ["hepatitis B surface antigen B", "GENE_OR_GENE_PRODUCT", 12, 41], ["SSB C", "GENE_OR_GENE_PRODUCT", 65, 70], ["TSH", "GENE_OR_GENE_PRODUCT", 114, 117], ["ferritin E", "GENE_OR_GENE_PRODUCT", 126, 136], ["patient", "ORGANISM", 168, 175], ["Positive hepatitis B surface antigen B", "PROTEIN", 3, 41], ["SSA", "PROTEIN", 57, 60], ["SSB C", "PROTEIN", 65, 70], ["Positive antihistone antibody D", "PROTEIN", 72, 103], ["ferritin E", "PROTEIN", 126, 136], ["patient", "SPECIES", 168, 175], ["hepatitis B surface antigen", "TEST", 12, 39], ["B", "TEST", 40, 41], ["anti-SSA", "TEST", 52, 60], ["SSB C", "TEST", 65, 70], ["Positive antihistone antibody D", "PROBLEM", 72, 103], ["Elevated TSH", "PROBLEM", 105, 117], ["low ferritin E", "PROBLEM", 122, 136], ["a systemic vasculitis", "PROBLEM", 215, 236], ["consistent with", "UNCERTAINTY", 199, 214], ["systemic", "OBSERVATION_MODIFIER", 217, 225], ["vasculitis", "OBSERVATION", 226, 236]]], ["Symptoms are consistent with nephrotic syndrome and polyarteritis nodosa (PAN); both of which occur in hepatitis B-induced vasculitis.", [["nephrotic syndrome", "DISEASE", 29, 47], ["polyarteritis nodosa", "DISEASE", 52, 72], ["PAN", "DISEASE", 74, 77], ["hepatitis B", "DISEASE", 103, 114], ["vasculitis", "DISEASE", 123, 133], ["hepatitis B", "ORGANISM", 103, 114], ["Symptoms", "PROBLEM", 0, 8], ["nephrotic syndrome", "PROBLEM", 29, 47], ["polyarteritis nodosa", "PROBLEM", 52, 72], ["hepatitis B", "PROBLEM", 103, 114], ["vasculitis", "PROBLEM", 123, 133], ["consistent with", "UNCERTAINTY", 13, 28], ["nephrotic syndrome", "OBSERVATION", 29, 47], ["polyarteritis", "OBSERVATION_MODIFIER", 52, 65], ["nodosa", "OBSERVATION", 66, 72], ["hepatitis", "OBSERVATION", 103, 112], ["vasculitis", "OBSERVATION", 123, 133]]], ["HBV-associated vasculitis almost always takes the form of PAN.", [["vasculitis", "DISEASE", 15, 25], ["PAN", "CHEMICAL", 58, 61], ["HBV", "ORGANISM", 0, 3], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["associated vasculitis", "PROBLEM", 4, 25], ["vasculitis", "OBSERVATION", 15, 25]]], ["Dermatologic symptoms are very common in PAN.", [["PAN", "CHEMICAL", 41, 44], ["Dermatologic symptoms", "PROBLEM", 0, 21]]], ["Skin involvement, which can be painful, occurs most frequently on the legs.", [["Skin", "ANATOMY", 0, 4], ["legs", "ANATOMY", 70, 74], ["Skin", "ORGAN", 0, 4], ["legs", "ORGANISM_SUBDIVISION", 70, 74], ["Skin involvement", "PROBLEM", 0, 16], ["painful", "PROBLEM", 31, 38], ["involvement", "OBSERVATION", 5, 16], ["legs", "ANATOMY", 70, 74]]], ["While lupus may be a possibility, antihistone antibody is most commonly associated with drug-induced lupus and this patient is no medications.", [["lupus", "DISEASE", 6, 11], ["lupus", "DISEASE", 101, 106], ["lupus", "CANCER", 6, 11], ["antihistone antibody", "GENE_OR_GENE_PRODUCT", 34, 54], ["patient", "ORGANISM", 116, 123], ["antihistone antibody", "PROTEIN", 34, 54], ["patient", "SPECIES", 116, 123], ["lupus", "PROBLEM", 6, 11], ["antihistone antibody", "PROBLEM", 34, 54], ["drug-induced lupus", "PROBLEM", 88, 106], ["medications", "TREATMENT", 130, 141], ["lupus", "OBSERVATION", 6, 11], ["may be a possibility", "UNCERTAINTY", 12, 32], ["lupus", "OBSERVATION", 101, 106]]], ["In addition, drug-induced lupus is less likely to cause renal disease.", [["renal", "ANATOMY", 56, 61], ["lupus", "DISEASE", 26, 31], ["renal disease", "DISEASE", 56, 69], ["renal", "ORGAN", 56, 61], ["drug-induced lupus", "PROBLEM", 13, 31], ["renal disease", "PROBLEM", 56, 69], ["lupus", "OBSERVATION", 26, 31], ["less likely", "UNCERTAINTY", 35, 46], ["renal", "ANATOMY", 56, 61], ["disease", "OBSERVATION", 62, 69]]], ["The presence of injection marks or history of intravenous drugs makes the acquisition of hepatitis B more likely.", [["intravenous", "ANATOMY", 46, 57], ["hepatitis B", "DISEASE", 89, 100], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 57], ["hepatitis B", "ORGANISM", 89, 100], ["injection marks", "TREATMENT", 16, 31], ["intravenous drugs", "TREATMENT", 46, 63], ["hepatitis B", "PROBLEM", 89, 100]]], ["He undergoes an ultrasound in the emergency room which reveals an incidental fi nding of three gallstones measuring 1 \u00d7 1 cm were seen.", [["gallstones", "ANATOMY", 95, 105], ["gallstones", "DISEASE", 95, 105], ["gallstones", "PATHOLOGICAL_FORMATION", 95, 105], ["an ultrasound", "TEST", 13, 26], ["three gallstones", "PROBLEM", 89, 105], ["incidental", "OBSERVATION", 66, 76], ["three", "OBSERVATION_MODIFIER", 89, 94], ["gallstones", "OBSERVATION", 95, 105], ["1 \u00d7 1 cm", "OBSERVATION_MODIFIER", 116, 124]]], ["The gallbladder and biliary tract is otherwise normal.", [["gallbladder", "ANATOMY", 4, 15], ["biliary tract", "ANATOMY", 20, 33], ["gallbladder and biliary tract", "DISEASE", 4, 33], ["gallbladder", "ORGAN", 4, 15], ["biliary tract", "ORGAN", 20, 33], ["gallbladder", "ANATOMY", 4, 15], ["biliary tract", "ANATOMY", 20, 33], ["otherwise", "OBSERVATION_MODIFIER", 37, 46], ["normal", "OBSERVATION", 47, 53]]], ["In the hospital, he has a good response to antibiotics and is ready for discharge.", [["antibiotics", "TREATMENT", 43, 54], ["good response", "OBSERVATION", 26, 39]]], ["This was his fi rst episode of diverticulitis.", [["diverticulitis", "DISEASE", 31, 45], ["diverticulitis", "PATHOLOGICAL_FORMATION", 31, 45], ["diverticulitis", "PROBLEM", 31, 45], ["diverticulitis", "OBSERVATION", 31, 45]]], ["He reports no other episodes of abdominal pain to suggest biliary disease.ReferenceWhat is the correct advice concerning management of his gallstones?", [["abdominal", "ANATOMY", 32, 41], ["biliary", "ANATOMY", 58, 65], ["abdominal pain", "DISEASE", 32, 46], ["biliary disease", "DISEASE", 58, 73], ["gallstones", "DISEASE", 139, 149], ["abdominal", "ORGANISM_SUBDIVISION", 32, 41], ["biliary", "ORGAN", 58, 65], ["abdominal pain", "PROBLEM", 32, 46], ["biliary disease", "PROBLEM", 58, 73], ["his gallstones", "PROBLEM", 135, 149], ["no", "UNCERTAINTY", 11, 13], ["abdominal", "ANATOMY", 32, 41], ["pain", "OBSERVATION", 42, 46], ["biliary", "ANATOMY", 58, 65], ["disease", "OBSERVATION", 66, 73], ["gallstones", "OBSERVATION", 139, 149]]], ["A) Recommend not having surgery and continue to monitor clinically B) Recommend in patient cholecystectomy C) Recommend surgery in four weeks D) HIDA scan Answer: A Prophylactic cholecystectomy is not indicated for this patient.", [["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 220, 227], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 220, 227], ["surgery", "TREATMENT", 24, 31], ["cholecystectomy", "TREATMENT", 91, 106], ["surgery", "TREATMENT", 120, 127], ["HIDA scan", "TEST", 145, 154], ["A Prophylactic cholecystectomy", "TREATMENT", 163, 193], ["cholecystectomy", "OBSERVATION", 91, 106], ["cholecystectomy", "OBSERVATION", 178, 193]]], ["Observation is the appropriate management.", [["the appropriate management", "TREATMENT", 15, 41]]], ["The consensus is that with a few exceptions asymptomatic gallstones should be followed.", [["gallstones", "DISEASE", 57, 67], ["gallstones", "PATHOLOGICAL_FORMATION", 57, 67], ["a few exceptions asymptomatic gallstones", "PROBLEM", 27, 67], ["gallstones", "OBSERVATION", 57, 67]]], ["Most patients with asymptomatic gallstones will never develop symptoms.", [["gallstones", "DISEASE", 32, 42], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["asymptomatic gallstones", "PROBLEM", 19, 42], ["symptoms", "PROBLEM", 62, 70], ["gallstones", "OBSERVATION", 32, 42]]], ["There are instances where prophylactic cholecystectomy should be considered.", [["prophylactic cholecystectomy", "TREATMENT", 26, 54], ["prophylactic", "OBSERVATION_MODIFIER", 26, 38], ["cholecystectomy", "OBSERVATION", 39, 54]]], ["These are when a patient is immunocompromised, awaiting organ transplantation, sickle cell disease, calculi greater than 3 cm in diameter, or when gallbladder cancer is likely.", [["organ", "ANATOMY", 56, 61], ["sickle cell", "ANATOMY", 79, 90], ["calculi", "ANATOMY", 100, 107], ["gallbladder cancer", "ANATOMY", 147, 165], ["sickle cell disease", "DISEASE", 79, 98], ["calculi", "DISEASE", 100, 107], ["gallbladder cancer", "DISEASE", 147, 165], ["patient", "ORGANISM", 17, 24], ["organ", "ORGAN", 56, 61], ["sickle cell", "CELL", 79, 90], ["calculi", "PATHOLOGICAL_FORMATION", 100, 107], ["gallbladder cancer", "CANCER", 147, 165], ["patient", "SPECIES", 17, 24], ["immunocompromised", "PROBLEM", 28, 45], ["organ transplantation", "TREATMENT", 56, 77], ["sickle cell disease", "PROBLEM", 79, 98], ["calculi", "PROBLEM", 100, 107], ["gallbladder cancer", "PROBLEM", 147, 165], ["immunocompromised", "OBSERVATION", 28, 45], ["sickle cell disease", "OBSERVATION", 79, 98], ["calculi", "OBSERVATION", 100, 107], ["than 3 cm", "OBSERVATION_MODIFIER", 116, 125], ["gallbladder", "ANATOMY", 147, 158], ["cancer", "OBSERVATION", 159, 165], ["is likely", "UNCERTAINTY", 166, 175]]], ["Cholecystectomy can be considered when other biliary tract abnormalities are present.", [["biliary tract", "ANATOMY", 45, 58], ["biliary tract abnormalities", "DISEASE", 45, 72], ["biliary tract", "ORGANISM_SUBDIVISION", 45, 58], ["Cholecystectomy", "TREATMENT", 0, 15], ["other biliary tract abnormalities", "PROBLEM", 39, 72], ["biliary tract", "ANATOMY", 45, 58], ["abnormalities", "OBSERVATION", 59, 72]]], ["In the past patients with diabetes mellitus were thought to be at higher risk, and prophylactic cholecystectomy was often recommended.", [["diabetes mellitus", "DISEASE", 26, 43], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["diabetes mellitus", "PROBLEM", 26, 43], ["prophylactic cholecystectomy", "TREATMENT", 83, 111], ["cholecystectomy", "OBSERVATION", 96, 111]]], ["Studies have shown that prophylactic cholecystectomy is of no clear benefi t and should not be routinely recommended for diabetics.", [["Studies", "TEST", 0, 7], ["prophylactic cholecystectomy", "TREATMENT", 24, 52], ["diabetics", "PROBLEM", 121, 130], ["prophylactic", "OBSERVATION_MODIFIER", 24, 36], ["cholecystectomy", "OBSERVATION", 37, 52]]], ["Patients with no other risk factors but who are going to be living or traveling for a long period of time in a location that is far from basic medical care such as missionary work, scientifi c expeditions, or space travel may be advised to have cholecystectomy prophylactically.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["cholecystectomy", "TREATMENT", 245, 260], ["cholecystectomy", "OBSERVATION", 245, 260]]], ["On physical examination, he appears ill and has obvious jaundice with scleral icterus.", [["scleral", "ANATOMY", 70, 77], ["jaundice", "DISEASE", 56, 64], ["scleral icterus", "DISEASE", 70, 85], ["physical examination", "TEST", 3, 23], ["ill", "PROBLEM", 36, 39], ["obvious jaundice", "PROBLEM", 48, 64], ["scleral icterus", "PROBLEM", 70, 85], ["ill", "OBSERVATION", 36, 39], ["obvious", "OBSERVATION_MODIFIER", 48, 55], ["jaundice", "OBSERVATION", 56, 64], ["scleral", "ANATOMY", 70, 77], ["icterus", "OBSERVATION", 78, 85]]], ["His liver is 14 cm upon percussion and is palpable 6 cm below the right costal margin.", [["liver", "ANATOMY", 4, 9], ["right costal margin", "ANATOMY", 66, 85], ["liver", "ORGAN", 4, 9], ["costal margin", "MULTI-TISSUE_STRUCTURE", 72, 85], ["percussion", "TEST", 24, 34], ["liver", "ANATOMY", 4, 9], ["14 cm", "OBSERVATION_MODIFIER", 13, 18], ["percussion", "OBSERVATION", 24, 34], ["palpable", "OBSERVATION", 42, 50], ["6 cm", "OBSERVATION_MODIFIER", 51, 55], ["right", "ANATOMY_MODIFIER", 66, 71], ["costal", "ANATOMY", 72, 78], ["margin", "ANATOMY_MODIFIER", 79, 85]]], ["The edge is smooth and tender upon pal-pation.", [["tender", "PROBLEM", 23, 29], ["edge", "OBSERVATION_MODIFIER", 4, 8], ["smooth", "OBSERVATION", 12, 18], ["tender", "OBSERVATION", 23, 29]]], ["The spleen is not enlarged.", [["spleen", "ANATOMY", 4, 10], ["spleen", "ORGAN", 4, 10], ["enlarged", "PROBLEM", 18, 26], ["spleen", "ANATOMY", 4, 10], ["not", "UNCERTAINTY", 14, 17], ["enlarged", "OBSERVATION", 18, 26]]], ["There are no stigmata of chronic liver disease.", [["liver", "ANATOMY", 33, 38], ["chronic liver disease", "DISEASE", 25, 46], ["liver", "ORGAN", 33, 38], ["chronic liver disease", "PROBLEM", 25, 46], ["no stigmata of", "UNCERTAINTY", 10, 24], ["chronic", "OBSERVATION_MODIFIER", 25, 32], ["liver", "ANATOMY", 33, 38], ["disease", "OBSERVATION", 39, 46]]], ["His AST is 1475 U/L, ALT is 1678 U/L, alkaline phosphatase is 547 U/L, total bilirubin is 13.8 mg/dL, and direct bilirubin is 13.2 mg/dL.", [["bilirubin", "CHEMICAL", 77, 86], ["bilirubin", "CHEMICAL", 113, 122], ["bilirubin", "CHEMICAL", 77, 86], ["bilirubin", "CHEMICAL", 113, 122], ["ALT", "GENE_OR_GENE_PRODUCT", 21, 24], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 38, 58], ["bilirubin", "GENE_OR_GENE_PRODUCT", 77, 86], ["bilirubin", "GENE_OR_GENE_PRODUCT", 113, 122], ["AST", "PROTEIN", 4, 7], ["ALT", "PROTEIN", 21, 24], ["alkaline phosphatase", "PROTEIN", 38, 58], ["His AST", "TEST", 0, 7], ["U", "TEST", 16, 17], ["ALT", "TEST", 21, 24], ["U", "TEST", 33, 34], ["alkaline phosphatase", "TEST", 38, 58], ["U/L", "TEST", 66, 69], ["total bilirubin", "TEST", 71, 86], ["direct bilirubin", "TEST", 106, 122]]], ["His INR is 2.4, and aPTT is 49 s.", [["INR", "PROTEIN", 4, 7], ["aPTT", "PROTEIN", 20, 24], ["His INR", "TEST", 0, 7], ["aPTT", "TEST", 20, 24]]], ["Serologic tests for hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) immunoglobulin M (IgM) are positive.ReferenceWhich of the following is the correct treatment?", [["hepatitis B surface antigen", "CHEMICAL", 20, 47], ["HBsAg", "CHEMICAL", 49, 54], ["hepatitis B", "DISEASE", 60, 71], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 20, 47], ["HBsAg", "GENE_OR_GENE_PRODUCT", 49, 54], ["hepatitis B core antibody", "GENE_OR_GENE_PRODUCT", 60, 85], ["anti-HBc) immunoglobulin M", "GENE_OR_GENE_PRODUCT", 87, 113], ["IgM", "GENE_OR_GENE_PRODUCT", 115, 118], ["hepatitis B surface antigen", "PROTEIN", 20, 47], ["HBsAg", "PROTEIN", 49, 54], ["hepatitis B core antibody", "PROTEIN", 60, 85], ["HBc", "PROTEIN", 92, 95], ["immunoglobulin M", "PROTEIN", 97, 113], ["IgM", "PROTEIN", 115, 118], ["hepatitis B", "SPECIES", 20, 31], ["Serologic tests", "TEST", 0, 15], ["hepatitis B surface antigen", "TEST", 20, 47], ["HBsAg", "TEST", 49, 54], ["hepatitis B core antibody", "TEST", 60, 85], ["anti-HBc", "TEST", 87, 95], ["immunoglobulin M", "TEST", 97, 113], ["IgM", "TEST", 115, 118], ["the correct treatment", "TREATMENT", 168, 189]]], ["A) Administration of anti-hepatitis A virus IgG.", [["anti-hepatitis A virus", "ORGANISM", 21, 43], ["IgG", "ORGANISM", 44, 47], ["anti-hepatitis A virus IgG", "PROTEIN", 21, 47], ["anti-hepatitis A virus", "SPECIES", 21, 43], ["anti-hepatitis A virus", "SPECIES", 21, 43], ["anti-hepatitis A virus IgG", "TREATMENT", 21, 47]]], ["B) Administration of lamivudine.", [["lamivudine", "CHEMICAL", 21, 31], ["lamivudine", "CHEMICAL", 21, 31], ["lamivudine", "SIMPLE_CHEMICAL", 21, 31], ["lamivudine", "TREATMENT", 21, 31]]], ["C) Administration of pegylated interferon \u03b1 plus ribavirin.", [["pegylated interferon \u03b1", "CHEMICAL", 21, 43], ["ribavirin", "CHEMICAL", 49, 58], ["ribavirin", "CHEMICAL", 49, 58], ["pegylated interferon \u03b1", "SIMPLE_CHEMICAL", 21, 43], ["ribavirin", "SIMPLE_CHEMICAL", 49, 58], ["pegylated interferon \u03b1", "PROTEIN", 21, 43], ["pegylated interferon", "TREATMENT", 21, 41], ["ribavirin", "TREATMENT", 49, 58]]], ["D) Administration of prednisone E) Do nothing and observe 147.", [["prednisone", "CHEMICAL", 21, 31], ["prednisone E", "CHEMICAL", 21, 33], ["prednisone", "SIMPLE_CHEMICAL", 21, 31], ["prednisone E", "TREATMENT", 21, 33]]], ["A 63-year-old woman with primary biliary cirrhosis which is being considered for liver transplantation is admitted for worsening ascites and shortness of breath.", [["primary biliary cirrhosis", "ANATOMY", 25, 50], ["liver", "ANATOMY", 81, 86], ["ascites", "ANATOMY", 129, 136], ["primary biliary cirrhosis", "DISEASE", 25, 50], ["ascites", "DISEASE", 129, 136], ["shortness of breath", "DISEASE", 141, 160], ["woman", "ORGANISM", 14, 19], ["biliary cirrhosis", "CANCER", 33, 50], ["liver", "ORGAN", 81, 86], ["woman", "SPECIES", 14, 19], ["primary biliary cirrhosis", "PROBLEM", 25, 50], ["liver transplantation", "TREATMENT", 81, 102], ["worsening ascites", "PROBLEM", 119, 136], ["shortness of breath", "PROBLEM", 141, 160], ["biliary", "ANATOMY", 33, 40], ["cirrhosis", "OBSERVATION", 41, 50], ["liver", "ANATOMY", 81, 86], ["transplantation", "OBSERVATION", 87, 102], ["worsening", "OBSERVATION_MODIFIER", 119, 128], ["ascites", "OBSERVATION", 129, 136]]], ["She has been followed closely by the hepatology service.ReferenceIn the past six weeks, she has had three paracenteses performed.", [["three paracenteses", "TREATMENT", 100, 118]]], ["Today, the shortness of breath has returned, but she has no fever, cough, or chills.", [["shortness of breath", "DISEASE", 11, 30], ["fever", "DISEASE", 60, 65], ["cough", "DISEASE", 67, 72], ["chills", "DISEASE", 77, 83], ["the shortness of breath", "PROBLEM", 7, 30], ["fever", "PROBLEM", 60, 65], ["cough", "PROBLEM", 67, 72], ["chills", "PROBLEM", 77, 83], ["no", "UNCERTAINTY", 57, 59], ["fever", "OBSERVATION", 60, 65], ["cough", "OBSERVATION", 67, 72]]], ["She reports meticulous attention to her sodium-restricted diet.ReferenceOn physical examination, she is afebrile.", [["sodium", "CHEMICAL", 40, 46], ["sodium", "CHEMICAL", 40, 46], ["sodium", "SIMPLE_CHEMICAL", 40, 46], ["her sodium-restricted diet", "TREATMENT", 36, 62], ["ReferenceOn physical examination", "TEST", 63, 95], ["afebrile", "PROBLEM", 104, 112]]], ["Pulse rate is 90 per minute, respirations are 24 per minute, and blood pressure is 108/57 mmHg.", [["blood", "ANATOMY", 65, 70], ["blood", "ORGANISM_SUBSTANCE", 65, 70], ["Pulse rate", "TEST", 0, 10], ["respirations", "TEST", 29, 41], ["blood pressure", "TEST", 65, 79]]], ["Breath sounds are absent in the lower half of the right lung fi eld; other pulmonary fi ndings are normal.", [["right lung", "ANATOMY", 50, 60], ["pulmonary", "ANATOMY", 75, 84], ["lung", "ORGAN", 56, 60], ["pulmonary", "ORGAN", 75, 84], ["Breath sounds", "TEST", 0, 13], ["other pulmonary fi ndings", "TEST", 69, 94], ["sounds", "OBSERVATION", 7, 13], ["absent", "OBSERVATION", 18, 24], ["lower", "ANATOMY_MODIFIER", 32, 37], ["half", "ANATOMY_MODIFIER", 38, 42], ["right", "ANATOMY_MODIFIER", 50, 55], ["lung", "ANATOMY", 56, 60], ["fi", "ANATOMY_MODIFIER", 61, 63], ["eld", "OBSERVATION", 64, 67], ["pulmonary", "ANATOMY", 75, 84], ["fi", "ANATOMY_MODIFIER", 85, 87], ["ndings", "OBSERVATION", 88, 94], ["normal", "OBSERVATION", 99, 105]]], ["The abdomen is distended, with a prominent, fl uid wave.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["distended", "PROBLEM", 15, 24], ["a prominent, fl uid wave", "PROBLEM", 31, 55], ["abdomen", "ANATOMY", 4, 11], ["distended", "OBSERVATION", 15, 24], ["prominent", "OBSERVATION_MODIFIER", 33, 42], ["fl", "OBSERVATION", 44, 46]]], ["She exhibits no confusion or asterixis.ReferenceUltrasonography of the liver reveals a nodular liver with patent hepatic vasculature; no focal mass was detected.", [["liver", "ANATOMY", 71, 76], ["nodular liver", "ANATOMY", 87, 100], ["hepatic vasculature", "ANATOMY", 113, 132], ["focal mass", "ANATOMY", 137, 147], ["confusion", "DISEASE", 16, 25], ["asterixis", "DISEASE", 29, 38], ["liver", "ORGAN", 71, 76], ["liver", "ORGAN", 95, 100], ["hepatic vasculature", "MULTI-TISSUE_STRUCTURE", 113, 132], ["confusion", "PROBLEM", 16, 25], ["asterixis", "PROBLEM", 29, 38], ["ReferenceUltrasonography of the liver", "TEST", 39, 76], ["a nodular liver", "PROBLEM", 85, 100], ["focal mass", "PROBLEM", 137, 147], ["no", "UNCERTAINTY", 13, 15], ["confusion", "OBSERVATION", 16, 25], ["asterixis", "OBSERVATION", 29, 38], ["liver", "ANATOMY", 71, 76], ["nodular", "OBSERVATION", 87, 94], ["liver", "ANATOMY", 95, 100], ["patent", "OBSERVATION", 106, 112], ["hepatic", "ANATOMY", 113, 120], ["vasculature", "ANATOMY_MODIFIER", 121, 132], ["no", "UNCERTAINTY", 134, 136], ["focal", "OBSERVATION_MODIFIER", 137, 142], ["mass", "OBSERVATION", 143, 147]]], ["Labs reveal an of INR 1.5, a serum creatinine of 1.4 mg/dL, and a sodium of 140.", [["serum", "ANATOMY", 29, 34], ["creatinine", "CHEMICAL", 35, 45], ["sodium", "CHEMICAL", 66, 72], ["creatinine", "CHEMICAL", 35, 45], ["sodium", "CHEMICAL", 66, 72], ["Labs", "GENE_OR_GENE_PRODUCT", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["creatinine", "SIMPLE_CHEMICAL", 35, 45], ["sodium", "SIMPLE_CHEMICAL", 66, 72], ["Labs", "TEST", 0, 4], ["INR", "TEST", 18, 21], ["a serum creatinine", "TEST", 27, 45], ["a sodium", "TEST", 64, 72]]], ["Her MELD score is 18.Which of the following should you recommend?", [["Her MELD score", "TEST", 0, 14]]], ["A) Serial paracenteses B) Serial thoracenteses C) Chest tube placement on the right side D) Transjugular intrahepatic portosystemic shunt (TIPS)Answer: D Refractory ascites may be treated with a TIPS procedure.Which of the following should you recommend?", [["ascites", "ANATOMY", 165, 172], ["Transjugular intrahepatic portosystemic shunt", "DISEASE", 92, 137], ["ascites", "DISEASE", 165, 172], ["Chest tube", "TISSUE", 50, 60], ["intrahepatic portosystemic", "MULTI-TISSUE_STRUCTURE", 105, 131], ["Serial paracenteses B", "TREATMENT", 3, 24], ["Serial thoracenteses C)", "TREATMENT", 26, 49], ["Chest tube placement on the right side D", "TREATMENT", 50, 90], ["Transjugular intrahepatic portosystemic shunt (TIPS", "TREATMENT", 92, 143], ["D Refractory ascites", "PROBLEM", 152, 172], ["a TIPS procedure", "TREATMENT", 193, 209], ["Chest", "ANATOMY", 50, 55], ["right", "ANATOMY_MODIFIER", 78, 83], ["Transjugular", "ANATOMY_MODIFIER", 92, 104], ["intrahepatic", "ANATOMY", 105, 117], ["portosystemic shunt", "OBSERVATION", 118, 137], ["Refractory", "OBSERVATION_MODIFIER", 154, 164], ["ascites", "OBSERVATION", 165, 172]]], ["A) Serial paracenteses B) Serial thoracenteses C) Chest tube placement on the right side D) Transjugular intrahepatic portosystemic shunt (TIPS)Previous meta-analysis shows possible benefi t, especially in those listed for transplant.", [["Transjugular intrahepatic portosystemic shunt", "DISEASE", 92, 137], ["tube", "TISSUE", 56, 60], ["intrahepatic portosystemic", "MULTI-TISSUE_STRUCTURE", 105, 131], ["Serial paracenteses B", "TREATMENT", 3, 24], ["Serial thoracenteses C)", "TREATMENT", 26, 49], ["Chest tube placement on the right side D", "TREATMENT", 50, 90], ["Transjugular intrahepatic portosystemic shunt (TIPS", "TREATMENT", 92, 143], ["Previous meta-analysis", "TEST", 144, 166], ["benefi t", "PROBLEM", 182, 190], ["transplant", "TREATMENT", 223, 233], ["Chest", "ANATOMY", 50, 55], ["right", "ANATOMY_MODIFIER", 78, 83], ["Transjugular", "ANATOMY_MODIFIER", 92, 104], ["intrahepatic", "ANATOMY", 105, 117], ["portosystemic shunt", "OBSERVATION", 118, 137], ["possible", "UNCERTAINTY", 173, 181], ["transplant", "OBSERVATION", 223, 233]]], ["Indications for TIPS include uncontrolled variceal hemorrhage from esophageal, gastric, and intestinal varices that do not respond to endoscopic and medical management, refractory ascites, and hepatic pleural effusion (hydrothorax).", [["variceal", "ANATOMY", 42, 50], ["esophageal", "ANATOMY", 67, 77], ["gastric", "ANATOMY", 79, 86], ["intestinal varices", "ANATOMY", 92, 110], ["ascites", "ANATOMY", 180, 187], ["hepatic pleural effusion", "ANATOMY", 193, 217], ["variceal hemorrhage", "DISEASE", 42, 61], ["esophageal, gastric, and intestinal varices", "DISEASE", 67, 110], ["ascites", "DISEASE", 180, 187], ["hepatic pleural effusion", "DISEASE", 193, 217], ["hydrothorax", "DISEASE", 219, 230], ["esophageal", "ORGAN", 67, 77], ["gastric", "ORGAN", 79, 86], ["intestinal varices", "PATHOLOGICAL_FORMATION", 92, 110], ["hepatic pleural", "PATHOLOGICAL_FORMATION", 193, 208], ["TIPS", "TREATMENT", 16, 20], ["uncontrolled variceal hemorrhage", "PROBLEM", 29, 61], ["esophageal, gastric, and intestinal varices", "PROBLEM", 67, 110], ["endoscopic", "TREATMENT", 134, 144], ["medical management", "TREATMENT", 149, 167], ["refractory ascites", "PROBLEM", 169, 187], ["hepatic pleural effusion", "PROBLEM", 193, 217], ["hydrothorax", "PROBLEM", 219, 230], ["uncontrolled", "OBSERVATION_MODIFIER", 29, 41], ["variceal", "OBSERVATION_MODIFIER", 42, 50], ["hemorrhage", "OBSERVATION", 51, 61], ["esophageal", "ANATOMY", 67, 77], ["gastric", "ANATOMY", 79, 86], ["intestinal", "ANATOMY", 92, 102], ["varices", "OBSERVATION", 103, 110], ["refractory", "OBSERVATION_MODIFIER", 169, 179], ["ascites", "OBSERVATION", 180, 187], ["hepatic", "ANATOMY", 193, 200], ["pleural", "ANATOMY", 201, 208], ["effusion", "OBSERVATION", 209, 217], ["hydrothorax", "OBSERVATION", 219, 230]]], ["Repeat paracentesis is unlikely to be of benefi t in this patient.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["Repeat paracentesis", "TREATMENT", 0, 19], ["paracentesis", "OBSERVATION", 7, 19], ["unlikely to be", "UNCERTAINTY", 23, 37]]], ["Chest tube placement is not recommended in patients with end-stage liver disease.", [["Chest tube", "ANATOMY", 0, 10], ["liver", "ANATOMY", 67, 72], ["end-stage liver disease", "DISEASE", 57, 80], ["Chest tube", "MULTI-TISSUE_STRUCTURE", 0, 10], ["patients", "ORGANISM", 43, 51], ["liver", "ORGAN", 67, 72], ["patients", "SPECIES", 43, 51], ["Chest tube placement", "TREATMENT", 0, 20], ["end-stage liver disease", "PROBLEM", 57, 80], ["tube", "OBSERVATION", 6, 10], ["stage", "OBSERVATION_MODIFIER", 61, 66], ["liver", "ANATOMY", 67, 72], ["disease", "OBSERVATION", 73, 80]]], ["All patients undergoing transjugular intrahepatic portosystemic shunt placement should receive prophylactic antibiotics.", [["patients", "ORGANISM", 4, 12], ["transjugular intrahepatic", "MULTI-TISSUE_STRUCTURE", 24, 49], ["portosystemic", "IMMATERIAL_ANATOMICAL_ENTITY", 50, 63], ["patients", "SPECIES", 4, 12], ["transjugular intrahepatic portosystemic shunt placement", "TREATMENT", 24, 79], ["prophylactic antibiotics", "TREATMENT", 95, 119], ["transjugular", "ANATOMY_MODIFIER", 24, 36], ["intrahepatic", "ANATOMY", 37, 49], ["portosystemic shunt", "OBSERVATION", 50, 69]]], ["Resuscitation with fl uid and blood products is indicated prior to the procedure.", [["blood", "ANATOMY", 30, 35], ["fl uid", "SIMPLE_CHEMICAL", 19, 25], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["Resuscitation", "TREATMENT", 0, 13], ["fl uid", "TREATMENT", 19, 25], ["blood products", "TREATMENT", 30, 44], ["the procedure", "TREATMENT", 67, 80]]], ["Portal vein patency should be confi rmed prior to attempts at TIPS placement.", [["Portal vein", "ANATOMY", 0, 11], ["Portal vein", "MULTI-TISSUE_STRUCTURE", 0, 11], ["Portal vein patency", "TREATMENT", 0, 19], ["TIPS placement", "TREATMENT", 62, 76], ["vein", "ANATOMY", 7, 11], ["patency", "OBSERVATION", 12, 19]]], ["A 71-year-old woman is admitted from a nursing home with confusion, fever, and fl ank pain.", [["confusion", "DISEASE", 57, 66], ["fever", "DISEASE", 68, 73], ["ank pain", "DISEASE", 82, 90], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["confusion", "PROBLEM", 57, 66], ["fever", "PROBLEM", 68, 73], ["fl ank pain", "PROBLEM", 79, 90], ["confusion", "OBSERVATION", 57, 66], ["fever", "OBSERVATION", 68, 73], ["ank", "ANATOMY", 82, 85], ["pain", "OBSERVATION", 86, 90]]], ["She has a presumed urinary tract infection.", [["urinary tract", "ANATOMY", 19, 32], ["urinary tract infection", "DISEASE", 19, 42], ["urinary tract", "ORGANISM_SUBDIVISION", 19, 32], ["urinary tract infection", "PROBLEM", 19, 42], ["presumed", "UNCERTAINTY", 10, 18], ["urinary tract", "ANATOMY", 19, 32], ["infection", "OBSERVATION", 33, 42]]], ["On physical exam, temperature is 38.8 \u00b0C (101.8 \u00b0F), blood pressure is 86/52 mmHg, pulse rate is 130/min, and respiration rate is 23/min.", [["blood", "ANATOMY", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 53, 58], ["physical exam", "TEST", 3, 16], ["temperature", "TEST", 18, 29], ["\u00b0C", "TEST", 38, 40], ["blood pressure", "TEST", 53, 67], ["pulse rate", "TEST", 83, 93], ["respiration rate", "TEST", 110, 126]]], ["Mucous membranes are dry and tender, and poor skin turgor is noted.", [["Mucous membranes", "ANATOMY", 0, 16], ["skin", "ANATOMY", 46, 50], ["Mucous membranes", "CELLULAR_COMPONENT", 0, 16], ["skin", "ORGAN", 46, 50], ["tender", "PROBLEM", 29, 35], ["poor skin turgor", "PROBLEM", 41, 57], ["dry", "OBSERVATION", 21, 24], ["tender", "OBSERVATION", 29, 35], ["poor", "OBSERVATION_MODIFIER", 41, 45], ["skin turgor", "OBSERVATION", 46, 57]]], ["She is oriented to name and place.ReferencesHemoglobin concentration is 9.5 g/dL and leukocyte count is 15,600/\u03bcL; urinalysis reveals 100 to 150leukocytes/hpf and many bacteria/hpf.", [["leukocyte", "ANATOMY", 85, 94], ["Hemoglobin", "GENE_OR_GENE_PRODUCT", 44, 54], ["leukocyte", "CELL", 85, 94], ["Hemoglobin", "PROTEIN", 44, 54], ["Hemoglobin concentration", "TEST", 44, 68], ["leukocyte count", "TEST", 85, 100], ["urinalysis", "TEST", 115, 125], ["150leukocytes", "TEST", 141, 154], ["hpf", "TEST", 155, 158], ["many bacteria/hpf", "PROBLEM", 163, 180], ["many", "OBSERVATION_MODIFIER", 163, 167], ["bacteria", "OBSERVATION", 168, 176]]], ["The patient has an increase anion gap metabolic acidosis.", [["acidosis", "DISEASE", 48, 56], ["patient", "ORGANISM", 4, 11], ["anion", "SIMPLE_CHEMICAL", 28, 33], ["patient", "SPECIES", 4, 11], ["an increase anion gap metabolic acidosis", "PROBLEM", 16, 56], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["anion gap", "OBSERVATION", 28, 37], ["metabolic acidosis", "OBSERVATION", 38, 56]]], ["The patient is admitted to the intensive care unit and antibiotic therapy is started.ReferencesWhich of the following is the fi rst goal of therapy?", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["antibiotic therapy", "TREATMENT", 55, 73], ["therapy", "TREATMENT", 140, 147]]], ["A) Aggressive fl uid resuscitation B) Hemodynamic monitoring with a pulmonary artery catheter C) Maintaining hemoglobin concentration above 12 g/ dL (120 g/L) D) Maintaining PCO2 below 50 mmHg E) Initiation of vasopressor drugs Answer: A The patient has severe sepsis from pyelonephritis.", [["pulmonary artery", "ANATOMY", 68, 84], ["sepsis", "DISEASE", 261, 267], ["pyelonephritis", "DISEASE", 273, 287], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 68, 84], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 109, 119], ["patient", "ORGANISM", 242, 249], ["hemoglobin", "PROTEIN", 109, 119], ["patient", "SPECIES", 242, 249], ["Aggressive fl uid resuscitation", "TREATMENT", 3, 34], ["Hemodynamic monitoring", "TEST", 38, 60], ["a pulmonary artery catheter C", "TREATMENT", 66, 95], ["hemoglobin concentration", "TEST", 109, 133], ["PCO2", "TEST", 174, 178], ["vasopressor drugs", "TREATMENT", 210, 227], ["severe sepsis", "PROBLEM", 254, 267], ["pyelonephritis", "PROBLEM", 273, 287], ["pulmonary artery", "ANATOMY", 68, 84], ["catheter", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 254, 260], ["sepsis", "OBSERVATION", 261, 267], ["pyelonephritis", "OBSERVATION", 273, 287]]], ["Initial treatment includes respiratory and circulatory support.", [["respiratory", "ANATOMY", 27, 38], ["Initial treatment", "TREATMENT", 0, 17], ["respiratory and circulatory support", "TREATMENT", 27, 62], ["circulatory support", "OBSERVATION", 43, 62]]], ["The fi rst 6 h of resuscitation of a critically ill patient with sepsis or septic shock are the most critical.", [["critically ill", "DISEASE", 37, 51], ["sepsis", "DISEASE", 65, 71], ["septic shock", "DISEASE", 75, 87], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["resuscitation", "TREATMENT", 18, 31], ["sepsis", "PROBLEM", 65, 71], ["septic shock", "PROBLEM", 75, 87], ["sepsis", "OBSERVATION", 65, 71], ["septic shock", "OBSERVATION", 75, 87]]], ["Resuscitation of the circulation should target a central venous oxygen saturation or mixed venous oxygen saturation of at least 70 %.", [["venous", "ANATOMY", 57, 63], ["venous", "ANATOMY", 91, 97], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 98, 104], ["oxygen", "CHEMICAL", 64, 70], ["oxygen", "CHEMICAL", 98, 104], ["venous", "MULTI-TISSUE_STRUCTURE", 57, 63], ["oxygen", "SIMPLE_CHEMICAL", 64, 70], ["venous", "IMMATERIAL_ANATOMICAL_ENTITY", 91, 97], ["oxygen", "SIMPLE_CHEMICAL", 98, 104], ["Resuscitation", "TREATMENT", 0, 13], ["a central venous oxygen saturation", "TEST", 47, 81], ["mixed venous oxygen saturation", "TEST", 85, 115], ["central", "ANATOMY_MODIFIER", 49, 56], ["venous", "ANATOMY", 57, 63], ["oxygen saturation", "OBSERVATION", 64, 81], ["venous", "ANATOMY", 91, 97], ["oxygen saturation", "OBSERVATION", 98, 115]]], ["This often requires of 5 to 6 L of fl uid.", [["fl uid", "GENE_OR_GENE_PRODUCT", 35, 41], ["fl uid", "PROTEIN", 35, 41]]], ["The time required to achieve resuscitative goals matters to survival.", [["resuscitative goals matters", "TREATMENT", 29, 56]]], ["Early goaldirected therapy that within the fi rst 6 h maintains a SCVO2 of greater than 70 % and resolves lactic acidosis results in higher survival rates than more delayed resuscitation attempts.", [["lactic acidosis", "DISEASE", 106, 121], ["Early goaldirected therapy", "TREATMENT", 0, 26], ["a SCVO2", "TEST", 64, 71], ["lactic acidosis", "PROBLEM", 106, 121], ["higher survival rates", "PROBLEM", 133, 154], ["delayed resuscitation attempts", "TREATMENT", 165, 195], ["lactic acidosis", "OBSERVATION", 106, 121]]], ["Blood transfusion may be part of resuscitation for anemic patients in shock.", [["Blood", "ANATOMY", 0, 5], ["anemic", "DISEASE", 51, 57], ["shock", "DISEASE", 70, 75], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["Blood transfusion", "TREATMENT", 0, 17], ["resuscitation", "TREATMENT", 33, 46], ["anemic patients", "PROBLEM", 51, 66], ["shock", "PROBLEM", 70, 75], ["shock", "OBSERVATION", 70, 75]]], ["In stable patients who are not in shock, a transfusion threshold of 7 g/dL is acceptable.ReferencesThere are no data to support that maintaining a lower PCO2 is of any benefi t.", [["shock", "DISEASE", 34, 39], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["shock", "PROBLEM", 34, 39], ["a transfusion threshold", "TEST", 41, 64], ["a lower PCO2", "TEST", 145, 157], ["stable", "OBSERVATION_MODIFIER", 3, 9]]], ["Placement of a pulmonary artery catheter would not help to increase survival in this patient.", [["pulmonary artery", "ANATOMY", 15, 31], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 15, 31], ["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["a pulmonary artery catheter", "TREATMENT", 13, 40], ["pulmonary artery", "ANATOMY", 15, 31], ["catheter", "OBSERVATION", 32, 40]]], ["She is on short-acting inhaled beta agonists at home.", [["beta agonists", "GENE_OR_GENE_PRODUCT", 31, 44], ["short-acting inhaled beta agonists", "TREATMENT", 10, 44]]], ["She is admitted for COPD exacerbation and improves to her baseline respiratory status with steroids and nebulized albuterol treatments.", [["respiratory", "ANATOMY", 67, 78], ["COPD", "DISEASE", 20, 24], ["steroids", "CHEMICAL", 91, 99], ["albuterol", "CHEMICAL", 114, 123], ["steroids", "CHEMICAL", 91, 99], ["albuterol", "CHEMICAL", 114, 123], ["steroids", "SIMPLE_CHEMICAL", 91, 99], ["albuterol", "SIMPLE_CHEMICAL", 114, 123], ["COPD exacerbation", "PROBLEM", 20, 37], ["steroids", "TREATMENT", 91, 99], ["nebulized albuterol treatments", "TREATMENT", 104, 134], ["COPD", "OBSERVATION", 20, 24]]], ["Her oxygen saturation on discharge is 89 % on room air with a PaO2 of 54 mmHg.ReferencesWhich of the following are appropriate treatment modalities to initiate for this patient upon discharge?", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["Her oxygen saturation", "TEST", 0, 21], ["a PaO2", "TEST", 60, 66], ["appropriate treatment modalities", "TREATMENT", 115, 147]]], ["A) Initiate long-acting inhaled B-agonist in conjunction with break through inhaled short-acting anticholinergic agent.", [["B-agonist", "CHEMICAL", 32, 41], ["inhaled B-agonist", "SIMPLE_CHEMICAL", 24, 41], ["long-acting inhaled B-agonist", "TREATMENT", 12, 41], ["inhaled short-acting anticholinergic agent", "TREATMENT", 76, 118]]], ["B) Prescribe continuous supplemental oxygen therapy.", [["oxygen", "CHEMICAL", 37, 43], ["oxygen", "CHEMICAL", 37, 43], ["oxygen", "SIMPLE_CHEMICAL", 37, 43], ["continuous supplemental oxygen therapy", "TREATMENT", 13, 51], ["oxygen therapy", "OBSERVATION", 37, 51]]], ["C) Recommend wearing oxygen supplementation only during exertion.", [["oxygen", "CHEMICAL", 21, 27], ["oxygen", "CHEMICAL", 21, 27], ["oxygen", "SIMPLE_CHEMICAL", 21, 27], ["oxygen supplementation", "TREATMENT", 21, 43]]], ["D) Begin inhaled corticosteroids as monotherapy.", [["inhaled corticosteroids", "TREATMENT", 9, 32], ["monotherapy", "TREATMENT", 36, 47]]], ["F) A and B. G) B and D. 150.", [["B. G) B", "GENE_OR_GENE_PRODUCT", 9, 16]]], ["An 81-year-old man is admitted to the hospital for altered mental status.", [["man", "ORGANISM", 15, 18], ["man", "SPECIES", 15, 18], ["altered mental status", "PROBLEM", 51, 72]]], ["He was found at home, confused and lethargic, by his son.", [["lethargic", "DISEASE", 35, 44], ["He", "ORGANISM", 0, 2], ["confused", "PROBLEM", 22, 30], ["lethargic", "PROBLEM", 35, 44]]], ["His medical history is significant for metastatic prostate cancer.", [["metastatic prostate cancer", "ANATOMY", 39, 65], ["prostate cancer", "DISEASE", 50, 65], ["metastatic prostate cancer", "CANCER", 39, 65], ["metastatic prostate cancer", "PROBLEM", 39, 65], ["significant for", "UNCERTAINTY", 23, 38], ["metastatic", "OBSERVATION_MODIFIER", 39, 49], ["prostate", "ANATOMY", 50, 58], ["cancer", "OBSERVATION", 59, 65]]], ["On physical examination, he is afebrile.", [["physical examination", "TEST", 3, 23], ["afebrile", "PROBLEM", 31, 39], ["afebrile", "OBSERVATION", 31, 39]]], ["Blood pressure is 110/50 mmHg, and the pulse rate is 115 bpm.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["the pulse rate", "TEST", 35, 49], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["He is lethargic and minimally responsive to sternal rub.", [["lethargic", "PROBLEM", 6, 15], ["minimally responsive", "PROBLEM", 20, 40], ["sternal rub", "TEST", 44, 55], ["sternal", "ANATOMY", 44, 51]]], ["He has bitemporal wasting, mucous membranes are dry and poor skin turgor is noted.", [["mucous membranes", "ANATOMY", 27, 43], ["skin", "ANATOMY", 61, 65], ["bitemporal wasting", "DISEASE", 7, 25], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 27, 43], ["skin", "ORGAN", 61, 65], ["bitemporal wasting", "PROBLEM", 7, 25], ["poor skin turgor", "PROBLEM", 56, 72], ["bitemporal", "OBSERVATION_MODIFIER", 7, 17], ["wasting", "OBSERVATION", 18, 25], ["mucous membranes", "ANATOMY", 27, 43], ["dry", "OBSERVATION", 48, 51], ["poor", "OBSERVATION_MODIFIER", 56, 60], ["skin turgor", "OBSERVATION", 61, 72]]], ["He is obtunded.", [["obtunded", "PROBLEM", 6, 14], ["obtunded", "OBSERVATION", 6, 14]]], ["The patient has an intact gag refl ex and withdraws to pain in all four extremities.", [["extremities", "ANATOMY", 72, 83], ["pain", "DISEASE", 55, 59], ["patient", "ORGANISM", 4, 11], ["extremities", "ORGANISM_SUBDIVISION", 72, 83], ["patient", "SPECIES", 4, 11], ["pain", "TEST", 55, 59], ["intact", "OBSERVATION_MODIFIER", 19, 25], ["gag", "OBSERVATION", 26, 29], ["refl ex", "OBSERVATION", 30, 37], ["four extremities", "ANATOMY", 67, 83]]], ["The rectal tone is normal.", [["rectal", "ANATOMY", 4, 10], ["rectal", "ORGAN", 4, 10], ["rectal tone", "ANATOMY", 4, 15], ["normal", "OBSERVATION", 19, 25]]], ["Laboratory values are signifi cant for a creatinine of 4.2 mg/dL, a calcium level of 14.6 meq/L, and an albumin of 2.6 g/dL.ReferencesAll of the following are appropriate initial management steps EXCEPT: A) Normal saline B) Dexamethasone C) Pamidronate D) Furosemide when the patient is euvolemic E) Calcitonin Answer: B In vitamin D toxicity or extrarenal synthesis of 1,25(OH) D3 such as sarcoid or lymphoid malignancies steroids may help reduce plasma calcium levels by reducing intestinal calcium absorption.", [["extrarenal", "ANATOMY", 346, 356], ["sarcoid", "ANATOMY", 390, 397], ["lymphoid malignancies", "ANATOMY", 401, 422], ["plasma", "ANATOMY", 448, 454], ["intestinal", "ANATOMY", 482, 492], ["creatinine", "CHEMICAL", 41, 51], ["calcium", "CHEMICAL", 68, 75], ["Pamidronate D", "CHEMICAL", 241, 254], ["Furosemide", "CHEMICAL", 256, 266], ["Calcitonin", "CHEMICAL", 300, 310], ["vitamin D", "CHEMICAL", 324, 333], ["toxicity", "DISEASE", 334, 342], ["1,25(OH) D3", "CHEMICAL", 370, 381], ["sarcoid or lymphoid malignancies", "DISEASE", 390, 422], ["steroids", "CHEMICAL", 423, 431], ["calcium", "CHEMICAL", 455, 462], ["calcium", "CHEMICAL", 493, 500], ["creatinine", "CHEMICAL", 41, 51], ["calcium", "CHEMICAL", 68, 75], ["Dexamethasone C", "CHEMICAL", 224, 239], ["Pamidronate D", "CHEMICAL", 241, 254], ["Furosemide", "CHEMICAL", 256, 266], ["vitamin D", "CHEMICAL", 324, 333], ["1,25(OH) D3", "CHEMICAL", 370, 381], ["steroids", "CHEMICAL", 423, 431], ["calcium", "CHEMICAL", 455, 462], ["calcium", "CHEMICAL", 493, 500], ["creatinine", "SIMPLE_CHEMICAL", 41, 51], ["calcium", "SIMPLE_CHEMICAL", 68, 75], ["albumin", "GENE_OR_GENE_PRODUCT", 104, 111], ["Dexamethasone C", "SIMPLE_CHEMICAL", 224, 239], ["Pamidronate D)", "SIMPLE_CHEMICAL", 241, 255], ["Furosemide", "SIMPLE_CHEMICAL", 256, 266], ["patient", "ORGANISM", 276, 283], ["vitamin D", "SIMPLE_CHEMICAL", 324, 333], ["1,25(OH) D3", "SIMPLE_CHEMICAL", 370, 381], ["lymphoid malignancies", "CANCER", 401, 422], ["plasma", "ORGANISM_SUBSTANCE", 448, 454], ["calcium", "SIMPLE_CHEMICAL", 455, 462], ["intestinal", "ORGAN", 482, 492], ["calcium", "SIMPLE_CHEMICAL", 493, 500], ["patient", "SPECIES", 276, 283], ["Laboratory values", "TEST", 0, 17], ["a creatinine", "TEST", 39, 51], ["a calcium level", "TEST", 66, 81], ["an albumin", "TEST", 101, 111], ["appropriate initial management steps", "TREATMENT", 159, 195], ["A) Normal saline B) Dexamethasone C) Pamidronate D) Furosemide", "TREATMENT", 204, 266], ["Calcitonin", "TREATMENT", 300, 310], ["vitamin D toxicity", "PROBLEM", 324, 342], ["extrarenal synthesis of 1,25(OH) D3", "TREATMENT", 346, 381], ["sarcoid", "PROBLEM", 390, 397], ["lymphoid malignancies steroids", "TREATMENT", 401, 431], ["plasma calcium levels", "TEST", 448, 469], ["intestinal calcium absorption", "TREATMENT", 482, 511], ["sarcoid", "OBSERVATION", 390, 397], ["lymphoid malignancies", "OBSERVATION", 401, 422], ["intestinal", "ANATOMY", 482, 492]]], ["However, in this patient with prostate cancer, dexamethasone will have little effect on the calcium level.ReferencesSeveral methods can lower calcium in the acute setting.", [["prostate cancer", "ANATOMY", 30, 45], ["prostate cancer", "DISEASE", 30, 45], ["dexamethasone", "CHEMICAL", 47, 60], ["calcium", "CHEMICAL", 92, 99], ["calcium", "CHEMICAL", 142, 149], ["dexamethasone", "CHEMICAL", 47, 60], ["calcium", "CHEMICAL", 92, 99], ["calcium", "CHEMICAL", 142, 149], ["patient", "ORGANISM", 17, 24], ["prostate cancer", "CANCER", 30, 45], ["dexamethasone", "SIMPLE_CHEMICAL", 47, 60], ["calcium", "SIMPLE_CHEMICAL", 92, 99], ["calcium", "SIMPLE_CHEMICAL", 142, 149], ["patient", "SPECIES", 17, 24], ["prostate cancer", "PROBLEM", 30, 45], ["dexamethasone", "TREATMENT", 47, 60], ["the calcium level", "TEST", 88, 105], ["ReferencesSeveral methods", "TREATMENT", 106, 131], ["prostate", "ANATOMY", 30, 38], ["cancer", "OBSERVATION", 39, 45]]], ["Volume depletion results from uncontrolled symptoms leading to decreased intake and enhanced renal sodium loss.", [["renal", "ANATOMY", 93, 98], ["sodium", "CHEMICAL", 99, 105], ["sodium", "CHEMICAL", 99, 105], ["renal", "ORGAN", 93, 98], ["sodium", "SIMPLE_CHEMICAL", 99, 105], ["Volume depletion", "PROBLEM", 0, 16], ["uncontrolled symptoms", "PROBLEM", 30, 51], ["decreased intake", "PROBLEM", 63, 79], ["enhanced renal sodium loss", "PROBLEM", 84, 110], ["depletion", "OBSERVATION", 7, 16], ["renal", "ANATOMY", 93, 98], ["sodium loss", "OBSERVATION", 99, 110]]], ["Hypercalcemia resolves with hydration alone, and when possible this should be begun immediately.", [["Hypercalcemia", "DISEASE", 0, 13], ["Hypercalcemia", "PROBLEM", 0, 13], ["hydration", "TREATMENT", 28, 37]]], ["Euvolumeia should be obtained fi rst.", [["Euvolumeia", "SIMPLE_CHEMICAL", 0, 10]]], ["When euvolemia is achieved, furosemide may be given to increasing calciuresis.", [["euvolemia", "DISEASE", 5, 14], ["furosemide", "CHEMICAL", 28, 38], ["calciuresis", "DISEASE", 66, 77], ["furosemide", "CHEMICAL", 28, 38], ["furosemide", "SIMPLE_CHEMICAL", 28, 38], ["euvolemia", "PROBLEM", 5, 14], ["furosemide", "TREATMENT", 28, 38], ["increasing calciuresis", "PROBLEM", 55, 77]]], ["This can usually decrease serum calcium by 1-3 mg/dL within 24 h.", [["serum", "ANATOMY", 26, 31], ["calcium", "CHEMICAL", 32, 39], ["calcium", "CHEMICAL", 32, 39], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["calcium", "SIMPLE_CHEMICAL", 32, 39], ["serum calcium", "TEST", 26, 39]]], ["Bisphosphonates, which can be given IV or oral, stabilize osteoclast resorption of calcium from the bone and are quite effective.", [["oral", "ANATOMY", 42, 46], ["osteoclast", "ANATOMY", 58, 68], ["bone", "ANATOMY", 100, 104], ["Bisphosphonates", "CHEMICAL", 0, 15], ["calcium", "CHEMICAL", 83, 90], ["Bisphosphonates", "CHEMICAL", 0, 15], ["calcium", "CHEMICAL", 83, 90], ["Bisphosphonates", "SIMPLE_CHEMICAL", 0, 15], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["osteoclast", "CELL", 58, 68], ["calcium", "SIMPLE_CHEMICAL", 83, 90], ["bone", "TISSUE", 100, 104], ["Bisphosphonates", "TREATMENT", 0, 15], ["IV", "TREATMENT", 36, 38], ["oral, stabilize osteoclast resorption of calcium", "TREATMENT", 42, 90], ["bone", "ANATOMY", 100, 104]]], ["Calcitonin can be given intramuscularly or subcutaneously, but it becomes less effective after several days of use.", [["subcutaneously", "ANATOMY", 43, 57], ["Calcitonin", "CHEMICAL", 0, 10], ["Calcitonin", "GENE_OR_GENE_PRODUCT", 0, 10], ["Calcitonin", "TREATMENT", 0, 10]]], ["When other measures fail, hemodialysis against calciumfree or lower calcium concentration dialysate solution is highly effective in lowering plasma calcium levels.", [["plasma", "ANATOMY", 141, 147], ["calciumfree", "CHEMICAL", 47, 58], ["calcium", "CHEMICAL", 68, 75], ["calcium", "CHEMICAL", 148, 155], ["calcium", "CHEMICAL", 68, 75], ["calcium", "CHEMICAL", 148, 155], ["calciumfree", "SIMPLE_CHEMICAL", 47, 58], ["calcium", "SIMPLE_CHEMICAL", 68, 75], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["calcium", "SIMPLE_CHEMICAL", 148, 155], ["hemodialysis", "TREATMENT", 26, 38], ["calciumfree", "TREATMENT", 47, 58], ["lower calcium concentration dialysate solution", "TREATMENT", 62, 108], ["lowering plasma calcium levels", "TEST", 132, 162]]], ["A 72-year-old man is admitted to the hospital with generalized fatigue and easy bruising.", [["fatigue", "DISEASE", 63, 70], ["bruising", "DISEASE", 80, 88], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["generalized fatigue", "PROBLEM", 51, 70], ["easy bruising", "PROBLEM", 75, 88], ["generalized", "OBSERVATION_MODIFIER", 51, 62], ["fatigue", "OBSERVATION", 63, 70], ["easy", "OBSERVATION_MODIFIER", 75, 79], ["bruising", "OBSERVATION", 80, 88]]], ["After a rapid workup, he is diagnosed with acute myelomonocytic leukemia.", [["acute myelomonocytic leukemia", "ANATOMY", 43, 72], ["acute myelomonocytic leukemia", "DISEASE", 43, 72], ["acute myelomonocytic leukemia", "CANCER", 43, 72], ["a rapid workup", "TEST", 6, 20], ["acute myelomonocytic leukemia", "PROBLEM", 43, 72], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["myelomonocytic leukemia", "OBSERVATION", 49, 72]]], ["The hematology service is planning induction chemotherapy to start in the morning.", [["induction chemotherapy", "TREATMENT", 35, 57]]], ["His physical examination is notable for normal vital signs and no focal fi ndings other than some bruising.", [["bruising", "DISEASE", 98, 106], ["His physical examination", "TEST", 0, 24], ["focal fi ndings", "PROBLEM", 66, 81], ["some bruising", "PROBLEM", 93, 106], ["no", "UNCERTAINTY", 63, 65], ["focal", "OBSERVATION_MODIFIER", 66, 71], ["bruising", "OBSERVATION", 98, 106]]], ["He is confused and somnolent.", [["confused", "PROBLEM", 6, 14], ["somnolent", "PROBLEM", 19, 28]]], ["Over the last hour, despite frequently urinating, he has not been able to drink water due to somnolence.ReferenceLaboratory studies are notable for a serum sodium of 159 mg//dl.ReferenceWhich of the following therapies should be administered immediately?", [["serum", "ANATOMY", 150, 155], ["somnolence", "DISEASE", 93, 103], ["sodium", "CHEMICAL", 156, 162], ["sodium", "CHEMICAL", 156, 162], ["serum", "ORGANISM_SUBSTANCE", 150, 155], ["sodium", "SIMPLE_CHEMICAL", 156, 162], ["somnolence", "PROBLEM", 93, 103], ["ReferenceLaboratory studies", "TEST", 104, 131], ["a serum sodium", "TEST", 148, 162], ["the following therapies", "TREATMENT", 195, 218]]], ["A) All-trans retinoic acid (ATRA) B) Hydrochlorothiazide C) Hydrocortisone D) Desmopressin E) Lithium Answer: D This patient has acute central diabetes insipidus (DI).ReferenceDiabetes insipidus (DI) is defi ned as the passage of large volumes (>3 L/24 h) of dilute urine (<300 m Osm/kg).", [["urine", "ANATOMY", 266, 271], ["All-trans retinoic acid", "CHEMICAL", 3, 26], ["ATRA", "CHEMICAL", 28, 32], ["Hydrochlorothiazide", "CHEMICAL", 37, 56], ["Hydrocortisone", "CHEMICAL", 60, 74], ["Lithium", "CHEMICAL", 94, 101], ["acute central diabetes insipidus", "DISEASE", 129, 161], ["DI", "DISEASE", 163, 165], ["ReferenceDiabetes insipidus", "DISEASE", 167, 194], ["All-trans retinoic acid", "CHEMICAL", 3, 26], ["ATRA) B", "CHEMICAL", 28, 35], ["Hydrochlorothiazide C", "CHEMICAL", 37, 58], ["Hydrocortisone D", "CHEMICAL", 60, 76], ["Desmopressin E", "CHEMICAL", 78, 92], ["Lithium", "CHEMICAL", 94, 101], ["All-trans retinoic acid", "SIMPLE_CHEMICAL", 3, 26], ["ATRA) B) Hydrochlorothiazide C", "SIMPLE_CHEMICAL", 28, 58], ["Hydrocortisone D) Desmopressin E", "SIMPLE_CHEMICAL", 60, 92], ["patient", "ORGANISM", 117, 124], ["urine", "ORGANISM_SUBSTANCE", 266, 271], ["patient", "SPECIES", 117, 124], ["All-trans retinoic acid (ATRA)", "TREATMENT", 3, 33], ["Hydrochlorothiazide C) Hydrocortisone D) Desmopressin E) Lithium", "TREATMENT", 37, 101], ["acute central diabetes insipidus", "PROBLEM", 129, 161], ["ReferenceDiabetes insipidus", "PROBLEM", 167, 194], ["dilute urine", "TEST", 259, 271], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["central", "OBSERVATION_MODIFIER", 135, 142], ["diabetes", "OBSERVATION", 143, 151], ["large", "OBSERVATION_MODIFIER", 230, 235], ["volumes", "OBSERVATION_MODIFIER", 236, 243]]], ["In patients with central DI, desmopressin is the drug of choice.", [["desmopressin", "CHEMICAL", 29, 41], ["desmopressin", "CHEMICAL", 29, 41], ["patients", "ORGANISM", 3, 11], ["desmopressin", "SIMPLE_CHEMICAL", 29, 41], ["patients", "SPECIES", 3, 11], ["central DI", "PROBLEM", 17, 27], ["desmopressin", "TREATMENT", 29, 41], ["central DI", "OBSERVATION", 17, 27]]], ["It can be given nasally or intravenously with rapid onset.", [["intravenously", "ANATOMY", 27, 40], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40]]], ["IVF should be administered as well.", [["IVF", "TREATMENT", 0, 3]]], ["It is recommended that fl uid replacement should be provided at a rate no greater than 500-750 mL/h.", [["fl uid", "SIMPLE_CHEMICAL", 23, 29], ["fl uid replacement", "TREATMENT", 23, 41]]], ["Serum sodium should be reduced no greater than by 0.5 mmol/L (0.5 mEq/L) every hour.", [["Serum", "ANATOMY", 0, 5], ["sodium", "CHEMICAL", 6, 12], ["sodium", "CHEMICAL", 6, 12], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["sodium", "SIMPLE_CHEMICAL", 6, 12], ["Serum sodium", "TEST", 0, 12]]], ["This is to avoid hyperglycemia, volume overload, and overly rapid correction of hypernatremia, Altered mental status is likely due to the hypernatremia, which typically develops in central DI as water intake cannot keep up with urine output.", [["urine", "ANATOMY", 228, 233], ["hyperglycemia", "DISEASE", 17, 30], ["volume overload", "DISEASE", 32, 47], ["hypernatremia", "DISEASE", 80, 93], ["hypernatremia", "DISEASE", 138, 151], ["urine", "ORGANISM_SUBSTANCE", 228, 233], ["hyperglycemia", "PROBLEM", 17, 30], ["volume overload", "PROBLEM", 32, 47], ["hypernatremia", "PROBLEM", 80, 93], ["Altered mental status", "PROBLEM", 95, 116], ["the hypernatremia", "PROBLEM", 134, 151], ["urine output", "TEST", 228, 240], ["hyperglycemia", "OBSERVATION", 17, 30], ["volume overload", "OBSERVATION", 32, 47], ["hypernatremia", "OBSERVATION", 80, 93], ["hypernatremia", "OBSERVATION", 138, 151]]], ["Immediate replacement of ADH in the form of desmopressin will be both diagnostic and therapeutic.", [["desmopressin", "CHEMICAL", 44, 56], ["desmopressin", "CHEMICAL", 44, 56], ["ADH", "GENE_OR_GENE_PRODUCT", 25, 28], ["desmopressin", "SIMPLE_CHEMICAL", 44, 56], ["ADH", "PROTEIN", 25, 28], ["Immediate replacement of ADH", "TREATMENT", 0, 28], ["desmopressin", "TREATMENT", 44, 56], ["replacement", "OBSERVATION", 10, 21]]], ["Hydrochlorothiazide may be used in nephrogenic DI to increase proximal sodium and water reabsorption.", [["Hydrochlorothiazide", "CHEMICAL", 0, 19], ["sodium", "CHEMICAL", 71, 77], ["Hydrochlorothiazide", "CHEMICAL", 0, 19], ["sodium", "CHEMICAL", 71, 77], ["Hydrochlorothiazide", "SIMPLE_CHEMICAL", 0, 19], ["sodium", "SIMPLE_CHEMICAL", 71, 77], ["water", "SIMPLE_CHEMICAL", 82, 87], ["Hydrochlorothiazide", "TREATMENT", 0, 19], ["nephrogenic DI", "PROBLEM", 35, 49], ["proximal sodium and water reabsorption", "TREATMENT", 62, 100]]], ["Lithium is a well-known cause of nephrogenic DI.", [["Lithium", "CHEMICAL", 0, 7], ["nephrogenic DI", "DISEASE", 33, 47], ["Lithium", "CHEMICAL", 0, 7], ["Lithium", "SIMPLE_CHEMICAL", 0, 7], ["Lithium", "TREATMENT", 0, 7], ["nephrogenic DI", "PROBLEM", 33, 47], ["nephrogenic DI", "OBSERVATION", 33, 47]]], ["On physical exam, her heart rate is 178 beats/min on telemetry, and blood pressure is 100/65 mmHg with normal oxygen saturation.", [["heart", "ANATOMY", 22, 27], ["blood", "ANATOMY", 68, 73], ["oxygen", "CHEMICAL", 110, 116], ["oxygen", "CHEMICAL", 110, 116], ["heart", "ORGAN", 22, 27], ["blood", "ORGANISM_SUBSTANCE", 68, 73], ["oxygen", "SIMPLE_CHEMICAL", 110, 116], ["physical exam", "TEST", 3, 16], ["her heart rate", "TEST", 18, 32], ["telemetry", "TEST", 53, 62], ["blood pressure", "TEST", 68, 82], ["heart", "ANATOMY", 22, 27], ["oxygen saturation", "OBSERVATION", 110, 127]]], ["She has marked venous pulsations in her neck.", [["venous", "ANATOMY", 15, 21], ["neck", "ANATOMY", 40, 44], ["venous pulsations", "PATHOLOGICAL_FORMATION", 15, 32], ["neck", "ORGANISM_SUBDIVISION", 40, 44], ["marked venous pulsations in her neck", "PROBLEM", 8, 44], ["marked", "OBSERVATION_MODIFIER", 8, 14], ["venous", "ANATOMY", 15, 21], ["pulsations", "OBSERVATION", 22, 32], ["neck", "ANATOMY", 40, 44]]], ["ECG shows a narrow complex tachycardia without identifi able P waves.ReferenceWhich of the following is the most appropriate fi rst step to managing her tachycardia?", [["tachycardia", "DISEASE", 27, 38], ["tachycardia", "DISEASE", 153, 164], ["ECG", "TEST", 0, 3], ["a narrow complex tachycardia", "PROBLEM", 10, 38], ["her tachycardia", "PROBLEM", 149, 164], ["narrow", "OBSERVATION_MODIFIER", 12, 18]]], ["A) 5 mg metoprolol IV B) 6 mg adenosine IV C) 10 mg verapamil IV D) Carotid sinus massage E) DC cardioversion using 100 J Answer: D The patient has probable AV nodal reentrant tachycardia.ReferenceShe has prominent venous pulsations in the neck due to cannon A waves, as seen in AV dissociation.", [["Carotid", "ANATOMY", 68, 75], ["DC", "ANATOMY", 93, 95], ["AV nodal", "ANATOMY", 157, 165], ["venous", "ANATOMY", 215, 221], ["neck", "ANATOMY", 240, 244], ["metoprolol IV B", "CHEMICAL", 8, 23], ["adenosine", "CHEMICAL", 30, 39], ["verapamil", "CHEMICAL", 52, 61], ["tachycardia", "DISEASE", 176, 187], ["AV dissociation", "DISEASE", 279, 294], ["metoprolol IV B", "CHEMICAL", 8, 23], ["adenosine IV C", "CHEMICAL", 30, 44], ["verapamil IV D", "CHEMICAL", 52, 66], ["adenosine IV C", "SIMPLE_CHEMICAL", 30, 44], ["patient", "ORGANISM", 136, 143], ["AV nodal", "MULTI-TISSUE_STRUCTURE", 157, 165], ["venous pulsations", "PATHOLOGICAL_FORMATION", 215, 232], ["neck", "ORGAN", 240, 244], ["DC", "CELL_TYPE", 93, 95], ["patient", "SPECIES", 136, 143], ["A) 5 mg metoprolol IV B)", "TREATMENT", 0, 24], ["adenosine IV C)", "TREATMENT", 30, 45], ["verapamil IV D", "TREATMENT", 52, 66], ["Carotid sinus massage E", "TREATMENT", 68, 91], ["DC cardioversion", "TREATMENT", 93, 109], ["AV nodal reentrant tachycardia", "PROBLEM", 157, 187], ["prominent venous pulsations in the neck", "PROBLEM", 205, 244], ["AV dissociation", "PROBLEM", 279, 294], ["Carotid sinus", "ANATOMY", 68, 81], ["probable", "UNCERTAINTY", 148, 156], ["AV", "ANATOMY", 157, 159], ["nodal reentrant tachycardia", "OBSERVATION", 160, 187], ["prominent", "OBSERVATION_MODIFIER", 205, 214], ["venous", "ANATOMY", 215, 221], ["pulsations", "OBSERVATION", 222, 232], ["neck", "ANATOMY", 240, 244], ["AV", "ANATOMY", 279, 281], ["dissociation", "OBSERVATION", 282, 294]]], ["This occurs with simultaneous atrial and ventricular contraction.", [["atrial", "ANATOMY", 30, 36], ["ventricular", "ANATOMY", 41, 52], ["atrial", "MULTI-TISSUE_STRUCTURE", 30, 36], ["ventricular", "MULTI-TISSUE_STRUCTURE", 41, 52], ["simultaneous atrial and ventricular contraction", "PROBLEM", 17, 64], ["ventricular", "ANATOMY", 41, 52], ["contraction", "OBSERVATION", 53, 64]]], ["First-line therapy for these reentrant narrow complex tachyarrhythmias is carotid sinus massage to increase vagal tone.", [["carotid sinus", "ANATOMY", 74, 87], ["vagal", "ANATOMY", 108, 113], ["tachyarrhythmias", "DISEASE", 54, 70], ["carotid sinus", "MULTI-TISSUE_STRUCTURE", 74, 87], ["First-line therapy", "TREATMENT", 0, 18], ["these reentrant narrow complex tachyarrhythmias", "PROBLEM", 23, 70], ["carotid sinus massage", "TREATMENT", 74, 95], ["increase vagal tone", "PROBLEM", 99, 118], ["line therapy", "OBSERVATION", 6, 18], ["narrow", "OBSERVATION_MODIFIER", 39, 45], ["complex", "OBSERVATION_MODIFIER", 46, 53], ["tachyarrhythmias", "OBSERVATION", 54, 70], ["carotid sinus", "ANATOMY", 74, 87], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["vagal tone", "OBSERVATION", 108, 118]]], ["Often this simple maneuver is all that is required to return the patient to sinus rhythm.", [["sinus", "ANATOMY", 76, 81], ["patient", "ORGANISM", 65, 72], ["sinus", "ORGAN", 76, 81], ["patient", "SPECIES", 65, 72]]], ["Carotid sinus massage is a bedside vagal maneuver technique involving digital pressure on the richly innervated carotid sinus.", [["Carotid sinus", "ANATOMY", 0, 13], ["innervated carotid sinus", "ANATOMY", 101, 125], ["Carotid sinus", "MULTI-TISSUE_STRUCTURE", 0, 13], ["carotid sinus", "MULTI-TISSUE_STRUCTURE", 112, 125], ["Carotid sinus massage", "TREATMENT", 0, 21], ["a bedside vagal maneuver technique", "TREATMENT", 25, 59], ["sinus", "ANATOMY", 8, 13], ["massage", "OBSERVATION", 14, 21], ["pressure", "OBSERVATION_MODIFIER", 78, 86], ["richly", "ANATOMY_MODIFIER", 94, 100], ["innervated", "ANATOMY_MODIFIER", 101, 111], ["carotid sinus", "ANATOMY", 112, 125]]], ["It takes advantage of the accessible position of this baroreceptor for diagnostic and therapeutic purposes.", [["this baroreceptor", "TREATMENT", 49, 66], ["therapeutic purposes", "TEST", 86, 106]]], ["Its main therapeutic application is for termination of SVTs owing to paroxysmal atrial tachycardia (PAT).ReferenceCarotid massage is contraindicated in patients with known or suspected carotid artery disease.", [["atrial", "ANATOMY", 80, 86], ["carotid artery", "ANATOMY", 185, 199], ["SVTs", "DISEASE", 55, 59], ["paroxysmal atrial tachycardia", "DISEASE", 69, 98], ["PAT", "DISEASE", 100, 103], ["carotid artery disease", "DISEASE", 185, 207], ["atrial", "MULTI-TISSUE_STRUCTURE", 80, 86], ["patients", "ORGANISM", 152, 160], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 185, 199], ["patients", "SPECIES", 152, 160], ["SVTs", "PROBLEM", 55, 59], ["paroxysmal atrial tachycardia", "PROBLEM", 69, 98], ["ReferenceCarotid massage", "TREATMENT", 105, 129], ["suspected carotid artery disease", "PROBLEM", 175, 207], ["main", "OBSERVATION_MODIFIER", 4, 8], ["atrial", "ANATOMY", 80, 86], ["tachycardia", "OBSERVATION", 87, 98], ["carotid artery", "ANATOMY", 185, 199], ["disease", "OBSERVATION", 200, 207]]], ["The carotid sinus should be massaged fi rmly.", [["carotid sinus", "ANATOMY", 4, 17], ["carotid sinus", "MULTI-TISSUE_STRUCTURE", 4, 17], ["carotid sinus", "ANATOMY", 4, 17]]], ["In training, it has been described as the amount of pressure needed to indent a tennis ball.", [["amount", "OBSERVATION_MODIFIER", 42, 48], ["pressure", "OBSERVATION", 52, 60], ["tennis ball", "OBSERVATION", 80, 91]]], ["Carotid sinus massage should be discontinued immediately if the ECG shows asystole for more than three seconds.", [["Carotid sinus", "ANATOMY", 0, 13], ["asystole", "DISEASE", 74, 82], ["Carotid sinus", "MULTI-TISSUE_STRUCTURE", 0, 13], ["Carotid sinus massage", "TREATMENT", 0, 21], ["the ECG", "TEST", 60, 67], ["asystole", "PROBLEM", 74, 82], ["sinus", "ANATOMY", 8, 13], ["massage", "OBSERVATION", 14, 21], ["asystole", "OBSERVATION", 74, 82]]], ["If that is not successful, IV adenosine 6 mg may be attempted.", [["adenosine", "CHEMICAL", 30, 39], ["adenosine", "CHEMICAL", 30, 39], ["adenosine", "SIMPLE_CHEMICAL", 30, 39], ["IV adenosine", "TREATMENT", 27, 39]]], ["If adenosine fails, intravenous beta-blockers or calcium channel blockers may be used.", [["intravenous", "ANATOMY", 20, 31], ["adenosine", "CHEMICAL", 3, 12], ["calcium", "CHEMICAL", 49, 56], ["adenosine", "CHEMICAL", 3, 12], ["calcium", "CHEMICAL", 49, 56], ["adenosine", "SIMPLE_CHEMICAL", 3, 12], ["intravenous beta-blockers", "SIMPLE_CHEMICAL", 20, 45], ["calcium channel blockers", "SIMPLE_CHEMICAL", 49, 73], ["adenosine fails", "TREATMENT", 3, 18], ["intravenous beta-blockers", "TREATMENT", 20, 45], ["calcium channel blockers", "TREATMENT", 49, 73]]], ["In hemodynamically compromised patients or those who have failed to respond to previous measures, DC cardioversion with 100-200 J is indicated.Reference154.", [["DC", "ANATOMY", 98, 100], ["patients", "ORGANISM", 31, 39], ["DC", "CELL_TYPE", 98, 100], ["patients", "SPECIES", 31, 39], ["previous measures", "TREATMENT", 79, 96], ["DC cardioversion", "TREATMENT", 98, 114]]], ["An 82-year-old female is admitted with a diagnosis of urosepsis.", [["urosepsis", "DISEASE", 54, 63], ["female", "ORGANISM", 15, 21], ["urosepsis", "PROBLEM", 54, 63], ["urosepsis", "OBSERVATION", 54, 63]]], ["She was noted to be hypotensive with an admitting blood pressure of 80/60 mmHg.", [["blood", "ANATOMY", 50, 55], ["hypotensive", "DISEASE", 20, 31], ["She", "ORGANISM", 0, 3], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["hypotensive", "PROBLEM", 20, 31], ["an admitting blood pressure", "TEST", 37, 64], ["hypotensive", "OBSERVATION", 20, 31]]], ["During the fi rst 24 h of her admission, her blood pressure has improved to 110/60 mmHg, but she is noted to have decreased urine output.", [["blood", "ANATOMY", 45, 50], ["urine", "ANATOMY", 124, 129], ["decreased urine output", "DISEASE", 114, 136], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["urine", "ORGANISM_SUBSTANCE", 124, 129], ["her blood pressure", "TEST", 41, 59], ["decreased urine output", "PROBLEM", 114, 136], ["decreased", "OBSERVATION", 114, 123], ["urine output", "OBSERVATION", 124, 136]]], ["Which of the following tests would be the most accurate for predicting the development of ongoing acute kidney injury?", [["kidney", "ANATOMY", 104, 110], ["acute kidney injury", "DISEASE", 98, 117], ["kidney", "ORGAN", 104, 110], ["the following tests", "TEST", 9, 28], ["ongoing acute kidney injury", "PROBLEM", 90, 117], ["acute", "OBSERVATION_MODIFIER", 98, 103], ["kidney", "ANATOMY", 104, 110], ["injury", "OBSERVATION", 111, 117]]], ["A) Serum creatinine B) Urinalysis C) Neutrophil gelatinase-associated lipocalin (NGAL) D) Ultrasound E) Urinary tubular enzyme assay Answer: C NGAL may aid in the diagnosis of early acute tubular necrosis (ATN) and differentiate it from prerenal disease.", [["Serum", "ANATOMY", 3, 8], ["tubular", "ANATOMY", 188, 195], ["prerenal", "ANATOMY", 237, 245], ["creatinine", "CHEMICAL", 9, 19], ["acute tubular necrosis", "DISEASE", 182, 204], ["ATN", "DISEASE", 206, 209], ["prerenal disease", "DISEASE", 237, 253], ["creatinine B", "CHEMICAL", 9, 21], ["Serum", "ORGANISM_SUBSTANCE", 3, 8], ["Neutrophil gelatinase-associated lipocalin", "GENE_OR_GENE_PRODUCT", 37, 79], ["NGAL) D", "SIMPLE_CHEMICAL", 81, 88], ["C NGAL", "SIMPLE_CHEMICAL", 141, 147], ["tubular", "PATHOLOGICAL_FORMATION", 188, 195], ["prerenal disease", "CANCER", 237, 253], ["Serum creatinine B) Urinalysis C) Neutrophil gelatinase-associated lipocalin (NGAL) D", "PROTEIN", 3, 88], ["Urinary tubular enzyme", "PROTEIN", 104, 126], ["NGAL", "PROTEIN", 143, 147], ["A) Serum creatinine B", "TEST", 0, 21], ["Urinalysis C", "TEST", 23, 35], ["Neutrophil gelatinase", "TEST", 37, 58], ["lipocalin (NGAL) D) Ultrasound E", "TEST", 70, 102], ["Urinary tubular enzyme assay", "TEST", 104, 132], ["early acute tubular necrosis", "PROBLEM", 176, 204], ["ATN)", "PROBLEM", 206, 210], ["prerenal disease", "PROBLEM", 237, 253], ["Urinary tubular", "ANATOMY", 104, 119], ["early", "OBSERVATION_MODIFIER", 176, 181], ["acute", "OBSERVATION_MODIFIER", 182, 187], ["tubular", "ANATOMY_MODIFIER", 188, 195], ["necrosis", "OBSERVATION", 196, 204], ["prerenal disease", "OBSERVATION", 237, 253]]], ["NGAL is a novel urinary biomarker for ischemic injury.", [["urinary", "ANATOMY", 16, 23], ["ischemic injury", "DISEASE", 38, 53], ["NGAL", "GENE_OR_GENE_PRODUCT", 0, 4], ["urinary", "ORGANISM_SUBSTANCE", 16, 23], ["NGAL", "PROTEIN", 0, 4], ["ischemic injury", "PROBLEM", 38, 53], ["ischemic", "OBSERVATION_MODIFIER", 38, 46], ["injury", "OBSERVATION", 47, 53]]], ["This patient has decreased urine output secondary to either prerenal azotemia or acute tubular necrosis (ATN).", [["urine", "ANATOMY", 27, 32], ["prerenal", "ANATOMY", 60, 68], ["tubular", "ANATOMY", 87, 94], ["decreased urine output", "DISEASE", 17, 39], ["azotemia", "DISEASE", 69, 77], ["acute tubular necrosis", "DISEASE", 81, 103], ["ATN", "DISEASE", 105, 108], ["patient", "ORGANISM", 5, 12], ["urine", "ORGANISM_SUBSTANCE", 27, 32], ["tubular", "PATHOLOGICAL_FORMATION", 87, 94], ["patient", "SPECIES", 5, 12], ["decreased urine output", "PROBLEM", 17, 39], ["prerenal azotemia", "PROBLEM", 60, 77], ["acute tubular necrosis", "PROBLEM", 81, 103], ["ATN", "PROBLEM", 105, 108], ["decreased", "OBSERVATION_MODIFIER", 17, 26], ["urine output", "OBSERVATION", 27, 39], ["prerenal", "OBSERVATION_MODIFIER", 60, 68], ["azotemia", "OBSERVATION", 69, 77], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["tubular", "ANATOMY_MODIFIER", 87, 94], ["necrosis", "OBSERVATION", 95, 103], ["ATN", "OBSERVATION", 105, 108]]], ["Acute tubular necrosis generally results in muddy brown, granular, and epithelial casts.", [["tubular", "ANATOMY", 6, 13], ["epithelial", "ANATOMY", 71, 81], ["Acute tubular necrosis", "DISEASE", 0, 22], ["tubular", "MULTI-TISSUE_STRUCTURE", 6, 13], ["epithelial casts", "TISSUE", 71, 87], ["Acute tubular necrosis", "PROBLEM", 0, 22], ["muddy brown, granular, and epithelial casts", "PROBLEM", 44, 87], ["tubular", "ANATOMY_MODIFIER", 6, 13], ["necrosis", "OBSERVATION", 14, 22], ["muddy brown", "OBSERVATION_MODIFIER", 44, 55], ["granular", "OBSERVATION_MODIFIER", 57, 65], ["epithelial casts", "OBSERVATION", 71, 87]]], ["The formation of these may not be prominent in the early stages and may take several hours or days to develop.", [["may not be", "UNCERTAINTY", 23, 33], ["prominent", "OBSERVATION_MODIFIER", 34, 43], ["early stages", "OBSERVATION_MODIFIER", 51, 63]]], ["NGAL has been validated in multiple studies of patients at risk for AKI.", [["AKI", "DISEASE", 68, 71], ["NGAL", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 47, 55], ["NGAL", "PROTEIN", 0, 4], ["patients", "SPECIES", 47, 55], ["NGAL", "TREATMENT", 0, 4], ["multiple studies", "TEST", 27, 43], ["AKI", "PROBLEM", 68, 71], ["AKI", "OBSERVATION", 68, 71]]], ["NGAL levels were demonstrated to improve risk classifi cation prior to fulminant AKI.", [["AKI", "DISEASE", 81, 84], ["NGAL", "GENE_OR_GENE_PRODUCT", 0, 4], ["cation", "SIMPLE_CHEMICAL", 55, 61], ["NGAL", "PROTEIN", 0, 4], ["NGAL levels", "TEST", 0, 11], ["fulminant AKI", "PROBLEM", 71, 84], ["fulminant", "OBSERVATION_MODIFIER", 71, 80], ["AKI", "OBSERVATION", 81, 84]]], ["NGAL in patients who later developed AKI occurred before any change in serum creatinine level.", [["serum", "ANATOMY", 71, 76], ["AKI", "DISEASE", 37, 40], ["creatinine", "CHEMICAL", 77, 87], ["creatinine", "CHEMICAL", 77, 87], ["NGAL", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 8, 16], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["creatinine", "SIMPLE_CHEMICAL", 77, 87], ["NGAL", "PROTEIN", 0, 4], ["patients", "SPECIES", 8, 16], ["AKI", "PROBLEM", 37, 40], ["any change in serum creatinine level", "PROBLEM", 57, 93], ["AKI", "OBSERVATION", 37, 40]]], ["NGAL has also shown some potential to aid in the diagnosis of early acute tubular necrosis and differentiate it from prerenal disease.", [["tubular", "ANATOMY", 74, 81], ["prerenal", "ANATOMY", 117, 125], ["acute tubular necrosis", "DISEASE", 68, 90], ["prerenal disease", "DISEASE", 117, 133], ["NGAL", "GENE_OR_GENE_PRODUCT", 0, 4], ["tubular", "ORGAN", 74, 81], ["prerenal disease", "CANCER", 117, 133], ["NGAL", "PROTEIN", 0, 4], ["NGAL", "TEST", 0, 4], ["early acute tubular necrosis", "PROBLEM", 62, 90], ["prerenal disease", "PROBLEM", 117, 133], ["early", "OBSERVATION_MODIFIER", 62, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["tubular", "ANATOMY", 74, 81], ["necrosis", "OBSERVATION", 82, 90], ["prerenal disease", "OBSERVATION", 117, 133]]], ["It is still to be determined if NGAL is cost effective for routine use in the hospital.", [["NGAL", "GENE_OR_GENE_PRODUCT", 32, 36], ["NGAL", "PROTEIN", 32, 36]]], ["Old records were obtained that reveal that he has had six endoscopies in the past four years, each with evidence of PUD and each was H. pylori negative.", [["PUD", "DISEASE", 116, 119], ["H. pylori", "ORGANISM", 133, 142], ["H. pylori", "SPECIES", 133, 142], ["H. pylori", "SPECIES", 133, 142], ["Old records", "TEST", 0, 11], ["six endoscopies", "TREATMENT", 54, 69], ["PUD", "PROBLEM", 116, 119], ["H. pylori", "PROBLEM", 133, 142], ["PUD", "OBSERVATION", 116, 119]]], ["No specifi c cause was found for the diarrhea.ReferenceWhich of the following is the most appropriate next step in his diagnostic evaluation?", [["diarrhea", "DISEASE", 37, 45], ["specifi c", "GENE_OR_GENE_PRODUCT", 3, 12], ["the diarrhea", "PROBLEM", 33, 45], ["his diagnostic evaluation", "TEST", 115, 140]]], ["A) CT scan of the abdomen.", [["abdomen", "ANATOMY", 18, 25], ["abdomen", "ORGAN", 18, 25], ["A) CT scan of the abdomen", "TEST", 0, 25], ["abdomen", "ANATOMY", 18, 25]]], ["B) Discontinue omeprazole for 1 week and measure plasma gastrin level.", [["plasma", "ANATOMY", 49, 55], ["omeprazole", "CHEMICAL", 15, 25], ["omeprazole", "CHEMICAL", 15, 25], ["omeprazole", "SIMPLE_CHEMICAL", 15, 25], ["plasma", "ORGANISM_SUBSTANCE", 49, 55], ["gastrin", "GENE_OR_GENE_PRODUCT", 56, 63], ["omeprazole", "TREATMENT", 15, 25], ["plasma gastrin level", "TEST", 49, 69]]], ["C) Gastric pH measurement.", [["Gastric", "ANATOMY", 3, 10], ["Gastric", "MULTI-TISSUE_STRUCTURE", 3, 10], ["Gastric pH measurement", "TEST", 3, 25], ["Gastric", "ANATOMY", 3, 10]]], ["D) Screen for parathyroid hyperplasia.", [["parathyroid hyperplasia", "ANATOMY", 14, 37], ["parathyroid hyperplasia", "DISEASE", 14, 37], ["parathyroid hyperplasia", "PATHOLOGICAL_FORMATION", 14, 37], ["parathyroid hyperplasia", "PROBLEM", 14, 37], ["parathyroid", "ANATOMY", 14, 25], ["hyperplasia", "OBSERVATION", 26, 37]]], ["E) Emperic H. pylori treatment.ReferenceAnswer: C The patient has Zollinger-Ellison syndrome.", [["Zollinger-Ellison syndrome", "DISEASE", 66, 92], ["H. pylori", "ORGANISM", 11, 20], ["patient", "ORGANISM", 54, 61], ["H. pylori", "SPECIES", 11, 20], ["patient", "SPECIES", 54, 61], ["H. pylori", "SPECIES", 11, 20], ["Emperic H. pylori treatment", "TREATMENT", 3, 30], ["Zollinger", "TREATMENT", 66, 75], ["Ellison syndrome", "PROBLEM", 76, 92], ["H. pylori treatment", "OBSERVATION", 11, 30]]], ["Zollinger-Ellison syndrome (ZES) is caused by a non-beta islet cell, gastrinsecreting tumor of the pancreas that stimulates maximum acid secretion.", [["non-beta islet cell", "ANATOMY", 48, 67], ["gastrinsecreting tumor", "ANATOMY", 69, 91], ["pancreas", "ANATOMY", 99, 107], ["Zollinger-Ellison syndrome", "DISEASE", 0, 26], ["ZES", "DISEASE", 28, 31], ["tumor", "DISEASE", 86, 91], ["non-beta islet cell", "CELL", 48, 67], ["gastrinsecreting tumor", "CANCER", 69, 91], ["pancreas", "ORGAN", 99, 107], ["Zollinger-Ellison syndrome (ZES", "TREATMENT", 0, 31], ["a non-beta islet cell", "PROBLEM", 46, 67], ["gastrinsecreting tumor of the pancreas", "PROBLEM", 69, 107], ["maximum acid secretion", "PROBLEM", 124, 146], ["islet cell", "OBSERVATION", 57, 67], ["tumor", "OBSERVATION", 86, 91], ["pancreas", "ANATOMY", 99, 107], ["maximum", "OBSERVATION_MODIFIER", 124, 131], ["acid secretion", "OBSERVATION", 132, 146]]], ["This leads to mucosal ulceration.", [["mucosal", "ANATOMY", 14, 21], ["mucosal ulceration", "PATHOLOGICAL_FORMATION", 14, 32], ["mucosal ulceration", "PROBLEM", 14, 32], ["mucosal", "ANATOMY", 14, 21], ["ulceration", "OBSERVATION", 22, 32]]], ["This patient presents with recurrent peptic ulcers without evidence of H. pylori infection.", [["peptic", "ANATOMY", 37, 43], ["ulcers", "DISEASE", 44, 50], ["H. pylori infection", "DISEASE", 71, 90], ["patient", "ORGANISM", 5, 12], ["peptic ulcers", "PATHOLOGICAL_FORMATION", 37, 50], ["H. pylori", "ORGANISM", 71, 80], ["patient", "SPECIES", 5, 12], ["H. pylori", "SPECIES", 71, 80], ["H. pylori", "SPECIES", 71, 80], ["recurrent peptic ulcers", "PROBLEM", 27, 50], ["H. pylori infection", "PROBLEM", 71, 90], ["recurrent", "OBSERVATION_MODIFIER", 27, 36], ["peptic", "OBSERVATION_MODIFIER", 37, 43], ["ulcers", "OBSERVATION", 44, 50], ["without evidence of", "UNCERTAINTY", 51, 70], ["H. pylori infection", "OBSERVATION", 71, 90]]], ["Additional features that suggest nonclassic ulcer disease include the presence of diarrhea, which is present in 73 % in Zollinger-Ellison syndrome.", [["nonclassic ulcer", "ANATOMY", 33, 49], ["ulcer", "DISEASE", 44, 49], ["diarrhea", "DISEASE", 82, 90], ["Zollinger-Ellison syndrome", "DISEASE", 120, 146], ["ulcer", "PATHOLOGICAL_FORMATION", 44, 49], ["nonclassic ulcer disease", "PROBLEM", 33, 57], ["diarrhea", "PROBLEM", 82, 90], ["Ellison syndrome", "PROBLEM", 130, 146], ["suggest", "UNCERTAINTY", 25, 32], ["nonclassic", "OBSERVATION_MODIFIER", 33, 43], ["ulcer", "OBSERVATION", 44, 49], ["diarrhea", "OBSERVATION", 82, 90], ["73 %", "OBSERVATION_MODIFIER", 112, 116], ["Ellison syndrome", "OBSERVATION", 130, 146]]], ["Fasting serum gastrin is the best single screening test.", [["serum", "ANATOMY", 8, 13], ["gastrin", "CHEMICAL", 14, 21], ["Fasting", "ORGANISM_SUBSTANCE", 0, 7], ["serum", "ORGANISM_SUBSTANCE", 8, 13], ["gastrin", "GENE_OR_GENE_PRODUCT", 14, 21], ["Fasting serum gastrin", "TEST", 0, 21], ["single screening test", "TEST", 34, 55]]], ["Because PPI use suppresses gastric acid production, it should be discontinued for at least 1 week prior to the measurement of gastrin in plasma.ReferenceOnce hypergastrinemia is confi rmed, the presence of low gastric pH must be confi rmed.", [["gastric", "ANATOMY", 27, 34], ["plasma", "ANATOMY", 137, 143], ["gastric", "ANATOMY", 210, 217], ["PPI", "CHEMICAL", 8, 11], ["gastrin", "CHEMICAL", 126, 133], ["hypergastrinemia", "DISEASE", 158, 174], ["gastric acid", "SIMPLE_CHEMICAL", 27, 39], ["gastrin", "GENE_OR_GENE_PRODUCT", 126, 133], ["plasma", "ORGANISM_SUBSTANCE", 137, 143], ["gastric", "ORGAN", 210, 217], ["PPI", "TREATMENT", 8, 11], ["gastric acid production", "TREATMENT", 27, 50], ["gastrin in plasma", "TEST", 126, 143], ["hypergastrinemia", "PROBLEM", 158, 174], ["confi", "PROBLEM", 178, 183], ["low gastric pH", "PROBLEM", 206, 220], ["gastric", "ANATOMY", 27, 34], ["acid production", "OBSERVATION", 35, 50], ["hypergastrinemia", "OBSERVATION", 158, 174], ["low gastric pH", "OBSERVATION", 206, 220]]], ["The most common cause of elevated gastrin is achlorhydria due to pernicious anemia.", [["gastrin", "CHEMICAL", 34, 41], ["achlorhydria", "DISEASE", 45, 57], ["pernicious anemia", "DISEASE", 65, 82], ["gastrin", "GENE_OR_GENE_PRODUCT", 34, 41], ["elevated gastrin", "PROBLEM", 25, 41], ["achlorhydria", "PROBLEM", 45, 57], ["pernicious anemia", "PROBLEM", 65, 82], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["elevated", "OBSERVATION_MODIFIER", 25, 33], ["gastrin", "OBSERVATION", 34, 41], ["pernicious", "OBSERVATION_MODIFIER", 65, 75], ["anemia", "OBSERVATION", 76, 82]]], ["Imaging of the abdomen is indicated after demonstration of hypergastrinemia.", [["abdomen", "ANATOMY", 15, 22], ["hypergastrinemia", "DISEASE", 59, 75], ["abdomen", "ORGAN", 15, 22], ["Imaging of the abdomen", "TEST", 0, 22], ["hypergastrinemia", "PROBLEM", 59, 75], ["abdomen", "ANATOMY", 15, 22], ["hypergastrinemia", "OBSERVATION", 59, 75]]], ["Zollinger-Ellison syndrome may be associated with multiple endocrine neoplasia type 1.", [["Zollinger-Ellison syndrome", "DISEASE", 0, 26], ["multiple endocrine neoplasia", "DISEASE", 50, 78], ["multiple endocrine neoplasia type 1", "CANCER", 50, 85], ["Zollinger", "TREATMENT", 0, 9], ["Ellison syndrome", "PROBLEM", 10, 26], ["multiple endocrine neoplasia type 1", "PROBLEM", 50, 85], ["may be associated with", "UNCERTAINTY", 27, 49], ["endocrine", "ANATOMY", 59, 68], ["neoplasia", "OBSERVATION", 69, 78]]], ["Elevated serum calcium levels with Zollinger-Ellison should prompt a search for MEN 1 syndrome.Reference157.", [["serum", "ANATOMY", 9, 14], ["calcium", "CHEMICAL", 15, 22], ["MEN 1 syndrome", "DISEASE", 80, 94], ["calcium", "CHEMICAL", 15, 22], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["calcium", "SIMPLE_CHEMICAL", 15, 22], ["MEN 1", "GENE_OR_GENE_PRODUCT", 80, 85], ["Elevated serum calcium levels", "PROBLEM", 0, 29], ["Zollinger", "TREATMENT", 35, 44], ["Ellison", "TREATMENT", 45, 52], ["MEN 1 syndrome", "PROBLEM", 80, 94]]], ["You are called to see a 76-year-old male in consultation for acute kidney injury.", [["kidney", "ANATOMY", 67, 73], ["acute kidney injury", "DISEASE", 61, 80], ["kidney", "ORGAN", 67, 73], ["acute kidney injury", "PROBLEM", 61, 80], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["kidney", "ANATOMY", 67, 73], ["injury", "OBSERVATION", 74, 80]]], ["The patient is four days post-op abdominal aneurysm repair.", [["abdominal aneurysm", "ANATOMY", 33, 51], ["abdominal aneurysm", "DISEASE", 33, 51], ["patient", "ORGANISM", 4, 11], ["abdominal aneurysm", "PATHOLOGICAL_FORMATION", 33, 51], ["patient", "SPECIES", 4, 11], ["abdominal aneurysm repair", "TREATMENT", 33, 58], ["abdominal", "ANATOMY", 33, 42], ["aneurysm", "OBSERVATION", 43, 51], ["repair", "OBSERVATION", 52, 58]]], ["For the past 3 days, urine output has decreased.", [["urine", "ANATOMY", 21, 26], ["urine", "ORGANISM_SUBSTANCE", 21, 26], ["urine output", "TEST", 21, 33], ["output", "OBSERVATION_MODIFIER", 27, 33], ["decreased", "OBSERVATION_MODIFIER", 38, 47]]], ["He is now oliguric.", [["oliguric", "DISEASE", 10, 18], ["oliguric", "PROBLEM", 10, 18], ["oliguric", "OBSERVATION", 10, 18]]], ["A bladder scan shows minimal urine.", [["bladder", "ANATOMY", 2, 9], ["urine", "ANATOMY", 29, 34], ["bladder", "ORGAN", 2, 9], ["urine", "ORGANISM_SUBSTANCE", 29, 34], ["A bladder scan", "TEST", 0, 14], ["minimal urine", "PROBLEM", 21, 34], ["bladder", "ANATOMY", 2, 9], ["minimal", "OBSERVATION_MODIFIER", 21, 28], ["urine", "OBSERVATION", 29, 34]]], ["An indwelling catheter is in place.", [["An indwelling catheter", "TREATMENT", 0, 22], ["indwelling", "OBSERVATION_MODIFIER", 3, 13], ["catheter", "OBSERVATION", 14, 22]]], ["It fl ushes without complications.", [["complications", "PROBLEM", 20, 33]]], ["The patient has received two doses of vancomycin postoperatively.", [["vancomycin", "CHEMICAL", 38, 48], ["vancomycin", "CHEMICAL", 38, 48], ["patient", "ORGANISM", 4, 11], ["vancomycin", "SIMPLE_CHEMICAL", 38, 48], ["patient", "SPECIES", 4, 11], ["vancomycin", "TREATMENT", 38, 48]]], ["On physical examination, temperature is 37.8 \u00b0C (100.1 \u00b0F), blood pressure is 117/68, pulse rate is 114, and respirations are 17 per minute.", [["blood", "ANATOMY", 60, 65], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["\u00b0C", "TEST", 45, 47], ["blood pressure", "TEST", 60, 74], ["pulse rate", "TEST", 86, 96], ["respirations", "TEST", 109, 121]]], ["Abdominal examination reveals a tense and distended abdomen.", [["Abdominal", "ANATOMY", 0, 9], ["abdomen", "ANATOMY", 52, 59], ["abdomen", "ORGAN", 52, 59], ["Abdominal examination", "TEST", 0, 21], ["a tense and distended abdomen", "PROBLEM", 30, 59], ["tense", "OBSERVATION", 32, 37], ["distended", "OBSERVATION", 42, 51], ["abdomen", "ANATOMY", 52, 59]]], ["Bowel sounds are decreased.ReferenceLaboratory data reveals a blood urea nitrogen of 57 mg/dL and a serum creatinine of 3.8 mg/dL.", [["Bowel", "ANATOMY", 0, 5], ["blood", "ANATOMY", 62, 67], ["serum", "ANATOMY", 100, 105], ["blood urea nitrogen", "CHEMICAL", 62, 81], ["creatinine", "CHEMICAL", 106, 116], ["urea", "CHEMICAL", 68, 72], ["nitrogen", "CHEMICAL", 73, 81], ["creatinine", "CHEMICAL", 106, 116], ["Bowel", "ORGAN", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["urea", "SIMPLE_CHEMICAL", 68, 72], ["serum", "ORGANISM_SUBSTANCE", 100, 105], ["creatinine", "SIMPLE_CHEMICAL", 106, 116], ["ReferenceLaboratory data", "TEST", 27, 51], ["a blood urea nitrogen", "TEST", 60, 81], ["a serum creatinine", "TEST", 98, 116], ["sounds", "OBSERVATION", 6, 12], ["decreased", "OBSERVATION", 17, 26]]], ["Fraction excretion of sodium is 1.7 %.", [["sodium", "CHEMICAL", 22, 28], ["sodium", "CHEMICAL", 22, 28], ["sodium", "SIMPLE_CHEMICAL", 22, 28], ["Fraction excretion of sodium", "TEST", 0, 28], ["excretion", "OBSERVATION_MODIFIER", 9, 18]]], ["A kidney ultrasound is ordered which reveals normal-sized kidneys and no hydronephrosis.ReferenceWhich of the following is the most likely cause of this patient's condition?", [["kidney", "ANATOMY", 2, 8], ["kidneys", "ANATOMY", 58, 65], ["hydronephrosis", "DISEASE", 73, 87], ["kidney", "ORGAN", 2, 8], ["kidneys", "ORGAN", 58, 65], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["A kidney ultrasound", "TEST", 0, 19], ["hydronephrosis", "PROBLEM", 73, 87], ["this patient's condition", "PROBLEM", 148, 172], ["kidney", "ANATOMY", 2, 8], ["normal", "OBSERVATION", 45, 51], ["sized", "OBSERVATION_MODIFIER", 52, 57], ["kidneys", "ANATOMY", 58, 65], ["no", "UNCERTAINTY", 70, 72], ["hydronephrosis", "OBSERVATION", 73, 87], ["most likely", "UNCERTAINTY", 127, 138]]], ["A) Aminoglycoside toxicity B) Abdominal compartment syndrome C) Prerenal acute injury D) Urinary obstruction E) Ischemic bowel Answer: B This patient has an abdominal compartment syndrome.ReferenceAbdominal compartment syndrome is increasingly recognized as the cause of morbidity such as metabolic acidosis, decreased urine output, and decreased cardiac output.", [["bowel", "ANATOMY", 121, 126], ["abdominal compartment", "ANATOMY", 157, 178], ["urine", "ANATOMY", 319, 324], ["cardiac", "ANATOMY", 347, 354], ["Aminoglycoside", "CHEMICAL", 3, 17], ["toxicity", "DISEASE", 18, 26], ["Abdominal compartment syndrome", "DISEASE", 30, 60], ["Urinary obstruction", "DISEASE", 89, 108], ["abdominal compartment syndrome", "DISEASE", 157, 187], ["compartment syndrome", "DISEASE", 207, 227], ["metabolic acidosis", "DISEASE", 289, 307], ["decreased urine output", "DISEASE", 309, 331], ["decreased cardiac output", "DISEASE", 337, 361], ["Aminoglycoside", "CHEMICAL", 3, 17], ["Aminoglycoside", "SIMPLE_CHEMICAL", 3, 17], ["bowel", "ORGAN", 121, 126], ["patient", "ORGANISM", 142, 149], ["urine", "ORGANISM_SUBSTANCE", 319, 324], ["cardiac", "ORGAN", 347, 354], ["patient", "SPECIES", 142, 149], ["A) Aminoglycoside toxicity", "PROBLEM", 0, 26], ["Abdominal compartment syndrome C", "PROBLEM", 30, 62], ["Prerenal acute injury D)", "PROBLEM", 64, 88], ["Urinary obstruction E) Ischemic bowel", "PROBLEM", 89, 126], ["an abdominal compartment syndrome", "PROBLEM", 154, 187], ["ReferenceAbdominal compartment syndrome", "PROBLEM", 188, 227], ["morbidity", "PROBLEM", 271, 280], ["metabolic acidosis", "PROBLEM", 289, 307], ["decreased urine output", "PROBLEM", 309, 331], ["decreased cardiac output", "PROBLEM", 337, 361], ["Abdominal", "ANATOMY", 30, 39], ["compartment syndrome", "OBSERVATION", 40, 60], ["Prerenal", "OBSERVATION_MODIFIER", 64, 72], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["injury", "OBSERVATION", 79, 85], ["Urinary", "ANATOMY", 89, 96], ["obstruction", "OBSERVATION", 97, 108], ["Ischemic", "OBSERVATION_MODIFIER", 112, 120], ["bowel", "ANATOMY", 121, 126], ["abdominal", "ANATOMY", 157, 166], ["compartment syndrome", "OBSERVATION", 167, 187], ["compartment syndrome", "OBSERVATION", 207, 227], ["morbidity", "OBSERVATION", 271, 280], ["metabolic acidosis", "OBSERVATION", 289, 307], ["decreased", "OBSERVATION_MODIFIER", 309, 318], ["urine output", "OBSERVATION", 319, 331], ["decreased", "OBSERVATION_MODIFIER", 337, 346], ["cardiac output", "OBSERVATION", 347, 361]]], ["The syndrome occurs when there is an abnormal increase in abdominal pressure resulting in new organ dysfunction.", [["abdominal", "ANATOMY", 58, 67], ["organ", "ANATOMY", 94, 99], ["organ dysfunction", "DISEASE", 94, 111], ["abdominal", "ORGANISM_SUBDIVISION", 58, 67], ["organ", "ORGAN", 94, 99], ["The syndrome", "PROBLEM", 0, 12], ["an abnormal increase in abdominal pressure", "PROBLEM", 34, 76], ["new organ dysfunction", "PROBLEM", 90, 111], ["syndrome", "OBSERVATION", 4, 12], ["abnormal", "OBSERVATION_MODIFIER", 37, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["abdominal", "ANATOMY", 58, 67], ["pressure", "OBSERVATION_MODIFIER", 68, 76], ["new", "OBSERVATION_MODIFIER", 90, 93], ["organ dysfunction", "OBSERVATION", 94, 111]]], ["This occurs when abdominal pressure is greater than 12 mmHg.", [["abdominal", "ANATOMY", 17, 26], ["abdominal", "ORGANISM_SUBDIVISION", 17, 26], ["abdominal pressure", "TEST", 17, 35], ["abdominal", "ANATOMY", 17, 26], ["pressure", "OBSERVATION", 27, 35], ["greater", "OBSERVATION_MODIFIER", 39, 46]]], ["Patients often have an abdomen clearly out of proportion to their body habitus.", [["abdomen", "ANATOMY", 23, 30], ["body", "ANATOMY", 66, 70], ["Patients", "ORGANISM", 0, 8], ["abdomen", "ORGANISM_SUBDIVISION", 23, 30], ["body", "ORGANISM_SUBDIVISION", 66, 70], ["Patients", "SPECIES", 0, 8], ["abdomen", "ANATOMY", 23, 30]]], ["The exact pathophysiol-ogy of acute compartment syndrome is uncertain.", [["compartment syndrome", "DISEASE", 36, 56], ["acute compartment syndrome", "PROBLEM", 30, 56], ["acute", "OBSERVATION_MODIFIER", 30, 35], ["compartment syndrome", "OBSERVATION", 36, 56]]], ["Other risk factors for the acute compartment syndrome include aggressive fl uid resuscitation, which can occur with surgery.", [["compartment syndrome", "DISEASE", 33, 53], ["Other risk factors", "PROBLEM", 0, 18], ["the acute compartment syndrome", "PROBLEM", 23, 53], ["aggressive fl uid resuscitation", "TREATMENT", 62, 93], ["surgery", "TREATMENT", 116, 123], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["compartment syndrome", "OBSERVATION", 33, 53]]], ["Measurement of intravesicular pressure through a bladder catheter is a common method for assessing intraabdominal pressure.", [["intravesicular", "ANATOMY", 15, 29], ["bladder", "ANATOMY", 49, 56], ["intraabdominal", "ANATOMY", 99, 113], ["intravesicular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 29], ["bladder", "ORGAN", 49, 56], ["intraabdominal", "ORGANISM_SUBDIVISION", 99, 113], ["intravesicular pressure", "TREATMENT", 15, 38], ["a bladder catheter", "TREATMENT", 47, 65], ["intraabdominal pressure", "TEST", 99, 122], ["intravesicular pressure", "OBSERVATION", 15, 38], ["bladder", "ANATOMY", 49, 56], ["catheter", "OBSERVATION", 57, 65], ["intraabdominal", "ANATOMY", 99, 113], ["pressure", "OBSERVATION", 114, 122]]], ["However, this may not correlate directly with measured intra-abdominal pressure.", [["intra-abdominal", "ANATOMY", 55, 70], ["intra-abdominal", "ORGANISM_SUBDIVISION", 55, 70], ["intra-abdominal pressure", "TEST", 55, 79], ["intra-abdominal", "ANATOMY", 55, 70], ["pressure", "OBSERVATION_MODIFIER", 71, 79]]], ["Surgical depression through various methods of the abdomen is the defi nitive treatment.", [["abdomen", "ANATOMY", 51, 58], ["depression", "DISEASE", 9, 19], ["abdomen", "ORGAN", 51, 58], ["Surgical depression through various methods of the abdomen", "PROBLEM", 0, 58], ["the defi nitive treatment", "TREATMENT", 62, 87], ["depression", "OBSERVATION", 9, 19], ["abdomen", "ANATOMY", 51, 58]]], ["Temporizing measures include removing any constricting garments and not placing anything on the patient's abdomen.", [["abdomen", "ANATOMY", 106, 113], ["patient", "ORGANISM", 96, 103], ["abdomen", "ORGANISM_SUBDIVISION", 106, 113], ["patient", "SPECIES", 96, 103], ["Temporizing measures", "TREATMENT", 0, 20], ["any constricting garments", "TREATMENT", 38, 63], ["abdomen", "ANATOMY", 106, 113]]], ["Aggressive fl uid resuscitation should be avoided.", [["Aggressive fl uid resuscitation", "TREATMENT", 0, 31]]], ["What is the best pre-endoscopic management of this patient?", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["A) Hold warfarin and administer IV vitamin K. B) Proceed with no changes.", [["warfarin", "CHEMICAL", 8, 16], ["vitamin", "CHEMICAL", 35, 42], ["warfarin", "CHEMICAL", 8, 16], ["vitamin K. B", "CHEMICAL", 35, 47], ["warfarin", "SIMPLE_CHEMICAL", 8, 16], ["warfarin", "TREATMENT", 8, 16], ["IV vitamin K.", "TREATMENT", 32, 45]]], ["C) Hold warfarin and start heparin once INR is less than 2.5 and continue through the procedure.", [["warfarin", "CHEMICAL", 8, 16], ["heparin", "CHEMICAL", 27, 34], ["warfarin", "CHEMICAL", 8, 16], ["warfarin", "SIMPLE_CHEMICAL", 8, 16], ["heparin", "SIMPLE_CHEMICAL", 27, 34], ["warfarin", "TREATMENT", 8, 16], ["heparin", "TREATMENT", 27, 34], ["INR", "TEST", 40, 43], ["the procedure", "TREATMENT", 82, 95]]], ["D) Hold warfarin and start heparin once INR is less than 2.5 and hold 4-6 h before the procedure.", [["warfarin", "CHEMICAL", 8, 16], ["heparin", "CHEMICAL", 27, 34], ["warfarin", "CHEMICAL", 8, 16], ["warfarin", "SIMPLE_CHEMICAL", 8, 16], ["heparin", "SIMPLE_CHEMICAL", 27, 34], ["warfarin", "TREATMENT", 8, 16], ["heparin", "TREATMENT", 27, 34], ["INR", "TEST", 40, 43], ["the procedure", "TREATMENT", 83, 96]]], ["E) Hold warfarin and administer two units of fresh frozen plasma.ReferenceAnswer: D This patient is considered a high-risk for bleeding, as she may require endoscopic hemostasis.", [["plasma", "ANATOMY", 58, 64], ["warfarin", "CHEMICAL", 8, 16], ["bleeding", "DISEASE", 127, 135], ["warfarin", "CHEMICAL", 8, 16], ["warfarin", "SIMPLE_CHEMICAL", 8, 16], ["plasma", "ORGANISM_SUBSTANCE", 58, 64], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["warfarin", "TREATMENT", 8, 16], ["fresh frozen plasma", "TREATMENT", 45, 64], ["bleeding", "PROBLEM", 127, 135], ["endoscopic hemostasis", "TREATMENT", 156, 177], ["bleeding", "OBSERVATION", 127, 135]]], ["A mechanical aortic valve requires that she be on anticoagulation to prevent thrombus formation.", [["aortic valve", "ANATOMY", 13, 25], ["thrombus", "ANATOMY", 77, 85], ["thrombus", "DISEASE", 77, 85], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 13, 25], ["thrombus", "PATHOLOGICAL_FORMATION", 77, 85], ["A mechanical aortic valve", "TREATMENT", 0, 25], ["anticoagulation", "TREATMENT", 50, 65], ["thrombus formation", "PROBLEM", 77, 95], ["mechanical", "OBSERVATION", 2, 12], ["aortic valve", "ANATOMY", 13, 25], ["thrombus", "OBSERVATION", 77, 85]]], ["A mechanical valve that is in the aortic position makes this lower risk for thromboembolism than a mechanical mitral valve, but still requires bridging.", [["aortic", "ANATOMY", 34, 40], ["mitral valve", "ANATOMY", 110, 122], ["thromboembolism", "DISEASE", 76, 91], ["valve", "MULTI-TISSUE_STRUCTURE", 13, 18], ["aortic", "MULTI-TISSUE_STRUCTURE", 34, 40], ["mitral valve", "PATHOLOGICAL_FORMATION", 110, 122], ["A mechanical valve", "TREATMENT", 0, 18], ["thromboembolism", "PROBLEM", 76, 91], ["a mechanical mitral valve", "TREATMENT", 97, 122], ["mechanical valve", "OBSERVATION", 2, 18], ["aortic", "ANATOMY", 34, 40], ["thromboembolism", "OBSERVATION", 76, 91], ["mechanical mitral valve", "OBSERVATION", 99, 122], ["bridging", "OBSERVATION", 143, 151]]], ["The best option given the non-emergent nature of her bleeding is to hold warfarin and start heparin with plans to hold 4-6 h pre-procedure.", [["bleeding", "DISEASE", 53, 61], ["warfarin", "CHEMICAL", 73, 81], ["heparin", "CHEMICAL", 92, 99], ["warfarin", "CHEMICAL", 73, 81], ["warfarin", "SIMPLE_CHEMICAL", 73, 81], ["heparin", "SIMPLE_CHEMICAL", 92, 99], ["her bleeding", "PROBLEM", 49, 61], ["warfarin", "TREATMENT", 73, 81], ["heparin", "TREATMENT", 92, 99], ["bleeding", "OBSERVATION", 53, 61]]], ["A 77-year-old woman presents to the emergency department with a 6-week history of a progressive worsening headache.", [["headache", "DISEASE", 106, 114], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["a progressive worsening headache", "PROBLEM", 82, 114], ["progressive", "OBSERVATION_MODIFIER", 84, 95], ["worsening", "OBSERVATION_MODIFIER", 96, 105], ["headache", "OBSERVATION", 106, 114]]], ["She states the headache occurs daily and is diffuse.", [["headache", "DISEASE", 15, 23], ["the headache", "PROBLEM", 11, 23], ["diffuse", "OBSERVATION_MODIFIER", 44, 51]]], ["She denies any localization of symptoms.", [["symptoms", "PROBLEM", 31, 39]]], ["She also reports fatigue and malaise during the same period.", [["fatigue", "DISEASE", 17, 24], ["fatigue", "PROBLEM", 17, 24], ["malaise", "PROBLEM", 29, 36], ["fatigue", "OBSERVATION", 17, 24], ["malaise", "OBSERVATION", 29, 36]]], ["She has taken acetaminophen for the headaches with mild relief.", [["acetaminophen", "CHEMICAL", 14, 27], ["headaches", "DISEASE", 36, 45], ["acetaminophen", "CHEMICAL", 14, 27], ["acetaminophen", "SIMPLE_CHEMICAL", 14, 27], ["acetaminophen", "TREATMENT", 14, 27], ["the headaches", "PROBLEM", 32, 45], ["mild relief", "PROBLEM", 51, 62]]], ["On physical examination, the temperature is normal.", [["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["normal", "OBSERVATION", 44, 50]]], ["Blood pressure is 140/70 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Pulse is 70 beats per minute.", [["Pulse", "TEST", 0, 5]]], ["Scalp tenderness is noted bilaterally over the temporal parietal area.", [["Scalp", "ANATOMY", 0, 5], ["temporal parietal area", "ANATOMY", 47, 69], ["tenderness", "DISEASE", 6, 16], ["parietal area", "MULTI-TISSUE_STRUCTURE", 56, 69], ["Scalp tenderness", "PROBLEM", 0, 16], ["tenderness", "OBSERVATION", 6, 16], ["bilaterally", "ANATOMY_MODIFIER", 26, 37], ["temporal", "ANATOMY_MODIFIER", 47, 55], ["parietal", "ANATOMY_MODIFIER", 56, 64], ["area", "ANATOMY_MODIFIER", 65, 69]]], ["No papilledema is noted.", [["papilledema", "DISEASE", 3, 14], ["papilledema", "PROBLEM", 3, 14], ["papilledema", "OBSERVATION", 3, 14]]], ["CT scan is performed which reveals no abnormalities.ReferenceSignifi cant laboratory data reveals a sedimentation rate of 80 mm/h, and leukocyte count is within normal limits.ReferenceWhich of the following is the most appropriate next step?", [["leukocyte", "ANATOMY", 135, 144], ["leukocyte", "CELL", 135, 144], ["CT scan", "TEST", 0, 7], ["abnormalities", "PROBLEM", 38, 51], ["ReferenceSignifi cant laboratory data", "TEST", 52, 89], ["a sedimentation rate", "TEST", 98, 118], ["leukocyte count", "TEST", 135, 150], ["no", "UNCERTAINTY", 35, 37], ["abnormalities", "OBSERVATION", 38, 51], ["leukocyte", "ANATOMY", 135, 144], ["within normal limits", "OBSERVATION", 154, 174]]], ["A) Cerebral angiography B) MRI of the head C) Referral for temporal artery biopsy D) Prednisone therapy Answer: D This patient has giant cell arteritis (GCA).", [["Cerebral", "ANATOMY", 3, 11], ["head", "ANATOMY", 38, 42], ["temporal artery", "ANATOMY", 59, 74], ["giant cell", "ANATOMY", 131, 141], ["Prednisone", "CHEMICAL", 85, 95], ["giant cell arteritis", "DISEASE", 131, 151], ["GCA", "DISEASE", 153, 156], ["Prednisone", "CHEMICAL", 85, 95], ["D", "CHEMICAL", 112, 113], ["temporal artery", "MULTI-TISSUE_STRUCTURE", 59, 74], ["Prednisone", "SIMPLE_CHEMICAL", 85, 95], ["patient", "ORGANISM", 119, 126], ["giant cell arteritis", "CANCER", 131, 151], ["GCA", "CANCER", 153, 156], ["patient", "SPECIES", 119, 126], ["A) Cerebral angiography", "TEST", 0, 23], ["MRI of the head C", "TEST", 27, 44], ["temporal artery biopsy D", "TREATMENT", 59, 83], ["Prednisone therapy", "TREATMENT", 85, 103], ["giant cell arteritis", "PROBLEM", 131, 151], ["Cerebral", "ANATOMY", 3, 11], ["head", "ANATOMY", 38, 42], ["temporal artery", "ANATOMY", 59, 74], ["giant cell arteritis", "OBSERVATION", 131, 151]]], ["The onset of GCA may be either abrupt or insidious.", [["GCA", "DISEASE", 13, 16], ["GCA", "PROBLEM", 13, 16], ["insidious", "PROBLEM", 41, 50], ["GCA", "OBSERVATION", 13, 16], ["may be either", "UNCERTAINTY", 17, 30], ["abrupt", "OBSERVATION_MODIFIER", 31, 37], ["insidious", "OBSERVATION_MODIFIER", 41, 50]]], ["GCA may begin with constitutional manifestations such as anorexia, fever, myalgia, night sweats, and weight loss.", [["GCA", "DISEASE", 0, 3], ["anorexia", "DISEASE", 57, 65], ["fever", "DISEASE", 67, 72], ["myalgia", "DISEASE", 74, 81], ["night sweats", "DISEASE", 83, 95], ["weight loss", "DISEASE", 101, 112], ["GCA", "PROBLEM", 0, 3], ["constitutional manifestations", "PROBLEM", 19, 48], ["anorexia", "PROBLEM", 57, 65], ["fever", "PROBLEM", 67, 72], ["myalgia", "PROBLEM", 74, 81], ["night sweats", "PROBLEM", 83, 95], ["weight loss", "PROBLEM", 101, 112], ["weight loss", "OBSERVATION", 101, 112]]], ["These symptoms may occur for a few days or weeks.", [["These symptoms", "PROBLEM", 0, 14]]], ["Patients suspected of GCA should undergo immediate treatment with prednisone therapy, followed by temporal artery biopsy.", [["temporal artery", "ANATOMY", 98, 113], ["GCA", "DISEASE", 22, 25], ["prednisone", "CHEMICAL", 66, 76], ["prednisone", "CHEMICAL", 66, 76], ["Patients", "ORGANISM", 0, 8], ["prednisone", "SIMPLE_CHEMICAL", 66, 76], ["temporal artery biopsy", "MULTI-TISSUE_STRUCTURE", 98, 120], ["Patients", "SPECIES", 0, 8], ["GCA", "PROBLEM", 22, 25], ["immediate treatment", "TREATMENT", 41, 60], ["prednisone therapy", "TREATMENT", 66, 84], ["temporal artery biopsy", "TEST", 98, 120], ["GCA", "OBSERVATION", 22, 25], ["temporal artery", "ANATOMY", 98, 113], ["biopsy", "OBSERVATION", 114, 120]]], ["Patients who present with visual symptoms have a 22-fold increased chance of visual improvement if therapy is started within the fi rst day.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["visual symptoms", "PROBLEM", 26, 41], ["therapy", "TREATMENT", 99, 106]]], ["Further diagnostic workup should not delay the initiation of steroid therapy.", [["steroid", "CHEMICAL", 61, 68], ["steroid", "CHEMICAL", 61, 68], ["steroid", "SIMPLE_CHEMICAL", 61, 68], ["Further diagnostic workup", "TEST", 0, 25], ["steroid therapy", "TREATMENT", 61, 76]]], ["In this patient who is >50 years of age who develops new-onset headaches with elevated sedimentation rate, temporal arteritis is the probable diagnosis.", [["headaches", "DISEASE", 63, 72], ["temporal arteritis", "DISEASE", 107, 125], ["patient", "ORGANISM", 8, 15], ["patient", "SPECIES", 8, 15], ["new-onset headaches", "PROBLEM", 53, 72], ["elevated sedimentation rate", "PROBLEM", 78, 105], ["temporal arteritis", "PROBLEM", 107, 125], ["new", "OBSERVATION_MODIFIER", 53, 56], ["-onset", "OBSERVATION_MODIFIER", 56, 62], ["headaches", "OBSERVATION", 63, 72], ["elevated", "OBSERVATION_MODIFIER", 78, 86], ["sedimentation", "OBSERVATION", 87, 100], ["temporal", "OBSERVATION_MODIFIER", 107, 115], ["arteritis", "OBSERVATION", 116, 125], ["probable", "UNCERTAINTY", 133, 141]]], ["Available data suggests that when the biopsy is performed within four weeks of initiating corticosteroid therapy, the results will be unaffected.", [["corticosteroid", "SIMPLE_CHEMICAL", 90, 104], ["the biopsy", "TEST", 34, 44], ["corticosteroid therapy", "TREATMENT", 90, 112]]], ["Few studies exist regarding the effi cacy of different dosing protocols for corticosteroids in GCA.", [["GCA", "DISEASE", 95, 98], ["corticosteroids", "SIMPLE_CHEMICAL", 76, 91], ["Few studies", "TEST", 0, 11], ["different dosing protocols", "TREATMENT", 45, 71], ["corticosteroids in GCA", "PROBLEM", 76, 98]]], ["Several dosing regimens are recommended depending on the severity of symptoms.", [["Several dosing regimens", "TREATMENT", 0, 23], ["symptoms", "PROBLEM", 69, 77]]], ["A 55-year-old man is in the hospital for the evaluation of ongoing fevers and weight loss.", [["fevers", "DISEASE", 67, 73], ["weight loss", "DISEASE", 78, 89], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["the evaluation", "TEST", 41, 55], ["ongoing fevers", "PROBLEM", 59, 73], ["weight loss", "PROBLEM", 78, 89], ["fevers", "OBSERVATION", 67, 73], ["weight loss", "OBSERVATION", 78, 89]]], ["He fi rst developed symptoms 3 months previously.", [["symptoms", "PROBLEM", 20, 28]]], ["He reports daily fevers to as high as 39.2 \u00b0C (102.6 \u00b0F) with night sweats and fatigue.", [["fevers", "DISEASE", 17, 23], ["night sweats", "DISEASE", 62, 74], ["fatigue", "DISEASE", 79, 86], ["He", "ORGANISM", 0, 2], ["daily fevers", "PROBLEM", 11, 23], ["night sweats", "PROBLEM", 62, 74], ["fatigue", "PROBLEM", 79, 86], ["fevers", "OBSERVATION", 17, 23]]], ["He has lost 37 lb compared with his weight at his last annual examination.", [["He", "ORGANISM", 0, 2], ["his weight", "TEST", 32, 42], ["his last annual examination", "TEST", 46, 73], ["37 lb", "OBSERVATION_MODIFIER", 12, 17]]], ["Diagnostic tests have been negative so far with exception of an elevated calcium at 11.6 g/dL.", [["calcium", "CHEMICAL", 73, 80], ["calcium", "CHEMICAL", 73, 80], ["calcium", "SIMPLE_CHEMICAL", 73, 80], ["Diagnostic tests", "TEST", 0, 16], ["an elevated calcium", "PROBLEM", 61, 80], ["elevated", "OBSERVATION", 64, 72]]], ["The serum protein electrophoresis demonstrated polyclonal gammopathy.", [["serum", "ANATOMY", 4, 9], ["gammopathy", "DISEASE", 58, 68], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["The serum protein electrophoresis", "TEST", 0, 33], ["polyclonal gammopathy", "PROBLEM", 47, 68], ["polyclonal gammopathy", "OBSERVATION", 47, 68]]], ["HIV, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) testing are negative.", [["Epstein-Barr virus (EBV), and cytomegalovirus (CMV)", "DISEASE", 5, 56], ["HIV", "ORGANISM", 0, 3], ["Epstein-Barr virus", "ORGANISM", 5, 23], ["EBV", "ORGANISM", 25, 28], ["cytomegalovirus", "ORGANISM", 35, 50], ["CMV", "ORGANISM", 52, 55], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["Epstein-Barr virus", "SPECIES", 5, 23], ["EBV", "SPECIES", 25, 28], ["CMV", "SPECIES", 52, 55], ["HIV", "PROBLEM", 0, 3], ["Barr virus", "PROBLEM", 13, 23], ["cytomegalovirus (CMV) testing", "TEST", 35, 64], ["Barr virus", "OBSERVATION", 13, 23], ["cytomegalovirus", "OBSERVATION", 35, 50]]], ["Blood cultures for bacteria have been negative on three separate occasions.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14], ["bacteria", "PROBLEM", 19, 27]]], ["Chest radiograph and purifi ed protein derivative (PPD) testing results are negative.", [["Chest radiograph", "TEST", 0, 16], ["purifi ed protein derivative (PPD) testing", "TEST", 21, 63]]], ["A CT scan of the chest, abdomen, and pelvis has borderline enlargement of lymph nodes in the abdomen and retroperitoneum to 1.4 cm.ReferencesWhat would be the next best step in determining the etiology of fever in this patient?", [["chest", "ANATOMY", 17, 22], ["abdomen", "ANATOMY", 24, 31], ["pelvis", "ANATOMY", 37, 43], ["lymph nodes", "ANATOMY", 74, 85], ["abdomen", "ANATOMY", 93, 100], ["retroperitoneum", "ANATOMY", 105, 120], ["fever", "DISEASE", 205, 210], ["chest", "ORGAN", 17, 22], ["abdomen", "ORGAN", 24, 31], ["pelvis", "ORGAN", 37, 43], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 74, 85], ["abdomen", "ORGAN", 93, 100], ["retroperitoneum", "ORGAN", 105, 120], ["patient", "ORGANISM", 219, 226], ["patient", "SPECIES", 219, 226], ["A CT scan of the chest, abdomen, and pelvis", "TEST", 0, 43], ["borderline enlargement of lymph nodes in the abdomen and retroperitoneum", "PROBLEM", 48, 120], ["fever", "PROBLEM", 205, 210], ["chest", "ANATOMY", 17, 22], ["abdomen", "ANATOMY", 24, 31], ["pelvis", "ANATOMY", 37, 43], ["borderline", "OBSERVATION_MODIFIER", 48, 58], ["enlargement", "OBSERVATION", 59, 70], ["lymph nodes", "OBSERVATION", 74, 85], ["abdomen", "ANATOMY", 93, 100], ["retroperitoneum", "ANATOMY", 105, 120], ["1.4 cm", "OBSERVATION_MODIFIER", 124, 130], ["fever", "OBSERVATION", 205, 210]]], ["A) Empiric treatment with corticosteroids B) Exploratory laparotomy C) Needle biopsy of enlarged lymph nodes D) PET-CT imaging E) Serum angiotensin-converting enzyme levels F) Flow cytometry of leukocytes Answer: C The next step in the workup of this patient would be to obtain a sample from an enlarged lymph node for cultures and pathology.", [["lymph nodes", "ANATOMY", 97, 108], ["leukocytes", "ANATOMY", 194, 204], ["sample", "ANATOMY", 280, 286], ["lymph node", "ANATOMY", 304, 314], ["cultures", "ANATOMY", 319, 327], ["angiotensin", "CHEMICAL", 136, 147], ["corticosteroids B", "CHEMICAL", 26, 43], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 97, 108], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 136, 165], ["leukocytes", "CELL", 194, 204], ["patient", "ORGANISM", 251, 258], ["lymph node", "MULTI-TISSUE_STRUCTURE", 304, 314], ["Serum angiotensin-converting enzyme", "PROTEIN", 130, 165], ["leukocytes", "CELL_TYPE", 194, 204], ["patient", "SPECIES", 251, 258], ["Empiric treatment", "TREATMENT", 3, 20], ["corticosteroids B", "TREATMENT", 26, 43], ["Exploratory laparotomy C", "TREATMENT", 45, 69], ["Needle biopsy", "TEST", 71, 84], ["enlarged lymph nodes", "PROBLEM", 88, 108], ["PET-CT imaging E", "TEST", 112, 128], ["Serum angiotensin", "TEST", 130, 147], ["enzyme levels", "TEST", 159, 172], ["Flow cytometry", "TEST", 176, 190], ["the workup", "TEST", 232, 242], ["a sample", "TEST", 278, 286], ["an enlarged lymph node", "PROBLEM", 292, 314], ["cultures", "TEST", 319, 327], ["pathology", "TEST", 332, 341], ["enlarged", "OBSERVATION_MODIFIER", 88, 96], ["lymph nodes", "OBSERVATION", 97, 108], ["enlarged", "OBSERVATION_MODIFIER", 295, 303], ["lymph node", "OBSERVATION", 304, 314]]], ["His elevated calcium with prominent lymph nodes suggest granulomatous diseases, including disseminated tuberculosis, fungal infections, or sarcoidosis.", [["lymph nodes", "ANATOMY", 36, 47], ["granulomatous", "ANATOMY", 56, 69], ["calcium", "CHEMICAL", 13, 20], ["granulomatous diseases", "DISEASE", 56, 78], ["tuberculosis", "DISEASE", 103, 115], ["fungal infections", "DISEASE", 117, 134], ["sarcoidosis", "DISEASE", 139, 150], ["calcium", "CHEMICAL", 13, 20], ["calcium", "SIMPLE_CHEMICAL", 13, 20], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 36, 47], ["His elevated calcium", "PROBLEM", 0, 20], ["prominent lymph nodes", "PROBLEM", 26, 47], ["granulomatous diseases", "PROBLEM", 56, 78], ["disseminated tuberculosis", "PROBLEM", 90, 115], ["fungal infections", "PROBLEM", 117, 134], ["sarcoidosis", "PROBLEM", 139, 150], ["elevated", "OBSERVATION_MODIFIER", 4, 12], ["calcium", "OBSERVATION_MODIFIER", 13, 20], ["prominent", "OBSERVATION_MODIFIER", 26, 35], ["lymph nodes", "OBSERVATION", 36, 47], ["suggest", "UNCERTAINTY", 48, 55], ["granulomatous diseases", "OBSERVATION", 56, 78], ["disseminated", "OBSERVATION_MODIFIER", 90, 102], ["tuberculosis", "OBSERVATION", 103, 115], ["fungal", "OBSERVATION_MODIFIER", 117, 123], ["infections", "OBSERVATION", 124, 134], ["sarcoidosis", "OBSERVATION", 139, 150]]], ["Before treatment can begin, every effort should be made to confi rm a diagnosis.", [["treatment", "TREATMENT", 7, 16]]], ["Sarcoid is a possibility.", [["Sarcoid", "DISEASE", 0, 7], ["Sarcoid", "PROBLEM", 0, 7], ["is a possibility", "UNCERTAINTY", 8, 24]]], ["However, serum angiotensin-converting enzyme levels are neither appropriately sensitive nor specifi c for diagnosis of sarcoidosis and should not be used to determine if therapy is needed.", [["serum", "ANATOMY", 9, 14], ["angiotensin", "CHEMICAL", 15, 26], ["sarcoidosis", "DISEASE", 119, 130], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 15, 44], ["serum angiotensin-converting enzyme", "PROTEIN", 9, 44], ["serum angiotensin", "TEST", 9, 26], ["converting enzyme levels", "TEST", 27, 51], ["sarcoidosis", "PROBLEM", 119, 130], ["therapy", "TREATMENT", 170, 177], ["sarcoidosis", "OBSERVATION", 119, 130]]], ["Two of these episodes were accompanied by delirium.", [["delirium", "DISEASE", 42, 50], ["these episodes", "PROBLEM", 7, 21], ["delirium", "PROBLEM", 42, 50], ["episodes", "OBSERVATION", 13, 21], ["delirium", "OBSERVATION", 42, 50]]], ["After each attack, she reports bilateral leg weakness.", [["leg", "ANATOMY", 41, 44], ["leg weakness", "DISEASE", 41, 53], ["leg", "ORGANISM_SUBDIVISION", 41, 44], ["bilateral leg weakness", "PROBLEM", 31, 53], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["leg", "ANATOMY", 41, 44], ["weakness", "OBSERVATION", 45, 53]]], ["On physical exam, the pain is diffuse with distention and not accompanied by vomiting or diarrhea.", [["pain", "DISEASE", 22, 26], ["vomiting", "DISEASE", 77, 85], ["diarrhea", "DISEASE", 89, 97], ["physical exam", "TEST", 3, 16], ["the pain", "PROBLEM", 18, 26], ["distention", "PROBLEM", 43, 53], ["vomiting", "PROBLEM", 77, 85], ["diarrhea", "PROBLEM", 89, 97], ["diffuse", "OBSERVATION_MODIFIER", 30, 37], ["distention", "OBSERVATION", 43, 53], ["diarrhea", "OBSERVATION", 89, 97]]], ["She is otherwise healthy and active.", [["otherwise", "UNCERTAINTY", 7, 16], ["healthy", "OBSERVATION", 17, 24], ["active", "OBSERVATION_MODIFIER", 29, 35]]], ["She reports no past medical history and only medicines are birth control pills which she has been on for fi ve years.ReferenceWhich of the following is the next most appropriate step in his evaluation?", [["medicines", "TREATMENT", 45, 54], ["birth control pills", "TREATMENT", 59, 78], ["his evaluation", "TEST", 186, 200]]], ["A) Endoscopy and colonoscopy B) Measurement of P-ANCA C) Prescription of hyoscyamine D) Referral to psychiatry E) Measurement of urine porphobilinogen during attack Answer: E The patient has acute intermittent porphyria.", [["urine", "ANATOMY", 129, 134], ["porphobilinogen", "CHEMICAL", 135, 150], ["porphyria", "DISEASE", 210, 219], ["hyoscyamine D", "CHEMICAL", 73, 86], ["porphobilinogen", "CHEMICAL", 135, 150], ["hyoscyamine D", "SIMPLE_CHEMICAL", 73, 86], ["urine", "ORGANISM_SUBSTANCE", 129, 134], ["porphobilinogen", "SIMPLE_CHEMICAL", 135, 150], ["patient", "ORGANISM", 179, 186], ["urine porphobilinogen", "PROTEIN", 129, 150], ["patient", "SPECIES", 179, 186], ["E", "SPECIES", 173, 174], ["Endoscopy", "TEST", 3, 12], ["colonoscopy", "TEST", 17, 28], ["hyoscyamine D)", "TREATMENT", 73, 87], ["urine porphobilinogen", "TEST", 129, 150], ["acute intermittent porphyria", "PROBLEM", 191, 219], ["acute", "OBSERVATION_MODIFIER", 191, 196], ["intermittent", "OBSERVATION_MODIFIER", 197, 209], ["porphyria", "OBSERVATION", 210, 219]]], ["It is most commonly associated with attacks of abdominal pain and neurologic symptoms that develop after puberty.", [["abdominal", "ANATOMY", 47, 56], ["neurologic", "ANATOMY", 66, 76], ["abdominal pain", "DISEASE", 47, 61], ["neurologic symptoms", "DISEASE", 66, 85], ["abdominal", "ORGANISM_SUBDIVISION", 47, 56], ["abdominal pain", "PROBLEM", 47, 61], ["neurologic symptoms", "PROBLEM", 66, 85], ["abdominal", "ANATOMY", 47, 56], ["pain", "OBSERVATION", 57, 61]]], ["Often a precipitating cause of symptomatic episodes can be iden- Which of the following is the most appropriate treatment?", [["symptomatic episodes", "PROBLEM", 31, 51]]], ["A) Cefazolin B) Clindamycin C) Daptomycin D) Nafcillin E) Vancomycin Answer: C This patient has nosocomially acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, and endocarditis.", [["Cefazolin B", "CHEMICAL", 3, 14], ["Clindamycin", "CHEMICAL", 16, 27], ["Daptomycin", "CHEMICAL", 31, 41], ["Nafcillin E", "CHEMICAL", 45, 56], ["Vancomycin", "CHEMICAL", 58, 68], ["methicillin", "CHEMICAL", 118, 129], ["Staphylococcus aureus (MRSA) bacteremia", "DISEASE", 140, 179], ["endocarditis", "DISEASE", 185, 197], ["Cefazolin B", "CHEMICAL", 3, 14], ["Clindamycin C", "CHEMICAL", 16, 29], ["Daptomycin D", "CHEMICAL", 31, 43], ["Nafcillin E", "CHEMICAL", 45, 56], ["Vancomycin", "CHEMICAL", 58, 68], ["methicillin", "CHEMICAL", 118, 129], ["Cefazolin B)", "SIMPLE_CHEMICAL", 3, 15], ["Clindamycin C) Daptomycin D) Nafcillin E", "SIMPLE_CHEMICAL", 16, 56], ["Vancomycin", "SIMPLE_CHEMICAL", 58, 68], ["patient", "ORGANISM", 84, 91], ["methicillin-resistant Staphylococcus aureus", "ORGANISM", 118, 161], ["MRSA", "CANCER", 163, 167], ["patient", "SPECIES", 84, 91], ["Staphylococcus aureus", "SPECIES", 140, 161], ["MRSA", "SPECIES", 163, 167], ["Staphylococcus aureus", "SPECIES", 140, 161], ["MRSA", "SPECIES", 163, 167], ["A) Cefazolin B)", "TREATMENT", 0, 15], ["Clindamycin C) Daptomycin D) Nafcillin E) Vancomycin", "TREATMENT", 16, 68], ["nosocomially acquired methicillin-resistant Staphylococcus aureus (MRSA) bacteremia", "PROBLEM", 96, 179], ["endocarditis", "PROBLEM", 185, 197], ["Staphylococcus aureus", "OBSERVATION", 140, 161], ["bacteremia", "OBSERVATION", 169, 179], ["endocarditis", "OBSERVATION", 185, 197]]], ["In addition to catheter removal, this patient requires a 6-week course of intravenous antibiotics.", [["intravenous", "ANATOMY", 74, 85], ["patient", "ORGANISM", 38, 45], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 74, 85], ["patient", "SPECIES", 38, 45], ["catheter removal", "TREATMENT", 15, 31], ["intravenous antibiotics", "TREATMENT", 74, 97], ["catheter", "OBSERVATION", 15, 23]]], ["Daptomycin is currently approved for treatment for bacteremia and right-sided endocarditis.", [["Daptomycin", "CHEMICAL", 0, 10], ["bacteremia", "DISEASE", 51, 61], ["right-sided endocarditis", "DISEASE", 66, 90], ["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["Daptomycin", "TREATMENT", 0, 10], ["treatment", "TREATMENT", 37, 46], ["bacteremia", "PROBLEM", 51, 61], ["right-sided endocarditis", "PROBLEM", 66, 90], ["bacteremia", "OBSERVATION", 51, 61], ["right", "ANATOMY_MODIFIER", 66, 71], ["sided", "ANATOMY_MODIFIER", 72, 77], ["endocarditis", "OBSERVATION", 78, 90]]], ["Daptomycin has been shown to be non-inferior to standard therapies in the treatment of bacteremia and right-sided endocarditis caused by S. aureus.", [["Daptomycin", "CHEMICAL", 0, 10], ["bacteremia", "DISEASE", 87, 97], ["right-sided endocarditis", "DISEASE", 102, 126], ["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["S. aureus", "ORGANISM", 137, 146], ["S. aureus", "SPECIES", 137, 146], ["S. aureus", "SPECIES", 137, 146], ["Daptomycin", "TREATMENT", 0, 10], ["standard therapies", "TREATMENT", 48, 66], ["bacteremia", "PROBLEM", 87, 97], ["right-sided endocarditis", "PROBLEM", 102, 126], ["S. aureus", "PROBLEM", 137, 146], ["bacteremia", "OBSERVATION", 87, 97], ["right", "ANATOMY_MODIFIER", 102, 107], ["sided", "ANATOMY_MODIFIER", 108, 113], ["endocarditis", "OBSERVATION", 114, 126], ["aureus", "OBSERVATION", 140, 146]]], ["Daptomycin resistance is still uncommon.", [["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["Daptomycin resistance", "TREATMENT", 0, 21]]], ["Clindamycin is not included in the consensus guidelines for treatment of MRSA-associated infective endocarditis.", [["Clindamycin", "CHEMICAL", 0, 11], ["MRSA", "CHEMICAL", 73, 77], ["infective endocarditis", "DISEASE", 89, 111], ["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["MRSA", "SPECIES", 73, 77], ["MRSA", "SPECIES", 73, 77], ["Clindamycin", "TREATMENT", 0, 11], ["treatment", "TREATMENT", 60, 69], ["MRSA", "PROBLEM", 73, 77], ["infective endocarditis", "PROBLEM", 89, 111], ["MRSA", "OBSERVATION", 73, 77], ["infective", "OBSERVATION_MODIFIER", 89, 98], ["endocarditis", "OBSERVATION", 99, 111]]], ["Clindamycin has a primarily bacteriostatic effect.", [["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "CHEMICAL", 0, 11], ["Clindamycin", "SIMPLE_CHEMICAL", 0, 11], ["Clindamycin", "TREATMENT", 0, 11], ["a primarily bacteriostatic effect", "PROBLEM", 16, 49], ["bacteriostatic effect", "OBSERVATION", 28, 49]]], ["It has been associated with treatment failure and relapse when used to treat methicillin-susceptible S. aureus bacteremia and infective endocarditis.ReferenceResults from studies support the practice of switching from vancomycin to daptomycin for the treatment of MRSA bacteremia when the vancomycin MIC is >1 \u03bcg/ mL.", [["methicillin", "CHEMICAL", 77, 88], ["S. aureus bacteremia", "DISEASE", 101, 121], ["infective endocarditis", "DISEASE", 126, 148], ["vancomycin", "CHEMICAL", 218, 228], ["daptomycin", "CHEMICAL", 232, 242], ["bacteremia", "DISEASE", 269, 279], ["vancomycin", "CHEMICAL", 289, 299], ["methicillin", "CHEMICAL", 77, 88], ["vancomycin", "CHEMICAL", 218, 228], ["daptomycin", "CHEMICAL", 232, 242], ["vancomycin", "CHEMICAL", 289, 299], ["methicillin-susceptible", "ORGANISM", 77, 100], ["S. aureus", "ORGANISM", 101, 110], ["vancomycin", "SIMPLE_CHEMICAL", 218, 228], ["daptomycin", "SIMPLE_CHEMICAL", 232, 242], ["vancomycin", "SIMPLE_CHEMICAL", 289, 299], ["S. aureus", "SPECIES", 101, 110], ["MRSA", "SPECIES", 264, 268], ["S. aureus", "SPECIES", 101, 110], ["MRSA", "SPECIES", 264, 268], ["treatment failure", "PROBLEM", 28, 45], ["relapse", "PROBLEM", 50, 57], ["methicillin", "TREATMENT", 77, 88], ["susceptible S. aureus bacteremia", "PROBLEM", 89, 121], ["infective endocarditis", "PROBLEM", 126, 148], ["vancomycin", "TREATMENT", 218, 228], ["daptomycin", "TREATMENT", 232, 242], ["MRSA bacteremia", "PROBLEM", 264, 279], ["the vancomycin MIC", "TREATMENT", 285, 303], ["associated with", "UNCERTAINTY", 12, 27], ["treatment", "OBSERVATION_MODIFIER", 28, 37], ["failure", "OBSERVATION", 38, 45], ["aureus", "OBSERVATION_MODIFIER", 104, 110], ["bacteremia", "OBSERVATION", 111, 121], ["infective", "OBSERVATION_MODIFIER", 126, 135], ["endocarditis", "OBSERVATION", 136, 148], ["MRSA", "OBSERVATION_MODIFIER", 264, 268], ["bacteremia", "OBSERVATION", 269, 279]]], ["Treatment with daptomycin results in signifi cantly improved outcomes with the patients.ReferenceFowler VG, Boucher HW, Corey GR.", [["daptomycin", "CHEMICAL", 15, 25], ["daptomycin", "CHEMICAL", 15, 25], ["daptomycin", "SIMPLE_CHEMICAL", 15, 25], ["patients", "ORGANISM", 79, 87], ["GR", "GENE_OR_GENE_PRODUCT", 126, 128], ["GR", "PROTEIN", 126, 128], ["patients", "SPECIES", 79, 87], ["daptomycin", "TREATMENT", 15, 25]]], ["Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus\".", [["Daptomycin", "CHEMICAL", 0, 10], ["bacteremia", "DISEASE", 39, 49], ["endocarditis", "DISEASE", 54, 66], ["Staphylococcus aureus", "DISEASE", 77, 98], ["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["Staphylococcus aureus", "ORGANISM", 77, 98], ["Staphylococcus aureus", "SPECIES", 77, 98], ["Staphylococcus aureus", "SPECIES", 77, 98], ["Daptomycin", "TREATMENT", 0, 10], ["standard therapy", "TREATMENT", 18, 34], ["bacteremia", "PROBLEM", 39, 49], ["endocarditis", "PROBLEM", 54, 66], ["Staphylococcus aureus\"", "PROBLEM", 77, 99], ["bacteremia", "OBSERVATION", 39, 49], ["endocarditis", "OBSERVATION", 54, 66], ["Staphylococcus aureus", "OBSERVATION", 77, 98]]], ["N Engl J Med.2006; 355 (7): 653-65.165.A 27-year-old man is evaluated for the third time in the past two months for recurrent nausea, vomiting, and cramping epigastric pain.", [["epigastric", "ANATOMY", 157, 167], ["nausea", "DISEASE", 126, 132], ["vomiting", "DISEASE", 134, 142], ["cramping epigastric pain", "DISEASE", 148, 172], ["man", "ORGANISM", 53, 56], ["epigastric", "ORGANISM_SUBDIVISION", 157, 167], ["man", "SPECIES", 53, 56], ["recurrent nausea", "PROBLEM", 116, 132], ["vomiting", "PROBLEM", 134, 142], ["cramping epigastric pain", "PROBLEM", 148, 172], ["27-", "OBSERVATION_MODIFIER", 41, 44], ["nausea", "OBSERVATION", 126, 132], ["epigastric", "ANATOMY", 157, 167], ["pain", "OBSERVATION", 168, 172]]], ["Since his symptoms began six months ago, the patient has lost 10 kg (22 lbs).", [["patient", "ORGANISM", 45, 52], ["patient", "SPECIES", 45, 52], ["his symptoms", "PROBLEM", 6, 18]]], ["He vomits several times weekly, usually in the morning.", [["He", "ORGANISM", 0, 2]]], ["He reports that his nausea persists until he takes a hot bath, which he does every day for greater than one hour.", [["nausea", "DISEASE", 20, 26], ["his nausea", "PROBLEM", 16, 26], ["a hot bath", "TREATMENT", 51, 61]]], ["Symptoms are not exacerbated by any particular food and are not alleviated by eating, bowel movements, or nonprescription proton-pump inhibitors.", [["bowel", "ANATOMY", 86, 91], ["bowel movements", "DISEASE", 86, 101], ["bowel", "ORGAN", 86, 91], ["Symptoms", "PROBLEM", 0, 8], ["nonprescription proton-pump inhibitors", "TREATMENT", 106, 144], ["bowel", "ANATOMY", 86, 91]]], ["The patient does not smoke cigarettes or drink alcoholic beverages.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Comprehensive metabolic panel and serum amylase and lipase levels were normal two months ago.165.On physical exam temperature is 36.7 C (98.0 F), pulse rate is 70 per minute, respirations are 16 per minute, and blood pressure is 127/4 mmHg.", [["serum", "ANATOMY", 34, 39], ["blood", "ANATOMY", 211, 216], ["serum", "ORGANISM_SUBSTANCE", 34, 39], ["amylase", "GENE_OR_GENE_PRODUCT", 40, 47], ["lipase", "GENE_OR_GENE_PRODUCT", 52, 58], ["blood", "ORGANISM_SUBSTANCE", 211, 216], ["serum amylase", "PROTEIN", 34, 47], ["lipase", "PROTEIN", 52, 58], ["Comprehensive metabolic panel", "TEST", 0, 29], ["serum amylase", "TEST", 34, 47], ["lipase levels", "TEST", 52, 65], ["physical exam", "TEST", 100, 113], ["temperature", "TEST", 114, 125], ["pulse rate", "TEST", 146, 156], ["respirations", "TEST", 175, 187], ["blood pressure", "TEST", 211, 225]]], ["Minimal epigastric tenderness without rebound is noted.", [["epigastric", "ANATOMY", 8, 18], ["epigastric tenderness", "DISEASE", 8, 29], ["epigastric", "ORGANISM_SUBDIVISION", 8, 18], ["Minimal epigastric tenderness", "PROBLEM", 0, 29], ["rebound", "PROBLEM", 38, 45], ["epigastric", "ANATOMY", 8, 18], ["tenderness", "OBSERVATION", 19, 29], ["without", "UNCERTAINTY", 30, 37], ["rebound", "OBSERVATION", 38, 45]]], ["The comprehensive metabolic panel, complete blood count, and serum amylase, and lipase levels are normal.165.Which of the following should be ordered to confi rm the diagnosis?", [["blood", "ANATOMY", 44, 49], ["serum", "ANATOMY", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["amylase", "GENE_OR_GENE_PRODUCT", 67, 74], ["lipase", "GENE_OR_GENE_PRODUCT", 80, 86], ["serum amylase", "PROTEIN", 61, 74], ["lipase", "PROTEIN", 80, 86], ["The comprehensive metabolic panel", "TEST", 0, 33], ["complete blood count", "TEST", 35, 55], ["serum amylase", "TEST", 61, 74], ["lipase levels", "TEST", 80, 93], ["metabolic panel", "OBSERVATION", 18, 33], ["lipase", "ANATOMY", 80, 86], ["normal", "OBSERVATION", 98, 104]]], ["A) Urine test for cannabis B) Serum alpha-fetoprotein and human chorionic gonadotropin levels C) Mesenteric artery Doppler ultrasonography D) Magnetic resonance cholangiopancreatography E) Upper endoscopy Answer: A This is a classic case of cannabis-induced hyperemesis.", [["Mesenteric artery", "ANATOMY", 97, 114], ["cannabis", "CHEMICAL", 18, 26], ["cannabis", "CHEMICAL", 241, 249], ["hyperemesis", "DISEASE", 258, 269], ["Urine", "ORGANISM_SUBSTANCE", 3, 8], ["Serum", "ORGANISM_SUBSTANCE", 30, 35], ["alpha-fetoprotein", "GENE_OR_GENE_PRODUCT", 36, 53], ["human", "ORGANISM", 58, 63], ["chorionic gonadotropin", "GENE_OR_GENE_PRODUCT", 64, 86], ["Mesenteric artery", "MULTI-TISSUE_STRUCTURE", 97, 114], ["Serum alpha-fetoprotein", "PROTEIN", 30, 53], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["A) Urine test", "TEST", 0, 13], ["cannabis", "TEST", 18, 26], ["Serum alpha-fetoprotein", "TEST", 30, 53], ["human chorionic gonadotropin levels C", "TEST", 58, 95], ["Mesenteric artery Doppler ultrasonography", "TEST", 97, 138], ["Magnetic resonance cholangiopancreatography", "TEST", 142, 185], ["Upper endoscopy", "TREATMENT", 189, 204], ["hyperemesis", "PROBLEM", 258, 269], ["Mesenteric artery", "ANATOMY", 97, 114], ["cannabis", "OBSERVATION", 241, 249], ["hyperemesis", "OBSERVATION", 258, 269]]], ["In this otherwise healthy male, excessive cannabis use may be suspected as a potential cause of unexplained symptoms of nausea.", [["cannabis", "CHEMICAL", 42, 50], ["nausea", "DISEASE", 120, 126], ["unexplained symptoms", "PROBLEM", 96, 116], ["nausea", "PROBLEM", 120, 126], ["nausea", "OBSERVATION", 120, 126]]], ["This occurs most commonly in men younger than age 50 and is associated with cyclic vomiting and occurs in the morning.", [["vomiting", "DISEASE", 83, 91], ["men", "ORGANISM", 29, 32], ["men", "SPECIES", 29, 32], ["cyclic vomiting", "PROBLEM", 76, 91]]], ["Most patients are nonsmokers, do not use other illicit drugs, and do not drink alcoholic beverages.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["The most prominent developers of this syndrome are the recreational cannabis users who began using cannabis from a very early age and also those who use it chronically or daily.", [["cannabis", "CHEMICAL", 68, 76], ["cannabis", "CHEMICAL", 99, 107], ["this syndrome", "PROBLEM", 33, 46], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["syndrome", "OBSERVATION", 38, 46]]], ["Criteria have been suggested to confi rm the diagnosis.166.A 54-year-old woman is admitted with episodes of diaphoresis, asthenia, near syncope, and confusion.", [["diaphoresis", "DISEASE", 108, 119], ["asthenia", "DISEASE", 121, 129], ["syncope", "DISEASE", 136, 143], ["confusion", "DISEASE", 149, 158], ["woman", "ORGANISM", 73, 78], ["woman", "SPECIES", 73, 78], ["diaphoresis", "PROBLEM", 108, 119], ["asthenia", "PROBLEM", 121, 129], ["near syncope", "PROBLEM", 131, 143], ["confusion", "PROBLEM", 149, 158], ["diaphoresis", "OBSERVATION", 108, 119], ["syncope", "OBSERVATION", 136, 143]]], ["She reports these symptoms for several months.", [["these symptoms", "PROBLEM", 12, 26]]], ["These episodes most commonly occur several hours after she eats.", [["These episodes", "PROBLEM", 0, 14]]], ["She has no other signifi cant medical history and takes no medications.", [["medications", "TREATMENT", 59, 70], ["no", "UNCERTAINTY", 8, 10]]], ["She has checked her glucose with her husband's glucometer and at times it has been below 50 mg/dl.", [["glucose", "CHEMICAL", 20, 27], ["glucose", "CHEMICAL", 20, 27], ["glucose", "SIMPLE_CHEMICAL", 20, 27], ["her glucose", "TEST", 16, 27], ["her husband's glucometer", "TEST", 33, 57]]], ["She is admitted for the confi rmation of hypoglycemia.", [["hypoglycemia", "DISEASE", 41, 53], ["hypoglycemia", "PROBLEM", 41, 53], ["hypoglycemia", "OBSERVATION", 41, 53]]], ["During this period the patient becomes symptomatic.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["symptomatic", "PROBLEM", 39, 50], ["symptomatic", "OBSERVATION", 39, 50]]], ["Her serum glucose concentration at the time is 41 mg/dl.", [["serum", "ANATOMY", 4, 9], ["glucose", "CHEMICAL", 10, 17], ["glucose", "CHEMICAL", 10, 17], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["glucose", "SIMPLE_CHEMICAL", 10, 17], ["Her serum glucose concentration", "TEST", 0, 31]]], ["The insulin level is elevated, and no insulin antibodies are present.", [["insulin", "GENE_OR_GENE_PRODUCT", 4, 11], ["insulin antibodies", "GENE_OR_GENE_PRODUCT", 38, 56], ["insulin", "PROTEIN", 4, 11], ["insulin antibodies", "PROTEIN", 38, 56], ["The insulin level", "TEST", 0, 17], ["elevated", "PROBLEM", 21, 29], ["insulin antibodies", "PROBLEM", 38, 56], ["elevated", "OBSERVATION_MODIFIER", 21, 29], ["no", "UNCERTAINTY", 35, 37], ["insulin antibodies", "OBSERVATION", 38, 56]]], ["The C-peptide level is high.", [["C-peptide", "GENE_OR_GENE_PRODUCT", 4, 13], ["The C-peptide level", "TEST", 0, 19], ["high", "OBSERVATION_MODIFIER", 23, 27]]], ["Tests for the use of sulfonylureas and meglitinides are negative.166.What is the diagnosis and most effective therapy for this patient's condition?", [["sulfonylureas", "CHEMICAL", 21, 34], ["meglitinides", "CHEMICAL", 39, 51], ["sulfonylureas", "CHEMICAL", 21, 34], ["meglitinides", "CHEMICAL", 39, 51], ["sulfonylureas", "SIMPLE_CHEMICAL", 21, 34], ["meglitinides", "SIMPLE_CHEMICAL", 39, 51], ["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134], ["Tests", "TEST", 0, 5], ["sulfonylureas", "TREATMENT", 21, 34], ["meglitinides", "TREATMENT", 39, 51], ["this patient's condition", "PROBLEM", 122, 146]]], ["A) Factitious insulin use, psychiatric consultation.", [["psychiatric", "DISEASE", 27, 38], ["insulin", "GENE_OR_GENE_PRODUCT", 14, 21], ["psychiatric consultation", "TEST", 27, 51]]], ["B) Observe the patient and schedule a follow-up fast 2 to 3 months from now.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["C) Begin diazoxide 400 mg TID and verapamil 180 mg QD.", [["diazoxide", "CHEMICAL", 9, 18], ["TID", "CHEMICAL", 26, 29], ["verapamil", "CHEMICAL", 34, 43], ["diazoxide", "CHEMICAL", 9, 18], ["TID", "CHEMICAL", 26, 29], ["verapamil", "CHEMICAL", 34, 43], ["diazoxide", "SIMPLE_CHEMICAL", 9, 18], ["TID", "SIMPLE_CHEMICAL", 26, 29], ["verapamil", "SIMPLE_CHEMICAL", 34, 43], ["diazoxide", "TREATMENT", 9, 18], ["verapamil", "TREATMENT", 34, 43]]], ["D) Refer the patient to surgery for imaging and resection.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["imaging", "TEST", 36, 43], ["resection", "TREATMENT", 48, 57], ["resection", "OBSERVATION", 48, 57]]], ["E) Begin phenytoin and octreotide.166.Answer: D This patient has an insulinoma.", [["insulinoma", "ANATOMY", 68, 78], ["phenytoin", "CHEMICAL", 9, 18], ["octreotide", "CHEMICAL", 23, 33], ["insulinoma", "DISEASE", 68, 78], ["phenytoin", "CHEMICAL", 9, 18], ["octreotide", "CHEMICAL", 23, 33], ["phenytoin", "SIMPLE_CHEMICAL", 9, 18], ["octreotide", "SIMPLE_CHEMICAL", 23, 33], ["patient", "ORGANISM", 53, 60], ["insulinoma", "CANCER", 68, 78], ["patient", "SPECIES", 53, 60], ["phenytoin", "TREATMENT", 9, 18], ["octreotide", "TREATMENT", 23, 33], ["an insulinoma", "PROBLEM", 65, 78], ["insulinoma", "OBSERVATION", 68, 78]]], ["C -peptide levels are high in patients with insulinomas as well as with sulfonylurea ingestion.", [["insulinomas", "ANATOMY", 44, 55], ["insulinomas", "DISEASE", 44, 55], ["sulfonylurea", "CHEMICAL", 72, 84], ["sulfonylurea", "CHEMICAL", 72, 84], ["C -peptide", "GENE_OR_GENE_PRODUCT", 0, 10], ["patients", "ORGANISM", 30, 38], ["insulinomas", "CANCER", 44, 55], ["sulfonylurea", "SIMPLE_CHEMICAL", 72, 84], ["patients", "SPECIES", 30, 38], ["C -peptide levels", "TEST", 0, 17], ["insulinomas", "PROBLEM", 44, 55], ["sulfonylurea ingestion", "PROBLEM", 72, 94], ["high", "OBSERVATION_MODIFIER", 22, 26], ["insulinomas", "OBSERVATION", 44, 55]]], ["Insulinoma is characterized by hypoglycemia caused by elevated levels of endogenous insulin.", [["Insulinoma", "DISEASE", 0, 10], ["hypoglycemia", "DISEASE", 31, 43], ["insulin", "GENE_OR_GENE_PRODUCT", 84, 91], ["endogenous insulin", "PROTEIN", 73, 91], ["Insulinoma", "PROBLEM", 0, 10], ["hypoglycemia", "PROBLEM", 31, 43], ["elevated levels", "PROBLEM", 54, 69], ["endogenous insulin", "TREATMENT", 73, 91], ["hypoglycemia", "OBSERVATION", 31, 43], ["elevated", "OBSERVATION_MODIFIER", 54, 62], ["levels", "OBSERVATION_MODIFIER", 63, 69], ["endogenous insulin", "OBSERVATION", 73, 91]]], ["Insulinomas are rare and alternative diagnosis should be actively pursued in cases of hypoglycemia.", [["Insulinomas", "DISEASE", 0, 11], ["hypoglycemia", "DISEASE", 86, 98], ["Insulinomas", "PROBLEM", 0, 11], ["hypoglycemia", "PROBLEM", 86, 98], ["hypoglycemia", "OBSERVATION", 86, 98]]], ["Once a clinical and biochemical diagnosis of insulinoma is made, the next step is localization.", [["insulinoma", "ANATOMY", 45, 55], ["insulinoma", "DISEASE", 45, 55], ["insulinoma", "CANCER", 45, 55], ["insulinoma", "PROBLEM", 45, 55], ["insulinoma", "OBSERVATION", 45, 55]]], ["There are several effective modalities.", [["several", "OBSERVATION_MODIFIER", 10, 17], ["effective", "OBSERVATION_MODIFIER", 18, 27]]], ["They include abdominal ultrasound, triple-phase spiral computed tomography, magnetic resonance imaging, and octreotide scan.", [["abdominal", "ANATOMY", 13, 22], ["octreotide", "CHEMICAL", 108, 118], ["octreotide", "CHEMICAL", 108, 118], ["abdominal", "ORGANISM_SUBDIVISION", 13, 22], ["octreotide", "SIMPLE_CHEMICAL", 108, 118], ["abdominal ultrasound", "TEST", 13, 33], ["triple-phase spiral computed tomography", "TEST", 35, 74], ["magnetic resonance imaging", "TEST", 76, 102], ["octreotide scan", "TEST", 108, 123], ["abdominal", "ANATOMY", 13, 22]]], ["This should be guided by a surgical consultation.", [["a surgical consultation", "TEST", 25, 48]]], ["The treatment of choice for insulinomas is surgical removal.166.Approximately 90-95 % of insulinomas are benign, and long-term cure with total resolution of preoperative symptoms is expected after complete resection on the lesion.", [["insulinomas", "ANATOMY", 28, 39], ["insulinomas", "ANATOMY", 89, 100], ["lesion", "ANATOMY", 223, 229], ["insulinomas", "DISEASE", 28, 39], ["insulinomas", "DISEASE", 89, 100], ["insulinomas", "CANCER", 28, 39], ["insulinomas", "CANCER", 89, 100], ["lesion", "PATHOLOGICAL_FORMATION", 223, 229], ["The treatment of choice", "TREATMENT", 0, 23], ["insulinomas", "PROBLEM", 28, 39], ["surgical removal", "TREATMENT", 43, 59], ["insulinomas", "PROBLEM", 89, 100], ["preoperative symptoms", "PROBLEM", 157, 178], ["complete resection", "TREATMENT", 197, 215], ["the lesion", "PROBLEM", 219, 229], ["insulinomas", "OBSERVATION", 89, 100], ["benign", "OBSERVATION_MODIFIER", 105, 111], ["resection", "OBSERVATION", 206, 215], ["lesion", "OBSERVATION", 223, 229]]], ["Medical therapy is less effective than tumor resection but can be used in patients who are not candidates for surgery.", [["tumor", "ANATOMY", 39, 44], ["tumor", "DISEASE", 39, 44], ["tumor", "CANCER", 39, 44], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Medical therapy", "TREATMENT", 0, 15], ["tumor resection", "TREATMENT", 39, 54], ["surgery", "TREATMENT", 110, 117], ["less effective", "OBSERVATION_MODIFIER", 19, 33]]], ["Diazoxide is the drug of choice because it inhibits insulin release from the tumor.", [["tumor", "ANATOMY", 77, 82], ["Diazoxide", "CHEMICAL", 0, 9], ["tumor", "DISEASE", 77, 82], ["Diazoxide", "CHEMICAL", 0, 9], ["Diazoxide", "SIMPLE_CHEMICAL", 0, 9], ["insulin", "GENE_OR_GENE_PRODUCT", 52, 59], ["tumor", "CANCER", 77, 82], ["Diazoxide", "TREATMENT", 0, 9], ["insulin release", "TREATMENT", 52, 67], ["the tumor", "PROBLEM", 73, 82], ["tumor", "OBSERVATION", 77, 82]]], ["Adverse effects must be treated with hydrochlorothiazide.", [["hydrochlorothiazide", "CHEMICAL", 37, 56], ["hydrochlorothiazide", "CHEMICAL", 37, 56], ["hydrochlorothiazide", "SIMPLE_CHEMICAL", 37, 56], ["hydrochlorothiazide", "TREATMENT", 37, 56]]], ["In patients not responsive to or intolerant of diazoxide, somatostatin may be indicated to prevent hypoglycemia.", [["diazoxide", "CHEMICAL", 47, 56], ["hypoglycemia", "DISEASE", 99, 111], ["diazoxide", "CHEMICAL", 47, 56], ["somatostatin", "CHEMICAL", 58, 70], ["patients", "ORGANISM", 3, 11], ["diazoxide", "SIMPLE_CHEMICAL", 47, 56], ["somatostatin", "GENE_OR_GENE_PRODUCT", 58, 70], ["patients", "SPECIES", 3, 11], ["diazoxide", "TREATMENT", 47, 56], ["somatostatin", "TREATMENT", 58, 70], ["hypoglycemia", "PROBLEM", 99, 111]]], ["A 31-year-old woman is admitted with episodes of dizziness, lightheadedness, palpitations, sweats, anxiety, and confusion.", [["dizziness", "DISEASE", 49, 58], ["lightheadedness", "DISEASE", 60, 75], ["palpitations", "DISEASE", 77, 89], ["sweats", "DISEASE", 91, 97], ["anxiety", "DISEASE", 99, 106], ["confusion", "DISEASE", 112, 121], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["dizziness", "PROBLEM", 49, 58], ["lightheadedness", "PROBLEM", 60, 75], ["palpitations", "PROBLEM", 77, 89], ["sweats", "PROBLEM", 91, 97], ["anxiety", "PROBLEM", 99, 106], ["confusion", "PROBLEM", 112, 121]]], ["Her husband checked her blood sugar level and noted it to be low.", [["blood", "ANATOMY", 24, 29], ["sugar", "CHEMICAL", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 24, 29], ["sugar", "SIMPLE_CHEMICAL", 30, 35], ["her blood sugar level", "TEST", 20, 41], ["low", "OBSERVATION", 61, 64]]], ["Her symptoms resolved after drinking some orange juice.", [["orange juice", "ANATOMY", 42, 54], ["juice", "ORGANISM_SUBSTANCE", 49, 54], ["Her symptoms", "PROBLEM", 0, 12]]], ["Physical exam is unremarkable and she is admitted for glucose monitoring.", [["glucose", "CHEMICAL", 54, 61], ["glucose", "CHEMICAL", 54, 61], ["glucose", "SIMPLE_CHEMICAL", 54, 61], ["Physical exam", "TEST", 0, 13], ["glucose monitoring", "TEST", 54, 72], ["unremarkable", "OBSERVATION", 17, 29]]], ["After 18 h, she becomes symptomatic, and her blood is drawn.", [["blood", "ANATOMY", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["symptomatic", "PROBLEM", 24, 35], ["her blood", "TEST", 41, 50], ["symptomatic", "OBSERVATION", 24, 35]]], ["The serum glucose concentration is 48 mg/dl, the serum insulin level is high, and test results are negative for insulin antibodies.", [["serum", "ANATOMY", 4, 9], ["serum", "ANATOMY", 49, 54], ["glucose", "CHEMICAL", 10, 17], ["glucose", "CHEMICAL", 10, 17], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["glucose", "SIMPLE_CHEMICAL", 10, 17], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["insulin", "GENE_OR_GENE_PRODUCT", 55, 62], ["insulin antibodies", "GENE_OR_GENE_PRODUCT", 112, 130], ["insulin antibodies", "PROTEIN", 112, 130], ["The serum glucose concentration", "TEST", 0, 31], ["the serum insulin level", "TEST", 45, 68], ["test", "TEST", 82, 86], ["insulin antibodies", "PROBLEM", 112, 130]]], ["The C-peptide level is low, and tests for sulfonylurea and meglitinides are negative.166.Which of the following is the most likely diagnosis for this patient?", [["sulfonylurea", "CHEMICAL", 42, 54], ["meglitinides", "CHEMICAL", 59, 71], ["sulfonylurea", "CHEMICAL", 42, 54], ["meglitinides", "CHEMICAL", 59, 71], ["C-peptide", "GENE_OR_GENE_PRODUCT", 4, 13], ["sulfonylurea", "SIMPLE_CHEMICAL", 42, 54], ["meglitinides", "SIMPLE_CHEMICAL", 59, 71], ["patient", "ORGANISM", 150, 157], ["patient", "SPECIES", 150, 157], ["The C-peptide level", "TEST", 0, 19], ["tests", "TEST", 32, 37], ["sulfonylurea", "TEST", 42, 54], ["meglitinides", "TEST", 59, 71]]], ["A) Insulinoma B) Factitious hypoglycemia C) Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) D) Insulin autoimmune hypoglycemia Answer: B A review of the medical literature indicates a considerable increase in the frequency of recognized factitious disorders.", [["hypoglycemia", "DISEASE", 28, 40], ["hypoglycemia syndrome", "DISEASE", 74, 95], ["NIPHS", "DISEASE", 97, 102], ["autoimmune hypoglycemia", "DISEASE", 115, 138], ["factitious disorders", "DISEASE", 249, 269], ["A) Insulinoma B", "PROBLEM", 0, 15], ["Factitious hypoglycemia C", "PROBLEM", 17, 42], ["Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS)", "PROBLEM", 44, 103], ["Insulin autoimmune hypoglycemia", "PROBLEM", 107, 138], ["factitious disorders", "PROBLEM", 249, 269], ["Insulinoma", "OBSERVATION", 3, 13], ["hypoglycemia syndrome", "OBSERVATION", 74, 95], ["considerable", "OBSERVATION_MODIFIER", 196, 208], ["increase", "OBSERVATION_MODIFIER", 209, 217]]], ["This has a signifi cant impact on the practice of hospital medicine.", [["hospital medicine", "TREATMENT", 50, 67]]], ["Factitious hypoglycemia should be considered in any patient who requires a fasting glucose test.", [["hypoglycemia", "DISEASE", 11, 23], ["glucose", "CHEMICAL", 83, 90], ["patient", "ORGANISM", 52, 59], ["glucose", "SIMPLE_CHEMICAL", 83, 90], ["patient", "SPECIES", 52, 59], ["Factitious hypoglycemia", "PROBLEM", 0, 23], ["a fasting glucose test", "TEST", 73, 95], ["hypoglycemia", "OBSERVATION", 11, 23]]], ["Factitious hypoglycemia, one of the bestcharacterized factitious diseases, is a deliberate attempt to induce hypoglycemia by means of insulin or oral hypoglycemic drugs.", [["oral", "ANATOMY", 145, 149], ["hypoglycemia", "DISEASE", 11, 23], ["factitious diseases", "DISEASE", 54, 73], ["hypoglycemia", "DISEASE", 109, 121], ["insulin", "GENE_OR_GENE_PRODUCT", 134, 141], ["oral", "ORGANISM_SUBDIVISION", 145, 149], ["Factitious hypoglycemia", "PROBLEM", 0, 23], ["the bestcharacterized factitious diseases", "PROBLEM", 32, 73], ["hypoglycemia", "PROBLEM", 109, 121], ["insulin", "TREATMENT", 134, 141], ["oral hypoglycemic drugs", "TREATMENT", 145, 168], ["hypoglycemia", "OBSERVATION", 11, 23], ["diseases", "OBSERVATION", 65, 73]]], ["Diagnosis of sulfonylurea-induced hypoglycemia requires the measurement of the drug in the serum or urine.", [["serum", "ANATOMY", 91, 96], ["urine", "ANATOMY", 100, 105], ["sulfonylurea", "CHEMICAL", 13, 25], ["hypoglycemia", "DISEASE", 34, 46], ["sulfonylurea", "CHEMICAL", 13, 25], ["sulfonylurea", "SIMPLE_CHEMICAL", 13, 25], ["serum", "ORGANISM_SUBSTANCE", 91, 96], ["urine", "ORGANISM_SUBSTANCE", 100, 105], ["sulfonylurea", "PROBLEM", 13, 25], ["induced hypoglycemia", "PROBLEM", 26, 46], ["sulfonylurea", "OBSERVATION", 13, 25], ["hypoglycemia", "OBSERVATION", 34, 46]]], ["When a diagnosis of factitious hypoglycemia is suspected, the patient's medical records should be reviewed for similar hospital admissions.", [["factitious hypoglycemia", "DISEASE", 20, 43], ["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["factitious hypoglycemia", "PROBLEM", 20, 43]]], ["Factitious hypoglycemia is more common in women.", [["hypoglycemia", "DISEASE", 11, 23], ["women", "ORGANISM", 42, 47], ["women", "SPECIES", 42, 47], ["Factitious hypoglycemia", "PROBLEM", 0, 23], ["hypoglycemia", "OBSERVATION", 11, 23], ["more common", "OBSERVATION_MODIFIER", 27, 38]]], ["It occurs most often in the third or fourth decade of life.", [["most often", "OBSERVATION_MODIFIER", 10, 20]]], ["Many of these patients work in health-related occupations.ReferenceGrunberger G, Weiner JL, Silverman R, et al. Factitious hypoglycemia due to surreptitious administration of insulin.", [["hypoglycemia", "DISEASE", 123, 135], ["patients", "ORGANISM", 14, 22], ["insulin", "GENE_OR_GENE_PRODUCT", 175, 182], ["insulin", "PROTEIN", 175, 182], ["patients", "SPECIES", 14, 22], ["Factitious hypoglycemia", "PROBLEM", 112, 135], ["surreptitious administration of insulin", "TREATMENT", 143, 182], ["hypoglycemia", "OBSERVATION", 123, 135]]], ["Diagnosis, treatment, and long-term follow-up.", [["treatment", "TREATMENT", 11, 20]]], ["A 37-year-old female with a history of intravenous drug use presents with fever and decreased urine output.", [["intravenous", "ANATOMY", 39, 50], ["urine", "ANATOMY", 94, 99], ["fever", "DISEASE", 74, 79], ["decreased urine output", "DISEASE", 84, 106], ["female", "ORGANISM", 14, 20], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 39, 50], ["urine", "ORGANISM_SUBSTANCE", 94, 99], ["fever", "PROBLEM", 74, 79], ["decreased urine output", "PROBLEM", 84, 106], ["37-", "OBSERVATION_MODIFIER", 2, 5], ["fever", "OBSERVATION", 74, 79], ["decreased", "OBSERVATION_MODIFIER", 84, 93], ["urine output", "OBSERVATION", 94, 106]]], ["She is noted to have a new cardiac murmur, and a transthoracic echocardiogram reveals vegetation on the tricuspid valve.", [["cardiac", "ANATOMY", 27, 34], ["tricuspid valve", "ANATOMY", 104, 119], ["cardiac murmur", "DISEASE", 27, 41], ["cardiac", "ORGAN", 27, 34], ["tricuspid valve", "PATHOLOGICAL_FORMATION", 104, 119], ["a new cardiac murmur", "PROBLEM", 21, 41], ["a transthoracic echocardiogram", "TEST", 47, 77], ["vegetation on the tricuspid valve", "PROBLEM", 86, 119], ["new", "OBSERVATION_MODIFIER", 23, 26], ["cardiac", "ANATOMY", 27, 34], ["murmur", "OBSERVATION", 35, 41], ["vegetation", "OBSERVATION", 86, 96], ["tricuspid valve", "ANATOMY", 104, 119]]], ["She is started on antibiotics.", [["antibiotics", "TREATMENT", 18, 29]]], ["Acute renal failure does not resolve.", [["renal", "ANATOMY", 6, 11], ["Acute renal failure", "DISEASE", 0, 19], ["renal", "ORGAN", 6, 11], ["Acute renal failure", "PROBLEM", 0, 19], ["renal", "ANATOMY", 6, 11], ["failure", "OBSERVATION", 12, 19], ["not", "UNCERTAINTY", 25, 28], ["resolve", "OBSERVATION_MODIFIER", 29, 36]]], ["On initial workup complement, levels are checked and are low.", [["initial workup complement", "TEST", 3, 28], ["levels", "TEST", 30, 36], ["low", "OBSERVATION_MODIFIER", 57, 60]]], ["Hepatitis C serology is positive.", [["Hepatitis C", "DISEASE", 0, 11], ["Hepatitis C", "ORGANISM", 0, 11], ["Hepatitis C serology", "TEST", 0, 20]]], ["A renal biopsy is pursued.", [["renal", "ANATOMY", 2, 7], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 2, 14], ["A renal biopsy", "TEST", 0, 14], ["renal", "ANATOMY", 2, 7], ["biopsy", "OBSERVATION", 8, 14]]], ["What is the most likely fi nding on kidney histology?", [["kidney", "ANATOMY", 36, 42], ["kidney", "ORGAN", 36, 42], ["kidney histology", "TEST", 36, 52], ["most likely", "UNCERTAINTY", 12, 23], ["kidney", "ANATOMY", 36, 42], ["histology", "OBSERVATION", 43, 52]]], ["A) Normal biopsy B) \"Tram-track\" double-layered basement membrane C) \"Spike and dome\" granular deposits at the basement membrane D) Subendothelial immune complex deposition E) Apple-green birefringence under polarized light Answer: B Membranoproliferative glomerulonephritis (MPGN) is the most likely diagnosis.", [["basement membrane", "ANATOMY", 48, 65], ["basement membrane", "ANATOMY", 111, 128], ["glomerulonephritis", "DISEASE", 256, 274], ["MPGN", "DISEASE", 276, 280], ["Tram", "TEST", 21, 25], ["double-layered basement membrane", "TREATMENT", 33, 65], ["Spike", "PROBLEM", 70, 75], ["dome\" granular deposits", "PROBLEM", 80, 103], ["Subendothelial immune complex deposition E", "TREATMENT", 132, 174], ["B Membranoproliferative glomerulonephritis", "PROBLEM", 232, 274], ["granular deposits", "OBSERVATION", 86, 103], ["Membranoproliferative", "OBSERVATION_MODIFIER", 234, 255], ["glomerulonephritis", "OBSERVATION", 256, 274], ["most likely", "UNCERTAINTY", 289, 300]]], ["Several factors suggest this including hepatitis C infection and endocarditis, along with low complement levels.", [["hepatitis C infection", "DISEASE", 39, 60], ["endocarditis", "DISEASE", 65, 77], ["hepatitis C", "ORGANISM", 39, 50], ["hepatitis C infection", "PROBLEM", 39, 60], ["endocarditis", "PROBLEM", 65, 77], ["low complement levels", "PROBLEM", 90, 111], ["suggest this including", "UNCERTAINTY", 16, 38], ["hepatitis", "OBSERVATION", 39, 48], ["infection", "OBSERVATION", 51, 60], ["endocarditis", "OBSERVATION", 65, 77]]], ["A biopsy will likely show classic \"tram-tracking\" of the basement membrane.", [["basement membrane", "ANATOMY", 57, 74], ["basement membrane", "CELLULAR_COMPONENT", 57, 74], ["A biopsy", "TEST", 0, 8], ["basement membrane", "ANATOMY", 57, 74]]], ["Normal biopsies may be seen with minimal change disease.", [["biopsies", "ANATOMY", 7, 15], ["biopsies", "CANCER", 7, 15], ["minimal change disease", "PROBLEM", 33, 55], ["biopsies", "OBSERVATION", 7, 15], ["may be seen with", "UNCERTAINTY", 16, 32], ["minimal", "OBSERVATION_MODIFIER", 33, 40], ["change", "OBSERVATION", 41, 47]]], ["Granular spike and dome deposits are more characteristic of membranous nephropathy.", [["nephropathy", "DISEASE", 71, 82], ["Granular spike", "PROBLEM", 0, 14], ["dome deposits", "PROBLEM", 19, 32], ["membranous nephropathy", "PROBLEM", 60, 82], ["spike", "OBSERVATION_MODIFIER", 9, 14], ["dome deposits", "OBSERVATION", 19, 32], ["more characteristic", "OBSERVATION_MODIFIER", 37, 56], ["membranous", "OBSERVATION_MODIFIER", 60, 70], ["nephropathy", "OBSERVATION", 71, 82]]], ["Subendothelial immune complexes are seen in lupus nephritis.", [["lupus nephritis", "DISEASE", 44, 59], ["Subendothelial immune complexes", "PROTEIN", 0, 31], ["Subendothelial immune complexes", "PROBLEM", 0, 31], ["lupus nephritis", "PROBLEM", 44, 59], ["immune complexes", "OBSERVATION", 15, 31], ["lupus", "OBSERVATION_MODIFIER", 44, 49], ["nephritis", "OBSERVATION", 50, 59]]], ["Apple-green birefringence is characteristic of amyloidosis.", [["amyloidosis", "DISEASE", 47, 58], ["amyloidosis", "PROBLEM", 47, 58], ["green birefringence", "OBSERVATION_MODIFIER", 6, 25], ["characteristic of", "UNCERTAINTY", 29, 46], ["amyloidosis", "OBSERVATION", 47, 58]]], ["A 20-year-old female presents with diarrhea, nausea, and fever.", [["diarrhea", "DISEASE", 35, 43], ["nausea", "DISEASE", 45, 51], ["fever", "DISEASE", 57, 62], ["female", "ORGANISM", 14, 20], ["diarrhea", "PROBLEM", 35, 43], ["nausea", "PROBLEM", 45, 51], ["fever", "PROBLEM", 57, 62], ["20-", "OBSERVATION_MODIFIER", 2, 5], ["diarrhea", "OBSERVATION", 35, 43], ["nausea", "OBSERVATION", 45, 51], ["fever", "OBSERVATION", 57, 62]]], ["She reports greater than ten stools in the past 24 h.", [["greater", "OBSERVATION_MODIFIER", 12, 19]]], ["In addition, she has a temperature of 38.9 C (102.0 \u00b0F).", [["a temperature", "TEST", 21, 34]]], ["She is started on ciprofl oxacin.", [["ciprofl oxacin", "CHEMICAL", 18, 32], ["ciprofl oxacin", "CHEMICAL", 18, 32], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 18, 32], ["ciprofl oxacin", "TREATMENT", 18, 32]]], ["Stool cultures are sent.", [["Stool cultures", "ANATOMY", 0, 14], ["Stool cultures", "TEST", 0, 14]]], ["Clostridium diffi cile is negative.", [["Clostridium diffi cile", "ORGANISM", 0, 22], ["Clostridium diffi", "SPECIES", 0, 17], ["Clostridium diffi cile", "SPECIES", 0, 22], ["Clostridium diffi cile", "TEST", 0, 22], ["negative", "OBSERVATION", 26, 34]]], ["On the second day of her hospitalization, the patient has a grand mal seizure.", [["seizure", "DISEASE", 70, 77], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["a grand mal seizure", "PROBLEM", 58, 77]]], ["Which of the following is the most likely cause?ReferenceAnswer: B This patient has gastroenteritis consistent with an enteroinvasive bacterial infection.", [["gastroenteritis", "DISEASE", 84, 99], ["bacterial infection", "DISEASE", 134, 153], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["gastroenteritis", "PROBLEM", 84, 99], ["an enteroinvasive bacterial infection", "PROBLEM", 116, 153], ["most likely", "UNCERTAINTY", 30, 41], ["gastroenteritis", "OBSERVATION", 84, 99], ["consistent with", "UNCERTAINTY", 100, 115], ["enteroinvasive", "OBSERVATION_MODIFIER", 119, 133], ["bacterial", "OBSERVATION_MODIFIER", 134, 143], ["infection", "OBSERVATION", 144, 153]]], ["Shigella is the most common bacterial cause of acute gastroenteritis in the United States and has been associated with seizures.ReferenceShigella infection presents with the sudden onset of severe abdominal cramping, high-grade fever, emesis, anorexia, and large-volume watery diarrhea.", [["abdominal", "ANATOMY", 197, 206], ["gastroenteritis", "DISEASE", 53, 68], ["seizures", "DISEASE", 119, 127], ["Shigella infection", "DISEASE", 137, 155], ["abdominal cramping", "DISEASE", 197, 215], ["fever", "DISEASE", 228, 233], ["emesis", "DISEASE", 235, 241], ["anorexia", "DISEASE", 243, 251], ["watery diarrhea", "DISEASE", 270, 285], ["Shigella", "ORGANISM", 0, 8], ["abdominal", "ORGANISM_SUBDIVISION", 197, 206], ["Shigella", "PROBLEM", 0, 8], ["acute gastroenteritis", "PROBLEM", 47, 68], ["seizures", "PROBLEM", 119, 127], ["ReferenceShigella infection", "PROBLEM", 128, 155], ["severe abdominal cramping", "PROBLEM", 190, 215], ["high-grade fever", "PROBLEM", 217, 233], ["emesis", "PROBLEM", 235, 241], ["anorexia", "PROBLEM", 243, 251], ["large-volume watery diarrhea", "PROBLEM", 257, 285], ["most common", "OBSERVATION_MODIFIER", 16, 27], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["gastroenteritis", "OBSERVATION", 53, 68], ["associated with", "UNCERTAINTY", 103, 118], ["seizures", "OBSERVATION", 119, 127], ["Shigella", "OBSERVATION_MODIFIER", 137, 145], ["infection", "OBSERVATION", 146, 155], ["severe", "OBSERVATION_MODIFIER", 190, 196], ["abdominal", "ANATOMY", 197, 206], ["cramping", "OBSERVATION", 207, 215], ["high-grade", "OBSERVATION_MODIFIER", 217, 227], ["fever", "OBSERVATION", 228, 233], ["emesis", "OBSERVATION", 235, 241], ["anorexia", "OBSERVATION", 243, 251], ["large", "OBSERVATION_MODIFIER", 257, 262], ["-volume", "OBSERVATION_MODIFIER", 262, 269], ["watery diarrhea", "OBSERVATION", 270, 285]]], ["Seizures may be an early manifestation.", [["Seizures", "DISEASE", 0, 8], ["Seizures", "PROBLEM", 0, 8], ["early", "OBSERVATION_MODIFIER", 19, 24]]], ["Campylobacter and Yersinia may cause a febrile illness that mimics appendicitis.", [["Campylobacter and Yersinia", "DISEASE", 0, 26], ["febrile illness", "DISEASE", 39, 54], ["appendicitis", "DISEASE", 67, 79], ["Campylobacter", "PROBLEM", 0, 13], ["Yersinia", "PROBLEM", 18, 26], ["a febrile illness", "PROBLEM", 37, 54], ["appendicitis", "PROBLEM", 67, 79], ["Yersinia", "OBSERVATION", 18, 26], ["may cause", "UNCERTAINTY", 27, 36], ["febrile", "OBSERVATION_MODIFIER", 39, 46], ["appendicitis", "OBSERVATION", 67, 79]]], ["Vibrio species usually cause a nonspecifi c gastroenteritis.ReferenceKhan WA, Dhar U, Salam MA, et al. Central nervous system manifestations of childhood shigellosis: prevalence, risk factors, and outcome.", [["Central nervous system", "ANATOMY", 103, 125], ["gastroenteritis", "DISEASE", 44, 59], ["shigellosis", "DISEASE", 154, 165], ["Vibrio species", "ORGANISM", 0, 14], ["nervous system", "ANATOMICAL_SYSTEM", 111, 125], ["Vibrio species", "PROBLEM", 0, 14], ["a nonspecifi c gastroenteritis", "PROBLEM", 29, 59], ["childhood shigellosis", "PROBLEM", 144, 165], ["gastroenteritis", "OBSERVATION", 44, 59], ["nervous system", "ANATOMY", 111, 125], ["childhood", "OBSERVATION_MODIFIER", 144, 153], ["shigellosis", "OBSERVATION", 154, 165]]], ["A 37-year-old man form a nursing home is evaluated for the acute onset of headache, nausea, and lethargy.", [["headache", "DISEASE", 74, 82], ["nausea", "DISEASE", 84, 90], ["lethargy", "DISEASE", 96, 104], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["headache", "PROBLEM", 74, 82], ["nausea", "PROBLEM", 84, 90], ["lethargy", "PROBLEM", 96, 104], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["headache", "OBSERVATION", 74, 82], ["nausea", "OBSERVATION", 84, 90]]], ["He has a history of obstructive hydrocephalus for which he underwent ventriculoperitoneal shunt placement approximately 3 months ago.", [["ventriculoperitoneal", "ANATOMY", 69, 89], ["obstructive hydrocephalus", "DISEASE", 20, 45], ["obstructive hydrocephalus", "PROBLEM", 20, 45], ["ventriculoperitoneal shunt placement", "TREATMENT", 69, 105], ["obstructive", "OBSERVATION_MODIFIER", 20, 31], ["hydrocephalus", "OBSERVATION", 32, 45], ["ventriculoperitoneal", "ANATOMY", 69, 89], ["shunt", "OBSERVATION", 90, 95]]], ["Per family, he has baseline mental retardation but currently has had subtle changes in his behavior.", [["retardation", "DISEASE", 35, 46], ["baseline mental retardation", "PROBLEM", 19, 46], ["subtle changes in his behavior", "PROBLEM", 69, 99], ["mental retardation", "OBSERVATION", 28, 46]]], ["This has occurred with prior urinary tract infections.", [["urinary tract", "ANATOMY", 29, 42], ["urinary tract infections", "DISEASE", 29, 53], ["urinary tract", "ORGANISM_SUBDIVISION", 29, 42], ["prior urinary tract infections", "PROBLEM", 23, 53], ["urinary tract", "ANATOMY", 29, 42], ["infections", "OBSERVATION", 43, 53]]], ["On physical examination, the temperature is 38.0 \u00b0 C (100.4 \u00b0 F), blood pressure is 115/70 mmHg, pulse rate is 95 bpm, and respiration rate is 14/min.", [["blood", "ANATOMY", 66, 71], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["C", "TEST", 51, 52], ["blood pressure", "TEST", 66, 80], ["pulse rate", "TEST", 97, 107], ["respiration rate", "TEST", 123, 139]]], ["Examination of the scalp reveals the presence of the shunt catheter without tenderness or erythema along the site.", [["scalp", "ANATOMY", 19, 24], ["tenderness", "DISEASE", 76, 86], ["erythema", "DISEASE", 90, 98], ["scalp", "ORGAN", 19, 24], ["erythema", "PATHOLOGICAL_FORMATION", 90, 98], ["Examination of the scalp", "TEST", 0, 24], ["the shunt catheter", "TREATMENT", 49, 67], ["tenderness", "PROBLEM", 76, 86], ["erythema along the site", "PROBLEM", 90, 113], ["scalp", "ANATOMY", 19, 24], ["shunt catheter", "OBSERVATION", 53, 67], ["without", "UNCERTAINTY", 68, 75], ["tenderness", "OBSERVATION", 76, 86], ["erythema", "OBSERVATION", 90, 98]]], ["He is oriented only to person and place as is his baseline.", [["person", "SPECIES", 23, 29]]], ["The remainder of the physical examination is normal.ReferenceLaboratory studies indicate a leukocyte count of 15,000/\u03bcL (11 \u00d7 109/L) with a normal differential.", [["leukocyte", "ANATOMY", 91, 100], ["leukocyte", "CELL", 91, 100], ["the physical examination", "TEST", 17, 41], ["ReferenceLaboratory studies", "TEST", 52, 79], ["a leukocyte count", "TEST", 89, 106], ["remainder", "ANATOMY_MODIFIER", 4, 13], ["normal", "OBSERVATION", 45, 51], ["normal differential", "OBSERVATION_MODIFIER", 140, 159]]], ["Urinalysis is within normal limits.", [["Urinalysis", "TEST", 0, 10], ["within normal limits", "OBSERVATION", 14, 34]]], ["Blood cultures are pending.", [["Blood cultures", "ANATOMY", 0, 14], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14]]], ["Neurosurgery is consulted for tapping of the shunt.ReferencePending culture results, which of the following antimicrobial regimens should be initiated in this patient?", [["patient", "ORGANISM", 159, 166], ["patient", "SPECIES", 159, 166], ["the shunt", "TREATMENT", 41, 50], ["ReferencePending culture", "TEST", 51, 75], ["antimicrobial regimens", "TREATMENT", 108, 130], ["shunt", "OBSERVATION", 45, 50]]], ["A) Trimethoprim-sulfamethoxazole B) Trimethoprim-sulfamethoxazole plus rifampin C) Vancomycin D) Vancomycin, ampicillin, plus ceftriaxone E) Vancomycin plus cefepime Answer: E This patient may have a cerebrospinal fl uid (CSF) shunt infection.", [["Trimethoprim-sulfamethoxazole B", "CHEMICAL", 3, 34], ["Trimethoprim-sulfamethoxazole", "CHEMICAL", 36, 65], ["rifampin", "CHEMICAL", 71, 79], ["Vancomycin D", "CHEMICAL", 83, 95], ["Vancomycin", "CHEMICAL", 97, 107], ["ampicillin", "CHEMICAL", 109, 119], ["ceftriaxone", "CHEMICAL", 126, 137], ["Vancomycin", "CHEMICAL", 141, 151], ["cefepime", "CHEMICAL", 157, 165], ["cerebrospinal fl uid", "DISEASE", 200, 220], ["shunt infection", "DISEASE", 227, 242], ["Trimethoprim-sulfamethoxazole B", "CHEMICAL", 3, 34], ["Trimethoprim-sulfamethoxazole", "CHEMICAL", 36, 65], ["rifampin C", "CHEMICAL", 71, 81], ["Vancomycin D", "CHEMICAL", 83, 95], ["Vancomycin", "CHEMICAL", 97, 107], ["ampicillin", "CHEMICAL", 109, 119], ["ceftriaxone E", "CHEMICAL", 126, 139], ["Vancomycin", "CHEMICAL", 141, 151], ["cefepime", "CHEMICAL", 157, 165], ["Trimethoprim-sulfamethoxazole B", "SIMPLE_CHEMICAL", 3, 34], ["Trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 36, 65], ["rifampin C", "SIMPLE_CHEMICAL", 71, 81], ["Vancomycin D", "SIMPLE_CHEMICAL", 83, 95], ["Vancomycin", "SIMPLE_CHEMICAL", 97, 107], ["ampicillin", "SIMPLE_CHEMICAL", 109, 119], ["ceftriaxone E", "SIMPLE_CHEMICAL", 126, 139], ["Vancomycin", "SIMPLE_CHEMICAL", 141, 151], ["cefepime", "SIMPLE_CHEMICAL", 157, 165], ["patient", "ORGANISM", 181, 188], ["cerebrospinal fl uid", "GENE_OR_GENE_PRODUCT", 200, 220], ["CSF", "GENE_OR_GENE_PRODUCT", 222, 225], ["patient", "SPECIES", 181, 188], ["E", "SPECIES", 174, 175], ["A) Trimethoprim-sulfamethoxazole B", "TREATMENT", 0, 34], ["Trimethoprim", "TREATMENT", 36, 48], ["sulfamethoxazole plus rifampin C", "TREATMENT", 49, 81], ["Vancomycin D", "TREATMENT", 83, 95], ["Vancomycin", "TREATMENT", 97, 107], ["ampicillin", "TREATMENT", 109, 119], ["ceftriaxone E", "TREATMENT", 126, 139], ["Vancomycin", "TREATMENT", 141, 151], ["cefepime", "TREATMENT", 157, 165], ["a cerebrospinal fl uid (CSF) shunt infection", "PROBLEM", 198, 242], ["cerebrospinal fl", "ANATOMY", 200, 216], ["shunt", "OBSERVATION_MODIFIER", 227, 232], ["infection", "OBSERVATION", 233, 242]]], ["Ventriculoperitoneal shunt infections can be diffi cult to diagnose owing to the mild and variable clinical presentation.", [["Ventriculoperitoneal", "ANATOMY", 0, 20], ["shunt infections", "DISEASE", 21, 37], ["Ventriculoperitoneal", "MULTI-TISSUE_STRUCTURE", 0, 20], ["Ventriculoperitoneal shunt infections", "PROBLEM", 0, 37], ["the mild and variable clinical presentation", "PROBLEM", 77, 120], ["shunt", "OBSERVATION", 21, 26], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["variable", "OBSERVATION_MODIFIER", 90, 98]]], ["Symptoms may refl ect increased intracranial pressure and may be subtle, such as lethargy, nausea, and headache.", [["intracranial", "ANATOMY", 32, 44], ["lethargy", "DISEASE", 81, 89], ["nausea", "DISEASE", 91, 97], ["headache", "DISEASE", 103, 111], ["intracranial", "IMMATERIAL_ANATOMICAL_ENTITY", 32, 44], ["Symptoms", "PROBLEM", 0, 8], ["ect increased intracranial pressure", "PROBLEM", 18, 53], ["lethargy", "PROBLEM", 81, 89], ["nausea", "PROBLEM", 91, 97], ["headache", "PROBLEM", 103, 111], ["intracranial pressure", "OBSERVATION", 32, 53], ["may be", "UNCERTAINTY", 58, 64], ["subtle", "OBSERVATION_MODIFIER", 65, 71]]], ["Classic meningeal symptoms may be absent, and fever may or may not be present.", [["meningeal", "ANATOMY", 8, 17], ["fever", "DISEASE", 46, 51], ["Classic meningeal symptoms", "PROBLEM", 0, 26], ["fever", "PROBLEM", 46, 51], ["meningeal", "ANATOMY", 8, 17], ["may not be", "UNCERTAINTY", 59, 69]]], ["Patterns may be consistent with previous infections.", [["infections", "DISEASE", 41, 51], ["previous infections", "PROBLEM", 32, 51], ["may be consistent with", "UNCERTAINTY", 9, 31], ["infections", "OBSERVATION", 41, 51]]], ["The recent placement of a shunt warrants antibiotic coverage for a possible infection.", [["infection", "DISEASE", 76, 85], ["a shunt", "TREATMENT", 24, 31], ["antibiotic coverage", "TREATMENT", 41, 60], ["infection", "PROBLEM", 76, 85], ["shunt", "OBSERVATION", 26, 31], ["possible", "UNCERTAINTY", 67, 75], ["infection", "OBSERVATION", 76, 85]]], ["The most likely causative micro-organisms of a shunt infection are coagulase-negative staphylococci S. aureus , diphtheroids including Propionibacterium acnes , and gram-negative bacilli such as Pseudomonas aeruginosa .", [["shunt infection", "DISEASE", 47, 62], ["Propionibacterium acnes", "DISEASE", 135, 158], ["S. aureus", "ORGANISM", 100, 109], ["Propionibacterium acnes", "ORGANISM", 135, 158], ["Pseudomonas aeruginosa", "ORGANISM", 195, 217], ["S. aureus", "SPECIES", 100, 109], ["Propionibacterium acnes", "SPECIES", 135, 158], ["Pseudomonas aeruginosa", "SPECIES", 195, 217], ["S. aureus", "SPECIES", 100, 109], ["Propionibacterium acnes", "SPECIES", 135, 158], ["Pseudomonas aeruginosa", "SPECIES", 195, 217], ["a shunt infection", "PROBLEM", 45, 62], ["coagulase", "TEST", 67, 76], ["staphylococci S. aureus", "PROBLEM", 86, 109], ["diphtheroids", "PROBLEM", 112, 124], ["Propionibacterium acnes", "PROBLEM", 135, 158], ["gram-negative bacilli", "PROBLEM", 165, 186], ["Pseudomonas aeruginosa", "PROBLEM", 195, 217], ["most likely", "UNCERTAINTY", 4, 15], ["causative", "OBSERVATION_MODIFIER", 16, 25], ["micro-organisms", "OBSERVATION", 26, 41], ["shunt infection", "OBSERVATION", 47, 62], ["negative staphylococci", "OBSERVATION_MODIFIER", 77, 99], ["aureus", "OBSERVATION_MODIFIER", 103, 109], ["negative bacilli", "OBSERVATION", 170, 186]]], ["Empiric therapy with vancomycin to cover staphylococci and diphtheroids and ceftazidime, cefepime, or meropenem to treat the gram-negative bacilli is appropriate pending CSF tap results.", [["vancomycin", "CHEMICAL", 21, 31], ["staphylococci", "DISEASE", 41, 54], ["diphtheroids", "CHEMICAL", 59, 71], ["ceftazidime", "CHEMICAL", 76, 87], ["cefepime", "CHEMICAL", 89, 97], ["meropenem", "CHEMICAL", 102, 111], ["vancomycin", "CHEMICAL", 21, 31], ["ceftazidime", "CHEMICAL", 76, 87], ["cefepime", "CHEMICAL", 89, 97], ["meropenem", "CHEMICAL", 102, 111], ["vancomycin", "SIMPLE_CHEMICAL", 21, 31], ["diphtheroids", "SIMPLE_CHEMICAL", 59, 71], ["ceftazidime", "SIMPLE_CHEMICAL", 76, 87], ["cefepime", "SIMPLE_CHEMICAL", 89, 97], ["meropenem", "SIMPLE_CHEMICAL", 102, 111], ["CSF", "GENE_OR_GENE_PRODUCT", 170, 173], ["Empiric therapy", "TREATMENT", 0, 15], ["vancomycin", "TREATMENT", 21, 31], ["staphylococci", "PROBLEM", 41, 54], ["diphtheroids", "TREATMENT", 59, 71], ["ceftazidime", "TREATMENT", 76, 87], ["cefepime", "TREATMENT", 89, 97], ["meropenem", "TREATMENT", 102, 111], ["the gram", "TEST", 121, 129], ["negative bacilli", "PROBLEM", 130, 146], ["CSF tap", "TEST", 170, 177], ["negative bacilli", "OBSERVATION", 130, 146]]], ["A shunt tap should only be considered after imaging of the brain and a shunt series is performed.", [["brain", "ANATOMY", 59, 64], ["brain", "ORGAN", 59, 64], ["A shunt tap", "TREATMENT", 0, 11], ["imaging of the brain", "TEST", 44, 64], ["a shunt series", "TEST", 69, 83], ["shunt", "OBSERVATION", 2, 7], ["brain", "ANATOMY", 59, 64]]], ["Other infections should also be excluded, since shunt infections are less likely less than 3 months after placement.", [["infections", "DISEASE", 6, 16], ["shunt infections", "DISEASE", 48, 64], ["Other infections", "PROBLEM", 0, 16], ["shunt infections", "PROBLEM", 48, 64], ["placement", "TREATMENT", 106, 115], ["infections", "OBSERVATION", 6, 16], ["should also be excluded", "UNCERTAINTY", 17, 40], ["infections", "OBSERVATION", 54, 64]]], ["On physical exam temperature is 38.8 \u00b0C(100.8\u00b0), heart rate is102 bpm, blood pressure is 108/80 mmHg, and oxygen saturation of 92 % on room air at rest.", [["heart", "ANATOMY", 49, 54], ["blood", "ANATOMY", 71, 76], ["oxygen", "CHEMICAL", 106, 112], ["oxygen", "CHEMICAL", 106, 112], ["heart", "ORGAN", 49, 54], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["oxygen", "SIMPLE_CHEMICAL", 106, 112], ["physical exam", "TEST", 3, 16], ["temperature", "TEST", 17, 28], ["\u00b0C", "TEST", 37, 39], ["heart rate", "TEST", 49, 59], ["blood pressure", "TEST", 71, 85], ["oxygen saturation", "TEST", 106, 123]]], ["Decreased breath sounds and dullness upon percussion are noted at the left lung base.ReferencesChest radiograph reveals a signifi cant pleural effusion.", [["left lung", "ANATOMY", 70, 79], ["pleural", "ANATOMY", 135, 142], ["pleural effusion", "DISEASE", 135, 151], ["lung", "ORGAN", 75, 79], ["pleural", "PATHOLOGICAL_FORMATION", 135, 142], ["Decreased breath sounds", "PROBLEM", 0, 23], ["dullness", "PROBLEM", 28, 36], ["percussion", "TEST", 42, 52], ["Chest radiograph", "TEST", 95, 111], ["a signifi cant pleural effusion", "PROBLEM", 120, 151], ["breath sounds", "OBSERVATION", 10, 23], ["dullness", "OBSERVATION", 28, 36], ["percussion", "OBSERVATION_MODIFIER", 42, 52], ["left lung", "ANATOMY", 70, 79], ["base", "ANATOMY_MODIFIER", 80, 84], ["pleural", "ANATOMY", 135, 142], ["effusion", "OBSERVATION", 143, 151]]], ["A thoracentesis is performed at the bedside.ReferencesWhich of the following results from the fl uid analysis match the accompanying diagnosis?", [["A thoracentesis", "TREATMENT", 0, 15], ["the fl uid analysis", "TEST", 90, 109], ["thoracentesis", "OBSERVATION", 2, 15]]], ["A) Pleural protein LDH of 260, a serum LDH of 100, WBC count differential 80 % neutrophils; parapneumonic effusion B) Pleural protein of 1.5 with a serum protein of 4; tuberculosis C) Pleural amylase of 250; pancreatitis D) A and C E) A and B Answer: D In the evaluation of pleural fl uid, the initial diagnostic consideration is distinguishing transudates from exudates.", [["Pleural", "ANATOMY", 3, 10], ["serum", "ANATOMY", 33, 38], ["WBC", "ANATOMY", 51, 54], ["neutrophils", "ANATOMY", 79, 90], ["serum", "ANATOMY", 148, 153], ["pleural fl uid", "ANATOMY", 274, 288], ["exudates", "ANATOMY", 362, 370], ["parapneumonic effusion", "DISEASE", 92, 114], ["tuberculosis", "DISEASE", 168, 180], ["pancreatitis", "DISEASE", 208, 220], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["LDH", "GENE_OR_GENE_PRODUCT", 39, 42], ["neutrophils", "CELL", 79, 90], ["serum", "ORGANISM_SUBSTANCE", 148, 153], ["exudates", "TISSUE", 362, 370], ["neutrophils", "CELL_TYPE", 79, 90], ["serum protein", "PROTEIN", 148, 161], ["A) Pleural protein LDH", "TEST", 0, 22], ["a serum LDH", "TEST", 31, 42], ["WBC count", "TEST", 51, 60], ["differential", "TEST", 61, 73], ["neutrophils", "TEST", 79, 90], ["parapneumonic effusion", "PROBLEM", 92, 114], ["Pleural protein", "TEST", 118, 133], ["a serum protein", "TEST", 146, 161], ["tuberculosis C", "TEST", 168, 182], ["Pleural amylase", "TEST", 184, 199], ["pancreatitis", "PROBLEM", 208, 220], ["the evaluation", "TEST", 256, 270], ["transudates", "PROBLEM", 345, 356], ["exudates", "PROBLEM", 362, 370], ["Pleural", "ANATOMY", 3, 10], ["parapneumonic", "OBSERVATION_MODIFIER", 92, 105], ["effusion", "OBSERVATION", 106, 114], ["Pleural", "ANATOMY", 118, 125], ["Pleural", "ANATOMY", 184, 191], ["pleural", "ANATOMY", 274, 281], ["fl", "OBSERVATION", 282, 284], ["transudates", "OBSERVATION", 345, 356], ["exudates", "OBSERVATION", 362, 370]]], ["Although a number of chemical tests have been proposed to differentiate pleural fl uid transudates from exudates, the tests fi rst proposed by Light have become the standard.", [["pleural", "ANATOMY", 72, 79], ["exudates", "ANATOMY", 104, 112], ["chemical tests", "TEST", 21, 35], ["pleural fl uid transudates", "PROBLEM", 72, 98], ["exudates", "PROBLEM", 104, 112], ["the tests fi rst", "TEST", 114, 130], ["pleural", "ANATOMY", 72, 79], ["exudates", "OBSERVATION_MODIFIER", 104, 112]]], ["Common causes of exudative pleural effusions include parapneumonic effusions from typical bacterial infections, tuberculosis, connective tissue diseases, malignancy, and pancreatitis.", [["exudative pleural effusions", "ANATOMY", 17, 44], ["connective tissue", "ANATOMY", 126, 143], ["pleural effusions", "DISEASE", 27, 44], ["parapneumonic effusions", "DISEASE", 53, 76], ["bacterial infections", "DISEASE", 90, 110], ["tuberculosis", "DISEASE", 112, 124], ["connective tissue diseases", "DISEASE", 126, 152], ["malignancy", "DISEASE", 154, 164], ["pancreatitis", "DISEASE", 170, 182], ["pleural effusions", "PATHOLOGICAL_FORMATION", 27, 44], ["connective tissue", "TISSUE", 126, 143], ["exudative pleural effusions", "PROBLEM", 17, 44], ["parapneumonic effusions", "PROBLEM", 53, 76], ["typical bacterial infections", "PROBLEM", 82, 110], ["tuberculosis", "PROBLEM", 112, 124], ["connective tissue diseases", "PROBLEM", 126, 152], ["malignancy", "PROBLEM", 154, 164], ["pancreatitis", "PROBLEM", 170, 182], ["exudative", "OBSERVATION_MODIFIER", 17, 26], ["pleural", "ANATOMY", 27, 34], ["effusions", "OBSERVATION", 35, 44], ["parapneumonic", "OBSERVATION_MODIFIER", 53, 66], ["effusions", "OBSERVATION", 67, 76], ["typical", "OBSERVATION_MODIFIER", 82, 89], ["bacterial", "OBSERVATION_MODIFIER", 90, 99], ["infections", "OBSERVATION", 100, 110], ["tuberculosis", "OBSERVATION", 112, 124], ["connective tissue diseases", "OBSERVATION", 126, 152], ["malignancy", "OBSERVATION", 154, 164], ["pancreatitis", "OBSERVATION", 170, 182]]], ["A high pleural amylase level (>200) may indicate pancreatitis or esophageal rupture.", [["pleural", "ANATOMY", 7, 14], ["esophageal", "ANATOMY", 65, 75], ["pancreatitis", "DISEASE", 49, 61], ["esophageal rupture", "DISEASE", 65, 83], ["pleural", "ORGANISM_SUBSTANCE", 7, 14], ["amylase", "GENE_OR_GENE_PRODUCT", 15, 22], ["esophageal", "ORGAN", 65, 75], ["A high pleural amylase level", "TEST", 0, 28], ["pancreatitis", "PROBLEM", 49, 61], ["esophageal rupture", "PROBLEM", 65, 83], ["high", "OBSERVATION_MODIFIER", 2, 6], ["pleural", "ANATOMY", 7, 14], ["amylase", "OBSERVATION", 15, 22], ["may indicate", "UNCERTAINTY", 36, 48], ["pancreatitis", "OBSERVATION", 49, 61], ["esophageal", "ANATOMY", 65, 75], ["rupture", "OBSERVATION", 76, 83]]], ["The criteria from Light identify nearly all exudates correctly, but they misclassify approximately 20-25 % of transudates as exudates.", [["exudates", "ANATOMY", 125, 133], ["transudates", "PROBLEM", 110, 121], ["exudates", "PROBLEM", 125, 133], ["exudates", "OBSERVATION", 125, 133]]], ["This usually occurs in patients on longterm diuretic therapy for congestive heart failure.", [["heart", "ANATOMY", 76, 81], ["congestive heart failure", "DISEASE", 65, 89], ["patients", "ORGANISM", 23, 31], ["heart", "ORGAN", 76, 81], ["patients", "SPECIES", 23, 31], ["longterm diuretic therapy", "TREATMENT", 35, 60], ["congestive heart failure", "PROBLEM", 65, 89], ["heart", "ANATOMY", 76, 81], ["failure", "OBSERVATION", 82, 89]]], ["This tends to concentrate the protein and LDH levels within the pleural space.", [["pleural space", "ANATOMY", 64, 77], ["LDH", "GENE_OR_GENE_PRODUCT", 42, 45], ["pleural space", "MULTI-TISSUE_STRUCTURE", 64, 77], ["LDH", "PROTEIN", 42, 45], ["the protein and LDH levels", "TEST", 26, 52], ["LDH levels", "OBSERVATION", 42, 52], ["pleural", "ANATOMY", 64, 71]]], ["A 57-year-old male with a known 35-year history of alcohol abuse presents with jaundice, ascites, and a left shoulder fracture following a bar room brawl last night.", [["ascites", "ANATOMY", 89, 96], ["left shoulder", "ANATOMY", 104, 117], ["alcohol abuse", "DISEASE", 51, 64], ["jaundice", "DISEASE", 79, 87], ["ascites", "DISEASE", 89, 96], ["left shoulder fracture", "DISEASE", 104, 126], ["alcohol", "CHEMICAL", 51, 58], ["male", "ORGANISM", 14, 18], ["alcohol", "ORGANISM", 51, 58], ["shoulder", "ORGANISM_SUBDIVISION", 109, 117], ["jaundice", "PROBLEM", 79, 87], ["ascites", "PROBLEM", 89, 96], ["a left shoulder fracture", "PROBLEM", 102, 126], ["alcohol abuse", "OBSERVATION", 51, 64], ["jaundice", "OBSERVATION", 79, 87], ["ascites", "OBSERVATION", 89, 96], ["left", "ANATOMY_MODIFIER", 104, 108], ["shoulder", "ANATOMY", 109, 117], ["fracture", "OBSERVATION", 118, 126]]], ["On admission his liver functions are elevated but not markedly different from baseline.", [["liver", "ANATOMY", 17, 22], ["liver", "ORGAN", 17, 22], ["his liver functions", "TEST", 13, 32], ["elevated", "PROBLEM", 37, 45], ["liver", "ANATOMY", 17, 22], ["elevated", "OBSERVATION", 37, 45], ["markedly", "OBSERVATION_MODIFIER", 54, 62], ["different", "OBSERVATION_MODIFIER", 63, 72]]], ["Due to intoxication and possible management of alcohol withdrawal, he is admitted to the hospital medicine service.", [["alcohol", "CHEMICAL", 47, 54], ["alcohol", "CHEMICAL", 47, 54], ["alcohol", "SIMPLE_CHEMICAL", 47, 54], ["intoxication", "PROBLEM", 7, 19], ["management", "TREATMENT", 33, 43], ["alcohol withdrawal", "PROBLEM", 47, 65], ["alcohol withdrawal", "OBSERVATION", 47, 65]]], ["He has been followed by hepatology for possible liver transplant but has not been abstinent from alcohol.", [["liver", "ANATOMY", 48, 53], ["alcohol", "CHEMICAL", 97, 104], ["alcohol", "CHEMICAL", 97, 104], ["liver", "ORGAN", 48, 53], ["alcohol", "SIMPLE_CHEMICAL", 97, 104], ["liver transplant", "TREATMENT", 48, 64], ["liver", "ANATOMY", 48, 53], ["transplant", "OBSERVATION", 54, 64]]], ["He is in moderate to severe pain.", [["pain", "DISEASE", 28, 32], ["moderate to severe pain", "PROBLEM", 9, 32], ["moderate", "OBSERVATION_MODIFIER", 9, 17], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["pain", "OBSERVATION", 28, 32]]], ["In reference to pain control, which of the following should be avoided in this patient?", [["pain", "DISEASE", 16, 20], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["pain control", "TREATMENT", 16, 28]]], ["A) Acetaminophen 325 mg every 6 h B) Hydrocodone 5 mg every 6 h C) Hydromorphone 0.5 mg iv every 6 h D) NSAIDS Answer: D Analgesia in cirrhotic patients can be challenging.", [["Acetaminophen", "CHEMICAL", 3, 16], ["Hydrocodone", "CHEMICAL", 37, 48], ["Hydromorphone", "CHEMICAL", 67, 80], ["cirrhotic", "DISEASE", 134, 143], ["Acetaminophen", "CHEMICAL", 3, 16], ["Hydrocodone", "CHEMICAL", 37, 48], ["Hydromorphone", "CHEMICAL", 67, 80], ["Acetaminophen", "SIMPLE_CHEMICAL", 3, 16], ["Hydromorphone", "SIMPLE_CHEMICAL", 67, 80], ["D", "SIMPLE_CHEMICAL", 119, 120], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["Acetaminophen", "TREATMENT", 3, 16], ["Hydrocodone", "TREATMENT", 37, 48], ["Hydromorphone", "TREATMENT", 67, 80], ["NSAIDS", "TREATMENT", 104, 110], ["D Analgesia", "TREATMENT", 119, 130]]], ["Few prospective studies have offered an evidence-based approach.", [["Few prospective studies", "TEST", 0, 23]]], ["End-stage liver disease patients have important issues that make analgesia potentially risky.", [["liver", "ANATOMY", 10, 15], ["End-stage liver disease", "DISEASE", 0, 23], ["liver", "ORGAN", 10, 15], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["End-stage liver disease", "PROBLEM", 0, 23], ["important issues", "PROBLEM", 38, 54], ["analgesia", "TREATMENT", 65, 74], ["-stage", "OBSERVATION_MODIFIER", 3, 9], ["liver", "ANATOMY", 10, 15], ["disease", "OBSERVATION", 16, 23]]], ["These include hepatic impairments in drug metabolism, chronic mental status changes, and renal dysfunction.", [["hepatic", "ANATOMY", 14, 21], ["renal", "ANATOMY", 89, 94], ["hepatic impairments", "DISEASE", 14, 33], ["renal dysfunction", "DISEASE", 89, 106], ["hepatic", "MULTI-TISSUE_STRUCTURE", 14, 21], ["renal", "ORGAN", 89, 94], ["hepatic impairments", "PROBLEM", 14, 33], ["drug metabolism", "PROBLEM", 37, 52], ["chronic mental status changes", "PROBLEM", 54, 83], ["renal dysfunction", "PROBLEM", 89, 106], ["hepatic", "ANATOMY", 14, 21], ["impairments", "OBSERVATION", 22, 33], ["drug metabolism", "OBSERVATION", 37, 52], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["mental status", "OBSERVATION", 62, 75], ["renal", "ANATOMY", 89, 94], ["dysfunction", "OBSERVATION", 95, 106]]], ["Acetaminophen is the most common cause of fulminant hepatic failure in the United States.", [["hepatic", "ANATOMY", 52, 59], ["Acetaminophen", "CHEMICAL", 0, 13], ["fulminant hepatic failure", "DISEASE", 42, 67], ["Acetaminophen", "CHEMICAL", 0, 13], ["Acetaminophen", "SIMPLE_CHEMICAL", 0, 13], ["hepatic", "ORGAN", 52, 59], ["Acetaminophen", "TREATMENT", 0, 13], ["fulminant hepatic failure", "PROBLEM", 42, 67], ["most common", "OBSERVATION_MODIFIER", 21, 32], ["fulminant", "OBSERVATION_MODIFIER", 42, 51], ["hepatic", "ANATOMY", 52, 59], ["failure", "OBSERVATION", 60, 67]]], ["NSAIDS may be contraindicated in cirrhotic patients because of decreased renal blood fl ow and ensuing hepatorenal syndrome.", [["renal blood", "ANATOMY", 73, 84], ["NSAIDS", "CHEMICAL", 0, 6], ["cirrhotic", "DISEASE", 33, 42], ["hepatorenal syndrome", "DISEASE", 103, 123], ["NSAIDS", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 43, 51], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["patients", "SPECIES", 43, 51], ["NSAIDS", "TREATMENT", 0, 6], ["decreased renal blood fl ow", "PROBLEM", 63, 90], ["hepatorenal syndrome", "PROBLEM", 103, 123], ["may be contraindicated", "UNCERTAINTY", 7, 29], ["cirrhotic", "OBSERVATION", 33, 42], ["decreased", "OBSERVATION", 63, 72], ["renal", "ANATOMY", 73, 78], ["blood fl ow", "OBSERVATION", 79, 90], ["hepatorenal syndrome", "OBSERVATION", 103, 123]]], ["The approach to analgesia in the cirrhotic population should be cautious but practical.", [["cirrhotic", "DISEASE", 33, 42], ["analgesia", "TREATMENT", 16, 25], ["the cirrhotic population", "TREATMENT", 29, 53], ["cirrhotic", "OBSERVATION", 33, 42]]], ["Frequent monitoring is needed, including mental status, hepatic function, and renal function.", [["hepatic", "ANATOMY", 56, 63], ["renal", "ANATOMY", 78, 83], ["hepatic", "MULTI-TISSUE_STRUCTURE", 56, 63], ["renal", "ORGAN", 78, 83], ["Frequent monitoring", "TEST", 0, 19], ["hepatic function", "TEST", 56, 72], ["hepatic", "ANATOMY", 56, 63], ["renal", "ANATOMY", 78, 83]]], ["You are called to see a 67-year-old man to evaluate a change in his mental status.", [["man", "ORGANISM", 36, 39], ["man", "SPECIES", 36, 39], ["a change in his mental status", "PROBLEM", 52, 81]]], ["He was admitted 36 h ago for treatment of community-acquired pneumonia.", [["pneumonia", "DISEASE", 61, 70], ["He", "ORGANISM", 0, 2], ["treatment", "TREATMENT", 29, 38], ["community-acquired pneumonia", "PROBLEM", 42, 70], ["pneumonia", "OBSERVATION", 61, 70]]], ["On a brief review of his past medical and social history, you note that he has been on no prior medications and reports alcohol intake of no greater than one beer daily.", [["alcohol", "CHEMICAL", 120, 127], ["alcohol", "CHEMICAL", 120, 127], ["alcohol", "SIMPLE_CHEMICAL", 120, 127], ["prior medications", "TREATMENT", 90, 107]]], ["On admission his mental status was normal.ReferenceOn physical exam his blood pressure is 160/85 mmHg, heart rate of 92 beats/min, respiratory rate of 20 breaths/min, temperature of 37.4 \u00b0C (99.3 \u00b0F), and SaO2 of 92 % on oxygen 2 L/min.", [["blood", "ANATOMY", 72, 77], ["heart", "ANATOMY", 103, 108], ["oxygen", "CHEMICAL", 221, 227], ["oxygen", "CHEMICAL", 221, 227], ["blood", "ORGANISM_SUBSTANCE", 72, 77], ["heart", "ORGAN", 103, 108], ["ReferenceOn physical exam", "TEST", 42, 67], ["his blood pressure", "TEST", 68, 86], ["heart rate", "TEST", 103, 113], ["respiratory rate", "TEST", 131, 147], ["temperature", "TEST", 167, 178], ["\u00b0C", "TEST", 187, 189], ["SaO2", "TEST", 205, 209], ["oxygen", "TREATMENT", 221, 227], ["normal", "OBSERVATION", 35, 41]]], ["He is agitated and restless in bed.", [["agitated", "PROBLEM", 6, 14], ["restless", "PROBLEM", 19, 27], ["agitated", "OBSERVATION", 6, 14]]], ["He has removed his IV and oxygen tubing from his nose.", [["nose", "ANATOMY", 49, 53], ["oxygen", "CHEMICAL", 26, 32], ["oxygen", "CHEMICAL", 26, 32], ["He", "ORGANISM", 0, 2], ["oxygen", "SIMPLE_CHEMICAL", 26, 32], ["nose", "ORGANISM_SUBDIVISION", 49, 53], ["his IV and oxygen tubing", "TREATMENT", 15, 39], ["oxygen tubing", "OBSERVATION", 26, 39], ["nose", "ANATOMY", 49, 53]]], ["He is noted to be somewhat tremulous and diaphoretic.ReferenceWhich of the following is most likely to be beneficial in establishing the diagnosis?", [["somewhat tremulous", "PROBLEM", 18, 36], ["diaphoretic", "PROBLEM", 41, 52], ["somewhat", "OBSERVATION_MODIFIER", 18, 26], ["tremulous", "OBSERVATION", 27, 36], ["most likely", "UNCERTAINTY", 88, 99]]], ["A) Arterial blood gas testing B) MRI or head CT C) Fingerstick glucose testing D) Review of the patient's alcohol intake with his wife E) Review of the recent medications received by the patient Answer: D This patient has features of acute delirium, which can be precipitated by many causes in hospitalized patients.", [["Arterial blood", "ANATOMY", 3, 17], ["head", "ANATOMY", 40, 44], ["alcohol", "CHEMICAL", 106, 113], ["delirium", "DISEASE", 240, 248], ["glucose", "CHEMICAL", 63, 70], ["alcohol", "CHEMICAL", 106, 113], ["D", "CHEMICAL", 203, 204], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["glucose", "SIMPLE_CHEMICAL", 63, 70], ["patient", "ORGANISM", 96, 103], ["alcohol", "ORGANISM_SUBDIVISION", 106, 113], ["patient", "ORGANISM", 187, 194], ["patient", "ORGANISM", 210, 217], ["patients", "ORGANISM", 307, 315], ["patient", "SPECIES", 96, 103], ["patient", "SPECIES", 187, 194], ["patient", "SPECIES", 210, 217], ["patients", "SPECIES", 307, 315], ["A) Arterial blood gas testing", "TEST", 0, 29], ["MRI", "TEST", 33, 36], ["head CT C", "TEST", 40, 49], ["Fingerstick glucose testing", "TEST", 51, 78], ["the recent medications", "TREATMENT", 148, 170], ["acute delirium", "PROBLEM", 234, 248], ["Arterial", "ANATOMY", 3, 11], ["head", "ANATOMY", 40, 44], ["acute", "OBSERVATION_MODIFIER", 234, 239], ["delirium", "OBSERVATION", 240, 248]]], ["The clinical picture is most consistent with alcohol withdrawal.", [["alcohol", "CHEMICAL", 45, 52], ["alcohol", "CHEMICAL", 45, 52], ["alcohol", "SIMPLE_CHEMICAL", 45, 52], ["alcohol withdrawal", "PROBLEM", 45, 63], ["most consistent with", "UNCERTAINTY", 24, 44], ["alcohol withdrawal", "OBSERVATION", 45, 63]]], ["Alcohol withdrawal is common and despite minimal reported use in this patient, it is the most likely diagnosis.", [["Alcohol", "CHEMICAL", 0, 7], ["patient", "ORGANISM", 70, 77], ["patient", "SPECIES", 70, 77], ["Alcohol withdrawal", "PROBLEM", 0, 18], ["most likely", "UNCERTAINTY", 89, 100]]], ["Further discussion with a second source may reveal his actual alcohol use.", [["alcohol", "CHEMICAL", 62, 69], ["alcohol", "CHEMICAL", 62, 69], ["alcohol", "SIMPLE_CHEMICAL", 62, 69]]], ["Although commonly ordered, brain imaging is often not helpful in the evaluation of delirium.", [["brain", "ANATOMY", 27, 32], ["delirium", "DISEASE", 83, 91], ["brain", "ORGAN", 27, 32], ["brain imaging", "TEST", 27, 40], ["the evaluation", "TEST", 65, 79], ["delirium", "PROBLEM", 83, 91], ["delirium", "OBSERVATION", 83, 91]]], ["Patients vastly underestimate and report the actual amount of alcohol consumed.", [["alcohol", "CHEMICAL", 62, 69], ["alcohol", "CHEMICAL", 62, 69], ["Patients", "ORGANISM", 0, 8], ["alcohol", "SIMPLE_CHEMICAL", 62, 69], ["Patients", "SPECIES", 0, 8]]], ["It has been suggested that asking if alcohol has been ingested in the past 24 h is a better, nonthreatening screening question to identify heavy drinkers.", [["alcohol", "CHEMICAL", 37, 44], ["alcohol", "CHEMICAL", 37, 44], ["alcohol", "SIMPLE_CHEMICAL", 37, 44]]], ["A 67-year-old female presents with confusion and slurred speech.", [["confusion", "DISEASE", 35, 44], ["female", "ORGANISM", 14, 20], ["confusion", "PROBLEM", 35, 44], ["slurred speech", "PROBLEM", 49, 63]]], ["The mother who brought the patient to the emergency room says that they went out to eat the previous night and developed symptoms this morning.ReferencesOther than a jejunoileal bypass many years ago, the patient has enjoyed good health.", [["patient", "ORGANISM", 27, 34], ["patient", "ORGANISM", 205, 212], ["patient", "SPECIES", 27, 34], ["patient", "SPECIES", 205, 212], ["symptoms", "PROBLEM", 121, 129], ["a jejunoileal bypass", "TREATMENT", 164, 184], ["jejunoileal bypass", "OBSERVATION", 166, 184]]], ["There is no history of alcohol or substance abuse.", [["alcohol", "CHEMICAL", 23, 30], ["substance abuse", "DISEASE", 34, 49], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "SIMPLE_CHEMICAL", 23, 30], ["no", "UNCERTAINTY", 9, 11]]], ["She is on no medicines.ReferencesOn examination, the patient has appearance of being intoxicated.", [["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["medicines", "TREATMENT", 13, 22], ["ReferencesOn examination", "TEST", 23, 47], ["being intoxicated", "PROBLEM", 79, 96]]], ["Temperature is 37.4 C (99.3 F), pulse rate is 96 per minute, respirations are 24 per minute, and blood pressure is 130/80 mmHg.", [["blood", "ANATOMY", 97, 102], ["blood", "ORGANISM_SUBSTANCE", 97, 102], ["Temperature", "TEST", 0, 11], ["pulse rate", "TEST", 32, 42], ["respirations", "TEST", 61, 73], ["blood pressure", "TEST", 97, 111]]], ["The lungs are clear.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["lungs", "ANATOMY", 4, 9], ["clear", "OBSERVATION", 14, 19]]], ["The abdomen is soft and nontender, and a healed midline scar is noted.", [["abdomen", "ANATOMY", 4, 11], ["midline scar", "ANATOMY", 48, 60], ["abdomen", "ORGAN", 4, 11], ["midline scar", "PATHOLOGICAL_FORMATION", 48, 60], ["nontender", "PROBLEM", 24, 33], ["a healed midline scar", "PROBLEM", 39, 60], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33], ["healed", "OBSERVATION_MODIFIER", 41, 47], ["midline", "OBSERVATION_MODIFIER", 48, 55], ["scar", "OBSERVATION", 56, 60]]], ["No edema, cyanosis, or clubbing of the extremities is noted.", [["edema", "ANATOMY", 3, 8], ["extremities", "ANATOMY", 39, 50], ["edema", "DISEASE", 3, 8], ["cyanosis", "DISEASE", 10, 18], ["clubbing of the extremities", "DISEASE", 23, 50], ["edema", "PATHOLOGICAL_FORMATION", 3, 8], ["extremities", "ORGANISM_SUBDIVISION", 39, 50], ["edema", "PROBLEM", 3, 8], ["cyanosis", "PROBLEM", 10, 18], ["clubbing of the extremities", "PROBLEM", 23, 50], ["edema", "OBSERVATION", 3, 8], ["cyanosis", "OBSERVATION", 10, 18], ["clubbing", "OBSERVATION", 23, 31], ["extremities", "ANATOMY", 39, 50]]], ["The patient is oriented to person only.ReferencesPlasma glucose is 152 mg/dL, blood urea nitrogen is 17 mg/dL, serum ammonia is 18 ug/dL, and bicarbonate is mEq/L 13 mEq/L. Arterial blood gas studies reveals a pH 7.26 a PCO2 0f 227 mmHg.", [["blood", "ANATOMY", 78, 83], ["serum", "ANATOMY", 111, 116], ["Arterial blood", "ANATOMY", 173, 187], ["glucose", "CHEMICAL", 56, 63], ["blood urea nitrogen", "CHEMICAL", 78, 97], ["ammonia", "CHEMICAL", 117, 124], ["bicarbonate", "CHEMICAL", 142, 153], ["glucose", "CHEMICAL", 56, 63], ["urea", "CHEMICAL", 84, 88], ["nitrogen", "CHEMICAL", 89, 97], ["ammonia", "CHEMICAL", 117, 124], ["bicarbonate", "CHEMICAL", 142, 153], ["patient", "ORGANISM", 4, 11], ["Plasma", "ORGANISM_SUBSTANCE", 49, 55], ["glucose", "SIMPLE_CHEMICAL", 56, 63], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["urea", "SIMPLE_CHEMICAL", 84, 88], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["ammonia", "SIMPLE_CHEMICAL", 117, 124], ["bicarbonate", "SIMPLE_CHEMICAL", 142, 153], ["blood", "ORGANISM_SUBSTANCE", 182, 187], ["patient", "SPECIES", 4, 11], ["person", "SPECIES", 27, 33], ["Plasma glucose", "TEST", 49, 63], ["blood urea nitrogen", "TEST", 78, 97], ["serum ammonia", "TEST", 111, 124], ["bicarbonate", "TEST", 142, 153], ["Arterial blood gas studies", "TEST", 173, 199], ["a pH", "TEST", 208, 212], ["a PCO2", "TEST", 218, 224], ["mmHg", "TEST", 232, 236], ["Arterial", "ANATOMY", 173, 181]]], ["Venous blood lactate is 1.3 mmol/L. Blood ethanol is negative.", [["Venous blood", "ANATOMY", 0, 12], ["Blood", "ANATOMY", 36, 41], ["lactate", "CHEMICAL", 13, 20], ["ethanol", "CHEMICAL", 42, 49], ["lactate", "CHEMICAL", 13, 20], ["ethanol", "CHEMICAL", 42, 49], ["Venous", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["lactate", "SIMPLE_CHEMICAL", 13, 20], ["Blood", "ORGANISM_SUBSTANCE", 36, 41], ["ethanol", "SIMPLE_CHEMICAL", 42, 49], ["Venous blood lactate", "TEST", 0, 20], ["Blood ethanol", "TEST", 36, 49], ["negative", "OBSERVATION", 53, 61]]], ["Urine drug screen is negative.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine drug screen", "TEST", 0, 17]]], ["CT imaging of her head is normal.", [["head", "ANATOMY", 18, 22], ["head", "ORGANISM_SUBDIVISION", 18, 22], ["CT imaging of her head", "TEST", 0, 22], ["head", "ANATOMY", 18, 22], ["normal", "OBSERVATION", 26, 32]]], ["A) Serotonin syndrome B) Salicylate poisoning C) D-lactic acidosis D) Vitamin B1 defi ciency E) Vitamin B6 Answer: C D-lactic acidosis can occur in patients with jejunoileal bypass or short bowel syndrome.", [["jejunoileal", "ANATOMY", 162, 173], ["bowel", "ANATOMY", 190, 195], ["Serotonin", "CHEMICAL", 3, 12], ["Salicylate", "CHEMICAL", 25, 35], ["poisoning", "DISEASE", 36, 45], ["acidosis", "DISEASE", 58, 66], ["Vitamin B1", "CHEMICAL", 70, 80], ["Vitamin B6", "CHEMICAL", 96, 106], ["D-lactic acidosis", "DISEASE", 117, 134], ["short bowel syndrome", "DISEASE", 184, 204], ["Serotonin", "CHEMICAL", 3, 12], ["Salicylate", "CHEMICAL", 25, 35], ["Vitamin B1", "CHEMICAL", 70, 80], ["Vitamin B6", "CHEMICAL", 96, 106], ["Vitamin B1 defi ciency E) Vitamin B6", "SIMPLE_CHEMICAL", 70, 106], ["C D-lactic acidosis", "SIMPLE_CHEMICAL", 115, 134], ["patients", "ORGANISM", 148, 156], ["bowel", "ORGAN", 190, 195], ["patients", "SPECIES", 148, 156], ["A) Serotonin syndrome", "PROBLEM", 0, 21], ["Salicylate poisoning C", "PROBLEM", 25, 47], ["D-lactic acidosis D", "PROBLEM", 49, 68], ["Vitamin B1 defi ciency E", "TREATMENT", 70, 94], ["Vitamin B6", "TREATMENT", 96, 106], ["C D-lactic acidosis", "PROBLEM", 115, 134], ["jejunoileal bypass", "TREATMENT", 162, 180], ["short bowel syndrome", "PROBLEM", 184, 204], ["Serotonin syndrome", "OBSERVATION", 3, 21], ["jejunoileal", "ANATOMY", 162, 173], ["bypass", "OBSERVATION", 174, 180], ["bowel", "ANATOMY", 190, 195], ["syndrome", "OBSERVATION", 196, 204]]], ["Symptoms typically present after the ingestion of high-carbohydrate feedings.ReferencesIn abnormal bowel, the overgrowth of gram-positive anaerobes such as lactobacilli is able to produce excessive lactate from carbohydrates.", [["bowel", "ANATOMY", 99, 104], ["lactobacilli", "CHEMICAL", 156, 168], ["lactate", "CHEMICAL", 198, 205], ["carbohydrate", "CHEMICAL", 55, 67], ["lactate", "CHEMICAL", 198, 205], ["carbohydrates", "CHEMICAL", 211, 224], ["bowel", "ORGAN", 99, 104], ["lactobacilli", "SIMPLE_CHEMICAL", 156, 168], ["lactate", "SIMPLE_CHEMICAL", 198, 205], ["carbohydrates", "SIMPLE_CHEMICAL", 211, 224], ["Symptoms", "PROBLEM", 0, 8], ["high-carbohydrate feedings", "TREATMENT", 50, 76], ["abnormal bowel", "PROBLEM", 90, 104], ["the overgrowth of gram-positive anaerobes", "PROBLEM", 106, 147], ["lactobacilli", "TREATMENT", 156, 168], ["excessive lactate from carbohydrates", "PROBLEM", 188, 224], ["abnormal", "OBSERVATION_MODIFIER", 90, 98], ["bowel", "ANATOMY", 99, 104], ["overgrowth", "OBSERVATION_MODIFIER", 110, 120], ["positive anaerobes", "OBSERVATION_MODIFIER", 129, 147]]], ["These patients develop the appearance of intoxication including confusion, ataxia, and slurred speech.", [["confusion", "DISEASE", 64, 73], ["ataxia", "DISEASE", 75, 81], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["intoxication", "PROBLEM", 41, 53], ["confusion", "PROBLEM", 64, 73], ["ataxia", "PROBLEM", 75, 81], ["slurred speech", "PROBLEM", 87, 101], ["intoxication", "OBSERVATION", 41, 53]]], ["Jejunoileal bypass was a surgical weight loss procedure performed for the relief of morbid obesity.", [["weight loss", "DISEASE", 34, 45], ["obesity", "DISEASE", 91, 98], ["Jejunoileal bypass", "TREATMENT", 0, 18], ["a surgical weight loss procedure", "TREATMENT", 23, 55], ["morbid obesity", "PROBLEM", 84, 98], ["bypass", "OBSERVATION", 12, 18], ["morbid", "OBSERVATION_MODIFIER", 84, 90], ["obesity", "OBSERVATION", 91, 98]]], ["Many patients developed complications secondary to malabsorption.", [["malabsorption", "DISEASE", 51, 64], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["complications", "PROBLEM", 24, 37], ["malabsorption", "PROBLEM", 51, 64], ["complications", "OBSERVATION", 24, 37], ["malabsorption", "OBSERVATION", 51, 64]]], ["As a consequence of all these complications, jejunoileal bypass is no longer a recommended bariatric surgical procedure.", [["jejunoileal", "ANATOMY", 45, 56], ["all these complications", "PROBLEM", 20, 43], ["jejunoileal bypass", "TREATMENT", 45, 63], ["bariatric surgical procedure", "TREATMENT", 91, 119], ["complications", "OBSERVATION", 30, 43], ["jejunoileal bypass", "OBSERVATION", 45, 63], ["no longer", "UNCERTAINTY", 67, 76]]], ["Many patients have required reversal of the procedure.ReferencesOver the next 3 days of hospitalization, his BUN and Cr fall.", [["Cr", "CHEMICAL", 117, 119], ["Cr", "CHEMICAL", 117, 119], ["patients", "ORGANISM", 5, 13], ["BUN", "SIMPLE_CHEMICAL", 109, 112], ["patients", "SPECIES", 5, 13], ["the procedure", "TREATMENT", 40, 53], ["his BUN", "TEST", 105, 112], ["Cr fall", "PROBLEM", 117, 124]]], ["On the second day, his urine output is found to be rising.", [["urine", "ANATOMY", 23, 28], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["his urine output", "TEST", 19, 35], ["rising", "OBSERVATION_MODIFIER", 51, 57]]], ["He is not receiving intravenous fl uids.", [["intravenous", "ANATOMY", 20, 31], ["He", "ORGANISM", 0, 2], ["intravenous fl uids", "TREATMENT", 20, 39]]], ["He passes 6.5 L of urine on the third and fourth hospital days.ReferencesThe patient is at risk for which of the following complications?", [["urine", "ANATOMY", 19, 24], ["urine", "ORGANISM_SUBSTANCE", 19, 24], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["the following complications", "PROBLEM", 109, 136], ["6.5 L", "OBSERVATION_MODIFIER", 10, 15]]], ["A) Erythrocytosis B) Hyperchloremic metabolic acidosis C) Hyperkalemia D) Prerenal azotemia E) Systemic hypertension Answer: D Postobstructive diuresis is defi ned as high urine output exceeding 0.5 L per hour occurring after an obstruction is relieved.", [["urine", "ANATOMY", 172, 177], ["metabolic acidosis", "DISEASE", 36, 54], ["azotemia", "DISEASE", 83, 91], ["hypertension", "DISEASE", 104, 116], ["urine", "ORGANISM_SUBSTANCE", 172, 177], ["A) Erythrocytosis B", "PROBLEM", 0, 19], ["Hyperchloremic metabolic acidosis C", "PROBLEM", 21, 56], ["Hyperkalemia D", "PROBLEM", 58, 72], ["Prerenal azotemia E", "PROBLEM", 74, 93], ["Systemic hypertension", "PROBLEM", 95, 116], ["D Postobstructive diuresis", "TREATMENT", 125, 151], ["high urine output", "PROBLEM", 167, 184], ["an obstruction", "PROBLEM", 226, 240], ["Erythrocytosis", "OBSERVATION", 3, 17], ["Hyperchloremic", "OBSERVATION_MODIFIER", 21, 35], ["metabolic acidosis", "OBSERVATION", 36, 54], ["azotemia", "OBSERVATION", 83, 91], ["Systemic", "ANATOMY", 95, 103], ["hypertension", "OBSERVATION", 104, 116], ["obstruction", "OBSERVATION", 229, 240]]], ["This happens particularly in patients with chronic obstruction.", [["chronic obstruction", "DISEASE", 43, 62], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["chronic obstruction", "PROBLEM", 43, 62], ["chronic", "OBSERVATION_MODIFIER", 43, 50], ["obstruction", "OBSERVATION", 51, 62]]], ["Severity ranges from a self-limiting physiologic process lasting 48 h to a pathologic sodiumwasting form.", [["Severity ranges", "PROBLEM", 0, 15], ["a self-limiting physiologic process", "PROBLEM", 21, 56], ["self-limiting", "OBSERVATION_MODIFIER", 23, 36]]], ["Postobstructive diuresis is usually selflimited.", [["Postobstructive diuresis", "TREATMENT", 0, 24], ["diuresis", "OBSERVATION", 16, 24]]], ["Urea diuresis is the most common and resolves by itself within 24-48 h.", [["Urea", "CHEMICAL", 0, 4], ["Urea", "CHEMICAL", 0, 4], ["Urea", "SIMPLE_CHEMICAL", 0, 4], ["Urea diuresis", "TREATMENT", 0, 13], ["diuresis", "OBSERVATION", 5, 13], ["most common", "OBSERVATION_MODIFIER", 21, 32]]], ["The next in frequency is sodium diuresis, which may last longer, over 72 h.", [["sodium", "CHEMICAL", 25, 31], ["sodium", "CHEMICAL", 25, 31], ["sodium", "SIMPLE_CHEMICAL", 25, 31], ["sodium diuresis", "TREATMENT", 25, 40], ["diuresis", "OBSERVATION", 32, 40]]], ["Management involves avoiding severe volume depletion, hypokalemia, hyponatremia, hypernatremia, and hypomagnesemia.", [["hypokalemia", "DISEASE", 54, 65], ["hyponatremia", "DISEASE", 67, 79], ["hypernatremia", "DISEASE", 81, 94], ["hypomagnesemia", "DISEASE", 100, 114], ["Management", "TREATMENT", 0, 10], ["severe volume depletion", "PROBLEM", 29, 52], ["hypokalemia", "PROBLEM", 54, 65], ["hyponatremia", "PROBLEM", 67, 79], ["hypernatremia", "PROBLEM", 81, 94], ["hypomagnesemia", "PROBLEM", 100, 114], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["volume depletion", "OBSERVATION", 36, 52], ["hypokalemia", "OBSERVATION", 54, 65], ["hyponatremia", "OBSERVATION", 67, 79], ["hypernatremia", "OBSERVATION", 81, 94], ["hypomagnesemia", "OBSERVATION", 100, 114]]], ["In the fi rst 24 h, urine output should be checked and approximately matched hourly.", [["urine", "ANATOMY", 20, 25], ["urine", "ORGANISM_SUBSTANCE", 20, 25], ["urine output", "TEST", 20, 32]]], ["If the urine output is over 200 mL/h, then 80 % of the hourly output should be replaced intravenously with either 0.9 % saline or 2/3-1/3 solution.ReferencesOverhydration can prolong the polyuria phase.", [["urine", "ANATOMY", 7, 12], ["intravenously", "ANATOMY", 88, 101], ["polyuria", "DISEASE", 187, 195], ["urine", "ORGANISM_SUBSTANCE", 7, 12], ["saline", "SIMPLE_CHEMICAL", 120, 126], ["the urine output", "TEST", 3, 19], ["the hourly output", "TEST", 51, 68], ["0.9 % saline", "TREATMENT", 114, 126], ["the polyuria phase", "PROBLEM", 183, 201]]], ["After 24 h of persistent diuresis, total fl uids infused should be about 1 L less than the previous day's output.", [["persistent diuresis", "TREATMENT", 14, 33], ["total fl uids", "TREATMENT", 35, 48], ["persistent", "OBSERVATION_MODIFIER", 14, 24], ["diuresis", "OBSERVATION", 25, 33]]], ["Once the urine output is less than 3 L per day, oral fl uids should suffi ce.ReferenceLoo MH, Vaughan ED.", [["urine", "ANATOMY", 9, 14], ["oral", "ANATOMY", 48, 52], ["urine", "ORGANISM_SUBSTANCE", 9, 14], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["the urine output", "TEST", 5, 21], ["oral fl uids", "TREATMENT", 48, 60], ["output", "OBSERVATION_MODIFIER", 15, 21]]], ["Obstructive nephropathy and postobstructive diuresis.", [["Obstructive nephropathy", "DISEASE", 0, 23], ["Obstructive nephropathy", "PROBLEM", 0, 23], ["postobstructive diuresis", "TREATMENT", 28, 52], ["nephropathy", "OBSERVATION", 12, 23], ["postobstructive", "OBSERVATION_MODIFIER", 28, 43], ["diuresis", "OBSERVATION", 44, 52]]], ["An 86-year-old woman is admitted to the intensive care unit with depressed level of consciousness, hypothermia, sinus bradycardia, hypotension, and hypoglycemia.", [["sinus", "ANATOMY", 112, 117], ["depressed level of consciousness", "DISEASE", 65, 97], ["hypothermia", "DISEASE", 99, 110], ["sinus bradycardia", "DISEASE", 112, 129], ["hypotension", "DISEASE", 131, 142], ["hypoglycemia", "DISEASE", 148, 160], ["woman", "ORGANISM", 15, 20], ["sinus", "MULTI-TISSUE_STRUCTURE", 112, 117], ["woman", "SPECIES", 15, 20], ["depressed level of consciousness", "PROBLEM", 65, 97], ["hypothermia", "PROBLEM", 99, 110], ["sinus bradycardia", "PROBLEM", 112, 129], ["hypotension", "PROBLEM", 131, 142], ["hypoglycemia", "PROBLEM", 148, 160], ["depressed", "OBSERVATION", 65, 74], ["hypothermia", "OBSERVATION", 99, 110], ["sinus", "ANATOMY", 112, 117], ["bradycardia", "OBSERVATION", 118, 129], ["hypotension", "OBSERVATION", 131, 142], ["hypoglycemia", "OBSERVATION", 148, 160]]], ["She was previously healthy with the exception of a history of hypothyroidism and systemic hypertension.", [["hypothyroidism", "DISEASE", 62, 76], ["hypertension", "DISEASE", 90, 102], ["hypothyroidism", "PROBLEM", 62, 76], ["systemic hypertension", "PROBLEM", 81, 102], ["hypothyroidism", "OBSERVATION", 62, 76], ["systemic", "OBSERVATION_MODIFIER", 81, 89], ["hypertension", "OBSERVATION", 90, 102]]], ["She recently ran out of her medicines.", [["her medicines", "TREATMENT", 24, 37]]], ["Her serum chemistries reveal hyponatremia and a glucose of 52.", [["serum", "ANATOMY", 4, 9], ["hyponatremia", "DISEASE", 29, 41], ["glucose", "CHEMICAL", 48, 55], ["glucose", "CHEMICAL", 48, 55], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["glucose", "SIMPLE_CHEMICAL", 48, 55], ["Her serum chemistries", "TEST", 0, 21], ["hyponatremia", "PROBLEM", 29, 41], ["a glucose", "TEST", 46, 55], ["hyponatremia", "OBSERVATION", 29, 41]]], ["TSH is above 100 mU/L. All of the following statements regarding this condition are true, EXCEPT: A) External warming is a critical feature of therapy in all patients.", [["TSH", "GENE_OR_GENE_PRODUCT", 0, 3], ["patients", "ORGANISM", 158, 166], ["patients", "SPECIES", 158, 166], ["TSH", "TEST", 0, 3], ["therapy", "TREATMENT", 143, 150]]], ["B) Hypotonic intravenous solutions should be avoided.", [["intravenous", "ANATOMY", 13, 24], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 13, 24], ["Hypotonic intravenous solutions", "TREATMENT", 3, 34]]], ["C) IV levothyroxine should be administered with IV glucocorticoids.ReferenceD) Sedation and narcotics should be avoided if possible.", [["levothyroxine", "CHEMICAL", 6, 19], ["levothyroxine", "CHEMICAL", 6, 19], ["levothyroxine", "SIMPLE_CHEMICAL", 6, 19], ["IV levothyroxine", "TREATMENT", 3, 19], ["IV glucocorticoids", "TREATMENT", 48, 66], ["Sedation", "TREATMENT", 79, 87], ["narcotics", "TREATMENT", 92, 101]]], ["E) This condition occurs almost commonly in the elderly and often is precipitated by infection.ReferenceAnswer: A The patient has myxedema coma.", [["infection", "DISEASE", 85, 94], ["myxedema coma", "DISEASE", 130, 143], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["infection", "PROBLEM", 85, 94], ["myxedema coma", "PROBLEM", 130, 143], ["infection", "OBSERVATION", 85, 94], ["myxedema", "OBSERVATION", 130, 138]]], ["Management includes rapid repletion of thyroid hormone through IV levothyroxine and glucocorticoids.", [["levothyroxine", "CHEMICAL", 66, 79], ["glucocorticoids", "CHEMICAL", 84, 99], ["levothyroxine", "CHEMICAL", 66, 79], ["thyroid", "ORGAN", 39, 46], ["levothyroxine", "SIMPLE_CHEMICAL", 66, 79], ["glucocorticoids", "SIMPLE_CHEMICAL", 84, 99], ["Management", "TREATMENT", 0, 10], ["rapid repletion", "TREATMENT", 20, 35], ["thyroid hormone", "TREATMENT", 39, 54], ["IV levothyroxine", "TREATMENT", 63, 79], ["glucocorticoids", "TREATMENT", 84, 99], ["thyroid", "ANATOMY", 39, 46]]], ["There may be a lack of adrenal reserve in severe hypothyroidism.", [["adrenal", "ANATOMY", 23, 30], ["hypothyroidism", "DISEASE", 49, 63], ["adrenal", "ORGAN", 23, 30], ["adrenal reserve", "PROBLEM", 23, 38], ["severe hypothyroidism", "PROBLEM", 42, 63], ["adrenal", "ANATOMY", 23, 30], ["reserve", "OBSERVATION", 31, 38], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["hypothyroidism", "OBSERVATION", 49, 63]]], ["Warming is not indicated in all circumstances and must be done with caution.", [["Warming", "TREATMENT", 0, 7]]], ["It is only recommended for a temperature of less than 30 \u00b0C. Care must be taken with rewarming as it may precipitate a cardiovascular collapse.", [["cardiovascular", "ANATOMY", 119, 133], ["cardiovascular collapse", "DISEASE", 119, 142], ["a temperature", "TEST", 27, 40], ["rewarming", "TREATMENT", 85, 94], ["a cardiovascular collapse", "PROBLEM", 117, 142], ["cardiovascular", "ANATOMY", 119, 133], ["collapse", "OBSERVATION", 134, 142]]], ["Profound hypothyroidism most commonly occurs in the elderly.", [["hypothyroidism", "DISEASE", 9, 23], ["Profound hypothyroidism", "PROBLEM", 0, 23], ["hypothyroidism", "OBSERVATION", 9, 23]]], ["It can be precipitated by an underlying condition such as myocardial infarction or infection.", [["myocardial", "ANATOMY", 58, 68], ["myocardial infarction", "DISEASE", 58, 79], ["infection", "DISEASE", 83, 92], ["myocardial", "MULTI-TISSUE_STRUCTURE", 58, 68], ["an underlying condition", "PROBLEM", 26, 49], ["myocardial infarction", "PROBLEM", 58, 79], ["infection", "PROBLEM", 83, 92], ["myocardial", "ANATOMY", 58, 68], ["infarction", "OBSERVATION", 69, 79], ["infection", "OBSERVATION", 83, 92]]], ["Clinical manifestations include an altered level of consciousness, bradycardia, and hypothermia.", [["bradycardia", "DISEASE", 67, 78], ["hypothermia", "DISEASE", 84, 95], ["Clinical manifestations", "PROBLEM", 0, 23], ["an altered level of consciousness", "PROBLEM", 32, 65], ["bradycardia", "PROBLEM", 67, 78], ["hypothermia", "PROBLEM", 84, 95], ["altered", "OBSERVATION_MODIFIER", 35, 42], ["hypothermia", "OBSERVATION", 84, 95]]], ["Hypertonic saline and glucose may be used if hyponatremia or hypoglycemia is severe.", [["glucose", "CHEMICAL", 22, 29], ["hyponatremia", "DISEASE", 45, 57], ["hypoglycemia", "DISEASE", 61, 73], ["glucose", "CHEMICAL", 22, 29], ["Hypertonic saline", "SIMPLE_CHEMICAL", 0, 17], ["glucose", "SIMPLE_CHEMICAL", 22, 29], ["Hypertonic saline", "TREATMENT", 0, 17], ["glucose", "TREATMENT", 22, 29], ["hyponatremia", "PROBLEM", 45, 57], ["hypoglycemia", "PROBLEM", 61, 73], ["severe", "OBSERVATION_MODIFIER", 77, 83]]], ["Hypotonic solutions should be avoided as they may worsen fl uid retention.", [["Hypotonic solutions", "TREATMENT", 0, 19], ["fl uid retention", "PROBLEM", 57, 73]]], ["A 42-year-old woman is admitted with a temperature of 38.9 \u00b0C (102 \u00b0F), sweats, shaking chills, headache, and slight constipation for the past two days.", [["sweats", "DISEASE", 72, 78], ["chills", "DISEASE", 88, 94], ["headache", "DISEASE", 96, 104], ["constipation", "DISEASE", 117, 129], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["a temperature", "TEST", 37, 50], ["sweats", "PROBLEM", 72, 78], ["shaking chills", "PROBLEM", 80, 94], ["headache", "PROBLEM", 96, 104], ["slight constipation", "PROBLEM", 110, 129], ["slight", "OBSERVATION_MODIFIER", 110, 116], ["constipation", "OBSERVATION", 117, 129]]], ["She had not taken malaria prophylaxis during her stay in that country.", [["malaria", "DISEASE", 18, 25], ["malaria prophylaxis", "TREATMENT", 18, 37], ["malaria", "OBSERVATION", 18, 25]]], ["On the physical exam, her temperature is 39.4 \u00b0C (103 \u00b0F), and she has tenderness in the right upper quadrant of the abdomen.ReferencesHer white blood cell count is 28,000 per mm3 (28 \u00d7 109 per L) with a left shift.", [["right upper quadrant", "ANATOMY", 89, 109], ["abdomen", "ANATOMY", 117, 124], ["white blood cell", "ANATOMY", 139, 155], ["tenderness", "DISEASE", 71, 81], ["upper quadrant", "ORGANISM_SUBDIVISION", 95, 109], ["abdomen", "ORGAN", 117, 124], ["blood cell", "CELL", 145, 155], ["the physical exam", "TEST", 3, 20], ["her temperature", "TEST", 22, 37], ["tenderness in the right upper quadrant of the abdomen", "PROBLEM", 71, 124], ["Her white blood cell count", "TEST", 135, 161], ["tenderness", "OBSERVATION", 71, 81], ["right", "ANATOMY_MODIFIER", 89, 94], ["upper", "ANATOMY_MODIFIER", 95, 100], ["quadrant", "ANATOMY_MODIFIER", 101, 109], ["abdomen", "ANATOMY", 117, 124], ["left", "ANATOMY_MODIFIER", 204, 208]]], ["Serum electrolyte and transaminase levels are unremarkable.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["electrolyte", "SIMPLE_CHEMICAL", 6, 17], ["transaminase", "SIMPLE_CHEMICAL", 22, 34], ["Serum electrolyte", "TEST", 0, 17], ["transaminase levels", "TEST", 22, 41], ["transaminase", "ANATOMY", 22, 34], ["unremarkable", "OBSERVATION", 46, 58]]], ["A chest radiograph showed minimal blunting of the right costophrenic angle.ReferencesComputed tomographic (CT) scanning of the abdomen revealed four large abscesses in the right lobe of the patient's liver.", [["chest", "ANATOMY", 2, 7], ["right costophrenic", "ANATOMY", 50, 68], ["abdomen", "ANATOMY", 127, 134], ["abscesses", "ANATOMY", 155, 164], ["right lobe", "ANATOMY", 172, 182], ["liver", "ANATOMY", 200, 205], ["abscesses", "DISEASE", 155, 164], ["abdomen", "ORGAN", 127, 134], ["abscesses", "PATHOLOGICAL_FORMATION", 155, 164], ["lobe", "ORGAN", 178, 182], ["patient", "ORGANISM", 190, 197], ["liver", "ORGAN", 200, 205], ["patient", "SPECIES", 190, 197], ["A chest radiograph", "TEST", 0, 18], ["minimal blunting of the right costophrenic angle", "PROBLEM", 26, 74], ["ReferencesComputed tomographic (CT) scanning of the abdomen", "TEST", 75, 134], ["four large abscesses in the right lobe", "PROBLEM", 144, 182], ["chest", "ANATOMY", 2, 7], ["minimal", "OBSERVATION_MODIFIER", 26, 33], ["blunting", "OBSERVATION", 34, 42], ["right", "ANATOMY_MODIFIER", 50, 55], ["costophrenic angle", "ANATOMY", 56, 74], ["abdomen", "ANATOMY", 127, 134], ["large", "OBSERVATION_MODIFIER", 149, 154], ["abscesses", "OBSERVATION", 155, 164], ["right lobe", "ANATOMY_MODIFIER", 172, 182], ["liver", "ANATOMY", 200, 205]]], ["The two largest abscesses were each 4 cm in diameter.ReferencesCT-guided catheter drainage was undertaken.", [["abscesses", "ANATOMY", 16, 25], ["catheter", "ANATOMY", 73, 81], ["abscesses", "DISEASE", 16, 25], ["abscesses", "PATHOLOGICAL_FORMATION", 16, 25], ["The two largest abscesses", "PROBLEM", 0, 25], ["ReferencesCT-guided catheter drainage", "TREATMENT", 53, 90], ["two", "OBSERVATION_MODIFIER", 4, 7], ["largest", "OBSERVATION_MODIFIER", 8, 15], ["abscesses", "OBSERVATION", 16, 25], ["4 cm", "OBSERVATION_MODIFIER", 36, 40], ["diameter", "OBSERVATION_MODIFIER", 44, 52], ["catheter drainage", "OBSERVATION", 73, 90]]], ["Thick, nonmalodorous, brown fl uid was withdrawn.", [["brown fl uid", "SPECIES", 22, 34], ["Thick, nonmalodorous, brown fl uid", "PROBLEM", 0, 34], ["brown fl", "OBSERVATION", 22, 30]]], ["Cultures of fl uid are negative.ReferencesWhat is the most likely diagnosis?", [["fl uid", "GENE_OR_GENE_PRODUCT", 12, 18], ["fl uid", "PROTEIN", 12, 18], ["Cultures of fl uid", "TEST", 0, 18], ["negative", "OBSERVATION", 23, 31], ["most likely", "UNCERTAINTY", 54, 65]]], ["A) Malaria B) Entamoeba histolytica C) Echinococcus D) Leishmaniasis Answer: B Amebic liver abscess is the most common extraintestinal manifestation of infection with Entamoeba histolytica .", [["liver abscess", "ANATOMY", 86, 99], ["Leishmaniasis", "DISEASE", 55, 68], ["liver abscess", "DISEASE", 86, 99], ["infection", "DISEASE", 152, 161], ["Entamoeba histolytica", "DISEASE", 167, 188], ["Entamoeba histolytica C", "ORGANISM", 14, 37], ["Echinococcus D", "ORGANISM", 39, 53], ["liver", "ORGAN", 86, 91], ["Entamoeba histolytica", "ORGANISM", 167, 188], ["Entamoeba histolytica", "SPECIES", 14, 35], ["Entamoeba histolytica", "SPECIES", 167, 188], ["Entamoeba histolytica", "SPECIES", 14, 35], ["Entamoeba histolytica", "SPECIES", 167, 188], ["A) Malaria B) Entamoeba histolytica C) Echinococcus D) Leishmaniasis", "PROBLEM", 0, 68], ["B Amebic liver abscess", "PROBLEM", 77, 99], ["infection", "PROBLEM", 152, 161], ["Entamoeba histolytica", "PROBLEM", 167, 188], ["Malaria", "OBSERVATION", 3, 10], ["Amebic", "OBSERVATION_MODIFIER", 79, 85], ["liver", "ANATOMY", 86, 91], ["abscess", "OBSERVATION", 92, 99], ["most common", "OBSERVATION_MODIFIER", 107, 118], ["infection", "OBSERVATION", 152, 161], ["Entamoeba histolytica", "OBSERVATION", 167, 188]]], ["Untreated, it is associated with signifi cant morbidity and mortality.", [["signifi cant morbidity", "PROBLEM", 33, 55], ["morbidity", "OBSERVATION", 46, 55]]], ["It has a worldwide distribution, but amebiasis is more prevalent in tropical areas.", [["amebiasis", "DISEASE", 37, 46], ["amebiasis", "PROBLEM", 37, 46], ["worldwide", "OBSERVATION_MODIFIER", 9, 18], ["distribution", "OBSERVATION_MODIFIER", 19, 31], ["amebiasis", "OBSERVATION", 37, 46], ["more prevalent", "OBSERVATION_MODIFIER", 50, 64]]], ["E. histolytica is transmitted via the fecal-oral route.", [["oral", "ANATOMY", 44, 48], ["E. histolytica", "ORGANISM", 0, 14], ["fecal", "ORGANISM_SUBDIVISION", 38, 43], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["E. histolytica", "SPECIES", 0, 14], ["E. histolytica", "SPECIES", 0, 14], ["histolytica", "OBSERVATION", 3, 14], ["fecal", "ANATOMY", 38, 43]]], ["It is generally acquired by the ingestion of contaminated food and water containing the infective cysts.", [["cysts", "ANATOMY", 98, 103], ["infective cysts", "DISEASE", 88, 103], ["infective cysts", "PATHOLOGICAL_FORMATION", 88, 103], ["the infective cysts", "PROBLEM", 84, 103], ["infective", "OBSERVATION_MODIFIER", 88, 97], ["cysts", "OBSERVATION", 98, 103]]], ["The incubation period for E. histolytica infection is commonly 2-4 weeks but may range from a few days to years.", [["E. histolytica infection", "DISEASE", 26, 50], ["E. histolytica", "ORGANISM", 26, 40], ["E. histolytica", "SPECIES", 26, 40], ["E. histolytica", "SPECIES", 26, 40], ["E. histolytica infection", "PROBLEM", 26, 50], ["histolytica", "OBSERVATION_MODIFIER", 29, 40], ["infection", "OBSERVATION", 41, 50]]], ["Most patients with amebic liver abscess present within 2-4 weeks of infection and almost all within 5 months.", [["liver abscess", "ANATOMY", 26, 39], ["amebic liver abscess", "DISEASE", 19, 39], ["infection", "DISEASE", 68, 77], ["patients", "ORGANISM", 5, 13], ["liver", "ORGAN", 26, 31], ["patients", "SPECIES", 5, 13], ["amebic liver abscess", "PROBLEM", 19, 39], ["infection", "PROBLEM", 68, 77], ["amebic", "OBSERVATION_MODIFIER", 19, 25], ["liver", "ANATOMY", 26, 31], ["abscess", "OBSERVATION", 32, 39], ["infection", "OBSERVATION", 68, 77]]], ["The mainstay of therapy is metronidazole, which is usually effective in eliminating the intestinal and extraintestinal amoeba.", [["intestinal", "ANATOMY", 88, 98], ["metronidazole", "CHEMICAL", 27, 40], ["metronidazole", "CHEMICAL", 27, 40], ["metronidazole", "SIMPLE_CHEMICAL", 27, 40], ["intestinal", "ORGAN", 88, 98], ["therapy", "TREATMENT", 16, 23], ["metronidazole", "TREATMENT", 27, 40], ["the intestinal and extraintestinal amoeba", "PROBLEM", 84, 125], ["mainstay", "OBSERVATION_MODIFIER", 4, 12], ["intestinal", "ANATOMY", 88, 98], ["extraintestinal", "ANATOMY", 103, 118], ["amoeba", "OBSERVATION", 119, 125]]], ["Amebic liver abscess of up to 10 cm can be cured with metronidazole without drainage.", [["liver abscess", "ANATOMY", 7, 20], ["liver abscess", "DISEASE", 7, 20], ["metronidazole", "CHEMICAL", 54, 67], ["metronidazole", "CHEMICAL", 54, 67], ["liver", "ORGAN", 7, 12], ["metronidazole", "SIMPLE_CHEMICAL", 54, 67], ["Amebic liver abscess", "PROBLEM", 0, 20], ["metronidazole", "TREATMENT", 54, 67], ["drainage", "TREATMENT", 76, 84], ["liver", "ANATOMY", 7, 12], ["abscess", "OBSERVATION", 13, 20], ["up to 10 cm", "OBSERVATION_MODIFIER", 24, 35], ["drainage", "OBSERVATION", 76, 84]]], ["Indications for percutaneous drainage include large liver abscess, abscesses in the left hepatic lobe at risk for rupturing into the pericardium, and treatment failure.", [["percutaneous", "ANATOMY", 16, 28], ["liver abscess", "ANATOMY", 52, 65], ["abscesses", "ANATOMY", 67, 76], ["left hepatic lobe", "ANATOMY", 84, 101], ["pericardium", "ANATOMY", 133, 144], ["liver abscess", "DISEASE", 52, 65], ["abscesses", "DISEASE", 67, 76], ["liver", "ORGAN", 52, 57], ["abscesses", "PATHOLOGICAL_FORMATION", 67, 76], ["hepatic lobe", "MULTI-TISSUE_STRUCTURE", 89, 101], ["pericardium", "ORGAN", 133, 144], ["percutaneous drainage", "TREATMENT", 16, 37], ["large liver abscess", "PROBLEM", 46, 65], ["abscesses in the left hepatic lobe", "PROBLEM", 67, 101], ["rupturing into the pericardium", "PROBLEM", 114, 144], ["treatment failure", "PROBLEM", 150, 167], ["percutaneous", "OBSERVATION_MODIFIER", 16, 28], ["drainage", "OBSERVATION", 29, 37], ["large", "OBSERVATION_MODIFIER", 46, 51], ["liver", "ANATOMY", 52, 57], ["abscess", "OBSERVATION", 58, 65], ["abscesses", "OBSERVATION", 67, 76], ["left", "ANATOMY_MODIFIER", 84, 88], ["hepatic", "ANATOMY", 89, 96], ["lobe", "ANATOMY_MODIFIER", 97, 101], ["rupturing", "OBSERVATION", 114, 123], ["pericardium", "ANATOMY", 133, 144], ["treatment", "OBSERVATION_MODIFIER", 150, 159], ["failure", "OBSERVATION", 160, 167]]], ["This is defi ned as fever and pain persist for 3 to 5 days after the initiation of therapy.ReferencesReference Stanley SL Jr. Amoebiasis.", [["fever", "DISEASE", 20, 25], ["pain", "DISEASE", 30, 34], ["fever", "PROBLEM", 20, 25], ["pain", "PROBLEM", 30, 34], ["therapy", "TREATMENT", 83, 90]]], ["An 80-year-old woman presents with a two-day history of persistent vomiting.", [["vomiting", "DISEASE", 67, 75], ["woman", "ORGANISM", 15, 20], ["woman", "SPECIES", 15, 20], ["persistent vomiting", "PROBLEM", 56, 75], ["persistent", "OBSERVATION_MODIFIER", 56, 66], ["vomiting", "OBSERVATION", 67, 75]]], ["She is lethargic and weak and has myalgia.", [["myalgia", "DISEASE", 34, 41], ["lethargic", "PROBLEM", 7, 16], ["weak", "PROBLEM", 21, 25], ["myalgia", "PROBLEM", 34, 41], ["myalgia", "OBSERVATION", 34, 41]]], ["Her mucous membranes are dry.", [["mucous membranes", "ANATOMY", 4, 20], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 4, 20], ["mucous membranes", "ANATOMY", 4, 20], ["dry", "OBSERVATION", 25, 28]]], ["She is diagnosed as having gastroenteritis and dehydration and is admitted.ReferencesMeasurement of arterial blood gas shows pH 7.51, PaO2 86 mmHg, PaCO2 46 mmHg, and HCO3 38 mmol/L.ReferencesWhat acid-base disorder is shown?", [["arterial blood", "ANATOMY", 100, 114], ["gastroenteritis", "DISEASE", 27, 42], ["dehydration", "DISEASE", 47, 58], ["HCO3", "CHEMICAL", 167, 171], ["arterial", "MULTI-TISSUE_STRUCTURE", 100, 108], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["gastroenteritis", "PROBLEM", 27, 42], ["dehydration", "PROBLEM", 47, 58], ["arterial blood gas", "TEST", 100, 118], ["pH", "TEST", 125, 127], ["PaO2", "TEST", 134, 138], ["mmHg", "TEST", 142, 146], ["PaCO2", "TEST", 148, 153], ["mmHg", "TEST", 157, 161], ["HCO3", "TEST", 167, 171], ["What acid-base disorder", "PROBLEM", 192, 215], ["gastroenteritis", "OBSERVATION", 27, 42], ["dehydration", "OBSERVATION", 47, 58], ["arterial", "ANATOMY", 100, 108]]], ["A) Metabolic alkalosis/respiratory acidosis B) Metabolic alkalosis C) Respiratory alkalosis D) Metabolic alkalosis/respiratory alkalosis E) None of the above Answer: B The primary disorder is metabolic alkalosis.", [["Metabolic alkalosis", "DISEASE", 3, 22], ["respiratory acidosis", "DISEASE", 23, 43], ["alkalosis", "DISEASE", 57, 66], ["alkalosis", "DISEASE", 82, 91], ["Metabolic alkalosis", "DISEASE", 95, 114], ["respiratory alkalosis", "DISEASE", 115, 136], ["primary disorder", "DISEASE", 172, 188], ["metabolic alkalosis", "DISEASE", 192, 211], ["Metabolic alkalosis", "PROBLEM", 3, 22], ["respiratory acidosis", "PROBLEM", 23, 43], ["Metabolic alkalosis", "PROBLEM", 47, 66], ["Respiratory alkalosis D", "PROBLEM", 70, 93], ["Metabolic alkalosis", "PROBLEM", 95, 114], ["respiratory alkalosis", "PROBLEM", 115, 136], ["The primary disorder", "PROBLEM", 168, 188], ["metabolic alkalosis", "PROBLEM", 192, 211], ["Metabolic alkalosis", "OBSERVATION", 3, 22], ["respiratory acidosis", "OBSERVATION", 23, 43], ["Metabolic alkalosis", "OBSERVATION", 47, 66], ["Respiratory alkalosis", "OBSERVATION", 70, 91], ["Metabolic alkalosis", "OBSERVATION", 95, 114], ["respiratory alkalosis", "OBSERVATION", 115, 136], ["metabolic alkalosis", "OBSERVATION", 192, 211]]], ["Contraction alkalosis is by far the most common cause in the hospitalized patient.", [["alkalosis", "DISEASE", 12, 21], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["Contraction alkalosis", "PROBLEM", 0, 21], ["alkalosis", "OBSERVATION", 12, 21], ["most common", "OBSERVATION_MODIFIER", 36, 47]]], ["CO2 is the strongest driver of respiration.", [["CO2", "CHEMICAL", 0, 3], ["CO2", "CHEMICAL", 0, 3], ["CO2", "SIMPLE_CHEMICAL", 0, 3], ["CO2", "TEST", 0, 3]]], ["It generally will not allow hypoventilation as a full compensation for metabolic alkalosis.", [["hypoventilation", "DISEASE", 28, 43], ["metabolic alkalosis", "DISEASE", 71, 90], ["hypoventilation", "PROBLEM", 28, 43], ["metabolic alkalosis", "PROBLEM", 71, 90], ["metabolic alkalosis", "OBSERVATION", 71, 90]]], ["An elevated serum bicarbonate concentration may also be observed as a compensatory response to primary respiratory acidosis.", [["serum", "ANATOMY", 12, 17], ["respiratory", "ANATOMY", 103, 114], ["bicarbonate", "CHEMICAL", 18, 29], ["primary respiratory acidosis", "DISEASE", 95, 123], ["bicarbonate", "CHEMICAL", 18, 29], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["bicarbonate", "SIMPLE_CHEMICAL", 18, 29], ["An elevated serum bicarbonate concentration", "PROBLEM", 0, 43], ["primary respiratory acidosis", "PROBLEM", 95, 123], ["elevated", "OBSERVATION_MODIFIER", 3, 11], ["serum", "OBSERVATION_MODIFIER", 12, 17], ["bicarbonate concentration", "OBSERVATION", 18, 43], ["may also be observed", "UNCERTAINTY", 44, 64], ["compensatory response", "OBSERVATION", 70, 91], ["primary", "OBSERVATION_MODIFIER", 95, 102], ["respiratory acidosis", "OBSERVATION", 103, 123]]], ["If continuous removal of gastric contents occurs, gastric acid secretion can be reduced with H2-blockers or more effi ciently with proton-pump inhibitors.ReferencesThis patient should be treated with normal saline and electrolyte replacement.", [["gastric", "ANATOMY", 25, 32], ["gastric", "ANATOMY", 50, 57], ["gastric", "ORGAN", 25, 32], ["gastric acid", "SIMPLE_CHEMICAL", 50, 62], ["H2-blockers", "SIMPLE_CHEMICAL", 93, 104], ["proton-pump inhibitors", "SIMPLE_CHEMICAL", 131, 153], ["patient", "ORGANISM", 169, 176], ["saline", "SIMPLE_CHEMICAL", 207, 213], ["electrolyte", "SIMPLE_CHEMICAL", 218, 229], ["patient", "SPECIES", 169, 176], ["continuous removal of gastric contents", "TREATMENT", 3, 41], ["gastric acid secretion", "PROBLEM", 50, 72], ["H2-blockers", "TREATMENT", 93, 104], ["proton-pump inhibitors", "TREATMENT", 131, 153], ["normal saline", "TREATMENT", 200, 213], ["electrolyte replacement", "TREATMENT", 218, 241], ["gastric", "ANATOMY", 25, 32], ["contents", "OBSERVATION", 33, 41], ["gastric", "ANATOMY", 50, 57]]], ["This should be delivered slowly, to expand the extracellular fl uid volume.", [["extracellular", "ANATOMY", 47, 60], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60]]], ["In this elderly patient, evidence of volume overload should be followed closely.", [["volume overload", "DISEASE", 37, 52], ["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23], ["volume overload", "PROBLEM", 37, 52], ["volume overload", "OBSERVATION", 37, 52]]], ["As the body rehydrates, the kidneys will excrete the excess HCO3 and correct the alkalosis.ReferencesReference HJ, Madias NE.", [["body", "ANATOMY", 7, 11], ["kidneys", "ANATOMY", 28, 35], ["HCO3", "CHEMICAL", 60, 64], ["alkalosis", "DISEASE", 81, 90], ["HCO3", "CHEMICAL", 60, 64], ["body", "ORGANISM_SUBDIVISION", 7, 11], ["kidneys", "ORGAN", 28, 35], ["HCO3", "SIMPLE_CHEMICAL", 60, 64], ["the body rehydrates", "TEST", 3, 22], ["the excess HCO3", "TEST", 49, 64], ["the alkalosis", "PROBLEM", 77, 90], ["kidneys", "ANATOMY", 28, 35], ["excess HCO3", "OBSERVATION", 53, 64], ["alkalosis", "OBSERVATION", 81, 90]]], ["Secondary responses to altered acid-base status: the rules of engagement.", [["altered acid-base status", "PROBLEM", 23, 47], ["acid", "OBSERVATION_MODIFIER", 31, 35]]], ["J Am Soc Nephrol 2010;21:920-3ty.179.A 72-year-old woman has been admitted during the day for a bronchitis.", [["bronchitis", "DISEASE", 96, 106], ["woman", "ORGANISM", 51, 56], ["woman", "SPECIES", 51, 56], ["a bronchitis", "PROBLEM", 94, 106], ["bronchitis", "OBSERVATION", 96, 106]]], ["You are called to see her urgently for chest pain that night.", [["chest", "ANATOMY", 39, 44], ["chest pain", "DISEASE", 39, 49], ["chest", "ORGANISM_SUBDIVISION", 39, 44], ["chest pain", "PROBLEM", 39, 49], ["chest", "ANATOMY", 39, 44]]], ["On physical exam, she has developed acute pulmonary edema.", [["pulmonary", "ANATOMY", 42, 51], ["acute pulmonary edema", "DISEASE", 36, 57], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 42, 57], ["physical exam", "TEST", 3, 16], ["acute pulmonary edema", "PROBLEM", 36, 57], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["pulmonary", "ANATOMY", 42, 51], ["edema", "OBSERVATION", 52, 57]]], ["Blood pressure is 110/60 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Evidence of myocardial ischemia is seen on telemetry.", [["myocardial", "ANATOMY", 12, 22], ["myocardial ischemia", "DISEASE", 12, 31], ["myocardial", "MULTI-TISSUE_STRUCTURE", 12, 22], ["myocardial ischemia", "PROBLEM", 12, 31], ["telemetry", "TEST", 43, 52], ["myocardial", "ANATOMY", 12, 22], ["ischemia", "OBSERVATION", 23, 31]]], ["An ECG shows ST segment elevation of 3 mm in the precordial leads.", [["An ECG", "TEST", 0, 6], ["ST segment elevation", "PROBLEM", 13, 33], ["ST", "OBSERVATION", 13, 15], ["segment", "ANATOMY_MODIFIER", 16, 23], ["elevation", "OBSERVATION", 24, 33], ["3 mm", "ANATOMY_MODIFIER", 37, 41], ["precordial leads", "ANATOMY_MODIFIER", 49, 65]]], ["She has no known prior contraindications to thrombolytic therapy.179.Which of the following statements regarding thrombolytic therapy is true?", [["thrombolytic therapy", "TREATMENT", 44, 64], ["thrombolytic therapy", "TREATMENT", 113, 133], ["no", "UNCERTAINTY", 8, 10]]], ["A) Thrombolytic therapy or direct revascularization is indicated.", [["A) Thrombolytic therapy", "TREATMENT", 0, 23], ["direct revascularization", "TREATMENT", 27, 51]]], ["B) Thrombolytic therapy is contraindicated because of her age.", [["Thrombolytic therapy", "TREATMENT", 3, 23], ["Thrombolytic", "OBSERVATION", 3, 15]]], ["C) Thrombolytic therapy is contraindicated because of the presence of cardiogenic shock.", [["cardiogenic shock", "DISEASE", 70, 87], ["Thrombolytic therapy", "TREATMENT", 3, 23], ["cardiogenic shock", "PROBLEM", 70, 87], ["cardiogenic shock", "OBSERVATION", 70, 87]]], ["D) Thrombolytic therapy will establish antegrade coronary artery perfusion in 75 % of cases.", [["coronary artery", "ANATOMY", 49, 64], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 49, 64], ["Thrombolytic therapy", "TREATMENT", 3, 23], ["antegrade coronary artery perfusion", "TREATMENT", 39, 74], ["antegrade", "OBSERVATION", 39, 48], ["coronary artery", "ANATOMY", 49, 64]]], ["E) Thrombolytic therapy is contraindicated because of her low blood pressure.179.Answer: A This patient's age or underlying medical condition is not a contraindication to thrombolytic therapy nor is the presence of cardiogenic shock.", [["blood", "ANATOMY", 62, 67], ["cardiogenic shock", "DISEASE", 215, 232], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["patient", "ORGANISM", 96, 103], ["patient", "SPECIES", 96, 103], ["Thrombolytic therapy", "TREATMENT", 3, 23], ["her low blood pressure", "PROBLEM", 54, 76], ["underlying medical condition", "PROBLEM", 113, 141], ["thrombolytic therapy", "TREATMENT", 171, 191], ["cardiogenic shock", "PROBLEM", 215, 232], ["cardiogenic shock", "OBSERVATION", 215, 232]]], ["Direct revascularization is preferable if it can be obtained quickly.", [["Direct revascularization", "TREATMENT", 0, 24], ["revascularization", "OBSERVATION", 7, 24]]], ["Patients who develop cardiogenic shock because of a myocardial infarction have high mortality rates.", [["myocardial", "ANATOMY", 52, 62], ["cardiogenic shock", "DISEASE", 21, 38], ["myocardial infarction", "DISEASE", 52, 73], ["Patients", "ORGANISM", 0, 8], ["myocardial", "MULTI-TISSUE_STRUCTURE", 52, 62], ["Patients", "SPECIES", 0, 8], ["cardiogenic shock", "PROBLEM", 21, 38], ["a myocardial infarction", "PROBLEM", 50, 73], ["high mortality rates", "PROBLEM", 79, 99], ["cardiogenic shock", "OBSERVATION", 21, 38], ["myocardial", "ANATOMY", 52, 62], ["infarction", "OBSERVATION", 63, 73]]], ["Mortality can be lowered from 85 % to less than 60 % if fl ow can be reestablished in the infarct-related artery.", [["infarct", "ANATOMY", 90, 97], ["artery", "ANATOMY", 106, 112], ["infarct", "DISEASE", 90, 97], ["artery", "MULTI-TISSUE_STRUCTURE", 106, 112], ["infarct", "OBSERVATION", 90, 97], ["artery", "ANATOMY", 106, 112]]], ["Thrombolytic therapy is able to achieve this in only 50 % of cases.", [["Thrombolytic therapy", "TREATMENT", 0, 20]]], ["Percutaneous angioplasty has a higher success rate.", [["Percutaneous angioplasty", "TREATMENT", 0, 24], ["angioplasty", "OBSERVATION", 13, 24]]], ["If angioplasty is not available or delayed, thrombolytic therapy is indicated.", [["angioplasty", "TREATMENT", 3, 14], ["thrombolytic therapy", "TREATMENT", 44, 64], ["angioplasty", "OBSERVATION", 3, 14]]], ["A 25-year-old woman is admitted with cellulitis.", [["cellulitis", "DISEASE", 37, 47], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["cellulitis", "PROBLEM", 37, 47], ["25-", "OBSERVATION_MODIFIER", 2, 5], ["cellulitis", "OBSERVATION", 37, 47]]], ["She states that she was working in the garden outside of her house the evening before and felt a sharp pain on the back of her left hand.", [["left hand", "ANATOMY", 127, 136], ["pain", "DISEASE", 103, 107], ["hand", "ORGANISM_SUBDIVISION", 132, 136], ["a sharp pain", "PROBLEM", 95, 107], ["sharp", "OBSERVATION_MODIFIER", 97, 102], ["pain", "OBSERVATION", 103, 107], ["back", "ANATOMY", 115, 119], ["left", "ANATOMY_MODIFIER", 127, 131], ["hand", "ANATOMY", 132, 136]]], ["On physical examination, you note an area of pallor with surrounding erythema over the dorsum of the patient's left hand.", [["dorsum", "ANATOMY", 87, 93], ["left hand", "ANATOMY", 111, 120], ["pallor", "DISEASE", 45, 51], ["erythema", "DISEASE", 69, 77], ["erythema", "PATHOLOGICAL_FORMATION", 69, 77], ["dorsum", "ORGANISM_SUBDIVISION", 87, 93], ["patient", "ORGANISM", 101, 108], ["hand", "ORGANISM_SUBDIVISION", 116, 120], ["patient", "SPECIES", 101, 108], ["physical examination", "TEST", 3, 23], ["pallor", "PROBLEM", 45, 51], ["surrounding erythema", "PROBLEM", 57, 77], ["pallor", "OBSERVATION", 45, 51], ["surrounding", "OBSERVATION_MODIFIER", 57, 68], ["erythema", "OBSERVATION", 69, 77], ["dorsum", "ANATOMY", 87, 93], ["left", "ANATOMY_MODIFIER", 111, 115], ["hand", "ANATOMY", 116, 120]]], ["You suspect that she was bitten by a brown recluse spider.179.Which of the following therapies may benefi t the victim of a brown recluse spider bite?", [["spider bite", "DISEASE", 138, 149], ["a brown recluse spider", "PROBLEM", 35, 57], ["a brown recluse spider bite", "PROBLEM", 122, 149]]], ["A) Administration of dapsone in patients who do not have glucose-6-phosphate dehydrogenase defi ciency C) Use of antibiotics if there are signs of infection at the bite site D) Administration of steroids within 24 h of the bite E) All of the above Answer: E Brown recluse spiders are found under rocks, woodpiles, and in gardens.", [["dapsone", "CHEMICAL", 21, 28], ["glucose-6-phosphate", "CHEMICAL", 57, 76], ["infection", "DISEASE", 147, 156], ["steroids", "CHEMICAL", 195, 203], ["dapsone", "CHEMICAL", 21, 28], ["glucose-6-phosphate", "CHEMICAL", 57, 76], ["steroids", "CHEMICAL", 195, 203], ["dapsone", "SIMPLE_CHEMICAL", 21, 28], ["patients", "ORGANISM", 32, 40], ["glucose-6-phosphate dehydrogenase defi ciency C", "SIMPLE_CHEMICAL", 57, 104], ["glucose-6-phosphate dehydrogenase", "PROTEIN", 57, 90], ["patients", "SPECIES", 32, 40], ["dapsone", "TREATMENT", 21, 28], ["glucose", "TEST", 57, 64], ["phosphate dehydrogenase defi", "TREATMENT", 67, 95], ["antibiotics", "TREATMENT", 113, 124], ["infection", "PROBLEM", 147, 156], ["steroids", "TREATMENT", 195, 203], ["infection", "OBSERVATION", 147, 156]]], ["Characteristic violin-shaped markings on their backs have led brown recluse spiders to also be known as fi ddleback spiders.", [["violin", "CHEMICAL", 15, 21], ["backs", "ORGANISM_SUBDIVISION", 47, 52], ["Characteristic violin-shaped markings", "PROBLEM", 0, 37], ["brown recluse spiders", "PROBLEM", 62, 83], ["shaped", "OBSERVATION_MODIFIER", 22, 28], ["markings", "OBSERVATION", 29, 37], ["brown", "OBSERVATION_MODIFIER", 62, 67], ["recluse spiders", "OBSERVATION", 68, 83]]], ["They are most active at night in moderate temperature.", [["active", "OBSERVATION_MODIFIER", 14, 20], ["moderate", "OBSERVATION_MODIFIER", 33, 41], ["temperature", "OBSERVATION_MODIFIER", 42, 53]]], ["Bites can cause pain within the fi rst few hours.", [["Bites", "DISEASE", 0, 5], ["pain", "DISEASE", 16, 20], ["pain", "PROBLEM", 16, 20]]], ["Physical fi ndings are a ring of pallor surrounded by erythema.", [["pallor", "DISEASE", 33, 39], ["erythema", "DISEASE", 54, 62], ["erythema", "PATHOLOGICAL_FORMATION", 54, 62], ["pallor", "PROBLEM", 33, 39], ["erythema", "PROBLEM", 54, 62], ["erythema", "OBSERVATION", 54, 62]]], ["This patient has gallstone-induced pancreatitis.", [["gallstone", "DISEASE", 17, 26], ["pancreatitis", "DISEASE", 35, 47], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["gallstone", "PROBLEM", 17, 26], ["pancreatitis", "PROBLEM", 35, 47], ["gallstone", "OBSERVATION", 17, 26], ["pancreatitis", "OBSERVATION", 35, 47]]], ["Ultrasonography of the abdomen is the most useful initial test in determining the etiology of pancreatitis.", [["abdomen", "ANATOMY", 23, 30], ["pancreatitis", "DISEASE", 94, 106], ["abdomen", "ORGAN", 23, 30], ["Ultrasonography of the abdomen", "TEST", 0, 30], ["initial test", "TEST", 50, 62], ["pancreatitis", "PROBLEM", 94, 106], ["abdomen", "ANATOMY", 23, 30], ["pancreatitis", "OBSERVATION", 94, 106]]], ["It is more sensitive than CT for the diagnosis of gallstone disease.", [["gallstone", "ANATOMY", 50, 59], ["gallstone disease", "DISEASE", 50, 67], ["gallstone disease", "CANCER", 50, 67], ["CT", "TEST", 26, 28], ["gallstone disease", "PROBLEM", 50, 67], ["gallstone", "OBSERVATION", 50, 59]]], ["CT is better at demonstrating morphologic changes in the pancreas caused by infl ammation.", [["pancreas", "ANATOMY", 57, 65], ["pancreas", "ORGAN", 57, 65], ["CT", "TEST", 0, 2], ["morphologic changes in the pancreas", "PROBLEM", 30, 65], ["morphologic", "OBSERVATION", 30, 41], ["pancreas", "ANATOMY", 57, 65], ["infl ammation", "OBSERVATION", 76, 89]]], ["It is generally indicated in those with severe pancreatitis.", [["pancreatitis", "DISEASE", 47, 59], ["severe pancreatitis", "PROBLEM", 40, 59], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["pancreatitis", "OBSERVATION", 47, 59]]], ["ERCP can be useful in the management of pancreatitis but has no role in diagnoses.", [["pancreatitis", "DISEASE", 40, 52], ["ERCP", "TREATMENT", 0, 4], ["pancreatitis", "PROBLEM", 40, 52], ["pancreatitis", "OBSERVATION", 40, 52], ["no role", "UNCERTAINTY", 61, 68]]], ["His age and elevated total bilirubin make alcohol a less likely cause.", [["bilirubin", "CHEMICAL", 27, 36], ["alcohol", "CHEMICAL", 42, 49], ["bilirubin", "CHEMICAL", 27, 36], ["alcohol", "CHEMICAL", 42, 49], ["bilirubin", "GENE_OR_GENE_PRODUCT", 27, 36], ["alcohol", "SIMPLE_CHEMICAL", 42, 49], ["elevated total bilirubin", "PROBLEM", 12, 36]]], ["For alcohol, it is 39 and for biliary tract disease it is 69.", [["biliary tract", "ANATOMY", 30, 43], ["alcohol", "CHEMICAL", 4, 11], ["biliary tract disease", "DISEASE", 30, 51], ["alcohol", "CHEMICAL", 4, 11], ["alcohol", "SIMPLE_CHEMICAL", 4, 11], ["biliary tract", "CANCER", 30, 43], ["biliary tract disease", "PROBLEM", 30, 51], ["biliary tract", "ANATOMY", 30, 43]]], ["A 75-year-old male presents with bright red blood per rectum.", [["blood", "ANATOMY", 44, 49], ["rectum", "ANATOMY", 54, 60], ["male", "ORGANISM", 14, 18], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["rectum", "ORGAN", 54, 60], ["bright red blood per rectum", "PROBLEM", 33, 60], ["bright red blood", "OBSERVATION", 33, 49], ["rectum", "ANATOMY", 54, 60]]], ["He states he has had bleeding for the past eight years for which he has been admitted several times to various hospitals outside of the current state.", [["bleeding", "DISEASE", 21, 29], ["bleeding", "PROBLEM", 21, 29], ["bleeding", "OBSERVATION", 21, 29]]], ["He occasionally is transfused during these admissions.", [["He", "ORGANISM", 0, 2], ["transfused", "OBSERVATION", 19, 29]]], ["He has had several colonoscopies but reports they are always normal.", [["several colonoscopies", "TEST", 11, 32], ["colonoscopies", "OBSERVATION", 19, 32], ["normal", "OBSERVATION", 61, 67]]], ["He reports no weight loss and, otherwise, is enjoying good health.", [["weight loss", "DISEASE", 14, 25], ["weight loss", "PROBLEM", 14, 25], ["no", "UNCERTAINTY", 11, 13], ["weight loss", "OBSERVATION", 14, 25]]], ["The most likely diagnosis is: A) Diverticula B) Arterial venous malformations C) Malignancy D) Hemorrhoids Answer: B Arterial venous malformations (AVM) are a common cause of lower intestinal bleeding.", [["Arterial venous", "ANATOMY", 48, 63], ["Arterial venous", "ANATOMY", 117, 132], ["AVM", "ANATOMY", 148, 151], ["lower intestinal", "ANATOMY", 175, 191], ["Arterial venous malformations", "DISEASE", 48, 77], ["Hemorrhoids", "DISEASE", 95, 106], ["Arterial venous malformations", "DISEASE", 117, 146], ["AVM", "DISEASE", 148, 151], ["lower intestinal bleeding", "DISEASE", 175, 200], ["Arterial venous", "MULTI-TISSUE_STRUCTURE", 48, 63], ["B Arterial venous malformations", "PATHOLOGICAL_FORMATION", 115, 146], ["lower intestinal", "ORGANISM_SUBDIVISION", 175, 191], ["Diverticula B) Arterial venous malformations C", "PROBLEM", 33, 79], ["Malignancy D)", "PROBLEM", 81, 94], ["Hemorrhoids", "PROBLEM", 95, 106], ["B Arterial venous malformations (AVM", "PROBLEM", 115, 151], ["lower intestinal bleeding", "PROBLEM", 175, 200], ["most likely", "UNCERTAINTY", 4, 15], ["Diverticula", "OBSERVATION", 33, 44], ["Arterial venous", "ANATOMY", 48, 63], ["malformations", "OBSERVATION", 64, 77], ["Malignancy", "OBSERVATION", 81, 91], ["Hemorrhoids", "OBSERVATION", 95, 106], ["Arterial", "ANATOMY_MODIFIER", 117, 125], ["venous", "ANATOMY", 126, 132], ["malformations", "OBSERVATION", 133, 146], ["AVM", "OBSERVATION", 148, 151], ["lower", "ANATOMY_MODIFIER", 175, 180], ["intestinal", "ANATOMY", 181, 191], ["bleeding", "OBSERVATION", 192, 200]]], ["Over half are located in the right colon, and approximately 50 % of patients experience painless hematochezia.", [["right colon", "ANATOMY", 29, 40], ["hematochezia", "DISEASE", 97, 109], ["colon", "ORGAN", 35, 40], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 68, 76], ["painless hematochezia", "PROBLEM", 88, 109], ["right", "ANATOMY_MODIFIER", 29, 34], ["colon", "ANATOMY", 35, 40], ["painless", "OBSERVATION_MODIFIER", 88, 96], ["hematochezia", "OBSERVATION", 97, 109]]], ["Colonic lesions most often bleed chronically and slow.", [["Colonic lesions", "ANATOMY", 0, 15], ["Colonic lesions", "PATHOLOGICAL_FORMATION", 0, 15], ["Colonic lesions", "PROBLEM", 0, 15], ["often bleed", "PROBLEM", 21, 32], ["lesions", "OBSERVATION", 8, 15], ["bleed", "OBSERVATION", 27, 32], ["slow", "OBSERVATION_MODIFIER", 49, 53]]], ["However, as many as 15 % of patients present with acute massive hemorrhage.", [["hemorrhage", "DISEASE", 64, 74], ["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["acute massive hemorrhage", "PROBLEM", 50, 74], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["massive", "OBSERVATION_MODIFIER", 56, 63], ["hemorrhage", "OBSERVATION", 64, 74]]], ["AVMs can be acute, chronic, and intermittent in nature.", [["AVMs", "ANATOMY", 0, 4], ["AVMs", "DISEASE", 0, 4], ["AVMs", "PROBLEM", 0, 4], ["acute", "PROBLEM", 12, 17], ["can be", "UNCERTAINTY", 5, 11], ["acute", "OBSERVATION_MODIFIER", 12, 17], ["chronic", "OBSERVATION_MODIFIER", 19, 26], ["intermittent", "OBSERVATION_MODIFIER", 32, 44]]], ["Angiography is considered the gold standard in diagnosing arterial venous malformations.", [["arterial venous", "ANATOMY", 58, 73], ["arterial venous malformations", "DISEASE", 58, 87], ["arterial venous malformations", "PATHOLOGICAL_FORMATION", 58, 87], ["Angiography", "TEST", 0, 11], ["diagnosing arterial venous malformations", "PROBLEM", 47, 87], ["arterial venous", "ANATOMY", 58, 73], ["malformations", "OBSERVATION", 74, 87]]], ["Management of AVMs is often diffi cult.", [["AVMs", "ANATOMY", 14, 18], ["AVMs", "DISEASE", 14, 18], ["AVMs", "CANCER", 14, 18], ["AVMs", "PROBLEM", 14, 18], ["cult", "TEST", 34, 38], ["AVMs", "OBSERVATION", 14, 18]]], ["Electrocautery has been used to obliterate angiodysplasias.", [["angiodysplasias", "DISEASE", 43, 58], ["angiodysplasias", "CANCER", 43, 58], ["Electrocautery", "TREATMENT", 0, 14], ["angiodysplasias", "PROBLEM", 43, 58], ["obliterate", "OBSERVATION_MODIFIER", 32, 42], ["angiodysplasias", "OBSERVATION", 43, 58]]], ["However, bleeding recurs in approximately 50 % of subjects.", [["bleeding", "DISEASE", 9, 17], ["bleeding", "PROBLEM", 9, 17], ["bleeding", "OBSERVATION", 9, 17]]], ["A reduction in the posttherapy transfusion requirements in patients' cauterized was not reported to be statistically superior to no therapy.ReferencesCurrently, no medical therapy has been proven to effectively prevent bleeding from AVM.", [["AVM", "ANATOMY", 233, 236], ["bleeding", "DISEASE", 219, 227], ["AVM", "DISEASE", 233, 236], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["A reduction", "TREATMENT", 0, 11], ["the posttherapy transfusion requirements", "TREATMENT", 15, 55], ["therapy", "TREATMENT", 132, 139], ["medical therapy", "TREATMENT", 164, 179], ["bleeding", "PROBLEM", 219, 227], ["AVM", "PROBLEM", 233, 236], ["reduction", "OBSERVATION_MODIFIER", 2, 11], ["bleeding", "OBSERVATION", 219, 227], ["AVM", "OBSERVATION", 233, 236]]], ["No preventive methods for angiodysplasia have been defi nitely identifi ed at this time.ReferencesAvoidance of nonsteroidal anti-infl ammatory drugs (NSAIDs) is recommended.", [["angiodysplasia", "DISEASE", 26, 40], ["NSAIDs", "CHEMICAL", 150, 156], ["angiodysplasia", "PATHOLOGICAL_FORMATION", 26, 40], ["nonsteroidal anti-infl ammatory drugs", "SIMPLE_CHEMICAL", 111, 148], ["NSAIDs", "SIMPLE_CHEMICAL", 150, 156], ["angiodysplasia", "PROBLEM", 26, 40], ["nonsteroidal anti-infl ammatory drugs", "TREATMENT", 111, 148], ["NSAIDs", "TREATMENT", 150, 156], ["angiodysplasia", "OBSERVATION", 26, 40]]], ["A 78-year-old male presents with worsening confusion and a signifi cant change in personality over the past four weeks.", [["confusion", "DISEASE", 43, 52], ["male", "ORGANISM", 14, 18], ["worsening confusion", "PROBLEM", 33, 52], ["a signifi cant change in personality", "PROBLEM", 57, 93], ["worsening", "OBSERVATION_MODIFIER", 33, 42], ["confusion", "OBSERVATION", 43, 52]]], ["He has a history of mild dementia, as reported by his family but has been living independently.", [["dementia", "DISEASE", 25, 33], ["mild dementia", "PROBLEM", 20, 33], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["dementia", "OBSERVATION", 25, 33]]], ["He has been in the hospital for ten days, and despite extensive workup including computed tomography of the head, EEG, and cerebrospinal fl uid analysis, no defi nitive diagnosis is found.", [["head", "ANATOMY", 108, 112], ["head", "ORGANISM_SUBDIVISION", 108, 112], ["extensive workup", "TEST", 54, 70], ["computed tomography of the head", "TEST", 81, 112], ["EEG", "TEST", 114, 117], ["cerebrospinal fl uid analysis", "TEST", 123, 152], ["head", "ANATOMY", 108, 112], ["cerebrospinal fl", "ANATOMY", 123, 139]]], ["During the past week, his confusion has become worse.", [["confusion", "DISEASE", 26, 35], ["his confusion", "PROBLEM", 22, 35]]], ["He is now mainly nonresponsive.", [["mainly nonresponsive", "PROBLEM", 10, 30], ["mainly", "OBSERVATION_MODIFIER", 10, 16], ["nonresponsive", "OBSERVATION", 17, 30]]], ["He has developed a progressive myoclonus starting in his right arm.", [["right arm", "ANATOMY", 57, 66], ["myoclonus", "DISEASE", 31, 40], ["arm", "ORGANISM_SUBDIVISION", 63, 66], ["a progressive myoclonus", "PROBLEM", 17, 40], ["progressive", "OBSERVATION_MODIFIER", 19, 30], ["myoclonus", "OBSERVATION", 31, 40], ["right", "ANATOMY_MODIFIER", 57, 62], ["arm", "ANATOMY", 63, 66]]], ["Repeat computed tomography of his head is still normal.", [["head", "ANATOMY", 34, 38], ["head", "ORGAN", 34, 38], ["Repeat computed tomography of his head", "TEST", 0, 38], ["head", "ANATOMY", 34, 38], ["normal", "OBSERVATION", 48, 54]]], ["Repeat EEG is pending.", [["Repeat EEG", "TEST", 0, 10]]], ["The most likely diagnosis is: A) Creutzfeldt-Jakob disease (CJD) B) Multi-infarct dementia C) Recurrent seizure disorder D) Catatonic depression E) Herpes simplex encephalitis Answer: A This patient has Creutzfeldt-Jakob disease (CJD).", [["Creutzfeldt-Jakob disease", "DISEASE", 33, 58], ["CJD", "DISEASE", 60, 63], ["dementia", "DISEASE", 82, 90], ["seizure disorder", "DISEASE", 104, 120], ["Catatonic depression", "DISEASE", 124, 144], ["Herpes simplex encephalitis", "DISEASE", 148, 175], ["Creutzfeldt-Jakob disease", "DISEASE", 203, 228], ["CJD", "DISEASE", 230, 233], ["Herpes simplex", "ORGANISM", 148, 162], ["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 191, 198], ["Jakob disease (CJD)", "PROBLEM", 45, 64], ["Multi-infarct dementia C", "PROBLEM", 68, 92], ["Recurrent seizure disorder D)", "PROBLEM", 94, 123], ["Catatonic depression E", "PROBLEM", 124, 146], ["Herpes simplex encephalitis", "PROBLEM", 148, 175], ["Creutzfeldt", "PROBLEM", 203, 214], ["Jakob disease (CJD)", "PROBLEM", 215, 234], ["most likely", "UNCERTAINTY", 4, 15], ["Jakob", "ANATOMY", 215, 220], ["disease", "OBSERVATION", 221, 228]]], ["The differential diagnosis of rapidly progressive dementia is limited.", [["dementia", "DISEASE", 50, 58], ["rapidly progressive dementia", "PROBLEM", 30, 58], ["differential diagnosis of", "UNCERTAINTY", 4, 29], ["rapidly", "OBSERVATION_MODIFIER", 30, 37], ["progressive", "OBSERVATION_MODIFIER", 38, 49], ["dementia", "OBSERVATION", 50, 58]]], ["The clues to CJD in this patient are the appearance of relatively normal imaging, the unexplained rapidly progressive dementia, and the subsequent appearance of myoclonus.", [["CJD", "DISEASE", 13, 16], ["dementia", "DISEASE", 118, 126], ["myoclonus", "DISEASE", 161, 170], ["patient", "ORGANISM", 25, 32], ["patient", "SPECIES", 25, 32], ["CJD", "PROBLEM", 13, 16], ["the unexplained rapidly progressive dementia", "PROBLEM", 82, 126], ["myoclonus", "PROBLEM", 161, 170], ["unexplained", "OBSERVATION_MODIFIER", 86, 97], ["rapidly", "OBSERVATION_MODIFIER", 98, 105], ["progressive", "OBSERVATION_MODIFIER", 106, 117], ["dementia", "OBSERVATION", 118, 126], ["myoclonus", "OBSERVATION", 161, 170]]], ["Initially, individuals experience problems with muscular coordination and personality changes, including impaired memory suggestive of typical dementia.", [["muscular", "ANATOMY", 48, 56], ["muscular coordination", "DISEASE", 48, 69], ["impaired memory", "DISEASE", 105, 120], ["dementia", "DISEASE", 143, 151], ["muscular", "ORGANISM_SUBDIVISION", 48, 56], ["muscular coordination", "PROBLEM", 48, 69], ["personality changes", "PROBLEM", 74, 93], ["impaired memory", "PROBLEM", 105, 120], ["typical dementia", "PROBLEM", 135, 151], ["suggestive of", "UNCERTAINTY", 121, 134], ["typical", "OBSERVATION_MODIFIER", 135, 142], ["dementia", "OBSERVATION", 143, 151]]], ["Most patients die within six months after initial symptoms appear.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["initial symptoms", "PROBLEM", 42, 58]]], ["The current accepted theory is that CJD is caused by prions.ReferencePrions are misfolded proteins that replicate by converting their properly folded counterparts to the same misfolded structure they possess.", [["CJD", "DISEASE", 36, 39], ["misfolded proteins", "PROTEIN", 80, 98], ["CJD", "PROBLEM", 36, 39], ["misfolded proteins", "PROBLEM", 80, 98], ["CJD", "OBSERVATION", 36, 39], ["misfolded", "OBSERVATION", 80, 89], ["misfolded structure", "OBSERVATION", 175, 194]]], ["The disease leads to neurodegeneration, causing the brain tissue to take a more sponge-like texture.", [["brain tissue", "ANATOMY", 52, 64], ["neurodegeneration", "DISEASE", 21, 38], ["brain tissue", "TISSUE", 52, 64], ["The disease", "PROBLEM", 0, 11], ["neurodegeneration", "PROBLEM", 21, 38], ["the brain tissue", "PROBLEM", 48, 64], ["a more sponge-like texture", "PROBLEM", 73, 99], ["disease", "OBSERVATION", 4, 11], ["neurodegeneration", "OBSERVATION", 21, 38], ["brain", "ANATOMY", 52, 57], ["tissue", "OBSERVATION", 58, 64], ["more sponge-like texture", "OBSERVATION_MODIFIER", 75, 99]]], ["Although most patient have a rapidly declining course, there is some variation.", [["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["rapidly", "OBSERVATION_MODIFIER", 29, 36], ["declining", "OBSERVATION_MODIFIER", 37, 46], ["some", "OBSERVATION_MODIFIER", 64, 68], ["variation", "OBSERVATION_MODIFIER", 69, 78]]], ["15 % of patients survive for two or more years.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16]]], ["Some patients have been known to live 4-5 years.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13]]], ["Clinical testing for CJD has been problematic.ReferenceElectroencepgraphy may be normal on presentation as was here.", [["CJD", "DISEASE", 21, 24], ["Clinical testing", "TEST", 0, 16], ["CJD", "PROBLEM", 21, 24], ["ReferenceElectroencepgraphy", "TEST", 46, 73], ["normal", "OBSERVATION", 81, 87]]], ["Triphasic spikes often occur later on and may be the fi rst clue to diagnosis.", [["Triphasic spikes", "PROBLEM", 0, 16]]], ["Confi rmation is often made by a combination of tests, symptoms, and marker proteins found in the CSF.184.A 33-year-old woman is admitted because of headache that began suddenly while playing tennis.", [["headache", "DISEASE", 149, 157], ["CSF", "GENE_OR_GENE_PRODUCT", 98, 101], ["woman", "ORGANISM", 120, 125], ["marker proteins", "PROTEIN", 69, 84], ["CSF", "PROTEIN", 98, 101], ["woman", "SPECIES", 120, 125], ["tests", "TEST", 48, 53], ["symptoms", "PROBLEM", 55, 63], ["marker proteins", "TEST", 69, 84], ["headache", "PROBLEM", 149, 157], ["CSF", "ANATOMY", 98, 101], ["33-", "OBSERVATION_MODIFIER", 108, 111], ["headache", "OBSERVATION", 149, 157]]], ["The headache is diffuse and reached its greatest intensity over three hours.", [["headache", "DISEASE", 4, 12], ["The headache", "PROBLEM", 0, 12], ["headache", "OBSERVATION", 4, 12], ["diffuse", "OBSERVATION_MODIFIER", 16, 23], ["greatest", "OBSERVATION_MODIFIER", 40, 48], ["intensity", "OBSERVATION_MODIFIER", 49, 58]]], ["She denies any head trauma, loss of consciousness, or other symptoms.", [["head", "ANATOMY", 15, 19], ["trauma", "DISEASE", 20, 26], ["loss of consciousness", "DISEASE", 28, 49], ["head", "ORGANISM_SUBDIVISION", 15, 19], ["head trauma", "PROBLEM", 15, 26], ["loss of consciousness", "PROBLEM", 28, 49], ["other symptoms", "PROBLEM", 54, 68], ["head", "ANATOMY", 15, 19], ["trauma", "OBSERVATION", 20, 26]]], ["She has had four similar headaches in the past year.", [["headaches", "DISEASE", 25, 34], ["four similar headaches", "PROBLEM", 12, 34], ["four", "OBSERVATION_MODIFIER", 12, 16], ["similar", "OBSERVATION_MODIFIER", 17, 24], ["headaches", "OBSERVATION", 25, 34]]], ["On physical exam, the patient appears uncomfortable.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["physical exam", "TEST", 3, 16], ["uncomfortable", "PROBLEM", 38, 51], ["uncomfortable", "OBSERVATION", 38, 51]]], ["Blood pressure is 160/92 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["No focal defi cits are noted.", [["focal defi cits", "PROBLEM", 3, 18], ["focal", "OBSERVATION_MODIFIER", 3, 8], ["defi cits", "OBSERVATION", 9, 18]]], ["Cranial nerves are normal.", [["Cranial nerves", "ANATOMY", 0, 14], ["Cranial nerves", "MULTI-TISSUE_STRUCTURE", 0, 14], ["nerves", "ANATOMY", 8, 14], ["normal", "OBSERVATION", 19, 25]]], ["Neck fl exion is normal.184.The only medicine she reports is birth control pills.", [["fl", "ANATOMY", 5, 7], ["exion", "OBSERVATION", 8, 13], ["normal", "OBSERVATION", 17, 23]]], ["Which of the following aspects suggests subarachnoid hemorrhage (SAH)?", [["subarachnoid", "ANATOMY", 40, 52], ["subarachnoid hemorrhage", "DISEASE", 40, 63], ["SAH", "DISEASE", 65, 68], ["subarachnoid hemorrhage", "PATHOLOGICAL_FORMATION", 40, 63], ["subarachnoid hemorrhage", "PROBLEM", 40, 63], ["SAH", "PROBLEM", 65, 68], ["subarachnoid", "ANATOMY", 40, 52], ["hemorrhage", "OBSERVATION", 53, 63], ["SAH", "OBSERVATION", 65, 68]]], ["A) Onset during exertion B) Age of 29 C) Peak intensity of headache at three hours D) Three or more headaches during the past six to 12 months E) Use of estrogens Answer: A Diagnosis of SAH usually depends on a high index of clinical suspicion combined with radiologic confi rmation.", [["headache", "DISEASE", 59, 67], ["headaches", "DISEASE", 100, 109], ["estrogens", "CHEMICAL", 153, 162], ["SAH", "DISEASE", 186, 189], ["estrogens", "CHEMICAL", 153, 162], ["estrogens", "SIMPLE_CHEMICAL", 153, 162], ["Peak intensity of headache", "PROBLEM", 41, 67], ["more headaches", "PROBLEM", 95, 109], ["SAH", "PROBLEM", 186, 189], ["headaches", "OBSERVATION", 100, 109], ["SAH", "OBSERVATION", 186, 189]]], ["Noncontrast CT is recommended, followed by lumbar puncture or CT angiography of the brain.", [["lumbar", "ANATOMY", 43, 49], ["brain", "ANATOMY", 84, 89], ["brain", "ORGAN", 84, 89], ["Noncontrast CT", "TEST", 0, 14], ["lumbar puncture", "TEST", 43, 58], ["CT angiography of the brain", "TEST", 62, 89], ["lumbar", "ANATOMY", 43, 49], ["brain", "ANATOMY", 84, 89]]], ["Physical or emotional strain, defecation, coitus, and head trauma contribute to varying degrees in 60-70 % of cases.", [["head", "ANATOMY", 54, 58], ["trauma", "DISEASE", 59, 65], ["head", "ORGANISM_SUBDIVISION", 54, 58], ["emotional strain", "PROBLEM", 12, 28], ["defecation", "PROBLEM", 30, 40], ["coitus", "PROBLEM", 42, 48], ["head trauma", "PROBLEM", 54, 65], ["head", "ANATOMY", 54, 58]]], ["The central feature of classic SAH is sudden onset of severe headache, often described as the \"worst headache of my life.\"", [["SAH", "DISEASE", 31, 34], ["headache", "DISEASE", 61, 69], ["headache", "DISEASE", 101, 109], ["classic SAH", "PROBLEM", 23, 34], ["severe headache", "PROBLEM", 54, 69], ["central", "OBSERVATION_MODIFIER", 4, 11], ["classic", "OBSERVATION_MODIFIER", 23, 30], ["SAH", "OBSERVATION", 31, 34], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["headache", "OBSERVATION", 61, 69]]], ["Other factors strongly associated with SAH diagnosis are aged 40 years or older, syncope, complaint of neck pain or stiffness, arrival by ambulance, vomiting, and diastolic blood pressure \u2265100 mmHg or systolic blood pressure \u2265160 mmHg.ReferencePerry JJ, Stiell IG, Sivilotti ML, Bullard MJ, Lee JS, Eisenhauer M. High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study.", [["neck", "ANATOMY", 103, 107], ["blood", "ANATOMY", 173, 178], ["blood", "ANATOMY", 210, 215], ["subarachnoid", "ANATOMY", 352, 364], ["SAH", "DISEASE", 39, 42], ["syncope", "DISEASE", 81, 88], ["neck pain", "DISEASE", 103, 112], ["stiffness", "DISEASE", 116, 125], ["vomiting", "DISEASE", 149, 157], ["subarachnoid haemorrhage", "DISEASE", 352, 376], ["acute headache", "DISEASE", 394, 408], ["neck", "ORGANISM_SUBDIVISION", 103, 107], ["blood", "ORGANISM_SUBSTANCE", 173, 178], ["blood", "ORGANISM_SUBSTANCE", 210, 215], ["subarachnoid", "IMMATERIAL_ANATOMICAL_ENTITY", 352, 364], ["patients", "ORGANISM", 380, 388], ["patients", "SPECIES", 380, 388], ["SAH", "PROBLEM", 39, 42], ["syncope", "PROBLEM", 81, 88], ["neck pain", "PROBLEM", 103, 112], ["stiffness", "PROBLEM", 116, 125], ["vomiting", "PROBLEM", 149, 157], ["diastolic blood pressure", "TEST", 163, 187], ["systolic blood pressure", "TEST", 201, 224], ["ReferencePerry JJ", "TREATMENT", 235, 252], ["subarachnoid haemorrhage", "PROBLEM", 352, 376], ["acute headache", "PROBLEM", 394, 408], ["prospective cohort study", "TEST", 410, 434], ["neck", "ANATOMY", 103, 107], ["pain", "OBSERVATION", 108, 112], ["Lee JS", "ANATOMY", 291, 297], ["subarachnoid", "ANATOMY", 352, 364], ["haemorrhage", "OBSERVATION", 365, 376], ["acute", "OBSERVATION_MODIFIER", 394, 399], ["headache", "OBSERVATION", 400, 408]]], ["2010; 341:c5204.", [["341:c5204", "CHEMICAL", 6, 15]]], ["A 72-year-old man who has chronic systolic heart failure presents with increasing shortness of breath.", [["heart", "ANATOMY", 43, 48], ["systolic heart failure", "DISEASE", 34, 56], ["shortness of breath", "DISEASE", 82, 101], ["man", "ORGANISM", 14, 17], ["heart", "ORGAN", 43, 48], ["man", "SPECIES", 14, 17], ["chronic systolic heart failure", "PROBLEM", 26, 56], ["increasing shortness of breath", "PROBLEM", 71, 101], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["systolic", "OBSERVATION", 34, 42], ["heart", "ANATOMY", 43, 48], ["failure", "OBSERVATION", 49, 56], ["increasing", "OBSERVATION_MODIFIER", 71, 81]]], ["He has gained 5 kg (10 lb) since his last outpatient appointment one month ago.", [["He", "ORGANISM", 0, 2]]], ["He has not been following sodium and fl uid restrictions as prescribed by his cardiologist.", [["sodium", "CHEMICAL", 26, 32], ["sodium", "CHEMICAL", 26, 32], ["sodium", "SIMPLE_CHEMICAL", 26, 32], ["fl uid", "SIMPLE_CHEMICAL", 37, 43], ["fl uid restrictions", "TREATMENT", 37, 56]]], ["Temperature is 37.7 C (100.0 F), pulse rate is 90 per minute, respirations are 24 per minute, and blood pressure is 150/77 mmHg.", [["blood", "ANATOMY", 98, 103], ["blood", "ORGANISM_SUBSTANCE", 98, 103], ["Temperature", "TEST", 0, 11], ["pulse rate", "TEST", 33, 43], ["respirations", "TEST", 62, 74], ["blood pressure", "TEST", 98, 112]]], ["Oxygen saturation by pulse oximetry is 88 %.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17], ["pulse oximetry", "TEST", 21, 35]]], ["Physical examination is remarkable for jugular venous distention.", [["jugular venous", "ANATOMY", 39, 53], ["jugular venous distention", "DISEASE", 39, 64], ["jugular venous", "MULTI-TISSUE_STRUCTURE", 39, 53], ["Physical examination", "TEST", 0, 20], ["jugular venous distention", "PROBLEM", 39, 64], ["jugular venous", "ANATOMY", 39, 53], ["distention", "OBSERVATION", 54, 64]]], ["An S3 gallop is noted.", [["S3 gallop", "ANATOMY", 3, 12]]], ["He has bilateral crackles to the mid-lung fi elds, and 2+ edema in the legs.ReferenceWhich of the following interventions has not been proven to be benefi cial in the treatment of this patient in the inpatient setting?", [["mid-lung fi elds", "ANATOMY", 33, 49], ["edema", "ANATOMY", 58, 63], ["legs", "ANATOMY", 71, 75], ["edema", "DISEASE", 58, 63], ["He", "ORGANISM", 0, 2], ["edema", "PATHOLOGICAL_FORMATION", 58, 63], ["legs", "ORGANISM_SUBDIVISION", 71, 75], ["patient", "ORGANISM", 185, 192], ["patient", "SPECIES", 185, 192], ["bilateral crackles to the mid-lung fi elds", "PROBLEM", 7, 49], ["2+ edema in the legs", "PROBLEM", 55, 75], ["bilateral", "ANATOMY_MODIFIER", 7, 16], ["crackles", "OBSERVATION", 17, 25], ["mid-lung", "ANATOMY", 33, 41], ["+", "OBSERVATION_MODIFIER", 56, 57], ["edema", "OBSERVATION", 58, 63], ["legs", "ANATOMY", 71, 75]]], ["A) Supplemental oxygen B) Continuation of the ACE inhibitor C) Intravenous furosemide D) Daily weights E) Strict sodium and fl uid restriction Answer: E Despite what is recommended for outpatient management of CHF, a randomized controlled trial of patients who have acute decompensated heart failure demonstrated that aggressive sodium and fl uid restriction demonstrated no additional weight loss or benefi ts to heart failure symptoms compared with a liberal standard hospital diet with no restrictions on sodium or fl uid intake.ReferenceAliti GB, Rabelo ER, Clausell N, Rohde LE, Biolo A, Beckda-Silva L. Aggressive fl uid and sodium restriction in acute decompensated heart failure: a randomized clinical trial.", [["heart", "ANATOMY", 286, 291], ["heart", "ANATOMY", 414, 419], ["heart", "ANATOMY", 673, 678], ["oxygen B", "CHEMICAL", 16, 24], ["furosemide", "CHEMICAL", 75, 85], ["sodium", "CHEMICAL", 113, 119], ["CHF", "DISEASE", 210, 213], ["decompensated heart failure", "DISEASE", 272, 299], ["sodium", "CHEMICAL", 329, 335], ["fl uid", "CHEMICAL", 340, 346], ["weight loss", "DISEASE", 386, 397], ["heart failure", "DISEASE", 414, 427], ["sodium", "CHEMICAL", 508, 514], ["sodium", "CHEMICAL", 631, 637], ["decompensated heart failure", "DISEASE", 659, 686], ["oxygen B", "CHEMICAL", 16, 24], ["furosemide D)", "CHEMICAL", 75, 88], ["sodium", "CHEMICAL", 113, 119], ["sodium", "CHEMICAL", 329, 335], ["sodium", "CHEMICAL", 508, 514], ["sodium", "CHEMICAL", 631, 637], ["oxygen B", "SIMPLE_CHEMICAL", 16, 24], ["Intravenous furosemide D", "SIMPLE_CHEMICAL", 63, 87], ["sodium", "SIMPLE_CHEMICAL", 113, 119], ["patients", "ORGANISM", 248, 256], ["heart", "ORGAN", 286, 291], ["sodium", "SIMPLE_CHEMICAL", 329, 335], ["fl uid", "SIMPLE_CHEMICAL", 340, 346], ["heart", "ORGAN", 414, 419], ["sodium", "SIMPLE_CHEMICAL", 508, 514], ["fl uid", "SIMPLE_CHEMICAL", 518, 524], ["sodium", "SIMPLE_CHEMICAL", 631, 637], ["heart", "ORGAN", 673, 678], ["patients", "SPECIES", 248, 256], ["Supplemental oxygen B)", "TREATMENT", 3, 25], ["the ACE inhibitor C) Intravenous furosemide D)", "TREATMENT", 42, 88], ["Daily weights", "TEST", 89, 102], ["Strict sodium and fl uid restriction", "TREATMENT", 106, 142], ["outpatient management", "TREATMENT", 185, 206], ["CHF", "PROBLEM", 210, 213], ["acute decompensated heart failure", "PROBLEM", 266, 299], ["aggressive sodium", "TREATMENT", 318, 335], ["fl uid restriction", "TREATMENT", 340, 358], ["weight loss", "PROBLEM", 386, 397], ["benefi ts to heart failure symptoms", "PROBLEM", 401, 436], ["a liberal standard hospital diet", "TREATMENT", 451, 483], ["sodium", "TREATMENT", 508, 514], ["ReferenceAliti", "TEST", 532, 546], ["GB", "TEST", 547, 549], ["Rabelo", "TEST", 551, 557], ["Clausell", "TEST", 562, 570], ["Aggressive fl uid", "TREATMENT", 609, 626], ["sodium restriction", "TREATMENT", 631, 649], ["acute decompensated heart failure", "PROBLEM", 653, 686], ["a randomized clinical trial", "TREATMENT", 688, 715], ["CHF", "OBSERVATION", 210, 213], ["acute", "OBSERVATION_MODIFIER", 266, 271], ["decompensated", "OBSERVATION", 272, 285], ["heart", "ANATOMY", 286, 291], ["failure", "OBSERVATION", 292, 299], ["no", "UNCERTAINTY", 372, 374], ["heart", "ANATOMY", 414, 419], ["failure", "OBSERVATION", 420, 427], ["acute", "OBSERVATION_MODIFIER", 653, 658], ["decompensated", "OBSERVATION", 659, 672], ["heart", "ANATOMY", 673, 678], ["failure", "OBSERVATION", 679, 686]]], ["An 82-year-old female is admitted to the hospital because of community-acquired pneumonia.", [["pneumonia", "DISEASE", 80, 89], ["female", "ORGANISM", 15, 21], ["community-acquired pneumonia", "PROBLEM", 61, 89], ["pneumonia", "OBSERVATION", 80, 89]]], ["On physical exam, vital signs are normal, and oxygen saturation by pulse oximetry is 90 %.", [["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["physical exam", "TEST", 3, 16], ["vital signs", "TEST", 18, 29], ["oxygen saturation", "TEST", 46, 63], ["pulse oximetry", "TEST", 67, 81], ["normal", "OBSERVATION", 34, 40]]], ["Leukocyte count is 13,000/\u03bcL 000] .", [["Leukocyte", "ANATOMY", 0, 9], ["Leukocyte", "CELL", 0, 9], ["Leukocyte count", "TEST", 0, 15]]], ["Radiograph of the chest shows opacity in the base of the left lung.ReferenceTreatment with supplemental oxygen, ceftriaxone, and intravenous azithromycin is started.", [["chest", "ANATOMY", 18, 23], ["left lung", "ANATOMY", 57, 66], ["intravenous", "ANATOMY", 129, 140], ["oxygen", "CHEMICAL", 104, 110], ["ceftriaxone", "CHEMICAL", 112, 123], ["azithromycin", "CHEMICAL", 141, 153], ["oxygen", "CHEMICAL", 104, 110], ["ceftriaxone", "CHEMICAL", 112, 123], ["azithromycin", "CHEMICAL", 141, 153], ["chest", "ORGAN", 18, 23], ["lung", "ORGAN", 62, 66], ["oxygen", "SIMPLE_CHEMICAL", 104, 110], ["ceftriaxone", "SIMPLE_CHEMICAL", 112, 123], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 129, 140], ["azithromycin", "SIMPLE_CHEMICAL", 141, 153], ["Radiograph of the chest", "TEST", 0, 23], ["opacity", "PROBLEM", 30, 37], ["ReferenceTreatment", "TREATMENT", 67, 85], ["supplemental oxygen", "TREATMENT", 91, 110], ["ceftriaxone", "TREATMENT", 112, 123], ["intravenous azithromycin", "TREATMENT", 129, 153], ["chest", "ANATOMY", 18, 23], ["opacity", "OBSERVATION", 30, 37], ["base", "ANATOMY_MODIFIER", 45, 49], ["left", "ANATOMY_MODIFIER", 57, 61], ["lung", "ANATOMY", 62, 66]]], ["She improves and is weaned off supplemental oxygen during the next two days.", [["oxygen", "CHEMICAL", 44, 50], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["supplemental oxygen", "TREATMENT", 31, 50]]], ["Repeat mental status testing shows that she is oriented but is still not to her baseline mental status.", [["Repeat mental status testing", "TEST", 0, 28]]], ["There has been some mild agitation in the hospital but she is sleeping through the night.", [["agitation", "DISEASE", 25, 34], ["some mild agitation", "PROBLEM", 15, 34], ["some", "OBSERVATION_MODIFIER", 15, 19], ["mild", "OBSERVATION_MODIFIER", 20, 24], ["agitation", "OBSERVATION", 25, 34]]], ["The family inquires if anything can be done to improve cognitive function and control of her mild agitation.ReferenceWhich of the following is the best option?", [["agitation", "DISEASE", 98, 107], ["her mild agitation", "PROBLEM", 89, 107], ["mild", "OBSERVATION_MODIFIER", 93, 97], ["agitation", "OBSERVATION", 98, 107]]], ["A) Magnetic resonance imaging B) Prescribe donepezil C) Prescribe lorazepam D) Prescribe haloperidol E) Arrange outpatient follow-up to address cognitive functionReferenceAnswer: E Delirium is the most common cause of cognitive changes in the inpatient setting.", [["donepezil", "CHEMICAL", 43, 52], ["lorazepam", "CHEMICAL", 66, 75], ["haloperidol", "CHEMICAL", 89, 100], ["Delirium", "DISEASE", 181, 189], ["donepezil C", "CHEMICAL", 43, 54], ["lorazepam D", "CHEMICAL", 66, 77], ["haloperidol E", "CHEMICAL", 89, 102], ["lorazepam D", "SIMPLE_CHEMICAL", 66, 77], ["Magnetic resonance imaging", "TEST", 3, 29], ["donepezil C)", "TREATMENT", 43, 55], ["lorazepam D", "TREATMENT", 66, 77], ["haloperidol E", "TREATMENT", 89, 102], ["Delirium", "PROBLEM", 181, 189], ["cognitive changes", "PROBLEM", 218, 235], ["cognitive", "OBSERVATION", 218, 227]]], ["This patient likely has baseline cognitive impairment, which puts her at higher risk for delirium.", [["cognitive impairment", "DISEASE", 33, 53], ["delirium", "DISEASE", 89, 97], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["baseline cognitive impairment", "PROBLEM", 24, 53], ["delirium", "PROBLEM", 89, 97], ["cognitive", "OBSERVATION_MODIFIER", 33, 42], ["impairment", "OBSERVATION", 43, 53]]], ["The most common differential diagnostic issue when evaluating confusion in older adults involves differentiating symptoms of delirium and dementia.", [["confusion", "DISEASE", 62, 71], ["delirium", "DISEASE", 125, 133], ["dementia", "DISEASE", 138, 146], ["confusion", "PROBLEM", 62, 71], ["delirium", "PROBLEM", 125, 133], ["dementia", "PROBLEM", 138, 146], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["delirium", "OBSERVATION", 125, 133], ["dementia", "OBSERVATION", 138, 146]]], ["It is not possible to accurately diagnose the extent of her dementia in the current setting.", [["dementia", "DISEASE", 60, 68], ["her dementia", "PROBLEM", 56, 68], ["not possible", "UNCERTAINTY", 6, 18], ["dementia", "OBSERVATION", 60, 68]]], ["Despite the lack of evidence of benefi t in the acute setting, nearly 10 % of all new cholinesterase inhibitors are started in the hospital.", [["cholinesterase", "GENE_OR_GENE_PRODUCT", 86, 100], ["all new cholinesterase inhibitors", "TREATMENT", 78, 111]]], ["Once she has fully recovered from her community-acquired pneumonia, an accurate assessment can be made and treatment considered.", [["pneumonia", "DISEASE", 57, 66], ["her community-acquired pneumonia", "PROBLEM", 34, 66], ["an accurate assessment", "TEST", 68, 90], ["treatment", "TREATMENT", 107, 116], ["pneumonia", "OBSERVATION", 57, 66]]], ["Further medications are likely to increase confusion and should be avoided.ReferenceFong TG, Tulebaev SR, Inouye SK.", [["confusion", "DISEASE", 43, 52], ["Further medications", "TREATMENT", 0, 19], ["confusion", "PROBLEM", 43, 52], ["SK", "ANATOMY", 113, 115]]], ["Delirium in elderly adults: diagnosis, prevention and treatment.", [["Delirium", "DISEASE", 0, 8], ["Delirium", "PROBLEM", 0, 8], ["treatment", "TREATMENT", 54, 63]]], ["Nat Rev Neurol.", [["Rev Neurol", "PROTEIN", 4, 14]]], ["A 52-year-old man is brought to the emergency department by nursing home staff because of polyuria and polydipsia.", [["polyuria", "DISEASE", 90, 98], ["polydipsia", "DISEASE", 103, 113], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["polyuria", "PROBLEM", 90, 98], ["polydipsia", "PROBLEM", 103, 113], ["polyuria", "OBSERVATION", 90, 98], ["polydipsia", "OBSERVATION", 103, 113]]], ["Over the past week, they have noted increased urination and almost constant thirst.", [["increased urination", "PROBLEM", 36, 55], ["almost constant thirst", "PROBLEM", 60, 82], ["increased", "OBSERVATION_MODIFIER", 36, 45], ["urination", "OBSERVATION", 46, 55], ["constant", "OBSERVATION_MODIFIER", 67, 75], ["thirst", "OBSERVATION", 76, 82]]], ["His only medication is lithium, On physical examination, temperature is normal, blood pressure is 120/80 mmHg, pulse rate is 67/min, and respiration rate is 16/min.", [["blood", "ANATOMY", 80, 85], ["lithium", "CHEMICAL", 23, 30], ["lithium", "CHEMICAL", 23, 30], ["lithium", "SIMPLE_CHEMICAL", 23, 30], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["lithium", "TREATMENT", 23, 30], ["physical examination", "TEST", 35, 55], ["temperature", "TEST", 57, 68], ["blood pressure", "TEST", 80, 94], ["pulse rate", "TEST", 111, 121], ["respiration rate", "TEST", 137, 153], ["normal", "OBSERVATION", 72, 78]]], ["The remainder of the examination is normal.ReferenceResults of laboratory studies show a serum sodium level of 157 mEq/L, random plasma glucose level of 109 mg/dL, and urine osmolality of 110 mOsm/kg.", [["serum", "ANATOMY", 89, 94], ["plasma", "ANATOMY", 129, 135], ["urine", "ANATOMY", 168, 173], ["sodium", "CHEMICAL", 95, 101], ["glucose", "CHEMICAL", 136, 143], ["sodium", "CHEMICAL", 95, 101], ["glucose", "CHEMICAL", 136, 143], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["sodium", "SIMPLE_CHEMICAL", 95, 101], ["plasma", "ORGANISM_SUBSTANCE", 129, 135], ["glucose", "SIMPLE_CHEMICAL", 136, 143], ["urine", "ORGANISM_SUBSTANCE", 168, 173], ["the examination", "TEST", 17, 32], ["laboratory studies", "TEST", 63, 81], ["a serum sodium level", "TEST", 87, 107], ["random plasma glucose level", "TEST", 122, 149], ["urine osmolality", "TEST", 168, 184], ["remainder", "ANATOMY_MODIFIER", 4, 13], ["normal", "OBSERVATION", 36, 42]]], ["A trial of vasopressin results in no signifi cant increase in urine osmolality within 1 to 2 h.ReferenceWhich of the following is the most likely cause of this patient's hypernatremia?", [["urine", "ANATOMY", 62, 67], ["vasopressin", "CHEMICAL", 11, 22], ["hypernatremia", "DISEASE", 170, 183], ["vasopressin", "CHEMICAL", 11, 22], ["vasopressin", "SIMPLE_CHEMICAL", 11, 22], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["patient", "ORGANISM", 160, 167], ["patient", "SPECIES", 160, 167], ["vasopressin", "TREATMENT", 11, 22], ["signifi cant increase", "PROBLEM", 37, 58], ["urine osmolality", "TEST", 62, 78], ["this patient's hypernatremia", "PROBLEM", 155, 183], ["most likely", "UNCERTAINTY", 134, 145], ["hypernatremia", "OBSERVATION", 170, 183]]], ["A) Central diabetes insipidus B) Nephrogenic diabetes insipidus C) Osmotic diuresis D) Primary polydipsia 188.", [["diabetes insipidus B", "DISEASE", 11, 31], ["Nephrogenic diabetes insipidus", "DISEASE", 33, 63], ["polydipsia", "DISEASE", 95, 105], ["A) Central diabetes insipidus", "PROBLEM", 0, 29], ["Nephrogenic diabetes insipidus C", "PROBLEM", 33, 65], ["Osmotic diuresis", "PROBLEM", 67, 83], ["Primary polydipsia", "PROBLEM", 87, 105], ["Central", "ANATOMY_MODIFIER", 3, 10]]], ["A 28-year-old woman is evaluated in the emergency department because of dizziness for the last week.", [["dizziness", "DISEASE", 72, 81], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["dizziness", "PROBLEM", 72, 81], ["28-", "OBSERVATION_MODIFIER", 2, 5], ["dizziness", "OBSERVATION", 72, 81]]], ["She has not experienced chest pain, dyspnea, or orthopnea.", [["chest", "ANATOMY", 24, 29], ["chest pain", "DISEASE", 24, 34], ["dyspnea", "DISEASE", 36, 43], ["orthopnea", "DISEASE", 48, 57], ["chest", "ORGANISM_SUBDIVISION", 24, 29], ["chest pain", "PROBLEM", 24, 34], ["dyspnea", "PROBLEM", 36, 43], ["orthopnea", "PROBLEM", 48, 57], ["chest", "ANATOMY", 24, 29], ["pain", "OBSERVATION", 30, 34], ["dyspnea", "OBSERVATION", 36, 43], ["orthopnea", "OBSERVATION", 48, 57]]], ["She was ill six weeks ago with fever, fatigue, and myalgias.", [["fever", "DISEASE", 31, 36], ["fatigue", "DISEASE", 38, 45], ["myalgias", "DISEASE", 51, 59], ["fever", "PROBLEM", 31, 36], ["fatigue", "PROBLEM", 38, 45], ["myalgias", "PROBLEM", 51, 59], ["fever", "OBSERVATION", 31, 36], ["myalgias", "OBSERVATION", 51, 59]]], ["Her husband reports an erythematous rash on her abdomen that resolved over two weeks.", [["abdomen", "ANATOMY", 48, 55], ["rash", "DISEASE", 36, 40], ["abdomen", "ORGANISM_SUBDIVISION", 48, 55], ["an erythematous rash on her abdomen", "PROBLEM", 20, 55], ["erythematous", "OBSERVATION_MODIFIER", 23, 35], ["rash", "OBSERVATION", 36, 40], ["abdomen", "ANATOMY", 48, 55]]], ["She has no signifi cant medical history and is on no medicines.", [["medicines", "TREATMENT", 53, 62], ["no", "UNCERTAINTY", 8, 10]]], ["On physical examination, temperature is normal, blood pressure is 126/65 mmHg, and pulse rate is 42/ min.", [["blood", "ANATOMY", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["blood pressure", "TEST", 48, 62], ["pulse rate", "TEST", 83, 93], ["normal", "OBSERVATION", 40, 46]]], ["The cardiac examination reveals bradycardia.", [["cardiac", "ANATOMY", 4, 11], ["bradycardia", "DISEASE", 32, 43], ["cardiac", "ORGAN", 4, 11], ["The cardiac examination", "TEST", 0, 23], ["bradycardia", "PROBLEM", 32, 43], ["cardiac", "ANATOMY", 4, 11], ["bradycardia", "OBSERVATION", 32, 43]]], ["The remainder of the physical examination is normal.ReferenceAn electrocardiogram shows variable heart block and a junctional escape rate of 50/min.", [["heart", "ANATOMY", 97, 102], ["junctional", "ANATOMY", 115, 125], ["heart", "ORGAN", 97, 102], ["the physical examination", "TEST", 17, 41], ["ReferenceAn electrocardiogram", "TEST", 52, 81], ["variable heart block", "PROBLEM", 88, 108], ["a junctional escape rate", "TEST", 113, 137], ["remainder", "ANATOMY_MODIFIER", 4, 13], ["normal", "OBSERVATION", 45, 51], ["variable heart block", "OBSERVATION", 88, 108], ["junctional escape", "OBSERVATION", 115, 132]]], ["She is admitted to the telemetry unit.ReferenceWhich of the following would be the initial appropriate treatment?", [["the initial appropriate treatment", "TREATMENT", 79, 112]]], ["A) Electrophysiology study B) Intravenous ceftriaxone C) Permanent pacemaker placement D) Temporary pacemaker placement E) No treatment until further serological testing Answer: B This patient should be treated with intravenous ceftriaxone.ReferencePatients with atrioventricular (AV) heart block with early Lyme disease may be treated with either oral or parenteral antibiotic therapy for 14 days.", [["intravenous", "ANATOMY", 216, 227], ["atrioventricular", "ANATOMY", 263, 279], ["heart", "ANATOMY", 285, 290], ["oral", "ANATOMY", 348, 352], ["ceftriaxone", "CHEMICAL", 42, 53], ["ceftriaxone", "CHEMICAL", 228, 239], ["atrioventricular (AV) heart block", "DISEASE", 263, 296], ["Lyme disease", "DISEASE", 308, 320], ["ceftriaxone C", "CHEMICAL", 42, 55], ["ceftriaxone", "CHEMICAL", 228, 239], ["patient", "ORGANISM", 185, 192], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 216, 227], ["ceftriaxone", "SIMPLE_CHEMICAL", 228, 239], ["atrioventricular", "MULTI-TISSUE_STRUCTURE", 263, 279], ["heart", "ORGAN", 285, 290], ["oral", "ORGANISM_SUBDIVISION", 348, 352], ["patient", "SPECIES", 185, 192], ["Intravenous ceftriaxone C", "TREATMENT", 30, 55], ["Permanent pacemaker placement D", "TREATMENT", 57, 88], ["Temporary pacemaker placement E", "TREATMENT", 90, 121], ["treatment", "TREATMENT", 126, 135], ["further serological testing", "TEST", 142, 169], ["intravenous ceftriaxone", "TREATMENT", 216, 239], ["atrioventricular (AV) heart block", "PROBLEM", 263, 296], ["early Lyme disease", "PROBLEM", 302, 320], ["parenteral antibiotic therapy", "TREATMENT", 356, 385], ["atrioventricular", "ANATOMY", 263, 279], ["heart", "ANATOMY", 285, 290], ["early", "OBSERVATION_MODIFIER", 302, 307], ["Lyme", "OBSERVATION", 308, 312]]], ["Continuous monitoring is advisable for patients with second-or third-degree heart block.ReferenceThe prognosis is good, usually with the resolution of atrioventricular block within days to weeks.", [["heart", "ANATOMY", 76, 81], ["atrioventricular", "ANATOMY", 151, 167], ["atrioventricular block", "DISEASE", 151, 173], ["patients", "ORGANISM", 39, 47], ["heart", "ORGAN", 76, 81], ["patients", "SPECIES", 39, 47], ["Continuous monitoring", "TEST", 0, 21], ["third-degree heart block", "PROBLEM", 63, 87], ["atrioventricular block", "PROBLEM", 151, 173], ["heart", "ANATOMY", 76, 81], ["block", "OBSERVATION", 82, 87]]], ["Ceftriaxone is the drug of choice followed by a 21-day course of oral therapy.", [["oral", "ANATOMY", 65, 69], ["Ceftriaxone", "CHEMICAL", 0, 11], ["Ceftriaxone", "CHEMICAL", 0, 11], ["Ceftriaxone", "SIMPLE_CHEMICAL", 0, 11], ["oral", "ORGANISM_SUBDIVISION", 65, 69], ["Ceftriaxone", "TREATMENT", 0, 11], ["oral therapy", "TREATMENT", 65, 77]]], ["Temporary pacing would be required if the patient were hemodynamically unstable with bradycardia.", [["bradycardia", "DISEASE", 85, 96], ["patient", "ORGANISM", 42, 49], ["patient", "SPECIES", 42, 49], ["Temporary pacing", "TREATMENT", 0, 16], ["hemodynamically unstable", "PROBLEM", 55, 79], ["bradycardia", "PROBLEM", 85, 96], ["pacing", "OBSERVATION", 10, 16]]], ["Patients with probable erythema migrans and a recent tick exposure should be started with treatment without blood tests.", [["blood", "ANATOMY", 108, 113], ["erythema migrans", "DISEASE", 23, 39], ["Patients", "ORGANISM", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["Patients", "SPECIES", 0, 8], ["erythema migrans", "PROBLEM", 23, 39], ["a recent tick exposure", "TREATMENT", 44, 66], ["treatment", "TREATMENT", 90, 99], ["blood tests", "TEST", 108, 119], ["probable", "UNCERTAINTY", 14, 22], ["erythema", "OBSERVATION_MODIFIER", 23, 31], ["migrans", "OBSERVATION", 32, 39]]], ["For serologic testing, the CDC recommends a twotier testing procedure.", [["serologic testing", "TEST", 4, 21], ["a twotier testing procedure", "TREATMENT", 42, 69]]], ["An ELISA test can be done initially followed by confi rmation with Western blot testing.ReferenceCameron DJ, Johnson LB, Maloney EL.", [["An ELISA test", "TEST", 0, 13], ["Western blot testing", "TEST", 67, 87]]], ["Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.", [["Lyme disease", "DISEASE", 54, 66], ["tick bites", "DISEASE", 101, 111], ["erythema migrans rashes", "DISEASE", 113, 136], ["Evidence assessments", "TEST", 0, 20], ["the clinical management", "TREATMENT", 68, 91], ["known tick bites", "PROBLEM", 95, 111], ["erythema migrans rashes", "PROBLEM", 113, 136], ["persistent disease", "PROBLEM", 141, 159], ["tick bites", "OBSERVATION", 101, 111], ["persistent", "OBSERVATION_MODIFIER", 141, 151], ["disease", "OBSERVATION", 152, 159]]], ["Expert Rev Anti Infect Ther.", [["Ther", "PROTEIN", 23, 27], ["Anti Infect", "OBSERVATION_MODIFIER", 11, 22]]], ["2014;12(9):1103-35.189.A 72-year-old man with a history of COPD and hypertension is admitted for severe lower back pain that began suddenly two days ago.", [["lower back", "ANATOMY", 104, 114], ["COPD", "DISEASE", 59, 63], ["hypertension", "DISEASE", 68, 80], ["lower back pain", "DISEASE", 104, 119], ["man", "ORGANISM", 37, 40], ["man", "SPECIES", 37, 40], ["COPD", "PROBLEM", 59, 63], ["hypertension", "PROBLEM", 68, 80], ["severe lower back pain", "PROBLEM", 97, 119], ["COPD", "OBSERVATION", 59, 63], ["hypertension", "OBSERVATION", 68, 80], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["lower", "ANATOMY_MODIFIER", 104, 109], ["back", "ANATOMY", 110, 114], ["pain", "OBSERVATION", 115, 119]]], ["He also reports an unexplained syncopal episode.", [["syncopal", "DISEASE", 31, 39], ["an unexplained syncopal episode", "PROBLEM", 16, 47]]], ["Since that time, he has had vague lower abdominal and back discomfort.", [["lower abdominal", "ANATOMY", 34, 49], ["back", "ANATOMY", 54, 58], ["lower abdominal and back discomfort", "DISEASE", 34, 69], ["lower abdominal", "ORGANISM_SUBDIVISION", 34, 49], ["back", "ORGANISM_SUBDIVISION", 54, 58], ["vague lower abdominal and back discomfort", "PROBLEM", 28, 69], ["vague", "OBSERVATION_MODIFIER", 28, 33], ["lower", "ANATOMY_MODIFIER", 34, 39], ["abdominal", "ANATOMY", 40, 49], ["back", "ANATOMY", 54, 58], ["discomfort", "OBSERVATION", 59, 69]]], ["On physical examination, temperature is 37.4 \u00b0C (99.3 \u00b0F), blood pressure is 110/65 mmHg, pulse rate is 96/min and regular, and respiration rate is 18/min.", [["blood", "ANATOMY", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["\u00b0C", "TEST", 45, 47], ["blood pressure", "TEST", 59, 73], ["pulse rate", "TEST", 90, 100], ["respiration rate", "TEST", 128, 144]]], ["Abdominal examination shows moderate tenderness upon palpation in the infraumbilical and suprapubic regions.", [["Abdominal", "ANATOMY", 0, 9], ["infraumbilical", "ANATOMY", 70, 84], ["suprapubic regions", "ANATOMY", 89, 107], ["tenderness", "DISEASE", 37, 47], ["infraumbilical", "CANCER", 70, 84], ["Abdominal examination", "TEST", 0, 21], ["moderate tenderness upon palpation in the infraumbilical and suprapubic regions", "PROBLEM", 28, 107], ["moderate", "OBSERVATION_MODIFIER", 28, 36], ["tenderness", "OBSERVATION", 37, 47], ["palpation", "OBSERVATION", 53, 62], ["infraumbilical", "ANATOMY_MODIFIER", 70, 84], ["suprapubic", "ANATOMY", 89, 99], ["regions", "ANATOMY_MODIFIER", 100, 107]]], ["Some mild local distension is noted in that area.", [["Some mild local distension", "PROBLEM", 0, 26], ["mild", "OBSERVATION_MODIFIER", 5, 9], ["local", "OBSERVATION_MODIFIER", 10, 15], ["distension", "OBSERVATION", 16, 26]]], ["Findings on rectal examination are unremarkable, with guaiac-negative stool.189.Laboratory results include hematocrit of 34 %.", [["rectal", "ANATOMY", 12, 18], ["stool", "ANATOMY", 70, 75], ["rectal", "ORGAN", 12, 18], ["stool", "ORGANISM_SUBSTANCE", 70, 75], ["rectal examination", "TEST", 12, 30], ["guaiac", "TEST", 54, 60], ["hematocrit", "TEST", 107, 117], ["rectal", "ANATOMY", 12, 18], ["unremarkable", "OBSERVATION", 35, 47], ["negative stool", "OBSERVATION", 61, 75]]], ["Results of liver chemistry studies and urinalysis are normal.", [["liver", "ANATOMY", 11, 16], ["liver", "ORGAN", 11, 16], ["liver chemistry studies", "TEST", 11, 34], ["urinalysis", "TEST", 39, 49], ["liver", "ANATOMY", 11, 16], ["normal", "OBSERVATION", 54, 60]]], ["Plain abdominal radiograph shows no free air or air-fl uid levels.", [["abdominal", "ANATOMY", 6, 15], ["abdominal", "ORGAN", 6, 15], ["Plain abdominal radiograph", "TEST", 0, 26], ["free air", "PROBLEM", 36, 44], ["air-fl uid levels", "TEST", 48, 65], ["abdominal", "ANATOMY", 6, 15], ["no", "UNCERTAINTY", 33, 35], ["free air", "OBSERVATION", 36, 44], ["air", "OBSERVATION", 48, 51], ["fl uid", "OBSERVATION", 52, 58]]], ["Computed tomography of the abdomen is pending.189.Which of the following is the most likely diagnosis?", [["abdomen", "ANATOMY", 27, 34], ["abdomen", "ORGAN", 27, 34], ["Computed tomography of the abdomen", "TEST", 0, 34], ["abdomen", "ANATOMY", 27, 34], ["most likely", "UNCERTAINTY", 80, 91]]], ["A) Acute myocardial infarction B) Diverticulitis C) Nephrolithiasis or renal colic D) Ruptured abdominal aortic aneurysm E) Incarcerated hernia Answer: D This patient has a classical presentation of a locally contained ruptured aortic abdominal aneurysm.", [["myocardial", "ANATOMY", 9, 19], ["renal", "ANATOMY", 71, 76], ["abdominal aortic aneurysm", "ANATOMY", 95, 120], ["aortic abdominal aneurysm", "ANATOMY", 228, 253], ["Acute myocardial infarction", "DISEASE", 3, 30], ["Diverticulitis", "DISEASE", 34, 48], ["Nephrolithiasis", "DISEASE", 52, 67], ["renal colic", "DISEASE", 71, 82], ["Ruptured abdominal aortic aneurysm", "DISEASE", 86, 120], ["ruptured aortic abdominal aneurysm", "DISEASE", 219, 253], ["myocardial", "MULTI-TISSUE_STRUCTURE", 9, 19], ["renal", "ORGAN", 71, 76], ["patient", "ORGANISM", 159, 166], ["aortic abdominal aneurysm", "PATHOLOGICAL_FORMATION", 228, 253], ["patient", "SPECIES", 159, 166], ["A) Acute myocardial infarction B", "PROBLEM", 0, 32], ["Diverticulitis C) Nephrolithiasis", "PROBLEM", 34, 67], ["renal colic D", "PROBLEM", 71, 84], ["Ruptured abdominal aortic aneurysm E", "PROBLEM", 86, 122], ["Incarcerated hernia", "PROBLEM", 124, 143], ["a locally contained ruptured aortic abdominal aneurysm", "PROBLEM", 199, 253], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["myocardial", "ANATOMY", 9, 19], ["infarction", "OBSERVATION", 20, 30], ["Diverticulitis", "OBSERVATION", 34, 48], ["Nephrolithiasis", "OBSERVATION", 52, 67], ["renal colic", "ANATOMY", 71, 82], ["Ruptured", "OBSERVATION_MODIFIER", 86, 94], ["abdominal aortic", "ANATOMY", 95, 111], ["aneurysm", "OBSERVATION", 112, 120], ["Incarcerated", "OBSERVATION_MODIFIER", 124, 136], ["hernia", "OBSERVATION", 137, 143], ["locally", "OBSERVATION_MODIFIER", 201, 208], ["ruptured", "OBSERVATION", 219, 227], ["aortic", "ANATOMY_MODIFIER", 228, 234], ["abdominal", "ANATOMY", 235, 244], ["aneurysm", "OBSERVATION", 245, 253]]], ["Severe abdominal or back pain with syncope, followed by vague discomfort, is typical.", [["abdominal", "ANATOMY", 7, 16], ["back", "ANATOMY", 20, 24], ["abdominal or back pain", "DISEASE", 7, 29], ["syncope", "DISEASE", 35, 42], ["abdominal", "ORGANISM_SUBDIVISION", 7, 16], ["Severe abdominal or back pain", "PROBLEM", 0, 29], ["syncope", "PROBLEM", 35, 42], ["vague discomfort", "PROBLEM", 56, 72], ["abdominal", "ANATOMY", 7, 16], ["back", "ANATOMY", 20, 24], ["pain", "OBSERVATION", 25, 29], ["syncope", "OBSERVATION", 35, 42], ["vague", "OBSERVATION_MODIFIER", 56, 61], ["discomfort", "OBSERVATION", 62, 72]]], ["Patients at greatest risk for abdominal aortic aneurysms are those who are older than 65 years and have peripheral atherosclerotic vascular disease.", [["abdominal aortic aneurysms", "ANATOMY", 30, 56], ["peripheral atherosclerotic vascular", "ANATOMY", 104, 139], ["abdominal aortic aneurysms", "DISEASE", 30, 56], ["peripheral atherosclerotic vascular disease", "DISEASE", 104, 147], ["Patients", "ORGANISM", 0, 8], ["abdominal aortic", "MULTI-TISSUE_STRUCTURE", 30, 46], ["peripheral atherosclerotic vascular", "MULTI-TISSUE_STRUCTURE", 104, 139], ["Patients", "SPECIES", 0, 8], ["abdominal aortic aneurysms", "PROBLEM", 30, 56], ["peripheral atherosclerotic vascular disease", "PROBLEM", 104, 147], ["abdominal aortic", "ANATOMY", 30, 46], ["aneurysms", "OBSERVATION", 47, 56], ["peripheral", "ANATOMY_MODIFIER", 104, 114], ["atherosclerotic", "OBSERVATION", 115, 130], ["vascular", "ANATOMY", 131, 139], ["disease", "OBSERVATION", 140, 147]]], ["The temporary loss of consciousness is also a potential symptom of rupture.", [["loss of consciousness", "DISEASE", 14, 35], ["rupture", "DISEASE", 67, 74], ["The temporary loss of consciousness", "PROBLEM", 0, 35], ["rupture", "PROBLEM", 67, 74], ["temporary", "OBSERVATION_MODIFIER", 4, 13], ["loss", "OBSERVATION_MODIFIER", 14, 18], ["rupture", "OBSERVATION", 67, 74]]], ["The most typical manifestation of rupture is the acute onset of abdominal or back pain with a pulsatile abdominal mass.", [["abdominal", "ANATOMY", 64, 73], ["back", "ANATOMY", 77, 81], ["abdominal mass", "ANATOMY", 104, 118], ["rupture", "DISEASE", 34, 41], ["abdominal or back pain", "DISEASE", 64, 86], ["pulsatile abdominal mass", "DISEASE", 94, 118], ["abdominal", "ORGANISM_SUBDIVISION", 64, 73], ["abdominal", "ORGANISM_SUBDIVISION", 104, 113], ["rupture", "PROBLEM", 34, 41], ["abdominal or back pain", "PROBLEM", 64, 86], ["a pulsatile abdominal mass", "PROBLEM", 92, 118], ["most typical", "OBSERVATION_MODIFIER", 4, 16], ["rupture", "OBSERVATION", 34, 41], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["abdominal", "ANATOMY", 64, 73], ["back", "ANATOMY", 77, 81], ["pain", "OBSERVATION", 82, 86], ["pulsatile", "OBSERVATION_MODIFIER", 94, 103], ["abdominal", "ANATOMY", 104, 113], ["mass", "OBSERVATION", 114, 118]]], ["The symptoms of a ruptured aneurysm may be confused with renal calculus, diverticulitis, incarcerated hernia, or lumbar spine disease.", [["ruptured aneurysm", "ANATOMY", 18, 35], ["renal", "ANATOMY", 57, 62], ["hernia", "ANATOMY", 102, 108], ["lumbar spine", "ANATOMY", 113, 125], ["ruptured aneurysm", "DISEASE", 18, 35], ["renal calculus", "DISEASE", 57, 71], ["diverticulitis", "DISEASE", 73, 87], ["hernia", "DISEASE", 102, 108], ["lumbar spine disease", "DISEASE", 113, 133], ["renal", "ORGAN", 57, 62], ["hernia", "PATHOLOGICAL_FORMATION", 102, 108], ["lumbar spine", "MULTI-TISSUE_STRUCTURE", 113, 125], ["The symptoms", "PROBLEM", 0, 12], ["a ruptured aneurysm", "PROBLEM", 16, 35], ["confused", "PROBLEM", 43, 51], ["renal calculus", "PROBLEM", 57, 71], ["diverticulitis", "PROBLEM", 73, 87], ["incarcerated hernia", "PROBLEM", 89, 108], ["lumbar spine disease", "PROBLEM", 113, 133], ["ruptured", "OBSERVATION_MODIFIER", 18, 26], ["aneurysm", "OBSERVATION", 27, 35], ["may be", "UNCERTAINTY", 36, 42], ["renal", "ANATOMY", 57, 62], ["calculus", "OBSERVATION", 63, 71], ["diverticulitis", "OBSERVATION", 73, 87], ["incarcerated", "OBSERVATION_MODIFIER", 89, 101], ["hernia", "OBSERVATION", 102, 108], ["lumbar", "ANATOMY_MODIFIER", 113, 119], ["spine", "ANATOMY", 120, 125], ["disease", "OBSERVATION", 126, 133]]], ["The prognosis is poor with as many as 65 % of patients dying before arriving at a hospital.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["A 65-year-old woman is admitted for the acute onset of dyspnea, wheezing, and progressive respiratory distress.", [["respiratory", "ANATOMY", 90, 101], ["dyspnea", "DISEASE", 55, 62], ["wheezing", "DISEASE", 64, 72], ["respiratory distress", "DISEASE", 90, 110], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["dyspnea", "PROBLEM", 55, 62], ["wheezing", "PROBLEM", 64, 72], ["progressive respiratory distress", "PROBLEM", 78, 110], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["dyspnea", "OBSERVATION", 55, 62], ["wheezing", "OBSERVATION", 64, 72], ["progressive", "OBSERVATION_MODIFIER", 78, 89], ["respiratory distress", "OBSERVATION", 90, 110]]], ["She has a history of severe chronic asthma.", [["asthma", "DISEASE", 36, 42], ["severe chronic asthma", "PROBLEM", 21, 42], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["asthma", "OBSERVATION", 36, 42]]], ["She has been intubated once previously.", [["intubated", "TREATMENT", 13, 22]]], ["On physical examination, she is in marked distress and is anxious.", [["physical examination", "TEST", 3, 23], ["marked distress", "PROBLEM", 35, 50], ["anxious", "PROBLEM", 58, 65], ["marked", "OBSERVATION_MODIFIER", 35, 41], ["distress", "OBSERVATION", 42, 50]]], ["Temperature is 37.7 \u00b0C (100.0 \u00b0F), blood pressure is 160/100 mmHg, pulse rate is 127/min, and respiration rate is 28/min; BMI is 33.", [["blood", "ANATOMY", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["Temperature", "TEST", 0, 11], ["\u00b0C", "TEST", 20, 22], ["blood pressure", "TEST", 35, 49], ["pulse rate", "TEST", 67, 77], ["respiration rate", "TEST", 94, 110], ["BMI", "TEST", 122, 125]]], ["She has a rapid and regular rhythm with no murmurs.", [["murmurs", "PROBLEM", 43, 50], ["rapid", "OBSERVATION_MODIFIER", 10, 15], ["no", "UNCERTAINTY", 40, 42], ["murmurs", "OBSERVATION", 43, 50]]], ["Pulmonary examination reveals very faint wheezing with poor air movement.ReferencesArterial blood gas studies breathing ambient air show a PCO2 of 84 mmHg, a PO2 of 51 mmHg, and a pH of 7.00.", [["Pulmonary", "ANATOMY", 0, 9], ["Arterial blood", "ANATOMY", 83, 97], ["wheezing", "DISEASE", 41, 49], ["PO2", "CHEMICAL", 158, 161], ["Pulmonary", "ORGAN", 0, 9], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["Pulmonary examination", "TEST", 0, 21], ["very faint wheezing", "PROBLEM", 30, 49], ["poor air movement", "PROBLEM", 55, 72], ["Arterial blood gas studies", "TEST", 83, 109], ["breathing ambient air", "TEST", 110, 131], ["a PCO2", "TEST", 137, 143], ["a PO2", "TEST", 156, 161], ["a pH", "TEST", 178, 182], ["very", "OBSERVATION_MODIFIER", 30, 34], ["faint", "OBSERVATION_MODIFIER", 35, 40], ["wheezing", "OBSERVATION", 41, 49], ["poor", "OBSERVATION_MODIFIER", 55, 59], ["air movement", "OBSERVATION", 60, 72]]], ["Chest X-ray shows hyperinfl ation.ReferencesShe is intubated and is started on mechanical ventilation.ReferencesWhich of the following strategies in establishing ventilator settings is most appropriate for this patient?", [["patient", "ORGANISM", 211, 218], ["patient", "SPECIES", 211, 218], ["Chest X-ray", "TEST", 0, 11], ["hyperinfl ation", "PROBLEM", 18, 33], ["intubated", "TREATMENT", 51, 60], ["mechanical ventilation", "TREATMENT", 79, 101], ["establishing ventilator settings", "TREATMENT", 149, 181], ["hyperinfl ation", "OBSERVATION", 18, 33], ["mechanical ventilation", "OBSERVATION", 79, 101]]], ["A) Decreased inspiratory fl ow B) Increased minute ventilation C) Prolonged expiratory time D) Prolonged inspiratory time Answer: C Patient with acute asthma exacerbations have primary expiratory fl ow problem.", [["asthma exacerbations", "DISEASE", 151, 171], ["Patient", "SPECIES", 132, 139], ["Increased minute ventilation C", "TREATMENT", 34, 64], ["Prolonged expiratory time D", "TREATMENT", 66, 93], ["acute asthma exacerbations", "PROBLEM", 145, 171], ["Decreased", "OBSERVATION_MODIFIER", 3, 12], ["inspiratory fl", "OBSERVATION", 13, 27], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["asthma", "OBSERVATION", 151, 157], ["expiratory fl", "OBSERVATION", 185, 198]]], ["This limitation results from both anatomic and dynamic obstruction of the airways.", [["airways", "ANATOMY", 74, 81], ["airways", "MULTI-TISSUE_STRUCTURE", 74, 81], ["dynamic obstruction of the airways", "PROBLEM", 47, 81], ["dynamic", "OBSERVATION_MODIFIER", 47, 54], ["obstruction", "OBSERVATION", 55, 66], ["airways", "ANATOMY", 74, 81]]], ["As a consequence, these patients require prolonged expiratory times to reach static lung volumes.", [["lung", "ANATOMY", 84, 88], ["patients", "ORGANISM", 24, 32], ["lung", "ORGAN", 84, 88], ["patients", "SPECIES", 24, 32], ["prolonged expiratory times", "TREATMENT", 41, 67], ["static lung volumes", "TEST", 77, 96], ["lung", "ANATOMY", 84, 88]]], ["Minimizing hyperinfl ation and avoiding excessive airway pressures are key goals in ventilating the patient with asthma.", [["airway", "ANATOMY", 50, 56], ["asthma", "DISEASE", 113, 119], ["airway", "MULTI-TISSUE_STRUCTURE", 50, 56], ["patient", "ORGANISM", 100, 107], ["patient", "SPECIES", 100, 107], ["hyperinfl ation", "TREATMENT", 11, 26], ["excessive airway pressures", "TREATMENT", 40, 66], ["asthma", "PROBLEM", 113, 119], ["airway pressures", "OBSERVATION", 50, 66], ["asthma", "OBSERVATION", 113, 119]]], ["These goals are best accomplished by selective hypoventilation.", [["hypoventilation", "DISEASE", 47, 62], ["selective hypoventilation", "PROBLEM", 37, 62], ["selective", "OBSERVATION_MODIFIER", 37, 46], ["hypoventilation", "OBSERVATION", 47, 62]]], ["This is accomplished by selecting a low respiratory rate and tidal volume in an effort to give the patient suffi cient time for exhalation.", [["patient", "ORGANISM", 99, 106], ["patient", "SPECIES", 99, 106], ["a low respiratory rate", "TREATMENT", 34, 56], ["tidal volume", "TREATMENT", 61, 73], ["tidal volume", "OBSERVATION", 61, 73]]], ["Suggested initial ventilator settings for intubated patients with asthma are:References\u2022 Assist control mode \u2022 Tidal volume: 7-8 mL/kg (using ideal body weight) \u2022 Respiratory rate: 10-12 breaths/min 191 .", [["body", "ANATOMY", 148, 152], ["asthma", "DISEASE", 66, 72], ["patients", "ORGANISM", 52, 60], ["body", "ORGANISM_SUBDIVISION", 148, 152], ["patients", "SPECIES", 52, 60], ["initial ventilator settings", "TREATMENT", 10, 37], ["asthma", "PROBLEM", 66, 72], ["Tidal volume", "TEST", 111, 123], ["Respiratory rate", "TEST", 163, 179]]], ["You are called to see a 24-year-old patient on the fl oor which has become markedly obtunded.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43], ["markedly obtunded", "PROBLEM", 75, 92], ["markedly", "OBSERVATION_MODIFIER", 75, 83], ["obtunded", "OBSERVATION", 84, 92]]], ["He was recently admitted two hours ago for possible suicide attempt by ingestion of an unknown substance.", [["He", "ORGANISM", 0, 2]]], ["His respiratory status was good on admission but he is having diffi culty handling secretions and a decision is made to intubate him urgently.", [["respiratory", "ANATOMY", 4, 15], ["diffi culty handling secretions", "PROBLEM", 62, 93], ["respiratory", "ANATOMY", 4, 15]]], ["Chest radiograph on admission was normal.", [["Chest radiograph", "TEST", 0, 16], ["normal", "OBSERVATION", 34, 40]]], ["Initial tidal volumes (TV) on the ventilator should be set to what setting?", [["Initial tidal volumes", "TEST", 0, 21], ["TV", "TEST", 23, 25], ["the ventilator", "TREATMENT", 30, 44], ["tidal volumes", "OBSERVATION", 8, 21]]], ["A) 4 ml/kg B) 6 ml/kg C) 10 ml/kg D) 12 ml/kg Answer: B Synchronous intermittent mandatory ventilation (SIMV) and assist-control ventilation (A/C) are versatile modes that can be used for initial settings.", [["B Synchronous intermittent mandatory ventilation", "TREATMENT", 54, 102], ["SIMV", "TREATMENT", 104, 108], ["assist-control ventilation", "TREATMENT", 114, 140], ["A/C)", "TREATMENT", 142, 146], ["versatile modes", "TREATMENT", 151, 166]]], ["Lower tidal volumes (TV) are recommended than in the past years, when tidal volumes of 10-15 mL/kg were routinely used.", [["Lower tidal volumes", "TEST", 0, 19], ["TV", "TEST", 21, 23], ["tidal volumes", "TEST", 70, 83], ["tidal volumes", "OBSERVATION", 6, 19]]], ["This is thought to reduce barotrauma.", [["barotrauma", "DISEASE", 26, 36], ["barotrauma", "PROBLEM", 26, 36], ["thought to reduce", "UNCERTAINTY", 8, 25], ["barotrauma", "OBSERVATION", 26, 36]]], ["An initial TV of 5-8 mL/kg of ideal body weight is generally recommended.", [["body", "ANATOMY", 36, 40], ["body", "ORGANISM_SUBDIVISION", 36, 40], ["An initial TV", "TEST", 0, 13], ["ideal body weight", "TEST", 30, 47]]], ["The lower range is recommended in the presence of obstructive airway disease and ARDS.", [["airway", "ANATOMY", 62, 68], ["obstructive airway disease", "DISEASE", 50, 76], ["ARDS", "DISEASE", 81, 85], ["airway", "MULTI-TISSUE_STRUCTURE", 62, 68], ["obstructive airway disease", "PROBLEM", 50, 76], ["ARDS", "PROBLEM", 81, 85], ["lower range", "OBSERVATION_MODIFIER", 4, 15], ["obstructive", "OBSERVATION_MODIFIER", 50, 61], ["airway", "ANATOMY", 62, 68], ["disease", "OBSERVATION", 69, 76], ["ARDS", "OBSERVATION", 81, 85]]], ["The goal is to adjust the TV so that plateau pressures are less than 35 cm H2 O. What is the correct initial treatment for sedation ?", [["the TV", "TEST", 22, 28], ["plateau pressures", "TEST", 37, 54], ["sedation", "TREATMENT", 123, 131], ["plateau", "OBSERVATION_MODIFIER", 37, 44], ["pressures", "OBSERVATION_MODIFIER", 45, 54]]], ["A) Lorazepam 5 mg by mouth B) Haloperidol 10 mg intramuscular and lorazepam 2 mg intramuscular C) Haloperidol 5 mg PO D) Lorazepam 2 mg intramuscular E) Place IV fi rst Answer: B This is a medical emergency that requires rapid action, for patient, staff, and fellow patient safety.", [["intramuscular", "ANATOMY", 48, 61], ["Lorazepam", "CHEMICAL", 3, 12], ["Haloperidol", "CHEMICAL", 30, 41], ["lorazepam", "CHEMICAL", 66, 75], ["Haloperidol", "CHEMICAL", 98, 109], ["Lorazepam", "CHEMICAL", 121, 130], ["Lorazepam", "CHEMICAL", 3, 12], ["Haloperidol", "CHEMICAL", 30, 41], ["lorazepam", "CHEMICAL", 66, 75], ["Haloperidol", "CHEMICAL", 98, 109], ["PO D", "CHEMICAL", 115, 119], ["Lorazepam", "CHEMICAL", 121, 130], ["Haloperidol", "SIMPLE_CHEMICAL", 30, 41], ["lorazepam", "SIMPLE_CHEMICAL", 66, 75], ["Haloperidol", "SIMPLE_CHEMICAL", 98, 109], ["patient", "ORGANISM", 239, 246], ["patient", "ORGANISM", 266, 273], ["patient", "SPECIES", 239, 246], ["patient", "SPECIES", 266, 273], ["Lorazepam", "TREATMENT", 3, 12], ["Haloperidol", "TREATMENT", 30, 41], ["lorazepam", "TREATMENT", 66, 75], ["Haloperidol", "TREATMENT", 98, 109], ["Lorazepam", "TREATMENT", 121, 130]]], ["The acutely agitated patient often does not have IV access, and gaining access is often diffi cult.", [["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["The acutely agitated", "PROBLEM", 0, 20], ["IV access", "TREATMENT", 49, 58], ["acutely", "OBSERVATION_MODIFIER", 4, 11], ["agitated", "OBSERVATION", 12, 20]]], ["Both benzodiazepines and atypical antipsychotics have shown similar effectiveness in reducing aggression and time to sedation when use as single agents.", [["benzodiazepines", "CHEMICAL", 5, 20], ["aggression", "DISEASE", 94, 104], ["benzodiazepines", "CHEMICAL", 5, 20], ["benzodiazepines", "SIMPLE_CHEMICAL", 5, 20], ["Both benzodiazepines", "TREATMENT", 0, 20], ["atypical antipsychotics", "TREATMENT", 25, 48], ["sedation", "TREATMENT", 117, 125]]], ["Oral medications have been shown to have similar onset of action compared to intramuscular (IM) administration, are less invasive, and are more widely accepted by patients.", [["Oral", "ANATOMY", 0, 4], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 163, 171], ["Oral medications", "TREATMENT", 0, 16], ["intramuscular (IM) administration", "TREATMENT", 77, 110], ["less invasive", "OBSERVATION_MODIFIER", 116, 129], ["more widely", "OBSERVATION_MODIFIER", 139, 150]]], ["However in this situation the risk of harm to patient and the staff is too high that attempting an oral route may not be successful.", [["oral", "ANATOMY", 99, 103], ["patient", "ORGANISM", 46, 53], ["oral", "ORGANISM_SUBDIVISION", 99, 103], ["patient", "SPECIES", 46, 53], ["an oral route", "TREATMENT", 96, 109]]], ["A few randomized trials have indicated that the combination of a benzodiazepine with a traditional or classic antipsychotic results in a more rapid onset of sedation with a similar adverse effect profi le.", [["benzodiazepine", "CHEMICAL", 65, 79], ["benzodiazepine", "CHEMICAL", 65, 79], ["benzodiazepine", "SIMPLE_CHEMICAL", 65, 79], ["A few randomized trials", "TREATMENT", 0, 23], ["a benzodiazepine", "TREATMENT", 63, 79], ["sedation", "TREATMENT", 157, 165], ["a similar adverse effect profi le", "PROBLEM", 171, 204], ["few", "OBSERVATION_MODIFIER", 2, 5]]], ["In this situation, a combination approach may be the most effective.", [["a combination approach", "TREATMENT", 19, 41]]], ["A dose of 10 mg of haloperidol and 2 mg of Ativan intramuscularly is often suggested.195.A 46-year-old woman is admitted for nausea, vomiting, headache, and blurry vision which developed 6 h ago.", [["haloperidol", "CHEMICAL", 19, 30], ["Ativan", "CHEMICAL", 43, 49], ["nausea", "DISEASE", 125, 131], ["vomiting", "DISEASE", 133, 141], ["headache", "DISEASE", 143, 151], ["blurry vision", "DISEASE", 157, 170], ["haloperidol", "CHEMICAL", 19, 30], ["Ativan", "CHEMICAL", 43, 49], ["haloperidol", "SIMPLE_CHEMICAL", 19, 30], ["Ativan", "SIMPLE_CHEMICAL", 43, 49], ["woman", "ORGANISM", 103, 108], ["woman", "SPECIES", 103, 108], ["haloperidol", "TREATMENT", 19, 30], ["Ativan", "TREATMENT", 43, 49], ["nausea", "PROBLEM", 125, 131], ["vomiting", "PROBLEM", 133, 141], ["headache", "PROBLEM", 143, 151], ["blurry vision", "PROBLEM", 157, 170], ["blurry vision", "OBSERVATION", 157, 170]]], ["The patient was previously well and takes no medications.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["medications", "TREATMENT", 45, 56]]], ["On physical examination, she appears restless and confused with dysarthric speech.", [["restless", "DISEASE", 37, 45], ["physical examination", "TEST", 3, 23], ["restless", "PROBLEM", 37, 45], ["confused", "PROBLEM", 50, 58], ["dysarthric speech", "PROBLEM", 64, 81]]], ["Temperature is 38.1 \u00b0C (100.5 \u00b0F), blood pressure is 150/92 mmHg, pulse rate is 110/min, and respiration rate is 22/min.", [["blood", "ANATOMY", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["Temperature", "TEST", 0, 11], ["\u00b0C", "TEST", 20, 22], ["blood pressure", "TEST", 35, 49], ["pulse rate", "TEST", 66, 76], ["respiration rate", "TEST", 93, 109]]], ["Oxygen saturation is 95 %.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17]]], ["There is mild nuchal rigidity, but no photophobia.", [["nuchal", "ANATOMY", 14, 20], ["nuchal rigidity", "DISEASE", 14, 29], ["photophobia", "DISEASE", 38, 49], ["nuchal", "ORGANISM_SUBDIVISION", 14, 20], ["mild nuchal rigidity", "PROBLEM", 9, 29], ["photophobia", "PROBLEM", 38, 49], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["nuchal rigidity", "OBSERVATION", 14, 29], ["no", "UNCERTAINTY", 35, 37], ["photophobia", "OBSERVATION", 38, 49]]], ["Abdominal examination reveals moderate diffuse tenderness without guarding upon palpation.", [["Abdominal", "ANATOMY", 0, 9], ["tenderness", "DISEASE", 47, 57], ["Abdominal examination", "TEST", 0, 21], ["moderate diffuse tenderness", "PROBLEM", 30, 57], ["guarding", "PROBLEM", 66, 74], ["palpation", "TEST", 80, 89], ["moderate", "OBSERVATION_MODIFIER", 30, 38], ["diffuse", "OBSERVATION_MODIFIER", 39, 46], ["tenderness", "OBSERVATION", 47, 57], ["without", "UNCERTAINTY", 58, 65], ["guarding", "OBSERVATION", 66, 74]]], ["Bowel sounds are present.195.Laboratory studies include a hemoglobin of 9.7 g/ dL, leukocyte count of 6600/\u03bcL, platlet count of 28,000 and lactate dehydrogenase of 546 U/L. P. Prothrombin time and activated partial thromboplastin time are within normal limits.", [["Bowel", "ANATOMY", 0, 5], ["leukocyte", "ANATOMY", 83, 92], ["lactate", "CHEMICAL", 139, 146], ["lactate", "CHEMICAL", 139, 146], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 58, 68], ["leukocyte", "CELL", 83, 92], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 139, 160], ["Prothrombin", "GENE_OR_GENE_PRODUCT", 176, 187], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 215, 229], ["hemoglobin", "PROTEIN", 58, 68], ["lactate dehydrogenase", "PROTEIN", 139, 160], ["Laboratory studies", "TEST", 29, 47], ["a hemoglobin", "TEST", 56, 68], ["leukocyte count", "TEST", 83, 98], ["platlet count", "TEST", 111, 124], ["lactate dehydrogenase", "TEST", 139, 160], ["U/L.", "TEST", 168, 172], ["Prothrombin time", "TEST", 176, 192], ["activated partial thromboplastin time", "TEST", 197, 234], ["sounds", "OBSERVATION", 6, 12], ["partial thromboplastin", "OBSERVATION", 207, 229], ["within normal limits", "OBSERVATION", 239, 259]]], ["A peripheral blood smear reveals schistocytes.195.What is the most likely diagnosis?", [["peripheral blood smear", "ANATOMY", 2, 24], ["schistocytes", "ANATOMY", 33, 45], ["peripheral blood smear", "ORGANISM_SUBSTANCE", 2, 24], ["schistocytes", "CELL", 33, 45], ["A peripheral blood smear", "TEST", 0, 24], ["schistocytes", "PROBLEM", 33, 45], ["peripheral", "ANATOMY_MODIFIER", 2, 12], ["blood", "ANATOMY", 13, 18], ["schistocytes", "OBSERVATION", 33, 45], ["most likely", "UNCERTAINTY", 62, 73]]], ["A) Aplastic anemia B) Disseminated intravascular coagulation C) Thrombotic thrombocytopenic purpura (TTP) D) Warm autoimmune hemolytic anemia with immune thrombocytopenic purpura E) Hemolytic uremic syndrome (HUS) Answer: C Patients with thrombotic thrombocytopenic purpura (TTP) typically report an acute or subacute onset of neurologic dysfunction, anemia, and thrombocytopenia.", [["intravascular", "ANATOMY", 35, 48], ["neurologic", "ANATOMY", 327, 337], ["anemia", "DISEASE", 12, 18], ["Disseminated intravascular coagulation", "DISEASE", 22, 60], ["Thrombotic thrombocytopenic purpura", "DISEASE", 64, 99], ["TTP", "DISEASE", 101, 104], ["autoimmune hemolytic anemia", "DISEASE", 114, 141], ["immune thrombocytopenic purpura", "DISEASE", 147, 178], ["Hemolytic uremic syndrome", "DISEASE", 182, 207], ["HUS", "DISEASE", 209, 212], ["thrombotic thrombocytopenic purpura", "DISEASE", 238, 273], ["TTP", "DISEASE", 275, 278], ["neurologic dysfunction", "DISEASE", 327, 349], ["anemia", "DISEASE", 351, 357], ["thrombocytopenia", "DISEASE", 363, 379], ["Patients", "SPECIES", 224, 232], ["A) Aplastic anemia B", "PROBLEM", 0, 20], ["Disseminated intravascular coagulation C", "PROBLEM", 22, 62], ["Thrombotic thrombocytopenic purpura", "PROBLEM", 64, 99], ["TTP)", "PROBLEM", 101, 105], ["Warm autoimmune hemolytic anemia", "PROBLEM", 109, 141], ["immune thrombocytopenic purpura", "PROBLEM", 147, 178], ["Hemolytic uremic syndrome", "PROBLEM", 182, 207], ["HUS)", "PROBLEM", 209, 213], ["thrombotic thrombocytopenic purpura", "PROBLEM", 238, 273], ["TTP)", "PROBLEM", 275, 279], ["neurologic dysfunction", "PROBLEM", 327, 349], ["anemia", "PROBLEM", 351, 357], ["thrombocytopenia", "PROBLEM", 363, 379], ["Aplastic", "OBSERVATION", 3, 11], ["Disseminated", "OBSERVATION_MODIFIER", 22, 34], ["intravascular coagulation", "OBSERVATION", 35, 60], ["Thrombotic", "OBSERVATION_MODIFIER", 64, 74], ["thrombocytopenic purpura", "OBSERVATION", 75, 99], ["Warm", "OBSERVATION_MODIFIER", 109, 113], ["autoimmune", "OBSERVATION_MODIFIER", 114, 124], ["hemolytic", "OBSERVATION_MODIFIER", 125, 134], ["immune thrombocytopenic purpura", "OBSERVATION", 147, 178], ["Hemolytic", "OBSERVATION_MODIFIER", 182, 191], ["uremic syndrome", "OBSERVATION", 192, 207], ["thrombotic", "OBSERVATION_MODIFIER", 238, 248], ["thrombocytopenic purpura", "OBSERVATION", 249, 273], ["acute", "OBSERVATION_MODIFIER", 300, 305], ["subacute", "OBSERVATION_MODIFIER", 309, 317], ["neurologic dysfunction", "OBSERVATION", 327, 349], ["anemia", "OBSERVATION", 351, 357], ["thrombocytopenia", "OBSERVATION", 363, 379]]], ["Neurologic manifestations are extensive.", [["Neurologic manifestations", "PROBLEM", 0, 25], ["extensive", "OBSERVATION_MODIFIER", 30, 39]]], ["They include alteration in mental status, seizures, hemiplegia, paresthesias, visual disturbance, and aphasia.", [["seizures", "DISEASE", 42, 50], ["hemiplegia", "DISEASE", 52, 62], ["paresthesias", "DISEASE", 64, 76], ["visual disturbance", "DISEASE", 78, 96], ["aphasia", "DISEASE", 102, 109], ["alteration in mental status", "PROBLEM", 13, 40], ["seizures", "PROBLEM", 42, 50], ["hemiplegia", "PROBLEM", 52, 62], ["paresthesias", "PROBLEM", 64, 76], ["visual disturbance", "PROBLEM", 78, 96], ["aphasia", "PROBLEM", 102, 109], ["hemiplegia", "OBSERVATION", 52, 62], ["aphasia", "OBSERVATION", 102, 109]]], ["Severe bleeding from thrombocytopenia is unusual, although petechiae are common.", [["petechiae", "ANATOMY", 59, 68], ["bleeding", "DISEASE", 7, 15], ["thrombocytopenia", "DISEASE", 21, 37], ["petechiae", "DISEASE", 59, 68], ["petechiae", "PATHOLOGICAL_FORMATION", 59, 68], ["Severe bleeding", "PROBLEM", 0, 15], ["thrombocytopenia", "PROBLEM", 21, 37], ["petechiae", "PROBLEM", 59, 68], ["bleeding", "OBSERVATION", 7, 15], ["thrombocytopenia", "OBSERVATION", 21, 37], ["petechiae", "OBSERVATION", 59, 68]]], ["Other clinical features may include nausea, vomiting, and abdominal pain with or without elevations of serum amylase and lipase levels.", [["abdominal", "ANATOMY", 58, 67], ["serum", "ANATOMY", 103, 108], ["nausea", "DISEASE", 36, 42], ["vomiting", "DISEASE", 44, 52], ["abdominal pain", "DISEASE", 58, 72], ["abdominal", "ORGANISM_SUBDIVISION", 58, 67], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["amylase", "GENE_OR_GENE_PRODUCT", 109, 116], ["lipase", "GENE_OR_GENE_PRODUCT", 121, 127], ["serum amylase", "PROTEIN", 103, 116], ["lipase", "PROTEIN", 121, 127], ["nausea", "PROBLEM", 36, 42], ["vomiting", "PROBLEM", 44, 52], ["abdominal pain", "PROBLEM", 58, 72], ["elevations of serum amylase", "PROBLEM", 89, 116], ["lipase levels", "TEST", 121, 134], ["abdominal", "ANATOMY", 58, 67], ["pain", "OBSERVATION", 68, 72]]], ["Differentiation of hemolytic uremic syndrome (HUS) and TTP can be problematic, although treatment protocols may be the same.", [["hemolytic uremic syndrome", "DISEASE", 19, 44], ["HUS", "DISEASE", 46, 49], ["TTP", "DISEASE", 55, 58], ["hemolytic uremic syndrome", "PROBLEM", 19, 44], ["HUS", "PROBLEM", 46, 49], ["TTP", "PROBLEM", 55, 58], ["treatment protocols", "TREATMENT", 88, 107], ["hemolytic", "OBSERVATION_MODIFIER", 19, 28], ["uremic syndrome", "OBSERVATION", 29, 44]]], ["Plasma exchange may be considered for both.", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["Plasma exchange", "TREATMENT", 0, 15], ["may be considered", "UNCERTAINTY", 16, 33]]], ["It is often based on the presence of central nervous system involvement in TTP and the more severe renal involvement in HUS.", [["central nervous system", "ANATOMY", 37, 59], ["renal", "ANATOMY", 99, 104], ["TTP", "DISEASE", 75, 78], ["HUS", "DISEASE", 120, 123], ["central nervous system", "ANATOMICAL_SYSTEM", 37, 59], ["renal", "ORGAN", 99, 104], ["central nervous system involvement", "PROBLEM", 37, 71], ["TTP", "PROBLEM", 75, 78], ["the more severe renal involvement in HUS", "PROBLEM", 83, 123], ["central", "ANATOMY_MODIFIER", 37, 44], ["nervous system", "ANATOMY", 45, 59], ["TTP", "OBSERVATION", 75, 78], ["severe", "OBSERVATION_MODIFIER", 92, 98], ["renal", "ANATOMY", 99, 104], ["involvement", "OBSERVATION", 105, 116]]], ["A peripheral blood smear is essential to determine whether the anemia is caused by a microangiopathic hemolytic process, as indicated by the presence of schistocytes.", [["peripheral blood", "ANATOMY", 2, 18], ["schistocytes", "ANATOMY", 153, 165], ["anemia", "DISEASE", 63, 69], ["microangiopathic hemolytic process", "DISEASE", 85, 119], ["schistocytes", "DISEASE", 153, 165], ["peripheral blood", "ORGANISM_SUBSTANCE", 2, 18], ["schistocytes", "CANCER", 153, 165], ["A peripheral blood smear", "TEST", 0, 24], ["the anemia", "PROBLEM", 59, 69], ["a microangiopathic hemolytic process", "PROBLEM", 83, 119], ["schistocytes", "PROBLEM", 153, 165], ["peripheral", "ANATOMY_MODIFIER", 2, 12], ["blood", "ANATOMY", 13, 18], ["anemia", "OBSERVATION", 63, 69], ["microangiopathic", "OBSERVATION_MODIFIER", 85, 101], ["hemolytic", "OBSERVATION", 102, 111], ["schistocytes", "OBSERVATION", 153, 165]]], ["This patient has fever in association with neurologic symptoms, anemia, and thrombocytopenia with normal coagulation parameters (prothrombin time and activated partial thromboplastin time) and a peripheral blood smear showing fragmented erythrocytes (schistocytes), the hallmark of a microangiopathic process.", [["neurologic", "ANATOMY", 43, 53], ["peripheral blood", "ANATOMY", 195, 211], ["erythrocytes", "ANATOMY", 237, 249], ["schistocytes", "ANATOMY", 251, 263], ["fever", "DISEASE", 17, 22], ["neurologic symptoms", "DISEASE", 43, 62], ["anemia", "DISEASE", 64, 70], ["thrombocytopenia", "DISEASE", 76, 92], ["patient", "ORGANISM", 5, 12], ["prothrombin", "GENE_OR_GENE_PRODUCT", 129, 140], ["thromboplastin", "GENE_OR_GENE_PRODUCT", 168, 182], ["peripheral blood smear", "ORGANISM_SUBSTANCE", 195, 217], ["erythrocytes", "CELL", 237, 249], ["schistocytes", "CELL", 251, 263], ["fragmented erythrocytes", "CELL_TYPE", 226, 249], ["schistocytes", "CELL_TYPE", 251, 263], ["patient", "SPECIES", 5, 12], ["fever", "PROBLEM", 17, 22], ["neurologic symptoms", "PROBLEM", 43, 62], ["anemia", "PROBLEM", 64, 70], ["thrombocytopenia", "PROBLEM", 76, 92], ["prothrombin time", "TEST", 129, 145], ["activated partial thromboplastin time", "TREATMENT", 150, 187], ["a peripheral blood smear", "TEST", 193, 217], ["fragmented erythrocytes (schistocytes)", "PROBLEM", 226, 264], ["a microangiopathic process", "PROBLEM", 282, 308], ["fever", "OBSERVATION", 17, 22], ["anemia", "OBSERVATION", 64, 70], ["thrombocytopenia", "OBSERVATION", 76, 92], ["coagulation parameters", "OBSERVATION_MODIFIER", 105, 127], ["peripheral", "ANATOMY_MODIFIER", 195, 205], ["blood", "ANATOMY", 206, 211], ["fragmented erythrocytes", "OBSERVATION", 226, 249], ["schistocytes", "OBSERVATION", 251, 263], ["microangiopathic", "OBSERVATION_MODIFIER", 284, 300], ["process", "OBSERVATION", 301, 308]]], ["Plasma exchange should be instituted emergently at diagnosis because 10 % of patients die of this disease despite therapy.ReferenceLau DH, Wun T. Early manifestation of thrombotic thrombocytopenic purpura.", [["thrombotic thrombocytopenic purpura", "DISEASE", 169, 204], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Plasma exchange", "TREATMENT", 0, 15], ["this disease", "PROBLEM", 93, 105], ["therapy", "TREATMENT", 114, 121], ["thrombotic thrombocytopenic purpura", "PROBLEM", 169, 204], ["thrombotic", "OBSERVATION_MODIFIER", 169, 179], ["thrombocytopenic purpura", "OBSERVATION", 180, 204]]], ["A 68-year-old woman is admitted for a 3-day history of headache, fever, diarrhea, and nausea.", [["headache", "DISEASE", 55, 63], ["fever", "DISEASE", 65, 70], ["diarrhea", "DISEASE", 72, 80], ["nausea", "DISEASE", 86, 92], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["headache", "PROBLEM", 55, 63], ["fever", "PROBLEM", 65, 70], ["diarrhea", "PROBLEM", 72, 80], ["nausea", "PROBLEM", 86, 92], ["headache", "OBSERVATION", 55, 63], ["fever", "OBSERVATION", 65, 70], ["diarrhea", "OBSERVATION", 72, 80], ["nausea", "OBSERVATION", 86, 92]]], ["Once admitted to the fl oor, she rapidly becomes confused.", [["confused", "PROBLEM", 49, 57]]], ["Medical history is signifi cant for diabetes mellitus.", [["diabetes mellitus", "DISEASE", 36, 53], ["diabetes mellitus", "PROBLEM", 36, 53]]], ["On physical examination on the fl oor, the patient is disoriented.", [["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["physical examination", "TEST", 3, 23], ["disoriented", "PROBLEM", 54, 65]]], ["Temperature is 38.7 \u00b0C (101.9 \u00b0F), blood pressure is 100/65 mmHg, pulse rate is 110/min, and respiration rate is 19/min.", [["blood", "ANATOMY", 35, 40], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["Temperature", "TEST", 0, 11], ["\u00b0C", "TEST", 20, 22], ["blood pressure", "TEST", 35, 49], ["pulse rate", "TEST", 66, 76], ["respiration rate", "TEST", 93, 109]]], ["Oxygen saturation is 94 % on room air.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17]]], ["There are no focal neurologic abnormalities, but neck stiffness is noted.ReferenceEmpiric treatment is initiated with ampicillin, ceftriaxone, and vancomycin.ReferenceComplete blood count reveals a leukocyte count of 21,000/\u03bcL.", [["neurologic", "ANATOMY", 19, 29], ["neck", "ANATOMY", 49, 53], ["blood", "ANATOMY", 176, 181], ["leukocyte", "ANATOMY", 198, 207], ["neurologic abnormalities", "DISEASE", 19, 43], ["neck stiffness", "DISEASE", 49, 63], ["ampicillin", "CHEMICAL", 118, 128], ["ceftriaxone", "CHEMICAL", 130, 141], ["vancomycin", "CHEMICAL", 147, 157], ["ampicillin", "CHEMICAL", 118, 128], ["ceftriaxone", "CHEMICAL", 130, 141], ["vancomycin", "CHEMICAL", 147, 157], ["neck", "ORGANISM_SUBDIVISION", 49, 53], ["ampicillin", "SIMPLE_CHEMICAL", 118, 128], ["ceftriaxone", "SIMPLE_CHEMICAL", 130, 141], ["vancomycin", "SIMPLE_CHEMICAL", 147, 157], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["leukocyte", "CELL", 198, 207], ["focal neurologic abnormalities", "PROBLEM", 13, 43], ["neck stiffness", "PROBLEM", 49, 63], ["ReferenceEmpiric treatment", "TREATMENT", 73, 99], ["ampicillin", "TREATMENT", 118, 128], ["ceftriaxone", "TREATMENT", 130, 141], ["vancomycin", "TREATMENT", 147, 157], ["ReferenceComplete blood count", "TEST", 158, 187], ["a leukocyte count", "TEST", 196, 213], ["no", "UNCERTAINTY", 10, 12], ["focal", "OBSERVATION_MODIFIER", 13, 18], ["neurologic", "OBSERVATION_MODIFIER", 19, 29], ["abnormalities", "OBSERVATION", 30, 43], ["neck", "ANATOMY", 49, 53], ["stiffness", "OBSERVATION", 54, 63]]], ["Noncontrast computed tomographic scan of the head is normal.", [["head", "ANATOMY", 45, 49], ["head", "ORGAN", 45, 49], ["Noncontrast computed tomographic scan of the head", "TEST", 0, 49], ["head", "ANATOMY", 45, 49], ["normal", "OBSERVATION", 53, 59]]], ["Blood cultures are obtained.ReferenceA lumbar puncture is performed, and the cerebrospinal fl uid (CSF) examination reveals that leukocyte count is 950/\u03bcL with 85 % neutrophils and 20 % lymphocytes; the protein level is 95 mg/dL; and the glucose level is 15 mg/dL.", [["Blood cultures", "ANATOMY", 0, 14], ["lumbar", "ANATOMY", 39, 45], ["leukocyte", "ANATOMY", 129, 138], ["neutrophils", "ANATOMY", 165, 176], ["lymphocytes", "ANATOMY", 186, 197], ["glucose", "CHEMICAL", 238, 245], ["glucose", "CHEMICAL", 238, 245], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["cerebrospinal fl uid", "GENE_OR_GENE_PRODUCT", 77, 97], ["leukocyte", "CELL", 129, 138], ["neutrophils", "CELL", 165, 176], ["lymphocytes", "CELL", 186, 197], ["glucose", "SIMPLE_CHEMICAL", 238, 245], ["neutrophils", "CELL_TYPE", 165, 176], ["lymphocytes", "CELL_TYPE", 186, 197], ["Blood cultures", "TEST", 0, 14], ["ReferenceA lumbar puncture", "TEST", 28, 54], ["the cerebrospinal fl uid (CSF) examination", "TEST", 73, 115], ["leukocyte count", "TEST", 129, 144], ["neutrophils", "TEST", 165, 176], ["lymphocytes", "TEST", 186, 197], ["the protein level", "TEST", 199, 216], ["the glucose level", "TEST", 234, 251], ["lumbar", "ANATOMY", 39, 45], ["cerebrospinal fl", "ANATOMY", 77, 93]]], ["Gram stain of the CSF reveals gram-positive bacillus.", [["CSF", "GENE_OR_GENE_PRODUCT", 18, 21], ["CSF", "PROTEIN", 18, 21], ["Gram stain", "TEST", 0, 10], ["the CSF", "TEST", 14, 21], ["gram", "TEST", 30, 34], ["positive bacillus", "PROBLEM", 35, 52], ["positive bacillus", "OBSERVATION", 35, 52]]], ["She improves in the fi rst 12 h of treatment.ReferenceThis patient's antibiotic regimen should be narrowed to intravenous administration of which of the following?", [["intravenous", "ANATOMY", 110, 121], ["patient", "ORGANISM", 59, 66], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 110, 121], ["patient", "SPECIES", 59, 66], ["treatment", "TREATMENT", 35, 44], ["This patient's antibiotic regimen", "TREATMENT", 54, 87], ["intravenous administration", "TREATMENT", 110, 136]]], ["A) Ampicillin B) Ceftriaxone C) Vancomycin D) No change of antibiotic regimen Ampicillin is included in empiric therapy for bacterial meningitis in patients who are at risk for developing invasive infections with this Gram-positive bacillus.", [["Ampicillin B", "CHEMICAL", 3, 15], ["Ceftriaxone", "CHEMICAL", 17, 28], ["Vancomycin", "CHEMICAL", 32, 42], ["Ampicillin", "CHEMICAL", 78, 88], ["bacterial meningitis", "DISEASE", 124, 144], ["infections", "DISEASE", 197, 207], ["Ampicillin B", "CHEMICAL", 3, 15], ["Ceftriaxone C", "CHEMICAL", 17, 30], ["Vancomycin D)", "CHEMICAL", 32, 45], ["Ampicillin", "CHEMICAL", 78, 88], ["Ampicillin B", "SIMPLE_CHEMICAL", 3, 15], ["Ceftriaxone C) Vancomycin D", "SIMPLE_CHEMICAL", 17, 44], ["Ampicillin", "SIMPLE_CHEMICAL", 78, 88], ["patients", "ORGANISM", 148, 156], ["Gram", "GENE_OR_GENE_PRODUCT", 218, 222], ["patients", "SPECIES", 148, 156], ["A) Ampicillin B) Ceftriaxone C) Vancomycin D)", "TREATMENT", 0, 45], ["antibiotic regimen", "TREATMENT", 59, 77], ["Ampicillin", "TREATMENT", 78, 88], ["empiric therapy", "TREATMENT", 104, 119], ["bacterial meningitis", "PROBLEM", 124, 144], ["developing invasive infections", "PROBLEM", 177, 207], ["this Gram", "TEST", 213, 222], ["positive bacillus", "PROBLEM", 223, 240], ["change", "OBSERVATION_MODIFIER", 49, 55], ["bacterial", "OBSERVATION_MODIFIER", 124, 133], ["meningitis", "OBSERVATION", 134, 144], ["invasive", "OBSERVATION_MODIFIER", 188, 196], ["infections", "OBSERVATION", 197, 207], ["positive bacillus", "OBSERVATION", 223, 240]]], ["L. monocytogenes meningitis develops most frequently in neonates, older adults (>50 years of age), and those who are immunocompromised.", [["L.", "CHEMICAL", 0, 2], ["meningitis", "DISEASE", 17, 27], ["monocytogenes", "ORGANISM", 3, 16], ["neonates", "ORGANISM", 56, 64], ["L.", "SPECIES", 0, 2], ["monocytogenes", "SPECIES", 3, 16], ["L.", "SPECIES", 0, 2], ["monocytogenes", "SPECIES", 3, 16], ["monocytogenes meningitis", "PROBLEM", 3, 27], ["immunocompromised", "PROBLEM", 117, 134], ["meningitis", "OBSERVATION", 17, 27], ["immunocompromised", "OBSERVATION", 117, 134]]], ["She has had progressive behavioral change over the course of two years.", [["progressive behavioral change", "PROBLEM", 12, 41], ["progressive", "OBSERVATION_MODIFIER", 12, 23], ["behavioral", "OBSERVATION_MODIFIER", 24, 34], ["change", "OBSERVATION", 35, 41]]], ["She has developed poor personal hygiene and refused to take a bath.", [["a bath", "TREATMENT", 60, 66], ["poor", "OBSERVATION_MODIFIER", 18, 22]]], ["Five years ago she appeared to be completely functional.ReferenceOn physical examination, vital signs are normal.", [["ReferenceOn physical examination", "TEST", 56, 88], ["vital signs", "TEST", 90, 101], ["functional", "OBSERVATION", 45, 55], ["normal", "OBSERVATION", 106, 112]]], ["The patient's appearance is disheveled and unkempt.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["There is a loss of verbal fl uency.", [["loss of verbal fl uency", "DISEASE", 11, 34], ["a loss of verbal fl uency", "PROBLEM", 9, 34], ["loss", "OBSERVATION_MODIFIER", 11, 15]]], ["Mental status examination shows minimal memory loss and diffi culty drawing a complex fi gure.ReferenceWhich of the following is the most likely diagnosis?", [["memory loss", "DISEASE", 40, 51], ["complex fi gure", "PROTEIN", 78, 93], ["Mental status examination", "TEST", 0, 25], ["minimal memory loss", "PROBLEM", 32, 51], ["diffi culty", "PROBLEM", 56, 67], ["minimal", "OBSERVATION_MODIFIER", 32, 39], ["memory loss", "OBSERVATION", 40, 51], ["most likely", "UNCERTAINTY", 133, 144]]], ["A) Alzheimer disease B) Creutzfeldt-Jakob disease C) Dementia with Lewy bodies D) Frontotemporal dementia (FTD) E) Multi-infarct dementia Answer: E This patient has the clinical features of frontotemporal dementia (FTD).", [["Alzheimer disease B", "DISEASE", 3, 22], ["Creutzfeldt-Jakob disease", "DISEASE", 24, 49], ["Dementia", "DISEASE", 53, 61], ["Frontotemporal dementia", "DISEASE", 82, 105], ["FTD", "DISEASE", 107, 110], ["Multi-infarct dementia", "DISEASE", 115, 137], ["frontotemporal dementia", "DISEASE", 190, 213], ["FTD", "DISEASE", 215, 218], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["A) Alzheimer disease B)", "PROBLEM", 0, 23], ["Creutzfeldt", "PROBLEM", 24, 35], ["Jakob disease C)", "PROBLEM", 36, 52], ["Dementia", "PROBLEM", 53, 61], ["Lewy bodies D) Frontotemporal dementia (FTD)", "PROBLEM", 67, 111], ["Multi-infarct dementia", "PROBLEM", 115, 137], ["frontotemporal dementia (FTD)", "PROBLEM", 190, 219], ["Alzheimer disease", "OBSERVATION", 3, 20], ["Lewy bodies", "OBSERVATION", 67, 78], ["Frontotemporal", "ANATOMY", 82, 96], ["dementia", "OBSERVATION", 97, 105], ["Multi-infarct dementia", "OBSERVATION", 115, 137], ["frontotemporal", "OBSERVATION_MODIFIER", 190, 204], ["dementia", "OBSERVATION", 205, 213]]], ["This includes an emphasis on prominent personality and behavioral changes with less prominent memory loss early in the course.", [["memory loss", "DISEASE", 94, 105], ["prominent personality", "PROBLEM", 29, 50], ["behavioral changes", "PROBLEM", 55, 73], ["less prominent memory loss", "PROBLEM", 79, 105], ["prominent", "OBSERVATION_MODIFIER", 29, 38], ["personality", "OBSERVATION", 39, 50], ["less", "OBSERVATION_MODIFIER", 79, 83], ["prominent", "OBSERVATION_MODIFIER", 84, 93], ["memory loss", "OBSERVATION", 94, 105]]], ["The approach to treatment may be different with FTD as compared to Alzheimer disease.", [["FTD", "DISEASE", 48, 51], ["Alzheimer disease", "DISEASE", 67, 84], ["treatment", "TREATMENT", 16, 25], ["FTD", "PROBLEM", 48, 51], ["Alzheimer disease", "PROBLEM", 67, 84], ["Alzheimer disease", "OBSERVATION", 67, 84]]], ["Generally, cholinesterase inhibitors are not recommended for patients diagnosed with FTD.", [["FTD", "DISEASE", 85, 88], ["cholinesterase", "SIMPLE_CHEMICAL", 11, 25], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["cholinesterase inhibitors", "TREATMENT", 11, 36], ["FTD", "PROBLEM", 85, 88]]], ["People with FTD usually tolerate SSRIs well, and they are generally considered the best available medications for controlling problematic behaviors.", [["FTD", "DISEASE", 12, 15], ["SSRIs", "CHEMICAL", 33, 38], ["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["FTD", "PROBLEM", 12, 15], ["SSRIs", "TREATMENT", 33, 38], ["medications", "TREATMENT", 98, 109], ["controlling problematic behaviors", "PROBLEM", 114, 147]]], ["Antipsychotics should be used with caution.", [["Antipsychotics", "TREATMENT", 0, 14]]], ["Their potential benefi t must be weighed against potential risks including weight gain, slowing of movement and thinking, accelerating heart disease, and, in rare instances, death.", [["heart", "ANATOMY", 135, 140], ["weight gain", "DISEASE", 75, 86], ["heart disease", "DISEASE", 135, 148], ["death", "DISEASE", 174, 179], ["heart", "ORGAN", 135, 140], ["weight gain", "PROBLEM", 75, 86], ["slowing of movement", "PROBLEM", 88, 107], ["accelerating heart disease", "PROBLEM", 122, 148], ["death", "PROBLEM", 174, 179], ["heart", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148]]], ["Typical antipsychotics should be avoided, since patients with FTD are likely to show muscle stiffness and trembling which may be made worse with typical antipsychotic use.", [["muscle", "ANATOMY", 85, 91], ["FTD", "DISEASE", 62, 65], ["muscle stiffness", "DISEASE", 85, 101], ["patients", "ORGANISM", 48, 56], ["muscle", "ORGAN", 85, 91], ["patients", "SPECIES", 48, 56], ["Typical antipsychotics", "TREATMENT", 0, 22], ["FTD", "PROBLEM", 62, 65], ["muscle stiffness", "PROBLEM", 85, 101], ["trembling", "PROBLEM", 106, 115], ["muscle", "ANATOMY", 85, 91], ["stiffness", "OBSERVATION", 92, 101]]], ["The main clinical features of CJD are dementia that progresses rapidly over months and startle myoclonus, although the latter may not be present early in the illness.", [["CJD", "DISEASE", 30, 33], ["dementia", "DISEASE", 38, 46], ["myoclonus", "DISEASE", 95, 104], ["CJD", "PROBLEM", 30, 33], ["dementia", "PROBLEM", 38, 46], ["startle myoclonus", "PROBLEM", 87, 104], ["main", "OBSERVATION_MODIFIER", 4, 8], ["CJD", "OBSERVATION", 30, 33], ["dementia", "OBSERVATION", 38, 46]]], ["Other prominent features include visual or cerebellar disturbance, pyramidal/extrapyramidal dysfunction, and akinetic mutism.", [["cerebellar", "ANATOMY", 43, 53], ["pyramidal", "ANATOMY", 67, 76], ["visual or cerebellar disturbance", "DISEASE", 33, 65], ["extrapyramidal dysfunction", "DISEASE", 77, 103], ["akinetic mutism", "DISEASE", 109, 124], ["cerebellar", "ORGAN", 43, 53], ["Other prominent features", "PROBLEM", 0, 24], ["visual or cerebellar disturbance", "PROBLEM", 33, 65], ["pyramidal/extrapyramidal dysfunction", "PROBLEM", 67, 103], ["akinetic mutism", "PROBLEM", 109, 124], ["prominent", "OBSERVATION_MODIFIER", 6, 15], ["cerebellar", "ANATOMY", 43, 53], ["disturbance", "OBSERVATION", 54, 65], ["pyramidal", "OBSERVATION_MODIFIER", 67, 76], ["extrapyramidal dysfunction", "OBSERVATION", 77, 103], ["akinetic mutism", "OBSERVATION", 109, 124]]], ["Dementia with Lewy bodies is accompanied by parkinsonism, visual hallucinations, and fl uctuating symptoms.", [["Dementia", "DISEASE", 0, 8], ["Lewy bodies", "DISEASE", 14, 25], ["parkinsonism", "DISEASE", 44, 56], ["visual hallucinations", "DISEASE", 58, 79], ["Dementia", "PROBLEM", 0, 8], ["Lewy bodies", "PROBLEM", 14, 25], ["parkinsonism", "PROBLEM", 44, 56], ["visual hallucinations", "PROBLEM", 58, 79], ["fl uctuating symptoms", "PROBLEM", 85, 106], ["Lewy bodies", "OBSERVATION", 14, 25], ["parkinsonism", "OBSERVATION", 44, 56], ["visual hallucinations", "OBSERVATION", 58, 79]]], ["The characteristic cognitive profi le of dementia in patients with dementia with Lewy bodies includes impaired learning and attention, psychomotor slowing, and constructional apraxia, but less memory impairment than in similarly staged patients with Alzheimer disease.ReferenceManning C. Beyond memory: neuropsychologic features in differential diagnosis of dementia.", [["dementia", "DISEASE", 41, 49], ["dementia", "DISEASE", 67, 75], ["impaired learning and attention, psychomotor slowing", "DISEASE", 102, 154], ["constructional apraxia", "DISEASE", 160, 182], ["memory impairment", "DISEASE", 193, 210], ["Alzheimer disease", "DISEASE", 250, 267], ["dementia", "DISEASE", 358, 366], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 236, 244], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 236, 244], ["dementia", "PROBLEM", 41, 49], ["dementia", "PROBLEM", 67, 75], ["Lewy bodies", "PROBLEM", 81, 92], ["impaired learning", "PROBLEM", 102, 119], ["psychomotor slowing", "PROBLEM", 135, 154], ["constructional apraxia", "PROBLEM", 160, 182], ["less memory impairment", "PROBLEM", 188, 210], ["Alzheimer disease", "PROBLEM", 250, 267], ["dementia", "PROBLEM", 358, 366], ["dementia", "OBSERVATION", 41, 49], ["apraxia", "OBSERVATION", 175, 182], ["Alzheimer disease", "OBSERVATION", 250, 267], ["dementia", "OBSERVATION", 358, 366]]], ["A 58-year-old male is transferred from an outside hospital because of ascites and worsening renal function.ReferenceHe has hepatitis C cirrhosis, portal hypertension, and near end-stage liver disease.", [["ascites", "ANATOMY", 70, 77], ["renal", "ANATOMY", 92, 97], ["portal", "ANATOMY", 146, 152], ["liver", "ANATOMY", 186, 191], ["ascites", "DISEASE", 70, 77], ["ReferenceHe", "CHEMICAL", 107, 118], ["hepatitis C cirrhosis", "DISEASE", 123, 144], ["portal hypertension", "DISEASE", 146, 165], ["end-stage liver disease", "DISEASE", 176, 199], ["male", "ORGANISM", 14, 18], ["renal", "ORGAN", 92, 97], ["portal", "MULTI-TISSUE_STRUCTURE", 146, 152], ["liver", "ORGAN", 186, 191], ["ascites", "PROBLEM", 70, 77], ["worsening renal function", "PROBLEM", 82, 106], ["hepatitis C cirrhosis", "PROBLEM", 123, 144], ["portal hypertension", "PROBLEM", 146, 165], ["near end-stage liver disease", "PROBLEM", 171, 199], ["ascites", "OBSERVATION", 70, 77], ["worsening", "OBSERVATION_MODIFIER", 82, 91], ["renal", "ANATOMY", 92, 97], ["function", "OBSERVATION", 98, 106], ["hepatitis", "OBSERVATION", 123, 132], ["cirrhosis", "OBSERVATION", 135, 144], ["portal", "ANATOMY", 146, 152], ["hypertension", "OBSERVATION", 153, 165], ["stage", "OBSERVATION_MODIFIER", 180, 185], ["liver", "ANATOMY", 186, 191], ["disease", "OBSERVATION", 192, 199]]], ["Contrast-enhanced computed tomography of the abdomen was performed at the outside hospital 3 days before transfer because of abdominal pain.", [["abdomen", "ANATOMY", 45, 52], ["abdominal", "ANATOMY", 125, 134], ["abdominal pain", "DISEASE", 125, 139], ["abdomen", "ORGAN", 45, 52], ["abdominal", "ORGANISM_SUBDIVISION", 125, 134], ["Contrast-enhanced computed tomography of the abdomen", "TEST", 0, 52], ["abdominal pain", "PROBLEM", 125, 139], ["abdomen", "ANATOMY", 45, 52], ["abdominal", "ANATOMY", 125, 134], ["pain", "OBSERVATION", 135, 139]]], ["His oral fl uid intake has been restricted.", [["oral", "ANATOMY", 4, 8], ["oral", "ORGANISM_SUBDIVISION", 4, 8]]], ["Urine output in the past 24 h is 300 mL.", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Urine output", "TEST", 0, 12], ["output", "OBSERVATION_MODIFIER", 6, 12]]], ["On physical examination today, he is afebrile.", [["physical examination", "TEST", 3, 23], ["afebrile", "PROBLEM", 37, 45]]], ["Pulse rate is 75 per minute, and blood pressure is 100/70 mmHg.", [["blood", "ANATOMY", 33, 38], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["Pulse rate", "TEST", 0, 10], ["blood pressure", "TEST", 33, 47]]], ["Decreased breath sounds are noted in the bases of both lungs.", [["lungs", "ANATOMY", 55, 60], ["lungs", "ORGAN", 55, 60], ["Decreased breath sounds", "PROBLEM", 0, 23], ["breath sounds", "OBSERVATION", 10, 23], ["bases", "ANATOMY_MODIFIER", 41, 46], ["both", "ANATOMY_MODIFIER", 50, 54], ["lungs", "ANATOMY", 55, 60]]], ["He has tense ascites, no worse than his baseline and pitting edema (3+) in his legs.ReferenceHis MELD score is 25.", [["ascites", "ANATOMY", 13, 20], ["legs", "ANATOMY", 79, 83], ["ascites", "DISEASE", 13, 20], ["edema", "DISEASE", 61, 66], ["He", "ORGANISM", 0, 2], ["legs", "ORGANISM_SUBDIVISION", 79, 83], ["tense ascites", "PROBLEM", 7, 20], ["pitting edema", "PROBLEM", 53, 66], ["MELD score", "TEST", 97, 107], ["tense", "OBSERVATION_MODIFIER", 7, 12], ["ascites", "OBSERVATION", 13, 20], ["no", "UNCERTAINTY", 22, 24], ["worse", "OBSERVATION_MODIFIER", 25, 30], ["pitting", "OBSERVATION_MODIFIER", 53, 60], ["edema", "OBSERVATION", 61, 66], ["legs", "ANATOMY", 79, 83]]], ["Creatine is 5.1 \u03bcg/dl with a baseline of 1.5 two weeks ago.ReferenceParacentesis reveals a peritoneal fl uid leukocyte count of 1672/\u03bcL.ReferenceWhich of the following is the most important next step in this patient's management?", [["peritoneal fl uid leukocyte", "ANATOMY", 91, 118], ["Creatine", "CHEMICAL", 0, 8], ["Creatine", "CHEMICAL", 0, 8], ["Creatine", "SIMPLE_CHEMICAL", 0, 8], ["peritoneal fl uid leukocyte", "CELL", 91, 118], ["patient", "ORGANISM", 208, 215], ["patient", "SPECIES", 208, 215], ["Creatine", "TEST", 0, 8], ["ReferenceParacentesis", "TEST", 59, 80], ["a peritoneal fl uid leukocyte count", "TEST", 89, 124], ["this patient's management", "TREATMENT", 203, 228], ["peritoneal", "ANATOMY", 91, 101]]], ["A) Trial of octreotide and midodrine B) Nephrology consultation C) Listing for emergency liver transplantation D) Fluid challenge test E) Hemodialysis Answer: D Requirements for the diagnosis of hepatorenal syndrome (HRS) include a doubling of the serum creatinine level and at least a 1.5 L fl uid challenge.", [["liver", "ANATOMY", 89, 94], ["serum", "ANATOMY", 248, 253], ["octreotide", "CHEMICAL", 12, 22], ["midodrine B", "CHEMICAL", 27, 38], ["hepatorenal syndrome", "DISEASE", 195, 215], ["HRS", "DISEASE", 217, 220], ["creatinine", "CHEMICAL", 254, 264], ["octreotide", "CHEMICAL", 12, 22], ["midodrine B", "CHEMICAL", 27, 38], ["creatinine", "CHEMICAL", 254, 264], ["octreotide", "SIMPLE_CHEMICAL", 12, 22], ["liver", "ORGAN", 89, 94], ["serum", "ORGANISM_SUBSTANCE", 248, 253], ["creatinine", "SIMPLE_CHEMICAL", 254, 264], ["octreotide", "TREATMENT", 12, 22], ["midodrine", "TREATMENT", 27, 36], ["emergency liver transplantation", "TREATMENT", 79, 110], ["Fluid challenge test", "TEST", 114, 134], ["Hemodialysis", "TREATMENT", 138, 150], ["hepatorenal syndrome", "PROBLEM", 195, 215], ["the serum creatinine level", "TEST", 244, 270], ["a 1.5 L fl uid challenge", "TREATMENT", 284, 308], ["liver", "ANATOMY", 89, 94], ["hepatorenal syndrome", "OBSERVATION", 195, 215]]], ["This should be considered despite the presence of ascites.", [["ascites", "ANATOMY", 50, 57], ["ascites", "DISEASE", 50, 57], ["ascites", "CANCER", 50, 57], ["ascites", "PROBLEM", 50, 57], ["ascites", "OBSERVATION", 50, 57]]], ["Urgent transplantation or hemodialysis may be considered after HRS has been established.", [["Urgent transplantation", "TREATMENT", 0, 22], ["hemodialysis", "TREATMENT", 26, 38], ["transplantation", "OBSERVATION", 7, 22]]], ["Octreotide and midodrine may be of some limited benefi t once the diagnosis of HRS has been made.ReferenceHasper D, Jorres A. New insights into the management of hepato-renal syndrome.", [["hepato-renal", "ANATOMY", 162, 174], ["Octreotide", "CHEMICAL", 0, 10], ["midodrine", "CHEMICAL", 15, 24], ["HRS", "DISEASE", 79, 82], ["hepato-renal syndrome", "DISEASE", 162, 183], ["Octreotide", "CHEMICAL", 0, 10], ["midodrine", "CHEMICAL", 15, 24], ["Octreotide", "SIMPLE_CHEMICAL", 0, 10], ["midodrine", "SIMPLE_CHEMICAL", 15, 24], ["HRS", "CANCER", 79, 82], ["hepato-renal", "CANCER", 162, 174], ["Octreotide", "TREATMENT", 0, 10], ["midodrine", "TREATMENT", 15, 24], ["HRS", "TEST", 79, 82], ["the management", "TREATMENT", 144, 158], ["hepato-renal syndrome", "PROBLEM", 162, 183], ["renal", "ANATOMY", 169, 174], ["syndrome", "OBSERVATION", 175, 183]]], ["Liver Int.", [["Liver", "ANATOMY", 0, 5], ["Liver", "ORGAN", 0, 5], ["Int.", "OBSERVATION", 6, 10]]], ["A 39-year-old woman is admitted for diarrhea.", [["diarrhea", "DISEASE", 36, 44], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["diarrhea", "PROBLEM", 36, 44]]], ["The purpose of the admission is to quantify and document her diarrhea before and after a fast has begun.", [["diarrhea", "DISEASE", 61, 69], ["her diarrhea", "PROBLEM", 57, 69]]], ["She has been seen in clinic for diarrhea many times in the past two months.", [["diarrhea", "DISEASE", 32, 40], ["diarrhea", "PROBLEM", 32, 40]]], ["She reports that the diarrhea has been present since she developed a presumed food-borne illness three months ago.", [["diarrhea", "DISEASE", 21, 29], ["food-borne illness", "DISEASE", 78, 96], ["the diarrhea", "PROBLEM", 17, 29], ["diarrhea", "OBSERVATION", 21, 29]]], ["At that time, she had severe nausea, vomiting, and watery diarrhea for two days.", [["nausea", "DISEASE", 29, 35], ["vomiting", "DISEASE", 37, 45], ["watery diarrhea", "DISEASE", 51, 66], ["severe nausea", "PROBLEM", 22, 35], ["vomiting", "PROBLEM", 37, 45], ["watery diarrhea", "PROBLEM", 51, 66], ["severe", "OBSERVATION_MODIFIER", 22, 28], ["nausea", "OBSERVATION", 29, 35]]], ["Although her symptoms improved, she has continued to have episodic diarrhea with four to fi ve watery stools each day, often following meals.", [["diarrhea", "DISEASE", 67, 75], ["her symptoms", "PROBLEM", 9, 21], ["episodic diarrhea", "PROBLEM", 58, 75], ["watery stools", "PROBLEM", 95, 108], ["diarrhea", "OBSERVATION", 67, 75]]], ["She also has had excessive fl atus and abdominal distension over the past two months.", [["abdominal", "ANATOMY", 39, 48], ["abdominal distension", "DISEASE", 39, 59], ["abdominal", "ORGANISM_SUBDIVISION", 39, 48], ["excessive fl atus", "PROBLEM", 17, 34], ["abdominal distension", "PROBLEM", 39, 59], ["excessive", "OBSERVATION_MODIFIER", 17, 26], ["fl atus", "OBSERVATION", 27, 34], ["abdominal", "ANATOMY", 39, 48], ["distension", "OBSERVATION", 49, 59]]], ["She denies nocturnal stools, weight loss, fever, or blood in her stool.", [["stools", "ANATOMY", 21, 27], ["blood", "ANATOMY", 52, 57], ["stool", "ANATOMY", 65, 70], ["nocturnal stools", "DISEASE", 11, 27], ["weight loss", "DISEASE", 29, 40], ["fever", "DISEASE", 42, 47], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["stool", "ORGANISM_SUBSTANCE", 65, 70], ["nocturnal stools", "PROBLEM", 11, 27], ["weight loss", "PROBLEM", 29, 40], ["fever", "PROBLEM", 42, 47], ["blood in her stool", "PROBLEM", 52, 70], ["stool", "OBSERVATION", 65, 70]]], ["She denies any recent antibiotics.", [["recent antibiotics", "TREATMENT", 15, 33]]], ["Medical history is notable for diabetes, hypertension, and a cholecystectomy performed two years ago.ReferenceOn physical examination, vital signs are normal.", [["diabetes", "DISEASE", 31, 39], ["hypertension", "DISEASE", 41, 53], ["diabetes", "PROBLEM", 31, 39], ["hypertension", "PROBLEM", 41, 53], ["a cholecystectomy", "TREATMENT", 59, 76], ["ReferenceOn physical examination", "TEST", 101, 133], ["vital signs", "TEST", 135, 146], ["notable for", "UNCERTAINTY", 19, 30], ["diabetes", "OBSERVATION", 31, 39], ["hypertension", "OBSERVATION", 41, 53], ["cholecystectomy", "OBSERVATION", 61, 76], ["normal", "OBSERVATION", 151, 157]]], ["Abdominal examination reveals normal bowel sounds and a nontender abdomen.", [["Abdominal", "ANATOMY", 0, 9], ["bowel", "ANATOMY", 37, 42], ["abdomen", "ANATOMY", 66, 73], ["bowel", "ORGAN", 37, 42], ["abdomen", "ORGAN", 66, 73], ["Abdominal examination", "TEST", 0, 21], ["normal", "OBSERVATION", 30, 36], ["bowel", "ANATOMY", 37, 42], ["sounds", "OBSERVATION", 43, 49], ["nontender", "OBSERVATION", 56, 65], ["abdomen", "ANATOMY", 66, 73]]], ["Rectal examination is normal.ReferenceA complete blood count, stool cultures, stool examination for ova and parasites, and tests for Clostridium diffi cile are negative.", [["Rectal", "ANATOMY", 0, 6], ["blood", "ANATOMY", 49, 54], ["stool cultures", "ANATOMY", 62, 76], ["stool", "ANATOMY", 78, 83], ["ova", "ANATOMY", 100, 103], ["Rectal", "ORGAN", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["stool", "ORGANISM_SUBSTANCE", 78, 83], ["ova", "ORGANISM_SUBSTANCE", 100, 103], ["Clostridium diffi cile", "ORGANISM", 133, 155], ["Clostridium diffi cile", "SPECIES", 133, 155], ["Clostridium diffi cile", "SPECIES", 133, 155], ["Rectal examination", "TEST", 0, 18], ["ReferenceA complete blood count", "TEST", 29, 60], ["stool cultures", "TEST", 62, 76], ["stool examination", "TEST", 78, 95], ["ova", "PROBLEM", 100, 103], ["parasites", "PROBLEM", 108, 117], ["tests", "TEST", 123, 128], ["Clostridium diffi cile", "TEST", 133, 155], ["normal", "OBSERVATION", 22, 28]]], ["Before a fast is begun, the nurses report six bowel movements in one shift.", [["bowel", "ANATOMY", 46, 51], ["bowel movements", "DISEASE", 46, 61], ["bowel", "ORGAN", 46, 51], ["bowel", "ANATOMY", 46, 51], ["movements", "OBSERVATION", 52, 61]]], ["Stool osmotic gap is measured at 170 mOsm/kg.", [["Stool", "ORGANISM_SUBSTANCE", 0, 5], ["Stool osmotic gap", "TEST", 0, 17], ["osmotic gap", "OBSERVATION", 6, 17]]], ["A) Bile-salt-induced diarrhea B) Diabetic gastropathy C) Irritable bowel syndrome D) Lactose malabsorption E) Microscopic colitis Answer: D This patient has lactose malabsorption that developed as a result of her recent food-borne illness or gastroenteritis.", [["Bile-salt", "CHEMICAL", 3, 12], ["diarrhea", "DISEASE", 21, 29], ["Diabetic gastropathy", "DISEASE", 33, 53], ["Irritable bowel syndrome", "DISEASE", 57, 81], ["malabsorption", "DISEASE", 93, 106], ["colitis", "DISEASE", 122, 129], ["lactose", "CHEMICAL", 157, 164], ["malabsorption", "DISEASE", 165, 178], ["food-borne illness", "DISEASE", 220, 238], ["gastroenteritis", "DISEASE", 242, 257], ["Bile-salt", "CHEMICAL", 3, 12], ["Lactose", "CHEMICAL", 85, 92], ["D", "CHEMICAL", 138, 139], ["lactose", "CHEMICAL", 157, 164], ["Bile-salt", "SIMPLE_CHEMICAL", 3, 12], ["bowel", "ORGAN", 67, 72], ["patient", "ORGANISM", 145, 152], ["lactose", "SIMPLE_CHEMICAL", 157, 164], ["patient", "SPECIES", 145, 152], ["diarrhea", "PROBLEM", 21, 29], ["Diabetic gastropathy C", "PROBLEM", 33, 55], ["Irritable bowel syndrome", "PROBLEM", 57, 81], ["Lactose malabsorption E", "PROBLEM", 85, 108], ["Microscopic colitis", "PROBLEM", 110, 129], ["lactose malabsorption", "PROBLEM", 157, 178], ["her recent food-borne illness", "PROBLEM", 209, 238], ["gastroenteritis", "PROBLEM", 242, 257], ["Bile", "ANATOMY", 3, 7], ["gastropathy", "OBSERVATION", 42, 53], ["bowel", "ANATOMY", 67, 72], ["colitis", "OBSERVATION", 122, 129], ["lactose malabsorption", "OBSERVATION", 157, 178], ["gastroenteritis", "OBSERVATION", 242, 257]]], ["This is a relatively common occurrence, may occur after a nonspecifi c gastrointestinal event, and is usually selflimited.", [["gastrointestinal", "ANATOMY", 71, 87], ["gastrointestinal", "ORGAN", 71, 87], ["a nonspecifi c gastrointestinal event", "PROBLEM", 56, 93], ["gastrointestinal", "ANATOMY", 71, 87]]], ["Estimating the stool osmotic gap using stool electrolytes evaluates for the presence of an osmotic diarrhea.", [["diarrhea", "DISEASE", 99, 107], ["the stool osmotic gap", "TEST", 11, 32], ["stool electrolytes", "TEST", 39, 57], ["an osmotic diarrhea", "PROBLEM", 88, 107], ["stool", "OBSERVATION", 15, 20], ["osmotic diarrhea", "OBSERVATION", 91, 107]]], ["A gap greater than 100 mOsm/kg (100 mmol/kg) indicates an osmotic cause of diarrhea.", [["diarrhea", "DISEASE", 75, 83], ["A gap", "TEST", 0, 5], ["diarrhea", "PROBLEM", 75, 83], ["diarrhea", "OBSERVATION", 75, 83]]], ["Lactose malabsorption is the most common cause of a stool osmotic gap.", [["stool", "ANATOMY", 52, 57], ["Lactose", "CHEMICAL", 0, 7], ["malabsorption", "DISEASE", 8, 21], ["Lactose", "CHEMICAL", 0, 7], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["Lactose malabsorption", "PROBLEM", 0, 21], ["a stool osmotic gap", "PROBLEM", 50, 69], ["malabsorption", "OBSERVATION", 8, 21], ["most common", "OBSERVATION_MODIFIER", 29, 40], ["stool", "OBSERVATION", 52, 57], ["osmotic gap", "OBSERVATION", 58, 69]]], ["Reducing this patient's lactose intake will often result in symptom improvement.", [["lactose", "CHEMICAL", 24, 31], ["lactose", "CHEMICAL", 24, 31], ["patient", "ORGANISM", 14, 21], ["lactose", "SIMPLE_CHEMICAL", 24, 31], ["patient", "SPECIES", 14, 21], ["this patient's lactose intake", "TREATMENT", 9, 38], ["symptom", "PROBLEM", 60, 67]]], ["Lactose intake can slowly be increased as more time elapses and her lactose intolerance improves.", [["Lactose", "CHEMICAL", 0, 7], ["lactose", "CHEMICAL", 68, 75], ["Lactose", "CHEMICAL", 0, 7], ["lactose", "CHEMICAL", 68, 75], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["lactose", "SIMPLE_CHEMICAL", 68, 75], ["Lactose intake", "PROBLEM", 0, 14], ["her lactose intolerance", "PROBLEM", 64, 87], ["increased", "OBSERVATION_MODIFIER", 29, 38]]], ["Even though some patients may have an increase in stool frequency after cholecystectomy, this patient's surgery was remote enough that it would not cause her current symptoms.", [["stool", "ANATOMY", 50, 55], ["patients", "ORGANISM", 17, 25], ["stool", "ORGANISM_SUBSTANCE", 50, 55], ["patient", "ORGANISM", 94, 101], ["patients", "SPECIES", 17, 25], ["patient", "SPECIES", 94, 101], ["an increase in stool frequency", "PROBLEM", 35, 65], ["cholecystectomy", "TREATMENT", 72, 87], ["this patient's surgery", "TREATMENT", 89, 111], ["her current symptoms", "PROBLEM", 154, 174], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["stool frequency", "OBSERVATION_MODIFIER", 50, 65], ["cholecystectomy", "OBSERVATION", 72, 87]]], ["Bile-salt-induced diarrhea tends to cause a secretory diarrhea.", [["Bile-salt", "CHEMICAL", 0, 9], ["diarrhea", "DISEASE", 18, 26], ["diarrhea", "DISEASE", 54, 62], ["Bile-salt", "CHEMICAL", 0, 9], ["Bile-salt", "SIMPLE_CHEMICAL", 0, 9], ["diarrhea", "PROBLEM", 18, 26], ["a secretory diarrhea", "PROBLEM", 42, 62], ["salt-induced", "OBSERVATION_MODIFIER", 5, 17], ["diarrhea", "OBSERVATION", 18, 26], ["diarrhea", "OBSERVATION", 54, 62]]], ["A stool osmotic gap is not consistent with the diagnosis of IBS.", [["stool", "ANATOMY", 2, 7], ["IBS", "DISEASE", 60, 63], ["A stool osmotic gap", "TEST", 0, 19], ["IBS", "PROBLEM", 60, 63], ["stool osmotic gap", "OBSERVATION", 2, 19], ["not consistent with", "UNCERTAINTY", 23, 42], ["IBS", "OBSERVATION", 60, 63]]], ["Microscopic colitis causes a secretory diarrhea.ReferenceMattar R, de Campos Mazo DF, Carrilho FJ.", [["colitis", "DISEASE", 12, 19], ["diarrhea", "DISEASE", 39, 47], ["Microscopic colitis", "PROBLEM", 0, 19], ["a secretory diarrhea", "PROBLEM", 27, 47], ["colitis", "OBSERVATION", 12, 19], ["secretory diarrhea", "OBSERVATION", 29, 47]]], ["Lactose intolerance: diagnosis, genetic, and clinical factors.", [["Lactose", "CHEMICAL", 0, 7], ["Lactose", "CHEMICAL", 0, 7], ["Lactose", "SIMPLE_CHEMICAL", 0, 7], ["Lactose intolerance", "PROBLEM", 0, 19]]], ["Clin Exp Gastroenterol.", [["Gastroenterol", "CHEMICAL", 9, 22], ["Clin Exp Gastroenterol", "TREATMENT", 0, 22]]], ["A 68-year-old man is admitted to the ICU for of a 10-day history of fever, headache, diarrhea, and cough productive of yellow sputum.", [["sputum", "ANATOMY", 126, 132], ["fever", "DISEASE", 68, 73], ["headache", "DISEASE", 75, 83], ["diarrhea", "DISEASE", 85, 93], ["cough productive of yellow sputum", "DISEASE", 99, 132], ["man", "ORGANISM", 14, 17], ["man", "SPECIES", 14, 17], ["fever", "PROBLEM", 68, 73], ["headache", "PROBLEM", 75, 83], ["diarrhea", "PROBLEM", 85, 93], ["cough productive of yellow sputum", "PROBLEM", 99, 132], ["fever", "OBSERVATION", 68, 73], ["headache", "OBSERVATION", 75, 83], ["diarrhea", "OBSERVATION", 85, 93]]], ["He also has a 2-day history of progressive dyspnea.", [["dyspnea", "DISEASE", 43, 50], ["progressive dyspnea", "PROBLEM", 31, 50], ["progressive", "OBSERVATION_MODIFIER", 31, 42], ["dyspnea", "OBSERVATION", 43, 50]]], ["He has been on oral antibiotics for the past two days.", [["oral", "ANATOMY", 15, 19], ["oral", "ORGANISM_SUBDIVISION", 15, 19], ["oral antibiotics", "TREATMENT", 15, 31]]], ["On physical examination, the temperature is 38.9 \u00b0C (101.9 \u00b0F), blood pressure is 100/60 mmHg, pulse rate is 120 bpm, and respiration rate is 30/min.", [["blood", "ANATOMY", 64, 69], ["blood", "ORGANISM_SUBSTANCE", 64, 69], ["physical examination", "TEST", 3, 23], ["the temperature", "TEST", 25, 40], ["\u00b0C", "TEST", 49, 51], ["blood pressure", "TEST", 64, 78], ["pulse rate", "TEST", 95, 105], ["respiration rate", "TEST", 122, 138]]], ["Oxygen saturation is 83 % while breathing 100 % oxygen by nonrebreathing mask.", [["oxygen", "CHEMICAL", 48, 54], ["Oxygen", "CHEMICAL", 0, 6], ["oxygen", "CHEMICAL", 48, 54], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["Oxygen saturation", "TEST", 0, 17], ["nonrebreathing mask", "TREATMENT", 58, 77]]], ["Course breath sounds are heard over the left and right lower lung fi elds.ReferenceLaboratory studies show a leukocyte count of 9000/ \u03bcL, platelet count of 86,000/\u03bcL, and serum sodium level of 129 meq/L. Chest radiograph shows fi ndings consistent with consolidation in the right middle and lower lobes.ReferenceThe patient is intubated, and mechanical ventilation is initiated.", [["left", "ANATOMY", 40, 44], ["right lower lung", "ANATOMY", 49, 65], ["leukocyte", "ANATOMY", 109, 118], ["platelet", "ANATOMY", 138, 146], ["serum", "ANATOMY", 171, 176], ["right middle", "ANATOMY", 274, 286], ["lower lobes", "ANATOMY", 291, 302], ["sodium", "CHEMICAL", 177, 183], ["sodium", "CHEMICAL", 177, 183], ["lung", "ORGAN", 61, 65], ["leukocyte", "CELL", 109, 118], ["platelet", "CELL", 138, 146], ["serum", "ORGANISM_SUBSTANCE", 171, 176], ["sodium", "SIMPLE_CHEMICAL", 177, 183], ["middle", "ORGANISM_SUBDIVISION", 280, 286], ["lower lobes", "MULTI-TISSUE_STRUCTURE", 291, 302], ["patient", "ORGANISM", 316, 323], ["patient", "SPECIES", 316, 323], ["Course breath sounds", "TEST", 0, 20], ["ReferenceLaboratory studies", "TEST", 74, 101], ["a leukocyte count", "TEST", 107, 124], ["platelet count", "TEST", 138, 152], ["serum sodium level", "TEST", 171, 189], ["Chest radiograph", "TEST", 204, 220], ["fi ndings", "PROBLEM", 227, 236], ["consolidation in the right middle and lower lobes", "PROBLEM", 253, 302], ["intubated", "TREATMENT", 327, 336], ["mechanical ventilation", "TREATMENT", 342, 364], ["breath sounds", "OBSERVATION", 7, 20], ["left", "ANATOMY_MODIFIER", 40, 44], ["right", "ANATOMY_MODIFIER", 49, 54], ["lower", "ANATOMY_MODIFIER", 55, 60], ["lung", "ANATOMY", 61, 65], ["fi", "ANATOMY_MODIFIER", 66, 68], ["elds", "OBSERVATION", 69, 73], ["consistent with", "UNCERTAINTY", 237, 252], ["consolidation", "OBSERVATION", 253, 266], ["right middle", "ANATOMY_MODIFIER", 274, 286], ["lower lobes", "ANATOMY", 291, 302], ["mechanical ventilation", "OBSERVATION", 342, 364]]], ["Blood cultures are obtained, empiric antibiotic therapy is begun, and fl uid resuscitation is started.ReferenceIn addition to an endotracheal aspirate for Gram stain and culture, which of the following is the most appropriate next step in the evaluation?", [["Blood cultures", "ANATOMY", 0, 14], ["endotracheal aspirate", "ANATOMY", 129, 150], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood cultures", "TEST", 0, 14], ["empiric antibiotic therapy", "TREATMENT", 29, 55], ["fl uid resuscitation", "TREATMENT", 70, 90], ["an endotracheal aspirate", "TEST", 126, 150], ["Gram stain", "TEST", 155, 165], ["culture", "TEST", 170, 177], ["the evaluation", "TEST", 239, 253], ["endotracheal", "ANATOMY", 129, 141]]], ["A) Bronchoscopy with quantitative cultures B) Legionella and Streptococcus pneumonia urine antigen assays C) Legionella serologic testing D) No further testing Answer: B This patient may benefi t from Legionella and Streptococcus pneumonia urine antigen assays.", [["pneumonia", "DISEASE", 75, 84], ["pneumonia", "DISEASE", 230, 239], ["urine", "ORGANISM_SUBSTANCE", 85, 90], ["patient", "ORGANISM", 175, 182], ["urine", "ORGANISM_SUBSTANCE", 240, 245], ["Streptococcus pneumonia", "SPECIES", 61, 84], ["patient", "SPECIES", 175, 182], ["A) Bronchoscopy", "TEST", 0, 15], ["quantitative cultures", "TEST", 21, 42], ["Legionella", "PROBLEM", 46, 56], ["Streptococcus pneumonia", "TEST", 61, 84], ["urine antigen assays", "TEST", 85, 105], ["C", "TEST", 106, 107], ["Legionella serologic testing D", "TEST", 109, 139], ["Legionella", "PROBLEM", 201, 211], ["Streptococcus pneumonia", "PROBLEM", 216, 239], ["urine antigen assays", "TEST", 240, 260]]], ["The clinical value of diagnostic testing to determine the microbial cause of community-acquired pneumonia (CAP) is controversial.", [["pneumonia", "DISEASE", 96, 105], ["CAP", "DISEASE", 107, 110], ["diagnostic testing", "TEST", 22, 40], ["community-acquired pneumonia (CAP)", "PROBLEM", 77, 111], ["pneumonia", "OBSERVATION", 96, 105]]], ["This hospitalized patient has severe CAP, defi ned as CAP in a patient who requires admission to an intensive care unit or transfer to an intensive care unit within 24 h of admission.", [["CAP", "DISEASE", 37, 40], ["CAP", "DISEASE", 54, 57], ["patient", "ORGANISM", 18, 25], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 18, 25], ["patient", "SPECIES", 63, 70], ["severe CAP", "PROBLEM", 30, 40], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["CAP", "OBSERVATION_MODIFIER", 37, 40]]], ["The 2007 Infectious Diseases Society of America/American Thoracic Society guidelines recommend Streptococcus pneumonia and Legionella urine antigen assays for hospitalized patients with severe CAP.", [["Infectious Diseases", "DISEASE", 9, 28], ["Streptococcus pneumonia", "DISEASE", 95, 118], ["CAP", "DISEASE", 193, 196], ["Legionella", "ORGANISM", 123, 133], ["urine", "ORGANISM_SUBSTANCE", 134, 139], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["Streptococcus pneumonia", "PROBLEM", 95, 118], ["Legionella urine antigen assays", "TEST", 123, 154], ["severe CAP", "PROBLEM", 186, 196], ["Infectious", "OBSERVATION_MODIFIER", 9, 19], ["Thoracic", "ANATOMY", 57, 65], ["Streptococcus pneumonia", "OBSERVATION", 95, 118], ["severe", "OBSERVATION_MODIFIER", 186, 192], ["CAP", "OBSERVATION", 193, 196]]], ["The urinary antigen is useful to confi rm the presence of Legionella or S. pneumonia .", [["urinary", "ANATOMY", 4, 11], ["Legionella", "DISEASE", 58, 68], ["pneumonia", "DISEASE", 75, 84], ["urinary antigen", "GENE_OR_GENE_PRODUCT", 4, 19], ["S. pneumonia", "ORGANISM", 72, 84], ["S. pneumonia", "SPECIES", 72, 84], ["S. pneumonia", "SPECIES", 72, 84], ["The urinary antigen", "TEST", 0, 19], ["Legionella", "PROBLEM", 58, 68], ["S. pneumonia", "PROBLEM", 72, 84], ["urinary", "ANATOMY", 4, 11], ["Legionella", "OBSERVATION", 58, 68], ["pneumonia", "OBSERVATION", 75, 84]]], ["However, in HCAP the urinary antigen does not seem to be useful.", [["urinary", "ANATOMY", 21, 28], ["HCAP", "SIMPLE_CHEMICAL", 12, 16], ["urinary antigen", "GENE_OR_GENE_PRODUCT", 21, 36], ["HCAP", "PROTEIN", 12, 16], ["HCAP the urinary antigen", "TEST", 12, 36], ["HCAP", "OBSERVATION", 12, 16], ["urinary", "ANATOMY", 21, 28]]], ["Legionella should be suspected in this patient, who is older than 50 years of age and presents with severe pneumonia hyponatremia and extrapulmonary symptoms.", [["extrapulmonary", "ANATOMY", 134, 148], ["Legionella", "DISEASE", 0, 10], ["pneumonia", "DISEASE", 107, 116], ["hyponatremia", "DISEASE", 117, 129], ["extrapulmonary symptoms", "DISEASE", 134, 157], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["Legionella", "PROBLEM", 0, 10], ["severe pneumonia hyponatremia", "PROBLEM", 100, 129], ["extrapulmonary symptoms", "PROBLEM", 134, 157], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["pneumonia", "OBSERVATION", 107, 116], ["extrapulmonary", "ANATOMY", 134, 148], ["symptoms", "OBSERVATION", 149, 157]]], ["Bronchoscopy with quantitative culture can be used as a diagnostic tool in the evaluation of patients with ventilatorassociated pneumonia.", [["pneumonia", "DISEASE", 128, 137], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["Bronchoscopy", "TEST", 0, 12], ["quantitative culture", "TEST", 18, 38], ["the evaluation", "TEST", 75, 89], ["ventilatorassociated pneumonia", "PROBLEM", 107, 137], ["pneumonia", "OBSERVATION", 128, 137]]], ["However, bronchoscopy with quantitative culture has not been prospectively studied for the management of patients with severe CAP.", [["CAP", "DISEASE", 126, 129], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["bronchoscopy", "TEST", 9, 21], ["quantitative culture", "TEST", 27, 47], ["the management", "TREATMENT", 87, 101], ["severe CAP", "PROBLEM", 119, 129], ["severe", "OBSERVATION_MODIFIER", 119, 125], ["CAP", "OBSERVATION", 126, 129]]], ["Serologic testing for atypical pathogens such as Legionella species is not recommended because convalescent titers would need to be obtained 6 to 8 weeks after initial testing to establish a diagnosis.201.A 76-year-old man is evaluated in the emergency department because of fever, shortness of breath, and productive cough.", [["fever", "DISEASE", 275, 280], ["shortness of breath", "DISEASE", 282, 301], ["cough", "DISEASE", 318, 323], ["man", "ORGANISM", 219, 222], ["man", "SPECIES", 219, 222], ["Serologic testing", "TEST", 0, 17], ["atypical pathogens", "PROBLEM", 22, 40], ["Legionella species", "PROBLEM", 49, 67], ["convalescent titers", "PROBLEM", 95, 114], ["initial testing", "TEST", 160, 175], ["fever", "PROBLEM", 275, 280], ["shortness of breath", "PROBLEM", 282, 301], ["productive cough", "PROBLEM", 307, 323], ["fever", "OBSERVATION", 275, 280], ["productive", "OBSERVATION_MODIFIER", 307, 317], ["cough", "OBSERVATION", 318, 323]]], ["A month ago, he was hospitalized in the intensive care unit because of respiratory failure and was treated with broad-spectrum antibiotics.", [["respiratory", "ANATOMY", 71, 82], ["respiratory failure", "DISEASE", 71, 90], ["respiratory failure", "PROBLEM", 71, 90], ["broad-spectrum antibiotics", "TREATMENT", 112, 138], ["respiratory failure", "OBSERVATION", 71, 90]]], ["He was discharged in fair condition with antibiotics and steroid taper.", [["steroid", "CHEMICAL", 57, 64], ["steroid", "CHEMICAL", 57, 64], ["steroid", "SIMPLE_CHEMICAL", 57, 64], ["antibiotics", "TREATMENT", 41, 52], ["steroid taper", "TREATMENT", 57, 70]]], ["He has a history of chronic obstructive pulmonary disease.", [["pulmonary", "ANATOMY", 40, 49], ["chronic obstructive pulmonary disease", "DISEASE", 20, 57], ["pulmonary", "ORGAN", 40, 49], ["chronic obstructive pulmonary disease", "PROBLEM", 20, 57], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["obstructive", "OBSERVATION_MODIFIER", 28, 39], ["pulmonary", "ANATOMY", 40, 49], ["disease", "OBSERVATION", 50, 57]]], ["He has a 40-pack-year history of smoking.201.On physical examination, temperature is 38.6 \u00b0C (101.5 \u00b0F), blood pressure is 115/72 mmHg, pulse rate is 116/min, respiration rate is 27/min, and oxygen saturation is 89 % on ambient air.", [["blood", "ANATOMY", 105, 110], ["smoking", "CHEMICAL", 33, 40], ["oxygen", "CHEMICAL", 191, 197], ["oxygen", "CHEMICAL", 191, 197], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["oxygen", "SIMPLE_CHEMICAL", 191, 197], ["physical examination", "TEST", 48, 68], ["temperature", "TEST", 70, 81], ["\u00b0C", "TEST", 90, 92], ["blood pressure", "TEST", 105, 119], ["pulse rate", "TEST", 136, 146], ["respiration rate", "TEST", 159, 175], ["oxygen saturation", "TEST", 191, 208]]], ["Pulmonary examination shows crackles at the right base.201.The leukocyte count is 22,000/\u03bcL with 75 % segmented neutrophils and 10 % band forms.", [["Pulmonary", "ANATOMY", 0, 9], ["right base", "ANATOMY", 44, 54], ["leukocyte", "ANATOMY", 63, 72], ["neutrophils", "ANATOMY", 112, 123], ["Pulmonary", "ORGAN", 0, 9], ["leukocyte", "CELL", 63, 72], ["neutrophils", "CELL", 112, 123], ["neutrophils", "CELL_TYPE", 112, 123], ["Pulmonary examination", "TEST", 0, 21], ["crackles at the right base", "PROBLEM", 28, 54], ["The leukocyte count", "TEST", 59, 78], ["\u03bcL", "TEST", 89, 91], ["segmented neutrophils", "TEST", 102, 123], ["band forms", "TEST", 133, 143], ["crackles", "OBSERVATION", 28, 36], ["right", "ANATOMY_MODIFIER", 44, 49], ["base", "ANATOMY_MODIFIER", 50, 54], ["leukocyte count", "OBSERVATION", 63, 78]]], ["Chest radiograph shows a right lower lobe consolidation.", [["right lower lobe", "ANATOMY", 25, 41], ["right lower lobe consolidation", "DISEASE", 25, 55], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 31, 41], ["Chest radiograph", "TEST", 0, 16], ["a right lower lobe consolidation", "PROBLEM", 23, 55], ["right lower lobe", "ANATOMY", 25, 41], ["consolidation", "OBSERVATION", 42, 55]]], ["Blood cultures are obtained, and treatment with intravenous fl uids is initiated.201.Which of the following is the most appropriate empiric antibiotic treatment?", [["Blood cultures", "ANATOMY", 0, 14], ["fl uids", "CHEMICAL", 60, 67], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["intravenous fl uids", "SIMPLE_CHEMICAL", 48, 67], ["Blood cultures", "TEST", 0, 14], ["intravenous fl uids", "TREATMENT", 48, 67], ["appropriate empiric antibiotic treatment", "TREATMENT", 120, 160]]], ["A) Vancomycin and ciprofl oxacin B) Ceftriaxone and azithromycin C) Ceftriaxone and ciprofl oxacin D) Vancomycin, piperacillin/tazobactam, and amikacin Answer: D This patient is at high risk for Pseudomonas pneumonia.201.The most appropriate empiric antibiotic therapy for this patient is vancomycin, piperacillin/tazobactam, and amikacin.", [["Vancomycin", "CHEMICAL", 3, 13], ["ciprofl oxacin B", "CHEMICAL", 18, 34], ["Ceftriaxone", "CHEMICAL", 36, 47], ["azithromycin", "CHEMICAL", 52, 64], ["Ceftriaxone", "CHEMICAL", 68, 79], ["ciprofl oxacin D", "CHEMICAL", 84, 100], ["Vancomycin", "CHEMICAL", 102, 112], ["piperacillin/tazobactam", "CHEMICAL", 114, 137], ["amikacin", "CHEMICAL", 143, 151], ["Pseudomonas pneumonia", "DISEASE", 195, 216], ["vancomycin", "CHEMICAL", 289, 299], ["piperacillin/tazobactam", "CHEMICAL", 301, 324], ["amikacin", "CHEMICAL", 330, 338], ["Vancomycin", "CHEMICAL", 3, 13], ["ciprofl oxacin B", "CHEMICAL", 18, 34], ["Ceftriaxone", "CHEMICAL", 36, 47], ["azithromycin C", "CHEMICAL", 52, 66], ["Ceftriaxone", "CHEMICAL", 68, 79], ["ciprofl oxacin D", "CHEMICAL", 84, 100], ["Vancomycin", "CHEMICAL", 102, 112], ["piperacillin", "CHEMICAL", 114, 126], ["tazobactam", "CHEMICAL", 127, 137], ["amikacin", "CHEMICAL", 143, 151], ["D", "CHEMICAL", 160, 161], ["vancomycin", "CHEMICAL", 289, 299], ["piperacillin", "CHEMICAL", 301, 313], ["tazobactam", "CHEMICAL", 314, 324], ["amikacin", "CHEMICAL", 330, 338], ["Vancomycin", "SIMPLE_CHEMICAL", 3, 13], ["ciprofl oxacin B", "SIMPLE_CHEMICAL", 18, 34], ["Ceftriaxone", "SIMPLE_CHEMICAL", 36, 47], ["azithromycin C", "SIMPLE_CHEMICAL", 52, 66], ["Ceftriaxone", "SIMPLE_CHEMICAL", 68, 79], ["ciprofl oxacin D", "SIMPLE_CHEMICAL", 84, 100], ["Vancomycin", "SIMPLE_CHEMICAL", 102, 112], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 114, 137], ["amikacin", "SIMPLE_CHEMICAL", 143, 151], ["D", "SIMPLE_CHEMICAL", 160, 161], ["patient", "ORGANISM", 167, 174], ["patient", "ORGANISM", 278, 285], ["vancomycin", "SIMPLE_CHEMICAL", 289, 299], ["piperacillin/tazobactam", "SIMPLE_CHEMICAL", 301, 324], ["amikacin", "SIMPLE_CHEMICAL", 330, 338], ["patient", "SPECIES", 167, 174], ["patient", "SPECIES", 278, 285], ["Vancomycin", "TREATMENT", 3, 13], ["ciprofl oxacin B", "TREATMENT", 18, 34], ["Ceftriaxone", "TREATMENT", 36, 47], ["azithromycin C", "TREATMENT", 52, 66], ["Ceftriaxone", "TREATMENT", 68, 79], ["ciprofl oxacin D", "TREATMENT", 84, 100], ["Vancomycin", "TREATMENT", 102, 112], ["piperacillin", "TREATMENT", 114, 126], ["tazobactam", "TREATMENT", 127, 137], ["amikacin", "TREATMENT", 143, 151], ["Pseudomonas pneumonia", "PROBLEM", 195, 216], ["The most appropriate empiric antibiotic therapy", "TREATMENT", 221, 268], ["vancomycin", "TREATMENT", 289, 299], ["piperacillin", "TREATMENT", 301, 313], ["tazobactam", "TREATMENT", 314, 324], ["amikacin", "TREATMENT", 330, 338], ["Pseudomonas", "OBSERVATION_MODIFIER", 195, 206], ["pneumonia", "OBSERVATION", 207, 216]]], ["Pseudomonas pneumonia is observed in patients with immunosuppression and chronic lung disease.", [["lung", "ANATOMY", 81, 85], ["Pseudomonas pneumonia", "DISEASE", 0, 21], ["chronic lung disease", "DISEASE", 73, 93], ["patients", "ORGANISM", 37, 45], ["lung", "ORGAN", 81, 85], ["patients", "SPECIES", 37, 45], ["Pseudomonas pneumonia", "PROBLEM", 0, 21], ["immunosuppression", "TREATMENT", 51, 68], ["chronic lung disease", "PROBLEM", 73, 93], ["pneumonia", "OBSERVATION", 12, 21], ["immunosuppression", "OBSERVATION", 51, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["lung", "ANATOMY", 81, 85], ["disease", "OBSERVATION", 86, 93]]], ["It can be acquired nosocomially in the intensive care unit (ICU) setting and is associated with positivepressure ventilation and endotracheal tubes.", [["positivepressure ventilation", "TREATMENT", 96, 124], ["endotracheal tubes", "TREATMENT", 129, 147], ["endotracheal tubes", "OBSERVATION", 129, 147]]], ["Other risk factors for Pseudomonas pneumonia include broadspectrum antibiotic use in the previous month, recent hospitalization, malnutrition, neutropenia, and glucocorticoid use.", [["Pseudomonas pneumonia", "DISEASE", 23, 44], ["malnutrition", "DISEASE", 129, 141], ["neutropenia", "DISEASE", 143, 154], ["Pseudomonas pneumonia", "PROBLEM", 23, 44], ["broadspectrum antibiotic", "TREATMENT", 53, 77], ["malnutrition", "PROBLEM", 129, 141], ["neutropenia", "PROBLEM", 143, 154], ["glucocorticoid use", "TREATMENT", 160, 178], ["Pseudomonas", "OBSERVATION_MODIFIER", 23, 34], ["pneumonia", "OBSERVATION", 35, 44], ["malnutrition", "OBSERVATION", 129, 141], ["neutropenia", "OBSERVATION", 143, 154], ["glucocorticoid use", "OBSERVATION", 160, 178]]], ["Most guidelines recommend starting with two anti pseudomonal antibiotics and then de-escalating to monotherapy in fi ve days.", [["two anti pseudomonal antibiotics", "TREATMENT", 40, 72], ["monotherapy", "TREATMENT", 99, 110]]], ["It remains controversial whether combination therapy is more effi cacious than monotherapy.", [["combination therapy", "TREATMENT", 33, 52], ["monotherapy", "TREATMENT", 79, 90]]], ["Combination therapy has been recommended to broaden the empiric coverage and prevent the emergence of antibiotic resistance during therapy.202.A 75-year-old man is admitted for a 2-day history of fever, vomiting, and dysuria.", [["fever", "DISEASE", 196, 201], ["vomiting", "DISEASE", 203, 211], ["dysuria", "DISEASE", 217, 224], ["man", "ORGANISM", 157, 160], ["man", "SPECIES", 157, 160], ["Combination therapy", "TREATMENT", 0, 19], ["the empiric coverage", "TREATMENT", 52, 72], ["antibiotic resistance during therapy", "TREATMENT", 102, 138], ["fever", "PROBLEM", 196, 201], ["vomiting", "PROBLEM", 203, 211], ["dysuria", "PROBLEM", 217, 224], ["antibiotic resistance", "OBSERVATION", 102, 123], ["fever", "OBSERVATION", 196, 201], ["dysuria", "OBSERVATION", 217, 224]]], ["He has a history of prostatic hypertrophy.", [["prostatic", "ANATOMY", 20, 29], ["prostatic hypertrophy", "DISEASE", 20, 41], ["prostatic", "ORGAN", 20, 29], ["prostatic hypertrophy", "PROBLEM", 20, 41], ["prostatic", "ANATOMY", 20, 29], ["hypertrophy", "OBSERVATION", 30, 41]]], ["On physical examination, temperature is 39.0 \u00b0C (102.2 \u00b0F), blood pressure is 100/60 mmHg, and pulse rate is 122/min.", [["blood", "ANATOMY", 60, 65], ["blood", "ORGANISM_SUBSTANCE", 60, 65], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["\u00b0C", "TEST", 45, 47], ["blood pressure", "TEST", 60, 74], ["pulse rate", "TEST", 95, 105]]], ["Suprapubic tenderness is present.", [["tenderness", "DISEASE", 11, 21], ["Suprapubic tenderness", "PROBLEM", 0, 21], ["tenderness", "OBSERVATION", 11, 21]]], ["Careful rectal examination shows an enlarged and extremely tender prostate.202.Laboratory studies show a leukocyte count of 19,000/\u03bcL with 70 % segmented neutrophils.", [["rectal", "ANATOMY", 8, 14], ["tender prostate", "ANATOMY", 59, 74], ["leukocyte", "ANATOMY", 105, 114], ["neutrophils", "ANATOMY", 154, 165], ["rectal", "ORGAN", 8, 14], ["tender prostate", "CANCER", 59, 74], ["leukocyte", "CELL", 105, 114], ["neutrophils", "CELL", 154, 165], ["neutrophils", "CELL_TYPE", 154, 165], ["Careful rectal examination", "TEST", 0, 26], ["an enlarged and extremely tender prostate", "PROBLEM", 33, 74], ["Laboratory studies", "TEST", 79, 97], ["a leukocyte count", "TEST", 103, 120], ["\u03bcL", "TEST", 131, 133], ["segmented neutrophils", "TEST", 144, 165], ["rectal", "ANATOMY", 8, 14], ["enlarged", "OBSERVATION", 36, 44], ["extremely", "OBSERVATION_MODIFIER", 49, 58], ["tender", "OBSERVATION", 59, 65], ["prostate", "ANATOMY", 66, 74]]], ["Urinalysis shows more than 50 leukocytes/highpower fi eld and many bacteria.", [["leukocytes", "ANATOMY", 30, 40], ["leukocytes", "CELL", 30, 40], ["highpower fi eld", "CELL", 41, 57], ["leukocytes", "CELL_TYPE", 30, 40], ["Urinalysis", "TEST", 0, 10], ["leukocytes", "TEST", 30, 40], ["highpower fi eld", "PROBLEM", 41, 57], ["many bacteria", "PROBLEM", 62, 75], ["many", "OBSERVATION_MODIFIER", 62, 66], ["bacteria", "OBSERVATION", 67, 75]]], ["The serum creatinine level is normal.202.Treatment with intravenous fl uids and parenteral ciprofl oxacin is started.", [["serum", "ANATOMY", 4, 9], ["intravenous", "ANATOMY", 56, 67], ["creatinine", "CHEMICAL", 10, 20], ["fl uids", "CHEMICAL", 68, 75], ["ciprofl oxacin", "CHEMICAL", 91, 105], ["creatinine", "CHEMICAL", 10, 20], ["ciprofl oxacin", "CHEMICAL", 91, 105], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["creatinine", "GENE_OR_GENE_PRODUCT", 10, 20], ["intravenous fl uids", "SIMPLE_CHEMICAL", 56, 75], ["parenteral ciprofl oxacin", "SIMPLE_CHEMICAL", 80, 105], ["The serum creatinine level", "TEST", 0, 26], ["intravenous fl uids", "TREATMENT", 56, 75], ["parenteral ciprofl oxacin", "TREATMENT", 80, 105], ["normal", "OBSERVATION", 30, 36]]], ["Urine culture grows Escherichia coli sensitive to fl uoroquinolones.", [["Urine culture", "ANATOMY", 0, 13], ["fl uoroquinolones", "CHEMICAL", 50, 67], ["uoroquinolones", "CHEMICAL", 53, 67], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["Escherichia coli", "ORGANISM", 20, 36], ["fl uoroquinolones", "SIMPLE_CHEMICAL", 50, 67], ["Escherichia coli", "SPECIES", 20, 36], ["Escherichia coli", "SPECIES", 20, 36], ["Urine culture", "TEST", 0, 13], ["Escherichia coli", "PROBLEM", 20, 36], ["fl uoroquinolones", "TREATMENT", 50, 67], ["Escherichia coli", "OBSERVATION", 20, 36]]], ["Three days after admission, the patient continues to have fever.", [["fever", "DISEASE", 58, 63], ["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["fever", "PROBLEM", 58, 63], ["fever", "OBSERVATION", 58, 63]]], ["He develops abdominal and perineal pain.", [["abdominal", "ANATOMY", 12, 21], ["perineal", "ANATOMY", 26, 34], ["abdominal and perineal pain", "DISEASE", 12, 39], ["abdominal", "ORGANISM_SUBDIVISION", 12, 21], ["perineal", "ORGANISM_SUBDIVISION", 26, 34], ["abdominal and perineal pain", "PROBLEM", 12, 39], ["abdominal", "ANATOMY", 12, 21], ["perineal", "ANATOMY", 26, 34], ["pain", "OBSERVATION", 35, 39]]], ["A repeat leukocyte count shows a result of 19,000/\u03bcL.202.What should be done next?", [["leukocyte", "ANATOMY", 9, 18], ["leukocyte", "CELL", 9, 18], ["A repeat leukocyte count", "TEST", 0, 24]]], ["A) Discontinue ciprofl oxacin and start gentamicin.", [["ciprofl oxacin", "CHEMICAL", 15, 29], ["gentamicin", "CHEMICAL", 40, 50], ["ciprofl oxacin", "CHEMICAL", 15, 29], ["gentamicin", "CHEMICAL", 40, 50], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 15, 29], ["gentamicin", "SIMPLE_CHEMICAL", 40, 50], ["ciprofl oxacin", "TREATMENT", 15, 29], ["gentamicin", "TREATMENT", 40, 50]]], ["B) Insert a catheter for bladder drainage.", [["bladder", "ANATOMY", 25, 32], ["bladder", "ORGAN", 25, 32], ["Insert a catheter", "TREATMENT", 3, 20], ["bladder drainage", "TREATMENT", 25, 41], ["catheter", "OBSERVATION", 12, 20], ["bladder", "ANATOMY", 25, 32], ["drainage", "OBSERVATION", 33, 41]]], ["C) Renal ultrasound.", [["Renal", "ANATOMY", 3, 8], ["Renal", "ORGAN", 3, 8], ["Renal ultrasound", "TEST", 3, 19], ["Renal", "ANATOMY", 3, 8]]], ["D) Obtain a transrectal ultrasound.", [["transrectal", "ANATOMY", 12, 23], ["a transrectal ultrasound", "TEST", 10, 34]]], ["E) Perform prostate massage.202.Answer: D The patient presents with a clinical picture that is consistent with acute prostatitis.", [["prostate", "ANATOMY", 11, 19], ["prostatitis", "DISEASE", 117, 128], ["prostate", "ORGAN", 11, 19], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["prostate massage", "TREATMENT", 11, 27], ["a clinical picture", "PROBLEM", 68, 86], ["acute prostatitis", "PROBLEM", 111, 128], ["prostate", "ANATOMY", 11, 19], ["massage", "OBSERVATION", 20, 27], ["consistent with", "UNCERTAINTY", 95, 110], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["prostatitis", "OBSERVATION", 117, 128]]], ["If there is no clinical improvement after 36 to 72 h of treatment, the most likely cause is a complication, such as a prostatic abscess.", [["prostatic abscess", "ANATOMY", 118, 135], ["prostatic abscess", "DISEASE", 118, 135], ["prostatic abscess", "PATHOLOGICAL_FORMATION", 118, 135], ["treatment", "TREATMENT", 56, 65], ["a complication", "PROBLEM", 92, 106], ["a prostatic abscess", "PROBLEM", 116, 135], ["no", "UNCERTAINTY", 12, 14], ["most likely", "UNCERTAINTY", 71, 82], ["complication", "OBSERVATION", 94, 106], ["prostatic", "ANATOMY", 118, 127], ["abscess", "OBSERVATION", 128, 135]]], ["Appropriate management for this patient is a transrectal ultrasound to evaluate for a prostatic abscess.", [["transrectal", "ANATOMY", 45, 56], ["prostatic abscess", "ANATOMY", 86, 103], ["prostatic abscess", "DISEASE", 86, 103], ["patient", "ORGANISM", 32, 39], ["prostatic abscess", "PATHOLOGICAL_FORMATION", 86, 103], ["patient", "SPECIES", 32, 39], ["Appropriate management", "TREATMENT", 0, 22], ["a transrectal ultrasound", "TEST", 43, 67], ["a prostatic abscess", "PROBLEM", 84, 103], ["prostatic", "ANATOMY", 86, 95], ["abscess", "OBSERVATION", 96, 103]]], ["If a prostatic abscess is identifi ed, ultrasound-guided or surgical drainage may be indicated.", [["prostatic abscess", "ANATOMY", 5, 22], ["prostatic abscess", "DISEASE", 5, 22], ["prostatic abscess", "PATHOLOGICAL_FORMATION", 5, 22], ["a prostatic abscess", "PROBLEM", 3, 22], ["ultrasound", "TEST", 39, 49], ["surgical drainage", "TREATMENT", 60, 77], ["prostatic", "ANATOMY", 5, 14], ["abscess", "OBSERVATION", 15, 22]]], ["Causative organisms of acute prostatitis in older men are usually Gram-negative bacteria, with Escherichia coli being the most common.", [["prostatitis", "DISEASE", 29, 40], ["men", "ORGANISM", 50, 53], ["Escherichia coli", "ORGANISM", 95, 111], ["men", "SPECIES", 50, 53], ["Escherichia coli", "SPECIES", 95, 111], ["Escherichia coli", "SPECIES", 95, 111], ["acute prostatitis", "PROBLEM", 23, 40], ["Gram-negative bacteria", "PROBLEM", 66, 88], ["Escherichia coli", "PROBLEM", 95, 111], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["prostatitis", "OBSERVATION", 29, 40], ["negative bacteria", "OBSERVATION", 71, 88], ["Escherichia coli", "OBSERVATION", 95, 111], ["most common", "OBSERVATION_MODIFIER", 122, 133]]], ["Transurethral catheterization should be avoided in acute prostatitis.", [["prostatitis", "DISEASE", 57, 68], ["Transurethral catheterization", "TREATMENT", 0, 29], ["acute prostatitis", "PROBLEM", 51, 68], ["catheterization", "OBSERVATION", 14, 29], ["should be avoided", "UNCERTAINTY", 30, 47], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["prostatitis", "OBSERVATION", 57, 68]]], ["If bladder drainage is necessary, suprapubic drainage may be considered to reduce the risk of prostatic abscess and septicemia.", [["bladder", "ANATOMY", 3, 10], ["suprapubic", "ANATOMY", 34, 44], ["prostatic abscess", "ANATOMY", 94, 111], ["prostatic abscess", "DISEASE", 94, 111], ["septicemia", "DISEASE", 116, 126], ["bladder", "ORGAN", 3, 10], ["prostatic abscess", "PATHOLOGICAL_FORMATION", 94, 111], ["bladder drainage", "TREATMENT", 3, 19], ["suprapubic drainage", "TREATMENT", 34, 53], ["prostatic abscess", "PROBLEM", 94, 111], ["septicemia", "PROBLEM", 116, 126], ["bladder", "ANATOMY", 3, 10], ["drainage", "OBSERVATION", 11, 19], ["suprapubic", "ANATOMY", 34, 44], ["drainage", "OBSERVATION", 45, 53], ["prostatic", "ANATOMY", 94, 103], ["abscess", "OBSERVATION", 104, 111], ["septicemia", "OBSERVATION", 116, 126]]], ["Furthermore, there is no indication for placement of a bladder catheter, such as outfl ow obstruction.", [["bladder", "ANATOMY", 55, 62], ["obstruction", "DISEASE", 90, 101], ["bladder", "ORGAN", 55, 62], ["placement", "TREATMENT", 40, 49], ["a bladder catheter", "TREATMENT", 53, 71], ["outfl ow obstruction", "PROBLEM", 81, 101], ["no indication for", "UNCERTAINTY", 22, 39], ["bladder", "ANATOMY", 55, 62], ["catheter", "OBSERVATION", 63, 71], ["obstruction", "OBSERVATION", 90, 101]]], ["At one time prostate massage was believed to be therapeutically useful as a treatment for acute prostatitis.202.Vigorous massage of the prostate should be avoided in acute prostatitis.", [["prostate", "ANATOMY", 12, 20], ["prostate", "ANATOMY", 136, 144], ["prostatitis", "DISEASE", 96, 107], ["prostatitis", "DISEASE", 172, 183], ["prostate", "ORGAN", 12, 20], ["prostate", "ORGAN", 136, 144], ["prostate massage", "TREATMENT", 12, 28], ["a treatment", "TREATMENT", 74, 85], ["acute prostatitis", "PROBLEM", 90, 107], ["Vigorous massage of the prostate", "TREATMENT", 112, 144], ["acute prostatitis", "PROBLEM", 166, 183], ["prostate", "ANATOMY", 12, 20], ["massage", "OBSERVATION", 21, 28], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["prostatitis", "OBSERVATION", 96, 107], ["massage", "OBSERVATION", 121, 128], ["prostate", "ANATOMY", 136, 144], ["should be avoided", "UNCERTAINTY", 145, 162], ["acute", "OBSERVATION_MODIFIER", 166, 171], ["prostatitis", "OBSERVATION", 172, 183]]], ["It is not helpful diagnostically or therapeutically.ReferenceLudwig M, Schroeder-Printzen I, Schiefer HG, Weidner W. Diagnosis and therapeutic management of 18 patients with prostatic abscess.", [["prostatic abscess", "ANATOMY", 174, 191], ["prostatic abscess", "DISEASE", 174, 191], ["patients", "ORGANISM", 160, 168], ["prostatic abscess", "PATHOLOGICAL_FORMATION", 174, 191], ["patients", "SPECIES", 160, 168], ["therapeutic management", "TREATMENT", 131, 153], ["prostatic abscess", "PROBLEM", 174, 191], ["not helpful", "UNCERTAINTY", 6, 17], ["prostatic", "ANATOMY", 174, 183], ["abscess", "OBSERVATION", 184, 191]]], ["An 88-year-old woman has been admitted for a lower gastrointestinal bleed.", [["lower gastrointestinal", "ANATOMY", 45, 67], ["lower gastrointestinal bleed", "DISEASE", 45, 73], ["woman", "ORGANISM", 15, 20], ["gastrointestinal", "ORGANISM_SUBDIVISION", 51, 67], ["woman", "SPECIES", 15, 20], ["a lower gastrointestinal bleed", "PROBLEM", 43, 73], ["lower", "ANATOMY_MODIFIER", 45, 50], ["gastrointestinal", "ANATOMY", 51, 67], ["bleed", "OBSERVATION", 68, 73]]], ["She is found by imaging and colonoscopy to have a localized adenocarcinoma.", [["adenocarcinoma", "ANATOMY", 60, 74], ["adenocarcinoma", "DISEASE", 60, 74], ["adenocarcinoma", "CANCER", 60, 74], ["imaging", "TEST", 16, 23], ["colonoscopy", "TEST", 28, 39], ["a localized adenocarcinoma", "PROBLEM", 48, 74], ["localized", "OBSERVATION_MODIFIER", 50, 59], ["adenocarcinoma", "OBSERVATION", 60, 74]]], ["Surgery is offered to the patient who is receiving guidance from her family.", [["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["Surgery", "TREATMENT", 0, 7]]], ["The patient manages some of her activities of daily living but has help from her daughter.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Current medications are metoprolol 25 mg twice daily and acetaminophen 325 mg twice daily as needed.", [["metoprolol", "CHEMICAL", 24, 34], ["acetaminophen", "CHEMICAL", 57, 70], ["metoprolol", "CHEMICAL", 24, 34], ["acetaminophen", "CHEMICAL", 57, 70], ["metoprolol", "SIMPLE_CHEMICAL", 24, 34], ["acetaminophen", "SIMPLE_CHEMICAL", 57, 70], ["Current medications", "TREATMENT", 0, 19], ["metoprolol", "TREATMENT", 24, 34], ["acetaminophen", "TREATMENT", 57, 70]]], ["The patient's weight is 50 kg (110 lb) and height is 160 cm (5 ft 3 in).ReferenceOn physical examination, the patient is alert.", [["patient", "ORGANISM", 4, 11], ["patient", "ORGANISM", 110, 117], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 110, 117], ["The patient's weight", "TEST", 0, 20], ["height", "TEST", 43, 49], ["ReferenceOn physical examination", "TEST", 72, 104], ["160 cm", "OBSERVATION_MODIFIER", 53, 59]]], ["Heart rate is 80 beats per minute, and blood pressure is 140/70 mmHg.", [["Heart", "ANATOMY", 0, 5], ["blood", "ANATOMY", 39, 44], ["Heart", "ORGAN", 0, 5], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["Heart rate", "TEST", 0, 10], ["blood pressure", "TEST", 39, 53]]], ["The abdomen is soft and nontender.", [["abdomen", "ANATOMY", 4, 11], ["abdomen", "ORGAN", 4, 11], ["nontender", "PROBLEM", 24, 33], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33]]], ["On neurologic examination, the patient is oriented to person and place but seems confused concerning the issues of surgery.", [["neurologic", "ANATOMY", 3, 13], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["person", "SPECIES", 54, 60], ["neurologic examination", "TEST", 3, 25], ["confused", "PROBLEM", 81, 89], ["surgery", "TREATMENT", 115, 122], ["surgery", "OBSERVATION", 115, 122]]], ["There is mild weakness of the hip fl exors, and normal sensation and refl exes.", [["hip", "ANATOMY", 30, 33], ["mild weakness of the hip fl exors", "PROBLEM", 9, 42], ["mild", "OBSERVATION_MODIFIER", 9, 13], ["weakness", "OBSERVATION", 14, 22], ["hip", "ANATOMY", 30, 33], ["fl", "ANATOMY_MODIFIER", 34, 36], ["normal", "OBSERVATION", 48, 54]]], ["Before making the decision to have surgery, the family would like to know the risks of postsurgical complications.ReferenceWhich of the following would best help you determine this patient's risk of complications after surgery?", [["patient", "ORGANISM", 181, 188], ["patient", "SPECIES", 181, 188], ["surgery", "TREATMENT", 35, 42], ["postsurgical complications", "PROBLEM", 87, 113], ["complications", "PROBLEM", 199, 212], ["surgery", "TREATMENT", 219, 226]]], ["A) Urinalysis B) Radiograph of the chest C) 12-lead electrocardiogram D) Physical therapy consult E) Mini mental status exam testing (MMSE)ReferenceAnswer: E The most important predictor of functional decline following surgery in the older population is the patient's preexisting mental status.", [["chest", "ANATOMY", 35, 40], ["patient", "ORGANISM", 258, 265], ["patient", "SPECIES", 258, 265], ["A) Urinalysis", "TEST", 0, 13], ["Radiograph of the chest C", "TEST", 17, 42], ["Mini mental status exam testing", "TEST", 101, 132], ["functional decline", "PROBLEM", 190, 208], ["surgery", "TREATMENT", 219, 226], ["chest", "ANATOMY", 35, 40]]], ["MMSE scores of 28 or less are associated with more than a twofold increased risk of developing postoperative delirium.", [["postoperative delirium", "DISEASE", 95, 117], ["MMSE scores", "TEST", 0, 11], ["postoperative delirium", "PROBLEM", 95, 117], ["postoperative delirium", "OBSERVATION", 95, 117]]], ["The exact correlation with long-term functional and cognitive decline is uncertain.", [["cognitive decline", "DISEASE", 52, 69], ["long-term functional and cognitive decline", "PROBLEM", 27, 69]]], ["Sharing these factors with families may assist in decisionmaking and acceptance of postoperative cognitive decline.Referencemedical history of chronic obstructive pulmonary disease.", [["pulmonary", "ANATOMY", 163, 172], ["postoperative cognitive decline", "DISEASE", 83, 114], ["chronic obstructive pulmonary disease", "DISEASE", 143, 180], ["pulmonary", "ORGAN", 163, 172], ["postoperative cognitive decline", "PROBLEM", 83, 114], ["chronic obstructive pulmonary disease", "PROBLEM", 143, 180], ["chronic", "OBSERVATION_MODIFIER", 143, 150], ["obstructive", "OBSERVATION_MODIFIER", 151, 162], ["pulmonary", "ANATOMY", 163, 172], ["disease", "OBSERVATION", 173, 180]]], ["Vasopressors were needed but now have been stopped.", [["Vasopressors", "TREATMENT", 0, 12]]], ["The patient now has fl uctuating level of consciousness.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She has no prior history of dementia.", [["dementia", "DISEASE", 28, 36], ["dementia", "PROBLEM", 28, 36], ["no", "UNCERTAINTY", 8, 10], ["dementia", "OBSERVATION", 28, 36]]], ["She does not consistently follow commands and, at times, appears confused.", [["confused", "PROBLEM", 65, 73]]], ["She has no focal neurologic fi ndings.", [["neurologic", "ANATOMY", 17, 27], ["focal neurologic fi ndings", "PROBLEM", 11, 37], ["no", "UNCERTAINTY", 8, 10], ["focal", "OBSERVATION_MODIFIER", 11, 16]]], ["Her lungs are cleared upon auscultation.", [["lungs", "ANATOMY", 4, 9], ["lungs", "ORGAN", 4, 9], ["auscultation", "TEST", 27, 39], ["lungs", "ANATOMY", 4, 9], ["cleared", "OBSERVATION", 14, 21]]], ["The last time that she received a narcotic and sedatives was in the ICU 2 days ago.", [["a narcotic", "TREATMENT", 32, 42], ["sedatives", "TREATMENT", 47, 56]]], ["A) Obtain an electroencephalogram.", [["an electroencephalogram", "TEST", 10, 33]]], ["B) Obtain a computed tomography scan of the head.", [["head", "ANATOMY", 44, 48], ["head", "ORGANISM_SUBDIVISION", 44, 48], ["a computed tomography scan of the head", "TEST", 10, 48], ["head", "ANATOMY", 44, 48]]], ["C) Start an antipsychotic medication.", [["an antipsychotic medication", "TREATMENT", 9, 36]]], ["D) Start a benzodiazepine.", [["benzodiazepine", "CHEMICAL", 11, 25], ["benzodiazepine", "CHEMICAL", 11, 25], ["a benzodiazepine", "TREATMENT", 9, 25]]], ["E) Rapidly taper the corticosteroids.ReferenceAnswer: E Corticosteroids are associated with delirium and when possible should be either rapidly tapered or stopped.", [["delirium", "DISEASE", 92, 100], ["corticosteroids", "CHEMICAL", 21, 36], ["Rapidly taper the corticosteroids", "TREATMENT", 3, 36], ["E Corticosteroids", "TREATMENT", 54, 71], ["delirium", "PROBLEM", 92, 100], ["Rapidly", "OBSERVATION_MODIFIER", 3, 10], ["taper", "OBSERVATION_MODIFIER", 11, 16]]], ["In this patient, no clear indication exists for continued steroid use and rapid taper may resolve the delirium.", [["steroid", "CHEMICAL", 58, 65], ["delirium", "DISEASE", 102, 110], ["steroid", "CHEMICAL", 58, 65], ["patient", "ORGANISM", 8, 15], ["steroid", "SIMPLE_CHEMICAL", 58, 65], ["patient", "SPECIES", 8, 15], ["continued steroid use", "TREATMENT", 48, 69], ["rapid taper", "TREATMENT", 74, 85], ["the delirium", "PROBLEM", 98, 110]]], ["Steroid psychosis may be dose dependent.", [["psychosis", "DISEASE", 8, 17], ["Steroid", "CHEMICAL", 0, 7], ["Steroid", "SIMPLE_CHEMICAL", 0, 7], ["Steroid psychosis", "PROBLEM", 0, 17], ["dose dependent", "PROBLEM", 25, 39], ["may be", "UNCERTAINTY", 18, 24], ["dose dependent", "OBSERVATION_MODIFIER", 25, 39]]], ["In one study patients receiving more than 80 mg/day of prednisone or its equivalent had an 18.4 % incidence of steroid psychosis.", [["prednisone", "CHEMICAL", 55, 65], ["steroid", "CHEMICAL", 111, 118], ["psychosis", "DISEASE", 119, 128], ["prednisone", "CHEMICAL", 55, 65], ["steroid", "CHEMICAL", 111, 118], ["patients", "ORGANISM", 13, 21], ["prednisone", "SIMPLE_CHEMICAL", 55, 65], ["patients", "SPECIES", 13, 21], ["prednisone", "TREATMENT", 55, 65], ["steroid psychosis", "PROBLEM", 111, 128], ["steroid psychosis", "OBSERVATION", 111, 128]]], ["Which of the following noninvasive tests is the best way to screen for infl ammatory bowel disease in a patient such as this?", [["bowel", "ANATOMY", 85, 90], ["ammatory bowel disease", "DISEASE", 76, 98], ["bowel", "ORGAN", 85, 90], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["noninvasive tests", "TEST", 23, 40], ["infl ammatory bowel disease", "PROBLEM", 71, 98], ["bowel", "ANATOMY", 85, 90], ["disease", "OBSERVATION", 91, 98]]], ["A) ASCA and ANCA B) ASCA and anti-CBIR1 C) ASCA and anti-OmpC D) NOD-2 SNP testing E) Fecal calprotectin Answer: A Currently, no laboratory test is specifi c enough to adequately and defi nitively establish the diagnosis of IBD.", [["SNP", "CHEMICAL", 71, 74], ["IBD", "DISEASE", 224, 227], ["anti-OmpC D", "GENE_OR_GENE_PRODUCT", 52, 63], ["ASCA", "PROTEIN", 3, 7], ["ANCA B", "PROTEIN", 12, 18], ["ASCA", "PROTEIN", 20, 24], ["anti-CBIR1 C", "PROTEIN", 29, 41], ["ASCA", "PROTEIN", 43, 47], ["OmpC D", "PROTEIN", 57, 63], ["NOD", "PROTEIN", 65, 68], ["ANCA B)", "TREATMENT", 12, 19], ["ASCA and anti-CBIR1 C", "TREATMENT", 20, 41], ["ASCA and anti-OmpC D)", "TREATMENT", 43, 64], ["laboratory test", "TEST", 129, 144], ["IBD", "PROBLEM", 224, 227], ["Fecal", "ANATOMY", 86, 91], ["IBD", "OBSERVATION", 224, 227]]], ["Anti-Saccharomyces cerevisiae antibodies(ASCA) is the most sensitive serologic marker of Crohn's disease.", [["Crohn's disease", "DISEASE", 89, 104], ["Saccharomyces cerevisiae antibodies", "GENE_OR_GENE_PRODUCT", 5, 40], ["ASCA", "GENE_OR_GENE_PRODUCT", 41, 45], ["Crohn's disease", "CANCER", 89, 104], ["Anti-Saccharomyces cerevisiae antibodies", "PROTEIN", 0, 40], ["ASCA", "PROTEIN", 41, 45], ["Saccharomyces cerevisiae", "SPECIES", 5, 29], ["Saccharomyces cerevisiae", "SPECIES", 5, 29], ["Anti-Saccharomyces cerevisiae antibodies", "TEST", 0, 40], ["Crohn's disease", "PROBLEM", 89, 104], ["cerevisiae antibodies", "OBSERVATION", 19, 40], ["Crohn", "OBSERVATION", 89, 94]]], ["Antineutrophil cytoplasmic antibodies (pANCA) are a serologic marker of patients with ulcerative colitis.", [["ulcerative", "ANATOMY", 86, 96], ["ulcerative colitis", "DISEASE", 86, 104], ["Antineutrophil cytoplasmic antibodies", "GENE_OR_GENE_PRODUCT", 0, 37], ["pANCA", "GENE_OR_GENE_PRODUCT", 39, 44], ["patients", "ORGANISM", 72, 80], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 86, 104], ["Antineutrophil cytoplasmic antibodies", "PROTEIN", 0, 37], ["pANCA", "PROTEIN", 39, 44], ["patients", "SPECIES", 72, 80], ["Antineutrophil cytoplasmic antibodies", "TEST", 0, 37], ["pANCA", "TEST", 39, 44], ["a serologic marker", "TEST", 50, 68], ["ulcerative colitis", "PROBLEM", 86, 104], ["cytoplasmic antibodies", "OBSERVATION", 15, 37], ["ulcerative", "OBSERVATION_MODIFIER", 86, 96], ["colitis", "OBSERVATION", 97, 104]]], ["The combination of positive pANCA and negative ASCA has high specifi city for ulcerative colitis, whereas a positive ASCA and negative pANCA are more specifi c for Crohn's disease.", [["ulcerative", "ANATOMY", 78, 88], ["ulcerative colitis", "DISEASE", 78, 96], ["Crohn's disease", "DISEASE", 164, 179], ["pANCA", "GENE_OR_GENE_PRODUCT", 28, 33], ["ASCA", "GENE_OR_GENE_PRODUCT", 47, 51], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 78, 96], ["ASCA", "GENE_OR_GENE_PRODUCT", 117, 121], ["positive pANCA", "PROTEIN", 19, 33], ["ASCA", "PROTEIN", 47, 51], ["ASCA", "PROTEIN", 117, 121], ["negative pANCA", "PROTEIN", 126, 140], ["positive pANCA", "PROBLEM", 19, 33], ["ulcerative colitis", "PROBLEM", 78, 96], ["a positive ASCA", "PROBLEM", 106, 121], ["Crohn's disease", "PROBLEM", 164, 179], ["positive", "OBSERVATION_MODIFIER", 19, 27], ["pANCA", "OBSERVATION", 28, 33], ["ulcerative", "OBSERVATION_MODIFIER", 78, 88], ["colitis", "OBSERVATION", 89, 96], ["pANCA", "OBSERVATION", 135, 140]]], ["There primary use has been in differentiating Crohn's from ulcerative colitis and occasionally as a screening test in select patients.", [["ulcerative", "ANATOMY", 59, 69], ["Crohn's from ulcerative colitis", "DISEASE", 46, 77], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 59, 77], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["Crohn's", "PROBLEM", 46, 53], ["ulcerative colitis", "PROBLEM", 59, 77], ["a screening test", "TEST", 98, 114], ["Crohn", "OBSERVATION", 46, 51], ["ulcerative", "OBSERVATION_MODIFIER", 59, 69], ["colitis", "OBSERVATION", 70, 77]]], ["Answer: D Chikungunya fever is a self-remitting febrile viral illness that has been associated with frequent outbreaks in tropical countries and returning travelers.", [["Chikungunya fever", "DISEASE", 10, 27], ["febrile viral illness", "DISEASE", 48, 69], ["D Chikungunya", "ORGANISM", 8, 21], ["D Chikungunya fever", "PROBLEM", 8, 27], ["a self-remitting febrile viral illness", "PROBLEM", 31, 69]]], ["The illness has recently become a concern in Western countries and temperate zones around the world.", [["illness", "DISEASE", 4, 11], ["illness", "OBSERVATION", 4, 11]]], ["International travel is one of the major risk factors for the rapid global spread of the disease.", [["the rapid global spread of the disease", "PROBLEM", 58, 96], ["rapid", "OBSERVATION_MODIFIER", 62, 67], ["global", "OBSERVATION_MODIFIER", 68, 74], ["spread", "OBSERVATION", 75, 81], ["disease", "OBSERVATION", 89, 96]]], ["Patients present with abrupt onset of infl uenza type symptoms.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["infl uenza type symptoms", "PROBLEM", 38, 62], ["abrupt", "OBSERVATION_MODIFIER", 22, 28]]], ["Fever can reach up to 40.5 \u00b0C (105\u00b0), with shaking chills that last 2-3 days.", [["Fever", "DISEASE", 0, 5], ["chills", "DISEASE", 51, 57], ["Fever", "PROBLEM", 0, 5], ["shaking chills", "PROBLEM", 43, 57]]], ["The fever may return after an afebrile period of 4-10 days.", [["fever", "DISEASE", 4, 9], ["The fever", "PROBLEM", 0, 9], ["fever", "OBSERVATION", 4, 9]]], ["Chikungunya infection is confi rmed via serological tests, which take about 5-7 after the onset of symptoms.", [["Chikungunya infection", "DISEASE", 0, 21], ["Chikungunya", "ORGANISM", 0, 11], ["Chikungunya infection", "PROBLEM", 0, 21], ["serological tests", "TEST", 40, 57], ["symptoms", "PROBLEM", 99, 107], ["infection", "OBSERVATION", 12, 21]]], ["Severe arthralgia is best managed with nonsteroidal antiinfl ammatory drugs (NSAIDS) and early physical therapy.", [["nonsteroidal", "ANATOMY", 39, 51], ["arthralgia", "DISEASE", 7, 17], ["nonsteroidal antiinfl ammatory drugs", "SIMPLE_CHEMICAL", 39, 75], ["Severe arthralgia", "PROBLEM", 0, 17], ["nonsteroidal antiinfl ammatory drugs", "TREATMENT", 39, 75], ["NSAIDS", "TREATMENT", 77, 83], ["early physical therapy", "TREATMENT", 89, 111], ["arthralgia", "OBSERVATION", 7, 17]]], ["Ribavirin and steroids have been used but no studies have proven their benefi t.", [["Ribavirin", "CHEMICAL", 0, 9], ["steroids", "CHEMICAL", 14, 22], ["Ribavirin", "CHEMICAL", 0, 9], ["steroids", "CHEMICAL", 14, 22], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["steroids", "SIMPLE_CHEMICAL", 14, 22], ["Ribavirin", "TREATMENT", 0, 9], ["steroids", "TREATMENT", 14, 22], ["studies", "TEST", 45, 52]]], ["As of September 2014, there have been seven confi rmed cases of chikungunya in the United States in people who had acquired the disease locally.ReferenceMcCarthy M. First case of locally acquired chikungunya is reported in US.", [["chikungunya", "DISEASE", 64, 75], ["chikungunya", "DISEASE", 196, 207], ["people", "ORGANISM", 100, 106], ["chikungunya", "ORGANISM", 196, 207], ["people", "SPECIES", 100, 106], ["chikungunya", "PROBLEM", 64, 75], ["the disease locally", "PROBLEM", 124, 143], ["locally acquired chikungunya", "PROBLEM", 179, 207], ["chikungunya", "OBSERVATION", 64, 75], ["disease", "OBSERVATION", 128, 135], ["chikungunya", "OBSERVATION", 196, 207]]], ["A 46-year-old man presents with cough, fever, and sputum production.", [["sputum", "ANATOMY", 50, 56], ["cough", "DISEASE", 32, 37], ["fever", "DISEASE", 39, 44], ["man", "ORGANISM", 14, 17], ["sputum", "ORGANISM_SUBSTANCE", 50, 56], ["man", "SPECIES", 14, 17], ["cough", "PROBLEM", 32, 37], ["fever", "PROBLEM", 39, 44], ["sputum production", "PROBLEM", 50, 67], ["46-", "OBSERVATION_MODIFIER", 2, 5], ["cough", "OBSERVATION", 32, 37], ["fever", "OBSERVATION", 39, 44], ["sputum", "OBSERVATION", 50, 56]]], ["Six months ago, the patient traveled to Kuwait on business.", [["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27]]], ["The patient was well until fi ve days ago, when his symptoms gradually developed.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["his symptoms", "PROBLEM", 48, 60]]], ["He denies no chills, chest pain, or hemoptysis.", [["chest", "ANATOMY", 21, 26], ["chills", "DISEASE", 13, 19], ["chest pain", "DISEASE", 21, 31], ["hemoptysis", "DISEASE", 36, 46], ["chest", "ORGANISM_SUBDIVISION", 21, 26], ["chills", "PROBLEM", 13, 19], ["chest pain", "PROBLEM", 21, 31], ["hemoptysis", "PROBLEM", 36, 46], ["no", "UNCERTAINTY", 10, 12], ["chills", "OBSERVATION", 13, 19], ["chest", "ANATOMY", 21, 26], ["hemoptysis", "OBSERVATION", 36, 46]]], ["He works in the petroleum industry.", [["petroleum", "ANATOMY", 16, 25]]], ["He has no pets and takes no medications.", [["medications", "TREATMENT", 28, 39], ["no", "UNCERTAINTY", 7, 9], ["pets", "OBSERVATION", 10, 14]]], ["On physical exam, his temperature is 38.7 C (101.5 F), pulse rate is 90 per minute, respirations are 14 per minute, and blood pressure is 135/70 mmHg.", [["blood", "ANATOMY", 120, 125], ["blood", "ORGANISM_SUBSTANCE", 120, 125], ["physical exam", "TEST", 3, 16], ["his temperature", "TEST", 18, 33], ["pulse rate", "TEST", 55, 65], ["respirations", "TEST", 84, 96], ["blood pressure", "TEST", 120, 134]]], ["The skin is warm and dry.", [["skin", "ANATOMY", 4, 8], ["skin", "ORGAN", 4, 8], ["skin", "ANATOMY", 4, 8], ["warm", "OBSERVATION", 12, 16], ["dry", "OBSERVATION", 21, 24]]], ["Crackles are heard at the left lung base posteriorly.ReferenceThe leukocyte count is 15,000/\u03bcL, with increased bands.ReferenceWhich of the following is the best next step?", [["left lung", "ANATOMY", 26, 35], ["leukocyte", "ANATOMY", 66, 75], ["lung", "ORGAN", 31, 35], ["leukocyte", "CELL", 66, 75], ["Crackles", "PROBLEM", 0, 8], ["The leukocyte count", "TEST", 62, 81], ["increased bands", "PROBLEM", 101, 116], ["left lung", "ANATOMY", 26, 35], ["base", "ANATOMY_MODIFIER", 36, 40], ["posteriorly", "ANATOMY_MODIFIER", 41, 52], ["leukocyte count", "OBSERVATION", 66, 81], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["bands", "OBSERVATION", 111, 116]]], ["A) Test induced sputum for MERS by RT-PCR B) Test blood for MERS by RT-PCR C) Test blood for MERS by serology D) Treat for community-acquired pneumonia E) AFB stain of sputum Answer: A Middle Eastern respiratory syndrome (MERS) is an emerging concern among recent travelers to the Middle East.", [["sputum", "ANATOMY", 16, 22], ["blood", "ANATOMY", 50, 55], ["blood", "ANATOMY", 83, 88], ["pneumonia", "DISEASE", 142, 151], ["Middle Eastern respiratory syndrome", "DISEASE", 185, 220], ["MERS", "DISEASE", 222, 226], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["A) Test induced sputum", "TEST", 0, 22], ["MERS", "PROBLEM", 27, 31], ["RT", "TEST", 35, 37], ["PCR", "TEST", 38, 41], ["Test blood", "TEST", 45, 55], ["MERS", "TEST", 60, 64], ["RT", "TEST", 68, 70], ["PCR C", "TEST", 71, 76], ["Test blood", "TEST", 78, 88], ["MERS", "PROBLEM", 93, 97], ["community-acquired pneumonia", "PROBLEM", 123, 151], ["AFB stain", "TEST", 155, 164], ["sputum", "PROBLEM", 168, 174], ["A Middle Eastern respiratory syndrome", "PROBLEM", 183, 220], ["Middle", "ANATOMY_MODIFIER", 185, 191], ["respiratory syndrome", "OBSERVATION", 200, 220], ["Middle", "ANATOMY_MODIFIER", 281, 287]]], ["The interval is 7.6 days.", [["7.6 days", "OBSERVATION_MODIFIER", 16, 24]]], ["It is only a possibility in a patient who has had traveled within 14 days to the Middle East.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["only a possibility", "UNCERTAINTY", 6, 24], ["Middle", "ANATOMY_MODIFIER", 81, 87]]], ["MERS presents with a nonspecifi c triad of cough, fever, and shortness of breath.", [["MERS", "DISEASE", 0, 4], ["cough", "DISEASE", 43, 48], ["fever", "DISEASE", 50, 55], ["shortness of breath", "DISEASE", 61, 80], ["cough", "PROBLEM", 43, 48], ["fever", "PROBLEM", 50, 55], ["shortness of breath", "PROBLEM", 61, 80], ["cough", "OBSERVATION", 43, 48], ["fever", "OBSERVATION", 50, 55]]], ["Most individuals with confi rmed MERS have developed signifi cant acute respiratory illness.", [["respiratory", "ANATOMY", 72, 83], ["respiratory illness", "DISEASE", 72, 91], ["signifi cant acute respiratory illness", "PROBLEM", 53, 91], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory illness", "OBSERVATION", 72, 91]]], ["Among the probably underreported 536 cases reported through May 12, 2014, the mortality rate has been 30 %.", [["the mortality rate", "TEST", 74, 92]]], ["Diagnosis for MERS is best done using polymerase chain reaction (PCR) testing of induced sputum or blood.", [["sputum", "ANATOMY", 89, 95], ["blood", "ANATOMY", 99, 104], ["sputum", "ORGANISM_SUBSTANCE", 89, 95], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["MERS", "PROBLEM", 14, 18], ["polymerase chain reaction", "TEST", 38, 63], ["PCR", "TEST", 65, 68], ["induced sputum", "PROBLEM", 81, 95], ["blood", "PROBLEM", 99, 104], ["sputum", "OBSERVATION", 89, 95], ["blood", "ANATOMY", 99, 104]]], ["Serology, which is not widely available, can identify previous exposure.210.A 48-year-old man is admitted for increasing shortness of breath.", [["shortness of breath", "DISEASE", 121, 140], ["man", "ORGANISM", 90, 93], ["man", "SPECIES", 90, 93], ["Serology", "TEST", 0, 8], ["increasing shortness of breath", "PROBLEM", 110, 140]]], ["This admission is thought to be multifactorial including volume overload, reactive airway disease, and pulmonary hypertension.", [["airway", "ANATOMY", 83, 89], ["pulmonary", "ANATOMY", 103, 112], ["volume overload", "DISEASE", 57, 72], ["reactive airway disease", "DISEASE", 74, 97], ["pulmonary hypertension", "DISEASE", 103, 125], ["airway", "MULTI-TISSUE_STRUCTURE", 83, 89], ["pulmonary", "ORGAN", 103, 112], ["volume overload", "PROBLEM", 57, 72], ["reactive airway disease", "PROBLEM", 74, 97], ["pulmonary hypertension", "PROBLEM", 103, 125], ["thought to be", "UNCERTAINTY", 18, 31], ["volume overload", "OBSERVATION", 57, 72], ["reactive airway disease", "OBSERVATION", 74, 97], ["pulmonary", "ANATOMY", 103, 112], ["hypertension", "OBSERVATION", 113, 125]]], ["He has a history of sleep apnea and he is obese.", [["sleep apnea", "DISEASE", 20, 31], ["sleep apnea", "PROBLEM", 20, 31], ["obese", "PROBLEM", 42, 47], ["sleep apnea", "OBSERVATION", 20, 31], ["obese", "OBSERVATION", 42, 47]]], ["The patient also has hypertension and hyperlipidemia.", [["hypertension", "DISEASE", 21, 33], ["hyperlipidemia", "DISEASE", 38, 52], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["hypertension", "PROBLEM", 21, 33], ["hyperlipidemia", "PROBLEM", 38, 52], ["hypertension", "OBSERVATION", 21, 33], ["hyperlipidemia", "OBSERVATION", 38, 52]]], ["He drinks on average one alcoholic beverage every three days.", [["He", "ORGANISM", 0, 2]]], ["He takes no medications.", [["medications", "TREATMENT", 12, 23]]], ["On physical examination diffuse mild crackles are heard with 1+ lower extremity edema.", [["lower extremity edema", "ANATOMY", 64, 85], ["edema", "DISEASE", 80, 85], ["edema", "PATHOLOGICAL_FORMATION", 80, 85], ["physical examination", "TEST", 3, 23], ["diffuse mild crackles", "PROBLEM", 24, 45], ["lower extremity edema", "PROBLEM", 64, 85], ["diffuse", "OBSERVATION_MODIFIER", 24, 31], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["crackles", "OBSERVATION", 37, 45], ["lower", "ANATOMY_MODIFIER", 64, 69], ["extremity", "ANATOMY", 70, 79], ["edema", "OBSERVATION", 80, 85]]], ["The abdomen is soft and nontender.210.Laboratory studies reveal an ALT of 107 U/L and an AST of 95 U/L. Serum bilirubin is 0.5 mg/dL.", [["abdomen", "ANATOMY", 4, 11], ["Serum", "ANATOMY", 104, 109], ["bilirubin", "CHEMICAL", 110, 119], ["bilirubin", "CHEMICAL", 110, 119], ["abdomen", "ORGAN", 4, 11], ["Serum", "ORGANISM_SUBSTANCE", 104, 109], ["bilirubin", "GENE_OR_GENE_PRODUCT", 110, 119], ["ALT", "PROTEIN", 67, 70], ["nontender", "PROBLEM", 24, 33], ["Laboratory studies", "TEST", 38, 56], ["an ALT", "TEST", 64, 70], ["U/L", "TEST", 78, 81], ["an AST", "TEST", 86, 92], ["U/L.", "TEST", 99, 103], ["Serum bilirubin", "TEST", 104, 119], ["abdomen", "ANATOMY", 4, 11], ["soft", "OBSERVATION", 15, 19], ["nontender", "OBSERVATION", 24, 33]]], ["Serum alkaline phosphatase is 78 U/L. Hepatitis A, B, and C serologies are negative.210.Which of the following is the most likely cause of his elevated liver functions?", [["Serum", "ANATOMY", 0, 5], ["liver", "ANATOMY", 152, 157], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 6, 26], ["Hepatitis A", "ORGANISM", 38, 49], ["B", "GENE_OR_GENE_PRODUCT", 51, 52], ["C", "GENE_OR_GENE_PRODUCT", 58, 59], ["liver", "ORGAN", 152, 157], ["Serum alkaline phosphatase", "PROTEIN", 0, 26], ["Hepatitis A", "SPECIES", 38, 49], ["Serum alkaline phosphatase", "TEST", 0, 26], ["U/L.", "TEST", 33, 37], ["Hepatitis A", "TEST", 38, 49], ["B, and C serologies", "TEST", 51, 70], ["his elevated liver functions", "PROBLEM", 139, 167], ["Hepatitis", "OBSERVATION", 38, 47], ["most likely", "UNCERTAINTY", 118, 129], ["elevated", "OBSERVATION", 143, 151], ["liver", "ANATOMY", 152, 157]]], ["A) Alcoholic hepatitis B) Autoimmune hepatitis C) Gallbladder infl ammation D) Liver cancer E) Nonalcoholic fatty liver disease F) Congestive heart failure Answer: E Nonalcoholic fatty liver disease(NAFLD) is the most common cause of elevated liver enzymes in American adults.210.NAFLD liver disease affects 10 % to 24 % of adults, with a higher prevalence in individuals who have obesity and diabetes.", [["Liver cancer", "ANATOMY", 79, 91], ["Nonalcoholic fatty liver", "ANATOMY", 95, 119], ["heart", "ANATOMY", 142, 147], ["Nonalcoholic fatty liver", "ANATOMY", 166, 190], ["liver", "ANATOMY", 243, 248], ["liver", "ANATOMY", 286, 291], ["Alcoholic hepatitis B", "DISEASE", 3, 24], ["Autoimmune hepatitis C", "DISEASE", 26, 48], ["Liver cancer", "DISEASE", 79, 91], ["Nonalcoholic fatty liver disease", "DISEASE", 95, 127], ["Congestive heart failure", "DISEASE", 131, 155], ["Nonalcoholic fatty liver disease", "DISEASE", 166, 198], ["NAFLD", "DISEASE", 199, 204], ["elevated liver enzymes", "DISEASE", 234, 256], ["NAFLD liver disease", "DISEASE", 280, 299], ["obesity", "DISEASE", 381, 388], ["diabetes", "DISEASE", 393, 401], ["Gallbladder", "ORGAN", 50, 61], ["Liver cancer", "CANCER", 79, 91], ["liver", "ORGAN", 114, 119], ["heart", "ORGAN", 142, 147], ["liver", "ORGAN", 185, 190], ["liver", "ORGAN", 243, 248], ["liver", "ORGAN", 286, 291], ["adults", "ORGANISM", 324, 330], ["liver enzymes", "PROTEIN", 243, 256], ["Alcoholic hepatitis B", "PROBLEM", 3, 24], ["Autoimmune hepatitis C", "PROBLEM", 26, 48], ["Gallbladder infl ammation D", "PROBLEM", 50, 77], ["Liver cancer E", "PROBLEM", 79, 93], ["Nonalcoholic fatty liver disease F", "PROBLEM", 95, 129], ["Congestive heart failure", "PROBLEM", 131, 155], ["E Nonalcoholic fatty liver disease(NAFLD", "PROBLEM", 164, 204], ["elevated liver enzymes", "PROBLEM", 234, 256], ["NAFLD liver disease affects", "PROBLEM", 280, 307], ["obesity", "PROBLEM", 381, 388], ["diabetes", "PROBLEM", 393, 401], ["Alcoholic hepatitis", "OBSERVATION", 3, 22], ["Gallbladder", "ANATOMY", 50, 61], ["Liver", "ANATOMY", 79, 84], ["cancer", "OBSERVATION", 85, 91], ["liver", "ANATOMY", 114, 119], ["Congestive", "OBSERVATION_MODIFIER", 131, 141], ["heart", "ANATOMY", 142, 147], ["failure", "OBSERVATION", 148, 155], ["liver", "ANATOMY", 185, 190], ["elevated", "OBSERVATION", 234, 242], ["liver", "ANATOMY", 243, 248], ["liver", "ANATOMY", 286, 291], ["disease", "OBSERVATION", 292, 299], ["obesity", "OBSERVATION", 381, 388], ["diabetes", "OBSERVATION", 393, 401]]], ["OSA is associated with an increased prevalence of nonalcoholic steatohepatitis and fi brosis.", [["OSA", "DISEASE", 0, 3], ["nonalcoholic steatohepatitis", "DISEASE", 50, 78], ["OSA", "PROBLEM", 0, 3], ["nonalcoholic steatohepatitis", "PROBLEM", 50, 78], ["fi brosis", "PROBLEM", 83, 92], ["increased", "OBSERVATION_MODIFIER", 26, 35], ["prevalence", "OBSERVATION", 36, 46], ["nonalcoholic steatohepatitis", "OBSERVATION", 50, 78], ["fi brosis", "OBSERVATION", 83, 92]]], ["Etiology of this association is thought to be related to the intermittent hypoxia that occurs during OSA, leading to liver damage.", [["liver", "ANATOMY", 117, 122], ["hypoxia", "DISEASE", 74, 81], ["OSA", "DISEASE", 101, 104], ["liver damage", "DISEASE", 117, 129], ["liver", "ORGAN", 117, 122], ["the intermittent hypoxia", "PROBLEM", 57, 81], ["OSA", "PROBLEM", 101, 104], ["liver damage", "PROBLEM", 117, 129], ["thought to be related to", "UNCERTAINTY", 32, 56], ["intermittent", "OBSERVATION_MODIFIER", 61, 73], ["hypoxia", "OBSERVATION", 74, 81], ["liver", "ANATOMY", 117, 122], ["damage", "OBSERVATION", 123, 129]]], ["Diagnosis of NAFLD has historically been made based on abnormal hepatic histology, minimal alcohol consumption, and absence of viral hepatitis.", [["hepatic", "ANATOMY", 64, 71], ["NAFLD", "DISEASE", 13, 18], ["abnormal hepatic histology", "DISEASE", 55, 81], ["alcohol", "CHEMICAL", 91, 98], ["viral hepatitis", "DISEASE", 127, 142], ["alcohol", "CHEMICAL", 91, 98], ["hepatic", "ORGAN", 64, 71], ["NAFLD", "PROBLEM", 13, 18], ["abnormal hepatic histology", "PROBLEM", 55, 81], ["viral hepatitis", "PROBLEM", 127, 142], ["NAFLD", "OBSERVATION", 13, 18], ["hepatic", "ANATOMY", 64, 71], ["histology", "OBSERVATION", 72, 81], ["minimal", "OBSERVATION_MODIFIER", 83, 90], ["alcohol consumption", "OBSERVATION", 91, 110], ["viral hepatitis", "OBSERVATION", 127, 142]]], ["Ultrasound is typically used because of its lack of radiation exposure and its costeffectiveness.", [["Ultrasound", "TEST", 0, 10], ["radiation exposure", "PROBLEM", 52, 70], ["its costeffectiveness", "PROBLEM", 75, 96], ["radiation exposure", "OBSERVATION", 52, 70]]], ["A liver biopsy may be performed to confi rm the fi ndings and to assess disease status and potential progression to NASH.211.A 34-year-old female who is HIV positive is admitted with headache, fever, cough, chills, and weight loss during the past two weeks.", [["liver", "ANATOMY", 2, 7], ["NASH", "DISEASE", 116, 120], ["HIV positive", "DISEASE", 153, 165], ["headache", "DISEASE", 183, 191], ["fever", "DISEASE", 193, 198], ["cough", "DISEASE", 200, 205], ["chills", "DISEASE", 207, 213], ["weight loss", "DISEASE", 219, 230], ["liver", "ORGAN", 2, 7], ["female", "ORGANISM", 139, 145], ["HIV", "ORGANISM", 153, 156], ["HIV", "SPECIES", 153, 156], ["HIV", "SPECIES", 153, 156], ["A liver biopsy", "TEST", 0, 14], ["the fi ndings", "TEST", 44, 57], ["disease status", "PROBLEM", 72, 86], ["NASH", "PROBLEM", 116, 120], ["HIV positive", "PROBLEM", 153, 165], ["headache", "PROBLEM", 183, 191], ["fever", "PROBLEM", 193, 198], ["cough", "PROBLEM", 200, 205], ["chills", "PROBLEM", 207, 213], ["weight loss", "PROBLEM", 219, 230], ["liver", "ANATOMY", 2, 7], ["biopsy", "OBSERVATION", 8, 14], ["NASH", "OBSERVATION", 116, 120], ["34-", "OBSERVATION_MODIFIER", 127, 130], ["fever", "OBSERVATION", 193, 198], ["cough", "OBSERVATION", 200, 205], ["chills", "OBSERVATION", 207, 213]]], ["The patient was released from jail three months ago.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["She was admitted to the hospital fi ve weeks ago with cryptococcal meningitis.", [["cryptococcal meningitis", "DISEASE", 54, 77], ["She", "ORGANISM", 0, 3], ["cryptococcal meningitis", "PROBLEM", 54, 77], ["cryptococcal", "OBSERVATION_MODIFIER", 54, 66], ["meningitis", "OBSERVATION", 67, 77]]], ["At that time, CD4 (T4) lymphocyte count was 41/\u03bcL, and HIV RNA viral load was greater than 700,000 copies/mL.", [["CD4 (T4) lymphocyte", "ANATOMY", 14, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["HIV", "ORGANISM", 55, 58], ["CD4", "PROTEIN", 14, 17], ["HIV RNA", "RNA", 55, 62], ["HIV", "SPECIES", 55, 58], ["CD4 (T4) lymphocyte count", "TEST", 14, 39], ["\u03bcL", "TEST", 47, 49], ["HIV RNA viral load", "TEST", 55, 73]]], ["She was treated with two weeks of amphotericin B. and discharged home.", [["amphotericin", "CHEMICAL", 34, 46], ["amphotericin", "CHEMICAL", 34, 46], ["amphotericin B.", "TREATMENT", 34, 49]]], ["On follow-up care, two weeks ago, antiretroviral therapy was started.", [["antiretroviral therapy", "TREATMENT", 34, 56]]], ["Additional medications are double-strength trimethoprim-sulfamethoxazole (800 mg/160 mg twice daily) and fl uconazole (400 mg daily).", [["trimethoprim-sulfamethoxazole", "CHEMICAL", 43, 72], ["fl uconazole", "CHEMICAL", 105, 117], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 43, 72], ["uconazole", "CHEMICAL", 108, 117], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 43, 72], ["fl uconazole", "SIMPLE_CHEMICAL", 105, 117], ["Additional medications", "TREATMENT", 0, 22], ["double-strength trimethoprim", "TREATMENT", 27, 55], ["sulfamethoxazole", "TREATMENT", 56, 72], ["fl uconazole", "TREATMENT", 105, 117]]], ["The patient is thin and diaphoretic.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["diaphoretic", "PROBLEM", 24, 35], ["thin", "OBSERVATION_MODIFIER", 15, 19]]], ["Temperature is 38.9 C (101.8 F), pulse rate is 120 per minute, respirations are 22 per minute, and blood pressure is 128/74 mmHg.", [["blood", "ANATOMY", 99, 104], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["Temperature", "TEST", 0, 11], ["pulse rate", "TEST", 33, 43], ["respirations", "TEST", 63, 75], ["blood pressure", "TEST", 99, 113]]], ["Mild neck stiffness is noted.", [["neck", "ANATOMY", 5, 9], ["neck stiffness", "DISEASE", 5, 19], ["neck", "ORGANISM_SUBDIVISION", 5, 9], ["Mild neck stiffness", "PROBLEM", 0, 19], ["neck", "ANATOMY", 5, 9], ["stiffness", "OBSERVATION", 10, 19]]], ["Tachypnea and scattered crackles are noted on pulmonary examination.", [["pulmonary", "ANATOMY", 46, 55], ["Tachypnea", "DISEASE", 0, 9], ["pulmonary", "ORGAN", 46, 55], ["Tachypnea", "PROBLEM", 0, 9], ["scattered crackles", "PROBLEM", 14, 32], ["pulmonary examination", "TEST", 46, 67], ["scattered", "OBSERVATION_MODIFIER", 14, 23], ["crackles", "OBSERVATION", 24, 32], ["pulmonary", "ANATOMY", 46, 55]]], ["CD4 (T4) lymphocyte count is 206/\u03bcL, and HIV RNA viral load is 1275 copies/mL.", [["CD4 (T4) lymphocyte", "ANATOMY", 0, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["HIV", "ORGANISM", 41, 44], ["HIV RNA", "RNA", 41, 48], ["HIV", "SPECIES", 41, 44], ["CD4 (T4)", "TEST", 0, 8], ["lymphocyte count", "TEST", 9, 25], ["\u03bcL", "TEST", 33, 35], ["HIV RNA viral load", "TEST", 41, 59]]], ["Chest radiograph shows mild infi ltrates in the lower lung fi elds.211.Which of the following is the most likely diagnosis?", [["lung", "ANATOMY", 54, 58], ["lung", "ORGAN", 54, 58], ["Chest radiograph", "TEST", 0, 16], ["mild infi ltrates in the lower lung fi elds", "PROBLEM", 23, 66], ["mild", "OBSERVATION_MODIFIER", 23, 27], ["infi ltrates", "OBSERVATION", 28, 40], ["lower", "ANATOMY_MODIFIER", 48, 53], ["lung", "ANATOMY", 54, 58], ["fi", "ANATOMY_MODIFIER", 59, 61], ["elds", "OBSERVATION", 62, 66], ["most likely", "UNCERTAINTY", 101, 112]]], ["A) Pseudomonas aeruginosa pneumonia B) Pneumocystis jirovecii pneumonia C) Immune reconstitution infl ammatory syndrome D) Cryptococcal pneumonia E) AIDS encephalopathy Answer: C Immune reconstitution infl ammatory syndrome (IRIS) is an early complication of initiating antiretroviral therapy (ART) that involves rapid immune reconstitution in response to an uncovered or treated infection.", [["Pseudomonas aeruginosa pneumonia", "DISEASE", 3, 35], ["Pneumocystis jirovecii pneumonia", "DISEASE", 39, 71], ["Immune reconstitution infl ammatory syndrome", "DISEASE", 75, 119], ["Cryptococcal pneumonia", "DISEASE", 123, 145], ["AIDS encephalopathy", "DISEASE", 149, 168], ["Immune reconstitution infl ammatory syndrome", "DISEASE", 179, 223], ["IRIS", "DISEASE", 225, 229], ["infection", "DISEASE", 380, 389], ["Pseudomonas aeruginosa pneumonia B) Pneumocystis jirovecii", "ORGANISM", 3, 61], ["Pseudomonas aeruginosa pneumonia", "SPECIES", 3, 35], ["Pneumocystis jirovecii", "SPECIES", 39, 61], ["Pseudomonas aeruginosa", "SPECIES", 3, 25], ["Pneumocystis jirovecii", "SPECIES", 39, 61], ["A) Pseudomonas aeruginosa pneumonia", "PROBLEM", 0, 35], ["Pneumocystis jirovecii pneumonia C", "PROBLEM", 39, 73], ["Immune reconstitution", "TREATMENT", 75, 96], ["ammatory syndrome", "PROBLEM", 102, 119], ["Cryptococcal pneumonia E", "PROBLEM", 123, 147], ["AIDS encephalopathy", "PROBLEM", 149, 168], ["Immune reconstitution", "TREATMENT", 179, 200], ["ammatory syndrome", "PROBLEM", 206, 223], ["antiretroviral therapy", "TREATMENT", 270, 292], ["ART)", "TREATMENT", 294, 298], ["rapid immune reconstitution", "TREATMENT", 313, 340], ["an uncovered or treated infection", "PROBLEM", 356, 389], ["Pseudomonas", "OBSERVATION_MODIFIER", 3, 14], ["aeruginosa", "OBSERVATION_MODIFIER", 15, 25], ["pneumonia", "OBSERVATION", 26, 35], ["Pneumocystis jirovecii", "OBSERVATION", 39, 61], ["Cryptococcal", "OBSERVATION_MODIFIER", 123, 135], ["pneumonia", "OBSERVATION", 136, 145], ["IRIS", "ANATOMY", 225, 229], ["early", "OBSERVATION_MODIFIER", 237, 242], ["complication", "OBSERVATION", 243, 255], ["antiretroviral therapy", "OBSERVATION", 270, 292], ["rapid", "OBSERVATION_MODIFIER", 313, 318], ["immune reconstitution", "OBSERVATION", 319, 340], ["treated", "OBSERVATION_MODIFIER", 372, 379], ["infection", "OBSERVATION", 380, 389]]], ["IRIS is particularly problematic in cryptococcal meningitis.", [["IRIS", "DISEASE", 0, 4], ["cryptococcal meningitis", "DISEASE", 36, 59], ["IRIS", "PROBLEM", 0, 4], ["cryptococcal meningitis", "PROBLEM", 36, 59], ["cryptococcal", "OBSERVATION_MODIFIER", 36, 48], ["meningitis", "OBSERVATION", 49, 59]]], ["New neurologic symptoms can occur weeks or even months into cryptococcal treatment.", [["neurologic", "ANATOMY", 4, 14], ["neurologic symptoms", "DISEASE", 4, 23], ["New neurologic symptoms", "PROBLEM", 0, 23], ["cryptococcal treatment", "TREATMENT", 60, 82]]], ["This may present with a sudden onset of worsening meningitis symptoms.", [["meningitis", "DISEASE", 50, 60], ["worsening meningitis symptoms", "PROBLEM", 40, 69], ["worsening", "OBSERVATION_MODIFIER", 40, 49], ["meningitis", "OBSERVATION", 50, 60]]], ["This patient is less likely to have healthcare-associated pneumonia due to Pseudomonas because of the time course of symptoms.", [["pneumonia", "DISEASE", 58, 67], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["healthcare-associated pneumonia", "PROBLEM", 36, 67], ["Pseudomonas", "PROBLEM", 75, 86], ["symptoms", "PROBLEM", 117, 125], ["less likely", "UNCERTAINTY", 16, 27], ["pneumonia", "OBSERVATION", 58, 67], ["Pseudomonas", "OBSERVATION", 75, 86]]], ["Pneumocystis jirovecii (carinii) pneumonia is less likely in a patient taking appropriate prophylaxis.", [["Pneumocystis jirovecii (carinii) pneumonia", "DISEASE", 0, 42], ["Pneumocystis jirovecii", "ORGANISM", 0, 22], ["carinii", "ORGANISM", 24, 31], ["patient", "ORGANISM", 63, 70], ["Pneumocystis jirovecii", "SPECIES", 0, 22], ["carinii", "SPECIES", 24, 31], ["patient", "SPECIES", 63, 70], ["Pneumocystis jirovecii", "SPECIES", 0, 22], ["Pneumocystis jirovecii (carinii) pneumonia", "PROBLEM", 0, 42], ["appropriate prophylaxis", "TREATMENT", 78, 101], ["jirovecii", "OBSERVATION", 13, 22], ["carinii", "OBSERVATION", 24, 31], ["pneumonia", "OBSERVATION", 33, 42], ["less likely", "UNCERTAINTY", 46, 57]]], ["Cryptococcal lung disease more commonly presents with nodules and patchy infi ltrates.212.A 24-year-old man was initially unresponsive when he was rescued from a boating accident.", [["lung", "ANATOMY", 13, 17], ["nodules", "ANATOMY", 54, 61], ["Cryptococcal lung disease", "DISEASE", 0, 25], ["lung", "ORGAN", 13, 17], ["nodules", "CANCER", 54, 61], ["man", "ORGANISM", 104, 107], ["man", "SPECIES", 104, 107], ["Cryptococcal lung disease", "PROBLEM", 0, 25], ["nodules", "PROBLEM", 54, 61], ["patchy infi ltrates", "PROBLEM", 66, 85], ["unresponsive", "PROBLEM", 122, 134], ["lung", "ANATOMY", 13, 17], ["disease", "OBSERVATION", 18, 25], ["nodules", "OBSERVATION", 54, 61], ["patchy", "OBSERVATION_MODIFIER", 66, 72]]], ["He was given cardiopulmonary resuscitation (CPR) by the responding coast guard.", [["cardiopulmonary", "ANATOMY", 13, 28], ["He", "ORGANISM", 0, 2], ["cardiopulmonary resuscitation", "TREATMENT", 13, 42], ["CPR", "TREATMENT", 44, 47]]], ["Spontaneous respirations returned.", [["Spontaneous respirations", "PROBLEM", 0, 24], ["respirations", "OBSERVATION", 12, 24]]], ["On arrival in the emergency, the patient is afebrile.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["afebrile", "PROBLEM", 44, 52], ["afebrile", "OBSERVATION", 44, 52]]], ["Blood pressure is 110/80 mmHg.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood pressure", "TEST", 0, 14], ["pressure", "OBSERVATION_MODIFIER", 6, 14]]], ["Radiography of the chest reveals bilateral infi ltrates.", [["chest", "ANATOMY", 19, 24], ["chest", "ORGAN", 19, 24], ["Radiography of the chest", "TEST", 0, 24], ["bilateral infi ltrates", "PROBLEM", 33, 55], ["chest", "ANATOMY", 19, 24], ["bilateral", "ANATOMY_MODIFIER", 33, 42]]], ["The toxicological investigation is ongoing.212.Which of the following is the most appropriate management?", [["The toxicological investigation", "TEST", 0, 31]]], ["A) Monitor for fever, leukocytosis, and changes in infi ltrates.", [["fever", "DISEASE", 15, 20], ["leukocytosis", "DISEASE", 22, 34], ["fever", "PROBLEM", 15, 20], ["leukocytosis", "PROBLEM", 22, 34], ["changes in infi ltrates", "PROBLEM", 40, 63], ["leukocytosis", "OBSERVATION", 22, 34]]], ["B) Administer empirical antibiotics for communityacquired pneumonia.", [["pneumonia", "DISEASE", 58, 67], ["empirical antibiotics", "TREATMENT", 14, 35], ["communityacquired pneumonia", "PROBLEM", 40, 67], ["pneumonia", "OBSERVATION", 58, 67]]], ["C) Administer empirical antibiotics for nosocomial pathogens.", [["nosocomial pathogens", "DISEASE", 40, 60], ["empirical antibiotics", "TREATMENT", 14, 35], ["nosocomial pathogens", "PROBLEM", 40, 60]]], ["D) Administer steroids.212.Answer: A According to the World Health Organization (WHO), approximately 0.7 %, or 500,000, deaths each year are due to unintentional drowning.", [["steroids", "CHEMICAL", 14, 22], ["deaths", "DISEASE", 120, 126], ["drowning", "DISEASE", 162, 170], ["steroids", "CHEMICAL", 14, 22], ["steroids", "TREATMENT", 14, 22], ["unintentional drowning", "PROBLEM", 148, 170]]], ["Initial management of near drowning should place emphasis on immediate resuscitation in the field and supportive treatment of respiratory failure.", [["respiratory", "ANATOMY", 126, 137], ["drowning", "DISEASE", 27, 35], ["respiratory failure", "DISEASE", 126, 145], ["near drowning", "PROBLEM", 22, 35], ["immediate resuscitation", "TREATMENT", 61, 84], ["supportive treatment", "TREATMENT", 102, 122], ["respiratory failure", "PROBLEM", 126, 145], ["respiratory failure", "OBSERVATION", 126, 145]]], ["Frequent neurologic assessment should occur.", [["neurologic", "ANATOMY", 9, 19], ["Frequent neurologic assessment", "TEST", 0, 30]]], ["All drowning victims should have 100 % oxygen during their initial evaluations.", [["drowning", "DISEASE", 4, 12], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "CHEMICAL", 39, 45], ["oxygen", "SIMPLE_CHEMICAL", 39, 45], ["100 % oxygen", "TREATMENT", 33, 45], ["their initial evaluations", "TEST", 53, 78]]], ["Early use of intubation CPAP/bilevel positive airway pressure (BiPAP) in the awake, cooperative, and mildly hypoxic individual is warranted if dyspnea persists.", [["airway", "ANATOMY", 46, 52], ["BiPAP", "CHEMICAL", 63, 68], ["dyspnea", "DISEASE", 143, 150], ["airway", "MULTI-TISSUE_STRUCTURE", 46, 52], ["intubation CPAP", "TREATMENT", 13, 28], ["bilevel positive airway pressure", "TREATMENT", 29, 61], ["BiPAP", "TREATMENT", 63, 68], ["mildly hypoxic individual", "PROBLEM", 101, 126], ["dyspnea", "PROBLEM", 143, 150], ["airway pressure", "OBSERVATION", 46, 61], ["mildly", "OBSERVATION_MODIFIER", 101, 107], ["hypoxic", "OBSERVATION", 108, 115]]], ["The incidence of pneumonia is no greater than 12 %.", [["pneumonia", "DISEASE", 17, 26], ["pneumonia", "PROBLEM", 17, 26], ["pneumonia", "OBSERVATION", 17, 26], ["no", "UNCERTAINTY", 30, 32], ["greater", "OBSERVATION_MODIFIER", 33, 40]]], ["It is best to monitor patients daily for defi nite fever, sustained leukocytosis, and persistent or new infi ltrates prior to starting antibiotics.213.A 68-year-old female is admitted to the hospital for symptoms of shock.", [["fever", "DISEASE", 51, 56], ["leukocytosis", "DISEASE", 68, 80], ["shock", "DISEASE", 216, 221], ["patients", "ORGANISM", 22, 30], ["female", "ORGANISM", 165, 171], ["patients", "SPECIES", 22, 30], ["defi nite fever", "PROBLEM", 41, 56], ["sustained leukocytosis", "PROBLEM", 58, 80], ["persistent or new infi ltrates", "PROBLEM", 86, 116], ["antibiotics", "TREATMENT", 135, 146], ["symptoms", "PROBLEM", 204, 212], ["shock", "PROBLEM", 216, 221], ["leukocytosis", "OBSERVATION", 68, 80], ["persistent", "OBSERVATION_MODIFIER", 86, 96], ["shock", "OBSERVATION", 216, 221]]], ["She has a history of recurrent pyelonephritis and that is the presumed source of her sepsis.", [["pyelonephritis", "DISEASE", 31, 45], ["sepsis", "DISEASE", 85, 91], ["recurrent pyelonephritis", "PROBLEM", 21, 45], ["her sepsis", "PROBLEM", 81, 91], ["recurrent", "OBSERVATION_MODIFIER", 21, 30], ["pyelonephritis", "OBSERVATION", 31, 45], ["presumed source of", "UNCERTAINTY", 62, 80], ["sepsis", "OBSERVATION", 85, 91]]], ["Other history is signifi cant for hypertension.", [["hypertension", "DISEASE", 34, 46], ["hypertension", "PROBLEM", 34, 46], ["hypertension", "OBSERVATION", 34, 46]]], ["Physical examination reveals pulse rate of 130 per minute and blood pressure of 62/45 mmHg.", [["blood", "ANATOMY", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["Physical examination", "TEST", 0, 20], ["pulse rate", "TEST", 29, 39], ["blood pressure", "TEST", 62, 76]]], ["She is lethargic, and her extremities are cool.213.Fluid resuscitation is started with 0.9 % sodium chloride and albumin.", [["extremities", "ANATOMY", 26, 37], ["sodium chloride", "CHEMICAL", 93, 108], ["sodium chloride", "CHEMICAL", 93, 108], ["extremities", "ORGANISM_SUBDIVISION", 26, 37], ["sodium chloride", "SIMPLE_CHEMICAL", 93, 108], ["albumin", "GENE_OR_GENE_PRODUCT", 113, 120], ["lethargic", "PROBLEM", 7, 16], ["Fluid resuscitation", "TREATMENT", 51, 70], ["0.9 % sodium chloride", "TREATMENT", 87, 108], ["albumin", "TREATMENT", 113, 120], ["lethargic", "OBSERVATION", 7, 16], ["extremities", "ANATOMY", 26, 37], ["cool", "OBSERVATION", 42, 46]]], ["In addition, vasopressor therapy with norepinephrine is started because the patient's calculated mean arterial pressure (MAP) is only 48 mmHg.213.Urine and blood cultures are pending.", [["arterial", "ANATOMY", 102, 110], ["Urine", "ANATOMY", 146, 151], ["blood cultures", "ANATOMY", 156, 170], ["norepinephrine", "CHEMICAL", 38, 52], ["norepinephrine", "CHEMICAL", 38, 52], ["norepinephrine", "SIMPLE_CHEMICAL", 38, 52], ["patient", "ORGANISM", 76, 83], ["arterial", "MULTI-TISSUE_STRUCTURE", 102, 110], ["Urine", "ORGANISM_SUBSTANCE", 146, 151], ["blood", "ORGANISM_SUBSTANCE", 156, 161], ["patient", "SPECIES", 76, 83], ["vasopressor therapy", "TREATMENT", 13, 32], ["norepinephrine", "TREATMENT", 38, 52], ["the patient's calculated mean arterial pressure", "TEST", 72, 119], ["Urine", "TEST", 146, 151], ["blood cultures", "TEST", 156, 170], ["vasopressor therapy", "OBSERVATION", 13, 32], ["blood", "ANATOMY", 156, 161]]], ["Intravenous antibiotic therapy is started.213.Which of the following is the most likely result of increasing this patient's MAP to high blood pressure target of 75 mmHg as opposed to a low blood pressure target of 65 mmHg?", [["blood", "ANATOMY", 136, 141], ["blood", "ANATOMY", 189, 194], ["patient", "ORGANISM", 114, 121], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["patient", "SPECIES", 114, 121], ["Intravenous antibiotic therapy", "TREATMENT", 0, 30], ["blood pressure", "TEST", 136, 150], ["a low blood pressure target", "PROBLEM", 183, 210]]], ["A) Reduced need for renal replacement therapy.", [["renal", "ANATOMY", 20, 25], ["renal", "ORGAN", 20, 25], ["renal replacement therapy", "TREATMENT", 20, 45], ["renal", "ANATOMY", 20, 25], ["replacement", "OBSERVATION", 26, 37]]], ["B) Decreased risk of a cardiac arrhythmia.", [["cardiac", "ANATOMY", 23, 30], ["cardiac arrhythmia", "DISEASE", 23, 41], ["cardiac", "ORGAN", 23, 30], ["a cardiac arrhythmia", "PROBLEM", 21, 41], ["Decreased", "OBSERVATION_MODIFIER", 3, 12], ["cardiac", "ANATOMY", 23, 30], ["arrhythmia", "OBSERVATION", 31, 41]]], ["C) Mortality will be improved.", [["improved", "OBSERVATION_MODIFIER", 21, 29]]], ["D) Increased need for renal replacement therapy.213.Answer: A The specifi c target blood pressure of a patient with septic shock is complex.", [["renal", "ANATOMY", 22, 27], ["blood", "ANATOMY", 83, 88], ["septic shock", "DISEASE", 116, 128], ["renal", "ORGAN", 22, 27], ["specifi c", "GENE_OR_GENE_PRODUCT", 66, 75], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["renal replacement therapy", "TREATMENT", 22, 47], ["blood pressure", "TEST", 83, 97], ["septic shock", "PROBLEM", 116, 128], ["Increased", "OBSERVATION_MODIFIER", 3, 12], ["renal", "ANATOMY", 22, 27], ["replacement", "OBSERVATION", 28, 39], ["septic shock", "OBSERVATION", 116, 128]]], ["All authorities recommend fl uid resuscitation as the fi rst form of therapy.", [["fl uid resuscitation", "TREATMENT", 26, 46], ["therapy", "TREATMENT", 69, 76]]], ["The traditional pressure target is a (MAP) of 65-70 mmHg.", [["The traditional pressure target", "TEST", 0, 31], ["pressure", "OBSERVATION_MODIFIER", 16, 24]]], ["A recent study has shown that the level of MAP targeted makes no difference in the outcomes of patients.", [["MAP", "GENE_OR_GENE_PRODUCT", 43, 46], ["patients", "ORGANISM", 95, 103], ["MAP", "PROTEIN", 43, 46], ["patients", "SPECIES", 95, 103], ["A recent study", "TEST", 0, 14]]], ["There may be reasons to target a higher MAP in patients with preexisting hypertension since perfusion may decrease in these patients at a higher MAP.", [["hypertension", "DISEASE", 73, 85], ["patients", "ORGANISM", 47, 55], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 124, 132], ["a higher MAP", "PROBLEM", 31, 43], ["preexisting hypertension", "PROBLEM", 61, 85], ["hypertension", "OBSERVATION", 73, 85], ["decrease", "OBSERVATION_MODIFIER", 106, 114]]], ["In a recent study, MAP higher than 75 was associated with a reduced need for renal replacement therapy.", [["renal", "ANATOMY", 77, 82], ["renal", "ORGAN", 77, 82], ["a recent study", "TEST", 3, 17], ["MAP", "TEST", 19, 22], ["renal replacement therapy", "TREATMENT", 77, 102], ["renal", "ANATOMY", 77, 82], ["replacement", "OBSERVATION", 83, 94]]], ["This target also caused an increased incidence of atrial arrhythmias.", [["atrial", "ANATOMY", 50, 56], ["atrial arrhythmias", "DISEASE", 50, 68], ["atrial", "MULTI-TISSUE_STRUCTURE", 50, 56], ["atrial arrhythmias", "PROBLEM", 50, 68], ["increased", "OBSERVATION_MODIFIER", 27, 36], ["incidence", "OBSERVATION_MODIFIER", 37, 46], ["atrial", "ANATOMY", 50, 56], ["arrhythmias", "OBSERVATION", 57, 68]]], ["On physical examination, his pulse rate is 62 per minute, and his blood pressure is 160/87 mmHg.", [["blood", "ANATOMY", 66, 71], ["blood", "ORGANISM_SUBSTANCE", 66, 71], ["physical examination", "TEST", 3, 23], ["his pulse rate", "TEST", 25, 39], ["his blood pressure", "TEST", 62, 80]]], ["Lung are clear and cardiac exam is normal.ReferenceHis serum creatinine level is 1.3 mg/dL.", [["Lung", "ANATOMY", 0, 4], ["cardiac", "ANATOMY", 19, 26], ["serum", "ANATOMY", 55, 60], ["creatinine", "CHEMICAL", 61, 71], ["creatinine", "CHEMICAL", 61, 71], ["Lung", "ORGAN", 0, 4], ["cardiac", "ORGAN", 19, 26], ["serum", "ORGANISM_SUBSTANCE", 55, 60], ["creatinine", "SIMPLE_CHEMICAL", 61, 71], ["cardiac exam", "TEST", 19, 31], ["serum creatinine level", "TEST", 55, 77], ["clear", "OBSERVATION", 9, 14], ["cardiac", "ANATOMY", 19, 26], ["normal", "OBSERVATION", 35, 41]]], ["Renal magnetic resonance angiography reveals a 65 % stenosis of the right renal artery.ReferenceWhich of the following would provide the greatest benefi t in managing this patient's hypertension?", [["Renal", "ANATOMY", 0, 5], ["right renal artery", "ANATOMY", 68, 86], ["stenosis of the right renal artery", "DISEASE", 52, 86], ["hypertension", "DISEASE", 182, 194], ["Renal", "ORGAN", 0, 5], ["renal artery", "MULTI-TISSUE_STRUCTURE", 74, 86], ["patient", "ORGANISM", 172, 179], ["patient", "SPECIES", 172, 179], ["Renal magnetic resonance angiography", "TEST", 0, 36], ["a 65 % stenosis of the right renal artery", "PROBLEM", 45, 86], ["this patient's hypertension", "PROBLEM", 167, 194], ["stenosis", "OBSERVATION", 52, 60], ["right", "ANATOMY_MODIFIER", 68, 73], ["renal artery", "ANATOMY", 74, 86]]], ["A) Home BP telemonitoring and pharmacist case management B) Stent placement for the renal-artery stenosis C) Renal sympathetic nerve ablation D) Renal-artery angioplasty His BUN is 40 mg/dL], serum creatinine is 5.75 mg/ dL, sodium128 mEq/L, potassium is 5 mEq, and chloride is 90 mEq/L.ReferenceWhich of the following is the most likely cause of acute kidney injury in this patient?", [["renal-artery", "ANATOMY", 84, 96], ["Renal sympathetic nerve", "ANATOMY", 109, 132], ["Renal-artery", "ANATOMY", 145, 157], ["serum", "ANATOMY", 192, 197], ["kidney", "ANATOMY", 353, 359], ["renal-artery stenosis", "DISEASE", 84, 105], ["creatinine", "CHEMICAL", 198, 208], ["sodium", "CHEMICAL", 225, 231], ["potassium", "CHEMICAL", 242, 251], ["chloride", "CHEMICAL", 266, 274], ["acute kidney injury", "DISEASE", 347, 366], ["creatinine", "CHEMICAL", 198, 208], ["sodium", "CHEMICAL", 225, 231], ["potassium", "CHEMICAL", 242, 251], ["chloride", "CHEMICAL", 266, 274], ["renal-artery", "MULTI-TISSUE_STRUCTURE", 84, 96], ["Renal-artery", "MULTI-TISSUE_STRUCTURE", 145, 157], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["creatinine", "SIMPLE_CHEMICAL", 198, 208], ["sodium", "SIMPLE_CHEMICAL", 225, 231], ["potassium", "SIMPLE_CHEMICAL", 242, 251], ["chloride", "SIMPLE_CHEMICAL", 266, 274], ["kidney", "ORGAN", 353, 359], ["patient", "ORGANISM", 375, 382], ["patient", "SPECIES", 375, 382], ["Home BP telemonitoring", "TREATMENT", 3, 25], ["pharmacist case management", "TREATMENT", 30, 56], ["Stent placement", "TREATMENT", 60, 75], ["the renal-artery stenosis", "TREATMENT", 80, 105], ["Renal sympathetic nerve ablation", "TREATMENT", 109, 141], ["Renal-artery angioplasty", "TREATMENT", 145, 169], ["His BUN", "TEST", 170, 177], ["serum creatinine", "TEST", 192, 208], ["sodium", "TEST", 225, 231], ["potassium", "TEST", 242, 251], ["chloride", "TEST", 266, 274], ["acute kidney injury", "PROBLEM", 347, 366], ["Stent", "OBSERVATION", 60, 65], ["renal", "ANATOMY", 84, 89], ["artery", "ANATOMY", 90, 96], ["stenosis", "OBSERVATION", 97, 105], ["Renal", "ANATOMY", 109, 114], ["sympathetic nerve", "ANATOMY", 115, 132], ["Renal", "ANATOMY", 145, 150], ["artery", "ANATOMY", 151, 157], ["angioplasty", "OBSERVATION", 158, 169], ["most likely cause of", "UNCERTAINTY", 326, 346], ["acute", "OBSERVATION_MODIFIER", 347, 352], ["kidney", "ANATOMY", 353, 359], ["injury", "OBSERVATION", 360, 366]]], ["A) Rhabdomyolysis B) Renal arterial vasospasm C) Acute renal venous thrombosis D) Crystal-induced tubular obstruction E) Acute urinary retention Answer: A Intoxication with \"bath salts\" and similar derivatives (synthetic cathinones) have been increasingly reported.", [["Renal arterial", "ANATOMY", 21, 35], ["renal", "ANATOMY", 55, 60], ["tubular", "ANATOMY", 98, 105], ["urinary", "ANATOMY", 127, 134], ["Rhabdomyolysis", "DISEASE", 3, 17], ["Renal arterial vasospasm", "DISEASE", 21, 45], ["renal venous thrombosis", "DISEASE", 55, 78], ["tubular obstruction", "DISEASE", 98, 117], ["urinary retention", "DISEASE", 127, 144], ["cathinones", "CHEMICAL", 221, 231], ["cathinones", "CHEMICAL", 221, 231], ["Renal arterial", "MULTI-TISSUE_STRUCTURE", 21, 35], ["tubular", "MULTI-TISSUE_STRUCTURE", 98, 105], ["cathinones", "SIMPLE_CHEMICAL", 221, 231], ["Rhabdomyolysis", "PROBLEM", 3, 17], ["Renal arterial vasospasm C", "PROBLEM", 21, 47], ["Acute renal venous thrombosis D", "PROBLEM", 49, 80], ["Crystal-induced tubular obstruction E", "PROBLEM", 82, 119], ["Acute urinary retention", "PROBLEM", 121, 144], ["A Intoxication", "PROBLEM", 153, 167], ["\"bath salts", "TREATMENT", 173, 184], ["similar derivatives (synthetic cathinones", "PROBLEM", 190, 231], ["Rhabdomyolysis", "OBSERVATION", 3, 17], ["Renal arterial", "ANATOMY", 21, 35], ["vasospasm", "OBSERVATION", 36, 45], ["Acute", "OBSERVATION_MODIFIER", 49, 54], ["renal venous", "ANATOMY", 55, 67], ["thrombosis", "OBSERVATION", 68, 78], ["tubular", "ANATOMY_MODIFIER", 98, 105], ["obstruction", "OBSERVATION", 106, 117], ["Acute", "OBSERVATION_MODIFIER", 121, 126], ["urinary", "ANATOMY", 127, 134], ["retention", "OBSERVATION", 135, 144]]], ["Patients exhibit extreme agitation, hallucinations, and manic behavior that often leads to dehydration and excessive muscle breakdown.", [["muscle", "ANATOMY", 117, 123], ["agitation", "DISEASE", 25, 34], ["hallucinations", "DISEASE", 36, 50], ["manic behavior", "DISEASE", 56, 70], ["dehydration", "DISEASE", 91, 102], ["muscle breakdown", "DISEASE", 117, 133], ["Patients", "ORGANISM", 0, 8], ["muscle", "ORGAN", 117, 123], ["Patients", "SPECIES", 0, 8], ["extreme agitation", "PROBLEM", 17, 34], ["hallucinations", "PROBLEM", 36, 50], ["manic behavior", "PROBLEM", 56, 70], ["dehydration", "PROBLEM", 91, 102], ["excessive muscle breakdown", "PROBLEM", 107, 133], ["extreme", "OBSERVATION_MODIFIER", 17, 24], ["agitation", "OBSERVATION", 25, 34], ["hallucinations", "OBSERVATION", 36, 50], ["excessive", "OBSERVATION_MODIFIER", 107, 116], ["muscle", "ANATOMY", 117, 123], ["breakdown", "OBSERVATION", 124, 133]]], ["There have been reports of associated acute kidney injury, secondary to acute tubular necrosis due to rhabdomyolysis.", [["kidney", "ANATOMY", 44, 50], ["tubular", "ANATOMY", 78, 85], ["acute kidney injury", "DISEASE", 38, 57], ["acute tubular necrosis", "DISEASE", 72, 94], ["rhabdomyolysis", "DISEASE", 102, 116], ["kidney", "ORGAN", 44, 50], ["tubular", "MULTI-TISSUE_STRUCTURE", 78, 85], ["acute kidney injury", "PROBLEM", 38, 57], ["acute tubular necrosis", "PROBLEM", 72, 94], ["rhabdomyolysis", "PROBLEM", 102, 116], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["kidney", "ANATOMY", 44, 50], ["injury", "OBSERVATION", 51, 57], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["tubular", "ANATOMY_MODIFIER", 78, 85], ["necrosis", "OBSERVATION", 86, 94], ["rhabdomyolysis", "OBSERVATION", 102, 116]]], ["Recommended treatment is aggressive volume repletion.216.A 78-year-old female with type I diabetes presents with a cellulitis and a chronic ulcer of her great toe.", [["ulcer", "ANATOMY", 140, 145], ["toe", "ANATOMY", 159, 162], ["type I diabetes", "DISEASE", 83, 98], ["cellulitis", "DISEASE", 115, 125], ["ulcer", "DISEASE", 140, 145], ["female", "ORGANISM", 71, 77], ["ulcer", "PATHOLOGICAL_FORMATION", 140, 145], ["toe", "ORGANISM_SUBDIVISION", 159, 162], ["treatment", "TREATMENT", 12, 21], ["aggressive volume repletion", "TREATMENT", 25, 52], ["type I diabetes", "PROBLEM", 83, 98], ["a cellulitis", "PROBLEM", 113, 125], ["a chronic ulcer of her great toe", "PROBLEM", 130, 162], ["aggressive", "OBSERVATION_MODIFIER", 25, 35], ["volume repletion", "OBSERVATION", 36, 52], ["type I", "OBSERVATION_MODIFIER", 83, 89], ["diabetes", "OBSERVATION", 90, 98], ["cellulitis", "OBSERVATION", 115, 125], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["ulcer", "OBSERVATION", 140, 145], ["great toe", "ANATOMY", 153, 162]]], ["She reports the ulcer has been present for several weeks and lately her entire foot has become erythematous.", [["ulcer", "ANATOMY", 16, 21], ["foot", "ANATOMY", 79, 83], ["ulcer", "DISEASE", 16, 21], ["ulcer", "PATHOLOGICAL_FORMATION", 16, 21], ["foot", "ORGANISM_SUBDIVISION", 79, 83], ["the ulcer", "PROBLEM", 12, 21], ["erythematous", "PROBLEM", 95, 107], ["ulcer", "OBSERVATION", 16, 21], ["foot", "ANATOMY", 79, 83], ["erythematous", "OBSERVATION", 95, 107]]], ["On physical examination a 5 cm by 8 cm.", [["physical examination", "TEST", 3, 23], ["5 cm", "OBSERVATION_MODIFIER", 26, 30], ["8 cm", "OBSERVATION_MODIFIER", 34, 38]]], ["Ulcer is observed on her right great toe.", [["toe", "ANATOMY", 37, 40], ["Ulcer", "DISEASE", 0, 5], ["Ulcer", "PATHOLOGICAL_FORMATION", 0, 5], ["toe", "ORGANISM_SUBDIVISION", 37, 40], ["Ulcer", "PROBLEM", 0, 5], ["right", "ANATOMY_MODIFIER", 25, 30], ["great toe", "ANATOMY", 31, 40]]], ["There is surrounding edema.", [["edema", "ANATOMY", 21, 26], ["edema", "DISEASE", 21, 26], ["edema", "PATHOLOGICAL_FORMATION", 21, 26], ["surrounding edema", "PROBLEM", 9, 26], ["surrounding", "OBSERVATION_MODIFIER", 9, 20], ["edema", "OBSERVATION", 21, 26]]], ["On magnetic resonance imaging changes consistent with necrosis and osteomyelitis are noted in the fi rst metatarsal.", [["necrosis", "DISEASE", 54, 62], ["osteomyelitis", "DISEASE", 67, 80], ["magnetic resonance imaging changes", "TEST", 3, 37], ["necrosis", "PROBLEM", 54, 62], ["osteomyelitis", "PROBLEM", 67, 80], ["consistent with", "UNCERTAINTY", 38, 53], ["necrosis", "OBSERVATION", 54, 62], ["osteomyelitis", "OBSERVATION", 67, 80], ["fi", "ANATOMY_MODIFIER", 98, 100], ["rst metatarsal", "ANATOMY", 101, 115]]], ["At this time, no surgical intervention is planned.216.What is the expected duration and route of antibiotics for this patient?", [["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["surgical intervention", "TREATMENT", 17, 38], ["antibiotics", "TREATMENT", 97, 108], ["no", "UNCERTAINTY", 14, 16], ["surgical", "OBSERVATION", 17, 25]]], ["A) Two weeks of parenteral antibiotics B) Six weeks of oral antibiotics C) Three months of parenteral and oral antibiotics D) Two months of parenteral antibiotics Answer: C The choice for diabetic foot infections (DFI) can be complex.216.The current practice that is beginning to emerge is that the role of parenteral antibiotics may be primarily to treat acute, severe soft tissue infection, which may be life-or limb-threatening, followed by transition to oral antibiotics.", [["oral", "ANATOMY", 55, 59], ["oral", "ANATOMY", 106, 110], ["foot", "ANATOMY", 197, 201], ["parenteral", "ANATOMY", 307, 317], ["soft tissue", "ANATOMY", 370, 381], ["limb", "ANATOMY", 414, 418], ["oral", "ANATOMY", 458, 462], ["diabetic foot infections", "DISEASE", 188, 212], ["soft tissue infection", "DISEASE", 370, 391], ["oral", "ORGANISM_SUBDIVISION", 55, 59], ["oral", "ORGANISM_SUBDIVISION", 106, 110], ["foot", "ORGANISM_SUBDIVISION", 197, 201], ["soft tissue", "TISSUE", 370, 381], ["limb", "ORGANISM_SUBDIVISION", 414, 418], ["oral", "ORGANISM_SUBDIVISION", 458, 462], ["parenteral antibiotics B)", "TREATMENT", 16, 41], ["oral antibiotics C", "TREATMENT", 55, 73], ["parenteral and oral antibiotics D", "TREATMENT", 91, 124], ["parenteral antibiotics", "TREATMENT", 140, 162], ["diabetic foot infections", "PROBLEM", 188, 212], ["parenteral antibiotics", "TREATMENT", 307, 329], ["acute, severe soft tissue infection", "PROBLEM", 356, 391], ["oral antibiotics", "TREATMENT", 458, 474], ["foot", "ANATOMY", 197, 201], ["infections", "OBSERVATION", 202, 212], ["acute", "OBSERVATION_MODIFIER", 356, 361], ["severe", "OBSERVATION_MODIFIER", 363, 369], ["soft tissue", "OBSERVATION_MODIFIER", 370, 381], ["infection", "OBSERVATION", 382, 391]]], ["Treating chronic osteomyelitis is not an urgent matter, and the results may be just as good and more cost-effective with oral antibiotics as opposed to parenteral therapy.", [["oral", "ANATOMY", 121, 125], ["osteomyelitis", "DISEASE", 17, 30], ["oral", "ORGANISM_SUBDIVISION", 121, 125], ["Treating chronic osteomyelitis", "PROBLEM", 0, 30], ["oral antibiotics", "TREATMENT", 121, 137], ["parenteral therapy", "TREATMENT", 152, 170], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["osteomyelitis", "OBSERVATION", 17, 30]]], ["The recommended duration of antibiotic therapy for bone infections if identifi ed has traditionally been six weeks.", [["bone", "ANATOMY", 51, 55], ["bone infections", "DISEASE", 51, 66], ["bone", "TISSUE", 51, 55], ["antibiotic therapy", "TREATMENT", 28, 46], ["bone infections", "PROBLEM", 51, 66], ["bone", "ANATOMY", 51, 55], ["infections", "OBSERVATION", 56, 66]]], ["The Infectious Diseases Society of America (ISDA) clinical practice guidelines for the diagnosis and treatment of DFIs are useful for estimating the length of therapy required based on the extent of the infection and viability of affected bone.", [["bone", "ANATOMY", 239, 243], ["Infectious Diseases", "DISEASE", 4, 23], ["infection", "DISEASE", 203, 212], ["bone", "TISSUE", 239, 243], ["treatment of DFIs", "TREATMENT", 101, 118], ["therapy", "TREATMENT", 159, 166], ["the infection", "PROBLEM", 199, 212], ["affected bone", "PROBLEM", 230, 243], ["Infectious", "OBSERVATION_MODIFIER", 4, 14], ["infection", "OBSERVATION", 203, 212], ["bone", "ANATOMY", 239, 243]]], ["Initial parenteral and then switching to oral for at least three months may be appropriate for a patient who will not undergo extensive resection of the infected bone.", [["oral", "ANATOMY", 41, 45], ["bone", "ANATOMY", 162, 166], ["oral", "ORGANISM_SUBDIVISION", 41, 45], ["patient", "ORGANISM", 97, 104], ["bone", "TISSUE", 162, 166], ["patient", "SPECIES", 97, 104], ["Initial parenteral", "TREATMENT", 0, 18], ["extensive resection", "TREATMENT", 126, 145], ["the infected bone", "PROBLEM", 149, 166], ["extensive", "OBSERVATION_MODIFIER", 126, 135], ["resection", "OBSERVATION", 136, 145], ["infected", "OBSERVATION", 153, 161], ["bone", "ANATOMY", 162, 166]]], ["Current guidelines recommend at least three months or more of antibiotic therapy when diabetic foot osteomyelitis is not treated surgically or when residual dead bone remains after surgery.", [["bone", "ANATOMY", 162, 166], ["diabetic foot osteomyelitis", "DISEASE", 86, 113], ["foot", "ORGANISM_SUBDIVISION", 95, 99], ["bone", "TISSUE", 162, 166], ["antibiotic therapy", "TREATMENT", 62, 80], ["diabetic foot osteomyelitis", "PROBLEM", 86, 113], ["residual dead bone", "PROBLEM", 148, 166], ["surgery", "TREATMENT", 181, 188], ["foot", "ANATOMY", 95, 99], ["osteomyelitis", "OBSERVATION", 100, 113], ["bone", "ANATOMY", 162, 166]]], ["A defi nitive plan cannot be established at time of diagnoses, and close follow-up must be arranged to modify therapy as needed based upon cultures and healing response..", [["A defi nitive plan", "TREATMENT", 0, 18], ["therapy", "TREATMENT", 110, 117], ["cultures", "TEST", 139, 147]]], ["His sodium is 115 mEq/L; bicarbonate is 21 mEq/L. Which of the following is the most appropriate initial intravenous therapy for this patient?", [["intravenous", "ANATOMY", 105, 116], ["sodium", "CHEMICAL", 4, 10], ["bicarbonate", "CHEMICAL", 25, 36], ["sodium", "CHEMICAL", 4, 10], ["bicarbonate", "CHEMICAL", 25, 36], ["sodium", "SIMPLE_CHEMICAL", 4, 10], ["bicarbonate", "SIMPLE_CHEMICAL", 25, 36], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 105, 116], ["patient", "ORGANISM", 134, 141], ["patient", "SPECIES", 134, 141], ["His sodium", "TEST", 0, 10], ["bicarbonate", "TEST", 25, 36], ["initial intravenous therapy", "TREATMENT", 97, 124]]], ["A) Infuse 0.9 % sodium chloride at 100 mL/h.", [["sodium chloride", "CHEMICAL", 16, 31], ["sodium chloride", "CHEMICAL", 16, 31], ["sodium chloride", "SIMPLE_CHEMICAL", 16, 31], ["A) Infuse 0.9 % sodium chloride", "TREATMENT", 0, 31]]], ["B) Infuse 0.9 % sodium chloride at 200 mL/h.", [["sodium chloride", "CHEMICAL", 16, 31], ["sodium chloride", "CHEMICAL", 16, 31], ["sodium chloride", "SIMPLE_CHEMICAL", 16, 31], ["Infuse 0.9 % sodium chloride", "TREATMENT", 3, 31]]], ["C) Administer 100-mL boluses of 3 % sodium chloride every 10 min for up to three boluses or until her symptoms resolve.", [["sodium chloride", "CHEMICAL", 36, 51], ["sodium chloride", "CHEMICAL", 36, 51], ["sodium chloride", "SIMPLE_CHEMICAL", 36, 51], ["100-mL boluses", "TREATMENT", 14, 28], ["3 % sodium chloride", "TREATMENT", 32, 51], ["her symptoms", "PROBLEM", 98, 110]]], ["D) Fluid restriction alone.ReferenceAnswer: C This patient has early signs of encephalopathy from exerciseassociated hyponatremia (EAH).", [["encephalopathy", "DISEASE", 78, 92], ["hyponatremia", "DISEASE", 117, 129], ["EAH", "DISEASE", 131, 134], ["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58], ["Fluid restriction", "TREATMENT", 3, 20], ["encephalopathy", "PROBLEM", 78, 92], ["exerciseassociated hyponatremia", "PROBLEM", 98, 129], ["Fluid restriction", "OBSERVATION", 3, 20], ["encephalopathy", "OBSERVATION", 78, 92], ["hyponatremia", "OBSERVATION", 117, 129]]], ["This is a dilutional hyponatremia due to excessive intake of hypotonic fl uids.", [["hyponatremia", "DISEASE", 21, 33], ["a dilutional hyponatremia", "PROBLEM", 8, 33], ["hypotonic fl uids", "PROBLEM", 61, 78], ["dilutional hyponatremia", "OBSERVATION", 10, 33], ["hypotonic fl", "OBSERVATION", 61, 73]]], ["Rapid correction of the serum sodium with hypertonic saline is required to avoid further brain swelling, seizures, and death.", [["serum", "ANATOMY", 24, 29], ["brain", "ANATOMY", 89, 94], ["sodium", "CHEMICAL", 30, 36], ["brain swelling", "DISEASE", 89, 103], ["seizures", "DISEASE", 105, 113], ["death", "DISEASE", 119, 124], ["sodium", "CHEMICAL", 30, 36], ["serum", "ORGANISM_SUBSTANCE", 24, 29], ["sodium", "SIMPLE_CHEMICAL", 30, 36], ["brain", "ORGAN", 89, 94], ["the serum sodium", "TEST", 20, 36], ["hypertonic saline", "TREATMENT", 42, 59], ["further brain swelling", "PROBLEM", 81, 103], ["seizures", "PROBLEM", 105, 113], ["death", "PROBLEM", 119, 124], ["brain", "ANATOMY", 89, 94], ["swelling", "OBSERVATION", 95, 103], ["seizures", "OBSERVATION", 105, 113]]], ["A 62-year-old female is evaluated for a 5-week history of nonproductive cough and fatigue over the past several months.", [["cough", "DISEASE", 72, 77], ["fatigue", "DISEASE", 82, 89], ["female", "ORGANISM", 14, 20], ["nonproductive cough", "PROBLEM", 58, 77], ["fatigue", "PROBLEM", 82, 89], ["nonproductive", "OBSERVATION_MODIFIER", 58, 71], ["cough", "OBSERVATION", 72, 77], ["fatigue", "OBSERVATION", 82, 89]]], ["The patient underwent resection of localized rectal carcinoma 16 months ago.", [["rectal carcinoma", "ANATOMY", 45, 61], ["rectal carcinoma", "DISEASE", 45, 61], ["patient", "ORGANISM", 4, 11], ["rectal carcinoma", "CANCER", 45, 61], ["patient", "SPECIES", 4, 11], ["resection", "TREATMENT", 22, 31], ["localized rectal carcinoma", "PROBLEM", 35, 61], ["resection", "OBSERVATION", 22, 31], ["localized", "OBSERVATION_MODIFIER", 35, 44], ["rectal", "ANATOMY", 45, 51], ["carcinoma", "OBSERVATION", 52, 61]]], ["This was followed by chemotherapy and radiation therapy.", [["chemotherapy", "TREATMENT", 21, 33], ["radiation therapy", "TREATMENT", 38, 55]]], ["Chest radiograph at that time was normal.ReferenceChest radiograph now shows multiple pulmonary nodules.", [["pulmonary nodules", "ANATOMY", 86, 103], ["pulmonary nodules", "PATHOLOGICAL_FORMATION", 86, 103], ["Chest radiograph", "TEST", 0, 16], ["ReferenceChest radiograph", "TEST", 41, 66], ["multiple pulmonary nodules", "PROBLEM", 77, 103], ["normal", "OBSERVATION", 34, 40], ["multiple", "OBSERVATION_MODIFIER", 77, 85], ["pulmonary", "ANATOMY", 86, 95], ["nodules", "OBSERVATION", 96, 103]]], ["Contrast-enhanced CT scan of the chest shows three nodules ranging from 1.6 to 1.9 cm in diameter.", [["chest", "ANATOMY", 33, 38], ["nodules", "ANATOMY", 51, 58], ["chest", "ORGAN", 33, 38], ["nodules", "CANCER", 51, 58], ["Contrast-enhanced CT scan of the chest", "TEST", 0, 38], ["three nodules", "PROBLEM", 45, 58], ["chest", "ANATOMY", 33, 38], ["three", "OBSERVATION_MODIFIER", 45, 50], ["nodules", "OBSERVATION", 51, 58], ["1.6 to 1.9 cm", "OBSERVATION_MODIFIER", 72, 85], ["diameter", "OBSERVATION_MODIFIER", 89, 97]]], ["Two nodules are in the right lung, and one is in the left lower lobe.ReferenceWhat is the most appropriate next step in the management of this patient?", [["nodules", "ANATOMY", 4, 11], ["right lung", "ANATOMY", 23, 33], ["left lower lobe", "ANATOMY", 53, 68], ["nodules", "CANCER", 4, 11], ["lung", "ORGAN", 29, 33], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 58, 68], ["patient", "ORGANISM", 143, 150], ["patient", "SPECIES", 143, 150], ["Two nodules", "PROBLEM", 0, 11], ["nodules", "OBSERVATION", 4, 11], ["right", "ANATOMY_MODIFIER", 23, 28], ["lung", "ANATOMY", 29, 33], ["one", "OBSERVATION_MODIFIER", 39, 42], ["left lower lobe", "ANATOMY", 53, 68]]], ["A) Bronchoscopy and biopsy B) PET scan C) Transthoracic needle aspiration of a nodule D) Observe for now and repeat CT chest in 3 months E) Video-assisted thoracoscopic surgery (VAT) Answer: C The reported yield for transthoracic needle aspiration is about 90 % for nodules of 1 to 2 cm compared to less than 50 % for bronchoscopy.", [["nodule", "ANATOMY", 79, 85], ["nodules", "ANATOMY", 266, 273], ["nodules", "CANCER", 266, 273], ["A) Bronchoscopy", "TEST", 0, 15], ["biopsy", "TEST", 20, 26], ["PET scan C", "TEST", 30, 40], ["Transthoracic needle aspiration", "TEST", 42, 73], ["a nodule D", "PROBLEM", 77, 87], ["repeat CT chest", "TEST", 109, 124], ["Video-assisted thoracoscopic surgery", "TREATMENT", 140, 176], ["transthoracic needle aspiration", "TEST", 216, 247], ["nodules", "PROBLEM", 266, 273], ["bronchoscopy", "TEST", 318, 330], ["nodule", "OBSERVATION", 79, 85], ["chest", "ANATOMY", 119, 124], ["nodules", "OBSERVATION", 266, 273], ["1 to 2 cm", "OBSERVATION_MODIFIER", 277, 286]]], ["The diagnostic yield of fi beroptic bronchoscopy depends on the lesion location and size.", [["lesion", "ANATOMY", 64, 70], ["fi beroptic bronchoscopy", "TREATMENT", 24, 48], ["lesion", "OBSERVATION", 64, 70], ["size", "OBSERVATION_MODIFIER", 84, 88]]], ["The diagnostic yield for lesions greater than 3 cm in diameter by bronchoscopy is 80 %.", [["lesions", "ANATOMY", 25, 32], ["lesions", "CANCER", 25, 32], ["lesions", "PROBLEM", 25, 32], ["bronchoscopy", "TEST", 66, 78], ["lesions", "OBSERVATION", 25, 32], ["greater", "OBSERVATION_MODIFIER", 33, 40], ["than 3 cm", "OBSERVATION_MODIFIER", 41, 50]]], ["For lesions located in the lower lobe, basilar segments or in the apical segments of the upper lobes, yield is 58 %, compared with 83 % for other locations.", [["lesions", "ANATOMY", 4, 11], ["lower lobe", "ANATOMY", 27, 37], ["basilar segments", "ANATOMY", 39, 55], ["apical segments", "ANATOMY", 66, 81], ["upper lobes", "ANATOMY", 89, 100], ["lesions", "CANCER", 4, 11], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 27, 37], ["basilar segments", "MULTI-TISSUE_STRUCTURE", 39, 55], ["apical segments", "MULTI-TISSUE_STRUCTURE", 66, 81], ["upper lobes", "MULTI-TISSUE_STRUCTURE", 89, 100], ["lesions", "PROBLEM", 4, 11], ["lesions", "OBSERVATION", 4, 11], ["lower lobe", "ANATOMY", 27, 37], ["basilar", "ANATOMY_MODIFIER", 39, 46], ["segments", "ANATOMY_MODIFIER", 47, 55], ["apical", "ANATOMY_MODIFIER", 66, 72], ["segments", "ANATOMY_MODIFIER", 73, 81], ["upper lobes", "ANATOMY", 89, 100], ["58 %", "OBSERVATION_MODIFIER", 111, 115]]], ["CT-guided transthoracic needle biopsy would have signifi cantly higher yield for nodules of this size than would bronchoscopy.ReferenceLacasse Y, Wong E, Guyatt GH, Cook DJ.", [["nodules", "ANATOMY", 81, 88], ["CT-guided transthoracic needle biopsy", "TEST", 0, 37], ["nodules", "PROBLEM", 81, 88], ["bronchoscopy", "TEST", 113, 125], ["nodules", "OBSERVATION", 81, 88], ["size", "OBSERVATION_MODIFIER", 97, 101], ["Cook DJ", "OBSERVATION", 165, 172]]], ["Transthoracic needle aspiration biopsy for the diagnosis of localized pulmonary lesions: a meta-analysis.", [["pulmonary lesions", "ANATOMY", 70, 87], ["pulmonary lesions", "DISEASE", 70, 87], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 70, 87], ["Transthoracic needle aspiration biopsy", "TEST", 0, 38], ["localized pulmonary lesions", "PROBLEM", 60, 87], ["a meta-analysis", "TEST", 89, 104], ["localized", "OBSERVATION_MODIFIER", 60, 69], ["pulmonary", "ANATOMY", 70, 79], ["lesions", "OBSERVATION", 80, 87]]], ["You are called to see a patient on the cardiology service with right-sided weakness.", [["patient", "ORGANISM", 24, 31], ["patient", "SPECIES", 24, 31], ["right-sided weakness", "PROBLEM", 63, 83], ["right", "ANATOMY_MODIFIER", 63, 68], ["sided", "ANATOMY_MODIFIER", 69, 74], ["weakness", "OBSERVATION", 75, 83]]], ["He is a 75-year-old male who underwent cardiac catheterization procedure because of typical chest pain presentation.", [["cardiac", "ANATOMY", 39, 46], ["chest", "ANATOMY", 92, 97], ["chest pain", "DISEASE", 92, 102], ["male", "ORGANISM", 20, 24], ["cardiac", "ORGAN", 39, 46], ["chest", "ORGANISM_SUBDIVISION", 92, 97], ["cardiac catheterization procedure", "TREATMENT", 39, 72], ["typical chest pain", "PROBLEM", 84, 102], ["cardiac", "ANATOMY", 39, 46], ["catheterization", "OBSERVATION", 47, 62], ["chest", "ANATOMY", 92, 97], ["pain", "OBSERVATION", 98, 102]]], ["A coronary angiogram revealed signifi cant in-stent restenosis, which was managed by balloon angioplasty.", [["coronary", "ANATOMY", 2, 10], ["balloon", "ANATOMY", 85, 92], ["restenosis", "DISEASE", 52, 62], ["coronary", "MULTI-TISSUE_STRUCTURE", 2, 10], ["A coronary angiogram", "TEST", 0, 20], ["signifi cant in-stent restenosis", "PROBLEM", 30, 62], ["balloon angioplasty", "TREATMENT", 85, 104], ["coronary", "ANATOMY", 2, 10], ["stent", "OBSERVATION_MODIFIER", 46, 51], ["restenosis", "OBSERVATION", 52, 62], ["balloon angioplasty", "OBSERVATION", 85, 104]]], ["The patient was given 300 mg of Plavix in the catheterization lab.", [["Plavix", "CHEMICAL", 32, 38], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["Plavix", "TREATMENT", 32, 38]]], ["On physical exam, his blood pressure is 180/95 mmHg, heart rate of 110 BPM, and his temperature was normal.", [["blood", "ANATOMY", 22, 27], ["heart", "ANATOMY", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 22, 27], ["heart", "ORGAN", 53, 58], ["physical exam", "TEST", 3, 16], ["his blood pressure", "TEST", 18, 36], ["heart rate", "TEST", 53, 63], ["his temperature", "TEST", 80, 95], ["heart", "ANATOMY", 53, 58], ["normal", "OBSERVATION", 100, 106]]], ["Cardiac and chest examination are normal.", [["Cardiac", "ANATOMY", 0, 7], ["chest", "ANATOMY", 12, 17], ["Cardiac", "MULTI-TISSUE_STRUCTURE", 0, 7], ["chest", "ORGAN", 12, 17], ["Cardiac and chest examination", "TEST", 0, 29], ["chest", "ANATOMY", 12, 17], ["normal", "OBSERVATION", 34, 40]]], ["On neurologic examination, the right side of the body is 3/5, while the left side is 5/5.", [["neurologic", "ANATOMY", 3, 13], ["right side", "ANATOMY", 31, 41], ["body", "ANATOMY", 49, 53], ["body", "ORGANISM_SUBDIVISION", 49, 53], ["neurologic examination", "TEST", 3, 25], ["right", "ANATOMY_MODIFIER", 31, 36], ["body", "ANATOMY_MODIFIER", 49, 53], ["3/5", "OBSERVATION", 57, 60], ["left", "ANATOMY_MODIFIER", 72, 76]]], ["The patient denies chest pain, no nausea, or vomiting.ReferenceWhat is your next step in management?", [["chest", "ANATOMY", 19, 24], ["chest pain", "DISEASE", 19, 29], ["nausea", "DISEASE", 34, 40], ["vomiting", "DISEASE", 45, 53], ["patient", "ORGANISM", 4, 11], ["chest", "ORGANISM_SUBDIVISION", 19, 24], ["patient", "SPECIES", 4, 11], ["chest pain", "PROBLEM", 19, 29], ["nausea", "PROBLEM", 34, 40], ["vomiting", "PROBLEM", 45, 53], ["your next step in management", "TREATMENT", 71, 99], ["chest", "ANATOMY", 19, 24], ["no", "UNCERTAINTY", 31, 33], ["nausea", "OBSERVATION", 34, 40]]], ["A) MRI of the head B) CT angiogram of the chest C) Start tissue plasminogen activator (TPA) D) Carotid Doppler ultrasound E) Transesophageal echocardiogram (TEE) Answer: A Ischemic stroke related to catheterization should be suspected in a patient who develops neurologic symptoms during or immediately post catheterization.", [["head B", "ANATOMY", 14, 20], ["neurologic", "ANATOMY", 261, 271], ["Ischemic stroke", "DISEASE", 172, 187], ["head B", "CANCER", 14, 20], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 57, 85], ["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 240, 247], ["A) MRI of the head", "TEST", 0, 18], ["CT angiogram of the chest C", "TEST", 22, 49], ["Start tissue plasminogen activator (TPA)", "TREATMENT", 51, 91], ["Carotid Doppler ultrasound E", "TEST", 95, 123], ["Transesophageal echocardiogram", "TEST", 125, 155], ["TEE", "TEST", 157, 160], ["A Ischemic stroke", "PROBLEM", 170, 187], ["catheterization", "TREATMENT", 199, 214], ["neurologic symptoms", "PROBLEM", 261, 280], ["catheterization", "TEST", 308, 323], ["head", "ANATOMY", 14, 18], ["chest", "ANATOMY", 42, 47], ["Carotid", "ANATOMY", 95, 102], ["Ischemic", "OBSERVATION_MODIFIER", 172, 180], ["stroke", "OBSERVATION", 181, 187], ["catheterization", "OBSERVATION", 199, 214]]], ["MRI of the head would be appropriate to diagnose the stroke early as CT scan may miss early changes.", [["head", "ANATOMY", 11, 15], ["stroke", "DISEASE", 53, 59], ["head", "ORGAN", 11, 15], ["MRI of the head", "TEST", 0, 15], ["the stroke", "PROBLEM", 49, 59], ["CT scan", "TEST", 69, 76], ["head", "ANATOMY", 11, 15], ["stroke", "OBSERVATION", 53, 59]]], ["In most cases, the etiology is felt to be embolic due to atherosclerotic debris and not thrombus, and therefore acute therapy with systemic thrombolysis is not routinely performed.", [["atherosclerotic debris", "ANATOMY", 57, 79], ["thrombus", "ANATOMY", 88, 96], ["embolic", "DISEASE", 42, 49], ["atherosclerotic", "DISEASE", 57, 72], ["thrombus", "DISEASE", 88, 96], ["thrombus", "PATHOLOGICAL_FORMATION", 88, 96], ["embolic", "PROBLEM", 42, 49], ["atherosclerotic debris", "PROBLEM", 57, 79], ["thrombus", "PROBLEM", 88, 96], ["acute therapy", "TREATMENT", 112, 125], ["systemic thrombolysis", "TREATMENT", 131, 152], ["felt to be", "UNCERTAINTY", 31, 41], ["embolic", "OBSERVATION", 42, 49], ["atherosclerotic", "OBSERVATION_MODIFIER", 57, 72], ["debris", "OBSERVATION", 73, 79], ["not", "UNCERTAINTY", 84, 87], ["thrombus", "OBSERVATION", 88, 96], ["acute", "OBSERVATION_MODIFIER", 112, 117], ["therapy", "OBSERVATION", 118, 125], ["systemic", "OBSERVATION_MODIFIER", 131, 139], ["thrombolysis", "OBSERVATION", 140, 152]]], ["CT angiogram of the chest will help in diagnosing aortic dissection, which may also complicate cardiac catheterization.", [["chest", "ANATOMY", 20, 25], ["aortic", "ANATOMY", 50, 56], ["cardiac", "ANATOMY", 95, 102], ["chest", "ORGAN", 20, 25], ["aortic", "MULTI-TISSUE_STRUCTURE", 50, 56], ["cardiac", "ORGAN", 95, 102], ["CT angiogram of the chest", "TEST", 0, 25], ["aortic dissection", "PROBLEM", 50, 67], ["cardiac catheterization", "TEST", 95, 118], ["chest", "ANATOMY", 20, 25], ["aortic", "ANATOMY", 50, 56], ["dissection", "OBSERVATION", 57, 67], ["catheterization", "OBSERVATION", 103, 118]]], ["This patient did not have chest pain to suggest dissection.", [["chest", "ANATOMY", 26, 31], ["chest pain", "DISEASE", 26, 36], ["patient", "ORGANISM", 5, 12], ["chest", "ORGANISM_SUBDIVISION", 26, 31], ["patient", "SPECIES", 5, 12], ["chest pain", "PROBLEM", 26, 36], ["dissection", "PROBLEM", 48, 58], ["chest", "ANATOMY", 26, 31], ["dissection", "OBSERVATION", 48, 58]]], ["A previously healthy 25-year-old woman presents with a one-week history of polyuria, polydipsia, and 20-lb weight loss.", [["polyuria", "DISEASE", 75, 83], ["polydipsia", "DISEASE", 85, 95], ["weight loss", "DISEASE", 107, 118], ["woman", "ORGANISM", 33, 38], ["woman", "SPECIES", 33, 38], ["polyuria", "PROBLEM", 75, 83], ["polydipsia", "PROBLEM", 85, 95], ["20-lb weight loss", "PROBLEM", 101, 118], ["polyuria", "OBSERVATION", 75, 83], ["polydipsia", "OBSERVATION", 85, 95]]], ["On the day of presentation, she developed nausea and abdominal pain.", [["abdominal", "ANATOMY", 53, 62], ["nausea", "DISEASE", 42, 48], ["abdominal pain", "DISEASE", 53, 67], ["abdominal", "ORGANISM_SUBDIVISION", 53, 62], ["nausea", "PROBLEM", 42, 48], ["abdominal pain", "PROBLEM", 53, 67], ["nausea", "OBSERVATION", 42, 48], ["abdominal", "ANATOMY", 53, 62], ["pain", "OBSERVATION", 63, 67]]], ["Emergency room staff asks you to assess the patient.ReferenceOn physical exam, she is severely dehydrated with decreased skin turgor; blood pressure is 80/palp mmHg and heart rate is 120.", [["skin", "ANATOMY", 121, 125], ["blood", "ANATOMY", 134, 139], ["heart", "ANATOMY", 169, 174], ["patient", "ORGANISM", 44, 51], ["skin", "ORGAN", 121, 125], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["palp", "ORGANISM_SUBDIVISION", 155, 159], ["heart", "ORGAN", 169, 174], ["patient", "SPECIES", 44, 51], ["ReferenceOn physical exam", "TEST", 52, 77], ["severely dehydrated", "PROBLEM", 86, 105], ["decreased skin turgor", "PROBLEM", 111, 132], ["blood pressure", "TEST", 134, 148], ["heart rate", "TEST", 169, 179], ["severely", "OBSERVATION_MODIFIER", 86, 94], ["dehydrated", "OBSERVATION", 95, 105], ["skin turgor", "OBSERVATION", 121, 132], ["heart", "ANATOMY", 169, 174]]], ["Finger stick blood sugar is 700 and urine dipstick indicates 3+ ketones and 3+ blood.", [["blood", "ANATOMY", 13, 18], ["urine", "ANATOMY", 36, 41], ["blood", "ANATOMY", 79, 84], ["sugar", "CHEMICAL", 19, 24], ["3+ ketones", "CHEMICAL", 61, 71], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["sugar", "SIMPLE_CHEMICAL", 19, 24], ["urine", "ORGANISM_SUBSTANCE", 36, 41], ["3+ ketones", "SIMPLE_CHEMICAL", 61, 71], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["Finger stick blood sugar", "TEST", 0, 24], ["urine dipstick", "TEST", 36, 50], ["ketones", "TEST", 64, 71], ["blood", "TEST", 79, 84]]], ["Urine hCG is negative.ReferenceWhat is the most appropriate initial step in the treatment of this patient?", [["Urine", "ANATOMY", 0, 5], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["hCG", "GENE_OR_GENE_PRODUCT", 6, 9], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["Urine hCG", "TEST", 0, 9], ["negative", "OBSERVATION", 13, 21]]], ["A) 10 units SC insulin B) 10 units IV insulin C) 1 l half normal saline at 200 cc/h D) 1 l of normal saline bolus E) 0.5 l half normal saline at 200 cc/h Answer: D In patients with evidence of diabetic ketoacidosis (DKA), volume resuscitation should be given prior to insulin.", [["insulin B", "CHEMICAL", 15, 24], ["diabetic ketoacidosis", "DISEASE", 193, 214], ["DKA", "DISEASE", 216, 219], ["insulin B", "GENE_OR_GENE_PRODUCT", 15, 24], ["insulin C", "GENE_OR_GENE_PRODUCT", 38, 47], ["saline", "SIMPLE_CHEMICAL", 65, 71], ["saline", "SIMPLE_CHEMICAL", 101, 107], ["saline", "SIMPLE_CHEMICAL", 135, 141], ["patients", "ORGANISM", 167, 175], ["insulin", "GENE_OR_GENE_PRODUCT", 268, 275], ["insulin", "PROTEIN", 268, 275], ["patients", "SPECIES", 167, 175], ["SC insulin B)", "TREATMENT", 12, 25], ["IV insulin C)", "TREATMENT", 35, 48], ["normal saline", "TREATMENT", 58, 71], ["normal saline bolus E", "TREATMENT", 94, 115], ["normal saline", "TREATMENT", 128, 141], ["diabetic ketoacidosis", "PROBLEM", 193, 214], ["DKA", "PROBLEM", 216, 219], ["volume resuscitation", "TREATMENT", 222, 242], ["insulin", "TREATMENT", 268, 275], ["diabetic", "OBSERVATION_MODIFIER", 193, 201], ["ketoacidosis", "OBSERVATION", 202, 214]]], ["Fluid resuscitation is a critical component of treating patients with DKA.", [["DKA", "DISEASE", 70, 73], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Fluid resuscitation", "TREATMENT", 0, 19], ["DKA", "PROBLEM", 70, 73], ["DKA", "OBSERVATION", 70, 73]]], ["Insulin therapy will cause intracellular transport of glucose which may result in a significant fluid shift from the extracellular to the intracellular compartment.", [["intracellular", "ANATOMY", 27, 40], ["fluid", "ANATOMY", 96, 101], ["extracellular", "ANATOMY", 117, 130], ["intracellular compartment", "ANATOMY", 138, 163], ["Insulin", "CHEMICAL", 0, 7], ["glucose", "CHEMICAL", 54, 61], ["glucose", "CHEMICAL", 54, 61], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["glucose", "SIMPLE_CHEMICAL", 54, 61], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 117, 130], ["intracellular compartment", "CELLULAR_COMPONENT", 138, 163], ["Insulin therapy", "TREATMENT", 0, 15], ["intracellular transport of glucose", "PROBLEM", 27, 61], ["a significant fluid shift", "PROBLEM", 82, 107], ["significant", "OBSERVATION_MODIFIER", 84, 95], ["fluid shift", "OBSERVATION", 96, 107], ["extracellular", "ANATOMY_MODIFIER", 117, 130], ["intracellular", "ANATOMY_MODIFIER", 138, 151], ["compartment", "ANATOMY_MODIFIER", 152, 163]]], ["This may increase the risk of hypovolemic shock and thromboembolism.", [["hypovolemic shock", "DISEASE", 30, 47], ["thromboembolism", "DISEASE", 52, 67], ["hypovolemic shock", "PROBLEM", 30, 47], ["thromboembolism", "PROBLEM", 52, 67], ["risk of", "UNCERTAINTY", 22, 29], ["hypovolemic shock", "OBSERVATION", 30, 47], ["thromboembolism", "OBSERVATION", 52, 67]]], ["Insulin should be started after IV fluid replacement is started.", [["Insulin", "CHEMICAL", 0, 7], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["fluid", "ORGANISM_SUBSTANCE", 35, 40], ["Insulin", "TREATMENT", 0, 7], ["IV fluid replacement", "TREATMENT", 32, 52]]], ["Guidelines suggest one liter of fluid given before insulin is started.", [["fluid", "ORGANISM_SUBSTANCE", 32, 37], ["insulin", "GENE_OR_GENE_PRODUCT", 51, 58], ["fluid", "TREATMENT", 32, 37], ["insulin", "TREATMENT", 51, 58], ["fluid", "OBSERVATION", 32, 37]]], ["Which of the following is the most appropriate medications for this patient's presumed MRSA pneumonia?", [["pneumonia", "DISEASE", 92, 101], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["MRSA", "SPECIES", 87, 91], ["appropriate medications", "TREATMENT", 35, 58], ["MRSA pneumonia", "PROBLEM", 87, 101], ["MRSA", "OBSERVATION_MODIFIER", 87, 91], ["pneumonia", "OBSERVATION", 92, 101]]], ["A) Vancomycin B) Daptomycin C) Linezolid D) Ceftriaxone and erythromycin E) Clindamycin Answer: C United States guidelines recommend either linezolid or vancomycin as the fi rst-line treatment for hospital-acquired (nosocomial) MRSA pneumonia.", [["Vancomycin B", "CHEMICAL", 3, 15], ["Daptomycin", "CHEMICAL", 17, 27], ["Linezolid", "CHEMICAL", 31, 40], ["Ceftriaxone", "CHEMICAL", 44, 55], ["erythromycin", "CHEMICAL", 60, 72], ["Clindamycin", "CHEMICAL", 76, 87], ["linezolid", "CHEMICAL", 140, 149], ["vancomycin", "CHEMICAL", 153, 163], ["hospital-acquired (nosocomial) MRSA pneumonia", "DISEASE", 197, 242], ["Vancomycin B", "CHEMICAL", 3, 15], ["Daptomycin C", "CHEMICAL", 17, 29], ["Linezolid D", "CHEMICAL", 31, 42], ["Ceftriaxone", "CHEMICAL", 44, 55], ["erythromycin E", "CHEMICAL", 60, 74], ["Clindamycin", "CHEMICAL", 76, 87], ["linezolid", "CHEMICAL", 140, 149], ["vancomycin", "CHEMICAL", 153, 163], ["Vancomycin B) Daptomycin C", "SIMPLE_CHEMICAL", 3, 29], ["Linezolid D", "SIMPLE_CHEMICAL", 31, 42], ["Ceftriaxone", "SIMPLE_CHEMICAL", 44, 55], ["erythromycin E", "SIMPLE_CHEMICAL", 60, 74], ["Clindamycin", "SIMPLE_CHEMICAL", 76, 87], ["linezolid", "SIMPLE_CHEMICAL", 140, 149], ["vancomycin", "SIMPLE_CHEMICAL", 153, 163], ["MRSA", "SPECIES", 228, 232], ["A) Vancomycin B) Daptomycin C) Linezolid D", "TREATMENT", 0, 42], ["Ceftriaxone", "TREATMENT", 44, 55], ["erythromycin E)", "TREATMENT", 60, 75], ["Clindamycin", "TREATMENT", 76, 87], ["linezolid", "TREATMENT", 140, 149], ["vancomycin", "TREATMENT", 153, 163], ["the fi rst-line treatment", "TREATMENT", 167, 192], ["hospital-acquired (nosocomial) MRSA pneumonia", "PROBLEM", 197, 242], ["MRSA", "OBSERVATION_MODIFIER", 228, 232], ["pneumonia", "OBSERVATION", 233, 242]]], ["Some studies have suggested that linezolid is better than vancomycin against probable MRSA nosocomial pneumonia.", [["linezolid", "CHEMICAL", 33, 42], ["vancomycin", "CHEMICAL", 58, 68], ["nosocomial pneumonia", "DISEASE", 91, 111], ["linezolid", "CHEMICAL", 33, 42], ["vancomycin", "CHEMICAL", 58, 68], ["linezolid", "SIMPLE_CHEMICAL", 33, 42], ["vancomycin", "SIMPLE_CHEMICAL", 58, 68], ["MRSA", "SPECIES", 86, 90], ["Some studies", "TEST", 0, 12], ["linezolid", "TREATMENT", 33, 42], ["vancomycin", "TREATMENT", 58, 68], ["MRSA nosocomial pneumonia", "PROBLEM", 86, 111], ["MRSA", "OBSERVATION_MODIFIER", 86, 90], ["nosocomial", "OBSERVATION_MODIFIER", 91, 101], ["pneumonia", "OBSERVATION", 102, 111]]], ["This may be due to the fact that the penetration of linezolid into bronchial fl uids is much higher than that of vancomycin.", [["bronchial fl uids", "ANATOMY", 67, 84], ["linezolid", "CHEMICAL", 52, 61], ["vancomycin", "CHEMICAL", 113, 123], ["linezolid", "CHEMICAL", 52, 61], ["vancomycin", "CHEMICAL", 113, 123], ["linezolid", "SIMPLE_CHEMICAL", 52, 61], ["vancomycin", "SIMPLE_CHEMICAL", 113, 123], ["linezolid", "TREATMENT", 52, 61], ["bronchial fl uids", "TEST", 67, 84], ["vancomycin", "TREATMENT", 113, 123], ["may be due to", "UNCERTAINTY", 5, 18], ["bronchial", "ANATOMY", 67, 76]]], ["Daptomycin is inhibited by pulmonary surfactant and this is not indicated here.229.A 47-year-old man is admitted to the hospital with an acute decompensation of his alcoholic-related cirrhosis.", [["pulmonary", "ANATOMY", 27, 36], ["Daptomycin", "CHEMICAL", 0, 10], ["cirrhosis", "DISEASE", 183, 192], ["Daptomycin", "CHEMICAL", 0, 10], ["Daptomycin", "SIMPLE_CHEMICAL", 0, 10], ["pulmonary", "ORGAN", 27, 36], ["man", "ORGANISM", 97, 100], ["man", "SPECIES", 97, 100], ["Daptomycin", "TREATMENT", 0, 10], ["pulmonary surfactant", "TREATMENT", 27, 47], ["an acute decompensation", "PROBLEM", 134, 157], ["his alcoholic-related cirrhosis", "PROBLEM", 161, 192], ["pulmonary", "ANATOMY", 27, 36], ["surfactant", "OBSERVATION", 37, 47], ["acute", "OBSERVATION_MODIFIER", 137, 142], ["decompensation", "OBSERVATION", 143, 157], ["alcoholic", "OBSERVATION", 165, 174], ["cirrhosis", "OBSERVATION", 183, 192]]], ["He presents to the emergency room confused with ascites.", [["ascites", "ANATOMY", 48, 55], ["ascites", "DISEASE", 48, 55], ["ascites", "PROBLEM", 48, 55], ["ascites", "OBSERVATION", 48, 55]]], ["On physical exam, he is clearly jaundiced with icteric sclera.", [["sclera", "ANATOMY", 55, 61], ["sclera", "TISSUE", 55, 61], ["physical exam", "TEST", 3, 16], ["clearly jaundiced", "PROBLEM", 24, 41], ["icteric sclera", "PROBLEM", 47, 61], ["jaundiced", "OBSERVATION", 32, 41], ["icteric sclera", "OBSERVATION", 47, 61]]], ["Additionally, he has a distended abdomen with a fl uid wave on physical exam.", [["abdomen", "ANATOMY", 33, 40], ["abdomen", "ORGAN", 33, 40], ["a distended abdomen", "PROBLEM", 21, 40], ["physical exam", "TEST", 63, 76], ["distended", "OBSERVATION", 23, 32], ["abdomen", "ANATOMY", 33, 40]]], ["There is poor skin turgor.", [["skin", "ANATOMY", 14, 18], ["skin", "ORGAN", 14, 18], ["poor skin turgor", "PROBLEM", 9, 25], ["poor", "OBSERVATION_MODIFIER", 9, 13], ["skin turgor", "OBSERVATION", 14, 25]]], ["He has asterixis on extension of his hands.", [["He", "ORGANISM", 0, 2], ["hands", "ORGANISM_SUBDIVISION", 37, 42], ["asterixis", "PROBLEM", 7, 16], ["asterixis", "OBSERVATION", 7, 16], ["hands", "ANATOMY", 37, 42]]], ["Preliminary workup reveals an ammonia level of 110 mg/dL, a total bilirubin of 7.1, an INR of 1.6, and a platelet count of 95,000.", [["platelet", "ANATOMY", 105, 113], ["ammonia", "CHEMICAL", 30, 37], ["bilirubin", "CHEMICAL", 66, 75], ["ammonia", "CHEMICAL", 30, 37], ["bilirubin", "CHEMICAL", 66, 75], ["ammonia", "SIMPLE_CHEMICAL", 30, 37], ["bilirubin", "SIMPLE_CHEMICAL", 66, 75], ["platelet", "CELL", 105, 113], ["Preliminary workup", "TEST", 0, 18], ["an ammonia level", "TEST", 27, 43], ["a total bilirubin", "TEST", 58, 75], ["an INR", "TEST", 84, 90], ["a platelet count", "TEST", 103, 119], ["platelet count", "OBSERVATION_MODIFIER", 105, 119]]], ["The potassium level is 3.1, BUN is 37, and creatinine is 1.5.229.Which of the following is NOT likely to be contributing to this patient's confusion?", [["potassium", "CHEMICAL", 4, 13], ["creatinine", "CHEMICAL", 43, 53], ["confusion", "DISEASE", 139, 148], ["potassium", "CHEMICAL", 4, 13], ["creatinine", "CHEMICAL", 43, 53], ["potassium", "SIMPLE_CHEMICAL", 4, 13], ["BUN", "SIMPLE_CHEMICAL", 28, 31], ["creatinine", "SIMPLE_CHEMICAL", 43, 53], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["The potassium level", "TEST", 0, 19], ["BUN", "TEST", 28, 31], ["creatinine", "TEST", 43, 53], ["this patient's confusion", "PROBLEM", 124, 148], ["NOT likely to be", "UNCERTAINTY", 91, 107]]], ["A) Bacterial infection of the ascites B) Hypokalemia C) Acute kidney injury D) Volume depletion E) Jaundice229.Answer: E The morbidity and mortality associated with elevated conjugated hyperbilirubinemia result from the underlying disease process.", [["ascites", "ANATOMY", 30, 37], ["kidney", "ANATOMY", 62, 68], ["infection", "DISEASE", 13, 22], ["ascites", "DISEASE", 30, 37], ["Acute kidney injury", "DISEASE", 56, 75], ["hyperbilirubinemia", "DISEASE", 185, 203], ["kidney", "ORGAN", 62, 68], ["Bacterial infection of the ascites", "PROBLEM", 3, 37], ["Hypokalemia C", "PROBLEM", 41, 54], ["Acute kidney injury", "PROBLEM", 56, 75], ["Volume depletion E", "PROBLEM", 79, 97], ["elevated conjugated hyperbilirubinemia", "PROBLEM", 165, 203], ["the underlying disease process", "PROBLEM", 216, 246], ["Bacterial", "OBSERVATION_MODIFIER", 3, 12], ["infection", "OBSERVATION", 13, 22], ["ascites", "OBSERVATION", 30, 37], ["Acute", "OBSERVATION_MODIFIER", 56, 61], ["kidney", "ANATOMY", 62, 68], ["injury", "OBSERVATION", 69, 75], ["Volume depletion", "OBSERVATION", 79, 95], ["hyperbilirubinemia", "OBSERVATION", 185, 203], ["disease", "OBSERVATION", 231, 238]]], ["Conjugated bilirubin causes no direct toxicity to neural tissue in adults.", [["neural tissue", "ANATOMY", 50, 63], ["bilirubin", "CHEMICAL", 11, 20], ["toxicity", "DISEASE", 38, 46], ["bilirubin", "CHEMICAL", 11, 20], ["bilirubin", "SIMPLE_CHEMICAL", 11, 20], ["neural tissue", "TISSUE", 50, 63], ["Conjugated bilirubin", "TEST", 0, 20], ["direct toxicity", "PROBLEM", 31, 46], ["no", "UNCERTAINTY", 28, 30], ["neural tissue", "OBSERVATION", 50, 63]]], ["Bilirubin levels often correlate strongly with, but do not contribute to, short-term mortality.", [["Bilirubin", "CHEMICAL", 0, 9], ["Bilirubin", "GENE_OR_GENE_PRODUCT", 0, 9], ["Bilirubin levels", "TEST", 0, 16], ["short-term mortality", "PROBLEM", 74, 94]]], ["Bacterial infections, including spontaneous bacterial peritonitis, dehydration, acute renal failure, electrolyte abnormalities, and metabolic acidosis are all very common causes of worsening hepatic encephalopathy.", [["renal", "ANATOMY", 86, 91], ["hepatic", "ANATOMY", 191, 198], ["Bacterial infections", "DISEASE", 0, 20], ["bacterial peritonitis", "DISEASE", 44, 65], ["dehydration", "DISEASE", 67, 78], ["acute renal failure", "DISEASE", 80, 99], ["electrolyte abnormalities", "DISEASE", 101, 126], ["metabolic acidosis", "DISEASE", 132, 150], ["hepatic encephalopathy", "DISEASE", 191, 213], ["renal", "ORGAN", 86, 91], ["hepatic", "ORGAN", 191, 198], ["Bacterial infections", "PROBLEM", 0, 20], ["spontaneous bacterial peritonitis", "PROBLEM", 32, 65], ["dehydration", "PROBLEM", 67, 78], ["acute renal failure", "PROBLEM", 80, 99], ["electrolyte abnormalities", "PROBLEM", 101, 126], ["metabolic acidosis", "PROBLEM", 132, 150], ["worsening hepatic encephalopathy", "PROBLEM", 181, 213], ["infections", "OBSERVATION", 10, 20], ["spontaneous", "OBSERVATION_MODIFIER", 32, 43], ["bacterial", "OBSERVATION_MODIFIER", 44, 53], ["peritonitis", "OBSERVATION", 54, 65], ["dehydration", "OBSERVATION_MODIFIER", 67, 78], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["renal", "ANATOMY", 86, 91], ["failure", "OBSERVATION", 92, 99], ["electrolyte abnormalities", "OBSERVATION", 101, 126], ["metabolic acidosis", "OBSERVATION", 132, 150], ["worsening", "OBSERVATION_MODIFIER", 181, 190], ["hepatic", "ANATOMY", 191, 198], ["encephalopathy", "OBSERVATION", 199, 213]]], ["A 58-year-old male is admitted for worsening ascites.", [["ascites", "ANATOMY", 45, 52], ["ascites", "DISEASE", 45, 52], ["male", "ORGANISM", 14, 18], ["worsening ascites", "PROBLEM", 35, 52], ["worsening", "OBSERVATION_MODIFIER", 35, 44], ["ascites", "OBSERVATION", 45, 52]]], ["His past medical history is signifi cant for chronic hepatitis C and hypertension.", [["chronic hepatitis C", "DISEASE", 45, 64], ["hypertension", "DISEASE", 69, 81], ["chronic hepatitis C", "PROBLEM", 45, 64], ["hypertension", "PROBLEM", 69, 81], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["hepatitis", "OBSERVATION", 53, 62], ["hypertension", "OBSERVATION", 69, 81]]], ["He denies nausea or vomiting.", [["nausea", "DISEASE", 10, 16], ["vomiting", "DISEASE", 20, 28], ["nausea", "PROBLEM", 10, 16], ["vomiting", "PROBLEM", 20, 28]]], ["On physical examination, he is afebrile, blood pressure is 110/70 mmHg, heart rate is 100 bpm, and respiratory rate is 22/min.", [["blood", "ANATOMY", 41, 46], ["heart", "ANATOMY", 72, 77], ["respiratory", "ANATOMY", 99, 110], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["heart", "ORGAN", 72, 77], ["physical examination", "TEST", 3, 23], ["afebrile", "PROBLEM", 31, 39], ["blood pressure", "TEST", 41, 55], ["heart rate", "TEST", 72, 82], ["respiratory rate", "TEST", 99, 115], ["heart", "ANATOMY", 72, 77]]], ["There is ascites and bipedal pitting edema.", [["ascites", "ANATOMY", 9, 16], ["ascites", "DISEASE", 9, 16], ["edema", "DISEASE", 37, 42], ["pitting edema", "PATHOLOGICAL_FORMATION", 29, 42], ["ascites", "PROBLEM", 9, 16], ["bipedal pitting edema", "PROBLEM", 21, 42], ["ascites", "OBSERVATION", 9, 16], ["bipedal", "OBSERVATION_MODIFIER", 21, 28], ["pitting", "OBSERVATION_MODIFIER", 29, 36], ["edema", "OBSERVATION", 37, 42]]], ["Lung auscultation reveals minimal crackles in both lung bases.", [["Lung", "ANATOMY", 0, 4], ["lung", "ANATOMY", 51, 55], ["Lung", "ORGAN", 0, 4], ["lung", "ORGAN", 51, 55], ["Lung auscultation", "TEST", 0, 17], ["minimal crackles in both lung bases", "PROBLEM", 26, 61], ["auscultation", "OBSERVATION", 5, 17], ["minimal", "OBSERVATION_MODIFIER", 26, 33], ["crackles", "OBSERVATION", 34, 42], ["both", "ANATOMY_MODIFIER", 46, 50], ["lung", "ANATOMY", 51, 55], ["bases", "ANATOMY_MODIFIER", 56, 61]]], ["Laboratory test reveals a serum creatinine of 3.7 mg/dL.", [["serum", "ANATOMY", 26, 31], ["creatinine", "CHEMICAL", 32, 42], ["creatinine", "CHEMICAL", 32, 42], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["creatinine", "SIMPLE_CHEMICAL", 32, 42], ["Laboratory test", "TEST", 0, 15], ["a serum creatinine", "TEST", 24, 42]]], ["Furosemide was stopped.", [["Furosemide", "CHEMICAL", 0, 10], ["Furosemide", "CHEMICAL", 0, 10], ["Furosemide", "SIMPLE_CHEMICAL", 0, 10], ["Furosemide", "TREATMENT", 0, 10]]], ["He was given 1.5 l of isotonic saline with no improvement of his renal function.ReferenceWhich of the following is the most appropriate diagnostic test to perform next?", [["renal", "ANATOMY", 65, 70], ["He", "ORGANISM", 0, 2], ["saline", "SIMPLE_CHEMICAL", 31, 37], ["renal", "ORGAN", 65, 70], ["isotonic saline", "TREATMENT", 22, 37], ["renal", "ANATOMY", 65, 70], ["function", "OBSERVATION", 71, 79]]], ["A) Paracentesis B) Serum osmolality C) Urine electrolytes and urine creatinine D) ALT and AST E) Renal ultrasound Answer: C This patient has possible hepatorenal syndrome.", [["Serum", "ANATOMY", 19, 24], ["urine", "ANATOMY", 62, 67], ["creatinine", "CHEMICAL", 68, 78], ["hepatorenal syndrome", "DISEASE", 150, 170], ["creatinine D", "CHEMICAL", 68, 80], ["Serum", "ORGANISM_SUBSTANCE", 19, 24], ["Urine", "ORGANISM_SUBSTANCE", 39, 44], ["urine", "ORGANISM_SUBSTANCE", 62, 67], ["creatinine", "SIMPLE_CHEMICAL", 68, 78], ["ALT", "SIMPLE_CHEMICAL", 82, 85], ["Renal", "ORGAN", 97, 102], ["patient", "ORGANISM", 129, 136], ["patient", "SPECIES", 129, 136], ["A) Paracentesis B) Serum osmolality C", "TEST", 0, 37], ["Urine electrolytes", "TEST", 39, 57], ["urine creatinine D", "TEST", 62, 80], ["ALT", "TEST", 82, 85], ["AST E", "TEST", 90, 95], ["Renal ultrasound", "TEST", 97, 113], ["hepatorenal syndrome", "PROBLEM", 150, 170], ["Renal", "ANATOMY", 97, 102], ["possible", "UNCERTAINTY", 141, 149], ["hepatorenal syndrome", "OBSERVATION", 150, 170]]], ["Urine electrolytes and urine creatinine should be performed to calculate the fractional excretion of sodium (FENa).", [["Urine", "ANATOMY", 0, 5], ["urine", "ANATOMY", 23, 28], ["creatinine", "CHEMICAL", 29, 39], ["sodium", "CHEMICAL", 101, 107], ["creatinine", "CHEMICAL", 29, 39], ["sodium", "CHEMICAL", 101, 107], ["FENa", "CHEMICAL", 109, 113], ["Urine", "ORGANISM_SUBSTANCE", 0, 5], ["electrolytes", "ORGANISM_SUBSTANCE", 6, 18], ["urine", "ORGANISM_SUBSTANCE", 23, 28], ["creatinine", "SIMPLE_CHEMICAL", 29, 39], ["sodium", "SIMPLE_CHEMICAL", 101, 107], ["FENa", "SIMPLE_CHEMICAL", 109, 113], ["Urine electrolytes", "TEST", 0, 18], ["urine creatinine", "TEST", 23, 39], ["the fractional excretion of sodium", "TEST", 73, 107], ["FENa", "TEST", 109, 113]]], ["A FENa value below 1 % would suggest prerenal causes, such as hepatorenal syndrome or hypovolemia.", [["prerenal", "ANATOMY", 37, 45], ["hepatorenal syndrome", "DISEASE", 62, 82], ["hypovolemia", "DISEASE", 86, 97], ["A FENa value", "TEST", 0, 12], ["prerenal causes", "PROBLEM", 37, 52], ["hepatorenal syndrome", "PROBLEM", 62, 82], ["hypovolemia", "PROBLEM", 86, 97], ["FENa", "OBSERVATION", 2, 6], ["prerenal causes", "OBSERVATION", 37, 52], ["hepatorenal syndrome", "OBSERVATION", 62, 82], ["hypovolemia", "OBSERVATION", 86, 97]]], ["A repeat fl uid challenge may help rule out hypovolemia as a cause.231.A 64-year-old male with no prior medical history had a witnessed arrest and was found to have ventricular fi brillation.", [["ventricular", "ANATOMY", 165, 176], ["hypovolemia", "DISEASE", 44, 55], ["ventricular fi brillation", "DISEASE", 165, 190], ["male", "ORGANISM", 85, 89], ["A repeat fl uid challenge", "TREATMENT", 0, 25], ["hypovolemia", "PROBLEM", 44, 55], ["a witnessed arrest", "PROBLEM", 124, 142], ["ventricular fi brillation", "PROBLEM", 165, 190], ["hypovolemia", "OBSERVATION", 44, 55], ["arrest", "OBSERVATION", 136, 142], ["ventricular fi", "ANATOMY", 165, 179], ["brillation", "OBSERVATION", 180, 190]]], ["He was successfully resuscitated and was admitted to the hospital medicine service.", [["He", "ORGANISM", 0, 2]]], ["All tests done on admission were within normal limits.", [["All tests", "TEST", 0, 9], ["normal limits", "OBSERVATION", 40, 53]]], ["Cardiac catheterization was performed and revealed nonobstructive coronary artery disease.", [["Cardiac", "ANATOMY", 0, 7], ["coronary artery", "ANATOMY", 66, 81], ["nonobstructive coronary artery disease", "DISEASE", 51, 89], ["Cardiac", "ORGAN", 0, 7], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 66, 81], ["Cardiac catheterization", "TEST", 0, 23], ["nonobstructive coronary artery disease", "PROBLEM", 51, 89], ["catheterization", "OBSERVATION", 8, 23], ["nonobstructive", "OBSERVATION", 51, 65], ["coronary artery", "ANATOMY", 66, 81], ["disease", "OBSERVATION", 82, 89]]], ["He has no residual neurologic defi cits.", [["neurologic", "ANATOMY", 19, 29], ["residual neurologic defi cits", "PROBLEM", 10, 39], ["no", "UNCERTAINTY", 7, 9], ["residual", "OBSERVATION_MODIFIER", 10, 18], ["neurologic defi cits", "OBSERVATION", 19, 39]]], ["A) Discharge the patient on metoprolol.", [["metoprolol", "CHEMICAL", 28, 38], ["metoprolol", "CHEMICAL", 28, 38], ["patient", "ORGANISM", 17, 24], ["metoprolol", "SIMPLE_CHEMICAL", 28, 38], ["patient", "SPECIES", 17, 24], ["metoprolol", "TREATMENT", 28, 38]]], ["B) Intracardiac defi brillator implantation.", [["Intracardiac defi brillator implantation", "TREATMENT", 3, 43], ["Intracardiac", "ANATOMY", 3, 15], ["defi", "OBSERVATION", 16, 20], ["brillator implantation", "OBSERVATION", 21, 43]]], ["C) Electrophysiology study.", [["Electrophysiology study", "TEST", 3, 26]]], ["D) Cardiac MRI.", [["Cardiac", "ANATOMY", 3, 10], ["Cardiac MRI", "TEST", 3, 14], ["Cardiac", "ANATOMY", 3, 10]]], ["E) 24-h home halter monitor.231.Answer: B The patient had survived a cardiac arrest with no obviously reversible cause of his ventricular fi brillation.", [["cardiac", "ANATOMY", 69, 76], ["ventricular", "ANATOMY", 126, 137], ["cardiac arrest", "DISEASE", 69, 83], ["ventricular fi brillation", "DISEASE", 126, 151], ["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["home halter monitor", "TEST", 8, 27], ["a cardiac arrest", "PROBLEM", 67, 83], ["his ventricular fi brillation", "PROBLEM", 122, 151], ["cardiac", "ANATOMY", 69, 76], ["arrest", "OBSERVATION", 77, 83], ["ventricular fi", "ANATOMY", 126, 140], ["brillation", "OBSERVATION", 141, 151]]], ["According to American College of Cardiology (ACC) guidelines, intracardiac defi brillator implantation is indicated for secondary prevention.", [["intracardiac", "ANATOMY", 62, 74], ["intracardiac defi brillator implantation", "TREATMENT", 62, 102], ["intracardiac", "ANATOMY", 62, 74]]], ["A 72-year-old female is admitted for a three-week rash not improving with topical steroids.", [["rash", "DISEASE", 50, 54], ["steroids", "CHEMICAL", 82, 90], ["steroids", "CHEMICAL", 82, 90], ["female", "ORGANISM", 14, 20], ["a three-week rash", "PROBLEM", 37, 54], ["topical steroids", "TREATMENT", 74, 90]]], ["He has a past medical history of hypertension and hyperlipidemia and has smoked at least one pack per day for the last 40 years.", [["hypertension", "DISEASE", 33, 45], ["hyperlipidemia", "DISEASE", 50, 64], ["hypertension", "PROBLEM", 33, 45], ["hyperlipidemia", "PROBLEM", 50, 64], ["hypertension", "OBSERVATION", 33, 45], ["hyperlipidemia", "OBSERVATION", 50, 64]]], ["He is on lisinopril 20 mg daily and simvastatin 40 mg at and has been taking these medications for the last 5 years.231.On physical exam, blood pressure is 128/82 mmHg.", [["blood", "ANATOMY", 138, 143], ["lisinopril", "CHEMICAL", 9, 19], ["simvastatin", "CHEMICAL", 36, 47], ["lisinopril", "CHEMICAL", 9, 19], ["simvastatin", "CHEMICAL", 36, 47], ["lisinopril", "SIMPLE_CHEMICAL", 9, 19], ["simvastatin", "SIMPLE_CHEMICAL", 36, 47], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["lisinopril", "TREATMENT", 9, 19], ["simvastatin", "TREATMENT", 36, 47], ["these medications", "TREATMENT", 77, 94], ["physical exam", "TEST", 123, 136], ["blood pressure", "TEST", 138, 152]]], ["Heart rate is 86 bpm.", [["Heart", "ANATOMY", 0, 5], ["Heart", "ORGAN", 0, 5], ["Heart rate", "TEST", 0, 10], ["86 bpm", "OBSERVATION", 14, 20]]], ["He has bilateral periorbital purplish hue and erythematous fl at rash on the chest and back and on shoulders.", [["periorbital", "ANATOMY", 17, 28], ["chest", "ANATOMY", 77, 82], ["back", "ANATOMY", 87, 91], ["shoulders", "ANATOMY", 99, 108], ["rash", "DISEASE", 65, 69], ["chest", "ORGANISM_SUBDIVISION", 77, 82], ["shoulders", "ORGANISM_SUBDIVISION", 99, 108], ["bilateral periorbital purplish hue", "PROBLEM", 7, 41], ["erythematous fl at rash on the chest", "PROBLEM", 46, 82], ["bilateral", "ANATOMY_MODIFIER", 7, 16], ["periorbital", "ANATOMY", 17, 28], ["purplish hue", "OBSERVATION", 29, 41], ["erythematous", "OBSERVATION_MODIFIER", 46, 58], ["fl", "OBSERVATION", 59, 61], ["rash", "OBSERVATION", 65, 69], ["chest", "ANATOMY", 77, 82], ["back", "ANATOMY", 87, 91], ["shoulders", "ANATOMY", 99, 108]]], ["CXR is normal.", [["CXR", "PROTEIN", 0, 3], ["CXR", "TEST", 0, 3], ["normal", "OBSERVATION", 7, 13]]], ["All admission labs are within normal limits except a CPK of 475 units/L.231.Which of the following is the next option?", [["CPK", "PROTEIN", 53, 56], ["All admission labs", "TEST", 0, 18], ["a CPK", "TEST", 51, 56]]], ["A) Muscle biopsy B) Electromyogram C) Chest CT D) Skin biopsy Answer: C This patient most likely has dermatomyositis secondary to small cell lung cancer.", [["Muscle biopsy", "ANATOMY", 3, 16], ["small cell lung cancer", "ANATOMY", 130, 152], ["dermatomyositis", "DISEASE", 101, 116], ["small cell lung cancer", "DISEASE", 130, 152], ["patient", "ORGANISM", 77, 84], ["small cell lung cancer", "CANCER", 130, 152], ["patient", "SPECIES", 77, 84], ["A) Muscle biopsy B) Electromyogram C", "TEST", 0, 36], ["Chest CT D) Skin biopsy", "TEST", 38, 61], ["dermatomyositis", "PROBLEM", 101, 116], ["small cell lung cancer", "PROBLEM", 130, 152], ["Muscle", "ANATOMY", 3, 9], ["Chest", "ANATOMY", 38, 43], ["Skin", "ANATOMY", 50, 54], ["dermatomyositis", "OBSERVATION", 101, 116], ["small cell", "OBSERVATION", 130, 140], ["lung", "ANATOMY", 141, 145], ["cancer", "OBSERVATION", 146, 152]]], ["The most important step to take is a CT chest to evaluate for lung malignancy.", [["chest", "ANATOMY", 40, 45], ["lung malignancy", "ANATOMY", 62, 77], ["lung malignancy", "DISEASE", 62, 77], ["chest", "ORGAN", 40, 45], ["lung malignancy", "CANCER", 62, 77], ["a CT chest", "TEST", 35, 45], ["lung malignancy", "PROBLEM", 62, 77], ["chest", "ANATOMY", 40, 45], ["lung", "ANATOMY", 62, 66], ["malignancy", "OBSERVATION", 67, 77]]], ["Given the characteristic heliotrope rash and erythematous rash on torso, dermatomyositis is the most likely condition.", [["torso", "ANATOMY", 66, 71], ["rash", "DISEASE", 36, 40], ["rash", "DISEASE", 58, 62], ["dermatomyositis", "DISEASE", 73, 88], ["torso", "ORGANISM_SUBDIVISION", 66, 71], ["the characteristic heliotrope rash", "PROBLEM", 6, 40], ["erythematous rash on torso", "PROBLEM", 45, 71], ["dermatomyositis", "PROBLEM", 73, 88], ["heliotrope rash", "OBSERVATION", 25, 40], ["erythematous", "OBSERVATION_MODIFIER", 45, 57], ["rash", "OBSERVATION", 58, 62], ["torso", "ANATOMY", 66, 71], ["dermatomyositis", "OBSERVATION", 73, 88], ["most likely", "UNCERTAINTY", 96, 107]]], ["Dermatomyositis has a 25 % association with malignancy.231.In this long-term smoker, greater than age 60, the rate of malignancy would be higher.", [["Dermatomyositis", "DISEASE", 0, 15], ["malignancy", "DISEASE", 44, 54], ["malignancy", "DISEASE", 118, 128], ["malignancy", "CANCER", 44, 54], ["malignancy", "CANCER", 118, 128], ["Dermatomyositis", "PROBLEM", 0, 15], ["malignancy", "PROBLEM", 44, 54], ["malignancy", "PROBLEM", 118, 128], ["25 %", "OBSERVATION_MODIFIER", 22, 26], ["malignancy", "OBSERVATION", 44, 54], ["malignancy", "OBSERVATION", 118, 128], ["higher", "OBSERVATION_MODIFIER", 138, 144]]], ["Autoantibodies, muscle biopsy, EMG, and skin biopsy would all be considered once malignancy has been ruled out.", [["muscle biopsy", "ANATOMY", 16, 29], ["skin", "ANATOMY", 40, 44], ["malignancy", "DISEASE", 81, 91], ["muscle biopsy", "MULTI-TISSUE_STRUCTURE", 16, 29], ["skin biopsy", "MULTI-TISSUE_STRUCTURE", 40, 51], ["Autoantibodies", "TEST", 0, 14], ["muscle biopsy", "TEST", 16, 29], ["EMG", "TEST", 31, 34], ["skin biopsy", "TEST", 40, 51], ["malignancy", "PROBLEM", 81, 91], ["muscle", "ANATOMY", 16, 22], ["biopsy", "OBSERVATION", 23, 29], ["skin", "ANATOMY", 40, 44]]], ["A 67-year-old female with history of hypertension, severe aortic stenosis, and diastolic congestive heart failure is admitted with one episode of bloody stool this morning.", [["aortic", "ANATOMY", 58, 64], ["heart", "ANATOMY", 100, 105], ["hypertension", "DISEASE", 37, 49], ["aortic stenosis", "DISEASE", 58, 73], ["diastolic congestive heart failure", "DISEASE", 79, 113], ["female", "ORGANISM", 14, 20], ["aortic", "MULTI-TISSUE_STRUCTURE", 58, 64], ["heart", "ORGAN", 100, 105], ["hypertension", "PROBLEM", 37, 49], ["severe aortic stenosis", "PROBLEM", 51, 73], ["diastolic congestive heart failure", "PROBLEM", 79, 113], ["bloody stool", "PROBLEM", 146, 158], ["hypertension", "OBSERVATION", 37, 49], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["aortic", "ANATOMY", 58, 64], ["stenosis", "OBSERVATION", 65, 73], ["diastolic", "OBSERVATION_MODIFIER", 79, 88], ["congestive", "OBSERVATION_MODIFIER", 89, 99], ["heart", "ANATOMY", 100, 105], ["failure", "OBSERVATION", 106, 113], ["bloody stool", "OBSERVATION", 146, 158]]], ["He has no prior history of lower gastrointestinal bleeding.", [["lower gastrointestinal", "ANATOMY", 27, 49], ["lower gastrointestinal bleeding", "DISEASE", 27, 58], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 27, 49], ["lower gastrointestinal bleeding", "PROBLEM", 27, 58], ["no", "UNCERTAINTY", 7, 9], ["lower", "ANATOMY_MODIFIER", 27, 32], ["gastrointestinal", "ANATOMY", 33, 49], ["bleeding", "OBSERVATION", 50, 58]]], ["He is currently on 81 mg. of aspirin.", [["aspirin", "CHEMICAL", 29, 36], ["aspirin", "CHEMICAL", 29, 36], ["He", "ORGANISM", 0, 2], ["aspirin", "SIMPLE_CHEMICAL", 29, 36], ["aspirin", "TREATMENT", 29, 36]]], ["Last colonoscopy was three years ago and was normal with no diverticular disease.", [["diverticular", "ANATOMY", 60, 72], ["diverticular disease", "DISEASE", 60, 80], ["Last colonoscopy", "TEST", 0, 16], ["diverticular disease", "PROBLEM", 60, 80], ["normal", "OBSERVATION", 45, 51], ["no", "UNCERTAINTY", 57, 59], ["diverticular", "OBSERVATION", 60, 72]]], ["On physical exam, his abdomen is nontender.", [["abdomen", "ANATOMY", 22, 29], ["abdomen", "ORGANISM_SUBDIVISION", 22, 29], ["physical exam", "TEST", 3, 16], ["nontender", "PROBLEM", 33, 42], ["abdomen", "ANATOMY", 22, 29], ["nontender", "OBSERVATION", 33, 42]]], ["A systolic ejection mummer is heard radiating to the carotids at the right second intercostal area.", [["carotids", "ANATOMY", 53, 61], ["right second intercostal area", "ANATOMY", 69, 98], ["carotids", "CANCER", 53, 61], ["intercostal area", "MULTI-TISSUE_STRUCTURE", 82, 98], ["A systolic ejection mummer", "TEST", 0, 26], ["systolic", "ANATOMY", 2, 10], ["ejection mummer", "OBSERVATION", 11, 26], ["carotids", "ANATOMY", 53, 61], ["right", "ANATOMY_MODIFIER", 69, 74], ["second", "ANATOMY_MODIFIER", 75, 81], ["intercostal", "ANATOMY", 82, 93], ["area", "ANATOMY_MODIFIER", 94, 98]]], ["Vitals are stable.", [["Vitals", "TEST", 0, 6], ["stable", "OBSERVATION_MODIFIER", 11, 17]]], ["Labs revealed normal platelet count with hemoglobin of 12.9 g/dl.", [["platelet", "ANATOMY", 21, 29], ["Labs", "GENE_OR_GENE_PRODUCT", 0, 4], ["platelet", "CELL", 21, 29], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 41, 51], ["hemoglobin", "PROTEIN", 41, 51], ["Labs", "TEST", 0, 4], ["hemoglobin", "TEST", 41, 51], ["normal platelet count", "OBSERVATION", 14, 35]]], ["Colonoscopy done on this admission shows angiodysplasia seen in the descending colon.ReferenceWhat is the best step to treating this condition?", [["descending colon", "ANATOMY", 68, 84], ["angiodysplasia", "DISEASE", 41, 55], ["angiodysplasia", "PATHOLOGICAL_FORMATION", 41, 55], ["colon", "ORGAN", 79, 84], ["Colonoscopy", "TEST", 0, 11], ["angiodysplasia", "PROBLEM", 41, 55], ["this condition", "PROBLEM", 128, 142], ["angiodysplasia", "OBSERVATION", 41, 55], ["descending", "ANATOMY_MODIFIER", 68, 78], ["colon", "ANATOMY", 79, 84]]], ["A) Aortic valve replacement B) Colon resection C) Mesenteric artery embolization D) Mechanical hemostasis using endoscopic clips E) Aortic valve replacement Answer: A This patient developed Heyde's syndrome, which is the occurrence of bleeding angiodysplasia in the colon in patients with severe aortic stenosis.", [["Aortic valve", "ANATOMY", 3, 15], ["Colon", "ANATOMY", 31, 36], ["Mesenteric artery", "ANATOMY", 50, 67], ["Aortic valve", "ANATOMY", 132, 144], ["colon", "ANATOMY", 266, 271], ["aortic", "ANATOMY", 296, 302], ["Heyde's syndrome", "DISEASE", 190, 206], ["bleeding angiodysplasia", "DISEASE", 235, 258], ["aortic stenosis", "DISEASE", 296, 311], ["Mesenteric artery", "MULTI-TISSUE_STRUCTURE", 50, 67], ["patient", "ORGANISM", 172, 179], ["bleeding angiodysplasia", "PATHOLOGICAL_FORMATION", 235, 258], ["colon", "ORGAN", 266, 271], ["patients", "ORGANISM", 275, 283], ["aortic", "MULTI-TISSUE_STRUCTURE", 296, 302], ["patient", "SPECIES", 172, 179], ["patients", "SPECIES", 275, 283], ["A) Aortic valve replacement B)", "TREATMENT", 0, 30], ["Colon resection C", "TREATMENT", 31, 48], ["Mesenteric artery embolization D", "TREATMENT", 50, 82], ["Mechanical hemostasis", "TREATMENT", 84, 105], ["endoscopic clips E", "TREATMENT", 112, 130], ["Aortic valve replacement", "TREATMENT", 132, 156], ["Heyde's syndrome", "PROBLEM", 190, 206], ["bleeding angiodysplasia in the colon", "PROBLEM", 235, 271], ["severe aortic stenosis", "PROBLEM", 289, 311], ["Aortic valve", "ANATOMY", 3, 15], ["replacement", "OBSERVATION", 16, 27], ["Colon", "ANATOMY", 31, 36], ["resection", "OBSERVATION", 37, 46], ["Mesenteric artery", "ANATOMY", 50, 67], ["embolization", "OBSERVATION", 68, 80], ["Aortic valve", "ANATOMY", 132, 144], ["bleeding", "OBSERVATION_MODIFIER", 235, 243], ["angiodysplasia", "OBSERVATION", 244, 258], ["colon", "ANATOMY", 266, 271], ["severe", "OBSERVATION_MODIFIER", 289, 295], ["aortic", "ANATOMY", 296, 302], ["stenosis", "OBSERVATION", 303, 311]]], ["A subtle form of von Willebrand disease present in Heyde's syndrome patients resolves rapidly after aortic valve replacement.ReferencesHeyde EC (1958) .", [["aortic valve", "ANATOMY", 100, 112], ["von Willebrand disease", "DISEASE", 17, 39], ["Heyde's syndrome", "DISEASE", 51, 67], ["Willebrand", "GENE_OR_GENE_PRODUCT", 21, 31], ["patients", "ORGANISM", 68, 76], ["aortic valve", "MULTI-TISSUE_STRUCTURE", 100, 112], ["Heyde EC", "CELL", 135, 143], ["patients", "SPECIES", 68, 76], ["von Willebrand disease", "PROBLEM", 17, 39], ["Heyde's syndrome", "PROBLEM", 51, 67], ["aortic valve replacement", "TREATMENT", 100, 124], ["von Willebrand disease", "OBSERVATION", 17, 39], ["aortic valve", "ANATOMY", 100, 112], ["replacement", "OBSERVATION", 113, 124]]], ["Gastrointestinal bleeding in aortic stenosis.", [["Gastrointestinal", "ANATOMY", 0, 16], ["aortic", "ANATOMY", 29, 35], ["Gastrointestinal bleeding", "DISEASE", 0, 25], ["aortic stenosis", "DISEASE", 29, 44], ["Gastrointestinal", "ORGAN", 0, 16], ["aortic", "MULTI-TISSUE_STRUCTURE", 29, 35], ["Gastrointestinal bleeding", "PROBLEM", 0, 25], ["aortic stenosis", "PROBLEM", 29, 44], ["bleeding", "OBSERVATION", 17, 25], ["aortic", "ANATOMY", 29, 35], ["stenosis", "OBSERVATION", 36, 44]]], ["N. Engl.", [["Engl", "OBSERVATION", 3, 7]]], ["\"Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?\".", [["Aortic", "ANATOMY", 1, 7], ["gastrointestinal", "ANATOMY", 30, 46], ["Aortic stenosis", "DISEASE", 1, 16], ["bleeding", "DISEASE", 21, 29], ["gastrointestinal angiodysplasia", "DISEASE", 30, 61], ["von Willebrand's disease", "DISEASE", 75, 99], ["Aortic", "MULTI-TISSUE_STRUCTURE", 1, 7], ["gastrointestinal angiodysplasia", "PATHOLOGICAL_FORMATION", 30, 61], ["Aortic stenosis", "PROBLEM", 1, 16], ["bleeding gastrointestinal angiodysplasia", "PROBLEM", 21, 61], ["Aortic", "ANATOMY", 1, 7], ["stenosis", "OBSERVATION", 8, 16], ["bleeding", "OBSERVATION_MODIFIER", 21, 29], ["gastrointestinal", "ANATOMY", 30, 46], ["angiodysplasia", "OBSERVATION", 47, 61]]], ["A 71-year-old man with a history of congestive heart failure, EF 30 %, and hypertension was admitted fi ve days ago for septic shock due to pneumonia.", [["heart", "ANATOMY", 47, 52], ["congestive heart failure", "DISEASE", 36, 60], ["hypertension", "DISEASE", 75, 87], ["septic shock", "DISEASE", 120, 132], ["pneumonia", "DISEASE", 140, 149], ["man", "ORGANISM", 14, 17], ["heart", "ORGAN", 47, 52], ["man", "SPECIES", 14, 17], ["congestive heart failure", "PROBLEM", 36, 60], ["EF", "TEST", 62, 64], ["hypertension", "PROBLEM", 75, 87], ["septic shock", "PROBLEM", 120, 132], ["pneumonia", "PROBLEM", 140, 149], ["congestive", "OBSERVATION_MODIFIER", 36, 46], ["heart", "ANATOMY", 47, 52], ["failure", "OBSERVATION", 53, 60], ["hypertension", "OBSERVATION", 75, 87], ["septic shock", "OBSERVATION", 120, 132], ["pneumonia", "OBSERVATION", 140, 149]]], ["He was intubated but is now extubated.", [["He", "ORGANISM", 0, 2], ["intubated", "TREATMENT", 7, 16]]], ["He is now hemodynamically stable.", [["hemodynamically", "OBSERVATION_MODIFIER", 10, 25], ["stable", "OBSERVATION", 26, 32]]], ["The patient developed the new onset of persistent abdominal pain and bloody stool.", [["abdominal", "ANATOMY", 50, 59], ["abdominal pain", "DISEASE", 50, 64], ["patient", "ORGANISM", 4, 11], ["abdominal", "ORGANISM_SUBDIVISION", 50, 59], ["stool", "ORGANISM_SUBSTANCE", 76, 81], ["patient", "SPECIES", 4, 11], ["persistent abdominal pain", "PROBLEM", 39, 64], ["bloody stool", "PROBLEM", 69, 81], ["new", "OBSERVATION_MODIFIER", 26, 29], ["persistent", "OBSERVATION_MODIFIER", 39, 49], ["abdominal", "ANATOMY", 50, 59], ["pain", "OBSERVATION", 60, 64], ["bloody stool", "OBSERVATION", 69, 81]]], ["Urgent C-scope revealed ischemic colitis.", [["ischemic colitis", "DISEASE", 24, 40], ["colitis", "PATHOLOGICAL_FORMATION", 33, 40], ["Urgent C-scope", "TEST", 0, 14], ["ischemic colitis", "PROBLEM", 24, 40], ["ischemic", "OBSERVATION_MODIFIER", 24, 32], ["colitis", "OBSERVATION", 33, 40]]], ["He is doing better, blood counts are stable but remains lethargic.", [["blood", "ANATOMY", 20, 25], ["blood", "ORGANISM_SUBSTANCE", 20, 25], ["blood counts", "TEST", 20, 32], ["lethargic", "PROBLEM", 56, 65], ["stable", "OBSERVATION_MODIFIER", 37, 43], ["lethargic", "OBSERVATION", 56, 65]]], ["No nutrition has been started yet.ReferencesWhich of the following would be the most appropriate nutritional support?", [["nutrition", "OBSERVATION", 3, 12]]], ["A) No nutrition B) Post-pyloric feedings C) Peripheral parenteral nutrition D) Intragastric tube feeding E) Central parenteral nutrition Answer: E The patient has been on NPO for fi ve days.", [["patient", "ORGANISM", 151, 158], ["NPO", "SIMPLE_CHEMICAL", 171, 174], ["patient", "SPECIES", 151, 158], ["nutrition B) Post-pyloric feedings C", "TREATMENT", 6, 42], ["Peripheral parenteral nutrition D", "TREATMENT", 44, 77], ["Intragastric tube feeding E", "TREATMENT", 79, 106], ["Central parenteral nutrition", "TREATMENT", 108, 136], ["NPO", "TREATMENT", 171, 174], ["pyloric", "ANATOMY", 24, 31]]], ["His ability to have an adequate oral intake in the next few days is unlikely.", [["oral", "ANATOMY", 32, 36], ["oral", "ORGANISM_SUBDIVISION", 32, 36]]], ["Initiation of nutritional support is warranted.", [["nutritional support", "TREATMENT", 14, 33]]], ["He has history of congestive heart failure and will not tolerate the large IV fl uid volume that has to be given with peripheral parenteral nutrition to keep solution osmolality less than 900.", [["heart", "ANATOMY", 29, 34], ["parenteral", "ANATOMY", 129, 139], ["congestive heart failure", "DISEASE", 18, 42], ["heart", "ORGAN", 29, 34], ["congestive heart failure", "PROBLEM", 18, 42], ["the large IV fl uid volume", "TREATMENT", 65, 91], ["peripheral parenteral nutrition", "TREATMENT", 118, 149], ["solution osmolality", "TEST", 158, 177], ["congestive", "OBSERVATION_MODIFIER", 18, 28], ["heart", "ANATOMY", 29, 34], ["failure", "OBSERVATION", 35, 42]]], ["Ischemic colitis will make enteral nutrition a poor option.", [["Ischemic colitis", "DISEASE", 0, 16], ["Ischemic colitis", "PROBLEM", 0, 16], ["enteral nutrition", "TREATMENT", 27, 44], ["colitis", "OBSERVATION", 9, 16]]], ["Although used with caution, the best option for this patient is central or total parenteral nutrition.", [["parenteral", "ANATOMY", 81, 91], ["patient", "ORGANISM", 53, 60], ["parenteral", "ORGANISM_SUBDIVISION", 81, 91], ["patient", "SPECIES", 53, 60], ["caution", "TREATMENT", 19, 26], ["total parenteral nutrition", "TREATMENT", 75, 101]]], ["A 42-year-old woman is admitted to the hospital with confusion, disorientation, and ataxia.", [["confusion", "DISEASE", 53, 62], ["disorientation", "DISEASE", 64, 78], ["ataxia", "DISEASE", 84, 90], ["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["confusion", "PROBLEM", 53, 62], ["disorientation", "PROBLEM", 64, 78], ["ataxia", "PROBLEM", 84, 90], ["confusion", "OBSERVATION", 53, 62], ["disorientation", "OBSERVATION", 64, 78]]], ["The patient feels weak and has memory loss.", [["memory loss", "DISEASE", 31, 42], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["weak", "PROBLEM", 18, 22], ["memory loss", "PROBLEM", 31, 42], ["weak", "OBSERVATION", 18, 22], ["memory loss", "OBSERVATION", 31, 42]]], ["During the past three months, she has lost 105 lb after gastric banding.", [["gastric", "ANATOMY", 56, 63], ["gastric", "ORGAN", 56, 63], ["gastric banding", "TREATMENT", 56, 71], ["105 lb", "OBSERVATION_MODIFIER", 43, 49], ["gastric", "ANATOMY", 56, 63], ["banding", "OBSERVATION", 64, 71]]], ["On physical exam, she appears confused.", [["physical exam", "TEST", 3, 16], ["confused", "PROBLEM", 30, 38]]], ["She has horizontal nystagmus.", [["nystagmus", "DISEASE", 19, 28], ["horizontal nystagmus", "PROBLEM", 8, 28], ["horizontal", "OBSERVATION_MODIFIER", 8, 18], ["nystagmus", "OBSERVATION", 19, 28]]], ["The tongue is slick.", [["tongue", "ANATOMY", 4, 10], ["tongue", "ORGAN", 4, 10], ["tongue", "ANATOMY", 4, 10], ["slick", "OBSERVATION", 14, 19]]], ["Examination revealed sensory and motor neuropathy in both lower extremities.", [["lower extremities", "ANATOMY", 58, 75], ["sensory and motor neuropathy", "DISEASE", 21, 49], ["lower extremities", "ORGANISM_SUBDIVISION", 58, 75], ["Examination", "TEST", 0, 11], ["sensory and motor neuropathy in both lower extremities", "PROBLEM", 21, 75], ["sensory", "OBSERVATION_MODIFIER", 21, 28], ["motor neuropathy", "OBSERVATION", 33, 49], ["both", "ANATOMY_MODIFIER", 53, 57], ["lower extremities", "ANATOMY", 58, 75]]], ["Laboratory fi ndings include Hb of 8.7 mg/ dL and MCV of 102 fL.ReferenceWhat is the most appropriate next step?", [["Hb", "GENE_OR_GENE_PRODUCT", 29, 31], ["Hb", "PROTEIN", 29, 31], ["Laboratory fi ndings", "TEST", 0, 20], ["Hb", "TEST", 29, 31], ["MCV", "TEST", 50, 53]]], ["A) Intravenous thiamine B) Intravenous immunoglobulin C) B12 injection D) Spinal tap E) Lipid infusion Answer: A In recent years, acute Wernicke encephalopathy has been more frequently recognized in patients after bariatric surgeries.", [["thiamine B", "CHEMICAL", 15, 25], ["B12", "CHEMICAL", 57, 60], ["acute Wernicke encephalopathy", "DISEASE", 130, 159], ["thiamine B", "CHEMICAL", 15, 25], ["Intravenous thiamine B", "SIMPLE_CHEMICAL", 3, 25], ["immunoglobulin C", "SIMPLE_CHEMICAL", 39, 55], ["B12", "SIMPLE_CHEMICAL", 57, 60], ["Lipid", "SIMPLE_CHEMICAL", 88, 93], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["A) Intravenous thiamine B) Intravenous immunoglobulin C) B12 injection D", "TREATMENT", 0, 72], ["Spinal tap E) Lipid infusion", "TREATMENT", 74, 102], ["acute Wernicke encephalopathy", "PROBLEM", 130, 159], ["bariatric surgeries", "TREATMENT", 214, 233], ["Spinal", "ANATOMY", 74, 80], ["acute", "OBSERVATION_MODIFIER", 130, 135], ["Wernicke encephalopathy", "OBSERVATION", 136, 159]]], ["Thiamine (vitamin B1) defi ciency can result in Wernicke encephalopathy (WE).", [["Thiamine", "CHEMICAL", 0, 8], ["vitamin B1", "CHEMICAL", 10, 20], ["Wernicke encephalopathy", "DISEASE", 48, 71], ["WE", "DISEASE", 73, 75], ["Thiamine", "CHEMICAL", 0, 8], ["vitamin B1)", "CHEMICAL", 10, 21], ["Thiamine", "SIMPLE_CHEMICAL", 0, 8], ["vitamin B1", "SIMPLE_CHEMICAL", 10, 20], ["Thiamine (vitamin B1) defi ciency", "TREATMENT", 0, 33], ["Wernicke encephalopathy", "PROBLEM", 48, 71], ["Wernicke encephalopathy", "OBSERVATION", 48, 71]]], ["It is typically a triad of acute mental confusion, ataxia, and ophthalmoplegia.", [["confusion", "DISEASE", 40, 49], ["ataxia", "DISEASE", 51, 57], ["ophthalmoplegia", "DISEASE", 63, 78], ["acute mental confusion", "PROBLEM", 27, 49], ["ataxia", "PROBLEM", 51, 57], ["ophthalmoplegia", "PROBLEM", 63, 78], ["acute", "OBSERVATION_MODIFIER", 27, 32], ["mental confusion", "OBSERVATION", 33, 49], ["ophthalmoplegia", "OBSERVATION", 63, 78]]], ["Symptoms develop 4 to 12 weeks postoperatively.", [["Symptoms", "PROBLEM", 0, 8]]], ["WE is a medical emergency and requires immediate administration of IV thiamine.", [["WE", "DISEASE", 0, 2], ["thiamine", "CHEMICAL", 70, 78], ["thiamine", "CHEMICAL", 70, 78], ["thiamine", "SIMPLE_CHEMICAL", 70, 78], ["IV thiamine", "TREATMENT", 67, 78]]], ["Frequently unrecognized, WE is more prevalent than commonly considered.", [["WE", "DISEASE", 25, 27], ["more prevalent", "OBSERVATION_MODIFIER", 31, 45]]], ["Ocular abnormalities are the hallmarks of WE.", [["Ocular", "ANATOMY", 0, 6], ["Ocular abnormalities", "DISEASE", 0, 20], ["WE", "DISEASE", 42, 44], ["Ocular", "ORGAN", 0, 6], ["Ocular abnormalities", "PROBLEM", 0, 20], ["abnormalities", "OBSERVATION", 7, 20]]], ["The oculomotor manifestations are nystagmus and bilateral and lateral rectus palsies.", [["oculomotor", "ANATOMY", 4, 14], ["lateral rectus", "ANATOMY", 62, 76], ["nystagmus", "DISEASE", 34, 43], ["rectus palsies", "DISEASE", 70, 84], ["rectus", "ORGANISM_SUBDIVISION", 70, 76], ["The oculomotor manifestations", "PROBLEM", 0, 29], ["nystagmus", "PROBLEM", 34, 43], ["bilateral and lateral rectus palsies", "PROBLEM", 48, 84], ["oculomotor manifestations", "OBSERVATION", 4, 29], ["nystagmus", "OBSERVATION", 34, 43], ["bilateral", "ANATOMY_MODIFIER", 48, 57], ["lateral", "ANATOMY_MODIFIER", 62, 69], ["rectus", "ANATOMY", 70, 76], ["palsies", "OBSERVATION", 77, 84]]], ["The most common presenting symptoms of WE are mental status changes.", [["WE", "DISEASE", 39, 41], ["The most common presenting symptoms", "PROBLEM", 0, 35], ["mental status changes", "PROBLEM", 46, 67], ["most common", "OBSERVATION_MODIFIER", 4, 15]]], ["Ataxia is due to a combination of polyneuropathy, cerebellar damage, and vestibular paresis.", [["cerebellar", "ANATOMY", 50, 60], ["vestibular", "ANATOMY", 73, 83], ["Ataxia", "DISEASE", 0, 6], ["polyneuropathy", "DISEASE", 34, 48], ["cerebellar damage", "DISEASE", 50, 67], ["vestibular paresis", "DISEASE", 73, 91], ["cerebellar", "ORGAN", 50, 60], ["vestibular", "ORGAN", 73, 83], ["Ataxia", "PROBLEM", 0, 6], ["polyneuropathy", "PROBLEM", 34, 48], ["cerebellar damage", "PROBLEM", 50, 67], ["vestibular paresis", "PROBLEM", 73, 91], ["polyneuropathy", "OBSERVATION", 34, 48], ["cerebellar", "ANATOMY", 50, 60], ["damage", "OBSERVATION", 61, 67], ["vestibular paresis", "OBSERVATION", 73, 91]]], ["It is important to test for truncal ataxia with the patient sitting or standing.", [["ataxia", "DISEASE", 36, 42], ["patient", "ORGANISM", 52, 59], ["patient", "SPECIES", 52, 59], ["truncal ataxia", "PROBLEM", 28, 42]]], ["T2-weighted MRI images typically demonstrate hyperintense signals in the midbrain, mammillary bodies, and thalamus, which may aid in diagnoses.238.A type 1diabetic patient with chronic renal insufficiency is admitted with cellulitis.", [["midbrain", "ANATOMY", 73, 81], ["mammillary bodies", "ANATOMY", 83, 100], ["thalamus", "ANATOMY", 106, 114], ["renal", "ANATOMY", 185, 190], ["chronic renal insufficiency", "DISEASE", 177, 204], ["cellulitis", "DISEASE", 222, 232], ["midbrain", "MULTI-TISSUE_STRUCTURE", 73, 81], ["mammillary bodies", "MULTI-TISSUE_STRUCTURE", 83, 100], ["thalamus", "ORGAN", 106, 114], ["patient", "ORGANISM", 164, 171], ["renal", "ORGAN", 185, 190], ["patient", "SPECIES", 164, 171], ["T2-weighted MRI images", "TEST", 0, 22], ["hyperintense signals in the midbrain, mammillary bodies, and thalamus", "PROBLEM", 45, 114], ["chronic renal insufficiency", "PROBLEM", 177, 204], ["cellulitis", "PROBLEM", 222, 232], ["hyperintense", "OBSERVATION", 45, 57], ["midbrain", "ANATOMY", 73, 81], ["mammillary", "ANATOMY_MODIFIER", 83, 93], ["bodies", "ANATOMY_MODIFIER", 94, 100], ["thalamus", "ANATOMY", 106, 114], ["chronic", "OBSERVATION_MODIFIER", 177, 184], ["renal", "ANATOMY", 185, 190], ["insufficiency", "OBSERVATION", 191, 204], ["cellulitis", "OBSERVATION", 222, 232]]], ["She has intermittent claudication and was found to have ABI of 0.4.", [["intermittent claudication", "DISEASE", 8, 33], ["intermittent claudication", "PROBLEM", 8, 33], ["ABI", "TEST", 56, 59], ["intermittent", "OBSERVATION_MODIFIER", 8, 20], ["claudication", "OBSERVATION", 21, 33]]], ["Lower extremity angiogram will be performed.", [["Lower extremity angiogram", "TEST", 0, 25], ["extremity", "ANATOMY", 6, 15]]], ["Her creatinine level 1.4 mg/dl.", [["creatinine", "CHEMICAL", 4, 14], ["creatinine", "CHEMICAL", 4, 14], ["creatinine", "GENE_OR_GENE_PRODUCT", 4, 14], ["Her creatinine level", "TEST", 0, 20]]], ["Which of the following pretreatments should be received to decrease the risk of contrast-induced nephropathy?", [["nephropathy", "DISEASE", 97, 108], ["contrast-induced nephropathy", "PROBLEM", 80, 108], ["nephropathy", "OBSERVATION", 97, 108]]], ["A) Intravenous steroid B) N-acetylcysteine C) Intravenous hydration D) Intravenous magnesium E) No pretreatment is needed Answer: C Contrast medium-induced nephropathy (CIN) is the third leading cause of acute renal failure in hospitalized patients.", [["renal", "ANATOMY", 210, 215], ["steroid B", "CHEMICAL", 15, 24], ["N-acetylcysteine", "CHEMICAL", 26, 42], ["magnesium", "CHEMICAL", 83, 92], ["nephropathy", "DISEASE", 156, 167], ["CIN", "DISEASE", 169, 172], ["acute renal failure", "DISEASE", 204, 223], ["steroid B", "CHEMICAL", 15, 24], ["N-acetylcysteine C", "CHEMICAL", 26, 44], ["magnesium E", "CHEMICAL", 83, 94], ["Intravenous steroid B) N-acetylcysteine C", "SIMPLE_CHEMICAL", 3, 44], ["Intravenous hydration D", "SIMPLE_CHEMICAL", 46, 69], ["Intravenous magnesium E", "SIMPLE_CHEMICAL", 71, 94], ["renal", "ORGAN", 210, 215], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 240, 248], ["A) Intravenous steroid B) N-acetylcysteine C) Intravenous hydration D) Intravenous magnesium E)", "TREATMENT", 0, 95], ["nephropathy", "PROBLEM", 156, 167], ["acute renal failure", "PROBLEM", 204, 223], ["nephropathy", "OBSERVATION", 156, 167], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["renal", "ANATOMY", 210, 215], ["failure", "OBSERVATION", 216, 223]]], ["Administration of fl uids remains the cornerstone of preventive therapy to reduce the risk of CIN.", [["fl uids", "CHEMICAL", 18, 25], ["CIN", "DISEASE", 94, 97], ["fl uids", "GENE_OR_GENE_PRODUCT", 18, 25], ["CIN", "CANCER", 94, 97], ["fl uids", "TREATMENT", 18, 25], ["preventive therapy", "TREATMENT", 53, 71], ["CIN", "PROBLEM", 94, 97], ["CIN", "OBSERVATION", 94, 97]]], ["It has proven to have renal protective effect even in patient with normal baseline renal function and is a reasonable option here.", [["renal", "ANATOMY", 22, 27], ["renal", "ANATOMY", 83, 88], ["renal", "CANCER", 22, 27], ["patient", "ORGANISM", 54, 61], ["renal", "ORGAN", 83, 88], ["patient", "SPECIES", 54, 61], ["renal protective effect", "PROBLEM", 22, 45], ["renal", "ANATOMY", 22, 27], ["protective", "OBSERVATION", 28, 38], ["renal", "ANATOMY", 83, 88], ["function", "OBSERVATION", 89, 97]]], ["If volume restriction is not an issue, the usual recommended infusion rate of intravenous 0.9 % sodium chloride is 1 ml/ kg/h.", [["intravenous", "ANATOMY", 78, 89], ["sodium chloride", "CHEMICAL", 96, 111], ["sodium chloride", "CHEMICAL", 96, 111], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 89], ["sodium chloride", "SIMPLE_CHEMICAL", 96, 111], ["volume restriction", "TREATMENT", 3, 21], ["intravenous 0.9 % sodium chloride", "TREATMENT", 78, 111]]], ["This should be started 12 h before and continued for 12 h after the procedure.", [["the procedure", "TREATMENT", 64, 77]]], ["N-acetylcysteine may be of benefi t in patients with baseline creatinine above 2 mg/dl.", [["N-acetylcysteine", "CHEMICAL", 0, 16], ["creatinine", "CHEMICAL", 62, 72], ["N-acetylcysteine", "CHEMICAL", 0, 16], ["creatinine", "CHEMICAL", 62, 72], ["N-acetylcysteine", "SIMPLE_CHEMICAL", 0, 16], ["patients", "ORGANISM", 39, 47], ["creatinine", "SIMPLE_CHEMICAL", 62, 72], ["patients", "SPECIES", 39, 47], ["acetylcysteine", "TREATMENT", 2, 16], ["baseline creatinine", "TEST", 53, 72]]], ["A 57-year-old male with a past medical history of diabetes, COPD was admitted for a severe exacerbation.", [["diabetes", "DISEASE", 50, 58], ["COPD", "DISEASE", 60, 64], ["male", "ORGANISM", 14, 18], ["diabetes", "PROBLEM", 50, 58], ["COPD", "PROBLEM", 60, 64], ["a severe exacerbation", "PROBLEM", 82, 103], ["diabetes", "OBSERVATION", 50, 58], ["COPD", "OBSERVATION", 60, 64], ["severe", "OBSERVATION_MODIFIER", 84, 90], ["exacerbation", "OBSERVATION", 91, 103]]], ["He declined rapidly in the emergency room and was intubated.ReferenceHis current ventilator settings are a rate of 15, tidal volume of 700 ml, FiO2 of 60 %, and a PEEP of 15.", [["intubated", "TREATMENT", 50, 59], ["a rate", "TEST", 105, 111], ["tidal volume", "TEST", 119, 131], ["FiO2", "TREATMENT", 143, 147], ["a PEEP", "TEST", 161, 167]]], ["His PCO2 on ABGs was 60 cm of H2O.", [["H2O", "CHEMICAL", 30, 33], ["PCO2", "CHEMICAL", 4, 8], ["H2O", "CHEMICAL", 30, 33], ["His PCO2", "TEST", 0, 8], ["ABGs", "TEST", 12, 16]]], ["His rate was increased to 20 breaths/min.", [["His rate", "TEST", 0, 8], ["increased", "OBSERVATION_MODIFIER", 13, 22]]], ["Fifteen minutes later his blood pressure dropped from 126/78 mm of Hg to 98/62 mm of Hg and his tidal volume fell to 350 cc.ReferencePhysical exam reveals engorged neck veins and slightly diminished breath sounds bilaterally.", [["blood", "ANATOMY", 26, 31], ["neck veins", "ANATOMY", 164, 174], ["breath", "ANATOMY", 199, 205], ["Hg", "CHEMICAL", 67, 69], ["Hg", "CHEMICAL", 85, 87], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["neck veins", "MULTI-TISSUE_STRUCTURE", 164, 174], ["his blood pressure", "TEST", 22, 40], ["Hg", "TEST", 67, 69], ["Hg", "TEST", 85, 87], ["his tidal volume", "TEST", 92, 108], ["ReferencePhysical exam", "TEST", 124, 146], ["engorged neck veins", "PROBLEM", 155, 174], ["slightly diminished breath sounds bilaterally", "PROBLEM", 179, 224], ["tidal volume", "OBSERVATION", 96, 108], ["engorged", "OBSERVATION", 155, 163], ["neck veins", "ANATOMY", 164, 174], ["slightly", "OBSERVATION_MODIFIER", 179, 187], ["diminished", "OBSERVATION_MODIFIER", 188, 198], ["breath sounds", "OBSERVATION", 199, 212], ["bilaterally", "ANATOMY_MODIFIER", 213, 224]]], ["Stat chest X-Ray is negative for pneumothorax.ReferenceWhat should be the next appropriate step?", [["pneumothorax", "DISEASE", 33, 45], ["Stat chest X-Ray", "TEST", 0, 16], ["pneumothorax", "PROBLEM", 33, 45], ["chest", "ANATOMY", 5, 10], ["negative for", "UNCERTAINTY", 20, 32], ["pneumothorax", "OBSERVATION", 33, 45]]], ["A) Increase the tidal volume and reduce the respiratory rate.", [["respiratory", "ANATOMY", 44, 55], ["Increase the tidal volume", "TREATMENT", 3, 28], ["the respiratory rate", "TEST", 40, 60], ["Increase", "OBSERVATION_MODIFIER", 3, 11], ["tidal volume", "OBSERVATION", 16, 28], ["respiratory rate", "OBSERVATION", 44, 60]]], ["B) Reduce the respiratory rate and PEEP.", [["respiratory", "ANATOMY", 14, 25], ["the respiratory rate", "TEST", 10, 30], ["PEEP", "TREATMENT", 35, 39], ["respiratory rate", "OBSERVATION", 14, 30]]], ["C) Increase the I: E ratio.", [["I: E", "GENE_OR_GENE_PRODUCT", 16, 20]]], ["D) Reduce the tidal volume, respiratory rate or I: E ratio.", [["respiratory", "ANATOMY", 28, 39], ["the tidal volume", "TEST", 10, 26], ["respiratory rate", "TEST", 28, 44], ["tidal volume", "OBSERVATION", 14, 26]]], ["E) Increase PEEP.ReferenceAnswer: D This patient has air trapping commonly seen in COPD patients who are being ventilated.", [["COPD", "DISEASE", 83, 87], ["patient", "ORGANISM", 41, 48], ["patients", "ORGANISM", 88, 96], ["patient", "SPECIES", 41, 48], ["patients", "SPECIES", 88, 96], ["Increase PEEP", "TREATMENT", 3, 16], ["air trapping", "PROBLEM", 53, 65], ["Increase PEEP", "OBSERVATION", 3, 16], ["air trapping", "OBSERVATION", 53, 65], ["COPD", "OBSERVATION", 83, 87], ["ventilated", "OBSERVATION", 111, 121]]], ["This has resulted in auto peep.", [["auto peep", "TREATMENT", 21, 30], ["auto peep", "OBSERVATION", 21, 30]]], ["Air trapping occurs due to repetitive breaths with high tidal volumes and higher rates with very minimal time for exhalation.", [["Air trapping", "PROBLEM", 0, 12], ["repetitive breaths", "PROBLEM", 27, 45], ["high tidal volumes", "PROBLEM", 51, 69], ["trapping", "OBSERVATION", 4, 12], ["high", "OBSERVATION_MODIFIER", 51, 55], ["tidal volumes", "OBSERVATION", 56, 69]]], ["This can lead to poor gas exchange and hemodynamic compromise.", [["poor gas exchange", "PROBLEM", 17, 34], ["hemodynamic compromise", "PROBLEM", 39, 61], ["poor", "OBSERVATION_MODIFIER", 17, 21], ["gas exchange", "OBSERVATION", 22, 34], ["hemodynamic compromise", "OBSERVATION", 39, 61]]], ["This can be treated by reducing rate and tidal volume and by increasing expiratory time.", [["tidal volume", "TEST", 41, 53], ["tidal volume", "OBSERVATION", 41, 53]]], ["The patient reports no other medical problems.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["other medical problems", "PROBLEM", 23, 45]]], ["He takes no medications.", [["medications", "TREATMENT", 12, 23]]], ["Six months ago he was seen in the emergency department for a spontaneous retroperitoneal bleeding.", [["retroperitoneal", "ANATOMY", 73, 88], ["retroperitoneal bleeding", "DISEASE", 73, 97], ["a spontaneous retroperitoneal bleeding", "PROBLEM", 59, 97], ["retroperitoneal", "ANATOMY", 73, 88], ["bleeding", "OBSERVATION", 89, 97]]], ["On physical exam the patient he is afebrile, blood pressure is 120/74 mmHg, heart rate is 78 bpm, respiratory rate is 16, and oxygen saturation is 97% on room air.", [["blood", "ANATOMY", 45, 50], ["heart", "ANATOMY", 76, 81], ["respiratory", "ANATOMY", 98, 109], ["oxygen", "CHEMICAL", 126, 132], ["oxygen", "CHEMICAL", 126, 132], ["patient", "ORGANISM", 21, 28], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["heart", "ORGAN", 76, 81], ["oxygen", "SIMPLE_CHEMICAL", 126, 132], ["patient", "SPECIES", 21, 28], ["physical exam", "TEST", 3, 16], ["afebrile", "PROBLEM", 35, 43], ["blood pressure", "TEST", 45, 59], ["heart rate", "TEST", 76, 86], ["respiratory rate", "TEST", 98, 114], ["oxygen saturation", "TEST", 126, 143]]], ["Bleeding from his gingival membranes is noted.", [["gingival membranes", "ANATOMY", 18, 36], ["Bleeding", "DISEASE", 0, 8], ["gingival membranes", "MULTI-TISSUE_STRUCTURE", 18, 36], ["Bleeding from his gingival membranes", "PROBLEM", 0, 36], ["gingival membranes", "ANATOMY", 18, 36]]], ["Otherwise, the rest of the exam is within normal limits.", [["the rest of the exam", "TEST", 11, 31], ["within normal limits", "OBSERVATION", 35, 55]]], ["Laboratory fi ndings reveal platelets of 250,000 and INR of 0.9.ReferenceWhich of the following defi ciency is suspected?", [["platelets", "ANATOMY", 28, 37], ["platelets", "CELL", 28, 37], ["platelets", "CELL_TYPE", 28, 37], ["Laboratory fi ndings", "TEST", 0, 20], ["platelets", "TEST", 28, 37], ["INR", "TEST", 53, 56], ["platelets", "OBSERVATION", 28, 37]]], ["A) Vitamin K B) Vitamin C C) Folate D) Vitamin A E) Thiamine Answer: A Fat-soluble vitamin defi ciencies occur in chronic alcoholics.ReferenceOne study found vitamin K defi ciency in the majority of chronic alcoholics.", [["Vitamin K B", "CHEMICAL", 3, 14], ["Vitamin C", "CHEMICAL", 16, 25], ["Folate", "CHEMICAL", 29, 35], ["Vitamin A", "CHEMICAL", 39, 48], ["Thiamine", "CHEMICAL", 52, 60], ["vitamin", "CHEMICAL", 83, 90], ["chronic alcoholics", "DISEASE", 114, 132], ["vitamin K", "CHEMICAL", 158, 167], ["alcoholics", "DISEASE", 207, 217], ["Vitamin K B", "CHEMICAL", 3, 14], ["Vitamin C C", "CHEMICAL", 16, 27], ["Folate D", "CHEMICAL", 29, 37], ["Vitamin A E", "CHEMICAL", 39, 50], ["Thiamine", "CHEMICAL", 52, 60], ["vitamin K", "CHEMICAL", 158, 167], ["Vitamin K B) Vitamin C C) Folate D", "SIMPLE_CHEMICAL", 3, 37], ["Vitamin A E", "SIMPLE_CHEMICAL", 39, 50], ["Thiamine", "SIMPLE_CHEMICAL", 52, 60], ["A Fat-soluble vitamin defi ciencies", "SIMPLE_CHEMICAL", 69, 104], ["vitamin K defi", "SIMPLE_CHEMICAL", 158, 172], ["A) Vitamin K B)", "TREATMENT", 0, 15], ["Vitamin C C) Folate D) Vitamin A E) Thiamine", "TREATMENT", 16, 60], ["A Fat-soluble vitamin defi ciencies", "TREATMENT", 69, 104], ["chronic alcoholics", "PROBLEM", 114, 132], ["One study", "TEST", 142, 151], ["vitamin K defi ciency", "TREATMENT", 158, 179], ["chronic alcoholics", "PROBLEM", 199, 217], ["chronic", "OBSERVATION_MODIFIER", 114, 121], ["alcoholics", "OBSERVATION", 122, 132], ["chronic", "OBSERVATION_MODIFIER", 199, 206], ["alcoholics", "OBSERVATION", 207, 217]]], ["Vitamin K plays an essential role in hemostasis.", [["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "CHEMICAL", 0, 9], ["Vitamin K", "SIMPLE_CHEMICAL", 0, 9], ["Vitamin K", "TREATMENT", 0, 9], ["hemostasis", "OBSERVATION", 37, 47]]], ["It is a fat-soluble vitamin that is absorbed in the small intestine and stored in the liver.", [["small intestine", "ANATOMY", 52, 67], ["liver", "ANATOMY", 86, 91], ["vitamin", "CHEMICAL", 20, 27], ["vitamin", "CHEMICAL", 20, 27], ["fat", "TISSUE", 8, 11], ["vitamin", "SIMPLE_CHEMICAL", 20, 27], ["small intestine", "ORGAN", 52, 67], ["liver", "ORGAN", 86, 91], ["a fat-soluble vitamin", "TREATMENT", 6, 27], ["small intestine", "ANATOMY", 52, 67], ["liver", "ANATOMY", 86, 91]]], ["Other causes of 182-195.2012;3:182-195.", [["182-195.2012;3:182-195", "CHEMICAL", 16, 38]]], ["A 43-year-old male is admitted for cellulitis.", [["cellulitis", "DISEASE", 35, 45], ["male", "ORGANISM", 14, 18], ["cellulitis", "PROBLEM", 35, 45], ["43-", "OBSERVATION_MODIFIER", 2, 5], ["cellulitis", "OBSERVATION", 35, 45]]], ["He reports that he works at a beef processing plant.", [["beef", "ORGANISM_SUBDIVISION", 30, 34]]], ["On presentation, his symptoms are fever, headache, and bilaterally swollen erythematous hands.", [["fever", "DISEASE", 34, 39], ["headache", "DISEASE", 41, 49], ["his symptoms", "PROBLEM", 17, 29], ["fever", "PROBLEM", 34, 39], ["headache", "PROBLEM", 41, 49], ["bilaterally swollen erythematous hands", "PROBLEM", 55, 93], ["bilaterally", "ANATOMY_MODIFIER", 55, 66], ["swollen", "OBSERVATION_MODIFIER", 67, 74], ["erythematous", "OBSERVATION", 75, 87], ["hands", "ANATOMY", 88, 93]]], ["On physical examination, his hands are noted to have small painless papules.", [["papules", "ANATOMY", 68, 75], ["papules", "DISEASE", 68, 75], ["hands", "ORGANISM_SUBDIVISION", 29, 34], ["papules", "PATHOLOGICAL_FORMATION", 68, 75], ["physical examination", "TEST", 3, 23], ["small painless papules", "PROBLEM", 53, 75], ["hands", "ANATOMY", 29, 34], ["small", "OBSERVATION_MODIFIER", 53, 58], ["painless", "OBSERVATION_MODIFIER", 59, 67], ["papules", "OBSERVATION", 68, 75]]], ["Over the course of the next 24 h, the papules progress to central vesicles.", [["papules", "ANATOMY", 38, 45], ["central vesicles", "ANATOMY", 58, 74], ["papules", "DISEASE", 38, 45], ["papules", "PATHOLOGICAL_FORMATION", 38, 45], ["central vesicles", "CELLULAR_COMPONENT", 58, 74], ["the papules", "PROBLEM", 34, 45], ["papules", "OBSERVATION", 38, 45], ["central vesicles", "ANATOMY", 58, 74]]], ["The vesicles are painless and have a black eschar.ReferenceWhich of the following is the most likely diagnosis?", [["vesicles", "ANATOMY", 4, 12], ["vesicles", "CELLULAR_COMPONENT", 4, 12], ["eschar", "PATHOLOGICAL_FORMATION", 43, 49], ["painless", "PROBLEM", 17, 25], ["a black eschar", "PROBLEM", 35, 49], ["vesicles", "ANATOMY", 4, 12], ["painless", "OBSERVATION", 17, 25], ["black", "OBSERVATION_MODIFIER", 37, 42], ["eschar", "OBSERVATION", 43, 49], ["most likely", "UNCERTAINTY", 89, 100]]], ["A) Cutaneous anthrax B) Bullous pemphigoid C) Methicillin-sensitive Staph. aureus infection D) Pasteurella infection Answer: A 95 % of anthrax is cutaneous.", [["cutaneous", "ANATOMY", 146, 155], ["anthrax B", "DISEASE", 13, 22], ["Bullous pemphigoid C", "DISEASE", 24, 44], ["Methicillin", "CHEMICAL", 46, 57], ["aureus infection", "DISEASE", 75, 91], ["Pasteurella infection", "DISEASE", 95, 116], ["anthrax", "DISEASE", 135, 142], ["aureus", "ORGANISM", 75, 81], ["anthrax", "ORGANISM", 135, 142], ["aureus", "SPECIES", 75, 81], ["aureus", "SPECIES", 75, 81], ["A) Cutaneous anthrax", "PROBLEM", 0, 20], ["Bullous pemphigoid C", "PROBLEM", 24, 44], ["Methicillin-sensitive Staph", "PROBLEM", 46, 73], ["aureus infection", "PROBLEM", 75, 91], ["Pasteurella infection", "PROBLEM", 95, 116], ["Cutaneous", "ANATOMY", 3, 12], ["Bullous", "OBSERVATION_MODIFIER", 24, 31], ["pemphigoid", "OBSERVATION", 32, 42], ["infection", "OBSERVATION", 82, 91], ["Pasteurella", "OBSERVATION_MODIFIER", 95, 106], ["infection", "OBSERVATION", 107, 116], ["cutaneous", "ANATOMY", 146, 155]]], ["The remaining cases are inhalational and gastrointestinal.", [["gastrointestinal", "ANATOMY", 41, 57], ["gastrointestinal", "ORGAN", 41, 57], ["gastrointestinal", "ANATOMY", 41, 57]]], ["Anthrax is primarily zoonotic.", [["Anthrax", "DISEASE", 0, 7], ["zoonotic", "OBSERVATION_MODIFIER", 21, 29]]], ["Those at highest risk are farmers, and workers in facilities that use animal products, especially previously contaminated goat hair, wool, or bone.", [["hair", "ANATOMY", 127, 131], ["wool", "ANATOMY", 133, 137], ["bone", "ANATOMY", 142, 146], ["goat", "ORGANISM", 122, 126], ["hair", "MULTI-TISSUE_STRUCTURE", 127, 131], ["bone", "TISSUE", 142, 146], ["goat", "SPECIES", 122, 126], ["goat", "SPECIES", 122, 126], ["animal products", "TREATMENT", 70, 85], ["bone", "ANATOMY", 142, 146]]], ["Cutaneous anthrax begins as a pruritic papule that enlarges within 24-48 h to form a vesicle.", [["papule", "ANATOMY", 39, 45], ["vesicle", "ANATOMY", 85, 92], ["anthrax", "DISEASE", 10, 17], ["papule", "PATHOLOGICAL_FORMATION", 39, 45], ["vesicle", "CELLULAR_COMPONENT", 85, 92], ["Cutaneous anthrax", "PROBLEM", 0, 17], ["a pruritic papule", "PROBLEM", 28, 45], ["anthrax", "OBSERVATION", 10, 17], ["pruritic", "OBSERVATION_MODIFIER", 30, 38], ["papule", "OBSERVATION", 39, 45], ["enlarges", "OBSERVATION_MODIFIER", 51, 59], ["vesicle", "ANATOMY", 85, 92]]], ["This subsequently becomes an ulcer surrounded progressing to a black eschar .", [["ulcer", "ANATOMY", 29, 34], ["ulcer", "DISEASE", 29, 34], ["eschar", "DISEASE", 69, 75], ["ulcer", "PATHOLOGICAL_FORMATION", 29, 34], ["eschar", "PATHOLOGICAL_FORMATION", 69, 75], ["an ulcer", "PROBLEM", 26, 34], ["a black eschar", "PROBLEM", 61, 75], ["ulcer", "OBSERVATION", 29, 34], ["black", "OBSERVATION_MODIFIER", 63, 68], ["eschar", "OBSERVATION", 69, 75]]], ["Gastrointestinal and cutaneous anthrax can be treated with ciprofl oxacin or doxycycline for 60 days.", [["Gastrointestinal", "ANATOMY", 0, 16], ["cutaneous", "ANATOMY", 21, 30], ["anthrax", "DISEASE", 31, 38], ["ciprofl oxacin", "CHEMICAL", 59, 73], ["doxycycline", "CHEMICAL", 77, 88], ["ciprofl oxacin", "CHEMICAL", 59, 73], ["doxycycline", "CHEMICAL", 77, 88], ["Gastrointestinal", "ORGAN", 0, 16], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 59, 73], ["doxycycline", "SIMPLE_CHEMICAL", 77, 88], ["Gastrointestinal and cutaneous anthrax", "PROBLEM", 0, 38], ["ciprofl oxacin", "TREATMENT", 59, 73], ["doxycycline", "TREATMENT", 77, 88], ["cutaneous", "ANATOMY", 21, 30]]], ["Amoxicillin or amoxicillin clavulanate may be used to complete the course if the strain is susceptible.", [["Amoxicillin", "CHEMICAL", 0, 11], ["amoxicillin clavulanate", "CHEMICAL", 15, 38], ["Amoxicillin", "CHEMICAL", 0, 11], ["amoxicillin clavulanate", "CHEMICAL", 15, 38], ["Amoxicillin", "SIMPLE_CHEMICAL", 0, 11], ["amoxicillin clavulanate", "SIMPLE_CHEMICAL", 15, 38], ["Amoxicillin", "TREATMENT", 0, 11], ["amoxicillin clavulanate", "TREATMENT", 15, 38], ["the strain", "PROBLEM", 77, 87]]], ["A 42-year-old man with sickle cell disease (SCD) is hospitalized for fever, bone pain, chest pain, and shortness of breath.", [["sickle cell", "ANATOMY", 23, 34], ["bone", "ANATOMY", 76, 80], ["chest", "ANATOMY", 87, 92], ["sickle cell disease", "DISEASE", 23, 42], ["SCD", "DISEASE", 44, 47], ["fever", "DISEASE", 69, 74], ["bone pain", "DISEASE", 76, 85], ["chest pain", "DISEASE", 87, 97], ["shortness of breath", "DISEASE", 103, 122], ["man", "ORGANISM", 14, 17], ["sickle cell", "CELL", 23, 34], ["bone", "TISSUE", 76, 80], ["chest", "ORGANISM_SUBDIVISION", 87, 92], ["man", "SPECIES", 14, 17], ["sickle cell disease", "PROBLEM", 23, 42], ["fever", "PROBLEM", 69, 74], ["bone pain", "PROBLEM", 76, 85], ["chest pain", "PROBLEM", 87, 97], ["shortness of breath", "PROBLEM", 103, 122], ["sickle cell disease", "OBSERVATION", 23, 42], ["bone", "ANATOMY", 76, 80], ["pain", "OBSERVATION", 81, 85], ["chest", "ANATOMY", 87, 92]]], ["His most recent blood transfusion was four weeks ago for symptomatic anemia.", [["blood", "ANATOMY", 16, 21], ["anemia", "DISEASE", 69, 75], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["His most recent blood transfusion", "TREATMENT", 0, 33], ["symptomatic anemia", "PROBLEM", 57, 75], ["symptomatic", "OBSERVATION_MODIFIER", 57, 68], ["anemia", "OBSERVATION", 69, 75]]], ["On physical examination, the patient appears in acute pain and audibly wheezing.", [["pain", "DISEASE", 54, 58], ["wheezing", "DISEASE", 71, 79], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["physical examination", "TEST", 3, 23], ["acute pain", "PROBLEM", 48, 58], ["audibly wheezing", "PROBLEM", 63, 79], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["pain", "OBSERVATION", 54, 58], ["wheezing", "OBSERVATION", 71, 79]]], ["Temperature is 37.6 \u00b0C(99.7) \u00b0F. The remainder of the examination is unremarkable.", [["Temperature", "TEST", 0, 11], ["\u00b0C", "TEST", 20, 22], ["the examination", "TEST", 50, 65], ["unremarkable", "OBSERVATION", 69, 81]]], ["CXR reveals multiple infi ltrates, most of which are old.ReferenceWhat would be the most common cause of death for this patient?", [["death", "DISEASE", 105, 110], ["patient", "ORGANISM", 120, 127], ["CXR", "PROTEIN", 0, 3], ["patient", "SPECIES", 120, 127], ["CXR", "TEST", 0, 3], ["multiple infi ltrates", "PROBLEM", 12, 33], ["multiple", "OBSERVATION_MODIFIER", 12, 20], ["infi ltrates", "OBSERVATION", 21, 33], ["old", "OBSERVATION", 53, 56]]], ["A) Acute chest syndrome B) Coronary artery disease C) Cerebral aneurysm rupture D) Anemia E) Heart failure Answer: A Acute chest syndrome in adults is a common cause of death in sickle cell patients.", [["chest", "ANATOMY", 9, 14], ["Coronary artery", "ANATOMY", 27, 42], ["Cerebral", "ANATOMY", 54, 62], ["Heart", "ANATOMY", 93, 98], ["sickle cell", "ANATOMY", 178, 189], ["chest syndrome B", "DISEASE", 9, 25], ["Coronary artery disease", "DISEASE", 27, 50], ["Cerebral aneurysm rupture", "DISEASE", 54, 79], ["Anemia", "DISEASE", 83, 89], ["Heart failure", "DISEASE", 93, 106], ["chest syndrome", "DISEASE", 123, 137], ["death", "DISEASE", 169, 174], ["sickle", "DISEASE", 178, 184], ["sickle cell", "CELL", 178, 189], ["patients", "ORGANISM", 190, 198], ["patients", "SPECIES", 190, 198], ["A) Acute chest syndrome", "PROBLEM", 0, 23], ["Coronary artery disease C", "PROBLEM", 27, 52], ["Cerebral aneurysm rupture D)", "PROBLEM", 54, 82], ["Anemia E)", "PROBLEM", 83, 92], ["Heart failure", "PROBLEM", 93, 106], ["A Acute chest syndrome", "PROBLEM", 115, 137], ["death", "PROBLEM", 169, 174], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["chest", "ANATOMY", 9, 14], ["syndrome", "OBSERVATION", 15, 23], ["Coronary artery", "ANATOMY", 27, 42], ["Cerebral", "ANATOMY", 54, 62], ["aneurysm", "OBSERVATION", 63, 71], ["Anemia", "OBSERVATION", 83, 89], ["Heart", "ANATOMY", 93, 98], ["failure", "OBSERVATION", 99, 106], ["Acute", "OBSERVATION_MODIFIER", 117, 122], ["chest", "ANATOMY", 123, 128], ["syndrome", "OBSERVATION", 129, 137], ["sickle cell", "OBSERVATION", 178, 189]]], ["This may be the result of infection, pain, or veno-occlusive disease.", [["infection", "DISEASE", 26, 35], ["pain", "DISEASE", 37, 41], ["veno-occlusive disease", "DISEASE", 46, 68], ["infection", "PROBLEM", 26, 35], ["pain", "PROBLEM", 37, 41], ["veno-occlusive disease", "PROBLEM", 46, 68], ["may be the result of", "UNCERTAINTY", 5, 25], ["infection", "OBSERVATION", 26, 35], ["veno-occlusive", "OBSERVATION_MODIFIER", 46, 60], ["disease", "OBSERVATION", 61, 68]]], ["Treatment of acute chest syndrome consists of oxygen, antibiotics, incentive spirometry, transfusion, and bronchodilators.", [["chest", "ANATOMY", 19, 24], ["acute chest syndrome", "DISEASE", 13, 33], ["oxygen", "CHEMICAL", 46, 52], ["oxygen", "CHEMICAL", 46, 52], ["chest", "ORGANISM_SUBDIVISION", 19, 24], ["oxygen", "SIMPLE_CHEMICAL", 46, 52], ["acute chest syndrome", "PROBLEM", 13, 33], ["oxygen", "TREATMENT", 46, 52], ["antibiotics", "TREATMENT", 54, 65], ["incentive spirometry", "TREATMENT", 67, 87], ["transfusion", "TREATMENT", 89, 100], ["bronchodilators", "TREATMENT", 106, 121], ["acute", "OBSERVATION_MODIFIER", 13, 18], ["chest", "ANATOMY", 19, 24], ["syndrome", "OBSERVATION", 25, 33], ["oxygen", "OBSERVATION_MODIFIER", 46, 52]]], ["Some patients have repeat presentations of acute chest syndrome.", [["chest", "ANATOMY", 49, 54], ["acute chest syndrome", "DISEASE", 43, 63], ["patients", "ORGANISM", 5, 13], ["chest", "ORGANISM_SUBDIVISION", 49, 54], ["patients", "SPECIES", 5, 13], ["acute chest syndrome", "PROBLEM", 43, 63], ["acute", "OBSERVATION_MODIFIER", 43, 48], ["chest", "ANATOMY", 49, 54], ["syndrome", "OBSERVATION", 55, 63]]], ["Chronic transfusion reduces the recurrence and hydroxyurea reduces the rate of acute chest syndrome by about half.ReferenceLife expectancy continues to improve with SCD patients, and now in developed countries, it is approaching 50.", [["chest", "ANATOMY", 85, 90], ["hydroxyurea", "CHEMICAL", 47, 58], ["acute chest syndrome", "DISEASE", 79, 99], ["SCD", "DISEASE", 165, 168], ["hydroxyurea", "CHEMICAL", 47, 58], ["hydroxyurea", "SIMPLE_CHEMICAL", 47, 58], ["chest", "ORGANISM_SUBDIVISION", 85, 90], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["Chronic transfusion", "TREATMENT", 0, 19], ["the recurrence", "PROBLEM", 28, 42], ["hydroxyurea", "TREATMENT", 47, 58], ["acute chest syndrome", "PROBLEM", 79, 99], ["transfusion", "OBSERVATION", 8, 19], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["chest", "ANATOMY", 85, 90], ["syndrome", "OBSERVATION", 91, 99]]], ["As the population of patients with SCD grows older, new chronic complications are appearing.", [["SCD", "DISEASE", 35, 38], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["SCD", "PROBLEM", 35, 38], ["new chronic complications", "PROBLEM", 52, 77], ["new", "OBSERVATION_MODIFIER", 52, 55], ["chronic", "OBSERVATION_MODIFIER", 56, 63], ["complications", "OBSERVATION", 64, 77]]], ["Pulmonary disease and in particular pulmonary hypertension is emerging as a relatively common complication.", [["Pulmonary", "ANATOMY", 0, 9], ["pulmonary", "ANATOMY", 36, 45], ["Pulmonary disease", "DISEASE", 0, 17], ["pulmonary hypertension", "DISEASE", 36, 58], ["Pulmonary", "ORGAN", 0, 9], ["pulmonary", "ORGAN", 36, 45], ["Pulmonary disease", "PROBLEM", 0, 17], ["particular pulmonary hypertension", "PROBLEM", 25, 58], ["a relatively common complication", "PROBLEM", 74, 106], ["disease", "OBSERVATION", 10, 17], ["pulmonary", "ANATOMY", 36, 45], ["hypertension", "OBSERVATION", 46, 58]]], ["There is no increase in cerebral aneurysm rupture in these patients.", [["cerebral aneurysm", "ANATOMY", 24, 41], ["cerebral aneurysm rupture", "DISEASE", 24, 49], ["cerebral aneurysm", "PATHOLOGICAL_FORMATION", 24, 41], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["increase in cerebral aneurysm rupture", "PROBLEM", 12, 49], ["no", "UNCERTAINTY", 9, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["cerebral", "ANATOMY", 24, 32], ["aneurysm", "OBSERVATION", 33, 41], ["rupture", "OBSERVATION", 42, 49]]], ["Coronary artery occlusion is not common in sickle cell patients, although valvular disease, pulmonary hypertension, and sudden arrhythmic death are.", [["Coronary artery", "ANATOMY", 0, 15], ["sickle cell", "ANATOMY", 43, 54], ["valvular", "ANATOMY", 74, 82], ["pulmonary", "ANATOMY", 92, 101], ["Coronary artery occlusion", "DISEASE", 0, 25], ["sickle", "DISEASE", 43, 49], ["valvular disease", "DISEASE", 74, 90], ["pulmonary hypertension", "DISEASE", 92, 114], ["sudden arrhythmic death", "DISEASE", 120, 143], ["Coronary artery", "MULTI-TISSUE_STRUCTURE", 0, 15], ["sickle cell", "CELL", 43, 54], ["patients", "ORGANISM", 55, 63], ["valvular", "ORGAN", 74, 82], ["pulmonary", "ORGAN", 92, 101], ["patients", "SPECIES", 55, 63], ["Coronary artery occlusion", "PROBLEM", 0, 25], ["valvular disease", "PROBLEM", 74, 90], ["pulmonary hypertension", "PROBLEM", 92, 114], ["sudden arrhythmic death", "PROBLEM", 120, 143], ["artery", "ANATOMY", 9, 15], ["occlusion", "OBSERVATION", 16, 25], ["not common", "UNCERTAINTY", 29, 39], ["sickle cell", "OBSERVATION", 43, 54], ["valvular", "ANATOMY", 74, 82], ["disease", "OBSERVATION", 83, 90], ["pulmonary", "ANATOMY", 92, 101], ["hypertension", "OBSERVATION", 102, 114], ["sudden", "OBSERVATION_MODIFIER", 120, 126], ["arrhythmic death", "OBSERVATION", 127, 143]]], ["A 68-year-old female with a history of hypertension, hypercholesterolemia, and tobacco use is admitted with lightheadedness and mild associated dyspnea.", [["hypertension", "DISEASE", 39, 51], ["hypercholesterolemia", "DISEASE", 53, 73], ["lightheadedness", "DISEASE", 108, 123], ["dyspnea", "DISEASE", 144, 151], ["female", "ORGANISM", 14, 20], ["tobacco", "ORGANISM", 79, 86], ["tobacco", "SPECIES", 79, 86], ["hypertension", "PROBLEM", 39, 51], ["hypercholesterolemia", "PROBLEM", 53, 73], ["lightheadedness", "PROBLEM", 108, 123], ["mild associated dyspnea", "PROBLEM", 128, 151], ["hypertension", "OBSERVATION", 39, 51], ["hypercholesterolemia", "OBSERVATION", 53, 73], ["mild", "OBSERVATION_MODIFIER", 128, 132], ["dyspnea", "OBSERVATION", 144, 151]]], ["The symptoms have been increasing in intensity over the past days.", [["The symptoms", "PROBLEM", 0, 12], ["increasing", "OBSERVATION_MODIFIER", 23, 33], ["intensity", "OBSERVATION_MODIFIER", 37, 46]]], ["She denies any symptoms at rest.", [["any symptoms", "PROBLEM", 11, 23]]], ["She denies any previous cardiac history.", [["cardiac", "ANATOMY", 24, 31], ["cardiac", "ANATOMY", 24, 31], ["history", "OBSERVATION", 32, 39]]], ["While you are evaluating her in the emergency room, she develops chest pain.", [["chest", "ANATOMY", 65, 70], ["chest pain", "DISEASE", 65, 75], ["chest", "ORGANISM_SUBDIVISION", 65, 70], ["chest pain", "PROBLEM", 65, 75], ["chest", "ANATOMY", 65, 70]]], ["Physical examination shows blood pressure of 100/64 mmHg and heart rate of 116/min.", [["blood", "ANATOMY", 27, 32], ["heart", "ANATOMY", 61, 66], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["heart", "ORGAN", 61, 66], ["Physical examination", "TEST", 0, 20], ["blood pressure", "TEST", 27, 41], ["heart rate", "TEST", 61, 71], ["heart", "ANATOMY", 61, 66]]], ["In general, she appears in moderate distress.", [["moderate distress", "PROBLEM", 27, 44], ["moderate", "OBSERVATION_MODIFIER", 27, 35], ["distress", "OBSERVATION", 36, 44]]], ["Cardiac examination shows normal S1 and S2 and sinus tachycardia.", [["Cardiac", "ANATOMY", 0, 7], ["sinus", "ANATOMY", 47, 52], ["sinus tachycardia", "DISEASE", 47, 64], ["Cardiac", "ORGAN", 0, 7], ["sinus", "ORGAN", 47, 52], ["Cardiac examination", "TEST", 0, 19], ["sinus tachycardia", "PROBLEM", 47, 64], ["normal", "OBSERVATION", 26, 32], ["S1", "ANATOMY", 33, 35], ["S2", "ANATOMY", 40, 42], ["sinus", "ANATOMY", 47, 52], ["tachycardia", "OBSERVATION", 53, 64]]], ["Stat ECG shows 1 mm ST segment depression in leads V4 through V6.ReferenceLaboratory data shows a troponin of 0.48 ng/mL, a WBC of 9,400/\u03bcL, and a hemoglobin of 6.8 g/dL.ReferenceWhich of the following is the most appropriate next step?", [["depression", "DISEASE", 31, 41], ["troponin", "GENE_OR_GENE_PRODUCT", 98, 106], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 147, 157], ["V6", "PROTEIN", 62, 64], ["troponin", "PROTEIN", 98, 106], ["hemoglobin", "PROTEIN", 147, 157], ["Stat ECG", "TEST", 0, 8], ["1 mm ST segment depression in leads V4 through V6", "PROBLEM", 15, 64], ["ReferenceLaboratory data", "TEST", 65, 89], ["a troponin", "TEST", 96, 106], ["a WBC", "TEST", 122, 127], ["a hemoglobin", "TEST", 145, 157], ["segment", "ANATOMY_MODIFIER", 23, 30], ["depression", "OBSERVATION", 31, 41], ["V4", "ANATOMY_MODIFIER", 51, 53]]], ["A) Emergent cardiac catheterization B) Intravenous nitroglycerin, aspirin, and intravenous heparin C) Pharmacologic stress test with nuclear imaging D) Intravenous metoprolol E) Stool guaiac testing Answer: E The fi rst and most important step for this patient with significant anemia is to determine the cause of her anemia and administer blood transfusion.", [["cardiac", "ANATOMY", 12, 19], ["intravenous", "ANATOMY", 79, 90], ["nuclear", "ANATOMY", 133, 140], ["blood", "ANATOMY", 340, 345], ["nitroglycerin", "CHEMICAL", 51, 64], ["aspirin", "CHEMICAL", 66, 73], ["heparin", "CHEMICAL", 91, 98], ["metoprolol", "CHEMICAL", 164, 174], ["anemia", "DISEASE", 278, 284], ["anemia", "DISEASE", 318, 324], ["nitroglycerin", "CHEMICAL", 51, 64], ["aspirin", "CHEMICAL", 66, 73], ["metoprolol E", "CHEMICAL", 164, 176], ["nitroglycerin", "SIMPLE_CHEMICAL", 51, 64], ["aspirin", "SIMPLE_CHEMICAL", 66, 73], ["intravenous heparin C", "SIMPLE_CHEMICAL", 79, 100], ["patient", "ORGANISM", 253, 260], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["patient", "SPECIES", 253, 260], ["Emergent cardiac catheterization", "TREATMENT", 3, 35], ["Intravenous nitroglycerin", "TREATMENT", 39, 64], ["aspirin", "TREATMENT", 66, 73], ["intravenous heparin C", "TREATMENT", 79, 100], ["Pharmacologic stress test", "TEST", 102, 127], ["nuclear imaging", "TEST", 133, 148], ["Intravenous metoprolol E", "TREATMENT", 152, 176], ["significant anemia", "PROBLEM", 266, 284], ["her anemia", "PROBLEM", 314, 324], ["blood transfusion", "TREATMENT", 340, 357], ["anemia", "OBSERVATION", 318, 324]]], ["Before starting the urgent treatment for ischemia, which involves aggressive anticoagulants, it is important to determine the source of blood loss.", [["blood", "ANATOMY", 136, 141], ["ischemia", "DISEASE", 41, 49], ["blood loss", "DISEASE", 136, 146], ["blood", "ORGANISM_SUBSTANCE", 136, 141], ["the urgent treatment", "TREATMENT", 16, 36], ["ischemia", "PROBLEM", 41, 49], ["aggressive anticoagulants", "TREATMENT", 66, 91], ["blood loss", "PROBLEM", 136, 146], ["ischemia", "OBSERVATION", 41, 49]]], ["Active bleeding can be worsened with anticoagulants and can actually cause further harm to a patient such as this.", [["bleeding", "DISEASE", 7, 15], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["Active bleeding", "PROBLEM", 0, 15], ["anticoagulants", "TREATMENT", 37, 51], ["bleeding", "OBSERVATION", 7, 15], ["worsened", "OBSERVATION_MODIFIER", 23, 31]]], ["The patient's symptoms and ECG may improve after transfusion, once the oxygen carrying capacity of her blood has been improved to normal levels, and stenting, which also involves the use of anticoagulants, can be detrimental in a patient such as this.ReferenceRao SV, Sherwood MW.", [["blood", "ANATOMY", 103, 108], ["oxygen", "CHEMICAL", 71, 77], ["oxygen", "CHEMICAL", 71, 77], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 71, 77], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["patient", "ORGANISM", 230, 237], ["patient", "SPECIES", 4, 11], ["patient", "SPECIES", 230, 237], ["The patient's symptoms", "PROBLEM", 0, 22], ["ECG", "TEST", 27, 30], ["transfusion", "TREATMENT", 49, 60], ["the oxygen carrying capacity", "PROBLEM", 67, 95], ["her blood", "TEST", 99, 108], ["stenting", "TREATMENT", 149, 157], ["anticoagulants", "TREATMENT", 190, 204], ["stenting", "OBSERVATION", 149, 157]]], ["Isn't it about time we learned how to use blood transfusion in patients with ischemic heart disease?", [["blood", "ANATOMY", 42, 47], ["heart", "ANATOMY", 86, 91], ["ischemic heart disease", "DISEASE", 77, 99], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["patients", "ORGANISM", 63, 71], ["heart", "ORGAN", 86, 91], ["patients", "SPECIES", 63, 71], ["blood transfusion", "TREATMENT", 42, 59], ["ischemic heart disease", "PROBLEM", 77, 99], ["heart", "ANATOMY", 86, 91], ["disease", "OBSERVATION", 92, 99]]], ["J Am Coll Cardiol.", [["Cardiol", "CHEMICAL", 10, 17]]], ["A 35-year-old woman is admitted with paresthesias that began in the left arm and spread to her left face over 30 min.", [["left arm", "ANATOMY", 68, 76], ["left face", "ANATOMY", 95, 104], ["paresthesias", "DISEASE", 37, 49], ["woman", "ORGANISM", 14, 19], ["left arm", "ORGANISM_SUBDIVISION", 68, 76], ["woman", "SPECIES", 14, 19], ["paresthesias", "PROBLEM", 37, 49], ["paresthesias", "OBSERVATION", 37, 49], ["left", "ANATOMY_MODIFIER", 68, 72], ["arm", "ANATOMY", 73, 76], ["left", "ANATOMY_MODIFIER", 95, 99]]], ["She also reports a severe frontal headache.", [["frontal", "ANATOMY", 26, 33], ["frontal headache", "DISEASE", 26, 42], ["a severe frontal headache", "PROBLEM", 17, 42], ["severe", "OBSERVATION_MODIFIER", 19, 25], ["frontal", "ANATOMY", 26, 33], ["headache", "OBSERVATION", 34, 42]]], ["She has a limited past medical history but has a family history of migraine.", [["migraine", "DISEASE", 67, 75], ["migraine", "PROBLEM", 67, 75], ["migraine", "OBSERVATION", 67, 75]]], ["She reports that she has had headaches in the past but not migraine headaches.", [["headaches", "DISEASE", 29, 38], ["migraine", "DISEASE", 59, 67], ["headaches", "DISEASE", 68, 77], ["headaches", "PROBLEM", 29, 38], ["migraine headaches", "PROBLEM", 59, 77], ["headaches", "OBSERVATION", 29, 38], ["headaches", "OBSERVATION", 68, 77]]], ["Her only medication is a daily oral contraceptive pill.", [["oral", "ANATOMY", 31, 35], ["oral contraceptive", "CHEMICAL", 31, 49], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["medication", "TREATMENT", 9, 19], ["a daily oral contraceptive pill", "TREATMENT", 23, 54]]], ["On physical examination, temperature is normal, blood pressure is 152/82 mmHg, pulse rate is 107/min, and respiration rate is 18/min.", [["blood", "ANATOMY", 48, 53], ["blood", "ORGANISM_SUBSTANCE", 48, 53], ["physical examination", "TEST", 3, 23], ["temperature", "TEST", 25, 36], ["blood pressure", "TEST", 48, 62], ["pulse rate", "TEST", 79, 89], ["respiration rate", "TEST", 106, 122], ["normal", "OBSERVATION", 40, 46]]], ["Her left arm feels heavy and numb, but focal defi cits are hard to illicit.", [["left arm", "ANATOMY", 4, 12], ["arm", "ORGANISM_SUBDIVISION", 9, 12], ["numb", "PROBLEM", 29, 33], ["focal defi cits", "PROBLEM", 39, 54], ["left", "ANATOMY_MODIFIER", 4, 8], ["arm", "ANATOMY", 9, 12], ["heavy", "OBSERVATION", 19, 24], ["numb", "OBSERVATION", 29, 33], ["focal", "OBSERVATION_MODIFIER", 39, 44]]], ["All other examination fi ndings are normal.ReferenceResults of laboratory studies and a CT scan of the head are also normal.ReferenceWhich of the following is the most likely diagnosis?", [["head", "ANATOMY", 103, 107], ["head", "ORGAN", 103, 107], ["All other examination fi ndings", "TEST", 0, 31], ["laboratory studies", "TEST", 63, 81], ["a CT scan of the head", "TEST", 86, 107], ["normal", "OBSERVATION", 36, 42], ["head", "ANATOMY", 103, 107], ["normal", "OBSERVATION", 117, 123], ["most likely", "UNCERTAINTY", 163, 174]]], ["A) Migraine with aura B) Multiple sclerosis C) Sensory seizure D) Transient ischemic attack E) Cluster headache Answer: A The migraine aura can present as a variety of neurologic symptoms that may precede or accompany the headache phase or may occur in isolation.", [["neurologic", "ANATOMY", 168, 178], ["Migraine", "DISEASE", 3, 11], ["aura", "DISEASE", 17, 21], ["Multiple sclerosis", "DISEASE", 25, 43], ["Sensory seizure", "DISEASE", 47, 62], ["headache", "DISEASE", 103, 111], ["migraine aura", "DISEASE", 126, 139], ["headache", "DISEASE", 222, 230], ["A) Migraine with aura B", "PROBLEM", 0, 23], ["Multiple sclerosis C)", "PROBLEM", 25, 46], ["Sensory seizure D", "PROBLEM", 47, 64], ["Transient ischemic attack E", "PROBLEM", 66, 93], ["Cluster headache", "PROBLEM", 95, 111], ["A The migraine aura", "PROBLEM", 120, 139], ["neurologic symptoms", "PROBLEM", 168, 187], ["the headache phase", "PROBLEM", 218, 236], ["Multiple", "OBSERVATION_MODIFIER", 25, 33], ["sclerosis", "OBSERVATION", 34, 43], ["ischemic", "OBSERVATION_MODIFIER", 76, 84]]], ["The aura can be a combination of visual, sensory, or motor symptoms.", [["aura", "DISEASE", 4, 8], ["visual, sensory, or motor symptoms", "DISEASE", 33, 67], ["The aura", "PROBLEM", 0, 8], ["visual, sensory, or motor symptoms", "PROBLEM", 33, 67], ["aura", "OBSERVATION", 4, 8]]], ["Motor symptoms may occur in up to 20 % of patients and usually are associated with sensory symptoms.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["Motor symptoms", "PROBLEM", 0, 14], ["sensory symptoms", "PROBLEM", 83, 99]]], ["Motor symptoms are often vague and described as a sense of heaviness of the limbs before a headache but without any true weakness.", [["limbs", "ANATOMY", 76, 81], ["headache", "DISEASE", 91, 99], ["limbs", "ORGANISM_SUBDIVISION", 76, 81], ["Motor symptoms", "PROBLEM", 0, 14], ["vague", "PROBLEM", 25, 30], ["heaviness of the limbs", "PROBLEM", 59, 81], ["a headache", "PROBLEM", 89, 99], ["any true weakness", "PROBLEM", 112, 129], ["limbs", "ANATOMY", 76, 81], ["headache", "OBSERVATION", 91, 99], ["weakness", "OBSERVATION", 121, 129]]], ["Patients presenting with migraines with an aura have a strong risk factor for future stroke.", [["migraines", "DISEASE", 25, 34], ["aura", "DISEASE", 43, 47], ["stroke", "DISEASE", 85, 91], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["migraines", "PROBLEM", 25, 34], ["an aura", "PROBLEM", 40, 47], ["future stroke", "PROBLEM", 78, 91], ["stroke", "OBSERVATION", 85, 91]]], ["In addition, they should also be counseled on the increased risk of stroke with smoking and oral contraceptive use.", [["oral", "ANATOMY", 92, 96], ["stroke", "DISEASE", 68, 74], ["smoking", "CHEMICAL", 80, 87], ["oral contraceptive", "CHEMICAL", 92, 110], ["oral", "ORGANISM_SUBDIVISION", 92, 96], ["stroke", "PROBLEM", 68, 74], ["oral contraceptive use", "TREATMENT", 92, 114], ["stroke", "OBSERVATION", 68, 74]]], ["Patients should be screened for cardiovascular risk factors.ReferenceHeadache Classifi cation Committee of the International Headache Society.", [["cardiovascular", "ANATOMY", 32, 46], ["Headache", "DISEASE", 69, 77], ["Headache", "DISEASE", 125, 133], ["Patients", "ORGANISM", 0, 8], ["cardiovascular", "ANATOMICAL_SYSTEM", 32, 46], ["Patients", "SPECIES", 0, 8], ["cardiovascular risk factors", "PROBLEM", 32, 59], ["Headache", "PROBLEM", 69, 77]]], ["Classifi cation and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.", [["cranial", "ANATOMY", 64, 71], ["facial", "ANATOMY", 87, 93], ["headache disorders", "DISEASE", 44, 62], ["cranial neuralgias", "DISEASE", 64, 82], ["facial pain", "DISEASE", 87, 98], ["cation", "SIMPLE_CHEMICAL", 9, 15], ["facial", "ORGANISM_SUBDIVISION", 87, 93], ["diagnostic criteria", "TEST", 20, 39], ["headache disorders", "PROBLEM", 44, 62], ["cranial neuralgias", "PROBLEM", 64, 82], ["facial pain", "PROBLEM", 87, 98], ["cranial", "ANATOMY", 64, 71], ["neuralgias", "OBSERVATION", 72, 82], ["facial", "ANATOMY", 87, 93], ["pain", "OBSERVATION", 94, 98]]], ["Cephalalgia.", [["Cephalalgia", "DISEASE", 0, 11], ["Cephalalgia", "PROBLEM", 0, 11]]], ["A 21-year-old female presents to the ED in sickle cell crisis with severe leg and arm pain.", [["sickle cell", "ANATOMY", 43, 54], ["leg", "ANATOMY", 74, 77], ["arm", "ANATOMY", 82, 85], ["sickle cell crisis", "DISEASE", 43, 61], ["leg and arm pain", "DISEASE", 74, 90], ["female", "ORGANISM", 14, 20], ["sickle cell", "CELL", 43, 54], ["leg", "ORGANISM_SUBDIVISION", 74, 77], ["arm", "ORGANISM_SUBDIVISION", 82, 85], ["sickle cell crisis", "PROBLEM", 43, 61], ["severe leg and arm pain", "PROBLEM", 67, 90], ["21-", "OBSERVATION_MODIFIER", 2, 5], ["sickle cell crisis", "OBSERVATION", 43, 61], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["leg", "ANATOMY", 74, 77], ["arm", "ANATOMY", 82, 85], ["pain", "OBSERVATION", 86, 90]]], ["She takes folic acid, hydroxyurea, and oxycodone IR at home.", [["folic acid", "CHEMICAL", 10, 20], ["hydroxyurea", "CHEMICAL", 22, 33], ["oxycodone", "CHEMICAL", 39, 48], ["folic acid", "CHEMICAL", 10, 20], ["hydroxyurea", "CHEMICAL", 22, 33], ["oxycodone", "CHEMICAL", 39, 48], ["folic acid", "SIMPLE_CHEMICAL", 10, 20], ["hydroxyurea", "SIMPLE_CHEMICAL", 22, 33], ["oxycodone", "SIMPLE_CHEMICAL", 39, 48], ["folic acid", "TREATMENT", 10, 20], ["hydroxyurea", "TREATMENT", 22, 33], ["oxycodone IR", "TREATMENT", 39, 51]]], ["She is admitted and started with normal saline IV at 125 ml/h, oxycodone IR 10 mg PO every 4 h, and hydromorphone 0.5 mg IV every 3 h PRN for pain 7-10/10.", [["oxycodone", "CHEMICAL", 63, 72], ["hydromorphone", "CHEMICAL", 100, 113], ["pain", "DISEASE", 142, 146], ["oxycodone", "CHEMICAL", 63, 72], ["hydromorphone", "CHEMICAL", 100, 113], ["oxycodone", "SIMPLE_CHEMICAL", 63, 72], ["hydromorphone", "SIMPLE_CHEMICAL", 100, 113], ["normal saline IV", "TREATMENT", 33, 49], ["oxycodone IR", "TREATMENT", 63, 75], ["hydromorphone", "TREATMENT", 100, 113], ["pain", "PROBLEM", 142, 146]]], ["In addition, her home medications, folic acid and hydroxyurea, will be resumed.", [["folic acid", "CHEMICAL", 35, 45], ["hydroxyurea", "CHEMICAL", 50, 61], ["folic acid", "CHEMICAL", 35, 45], ["hydroxyurea", "CHEMICAL", 50, 61], ["folic acid", "SIMPLE_CHEMICAL", 35, 45], ["hydroxyurea", "SIMPLE_CHEMICAL", 50, 61], ["her home medications", "TREATMENT", 13, 33], ["folic acid", "TREATMENT", 35, 45], ["hydroxyurea", "TREATMENT", 50, 61]]], ["What other medication would this patient benefi t from while in the hospital?", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40]]], ["A) Morphine 2 mg IV every 2 h PRN for pain B) Senna/docusate one tab PO BID C) Acetaminophen 500 mg PO every 6 h PRN pain D) Sodium bicarbonate 650 mg PO BID Answer: B Acetaminophen would not benefi t this patient because it is indicated to treat mild to moderate pain, and the PRN indication is not consistent with the patient's current condition.", [["Morphine", "CHEMICAL", 3, 11], ["pain", "DISEASE", 38, 42], ["Acetaminophen", "CHEMICAL", 79, 92], ["pain", "DISEASE", 117, 121], ["Sodium bicarbonate", "CHEMICAL", 125, 143], ["Acetaminophen", "CHEMICAL", 168, 181], ["pain", "DISEASE", 264, 268], ["Morphine", "CHEMICAL", 3, 11], ["Acetaminophen", "CHEMICAL", 79, 92], ["Sodium bicarbonate", "CHEMICAL", 125, 143], ["Acetaminophen", "CHEMICAL", 168, 181], ["Morphine", "SIMPLE_CHEMICAL", 3, 11], ["Acetaminophen", "SIMPLE_CHEMICAL", 79, 92], ["Sodium bicarbonate", "SIMPLE_CHEMICAL", 125, 143], ["B Acetaminophen", "SIMPLE_CHEMICAL", 166, 181], ["patient", "ORGANISM", 206, 213], ["patient", "ORGANISM", 320, 327], ["patient", "SPECIES", 206, 213], ["patient", "SPECIES", 320, 327], ["A) Morphine", "TREATMENT", 0, 11], ["pain", "PROBLEM", 38, 42], ["Senna", "TREATMENT", 46, 51], ["docusate", "TREATMENT", 52, 60], ["Acetaminophen", "TREATMENT", 79, 92], ["pain", "PROBLEM", 117, 121], ["Sodium bicarbonate", "TREATMENT", 125, 143], ["Acetaminophen", "TREATMENT", 168, 181], ["mild to moderate pain", "PROBLEM", 247, 268], ["the PRN indication", "TREATMENT", 274, 292], ["moderate", "OBSERVATION_MODIFIER", 255, 263], ["pain", "OBSERVATION", 264, 268]]], ["Morphine is a good opioid analgesic for severe pain experienced in a sickle cell crisis but would represent a therapeutic duplication as hydromorphone is already on the patient's profi le.", [["sickle cell", "ANATOMY", 69, 80], ["Morphine", "CHEMICAL", 0, 8], ["pain", "DISEASE", 47, 51], ["sickle cell crisis", "DISEASE", 69, 87], ["hydromorphone", "CHEMICAL", 137, 150], ["Morphine", "CHEMICAL", 0, 8], ["hydromorphone", "CHEMICAL", 137, 150], ["Morphine", "SIMPLE_CHEMICAL", 0, 8], ["sickle cell", "CELL", 69, 80], ["hydromorphone", "SIMPLE_CHEMICAL", 137, 150], ["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["Morphine", "TREATMENT", 0, 8], ["a good opioid analgesic", "TREATMENT", 12, 35], ["severe pain", "PROBLEM", 40, 51], ["a sickle cell crisis", "PROBLEM", 67, 87], ["a therapeutic duplication", "TREATMENT", 108, 133], ["hydromorphone", "TREATMENT", 137, 150], ["sickle cell crisis", "OBSERVATION", 69, 87]]], ["Sodium bicarbonate has no indication in this setting.", [["Sodium bicarbonate", "CHEMICAL", 0, 18], ["Sodium bicarbonate", "CHEMICAL", 0, 18], ["Sodium bicarbonate", "SIMPLE_CHEMICAL", 0, 18], ["Sodium bicarbonate", "TREATMENT", 0, 18], ["no indication in", "UNCERTAINTY", 23, 39]]], ["A common side effect of opioids such as hydromorphone and oxycodone is constipation.", [["hydromorphone", "CHEMICAL", 40, 53], ["oxycodone", "CHEMICAL", 58, 67], ["constipation", "DISEASE", 71, 83], ["hydromorphone", "CHEMICAL", 40, 53], ["oxycodone", "CHEMICAL", 58, 67], ["opioids", "SIMPLE_CHEMICAL", 24, 31], ["hydromorphone", "SIMPLE_CHEMICAL", 40, 53], ["oxycodone", "SIMPLE_CHEMICAL", 58, 67], ["opioids", "TREATMENT", 24, 31], ["hydromorphone", "TREATMENT", 40, 53], ["oxycodone", "TREATMENT", 58, 67], ["constipation", "PROBLEM", 71, 83]]], ["Bowel regimens are often neglected in the hospital which can lead to constipation and further discomfort.", [["Bowel", "ANATOMY", 0, 5], ["constipation", "DISEASE", 69, 81], ["Bowel regimens", "TREATMENT", 0, 14], ["constipation", "PROBLEM", 69, 81], ["further discomfort", "PROBLEM", 86, 104]]], ["It should be considered in any patient receiving around the clock narcotics.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["the clock narcotics", "TREATMENT", 56, 75]]], ["A 65-year-old man with a history of insulin-dependent diabetes, coronary artery disease, and depression is admitted to the hospital for recurrent abdominal pain and hematochezia.", [["coronary artery", "ANATOMY", 64, 79], ["abdominal", "ANATOMY", 146, 155], ["diabetes", "DISEASE", 54, 62], ["coronary artery disease", "DISEASE", 64, 87], ["depression", "DISEASE", 93, 103], ["abdominal pain", "DISEASE", 146, 160], ["hematochezia", "DISEASE", 165, 177], ["man", "ORGANISM", 14, 17], ["insulin", "GENE_OR_GENE_PRODUCT", 36, 43], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 64, 79], ["abdominal", "ORGANISM_SUBDIVISION", 146, 155], ["man", "SPECIES", 14, 17], ["insulin-dependent diabetes", "PROBLEM", 36, 62], ["coronary artery disease", "PROBLEM", 64, 87], ["depression", "PROBLEM", 93, 103], ["recurrent abdominal pain", "PROBLEM", 136, 160], ["hematochezia", "PROBLEM", 165, 177], ["insulin-dependent", "OBSERVATION_MODIFIER", 36, 53], ["diabetes", "OBSERVATION", 54, 62], ["coronary artery", "ANATOMY", 64, 79], ["disease", "OBSERVATION", 80, 87], ["depression", "OBSERVATION", 93, 103], ["abdominal", "ANATOMY", 146, 155], ["pain", "OBSERVATION", 156, 160], ["hematochezia", "OBSERVATION", 165, 177]]], ["During his admission he required two units of packed red blood cells.", [["red blood cells", "ANATOMY", 53, 68], ["red blood cells", "CELL", 53, 68], ["packed red blood cells", "CELL_TYPE", 46, 68], ["packed red blood cells", "TREATMENT", 46, 68]]], ["He underwent colonoscopy by the colorectal surgeon and was found to have active oozing and mucosa consistent with ischemic colitis.ReferenceAfter one week of supportive care and rehydration, he is eating well, the bleeding has stopped, and he is ready for discharge.", [["colorectal", "ANATOMY", 32, 42], ["mucosa", "ANATOMY", 91, 97], ["ischemic colitis", "DISEASE", 114, 130], ["bleeding", "DISEASE", 214, 222], ["oozing", "PATHOLOGICAL_FORMATION", 80, 86], ["mucosa", "MULTI-TISSUE_STRUCTURE", 91, 97], ["colitis", "PATHOLOGICAL_FORMATION", 123, 130], ["colonoscopy", "TEST", 13, 24], ["active oozing and mucosa", "PROBLEM", 73, 97], ["ischemic colitis", "PROBLEM", 114, 130], ["supportive care", "TREATMENT", 158, 173], ["rehydration", "TREATMENT", 178, 189], ["the bleeding", "PROBLEM", 210, 222], ["active", "OBSERVATION_MODIFIER", 73, 79], ["oozing", "OBSERVATION", 80, 86], ["mucosa", "ANATOMY", 91, 97], ["consistent with", "UNCERTAINTY", 98, 113], ["ischemic", "OBSERVATION_MODIFIER", 114, 122], ["colitis", "OBSERVATION", 123, 130], ["bleeding", "OBSERVATION", 214, 222]]], ["He is on an aspirin daily which will be restarted on discharge.ReferenceWhat is the most appropriate next step?", [["aspirin", "CHEMICAL", 12, 19], ["aspirin", "CHEMICAL", 12, 19], ["aspirin", "SIMPLE_CHEMICAL", 12, 19], ["an aspirin", "TREATMENT", 9, 19]]], ["A) Refer to general surgery for colectomy.", [["general surgery", "TREATMENT", 12, 27], ["colectomy", "TREATMENT", 32, 41], ["colectomy", "OBSERVATION", 32, 41]]], ["B) Refer to interventional radiology for diagnostic angiography.", [["diagnostic angiography", "TEST", 41, 63]]], ["C) Recommend Holter monitor study for arrhythmia.", [["arrhythmia", "DISEASE", 38, 48], ["Holter monitor study", "TEST", 13, 33], ["arrhythmia", "PROBLEM", 38, 48]]], ["D) Refer for follow-up colonoscopy.", [["colonoscopy", "TEST", 23, 34]]], ["E) Observation alone.ReferenceAnswer: D It is recommended that patients with ischemic colitis have follow-up colonoscopy within 4-6 weeks of the inciting event to determine resolution of underlying colonic injury, development of stricture, and rule out possible proximal malignancy.", [["colonic", "ANATOMY", 198, 205], ["ischemic colitis", "DISEASE", 77, 93], ["colonic injury", "DISEASE", 198, 212], ["stricture", "DISEASE", 229, 238], ["malignancy", "DISEASE", 271, 281], ["D", "CHEMICAL", 38, 39], ["patients", "ORGANISM", 63, 71], ["colonic", "ORGAN", 198, 205], ["stricture", "PATHOLOGICAL_FORMATION", 229, 238], ["malignancy", "CANCER", 271, 281], ["patients", "SPECIES", 63, 71], ["ischemic colitis", "PROBLEM", 77, 93], ["colonoscopy", "TEST", 109, 120], ["underlying colonic injury", "PROBLEM", 187, 212], ["stricture", "PROBLEM", 229, 238], ["proximal malignancy", "PROBLEM", 262, 281], ["ischemic", "OBSERVATION_MODIFIER", 77, 85], ["colitis", "OBSERVATION", 86, 93], ["colonic", "ANATOMY", 198, 205], ["injury", "OBSERVATION", 206, 212], ["stricture", "OBSERVATION", 229, 238], ["rule out possible", "UNCERTAINTY", 244, 261], ["proximal", "ANATOMY_MODIFIER", 262, 270], ["malignancy", "OBSERVATION", 271, 281]]], ["Diagnostic angiograph is not indicated based solely on developing ischemic colitis nor is Holter monitoring.", [["ischemic colitis", "DISEASE", 66, 82], ["colitis", "PATHOLOGICAL_FORMATION", 75, 82], ["Diagnostic angiograph", "TEST", 0, 21], ["developing ischemic colitis", "PROBLEM", 55, 82], ["Holter monitoring", "TEST", 90, 107], ["ischemic", "OBSERVATION_MODIFIER", 66, 74], ["colitis", "OBSERVATION", 75, 82]]], ["A 35-year-old woman with a history of ulcerative colitis and primary sclerosing cholangitis is scheduled for an elective biliary dilation for recurrent biliary stricture.", [["ulcerative", "ANATOMY", 38, 48], ["biliary", "ANATOMY", 121, 128], ["biliary", "ANATOMY", 152, 159], ["ulcerative colitis", "DISEASE", 38, 56], ["primary sclerosing cholangitis", "DISEASE", 61, 91], ["biliary stricture", "DISEASE", 152, 169], ["woman", "ORGANISM", 14, 19], ["ulcerative colitis", "PATHOLOGICAL_FORMATION", 38, 56], ["biliary", "MULTI-TISSUE_STRUCTURE", 121, 128], ["biliary stricture", "PATHOLOGICAL_FORMATION", 152, 169], ["woman", "SPECIES", 14, 19], ["ulcerative colitis", "PROBLEM", 38, 56], ["primary sclerosing cholangitis", "PROBLEM", 61, 91], ["an elective biliary dilation", "TREATMENT", 109, 137], ["recurrent biliary stricture", "PROBLEM", 142, 169], ["35-", "OBSERVATION_MODIFIER", 2, 5], ["ulcerative", "OBSERVATION_MODIFIER", 38, 48], ["colitis", "OBSERVATION", 49, 56], ["sclerosing", "OBSERVATION_MODIFIER", 69, 79], ["cholangitis", "OBSERVATION", 80, 91], ["biliary", "ANATOMY", 121, 128], ["dilation", "OBSERVATION", 129, 137], ["biliary", "ANATOMY", 152, 159], ["stricture", "OBSERVATION", 160, 169]]], ["She is hemodynamically stable, afebrile, and without leukocytosis on laboratory workup.", [["afebrile", "DISEASE", 31, 39], ["leukocytosis", "DISEASE", 53, 65], ["afebrile", "PROBLEM", 31, 39], ["leukocytosis", "PROBLEM", 53, 65], ["laboratory workup", "TEST", 69, 86], ["hemodynamically", "OBSERVATION_MODIFIER", 7, 22], ["stable", "OBSERVATION_MODIFIER", 23, 29], ["afebrile", "OBSERVATION", 31, 39], ["without", "UNCERTAINTY", 45, 52], ["leukocytosis", "OBSERVATION", 53, 65]]], ["What is the most appropriate step regarding pre-ERCP prophylaxis?", [["pre-ERCP", "SIMPLE_CHEMICAL", 44, 52], ["pre-ERCP prophylaxis", "TREATMENT", 44, 64]]], ["A) Ciprofl oxacin starting before the procedure and continuing for 7 days B) No antibiotics needed C) Ciprofl oxacin given once, one hour before the procedure D) Hold the procedure until the patient receives a full course of ciprofl oxacin E) Ciprofl oxacin given once following the procedure only if successful biliary dilation not achieved Answer: C According to guidelines on antibiotics in gastrointestinal endoscopy, patients with primary sclerosing cholangitis have a higher risk of incomplete biliary drainage during ERCP and therefore routine single dose pre-procedural ciprofl oxacin is recommended.", [["biliary", "ANATOMY", 312, 319], ["gastrointestinal", "ANATOMY", 394, 410], ["biliary", "ANATOMY", 500, 507], ["Ciprofl oxacin", "CHEMICAL", 3, 17], ["Ciprofl oxacin", "CHEMICAL", 102, 116], ["ciprofl oxacin E", "CHEMICAL", 225, 241], ["Ciprofl oxacin", "CHEMICAL", 243, 257], ["primary sclerosing cholangitis", "DISEASE", 436, 466], ["ciprofl oxacin", "CHEMICAL", 578, 592], ["Ciprofl oxacin", "CHEMICAL", 3, 17], ["Ciprofl oxacin", "CHEMICAL", 102, 116], ["ciprofl oxacin E", "CHEMICAL", 225, 241], ["Ciprofl oxacin", "CHEMICAL", 243, 257], ["ciprofl oxacin", "CHEMICAL", 578, 592], ["Ciprofl oxacin", "SIMPLE_CHEMICAL", 3, 17], ["Ciprofl oxacin", "SIMPLE_CHEMICAL", 102, 116], ["patient", "ORGANISM", 191, 198], ["ciprofl oxacin E", "SIMPLE_CHEMICAL", 225, 241], ["Ciprofl oxacin", "SIMPLE_CHEMICAL", 243, 257], ["biliary", "MULTI-TISSUE_STRUCTURE", 312, 319], ["gastrointestinal", "ORGAN", 394, 410], ["patients", "ORGANISM", 422, 430], ["biliary", "ORGAN", 500, 507], ["ciprofl oxacin", "SIMPLE_CHEMICAL", 578, 592], ["patient", "SPECIES", 191, 198], ["patients", "SPECIES", 422, 430], ["A) Ciprofl oxacin", "TREATMENT", 0, 17], ["the procedure", "TREATMENT", 34, 47], ["antibiotics", "TREATMENT", 80, 91], ["Ciprofl oxacin", "TREATMENT", 102, 116], ["the procedure", "TREATMENT", 167, 180], ["ciprofl oxacin E", "TREATMENT", 225, 241], ["Ciprofl oxacin", "TREATMENT", 243, 257], ["the procedure", "TREATMENT", 279, 292], ["successful biliary dilation", "TREATMENT", 301, 328], ["antibiotics", "TREATMENT", 379, 390], ["gastrointestinal endoscopy", "TEST", 394, 420], ["primary sclerosing cholangitis", "PROBLEM", 436, 466], ["incomplete biliary drainage", "PROBLEM", 489, 516], ["ERCP", "TEST", 524, 528], ["routine single dose pre-procedural ciprofl oxacin", "TREATMENT", 543, 592], ["biliary", "ANATOMY", 312, 319], ["dilation", "OBSERVATION", 320, 328], ["gastrointestinal", "ANATOMY", 394, 410], ["sclerosing", "OBSERVATION_MODIFIER", 444, 454], ["cholangitis", "OBSERVATION", 455, 466], ["biliary", "ANATOMY", 500, 507], ["drainage", "OBSERVATION", 508, 516]]], ["There is no requirement for a full course of antibiotics.", [["antibiotics", "TREATMENT", 45, 56], ["no", "UNCERTAINTY", 9, 11]]], ["ERCP for hilar cholangiocarcinoma also requires this regimen.", [["hilar cholangiocarcinoma", "ANATOMY", 9, 33], ["cholangiocarcinoma", "DISEASE", 15, 33], ["hilar cholangiocarcinoma", "CANCER", 9, 33], ["ERCP", "TREATMENT", 0, 4], ["hilar cholangiocarcinoma", "PROBLEM", 9, 33], ["this regimen", "TREATMENT", 48, 60], ["hilar", "ANATOMY", 9, 14], ["cholangiocarcinoma", "OBSERVATION", 15, 33]]], ["It is uncertain if antibiotic prophylaxis is benefi cial for all patients undergoing ERCP.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["antibiotic prophylaxis", "TREATMENT", 19, 41], ["ERCP", "TEST", 85, 89]]], ["A meta-analysis of fi ve randomized, placebo-controlled trials failed to show a decrease in the incidence of cholangitis and/or sepsis with routine antibiotic prophylaxis prior to ERCP in noncomplicated cases.", [["cholangitis", "DISEASE", 109, 120], ["sepsis", "DISEASE", 128, 134], ["A meta-analysis", "TEST", 0, 15], ["placebo", "TREATMENT", 37, 44], ["a decrease", "PROBLEM", 78, 88], ["cholangitis", "PROBLEM", 109, 120], ["sepsis", "PROBLEM", 128, 134], ["routine antibiotic prophylaxis", "TREATMENT", 140, 170], ["ERCP", "TEST", 180, 184], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["cholangitis", "OBSERVATION", 109, 120], ["sepsis", "OBSERVATION", 128, 134]]], ["However, this issue has not been resolved.", [["resolved", "OBSERVATION_MODIFIER", 33, 41]]], ["More trials are required to prove the effectiveness of prophylactic antibiotics in this setting.249.A 27-year-old female is admitted with complaints of intermittent abdominal discomfort.", [["abdominal", "ANATOMY", 165, 174], ["abdominal discomfort", "DISEASE", 165, 185], ["female", "ORGANISM", 114, 120], ["abdominal", "ORGANISM_SUBDIVISION", 165, 174], ["prophylactic antibiotics", "TREATMENT", 55, 79], ["intermittent abdominal discomfort", "PROBLEM", 152, 185], ["27-", "OBSERVATION_MODIFIER", 102, 105], ["abdominal", "ANATOMY", 165, 174], ["discomfort", "OBSERVATION", 175, 185]]], ["She has diffi culty working and stays at home most of the time.249.On physical exam, vital signs are within normal limits and abdominal exam is unremarkable.", [["abdominal", "ANATOMY", 126, 135], ["abdominal", "ORGANISM_SUBDIVISION", 126, 135], ["physical exam", "TEST", 70, 83], ["vital signs", "TEST", 85, 96], ["abdominal exam", "TEST", 126, 140], ["abdominal", "ANATOMY", 126, 135], ["unremarkable", "OBSERVATION", 144, 156]]], ["Laboratory values include WBC of 6,000, hematocrit of 30 %, normal electrolyte panel, and erythrocyte sedimentation rate of 57 mm/h.", [["erythrocyte", "ANATOMY", 90, 101], ["erythrocyte", "CELL", 90, 101], ["Laboratory values", "TEST", 0, 17], ["WBC", "TEST", 26, 29], ["hematocrit", "TEST", 40, 50], ["erythrocyte sedimentation rate", "TEST", 90, 120], ["electrolyte panel", "OBSERVATION", 67, 84]]], ["Stool studies show fecal leukocytes.", [["fecal leukocytes", "ANATOMY", 19, 35], ["fecal leukocytes", "CELL", 19, 35], ["fecal leukocytes", "CELL_TYPE", 19, 35], ["Stool studies", "TEST", 0, 13], ["fecal leukocytes", "PROBLEM", 19, 35], ["fecal leukocytes", "OBSERVATION", 19, 35]]], ["Irritable bowel syndrome has been the diagnosis in the past and is suspected now.249.Which intervention is most likely indicated at this time?", [["bowel", "ANATOMY", 10, 15], ["Irritable bowel syndrome", "DISEASE", 0, 24], ["bowel", "ORGAN", 10, 15], ["Irritable bowel syndrome", "PROBLEM", 0, 24], ["bowel", "ANATOMY", 10, 15], ["syndrome", "OBSERVATION", 16, 24], ["most likely", "UNCERTAINTY", 107, 118]]], ["A) Reassurance B) Fluoroquinolone antibiotic C) Stool bulking agents D) Selective serotonin reuptake inhibitor (antidepressant) E) Colonoscopy249.Answer: E Although irritable bowel syndrome (IBS) is suspected, there are alarm features that warrant further investigation.", [["bowel", "ANATOMY", 175, 180], ["Fluoroquinolone", "CHEMICAL", 18, 33], ["serotonin reuptake inhibitor", "CHEMICAL", 82, 110], ["antidepressant", "CHEMICAL", 112, 126], ["irritable bowel syndrome", "DISEASE", 165, 189], ["IBS", "DISEASE", 191, 194], ["Fluoroquinolone", "CHEMICAL", 18, 33], ["serotonin", "CHEMICAL", 82, 91], ["Fluoroquinolone", "SIMPLE_CHEMICAL", 18, 33], ["bowel", "ORGAN", 175, 180], ["A) Reassurance B) Fluoroquinolone antibiotic C)", "TREATMENT", 0, 47], ["Stool bulking agents", "TREATMENT", 48, 68], ["Selective serotonin reuptake inhibitor (antidepressant)", "TREATMENT", 72, 127], ["Colonoscopy", "TEST", 131, 142], ["irritable bowel syndrome", "PROBLEM", 165, 189], ["IBS", "PROBLEM", 191, 194], ["alarm features", "PROBLEM", 220, 234], ["further investigation", "TEST", 248, 269], ["bowel", "ANATOMY", 175, 180], ["syndrome", "OBSERVATION", 181, 189]]], ["The patient's low hematocrit, elevated erythrocyte sedimentation rate, and positive fecal leukocytes may suggest underlying gastrointestinal disorders.", [["erythrocyte", "ANATOMY", 39, 50], ["fecal leukocytes", "ANATOMY", 84, 100], ["gastrointestinal", "ANATOMY", 124, 140], ["gastrointestinal disorders", "DISEASE", 124, 150], ["patient", "ORGANISM", 4, 11], ["erythrocyte", "CELL", 39, 50], ["leukocytes", "CELL", 90, 100], ["gastrointestinal", "ORGAN", 124, 140], ["positive fecal leukocytes", "CELL_TYPE", 75, 100], ["patient", "SPECIES", 4, 11], ["The patient's low hematocrit", "PROBLEM", 0, 28], ["elevated erythrocyte sedimentation rate", "PROBLEM", 30, 69], ["positive fecal leukocytes", "PROBLEM", 75, 100], ["underlying gastrointestinal disorders", "PROBLEM", 113, 150], ["low hematocrit", "OBSERVATION_MODIFIER", 14, 28], ["elevated", "OBSERVATION_MODIFIER", 30, 38], ["erythrocyte sedimentation", "OBSERVATION", 39, 64], ["fecal leukocytes", "OBSERVATION", 84, 100], ["may suggest", "UNCERTAINTY", 101, 112], ["gastrointestinal", "ANATOMY", 124, 140], ["disorders", "OBSERVATION", 141, 150]]], ["Colonoscopy would be warranted as the next step in management for a diagnosis.", [["Colonoscopy", "TREATMENT", 0, 11]]], ["The American College of Gastroenterologists (ACG) statement on the management of IBS does not recommend laboratory testing or diagnostic imaging in patients younger than 50 years with typical IBS symptoms and without alarm features.", [["IBS", "DISEASE", 81, 84], ["IBS", "DISEASE", 192, 195], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 148, 156], ["IBS", "PROBLEM", 81, 84], ["laboratory testing", "TEST", 104, 122], ["diagnostic imaging", "TEST", 126, 144], ["typical IBS symptoms", "PROBLEM", 184, 204], ["alarm features", "PROBLEM", 217, 231], ["without", "UNCERTAINTY", 209, 216]]], ["In addition to the above, alarm features include weight loss, iron-defi ciency anemia, and a family history of colonic disease.249.Her heart rate is 120 bpm, and blood pressure is 100/60 mmHg.", [["colonic", "ANATOMY", 111, 118], ["heart", "ANATOMY", 135, 140], ["blood", "ANATOMY", 162, 167], ["weight loss", "DISEASE", 49, 60], ["iron", "CHEMICAL", 62, 66], ["anemia", "DISEASE", 79, 85], ["colonic disease", "DISEASE", 111, 126], ["iron", "CHEMICAL", 62, 66], ["iron", "SIMPLE_CHEMICAL", 62, 66], ["colonic", "ORGAN", 111, 118], ["heart", "ORGAN", 135, 140], ["blood", "ORGANISM_SUBSTANCE", 162, 167], ["weight loss", "PROBLEM", 49, 60], ["iron-defi ciency anemia", "PROBLEM", 62, 85], ["colonic disease", "PROBLEM", 111, 126], ["Her heart rate", "TEST", 131, 145], ["blood pressure", "TEST", 162, 176], ["weight loss", "OBSERVATION", 49, 60], ["colonic", "ANATOMY", 111, 118], ["disease", "OBSERVATION", 119, 126], ["heart", "ANATOMY", 135, 140]]], ["Her past medical history is signifi cant for chronic obstructive pulmonary disease and hypertension.", [["pulmonary", "ANATOMY", 65, 74], ["chronic obstructive pulmonary disease", "DISEASE", 45, 82], ["hypertension", "DISEASE", 87, 99], ["pulmonary", "ORGAN", 65, 74], ["chronic obstructive pulmonary disease", "PROBLEM", 45, 82], ["hypertension", "PROBLEM", 87, 99], ["chronic", "OBSERVATION_MODIFIER", 45, 52], ["obstructive", "OBSERVATION", 53, 64], ["pulmonary", "ANATOMY", 65, 74], ["disease", "OBSERVATION", 75, 82], ["hypertension", "OBSERVATION", 87, 99]]], ["Chest radiograph reveals patchy diffuse infi ltrates.", [["Chest radiograph", "TEST", 0, 16], ["patchy diffuse infi ltrates", "PROBLEM", 25, 52], ["patchy", "OBSERVATION_MODIFIER", 25, 31], ["diffuse", "OBSERVATION_MODIFIER", 32, 39], ["infi ltrates", "OBSERVATION", 40, 52]]], ["Rapid infl uenza screen is positive.249.In addition to resuscitative measures and broadspectrum antibiotics, which antivirals should be given?", [["infl uenza", "GENE_OR_GENE_PRODUCT", 6, 16], ["Rapid infl uenza screen", "TEST", 0, 23], ["resuscitative measures", "TREATMENT", 55, 77], ["broadspectrum antibiotics", "TREATMENT", 82, 107], ["antivirals", "TREATMENT", 115, 125], ["positive", "OBSERVATION", 27, 35]]], ["A) Oseltamivir B) Zanamivir C) Peramivir D) No treatment Answer: A Much of our information concerning the treatment of severe infl uenza comes from the 2009 H1N1 epidemic.", [["Oseltamivir B", "CHEMICAL", 3, 16], ["H1N1", "DISEASE", 157, 161], ["Oseltamivir B", "CHEMICAL", 3, 16], ["Zanamivir C", "CHEMICAL", 18, 29], ["Peramivir D", "CHEMICAL", 31, 42], ["Zanamivir C", "SIMPLE_CHEMICAL", 18, 29], ["Peramivir D", "SIMPLE_CHEMICAL", 31, 42], ["A) Oseltamivir B) Zanamivir C) Peramivir D)", "TREATMENT", 0, 43], ["severe infl uenza", "PROBLEM", 119, 136]]], ["In those patients, therapy with oseltamivir reduced length of hospital stay, need for intensive care, and progression to severe disease or death.", [["oseltamivir", "CHEMICAL", 32, 43], ["death", "DISEASE", 139, 144], ["oseltamivir", "CHEMICAL", 32, 43], ["patients", "ORGANISM", 9, 17], ["oseltamivir", "SIMPLE_CHEMICAL", 32, 43], ["patients", "SPECIES", 9, 17], ["therapy", "TREATMENT", 19, 26], ["oseltamivir", "TREATMENT", 32, 43], ["intensive care", "TREATMENT", 86, 100], ["severe disease", "PROBLEM", 121, 135], ["death", "PROBLEM", 139, 144], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["disease", "OBSERVATION", 128, 135]]], ["Ideally oseltamivir should be administered within 48 h of symptom onset.", [["oseltamivir", "CHEMICAL", 8, 19], ["oseltamivir", "CHEMICAL", 8, 19], ["oseltamivir", "SIMPLE_CHEMICAL", 8, 19], ["oseltamivir", "TREATMENT", 8, 19], ["symptom onset", "PROBLEM", 58, 71]]], ["For critically ill patients with infl uenza infection, initiation of oseltamivir therapy up to 6-8 days from onset of symptoms may reduce mortality.", [["critically ill", "DISEASE", 4, 18], ["infl uenza infection", "DISEASE", 33, 53], ["oseltamivir", "CHEMICAL", 69, 80], ["oseltamivir", "CHEMICAL", 69, 80], ["patients", "ORGANISM", 19, 27], ["oseltamivir", "SIMPLE_CHEMICAL", 69, 80], ["patients", "SPECIES", 19, 27], ["infl uenza infection", "PROBLEM", 33, 53], ["oseltamivir therapy", "TREATMENT", 69, 88], ["symptoms", "PROBLEM", 118, 126], ["infection", "OBSERVATION", 44, 53]]], ["Adjuvant treatments are often considered for patients with life-threatening illnesses related to infl uenza.", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["Adjuvant treatments", "TREATMENT", 0, 19], ["life-threatening illnesses", "PROBLEM", 59, 85], ["infl uenza", "PROBLEM", 97, 107]]], ["A study from Argentina described excellent outcomes in 13 patients with presumed H1N1 infl uenza A pneumonitis receiving a combination of oseltamivir and methylprednisolone (1 mg/kg/ day) or hydrocortisone (300 mg/day).", [["pneumonitis", "DISEASE", 99, 110], ["oseltamivir", "CHEMICAL", 138, 149], ["methylprednisolone", "CHEMICAL", 154, 172], ["hydrocortisone", "CHEMICAL", 191, 205], ["oseltamivir", "CHEMICAL", 138, 149], ["methylprednisolone", "CHEMICAL", 154, 172], ["hydrocortisone", "CHEMICAL", 191, 205], ["patients", "ORGANISM", 58, 66], ["oseltamivir", "SIMPLE_CHEMICAL", 138, 149], ["methylprednisolone", "SIMPLE_CHEMICAL", 154, 172], ["hydrocortisone", "SIMPLE_CHEMICAL", 191, 205], ["patients", "SPECIES", 58, 66], ["A study", "TEST", 0, 7], ["H1N1", "PROBLEM", 81, 85], ["A pneumonitis", "PROBLEM", 97, 110], ["oseltamivir", "TREATMENT", 138, 149], ["methylprednisolone", "TREATMENT", 154, 172], ["hydrocortisone", "TREATMENT", 191, 205], ["H1N1", "OBSERVATION", 81, 85], ["pneumonitis", "OBSERVATION", 99, 110]]], ["However, previous studies during earlier viral epidemics failed to demonstrate a benefi cial effect of corticosteroids.", [["corticosteroids", "CHEMICAL", 103, 118], ["corticosteroids", "CHEMICAL", 103, 118], ["corticosteroids", "SIMPLE_CHEMICAL", 103, 118], ["previous studies", "TEST", 9, 25], ["earlier viral epidemics", "PROBLEM", 33, 56], ["corticosteroids", "TREATMENT", 103, 118], ["corticosteroids", "OBSERVATION", 103, 118]]], ["Severe and even fatal bronchospasm has been reported during treatment with zanamivir, and it should not be in individuals with underlying airway diseases.", [["airway", "ANATOMY", 138, 144], ["bronchospasm", "DISEASE", 22, 34], ["zanamivir", "CHEMICAL", 75, 84], ["airway diseases", "DISEASE", 138, 153], ["zanamivir", "CHEMICAL", 75, 84], ["zanamivir", "SIMPLE_CHEMICAL", 75, 84], ["airway", "MULTI-TISSUE_STRUCTURE", 138, 144], ["Severe and even fatal bronchospasm", "PROBLEM", 0, 34], ["zanamivir", "TREATMENT", 75, 84], ["underlying airway diseases", "PROBLEM", 127, 153], ["fatal", "OBSERVATION_MODIFIER", 16, 21], ["bronchospasm", "OBSERVATION", 22, 34], ["airway", "ANATOMY", 138, 144], ["diseases", "OBSERVATION", 145, 153]]], ["Peramivir has not been extensively tested..", [["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "CHEMICAL", 0, 9], ["Peramivir", "SIMPLE_CHEMICAL", 0, 9], ["Peramivir", "TREATMENT", 0, 9]]], ["The drug was used on a compassionate and emergency basis during the H1N1 pandemic.", [["the H1N1 pandemic", "PROBLEM", 64, 81]]], ["It appeared to be relatively well tolerated but too few patients were enrolled to establish its effi cacy.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Its advantage is that it can be given intravenously.249.fi rst time she had had these symptoms.", [["intravenously", "ANATOMY", 38, 51], ["intravenously", "IMMATERIAL_ANATOMICAL_ENTITY", 38, 51], ["these symptoms", "PROBLEM", 80, 94]]], ["She reports no other past medical history.", [["no", "UNCERTAINTY", 12, 14]]], ["On physical exam, mild epigastric pain is noted.", [["epigastric", "ANATOMY", 23, 33], ["epigastric pain", "DISEASE", 23, 38], ["epigastric", "ORGANISM_SUBDIVISION", 23, 33], ["physical exam", "TEST", 3, 16], ["mild epigastric pain", "PROBLEM", 18, 38], ["mild", "OBSERVATION_MODIFIER", 18, 22], ["epigastric", "ANATOMY", 23, 33], ["pain", "OBSERVATION", 34, 38]]], ["She is in moderate distress.", [["moderate distress", "PROBLEM", 10, 27], ["moderate", "OBSERVATION_MODIFIER", 10, 18], ["distress", "OBSERVATION", 19, 27]]], ["Her WBC is 10,000 \u03bcL.", [["WBC", "CELL_TYPE", 4, 7], ["Her WBC", "TEST", 0, 7]]], ["Amylase is 330 units/L, and lipase is 300 units/L. An Abdominal radiograph is normal.", [["Amylase", "GENE_OR_GENE_PRODUCT", 0, 7], ["lipase", "GENE_OR_GENE_PRODUCT", 28, 34], ["Amylase", "PROTEIN", 0, 7], ["lipase", "PROTEIN", 28, 34], ["Amylase", "TEST", 0, 7], ["lipase", "TEST", 28, 34], ["An Abdominal radiograph", "TEST", 51, 74], ["lipase", "ANATOMY", 28, 34], ["Abdominal", "ANATOMY", 54, 63], ["normal", "OBSERVATION", 78, 84]]], ["She is admitted and placed on intravenous hydration.249.What further imaging is needed?", [["intravenous", "ANATOMY", 30, 41], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 30, 41], ["intravenous hydration", "TREATMENT", 30, 51], ["further imaging", "TEST", 61, 76]]], ["A) CT of abdomen B) EGD C) None D) MRCP E) Abdominal ultrasound Answer: E Despite this patient's alcohol use, the fi rst episode of pancreatitis warrants an abdominal ultrasound to assess the biliary tract.", [["abdominal", "ANATOMY", 157, 166], ["biliary tract", "ANATOMY", 192, 205], ["alcohol", "CHEMICAL", 97, 104], ["pancreatitis", "DISEASE", 132, 144], ["alcohol", "CHEMICAL", 97, 104], ["patient", "ORGANISM", 87, 94], ["alcohol", "SIMPLE_CHEMICAL", 97, 104], ["abdominal", "ORGANISM_SUBDIVISION", 157, 166], ["biliary tract", "ORGANISM_SUBDIVISION", 192, 205], ["patient", "SPECIES", 87, 94], ["A) CT of abdomen B) EGD C", "TEST", 0, 25], ["MRCP", "TEST", 35, 39], ["Abdominal ultrasound", "TEST", 43, 63], ["pancreatitis", "PROBLEM", 132, 144], ["an abdominal ultrasound", "TEST", 154, 177], ["abdomen", "ANATOMY", 9, 16], ["Abdominal", "ANATOMY", 43, 52], ["pancreatitis", "OBSERVATION", 132, 144], ["abdominal", "ANATOMY", 157, 166], ["biliary tract", "ANATOMY", 192, 205]]], ["Ultrasonography of the abdomen is the most useful initial test in determining the etiology of pancreatitis.", [["abdomen", "ANATOMY", 23, 30], ["pancreatitis", "DISEASE", 94, 106], ["abdomen", "ORGAN", 23, 30], ["Ultrasonography of the abdomen", "TEST", 0, 30], ["initial test", "TEST", 50, 62], ["pancreatitis", "PROBLEM", 94, 106], ["abdomen", "ANATOMY", 23, 30], ["pancreatitis", "OBSERVATION", 94, 106]]], ["In Europe and other developed nations, patients tend to have gallstone pancreatitis, whereas in the United States, alcoholic pancreatitis is the most common.", [["gallstone pancreatitis", "DISEASE", 61, 83], ["alcoholic pancreatitis", "DISEASE", 115, 137], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["gallstone pancreatitis", "PROBLEM", 61, 83], ["alcoholic pancreatitis", "PROBLEM", 115, 137], ["gallstone", "OBSERVATION_MODIFIER", 61, 70], ["pancreatitis", "OBSERVATION", 71, 83], ["alcoholic", "OBSERVATION_MODIFIER", 115, 124], ["pancreatitis", "OBSERVATION", 125, 137], ["most common", "OBSERVATION_MODIFIER", 145, 156]]], ["CT is not indicated as this patient has moderate pancreatitis.249.There is a limited role in the fi rst 48 h of admission.", [["pancreatitis", "DISEASE", 49, 61], ["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["CT", "TEST", 0, 2], ["moderate pancreatitis", "PROBLEM", 40, 61], ["moderate", "OBSERVATION_MODIFIER", 40, 48], ["pancreatitis", "OBSERVATION", 49, 61]]], ["This patient has pancreatitis likely secondary to alcohol use.", [["pancreatitis", "DISEASE", 17, 29], ["alcohol", "CHEMICAL", 50, 57], ["alcohol", "CHEMICAL", 50, 57], ["patient", "ORGANISM", 5, 12], ["alcohol", "SIMPLE_CHEMICAL", 50, 57], ["patient", "SPECIES", 5, 12], ["pancreatitis", "PROBLEM", 17, 29], ["pancreatitis", "OBSERVATION", 17, 29], ["alcohol use", "OBSERVATION", 50, 61]]], ["There are no current guidelines recommending CT scan in moderate cases of pancreatitis.", [["pancreatitis", "DISEASE", 74, 86], ["CT scan", "TEST", 45, 52], ["pancreatitis", "PROBLEM", 74, 86], ["no", "UNCERTAINTY", 10, 12], ["moderate", "OBSERVATION_MODIFIER", 56, 64], ["pancreatitis", "OBSERVATION", 74, 86]]], ["Necrosis which may be found by CT scan usually takes several days to develop.", [["Necrosis", "DISEASE", 0, 8], ["Necrosis", "PROBLEM", 0, 8], ["CT scan", "TEST", 31, 38], ["may be", "UNCERTAINTY", 15, 21]]], ["A 68-year-old male has been transferred from the intensive care unit to the fl oor.", [["male", "ORGANISM", 14, 18]]], ["He has been in the hospital for 14 days due to community-acquired pneumonia.", [["pneumonia", "DISEASE", 66, 75], ["community-acquired pneumonia", "PROBLEM", 47, 75], ["pneumonia", "OBSERVATION", 66, 75]]], ["His hospital course has been complicated by sepsis, adrenal insuffi ciency, multiple organ failure, and mechanical intubation lasting eight days.", [["adrenal", "ANATOMY", 52, 59], ["organ", "ANATOMY", 85, 90], ["sepsis", "DISEASE", 44, 50], ["adrenal insuffi ciency", "DISEASE", 52, 74], ["multiple organ failure", "DISEASE", 76, 98], ["adrenal", "ORGAN", 52, 59], ["organ", "ORGAN", 85, 90], ["sepsis", "PROBLEM", 44, 50], ["adrenal insuffi ciency", "PROBLEM", 52, 74], ["multiple organ failure", "PROBLEM", 76, 98], ["mechanical intubation", "TREATMENT", 104, 125], ["sepsis", "OBSERVATION", 44, 50], ["adrenal", "ANATOMY", 52, 59], ["insuffi", "OBSERVATION", 60, 67], ["multiple", "OBSERVATION_MODIFIER", 76, 84], ["organ", "ANATOMY", 85, 90], ["failure", "OBSERVATION", 91, 98], ["mechanical intubation", "OBSERVATION", 104, 125]]], ["He has received broad-spectrum antibiotics, steroids, and vasopressors.", [["steroids", "CHEMICAL", 44, 52], ["steroids", "CHEMICAL", 44, 52], ["steroids", "SIMPLE_CHEMICAL", 44, 52], ["broad-spectrum antibiotics", "TREATMENT", 16, 42], ["steroids", "TREATMENT", 44, 52], ["vasopressors", "TREATMENT", 58, 70], ["antibiotics", "OBSERVATION", 31, 42]]], ["On physical examination, he is alert, follows commands, and cooperates.", [["physical examination", "TEST", 3, 23]]], ["Vital signs are stable.", [["Vital signs", "TEST", 0, 11], ["stable", "OBSERVATION_MODIFIER", 16, 22]]], ["All cranial nerves are noticed to be intact.", [["cranial nerves", "ANATOMY", 4, 18], ["cranial nerves", "MULTI-TISSUE_STRUCTURE", 4, 18], ["cranial nerves", "ANATOMY", 4, 18], ["intact", "OBSERVATION", 37, 43]]], ["As his physical therapy is initiated, he is noted to have marked weakness of both the upper and lower extremities.", [["upper", "ANATOMY", 86, 91], ["lower extremities", "ANATOMY", 96, 113], ["upper", "ORGANISM_SUBDIVISION", 86, 91], ["lower extremities", "ORGANISM_SUBDIVISION", 96, 113], ["marked weakness of both the upper and lower extremities", "PROBLEM", 58, 113], ["marked", "OBSERVATION_MODIFIER", 58, 64], ["weakness", "OBSERVATION", 65, 73], ["both", "ANATOMY_MODIFIER", 77, 81], ["upper", "ANATOMY_MODIFIER", 86, 91], ["lower extremities", "ANATOMY", 96, 113]]], ["The weakness is greater proximally more than distally.", [["The weakness", "PROBLEM", 0, 12], ["weakness", "OBSERVATION", 4, 12], ["greater", "OBSERVATION_MODIFIER", 16, 23], ["proximally", "OBSERVATION_MODIFIER", 24, 34], ["distally", "ANATOMY_MODIFIER", 45, 53]]], ["Arefl exia is present.ReferenceCT scan of the head is normal.", [["head", "ANATOMY", 46, 50], ["head", "ORGAN", 46, 50], ["ReferenceCT scan of the head", "TEST", 22, 50], ["head", "ANATOMY", 46, 50], ["normal", "OBSERVATION", 54, 60]]], ["Electromyography reveals absent sensor responses in the legs and diffuse low amplitude throughout.", [["legs", "ANATOMY", 56, 60], ["legs", "ORGANISM_SUBDIVISION", 56, 60], ["Electromyography", "TEST", 0, 16], ["absent sensor responses in the legs", "PROBLEM", 25, 60], ["diffuse low amplitude throughout", "PROBLEM", 65, 97], ["absent", "OBSERVATION", 25, 31], ["sensor responses", "OBSERVATION", 32, 48], ["legs", "ANATOMY", 56, 60], ["diffuse", "OBSERVATION_MODIFIER", 65, 72], ["low amplitude", "OBSERVATION", 73, 86]]], ["Low amplitude motor units are consistent with myopathy.", [["myopathy", "DISEASE", 46, 54], ["Low amplitude motor units", "PROBLEM", 0, 25], ["myopathy", "PROBLEM", 46, 54], ["amplitude", "OBSERVATION_MODIFIER", 4, 13], ["motor units", "OBSERVATION", 14, 25], ["consistent with", "UNCERTAINTY", 30, 45], ["myopathy", "OBSERVATION", 46, 54]]], ["CPK is 2756.ReferenceWhich of the following is the most likely diagnosis?", [["CPK", "GENE_OR_GENE_PRODUCT", 0, 3], ["CPK", "TEST", 0, 3], ["most likely", "UNCERTAINTY", 51, 62]]], ["A) Critical illness myopathy B) Guillain-Barr\u00e9 syndrome C) Unmasked myasthenia gravis D) Corticosteroid myopathy E) Hospital-induced deconditioning Answer: A This patient has critical illness myopathy (CIM), which is seen in severely ill patients who often have a great than seven-day stay in the intensive care unit.", [["Critical illness myopathy B", "DISEASE", 3, 30], ["Guillain-Barr\u00e9 syndrome", "DISEASE", 32, 55], ["myasthenia gravis", "DISEASE", 68, 85], ["myopathy", "DISEASE", 104, 112], ["myopathy", "DISEASE", 192, 200], ["CIM", "DISEASE", 202, 205], ["patient", "ORGANISM", 163, 170], ["patients", "ORGANISM", 238, 246], ["patient", "SPECIES", 163, 170], ["patients", "SPECIES", 238, 246], ["Critical illness myopathy", "PROBLEM", 3, 28], ["Guillain", "TREATMENT", 32, 40], ["Barr\u00e9 syndrome C", "PROBLEM", 41, 57], ["Unmasked myasthenia gravis D", "PROBLEM", 59, 87], ["Corticosteroid myopathy", "PROBLEM", 89, 112], ["critical illness myopathy", "PROBLEM", 175, 200], ["illness myopathy", "OBSERVATION", 184, 200]]], ["Prolonged intubation is another risk factor.", [["Prolonged intubation", "TREATMENT", 0, 20], ["another risk factor", "PROBLEM", 24, 43], ["intubation", "OBSERVATION", 10, 20]]], ["His profound weakness is out of proportion to what is expected from deconditioning.", [["His profound weakness", "PROBLEM", 0, 21], ["deconditioning", "PROBLEM", 68, 82], ["profound", "OBSERVATION_MODIFIER", 4, 12], ["weakness", "OBSERVATION", 13, 21], ["deconditioning", "OBSERVATION", 68, 82]]], ["The diffi culty with extubation and proximal limb weakness are classic fi ndings as well.", [["limb", "ANATOMY", 45, 49], ["extubation and proximal limb weakness", "DISEASE", 21, 58], ["limb", "ORGANISM_SUBDIVISION", 45, 49], ["extubation", "TREATMENT", 21, 31], ["proximal limb weakness", "PROBLEM", 36, 58], ["classic fi ndings", "PROBLEM", 63, 80], ["proximal", "ANATOMY_MODIFIER", 36, 44], ["limb", "ANATOMY", 45, 49], ["weakness", "OBSERVATION", 50, 58]]], ["For uncertain reasons, creatinine kinase can be elevated.", [["creatinine", "CHEMICAL", 23, 33], ["creatinine", "CHEMICAL", 23, 33], ["creatinine kinase", "GENE_OR_GENE_PRODUCT", 23, 40], ["creatinine kinase", "PROTEIN", 23, 40], ["creatinine kinase", "TEST", 23, 40], ["elevated", "PROBLEM", 48, 56]]], ["The diagnosis of CIM is a clinical diagnosis, as there is no single laboratory, imaging, or nerve conduction test available to accurately make the diagnosis.", [["nerve", "ANATOMY", 92, 97], ["CIM", "DISEASE", 17, 20], ["CIM", "PROBLEM", 17, 20], ["imaging", "TEST", 80, 87], ["nerve conduction test", "TEST", 92, 113]]], ["Screening tools such as the Medical Research Council (MRC) score are primarily used in research but may gain acceptance as studies confi rm their validity.", [["Screening tools", "TEST", 0, 15]]], ["Prevention and treatment of CIM have focused on limiting vasopressors, sedation, corticosteroids, and other medications that may be a factor in disease progression.", [["CIM", "DISEASE", 28, 31], ["CIM", "PROBLEM", 28, 31], ["limiting vasopressors", "TREATMENT", 48, 69], ["sedation", "TREATMENT", 71, 79], ["corticosteroids", "TREATMENT", 81, 96], ["other medications", "TREATMENT", 102, 119], ["disease progression", "PROBLEM", 144, 163], ["disease", "OBSERVATION", 144, 151]]], ["Early physical therapy, electrical muscle stimulation, and immunoglobulins are also being investigated as possible treatment options.", [["muscle", "ANATOMY", 35, 41], ["muscle", "ORGAN", 35, 41], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 59, 74], ["immunoglobulins", "PROTEIN", 59, 74], ["Early physical therapy", "TREATMENT", 0, 22], ["electrical muscle stimulation", "TREATMENT", 24, 53], ["immunoglobulins", "TREATMENT", 59, 74], ["treatment options", "TREATMENT", 115, 132]]], ["Little information exists on the long-term outcomes of patients with CIM.", [["CIM", "DISEASE", 69, 72], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63]]], ["One limited study found that recovery from CIM was slow, with nearly all patients displaying abnormal clinical fi ndings 1.5 years after the onset of this syndrome.ReferencesTepper M, Rakic S, Haas JA, Woittiez AJJ.", [["CIM", "DISEASE", 43, 46], ["patients", "ORGANISM", 73, 81], ["patients", "SPECIES", 73, 81], ["One limited study", "TEST", 0, 17], ["CIM", "PROBLEM", 43, 46], ["abnormal clinical fi ndings", "PROBLEM", 93, 120], ["this syndrome", "PROBLEM", 150, 163]]], ["Incidence and onset of critical illness polyneuropathy in patients with septic shock.", [["polyneuropathy", "DISEASE", 40, 54], ["septic shock", "DISEASE", 72, 84], ["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["critical illness polyneuropathy", "PROBLEM", 23, 54], ["septic shock", "PROBLEM", 72, 84], ["critical", "OBSERVATION_MODIFIER", 23, 31], ["illness polyneuropathy", "OBSERVATION", 32, 54], ["septic shock", "OBSERVATION", 72, 84]]], ["Neth J Med 2000;56:211-1 Zifko UA.", [["UA", "CHEMICAL", 31, 33], ["UA", "TEST", 31, 33]]], ["Long-term outcome of critical illness polyneuropathy.", [["polyneuropathy", "DISEASE", 38, 52], ["critical illness polyneuropathy", "PROBLEM", 21, 52], ["illness polyneuropathy", "OBSERVATION", 30, 52]]], ["Muscle Nerve 2000;(suppl 9):S49-52 253.", [["Nerve", "ANATOMY", 7, 12]]], ["A 35-year-old woman is admitted for an asthmatic exacerbation.", [["woman", "ORGANISM", 14, 19], ["woman", "SPECIES", 14, 19], ["an asthmatic exacerbation", "PROBLEM", 36, 61], ["asthmatic", "OBSERVATION", 39, 48]]], ["Her medical history is signifi cant only for asthma she has had since a child.", [["asthma", "DISEASE", 45, 51], ["asthma", "PROBLEM", 45, 51], ["asthma", "OBSERVATION", 45, 51]]], ["Her medicines include beta-agonist inhalers and oral contraceptive pills.", [["oral", "ANATOMY", 48, 52], ["oral contraceptive", "CHEMICAL", 48, 66], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["Her medicines", "TREATMENT", 0, 13], ["beta-agonist inhalers", "TREATMENT", 22, 43], ["oral contraceptive pills", "TREATMENT", 48, 72]]], ["On physical examination, vital signs are normal.", [["physical examination", "TEST", 3, 23], ["vital signs", "TEST", 25, 36], ["normal", "OBSERVATION", 41, 47]]], ["She has diffuse wheezes.", [["wheezes", "DISEASE", 16, 23], ["diffuse wheezes", "PROBLEM", 8, 23], ["diffuse", "OBSERVATION_MODIFIER", 8, 15], ["wheezes", "OBSERVATION", 16, 23]]], ["Examination of the skin discloses no petechiae or ecchymosis.", [["skin", "ANATOMY", 19, 23], ["petechiae", "ANATOMY", 37, 46], ["petechiae", "DISEASE", 37, 46], ["ecchymosis", "DISEASE", 50, 60], ["skin", "ORGAN", 19, 23], ["petechiae", "PATHOLOGICAL_FORMATION", 37, 46], ["ecchymosis", "PATHOLOGICAL_FORMATION", 50, 60], ["Examination", "TEST", 0, 11], ["petechiae", "PROBLEM", 37, 46], ["ecchymosis", "PROBLEM", 50, 60], ["skin", "ANATOMY", 19, 23], ["no", "UNCERTAINTY", 34, 36], ["petechiae", "OBSERVATION", 37, 46], ["ecchymosis", "OBSERVATION", 50, 60]]], ["The remainder of the examination is normal.", [["the examination", "TEST", 17, 32], ["remainder", "ANATOMY_MODIFIER", 4, 13], ["normal", "OBSERVATION", 36, 42]]], ["The leukocyte count is 7000/\u03bcL with a normal differential, and the platelet count is 11,500/\u03bcL.", [["leukocyte", "ANATOMY", 4, 13], ["platelet", "ANATOMY", 67, 75], ["leukocyte", "CELL", 4, 13], ["platelet", "CELL", 67, 75], ["The leukocyte count", "TEST", 0, 19], ["the platelet count", "TEST", 63, 81], ["leukocyte count", "OBSERVATION", 4, 19], ["normal differential", "OBSERVATION_MODIFIER", 38, 57]]], ["Clumping of platelets is reported.ReferencesWhich of the following is the most appropriate management?", [["platelets", "ANATOMY", 12, 21], ["platelets", "CELL", 12, 21], ["platelets", "CELL_TYPE", 12, 21], ["Clumping of platelets", "PROBLEM", 0, 21], ["platelets", "OBSERVATION", 12, 21]]], ["A) Intravenous immune globulin B) Prednisone C) Platelet transfusion D) Repeat complete blood count in a heparin or citrate anticoagulated tube Answer: D Unexpected lab results can occur due to mislabeling, automated testing machine problems, and interaction with preservatives.", [["blood", "ANATOMY", 88, 93], ["globulin B", "CHEMICAL", 22, 32], ["Prednisone", "CHEMICAL", 34, 44], ["heparin", "CHEMICAL", 105, 112], ["citrate", "CHEMICAL", 116, 123], ["Prednisone C", "CHEMICAL", 34, 46], ["citrate", "CHEMICAL", 116, 123], ["Prednisone C", "SIMPLE_CHEMICAL", 34, 46], ["Platelet", "CELL", 48, 56], ["blood", "ORGANISM_SUBSTANCE", 88, 93], ["heparin", "SIMPLE_CHEMICAL", 105, 112], ["citrate", "SIMPLE_CHEMICAL", 116, 123], ["A) Intravenous immune globulin B", "TREATMENT", 0, 32], ["Prednisone C", "TREATMENT", 34, 46], ["Platelet transfusion D", "TREATMENT", 48, 70], ["Repeat complete blood count", "TEST", 72, 99], ["a heparin", "TREATMENT", 103, 112], ["citrate anticoagulated tube", "TREATMENT", 116, 143], ["preservatives", "TREATMENT", 264, 277]]], ["In this case, a repeat complete blood count in a heparin or citrate anticoagulated tube is needed.", [["blood", "ANATOMY", 32, 37], ["heparin", "CHEMICAL", 49, 56], ["citrate", "CHEMICAL", 60, 67], ["citrate", "CHEMICAL", 60, 67], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["heparin", "SIMPLE_CHEMICAL", 49, 56], ["citrate", "SIMPLE_CHEMICAL", 60, 67], ["a repeat complete blood count", "TEST", 14, 43], ["a heparin", "TREATMENT", 47, 56], ["citrate anticoagulated tube", "TREATMENT", 60, 87]]], ["The patient's peripheral blood smear shows platelet clumping.", [["peripheral blood", "ANATOMY", 14, 30], ["platelet", "ANATOMY", 43, 51], ["platelet clumping", "DISEASE", 43, 60], ["patient", "ORGANISM", 4, 11], ["peripheral blood smear", "ORGANISM_SUBSTANCE", 14, 36], ["platelet", "CELL", 43, 51], ["patient", "SPECIES", 4, 11], ["The patient's peripheral blood smear", "TEST", 0, 36], ["platelet clumping", "PROBLEM", 43, 60], ["peripheral", "ANATOMY_MODIFIER", 14, 24], ["blood", "ANATOMY", 25, 30], ["platelet clumping", "OBSERVATION", 43, 60]]], ["This suggests pseudothrombocytopenia.", [["pseudothrombocytopenia", "DISEASE", 14, 36], ["pseudothrombocytopenia", "PROBLEM", 14, 36], ["pseudothrombocytopenia", "OBSERVATION", 14, 36]]], ["Pseudothrombocytopenia is a laboratory artifact in which platelets drawn into an ethylenediaminetetraacetic acid (EDTA)anticoagulated test tube clump and fail to be counted accurately by the automated counter, resulting in a spuriously low platelet count.", [["platelets", "ANATOMY", 57, 66], ["platelet", "ANATOMY", 240, 248], ["Pseudothrombocytopenia", "DISEASE", 0, 22], ["ethylenediaminetetraacetic acid", "CHEMICAL", 81, 112], ["EDTA", "CHEMICAL", 114, 118], ["ethylenediaminetetraacetic acid", "CHEMICAL", 81, 112], ["EDTA", "CHEMICAL", 114, 118], ["platelets", "CELL", 57, 66], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 81, 112], ["EDTA", "SIMPLE_CHEMICAL", 114, 118], ["platelet", "CELL", 240, 248], ["platelets", "CELL_TYPE", 57, 66], ["Pseudothrombocytopenia", "PROBLEM", 0, 22], ["a laboratory artifact", "PROBLEM", 26, 47], ["platelets", "TEST", 57, 66], ["an ethylenediaminetetraacetic acid (EDTA)", "TREATMENT", 78, 119], ["anticoagulated test tube clump", "TREATMENT", 119, 149], ["a spuriously low platelet count", "PROBLEM", 223, 254], ["artifact", "OBSERVATION", 39, 47], ["tube clump", "OBSERVATION", 139, 149], ["low platelet count", "OBSERVATION", 236, 254]]]], "da7099a637fd99a10afca01fcb59000270c83896": [["I nfectious diseases have been a constant threat to humankind with plagues, leprosy, the Black Death in the Middle Ages, the 1918 \"Spanish Flu\" pandemic, and the HIV/AIDS pandemic introduced in the 1980s.", [["nfectious diseases", "DISEASE", 2, 20], ["plagues", "DISEASE", 67, 74], ["leprosy", "DISEASE", 76, 83], ["Death", "DISEASE", 95, 100], ["HIV/AIDS pandemic", "DISEASE", 162, 179], ["HIV", "SPECIES", 162, 165], ["I nfectious diseases", "PROBLEM", 0, 20], ["pandemic", "PROBLEM", 144, 152], ["the HIV/AIDS pandemic", "PROBLEM", 158, 179]]], ["1 Unfortunately, this trend has not decreased.", [["not", "UNCERTAINTY", 32, 35], ["decreased", "OBSERVATION_MODIFIER", 36, 45]]], ["New diseases continue to emerge, such as severe acute respiratory syndrome-associated coronavirus, avian influenza, and West Nile virus, along with the resurgence of more resistant and virulent pathogens, such as tuberculosis, malaria, Clostridium difficile, Staphylococcus aureus, Klebsiella species, and Enterococcus species.", [["acute respiratory syndrome", "DISEASE", 48, 74], ["coronavirus", "DISEASE", 86, 97], ["avian influenza", "DISEASE", 99, 114], ["West Nile virus", "DISEASE", 120, 135], ["tuberculosis", "DISEASE", 213, 225], ["malaria", "DISEASE", 227, 234], ["Clostridium difficile", "DISEASE", 236, 257], ["Staphylococcus aureus", "DISEASE", 259, 280], ["avian influenza", "ORGANISM", 99, 114], ["West Nile virus", "ORGANISM", 120, 135], ["Clostridium difficile", "ORGANISM", 236, 257], ["Staphylococcus aureus", "ORGANISM", 259, 280], ["Klebsiella species", "ORGANISM", 282, 300], ["Enterococcus species", "ORGANISM", 306, 326], ["avian influenza", "SPECIES", 99, 114], ["West Nile virus", "SPECIES", 120, 135], ["Clostridium difficile", "SPECIES", 236, 257], ["Staphylococcus aureus", "SPECIES", 259, 280], ["West Nile virus", "SPECIES", 120, 135], ["Clostridium difficile", "SPECIES", 236, 257], ["Staphylococcus aureus", "SPECIES", 259, 280], ["New diseases", "PROBLEM", 0, 12], ["severe acute respiratory syndrome", "PROBLEM", 41, 74], ["coronavirus", "PROBLEM", 86, 97], ["avian influenza", "PROBLEM", 99, 114], ["West Nile virus", "PROBLEM", 120, 135], ["more resistant and virulent pathogens", "PROBLEM", 166, 203], ["tuberculosis", "PROBLEM", 213, 225], ["malaria", "PROBLEM", 227, 234], ["Clostridium difficile", "PROBLEM", 236, 257], ["Staphylococcus aureus", "PROBLEM", 259, 280], ["Klebsiella species", "PROBLEM", 282, 300], ["Enterococcus species", "PROBLEM", 306, 326], ["diseases", "OBSERVATION", 4, 12], ["severe", "OBSERVATION_MODIFIER", 41, 47], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["respiratory syndrome", "OBSERVATION", 54, 74], ["coronavirus", "OBSERVATION", 86, 97], ["more resistant", "OBSERVATION_MODIFIER", 166, 180], ["virulent", "OBSERVATION_MODIFIER", 185, 193], ["pathogens", "OBSERVATION", 194, 203], ["tuberculosis", "OBSERVATION", 213, 225], ["Staphylococcus aureus", "OBSERVATION", 259, 280], ["Klebsiella species", "OBSERVATION", 282, 300], ["Enterococcus species", "OBSERVATION", 306, 326]]]], "PMC7150121": [["IntroductionJust as each part of the respiratory system has its particular function, so each part has its particular pathologies.", [["respiratory system", "ANATOMY", 37, 55], ["IntroductionJust", "TREATMENT", 0, 16], ["its particular pathologies", "PROBLEM", 102, 128]]], ["Respiratory structures are disrupted by disease, and the oft-repeated aphorism \u2018structure is related to function\u2019 is never more applicable than in the respiratory system in health and disease.", [["Respiratory structures", "ANATOMY", 0, 22], ["respiratory system", "ANATOMY", 151, 169], ["Respiratory structures", "MULTI-TISSUE_STRUCTURE", 0, 22], ["disease", "PROBLEM", 40, 47], ["disease", "PROBLEM", 184, 191], ["disease", "OBSERVATION", 40, 47], ["respiratory system", "ANATOMY", 151, 169], ["disease", "OBSERVATION", 184, 191]]], ["Study of its structure considerably eases understanding of how the respiratory system works.IntroductionWe will first describe the airways of the lung and then the tissues that surround them.Mouth and nose \u2013 rhinitis, the common cold and obstructive sleep apnoea ::: The upper airwaysIt is unlikely that any of our readers have escaped the unpleasant obstruction to breathing associated with the common cold.", [["airways", "ANATOMY", 131, 138], ["lung", "ANATOMY", 146, 150], ["tissues", "ANATOMY", 164, 171], ["Mouth", "ANATOMY", 191, 196], ["nose", "ANATOMY", 201, 205], ["upper airways", "ANATOMY", 271, 284], ["rhinitis", "DISEASE", 208, 216], ["obstructive sleep apnoea", "DISEASE", 238, 262], ["obstruction", "DISEASE", 351, 362], ["airways", "MULTI-TISSUE_STRUCTURE", 131, 138], ["lung", "ORGAN", 146, 150], ["tissues", "TISSUE", 164, 171], ["Mouth", "ORGANISM_SUBDIVISION", 191, 196], ["nose", "ORGANISM_SUBDIVISION", 201, 205], ["upper airways", "MULTI-TISSUE_STRUCTURE", 271, 284], ["Mouth and nose \u2013 rhinitis", "PROBLEM", 191, 216], ["the common cold and obstructive sleep apnoea", "PROBLEM", 218, 262], ["the unpleasant obstruction to breathing", "PROBLEM", 336, 375], ["the common cold", "PROBLEM", 392, 407], ["airways", "ANATOMY", 131, 138], ["lung", "ANATOMY", 146, 150], ["tissues", "ANATOMY", 164, 171], ["nose", "ANATOMY", 201, 205], ["rhinitis", "OBSERVATION", 208, 216], ["obstructive", "OBSERVATION_MODIFIER", 238, 249], ["sleep apnoea", "OBSERVATION", 250, 262], ["upper", "ANATOMY_MODIFIER", 271, 276], ["airways", "ANATOMY", 277, 284], ["obstruction", "OBSERVATION", 351, 362]]], ["The major discomfort of this condition is the result of an inflammation of the nose (rhinitis) and, if more severe, the paranasal sinuses.", [["nose", "ANATOMY", 79, 83], ["paranasal sinuses", "ANATOMY", 120, 137], ["inflammation of the nose", "DISEASE", 59, 83], ["rhinitis", "DISEASE", 85, 93], ["nose", "ORGAN", 79, 83], ["paranasal sinuses", "MULTI-TISSUE_STRUCTURE", 120, 137], ["The major discomfort", "PROBLEM", 0, 20], ["this condition", "PROBLEM", 24, 38], ["an inflammation of the nose (rhinitis", "PROBLEM", 56, 93], ["more severe, the paranasal sinuses", "PROBLEM", 103, 137], ["major", "OBSERVATION_MODIFIER", 4, 9], ["discomfort", "OBSERVATION", 10, 20], ["inflammation", "OBSERVATION", 59, 71], ["nose", "ANATOMY", 79, 83], ["rhinitis", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["paranasal sinuses", "ANATOMY", 120, 137]]], ["In about 50% of cases this rhinosinusitis is initially caused by rhinoviruses, 25% by corona viruses and the remainder by other viruses.", [["rhinosinusitis", "DISEASE", 27, 41], ["rhinoviruses", "DISEASE", 65, 77], ["rhinoviruses", "ORGANISM", 65, 77], ["this rhinosinusitis", "PROBLEM", 22, 41], ["rhinoviruses", "PROBLEM", 65, 77], ["rhinosinusitis", "OBSERVATION", 27, 41], ["rhinoviruses", "OBSERVATION", 65, 77], ["viruses", "OBSERVATION", 128, 135]]], ["A transient vasoconstriction of the mucous membrane (see below) is followed by vasodilatation, oedema and mucus production.", [["mucous membrane", "ANATOMY", 36, 51], ["mucus", "ANATOMY", 106, 111], ["oedema", "DISEASE", 95, 101], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 36, 51], ["mucus", "ORGANISM_SUBSTANCE", 106, 111], ["A transient vasoconstriction of the mucous membrane", "PROBLEM", 0, 51], ["oedema", "PROBLEM", 95, 101], ["mucus production", "PROBLEM", 106, 122], ["transient", "OBSERVATION_MODIFIER", 2, 11], ["vasoconstriction", "OBSERVATION", 12, 28], ["mucous membrane", "OBSERVATION", 36, 51], ["oedema", "OBSERVATION", 95, 101], ["mucus production", "OBSERVATION", 106, 122]]], ["With secondary bacterial infection the secretions become viscid, contain pus cells and bacteria, and contribute to the obstruction of breathing.Mouth and nose \u2013 rhinitis, the common cold and obstructive sleep apnoea ::: The upper airwaysRhinosinusitis may also be allergic in aetiology or idiopathic (i.e. intrinsic, of no external cause).", [["secretions", "ANATOMY", 39, 49], ["pus cells", "ANATOMY", 73, 82], ["Mouth", "ANATOMY", 144, 149], ["nose", "ANATOMY", 154, 158], ["upper airways", "ANATOMY", 224, 237], ["bacterial infection", "DISEASE", 15, 34], ["obstruction", "DISEASE", 119, 130], ["rhinitis", "DISEASE", 161, 169], ["obstructive sleep apnoea", "DISEASE", 191, 215], ["allergic", "DISEASE", 264, 272], ["secretions", "ORGANISM_SUBSTANCE", 39, 49], ["pus cells", "CELL", 73, 82], ["Mouth", "ORGANISM_SUBDIVISION", 144, 149], ["nose", "ORGANISM_SUBDIVISION", 154, 158], ["upper airways", "ORGANISM_SUBDIVISION", 224, 237], ["pus cells", "CELL_TYPE", 73, 82], ["secondary bacterial infection", "PROBLEM", 5, 34], ["the secretions", "PROBLEM", 35, 49], ["viscid", "PROBLEM", 57, 63], ["pus cells", "PROBLEM", 73, 82], ["bacteria", "PROBLEM", 87, 95], ["the obstruction of breathing", "PROBLEM", 115, 143], ["Mouth and nose \u2013 rhinitis", "PROBLEM", 144, 169], ["the common cold and obstructive sleep apnoea", "PROBLEM", 171, 215], ["The upper airwaysRhinosinusitis", "PROBLEM", 220, 251], ["allergic", "PROBLEM", 264, 272], ["idiopathic", "PROBLEM", 289, 299], ["external cause", "PROBLEM", 323, 337], ["secondary", "OBSERVATION_MODIFIER", 5, 14], ["bacterial", "OBSERVATION_MODIFIER", 15, 24], ["infection", "OBSERVATION", 25, 34], ["pus cells", "OBSERVATION", 73, 82], ["bacteria", "OBSERVATION_MODIFIER", 87, 95], ["obstruction", "OBSERVATION", 119, 130], ["breathing", "OBSERVATION", 134, 143], ["nose", "ANATOMY", 154, 158], ["rhinitis", "OBSERVATION", 161, 169], ["obstructive", "OBSERVATION_MODIFIER", 191, 202], ["sleep apnoea", "OBSERVATION", 203, 215], ["upper", "ANATOMY_MODIFIER", 224, 229], ["airways", "ANATOMY", 230, 237], ["Rhinosinusitis", "OBSERVATION", 237, 251], ["may also be", "UNCERTAINTY", 252, 263], ["allergic", "OBSERVATION", 264, 272], ["idiopathic", "OBSERVATION_MODIFIER", 289, 299]]], ["Idiopathic rhinitis is thought to be a result of an imbalance of the activity of the sympathetic and parasympathetic nerves serving the mucosal blood vessels, and in this type of rhinitis anticholinergic medication often relieves symptoms.Mouth and nose \u2013 rhinitis, the common cold and obstructive sleep apnoea ::: The upper airwaysAllergic rhinitis may be seasonal in response to allergens such as pollen, or perennial, where a major cause is the allergen Der pl in the faeces of the house-dust mite Dermatophagoides pteronyssinus.Mouth and nose \u2013 rhinitis, the common cold and obstructive sleep apnoea ::: The upper airwaysThe mite is just invisible to the unaided eye and lives on shed skin scales, particularly in human bedding.", [["parasympathetic nerves", "ANATOMY", 101, 123], ["mucosal blood vessels", "ANATOMY", 136, 157], ["Mouth", "ANATOMY", 239, 244], ["nose", "ANATOMY", 249, 253], ["upper airways", "ANATOMY", 319, 332], ["faeces", "ANATOMY", 471, 477], ["Mouth", "ANATOMY", 532, 537], ["nose", "ANATOMY", 542, 546], ["upper airways", "ANATOMY", 612, 625], ["eye", "ANATOMY", 667, 670], ["skin", "ANATOMY", 689, 693], ["Idiopathic rhinitis", "DISEASE", 0, 19], ["rhinitis", "DISEASE", 179, 187], ["rhinitis", "DISEASE", 256, 264], ["obstructive sleep apnoea", "DISEASE", 286, 310], ["Allergic rhinitis", "DISEASE", 332, 349], ["rhinitis", "DISEASE", 549, 557], ["obstructive sleep apnoea", "DISEASE", 579, 603], ["parasympathetic nerves", "MULTI-TISSUE_STRUCTURE", 101, 123], ["mucosal blood vessels", "MULTI-TISSUE_STRUCTURE", 136, 157], ["Mouth", "ORGANISM_SUBDIVISION", 239, 244], ["nose", "ORGANISM_SUBDIVISION", 249, 253], ["upper airways", "MULTI-TISSUE_STRUCTURE", 319, 332], ["Der pl", "GENE_OR_GENE_PRODUCT", 457, 463], ["faeces", "ORGANISM_SUBSTANCE", 471, 477], ["Dermatophagoides", "ORGANISM", 501, 517], ["pteronyssinus", "ORGANISM_SUBSTANCE", 518, 531], ["Mouth", "ORGANISM_SUBDIVISION", 532, 537], ["nose", "ORGANISM_SUBDIVISION", 542, 546], ["upper airways", "MULTI-TISSUE_STRUCTURE", 612, 625], ["eye", "ORGAN", 667, 670], ["skin", "ORGAN", 689, 693], ["human", "ORGANISM", 718, 723], ["Der pl", "PROTEIN", 457, 463], ["Dermatophagoides pteronyssinus", "SPECIES", 501, 531], ["human", "SPECIES", 718, 723], ["house-dust mite", "SPECIES", 485, 500], ["Dermatophagoides pteronyssinus", "SPECIES", 501, 531], ["human", "SPECIES", 718, 723], ["Idiopathic rhinitis", "PROBLEM", 0, 19], ["an imbalance", "PROBLEM", 49, 61], ["rhinitis anticholinergic medication", "TREATMENT", 179, 214], ["symptoms", "PROBLEM", 230, 238], ["Mouth and nose \u2013 rhinitis", "PROBLEM", 239, 264], ["the common cold and obstructive sleep apnoea", "PROBLEM", 266, 310], ["The upper airwaysAllergic rhinitis", "PROBLEM", 315, 349], ["allergens", "PROBLEM", 381, 390], ["Mouth and nose \u2013 rhinitis", "PROBLEM", 532, 557], ["the common cold and obstructive sleep apnoea", "PROBLEM", 559, 603], ["rhinitis", "OBSERVATION", 11, 19], ["thought to be", "UNCERTAINTY", 23, 36], ["imbalance", "OBSERVATION", 52, 61], ["sympathetic", "ANATOMY", 85, 96], ["parasympathetic nerves", "ANATOMY", 101, 123], ["mucosal", "ANATOMY_MODIFIER", 136, 143], ["blood vessels", "ANATOMY", 144, 157], ["rhinitis", "OBSERVATION", 179, 187], ["nose", "ANATOMY", 249, 253], ["rhinitis", "OBSERVATION", 256, 264], ["obstructive", "OBSERVATION_MODIFIER", 286, 297], ["sleep apnoea", "OBSERVATION", 298, 310], ["upper", "ANATOMY_MODIFIER", 319, 324], ["airways", "ANATOMY", 325, 332], ["Allergic rhinitis", "OBSERVATION", 332, 349], ["nose", "ANATOMY", 542, 546], ["rhinitis", "OBSERVATION", 549, 557], ["obstructive", "OBSERVATION_MODIFIER", 579, 590], ["sleep apnoea", "OBSERVATION", 591, 603], ["upper", "ANATOMY_MODIFIER", 612, 617], ["airways", "ANATOMY", 618, 625], ["eye", "ANATOMY", 667, 670], ["skin", "ANATOMY", 689, 693]]], ["The allergen from this creature is also responsible for much asthma, but the rhinitis it provokes demonstrates the filtering action of the upper airways in trapping it in the nose.Mouth and nose \u2013 rhinitis, the common cold and obstructive sleep apnoea ::: The upper airwaysMuch more sinister and life-threatening than rhinitis is obstructive sleep apnoea (OSA; apnoea = absence of breathing).", [["upper airways", "ANATOMY", 139, 152], ["nose", "ANATOMY", 175, 179], ["Mouth", "ANATOMY", 180, 185], ["nose", "ANATOMY", 190, 194], ["upper airways", "ANATOMY", 260, 273], ["asthma", "DISEASE", 61, 67], ["rhinitis", "DISEASE", 77, 85], ["rhinitis", "DISEASE", 197, 205], ["obstructive sleep apnoea", "DISEASE", 227, 251], ["rhinitis", "DISEASE", 318, 326], ["obstructive sleep apnoea", "DISEASE", 330, 354], ["OSA", "DISEASE", 356, 359], ["apnoea", "DISEASE", 361, 367], ["upper airways", "ORGANISM_SUBDIVISION", 139, 152], ["nose", "ORGANISM_SUBDIVISION", 175, 179], ["Mouth", "ORGANISM_SUBDIVISION", 180, 185], ["nose", "ORGANISM_SUBDIVISION", 190, 194], ["upper airways", "MULTI-TISSUE_STRUCTURE", 260, 273], ["The allergen", "PROBLEM", 0, 12], ["much asthma", "PROBLEM", 56, 67], ["the rhinitis", "PROBLEM", 73, 85], ["Mouth and nose \u2013 rhinitis", "PROBLEM", 180, 205], ["the common cold and obstructive sleep apnoea", "PROBLEM", 207, 251], ["rhinitis", "PROBLEM", 318, 326], ["obstructive sleep apnoea", "PROBLEM", 330, 354], ["OSA", "PROBLEM", 356, 359], ["apnoea", "PROBLEM", 361, 367], ["rhinitis", "OBSERVATION", 77, 85], ["filtering", "OBSERVATION", 115, 124], ["upper", "ANATOMY_MODIFIER", 139, 144], ["airways", "ANATOMY", 145, 152], ["nose", "ANATOMY", 175, 179], ["nose", "ANATOMY", 190, 194], ["rhinitis", "OBSERVATION", 197, 205], ["obstructive", "OBSERVATION_MODIFIER", 227, 238], ["sleep apnoea", "OBSERVATION", 239, 251], ["upper", "ANATOMY_MODIFIER", 260, 265], ["airways", "ANATOMY", 266, 273], ["obstructive", "OBSERVATION", 330, 341]]], ["This should not be confused with central sleep apnoea, where the patient ceases to make respiratory efforts while they are sleeping.", [["respiratory", "ANATOMY", 88, 99], ["apnoea", "DISEASE", 47, 53], ["patient", "ORGANISM", 65, 72], ["patient", "SPECIES", 65, 72], ["confused", "PROBLEM", 19, 27], ["central sleep apnoea", "PROBLEM", 33, 53]]], ["In OSA the patient's attempts to breathe are physically obstructed by anatomical and physiological peculiarities of the upper airways.", [["upper airways", "ANATOMY", 120, 133], ["OSA", "DISEASE", 3, 6], ["patient", "ORGANISM", 11, 18], ["upper airways", "MULTI-TISSUE_STRUCTURE", 120, 133], ["patient", "SPECIES", 11, 18], ["OSA", "PROBLEM", 3, 6], ["physically obstructed", "PROBLEM", 45, 66], ["OSA", "OBSERVATION", 3, 6], ["obstructed", "OBSERVATION", 56, 66], ["physiological peculiarities", "OBSERVATION", 85, 112], ["upper", "ANATOMY_MODIFIER", 120, 125], ["airways", "ANATOMY", 126, 133]]]], "dc1ab515b68e4cf9a05f283268f7d75195a37a5f": [["IntroductionApoptosis is a type of cell death characterized by the silent elimination of unnecessary or damaged cells, which is required for development and tissue homeostasis.", [["cell", "ANATOMY", 35, 39], ["cells", "ANATOMY", 112, 117], ["tissue", "ANATOMY", 157, 163], ["IntroductionApoptosis", "DISEASE", 0, 21], ["death", "DISEASE", 40, 45], ["cell", "CELL", 35, 39], ["cells", "CELL", 112, 117], ["tissue", "TISSUE", 157, 163], ["damaged cells", "CELL_TYPE", 104, 117], ["cell death", "PROBLEM", 35, 45], ["unnecessary or damaged cells", "PROBLEM", 89, 117], ["tissue homeostasis", "PROBLEM", 157, 175], ["damaged cells", "OBSERVATION", 104, 117], ["tissue homeostasis", "OBSERVATION", 157, 175]]], ["Two major routes of apoptosis have been described: the extrinsic route is initiated at the cell surface and mediated by death receptors, like Fas-CD95 [1] ; the intrinsic route is mediated by mitochondria [2] , where many different signals are integrated and the final decision about the fate of the cell is made.", [["cell surface", "ANATOMY", 91, 103], ["mitochondria", "ANATOMY", 192, 204], ["cell", "ANATOMY", 300, 304], ["death", "DISEASE", 120, 125], ["cell surface", "CELLULAR_COMPONENT", 91, 103], ["Fas-CD95", "GENE_OR_GENE_PRODUCT", 142, 150], ["mitochondria", "CELLULAR_COMPONENT", 192, 204], ["cell", "CELL", 300, 304], ["death receptors", "PROTEIN", 120, 135], ["Fas-CD95", "PROTEIN", 142, 150], ["apoptosis", "PROBLEM", 20, 29], ["death receptors", "TEST", 120, 135], ["apoptosis", "OBSERVATION", 20, 29]]], ["Both routes are linked in some cells by Bid, a member of the Bcl-2 protein family [3] .", [["cells", "ANATOMY", 31, 36], ["cells", "CELL", 31, 36], ["Bid", "GENE_OR_GENE_PRODUCT", 40, 43], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 61, 66], ["Bid", "PROTEIN", 40, 43], ["Bcl-2 protein family", "PROTEIN", 61, 81]]], ["Bcl-2 family members participate directly in the decision step [4] .", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Bcl-2 family members", "PROTEIN", 0, 20]]], ["Pro-apoptotic members of this family, Bax and Bak, have been shown to permeabilize the mitochondrial outer membrane (MOM), facilitating the release to the cytosol of intermembrane space (IMS) proteins like cytochrome c [5] , AIF [6] or Smac/DIABLO [7, 8] .", [["mitochondrial outer membrane", "ANATOMY", 87, 115], ["MOM", "ANATOMY", 117, 120], ["cytosol", "ANATOMY", 155, 162], ["intermembrane space", "ANATOMY", 166, 185], ["Bax", "GENE_OR_GENE_PRODUCT", 38, 41], ["Bak", "GENE_OR_GENE_PRODUCT", 46, 49], ["mitochondrial", "CELLULAR_COMPONENT", 87, 100], ["outer membrane", "CELLULAR_COMPONENT", 101, 115], ["MOM", "CELLULAR_COMPONENT", 117, 120], ["cytosol", "CELLULAR_COMPONENT", 155, 162], ["intermembrane space", "CELLULAR_COMPONENT", 166, 185], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 206, 218], ["AIF", "GENE_OR_GENE_PRODUCT", 225, 228], ["Smac", "GENE_OR_GENE_PRODUCT", 236, 240], ["Bax", "PROTEIN", 38, 41], ["Bak", "PROTEIN", 46, 49], ["intermembrane space (IMS) proteins", "PROTEIN", 166, 200], ["cytochrome c", "PROTEIN", 206, 218], ["AIF", "PROTEIN", 225, 228], ["Smac", "PROTEIN", 236, 240], ["cytochrome c", "TEST", 206, 218], ["AIF", "TEST", 225, 228], ["Smac/DIABLO", "TEST", 236, 247], ["outer membrane", "ANATOMY", 101, 115]]], ["These proteins then activate a series of caspase-dependent or -independent mechanisms that dismantle the cell.", [["cell", "ANATOMY", 105, 109], ["caspase", "GENE_OR_GENE_PRODUCT", 41, 48], ["cell", "CELL", 105, 109], ["caspase", "PROTEIN", 41, 48]]], ["A second mechanism for the release of apoptotic factors from the IMS involves permeability transition, which allows the entry of water in the matrix with subsequent burst of the MOM [9] .IntroductionA complex interplay between pro-apoptotic and pro-survival Bcl-2 family members controls MOM permeabilization (MOMP), considered the point-of-no-return during apoptosis induction.", [["matrix", "ANATOMY", 142, 148], ["water", "SIMPLE_CHEMICAL", 129, 134], ["matrix", "CELLULAR_COMPONENT", 142, 148], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 258, 263], ["MOM", "GENE_OR_GENE_PRODUCT", 288, 291], ["MOMP", "CELLULAR_COMPONENT", 310, 314], ["apoptotic factors", "PROTEIN", 38, 55], ["pro-apoptotic and pro-survival Bcl-2 family members", "PROTEIN", 227, 278], ["MOMP", "PROTEIN", 310, 314], ["apoptotic factors", "PROBLEM", 38, 55], ["permeability transition", "TREATMENT", 78, 101], ["pro-apoptotic and pro-survival Bcl", "TREATMENT", 227, 261], ["apoptosis induction", "TREATMENT", 358, 377], ["permeability transition", "OBSERVATION", 78, 101]]], ["Several models have been proposed to explain how Bcl-2 members regulate MOMP through interactions between pro-survival and pro-apoptotic proteins, both in solution and at the MOM [10] .", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 49, 54], ["MOMP", "GENE_OR_GENE_PRODUCT", 72, 76], ["Bcl-2 members", "PROTEIN", 49, 62], ["MOMP", "PROTEIN", 72, 76], ["pro-survival and pro-apoptotic proteins", "PROTEIN", 106, 145], ["pro-survival and pro-apoptotic proteins", "TREATMENT", 106, 145]]], ["Activation of these proteins involves conformational changes, specially relevant for Bax, which usually resides in the cytosol and requires a conformational change to expose hydrophobic domains required for membrane insertion, followed by further changes necessary for pore formation through oligomerization at the MOM [11] .IntroductionHomodimerization of the pro-survival protein Bcl-XL in the cytosol involves a C-terminal membrane-targeting a helix from one monomer and a hydrophobic groove on the other monomer [12] , although other dimerization modes have been described [13] [14] [15] [16] .", [["cytosol", "ANATOMY", 119, 126], ["membrane", "ANATOMY", 207, 215], ["pore", "ANATOMY", 269, 273], ["cytosol", "ANATOMY", 396, 403], ["membrane", "ANATOMY", 426, 434], ["C", "CHEMICAL", 415, 416], ["Bax", "GENE_OR_GENE_PRODUCT", 85, 88], ["cytosol", "CELLULAR_COMPONENT", 119, 126], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["pore", "CELLULAR_COMPONENT", 269, 273], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 382, 388], ["cytosol", "CELLULAR_COMPONENT", 396, 403], ["membrane", "CELLULAR_COMPONENT", 426, 434], ["[13] [14] [15] [16]", "SIMPLE_CHEMICAL", 577, 596], ["Bax", "PROTEIN", 85, 88], ["hydrophobic domains", "PROTEIN", 174, 193], ["pro-survival protein", "PROTEIN", 361, 381], ["Bcl-XL", "PROTEIN", 382, 388], ["conformational changes", "PROBLEM", 38, 60], ["Bax", "TREATMENT", 85, 88], ["a conformational change", "TREATMENT", 140, 163], ["expose hydrophobic domains", "TREATMENT", 167, 193], ["membrane insertion", "TREATMENT", 207, 225], ["pore formation through oligomerization", "TREATMENT", 269, 307], ["the pro-survival protein Bcl", "TEST", 357, 385], ["other dimerization modes", "PROBLEM", 532, 556], ["hydrophobic groove", "OBSERVATION_MODIFIER", 476, 494]]], ["Release of that helix from the hydrophobic groove allows its insertion into the MOM.", [["MOM", "CELLULAR_COMPONENT", 80, 83], ["the hydrophobic groove", "TREATMENT", 27, 49]]], ["Most interaction and structural studies Abbreviations: PSAP/Mtch1, presenilin 1-associated protein/mitochondrial carrier homolog 1; MOM, mitochondrial outer membrane; IMS, intermembrane space; MOMP, mitochondrial outer membrane permeabilization; TMD, transmembrane domain; mRFP, monomeric red fluorescent protein; VAMP2, vesicle-associated membrane protein 2 carried out with this protein employed deletion mutants lacking the C-terminal helix.", [["mitochondrial outer membrane", "ANATOMY", 137, 165], ["intermembrane space", "ANATOMY", 172, 191], ["mitochondrial", "ANATOMY", 199, 212], ["membrane", "ANATOMY", 219, 227], ["vesicle", "ANATOMY", 321, 328], ["C", "CHEMICAL", 427, 428], ["PSAP", "GENE_OR_GENE_PRODUCT", 55, 59], ["Mtch1", "GENE_OR_GENE_PRODUCT", 60, 65], ["presenilin 1-associated protein/mitochondrial carrier homolog 1", "GENE_OR_GENE_PRODUCT", 67, 130], ["MOM", "GENE_OR_GENE_PRODUCT", 132, 135], ["mitochondrial", "CELLULAR_COMPONENT", 137, 150], ["outer membrane", "CELLULAR_COMPONENT", 151, 165], ["intermembrane space", "CELLULAR_COMPONENT", 172, 191], ["MOMP", "CELLULAR_COMPONENT", 193, 197], ["mitochondrial", "CELLULAR_COMPONENT", 199, 212], ["outer membrane", "CELLULAR_COMPONENT", 213, 227], ["mRFP", "GENE_OR_GENE_PRODUCT", 273, 277], ["monomeric red fluorescent protein", "GENE_OR_GENE_PRODUCT", 279, 312], ["VAMP2", "GENE_OR_GENE_PRODUCT", 314, 319], ["vesicle-associated membrane protein 2", "GENE_OR_GENE_PRODUCT", 321, 358], ["PSAP", "PROTEIN", 55, 59], ["Mtch1", "PROTEIN", 60, 65], ["presenilin 1", "PROTEIN", 67, 79], ["associated protein", "PROTEIN", 80, 98], ["mitochondrial carrier homolog 1", "PROTEIN", 99, 130], ["MOM", "PROTEIN", 132, 135], ["IMS", "PROTEIN", 167, 170], ["intermembrane space", "PROTEIN", 172, 191], ["MOMP", "PROTEIN", 193, 197], ["TMD", "PROTEIN", 246, 249], ["transmembrane domain", "PROTEIN", 251, 271], ["mRFP", "PROTEIN", 273, 277], ["monomeric red fluorescent protein", "PROTEIN", 279, 312], ["VAMP2", "PROTEIN", 314, 319], ["vesicle-associated membrane protein 2", "PROTEIN", 321, 358], ["protein employed deletion mutants", "PROTEIN", 381, 414], ["C-terminal helix", "PROTEIN", 427, 443], ["structural studies", "TEST", 21, 39], ["PSAP/Mtch1", "TEST", 55, 65], ["presenilin", "TEST", 67, 77], ["protein/mitochondrial carrier homolog", "TREATMENT", 91, 128], ["intermembrane space", "PROBLEM", 172, 191], ["MOMP", "PROBLEM", 193, 197], ["mitochondrial outer membrane permeabilization", "TREATMENT", 199, 244], ["TMD", "PROBLEM", 246, 249], ["transmembrane domain", "TEST", 251, 271], ["mRFP", "PROBLEM", 273, 277], ["monomeric red fluorescent protein", "TEST", 279, 312], ["VAMP2", "TEST", 314, 319], ["membrane protein", "TEST", 340, 356], ["this protein employed deletion mutants", "PROBLEM", 376, 414], ["outer membrane", "ANATOMY", 151, 165], ["intermembrane space", "OBSERVATION", 172, 191], ["outer membrane", "ANATOMY", 213, 227], ["vesicle", "ANATOMY", 321, 328]]], ["This mutant can also bind membranes through its N-terminal domain [17] , and Bax, Bcl-2 and Bcl-XL have been reported to insert a-helices 5 and 6 into the MOM during apoptosis [18] [19] [20] .", [["membranes", "ANATOMY", 26, 35], ["N", "CHEMICAL", 48, 49], ["membranes", "CELLULAR_COMPONENT", 26, 35], ["Bax", "GENE_OR_GENE_PRODUCT", 77, 80], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 92, 98], ["MOM", "SIMPLE_CHEMICAL", 155, 158], ["N-terminal domain", "PROTEIN", 48, 65], ["Bax", "PROTEIN", 77, 80], ["Bcl-2", "PROTEIN", 82, 87], ["Bcl", "PROTEIN", 92, 95], ["XL", "PROTEIN", 96, 98], ["a-helices 5 and 6", "PROTEIN", 128, 145], ["Bax", "TEST", 77, 80], ["Bcl", "TEST", 82, 85], ["Bcl", "TEST", 92, 95]]], ["Many interaction and structural studies have been carried out in the absence of membranes, underestimating their role in protein interactions and conformational changes [17, 21] .IntroductionSince the C-terminal helix (transmembrane domain or TMD) of Bcl-XL and flanking sequences contain the necessary information for MOM targeting and insertion in a C-in N-out orientation [22] , we used this domain to target fragments of PSAP/Mtch1 to the outer mitochondrial membrane [23] .", [["membranes", "ANATOMY", 80, 89], ["outer mitochondrial membrane", "ANATOMY", 443, 471], ["C", "CHEMICAL", 201, 202], ["membranes", "CELLULAR_COMPONENT", 80, 89], ["transmembrane", "CELLULAR_COMPONENT", 219, 232], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 251, 257], ["MOM", "GENE_OR_GENE_PRODUCT", 319, 322], ["PSAP", "GENE_OR_GENE_PRODUCT", 425, 429], ["Mtch1", "GENE_OR_GENE_PRODUCT", 430, 435], ["outer", "CELLULAR_COMPONENT", 443, 448], ["mitochondrial membrane", "CELLULAR_COMPONENT", 449, 471], ["C-terminal helix", "PROTEIN", 201, 217], ["transmembrane domain", "PROTEIN", 219, 239], ["TMD", "PROTEIN", 243, 246], ["Bcl", "PROTEIN", 251, 254], ["XL", "PROTEIN", 255, 257], ["flanking sequences", "DNA", 262, 280], ["MOM", "PROTEIN", 319, 322], ["C-in N", "PROTEIN", 352, 358], ["PSAP", "PROTEIN", 425, 429], ["Mtch1", "PROTEIN", 430, 435], ["structural studies", "TEST", 21, 39], ["the C-terminal helix (transmembrane domain", "TREATMENT", 197, 239], ["Bcl", "TEST", 251, 254], ["flanking sequences", "TEST", 262, 280], ["insertion", "TREATMENT", 337, 346], ["a C-in N", "TREATMENT", 350, 358], ["this domain", "TREATMENT", 390, 401], ["PSAP/Mtch1", "TREATMENT", 425, 435], ["outer", "ANATOMY_MODIFIER", 443, 448], ["mitochondrial membrane", "ANATOMY", 449, 471]]], ["PSAP was first identified as a presenilin-1 associated protein with homology to inner membrane mitochondrial carriers, and therefore is also known as mitochondrial carrier homolog 1 (Mtch1) [24] .", [["inner membrane mitochondrial", "ANATOMY", 80, 108], ["mitochondrial", "ANATOMY", 150, 163], ["PSAP", "GENE_OR_GENE_PRODUCT", 0, 4], ["presenilin-1", "GENE_OR_GENE_PRODUCT", 31, 43], ["inner membrane", "CELLULAR_COMPONENT", 80, 94], ["mitochondrial", "CELLULAR_COMPONENT", 95, 108], ["mitochondrial carrier homolog 1", "GENE_OR_GENE_PRODUCT", 150, 181], ["Mtch1", "GENE_OR_GENE_PRODUCT", 183, 188], ["PSAP", "PROTEIN", 0, 4], ["presenilin-1 associated protein", "PROTEIN", 31, 62], ["mitochondrial carrier homolog 1", "PROTEIN", 150, 181], ["Mtch1", "PROTEIN", 183, 188], ["PSAP", "TEST", 0, 4], ["a presenilin", "TEST", 29, 41], ["mitochondrial carrier homolog", "TREATMENT", 150, 179]]], ["The importance of its closest homolog, Mtch2, in Bid-induced apoptosis has been reported recently [25] .", [["Mtch2", "GENE_OR_GENE_PRODUCT", 39, 44], ["Mtch2", "PROTEIN", 39, 44]]], ["We reported that PSAP is a MOM protein with two pro-apoptotic domains [23] .", [["PSAP", "GENE_OR_GENE_PRODUCT", 17, 21], ["MOM", "GENE_OR_GENE_PRODUCT", 27, 30], ["PSAP", "PROTEIN", 17, 21], ["MOM protein", "PROTEIN", 27, 38], ["pro-apoptotic domains", "PROTEIN", 48, 69]]], ["Since apoptosis induction by these domains could depend on interactions with other proteins, we sought to analyze PSAP interactions by crosslinking.", [["PSAP", "GENE_OR_GENE_PRODUCT", 114, 118], ["PSAP", "PROTEIN", 114, 118], ["apoptosis induction", "TREATMENT", 6, 25]]], ["These assays suggested that the TMD of Bcl-XL could be involved in oligomerization, which was confirmed analyzing fusions to monomeric red fluorescent protein (mRFP).General reagentsAll reagents were of molecular biology grade.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 39, 45], ["monomeric red fluorescent protein", "GENE_OR_GENE_PRODUCT", 125, 158], ["mRFP", "GENE_OR_GENE_PRODUCT", 160, 164], ["Bcl", "PROTEIN", 39, 42], ["monomeric red fluorescent protein", "PROTEIN", 125, 158], ["mRFP", "PROTEIN", 160, 164], ["These assays", "TEST", 0, 12], ["Bcl-XL", "TREATMENT", 39, 45], ["General reagents", "TREATMENT", 166, 182]]], ["Restriction enzymes were from Roche, Stratagene, Invitrogen, Fermentas and New England Biolabs; Accuprime Pfx DNA polymerase, custommade primers and T4 DNA Ligase were from Invitrogen; Pfu polymerase, from Stratagene.Construction of expression vectorsExpression vectors containing PSAP or Mtch2 sequences have been previously described [23] . pJAC295, expressing myc-mRFP-TMD Bcl-XL (39.1 kDa), was constructed by amplifying the mRFP sequence from another vector by PCR with primers containing Eco RI (mRFPEcoF: 5 0 -CTAGGATCGAATTCGGATGGCCTCCTCCGAG-GACGT-3 0 ) and Hind III (mRFPHindR: 5 0 -CTAGGATCAAGCTTGGC GCCGGTGGAGTGGCGGC-3 0 ) restriction sites.", [["Fermentas", "GENE_OR_GENE_PRODUCT", 61, 70], ["Biolabs", "GENE_OR_GENE_PRODUCT", 87, 94], ["DNA", "CELLULAR_COMPONENT", 110, 113], ["T4 DNA Ligase", "GENE_OR_GENE_PRODUCT", 149, 162], ["Pfu polymerase", "GENE_OR_GENE_PRODUCT", 185, 199], ["PSAP", "GENE_OR_GENE_PRODUCT", 281, 285], ["Mtch2", "GENE_OR_GENE_PRODUCT", 289, 294], ["pJAC295", "GENE_OR_GENE_PRODUCT", 343, 350], ["myc-mRFP-TMD Bcl-XL", "GENE_OR_GENE_PRODUCT", 363, 382], ["mRFP", "GENE_OR_GENE_PRODUCT", 429, 433], ["Eco RI", "GENE_OR_GENE_PRODUCT", 494, 500], ["Hind III", "GENE_OR_GENE_PRODUCT", 565, 573], ["Accuprime Pfx DNA polymerase, custommade primers", "DNA", 96, 144], ["T4 DNA Ligase", "PROTEIN", 149, 162], ["Pfu polymerase", "PROTEIN", 185, 199], ["PSAP or Mtch2 sequences", "DNA", 281, 304], ["pJAC295", "PROTEIN", 343, 350], ["myc-mRFP", "PROTEIN", 363, 371], ["TMD Bcl-XL", "PROTEIN", 372, 382], ["39.1 kDa", "PROTEIN", 384, 392], ["mRFP sequence", "DNA", 429, 442], ["Eco RI", "DNA", 494, 500], ["Hind III", "DNA", 565, 573], ["restriction sites", "DNA", 633, 650], ["Restriction enzymes", "TEST", 0, 19], ["Roche", "TEST", 30, 35], ["Stratagene", "TEST", 37, 47], ["Invitrogen", "TEST", 49, 59], ["Fermentas", "TEST", 61, 70], ["New England Biolabs", "TEST", 75, 94], ["Accuprime Pfx DNA polymerase", "PROBLEM", 96, 124], ["custommade primers", "TEST", 126, 144], ["T4 DNA Ligase", "TEST", 149, 162], ["Invitrogen", "TEST", 173, 183], ["Pfu polymerase", "TEST", 185, 199], ["Stratagene", "TREATMENT", 206, 216], ["PSAP or Mtch2 sequences", "TEST", 281, 304], ["TMD Bcl-XL", "TEST", 372, 382], ["the mRFP sequence", "TEST", 425, 442], ["Eco RI", "TEST", 494, 500], ["mRFPEcoF", "TEST", 502, 510], ["CTAGGATCGAATTCGGATGGCCTCCTCCGAG", "TEST", 517, 548], ["GACGT", "TEST", 549, 554], ["mRFPHindR", "TEST", 575, 584], ["GCCGGTGGAGTGGCGGC", "TEST", 609, 626], ["Hind", "ANATOMY", 565, 569]]], ["The digested PCR product was used to replace PSAP sequences in the vector expressing myc-PSAP65-112-Bcl (which contains the TMD of Bcl-XL) [23] .", [["PSAP", "GENE_OR_GENE_PRODUCT", 45, 49], ["Bcl", "GENE_OR_GENE_PRODUCT", 100, 103], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 131, 137], ["digested PCR product", "PROTEIN", 4, 24], ["PSAP sequences", "DNA", 45, 59], ["myc-PSAP65", "PROTEIN", 85, 95], ["Bcl", "PROTEIN", 100, 103], ["Bcl-XL", "PROTEIN", 131, 137], ["The digested PCR product", "TREATMENT", 0, 24], ["PSAP sequences", "TEST", 45, 59]]], ["The resulting vector expresses mRFP preceded by a myc tag and followed by the sequence KLESRKGQERFNRWFLTGMTVAGVVLL GSLFSRK, where the first two amino acids (kl) correspond to the Hind III site and the remaining amino acids, to the TMD of Bcl-XL.Construction of expression vectorsThe same approach was used to construct vector pAOC2, expressing myc-mRFP-TMD VAMP2 (32.2 kDa), replacing PSAP sequences in a vector that expresses myc-PSAP39-168-Vamp (which contains the TMD of VAMP2) [23] .", [["amino acids", "CHEMICAL", 144, 155], ["amino acids", "CHEMICAL", 211, 222], ["amino acids", "CHEMICAL", 144, 155], ["amino acids", "CHEMICAL", 211, 222], ["mRFP", "GENE_OR_GENE_PRODUCT", 31, 35], ["myc", "GENE_OR_GENE_PRODUCT", 50, 53], ["amino acids", "AMINO_ACID", 144, 155], ["Hind III", "GENE_OR_GENE_PRODUCT", 179, 187], ["amino acids", "AMINO_ACID", 211, 222], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 238, 244], ["pAOC2", "GENE_OR_GENE_PRODUCT", 326, 331], ["myc-mRFP-TMD VAMP2", "GENE_OR_GENE_PRODUCT", 344, 362], ["PSAP", "GENE_OR_GENE_PRODUCT", 385, 389], ["myc-PSAP39-168-Vamp", "GENE_OR_GENE_PRODUCT", 427, 446], ["VAMP2", "GENE_OR_GENE_PRODUCT", 474, 479], ["mRFP", "PROTEIN", 31, 35], ["myc tag", "PROTEIN", 50, 57], ["KLESRKGQERFNRWFLTGMTVAGVVLL GSLFSRK", "PROTEIN", 87, 122], ["kl", "PROTEIN", 157, 159], ["Hind III site", "PROTEIN", 179, 192], ["Bcl", "PROTEIN", 238, 241], ["expression vectors", "DNA", 261, 279], ["pAOC2", "DNA", 326, 331], ["myc-mRFP", "PROTEIN", 344, 352], ["TMD VAMP2", "PROTEIN", 353, 362], ["32.2 kDa", "PROTEIN", 364, 372], ["PSAP sequences", "DNA", 385, 399], ["myc-PSAP39", "PROTEIN", 427, 437], ["Vamp", "PROTEIN", 442, 446], ["VAMP2", "PROTEIN", 474, 479], ["a myc tag", "TEST", 48, 57], ["the Hind III site", "PROBLEM", 175, 192], ["the remaining amino acids", "TREATMENT", 197, 222], ["expression vectors", "TREATMENT", 261, 279], ["TMD VAMP2", "PROBLEM", 353, 362], ["PSAP sequences", "TEST", 385, 399], ["Hind", "ANATOMY", 179, 183], ["amino acids", "OBSERVATION", 211, 222]]], ["In this case, sequence KLLKRKYWWKNLKMMIILGVICAIILIIIIVYFSS followed mRFP. pAL2 (28.7 kDa), expressing myc-mRFP, was constructed by digesting pJAC295 with Hind III and Not I, to eliminate the TMD of Bcl-XL, blunting with Pfu polymerase, and re-ligating.", [["mRFP", "GENE_OR_GENE_PRODUCT", 68, 72], ["pAL2", "GENE_OR_GENE_PRODUCT", 74, 78], ["myc-mRFP", "GENE_OR_GENE_PRODUCT", 102, 110], ["pJAC295", "GENE_OR_GENE_PRODUCT", 141, 148], ["Hind III", "GENE_OR_GENE_PRODUCT", 154, 162], ["Not I", "GENE_OR_GENE_PRODUCT", 167, 172], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 198, 204], ["Pfu polymerase", "GENE_OR_GENE_PRODUCT", 220, 234], ["mRFP", "PROTEIN", 68, 72], ["pAL2", "PROTEIN", 74, 78], ["myc-mRFP", "PROTEIN", 102, 110], ["pJAC295", "PROTEIN", 141, 148], ["Hind III", "PROTEIN", 154, 162], ["Not I", "PROTEIN", 167, 172], ["Bcl", "PROTEIN", 198, 201], ["Pfu polymerase", "PROTEIN", 220, 234], ["pAL2", "TEST", 74, 78], ["Bcl", "TEST", 198, 201], ["blunting", "PROBLEM", 206, 214], ["Pfu polymerase", "PROBLEM", 220, 234]]], ["Vectors were transformed into E. coli JM109 from Promega.", [["E. coli", "ORGANISM", 30, 37], ["JM109", "ORGANISM", 38, 43], ["Promega", "ORGANISM", 49, 56], ["E. coli JM109", "SPECIES", 30, 43], ["E. coli JM109", "SPECIES", 30, 43], ["Vectors", "TREATMENT", 0, 7], ["Promega", "TREATMENT", 49, 56], ["coli JM109", "OBSERVATION", 33, 43]]], ["Correct clones were confirmed by restriction digestion and sequencing. pAOC5, expressing myc-Bcl-XL (full length Bcl-XL preceded by a myc tag, 28.6 kDa), was constructed by carrying out a PCR on a vector containing the cDNA for Bcl-XL with primers BCLXLECOF (5 0 -CTAGGATCGAA TTCGAATGTCTCAGAGCAACAACCGGGAGC-3 0 ) and BLCLXLNOTR (5 0 -CTAGGATCGCGGCCGCTCATTTCCGACTGAAGAGTGAG-3 0 ).", [["clones", "ANATOMY", 8, 14], ["clones", "CELL", 8, 14], ["pAOC5", "GENE_OR_GENE_PRODUCT", 71, 76], ["myc-Bcl-XL", "GENE_OR_GENE_PRODUCT", 89, 99], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 113, 119], ["myc", "GENE_OR_GENE_PRODUCT", 134, 137], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 228, 234], ["pAOC5", "PROTEIN", 71, 76], ["myc-Bcl", "PROTEIN", 89, 96], ["XL", "PROTEIN", 97, 99], ["Bcl", "PROTEIN", 113, 116], ["myc tag", "DNA", 134, 141], ["cDNA", "DNA", 219, 223], ["Bcl", "PROTEIN", 228, 231], ["Correct clones", "PROBLEM", 0, 14], ["pAOC5", "TEST", 71, 76], ["myc-Bcl", "TEST", 89, 96], ["Bcl", "TEST", 113, 116], ["a myc tag", "TEST", 132, 141], ["a PCR", "TEST", 186, 191], ["a vector", "TREATMENT", 195, 203], ["the cDNA", "TREATMENT", 215, 223], ["Bcl", "TEST", 228, 231], ["primers BCLXLECOF", "TEST", 240, 257], ["TTCGAATGTCTCAGAGCAACAACCGGGAGC", "TEST", 276, 306], ["BLCLXLNOTR", "TEST", 317, 327], ["CTAGGATCGCGGCCGCTCATTTCCGACTGAAGAGTGAG", "TEST", 334, 372]]], ["The PCR product was digested with Eco RI and Not I and inserted into pCMVMyc. pAOC6, expressing myc-BclXL-DTMD (Bcl-XL without its carboxyl terminal transmembrane domain, preceded by a myc tag, 26.7 kDa), was constructed by PCR with primers BCLXLECOF and BCLXLWOTMXHOR (5 0 -CTAGGATCCTCGAGGGCTGCTGCATT GTTCCCATAG-3 0 ).", [["carboxyl", "CHEMICAL", 131, 139], ["Eco RI", "GENE_OR_GENE_PRODUCT", 34, 40], ["Not I", "GENE_OR_GENE_PRODUCT", 45, 50], ["pCMVMyc", "GENE_OR_GENE_PRODUCT", 69, 76], ["pAOC6", "GENE_OR_GENE_PRODUCT", 78, 83], ["myc-BclXL-DTMD", "GENE_OR_GENE_PRODUCT", 96, 110], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 112, 118], ["myc", "GENE_OR_GENE_PRODUCT", 185, 188], ["Eco RI", "PROTEIN", 34, 40], ["Not I", "DNA", 45, 50], ["pCMVMyc", "DNA", 69, 76], ["pAOC6", "PROTEIN", 78, 83], ["myc-BclXL", "PROTEIN", 96, 105], ["DTMD", "PROTEIN", 106, 110], ["Bcl", "PROTEIN", 112, 115], ["XL", "PROTEIN", 116, 118], ["carboxyl terminal transmembrane domain", "PROTEIN", 131, 169], ["myc tag", "PROTEIN", 185, 192], ["26.7 kDa", "PROTEIN", 194, 202], ["The PCR product", "TREATMENT", 0, 15], ["Eco RI", "TREATMENT", 34, 40], ["pCMVMyc", "TREATMENT", 69, 76], ["pAOC6", "TEST", 78, 83], ["myc-BclXL", "TEST", 96, 105], ["DTMD", "PROBLEM", 106, 110], ["Bcl", "TEST", 112, 115], ["its carboxyl terminal transmembrane domain", "PROBLEM", 127, 169], ["a myc tag", "TEST", 183, 192], ["PCR", "TEST", 224, 227], ["primers BCLXLECOF", "TEST", 233, 250], ["BCLXLWOTMXHOR", "TEST", 255, 268], ["GTTCCCATAG", "TEST", 302, 312]]], ["The product was digested with Eco RI and Xho I and cloned into pCMVMyc. pAOC7, expressing myc-BclXL-TMD2Pit2 (BclXL preceded by a myc tag and with its carboxyl terminal domain replaced by the second transmembrane domain of Pit 2, 27.3 kDa) was constructed by doing PCR on vector pVLG60 (pEGFpN1-PSAP-DTM1-Pit2TM2, see Lamarca et al. [26] ) with primers Pit2TM2XhoF (5 0 -CTAGGATCCTCGAGAGGCAGGCATGCA TTTTAGCTTC-3 0 ) and Pit2TM2NotR (5 0 -CATGGTACGCGGCCGC TCATTTGGCGCCTAGTAACACGGAG), the product was digested with Xho I and Not I and used to replace the equivalent fragment in vector pAOC6.", [["carboxyl", "CHEMICAL", 151, 159], ["Eco RI", "GENE_OR_GENE_PRODUCT", 30, 36], ["Xho I", "GENE_OR_GENE_PRODUCT", 41, 46], ["pAOC7", "GENE_OR_GENE_PRODUCT", 72, 77], ["myc-BclXL-TMD2Pit2", "GENE_OR_GENE_PRODUCT", 90, 108], ["BclXL", "GENE_OR_GENE_PRODUCT", 110, 115], ["myc", "GENE_OR_GENE_PRODUCT", 130, 133], ["Pit 2", "GENE_OR_GENE_PRODUCT", 223, 228], ["Xho I", "GENE_OR_GENE_PRODUCT", 513, 518], ["Not I", "GENE_OR_GENE_PRODUCT", 523, 528], ["pAOC6", "GENE_OR_GENE_PRODUCT", 583, 588], ["Eco RI", "PROTEIN", 30, 36], ["Xho I", "PROTEIN", 41, 46], ["pAOC7", "PROTEIN", 72, 77], ["myc-BclXL-TMD2Pit2", "PROTEIN", 90, 108], ["BclXL", "PROTEIN", 110, 115], ["myc tag", "PROTEIN", 130, 137], ["carboxyl terminal domain", "PROTEIN", 151, 175], ["transmembrane domain", "PROTEIN", 199, 219], ["Pit 2", "PROTEIN", 223, 228], ["27.3 kDa", "PROTEIN", 230, 238], ["pVLG60", "DNA", 279, 285], ["pEGFpN1", "DNA", 287, 294], ["PSAP", "PROTEIN", 295, 299], ["DTM1", "DNA", 300, 304], ["Pit2TM2", "DNA", 305, 312], ["primers Pit2TM2XhoF", "DNA", 345, 364], ["Pit2TM2NotR", "DNA", 420, 431], ["Xho I and Not I", "DNA", 513, 528], ["pAOC6", "DNA", 583, 588], ["Eco RI", "TREATMENT", 30, 36], ["a myc tag", "TREATMENT", 128, 137], ["its carboxyl terminal domain", "TREATMENT", 147, 175], ["Pit", "TEST", 223, 226], ["pEGFpN1", "TEST", 287, 294], ["PSAP", "TEST", 295, 299], ["DTM1", "TEST", 300, 304], ["primers Pit2TM2XhoF", "TEST", 345, 364], ["TTTTAGCTTC", "TEST", 399, 409], ["Pit2TM2NotR", "TREATMENT", 420, 431], ["CATGGTACGCGGCCGC TCATTTGGCGCCTAGTAACACGGAG)", "TREATMENT", 438, 481], ["equivalent", "OBSERVATION_MODIFIER", 553, 563], ["fragment", "OBSERVATION", 564, 572]]], ["The sequence of the second transmembrane domain of Pit 2 (TMD2Pit2) used is RQACILASIFETTGSVLLGAK. pAOC8, which expresses myc-BclXL-TMD3Pit2 (BclXL preceded by a myc tag and with its carboxyl terminal domain replaced by the third transmembrane domain of Pit 2, 27.3 kDa), was generated by PCR with primers Pit2TM3XhoF (5 0 -CTAGGATCCTCGAGATGGCTGGGGAAGTT AGTGC-3 0 ) and Pit2TM3NotR (5 0 -CTAGGATCGCGGCCGCTCACAGG AAGGAAGCAATCAGCT-3 0 ) in the same way as done with pAOC7, but using vector pVLG61 (pEGFpN1-PSAP-DTMI-Pit2TM3, see Lamarca et al. [26] ) as template for the PCR.", [["transmembrane", "ANATOMY", 27, 40], ["carboxyl", "CHEMICAL", 183, 191], ["Pit 2", "GENE_OR_GENE_PRODUCT", 51, 56], ["TMD2Pit2", "GENE_OR_GENE_PRODUCT", 58, 66], ["pAOC8", "GENE_OR_GENE_PRODUCT", 99, 104], ["myc-BclXL-TMD3Pit2", "GENE_OR_GENE_PRODUCT", 122, 140], ["BclXL", "GENE_OR_GENE_PRODUCT", 142, 147], ["myc", "GENE_OR_GENE_PRODUCT", 162, 165], ["Pit 2", "GENE_OR_GENE_PRODUCT", 254, 259], ["pAOC7", "GENE_OR_GENE_PRODUCT", 464, 469], ["transmembrane domain", "PROTEIN", 27, 47], ["Pit 2", "PROTEIN", 51, 56], ["TMD2Pit2", "PROTEIN", 58, 66], ["RQACILASIFETTGSVLLGAK", "PROTEIN", 76, 97], ["pAOC8", "PROTEIN", 99, 104], ["myc-BclXL-TMD3Pit2", "PROTEIN", 122, 140], ["BclXL", "PROTEIN", 142, 147], ["myc tag", "PROTEIN", 162, 169], ["carboxyl terminal domain", "PROTEIN", 183, 207], ["third transmembrane domain", "PROTEIN", 224, 250], ["Pit 2", "PROTEIN", 254, 259], ["27.3 kDa", "PROTEIN", 261, 269], ["pAOC7", "PROTEIN", 464, 469], ["pVLG61", "DNA", 488, 494], ["pEGFpN1", "DNA", 496, 503], ["PSAP", "DNA", 504, 508], ["DTMI", "DNA", 509, 513], ["Pit2TM3", "DNA", 514, 521], ["the second transmembrane domain of Pit", "TREATMENT", 16, 54], ["a myc tag", "TREATMENT", 160, 169], ["its carboxyl terminal domain", "TREATMENT", 179, 207], ["Pit", "TEST", 254, 257], ["PCR", "TEST", 289, 292], ["primers Pit2TM3XhoF", "TEST", 298, 317], ["AGTGC", "TEST", 354, 359], ["Pit2TM3NotR", "TEST", 370, 381], ["AAGGAAGCAATCAGCT", "TEST", 412, 428], ["Pit2TM3", "TREATMENT", 514, 521], ["the PCR", "TEST", 565, 572]]], ["The sequence of the third transmembrane domain of Pit2 (TMD3Pit2) used is MAGEVSAMVGSAVWQLIASFL.Cell culture and transfectionHEK293 cells and HeLa cells were cultured as previously described [26] and transfected using GeneJuice Reagent (Novagen) at a confluence of 80% in 24-well plates. and samples agitated for 15 min at room temperature.", [["transmembrane", "ANATOMY", 26, 39], ["Cell culture", "ANATOMY", 96, 108], ["transfectionHEK293 cells", "ANATOMY", 113, 137], ["HeLa cells", "ANATOMY", 142, 152], ["samples", "ANATOMY", 292, 299], ["Pit2", "GENE_OR_GENE_PRODUCT", 50, 54], ["Cell", "CELL", 96, 100], ["transfectionHEK293 cells", "CELL", 113, 137], ["HeLa cells", "CELL", 142, 152], ["Novagen", "GENE_OR_GENE_PRODUCT", 237, 244], ["third transmembrane domain", "PROTEIN", 20, 46], ["Pit2", "PROTEIN", 50, 54], ["TMD3Pit2", "PROTEIN", 56, 64], ["MAGEVSAMVGSAVWQLIASFL", "PROTEIN", 74, 95], ["transfectionHEK293 cells", "CELL_LINE", 113, 137], ["HeLa cells", "CELL_LINE", 142, 152], ["Pit2 (TMD3Pit2)", "TREATMENT", 50, 65], ["Cell culture", "TEST", 96, 108], ["transfectionHEK293 cells", "PROBLEM", 113, 137], ["HeLa cells", "TEST", 142, 152], ["GeneJuice Reagent (Novagen", "TREATMENT", 218, 244], ["samples agitated", "PROBLEM", 292, 308], ["HeLa cells", "OBSERVATION", 142, 152]]], ["Cells were recovered by centrifugation and analyzed using SDS-PAGE (Laemmli) followed by immunoblotting with anti-myc (Invitrogen), anti-PSAP MGAS [26] , anti-Bax (Millipore) or anti-Bak (Millipore) antibodies after transfer onto polyvinylidene fluoride (PVDF) membranes (Invitrogen), as described [23] .", [["Cells", "ANATOMY", 0, 5], ["polyvinylidene fluoride", "CHEMICAL", 230, 253], ["polyvinylidene fluoride", "CHEMICAL", 230, 253], ["PVDF", "CHEMICAL", 255, 259], ["Cells", "CELL", 0, 5], ["anti-myc", "GENE_OR_GENE_PRODUCT", 109, 117], ["Invitrogen", "SIMPLE_CHEMICAL", 119, 129], ["Bax", "GENE_OR_GENE_PRODUCT", 159, 162], ["Millipore", "GENE_OR_GENE_PRODUCT", 164, 173], ["Bak", "GENE_OR_GENE_PRODUCT", 183, 186], ["polyvinylidene fluoride", "SIMPLE_CHEMICAL", 230, 253], ["anti-myc", "PROTEIN", 109, 117], ["PSAP MGAS", "PROTEIN", 137, 146], ["Bax", "PROTEIN", 159, 162], ["Millipore", "PROTEIN", 164, 173], ["Bak (Millipore) antibodies", "PROTEIN", 183, 209], ["SDS", "TEST", 58, 61], ["anti-myc (Invitrogen)", "TREATMENT", 109, 130], ["anti-PSAP MGAS", "TEST", 132, 146], ["anti-Bax (Millipore", "TREATMENT", 154, 173], ["anti-Bak (Millipore) antibodies", "TREATMENT", 178, 209], ["polyvinylidene fluoride (PVDF) membranes", "TREATMENT", 230, 270]]], ["Proteins were visualized by incubation with goat-anti mouse or goat anti-rabbit secondary antibodies conjugated to HRP and detected by ECL.", [["mouse", "ORGANISM", 54, 59], ["goat", "ORGANISM", 63, 67], ["HRP", "GENE_OR_GENE_PRODUCT", 115, 118], ["goat-anti mouse or goat anti-rabbit secondary antibodies", "PROTEIN", 44, 100], ["HRP", "PROTEIN", 115, 118], ["goat", "SPECIES", 44, 48], ["mouse", "SPECIES", 54, 59], ["goat", "SPECIES", 63, 67], ["anti-rabbit", "SPECIES", 68, 79], ["goat", "SPECIES", 44, 48], ["mouse", "SPECIES", 54, 59], ["goat", "SPECIES", 63, 67], ["anti-rabbit", "SPECIES", 68, 79], ["goat", "TEST", 44, 48], ["anti mouse", "TREATMENT", 49, 59], ["goat anti-rabbit secondary antibodies", "TREATMENT", 63, 100]]], ["Molecular mass markers were from Invitrogen (BenchMark Pre-Stained Protein Ladder) or Bio-Rad (Precision Plus Protein Standards).Blue-native electrophoresis (BN-PAGE)BN-PAGE was carried out with digitonin-treated cells using the NativePAGE\u2122 Novex \u00d2 Bis-Tris Gel System from Invitrogen, 4-16% gradient gels, following instructions supplied by the manufacturer.", [["cells", "ANATOMY", 213, 218], ["BN-PAGE", "CHEMICAL", 158, 165], ["digitonin", "CHEMICAL", 195, 204], ["digitonin", "CHEMICAL", 195, 204], ["Bis-Tris Gel", "CHEMICAL", 249, 261], ["digitonin", "SIMPLE_CHEMICAL", 195, 204], ["cells", "CELL", 213, 218], ["Bis-Tris Gel", "SIMPLE_CHEMICAL", 249, 261], ["digitonin-treated cells", "CELL_LINE", 195, 218], ["Molecular mass markers", "PROBLEM", 0, 22], ["Invitrogen (BenchMark Pre-Stained Protein Ladder", "TREATMENT", 33, 81], ["Bio-Rad (Precision Plus Protein Standards", "TREATMENT", 86, 127], ["Blue-native electrophoresis", "PROBLEM", 129, 156], ["digitonin", "TREATMENT", 195, 204], ["the NativePAGE", "TREATMENT", 225, 239], ["Invitrogen", "TEST", 274, 284], ["16% gradient gels", "TREATMENT", 288, 305], ["mass", "OBSERVATION", 10, 14]]], ["10 lg protein was loaded per well.", [["lg", "GENE_OR_GENE_PRODUCT", 3, 5], ["lg protein", "PROTEIN", 3, 13]]], ["Native protein standards were from Invitrogen (NativeMark Unstained Protein Standard).Cell viability and death assaysWe used the Cell Proliferation Kit II (XTT) (Roche) as a quick method to measure cell death induced by camptothecin.", [["Cell", "ANATOMY", 86, 90], ["Cell", "ANATOMY", 129, 133], ["cell", "ANATOMY", 198, 202], ["death", "DISEASE", 105, 110], ["death", "DISEASE", 203, 208], ["camptothecin", "CHEMICAL", 220, 232], ["camptothecin", "CHEMICAL", 220, 232], ["Cell", "CELL", 86, 90], ["Cell", "CELL", 129, 133], ["cell", "CELL", 198, 202], ["camptothecin", "SIMPLE_CHEMICAL", 220, 232], ["Native protein standards", "TEST", 0, 24], ["Invitrogen", "TEST", 35, 45], ["Cell viability", "PROBLEM", 86, 100], ["death assays", "TEST", 105, 117], ["the Cell Proliferation Kit II", "TREATMENT", 125, 154], ["cell death", "PROBLEM", 198, 208], ["camptothecin", "TREATMENT", 220, 232], ["Cell Proliferation", "OBSERVATION", 129, 147]]], ["HEK293 cells were cultured and transfected in 96-well plates, 12 h posttransfection cells were treated with 30 lM camptothecin or DMSO and 24 h later they were incubated with XTT.", [["HEK293 cells", "ANATOMY", 0, 12], ["cells", "ANATOMY", 84, 89], ["camptothecin", "CHEMICAL", 114, 126], ["DMSO", "CHEMICAL", 130, 134], ["XTT", "CHEMICAL", 175, 178], ["camptothecin", "CHEMICAL", 114, 126], ["DMSO", "CHEMICAL", 130, 134], ["XTT", "CHEMICAL", 175, 178], ["HEK293 cells", "CELL", 0, 12], ["cells", "CELL", 84, 89], ["camptothecin", "SIMPLE_CHEMICAL", 114, 126], ["DMSO", "SIMPLE_CHEMICAL", 130, 134], ["HEK293 cells", "CELL_LINE", 0, 12], ["posttransfection cells", "CELL_LINE", 67, 89], ["HEK293 cells", "TEST", 0, 12], ["30 lM camptothecin", "TREATMENT", 108, 126], ["DMSO", "TREATMENT", 130, 134], ["XTT", "TEST", 175, 178]]], ["Two independent assays were carried out in triplicate.Cell viability and death assaysFor trypan blue exclusion assays, HEK293 cells were cultured in 24-well plates until they reached 80% confluency and then transfected and treated with camptothecin or DMSO as indicated above.", [["Cell", "ANATOMY", 54, 58], ["HEK293 cells", "ANATOMY", 119, 131], ["death", "DISEASE", 73, 78], ["trypan blue", "CHEMICAL", 89, 100], ["camptothecin", "CHEMICAL", 236, 248], ["DMSO", "CHEMICAL", 252, 256], ["trypan blue", "CHEMICAL", 89, 100], ["camptothecin", "CHEMICAL", 236, 248], ["DMSO", "CHEMICAL", 252, 256], ["Cell", "CELL", 54, 58], ["trypan blue", "SIMPLE_CHEMICAL", 89, 100], ["HEK293 cells", "CELL", 119, 131], ["camptothecin", "SIMPLE_CHEMICAL", 236, 248], ["DMSO", "SIMPLE_CHEMICAL", 252, 256], ["HEK293 cells", "CELL_LINE", 119, 131], ["Two independent assays", "TEST", 0, 22], ["Cell viability", "TEST", 54, 68], ["death assays", "TEST", 73, 85], ["trypan blue exclusion assays", "TEST", 89, 117], ["HEK293 cells", "TEST", 119, 131], ["camptothecin", "TREATMENT", 236, 248], ["DMSO", "TREATMENT", 252, 256]]], ["24 h post-transfection wells were washed with PBS, which was transferred to tubes to avoid loosing detached cells.", [["tubes", "ANATOMY", 76, 81], ["cells", "ANATOMY", 108, 113], ["cells", "CELL", 108, 113], ["loosing detached cells", "CELL_LINE", 91, 113], ["transfection wells", "TREATMENT", 10, 28], ["PBS", "TREATMENT", 46, 49], ["tubes", "TREATMENT", 76, 81], ["loosing detached cells", "PROBLEM", 91, 113], ["detached cells", "OBSERVATION", 99, 113]]], ["Attached cells were trypsinized for 5 min and mixed with detached cells in PBS from the same well.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 66, 71], ["cells", "CELL", 9, 14], ["cells", "CELL", 66, 71], ["detached cells", "CELL_TYPE", 57, 71], ["Attached cells", "TREATMENT", 0, 14], ["detached cells in PBS", "TREATMENT", 57, 78]]], ["Complete media, with serum, was added to inactivate trypsin.", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["trypsin", "GENE_OR_GENE_PRODUCT", 52, 59], ["trypsin", "PROTEIN", 52, 59]]], ["Cells were mixed with trypan blue (Roche) in a 1:1 ratio and counted using a hemacytometer.", [["Cells", "ANATOMY", 0, 5], ["trypan blue", "CHEMICAL", 22, 33], ["trypan blue", "CHEMICAL", 22, 33], ["Cells", "CELL", 0, 5], ["trypan blue", "SIMPLE_CHEMICAL", 22, 33], ["Roche", "ORGANISM_SUBSTANCE", 35, 40], ["Cells", "TEST", 0, 5], ["trypan blue", "TEST", 22, 33], ["a 1:1 ratio", "TEST", 45, 56], ["a hemacytometer", "TREATMENT", 75, 90]]], ["For each sample, four quadrants were scored twice, with cell numbers ranging between 18 and 35 per quadrant.", [["sample", "ANATOMY", 9, 15], ["cell", "ANATOMY", 56, 60], ["cell", "CELL", 56, 60], ["cell numbers", "TEST", 56, 68], ["quadrant", "ANATOMY", 99, 107]]], ["For one of the experiments an automatic cell counter (Countess from Invitrogen) was used, obtaining similar results as with manual counts.", [["cell", "ANATOMY", 40, 44], ["cell", "CELL", 40, 44], ["manual counts", "TEST", 124, 137]]], ["Each experiment was carried out in triplicates three independent times.ImmunocytochemistryFor subcellular localization of Bcl-XL chimeras, cells grown on round coverslides in 24-well plates were first incubated with 25 nM Mitotracker Red CMX-Ros (Invitrogen) for 30 min at 37\u00b0C, the culture media replaced with fresh media and incubated again for 30 min at 37\u00b0C. Cells were then fixed with a solution containing 50% culture media and 50% of a 3.7% formaldehyde solution in Subcellular localization of mRFP chimeras was carried out as for Bcl-XL chimeras but using 100 nM Mitotracker Green.MicroscopyWe used a Leica DMI6000B inverted fluorescence microscope with structured illumination (Optigrid) and software Metamorph.", [["subcellular", "ANATOMY", 94, 105], ["cells", "ANATOMY", 139, 144], ["Cells", "ANATOMY", 363, 368], ["Subcellular", "ANATOMY", 473, 484], ["CMX-Ros", "CHEMICAL", 238, 245], ["formaldehyde", "CHEMICAL", 448, 460], ["Mitotracker Green", "CHEMICAL", 571, 588], ["CMX-Ros", "CHEMICAL", 238, 245], ["formaldehyde", "CHEMICAL", 448, 460], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 122, 128], ["cells", "CELL", 139, 144], ["CMX-Ros", "SIMPLE_CHEMICAL", 238, 245], ["Invitrogen", "SIMPLE_CHEMICAL", 247, 257], ["Cells", "CELL", 363, 368], ["formaldehyde", "SIMPLE_CHEMICAL", 448, 460], ["mRFP", "GENE_OR_GENE_PRODUCT", 501, 505], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 538, 544], ["Bcl-XL chimeras", "PROTEIN", 122, 137], ["mRFP chimeras", "PROTEIN", 501, 514], ["Bcl", "PROTEIN", 538, 541], ["Leica DMI6000B", "DNA", 609, 623], ["Immunocytochemistry", "TEST", 71, 90], ["Bcl-XL chimeras", "PROBLEM", 122, 137], ["round coverslides", "TEST", 154, 171], ["Red CMX", "TEST", 234, 241], ["the culture media", "TREATMENT", 279, 296], ["fresh media", "TREATMENT", 311, 322], ["a solution", "TREATMENT", 390, 400], ["50% culture media", "TREATMENT", 412, 429], ["a 3.7% formaldehyde solution", "TREATMENT", 441, 469], ["mRFP chimeras", "PROBLEM", 501, 514], ["Bcl-XL chimeras", "TREATMENT", 538, 553], ["100 nM Mitotracker Green", "TREATMENT", 564, 588], ["a Leica DMI6000B inverted fluorescence microscope", "TREATMENT", 607, 656], ["Bcl-XL chimeras", "OBSERVATION", 122, 137]]], ["For red fluorescent protein and Mitotracker red we used a BP560/ 40 excitation filter and a BP645/75 emission filter with a 595 nm dicroic, and for Mitotracker green and Alexa Fluor 488, we used a filter for GFP, excitation BP470/40, emission BP525/50 and 500 nm dicroic.ResultsIn order to study PSAP function we generated several deletion mutants which were used to study mitochondrial import and induction of apoptosis by this protein [23] .", [["mitochondrial", "ANATOMY", 373, 386], ["Mitotracker green", "CHEMICAL", 148, 165], ["Mitotracker green", "CHEMICAL", 148, 165], ["Alexa Fluor 488", "CHEMICAL", 170, 185], ["red fluorescent protein", "GENE_OR_GENE_PRODUCT", 4, 27], ["Mitotracker", "SIMPLE_CHEMICAL", 32, 43], ["Mitotracker green", "SIMPLE_CHEMICAL", 148, 165], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 170, 185], ["GFP", "GENE_OR_GENE_PRODUCT", 208, 211], ["PSAP", "GENE_OR_GENE_PRODUCT", 296, 300], ["mitochondrial", "CELLULAR_COMPONENT", 373, 386], ["red fluorescent protein", "PROTEIN", 4, 27], ["BP560", "PROTEIN", 58, 63], ["Alexa Fluor 488", "PROTEIN", 170, 185], ["GFP", "PROTEIN", 208, 211], ["PSAP", "PROTEIN", 296, 300], ["red fluorescent protein", "TEST", 4, 27], ["a BP560/ 40 excitation filter", "TREATMENT", 56, 85], ["a BP645/75 emission filter", "TREATMENT", 90, 116], ["a 595 nm dicroic", "TREATMENT", 122, 138], ["a filter", "TREATMENT", 195, 203], ["excitation", "TEST", 213, 223], ["study PSAP function", "TEST", 290, 309], ["several deletion mutants", "PROBLEM", 323, 347], ["apoptosis", "PROBLEM", 411, 420]]], ["We targeted PSAP fragments to the MOM by fusion to the TMD of Bcl-XL, demonstrating that MOM localization was required for apoptosis induction, since endoplasmic reticulum-targeting by fusion to the TMD of VAMP2 [27] did not induce apoptosis.ResultsSince apoptosis induction by PSAP could be mediated by interactions with other proteins, we attempted to detect PSAP-interacting proteins by crosslinking, using some of the above-mentioned chimeras.", [["PSAP fragments", "ANATOMY", 12, 26], ["endoplasmic reticulum", "ANATOMY", 150, 171], ["PSAP", "CHEMICAL", 278, 282], ["PSAP", "GENE_OR_GENE_PRODUCT", 12, 16], ["MOM", "GENE_OR_GENE_PRODUCT", 34, 37], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 62, 68], ["MOM", "GENE_OR_GENE_PRODUCT", 89, 92], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 150, 171], ["VAMP2", "GENE_OR_GENE_PRODUCT", 206, 211], ["PSAP", "SIMPLE_CHEMICAL", 278, 282], ["PSAP-interacting proteins", "GENE_OR_GENE_PRODUCT", 361, 386], ["PSAP fragments", "DNA", 12, 26], ["MOM", "DNA", 34, 37], ["Bcl", "PROTEIN", 62, 65], ["MOM", "PROTEIN", 89, 92], ["VAMP2", "PROTEIN", 206, 211], ["PSAP", "PROTEIN", 278, 282], ["PSAP", "PROTEIN", 361, 365], ["interacting proteins", "PROTEIN", 366, 386], ["apoptosis induction", "TREATMENT", 123, 142], ["endoplasmic reticulum", "PROBLEM", 150, 171], ["VAMP2", "TEST", 206, 211], ["apoptosis", "PROBLEM", 232, 241], ["apoptosis induction", "TREATMENT", 255, 274], ["PSAP", "TEST", 361, 365], ["apoptosis", "OBSERVATION", 232, 241]]], ["When HEK293 cells expressing the first 168 residues of PSAP fused to the TMD of Bcl-XL (PSAP 1-168 TMD Bcl-XL, 21 kDa) were treated with BSOCOES, a band was observed by western blot suggesting dimerization of the protein (Fig. 1, lane 2) .", [["HEK293 cells", "ANATOMY", 5, 17], ["HEK293 cells", "CELL", 5, 17], ["PSAP", "GENE_OR_GENE_PRODUCT", 55, 59], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 80, 86], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 103, 109], ["HEK293 cells", "CELL_LINE", 5, 17], ["PSAP", "PROTEIN", 55, 59], ["Bcl-XL", "PROTEIN", 80, 86], ["PSAP 1", "PROTEIN", 88, 94], ["Bcl-XL", "PROTEIN", 103, 109], ["BSOCOES", "PROTEIN", 137, 144], ["Fig. 1, lane 2", "PROTEIN", 222, 236], ["PSAP", "TEST", 55, 59], ["Bcl-XL", "TEST", 80, 86], ["PSAP", "TEST", 88, 92], ["TMD Bcl-XL", "TEST", 99, 109], ["BSOCOES", "TREATMENT", 137, 144], ["a band", "PROBLEM", 146, 152], ["the protein", "TEST", 209, 220]]], ["Similar results were obtained with the protein containing the TMD of VAMP2 (PSAP 1-168 TMD VAMP2, 21.2 kDa).", [["VAMP2", "GENE_OR_GENE_PRODUCT", 69, 74], ["VAMP2", "PROTEIN", 69, 74], ["VAMP2", "PROTEIN", 91, 96], ["the protein", "TEST", 35, 46], ["VAMP2", "TEST", 69, 74], ["PSAP", "TEST", 76, 80], ["TMD VAMP2", "TEST", 87, 96]]], ["Since both proteins share the same PSAP sequences, we first assumed that PSAP was mediating dimerization.", [["PSAP", "GENE_OR_GENE_PRODUCT", 35, 39], ["PSAP", "GENE_OR_GENE_PRODUCT", 73, 77], ["PSAP sequences", "DNA", 35, 49], ["PSAP", "PROTEIN", 73, 77], ["the same PSAP sequences", "TEST", 26, 49]]], ["Nevertheless, a literature search indicated that the TMD of VAMP2 is responsible for its homo or heteromerization at the ER membrane [28] , suggesting that the dimers observed in our experiments could depend on TMD instead of PSAP sequences.", [["ER membrane", "ANATOMY", 121, 132], ["TMD", "DISEASE", 53, 56], ["VAMP2", "GENE_OR_GENE_PRODUCT", 60, 65], ["ER membrane", "CELLULAR_COMPONENT", 121, 132], ["PSAP", "GENE_OR_GENE_PRODUCT", 226, 230], ["VAMP2", "PROTEIN", 60, 65], ["ER", "PROTEIN", 121, 123], ["PSAP sequences", "DNA", 226, 240], ["a literature search", "TEST", 14, 33], ["the TMD of VAMP2", "PROBLEM", 49, 65], ["the dimers", "PROBLEM", 156, 166], ["PSAP sequences", "TEST", 226, 240]]], ["This interpretation could also explain a band migrating between those corresponding to the monomer (21.2 kDa) and dimer (42.4 Fig. 1 , as a heterodimer between endogenous VAMP2 (12.6 kDa) and PSAP 1-168 TMD VAMP2 (expected molecular mass: 33.8 kDa, marked with an asterisk in Fig. 1 ).", [["VAMP2", "GENE_OR_GENE_PRODUCT", 171, 176], ["PSAP 1", "GENE_OR_GENE_PRODUCT", 192, 198], ["VAMP2", "GENE_OR_GENE_PRODUCT", 207, 212], ["dimer", "PROTEIN", 114, 119], ["VAMP2", "PROTEIN", 171, 176], ["PSAP 1", "PROTEIN", 192, 198], ["TMD VAMP2", "PROTEIN", 203, 212], ["a band migrating", "PROBLEM", 39, 55], ["dimer", "TEST", 114, 119], ["endogenous VAMP2", "TEST", 160, 176], ["kDa", "TEST", 183, 186], ["PSAP", "TEST", 192, 196], ["TMD VAMP2 (expected molecular mass", "PROBLEM", 203, 237], ["kDa", "TEST", 244, 247], ["an asterisk in Fig", "PROBLEM", 261, 279], ["mass", "OBSERVATION", 233, 237], ["33.8 kDa", "OBSERVATION_MODIFIER", 239, 247], ["marked", "OBSERVATION_MODIFIER", 249, 255]]], ["Note that some of the bands are also present in the absence of crosslinker, suggesting strong interactions.kDa) in lanes 3 and 4 ofWhen similar constructs containing shorter PSAP fragments were used, oligomerization was observed.", [["PSAP fragments", "ANATOMY", 174, 188], ["PSAP", "GENE_OR_GENE_PRODUCT", 174, 178], ["PSAP fragments", "DNA", 174, 188], ["the bands", "PROBLEM", 18, 27], ["shorter PSAP fragments", "PROBLEM", 166, 188], ["oligomerization", "TREATMENT", 200, 215], ["bands", "OBSERVATION", 22, 27], ["crosslinker", "OBSERVATION", 63, 74], ["suggesting", "UNCERTAINTY", 76, 86], ["strong", "OBSERVATION_MODIFIER", 87, 93], ["interactions", "OBSERVATION", 94, 106], ["shorter", "OBSERVATION_MODIFIER", 166, 173], ["PSAP fragments", "OBSERVATION", 174, 188]]], ["Fig. 2 shows the results obtained with a construct containing residues 65-112 preceded by a myc tag and followed by the TMD of Bcl-XL (11.2 kDa).", [["myc", "GENE_OR_GENE_PRODUCT", 92, 95], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 127, 133], ["myc tag", "PROTEIN", 92, 99], ["Bcl-XL", "PROTEIN", 127, 133], ["a construct containing residues", "TEST", 39, 70], ["a myc tag", "TEST", 90, 99], ["Bcl-XL", "TEST", 127, 133]]], ["Crosslinking of a protein chimera containing Mtch2 sequences (16 kDa) instead of PSAP sequences (lanes 3 and 4 in Fig. 2 ) also produced oligomers.kDa) in lanes 3 and 4 ofOur constructs contained parts of PSAP or Mtch2 and the TMD of Bcl-XL, proteins that can all be inserted into the MOM, therefore we could not rule out a mixed effect due to different sequences from either protein.", [["Mtch2", "GENE_OR_GENE_PRODUCT", 45, 50], ["PSAP", "GENE_OR_GENE_PRODUCT", 205, 209], ["Mtch2", "GENE_OR_GENE_PRODUCT", 213, 218], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 234, 240], ["MOM", "GENE_OR_GENE_PRODUCT", 285, 288], ["protein chimera", "PROTEIN", 18, 33], ["Mtch2 sequences", "DNA", 45, 60], ["PSAP sequences", "DNA", 81, 95], ["lanes 3 and 4 ofOur constructs", "DNA", 155, 185], ["PSAP", "PROTEIN", 205, 209], ["Mtch2", "PROTEIN", 213, 218], ["TMD", "PROTEIN", 227, 230], ["Bcl", "PROTEIN", 234, 237], ["XL", "PROTEIN", 238, 240], ["MOM", "PROTEIN", 285, 288], ["a protein chimera", "TREATMENT", 16, 33], ["Mtch2 sequences", "TEST", 45, 60], ["PSAP sequences (lanes", "TEST", 81, 102], ["oligomers", "PROBLEM", 137, 146], ["PSAP", "TEST", 205, 209], ["Mtch2", "TREATMENT", 213, 218], ["a mixed effect", "PROBLEM", 322, 336], ["oligomers", "OBSERVATION", 137, 146]]], ["In fact, whether dimers or oligomers were observed depended on the sequences attached to the TMD ( Fig. 1 and Fig. 2) .", [["dimers or oligomers", "PROBLEM", 17, 36]]], ["In order to clarify this subject, we fused the TMD of Bcl-XL or that of VAMP2 to monomeric red fluorescent protein (mRFP) preceded by a myc tag for detection.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 54, 60], ["VAMP2", "GENE_OR_GENE_PRODUCT", 72, 77], ["monomeric red fluorescent protein", "GENE_OR_GENE_PRODUCT", 81, 114], ["mRFP", "GENE_OR_GENE_PRODUCT", 116, 120], ["myc", "GENE_OR_GENE_PRODUCT", 136, 139], ["Bcl", "PROTEIN", 54, 57], ["VAMP2", "PROTEIN", 72, 77], ["monomeric red fluorescent protein", "PROTEIN", 81, 114], ["mRFP", "PROTEIN", 116, 120], ["myc tag", "PROTEIN", 136, 143], ["Bcl-XL", "TREATMENT", 54, 60]]], ["We used myc-mRFP (28.7 kDa) as control.", [["myc-mRFP", "TEST", 8, 16]]], ["Crosslinking assays indicated that similar complexes could be detected when each TMD was fused to mRFP (Fig. 3A) , whereas myc-mRFP remained as a monomer, therefore indicating that the TMDs were responsible for the dimers observed.", [["mRFP", "GENE_OR_GENE_PRODUCT", 98, 102], ["myc-mRFP", "SIMPLE_CHEMICAL", 123, 131], ["mRFP", "PROTEIN", 98, 102], ["Fig. 3A", "PROTEIN", 104, 111], ["myc-mRFP", "PROTEIN", 123, 131], ["Crosslinking assays", "TEST", 0, 19], ["the TMDs", "PROBLEM", 181, 189], ["the dimers", "PROBLEM", 211, 221]]], ["The contribution of PSAP sequences to dimers and oligomers shown in Fig. 1 and 2 is under investigation and will be reported elsewhere.kDa) in lanes 3 and 4 ofIn order to analyze these interactions with a different technique, we used blue-native electrophoresis (Fig. 3B) , confirming that fusion of mRFP to either the TMD of Bcl-XL or the TMD of VAMP2 induced oligomerization of the protein.", [["PSAP", "GENE_OR_GENE_PRODUCT", 20, 24], ["mRFP", "GENE_OR_GENE_PRODUCT", 300, 304], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 326, 332], ["VAMP2", "GENE_OR_GENE_PRODUCT", 347, 352], ["PSAP sequences", "DNA", 20, 34], ["mRFP", "PROTEIN", 300, 304], ["Bcl", "PROTEIN", 326, 329], ["VAMP2", "PROTEIN", 347, 352], ["PSAP sequences", "TEST", 20, 34], ["a different technique", "TREATMENT", 203, 224], ["blue-native electrophoresis", "TREATMENT", 234, 261], ["fusion of mRFP", "TREATMENT", 290, 304]]], ["The pattern obtained indicated the presence of oligomers up to pentamers, although less abundant (or less stable) than the dimers.", [["oligomers", "PROBLEM", 47, 56], ["less", "OBSERVATION_MODIFIER", 83, 87], ["abundant", "OBSERVATION_MODIFIER", 88, 96], ["less", "OBSERVATION_MODIFIER", 101, 105], ["stable", "OBSERVATION_MODIFIER", 106, 112]]], ["These data clearly indicate the involvement of the TMD of Bcl-XL in selfassociation, an event that had not been reported previously.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 58, 64], ["Bcl", "PROTEIN", 58, 61], ["the TMD of Bcl", "PROBLEM", 47, 61]]], ["The fact that only dimers could be observed upon crosslinking could be due to the location of the reacting amino groups in the oligomers.", [["amino", "CHEMICAL", 107, 112], ["amino", "CHEMICAL", 107, 112], ["the reacting amino groups in the oligomers", "PROBLEM", 94, 136]]], ["Crosslinking covalently fixes those interactions where reacting groups (amino groups in this case) are localized in close proximity, and uncrosslinked molecules are separated later during denaturing electrophoresis.", [["amino", "CHEMICAL", 72, 77], ["amino", "CHEMICAL", 72, 77], ["uncrosslinked molecules", "PROTEIN", 137, 160], ["Crosslinking covalently", "PROBLEM", 0, 23], ["denaturing electrophoresis", "PROBLEM", 188, 214]]], ["Blue native electrophoresis does not rely on specific reactive groups but on the overall stability of protein complexes where individual molecules are held together by non-covalent bonds.", [["protein complexes", "PROTEIN", 102, 119], ["Blue native electrophoresis", "PROBLEM", 0, 27], ["protein complexes", "PROBLEM", 102, 119], ["reactive", "OBSERVATION", 54, 62], ["non-covalent bonds", "OBSERVATION", 168, 186]]], ["It could be that, in our complexes, reacting amino groups are only located closely between monomers of a single dimer, and dimers associate in oligomers in such a way that adjacent dimers cannot be crosslinked with each other.", [["amino", "CHEMICAL", 45, 50], ["amino", "CHEMICAL", 45, 50], ["dimer", "PROTEIN", 112, 117]]], ["This could explain why dimers are mainly observed upon crosslinking whereas oligomers are observed after blue-native electrophoresis.kDa) in lanes 3 and 4 ofWe analyzed the subcellular localization of our chimeras by fluorescence microscopy, using Mitotracker green to label mitochondria.", [["subcellular", "ANATOMY", 173, 184], ["mitochondria", "ANATOMY", 275, 287], ["Mitotracker green", "CHEMICAL", 248, 265], ["Mitotracker green", "CHEMICAL", 248, 265], ["Mitotracker", "SIMPLE_CHEMICAL", 248, 259], ["mitochondria", "CELLULAR_COMPONENT", 275, 287], ["why dimers", "PROBLEM", 19, 29], ["fluorescence microscopy", "TEST", 217, 240]]], ["As expected, mRFP-TMD Bcl-XL localized to mitochondria, mRFP-TMD VAMP2 localized to membranes and mRFP distributed evenly throughout the cell (Fig. 4A) .kDa) in lanes 3 and 4 ofThe TMD of Bcl-XL fused to yellow fluorescent protein has been reported to alter mitochondrial morphology and to moderately protect cells against staurosporine-induced apoptosis [29] .", [["mitochondria", "ANATOMY", 42, 54], ["membranes", "ANATOMY", 84, 93], ["cell", "ANATOMY", 137, 141], ["mitochondrial", "ANATOMY", 258, 271], ["cells", "ANATOMY", 309, 314], ["staurosporine", "CHEMICAL", 323, 336], ["staurosporine", "CHEMICAL", 323, 336], ["mRFP-TMD Bcl-XL", "GENE_OR_GENE_PRODUCT", 13, 28], ["mitochondria", "CELLULAR_COMPONENT", 42, 54], ["mRFP-TMD VAMP2", "GENE_OR_GENE_PRODUCT", 56, 70], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["mRFP", "GENE_OR_GENE_PRODUCT", 98, 102], ["cell", "CELL", 137, 141], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 188, 194], ["yellow fluorescent protein", "GENE_OR_GENE_PRODUCT", 204, 230], ["mitochondrial", "CELLULAR_COMPONENT", 258, 271], ["cells", "CELL", 309, 314], ["staurosporine", "SIMPLE_CHEMICAL", 323, 336], ["mRFP", "PROTEIN", 13, 17], ["TMD Bcl-XL", "PROTEIN", 18, 28], ["mRFP", "PROTEIN", 56, 60], ["TMD VAMP2", "PROTEIN", 61, 70], ["mRFP", "PROTEIN", 98, 102], [".kDa", "PROTEIN", 152, 156], ["Bcl", "PROTEIN", 188, 191], ["XL", "PROTEIN", 192, 194], ["yellow fluorescent protein", "PROTEIN", 204, 230], ["mRFP", "TEST", 13, 17], ["TMD", "PROBLEM", 18, 21], ["mitochondria", "TEST", 42, 54], ["mRFP", "TEST", 56, 60], ["TMD VAMP2", "PROBLEM", 61, 70], ["mRFP", "PROBLEM", 98, 102], ["Bcl", "TEST", 188, 191], ["yellow fluorescent protein", "PROBLEM", 204, 230], ["staurosporine", "TEST", 323, 336]]], ["In order to find out if our mRFP-TMD Bcl-XL chimera also protected cells against camptothecin-induced cell death we carried out cell viability assays using XTT, which were later confirmed by trypan blue exclusion assays.", [["cells", "ANATOMY", 67, 72], ["cell", "ANATOMY", 102, 106], ["cell", "ANATOMY", 128, 132], ["camptothecin", "CHEMICAL", 81, 93], ["XTT", "CHEMICAL", 156, 159], ["trypan blue", "CHEMICAL", 191, 202], ["camptothecin", "CHEMICAL", 81, 93], ["XTT", "CHEMICAL", 156, 159], ["trypan blue", "CHEMICAL", 191, 202], ["mRFP", "GENE_OR_GENE_PRODUCT", 28, 32], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 37, 43], ["cells", "CELL", 67, 72], ["camptothecin", "SIMPLE_CHEMICAL", 81, 93], ["cell", "CELL", 102, 106], ["cell", "CELL", 128, 132], ["XTT", "SIMPLE_CHEMICAL", 156, 159], ["trypan blue", "SIMPLE_CHEMICAL", 191, 202], ["mRFP", "PROTEIN", 28, 32], ["TMD Bcl-XL chimera", "PROTEIN", 33, 51], ["our mRFP", "TEST", 24, 32], ["TMD Bcl", "TEST", 33, 40], ["XL chimera", "TREATMENT", 41, 51], ["camptothecin", "PROBLEM", 81, 93], ["induced cell death", "PROBLEM", 94, 112], ["cell viability assays", "TEST", 128, 149], ["XTT", "TEST", 156, 159]]], ["The results, shown in Fig 5, clearly indicated that the TMD of Bcl-XL fused to mRFP protected cells from death, whereas the TMD of VAMP2 fused to mRFP or mRFP alone did not.kDa) in lanes 3 and 4 ofSince Bcl-XL can prevent Bax and Bak oligomerization, we analyzed the state of oligomerization of these two proapoptotic proteins upon transfection of cells with mRFP chimeras and induction of apoptosis with camptothecin.", [["cells", "ANATOMY", 94, 99], ["cells", "ANATOMY", 348, 353], ["Bcl-XL", "CHEMICAL", 63, 69], ["death", "DISEASE", 105, 110], ["camptothecin", "CHEMICAL", 405, 417], ["camptothecin", "CHEMICAL", 405, 417], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 63, 69], ["mRFP", "GENE_OR_GENE_PRODUCT", 79, 83], ["cells", "CELL", 94, 99], ["VAMP2", "GENE_OR_GENE_PRODUCT", 131, 136], ["mRFP", "GENE_OR_GENE_PRODUCT", 146, 150], ["mRFP", "GENE_OR_GENE_PRODUCT", 154, 158], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 203, 209], ["Bax", "GENE_OR_GENE_PRODUCT", 222, 225], ["Bak", "GENE_OR_GENE_PRODUCT", 230, 233], ["cells", "CELL", 348, 353], ["mRFP", "GENE_OR_GENE_PRODUCT", 359, 363], ["camptothecin", "SIMPLE_CHEMICAL", 405, 417], ["Bcl", "PROTEIN", 63, 66], ["mRFP", "PROTEIN", 79, 83], ["VAMP2", "PROTEIN", 131, 136], ["mRFP", "PROTEIN", 146, 150], ["mRFP", "PROTEIN", 154, 158], [".kDa", "PROTEIN", 172, 176], ["Bax", "PROTEIN", 222, 225], ["Bak", "PROTEIN", 230, 233], ["proapoptotic proteins", "PROTEIN", 305, 326], ["mRFP chimeras", "PROTEIN", 359, 372], ["Bcl", "TEST", 63, 66], ["death", "PROBLEM", 105, 110], ["the TMD of VAMP2", "PROBLEM", 120, 136], ["mRFP", "TEST", 146, 150], ["Bcl-XL", "TREATMENT", 203, 209], ["Bax", "PROBLEM", 222, 225], ["Bak oligomerization", "PROBLEM", 230, 249], ["transfection of cells", "TREATMENT", 332, 353], ["mRFP chimeras", "TREATMENT", 359, 372], ["apoptosis", "PROBLEM", 390, 399], ["camptothecin", "TREATMENT", 405, 417], ["Bak oligomerization", "OBSERVATION", 230, 249]]], ["We did not see any effect on Bax and Bak oligomerization in cells transfected with either mRFP-TMD Bcl-XL, mRFP-TMD VAMP2 or mRFP alone (Fig 6) .kDa) in lanes 3 and 4 ofEven though Bcl-XL is able to dimerize in absence of its TMD under some conditions, we analyzed how the absence of its TMD Fig. 4 (continued) or the presence of a TMD from an unrelated protein affected its dimerization.", [["cells", "ANATOMY", 60, 65], ["TMD", "DISEASE", 332, 335], ["Bax", "GENE_OR_GENE_PRODUCT", 29, 32], ["Bak", "GENE_OR_GENE_PRODUCT", 37, 40], ["cells", "CELL", 60, 65], ["mRFP-TMD Bcl-XL", "GENE_OR_GENE_PRODUCT", 90, 105], ["mRFP-TMD VAMP2", "GENE_OR_GENE_PRODUCT", 107, 121], ["mRFP", "GENE_OR_GENE_PRODUCT", 125, 129], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 181, 187], ["TMD Fig. 4", "GENE_OR_GENE_PRODUCT", 288, 298], ["Bax", "PROTEIN", 29, 32], ["Bak", "PROTEIN", 37, 40], ["mRFP", "PROTEIN", 90, 94], ["TMD Bcl-XL", "PROTEIN", 95, 105], ["mRFP", "PROTEIN", 107, 111], ["TMD VAMP2", "PROTEIN", 112, 121], ["mRFP alone (Fig 6) .kDa", "PROTEIN", 125, 148], ["Bcl", "PROTEIN", 181, 184], ["XL", "PROTEIN", 185, 187], ["TMD Fig. 4", "PROTEIN", 288, 298], ["Bax", "TREATMENT", 29, 32], ["Bak oligomerization in cells", "TREATMENT", 37, 65], ["mRFP", "TEST", 90, 94], ["TMD Bcl-XL", "PROBLEM", 95, 105], ["mRFP", "TEST", 107, 111], ["TMD VAMP2", "PROBLEM", 112, 121], ["mRFP", "PROBLEM", 125, 129], ["Bcl", "TEST", 181, 184], ["its TMD", "PROBLEM", 222, 229], ["a TMD", "PROBLEM", 330, 335], ["an unrelated protein affected its dimerization", "PROBLEM", 341, 387]]], ["For this, we constructed a new vector to express Bcl-XL without its TMD, as well as another vector encoding Bcl-XL with its TMD replaced by the second TMD of Pit 2, a plasma membrane sodium transporter [30] .", [["plasma membrane", "ANATOMY", 167, 182], ["sodium", "CHEMICAL", 183, 189], ["sodium", "CHEMICAL", 183, 189], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 49, 55], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 108, 114], ["Pit 2", "GENE_OR_GENE_PRODUCT", 158, 163], ["plasma membrane", "CELLULAR_COMPONENT", 167, 182], ["sodium", "SIMPLE_CHEMICAL", 183, 189], ["Bcl-XL", "PROTEIN", 49, 55], ["Bcl", "PROTEIN", 108, 111], ["Pit 2", "PROTEIN", 158, 163], ["plasma membrane sodium transporter", "PROTEIN", 167, 201], ["its TMD", "PROBLEM", 64, 71], ["another vector encoding Bcl", "TREATMENT", 84, 111], ["its TMD", "PROBLEM", 120, 127], ["a plasma membrane sodium transporter", "TREATMENT", 165, 201]]], ["We expressed these constructs in cells and carried out crosslinking assays using BSOCOES.", [["cells", "ANATOMY", 33, 38], ["cells", "CELL", 33, 38], ["these constructs in cells", "PROBLEM", 13, 38]]], ["Under these conditions, we could detect dimers of full-length Bcl-XL (Fig 7, lane 2) and no dimers of Bcl-XL lacking its TMD (Fig 7, lane 4) .", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 62, 68], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 102, 108], ["Bcl-XL", "PROTEIN", 62, 68], ["Fig 7, lane 2", "PROTEIN", 70, 83], ["Bcl-XL", "PROTEIN", 102, 108], ["TMD", "PROTEIN", 121, 124], ["lane 4", "PROTEIN", 133, 139], ["full-length Bcl-XL", "TREATMENT", 50, 68], ["Fig", "TEST", 70, 73], ["Bcl-XL", "TREATMENT", 102, 108]]], ["Curiously, Bcl-XL with its TMD replaced by the second TMD of Pit2 was also able to dimerize (Fig 7, lane 6) .kDa) in lanes 3 and 4 ofAnalysis of the sequences of the TMD of Bcl-XL and the second TMD of Pit 2 revealed the presence of the sequence motif GXXXXG (where G is glycine and X, any amino acid), in tandem in Bcl-XL (GMTVAGVVLLG) and alone in the TMD of Pit2 (GSVLLG).", [["glycine", "CHEMICAL", 271, 278], ["amino acid", "CHEMICAL", 290, 300], ["glycine", "CHEMICAL", 271, 278], ["amino acid", "CHEMICAL", 290, 300], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 11, 17], ["Pit2", "GENE_OR_GENE_PRODUCT", 61, 65], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 173, 179], ["Pit 2", "GENE_OR_GENE_PRODUCT", 202, 207], ["glycine", "AMINO_ACID", 271, 278], ["amino acid", "AMINO_ACID", 290, 300], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 316, 322], ["Pit2", "GENE_OR_GENE_PRODUCT", 361, 365], ["Bcl", "PROTEIN", 11, 14], ["Pit2", "PROTEIN", 61, 65], ["Fig 7, lane 6) .kDa", "PROTEIN", 93, 112], ["Bcl", "PROTEIN", 173, 176], ["Pit 2", "PROTEIN", 202, 207], ["Bcl-XL", "PROTEIN", 316, 322], ["GMTVAGVVLLG", "PROTEIN", 324, 335], ["TMD", "PROTEIN", 354, 357], ["Pit2", "PROTEIN", 361, 365], ["GSVLLG", "PROTEIN", 367, 373], ["its TMD", "PROBLEM", 23, 30], ["the second TMD of Pit2", "TREATMENT", 43, 65], ["Bcl", "TEST", 173, 176], ["the second TMD of Pit", "TEST", 184, 205], ["the sequence motif GXXXXG", "TEST", 233, 258], ["any amino acid", "TREATMENT", 286, 300]]], ["Note that five out of six amino acids are conserved between sequence GVVLLG in Bcl-Xl and sequence GSVLLG in the second TMD of Pit2.", [["amino acids", "CHEMICAL", 26, 37], ["amino acids", "CHEMICAL", 26, 37], ["amino acids", "AMINO_ACID", 26, 37], ["Bcl-Xl", "GENE_OR_GENE_PRODUCT", 79, 85], ["Pit2", "GENE_OR_GENE_PRODUCT", 127, 131], ["Bcl", "PROTEIN", 79, 82], ["Xl", "PROTEIN", 83, 85], ["GSVLLG", "PROTEIN", 99, 105], ["Pit2", "PROTEIN", 127, 131], ["six amino acids", "TREATMENT", 22, 37], ["sequence GVVLLG", "TEST", 60, 75], ["Bcl", "TEST", 79, 82], ["sequence GSVLLG", "TEST", 90, 105], ["the second TMD of Pit2", "TREATMENT", 109, 131]]], ["Since the sequence motif GXXXG had been reported to be involved in dimerization of the BH3-only Bcl-2 family member BNIP3 through its TMD, and also in other proteins [31] [32] [33] [34] [35] [36] [37] [38] , which is very similar to the motifs found in the TMD of Bcl-XL and the second TMD of Pit2, we constructed a new vector where the TMD of Bcl-XL was replaced by the third TMD of Pit2, which lacks sequence GXXXXG.", [["Bcl-XL", "CHEMICAL", 344, 350], ["GXXXG", "GENE_OR_GENE_PRODUCT", 25, 30], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 96, 101], ["BNIP3", "GENE_OR_GENE_PRODUCT", 116, 121], ["[31] [32] [33] [34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 166, 205], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 264, 270], ["Pit2", "GENE_OR_GENE_PRODUCT", 293, 297], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 344, 350], ["Pit2", "GENE_OR_GENE_PRODUCT", 384, 388], ["GXXXXG", "GENE_OR_GENE_PRODUCT", 411, 417], ["GXXXG", "PROTEIN", 25, 30], ["BH3", "PROTEIN", 87, 90], ["Bcl-2 family member", "PROTEIN", 96, 115], ["BNIP3", "PROTEIN", 116, 121], ["TMD", "PROTEIN", 134, 137], ["Bcl", "PROTEIN", 264, 267], ["Pit2", "PROTEIN", 293, 297], ["Bcl", "PROTEIN", 344, 347], ["Pit2", "PROTEIN", 384, 388], ["GXXXXG", "PROTEIN", 411, 417], ["the sequence motif GXXXG", "TEST", 6, 30], ["the BH3", "TEST", 83, 90], ["Bcl", "TEST", 96, 99], ["the TMD of Bcl-XL", "TREATMENT", 333, 350]]], ["Crosslinking assays with this new chimera indicated that it was unable to dimerize (Fig 7, lane 8) .kDa) in lanes 3 and 4 ofWe analyzed the subcellular localization of these chimeras, with myc-BclXL localizing to mitochondria as expected and the remaining chimeras showing a diffuse localization in the cell (Fig 4B) .", [["subcellular", "ANATOMY", 140, 151], ["chimeras", "ANATOMY", 174, 182], ["mitochondria", "ANATOMY", 213, 225], ["cell", "ANATOMY", 303, 307], ["myc-BclXL", "GENE_OR_GENE_PRODUCT", 189, 198], ["mitochondria", "CELLULAR_COMPONENT", 213, 225], ["cell", "CELL", 303, 307], [".kDa", "PROTEIN", 99, 103], ["lanes 3 and 4 ofWe", "PROTEIN", 108, 126], ["myc-BclXL", "PROTEIN", 189, 198], ["Crosslinking assays", "TEST", 0, 19], ["this new chimera", "PROBLEM", 25, 41], ["a diffuse localization in the cell", "PROBLEM", 273, 307], ["diffuse", "OBSERVATION_MODIFIER", 275, 282]]], ["This also indicates that sequences involved in dimerization and mitochondrial targeting within the TMD of Bcl-XL are different, since the second TMD of Pit2 is able to induce oligomerization but not mitochondrial localization.DiscussionWe have shown that the transmembrane C-terminal domain of Bcl-XL can directly participate in oligomerization.", [["mitochondrial", "ANATOMY", 64, 77], ["mitochondrial", "ANATOMY", 199, 212], ["transmembrane", "ANATOMY", 259, 272], ["C", "CHEMICAL", 273, 274], ["mitochondrial", "CELLULAR_COMPONENT", 64, 77], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 106, 112], ["Pit2", "GENE_OR_GENE_PRODUCT", 152, 156], ["mitochondrial", "CELLULAR_COMPONENT", 199, 212], ["transmembrane", "CELLULAR_COMPONENT", 259, 272], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 294, 300], ["Bcl", "PROTEIN", 106, 109], ["Pit2", "PROTEIN", 152, 156], ["transmembrane C-terminal domain", "PROTEIN", 259, 290], ["Bcl", "PROTEIN", 294, 297], ["XL", "PROTEIN", 298, 300], ["the second TMD of Pit2", "TREATMENT", 134, 156], ["the transmembrane C", "TEST", 255, 274], ["Bcl-XL", "TREATMENT", 294, 300]]], ["This is a mode of self-association unreported for Bcl-XL.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 50, 56], ["Bcl", "PROTEIN", 50, 53]]], ["Bcl-2 family members control their activities through a complex network of protein-protein interactions, posttranslational modifications, transcriptional control or protein degradation [11] .", [["Bcl-2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Bcl-2 family members", "PROTEIN", 0, 20], ["Bcl", "TEST", 0, 3], ["protein-protein interactions", "TREATMENT", 75, 103], ["posttranslational modifications", "TREATMENT", 105, 136], ["transcriptional control", "TREATMENT", 138, 161]]], ["Conformational changes induced upon heteromeric or homomeric protein interactions are very important for their activities.DiscussionBcl-XL has been shown to dimerize by different mechanisms under several conditions [12] [13] [14] [15] [16] [17] .", [["DiscussionBcl-XL", "CHEMICAL", 122, 138], ["DiscussionBcl-XL", "GENE_OR_GENE_PRODUCT", 122, 138], ["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 215, 244], ["Conformational changes", "PROBLEM", 0, 22], ["homomeric protein interactions", "PROBLEM", 51, 81]]], ["Many of these studies, as well as structural studies, used Bcl-XL mutants lacking the C-terminal TMD under non-physiological assay conditions, although its presence is likely to affect the overall fold of the protein, conformational changes and protein interactions.DiscussionBcl-XL has been reported to regulate apoptosis by heterodimerization-dependent and -independent mechanisms.", [["DiscussionBcl-XL", "CHEMICAL", 266, 282], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 59, 65], ["DiscussionBcl-XL", "GENE_OR_GENE_PRODUCT", 266, 282], ["Bcl", "PROTEIN", 59, 62], ["C-terminal TMD", "PROTEIN", 86, 100], ["these studies", "TEST", 8, 21], ["structural studies", "TEST", 34, 52], ["Bcl-XL mutants", "TREATMENT", 59, 73], ["the C-terminal TMD", "PROBLEM", 82, 100], ["non-physiological assay conditions", "TEST", 107, 141], ["conformational changes and protein interactions", "PROBLEM", 218, 265]]], ["The former implies binding to pro-apoptotic proteins; the latter, could depend, at least in part, on the formation of an ion channel that can counteract the effects of MOM permeabilization by proteins like Bax or Bak [39] .", [["MOM", "SIMPLE_CHEMICAL", 168, 171], ["Bax", "GENE_OR_GENE_PRODUCT", 206, 209], ["Bak", "GENE_OR_GENE_PRODUCT", 213, 216], ["pro-apoptotic proteins", "PROTEIN", 30, 52], ["Bax", "PROTEIN", 206, 209], ["Bak", "PROTEIN", 213, 216], ["pro-apoptotic proteins", "PROBLEM", 30, 52], ["an ion channel", "TREATMENT", 118, 132], ["MOM permeabilization", "TREATMENT", 168, 188]]], ["Interestingly, C-terminal cleavage products of Bcl-XL can form a pore large enough to allow cytochrome c release [40] , changing a pro-survival protein into a pro-apoptotic one, what has been also described for Bcl-2 upon binding of a Nur77-derived peptide [41] .", [["pore", "ANATOMY", 65, 69], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 47, 53], ["cytochrome c", "GENE_OR_GENE_PRODUCT", 92, 104], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 211, 216], ["Nur77", "GENE_OR_GENE_PRODUCT", 235, 240], ["C-terminal cleavage products", "PROTEIN", 15, 43], ["Bcl", "PROTEIN", 47, 50], ["XL", "PROTEIN", 51, 53], ["cytochrome c", "PROTEIN", 92, 104], ["pro-survival protein", "PROTEIN", 131, 151], ["Bcl-2", "PROTEIN", 211, 216], ["Nur77", "PROTEIN", 235, 240], ["C-terminal cleavage products", "TREATMENT", 15, 43], ["Bcl-XL", "TREATMENT", 47, 53], ["a pore", "PROBLEM", 63, 69], ["cytochrome c release", "TREATMENT", 92, 112], ["a pro-survival protein", "TREATMENT", 129, 151], ["Bcl", "TEST", 211, 214]]], ["Zheng et al. [29] reported changes in mitochondrial morphology and protection against apoptosis mediated by a YFP-TM Bcl-XL fusion protein, suggesting that this TMD could be required for a bioenergetic function of Bcl-XL distinct from BH3 domain sequestration.", [["mitochondrial", "ANATOMY", 38, 51], ["mitochondrial", "CELLULAR_COMPONENT", 38, 51], ["YFP", "GENE_OR_GENE_PRODUCT", 110, 113], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 117, 123], ["TMD", "GENE_OR_GENE_PRODUCT", 161, 164], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 214, 220], ["YFP", "PROTEIN", 110, 113], ["TM Bcl-XL fusion protein", "PROTEIN", 114, 138], ["Bcl-XL", "PROTEIN", 214, 220], ["BH3 domain", "PROTEIN", 235, 245], ["changes in mitochondrial morphology", "PROBLEM", 27, 62], ["apoptosis", "PROBLEM", 86, 95], ["a YFP", "TEST", 108, 113], ["TM Bcl", "TEST", 114, 120], ["XL fusion protein", "TREATMENT", 121, 138], ["this TMD", "PROBLEM", 156, 164], ["Bcl-XL", "PROBLEM", 214, 220], ["BH3 domain sequestration", "PROBLEM", 235, 259], ["BH3 domain sequestration", "OBSERVATION", 235, 259]]], ["Our results suggest that oligomerization mediated by the TMD of Bcl-XL could be involved in these activities.DiscussionThe TM domains of other Bcl-2 family members have been also reported to be involved in protein dimerization, like the TMD of BH3-only protein BNIP3 [37] or the TMD of Bax [42] .", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 64, 70], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 143, 148], ["BNIP3 [37]", "GENE_OR_GENE_PRODUCT", 261, 271], ["Bax", "GENE_OR_GENE_PRODUCT", 286, 289], ["Bcl", "PROTEIN", 64, 67], ["TM domains", "PROTEIN", 123, 133], ["Bcl-2 family members", "PROTEIN", 143, 163], ["BH3", "PROTEIN", 244, 247], ["BNIP3", "PROTEIN", 261, 266], ["Bax", "PROTEIN", 286, 289], ["Bcl-XL", "TREATMENT", 64, 70], ["BH3", "TEST", 244, 247], ["protein BNIP3", "TEST", 253, 266], ["the TMD of Bax", "TEST", 275, 289]]], ["In the case of BNIP3, the sequence GXXXG has been shown to directly participate in dimerization.", [["BNIP3", "GENE_OR_GENE_PRODUCT", 15, 20], ["GXXXG", "GENE_OR_GENE_PRODUCT", 35, 40], ["BNIP3", "PROTEIN", 15, 20], ["GXXXG", "PROTEIN", 35, 40], ["the sequence GXXXG", "TEST", 22, 40]]], ["Interestingly, a similar sequence is present in the TMD of Bcl-XL, but in tandem (GMTVAGVVLLG: GMTVAG and GVVLLG), with one more amino acid between the two glycines (GXXXXG).", [["amino acid", "CHEMICAL", 129, 139], ["amino acid", "CHEMICAL", 129, 139], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 59, 65], ["amino acid", "AMINO_ACID", 129, 139], ["Bcl", "PROTEIN", 59, 62], ["GXXXXG", "PROTEIN", 166, 172], ["XL", "ANATOMY", 63, 65]]], ["The presence of sequence GXXXG in tandem had been previously described in other proteins [35, 38] .", [["GXXXG", "GENE_OR_GENE_PRODUCT", 25, 30], ["GXXXG", "DNA", 25, 30], ["sequence GXXXG in tandem", "PROBLEM", 16, 40]]], ["Curiously, a very similar sequence containing that motif is also present in the second TMD of Pit2 (GSVLLG), which we used to replace the TMD of BclXL expecting to block dimerization (before we analyzed the TMD sequences), and Bcl-XL with that TMD also dimerizes.", [["Pit2", "GENE_OR_GENE_PRODUCT", 94, 98], ["BclXL", "GENE_OR_GENE_PRODUCT", 145, 150], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 227, 233], ["Pit2", "PROTEIN", 94, 98], ["GSVLLG", "PROTEIN", 100, 106], ["BclXL", "PROTEIN", 145, 150], ["TMD sequences", "PROTEIN", 207, 220], ["Bcl", "PROTEIN", 227, 230], ["the TMD of BclXL", "TREATMENT", 134, 150], ["block dimerization", "PROBLEM", 164, 182], ["the TMD sequences", "TEST", 203, 220], ["Bcl-XL", "TREATMENT", 227, 233]]], ["BclXL with its TMD replaced by the third TMD of Pit2, which does not contain that sequence motif, does not dimerize, strongly suggesting the importance of motif GXXXXG in dimerization.DiscussionSequence GXXXG was first reported to be involved in TMD dimerization by Engelman and coworkers [34, 43] .", [["TMD", "DISEASE", 246, 249], ["BclXL", "GENE_OR_GENE_PRODUCT", 0, 5], ["Pit2", "GENE_OR_GENE_PRODUCT", 48, 52], ["GXXXXG", "GENE_OR_GENE_PRODUCT", 161, 167], ["GXXXG", "GENE_OR_GENE_PRODUCT", 203, 208], ["BclXL", "PROTEIN", 0, 5], ["Pit2", "PROTEIN", 48, 52], ["GXXXXG", "PROTEIN", 161, 167], ["GXXXG", "DNA", 203, 208], ["its TMD", "PROBLEM", 11, 18]]], ["Furthermore, within these motifs, residues V and L are also usually present close to G residues, as is the case for the TMD of Bcl-XL and the second TMD of Pit2.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 127, 133], ["Pit2", "GENE_OR_GENE_PRODUCT", 156, 160], ["G residues", "PROTEIN", 85, 95], ["Bcl", "PROTEIN", 127, 130], ["Pit2", "PROTEIN", 156, 160], ["Bcl-XL", "TREATMENT", 127, 133], ["the second TMD of Pit2", "TREATMENT", 138, 160]]], ["Sequence specificity in the dimerization of transmembrane alpha-helices was first reported by Lemmon et al. [31] , reporting later that the pattern LIxxGVxxGVxxT is involved in dimerization [44] .", [["transmembrane", "CELLULAR_COMPONENT", 44, 57], ["LIxxGVxxGVxxT", "GENE_OR_GENE_PRODUCT", 148, 161], ["transmembrane alpha-helices", "PROTEIN", 44, 71], ["LIxxGVxxGVxxT", "PROTEIN", 148, 161], ["Sequence specificity", "TEST", 0, 20]]], ["Furthermore, the GXXXG motif has been involved in the formation of a membrane channel by the Helicobacter pylori vacuolating toxin [38] , where this motif appears in three tandem repeats.", [["membrane", "ANATOMY", 69, 77], ["GXXXG", "GENE_OR_GENE_PRODUCT", 17, 22], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["Helicobacter pylori", "ORGANISM", 93, 112], ["vacuolating toxin [38]", "GENE_OR_GENE_PRODUCT", 113, 135], ["GXXXG motif", "DNA", 17, 28], ["membrane channel", "PROTEIN", 69, 85], ["Helicobacter pylori vacuolating toxin", "PROTEIN", 93, 130], ["Helicobacter pylori", "SPECIES", 93, 112], ["Helicobacter pylori", "SPECIES", 93, 112], ["the GXXXG motif", "PROBLEM", 13, 28], ["a membrane channel", "TREATMENT", 67, 85], ["the Helicobacter pylori vacuolating toxin", "PROBLEM", 89, 130]]], ["This motif has also been found in several other proteins, like subunits e [45] and g [46] of yeast mitochondrial ATP synthase, APH-1 [47] , ABCG2 [48] , the SARS coronavirus spike protein (were it is involved in trimerization) [49] , prion protein [50] , amyloid precursor protein [51] , the two-peptide bacteriocin lactococcin G [52] , carnitine palmitoyltransferase 1A [53] , ErbB [54] , protein FliH and its Type III secretion homologue YscL [55] , the Japanese encephalitis virus precursor membrane (prM) protein [56] , the PufX polypeptide of Rhodobacter sphaeroides RC-LH1 photosynthetic complex [57] , human organic anion transporter 1 (hOAT1) [58] , VDAC1 [59] and the NS4B protein of hepatitis c virus [60] .", [["mitochondrial", "ANATOMY", 99, 112], ["ATP", "CHEMICAL", 113, 116], ["carnitine", "CHEMICAL", 337, 346], ["Japanese encephalitis", "DISEASE", 456, 477], ["hepatitis c", "DISEASE", 693, 704], ["ATP", "CHEMICAL", 113, 116], ["carnitine", "CHEMICAL", 337, 346], ["mitochondrial", "CELLULAR_COMPONENT", 99, 112], ["ATP synthase", "GENE_OR_GENE_PRODUCT", 113, 125], ["APH-1", "GENE_OR_GENE_PRODUCT", 127, 132], ["ABCG2", "GENE_OR_GENE_PRODUCT", 140, 145], ["SARS coronavirus", "ORGANISM", 157, 173], ["prion protein", "GENE_OR_GENE_PRODUCT", 234, 247], ["amyloid precursor protein", "GENE_OR_GENE_PRODUCT", 255, 280], ["lactococcin G [52", "GENE_OR_GENE_PRODUCT", 316, 333], ["carnitine palmitoyltransferase 1A", "GENE_OR_GENE_PRODUCT", 337, 370], ["ErbB", "GENE_OR_GENE_PRODUCT", 378, 382], ["FliH", "GENE_OR_GENE_PRODUCT", 398, 402], ["Type III secretion homologue YscL [55]", "GENE_OR_GENE_PRODUCT", 411, 449], ["Japanese encephalitis virus", "ORGANISM", 456, 483], ["precursor membrane (prM) protein [56]", "GENE_OR_GENE_PRODUCT", 484, 521], ["Rhodobacter sphaeroides RC-LH1 photosynthetic complex [57", "GENE_OR_GENE_PRODUCT", 548, 605], ["human organic anion transporter 1", "GENE_OR_GENE_PRODUCT", 609, 642], ["hOAT1", "GENE_OR_GENE_PRODUCT", 644, 649], ["VDAC1", "GENE_OR_GENE_PRODUCT", 658, 663], ["hepatitis c virus", "ORGANISM", 693, 710], ["yeast mitochondrial ATP synthase", "PROTEIN", 93, 125], ["ABCG2", "PROTEIN", 140, 145], ["SARS coronavirus spike protein", "PROTEIN", 157, 187], ["prion protein", "PROTEIN", 234, 247], ["amyloid precursor protein", "PROTEIN", 255, 280], ["carnitine palmitoyltransferase 1A", "PROTEIN", 337, 370], ["ErbB", "PROTEIN", 378, 382], ["protein FliH", "PROTEIN", 390, 402], ["Type III secretion homologue", "PROTEIN", 411, 439], ["YscL", "PROTEIN", 440, 444], ["Japanese encephalitis virus precursor membrane (prM) protein", "PROTEIN", 456, 516], ["PufX polypeptide", "PROTEIN", 528, 544], ["Rhodobacter sphaeroides RC-LH1 photosynthetic complex", "PROTEIN", 548, 601], ["human organic anion transporter 1", "PROTEIN", 609, 642], ["hOAT1", "PROTEIN", 644, 649], ["VDAC1", "PROTEIN", 658, 663], ["NS4B protein", "PROTEIN", 677, 689], ["yeast", "SPECIES", 93, 98], ["Japanese encephalitis virus", "SPECIES", 456, 483], ["Rhodobacter sphaeroides", "SPECIES", 548, 571], ["human", "SPECIES", 609, 614], ["hepatitis c virus", "SPECIES", 693, 710], ["yeast", "SPECIES", 93, 98], ["SARS coronavirus", "SPECIES", 157, 173], ["Japanese encephalitis virus", "SPECIES", 456, 483], ["Rhodobacter sphaeroides", "SPECIES", 548, 571], ["human", "SPECIES", 609, 614], ["hepatitis c virus", "SPECIES", 693, 710], ["yeast mitochondrial ATP synthase", "TEST", 93, 125], ["APH", "TEST", 127, 130], ["ABCG2", "TEST", 140, 145], ["the SARS coronavirus spike protein", "PROBLEM", 153, 187], ["prion protein", "TEST", 234, 247], ["amyloid precursor protein", "TEST", 255, 280], ["carnitine palmitoyltransferase 1A", "TEST", 337, 370], ["ErbB", "TEST", 378, 382], ["protein FliH", "TEST", 390, 402], ["its", "TEST", 407, 410], ["Type III secretion homologue YscL", "PROBLEM", 411, 444], ["the Japanese encephalitis virus precursor membrane", "PROBLEM", 452, 502], ["protein", "TEST", 509, 516], ["the PufX polypeptide", "TEST", 524, 544], ["Rhodobacter sphaeroides", "PROBLEM", 548, 571], ["photosynthetic complex", "TEST", 579, 601], ["human organic anion transporter", "TEST", 609, 640], ["VDAC1", "TEST", 658, 663], ["the NS4B protein", "TEST", 673, 689], ["hepatitis c virus", "PROBLEM", 693, 710]]], ["A review about some of these proteins can be seen in Senes et al. [61] .DiscussionAlthough in the TMD of Bcl-XL the two glycines are separated by four residues instead of 3 as in the GXXXG motif, our results strongly suggest that this motif is mediating interaction of Bcl-XL molecules through their TMDs, since the second TMD of Pit2, with 5 out of 6 conserved residues within that GXXXXG motif also allows dimerization of the protein, whereas the third TMD of Pit2, which lacks that motif, does not dimerize when fused to Bcl-XL.DiscussionIn summary, we have shown that the TMD of Bcl-XL is involved in protein dimerization and that motif GXXXXG is very likely responsible for this interaction.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 105, 111], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 269, 275], ["Pit2", "GENE_OR_GENE_PRODUCT", 330, 334], ["Pit2", "GENE_OR_GENE_PRODUCT", 462, 466], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 524, 530], ["Bcl-XL", "GENE_OR_GENE_PRODUCT", 583, 589], ["GXXXXG", "GENE_OR_GENE_PRODUCT", 641, 647], ["Bcl", "PROTEIN", 105, 108], ["GXXXG motif", "PROTEIN", 183, 194], ["Bcl-XL molecules", "PROTEIN", 269, 285], ["TMDs", "PROTEIN", 300, 304], ["Pit2", "PROTEIN", 330, 334], ["GXXXXG motif", "PROTEIN", 383, 395], ["Pit2", "PROTEIN", 462, 466], ["Bcl-XL", "PROTEIN", 524, 530], ["Bcl", "PROTEIN", 583, 586], ["GXXXXG", "PROTEIN", 641, 647], ["these proteins", "PROBLEM", 23, 37], ["Bcl-XL the two glycines", "TREATMENT", 105, 128], ["Bcl-XL molecules", "TREATMENT", 269, 285], ["the second TMD of Pit2", "TREATMENT", 312, 334], ["the protein", "TEST", 424, 435], ["the third TMD of Pit2", "TREATMENT", 445, 466], ["Bcl-XL", "TREATMENT", 583, 589], ["protein dimerization", "PROBLEM", 605, 625], ["motif GXXXXG", "TEST", 635, 647]]], ["This will most likely have important implications in Bcl-XL function.", [["Bcl-XL", "GENE_OR_GENE_PRODUCT", 53, 59], ["Bcl-XL", "PROTEIN", 53, 59]]]], "a9d0788fe4d705919a8be4d1172adf181a6fb107": [["I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd (\"BMJ\") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our licence.", [["CC", "CHEMICAL", 284, 286], ["right", "ANATOMY_MODIFIER", 33, 38]]]], "PMC5634334": [["IntroductionCoronaviruses (CoVs) are enveloped, positive-stranded RNA viruses that cause mild to severe infections in a wide range of mammals and birds.", [["infections", "DISEASE", 104, 114], ["IntroductionCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 25], ["CoVs", "GENE_OR_GENE_PRODUCT", 27, 31], ["birds", "ORGANISM", 146, 151], ["CoVs", "PROTEIN", 27, 31], ["IntroductionCoronaviruses (CoVs)", "PROBLEM", 0, 32], ["stranded RNA viruses", "PROBLEM", 57, 77], ["mild to severe infections", "PROBLEM", 89, 114], ["stranded RNA viruses", "OBSERVATION", 57, 77], ["mild", "OBSERVATION_MODIFIER", 89, 93], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["infections", "OBSERVATION", 104, 114], ["wide range", "OBSERVATION_MODIFIER", 120, 130]]], ["Specifically, severe acute and Middle East respiratory syndrome CoVs (SARS-CoV and MERS-CoV) are well-recognized viral pathogens that have emerged from different animal reservoirs to cause deadly disease in humans.", [["Middle East respiratory syndrome CoVs", "DISEASE", 31, 68], ["SARS", "DISEASE", 70, 74], ["SARS-CoV", "ORGANISM", 70, 78], ["MERS-CoV", "ORGANISM", 83, 91], ["humans", "ORGANISM", 207, 213], ["humans", "SPECIES", 207, 213], ["Middle East respiratory syndrome CoVs", "SPECIES", 31, 68], ["SARS-CoV", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 83, 91], ["humans", "SPECIES", 207, 213], ["severe acute and Middle East respiratory syndrome CoVs", "PROBLEM", 14, 68], ["viral pathogens", "PROBLEM", 113, 128], ["deadly disease in humans", "PROBLEM", 189, 213], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["acute", "OBSERVATION_MODIFIER", 21, 26], ["Middle", "ANATOMY_MODIFIER", 31, 37], ["respiratory syndrome", "OBSERVATION", 43, 63], ["viral pathogens", "OBSERVATION", 113, 128]]], ["SARS-CoV first emerged in 2002 with a case fatality rate of 10%, claiming the lives of over 800 people and infecting more than 8000 [1], [2].", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["people", "ORGANISM", 96, 102], ["people", "SPECIES", 96, 102], ["SARS-CoV", "SPECIES", 0, 8]]], ["After 10 years, MERS-CoV emerged with a shocking case fatality rate of nearly 35% and has spread to 27 different countries to date [3].", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["MERS-CoV", "SPECIES", 16, 24], ["fatality rate", "TEST", 54, 67]]], ["The continuing threat of MERS-CoV was recently underscored by one of its most recent outbreaks in Republic of Korea.", [["MERS-CoV", "ORGANISM", 25, 33], ["MERS-CoV", "SPECIES", 25, 33], ["MERS-CoV", "PROBLEM", 25, 33], ["MERS", "OBSERVATION", 25, 29]]], ["This outbreak quickly led to 36 deaths, which has brought the total MERS-CoV global deaths to over 600 [4], [5].IntroductionSimilar to other positive-stranded RNA viruses, CoVs encode two types of cysteine proteases, including the papain-like protease [(PLP) for viruses that have more than one papain-like protease (PLpro)] and 3C-like protease, also known as the main protease.", [["deaths", "DISEASE", 32, 38], ["deaths", "DISEASE", 84, 90], ["cysteine", "CHEMICAL", 197, 205], ["CoVs", "GENE_OR_GENE_PRODUCT", 172, 176], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 231, 251], ["PLP", "GENE_OR_GENE_PRODUCT", 254, 257], ["papain-like protease", "GENE_OR_GENE_PRODUCT", 295, 315], ["PLpro", "GENE_OR_GENE_PRODUCT", 317, 322], ["3C-like protease", "GENE_OR_GENE_PRODUCT", 329, 345], ["CoVs", "PROTEIN", 172, 176], ["cysteine proteases", "PROTEIN", 197, 215], ["papain-like protease", "PROTEIN", 231, 251], ["PLP", "PROTEIN", 254, 257], ["papain-like protease", "PROTEIN", 295, 315], ["PLpro", "PROTEIN", 317, 322], ["3C", "PROTEIN", 329, 331], ["protease", "PROTEIN", 337, 345], ["protease", "PROTEIN", 370, 378], ["stranded RNA viruses", "PROBLEM", 150, 170], ["cysteine proteases", "TREATMENT", 197, 215], ["the papain", "TREATMENT", 227, 237], ["protease [(PLP)", "TREATMENT", 243, 258], ["viruses", "PROBLEM", 263, 270], ["protease (PLpro)", "TREATMENT", 307, 323], ["3C-like protease", "TREATMENT", 329, 345], ["stranded RNA viruses", "OBSERVATION", 150, 170]]], ["Together, these enzymes cleave the viral polyprotein into 16 different nonstructural proteins (Nsps 1\u201316) in order to generate the membrane-bound replicase complex for RNA replication [6], [7], [8], [9].", [["membrane", "ANATOMY", 131, 139], ["Nsps 1\u201316", "GENE_OR_GENE_PRODUCT", 95, 104], ["membrane", "CELLULAR_COMPONENT", 131, 139], ["[7]", "SIMPLE_CHEMICAL", 189, 192], ["[8]", "SIMPLE_CHEMICAL", 194, 197], ["enzymes", "PROTEIN", 16, 23], ["viral polyprotein", "PROTEIN", 35, 52], ["nonstructural proteins", "PROTEIN", 71, 93], ["Nsps 1\u201316", "PROTEIN", 95, 104], ["membrane-bound replicase complex", "PROTEIN", 131, 163], ["these enzymes", "TEST", 10, 23], ["the viral polyprotein", "TEST", 31, 52], ["Nsps", "TEST", 95, 99], ["the membrane-bound replicase complex", "TREATMENT", 127, 163], ["RNA replication", "TREATMENT", 168, 183], ["viral polyprotein", "OBSERVATION", 35, 52]]], ["CoVs encode either a single PLP, termed PLpro, or two PLPs that process a total of three cleavage sites within the polyprotein [7], [10].", [["PLP", "CHEMICAL", 28, 31], ["CoVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["PLP", "GENE_OR_GENE_PRODUCT", 28, 31], ["PLpro", "GENE_OR_GENE_PRODUCT", 40, 45], ["PLPs", "GENE_OR_GENE_PRODUCT", 54, 58], ["CoVs", "PROTEIN", 0, 4], ["PLP", "PROTEIN", 28, 31], ["PLpro", "PROTEIN", 40, 45], ["PLPs", "PROTEIN", 54, 58], ["cleavage sites", "PROTEIN", 89, 103], ["a single PLP", "TREATMENT", 19, 31], ["PLpro", "TREATMENT", 40, 45], ["three cleavage sites", "TREATMENT", 83, 103]]], ["For instance, SARS-CoV and MERS-CoV encode a single PLpro, while other CoVs such as mouse hepatitis virus (MHV) encode for both the PLP1 and PLP2 (Fig. 1a).IntroductionBeyond cleaving the viral polyprotein, PLPs have additional activities that promote virus replication.", [["hepatitis virus", "DISEASE", 90, 105], ["SARS-CoV", "ORGANISM", 14, 22], ["MERS-CoV", "ORGANISM", 27, 35], ["PLpro", "GENE_OR_GENE_PRODUCT", 52, 57], ["CoVs", "GENE_OR_GENE_PRODUCT", 71, 75], ["mouse hepatitis virus", "ORGANISM", 84, 105], ["MHV", "ORGANISM", 107, 110], ["PLP1", "GENE_OR_GENE_PRODUCT", 132, 136], ["PLP2", "GENE_OR_GENE_PRODUCT", 141, 145], ["Fig. 1a", "GENE_OR_GENE_PRODUCT", 147, 154], ["PLPs", "GENE_OR_GENE_PRODUCT", 207, 211], ["SARS-CoV and MERS-CoV", "DNA", 14, 35], ["PLpro", "DNA", 52, 57], ["CoVs", "DNA", 71, 75], ["PLP1", "PROTEIN", 132, 136], ["PLP2", "PROTEIN", 141, 145], ["Fig. 1a", "PROTEIN", 147, 154], ["PLPs", "PROTEIN", 207, 211], ["mouse", "SPECIES", 84, 89], ["hepatitis virus", "SPECIES", 90, 105], ["SARS-CoV", "SPECIES", 14, 22], ["MERS-CoV", "SPECIES", 27, 35], ["mouse hepatitis virus", "SPECIES", 84, 105], ["MHV", "SPECIES", 107, 110], ["SARS", "PROBLEM", 14, 18], ["a single PLpro", "TREATMENT", 43, 57], ["other CoVs", "PROBLEM", 65, 75], ["mouse hepatitis virus", "PROBLEM", 84, 105], ["the PLP1", "TEST", 128, 136], ["Introduction", "TREATMENT", 156, 168], ["the viral polyprotein", "TREATMENT", 184, 205], ["PLPs", "TREATMENT", 207, 211], ["virus replication", "TREATMENT", 252, 269], ["viral polyprotein", "OBSERVATION", 188, 205]]], ["The X-ray structure of the first CoV PLP determined from SARS revealed that these enzymes resemble the structure of human ubiquitin (Ub)-specific proteases (USPs) and are thereby known as viral USPs, often acting as deubiquitinating enzymes (DUBs) with the ability to remove the post-translational modification Ub from target proteins [8].", [["SARS", "DISEASE", 57, 61], ["PLP", "CHEMICAL", 37, 40], ["CoV", "ORGANISM", 33, 36], ["PLP", "GENE_OR_GENE_PRODUCT", 37, 40], ["human", "ORGANISM", 116, 121], ["ubiquitin (Ub)-specific proteases", "GENE_OR_GENE_PRODUCT", 122, 155], ["USPs", "GENE_OR_GENE_PRODUCT", 157, 161], ["USPs", "GENE_OR_GENE_PRODUCT", 194, 198], ["DUBs", "GENE_OR_GENE_PRODUCT", 242, 246], ["Ub", "GENE_OR_GENE_PRODUCT", 311, 313], ["CoV PLP", "PROTEIN", 33, 40], ["enzymes", "PROTEIN", 82, 89], ["human ubiquitin (Ub)-specific proteases", "PROTEIN", 116, 155], ["USPs", "PROTEIN", 157, 161], ["viral USPs", "PROTEIN", 188, 198], ["deubiquitinating enzymes", "PROTEIN", 216, 240], ["DUBs", "PROTEIN", 242, 246], ["Ub", "PROTEIN", 311, 313], ["target proteins", "PROTEIN", 319, 334], ["human", "SPECIES", 116, 121], ["human", "SPECIES", 116, 121], ["The X-ray structure", "TEST", 0, 19], ["the first CoV PLP", "TEST", 23, 40], ["SARS", "PROBLEM", 57, 61], ["these enzymes", "TEST", 76, 89], ["viral USPs", "PROBLEM", 188, 198]]], ["Some PLPs are also deISGylating enzymes with the ability to reverse the post-translational modification of the Ub-like (Ubl) protein interferon-stimulated gene product 15 (ISG15) from cellular proteins [11].", [["cellular", "ANATOMY", 184, 192], ["PLPs", "GENE_OR_GENE_PRODUCT", 5, 9], ["Ub", "GENE_OR_GENE_PRODUCT", 111, 113], ["interferon-stimulated gene product 15", "GENE_OR_GENE_PRODUCT", 133, 170], ["ISG15", "GENE_OR_GENE_PRODUCT", 172, 177], ["cellular", "CELL", 184, 192], ["PLPs", "PROTEIN", 5, 9], ["deISGylating enzymes", "PROTEIN", 19, 39], ["Ub-like (Ubl) protein interferon-stimulated gene product 15", "PROTEIN", 111, 170], ["ISG15", "PROTEIN", 172, 177], ["cellular proteins", "PROTEIN", 184, 201], ["Some PLPs", "PROBLEM", 0, 9], ["the Ub", "TEST", 107, 113], ["protein interferon", "TREATMENT", 125, 143], ["cellular proteins", "TEST", 184, 201]]], ["Such activities were implicated in SARS-CoV's suppression of the innate immune responses, particularly antagonizing type-I interferon (IFN) signaling and chemokine and cytokine production [12], [13].", [["SARS", "DISEASE", 35, 39], ["SARS-CoV", "ORGANISM", 35, 43], ["type-I interferon", "GENE_OR_GENE_PRODUCT", 116, 133], ["IFN", "GENE_OR_GENE_PRODUCT", 135, 138], ["[13]", "SIMPLE_CHEMICAL", 194, 198], ["type-I interferon", "PROTEIN", 116, 133], ["IFN", "PROTEIN", 135, 138], ["chemokine", "PROTEIN", 154, 163], ["cytokine", "PROTEIN", 168, 176], ["SARS-CoV", "SPECIES", 35, 43], ["SARS", "PROBLEM", 35, 39], ["the innate immune responses", "TREATMENT", 61, 88], ["antagonizing type-I interferon (IFN) signaling", "TREATMENT", 103, 149], ["chemokine and cytokine production", "TREATMENT", 154, 187]]], ["Simultaneous disruption of both activities, either by mutation in MERS CoV PLpro's Ub/Ubl binding region [14] or by a destabilizing mutation in MHV PLP's Ubl domain [10], has been observed to prevent the antagonization of IFN signaling, chemokine and cytokine production, and viral pathogenesis, respectively.", [["MERS CoV PLpro's Ub/Ubl binding region [14]", "GENE_OR_GENE_PRODUCT", 66, 109], ["MHV PLP's Ubl domain [10", "GENE_OR_GENE_PRODUCT", 144, 168], ["IFN", "GENE_OR_GENE_PRODUCT", 222, 225], ["MERS CoV PLpro", "PROTEIN", 66, 80], ["Ub", "PROTEIN", 83, 85], ["Ubl binding region", "PROTEIN", 86, 104], ["MHV PLP", "PROTEIN", 144, 151], ["Ubl domain", "PROTEIN", 154, 164], ["IFN", "PROTEIN", 222, 225], ["chemokine", "PROTEIN", 237, 246], ["cytokine", "PROTEIN", 251, 259], ["MERS CoV", "SPECIES", 66, 74], ["MHV", "SPECIES", 144, 147], ["Simultaneous disruption of both activities", "PROBLEM", 0, 42], ["PLpro's Ub/Ubl binding region", "TREATMENT", 75, 104], ["a destabilizing mutation", "PROBLEM", 116, 140], ["MHV PLP's Ubl domain", "TREATMENT", 144, 164], ["IFN signaling", "PROBLEM", 222, 235], ["chemokine and cytokine production", "PROBLEM", 237, 270], ["viral pathogenesis", "PROBLEM", 276, 294]]], ["Overall, these studies suggest that the deubiquitinating and deISGylating activities of PLPs, sometimes packaged together as DUB activity, are a likely contributor to viral pathogenesis.IntroductionIntriguingly, the precise role of each individual activity in promoting PLPs' ability to act as an IFN antagonist has yet to be precisely defined.", [["PLPs", "GENE_OR_GENE_PRODUCT", 88, 92], ["DUB", "GENE_OR_GENE_PRODUCT", 125, 128], ["PLPs", "GENE_OR_GENE_PRODUCT", 270, 274], ["PLPs", "PROTEIN", 88, 92], ["DUB", "PROTEIN", 125, 128], ["PLPs", "PROTEIN", 270, 274], ["IFN", "PROTEIN", 297, 300], ["these studies", "TEST", 9, 22], ["the deubiquitinating and deISGylating activities of PLPs", "PROBLEM", 36, 92], ["viral pathogenesis", "PROBLEM", 167, 185], ["an IFN antagonist", "TREATMENT", 294, 311], ["likely contributor to", "UNCERTAINTY", 145, 166], ["viral pathogenesis", "OBSERVATION", 167, 185]]], ["So far, several X-ray structures of PLpro and PLP2 bound with Ub molecules have been reported [8], [15], [16].", [["PLpro", "CHEMICAL", 36, 41], ["PLP2", "CHEMICAL", 46, 50], ["PLpro", "CHEMICAL", 36, 41], ["PLpro", "SIMPLE_CHEMICAL", 36, 41], ["PLP2", "SIMPLE_CHEMICAL", 46, 50], ["Ub", "GENE_OR_GENE_PRODUCT", 62, 64], ["[8]", "SIMPLE_CHEMICAL", 94, 97], ["[15]", "SIMPLE_CHEMICAL", 99, 103], ["[16]", "SIMPLE_CHEMICAL", 105, 109], ["PLpro", "PROTEIN", 36, 41], ["PLP2", "PROTEIN", 46, 50], ["Ub molecules", "PROTEIN", 62, 74], ["several X-ray structures", "TEST", 8, 32], ["PLpro", "TEST", 36, 41], ["Ub molecules", "TEST", 62, 74]]], ["However, no structure of any CoV PLP in complex with an ISG15 molecule has yet been reported.", [["PLP", "CHEMICAL", 33, 36], ["CoV PLP", "GENE_OR_GENE_PRODUCT", 29, 36], ["ISG15", "GENE_OR_GENE_PRODUCT", 56, 61], ["CoV PLP", "PROTEIN", 29, 36], ["ISG15 molecule", "PROTEIN", 56, 70], ["any CoV PLP", "PROBLEM", 25, 36], ["an ISG15 molecule", "PROBLEM", 53, 70], ["no", "UNCERTAINTY", 9, 11], ["CoV", "OBSERVATION_MODIFIER", 29, 32], ["PLP", "OBSERVATION", 33, 36], ["ISG15 molecule", "OBSERVATION", 56, 70]]], ["Due to the lack of structural detail about the interface between CoV PLPs and ISG15, understanding how CoVs' PLPs specifically engage with ISG15s versus Ub has been especially difficult to understand.", [["CoV", "GENE_OR_GENE_PRODUCT", 65, 68], ["PLPs", "GENE_OR_GENE_PRODUCT", 69, 73], ["ISG15", "GENE_OR_GENE_PRODUCT", 78, 83], ["CoVs", "GENE_OR_GENE_PRODUCT", 103, 107], ["PLPs", "GENE_OR_GENE_PRODUCT", 109, 113], ["ISG15s", "GENE_OR_GENE_PRODUCT", 139, 145], ["Ub", "GENE_OR_GENE_PRODUCT", 153, 155], ["CoV PLPs", "PROTEIN", 65, 73], ["ISG15", "PROTEIN", 78, 83], ["CoVs", "PROTEIN", 103, 107], ["ISG15s", "PROTEIN", 139, 145], ["Ub", "PROTEIN", 153, 155], ["CoV PLPs", "TREATMENT", 65, 73], ["ISG15", "TREATMENT", 78, 83]]], ["The lack of structural information has led to problems in defining the differences between CoV PLPs' deubiquitinating and deISGylating activities among different CoVs.", [["CoV", "ORGANISM", 91, 94], ["PLPs", "GENE_OR_GENE_PRODUCT", 95, 99], ["CoVs", "GENE_OR_GENE_PRODUCT", 162, 166], ["CoV PLPs", "PROTEIN", 91, 99], ["CoVs", "PROTEIN", 162, 166], ["CoV PLPs' deubiquitinating", "TREATMENT", 91, 117], ["deISGylating activities", "TREATMENT", 122, 145]]], ["A further complication in our understanding stems from the fact that the sequence identity of ISG15 among mammals is low, ranging from 58% to as low as 35% when a broader range of animals is compared (Fig. 1b).", [["ISG15", "GENE_OR_GENE_PRODUCT", 94, 99], ["ISG15", "PROTEIN", 94, 99], ["A further complication", "PROBLEM", 0, 22], ["ISG15 among mammals", "TEST", 94, 113], ["complication", "OBSERVATION", 10, 22], ["low", "OBSERVATION_MODIFIER", 117, 120]]], ["In contrast, Ub is highly conserved among eukaryotes.IntroductionThe sequence diversity of ISG15 among animals and the impact of this diversity on the recognition of these ISG15s by viral USPs have not been well studied despite the potential implications.", [["Ub", "GENE_OR_GENE_PRODUCT", 13, 15], ["ISG15", "GENE_OR_GENE_PRODUCT", 91, 96], ["ISG15s", "GENE_OR_GENE_PRODUCT", 172, 178], ["USPs", "GENE_OR_GENE_PRODUCT", 188, 192], ["Ub", "PROTEIN", 13, 15], ["ISG15", "PROTEIN", 91, 96], ["ISG15s", "DNA", 172, 178], ["ISG15 among animals", "PROBLEM", 91, 110], ["viral USPs", "PROBLEM", 182, 192]]], ["For example, certain CoVs, such as SARS-CoV and MERS-CoV, are known to replicate and survive in a broad range of animals including bats, camels, mice, civets, shrews, badgers, pigs, and humans [10], [17], [18].", [["CoVs", "GENE_OR_GENE_PRODUCT", 21, 25], ["SARS-CoV", "ORGANISM", 35, 43], ["MERS-CoV", "ORGANISM", 48, 56], ["camels", "ORGANISM_SUBDIVISION", 137, 143], ["mice", "ORGANISM", 145, 149], ["shrews", "ORGANISM_SUBDIVISION", 159, 165], ["pigs", "ORGANISM", 176, 180], ["humans", "ORGANISM", 186, 192], ["[17]", "SIMPLE_CHEMICAL", 199, 203], ["CoVs", "PROTEIN", 21, 25], ["mice", "SPECIES", 145, 149], ["pigs", "SPECIES", 176, 180], ["humans", "SPECIES", 186, 192], ["SARS-CoV", "SPECIES", 35, 43], ["MERS-CoV", "SPECIES", 48, 56], ["mice", "SPECIES", 145, 149], ["pigs", "SPECIES", 176, 180], ["humans", "SPECIES", 186, 192], ["certain CoVs", "PROBLEM", 13, 25]]], ["In contrast, other CoVs such as MHV only replicate in mice, suggesting that some CoV PLPs may have evolved strict specificity for their single host's ISG15 [19].", [["CoVs", "GENE_OR_GENE_PRODUCT", 19, 23], ["MHV", "ORGANISM", 32, 35], ["mice", "ORGANISM", 54, 58], ["CoV", "ORGANISM", 81, 84], ["PLPs", "GENE_OR_GENE_PRODUCT", 85, 89], ["ISG15", "GENE_OR_GENE_PRODUCT", 150, 155], ["CoVs", "PROTEIN", 19, 23], ["CoV PLPs", "PROTEIN", 81, 89], ["ISG15", "PROTEIN", 150, 155], ["mice", "SPECIES", 54, 58], ["MHV", "SPECIES", 32, 35], ["mice", "SPECIES", 54, 58], ["CoV", "SPECIES", 81, 84], ["some CoV PLPs", "PROBLEM", 76, 89]]], ["The potential for species\u2013species variances in ISG15 has already been shown to be a key factor in other viruses including influenza B where it was shown that NS1 is unable to bind mouse ISG15 (mISG15) unlike its non-human primate and human counterparts, limiting influenza B virus infection in mice [20], [21], [22].", [["influenza B", "DISEASE", 122, 133], ["influenza B virus infection", "DISEASE", 263, 290], ["ISG15", "GENE_OR_GENE_PRODUCT", 47, 52], ["influenza B", "ORGANISM", 122, 133], ["NS1", "GENE_OR_GENE_PRODUCT", 158, 161], ["mouse", "ORGANISM", 180, 185], ["ISG15", "GENE_OR_GENE_PRODUCT", 186, 191], ["mISG15", "GENE_OR_GENE_PRODUCT", 193, 199], ["non-human primate", "ORGANISM", 212, 229], ["human", "ORGANISM", 234, 239], ["influenza B virus", "ORGANISM", 263, 280], ["mice", "ORGANISM", 294, 298], ["ISG15", "PROTEIN", 47, 52], ["NS1", "PROTEIN", 158, 161], ["mouse ISG15", "PROTEIN", 180, 191], ["mISG15", "PROTEIN", 193, 199], ["mouse", "SPECIES", 180, 185], ["human", "SPECIES", 234, 239], ["influenza B virus", "SPECIES", 263, 280], ["mice", "SPECIES", 294, 298], ["mouse", "SPECIES", 180, 185], ["human", "SPECIES", 234, 239], ["influenza B virus", "SPECIES", 263, 280], ["mice", "SPECIES", 294, 298], ["species\u2013species variances in ISG15", "PROBLEM", 18, 52], ["influenza B", "PROBLEM", 122, 133], ["NS1", "PROBLEM", 158, 161], ["limiting influenza B virus infection", "PROBLEM", 254, 290], ["potential for", "UNCERTAINTY", 4, 17]]], ["Also, biodiversity that occurs between species within ISG15s was recently shown to impact the ability of nairovirus viral ovarian tumor domain proteases (vOTUs) to effectively process certain ISG15s [23].", [["tumor", "DISEASE", 130, 135], ["ISG15s", "GENE_OR_GENE_PRODUCT", 54, 60], ["ovarian tumor domain proteases", "GENE_OR_GENE_PRODUCT", 122, 152], ["vOTUs", "GENE_OR_GENE_PRODUCT", 154, 159], ["ISG15s", "PROTEIN", 54, 60], ["nairovirus viral ovarian tumor domain proteases", "PROTEIN", 105, 152], ["vOTUs", "PROTEIN", 154, 159], ["nairovirus viral ovarian tumor domain proteases", "PROBLEM", 105, 152], ["biodiversity", "OBSERVATION", 6, 18], ["ovarian", "ANATOMY", 122, 129], ["tumor", "OBSERVATION", 130, 135]]], ["Overall, many CoV PLPs have been observed to show robust deubiquitinating activities; [11], [24] however, recent in vivo studies have started to unveil the importance of PLPs deISGylating activity [25], [26].", [["CoV", "ORGANISM", 14, 17], ["PLPs", "GENE_OR_GENE_PRODUCT", 18, 22], ["PLPs", "GENE_OR_GENE_PRODUCT", 170, 174], ["CoV PLPs", "PROTEIN", 14, 22], ["PLPs", "PROTEIN", 170, 174], ["many CoV PLPs", "TEST", 9, 22], ["robust deubiquitinating activities", "PROBLEM", 50, 84], ["vivo studies", "TEST", 116, 128]]], ["This has led to a need for a better and more detailed understanding of the interactions between CoV PLPs and ISG15 at the molecular level.IntroductionAdding to the ambiguity of how CoV PLPs or other deISGylating enzymes interact with ISG15, especially when it comes to understanding species-to-species variations, is the lack of available full-length ISG15 structures that have been determined.", [["CoV", "ORGANISM", 96, 99], ["PLPs", "GENE_OR_GENE_PRODUCT", 100, 104], ["ISG15", "GENE_OR_GENE_PRODUCT", 109, 114], ["CoV", "ORGANISM", 181, 184], ["PLPs", "GENE_OR_GENE_PRODUCT", 185, 189], ["ISG15", "GENE_OR_GENE_PRODUCT", 234, 239], ["ISG15", "GENE_OR_GENE_PRODUCT", 351, 356], ["CoV PLPs", "PROTEIN", 96, 104], ["ISG15", "PROTEIN", 109, 114], ["CoV PLPs", "PROTEIN", 181, 189], ["deISGylating enzymes", "PROTEIN", 199, 219], ["ISG15", "PROTEIN", 234, 239], ["ISG15", "PROTEIN", 351, 356], ["CoV PLPs", "TEST", 96, 104], ["IntroductionAdding", "TREATMENT", 138, 156], ["how CoV PLPs", "PROBLEM", 177, 189], ["other deISGylating enzymes", "TEST", 193, 219], ["ISG15", "TREATMENT", 234, 239], ["available full-length ISG15 structures", "TREATMENT", 329, 367]]], ["This is especially important when the intramolecular arrangement of the two domains of ISG15 is considered.", [["ISG15", "GENE_OR_GENE_PRODUCT", 87, 92], ["ISG15", "PROTEIN", 87, 92], ["ISG15", "TREATMENT", 87, 92]]], ["For example, the hinge region of ISG15 shows a significant degree of sequence diversity between the different species (Fig. 1b).", [["ISG15", "GENE_OR_GENE_PRODUCT", 33, 38], ["hinge region", "PROTEIN", 17, 29], ["ISG15", "PROTEIN", 33, 38], ["the hinge region of ISG15", "PROBLEM", 13, 38], ["a significant degree of sequence diversity", "PROBLEM", 45, 87], ["significant", "OBSERVATION_MODIFIER", 47, 58], ["degree", "OBSERVATION_MODIFIER", 59, 65], ["diversity", "OBSERVATION_MODIFIER", 78, 87], ["different", "OBSERVATION_MODIFIER", 100, 109], ["species", "OBSERVATION_MODIFIER", 110, 117]]], ["Although several structures of human ISG15 (hISG15) have been reported, no complete structure of ISG15 from another species has been resolved.", [["human", "ORGANISM", 31, 36], ["ISG15", "GENE_OR_GENE_PRODUCT", 37, 42], ["hISG15", "GENE_OR_GENE_PRODUCT", 44, 50], ["ISG15", "GENE_OR_GENE_PRODUCT", 97, 102], ["human ISG15", "PROTEIN", 31, 42], ["hISG15", "PROTEIN", 44, 50], ["ISG15", "PROTEIN", 97, 102], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["ISG15", "PROBLEM", 97, 102], ["no", "UNCERTAINTY", 72, 74], ["complete", "OBSERVATION_MODIFIER", 75, 83], ["structure", "OBSERVATION", 84, 93], ["ISG15", "OBSERVATION", 97, 102], ["resolved", "OBSERVATION_MODIFIER", 133, 141]]], ["Moreover, the recent elucidation of the structure of the C-terminal domain portion of mISG15 prompted questions on the impact of ISG15 biodiversity on the overall ISG15 structural fold [23].IntroductionTo address these critical gaps in our understanding of ISG15 recognition by CoV PLPs, PLpro from SARS-CoV and MERS-CoV, and PLP2 from MHV were examined for differences in their selectivity among ISG15s from various animals.", [["mISG15", "GENE_OR_GENE_PRODUCT", 86, 92], ["ISG15", "GENE_OR_GENE_PRODUCT", 129, 134], ["ISG15", "GENE_OR_GENE_PRODUCT", 163, 168], ["ISG15", "GENE_OR_GENE_PRODUCT", 257, 262], ["CoV", "ORGANISM", 278, 281], ["PLPs", "GENE_OR_GENE_PRODUCT", 282, 286], ["PLpro", "GENE_OR_GENE_PRODUCT", 288, 293], ["SARS-CoV", "ORGANISM", 299, 307], ["MERS-CoV", "ORGANISM", 312, 320], ["PLP2", "GENE_OR_GENE_PRODUCT", 326, 330], ["MHV", "ORGANISM", 336, 339], ["ISG15s", "SIMPLE_CHEMICAL", 397, 403], ["C-terminal domain portion", "PROTEIN", 57, 82], ["mISG15", "PROTEIN", 86, 92], ["ISG15", "PROTEIN", 129, 134], ["ISG15", "PROTEIN", 163, 168], ["ISG15", "PROTEIN", 257, 262], ["CoV PLPs", "PROTEIN", 278, 286], ["PLpro", "PROTEIN", 288, 293], ["PLP2", "DNA", 326, 330], ["ISG15s", "DNA", 397, 403], ["SARS-CoV", "SPECIES", 299, 307], ["MERS-CoV", "SPECIES", 312, 320], ["MHV", "SPECIES", 336, 339], ["the C-terminal domain portion of mISG15", "PROBLEM", 53, 92], ["ISG15 biodiversity", "TREATMENT", 129, 147], ["ISG15 recognition", "TEST", 257, 274], ["CoV PLPs", "TEST", 278, 286], ["SARS", "PROBLEM", 299, 303], ["CoV", "TEST", 304, 307], ["CoV", "TEST", 317, 320], ["PLP2", "TEST", 326, 330], ["MHV", "TREATMENT", 336, 339]]], ["The X-ray crystal structures of SARS-CoV PLpro bound to the C-terminal domain of ISG15 originating from mouse and human were determined and analyzed in conjunction with enzyme kinetic and thermodynamic data derived from isothermal titration calorimetry (ITC).", [["C", "CHEMICAL", 60, 61], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 32, 46], ["ISG15", "GENE_OR_GENE_PRODUCT", 81, 86], ["mouse", "ORGANISM", 104, 109], ["human", "ORGANISM", 114, 119], ["SARS-CoV PLpro", "PROTEIN", 32, 46], ["C-terminal domain", "PROTEIN", 60, 77], ["ISG15", "PROTEIN", 81, 86], ["mouse", "SPECIES", 104, 109], ["human", "SPECIES", 114, 119], ["SARS-CoV", "SPECIES", 32, 40], ["mouse", "SPECIES", 104, 109], ["human", "SPECIES", 114, 119], ["The X-ray crystal structures", "TEST", 0, 28], ["SARS", "PROBLEM", 32, 36], ["enzyme kinetic", "TEST", 169, 183], ["thermodynamic data", "TEST", 188, 206], ["isothermal titration calorimetry", "TEST", 220, 252], ["SARS", "OBSERVATION", 32, 36]]], ["In addition, the first X-ray structure of a complete non-hISG15 structure, mISG15, was also determined to elucidate the potential sequence and structural differences that may account for species specificity of CoV PLPs.", [["non-hISG15", "GENE_OR_GENE_PRODUCT", 53, 63], ["mISG15", "GENE_OR_GENE_PRODUCT", 75, 81], ["CoV", "ORGANISM", 210, 213], ["PLPs", "GENE_OR_GENE_PRODUCT", 214, 218], ["non-hISG15 structure", "PROTEIN", 53, 73], ["mISG15", "PROTEIN", 75, 81], ["CoV PLPs", "PROTEIN", 210, 218], ["CoV PLPs", "SPECIES", 210, 218], ["CoV PLPs", "PROBLEM", 210, 218], ["may account for", "UNCERTAINTY", 171, 186]]], ["Together, these studies provide significant and new insight into the CoV PLP's ability to accommodate the structural differences not only between Ub and hISG15 but also in different species' ISG15s.Species-specific cleavage of proISG15s by CoV PLPs ::: ResultsCurrently, there is a paucity of available biochemical data on the impact of species-to-species sequence variations within ISG15 and the effect that these differences may have on the ability of CoV PLPs to recognize and cleave ISG15.", [["PLP", "CHEMICAL", 73, 76], ["CoV", "ORGANISM", 69, 72], ["PLP", "GENE_OR_GENE_PRODUCT", 73, 76], ["Ub", "GENE_OR_GENE_PRODUCT", 146, 148], ["hISG15", "GENE_OR_GENE_PRODUCT", 153, 159], ["ISG15s", "GENE_OR_GENE_PRODUCT", 191, 197], ["proISG15s", "GENE_OR_GENE_PRODUCT", 227, 236], ["CoV", "ORGANISM", 240, 243], ["ISG15", "GENE_OR_GENE_PRODUCT", 383, 388], ["CoV", "ORGANISM", 454, 457], ["PLPs", "GENE_OR_GENE_PRODUCT", 458, 462], ["ISG15", "GENE_OR_GENE_PRODUCT", 487, 492], ["CoV PLP", "PROTEIN", 69, 76], ["Ub", "PROTEIN", 146, 148], ["hISG15", "PROTEIN", 153, 159], ["ISG15s", "PROTEIN", 191, 197], ["proISG15s", "PROTEIN", 227, 236], ["CoV PLPs", "PROTEIN", 240, 248], ["ISG15", "PROTEIN", 383, 388], ["CoV PLPs", "PROTEIN", 454, 462], ["ISG15", "PROTEIN", 487, 492], ["CoV", "SPECIES", 454, 457], ["these studies", "TEST", 10, 23], ["species sequence variations", "PROBLEM", 348, 375], ["CoV PLPs", "TREATMENT", 454, 462], ["paucity", "OBSERVATION_MODIFIER", 282, 289]]], ["Therefore, we employed a recently developed assay for deISGylating vOTUs that takes advantage of the ability of a protease or DUB to cleave immature ISG15 [23].", [["DUB", "GENE_OR_GENE_PRODUCT", 126, 129], ["ISG15", "GENE_OR_GENE_PRODUCT", 149, 154], ["protease", "PROTEIN", 114, 122], ["DUB", "PROTEIN", 126, 129], ["ISG15", "PROTEIN", 149, 154], ["deISGylating vOTUs", "TREATMENT", 54, 72], ["a protease", "TREATMENT", 112, 122], ["DUB", "PROBLEM", 126, 129]]], ["The PLpro enzymes from SARS-CoV and MERS-CoV, and the enzyme PLP2 from MHV, were purified and assessed for their ability to cleave proISG15s derived from seven different species including human, sheep, northern tree shrew, jackknife fish, mouse, dromedary camel, and vesper bat (Fig. 2).", [["PLpro", "GENE_OR_GENE_PRODUCT", 4, 9], ["SARS-CoV", "ORGANISM", 23, 31], ["MERS-CoV", "ORGANISM", 36, 44], ["PLP2", "GENE_OR_GENE_PRODUCT", 61, 65], ["MHV", "ORGANISM", 71, 74], ["proISG15s", "GENE_OR_GENE_PRODUCT", 131, 140], ["human", "ORGANISM", 188, 193], ["sheep", "ORGANISM", 195, 200], ["shrew", "ORGANISM_SUBDIVISION", 216, 221], ["mouse", "ORGANISM", 239, 244], ["camel", "ORGANISM", 256, 261], ["vesper bat", "ORGANISM", 267, 277], ["PLpro enzymes", "PROTEIN", 4, 17], ["MERS", "PROTEIN", 36, 40], ["CoV", "PROTEIN", 41, 44], ["enzyme PLP2", "PROTEIN", 54, 65], ["MHV", "PROTEIN", 71, 74], ["proISG15s", "PROTEIN", 131, 140], ["human", "SPECIES", 188, 193], ["sheep", "SPECIES", 195, 200], ["mouse", "SPECIES", 239, 244], ["camel", "SPECIES", 256, 261], ["SARS-CoV", "SPECIES", 23, 31], ["MERS-CoV", "SPECIES", 36, 44], ["MHV", "SPECIES", 71, 74], ["human", "SPECIES", 188, 193], ["sheep", "SPECIES", 195, 200], ["northern tree shrew", "SPECIES", 202, 221], ["mouse", "SPECIES", 239, 244], ["vesper bat", "SPECIES", 267, 277], ["The PLpro enzymes", "TEST", 0, 17], ["SARS", "TEST", 23, 27], ["CoV", "TEST", 28, 31], ["MERS", "TEST", 36, 40], ["CoV", "TEST", 41, 44], ["the enzyme PLP2", "TEST", 50, 65]]], ["Each of these proISG15 proteins is appended with the proISG15 extension from Homo sapiens (Fig. 2).", [["proISG15", "GENE_OR_GENE_PRODUCT", 14, 22], ["proISG15", "GENE_OR_GENE_PRODUCT", 53, 61], ["Homo sapiens", "ORGANISM", 77, 89], ["proISG15 proteins", "PROTEIN", 14, 31], ["proISG15", "PROTEIN", 53, 61], ["Homo sapiens", "SPECIES", 77, 89], ["Homo sapiens", "SPECIES", 77, 89]]], ["ISG15 from jackknife fish was included in the analysis to add a more distantly related ISG15 homolog.Species-specific cleavage of proISG15s by CoV PLPs ::: ResultsSARS-CoV and MERS-CoV PLpros are both capable of fully processing proISG15 from human, mouse, camel, and bat within 60 min.", [["ISG15", "GENE_OR_GENE_PRODUCT", 0, 5], ["ISG15", "GENE_OR_GENE_PRODUCT", 87, 92], ["proISG15s", "GENE_OR_GENE_PRODUCT", 130, 139], ["CoV", "ORGANISM", 143, 146], ["ResultsSARS-CoV", "GENE_OR_GENE_PRODUCT", 156, 171], ["MERS-CoV PLpros", "ORGANISM", 176, 191], ["proISG15", "GENE_OR_GENE_PRODUCT", 229, 237], ["human", "ORGANISM", 243, 248], ["mouse", "ORGANISM", 250, 255], ["camel", "ORGANISM", 257, 262], ["bat", "ORGANISM", 268, 271], ["ISG15", "PROTEIN", 0, 5], ["ISG15 homolog", "PROTEIN", 87, 100], ["proISG15s", "PROTEIN", 130, 139], ["CoV PLPs", "PROTEIN", 143, 151], ["ResultsSARS-CoV and MERS-CoV PLpros", "DNA", 156, 191], ["proISG15", "PROTEIN", 229, 237], ["human", "SPECIES", 243, 248], ["mouse", "SPECIES", 250, 255], ["camel", "SPECIES", 257, 262], ["MERS-CoV", "SPECIES", 176, 184], ["human", "SPECIES", 243, 248], ["mouse", "SPECIES", 250, 255], ["camel", "SPECIES", 257, 262], ["jackknife fish", "TEST", 11, 25], ["ISG15 homolog", "TREATMENT", 87, 100], ["ResultsSARS", "TEST", 156, 167], ["CoV", "PROBLEM", 168, 171]]], ["SARS PLpro is also able to fully process proISG15 from sheep and shrew within that same time, but it has little to no activity against jackfish proISG15.", [["proISG15", "GENE_OR_GENE_PRODUCT", 41, 49], ["sheep", "ORGANISM", 55, 60], ["proISG15", "GENE_OR_GENE_PRODUCT", 144, 152], ["proISG15", "PROTEIN", 41, 49], ["jackfish proISG15", "PROTEIN", 135, 152], ["sheep", "SPECIES", 55, 60], ["sheep", "SPECIES", 55, 60]]], ["In contrast, MERS PLpro is fully capable of processing jackfish proISG15, but it processes proISG15 from shrew and sheep poorly.", [["MERS PLpro", "GENE_OR_GENE_PRODUCT", 13, 23], ["proISG15", "GENE_OR_GENE_PRODUCT", 64, 72], ["proISG15", "GENE_OR_GENE_PRODUCT", 91, 99], ["sheep", "ORGANISM", 115, 120], ["MERS PLpro", "PROTEIN", 13, 23], ["jackfish proISG15", "PROTEIN", 55, 72], ["proISG15", "PROTEIN", 91, 99], ["sheep", "SPECIES", 115, 120], ["sheep", "SPECIES", 115, 120]]], ["MHV PLP2, on the other hand, displays a much narrower specificity for ISG15s from different species.", [["MHV PLP2", "ORGANISM", 0, 8], ["ISG15s", "GENE_OR_GENE_PRODUCT", 70, 76], ["MHV PLP2", "PROTEIN", 0, 8], ["ISG15s", "PROTEIN", 70, 76], ["MHV", "SPECIES", 0, 3], ["MHV PLP2", "TEST", 0, 8], ["ISG15s", "PROBLEM", 70, 76], ["different species", "PROBLEM", 82, 99]]], ["It shows little to no cleavage of proISG15s derived from human, sheep, camel, or bat sources but does show modest activity for the northern tree shrew.", [["proISG15s", "GENE_OR_GENE_PRODUCT", 34, 43], ["human", "ORGANISM", 57, 62], ["sheep", "ORGANISM", 64, 69], ["camel", "ORGANISM", 71, 76], ["shrew", "ORGANISM_SUBDIVISION", 145, 150], ["proISG15s", "PROTEIN", 34, 43], ["human", "SPECIES", 57, 62], ["sheep", "SPECIES", 64, 69], ["human", "SPECIES", 57, 62], ["sheep", "SPECIES", 64, 69], ["camel", "SPECIES", 71, 76], ["northern tree shrew", "SPECIES", 131, 150], ["cleavage of proISG15s", "PROBLEM", 22, 43]]], ["MHV PLP2 shows strong activity toward jackfish and mouse proISG15, the latter activity being consistent with MHV's pathogenicity as a murine CoV.Species specific affinity of ISG15 for SARS-CoV and MERS-CoV PLpros ::: ResultsAnalysis of the cleavage patterns in Fig. 2 suggests that SARS and MERS PLpros are more promiscuous in recognizing and cleaving various proISG15s compared to MHV PLP2, which may relate to the fact that these human pathogens are capable of replicating in different hosts, for example, bats, camels, and the shrew, in contrast to MHV that can only replicate in the mouse.", [["SARS", "DISEASE", 184, 188], ["SARS", "DISEASE", 282, 286], ["MHV", "ORGANISM", 0, 3], ["PLP2", "GENE_OR_GENE_PRODUCT", 4, 8], ["jackfish", "CANCER", 38, 46], ["mouse", "ORGANISM", 51, 56], ["proISG15", "GENE_OR_GENE_PRODUCT", 57, 65], ["MHV", "ORGANISM", 109, 112], ["murine", "ORGANISM", 134, 140], ["CoV.", "ORGANISM", 141, 145], ["ISG15", "GENE_OR_GENE_PRODUCT", 174, 179], ["SARS-CoV", "ORGANISM", 184, 192], ["MERS-CoV", "ORGANISM", 197, 205], ["MERS PLpros", "GENE_OR_GENE_PRODUCT", 291, 302], ["proISG15s", "GENE_OR_GENE_PRODUCT", 360, 369], ["MHV PLP2", "ORGANISM", 382, 390], ["human", "ORGANISM", 432, 437], ["camels", "ORGANISM_SUBDIVISION", 514, 520], ["MHV", "ORGANISM", 552, 555], ["mouse", "ORGANISM", 587, 592], ["MHV PLP2", "PROTEIN", 0, 8], ["mouse proISG15", "PROTEIN", 51, 65], ["ISG15", "PROTEIN", 174, 179], ["MERS PLpros", "PROTEIN", 291, 302], ["proISG15s", "PROTEIN", 360, 369], ["MHV PLP2", "PROTEIN", 382, 390], ["mouse", "SPECIES", 51, 56], ["murine", "SPECIES", 134, 140], ["human", "SPECIES", 432, 437], ["mouse", "SPECIES", 587, 592], ["MHV", "SPECIES", 0, 3], ["mouse", "SPECIES", 51, 56], ["MHV", "SPECIES", 109, 112], ["CoV.", "SPECIES", 141, 145], ["SARS-CoV", "SPECIES", 184, 192], ["MERS-CoV", "SPECIES", 197, 205], ["MHV", "SPECIES", 382, 385], ["human", "SPECIES", 432, 437], ["MHV", "SPECIES", 552, 555], ["mouse", "SPECIES", 587, 592], ["MHV PLP2", "TEST", 0, 8], ["MHV's pathogenicity", "PROBLEM", 109, 128], ["SARS", "PROBLEM", 184, 188], ["the cleavage patterns", "TEST", 236, 257], ["SARS", "PROBLEM", 282, 286], ["MERS PLpros", "PROBLEM", 291, 302], ["MHV PLP2", "TEST", 382, 390], ["these human pathogens", "PROBLEM", 426, 447], ["strong", "OBSERVATION_MODIFIER", 15, 21], ["activity", "OBSERVATION_MODIFIER", 22, 30], ["may relate to", "UNCERTAINTY", 398, 411]]], ["Differences in cleaving ability of proISG15s by SARS and MERS PLpro may be due to sequence and structural differences, which may affect binding affinities for the ISG15s.", [["SARS", "DISEASE", 48, 52], ["proISG15s", "GENE_OR_GENE_PRODUCT", 35, 44], ["MERS PLpro", "GENE_OR_GENE_PRODUCT", 57, 67], ["ISG15s", "GENE_OR_GENE_PRODUCT", 163, 169], ["proISG15s", "PROTEIN", 35, 44], ["ISG15s", "PROTEIN", 163, 169], ["proISG15s", "PROBLEM", 35, 44], ["SARS", "PROBLEM", 48, 52], ["MERS PLpro", "TREATMENT", 57, 67]]], ["This possibility was explored using ITC to measure the binding affinities of different ISG15s missing the P\u2032-sites (Fig. 3).", [["ITC", "CELL", 36, 39], ["ISG15s", "GENE_OR_GENE_PRODUCT", 87, 93], ["ISG15s", "PROTEIN", 87, 93], ["P\u2032-sites", "DNA", 106, 114], ["ITC", "TREATMENT", 36, 39], ["the binding affinities", "PROBLEM", 51, 73]]], ["As deISGylases natural substrates include an isopetide bond, removal of the P\u2032-sites also allows the avoidance of potential confounding factors related to CoV PLPs' other prominent function of processing the viral polyprotein to promote viral replication.", [["isopetide", "CHEMICAL", 45, 54], ["isopetide", "SIMPLE_CHEMICAL", 45, 54], ["CoV", "GENE_OR_GENE_PRODUCT", 155, 158], ["P\u2032", "PROTEIN", 76, 78], ["deISGylases natural substrates", "TREATMENT", 3, 33], ["an isopetide bond", "TREATMENT", 42, 59], ["removal", "TREATMENT", 61, 68], ["the P\u2032-sites", "TREATMENT", 72, 84], ["potential confounding factors", "PROBLEM", 114, 143], ["CoV PLPs", "PROBLEM", 155, 163], ["the viral polyprotein", "TREATMENT", 204, 225], ["viral replication", "TREATMENT", 237, 254], ["viral polyprotein", "OBSERVATION", 208, 225], ["viral replication", "OBSERVATION", 237, 254]]], ["This part of the process requires that PLPs recognize and cleave the peptide bond after the LXGG sequences within the polyprotein, and the ability of PLPs to cleave this bond has been shown to be reliant on residues flanking the peptide cleavage site [6], [9].", [["PLPs", "CHEMICAL", 150, 154], ["PLPs", "SIMPLE_CHEMICAL", 39, 43], ["PLPs", "GENE_OR_GENE_PRODUCT", 150, 154], ["PLPs", "PROTEIN", 39, 43], ["LXGG sequences", "DNA", 92, 106], ["PLPs", "PROTEIN", 150, 154], ["the LXGG sequences", "TEST", 88, 106], ["the polyprotein", "TREATMENT", 114, 129], ["residues flanking the peptide cleavage site", "PROBLEM", 207, 250]]], ["This requisite function is not associated with other viral deISGylating proteases such as nairovirus vOTUs [23].", [["viral deISGylating proteases", "PROTEIN", 53, 81], ["nairovirus vOTUs", "PROTEIN", 90, 106], ["other viral deISGylating proteases", "PROBLEM", 47, 81], ["nairovirus vOTUs", "PROBLEM", 90, 106], ["not associated with", "UNCERTAINTY", 27, 46]]], ["Therefore, ITC measurements were performed using mature ISG15.", [["ITC", "ANATOMY", 11, 14], ["ITC", "CELL", 11, 14], ["ISG15", "GENE_OR_GENE_PRODUCT", 56, 61], ["ISG15", "PROTEIN", 56, 61], ["ITC measurements", "TEST", 11, 27]]], ["Although the mature ISG15s resemble the product by the absence of an isopetide bond, binding affinity could be assessed independent of any P\u2032-sites contribution associated with using the ISG15-pro-form protein.", [["isopetide", "CHEMICAL", 69, 78], ["ISG15s", "GENE_OR_GENE_PRODUCT", 20, 26], ["isopetide", "SIMPLE_CHEMICAL", 69, 78], ["ISG15", "GENE_OR_GENE_PRODUCT", 187, 192], ["mature ISG15s", "PROTEIN", 13, 26], ["P\u2032", "PROTEIN", 139, 141], ["ISG15-pro-form protein", "PROTEIN", 187, 209], ["binding affinity", "PROBLEM", 85, 101], ["the ISG15", "TREATMENT", 183, 192]]], ["This would also provide a more quantitative understanding of the thermodynamic parameters related solely to the species and virus-related variances of the protease and ISG15s, respectively.Species specific affinity of ISG15 for SARS-CoV and MERS-CoV PLpros ::: ResultsIntriguingly, both SARS-CoV and MERS-CoV PLpro have stronger affinity toward hISG15 than shISG15 and mISG15.", [["SARS", "DISEASE", 228, 232], ["ISG15s", "GENE_OR_GENE_PRODUCT", 168, 174], ["ISG15", "GENE_OR_GENE_PRODUCT", 218, 223], ["SARS-CoV", "ORGANISM", 228, 236], ["MERS-CoV", "ORGANISM", 241, 249], ["SARS-CoV", "ORGANISM", 287, 295], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 300, 314], ["hISG15", "GENE_OR_GENE_PRODUCT", 345, 351], ["shISG15", "GENE_OR_GENE_PRODUCT", 357, 364], ["mISG15", "GENE_OR_GENE_PRODUCT", 369, 375], ["protease", "PROTEIN", 155, 163], ["ISG15s", "PROTEIN", 168, 174], ["ISG15", "PROTEIN", 218, 223], ["SARS-CoV and MERS-CoV PLpro", "DNA", 287, 314], ["hISG15", "PROTEIN", 345, 351], ["shISG15", "DNA", 357, 364], ["mISG15", "DNA", 369, 375], ["SARS-CoV", "SPECIES", 228, 236], ["MERS-CoV", "SPECIES", 241, 249], ["SARS-CoV", "SPECIES", 287, 295], ["MERS-CoV", "SPECIES", 300, 308], ["the thermodynamic parameters", "TEST", 61, 89], ["virus", "PROBLEM", 124, 129], ["the protease", "TEST", 151, 163], ["SARS", "PROBLEM", 228, 232], ["mISG15", "TREATMENT", 369, 375]]], ["The dissociation constants (Kd) of SARS-CoV and MERS-CoV PLpro for hISG15 are 20.5 \u00b1 4.5 \u03bcM and 59.3 \u00b1 4.5 \u03bcM, respectively.", [["hISG15", "CHEMICAL", 67, 73], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 35, 43], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 48, 62], ["SARS-CoV", "SPECIES", 35, 43], ["MERS-CoV", "SPECIES", 48, 56], ["The dissociation constants", "PROBLEM", 0, 26], ["SARS", "PROBLEM", 35, 39], ["CoV", "TEST", 40, 43], ["MERS", "TEST", 48, 52], ["CoV PLpro", "TEST", 53, 62], ["hISG15", "TEST", 67, 73]]], ["Unlike their affinities for hISG15, the affinities of both PLpros for shISG15 and mISG15 were significantly weaker, and as a result, a competitive ITC binding assay (Table 2 and Fig. 3) had to be used to determine their Kd values.", [["hISG15", "GENE_OR_GENE_PRODUCT", 28, 34], ["PLpros", "GENE_OR_GENE_PRODUCT", 59, 65], ["shISG15", "GENE_OR_GENE_PRODUCT", 70, 77], ["mISG15", "GENE_OR_GENE_PRODUCT", 82, 88], ["ITC", "SIMPLE_CHEMICAL", 147, 150], ["hISG15", "PROTEIN", 28, 34], ["PLpros", "PROTEIN", 59, 65], ["shISG15", "PROTEIN", 70, 77], ["mISG15", "PROTEIN", 82, 88], ["hISG15", "TREATMENT", 28, 34], ["a competitive ITC binding assay", "TEST", 133, 164]]], ["In regard to SARS-CoV PLpro, ITC analyses revealed similar Kd's of 200 \u00b1 41 \u03bcM and 198 \u00b1 64 \u03bcM for shISG15 and mISG15.", [["SARS", "DISEASE", 13, 17], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["ITC", "CELL", 29, 32], ["shISG15", "GENE_OR_GENE_PRODUCT", 99, 106], ["mISG15", "GENE_OR_GENE_PRODUCT", 111, 117], ["shISG15", "PROTEIN", 99, 106], ["mISG15", "PROTEIN", 111, 117], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["CoV PLpro", "TEST", 18, 27], ["ITC analyses", "TEST", 29, 41], ["Kd's", "TEST", 59, 63], ["shISG15", "TEST", 99, 106], ["mISG15", "TEST", 111, 117]]], ["More divergence in affinity for mISG15 and shISG15 were seen with MERS-CoV PLpro.", [["mISG15", "GENE_OR_GENE_PRODUCT", 32, 38], ["shISG15", "GENE_OR_GENE_PRODUCT", 43, 50], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["mISG15", "PROTEIN", 32, 38], ["shISG15", "PROTEIN", 43, 50], ["MERS-CoV PLpro", "DNA", 66, 80], ["MERS-CoV", "SPECIES", 66, 74], ["mISG15 and shISG15", "TREATMENT", 32, 50]]], ["Like SARS-CoV PLpro, affinity of MERS-CoV PLpro for shISG15 was similar with a Kd of 147 \u00b1 36 \u03bcM.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 5, 13], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["shISG15", "GENE_OR_GENE_PRODUCT", 52, 59], ["MERS-CoV PLpro", "PROTEIN", 33, 47], ["shISG15", "PROTEIN", 52, 59], ["SARS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 5, 9]]], ["However, a substantially weaker affinity of MERS-CoV PLpro for mISG15 was observed (Kd of 376 \u00b1 53 \u03bcM).Species specific affinity of ISG15 for SARS-CoV and MERS-CoV PLpros ::: ResultsThe measured thermodynamic parameters revealed that both SARS-CoV and MERS-CoV PLpro follow a similar trend and prefer hISG15 over shISG15 and mISG15.", [["SARS", "DISEASE", 142, 146], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 44, 58], ["mISG15", "GENE_OR_GENE_PRODUCT", 63, 69], ["ISG15", "GENE_OR_GENE_PRODUCT", 132, 137], ["SARS-CoV", "ORGANISM", 142, 150], ["MERS-CoV", "ORGANISM", 155, 163], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 239, 247], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 252, 260], ["hISG15", "GENE_OR_GENE_PRODUCT", 301, 307], ["shISG15", "GENE_OR_GENE_PRODUCT", 313, 320], ["mISG15", "GENE_OR_GENE_PRODUCT", 325, 331], ["MERS-CoV PLpro", "PROTEIN", 44, 58], ["mISG15", "PROTEIN", 63, 69], ["ISG15", "PROTEIN", 132, 137], ["CoV PLpro", "PROTEIN", 257, 266], ["hISG15", "PROTEIN", 301, 307], ["shISG15", "PROTEIN", 313, 320], ["mISG15", "PROTEIN", 325, 331], ["MERS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 142, 150], ["MERS-CoV", "SPECIES", 155, 163], ["SARS-CoV", "SPECIES", 239, 247], ["MERS-CoV", "SPECIES", 252, 260], ["CoV PLpro", "TREATMENT", 49, 58], ["mISG15", "PROBLEM", 63, 69], ["SARS", "PROBLEM", 142, 146], ["The measured thermodynamic parameters", "TEST", 182, 219], ["both SARS", "TEST", 234, 243], ["CoV", "TEST", 244, 247], ["mISG15", "TREATMENT", 325, 331], ["weaker", "OBSERVATION_MODIFIER", 25, 31], ["both", "OBSERVATION_MODIFIER", 234, 238], ["SARS", "OBSERVATION", 239, 243]]], ["Specifically, the association of shISG15 and mISG15 to PLpros is unfavorable with increasingly higher entropic factors.", [["shISG15", "GENE_OR_GENE_PRODUCT", 33, 40], ["mISG15", "GENE_OR_GENE_PRODUCT", 45, 51], ["PLpros", "GENE_OR_GENE_PRODUCT", 55, 61], ["shISG15", "PROTEIN", 33, 40], ["mISG15", "PROTEIN", 45, 51], ["PLpros", "PROTEIN", 55, 61], ["entropic factors", "PROTEIN", 102, 118], ["increasingly higher entropic factors", "PROBLEM", 82, 118], ["higher", "OBSERVATION_MODIFIER", 95, 101], ["entropic factors", "OBSERVATION", 102, 118]]], ["Although PLpros originating from MERS-CoV and SARS-CoV exhibited a similar preference for hISG15, the thermodynamics driving the affinity differ.", [["PLpros", "GENE_OR_GENE_PRODUCT", 9, 15], ["MERS-CoV", "ORGANISM", 33, 41], ["SARS-CoV", "ORGANISM", 46, 54], ["hISG15", "GENE_OR_GENE_PRODUCT", 90, 96], ["PLpros", "PROTEIN", 9, 15], ["hISG15", "PROTEIN", 90, 96], ["MERS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 46, 54], ["PLpros", "TEST", 9, 15], ["MERS", "PROBLEM", 33, 37], ["CoV", "PROBLEM", 38, 41], ["SARS", "PROBLEM", 46, 50], ["CoV", "PROBLEM", 51, 54], ["hISG15", "TREATMENT", 90, 96]]], ["The SARS-CoV and hISG15 binding event was driven by enthalpic factors and was slightly entropically unfavorable.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["hISG15", "GENE_OR_GENE_PRODUCT", 17, 23], ["hISG15", "PROTEIN", 17, 23], ["enthalpic factors", "PROTEIN", 52, 69], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["hISG15 binding event", "PROBLEM", 17, 37], ["slightly entropically unfavorable", "PROBLEM", 78, 111]]], ["In contrast, the MERS-CoV affinity of hISG15 was more balanced, possessing an entropic and enthalpic component.Species specific affinity of ISG15 for SARS-CoV and MERS-CoV PLpros ::: ResultsAlthough some DUB proteases that possess deISGylating activity have been observed to engage only the C-terminal domain of ISG15, SARS-CoV has been suggested to interact with both domains [11], [15], [23], [27].", [["SARS", "DISEASE", 150, 154], ["C", "CHEMICAL", 291, 292], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["hISG15", "GENE_OR_GENE_PRODUCT", 38, 44], ["ISG15", "GENE_OR_GENE_PRODUCT", 140, 145], ["SARS-CoV", "ORGANISM", 150, 158], ["MERS-CoV", "ORGANISM", 163, 171], ["DUB", "GENE_OR_GENE_PRODUCT", 204, 207], ["ISG15", "GENE_OR_GENE_PRODUCT", 312, 317], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 319, 327], ["MERS", "PROTEIN", 17, 21], ["hISG15", "PROTEIN", 38, 44], ["ISG15", "PROTEIN", 140, 145], ["DUB proteases", "PROTEIN", 204, 217], ["C-terminal domain", "PROTEIN", 291, 308], ["ISG15", "PROTEIN", 312, 317], ["SARS-CoV", "PROTEIN", 319, 327], ["MERS-CoV", "SPECIES", 17, 25], ["SARS-CoV", "SPECIES", 150, 158], ["MERS-CoV", "SPECIES", 163, 171], ["SARS-CoV", "SPECIES", 319, 327], ["an entropic and enthalpic component", "PROBLEM", 75, 110], ["SARS", "PROBLEM", 150, 154], ["some DUB proteases", "PROBLEM", 199, 217], ["the C-terminal domain of ISG15", "PROBLEM", 287, 317], ["entropic", "OBSERVATION", 78, 86], ["enthalpic component", "OBSERVATION", 91, 110]]], ["To gain insight into the relative contributions of the C-terminal domain to their full-length counterparts, we performed ITC, utilizing both mouse and human C-terminal variants of ISG15.", [["C", "CHEMICAL", 55, 56], ["C", "CHEMICAL", 157, 158], ["ITC", "CELL", 121, 124], ["mouse", "ORGANISM", 141, 146], ["human", "ORGANISM", 151, 156], ["ISG15", "GENE_OR_GENE_PRODUCT", 180, 185], ["C-terminal domain", "PROTEIN", 55, 72], ["mouse and human C-terminal variants", "DNA", 141, 176], ["ISG15", "PROTEIN", 180, 185], ["mouse", "SPECIES", 141, 146], ["human", "SPECIES", 151, 156], ["mouse", "SPECIES", 141, 146], ["human", "SPECIES", 151, 156], ["the C-terminal domain", "PROBLEM", 51, 72], ["human C-terminal variants of ISG15", "TREATMENT", 151, 185]]], ["The Kd of 57.6 \u00b1 3.21 \u03bcM was observed for ChSIG15.", [["ChSIG15", "CHEMICAL", 42, 49], ["ChSIG15", "CHEMICAL", 42, 49], ["ChSIG15", "SIMPLE_CHEMICAL", 42, 49], ["ChSIG15", "PROTEIN", 42, 49], ["The Kd", "TEST", 0, 6]]], ["Although the binding event still was enthalpically favorable, this contribution was fourfold less than that observed for hISG15.", [["hISG15", "CHEMICAL", 121, 127], ["hISG15", "GENE_OR_GENE_PRODUCT", 121, 127], ["hISG15", "PROTEIN", 121, 127]]], ["Conversely, it possessed a markedly favorable entropic component over the slightly disfavorable one of its full-length counterpart.", [["a markedly favorable entropic component", "PROBLEM", 25, 64], ["markedly", "OBSERVATION_MODIFIER", 27, 35], ["favorable", "OBSERVATION_MODIFIER", 36, 45], ["entropic", "OBSERVATION_MODIFIER", 46, 54], ["component", "OBSERVATION_MODIFIER", 55, 64], ["slightly", "OBSERVATION_MODIFIER", 74, 82]]], ["Not unsurprisingly, the trend of SARS-CoV having a stronger affinity toward hISG15 over mISG15 was also observed in the C-terminal domain of each substrate.", [["SARS", "DISEASE", 33, 37], ["C", "CHEMICAL", 120, 121], ["SARS-CoV", "ORGANISM", 33, 41], ["hISG15", "GENE_OR_GENE_PRODUCT", 76, 82], ["mISG15", "GENE_OR_GENE_PRODUCT", 88, 94], ["hISG15", "PROTEIN", 76, 82], ["mISG15", "PROTEIN", 88, 94], ["C-terminal domain", "PROTEIN", 120, 137], ["SARS-CoV", "SPECIES", 33, 41], ["SARS", "PROBLEM", 33, 37], ["a stronger affinity", "PROBLEM", 49, 68]]], ["The Kd for C-terminal domain of ISG15 from mouse (CmISG15) was considerably weak at 1870 \u00b1 173 \u03bcM, showing marked decreases in both entropic and enthalphic binding contributions and suggesting that similar to hISG15, mISG15's N-terminal domain may also be involved in the protease\u2013ISG15 binding interface.Crystallization of SARS-CoV PLpro bound to the C-terminal domains of hISG15 and mISG15 ::: ResultsWhile X-ray crystal structures have been solved for SARS and MERS PLpro bound to Ub, our understanding of the interactions of these enzymes with ISG15 has been largely limited to enzymatic, mutational, and computational modeling studies [11], [15].", [["SARS", "DISEASE", 324, 328], ["SARS", "DISEASE", 455, 459], ["C", "CHEMICAL", 11, 12], ["mISG15", "CHEMICAL", 217, 223], ["N", "CHEMICAL", 226, 227], ["C", "CHEMICAL", 352, 353], ["ISG15", "GENE_OR_GENE_PRODUCT", 32, 37], ["mouse", "ORGANISM", 43, 48], ["hISG15", "GENE_OR_GENE_PRODUCT", 209, 215], ["mISG15", "GENE_OR_GENE_PRODUCT", 217, 223], ["ISG15", "GENE_OR_GENE_PRODUCT", 281, 286], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 324, 332], ["hISG15", "GENE_OR_GENE_PRODUCT", 374, 380], ["MERS PLpro", "GENE_OR_GENE_PRODUCT", 464, 474], ["Ub", "GENE_OR_GENE_PRODUCT", 484, 486], ["ISG15", "GENE_OR_GENE_PRODUCT", 548, 553], ["[15]", "SIMPLE_CHEMICAL", 646, 650], ["C-terminal domain", "PROTEIN", 11, 28], ["ISG15", "PROTEIN", 32, 37], ["CmISG15", "PROTEIN", 50, 57], ["hISG15", "PROTEIN", 209, 215], ["mISG15", "PROTEIN", 217, 223], ["N-terminal domain", "PROTEIN", 226, 243], ["ISG15", "PROTEIN", 281, 286], ["SARS-CoV PLpro", "PROTEIN", 324, 338], ["C-terminal domains", "PROTEIN", 352, 370], ["hISG15", "PROTEIN", 374, 380], ["mISG15", "PROTEIN", 385, 391], ["MERS PLpro", "PROTEIN", 464, 474], ["Ub", "PROTEIN", 484, 486], ["enzymes", "PROTEIN", 535, 542], ["ISG15", "PROTEIN", 548, 553], ["mouse", "SPECIES", 43, 48], ["mouse", "SPECIES", 43, 48], ["SARS-CoV", "SPECIES", 324, 332], ["The Kd", "TEST", 0, 6], ["marked decreases in both entropic and enthalphic binding contributions", "PROBLEM", 107, 177], ["SARS", "PROBLEM", 324, 328], ["ResultsWhile X-ray crystal structures", "TEST", 396, 433], ["SARS", "PROBLEM", 455, 459], ["these enzymes", "TEST", 529, 542], ["ISG15", "TREATMENT", 548, 553], ["computational modeling studies", "TEST", 609, 639], ["marked", "OBSERVATION_MODIFIER", 107, 113], ["decreases", "OBSERVATION_MODIFIER", 114, 123], ["both entropic", "OBSERVATION", 127, 140], ["SARS", "OBSERVATION", 324, 328]]], ["To gain molecular insight into the specific interactions between PLPs and ISG15, we crystallized and determined the X-ray structures of SARS PLpro bound to the C-terminal domains of ISG15, ChISG15 and CmISG15.", [["C", "CHEMICAL", 160, 161], ["PLPs", "GENE_OR_GENE_PRODUCT", 65, 69], ["ISG15", "GENE_OR_GENE_PRODUCT", 74, 79], ["PLpro", "GENE_OR_GENE_PRODUCT", 141, 146], ["ISG15", "GENE_OR_GENE_PRODUCT", 182, 187], ["ChISG15", "GENE_OR_GENE_PRODUCT", 189, 196], ["CmISG15", "GENE_OR_GENE_PRODUCT", 201, 208], ["PLPs", "PROTEIN", 65, 69], ["ISG15", "PROTEIN", 74, 79], ["SARS PLpro", "PROTEIN", 136, 146], ["C-terminal domains", "PROTEIN", 160, 178], ["ISG15", "PROTEIN", 182, 187], ["ChISG15", "PROTEIN", 189, 196], ["CmISG15", "PROTEIN", 201, 208], ["the X-ray structures", "TEST", 112, 132], ["SARS", "PROBLEM", 136, 140], ["the C-terminal domains of ISG15", "TREATMENT", 156, 187], ["ChISG15", "TREATMENT", 189, 196], ["CmISG15", "TREATMENT", 201, 208]]], ["Attempts at co-crystallization of full-length ISG15s from human and other species with SARS CoV PLpro, as either various covalent adducts or non-covalently bound species, were made but were unsuccessful.", [["ISG15s", "GENE_OR_GENE_PRODUCT", 46, 52], ["human", "ORGANISM", 58, 63], ["SARS CoV", "ORGANISM", 87, 95], ["ISG15s", "PROTEIN", 46, 52], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["SARS CoV", "SPECIES", 87, 95], ["full-length ISG15s", "TREATMENT", 34, 52], ["SARS CoV PLpro", "TREATMENT", 87, 101], ["various covalent adducts", "PROBLEM", 113, 137], ["non-covalently bound species", "PROBLEM", 141, 169]]], ["However, the complex of SARS-CoV PLpro bound to the ChISG15, which is the principle binding domain of ISG15, crystallized readily [11].", [["SARS", "DISEASE", 24, 28], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 24, 38], ["ChISG15", "GENE_OR_GENE_PRODUCT", 52, 59], ["ISG15", "GENE_OR_GENE_PRODUCT", 102, 107], ["SARS-CoV PLpro", "PROTEIN", 24, 38], ["ChISG15", "DNA", 52, 59], ["principle binding domain", "PROTEIN", 74, 98], ["ISG15", "PROTEIN", 102, 107], ["SARS-CoV", "SPECIES", 24, 32], ["SARS", "PROBLEM", 24, 28], ["complex", "OBSERVATION_MODIFIER", 13, 20], ["SARS", "OBSERVATION", 24, 28]]], ["Specifically, we utilized a form of ChISG15 and CmISG15 that were modified with propargylamine at the C terminus (ChISG15-PA or CmISG15-PA) to form a suicide substrate that covalently links to the active site cysteine.", [["propargylamine", "CHEMICAL", 80, 94], ["cysteine", "CHEMICAL", 209, 217], ["propargylamine", "CHEMICAL", 80, 94], ["C", "CHEMICAL", 102, 103], ["cysteine", "CHEMICAL", 209, 217], ["ChISG15", "GENE_OR_GENE_PRODUCT", 36, 43], ["CmISG15", "GENE_OR_GENE_PRODUCT", 48, 55], ["propargylamine", "SIMPLE_CHEMICAL", 80, 94], ["ChISG15-PA", "GENE_OR_GENE_PRODUCT", 114, 124], ["CmISG15-PA", "GENE_OR_GENE_PRODUCT", 128, 138], ["cysteine", "AMINO_ACID", 209, 217], ["ChISG15", "PROTEIN", 36, 43], ["CmISG15", "PROTEIN", 48, 55], ["C terminus", "PROTEIN", 102, 112], ["ChISG15", "PROTEIN", 114, 121], ["CmISG15", "PROTEIN", 128, 135], ["ChISG15", "TREATMENT", 36, 43], ["CmISG15", "TREATMENT", 48, 55], ["propargylamine", "TREATMENT", 80, 94], ["CmISG15-PA", "TREATMENT", 128, 138], ["a suicide substrate", "TREATMENT", 148, 167], ["active", "OBSERVATION_MODIFIER", 197, 203], ["site cysteine", "OBSERVATION", 204, 217]]], ["From here on in, these covalently modified complexes of SARS PLpro are designated as SARS-CoV PLpro\u2013ChISG15 and SARS-CoV PLpro\u2013CmISG15 for simplicity.X-ray SARS-CoV PLpro bound to the C-terminal domain of hISG15 ::: ResultsThe X-ray structure of the SARS-CoV PLpro\u2013ChISG15 complex was determined to 2.62 \u00c5 with two complete copies of SARS-CoV PLpro\u2013ChISG15 within the asymmetric unit (Table 3).", [["SARS", "DISEASE", 56, 60], ["SARS", "DISEASE", 250, 254], ["C", "CHEMICAL", 184, 185], ["PLpro", "SIMPLE_CHEMICAL", 61, 66], ["SARS-CoV PLpro\u2013ChISG15", "SIMPLE_CHEMICAL", 85, 107], ["SARS-CoV PLpro\u2013CmISG15", "SIMPLE_CHEMICAL", 112, 134], ["hISG15", "GENE_OR_GENE_PRODUCT", 205, 211], ["SARS-CoV PLpro\u2013ChISG15", "GENE_OR_GENE_PRODUCT", 250, 272], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 334, 342], ["SARS PLpro", "PROTEIN", 56, 66], ["C-terminal domain", "DNA", 184, 201], ["hISG15", "PROTEIN", 205, 211], ["SARS-CoV PLpro\u2013ChISG15 complex", "PROTEIN", 250, 280], ["SARS-CoV PLpro\u2013ChISG15", "PROTEIN", 334, 356], ["SARS-CoV", "SPECIES", 85, 93], ["SARS-CoV", "SPECIES", 112, 120], ["SARS-CoV", "SPECIES", 250, 258], ["SARS-CoV", "SPECIES", 334, 342], ["SARS PLpro", "TREATMENT", 56, 66], ["CoV PLpro\u2013CmISG15", "TREATMENT", 117, 134], ["X-ray SARS", "TEST", 150, 160], ["The X-ray structure", "TEST", 223, 242], ["the SARS", "TEST", 246, 254], ["SARS", "TEST", 334, 338], ["asymmetric", "OBSERVATION_MODIFIER", 368, 378]]], ["The structure of CoV PLPs contains the classic tertiary fold associated with PLPs consisting of the finger, palm, thumb, and Ubl domains (Fig. 4a).", [["CoV", "ORGANISM", 17, 20], ["CoV PLPs", "PROTEIN", 17, 25], ["PLPs", "PROTEIN", 77, 81], ["finger, palm, thumb, and Ubl domains", "PROTEIN", 100, 136], ["Fig. 4a", "PROTEIN", 138, 145], ["CoV PLPs", "PROBLEM", 17, 25], ["the classic tertiary fold", "PROBLEM", 35, 60], ["PLPs", "TREATMENT", 77, 81], ["CoV PLPs", "OBSERVATION", 17, 25], ["classic", "OBSERVATION_MODIFIER", 39, 46], ["tertiary fold", "OBSERVATION", 47, 60], ["finger", "ANATOMY", 100, 106], ["palm", "ANATOMY", 108, 112], ["thumb", "ANATOMY", 114, 119]]], ["However, despite sharing the same tertiary fold, the manner in which SARS-CoV PLpro engages the C-terminal domain of hISG15 is distinct from that of Ub.", [["SARS", "DISEASE", 69, 73], ["C", "CHEMICAL", 96, 97], ["SARS-CoV", "ORGANISM", 69, 77], ["hISG15", "GENE_OR_GENE_PRODUCT", 117, 123], ["SARS-CoV PLpro", "PROTEIN", 69, 83], ["C-terminal domain", "PROTEIN", 96, 113], ["hISG15", "PROTEIN", 117, 123], ["SARS-CoV", "SPECIES", 69, 77]]], ["Overlaying the SARS-CoV PLpro\u2013ChISG15 structure with the structure of SARS-CoV PLpro with mono-Ub (PDB entry: 4MM3) reveals that compared to Ub, ChISG15 is shifted by approximately 12\u00b0 in its global orientation (Fig. 4b).X-ray SARS-CoV PLpro bound to the C-terminal domain of hISG15 ::: ResultsCloser examination of the binding interface uncovered key differences in how each substrate engages the surface of the SARS-CoV PLpro.", [["surface", "ANATOMY", 398, 405], ["SARS", "DISEASE", 15, 19], ["SARS", "DISEASE", 70, 74], ["SARS", "DISEASE", 413, 417], ["C", "CHEMICAL", 255, 256], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["mono-Ub", "GENE_OR_GENE_PRODUCT", 90, 97], ["Ub", "GENE_OR_GENE_PRODUCT", 141, 143], ["ChISG15", "GENE_OR_GENE_PRODUCT", 145, 152], ["hISG15", "GENE_OR_GENE_PRODUCT", 276, 282], ["surface", "CELLULAR_COMPONENT", 398, 405], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 413, 427], ["SARS-CoV PLpro\u2013ChISG15 structure", "DNA", 15, 47], ["SARS-CoV PLpro", "PROTEIN", 70, 84], ["Ub", "PROTEIN", 95, 97], ["MM3", "PROTEIN", 111, 114], ["Ub", "PROTEIN", 141, 143], ["ChISG15", "PROTEIN", 145, 152], ["C-terminal domain", "PROTEIN", 255, 272], ["hISG15", "PROTEIN", 276, 282], ["SARS-CoV PLpro", "PROTEIN", 413, 427], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 70, 78], ["SARS-CoV", "SPECIES", 413, 421], ["the SARS", "PROBLEM", 11, 19], ["SARS", "PROBLEM", 70, 74], ["CoV PLpro", "TEST", 75, 84], ["X-ray SARS", "TEST", 221, 231], ["Closer examination", "TEST", 294, 312], ["CoV PLpro", "TREATMENT", 418, 427], ["SARS", "OBSERVATION", 15, 19], ["SARS", "OBSERVATION", 70, 74], ["Ub", "ANATOMY_MODIFIER", 95, 97], ["shifted", "OBSERVATION_MODIFIER", 156, 163]]], ["Although there is only a minor variation surrounding a 180\u00b0 flip of Trp123 between the two copies of ChISG15 in the asymmetric unit, both ChISG15 chains are analogous in how they are accommodated by SARS-CoV PLpro compared to Ub (Fig. 4e).", [["SARS", "DISEASE", 199, 203], ["Trp123", "GENE_OR_GENE_PRODUCT", 68, 74], ["ChISG15", "GENE_OR_GENE_PRODUCT", 101, 108], ["ChISG15 chains", "GENE_OR_GENE_PRODUCT", 138, 152], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 199, 213], ["Ub", "GENE_OR_GENE_PRODUCT", 226, 228], ["Trp123", "PROTEIN", 68, 74], ["ChISG15", "PROTEIN", 101, 108], ["ChISG15 chains", "PROTEIN", 138, 152], ["Ub", "PROTEIN", 226, 228], ["SARS-CoV", "SPECIES", 199, 207], ["a minor variation", "PROBLEM", 23, 40], ["both ChISG15 chains", "TREATMENT", 133, 152], ["minor", "OBSERVATION_MODIFIER", 25, 30], ["variation", "OBSERVATION_MODIFIER", 31, 40], ["asymmetric", "OBSERVATION_MODIFIER", 116, 126]]], ["The differences appear to be driven by how hISG15 and Ub differ in their ability to interact with a hydrophobic region consisting of residues Arg167, Met209, and Pro248.", [["Arg", "CHEMICAL", 142, 145], ["Met209", "CHEMICAL", 150, 156], ["Pro248", "CHEMICAL", 162, 168], ["hISG15", "GENE_OR_GENE_PRODUCT", 43, 49], ["Ub", "GENE_OR_GENE_PRODUCT", 54, 56], ["Arg167", "AMINO_ACID", 142, 148], ["Met209", "GENE_OR_GENE_PRODUCT", 150, 156], ["Pro248", "GENE_OR_GENE_PRODUCT", 162, 168], ["hISG15", "PROTEIN", 43, 49], ["Ub", "PROTEIN", 54, 56], ["hydrophobic region", "PROTEIN", 100, 118], ["Pro248", "PROTEIN", 162, 168], ["Arg", "TEST", 142, 145]]], ["For Ub, the interactions with this region occur by means of a hydrophobic patch consisting of Ile44, Val70, and Leu8 [15].", [["Ile44", "CHEMICAL", 94, 99], ["Val70", "CHEMICAL", 101, 106], ["Leu8", "CHEMICAL", 112, 116], ["Ub", "GENE_OR_GENE_PRODUCT", 4, 6], ["Ile44", "GENE_OR_GENE_PRODUCT", 94, 99], ["Val70", "GENE_OR_GENE_PRODUCT", 101, 106], ["Ub", "PROTEIN", 4, 6], ["Ile44", "PROTEIN", 94, 99], ["Val70", "PROTEIN", 101, 106], ["a hydrophobic patch", "TREATMENT", 60, 79]]], ["In contrast, ISG15 lacks such a hydrophobic patch.", [["ISG15", "GENE_OR_GENE_PRODUCT", 13, 18], ["ISG15", "PROTEIN", 13, 18], ["a hydrophobic patch", "TREATMENT", 30, 49]]], ["The interaction is primarily driven by two distinct sets of hydrophobic interactions: hISG15's Trp123 with Met209 of the protease's palm region, and hISG15's Phe149 with a second hydrophobic site driven by Pro224 of the protease's fingers region (Fig. 4c and d).", [["hISG15", "GENE_OR_GENE_PRODUCT", 86, 92], ["Trp123", "GENE_OR_GENE_PRODUCT", 95, 101], ["Met209", "GENE_OR_GENE_PRODUCT", 107, 113], ["hISG15", "GENE_OR_GENE_PRODUCT", 149, 155], ["Phe149", "GENE_OR_GENE_PRODUCT", 158, 164], ["Pro224", "GENE_OR_GENE_PRODUCT", 206, 212], ["hISG15", "PROTEIN", 86, 92], ["Trp123", "PROTEIN", 95, 101], ["Met209", "PROTEIN", 107, 113], ["protease's palm region", "PROTEIN", 121, 143], ["hISG15", "PROTEIN", 149, 155], ["Phe149", "PROTEIN", 158, 164], ["hydrophobic site", "PROTEIN", 179, 195], ["Pro224", "PROTEIN", 206, 212], ["protease's fingers region", "PROTEIN", 220, 245], ["Fig. 4c and d)", "PROTEIN", 247, 261], ["the protease's palm region", "TREATMENT", 117, 143], ["a second hydrophobic site", "TREATMENT", 170, 195], ["the protease's fingers region", "TREATMENT", 216, 245]]], ["This predominate hydrophobic binding nature was also seen in the ITC results of SARS-CoV with ChSIG15, with an observed increase in entropic favorable interactions when compared with the hISG15 (Table 2).", [["ITC", "ANATOMY", 65, 68], ["SARS", "DISEASE", 80, 84], ["ITC", "CELL", 65, 68], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 80, 88], ["ChSIG15", "SIMPLE_CHEMICAL", 94, 101], ["ChSIG15", "PROTEIN", 94, 101], ["hISG15", "PROTEIN", 187, 193], ["SARS-CoV", "SPECIES", 80, 88], ["SARS", "PROBLEM", 80, 84], ["ChSIG15", "TREATMENT", 94, 101], ["entropic favorable interactions", "PROBLEM", 132, 163], ["hydrophobic binding", "OBSERVATION", 17, 36], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["entropic favorable", "OBSERVATION", 132, 150]]], ["Surprisingly, while the Ub-bound structure contains other polar and water-mediated interactions between Ub and the palm region of the PLpro, such interactions seem to be less pronounced in the more charged ChISG15 structure [15].", [["ChISG15", "CHEMICAL", 206, 213], ["Ub", "GENE_OR_GENE_PRODUCT", 24, 26], ["water", "SIMPLE_CHEMICAL", 68, 73], ["Ub", "GENE_OR_GENE_PRODUCT", 104, 106], ["PLpro", "GENE_OR_GENE_PRODUCT", 134, 139], ["Ub", "PROTEIN", 24, 26], ["Ub", "PROTEIN", 104, 106], ["palm region", "PROTEIN", 115, 126], ["PLpro", "PROTEIN", 134, 139], ["ChISG15 structure", "PROTEIN", 206, 223], ["polar", "OBSERVATION_MODIFIER", 58, 63], ["palm", "ANATOMY_MODIFIER", 115, 119]]], ["Overall, there are only a few water molecules present within the interface between PLpro and ChISG15 compared to the larger number that is observed in the Ub-bound structure, potentially indicating a lesser role of water-mediated hydrogen bond interactions in the binding of hISG15.X-ray SARS-CoV PLpro bound to the C-terminal domain of hISG15 ::: ResultsTo gain a better understanding of the residues mediating specificity for Ub or ISG15, we constructed mutants targeting the palm and fingers regions of the SARS-CoV PLpro, and their catalytic activities toward various substrates were determined (Fig. 5and Table 1).", [["PLpro", "CHEMICAL", 83, 88], ["ChISG15", "CHEMICAL", 93, 100], ["hydrogen", "CHEMICAL", 230, 238], ["C", "CHEMICAL", 316, 317], ["PLpro", "GENE_OR_GENE_PRODUCT", 83, 88], ["ChISG15", "GENE_OR_GENE_PRODUCT", 93, 100], ["Ub", "GENE_OR_GENE_PRODUCT", 155, 157], ["water", "SIMPLE_CHEMICAL", 215, 220], ["hydrogen", "SIMPLE_CHEMICAL", 230, 238], ["hISG15", "GENE_OR_GENE_PRODUCT", 275, 281], ["hISG15", "GENE_OR_GENE_PRODUCT", 337, 343], ["Ub", "GENE_OR_GENE_PRODUCT", 428, 430], ["ISG15", "GENE_OR_GENE_PRODUCT", 434, 439], ["palm", "ORGANISM_SUBDIVISION", 478, 482], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 510, 518], ["PLpro", "PROTEIN", 83, 88], ["ChISG15", "PROTEIN", 93, 100], ["Ub", "PROTEIN", 155, 157], ["hISG15", "PROTEIN", 275, 281], ["C-terminal domain", "DNA", 316, 333], ["hISG15", "PROTEIN", 337, 343], ["Ub", "PROTEIN", 428, 430], ["ISG15", "PROTEIN", 434, 439], ["palm and fingers regions", "PROTEIN", 478, 502], ["SARS-CoV PLpro", "PROTEIN", 510, 524], ["SARS-CoV", "SPECIES", 510, 518], ["a few water molecules", "PROBLEM", 24, 45], ["PLpro and ChISG15", "TREATMENT", 83, 100], ["X-ray SARS", "TEST", 282, 292], ["ISG15", "TREATMENT", 434, 439], ["CoV PLpro", "TREATMENT", 515, 524], ["various substrates", "TREATMENT", 564, 582], ["few", "OBSERVATION_MODIFIER", 26, 29], ["water molecules", "OBSERVATION", 30, 45], ["larger", "OBSERVATION_MODIFIER", 117, 123], ["number", "OBSERVATION_MODIFIER", 124, 130], ["bound structure", "OBSERVATION", 158, 173], ["lesser", "OBSERVATION_MODIFIER", 200, 206], ["hydrogen bond", "OBSERVATION", 230, 243], ["palm", "ANATOMY", 478, 482]]], ["These substrates included Ub- and ISG15-AMC, which are composed of the respective substrate derivatized with the fluorescent leaving group 7-amido-4-methylcoumarin.", [["7-amido-4-methylcoumarin", "CHEMICAL", 139, 163], ["7-amido-4-methylcoumarin", "CHEMICAL", 139, 163], ["Ub", "GENE_OR_GENE_PRODUCT", 26, 28], ["ISG15-AMC", "SIMPLE_CHEMICAL", 34, 43], ["7-amido-4-methylcoumarin", "SIMPLE_CHEMICAL", 139, 163], ["Ub", "PROTEIN", 26, 28], ["ISG15", "PROTEIN", 34, 39], ["AMC", "PROTEIN", 40, 43], ["Ub", "TEST", 26, 28], ["ISG15-AMC", "PROBLEM", 34, 43], ["amido", "TREATMENT", 141, 146], ["methylcoumarin", "TREATMENT", 149, 163]]], ["Additionally, the small peptide Z-RLRGG representing the consensus recognition sequence for both Ub and ISG15 that is also attached to AMC was included to probe for potential changes affecting protein\u2013protein interactions versus changes that impact intrinsic catalytic activity.X-ray SARS-CoV PLpro bound to the C-terminal domain of hISG15 ::: ResultsOne of the mutants, M209A, reduces the activity toward Ub-AMC by almost twofold and increases its activity toward Z-RLRGG-AMC by nearly fivefold while retaining wild-type levels of activity for ISG15-AMC.", [["C", "CHEMICAL", 312, 313], ["Ub", "GENE_OR_GENE_PRODUCT", 97, 99], ["ISG15", "GENE_OR_GENE_PRODUCT", 104, 109], ["hISG15", "GENE_OR_GENE_PRODUCT", 333, 339], ["Ub-AMC", "GENE_OR_GENE_PRODUCT", 406, 412], ["Z-RLRGG-AMC", "SIMPLE_CHEMICAL", 465, 476], ["ISG15-AMC", "GENE_OR_GENE_PRODUCT", 545, 554], ["Z", "PROTEIN", 32, 33], ["RLRGG", "PROTEIN", 34, 39], ["consensus recognition sequence", "DNA", 57, 87], ["Ub", "PROTEIN", 97, 99], ["ISG15", "PROTEIN", 104, 109], ["AMC", "PROTEIN", 135, 138], ["C-terminal domain", "DNA", 312, 329], ["hISG15", "PROTEIN", 333, 339], ["Ub", "PROTEIN", 406, 408], ["AMC", "PROTEIN", 409, 412], ["Z-RLRGG", "PROTEIN", 465, 472], ["ISG15", "PROTEIN", 545, 550], ["AMC", "PROTEIN", 551, 554], ["the small peptide Z-RLRGG", "PROBLEM", 14, 39], ["ISG15", "TREATMENT", 104, 109], ["potential changes affecting protein\u2013protein interactions", "PROBLEM", 165, 221], ["X-ray SARS", "TEST", 278, 288], ["small", "OBSERVATION_MODIFIER", 18, 23], ["peptide Z", "OBSERVATION", 24, 33], ["catalytic activity", "OBSERVATION", 259, 277]]], ["From a structural prospective, the reduction of Ub-AMC activity is not surprising as M209A shrinks the hydrophobic patch that engages the Ile44-centered hydrophobic patch in Ub.", [["Ile44", "CHEMICAL", 138, 143], ["M209A", "CHEMICAL", 85, 90], ["Ub", "GENE_OR_GENE_PRODUCT", 48, 50], ["M209A", "SIMPLE_CHEMICAL", 85, 90], ["Ile44", "SIMPLE_CHEMICAL", 138, 143], ["Ub", "PROTEIN", 48, 50], ["AMC", "PROTEIN", 51, 54], ["M209A", "PROTEIN", 85, 90], ["Ile44", "PROTEIN", 138, 143], ["the hydrophobic patch", "TREATMENT", 99, 120], ["AMC activity", "OBSERVATION", 51, 63], ["hydrophobic patch", "OBSERVATION", 103, 120]]], ["The observed increase of the activity toward Z-RLRGG-AMC is less straightforward.", [["Z-RLRGG", "CHEMICAL", 45, 52], ["Z-RLRGG-AMC", "CHEMICAL", 45, 56], ["Z-RLRGG-AMC", "SIMPLE_CHEMICAL", 45, 56], ["Z-RLRGG", "PROTEIN", 45, 52], ["increase", "OBSERVATION_MODIFIER", 13, 21]]], ["M209 lacks direct interaction with the last 5 aa of Ub or ISG15.", [["M209", "CHEMICAL", 0, 4], ["Ub", "GENE_OR_GENE_PRODUCT", 52, 54], ["ISG15", "GENE_OR_GENE_PRODUCT", 58, 63], ["M209", "PROTEIN", 0, 4], ["Ub", "PROTEIN", 52, 54], ["ISG15", "PROTEIN", 58, 63], ["ISG15", "TREATMENT", 58, 63]]], ["However, its replacement by alanine could sterically open up a space that is more accommodating for the artificial Z-adduct of the peptide.", [["alanine", "CHEMICAL", 28, 35], ["alanine", "CHEMICAL", 28, 35], ["alanine", "AMINO_ACID", 28, 35], ["its replacement", "TREATMENT", 9, 24], ["alanine", "TREATMENT", 28, 35], ["the artificial Z-adduct of the peptide", "TREATMENT", 100, 138]]], ["The other two mutants were found to have increased catalytic efficiencies for processing either Ub or ISG15 with a corresponding reduction in activity for the other.", [["Ub", "GENE_OR_GENE_PRODUCT", 96, 98], ["ISG15", "GENE_OR_GENE_PRODUCT", 102, 107], ["Ub", "PROTEIN", 96, 98], ["ISG15", "PROTEIN", 102, 107], ["increased catalytic efficiencies", "PROBLEM", 41, 73], ["ISG15", "PROBLEM", 102, 107], ["a corresponding reduction in activity", "PROBLEM", 113, 150], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["catalytic efficiencies", "OBSERVATION", 51, 73], ["reduction", "OBSERVATION_MODIFIER", 129, 138]]], ["R167E is over 8 times more efficient than the wild-type enzyme at hydrolyzing Ub but is about 20 times less efficient at hydrolyzing ISG15 (Fig. 5c).", [["Ub", "GENE_OR_GENE_PRODUCT", 78, 80], ["ISG15", "GENE_OR_GENE_PRODUCT", 133, 138], ["wild-type enzyme", "PROTEIN", 46, 62], ["Ub", "PROTEIN", 78, 80], ["ISG15", "PROTEIN", 133, 138], ["type enzyme at hydrolyzing Ub", "PROBLEM", 51, 80], ["hydrolyzing ISG15 (Fig. 5c", "TREATMENT", 121, 147]]], ["In contrast, Q233E is nearly threefold more efficient than wild-type at hydrolyzing ISG15 and twofold less efficient at hydrolyzing Ub.", [["ISG15", "GENE_OR_GENE_PRODUCT", 84, 89], ["ISG15", "PROTEIN", 84, 89], ["type at hydrolyzing ISG15", "PROBLEM", 64, 89]]], ["In the case of Ub, the mono-Ub structure suggests that the charge flip with R167E may introduce an additional electrostatic interaction with either Arg42 or Gln49 of Ub.", [["Arg42", "CHEMICAL", 148, 153], ["Gln49", "CHEMICAL", 157, 162], ["Ub", "GENE_OR_GENE_PRODUCT", 15, 17], ["R167E", "AMINO_ACID", 76, 81], ["Arg42", "GENE_OR_GENE_PRODUCT", 148, 153], ["Ub", "PROTEIN", 15, 17], ["mono-Ub structure", "PROTEIN", 23, 40], ["R167E", "PROTEIN", 76, 81], ["Arg42", "PROTEIN", 148, 153], ["Gln49", "PROTEIN", 157, 162], ["the charge flip", "TREATMENT", 55, 70]]], ["For the ChISG15 structure, this change occurs in close proximity to the interaction between Trp123 and Met209.", [["Met209", "CHEMICAL", 103, 109], ["ChISG15", "GENE_OR_GENE_PRODUCT", 8, 15], ["Trp123", "GENE_OR_GENE_PRODUCT", 92, 98], ["Met209", "GENE_OR_GENE_PRODUCT", 103, 109], ["ChISG15 structure", "PROTEIN", 8, 25], ["Trp123", "PROTEIN", 92, 98], ["Met209", "PROTEIN", 103, 109]]], ["Examination of the structure reveals that Arg167 may contribute to \u03c0\u2013\u03c0 interactions involving Trp123 and Arg153 of ChISG15 (Figs.", [["Arg167", "CHEMICAL", 42, 48], ["Arg153", "CHEMICAL", 105, 111], ["Arg167", "CHEMICAL", 42, 48], ["Trp123", "CHEMICAL", 94, 100], ["Arg", "CHEMICAL", 105, 108], ["Arg167", "SIMPLE_CHEMICAL", 42, 48], ["\u03c0\u2013\u03c0", "GENE_OR_GENE_PRODUCT", 67, 70], ["Trp123", "GENE_OR_GENE_PRODUCT", 94, 100], ["Arg153", "AMINO_ACID", 105, 111], ["ChISG15", "GENE_OR_GENE_PRODUCT", 115, 122], ["Trp123", "PROTEIN", 94, 100], ["ChISG15", "PROTEIN", 115, 122], ["Examination of the structure", "TEST", 0, 28], ["Arg", "TEST", 42, 45], ["Arg", "TEST", 105, 108]]], ["Replacing the longer and positively charged arginine with the shorter glutamate removes this contribution.", [["arginine", "CHEMICAL", 44, 52], ["glutamate", "CHEMICAL", 70, 79], ["arginine", "CHEMICAL", 44, 52], ["glutamate", "CHEMICAL", 70, 79], ["arginine", "AMINO_ACID", 44, 52], ["glutamate", "SIMPLE_CHEMICAL", 70, 79], ["the shorter glutamate", "TREATMENT", 58, 79]]], ["Additionally, this charge flip may disrupt the electrostatic interaction between Arg153 and Glu168 of the PLpro, potentially resulting in a loss of affinity for ChISG15.", [["Arg153", "CHEMICAL", 81, 87], ["Arg", "CHEMICAL", 81, 84], ["Glu168", "CHEMICAL", 92, 98], ["Arg153", "AMINO_ACID", 81, 87], ["Glu168", "AMINO_ACID", 92, 98], ["PLpro", "GENE_OR_GENE_PRODUCT", 106, 111], ["ChISG15", "GENE_OR_GENE_PRODUCT", 161, 168], ["PLpro", "PROTEIN", 106, 111], ["ChISG15", "PROTEIN", 161, 168], ["this charge flip", "TREATMENT", 14, 30], ["Arg", "TEST", 81, 84], ["the PLpro", "TREATMENT", 102, 111], ["a loss of affinity", "PROBLEM", 138, 156], ["ChISG15", "TREATMENT", 161, 168]]], ["For Q233E, the change from a neutral polar to a charged group may create a potential electrostatic repulsion with the backbone carbonyl of Ala46 in Ub (Fig. 5b).", [["carbonyl", "CHEMICAL", 127, 135], ["Ala46", "CHEMICAL", 139, 144], ["Ala46", "SIMPLE_CHEMICAL", 139, 144], ["Ub", "GENE_OR_GENE_PRODUCT", 148, 150], ["Ub", "PROTEIN", 148, 150], ["a neutral polar", "TREATMENT", 27, 42], ["a potential electrostatic repulsion", "TREATMENT", 73, 108], ["the backbone carbonyl of Ala46 in Ub", "TREATMENT", 114, 150], ["electrostatic repulsion", "OBSERVATION", 85, 108]]], ["For the ChISG15 structure, in comparison, there is not a clear direct interaction between PLpro and ISG15 that would be affected.", [["ChISG15", "GENE_OR_GENE_PRODUCT", 8, 15], ["PLpro", "GENE_OR_GENE_PRODUCT", 90, 95], ["ISG15", "GENE_OR_GENE_PRODUCT", 100, 105], ["ChISG15 structure", "PROTEIN", 8, 25], ["PLpro", "PROTEIN", 90, 95], ["ISG15", "PROTEIN", 100, 105], ["PLpro and ISG15", "TREATMENT", 90, 105]]], ["This suggests that the impact of this mutation may stem from internal changes within the PLpro regarding the flexibility of the finger region rather than direct interactions with the substrate.X-ray structure of SARS-CoV PLpro bound to the C-terminal domain of mISG15 ::: ResultsIn light of the differences in the nature of interactions between different species' ISG15s revealed by ITC, and the apparent plasticity that can occur between Ub and hISG15 within the SARS-CoV PLpro active site, insights into the structural sources of this phenomenon were sought.", [["finger", "ANATOMY", 128, 134], ["C", "CHEMICAL", 240, 241], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 212, 220], ["ISG15s", "GENE_OR_GENE_PRODUCT", 364, 370], ["ITC", "CELL", 383, 386], ["Ub", "GENE_OR_GENE_PRODUCT", 439, 441], ["hISG15", "GENE_OR_GENE_PRODUCT", 446, 452], ["finger region", "PROTEIN", 128, 141], ["SARS-CoV PLpro", "PROTEIN", 212, 226], ["C-terminal domain", "PROTEIN", 240, 257], ["mISG15", "PROTEIN", 261, 267], ["ISG15s", "PROTEIN", 364, 370], ["Ub", "PROTEIN", 439, 441], ["hISG15", "PROTEIN", 446, 452], ["SARS-CoV PLpro active site", "DNA", 464, 490], ["SARS-CoV", "SPECIES", 212, 220], ["SARS-CoV", "SPECIES", 464, 472], ["this mutation", "PROBLEM", 33, 46], ["internal changes", "PROBLEM", 61, 77], ["SARS", "PROBLEM", 212, 216], ["Ub", "TEST", 439, 441], ["CoV PLpro active site", "TREATMENT", 469, 490], ["this phenomenon", "PROBLEM", 532, 547], ["finger", "ANATOMY", 128, 134], ["region", "ANATOMY_MODIFIER", 135, 141], ["SARS", "OBSERVATION", 212, 216]]], ["To this end, a structure of SARS-CoV PLpro with CmISG15 was determined to a resolution of 2.4 \u00c5 (Fig. 6a).", [["SARS", "DISEASE", 28, 32], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["CmISG15", "GENE_OR_GENE_PRODUCT", 48, 55], ["SARS-CoV PLpro", "PROTEIN", 28, 42], ["CmISG15", "PROTEIN", 48, 55], ["SARS-CoV", "SPECIES", 28, 36], ["SARS", "PROBLEM", 28, 32], ["CmISG15", "TREATMENT", 48, 55]]], ["The structure of the catalytic core domain of SARS-CoV PLpro is consistent with the structure of the ChISG15 SARS-CoV PLpro structure.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 46, 54], ["catalytic core domain", "PROTEIN", 21, 42], ["SARS-CoV PLpro", "PROTEIN", 46, 60], ["ChISG15 SARS-CoV PLpro structure", "PROTEIN", 101, 133], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 109, 117], ["SARS", "PROBLEM", 46, 50], ["SARS", "OBSERVATION", 46, 50], ["consistent with", "UNCERTAINTY", 64, 79]]], ["However, a major difference in the orientation of the Ubl domain of SARS-CoV PLpro is observed when bound to CmISG15.", [["SARS", "DISEASE", 68, 72], ["CmISG15", "CHEMICAL", 109, 116], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 68, 76], ["CmISG15", "GENE_OR_GENE_PRODUCT", 109, 116], ["Ubl domain", "PROTEIN", 54, 64], ["SARS-CoV PLpro", "PROTEIN", 68, 82], ["CmISG15", "PROTEIN", 109, 116], ["SARS-CoV", "SPECIES", 68, 76], ["SARS", "PROBLEM", 68, 72], ["CoV PLpro", "TREATMENT", 73, 82], ["major", "OBSERVATION_MODIFIER", 11, 16], ["difference", "OBSERVATION_MODIFIER", 17, 27]]], ["Unlike previous SARS-CoV PLpro structures where the Ubl domains differ only slightly in its position/orientation to the catalytic domain or are unobservable because of weak electron density, suggesting potential flexibility, the Ubl in the SARS-CoV PLpro\u2013CmISG15 structure takes a sharp, almost 90\u00b0 turn in orientation when compared with previous X-ray structures (Fig. 6c).", [["SARS", "DISEASE", 240, 244], ["electron", "SIMPLE_CHEMICAL", 173, 181], ["Ubl domains", "DNA", 52, 63], ["catalytic domain", "PROTEIN", 120, 136], ["Ubl", "DNA", 229, 232], ["SARS-CoV PLpro\u2013CmISG15 structure", "DNA", 240, 272], ["SARS-CoV", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 240, 248], ["previous SARS", "PROBLEM", 7, 20], ["CoV PLpro structures", "TREATMENT", 21, 41], ["the Ubl domains", "TEST", 48, 63], ["weak electron density", "PROBLEM", 168, 189], ["potential flexibility", "PROBLEM", 202, 223], ["the Ubl in the SARS", "PROBLEM", 225, 244], ["previous X-ray structures", "TEST", 338, 363], ["SARS", "OBSERVATION", 16, 20], ["slightly", "OBSERVATION_MODIFIER", 76, 84], ["density", "OBSERVATION", 182, 189], ["SARS", "OBSERVATION", 240, 244], ["sharp", "OBSERVATION_MODIFIER", 281, 286]]], ["The new orientation does not appear to form contacts with the bound CmISG15, suggesting that there is no direct influence on the Ubl domain to adopt this conformation.", [["CmISG15", "GENE_OR_GENE_PRODUCT", 68, 75], ["CmISG15", "PROTEIN", 68, 75], ["Ubl domain", "PROTEIN", 129, 139], ["the Ubl domain", "TREATMENT", 125, 139]]], ["Further analysis of the new orientation reveals a seam made up of several electrostatic interactions between the Ubl domain and the thumb domains of the PLpro, indicating that this orientation can be stabilized (Fig. 6b).X-ray structure of SARS-CoV PLpro bound to the C-terminal domain of mISG15 ::: ResultsThe Ubl domain was not the only global difference between the SARS-CoV PLpro\u2013CmISG15 and SARS-CoV PLpro\u2013ChISG15 complexes.", [["SARS", "DISEASE", 369, 373], ["C", "CHEMICAL", 268, 269], ["PLpro", "GENE_OR_GENE_PRODUCT", 153, 158], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 240, 248], ["SARS-CoV PLpro\u2013ChISG15", "GENE_OR_GENE_PRODUCT", 396, 418], ["Ubl domain", "PROTEIN", 113, 123], ["thumb domains", "PROTEIN", 132, 145], ["PLpro", "PROTEIN", 153, 158], ["SARS-CoV PLpro", "PROTEIN", 240, 254], ["C-terminal domain", "PROTEIN", 268, 285], ["mISG15", "PROTEIN", 289, 295], ["Ubl domain", "PROTEIN", 311, 321], ["SARS-CoV PLpro\u2013CmISG15", "PROTEIN", 369, 391], ["SARS-CoV PLpro\u2013ChISG15 complexes", "PROTEIN", 396, 428], ["SARS-CoV", "SPECIES", 240, 248], ["SARS-CoV", "SPECIES", 369, 377], ["SARS-CoV", "SPECIES", 396, 404], ["Further analysis", "TEST", 0, 16], ["the Ubl domain", "TREATMENT", 109, 123], ["the PLpro", "TREATMENT", 149, 158], ["X-ray structure", "TEST", 221, 236], ["SARS", "PROBLEM", 240, 244], ["the SARS", "TEST", 365, 373], ["SARS-CoV PLpro\u2013ChISG15 complexes", "TREATMENT", 396, 428], ["new", "OBSERVATION_MODIFIER", 24, 27], ["thumb", "ANATOMY", 132, 137], ["SARS", "OBSERVATION", 240, 244]]], ["Surprisingly, the global orientation of CmISG15 is tilted 27\u00b0 away from the fingers in SARS-CoV PLpro (Fig. 6d).", [["SARS", "DISEASE", 87, 91], ["CmISG15", "GENE_OR_GENE_PRODUCT", 40, 47], ["CmISG15", "DNA", 40, 47], ["SARS-CoV", "SPECIES", 87, 95], ["global", "OBSERVATION_MODIFIER", 18, 24], ["fingers", "ANATOMY", 76, 83]]], ["Interestingly, 4 aa appear to explain the lack of CmISG15's accommodation in the same orientation to that of bound ChISG15.", [["CmISG15", "GENE_OR_GENE_PRODUCT", 50, 57], ["ChISG15", "GENE_OR_GENE_PRODUCT", 115, 122], ["CmISG15", "PROTEIN", 50, 57], ["ChISG15", "PROTEIN", 115, 122], ["CmISG15's accommodation", "TREATMENT", 50, 73]]], ["At position 149 in ChISG15 and 147 in CmISG15, there is an amino acid difference of a phenylalanine and an isoleucine, respectively (Fig. 6e).", [["amino acid", "CHEMICAL", 59, 69], ["phenylalanine", "CHEMICAL", 86, 99], ["isoleucine", "CHEMICAL", 107, 117], ["amino acid", "CHEMICAL", 59, 69], ["phenylalanine", "CHEMICAL", 86, 99], ["isoleucine", "CHEMICAL", 107, 117], ["CmISG15", "GENE_OR_GENE_PRODUCT", 38, 45], ["amino acid", "AMINO_ACID", 59, 69], ["phenylalanine", "AMINO_ACID", 86, 99], ["isoleucine", "AMINO_ACID", 107, 117], ["an amino acid difference", "PROBLEM", 56, 80], ["a phenylalanine", "TREATMENT", 84, 99], ["an isoleucine", "TREATMENT", 104, 117]]], ["This change in CmISG15 eliminates the hydrophobic interaction with the finger region of SARS-CoV PLpro seen in the ChISG15-bound structure and likely aids in the tilt toward the Ubl domain.", [["CmISG15", "CHEMICAL", 15, 22], ["SARS", "DISEASE", 88, 92], ["CmISG15", "GENE_OR_GENE_PRODUCT", 15, 22], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 88, 96], ["CmISG15", "PROTEIN", 15, 22], ["finger region", "PROTEIN", 71, 84], ["SARS-CoV PLpro", "PROTEIN", 88, 102], ["ChISG15", "PROTEIN", 115, 122], ["Ubl domain", "PROTEIN", 178, 188], ["SARS-CoV", "SPECIES", 88, 96], ["This change in CmISG15", "PROBLEM", 0, 22], ["the hydrophobic interaction", "PROBLEM", 34, 61], ["SARS", "PROBLEM", 88, 92], ["CoV PLpro", "TREATMENT", 93, 102], ["hydrophobic interaction", "OBSERVATION", 38, 61], ["finger", "ANATOMY", 71, 77], ["SARS", "OBSERVATION", 88, 92], ["likely", "UNCERTAINTY", 143, 149], ["aids", "OBSERVATION", 150, 154]]], ["In addition, there is a change from Asn89, Thr125, and Asn151 in ChISG15 to Glu87, Ser123, and His149 in CmISG15 (Fig. 6f).", [["Asn89", "CHEMICAL", 36, 41], ["Thr", "CHEMICAL", 43, 46], ["Asn151", "CHEMICAL", 55, 61], ["Glu87", "CHEMICAL", 76, 81], ["Ser123", "CHEMICAL", 83, 89], ["His", "CHEMICAL", 95, 98], ["Asn89", "GENE_OR_GENE_PRODUCT", 36, 41], ["Thr125", "AMINO_ACID", 43, 49], ["Asn151", "GENE_OR_GENE_PRODUCT", 55, 61], ["ChISG15", "GENE_OR_GENE_PRODUCT", 65, 72], ["Glu87", "GENE_OR_GENE_PRODUCT", 76, 81], ["Ser123", "GENE_OR_GENE_PRODUCT", 83, 89], ["Asn89", "PROTEIN", 36, 41], ["ChISG15", "PROTEIN", 65, 72], ["Thr", "TEST", 43, 46], ["His", "TEST", 95, 98], ["change", "OBSERVATION_MODIFIER", 24, 30]]], ["These amino acid differences create a hydrogen bond network among Glu87, His149, and Ser123 in the CmISG15, which is absent in the ChISG15-bound structure.", [["amino acid", "CHEMICAL", 6, 16], ["amino acid", "CHEMICAL", 6, 16], ["hydrogen", "CHEMICAL", 38, 46], ["Glu87", "CHEMICAL", 66, 71], ["His", "CHEMICAL", 73, 76], ["Ser123", "CHEMICAL", 85, 91], ["amino acid", "AMINO_ACID", 6, 16], ["Glu87", "GENE_OR_GENE_PRODUCT", 66, 71], ["His149", "AMINO_ACID", 73, 79], ["Ser123", "AMINO_ACID", 85, 91], ["CmISG15", "GENE_OR_GENE_PRODUCT", 99, 106], ["Glu87", "PROTEIN", 66, 71], ["Ser123", "PROTEIN", 85, 91], ["CmISG15", "PROTEIN", 99, 106], ["ChISG15", "PROTEIN", 131, 138], ["These amino acid differences", "PROBLEM", 0, 28], ["a hydrogen bond network", "TEST", 36, 59], ["His", "TEST", 73, 76], ["hydrogen bond", "OBSERVATION", 38, 51], ["absent", "OBSERVATION", 117, 123]]], ["This network locks the Glu87 into an unfavorable position for CmISG15 to bind in the same manner as ChISG15.", [["Glu87", "GENE_OR_GENE_PRODUCT", 23, 28], ["CmISG15", "GENE_OR_GENE_PRODUCT", 62, 69], ["ChISG15", "GENE_OR_GENE_PRODUCT", 100, 107], ["Glu87", "PROTEIN", 23, 28], ["CmISG15", "PROTEIN", 62, 69], ["ChISG15", "PROTEIN", 100, 107], ["CmISG15", "TREATMENT", 62, 69]]], ["The unfavorable position ultimately results in the repulsion of CmISG15 against PLpro.X-ray structure of SARS-CoV PLpro bound to the C-terminal domain of mISG15 ::: ResultsIn concert with a loss of the hydrophobic interaction with the finger region and potential electrostatic repulsions that CmISG15 would incur in binding in the same orientation of ChISG15, the CmISG15 bound orientation facilitates the formation of numerous favorable interactions.", [["CmISG15", "CHEMICAL", 293, 300], ["C", "CHEMICAL", 133, 134], ["CmISG15", "GENE_OR_GENE_PRODUCT", 64, 71], ["PLpro", "GENE_OR_GENE_PRODUCT", 80, 85], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 105, 113], ["CmISG15", "SIMPLE_CHEMICAL", 293, 300], ["ChISG15", "GENE_OR_GENE_PRODUCT", 351, 358], ["CmISG15", "PROTEIN", 64, 71], ["PLpro", "PROTEIN", 80, 85], ["SARS-CoV PLpro", "PROTEIN", 105, 119], ["C-terminal domain", "PROTEIN", 133, 150], ["mISG15", "PROTEIN", 154, 160], ["finger region", "PROTEIN", 235, 248], ["CmISG15", "PROTEIN", 293, 300], ["ChISG15", "PROTEIN", 351, 358], ["CmISG15", "PROTEIN", 364, 371], ["SARS-CoV", "SPECIES", 105, 113], ["CmISG15", "TREATMENT", 64, 71], ["PLpro", "TREATMENT", 80, 85], ["SARS", "PROBLEM", 105, 109], ["the hydrophobic interaction with the finger region", "PROBLEM", 198, 248], ["potential electrostatic repulsions", "PROBLEM", 253, 287], ["unfavorable", "OBSERVATION_MODIFIER", 4, 15], ["position", "OBSERVATION_MODIFIER", 16, 24], ["SARS", "OBSERVATION", 105, 109], ["finger", "ANATOMY", 235, 241], ["electrostatic repulsions", "OBSERVATION", 263, 287], ["numerous", "OBSERVATION_MODIFIER", 419, 427], ["favorable", "OBSERVATION_MODIFIER", 428, 437]]], ["Consistent with the X-ray structures of other deISGylases bound to the C-terminal domain of hISG15 [27], [28], the conserved Trp121 of mISG15 is centric to the interface.", [["C", "CHEMICAL", 71, 72], ["deISGylases", "GENE_OR_GENE_PRODUCT", 46, 57], ["Trp121", "GENE_OR_GENE_PRODUCT", 125, 131], ["mISG15", "GENE_OR_GENE_PRODUCT", 135, 141], ["deISGylases", "PROTEIN", 46, 57], ["C-terminal domain", "PROTEIN", 71, 88], ["hISG15", "PROTEIN", 92, 98], ["Trp121", "PROTEIN", 125, 131], ["mISG15", "PROTEIN", 135, 141], ["the X-ray structures", "TEST", 16, 36], ["other deISGylases bound", "PROBLEM", 40, 63]]], ["However, unlike the interaction observed in the SARS-CoV PLpro\u2013ChISG15 structure, Trp121 in the mISG15 does not insert into a hydrophobic pocket.", [["SARS", "DISEASE", 48, 52], ["Trp121", "GENE_OR_GENE_PRODUCT", 82, 88], ["SARS-CoV PLpro\u2013ChISG15 structure", "DNA", 48, 80], ["Trp121", "PROTEIN", 82, 88], ["mISG15", "PROTEIN", 96, 102], ["SARS-CoV", "SPECIES", 48, 56], ["a hydrophobic pocket", "PROBLEM", 124, 144], ["hydrophobic pocket", "OBSERVATION", 126, 144]]], ["Instead, mISG15's Trp121 and Pro128 form significantly smaller hydrophobic interaction with SARS-CoV PLpro via the proteses' extended alkyl chain of Glu168 generated by the hydrogen bond formed between it and Thr171.", [["alkyl", "CHEMICAL", 134, 139], ["Glu168", "CHEMICAL", 149, 155], ["Glu168", "CHEMICAL", 149, 155], ["hydrogen", "CHEMICAL", 173, 181], ["Thr", "CHEMICAL", 209, 212], ["mISG15", "GENE_OR_GENE_PRODUCT", 9, 15], ["Trp121", "GENE_OR_GENE_PRODUCT", 18, 24], ["Pro128", "GENE_OR_GENE_PRODUCT", 29, 35], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 92, 106], ["Glu168", "SIMPLE_CHEMICAL", 149, 155], ["Thr171", "AMINO_ACID", 209, 215], ["mISG15", "PROTEIN", 9, 15], ["Trp121", "PROTEIN", 18, 24], ["Pro128", "PROTEIN", 29, 35], ["SARS-CoV PLpro", "PROTEIN", 92, 106], ["proteses' extended alkyl chain", "PROTEIN", 115, 145], ["Glu168", "PROTEIN", 149, 155], ["SARS-CoV", "SPECIES", 92, 100], ["significantly smaller hydrophobic interaction", "PROBLEM", 41, 86], ["SARS", "PROBLEM", 92, 96], ["CoV PLpro", "TREATMENT", 97, 106], ["the proteses' extended alkyl chain", "TREATMENT", 111, 145], ["hydrogen bond", "OBSERVATION", 173, 186]]], ["In contrast to the bound ChISG15 and outside the last five C terminus consensus amino acids of Ub and ISG15, this weak hydrophobic interaction between CmISG15 and the protease is the only one observed.", [["amino acids", "CHEMICAL", 80, 91], ["C", "CHEMICAL", 59, 60], ["amino acids", "CHEMICAL", 80, 91], ["ChISG15", "GENE_OR_GENE_PRODUCT", 25, 32], ["amino acids", "AMINO_ACID", 80, 91], ["Ub", "GENE_OR_GENE_PRODUCT", 95, 97], ["ISG15", "GENE_OR_GENE_PRODUCT", 102, 107], ["CmISG15", "GENE_OR_GENE_PRODUCT", 151, 158], ["ChISG15", "PROTEIN", 25, 32], ["C terminus consensus amino acids", "PROTEIN", 59, 91], ["Ub", "PROTEIN", 95, 97], ["ISG15", "PROTEIN", 102, 107], ["CmISG15", "PROTEIN", 151, 158], ["protease", "PROTEIN", 167, 175], ["amino acids", "TEST", 80, 91], ["Ub", "TEST", 95, 97], ["ISG15", "TREATMENT", 102, 107], ["this weak hydrophobic interaction", "PROBLEM", 109, 142], ["CmISG15", "TREATMENT", 151, 158], ["the protease", "TREATMENT", 163, 175]]], ["In addition to the hydrophobic binding contributions of mISG15 Trp121, a water molecule is observed to mediate a hydrogen-bonding network between Trp121's indole nitrogen and several nearby PLpro residues (Fig. 6g and h).", [["mISG15", "CHEMICAL", 56, 62], ["Trp121", "CHEMICAL", 63, 69], ["Trp121's indole nitrogen", "CHEMICAL", 146, 170], ["Trp", "CHEMICAL", 63, 66], ["hydrogen", "CHEMICAL", 113, 121], ["Trp", "CHEMICAL", 146, 149], ["indole", "CHEMICAL", 155, 161], ["nitrogen", "CHEMICAL", 162, 170], ["PLpro", "CHEMICAL", 190, 195], ["mISG15", "SIMPLE_CHEMICAL", 56, 62], ["Trp121", "AMINO_ACID", 63, 69], ["Trp121", "SIMPLE_CHEMICAL", 146, 152], ["indole nitrogen", "SIMPLE_CHEMICAL", 155, 170], ["mISG15 Trp", "TEST", 56, 66], ["a water molecule", "PROBLEM", 71, 87], ["Trp", "TEST", 146, 149], ["indole nitrogen", "TREATMENT", 155, 170], ["several nearby PLpro residues", "TREATMENT", 175, 204]]], ["Including this hydrogen bond network, CmISG15 forms almost 40% more hydrogen bonds with the protease that is then observed with ChISG15.", [["CmISG15", "CHEMICAL", 38, 45], ["hydrogen", "CHEMICAL", 15, 23], ["CmISG15", "CHEMICAL", 38, 45], ["hydrogen", "CHEMICAL", 68, 76], ["ChISG15", "CHEMICAL", 128, 135], ["CmISG15", "SIMPLE_CHEMICAL", 38, 45], ["ChISG15", "SIMPLE_CHEMICAL", 128, 135], ["CmISG15", "PROTEIN", 38, 45], ["protease", "PROTEIN", 92, 100], ["ChISG15", "PROTEIN", 128, 135], ["this hydrogen bond network", "TREATMENT", 10, 36], ["the protease", "TREATMENT", 88, 100], ["ChISG15", "TREATMENT", 128, 135]]], ["One set of these additional electrostatic interactions are centered on SARS-CoV PLpro's Arg83 and CmISG15's Lys132.", [["Lys132", "CHEMICAL", 108, 114], ["Lys", "CHEMICAL", 108, 111], ["Arg83", "SIMPLE_CHEMICAL", 88, 93], ["Lys132", "AMINO_ACID", 108, 114], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "TEST", 71, 75], ["CmISG15's Lys", "TREATMENT", 98, 111], ["electrostatic interactions", "OBSERVATION", 28, 54]]], ["Others are also observed to form between SARS-CoV PLpro's Asn157, Gln175, and Arg167 and CmISG15's Glu130, the carbonyl of Gly126, and His149, respectively (Fig. 6g and h).X-ray structure of SARS-CoV PLpro bound to the C-terminal domain of mISG15 ::: ResultsTaken overall, the interface of bound CmISG15 of 872.5 \u00c52 is similar in size to that of the ChISG15's ~ 767 \u00c52 interface, but it consists of predominately electrostatic interactions, whereas the former has a significantly greater hydrophobic component.", [["Arg", "CHEMICAL", 78, 81], ["Glu130", "CHEMICAL", 99, 105], ["carbonyl", "CHEMICAL", 111, 119], ["Gly126", "CHEMICAL", 123, 129], ["His149", "CHEMICAL", 135, 141], ["C", "CHEMICAL", 219, 220], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["Asn157", "GENE_OR_GENE_PRODUCT", 58, 64], ["Gln175", "GENE_OR_GENE_PRODUCT", 66, 72], ["Arg167", "AMINO_ACID", 78, 84], ["CmISG15", "GENE_OR_GENE_PRODUCT", 89, 96], ["Glu130", "GENE_OR_GENE_PRODUCT", 99, 105], ["Gly126", "GENE_OR_GENE_PRODUCT", 123, 129], ["His149", "AMINO_ACID", 135, 141], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 191, 199], ["SARS-CoV PLpro", "PROTEIN", 191, 205], ["C-terminal domain", "PROTEIN", 219, 236], ["mISG15", "PROTEIN", 240, 246], ["CmISG15", "PROTEIN", 296, 303], ["ChISG15", "PROTEIN", 350, 357], ["SARS-CoV", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 191, 199], ["SARS", "TEST", 41, 45], ["CoV PLpro", "TEST", 46, 55], ["Gln", "TEST", 66, 69], ["Arg", "TEST", 78, 81], ["CmISG15", "TEST", 89, 96], ["X-ray structure", "TEST", 172, 187], ["SARS", "PROBLEM", 191, 195], ["a significantly greater hydrophobic component", "PROBLEM", 464, 509], ["SARS", "OBSERVATION", 191, 195], ["similar", "OBSERVATION_MODIFIER", 319, 326], ["size", "OBSERVATION_MODIFIER", 330, 334], ["predominately", "OBSERVATION_MODIFIER", 399, 412], ["electrostatic interactions", "OBSERVATION", 413, 439], ["significantly", "OBSERVATION_MODIFIER", 466, 479], ["greater", "OBSERVATION_MODIFIER", 480, 487], ["hydrophobic", "OBSERVATION_MODIFIER", 488, 499], ["component", "OBSERVATION_MODIFIER", 500, 509]]], ["In line with this, a greater number of water molecules, approximately 10, can be observed within the interface, further indicating the degree to which binding may be driven by more hydrophilic interactions.", [["line", "OBSERVATION_MODIFIER", 3, 7], ["greater", "OBSERVATION_MODIFIER", 21, 28], ["number", "OBSERVATION_MODIFIER", 29, 35], ["water molecules", "OBSERVATION_MODIFIER", 39, 54], ["hydrophilic interactions", "OBSERVATION", 181, 205]]], ["This characterization of the binding interaction is consistent with the thermodynamic properties observed for the binding of CmISG15 to SARS-CoV PLpro (Table 2).", [["CmISG15", "SIMPLE_CHEMICAL", 125, 132], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 136, 144], ["CmISG15", "PROTEIN", 125, 132], ["SARS-CoV", "SPECIES", 136, 144], ["the binding interaction", "PROBLEM", 25, 48], ["CoV PLpro (Table", "TREATMENT", 141, 157]]], ["Also, when viewed in conjunction with the affinity data of mISG15 and hISG15 and their C-terminal domain counterparts, it suggests that the type of interface formed between CmISG15 and SARS-CoV PLpro is less stable than its ChISG15 counterpart and may be one of the contributing factors to the overall reduction in binding affinity observed for full-length mISG15 when compared to hISG15 via ITC.X-ray structure of the full-length, unbound form of mISG15 and comparison with hISG15 ::: ResultsWhereas some viral deISGylating enzymes, such as vOTUs, are thought to exclusively interact with the C terminus of ISG15, SARS PLpro has been shown to contain two Ub-binding sites that likely engage the N terminus of ISG15s [11], [15].", [["ITC", "ANATOMY", 392, 395], ["PLpro", "CHEMICAL", 620, 625], ["C", "CHEMICAL", 87, 88], ["C", "CHEMICAL", 594, 595], ["N", "CHEMICAL", 696, 697], ["mISG15", "GENE_OR_GENE_PRODUCT", 59, 65], ["hISG15", "GENE_OR_GENE_PRODUCT", 70, 76], ["CmISG15", "GENE_OR_GENE_PRODUCT", 173, 180], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 185, 193], ["ChISG15", "GENE_OR_GENE_PRODUCT", 224, 231], ["mISG15", "GENE_OR_GENE_PRODUCT", 357, 363], ["hISG15", "GENE_OR_GENE_PRODUCT", 381, 387], ["ITC", "CELL", 392, 395], ["mISG15", "GENE_OR_GENE_PRODUCT", 448, 454], ["vOTUs", "GENE_OR_GENE_PRODUCT", 542, 547], ["ISG15", "GENE_OR_GENE_PRODUCT", 608, 613], ["PLpro", "GENE_OR_GENE_PRODUCT", 620, 625], ["Ub", "GENE_OR_GENE_PRODUCT", 656, 658], ["mISG15", "PROTEIN", 59, 65], ["hISG15", "PROTEIN", 70, 76], ["C-terminal domain counterparts", "PROTEIN", 87, 117], ["CmISG15", "PROTEIN", 173, 180], ["SARS-CoV PLpro", "PROTEIN", 185, 199], ["ChISG15 counterpart", "PROTEIN", 224, 243], ["mISG15", "PROTEIN", 357, 363], ["hISG15", "PROTEIN", 381, 387], ["mISG15", "PROTEIN", 448, 454], ["hISG15", "PROTEIN", 475, 481], ["viral deISGylating enzymes", "PROTEIN", 506, 532], ["vOTUs", "PROTEIN", 542, 547], ["C terminus", "PROTEIN", 594, 604], ["ISG15", "PROTEIN", 608, 613], ["SARS PLpro", "PROTEIN", 615, 625], ["Ub", "PROTEIN", 656, 658], ["N terminus", "PROTEIN", 696, 706], ["ISG15s", "PROTEIN", 710, 716], ["SARS-CoV", "SPECIES", 185, 193], ["mISG15", "TEST", 59, 65], ["hISG15", "TREATMENT", 70, 76], ["their C-terminal domain counterparts", "TREATMENT", 81, 117], ["CmISG15", "TEST", 173, 180], ["SARS", "PROBLEM", 185, 189], ["CoV PLpro", "TEST", 190, 199], ["binding affinity", "PROBLEM", 315, 331], ["full-length mISG15", "TREATMENT", 345, 363], ["some viral deISGylating enzymes", "TEST", 501, 532], ["the C terminus of ISG15", "PROBLEM", 590, 613], ["SARS PLpro", "TREATMENT", 615, 625], ["less", "OBSERVATION_MODIFIER", 203, 207], ["stable", "OBSERVATION_MODIFIER", 208, 214], ["ray structure", "OBSERVATION_MODIFIER", 398, 411]]], ["With only the full-length hISG15 structure available, the impact of ISG15 biodiversity within the N-terminal region has been difficult to assess.", [["N", "CHEMICAL", 98, 99], ["hISG15", "GENE_OR_GENE_PRODUCT", 26, 32], ["ISG15", "GENE_OR_GENE_PRODUCT", 68, 73], ["hISG15 structure", "PROTEIN", 26, 42], ["ISG15", "PROTEIN", 68, 73], ["N-terminal region", "DNA", 98, 115], ["ISG15 biodiversity", "TREATMENT", 68, 86], ["ISG15 biodiversity", "OBSERVATION", 68, 86], ["terminal", "ANATOMY_MODIFIER", 100, 108], ["region", "ANATOMY_MODIFIER", 109, 115]]], ["To address this issue, we determined the X-ray structure of mISG15 with both domains to assess the conformational variability of mISG15 compared to hISG15.", [["mISG15", "GENE_OR_GENE_PRODUCT", 60, 66], ["mISG15", "GENE_OR_GENE_PRODUCT", 129, 135], ["hISG15", "GENE_OR_GENE_PRODUCT", 148, 154], ["mISG15", "PROTEIN", 60, 66], ["mISG15", "PROTEIN", 129, 135], ["hISG15", "PROTEIN", 148, 154], ["the X-ray structure", "TEST", 37, 56]]], ["Initially, only a low-resolution (4 \u00c5) structure could be determined.", [["a low-resolution (4 \u00c5) structure", "TREATMENT", 16, 48], ["low", "OBSERVATION_MODIFIER", 18, 21]]], ["Using the program Define Secondary Structure of Proteins (DSSP), the secondary structure of mISG15 was determined to be comparable to hISG15. mISG15 contains nine beta sheets, two helices, but only two 310 helices within the C-terminal domain; this differs from the hISG15 that contains two 310 helices per domain of ISG15 (Fig. 7a) [29].", [["C", "CHEMICAL", 225, 226], ["mISG15", "GENE_OR_GENE_PRODUCT", 92, 98], ["hISG15", "GENE_OR_GENE_PRODUCT", 134, 140], ["mISG15", "GENE_OR_GENE_PRODUCT", 142, 148], ["hISG15", "GENE_OR_GENE_PRODUCT", 266, 272], ["ISG15", "GENE_OR_GENE_PRODUCT", 317, 322], ["DSSP", "PROTEIN", 58, 62], ["mISG15", "PROTEIN", 92, 98], ["hISG15", "PROTEIN", 134, 140], ["mISG15", "PROTEIN", 142, 148], ["beta sheets", "PROTEIN", 163, 174], ["C-terminal domain", "PROTEIN", 225, 242], ["hISG15", "PROTEIN", 266, 272], ["310 helices per domain", "PROTEIN", 291, 313], ["ISG15", "PROTEIN", 317, 322], ["terminal domain", "ANATOMY", 227, 242]]], ["The asymmetric unit consists of 2 twisting filaments, containing 10 copies of mISG15.", [["filaments", "ANATOMY", 43, 52], ["mISG15", "GENE_OR_GENE_PRODUCT", 78, 84], ["mISG15", "PROTEIN", 78, 84], ["2 twisting filaments", "TREATMENT", 32, 52], ["asymmetric", "OBSERVATION_MODIFIER", 4, 14]]], ["Upon examining the differences between the monomers within the asymmetric unit, some flexibility between N- and C-terminal domains was observed (Fig. 7b and c).", [["N", "CHEMICAL", 105, 106], ["C", "CHEMICAL", 112, 113], ["N- and C-terminal domains", "PROTEIN", 105, 130], ["Fig. 7b and c", "PROTEIN", 145, 158], ["some flexibility between N- and C-terminal domains", "PROBLEM", 80, 130], ["asymmetric", "OBSERVATION_MODIFIER", 63, 73], ["flexibility", "OBSERVATION_MODIFIER", 85, 96]]], ["This flexibility was probed by aligning the C-terminal domains of each mISG15 monomer and measuring the angle between the point of divergence and the farthest N termini.", [["C", "CHEMICAL", 44, 45], ["N", "CHEMICAL", 159, 160], ["mISG15", "GENE_OR_GENE_PRODUCT", 71, 77], ["C-terminal domains", "PROTEIN", 44, 62], ["mISG15 monomer", "PROTEIN", 71, 85], ["N termini", "PROTEIN", 159, 168], ["angle", "OBSERVATION_MODIFIER", 104, 109]]], ["There is a 20.2\u00b0 range of motion between the N- and C-terminal domains of mISG15 (Fig. 7b).", [["N", "CHEMICAL", 45, 46], ["C", "CHEMICAL", 52, 53], ["N- and C-terminal domains", "PROTEIN", 45, 70], ["mISG15", "PROTEIN", 74, 80], ["Fig. 7b", "PROTEIN", 82, 89], ["the N", "TEST", 41, 46]]], ["Comparable flexibility was also observed in hISG15 structures, with an 18.3\u00b0 range of motion (Fig. 7c; PDB entries: 1Z2M, 3R66, 3PSE) [27], [29], [30].X-ray structure of the full-length, unbound form of mISG15 and comparison with hISG15 ::: ResultsWhile each individual domain of hISG15 and mISG15 is similar in the secondary structure and both show some structural variability between monomers, there is a drastic difference in the overall conformations of the tertiary structures between mISG15 and that of hISG15.", [["hISG15 structures", "ANATOMY", 44, 61], ["hISG15 structures", "TISSUE", 44, 61], ["mISG15", "GENE_OR_GENE_PRODUCT", 203, 209], ["hISG15", "GENE_OR_GENE_PRODUCT", 280, 286], ["mISG15", "GENE_OR_GENE_PRODUCT", 291, 297], ["mISG15", "GENE_OR_GENE_PRODUCT", 490, 496], ["hISG15", "GENE_OR_GENE_PRODUCT", 509, 515], ["mISG15", "PROTEIN", 203, 209], ["hISG15", "PROTEIN", 230, 236], ["hISG15", "PROTEIN", 280, 286], ["mISG15", "PROTEIN", 291, 297], ["mISG15", "PROTEIN", 490, 496], ["hISG15", "PROTEIN", 509, 515], ["PDB entries", "TEST", 103, 114], ["X-ray", "TEST", 151, 156], ["hISG15", "TEST", 280, 286], ["mISG15", "TREATMENT", 291, 297], ["some structural variability between monomers", "PROBLEM", 350, 394], ["a drastic difference", "PROBLEM", 405, 425], ["mISG15", "TREATMENT", 490, 496], ["secondary structure", "OBSERVATION", 316, 335], ["some", "OBSERVATION_MODIFIER", 350, 354], ["structural variability", "OBSERVATION", 355, 377], ["monomers", "OBSERVATION_MODIFIER", 386, 394], ["drastic", "OBSERVATION_MODIFIER", 407, 414], ["difference", "OBSERVATION_MODIFIER", 415, 425], ["overall conformations", "OBSERVATION", 433, 454], ["tertiary", "OBSERVATION_MODIFIER", 462, 470]]], ["This surprising difference is observed in the overall arrangement of the N- and C-terminal domains.", [["N", "CHEMICAL", 73, 74], ["C", "CHEMICAL", 80, 81], ["N- and C-terminal domains", "PROTEIN", 73, 98], ["the N", "TEST", 69, 74]]], ["Specifically, the twist about the C- and N-terminal domain of mISG15 in relation to hISG15 ranges from 43.0\u00b0 to 66.9\u00b0 (Fig. 8a).", [["C", "CHEMICAL", 34, 35], ["N", "CHEMICAL", 41, 42], ["mISG15", "GENE_OR_GENE_PRODUCT", 62, 68], ["hISG15", "GENE_OR_GENE_PRODUCT", 84, 90], ["C- and N-terminal domain", "PROTEIN", 34, 58], ["mISG15", "PROTEIN", 62, 68], ["hISG15", "PROTEIN", 84, 90], ["the C", "TEST", 30, 35]]], ["Closer investigation reveals that differences in tertiary arrangement can be attributed to several molecular interactions within the structures driven by the primary sequence differences of mISG15 compared to hISG15.", [["mISG15", "GENE_OR_GENE_PRODUCT", 190, 196], ["hISG15", "GENE_OR_GENE_PRODUCT", 209, 215], ["mISG15", "PROTEIN", 190, 196], ["hISG15", "PROTEIN", 209, 215], ["Closer investigation", "TEST", 0, 20], ["several", "OBSERVATION_MODIFIER", 91, 98], ["molecular", "OBSERVATION_MODIFIER", 99, 108], ["interactions", "OBSERVATION", 109, 121]]], ["Specifically, the presence of Asp79 creates a kink in the hinge region of hISG15 as a result of the carboxylate group of Asp79 forming a hydrogen bond with the hydroxyl group of Thr101 (Fig. 8b).", [["Asp79", "CHEMICAL", 30, 35], ["carboxylate", "CHEMICAL", 100, 111], ["Asp79", "CHEMICAL", 121, 126], ["hydroxyl", "CHEMICAL", 160, 168], ["Asp79", "CHEMICAL", 30, 35], ["carboxylate", "CHEMICAL", 100, 111], ["Asp79", "CHEMICAL", 121, 126], ["hydrogen", "CHEMICAL", 137, 145], ["hydroxyl", "CHEMICAL", 160, 168], ["Thr", "CHEMICAL", 178, 181], ["Asp79", "GENE_OR_GENE_PRODUCT", 30, 35], ["hISG15", "GENE_OR_GENE_PRODUCT", 74, 80], ["Asp79", "SIMPLE_CHEMICAL", 121, 126], ["hydroxyl", "SIMPLE_CHEMICAL", 160, 168], ["Thr101", "AMINO_ACID", 178, 184], ["Asp79", "PROTEIN", 30, 35], ["hinge region", "PROTEIN", 58, 70], ["hISG15", "PROTEIN", 74, 80], ["Asp79", "PROBLEM", 30, 35], ["a kink in the hinge region", "PROBLEM", 44, 70], ["the carboxylate group of Asp79", "TREATMENT", 96, 126], ["a hydrogen bond", "TREATMENT", 135, 150], ["the hydroxyl group of Thr", "TREATMENT", 156, 181], ["kink", "OBSERVATION_MODIFIER", 46, 50]]], ["This interaction does not occur in mISG15 since Ser77 replaces Asp79.X-ray structure of the full-length, unbound form of mISG15 and comparison with hISG15 ::: ResultsWhile amino acids in the hinge may play a part in the different conformational trajectory allowed in the region between the two domains in mISG15, the twisted feature of mISG15 may be stabilized by amino acid interactions in the core region of the protein.", [["Asp79", "CHEMICAL", 63, 68], ["amino acids", "CHEMICAL", 172, 183], ["mISG15", "CHEMICAL", 336, 342], ["amino acid", "CHEMICAL", 364, 374], ["Ser77", "CHEMICAL", 48, 53], ["Asp", "CHEMICAL", 63, 66], ["amino acids", "CHEMICAL", 172, 183], ["amino acid", "CHEMICAL", 364, 374], ["Ser77", "GENE_OR_GENE_PRODUCT", 48, 53], ["Asp79", "AMINO_ACID", 63, 68], ["mISG15", "GENE_OR_GENE_PRODUCT", 121, 127], ["amino acids", "AMINO_ACID", 172, 183], ["mISG15", "GENE_OR_GENE_PRODUCT", 305, 311], ["mISG15", "GENE_OR_GENE_PRODUCT", 336, 342], ["amino acid", "AMINO_ACID", 364, 374], ["mISG15", "PROTEIN", 35, 41], ["Ser77", "PROTEIN", 48, 53], ["mISG15", "PROTEIN", 121, 127], ["hISG15", "PROTEIN", 148, 154], ["mISG15", "PROTEIN", 305, 311], ["mISG15", "PROTEIN", 336, 342], ["core region", "PROTEIN", 395, 406], ["Asp", "TEST", 63, 66], ["amino acids", "TEST", 172, 183], ["mISG15", "TREATMENT", 336, 342], ["amino acid interactions", "TREATMENT", 364, 387], ["ray structure", "OBSERVATION_MODIFIER", 71, 84]]], ["This core region is centered near Phe41, at the interface between the two domains.", [["Phe41", "CHEMICAL", 34, 39], ["Phe41", "GENE_OR_GENE_PRODUCT", 34, 39], ["Phe41", "DNA", 34, 39], ["core", "OBSERVATION_MODIFIER", 5, 9], ["region", "ANATOMY_MODIFIER", 10, 16], ["two", "OBSERVATION_MODIFIER", 70, 73], ["domains", "OBSERVATION_MODIFIER", 74, 81]]], ["The hydrophobic interaction between the N-terminal and C-terminal domain at Leu134 and Phe41 may stabilize mISG15s' twisted arrangement (Fig. 8b).", [["Phe41", "CHEMICAL", 87, 92], ["C", "CHEMICAL", 55, 56], ["Leu134", "CHEMICAL", 76, 82], ["Phe41", "CHEMICAL", 87, 92], ["Leu134", "AMINO_ACID", 76, 82], ["Phe41", "AMINO_ACID", 87, 92], ["N-terminal and C-terminal domain", "PROTEIN", 40, 72], ["Leu134", "PROTEIN", 76, 82], ["Phe41", "PROTEIN", 87, 92], ["mISG15s", "PROTEIN", 107, 114], ["The hydrophobic interaction", "PROBLEM", 0, 27], ["hydrophobic interaction", "OBSERVATION", 4, 27]]], ["Other residues in close proximity, such as Pro39, appear to further stabilize this hydrophobic interaction in mISG15.", [["Pro39", "CHEMICAL", 43, 48], ["Pro39", "GENE_OR_GENE_PRODUCT", 43, 48], ["mISG15", "GENE_OR_GENE_PRODUCT", 110, 116], ["Pro39", "PROTEIN", 43, 48], ["mISG15", "PROTEIN", 110, 116]]], ["Specifically, Pro39 in mISG15 forms hydrophobic interactions with Phe41, contributing to the stabilization of mISG15s' tertiary arrangement (Fig. 8b).X-ray structure of the full-length, unbound form of mISG15 and comparison with hISG15 ::: ResultsIn addition to the presence of favorable interactions, steric clashes are also likely responsible for preventing the occurrence of a shared tertiary arrangement between the mISG15 and hISG15 species.", [["Pro39", "CHEMICAL", 14, 19], ["Phe41", "CHEMICAL", 66, 71], ["Phe41", "CHEMICAL", 66, 71], ["Pro39", "GENE_OR_GENE_PRODUCT", 14, 19], ["mISG15", "GENE_OR_GENE_PRODUCT", 23, 29], ["Phe41", "GENE_OR_GENE_PRODUCT", 66, 71], ["mISG15", "GENE_OR_GENE_PRODUCT", 202, 208], ["mISG15", "GENE_OR_GENE_PRODUCT", 420, 426], ["hISG15", "GENE_OR_GENE_PRODUCT", 431, 437], ["Pro39", "PROTEIN", 14, 19], ["mISG15", "PROTEIN", 23, 29], ["Phe41", "PROTEIN", 66, 71], ["mISG15s", "PROTEIN", 110, 117], ["mISG15", "PROTEIN", 202, 208], ["hISG15", "PROTEIN", 229, 235], ["mISG15 and hISG15 species", "PROTEIN", 420, 445], ["Phe41", "TREATMENT", 66, 71], ["mISG15s' tertiary arrangement", "TREATMENT", 110, 139], ["steric clashes", "PROBLEM", 302, 316], ["steric clashes", "OBSERVATION", 302, 316]]], ["When the N-terminal and C-terminal domains of mISG15 are configured to the arrangement of hISG15, there are no obvious clashes that prohibit mISG15 from adopting this conformation (Fig. 8c).", [["C", "CHEMICAL", 24, 25], ["mISG15", "GENE_OR_GENE_PRODUCT", 46, 52], ["hISG15", "GENE_OR_GENE_PRODUCT", 90, 96], ["mISG15", "GENE_OR_GENE_PRODUCT", 141, 147], ["N-terminal and C-terminal domains", "PROTEIN", 9, 42], ["mISG15", "PROTEIN", 46, 52], ["hISG15", "PROTEIN", 90, 96], ["mISG15", "PROTEIN", 141, 147], ["obvious clashes", "PROBLEM", 111, 126], ["no obvious", "UNCERTAINTY", 108, 118], ["clashes", "OBSERVATION", 119, 126]]], ["However, hISG15 may be incapable of adopting the mouse conformation due to the potential steric clash between His39 and Glu139 that typically forms a water-mediated interaction (Fig. 8c).", [["hISG15", "CHEMICAL", 9, 15], ["Glu139", "CHEMICAL", 120, 126], ["His39", "CHEMICAL", 110, 115], ["Glu139", "CHEMICAL", 120, 126], ["hISG15", "GENE_OR_GENE_PRODUCT", 9, 15], ["mouse", "ORGANISM", 49, 54], ["His39", "SIMPLE_CHEMICAL", 110, 115], ["Glu139", "SIMPLE_CHEMICAL", 120, 126], ["water", "SIMPLE_CHEMICAL", 150, 155], ["hISG15", "PROTEIN", 9, 15], ["His39", "PROTEIN", 110, 115], ["Glu139", "PROTEIN", 120, 126], ["mouse", "SPECIES", 49, 54], ["mouse", "SPECIES", 49, 54], ["the mouse conformation", "TREATMENT", 45, 67], ["the potential steric clash between His39 and Glu139", "PROBLEM", 75, 126], ["steric clash", "OBSERVATION", 89, 101]]], ["Thus, the presence of the His39 residue may prevent hISG15 from configuring to the mISG15 conformation.X-ray structure of the full-length, unbound form of mISG15 and comparison with hISG15 ::: ResultsBeyond the effects on tertiary structure, the sequence divergence between mISG15 and hISG15 also impacts the potential binding surfaces.", [["His39", "CHEMICAL", 26, 31], ["His39", "GENE_OR_GENE_PRODUCT", 26, 31], ["hISG15", "GENE_OR_GENE_PRODUCT", 52, 58], ["mISG15", "GENE_OR_GENE_PRODUCT", 83, 89], ["mISG15", "GENE_OR_GENE_PRODUCT", 155, 161], ["mISG15", "GENE_OR_GENE_PRODUCT", 274, 280], ["hISG15", "GENE_OR_GENE_PRODUCT", 285, 291], ["hISG15", "PROTEIN", 52, 58], ["mISG15", "PROTEIN", 83, 89], ["mISG15", "PROTEIN", 155, 161], ["hISG15", "PROTEIN", 182, 188], ["mISG15", "DNA", 274, 280], ["hISG15", "PROTEIN", 285, 291], ["the His39 residue", "PROBLEM", 22, 39], ["ray structure", "OBSERVATION_MODIFIER", 105, 118], ["binding surfaces", "OBSERVATION", 319, 335]]], ["These differences in amino acid sequence also give rise to different electrostatic potential plots.", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["amino acid sequence", "TEST", 21, 40]]], ["Unlike mISG15, hISG15 contains an uninterrupted negative surface band spanning across the two domains (Fig. 8d).", [["surface", "ANATOMY", 57, 64], ["mISG15", "GENE_OR_GENE_PRODUCT", 7, 13], ["hISG15", "GENE_OR_GENE_PRODUCT", 15, 21], ["mISG15", "PROTEIN", 7, 13], ["hISG15", "PROTEIN", 15, 21], ["uninterrupted negative surface band", "PROTEIN", 34, 69], ["an uninterrupted negative surface band", "TREATMENT", 31, 69], ["surface", "OBSERVATION_MODIFIER", 57, 64]]], ["When the surface of mISG15 corresponding to the same area is examined, this negative band dissipates as the comparable area on mISG15 is scattered with positive and neutral areas.Differences in hISG15 and mISG15 structure influence recognition by PLPs ::: DiscussionAmong Ub and Ubl proteins, ISG15 is unique for more than its divergent amino acid sequence.", [["surface", "ANATOMY", 9, 16], ["amino acid", "CHEMICAL", 337, 347], ["amino acid", "CHEMICAL", 337, 347], ["surface", "CELLULAR_COMPONENT", 9, 16], ["mISG15", "GENE_OR_GENE_PRODUCT", 20, 26], ["hISG15", "GENE_OR_GENE_PRODUCT", 194, 200], ["mISG15", "GENE_OR_GENE_PRODUCT", 205, 211], ["PLPs", "SIMPLE_CHEMICAL", 247, 251], ["Ub", "GENE_OR_GENE_PRODUCT", 272, 274], ["Ubl proteins", "GENE_OR_GENE_PRODUCT", 279, 291], ["ISG15", "GENE_OR_GENE_PRODUCT", 293, 298], ["amino acid", "AMINO_ACID", 337, 347], ["mISG15", "PROTEIN", 20, 26], ["mISG15", "DNA", 127, 133], ["hISG15", "PROTEIN", 194, 200], ["mISG15", "PROTEIN", 205, 211], ["PLPs", "PROTEIN", 247, 251], ["DiscussionAmong Ub and Ubl proteins", "PROTEIN", 256, 291], ["ISG15", "PROTEIN", 293, 298], ["divergent amino acid sequence", "PROTEIN", 327, 356], ["this negative band dissipates", "PROBLEM", 71, 100], ["positive and neutral areas", "PROBLEM", 152, 178], ["DiscussionAmong Ub and Ubl proteins", "TEST", 256, 291], ["its divergent amino acid sequence", "TEST", 323, 356], ["scattered", "OBSERVATION_MODIFIER", 137, 146], ["positive", "OBSERVATION_MODIFIER", 152, 160], ["neutral", "OBSERVATION_MODIFIER", 165, 172], ["areas", "OBSERVATION_MODIFIER", 173, 178]]], ["Similar to other Ubl proteins, ISG15 has not been observed to form polymeric chains like Ub [31].", [["Ubl proteins", "GENE_OR_GENE_PRODUCT", 17, 29], ["ISG15", "GENE_OR_GENE_PRODUCT", 31, 36], ["Ub", "GENE_OR_GENE_PRODUCT", 89, 91], ["Ubl proteins", "PROTEIN", 17, 29], ["ISG15", "PROTEIN", 31, 36], ["Ub", "PROTEIN", 89, 91], ["other Ubl proteins", "TEST", 11, 29], ["ISG15", "TEST", 31, 36]]], ["However, ISG15 is the sole family member of Ubl modifiers that is composed of two Ubl folded domains.", [["ISG15", "GENE_OR_GENE_PRODUCT", 9, 14], ["Ubl", "GENE_OR_GENE_PRODUCT", 44, 47], ["ISG15", "PROTEIN", 9, 14], ["Ubl modifiers", "PROTEIN", 44, 57], ["Ubl folded domains", "PROTEIN", 82, 100], ["Ubl modifiers", "TREATMENT", 44, 57], ["Ubl folded", "OBSERVATION", 82, 92]]], ["These two domains are tethered by a polypeptide linker that would suggest that the two domains can move freely and independent of each other.", [["a polypeptide linker", "TREATMENT", 34, 54]]], ["However, the four structures of hISG15 alone, or bound to viral proteins, suggest the opposite (Fig. 7c) [27], [28], [29], [30].", [["hISG15", "CHEMICAL", 32, 38], ["hISG15", "GENE_OR_GENE_PRODUCT", 32, 38], ["[29]", "SIMPLE_CHEMICAL", 117, 121], ["hISG15", "PROTEIN", 32, 38], ["viral proteins", "PROTEIN", 58, 72], ["viral proteins", "TEST", 58, 72]]], ["Akin to polymeric Ub, ISG15 appears to have relatively limited conformations between the two domains.", [["Ub", "GENE_OR_GENE_PRODUCT", 18, 20], ["ISG15", "GENE_OR_GENE_PRODUCT", 22, 27], ["polymeric Ub", "PROTEIN", 8, 20], ["ISG15", "PROTEIN", 22, 27], ["polymeric Ub", "OBSERVATION_MODIFIER", 8, 20]]], ["The structure of mISG15 (Fig. 7b) furthers this assertion with one important caveat: one species' ISG15s domain configuration may not be necessarily representative of others or ISG15s in general.Differences in hISG15 and mISG15 structure influence recognition by PLPs ::: DiscussionIn both hISG15 and mISG15, there is a hydrophobic interface mediated by a conserved phenylalanine (Phe41; see Fig. 8).", [["phenylalanine", "CHEMICAL", 366, 379], ["phenylalanine", "CHEMICAL", 366, 379], ["Phe41", "CHEMICAL", 381, 386], ["ISG15s", "GENE_OR_GENE_PRODUCT", 177, 183], ["hISG15", "GENE_OR_GENE_PRODUCT", 210, 216], ["mISG15", "GENE_OR_GENE_PRODUCT", 221, 227], ["PLPs", "SIMPLE_CHEMICAL", 263, 267], ["hISG15", "GENE_OR_GENE_PRODUCT", 290, 296], ["mISG15", "GENE_OR_GENE_PRODUCT", 301, 307], ["phenylalanine", "SIMPLE_CHEMICAL", 366, 379], ["mISG15", "PROTEIN", 17, 23], ["ISG15s domain", "PROTEIN", 98, 111], ["ISG15s", "PROTEIN", 177, 183], ["hISG15", "PROTEIN", 210, 216], ["mISG15", "PROTEIN", 221, 227], ["PLPs", "PROTEIN", 263, 267], ["hISG15", "PROTEIN", 290, 296], ["mISG15", "PROTEIN", 301, 307], ["a conserved phenylalanine (Phe41", "TREATMENT", 354, 386], ["may not be necessarily", "UNCERTAINTY", 126, 148]]], ["The highly conserved nature of this phenylalanine and other surrounding residues suggests that ISG15s in general likely utilize hydrophobic forces to adhere the two domains together (Fig. 1b, residues involved are boxed in blue).", [["phenylalanine", "CHEMICAL", 36, 49], ["phenylalanine", "CHEMICAL", 36, 49], ["phenylalanine", "AMINO_ACID", 36, 49], ["ISG15s", "SIMPLE_CHEMICAL", 95, 101], ["ISG15s", "PROTEIN", 95, 101], ["this phenylalanine", "TREATMENT", 31, 49], ["hydrophobic forces", "TREATMENT", 128, 146]]], ["However, as shown with mISG15, the influence of the core on the orientation of the domains can vary.", [["mISG15", "GENE_OR_GENE_PRODUCT", 23, 29], ["mISG15", "PROTEIN", 23, 29]]], ["In mISG15, residues forming the core solely dictate its interdomain orientation, whereas in hISG15, additional electrostatic interactions involving Glu139 and His39, and to a lesser extent Thr101 and Asp79, appear to play an additional role to favor one orientation over another (Fig. 8b and c).", [["Glu139", "CHEMICAL", 148, 154], ["His39", "CHEMICAL", 159, 164], ["Thr", "CHEMICAL", 189, 192], ["mISG15", "GENE_OR_GENE_PRODUCT", 3, 9], ["hISG15", "GENE_OR_GENE_PRODUCT", 92, 98], ["Glu139", "GENE_OR_GENE_PRODUCT", 148, 154], ["His39", "GENE_OR_GENE_PRODUCT", 159, 164], ["Asp79", "GENE_OR_GENE_PRODUCT", 200, 205], ["mISG15", "PROTEIN", 3, 9], ["hISG15", "PROTEIN", 92, 98], ["Glu139", "PROTEIN", 148, 154], ["His39", "PROTEIN", 159, 164], ["Thr101", "PROTEIN", 189, 195], ["Asp79", "PROTEIN", 200, 205], ["Asp79", "TEST", 200, 205]]], ["Intriguingly, the pairing of Glu139 and His39 is extremely unique to hISG15.", [["Glu139", "GENE_OR_GENE_PRODUCT", 29, 35], ["His39", "GENE_OR_GENE_PRODUCT", 40, 45], ["hISG15", "GENE_OR_GENE_PRODUCT", 69, 75], ["Glu139", "PROTEIN", 29, 35], ["His39", "PROTEIN", 40, 45], ["hISG15", "DNA", 69, 75]]], ["Although Glu139 or another acidic residue is well conserved at that position, His39 is typically a proline.", [["Glu139", "CHEMICAL", 9, 15], ["proline", "CHEMICAL", 99, 106], ["Glu139", "CHEMICAL", 9, 15], ["His39", "CHEMICAL", 78, 83], ["proline", "CHEMICAL", 99, 106], ["Glu139", "GENE_OR_GENE_PRODUCT", 9, 15], ["His39", "SIMPLE_CHEMICAL", 78, 83], ["proline", "AMINO_ACID", 99, 106], ["Glu139", "PROTEIN", 9, 15], ["His39", "PROTEIN", 78, 83], ["Glu139", "TEST", 9, 15], ["another acidic residue", "PROBLEM", 19, 41], ["acidic residue", "OBSERVATION", 27, 41]]], ["In hISG15, it appears that this favorable electrostatic interaction may promote hISG15's domain orientations.", [["hISG15", "GENE_OR_GENE_PRODUCT", 3, 9], ["hISG15", "GENE_OR_GENE_PRODUCT", 80, 86], ["hISG15", "PROTEIN", 3, 9], ["hISG15", "PROTEIN", 80, 86]]], ["Multiple crystal structures reveal this conformation to be consistent despite differences in space groups and crystallization conditions, suggesting that the observed tertiary structure is a stable and likely preferred conformation (Fig. 7c).", [["Multiple crystal structures", "PROBLEM", 0, 27], ["differences in space groups and crystallization conditions", "PROBLEM", 78, 136], ["the observed tertiary structure", "PROBLEM", 154, 185], ["crystal", "OBSERVATION", 9, 16], ["tertiary structure", "OBSERVATION", 167, 185], ["stable", "OBSERVATION_MODIFIER", 191, 197]]], ["In addition to favoring hISG15's conformation, His39 may also act as a steric block preventing hISG15 from adopting a similar tertiary structure and conformation as that of mISG15.Differences in hISG15 and mISG15 structure influence recognition by PLPs ::: DiscussionThe observation of a potential steric block may result in MHV PLP2 not being able to recognize hISG15, which is why no cleavage of pro-hISG15 is observed (Fig. 2).", [["His39", "CHEMICAL", 47, 52], ["hISG15", "CHEMICAL", 95, 101], ["His39", "CHEMICAL", 47, 52], ["hISG15", "GENE_OR_GENE_PRODUCT", 24, 30], ["His39", "SIMPLE_CHEMICAL", 47, 52], ["hISG15", "GENE_OR_GENE_PRODUCT", 95, 101], ["mISG15", "GENE_OR_GENE_PRODUCT", 173, 179], ["hISG15", "GENE_OR_GENE_PRODUCT", 195, 201], ["mISG15", "GENE_OR_GENE_PRODUCT", 206, 212], ["PLPs", "SIMPLE_CHEMICAL", 248, 252], ["MHV", "ORGANISM", 325, 328], ["PLP2", "GENE_OR_GENE_PRODUCT", 329, 333], ["hISG15", "GENE_OR_GENE_PRODUCT", 362, 368], ["pro-hISG15", "GENE_OR_GENE_PRODUCT", 398, 408], ["hISG15", "PROTEIN", 24, 30], ["hISG15", "PROTEIN", 95, 101], ["mISG15", "PROTEIN", 173, 179], ["hISG15", "PROTEIN", 195, 201], ["mISG15", "PROTEIN", 206, 212], ["PLPs", "PROTEIN", 248, 252], ["PLP2", "PROTEIN", 329, 333], ["hISG15", "PROTEIN", 362, 368], ["pro-hISG15", "PROTEIN", 398, 408], ["MHV", "SPECIES", 325, 328], ["a steric block", "TREATMENT", 69, 83], ["a potential steric block", "TREATMENT", 286, 310], ["MHV PLP2", "PROBLEM", 325, 333], ["cleavage of pro-hISG15", "PROBLEM", 386, 408]]], ["In contrast, no apparent steric hurdle is present for mISG15 in adopting a hISG15-like interdomain orientation, which is likely why SARS-CoV and MERS-CoV PLpro are able to readily recognize mISG15.", [["mISG15", "GENE_OR_GENE_PRODUCT", 54, 60], ["hISG15", "GENE_OR_GENE_PRODUCT", 75, 81], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 132, 140], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 145, 159], ["mISG15", "GENE_OR_GENE_PRODUCT", 190, 196], ["mISG15", "PROTEIN", 54, 60], ["hISG15", "PROTEIN", 75, 81], ["SARS-CoV and MERS-CoV PLpro", "PROTEIN", 132, 159], ["mISG15", "PROTEIN", 190, 196], ["SARS-CoV", "SPECIES", 132, 140], ["MERS-CoV", "SPECIES", 145, 153], ["SARS", "PROBLEM", 132, 136], ["CoV PLpro", "TREATMENT", 150, 159], ["no apparent", "UNCERTAINTY", 13, 24], ["steric hurdle", "OBSERVATION", 25, 38], ["is likely", "UNCERTAINTY", 118, 127]]], ["The lack of a steric hurdle might suggest that there are more allowable domain arrangements of mISG15 than hISG15 in solution that allow for a broader spectrum of PLPs to recognize mISG15.", [["mISG15", "GENE_OR_GENE_PRODUCT", 95, 101], ["hISG15", "SIMPLE_CHEMICAL", 107, 113], ["PLPs", "GENE_OR_GENE_PRODUCT", 163, 167], ["mISG15", "GENE_OR_GENE_PRODUCT", 181, 187], ["mISG15", "PROTEIN", 95, 101], ["hISG15", "PROTEIN", 107, 113], ["PLPs", "PROTEIN", 163, 167], ["mISG15", "PROTEIN", 181, 187], ["a steric hurdle", "TREATMENT", 12, 27], ["mISG15", "TREATMENT", 95, 101], ["hISG15 in solution", "TREATMENT", 107, 125], ["PLPs", "TREATMENT", 163, 167]]], ["The potential uniqueness of hISG15's structure may also fall in line with the inability of other viral proteins, such as influenza NS1, to effectively engage ISG15s beyond those of human and primates [30].", [["hISG15", "GENE_OR_GENE_PRODUCT", 28, 34], ["influenza NS1", "ORGANISM", 121, 134], ["ISG15s", "GENE_OR_GENE_PRODUCT", 158, 164], ["human", "ORGANISM", 181, 186], ["hISG15", "PROTEIN", 28, 34], ["viral proteins", "PROTEIN", 97, 111], ["influenza NS1", "PROTEIN", 121, 134], ["ISG15s", "PROTEIN", 158, 164], ["human", "SPECIES", 181, 186], ["human", "SPECIES", 181, 186], ["hISG15's structure", "PROBLEM", 28, 46], ["other viral proteins", "PROBLEM", 91, 111], ["influenza NS1", "PROBLEM", 121, 134]]], ["Moreover, the distinctiveness of hISG15 may also fit into the recent assertions that hISG15 plays a divergent immune regulation role in humans compared to other animals [32].Viral USP-like PLPs' accommodation of Ub versus ISG15s ::: DiscussionUb interactions with proteins possessing a Ub-binding site have been observed to be reliant largely on the involvement of a hydrophobic patch composed of several residues surrounding Ile44 [15].", [["hISG15", "CHEMICAL", 85, 91], ["Ile44", "CHEMICAL", 426, 431], ["hISG15", "GENE_OR_GENE_PRODUCT", 33, 39], ["hISG15", "GENE_OR_GENE_PRODUCT", 85, 91], ["humans", "ORGANISM", 136, 142], ["Ub", "GENE_OR_GENE_PRODUCT", 212, 214], ["Ub", "GENE_OR_GENE_PRODUCT", 286, 288], ["hISG15", "PROTEIN", 33, 39], ["hISG15", "PROTEIN", 85, 91], ["Viral USP", "PROTEIN", 174, 183], ["Ub", "PROTEIN", 212, 214], ["ISG15s", "PROTEIN", 222, 228], ["Ub", "PROTEIN", 286, 288], ["humans", "SPECIES", 136, 142], ["humans", "SPECIES", 136, 142], ["Viral USP", "TEST", 174, 183], ["a hydrophobic patch", "TREATMENT", 365, 384]]], ["The absence of such a comparable patch in ISG15 and the more generally charged surface of hISG15 naturally spurred speculation on mechanisms behind how PLPs may engage ISG15s.", [["surface", "ANATOMY", 79, 86], ["hISG15", "CHEMICAL", 90, 96], ["ISG15", "GENE_OR_GENE_PRODUCT", 42, 47], ["surface", "CELLULAR_COMPONENT", 79, 86], ["hISG15", "GENE_OR_GENE_PRODUCT", 90, 96], ["PLPs", "GENE_OR_GENE_PRODUCT", 152, 156], ["ISG15s", "GENE_OR_GENE_PRODUCT", 168, 174], ["ISG15", "PROTEIN", 42, 47], ["hISG15", "PROTEIN", 90, 96], ["PLPs", "PROTEIN", 152, 156], ["ISG15s", "PROTEIN", 168, 174], ["a comparable patch in ISG15", "TREATMENT", 20, 47]]], ["The SARS-CoV PLpro\u2013ChISG15 complex reveals that in PLPs, the binding interface may have evolved to recognize specific features of ISG15s from different species outside the 5-aa C-terminal sequence (Arg-Leu-Arg-Gly-Gly) they share with Ub.", [["Arg-Leu-Arg-Gly-Gly", "CHEMICAL", 198, 217], ["SARS-CoV PLpro\u2013ChISG15", "GENE_OR_GENE_PRODUCT", 4, 26], ["PLPs", "GENE_OR_GENE_PRODUCT", 51, 55], ["ISG15s", "GENE_OR_GENE_PRODUCT", 130, 136], ["Gly-Gly", "AMINO_ACID", 210, 217], ["SARS-CoV PLpro\u2013ChISG15 complex", "PROTEIN", 4, 34], ["PLPs", "PROTEIN", 51, 55], ["ISG15s", "PROTEIN", 130, 136], ["5-aa C-terminal sequence", "PROTEIN", 172, 196], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV PLpro\u2013ChISG15 complex", "TEST", 0, 34], ["ISG15s", "PROBLEM", 130, 136], ["different species", "PROBLEM", 142, 159], ["aa C-terminal sequence", "TEST", 174, 196], ["Arg", "TEST", 198, 201]]], ["For hISG15, this includes not only the highly conserved Trp123 of ISG15s but also the specific interactions that are unique to hISG15.", [["hISG15", "GENE_OR_GENE_PRODUCT", 4, 10], ["Trp123", "GENE_OR_GENE_PRODUCT", 56, 62], ["ISG15s", "GENE_OR_GENE_PRODUCT", 66, 72], ["hISG15", "GENE_OR_GENE_PRODUCT", 127, 133], ["hISG15", "PROTEIN", 4, 10], ["Trp123", "PROTEIN", 56, 62], ["ISG15s", "PROTEIN", 66, 72], ["hISG15", "DNA", 127, 133], ["hISG15", "TREATMENT", 4, 10]]], ["For instance, Arg87 in hISG15 is often substituted for a lysine residue that is too short to form any water-mediated interactions with the SARS-CoV PLpro's Asp230 and Ser222.", [["Arg87", "CHEMICAL", 14, 19], ["lysine", "CHEMICAL", 57, 63], ["Arg87", "CHEMICAL", 14, 19], ["lysine", "CHEMICAL", 57, 63], ["Ser222", "CHEMICAL", 167, 173], ["Arg87", "GENE_OR_GENE_PRODUCT", 14, 19], ["hISG15", "GENE_OR_GENE_PRODUCT", 23, 29], ["water", "SIMPLE_CHEMICAL", 102, 107], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 139, 147], ["Asp230", "GENE_OR_GENE_PRODUCT", 156, 162], ["Ser222", "AMINO_ACID", 167, 173], ["Arg87", "PROTEIN", 14, 19], ["hISG15", "PROTEIN", 23, 29], ["SARS-CoV PLpro", "PROTEIN", 139, 153], ["Asp230", "PROTEIN", 156, 162], ["Ser222", "PROTEIN", 167, 173], ["SARS-CoV", "SPECIES", 139, 147], ["a lysine residue", "PROBLEM", 55, 71], ["the SARS", "TEST", 135, 143], ["CoV PLpro's Asp230", "TREATMENT", 144, 162], ["Ser222", "TREATMENT", 167, 173], ["too short", "OBSERVATION_MODIFIER", 80, 89]]], ["Interestingly, Phe149, which forms a second hydrophobic interaction site with the protease's Pro224, is one of the 3 aa recently implicated in species specificity among nairovirus vOTUs [23].", [["Phe149", "CHEMICAL", 15, 21], ["Phe149", "GENE_OR_GENE_PRODUCT", 15, 21], ["Pro224", "GENE_OR_GENE_PRODUCT", 93, 99], ["Phe149", "PROTEIN", 15, 21], ["hydrophobic interaction site", "PROTEIN", 44, 72], ["protease", "PROTEIN", 82, 90], ["Pro224", "PROTEIN", 93, 99], ["a second hydrophobic interaction site", "PROBLEM", 35, 72], ["the protease's", "TREATMENT", 78, 92]]], ["Residue changes between hISG15 and mISG15 at the other two positions, Asn151 and Asn89, appear to impede the accommodation of mISG15 in the active site of SARS-CoV PLpro compared to the more favorable hISG15 orientation.", [["SARS", "DISEASE", 155, 159], ["hISG15", "GENE_OR_GENE_PRODUCT", 24, 30], ["mISG15", "GENE_OR_GENE_PRODUCT", 35, 41], ["Asn151", "GENE_OR_GENE_PRODUCT", 70, 76], ["Asn89", "GENE_OR_GENE_PRODUCT", 81, 86], ["mISG15", "GENE_OR_GENE_PRODUCT", 126, 132], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 155, 163], ["hISG15", "GENE_OR_GENE_PRODUCT", 201, 207], ["hISG15", "PROTEIN", 24, 30], ["mISG15", "PROTEIN", 35, 41], ["Asn89", "DNA", 81, 86], ["mISG15", "DNA", 126, 132], ["SARS-CoV PLpro", "DNA", 155, 169], ["hISG15", "DNA", 201, 207], ["SARS-CoV", "SPECIES", 155, 163], ["Residue changes", "PROBLEM", 0, 15], ["hISG15", "TREATMENT", 24, 30], ["mISG15", "TREATMENT", 35, 41], ["CoV PLpro", "TREATMENT", 160, 169]]], ["This appears to advocate that differences at these three ISG15 positions have a broader range of influence beyond only one class of viral proteases and could conceivable represent an evolutionary pressure that underlies a part of ISG15 sequence diversity.", [["ISG15", "GENE_OR_GENE_PRODUCT", 57, 62], ["ISG15", "GENE_OR_GENE_PRODUCT", 230, 235], ["ISG15", "PROTEIN", 57, 62], ["viral proteases", "PROTEIN", 132, 147], ["ISG15", "PROTEIN", 230, 235], ["viral proteases", "PROBLEM", 132, 147], ["an evolutionary pressure", "PROBLEM", 180, 204], ["ISG15 sequence diversity", "PROBLEM", 230, 254], ["viral proteases", "OBSERVATION", 132, 147], ["evolutionary pressure", "OBSERVATION", 183, 204]]], ["Also, SARS-CoV residues that interact with these residues and SARS-CoV PLpro deubiquitinating and deISGylating altering mutants, R167E, M209A, and Q233E, may offer advantageous starting points for developing SARS-CoV PLpros with directed shifts in substrate specificities.Viral USP-like PLPs' accommodation of Ub versus ISG15s ::: DiscussionBeyond the C-terminal domains' interaction with PLPs, the N terminus of hISG15 has been previously proposed to interact with a ridge helix spanning the conical PLP thumb domain with the Ubl domain to enhance affinity.", [["SARS", "DISEASE", 208, 212], ["C", "CHEMICAL", 352, 353], ["N", "CHEMICAL", 399, 400], ["PLP", "CHEMICAL", 501, 504], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 208, 216], ["Ub", "GENE_OR_GENE_PRODUCT", 310, 312], ["PLPs", "GENE_OR_GENE_PRODUCT", 389, 393], ["hISG15", "GENE_OR_GENE_PRODUCT", 413, 419], ["SARS-CoV PLpro deubiquitinating and deISGylating altering mutants", "PROTEIN", 62, 127], ["R167E", "PROTEIN", 129, 134], ["M209A", "PROTEIN", 136, 141], ["Q233E", "PROTEIN", 147, 152], ["Viral USP", "PROTEIN", 272, 281], ["Ub", "PROTEIN", 310, 312], ["ISG15s", "PROTEIN", 320, 326], ["C-terminal domains", "PROTEIN", 352, 370], ["PLPs", "PROTEIN", 389, 393], ["N terminus", "PROTEIN", 399, 409], ["hISG15", "PROTEIN", 413, 419], ["ridge helix", "PROTEIN", 468, 479], ["conical PLP thumb domain", "PROTEIN", 493, 517], ["Ubl domain", "PROTEIN", 527, 537], ["SARS-CoV", "SPECIES", 6, 14], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 208, 216], ["SARS-CoV residues", "PROBLEM", 6, 23], ["these residues", "PROBLEM", 43, 57], ["SARS", "PROBLEM", 62, 66], ["CoV PLpro deubiquitinating", "TREATMENT", 67, 93], ["developing SARS", "PROBLEM", 197, 212], ["CoV PLpros", "TREATMENT", 213, 223], ["Viral USP", "TEST", 272, 281], ["the C-terminal domains' interaction", "PROBLEM", 348, 383], ["PLPs", "TREATMENT", 389, 393], ["a ridge helix spanning the conical PLP thumb domain", "TREATMENT", 466, 517], ["the Ubl domain", "TREATMENT", 523, 537], ["CoV residues", "OBSERVATION", 11, 23]]], ["Currently, no X-ray structures of a PLP with full-length ISG15 exist, and previous computational models utilizing existing SARS-CoV PLpro structures bound with mono-Ub have had difficulty reconciling the significant gap that occurs between hISG15's N-terminal domain and the protease when anchoring C-terminal hISG15 domain on bound Ub.", [["PLP", "CHEMICAL", 36, 39], ["hISG15", "CHEMICAL", 240, 246], ["N", "CHEMICAL", 249, 250], ["C", "CHEMICAL", 299, 300], ["PLP", "GENE_OR_GENE_PRODUCT", 36, 39], ["ISG15", "GENE_OR_GENE_PRODUCT", 57, 62], ["mono-Ub", "GENE_OR_GENE_PRODUCT", 160, 167], ["hISG15", "GENE_OR_GENE_PRODUCT", 240, 246], ["PLP", "PROTEIN", 36, 39], ["ISG15", "PROTEIN", 57, 62], ["Ub", "PROTEIN", 165, 167], ["hISG15", "PROTEIN", 240, 246], ["N-terminal domain", "PROTEIN", 249, 266], ["protease", "PROTEIN", 275, 283], ["C-terminal hISG15 domain", "PROTEIN", 299, 323], ["a PLP", "TEST", 34, 39], ["existing SARS", "PROBLEM", 114, 127], ["the significant gap", "PROBLEM", 200, 219], ["terminal domain", "PROBLEM", 251, 266], ["the protease", "TREATMENT", 271, 283], ["no", "UNCERTAINTY", 11, 13], ["X-ray structures", "OBSERVATION_MODIFIER", 14, 30], ["significant", "OBSERVATION_MODIFIER", 204, 215], ["gap", "OBSERVATION", 216, 219]]], ["The SARS-CoV PLpro\u2013CxISG15 structures offer two synergistic explanations.", [["SARS-CoV PLpro\u2013CxISG15 structures", "DNA", 4, 37], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV PLpro\u2013CxISG15 structures", "TREATMENT", 0, 37]]], ["First, the 6.3-\u00c5 shift of ChISG15 relative to bound Ub translates the N-terminal domain toward the ridge helix (Fig. 9a).", [["N", "CHEMICAL", 70, 71], ["ChISG15", "GENE_OR_GENE_PRODUCT", 26, 33], ["Ub", "GENE_OR_GENE_PRODUCT", 52, 54], ["ChISG15", "PROTEIN", 26, 33], ["Ub", "PROTEIN", 52, 54], ["N-terminal domain", "PROTEIN", 70, 87], ["ridge helix", "PROTEIN", 99, 110], ["ChISG15", "TREATMENT", 26, 33], ["the N-terminal domain", "TREATMENT", 66, 87], ["ridge", "ANATOMY_MODIFIER", 99, 104], ["helix", "ANATOMY_MODIFIER", 105, 110]]], ["In addition, the alternate Ubl conformation found in the SARS-CoV PLpro\u2013CmISG15 structure reveals that such a conformation translates the ridge helix up to 14 \u00c5 toward the location of the ridge helix (Fig. 9b and c).", [["Ubl conformation", "PROTEIN", 27, 43], ["SARS-CoV PLpro\u2013CmISG15 structure", "PROTEIN", 57, 89], ["ridge helix", "PROTEIN", 138, 149], ["ridge helix", "PROTEIN", 188, 199], ["Fig. 9b and c)", "PROTEIN", 201, 215], ["SARS-CoV", "SPECIES", 57, 65], ["the alternate Ubl conformation", "PROBLEM", 13, 43], ["the SARS", "TEST", 53, 61], ["a conformation", "PROBLEM", 108, 122], ["the ridge helix", "TREATMENT", 134, 149], ["ridge", "OBSERVATION_MODIFIER", 138, 143], ["helix", "OBSERVATION_MODIFIER", 144, 149], ["ridge", "ANATOMY_MODIFIER", 188, 193], ["helix", "ANATOMY_MODIFIER", 194, 199]]], ["Interestingly, comparing this model to the X-ray structure of SARS-CoV PLpro bound to K48-linked di-Ub highlights that different facets of the Ubl fold found in the N-terminal domain ISG15 are likely involved in the interaction (Fig. 9d).", [["SARS", "DISEASE", 62, 66], ["N", "CHEMICAL", 165, 166], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 62, 70], ["K48", "GENE_OR_GENE_PRODUCT", 86, 89], ["di-Ub", "GENE_OR_GENE_PRODUCT", 97, 102], ["Ubl", "GENE_OR_GENE_PRODUCT", 143, 146], ["ISG15", "GENE_OR_GENE_PRODUCT", 183, 188], ["SARS-CoV PLpro", "PROTEIN", 62, 76], ["K48", "PROTEIN", 86, 89], ["di-Ub", "PROTEIN", 97, 102], ["Ubl fold", "PROTEIN", 143, 151], ["N-terminal domain", "PROTEIN", 165, 182], ["ISG15", "PROTEIN", 183, 188], ["SARS-CoV", "SPECIES", 62, 70], ["the X-ray structure", "TEST", 39, 58], ["SARS", "PROBLEM", 62, 66], ["K48", "TEST", 86, 89], ["the Ubl fold", "PROBLEM", 139, 151], ["different", "OBSERVATION_MODIFIER", 119, 128], ["facets", "OBSERVATION_MODIFIER", 129, 135], ["Ubl fold", "ANATOMY", 143, 151]]], ["Specifically, in this model, a triple serine repeat, Ser20\u201322, and Glu27 located in hISG15's \u03b22\u03b13 loop and \u03b13, respectively, point toward the protease's ridge helix, creating a surface that is available to be engaged by the bevy of charged and polar residues located on SAR-CoV PLpro's ridge helix that has been previously implicated in binding [15].", [["surface", "ANATOMY", 177, 184], ["serine", "CHEMICAL", 38, 44], ["Ser20\u201322", "GENE_OR_GENE_PRODUCT", 53, 61], ["Glu27", "GENE_OR_GENE_PRODUCT", 67, 72], ["hISG15's \u03b22\u03b13", "GENE_OR_GENE_PRODUCT", 84, 97], ["\u03b13", "GENE_OR_GENE_PRODUCT", 107, 109], ["surface", "CELLULAR_COMPONENT", 177, 184], ["hISG15", "PROTEIN", 84, 90], ["\u03b22\u03b13 loop", "DNA", 93, 102], ["\u03b13", "DNA", 107, 109], ["protease's ridge helix", "PROTEIN", 142, 164], ["SAR-CoV PLpro's ridge helix", "PROTEIN", 270, 297], ["a triple serine repeat", "TEST", 29, 51], ["Glu27", "TEST", 67, 72], ["the protease's ridge helix", "TREATMENT", 138, 164], ["polar residues", "PROBLEM", 244, 258], ["CoV PLpro's ridge helix", "TREATMENT", 274, 297]]], ["These potential electrostatic interactions may contribute to the four-times-larger enthalpy binding component observed in the interaction of full-length over the C-terminal domain of hISG15 when being accommodated by SARS-CoV PLpro.", [["C", "CHEMICAL", 162, 163], ["hISG15", "GENE_OR_GENE_PRODUCT", 183, 189], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 217, 231], ["C-terminal domain", "PROTEIN", 162, 179], ["hISG15", "PROTEIN", 183, 189], ["SARS-CoV", "SPECIES", 217, 225], ["larger enthalpy binding component", "PROBLEM", 76, 109], ["the C-terminal domain of hISG15", "TREATMENT", 158, 189], ["electrostatic interactions", "OBSERVATION", 16, 42], ["enthalpy binding", "OBSERVATION", 83, 99]]], ["The impact of mISG15's divergent domain orientation from hISG15 is also apparent.", [["mISG15", "GENE_OR_GENE_PRODUCT", 14, 20], ["hISG15", "GENE_OR_GENE_PRODUCT", 57, 63], ["mISG15", "PROTEIN", 14, 20], ["hISG15", "PROTEIN", 57, 63], ["mISG15's", "TREATMENT", 14, 22]]], ["Initial molecular modeling of the hISG15 structure onto the CmISG15-bound SARS-CoV PLpro structure with CmISG15 as an anchor reveals a steric clash with the ridge helix.", [["CmISG15", "CHEMICAL", 104, 111], ["hISG15", "GENE_OR_GENE_PRODUCT", 34, 40], ["CmISG15", "GENE_OR_GENE_PRODUCT", 60, 67], ["CmISG15", "SIMPLE_CHEMICAL", 104, 111], ["hISG15 structure", "PROTEIN", 34, 50], ["CmISG15", "PROTEIN", 60, 67], ["SARS-CoV PLpro structure", "DNA", 74, 98], ["CmISG15", "PROTEIN", 104, 111], ["ridge helix", "PROTEIN", 157, 168], ["SARS-CoV", "SPECIES", 74, 82], ["CmISG15", "TREATMENT", 104, 111], ["a steric clash", "TREATMENT", 133, 147], ["the ridge helix", "TREATMENT", 153, 168], ["steric clash", "OBSERVATION", 135, 147], ["ridge helix", "OBSERVATION", 157, 168]]], ["This is the same for hISG15 drawn from any of its known X-ray structures.", [["hISG15", "GENE_OR_GENE_PRODUCT", 21, 27], ["hISG15", "DNA", 21, 27], ["X-ray structures", "DNA", 56, 72]]], ["However, the divergent interdomain orientation found in full-length mISG15 structure determined here allows for the mISG15's N-terminal domain to fit unobstructed (Fig. 9e).", [["N", "CHEMICAL", 125, 126], ["mISG15", "GENE_OR_GENE_PRODUCT", 68, 74], ["mISG15 structure", "PROTEIN", 68, 84], ["mISG15", "PROTEIN", 116, 122], ["N-terminal domain", "PROTEIN", 125, 142], ["the divergent interdomain orientation", "PROBLEM", 9, 46], ["terminal domain", "TREATMENT", 127, 142], ["unobstructed", "OBSERVATION", 150, 162]]], ["The significant domain\u2013domain orientation differences between hISG15 and mISG15 result in a different facet of mISG15 facing the protease.", [["hISG15", "GENE_OR_GENE_PRODUCT", 62, 68], ["mISG15", "GENE_OR_GENE_PRODUCT", 73, 79], ["mISG15", "GENE_OR_GENE_PRODUCT", 111, 117], ["hISG15", "PROTEIN", 62, 68], ["mISG15", "PROTEIN", 73, 79], ["mISG15", "PROTEIN", 111, 117], ["protease", "PROTEIN", 129, 137], ["The significant domain\u2013domain orientation differences", "PROBLEM", 0, 53], ["the protease", "TREATMENT", 125, 137], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["domain\u2013domain", "OBSERVATION", 16, 29]]], ["Specifically, mISG15's \u03b11\u03b23 loop comprises the surface oriented toward the ridge helix presenting a polar interface that ITC suggests may be involved in forming additional electrostatic interactions beyond those of the C-terminal domain.", [["surface", "ANATOMY", 47, 54], ["C", "CHEMICAL", 219, 220], ["mISG15", "GENE_OR_GENE_PRODUCT", 14, 20], ["\u03b11\u03b23", "GENE_OR_GENE_PRODUCT", 23, 27], ["surface", "CELLULAR_COMPONENT", 47, 54], ["ITC", "SIMPLE_CHEMICAL", 121, 124], ["mISG15", "PROTEIN", 14, 20], ["\u03b11\u03b23 loop", "PROTEIN", 23, 32], ["ridge helix", "PROTEIN", 75, 86], ["C-terminal domain", "PROTEIN", 219, 236], ["mISG15", "TEST", 14, 20], ["surface", "OBSERVATION_MODIFIER", 47, 54], ["ridge", "ANATOMY_MODIFIER", 75, 80], ["helix", "ANATOMY_MODIFIER", 81, 86], ["polar interface", "OBSERVATION", 100, 115], ["may be", "UNCERTAINTY", 134, 140], ["electrostatic interactions", "OBSERVATION", 172, 198], ["terminal", "ANATOMY_MODIFIER", 221, 229]]], ["However, when comparing the ITC data for full-length and its CmISG15 counterpart, these additional interactions might potentially come at an ethalpic cost.", [["ITC", "CELL", 28, 31], ["CmISG15", "GENE_OR_GENE_PRODUCT", 61, 68], ["CmISG15 counterpart", "CELL_LINE", 61, 80], ["the ITC data", "TEST", 24, 36]]], ["This may suggest that different ISG15 N-terminal domains may engage the protease's ridge helix to differing degrees and thermodynamic characteristics.", [["N", "CHEMICAL", 38, 39], ["ISG15", "GENE_OR_GENE_PRODUCT", 32, 37], ["ISG15 N-terminal domains", "PROTEIN", 32, 56], ["protease", "PROTEIN", 72, 80], ["ridge helix", "PROTEIN", 83, 94], ["different ISG15 N-terminal domains", "PROBLEM", 22, 56], ["the protease's ridge helix", "TREATMENT", 68, 94], ["may suggest", "UNCERTAINTY", 5, 16], ["thermodynamic characteristics", "OBSERVATION", 120, 149]]], ["The need for PLPs to accommodate not only surface differences between species ISG15s but also divergent interdomain orientations highlights the difficulties for a CoV PLP to be active to all species ISG15s.", [["surface", "ANATOMY", 42, 49], ["PLP", "CHEMICAL", 167, 170], ["PLPs", "GENE_OR_GENE_PRODUCT", 13, 17], ["surface", "CELLULAR_COMPONENT", 42, 49], ["ISG15s", "GENE_OR_GENE_PRODUCT", 78, 84], ["CoV", "ORGANISM", 163, 166], ["PLP", "GENE_OR_GENE_PRODUCT", 167, 170], ["ISG15s", "GENE_OR_GENE_PRODUCT", 199, 205], ["PLPs", "PROTEIN", 13, 17], ["ISG15s", "PROTEIN", 78, 84], ["CoV PLP", "PROTEIN", 163, 170], ["ISG15s", "PROTEIN", 199, 205], ["PLPs", "TREATMENT", 13, 17], ["species ISG15s", "PROBLEM", 70, 84], ["divergent interdomain orientations", "PROBLEM", 94, 128], ["a CoV PLP", "PROBLEM", 161, 170]]], ["This could also be perceived as a possible benefit to ISG15's unique tandem Ubl arrangement.", [["ISG15", "GENE_OR_GENE_PRODUCT", 54, 59], ["ISG15", "PROTEIN", 54, 59], ["ISG15's unique tandem Ubl arrangement", "TREATMENT", 54, 91]]], ["Also, the improved structural perspective on how the N terminus of ISG15s from different species may engage CoV PLPs provides a clearer path toward utilizing this region to influence the deIGylating activities of CoV PLPs.", [["N", "CHEMICAL", 53, 54], ["ISG15s", "GENE_OR_GENE_PRODUCT", 67, 73], ["CoV", "ORGANISM", 108, 111], ["CoV", "ORGANISM", 213, 216], ["PLPs", "GENE_OR_GENE_PRODUCT", 217, 221], ["N terminus", "PROTEIN", 53, 63], ["ISG15s", "PROTEIN", 67, 73], ["CoV PLPs", "PROTEIN", 108, 116], ["CoV PLPs", "PROTEIN", 213, 221], ["different species", "PROBLEM", 79, 96], ["CoV PLPs", "TEST", 108, 116], ["CoV PLPs", "TREATMENT", 213, 221]]], ["As a result, combining this information along with the alterations possible in the C-terminal domain, we can envision fresh tools to address the role of deubiquitination and deISGylation through the use of reverse genetics systems.Possible evolution of CoV PLP recognition of species variances in ISG15s ::: DiscussionOverall, the X-ray structural, enzymatic, and biophysical data point to CoV PLP deISGylase activities being sensitive to species-specific amino acid differences within ISG15.", [["amino acid", "CHEMICAL", 456, 466], ["C", "CHEMICAL", 83, 84], ["PLP", "CHEMICAL", 257, 260], ["PLP", "CHEMICAL", 394, 397], ["amino acid", "CHEMICAL", 456, 466], ["CoV", "ORGANISM", 253, 256], ["PLP", "GENE_OR_GENE_PRODUCT", 257, 260], ["CoV", "ORGANISM", 390, 393], ["PLP", "GENE_OR_GENE_PRODUCT", 394, 397], ["amino acid", "AMINO_ACID", 456, 466], ["ISG15", "GENE_OR_GENE_PRODUCT", 486, 491], ["C-terminal domain", "PROTEIN", 83, 100], ["ISG15", "PROTEIN", 486, 491], ["deubiquitination", "TREATMENT", 153, 169], ["deISGylation", "TREATMENT", 174, 186], ["CoV PLP recognition", "TEST", 253, 272], ["the X-ray structural", "TEST", 327, 347], ["biophysical data", "TEST", 364, 380], ["CoV PLP deISGylase activities", "PROBLEM", 390, 419], ["specific amino acid differences", "PROBLEM", 447, 478], ["CoV PLP", "OBSERVATION", 253, 260], ["species variances", "OBSERVATION", 276, 293]]], ["Intriguingly, SARS-CoV and MERS-CoV PLpros, whose viruses replicate in a wide range of hosts, recognize and cleave proISG15 from almost all of the species tested.", [["SARS-CoV", "ORGANISM", 14, 22], ["MERS-CoV PLpros", "ORGANISM", 27, 42], ["proISG15", "GENE_OR_GENE_PRODUCT", 115, 123], ["SARS-CoV and MERS-CoV PLpros", "DNA", 14, 42], ["proISG15", "PROTEIN", 115, 123], ["SARS-CoV", "SPECIES", 14, 22], ["MERS-CoV", "SPECIES", 27, 35], ["SARS", "PROBLEM", 14, 18], ["MERS", "PROBLEM", 27, 31], ["CoV PLpros", "TREATMENT", 32, 42]]], ["In contrast, the mouse-specific MHV PLP2 is limited predominantly to the mouse substrate.", [["mouse", "ORGANISM", 17, 22], ["MHV", "ORGANISM", 32, 35], ["PLP2", "GENE_OR_GENE_PRODUCT", 36, 40], ["mouse", "ORGANISM", 73, 78], ["MHV PLP2", "PROTEIN", 32, 40], ["mouse", "SPECIES", 17, 22], ["mouse", "SPECIES", 73, 78], ["mouse", "SPECIES", 17, 22], ["MHV", "SPECIES", 32, 35], ["mouse", "SPECIES", 73, 78]]], ["This wider range of specificities appears substantially larger than that found recently in nairovirus vOTUs.", [["substantially", "OBSERVATION_MODIFIER", 42, 55], ["larger", "OBSERVATION_MODIFIER", 56, 62]]], ["This may imply that with the greater binding interface provided by the palm, fingers, and thumb domains of the USP fold, CoV PLPs can either engage a wider array of ISG15s than that of vOTUs or be highly selective for just one or two ISG15s as in the case of MHV.Possible evolution of CoV PLP recognition of species variances in ISG15s ::: DiscussionIntriguingly, in all of the PLPs examined, their potential ability to engage different species ISG15s is not fully restricted to only those from species their parent viruses infect.", [["PLP", "CHEMICAL", 289, 292], ["palm", "ORGANISM_SUBDIVISION", 71, 75], ["USP", "GENE_OR_GENE_PRODUCT", 111, 114], ["CoV PLPs", "GENE_OR_GENE_PRODUCT", 121, 129], ["ISG15s", "GENE_OR_GENE_PRODUCT", 165, 171], ["vOTUs", "GENE_OR_GENE_PRODUCT", 185, 190], ["ISG15s", "GENE_OR_GENE_PRODUCT", 234, 240], ["MHV", "ORGANISM", 259, 262], ["CoV", "ORGANISM", 285, 288], ["PLP", "GENE_OR_GENE_PRODUCT", 289, 292], ["PLPs", "CANCER", 378, 382], ["ISG15s", "GENE_OR_GENE_PRODUCT", 445, 451], ["palm, fingers, and thumb domains", "PROTEIN", 71, 103], ["USP fold", "PROTEIN", 111, 119], ["CoV PLPs", "PROTEIN", 121, 129], ["ISG15s", "PROTEIN", 165, 171], ["vOTUs", "PROTEIN", 185, 190], ["ISG15s", "PROTEIN", 234, 240], ["MHV", "SPECIES", 259, 262], ["CoV PLPs", "PROBLEM", 121, 129], ["CoV PLP recognition", "TEST", 285, 304], ["the PLPs", "TEST", 374, 382], ["palm", "ANATOMY", 71, 75], ["fingers", "ANATOMY", 77, 84], ["thumb", "ANATOMY", 90, 95], ["USP fold", "ANATOMY", 111, 119], ["CoV PLP", "OBSERVATION", 285, 292], ["species variances", "OBSERVATION", 308, 325]]], ["Understandably, this could be a by-product in the evolutionary process of a specific viral protease seeking to optimize toward a certain species ISG15 and inadvertently picking up enzymatic activity toward another ISG15; or, in an environment where a virus only has to optimize its replication in one species, there is less selective pressure and hence a greater chance of losing the ability of recognizing ISG15s from other species.", [["ISG15", "GENE_OR_GENE_PRODUCT", 145, 150], ["ISG15", "GENE_OR_GENE_PRODUCT", 214, 219], ["ISG15s", "GENE_OR_GENE_PRODUCT", 407, 413], ["viral protease", "PROTEIN", 85, 99], ["ISG15", "PROTEIN", 145, 150], ["ISG15", "PROTEIN", 214, 219], ["ISG15s", "PROTEIN", 407, 413], ["a specific viral protease", "TREATMENT", 74, 99], ["a certain species ISG15", "PROBLEM", 127, 150], ["a virus", "PROBLEM", 249, 256], ["other species", "PROBLEM", 419, 432], ["less", "OBSERVATION_MODIFIER", 319, 323], ["selective", "OBSERVATION_MODIFIER", 324, 333], ["pressure", "OBSERVATION_MODIFIER", 334, 342], ["greater", "OBSERVATION_MODIFIER", 355, 362]]], ["Alternatively, some of these types of off-species PLP activities could be indicative of evolutionary memory for ISG15s.", [["PLP", "CHEMICAL", 50, 53], ["PLP", "GENE_OR_GENE_PRODUCT", 50, 53], ["ISG15s", "GENE_OR_GENE_PRODUCT", 112, 118], ["ISG15s", "PROTEIN", 112, 118], ["species PLP activities", "PROBLEM", 42, 64], ["ISG15s", "PROBLEM", 112, 118]]], ["In essence, this could give a possible view into the zoonotic evolutionary history or potential future zoonotic drift for a certain virus.", [["zoonotic drift", "PROBLEM", 103, 117], ["a certain virus", "PROBLEM", 122, 137]]], ["Naturally, a wider sampling of CoV PLPs' affinities for certain species ISG15s, knowledge of what species their parent viruses infect, and a multitude of reverse genetics experiments will be necessary to discern which of the above scenarios take place in the evolution of virus recognition of host ISG15s.Construct, expression, and purification of PLPs for the ISG15 protease activity assay and ITC ::: Materials and MethodsMHV PLP2 was expressed and purified as previously described [10], [24].", [["CoV", "ORGANISM", 31, 34], ["ISG15s", "GENE_OR_GENE_PRODUCT", 298, 304], ["PLPs", "GENE_OR_GENE_PRODUCT", 348, 352], ["ISG15", "GENE_OR_GENE_PRODUCT", 361, 366], ["MethodsMHV PLP2", "GENE_OR_GENE_PRODUCT", 417, 432], ["ISG15s", "PROTEIN", 298, 304], ["PLPs", "PROTEIN", 348, 352], ["ISG15", "PROTEIN", 361, 366], ["MethodsMHV PLP2", "DNA", 417, 432], ["CoV PLPs' affinities", "PROBLEM", 31, 51], ["certain species ISG15s", "PROBLEM", 56, 78], ["PLPs", "TREATMENT", 348, 352], ["the ISG15 protease activity", "TREATMENT", 357, 384], ["MethodsMHV PLP2", "TREATMENT", 417, 432]]], ["SARS-CoV PLpro in expression vector pET21a and MERS-CoV PLpro in pET15b were transformed into Escherichia coli BL21(DE3) competent cells (New England Biolabs) by heat shock.", [["cells", "ANATOMY", 131, 136], ["heat shock", "DISEASE", 162, 172], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 0, 14], ["pET21a", "GENE_OR_GENE_PRODUCT", 36, 42], ["MERS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 47, 61], ["pET15b", "GENE_OR_GENE_PRODUCT", 65, 71], ["Escherichia coli", "ORGANISM", 94, 110], ["BL21", "ORGANISM", 111, 115], ["DE3", "GENE_OR_GENE_PRODUCT", 116, 119], ["cells", "CELL", 131, 136], ["Biolabs", "GENE_OR_GENE_PRODUCT", 150, 157], ["SARS-CoV PLpro", "DNA", 0, 14], ["pET21a", "DNA", 36, 42], ["MERS-CoV PLpro", "DNA", 47, 61], ["pET15b", "DNA", 65, 71], ["Escherichia coli BL21(DE3) competent cells", "CELL_LINE", 94, 136], ["Escherichia coli BL21", "SPECIES", 94, 115], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 47, 55], ["Escherichia coli BL21", "SPECIES", 94, 115], ["DE3", "SPECIES", 116, 119], ["SARS", "PROBLEM", 0, 4], ["CoV PLpro in expression vector pET21a", "TREATMENT", 5, 42], ["CoV PLpro in pET15b", "TREATMENT", 52, 71], ["Escherichia coli BL21", "TREATMENT", 94, 115], ["heat shock", "PROBLEM", 162, 172], ["Escherichia coli", "OBSERVATION", 94, 110], ["shock", "OBSERVATION", 167, 172]]], ["Cells were grown at 37 \u00b0C in LB broth supplemented with 100 \u03bcg/mL of ampicillin to OD600 of 0.6\u20130.8, and expression was induced with 0.8 mM IPTG at 25 \u00b0C overnight for SARS-CoV PLpro and 1 mM IPTG at 18 \u00b0C overnight for MERS-CoV PLpro.", [["Cells", "ANATOMY", 0, 5], ["ampicillin", "CHEMICAL", 69, 79], ["IPTG", "CHEMICAL", 140, 144], ["IPTG", "CHEMICAL", 192, 196], ["ampicillin", "CHEMICAL", 69, 79], ["IPTG", "CHEMICAL", 140, 144], ["IPTG", "CHEMICAL", 192, 196], ["Cells", "CELL", 0, 5], ["ampicillin", "SIMPLE_CHEMICAL", 69, 79], ["IPTG", "SIMPLE_CHEMICAL", 140, 144], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 220, 228], ["SARS-CoV", "SPECIES", 168, 176], ["MERS-CoV", "SPECIES", 220, 228], ["Cells", "TEST", 0, 5], ["ampicillin", "TREATMENT", 69, 79], ["0.8 mM IPTG", "TREATMENT", 133, 144], ["SARS", "PROBLEM", 168, 172], ["CoV PLpro", "TREATMENT", 173, 182], ["1 mM IPTG", "TREATMENT", 187, 196], ["MERS", "PROBLEM", 220, 224], ["CoV PLpro", "TREATMENT", 225, 234]]], ["Cells were collected by centrifugation at 6000g for 10 min and stored at \u2212 80 \u00b0C. Cells were lysed in Buffer A [20 mM Tris (pH 7.5 for SARS-CoV PLpro and pH 7.0 for MERS-CoV PLpro), 500 mM NaCl, and 10 mM \u03b2-mercaptoethanol (BME)] supplemented with lysozyme for 30 min at 4 \u00b0C, followed by sonication on ice at 50% power with a 50% duty cycle for a total of 6 min.", [["Cells", "ANATOMY", 0, 5], ["Cells", "ANATOMY", 82, 87], ["NaCl", "CHEMICAL", 189, 193], ["\u03b2-mercaptoethanol", "CHEMICAL", 205, 222], ["BME", "CHEMICAL", 224, 227], ["Tris", "CHEMICAL", 118, 122], ["NaCl", "CHEMICAL", 189, 193], ["\u03b2-mercaptoethanol", "CHEMICAL", 205, 222], ["BME", "CHEMICAL", 224, 227], ["Cells", "CELL", 0, 5], ["Cells", "CELL", 82, 87], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 205, 222], ["BME", "SIMPLE_CHEMICAL", 224, 227], ["lysozyme", "GENE_OR_GENE_PRODUCT", 248, 256], ["lysozyme", "PROTEIN", 248, 256], ["Cells", "TEST", 82, 87], ["Tris", "TEST", 118, 122], ["pH", "TEST", 124, 126], ["SARS", "TEST", 135, 139], ["CoV", "TEST", 140, 143], ["PLpro", "TEST", 144, 149], ["pH", "TEST", 154, 156], ["MERS", "TEST", 165, 169], ["CoV PLpro)", "TREATMENT", 170, 180], ["NaCl", "TREATMENT", 189, 193], ["mercaptoethanol (BME)", "TREATMENT", 207, 228], ["lysozyme", "TREATMENT", 248, 256], ["ice", "TREATMENT", 303, 306]]], ["Insoluble protein was removed by centrifugation at 70,600g for 30 min and the supernatant filtered through a 0.8-\u03bcm filter.", [["supernatant", "ANATOMY", 78, 89], ["Insoluble protein", "TREATMENT", 0, 17], ["a 0.8-\u03bcm filter", "TREATMENT", 107, 122]]], ["The clarified supernatant was flowed over high density nickel agarose beads (Gold Biotechnology, Olivette, MO) pre-equilibrated with Buffer A. The column was washed with 10 column volumes of Buffer A supplemented with 30 mM imidazole, and the protein was eluted with 10 column volumes of Buffer A supplemented with 300 mM imidazole.", [["supernatant", "ANATOMY", 14, 25], ["nickel", "CHEMICAL", 55, 61], ["imidazole", "CHEMICAL", 224, 233], ["imidazole", "CHEMICAL", 322, 331], ["nickel", "CHEMICAL", 55, 61], ["imidazole", "CHEMICAL", 224, 233], ["imidazole", "CHEMICAL", 322, 331], ["imidazole", "SIMPLE_CHEMICAL", 224, 233], ["imidazole", "SIMPLE_CHEMICAL", 322, 331], ["high density nickel agarose beads", "TREATMENT", 42, 75], ["Buffer A. The column", "TREATMENT", 133, 153], ["30 mM imidazole", "TREATMENT", 218, 233], ["the protein", "TREATMENT", 239, 250], ["300 mM imidazole", "TREATMENT", 315, 331], ["supernatant", "OBSERVATION_MODIFIER", 14, 25], ["high density", "OBSERVATION_MODIFIER", 42, 54], ["nickel", "OBSERVATION_MODIFIER", 55, 61], ["agarose beads", "OBSERVATION", 62, 75], ["column", "ANATOMY", 147, 153]]], ["The PLpro was further purified by size-exclusion chromatography using a Superdex 200 column (GE Healthcare, Pittsburgh, PA) pre-equilibrated with 100 mM NaCl, 5 mM Hepes (pH 7.5 for SARS-CoV PLpro and pH 7.0 for MERS-CoV PLpro), and 2 mM DTT.Purification of SARS-CoV PLpro for complexation and crystallization ::: Materials and MethodsPurification of SARS-CoV PLpro in expression vector pET11a for complexing with ChISG15 and CmISG15 was adapted from the previously described method [7].", [["NaCl", "CHEMICAL", 153, 157], ["SARS", "DISEASE", 351, 355], ["NaCl", "CHEMICAL", 153, 157], ["DTT", "CHEMICAL", 238, 241], ["PLpro", "SIMPLE_CHEMICAL", 4, 9], ["DTT", "SIMPLE_CHEMICAL", 238, 241], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 258, 266], ["pET11a", "GENE_OR_GENE_PRODUCT", 387, 393], ["ChISG15", "GENE_OR_GENE_PRODUCT", 414, 421], ["PLpro", "PROTEIN", 4, 9], ["pET11a", "DNA", 387, 393], ["ChISG15", "DNA", 414, 421], ["CmISG15", "DNA", 426, 433], ["SARS-CoV", "SPECIES", 258, 266], ["SARS-CoV", "SPECIES", 351, 359], ["The PLpro", "TREATMENT", 0, 9], ["a Superdex 200 column", "TREATMENT", 70, 91], ["100 mM NaCl", "TREATMENT", 146, 157], ["5 mM Hepes", "TREATMENT", 159, 169], ["pH", "TEST", 171, 173], ["SARS", "TEST", 182, 186], ["CoV PLpro", "TEST", 187, 196], ["pH", "TEST", 201, 203], ["MERS", "TEST", 212, 216], ["CoV PLpro)", "TREATMENT", 217, 227], ["2 mM DTT", "TREATMENT", 233, 241], ["SARS", "PROBLEM", 258, 262], ["SARS", "PROBLEM", 351, 355], ["CoV PLpro in expression vector pET11a", "TREATMENT", 356, 393], ["ChISG15 and CmISG15", "TREATMENT", 414, 433], ["size", "OBSERVATION_MODIFIER", 34, 38]]], ["The cells were chemically lysed by resuspending them in 150 mL of Buffer B [20 mM Tris (pH 7.5) and 10 mM BME] and lysozyme and were incubated at 4 \u00b0C for 30 min.", [["cells", "ANATOMY", 4, 9], ["BME", "CHEMICAL", 106, 109], ["Tris", "CHEMICAL", 82, 86], ["BME", "CHEMICAL", 106, 109], ["cells", "CELL", 4, 9], ["lysozyme", "ORGANISM_SUBSTANCE", 115, 123], ["lysozyme", "PROTEIN", 115, 123], ["Buffer B", "TREATMENT", 66, 74], ["pH", "TEST", 88, 90], ["lysozyme", "TREATMENT", 115, 123]]], ["The suspension was sonicated on ice at 50% power with a 50% duty cycle for a total of 6 min and centrifuged for 30 min at 40,900g.", [["The suspension", "TREATMENT", 0, 14], ["ice", "TREATMENT", 32, 35], ["a 50% duty cycle", "TREATMENT", 54, 70], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["The cell lysate was filtered and subjected to a 40% ammonium sulfate fractionation then centrifuged again for 30 min at 40,900g.", [["cell lysate", "ANATOMY", 4, 15], ["ammonium sulfate", "CHEMICAL", 52, 68], ["ammonium sulfate", "CHEMICAL", 52, 68], ["cell lysate", "CELL", 4, 15], ["ammonium sulfate", "SIMPLE_CHEMICAL", 52, 68], ["The cell lysate", "TREATMENT", 0, 15], ["a 40% ammonium sulfate fractionation", "TREATMENT", 46, 82], ["cell lysate", "OBSERVATION", 4, 15]]], ["The resulting pellet was resuspended in 250 mL of 1 M ammonium sulfate, 20 mM Tris (pH 7.5), and 10 mM BME and incubated at room temperature for 1 h.", [["ammonium sulfate", "CHEMICAL", 54, 70], ["BME", "CHEMICAL", 103, 106], ["ammonium sulfate", "CHEMICAL", 54, 70], ["Tris", "CHEMICAL", 78, 82], ["BME", "CHEMICAL", 103, 106], ["ammonium sulfate", "SIMPLE_CHEMICAL", 54, 70], ["The resulting pellet", "TREATMENT", 0, 20], ["1 M ammonium sulfate", "TREATMENT", 50, 70], ["pH", "TEST", 84, 86]]], ["The suspension was filtered and loaded onto a 50-mL Phenyl-Sepharose CL-4B column (GE Healthcare, Pittsburgh, PA) equilibrated with 1.5 M ammonium sulfate, 20 mM Tris (pH 7.5), and 10 mM BME.", [["Phenyl-Sepharose CL-4B", "CHEMICAL", 52, 74], ["ammonium sulfate", "CHEMICAL", 138, 154], ["BME", "CHEMICAL", 187, 190], ["Phenyl", "CHEMICAL", 52, 58], ["ammonium sulfate", "CHEMICAL", 138, 154], ["Tris", "CHEMICAL", 162, 166], ["BME", "CHEMICAL", 187, 190], ["ammonium sulfate", "SIMPLE_CHEMICAL", 138, 154], ["The suspension", "TREATMENT", 0, 14], ["Phenyl-Sepharose CL-4B column", "TREATMENT", 52, 81], ["1.5 M ammonium sulfate", "TREATMENT", 132, 154], ["pH", "TEST", 168, 170], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["The protein was eluted using a 10-column-volume gradient to 100% Buffer B and washed with 2 additional column volumes of 100% Buffer B. The fractions were pooled together and then diluted fivefold with Buffer B. The protein was loaded onto a MonoQ 10/100 column (GE Healthcare, Pittsburgh, PA) equilibrated with Buffer B. The protein was eluted using a 10-column-volume gradient to 100% of a buffer composed of 0.5 M NaCl, 20 mM Tris (pH 7.5), and 10 mM BME with the initial flow-through off the column collected.", [["NaCl", "CHEMICAL", 417, 421], ["BME", "CHEMICAL", 454, 457], ["NaCl", "CHEMICAL", 417, 421], ["Tris", "CHEMICAL", 429, 433], ["The protein", "TEST", 0, 11], ["a 10-column-volume gradient", "TREATMENT", 29, 56], ["2 additional column volumes", "TREATMENT", 90, 117], ["Buffer B.", "TREATMENT", 202, 211], ["a MonoQ 10/100 column", "TREATMENT", 240, 261], ["Buffer B.", "TREATMENT", 312, 321], ["The protein", "TEST", 322, 333], ["a 10-column-volume gradient", "TREATMENT", 351, 378], ["a buffer", "TREATMENT", 390, 398], ["pH", "TEST", 435, 437], ["the initial flow", "TEST", 463, 479], ["column", "ANATOMY", 496, 502]]], ["The flow-through was concentrated and put into dialysis in a 50 mM NaCl, 20 mM Tris (pH 7.5), and 10 mM BME buffer at 4 \u00b0C overnight.Construct, expression, and purification of proISG15s and mature ISG15s ::: Materials and MethodsISG15s from human (H. sapiens; Accession: AAH09507.1), mouse (Mus musculus; Accession: AAB02697.1), northern tree shrew (Tupaia belangeri; Accession: AFH66859.1), sheep (Ovis aries; Accession: AF152103.1), dromedary camel (Camelus dromedarius; Accession: XP_010997700.1), vesper bat (Myotis davidii; Accession: ELK23605.1), and jackknife fish (Oplegnathus fasciatus; Accession: BAJ16365.1) in both pro and mature forms were prepared as described elsewhere [23].ISG15 protease activity assay ::: Materials and MethodsActivity assays of SARS-CoV PLpro, MERS-CoV PLpro, and MHV PLP2 with purified northern tree shrew proISG15 (pro-nsISG15), sheep proISG15 (pro-shISG15), fish proISG15 (pro-fISG15), mouse proISG15 (pro-mISG15), camel proISG15 (pro-cISG15), bat proISG15 (pro-bISG15), and human proISG15 (pro-hISG15) were adapted from the previously described methods [23].ITC of ISG15 with PLpros from MERS-CoV and SARS-CoV ::: Materials and MethodsITC was performed using a Microcal PEAQ-ITC (Malvern, Worcestershire, UK).", [["NaCl", "CHEMICAL", 67, 71], ["NaCl", "CHEMICAL", 67, 71], ["Tris", "CHEMICAL", 79, 83], ["proISG15s", "GENE_OR_GENE_PRODUCT", 176, 185], ["ISG15s", "GENE_OR_GENE_PRODUCT", 197, 203], ["human", "ORGANISM", 241, 246], ["H. sapiens", "ORGANISM", 248, 258], ["mouse", "ORGANISM", 284, 289], ["Mus musculus", "ORGANISM", 291, 303], ["tree shrew", "ORGANISM", 338, 348], ["Tupaia belangeri", "ORGANISM", 350, 366], ["sheep", "ORGANISM", 392, 397], ["dromedary camel", "ORGANISM", 435, 450], ["Camelus dromedarius", "ORGANISM", 452, 471], ["vesper bat", "ORGANISM", 501, 511], ["Myotis davidii", "ORGANISM", 513, 527], ["jackknife fish", "ORGANISM", 557, 571], ["Oplegnathus fasciatus", "ORGANISM", 573, 594], ["BAJ16365.1", "ORGANISM", 607, 617], ["ISG15", "GENE_OR_GENE_PRODUCT", 690, 695], ["SARS-CoV PLpro", "ORGANISM", 764, 778], ["MERS-CoV PLpro", "ORGANISM", 780, 794], ["MHV PLP2", "ORGANISM", 800, 808], ["shrew proISG15", "ORGANISM", 837, 851], ["pro-nsISG15", "GENE_OR_GENE_PRODUCT", 853, 864], ["sheep", "ORGANISM", 867, 872], ["proISG15", "GENE_OR_GENE_PRODUCT", 873, 881], ["pro-shISG15", "GENE_OR_GENE_PRODUCT", 883, 894], ["fish", "ORGANISM", 897, 901], ["proISG15", "GENE_OR_GENE_PRODUCT", 902, 910], ["pro-fISG15", "GENE_OR_GENE_PRODUCT", 912, 922], ["mouse", "ORGANISM", 925, 930], ["proISG15", "GENE_OR_GENE_PRODUCT", 931, 939], ["pro-mISG15", "GENE_OR_GENE_PRODUCT", 941, 951], ["camel", "ORGANISM", 954, 959], ["proISG15", "GENE_OR_GENE_PRODUCT", 960, 968], ["pro-cISG15", "GENE_OR_GENE_PRODUCT", 970, 980], ["bat proISG15", "GENE_OR_GENE_PRODUCT", 983, 995], ["pro-bISG15", "GENE_OR_GENE_PRODUCT", 997, 1007], ["human", "ORGANISM", 1014, 1019], ["proISG15", "GENE_OR_GENE_PRODUCT", 1020, 1028], ["pro-hISG15", "GENE_OR_GENE_PRODUCT", 1030, 1040], ["ITC", "CELL", 1098, 1101], ["ISG15", "GENE_OR_GENE_PRODUCT", 1105, 1110], ["MERS-CoV", "ORGANISM", 1128, 1136], ["SARS-CoV", "ORGANISM", 1141, 1149], ["proISG15s", "PROTEIN", 176, 185], ["ISG15s", "PROTEIN", 197, 203], ["ISG15", "PROTEIN", 690, 695], ["MERS-CoV PLpro", "DNA", 780, 794], ["MHV PLP2", "DNA", 800, 808], ["proISG15", "PROTEIN", 843, 851], ["pro-nsISG15", "PROTEIN", 853, 864], ["sheep proISG15", "DNA", 867, 881], ["pro-shISG15", "DNA", 883, 894], ["fish proISG15", "DNA", 897, 910], ["pro-fISG15", "DNA", 912, 922], ["mouse proISG15", "DNA", 925, 939], ["pro-mISG15", "DNA", 941, 951], ["camel proISG15", "DNA", 954, 968], ["pro-cISG15", "DNA", 970, 980], ["bat proISG15", "DNA", 983, 995], ["pro-bISG15", "DNA", 997, 1007], ["human proISG15", "DNA", 1014, 1028], ["pro-hISG15", "DNA", 1030, 1040], ["ISG15", "PROTEIN", 1105, 1110], ["PLpros", "PROTEIN", 1116, 1122], ["human", "SPECIES", 241, 246], ["H. sapiens", "SPECIES", 248, 258], ["mouse", "SPECIES", 284, 289], ["Mus musculus", "SPECIES", 291, 303], ["shrew", "SPECIES", 343, 348], ["Tupaia belangeri", "SPECIES", 350, 366], ["sheep", "SPECIES", 392, 397], ["Ovis aries", "SPECIES", 399, 409], ["camel", "SPECIES", 445, 450], ["Camelus dromedarius", "SPECIES", 452, 471], ["vesper bat", "SPECIES", 501, 511], ["Myotis davidii", "SPECIES", 513, 527], ["Oplegnathus fasciatus", "SPECIES", 573, 594], ["sheep", "SPECIES", 867, 872], ["mouse", "SPECIES", 925, 930], ["camel", "SPECIES", 954, 959], ["human", "SPECIES", 1014, 1019], ["human", "SPECIES", 241, 246], ["H. sapiens", "SPECIES", 248, 258], ["mouse", "SPECIES", 284, 289], ["Mus musculus", "SPECIES", 291, 303], ["northern tree shrew", "SPECIES", 329, 348], ["Tupaia belangeri", "SPECIES", 350, 366], ["sheep", "SPECIES", 392, 397], ["Ovis aries", "SPECIES", 399, 409], ["Camelus dromedarius", "SPECIES", 452, 471], ["Myotis davidii", "SPECIES", 513, 527], ["Oplegnathus fasciatus", "SPECIES", 573, 594], ["SARS-CoV", "SPECIES", 764, 772], ["MERS-CoV", "SPECIES", 780, 788], ["MHV", "SPECIES", 800, 803], ["northern tree shrew", "SPECIES", 823, 842], ["sheep", "SPECIES", 867, 872], ["mouse", "SPECIES", 925, 930], ["human", "SPECIES", 1014, 1019], ["MERS-CoV", "SPECIES", 1128, 1136], ["SARS-CoV", "SPECIES", 1141, 1149], ["dialysis", "TREATMENT", 47, 55], ["a 50 mM NaCl", "TREATMENT", 59, 71], ["pH", "TEST", 85, 87], ["jackknife fish", "TEST", 557, 571], ["BAJ", "TEST", 607, 610], ["MethodsActivity assays", "TEST", 738, 760], ["SARS", "PROBLEM", 764, 768], ["CoV PLpro", "TREATMENT", 785, 794], ["MHV PLP2", "TREATMENT", 800, 808], ["sheep proISG15 (pro-shISG15)", "TREATMENT", 867, 895], ["fish proISG15 (pro-fISG15)", "TREATMENT", 897, 923], ["mouse proISG15 (pro-mISG15)", "TREATMENT", 925, 952], ["MethodsITC", "TREATMENT", 1168, 1178], ["a Microcal PEAQ", "TREATMENT", 1199, 1214], ["flow", "OBSERVATION_MODIFIER", 4, 8]]], ["The mature forms of ISG15s along with PLpros from MERS-CoV and SARS-CoV were dialyzed at 4 \u00b0C in 50 mM Hepes (pH 7.4), 200 mM NaCl, and 1 mM DTT.", [["NaCl", "CHEMICAL", 126, 130], ["NaCl", "CHEMICAL", 126, 130], ["DTT", "CHEMICAL", 141, 144], ["ISG15s", "GENE_OR_GENE_PRODUCT", 20, 26], ["PLpros", "GENE_OR_GENE_PRODUCT", 38, 44], ["MERS-CoV", "ORGANISM", 50, 58], ["SARS-CoV", "ORGANISM", 63, 71], ["DTT", "SIMPLE_CHEMICAL", 141, 144], ["ISG15s", "PROTEIN", 20, 26], ["PLpros", "PROTEIN", 38, 44], ["MERS-CoV", "SPECIES", 50, 58], ["SARS-CoV", "SPECIES", 63, 71], ["The mature forms of ISG15s", "PROBLEM", 0, 26], ["PLpros from MERS", "PROBLEM", 38, 54], ["CoV", "PROBLEM", 55, 58], ["SARS", "PROBLEM", 63, 67], ["CoV", "PROBLEM", 68, 71], ["Hepes", "TEST", 103, 108], ["pH", "TEST", 110, 112], ["200 mM NaCl", "TREATMENT", 119, 130], ["1 mM DTT", "TREATMENT", 136, 144], ["mature", "OBSERVATION_MODIFIER", 4, 10]]], ["For direct binding experiments, 227 \u03bcM and 276 \u03bcM of SARS-CoV and MERS-CoV PLpro, respectively, were placed in the cell with 2.3\u20132.6 mM of mature hISG15 in the syringe.", [["cell", "ANATOMY", 115, 119], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["cell", "CELL", 115, 119], ["hISG15", "GENE_OR_GENE_PRODUCT", 146, 152], ["MERS", "PROTEIN", 66, 70], ["mature hISG15", "PROTEIN", 139, 152], ["SARS-CoV", "SPECIES", 53, 61], ["MERS-CoV", "SPECIES", 66, 74], ["direct binding experiments", "TEST", 4, 30], ["SARS", "TEST", 53, 57], ["CoV PLpro", "TREATMENT", 71, 80], ["mature hISG15 in the syringe", "TREATMENT", 139, 167]]], ["For direct binding experiments of SARS-CoV with ChISG15, 303 \u03bcM was placed in the cell with 3.4 mM in the syringe, and for SARS-CoV with CmISG15, 393 \u03bcM was placed in the cell with 3.8 mM in the syringe.", [["cell", "ANATOMY", 82, 86], ["cell", "ANATOMY", 171, 175], ["SARS", "DISEASE", 34, 38], ["SARS", "DISEASE", 123, 127], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["ChISG15", "SIMPLE_CHEMICAL", 48, 55], ["cell", "CELL", 82, 86], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["CmISG15", "SIMPLE_CHEMICAL", 137, 144], ["cell", "CELL", 171, 175], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 123, 131], ["SARS", "PROBLEM", 34, 38], ["ChISG15", "TREATMENT", 48, 55], ["SARS", "PROBLEM", 123, 127], ["CmISG15", "TREATMENT", 137, 144], ["3.8 mM", "OBSERVATION_MODIFIER", 181, 187]]], ["For competitive experiments related to SARS-CoV PLpro, mixtures containing 100 \u03bcM of protease with 50 \u03bcM of either sheep ISG15 (shISG15) or mISG15 were placed in the cell with 1 mM of mature hISG15 in the syringe.", [["cell", "ANATOMY", 166, 170], ["SARS", "DISEASE", 39, 43], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["ISG15", "GENE_OR_GENE_PRODUCT", 121, 126], ["shISG15", "GENE_OR_GENE_PRODUCT", 128, 135], ["mISG15", "GENE_OR_GENE_PRODUCT", 140, 146], ["cell", "CELL", 166, 170], ["hISG15", "GENE_OR_GENE_PRODUCT", 191, 197], ["protease", "PROTEIN", 85, 93], ["sheep ISG15", "PROTEIN", 115, 126], ["shISG15", "PROTEIN", 128, 135], ["mISG15", "PROTEIN", 140, 146], ["mature hISG15", "PROTEIN", 184, 197], ["sheep", "SPECIES", 115, 120], ["SARS-CoV", "SPECIES", 39, 47], ["sheep", "SPECIES", 115, 120], ["competitive experiments", "PROBLEM", 4, 27], ["SARS", "PROBLEM", 39, 43], ["CoV PLpro, mixtures", "TREATMENT", 44, 63], ["protease", "TREATMENT", 85, 93], ["sheep ISG15 (shISG15)", "TREATMENT", 115, 136], ["mISG15", "TREATMENT", 140, 146], ["mature hISG15 in the syringe", "TREATMENT", 184, 212]]], ["For competitive experiments related to MERS-CoV PLpro, mixtures containing 220 \u03bcM and 270 \u03bcM of protease with 110 \u03bcM and 170 \u03bcM of shISG15 and mISG15, respectively, were placed in the cell.", [["cell", "ANATOMY", 184, 188], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["shISG15", "GENE_OR_GENE_PRODUCT", 131, 138], ["mISG15", "GENE_OR_GENE_PRODUCT", 143, 149], ["cell", "CELL", 184, 188], ["protease", "PROTEIN", 96, 104], ["shISG15", "PROTEIN", 131, 138], ["mISG15", "PROTEIN", 143, 149], ["MERS-CoV", "SPECIES", 39, 47], ["competitive experiments", "PROBLEM", 4, 27], ["CoV PLpro, mixtures", "TREATMENT", 44, 63], ["protease", "TREATMENT", 96, 104], ["cell", "ANATOMY", 184, 188]]], ["The syringe contained 2.3 mM and 2.7 mM of mature hISG15 in the syringe for shISG15 and mISG15 assays, respectively.", [["hISG15", "GENE_OR_GENE_PRODUCT", 50, 56], ["mISG15", "PROTEIN", 88, 94], ["The syringe", "TEST", 0, 11], ["mature hISG15 in the syringe", "TREATMENT", 43, 71], ["2.3 mM", "OBSERVATION_MODIFIER", 22, 28]]], ["The data were processed using Microcal PEAQ-ITC Analysis Software.Functional studies of SARS-CoV PLpro mutants ::: Materials and MethodsThe SARS-CoV pET-15b-PLpro mutants (residues 1541\u20131855 of the SARS-CoV viral polyprotein) were generated using site-directed mutagenesis and the QuickChange\u00ae approach (Agilent).", [["SARS-CoV", "ORGANISM", 88, 96], ["15b", "GENE_OR_GENE_PRODUCT", 153, 156], ["PLpro", "GENE_OR_GENE_PRODUCT", 157, 162], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 198, 206], ["SARS-CoV pET-15b-PLpro mutants", "DNA", 140, 170], ["SARS-CoV viral polyprotein", "DNA", 198, 224], ["SARS-CoV", "SPECIES", 88, 96], ["SARS-CoV", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 198, 206], ["The data", "TEST", 0, 8], ["Microcal PEAQ", "TREATMENT", 30, 43], ["Methods", "TEST", 129, 136], ["The SARS", "TEST", 136, 144], ["CoV pET", "TEST", 145, 152], ["the SARS", "TEST", 194, 202], ["CoV viral polyprotein)", "TREATMENT", 203, 225], ["the QuickChange\u00ae approach", "TREATMENT", 277, 302]]], ["Expression and purification for the wild type and each mutant of the SARS-CoV PLpro were performed as previously described [33].Functional studies of SARS-CoV PLpro mutants ::: Materials and MethodsThe steady-state kinetic parameters of SARS-CoV PLpro wild-type and mutants were determined for three different Ub-based fluorescent substrates, utilizing 7-amino-4-methylcoumarin (AMC), commonly used to assess the protease, deubiquitinating, and deISGylating activity of PLPs, including a small peptide substrate, Z-RLRGG-AMC (Bachem), Ub-AMC (LifeSensors, Inc.), and ISG15-AMC (Boston Biochem/R&D Systems).", [["7-amino-4-methylcoumarin", "CHEMICAL", 353, 377], ["AMC", "CHEMICAL", 379, 382], ["7-amino-4-methylcoumarin", "CHEMICAL", 353, 377], ["AMC", "CHEMICAL", 379, 382], ["SARS-CoV PLpro", "ORGANISM", 69, 83], ["SARS-CoV", "ORGANISM", 150, 158], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 237, 245], ["Ub", "GENE_OR_GENE_PRODUCT", 310, 312], ["7-amino-4-methylcoumarin", "SIMPLE_CHEMICAL", 353, 377], ["AMC", "SIMPLE_CHEMICAL", 379, 382], ["PLPs", "SIMPLE_CHEMICAL", 470, 474], ["Bachem", "SIMPLE_CHEMICAL", 526, 532], ["Ub-AMC", "SIMPLE_CHEMICAL", 535, 541], ["LifeSensors", "SIMPLE_CHEMICAL", 543, 554], ["ISG15-AMC", "SIMPLE_CHEMICAL", 567, 576], ["SARS-CoV PLpro", "DNA", 69, 83], ["Ub", "PROTEIN", 310, 312], ["protease", "PROTEIN", 413, 421], ["PLPs", "PROTEIN", 470, 474], ["Ub", "PROTEIN", 535, 537], ["ISG15", "PROTEIN", 567, 572], ["SARS-CoV", "SPECIES", 69, 77], ["SARS-CoV", "SPECIES", 150, 158], ["SARS-CoV", "SPECIES", 237, 245], ["purification", "TREATMENT", 15, 27], ["CoV PLpro", "TREATMENT", 74, 83], ["Methods", "TEST", 191, 198], ["SARS", "PROBLEM", 237, 241], ["the protease", "TREATMENT", 409, 421], ["deISGylating activity of PLPs", "PROBLEM", 445, 474], ["a small peptide substrate", "PROBLEM", 486, 511], ["Z", "TEST", 513, 514], ["AMC", "PROBLEM", 521, 524], ["AMC", "ANATOMY", 538, 541]]], ["Kinetic assays with Ub-AMC and ISG15-AMC were performed on the same day and side-by-side in the same assay plate to directly compare the enzymatic activity of SARS-CoV PLpro to that of each of the mutants.", [["Ub-AMC", "GENE_OR_GENE_PRODUCT", 20, 26], ["ISG15-AMC", "GENE_OR_GENE_PRODUCT", 31, 40], ["SARS-CoV PLpro", "GENE_OR_GENE_PRODUCT", 159, 173], ["Ub", "PROTEIN", 20, 22], ["AMC", "PROTEIN", 23, 26], ["ISG15", "PROTEIN", 31, 36], ["AMC", "PROTEIN", 37, 40], ["SARS-CoV", "SPECIES", 159, 167], ["Kinetic assays", "TEST", 0, 14], ["Ub", "TEST", 20, 22], ["ISG15-AMC", "TEST", 31, 40], ["CoV PLpro", "TREATMENT", 164, 173]]], ["The steady-state kinetic studies were also repeated for the wild type and mutants approximately 5 months apart, and the resulting duplicate data were combined for analysis.", [["state kinetic studies", "TEST", 11, 32], ["analysis", "TEST", 163, 171]]], ["Kinetic assays with the peptide substrate were also performed in triplicate.", [["Kinetic assays", "TEST", 0, 14], ["the peptide substrate", "TEST", 20, 41]]], ["For all experiments, the assay conditions (i.e., buffering conditions and assay volume, etc.) were set up as previously described [24].", [["the assay conditions", "TEST", 21, 41], ["buffering conditions", "TREATMENT", 49, 69], ["assay volume", "TEST", 74, 86]]], ["The exception was that the stock substrates purchased from the vendors had different lot numbers.", [["the stock substrates", "TREATMENT", 23, 43]]], ["The steady-state kinetic data obtained from separate experiments performed on different days and with different substrate lot numbers helped ensure that the trends in the resulting kinetic parameters were reproducible.Functional studies of SARS-CoV PLpro mutants ::: Materials and MethodsThe enzymatic activity of PLpro-mediated hydrolysis of the fluorophore AMC group was determined using a BioTEK Synergy H1 multimode microplate reader at 25 \u00b0C with an excitation wavelength of 360 nm (bandwidth = 40 nm) and an emission wavelength of 460 nm (bandwidth = 40 nm).", [["PLpro", "CHEMICAL", 314, 319], ["PLpro", "CHEMICAL", 314, 319], ["SARS-CoV", "ORGANISM", 240, 248], ["PLpro", "SIMPLE_CHEMICAL", 314, 319], ["fluorophore AMC", "SIMPLE_CHEMICAL", 347, 362], ["SARS-CoV", "SPECIES", 240, 248], ["Methods", "TREATMENT", 281, 288], ["PLpro-mediated hydrolysis", "TREATMENT", 314, 339], ["the fluorophore AMC group", "TREATMENT", 343, 368], ["a BioTEK Synergy H1 multimode microplate", "TREATMENT", 390, 430], ["an excitation wavelength", "TREATMENT", 452, 476], ["bandwidth", "TEST", 488, 497], ["an emission wavelength", "TEST", 511, 533], ["bandwidth", "TEST", 545, 554], ["activity", "OBSERVATION_MODIFIER", 302, 310]]], ["The change in the relative fluorescence as a function of time (RFU/min) was monitored over a sufficient time period to allow the determination of the enzymatic rate in the steady-state region.", [["the enzymatic rate", "TEST", 146, 164], ["change", "OBSERVATION_MODIFIER", 4, 10]]], ["For the ISG15-AMC assay, the substrate concentrations were varied from 0.2 \u03bcM up to 19.2 \u03bcM.", [["ISG15", "GENE_OR_GENE_PRODUCT", 8, 13], ["ISG15", "PROTEIN", 8, 13], ["the ISG15-AMC assay", "TEST", 4, 23], ["the substrate concentrations", "TEST", 25, 53]]], ["The reactions were initiated by the addition of enzyme with the final enzyme concentrations as follows: 0.48 nM WT, 0.23 nM Q233E, 0.23 nM M209A, or 7.3 nM R167E.", [["enzyme", "PROTEIN", 48, 54], ["enzyme", "TEST", 48, 54], ["the final enzyme concentrations", "TEST", 60, 91], ["nM WT", "TEST", 109, 114], ["nM M209A", "TEST", 136, 144]]], ["For the Ub-AMC assay, substrate concentrations were varied from 0.5 \u03bcM to 17.6 \u03bcM.", [["Ub", "GENE_OR_GENE_PRODUCT", 8, 10], ["Ub", "PROTEIN", 8, 10], ["the Ub-AMC assay", "TEST", 4, 20]]], ["The final enzyme concentrations were 3.7 nM WT, 7.3 nM Q233E, 7.3 nM M209A, or 0.23 nM R167E.", [["The final enzyme concentrations", "TEST", 0, 31], ["nM WT", "TEST", 41, 46], ["nM", "TEST", 52, 54], ["nM M209A", "TEST", 66, 74]]], ["For the Z-RLRGG-AMC assay, the concentrations of substrate were varied from 0.8 \u03bcM to 50 \u03bcM, and the final concentration of the wild-type enzyme was 0.14 \u03bcM.", [["wild-type enzyme", "PROTEIN", 128, 144], ["the wild-type enzyme", "TEST", 124, 144]]], ["To capture the initial rate of peptide hydrolysis for the M209A mutant, we used a lower enzyme concentration of 25 nM.", [["M209A", "GENE_OR_GENE_PRODUCT", 58, 63], ["M209A mutant", "PROTEIN", 58, 70], ["peptide hydrolysis", "PROBLEM", 31, 49], ["a lower enzyme concentration", "TREATMENT", 80, 108]]], ["As is typical for SARS-CoV PLpro, the enzyme could not be saturated with the Ub-AMC and Z-RLRGG-AMC substrates.", [["SARS", "DISEASE", 18, 22], ["Z-RLRGG-AMC", "CHEMICAL", 88, 99], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 18, 26], ["Ub-AMC", "SIMPLE_CHEMICAL", 77, 83], ["Z-RLRGG", "SIMPLE_CHEMICAL", 88, 95], ["Ub", "PROTEIN", 77, 79], ["AMC", "PROTEIN", 80, 83], ["Z", "PROTEIN", 88, 89], ["RLRGG", "PROTEIN", 90, 95], ["SARS-CoV", "SPECIES", 18, 26], ["SARS", "PROBLEM", 18, 22], ["the enzyme", "TEST", 34, 44], ["the Ub", "TEST", 73, 79], ["AMC", "TEST", 80, 83], ["Z", "TEST", 88, 89]]], ["As such, the kinetic response of the enzyme to these substrates was linear, and thus, the data were fit to a line to approximate the catalytic efficiency (kcat/Km) for each enzyme.", [["enzyme", "PROTEIN", 37, 43], ["enzyme", "PROTEIN", 173, 179], ["the enzyme", "TEST", 33, 43], ["a line", "TREATMENT", 107, 113], ["each enzyme", "TEST", 168, 179]]], ["For the ISG15-AMC assays, the data were fit to the Michaelis\u2013Menten equation to determine the associated kinetic parameters (kcat, Km, and kcat/Km) for each enzyme [24].", [["ISG15", "GENE_OR_GENE_PRODUCT", 8, 13], ["ISG15", "PROTEIN", 8, 13], ["the ISG15-AMC assays", "TEST", 4, 24], ["kcat", "TEST", 125, 129], ["Km", "TEST", 131, 133], ["kcat", "TEST", 139, 143], ["each enzyme", "TEST", 152, 163]]], ["Saturation was not attained with the R167E mutant enzyme for ISG15-AMC, and therefore, these kinetic data were also fit to a line to determine the apparent kcat/Km.", [["ISG15", "GENE_OR_GENE_PRODUCT", 61, 66], ["R167E mutant enzyme", "PROTEIN", 37, 56], ["ISG15", "PROTEIN", 61, 66], ["Saturation", "TEST", 0, 10], ["ISG15", "TEST", 61, 66], ["these kinetic data", "TEST", 87, 105], ["a line", "TREATMENT", 123, 129]]], ["The errors associated with each kinetic parameter were obtained from the best-fit line or curves for each mutant.", [["The errors", "PROBLEM", 0, 10], ["each kinetic parameter", "TEST", 27, 49]]], ["All data, from separate experiments, were included in the fits to arrive at the final errors (Table 1).SARS-CoV PLpro\u2013CmISG15 and SARS-CoV PLpro\u2013ChISG15 complex formation ::: Materials and MethodsExpression of CmISG15 or ChISG15 occurred using a vector pTYB2 and was purified as previously described to form a propargylamine-derivatized thioester product (CmISG15-PA, ChISG15-PA) [23].", [["SARS", "DISEASE", 103, 107], ["propargylamine", "CHEMICAL", 310, 324], ["propargylamine", "CHEMICAL", 310, 324], ["thioester", "CHEMICAL", 337, 346], ["ChISG15-PA", "CHEMICAL", 368, 378], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["SARS-CoV", "ORGANISM", 130, 138], ["CmISG15", "GENE_OR_GENE_PRODUCT", 210, 217], ["ChISG15", "GENE_OR_GENE_PRODUCT", 221, 228], ["pTYB2", "GENE_OR_GENE_PRODUCT", 253, 258], ["propargylamine", "SIMPLE_CHEMICAL", 310, 324], ["CmISG15-PA", "SIMPLE_CHEMICAL", 356, 366], ["ChISG15-PA", "SIMPLE_CHEMICAL", 368, 378], ["CmISG15", "DNA", 210, 217], ["ChISG15", "DNA", 221, 228], ["pTYB2", "DNA", 253, 258], ["SARS-CoV", "SPECIES", 103, 111], ["SARS-CoV", "SPECIES", 130, 138], ["All data", "TEST", 0, 8], ["SARS", "PROBLEM", 103, 107], ["CmISG15", "TREATMENT", 210, 217], ["a vector pTYB2", "TREATMENT", 244, 258], ["a propargylamine-derivatized thioester product", "TREATMENT", 308, 354]]], ["Briefly, to obtain complex, we added directly purified protease to the mixture in equimolar ratios and incubated it for 2\u20134 h at room temperature and left it 4 \u00b0C overnight.", [["protease", "PROTEIN", 55, 63], ["directly purified protease", "TREATMENT", 37, 63], ["left", "ANATOMY_MODIFIER", 150, 154]]], ["To further purify the complex, we used anion exchange chromatography, eluting from a MonoQ 10/100 column using a linear gradient from 0 to 1 M NaCl (SARS-CoV PLpro\u2013CmISG15) or 250 mM NaCl (SARS-CoV PLpro\u2013ChISG15) with 50 mM Tris (pH 8.0 for SARS-CoV PLpro\u2013CmISG15 and pH 9.0 for SARS-CoV PLpro\u2013ChISG15), followed by size-exclusion chromatography on a Superdex 75 column (GE Healthcare, Pittsburgh, PA) pre-equilibrated with 100 mM NaCl, 5 mM Hepes (pH 7.5), and 2 mM DTT.", [["NaCl", "CHEMICAL", 143, 147], ["NaCl", "CHEMICAL", 183, 187], ["NaCl", "CHEMICAL", 431, 435], ["NaCl", "CHEMICAL", 143, 147], ["NaCl", "CHEMICAL", 183, 187], ["Tris", "CHEMICAL", 224, 228], ["NaCl", "CHEMICAL", 431, 435], ["DTT", "CHEMICAL", 467, 470], ["anion", "SIMPLE_CHEMICAL", 39, 44], ["anion exchange chromatography", "TREATMENT", 39, 68], ["a linear gradient", "TEST", 111, 128], ["SARS-CoV PLpro\u2013CmISG15)", "TREATMENT", 149, 172], ["250 mM NaCl (SARS-CoV PLpro\u2013ChISG15)", "TREATMENT", 176, 212], ["pH", "TEST", 230, 232], ["SARS", "TEST", 241, 245], ["CoV PLpro\u2013CmISG15", "TEST", 246, 263], ["pH", "TEST", 268, 270], ["SARS", "PROBLEM", 279, 283], ["a Superdex 75 column", "TREATMENT", 349, 369], ["100 mM NaCl", "TREATMENT", 424, 435], ["5 mM Hepes", "TREATMENT", 437, 447], ["pH", "TEST", 449, 451]]], ["For SARS-CoV PLpro\u2013ChISG15, an additional purification step prior to anion exchange chromatography was used to eliminate residual ChISG15 by size-exclusion chromatography using a Superdex 200 column (GE Healthcare, Pittsburgh, PA) pre-equilibrated with 100 mM NaCl, 50 mM Tris (pH 7.5), and 2 mM DTT.Crystallization of SARS-CoV PLpro\u2013CmISG15, SARS-CoV PLpro\u2013ChISG15, and mISG15 ::: Materials and MethodsPurified SARS-CoV PLpro\u2013CmISG15, SARS-CoV PLpro\u2013ChISG15, and mISG15 were screened against a series of Qiagen NeXtal suites by hanging drop using a TTP Labtech Mosquito (TTP Labtech, Herfordshire, UK) at 8.8 mg/ml, 8.88 mg/ml, and 16 mg/ml, respectively.", [["ChISG15", "CHEMICAL", 130, 137], ["NaCl", "CHEMICAL", 260, 264], ["SARS", "DISEASE", 319, 323], ["NaCl", "CHEMICAL", 260, 264], ["Tris", "CHEMICAL", 272, 276], ["DTT", "CHEMICAL", 296, 299], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["anion", "SIMPLE_CHEMICAL", 69, 74], ["ChISG15", "SIMPLE_CHEMICAL", 130, 137], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 319, 327], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 343, 351], ["mISG15", "SIMPLE_CHEMICAL", 371, 377], ["SARS-CoV", "ORGANISM", 436, 444], ["PLpro\u2013ChISG15", "ORGANISM", 445, 458], ["mISG15", "GENE_OR_GENE_PRODUCT", 464, 470], ["mISG15", "PROTEIN", 371, 377], ["SARS-CoV PLpro\u2013ChISG15", "DNA", 436, 458], ["mISG15", "DNA", 464, 470], ["SARS-CoV", "SPECIES", 4, 12], ["SARS-CoV", "SPECIES", 319, 327], ["SARS-CoV", "SPECIES", 343, 351], ["SARS-CoV", "SPECIES", 412, 420], ["SARS-CoV", "SPECIES", 436, 444], ["SARS", "PROBLEM", 4, 8], ["an additional purification", "TREATMENT", 28, 54], ["anion exchange chromatography", "TEST", 69, 98], ["a Superdex 200 column", "TREATMENT", 177, 198], ["100 mM NaCl", "TREATMENT", 253, 264], ["pH", "TEST", 278, 280], ["SARS", "PROBLEM", 319, 323], ["Materials", "TEST", 382, 391], ["MethodsPurified SARS", "TEST", 396, 416], ["mISG15", "TREATMENT", 464, 470], ["Qiagen NeXtal suites", "TREATMENT", 505, 525], ["a TTP Labtech Mosquito (TTP Labtech", "TREATMENT", 548, 583], ["size", "OBSERVATION_MODIFIER", 141, 145]]], ["For SARS-CoV PLpro\u2013CmISG15, the initial screen yielded the best crystals in a solution containing 65% (vol/vol) MPD and 0.1 M Tris (pH 8.0).", [["MPD", "CHEMICAL", 112, 115], ["Tris", "CHEMICAL", 126, 130], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["the initial screen", "TEST", 28, 46], ["MPD", "TEST", 112, 115], ["Tris", "TEST", 126, 130], ["pH", "TEST", 132, 134]]], ["These crystals were optimized using the Additive HT Screen from Hampton Research.", [["HT", "DISEASE", 49, 51]]], ["The final SARS-CoV PLpro\u2013CmISG15 crystals were obtained through vapor diffusion using a 500-\u03bcL reservoir with 4-\u03bcL hanging drops mixed (1:1) with protein solution and reservoir solution, which also contained 0.25 \u03bcl of 30% (wt/vol) trimethylamine N-oxide dihydrate.", [["SARS", "DISEASE", 10, 14], ["trimethylamine N-oxide", "CHEMICAL", 232, 254], ["trimethylamine N-oxide dihydrate", "CHEMICAL", 232, 264], ["trimethylamine N-oxide dihydrate", "SIMPLE_CHEMICAL", 232, 264], ["SARS-CoV", "SPECIES", 10, 18], ["a 500-\u03bcL reservoir", "TREATMENT", 86, 104], ["4-\u03bcL hanging drops", "TREATMENT", 110, 128], ["protein solution", "TREATMENT", 146, 162], ["reservoir solution", "TREATMENT", 167, 185], ["trimethylamine N-oxide dihydrate", "TREATMENT", 232, 264]]], ["For SARS-CoV PLpro\u2013ChISG15, the initial screen yielded the best crystals in a solution containing 0.2 M lithium sulfate, 0.1 M bis-Tris (pH 6.5), and 25% (wt/vol) polyethylene glycol (PEG) 3350.", [["lithium sulfate", "CHEMICAL", 104, 119], ["M bis-Tris", "CHEMICAL", 125, 135], ["polyethylene glycol", "CHEMICAL", 163, 182], ["PEG) 3350", "CHEMICAL", 184, 193], ["lithium sulfate", "CHEMICAL", 104, 119], ["bis-Tris", "CHEMICAL", 127, 135], ["polyethylene glycol", "CHEMICAL", 163, 182], ["PEG) 3350", "CHEMICAL", 184, 193], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["lithium sulfate", "SIMPLE_CHEMICAL", 104, 119], ["bis-Tris", "SIMPLE_CHEMICAL", 127, 135], ["polyethylene glycol", "SIMPLE_CHEMICAL", 163, 182], ["PEG) 3350", "SIMPLE_CHEMICAL", 184, 193], ["SARS-CoV", "SPECIES", 4, 12], ["SARS", "PROBLEM", 4, 8], ["the initial screen", "TEST", 28, 46], ["a solution containing 0.2 M lithium sulfate", "TREATMENT", 76, 119], ["pH", "TEST", 137, 139], ["wt/vol) polyethylene glycol (PEG)", "TREATMENT", 155, 188]]], ["The initial crystal conditions for SARS-CoV PLpro\u2013ChISG15 crystals were optimized along salt and PEG3350 gradients and by using the Additive Screen from Hampton Research.", [["SARS", "DISEASE", 35, 39], ["PEG3350", "CHEMICAL", 97, 104], ["SARS-CoV PLpro\u2013ChISG15", "SIMPLE_CHEMICAL", 35, 57], ["salt", "SIMPLE_CHEMICAL", 88, 92], ["PEG3350", "SIMPLE_CHEMICAL", 97, 104], ["SARS-CoV", "SPECIES", 35, 43], ["The initial crystal conditions", "PROBLEM", 0, 30], ["SARS", "PROBLEM", 35, 39], ["CoV PLpro\u2013ChISG15 crystals", "TREATMENT", 40, 66]]], ["The final SARS-CoV PLpro\u2013ChISG15 crystals were obtained through vapor diffusion using a 500-\u03bcL reservoir with 4-\u03bcL hanging drops mixed (1:1) with protein solution (6.99 mg/mL) and reservoir solution [0.1 M lithium sulfate, 0.1 M bis-Tris, (pH 6.5), and 22% PEG3350], which also contained 0.25 \u03bcl of 30% (vol/vol) glycerol.", [["SARS", "DISEASE", 10, 14], ["lithium sulfate", "CHEMICAL", 206, 221], ["bis-Tris", "CHEMICAL", 229, 237], ["PEG3350", "CHEMICAL", 257, 264], ["glycerol", "CHEMICAL", 313, 321], ["lithium sulfate", "CHEMICAL", 206, 221], ["bis-Tris", "CHEMICAL", 229, 237], ["glycerol", "CHEMICAL", 313, 321], ["lithium sulfate", "SIMPLE_CHEMICAL", 206, 221], ["bis-Tris", "SIMPLE_CHEMICAL", 229, 237], ["PEG3350", "SIMPLE_CHEMICAL", 257, 264], ["vol/vol) glycerol", "SIMPLE_CHEMICAL", 304, 321], ["SARS-CoV", "SPECIES", 10, 18], ["a 500-\u03bcL reservoir", "TREATMENT", 86, 104], ["4-\u03bcL hanging drops", "TREATMENT", 110, 128], ["protein solution", "TREATMENT", 146, 162], ["reservoir solution", "TREATMENT", 180, 198], ["lithium sulfate", "TREATMENT", 206, 221], ["pH", "TEST", 240, 242], ["glycerol", "TREATMENT", 313, 321]]], ["For mISG15, the initial screen yielded the best crystals in a solution containing 0.2 M ammonium sulfate, 0.1 M trisodium citrate (pH 5.6), and 15% (wt/vol) PEG4000.", [["ammonium sulfate", "CHEMICAL", 88, 104], ["trisodium citrate", "CHEMICAL", 112, 129], ["PEG4000", "CHEMICAL", 157, 164], ["ammonium sulfate", "CHEMICAL", 88, 104], ["trisodium citrate", "CHEMICAL", 112, 129], ["PEG4000", "CHEMICAL", 157, 164], ["ammonium sulfate", "SIMPLE_CHEMICAL", 88, 104], ["0.1 M trisodium citrate", "SIMPLE_CHEMICAL", 106, 129], ["PEG4000", "SIMPLE_CHEMICAL", 157, 164], ["mISG15", "PROTEIN", 4, 10], ["the initial screen", "TEST", 12, 30], ["a solution", "TREATMENT", 60, 70], ["0.2 M ammonium sulfate", "TREATMENT", 82, 104], ["M trisodium citrate", "TREATMENT", 110, 129], ["pH", "TEST", 131, 133]]], ["This condition was further optimized along buffer, pH, and PEG4000 gradients in addition to using the Additive Screen from Hampton Research.", [["PEG4000", "SIMPLE_CHEMICAL", 59, 66], ["pH", "TEST", 51, 53]]], ["In conjunction with using these optimization methods, the mISG15 was shorted by 5 aa.", [["mISG15", "GENE_OR_GENE_PRODUCT", 58, 64], ["mISG15", "DNA", 58, 64]]], ["The final crystals of the 5-aa-shortened mISG15 were obtained through vapor diffusion using a 500-\u03bcL reservoir with 4-\u03bcL hanging drops mixed (1:1) with protein solution (6.9 mg/mL) and reservoir solution [0.2 M ammonium sulfate, 0.1 M sodium acetate (pH 4.6), 12% PEG4000, and 0.2 M sodium malonate].Crystallization of SARS-CoV PLpro\u2013CmISG15, SARS-CoV PLpro\u2013ChISG15, and mISG15 ::: Materials and MethodsCrystals of SARS-CoV PLpro\u2013CmISG15, SARS-CoV PLpro\u2013ChISG15, and mISG15 were collected and flash frozen in liquid N2.", [["5-aa", "CHEMICAL", 26, 30], ["ammonium sulfate", "CHEMICAL", 211, 227], ["sodium acetate", "CHEMICAL", 235, 249], ["PEG4000", "CHEMICAL", 264, 271], ["sodium malonate", "CHEMICAL", 283, 298], ["SARS", "DISEASE", 319, 323], ["ammonium sulfate", "CHEMICAL", 211, 227], ["sodium acetate", "CHEMICAL", 235, 249], ["PEG4000", "CHEMICAL", 264, 271], ["sodium malonate", "CHEMICAL", 283, 298], ["N2", "CHEMICAL", 516, 518], ["5-aa", "SIMPLE_CHEMICAL", 26, 30], ["mISG15", "SIMPLE_CHEMICAL", 41, 47], ["ammonium sulfate", "SIMPLE_CHEMICAL", 211, 227], ["sodium acetate", "SIMPLE_CHEMICAL", 235, 249], ["PEG4000", "SIMPLE_CHEMICAL", 264, 271], ["sodium malonate", "SIMPLE_CHEMICAL", 283, 298], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 319, 327], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 343, 351], ["SARS-CoV PLpro\u2013CmISG15", "ORGANISM", 415, 437], ["SARS-CoV PLpro\u2013ChISG15", "ORGANISM", 439, 461], ["mISG15", "GENE_OR_GENE_PRODUCT", 467, 473], ["mISG15", "PROTEIN", 41, 47], ["SARS-CoV PLpro\u2013ChISG15", "DNA", 439, 461], ["mISG15", "DNA", 467, 473], ["SARS-CoV", "SPECIES", 319, 327], ["SARS-CoV", "SPECIES", 343, 351], ["SARS-CoV", "SPECIES", 415, 423], ["SARS-CoV", "SPECIES", 439, 447], ["a 500-\u03bcL reservoir", "TREATMENT", 92, 110], ["4-\u03bcL hanging drops", "TREATMENT", 116, 134], ["protein solution", "TREATMENT", 152, 168], ["reservoir solution [0.2 M ammonium sulfate", "TREATMENT", 185, 227], ["M sodium acetate", "TREATMENT", 233, 249], ["pH", "TEST", 251, 253], ["SARS", "PROBLEM", 319, 323], ["SARS", "PROBLEM", 415, 419], ["CoV PLpro\u2013ChISG15", "TREATMENT", 444, 461], ["mISG15", "TREATMENT", 467, 473], ["liquid N2", "OBSERVATION", 509, 518]]], ["Cryogenic solutions for SARS-CoV PLpro\u2013CmISG15 and SARS-CoV PLpro\u2013ChISG15 constituted their respective mother liquors.", [["SARS-CoV PLpro\u2013ChISG15", "SIMPLE_CHEMICAL", 51, 73], ["SARS-CoV PLpro\u2013ChISG15", "DNA", 51, 73], ["SARS-CoV", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 51, 59], ["Cryogenic solutions", "TREATMENT", 0, 19], ["SARS", "PROBLEM", 24, 28], ["CoV PLpro\u2013CmISG15", "TREATMENT", 29, 46], ["SARS-CoV PLpro\u2013ChISG15", "TREATMENT", 51, 73]]], ["For mISG15 crystals, they were passed from a 5% to a 12% solution (1:1:1) of glycerol, dimethyl sulphoxide, and PEG known as EDG [34].", [["glycerol", "CHEMICAL", 77, 85], ["dimethyl sulphoxide", "CHEMICAL", 87, 106], ["PEG", "CHEMICAL", 112, 115], ["EDG", "CHEMICAL", 125, 128], ["glycerol", "CHEMICAL", 77, 85], ["dimethyl sulphoxide", "CHEMICAL", 87, 106], ["PEG", "CHEMICAL", 112, 115], ["EDG", "CHEMICAL", 125, 128], ["glycerol", "SIMPLE_CHEMICAL", 77, 85], ["dimethyl sulphoxide", "SIMPLE_CHEMICAL", 87, 106], ["PEG", "SIMPLE_CHEMICAL", 112, 115], ["EDG", "SIMPLE_CHEMICAL", 125, 128], ["mISG15 crystals", "TREATMENT", 4, 19], ["glycerol, dimethyl sulphoxide", "TREATMENT", 77, 106], ["PEG", "TREATMENT", 112, 115]]], ["Data sets were collected at the Advanced Photon Source (Argonne National Labs, Argonne, IL).", [["Data sets", "TEST", 0, 9]]], ["A data set for SARS-CoV PLpro\u2013CmISG15 was collected at the LS-CAT beamline 21G at a wavelength of 0.9786 \u00c5 using a MAR300 detector, whereas data sets for SARS-CoV PLpro\u2013ChISG15 and mISG15 were collected at the SER-CAT beamlines 22ID and 22BM at 1 \u00c5 using MAR300hs detectors.", [["CoV", "ORGANISM", 20, 23], ["SARS-CoV PLpro\u2013ChISG15", "GENE_OR_GENE_PRODUCT", 154, 176], ["mISG15", "SIMPLE_CHEMICAL", 181, 187], ["SARS-CoV PLpro\u2013CmISG15", "DNA", 15, 37], ["CAT beamline 21G", "DNA", 62, 78], ["SARS-CoV PLpro\u2013ChISG15", "DNA", 154, 176], ["mISG15", "DNA", 181, 187], ["SER-CAT beamlines 22ID and 22BM", "DNA", 210, 241], ["SARS-CoV", "SPECIES", 15, 23], ["SARS-CoV", "SPECIES", 154, 162], ["A data", "TEST", 0, 6], ["SARS", "PROBLEM", 15, 19], ["CoV PLpro\u2013CmISG15", "TREATMENT", 20, 37], ["a MAR300 detector", "TEST", 113, 130], ["SARS", "PROBLEM", 154, 158], ["CoV PLpro\u2013ChISG15", "TREATMENT", 159, 176], ["mISG15", "TREATMENT", 181, 187]]], ["All data sets were collected at 100 K.Data processing and structure solutions ::: Materials and MethodsData sets were indexed, integrated, and scaled using HKL-2000 [35].", [["All data sets", "TEST", 0, 13], ["MethodsData sets", "TEST", 96, 112]]], ["Subsequently, each structure was rebuilt initially using Autobuild [37] followed by successive rounds of manual model building and refinement using Coot [38] and Phenix [39].", [["manual model building", "TREATMENT", 105, 126]]], ["The initial solution for the SARS-CoV PLpro\u2013CmISG15 complex was achieved by using the catalytic core of a previous SARS-CoV PLpro structure (PDB entry: 3E9S).", [["SARS", "DISEASE", 29, 33], ["SARS-CoV PLpro\u2013CmISG15 complex", "PROTEIN", 29, 59], ["SARS-CoV PLpro structure", "PROTEIN", 115, 139], ["3E9S", "PROTEIN", 152, 156], ["SARS-CoV", "SPECIES", 29, 37], ["The initial solution", "TREATMENT", 0, 20], ["the SARS-CoV PLpro\u2013CmISG15 complex", "TREATMENT", 25, 59]]], ["Density from the last 10 aa of the CmISG15 molecule served as an anchor for the initial global placement of the CmISG15 from a Erve nairovirus vOTU-CmISG15 complex (PDB entry: 5JZE).", [["CmISG15", "GENE_OR_GENE_PRODUCT", 112, 119], ["CmISG15 molecule", "PROTEIN", 35, 51], ["CmISG15", "PROTEIN", 112, 119], ["Erve nairovirus vOTU", "PROTEIN", 127, 147], ["CmISG15 complex", "PROTEIN", 148, 163], ["PDB entry: 5JZE", "PROTEIN", 165, 180], ["an anchor", "TREATMENT", 62, 71], ["the initial global placement", "TREATMENT", 76, 104]]], ["This partial model was then used as a search model along with the Ubl SARS-CoV PLpro domain from PDB entry: 4MM3 to obtain a complete global model using Phaser [36].", [["Ubl SARS-CoV PLpro domain", "PROTEIN", 66, 91], ["4MM3", "PROTEIN", 108, 112], ["Ubl SARS-CoV", "SPECIES", 66, 78], ["a search model", "TREATMENT", 36, 50], ["the Ubl SARS", "TEST", 62, 74]]], ["For the SARS-CoV PLpro\u2013ChISG15 complex, an initial molecular replacement solution was obtained by using the core and other elements from the SARS-CoV PLpro\u2013CmISG15 as a search model.", [["SARS", "DISEASE", 8, 12], ["SARS-CoV PLpro\u2013ChISG15 complex", "PROTEIN", 8, 38], ["SARS-CoV PLpro\u2013CmISG15", "DNA", 141, 163], ["SARS-CoV", "SPECIES", 8, 16], ["SARS-CoV", "SPECIES", 141, 149], ["the SARS-CoV PLpro\u2013ChISG15 complex", "TREATMENT", 4, 38], ["an initial molecular replacement solution", "TREATMENT", 40, 81], ["replacement", "OBSERVATION", 61, 72]]], ["A partial molecular replacement solution using Phaser [36] for mISG15 was obtained by searching with the CmISG15 from the Erve nairovirus vOTU\u2013CmISG15 complex structure (PDB entry: 5JZE).", [["mISG15", "GENE_OR_GENE_PRODUCT", 63, 69], ["CmISG15", "GENE_OR_GENE_PRODUCT", 105, 112], ["mISG15", "PROTEIN", 63, 69], ["CmISG15", "PROTEIN", 105, 112], ["Erve nairovirus vOTU\u2013CmISG15 complex structure", "PROTEIN", 122, 168], ["5JZE", "PROTEIN", 181, 185], ["A partial molecular replacement solution", "TREATMENT", 0, 40], ["replacement", "OBSERVATION", 20, 31]]], ["This partial model was used in a sequential Phaser [36] run using a mISG15 N-terminal domain homology model based on the previously solved hISG15 structure (PDB entry: 1Z2M).", [["N", "CHEMICAL", 75, 76], ["mISG15 N-terminal domain", "PROTEIN", 68, 92], ["hISG15 structure", "PROTEIN", 139, 155], ["1Z2M", "PROTEIN", 168, 172], ["a mISG15 N-terminal domain homology model", "TREATMENT", 66, 107]]], ["All structures were validated using Molprobity [40] and have good Ramachandran statistics: SARS-CoV PLpro\u2013CmISG15 (96% favored and 4% allowed), SARS-CoV PLpro\u2013ChISG15 (96% favored and 4% allowed), and mISG15 (99.08% favored and 0.92% allowed).", [["SARS-CoV", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 144, 152], ["CoV PLpro\u2013CmISG15", "TREATMENT", 96, 113], ["SARS-CoV PLpro\u2013ChISG15", "TREATMENT", 144, 166], ["mISG15", "TREATMENT", 201, 207]]], ["All structures have been deposited in the Protein Data Bank.", [["deposited", "OBSERVATION", 25, 34]]], ["Codes can be found on Table 3.Electropotential plots ::: Materials and MethodsFigure renderings involving electropotential plots were performed using the PDB2PQR server and the surface generated using the adaptive Poisson\u2013Boltzmann solver [41].Accession numbers ::: Materials and MethodsAll structures have been deposited in the Protein Data Bank (PDB entry: 5TL7 for SARS-CoV PLpro\u2013CmISG15, 5TL6 for SARS-CoV PLpro\u2013ChISG15, and 5TLA for mISG15).", [["surface", "ANATOMY", 177, 184], ["surface", "CELLULAR_COMPONENT", 177, 184], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 401, 409], ["PDB2PQR server", "DNA", 154, 168], ["Protein Data Bank", "PROTEIN", 329, 346], ["5TL7", "PROTEIN", 359, 363], ["SARS-CoV PLpro\u2013CmISG15", "PROTEIN", 368, 390], ["5TL6", "PROTEIN", 392, 396], ["SARS", "PROTEIN", 401, 405], ["CoV PLpro\u2013ChISG15", "PROTEIN", 406, 423], ["5TLA", "PROTEIN", 429, 433], ["mISG15", "PROTEIN", 438, 444], ["SARS-CoV", "SPECIES", 368, 376], ["SARS-CoV", "SPECIES", 401, 409], ["electropotential plots", "TEST", 106, 128], ["the PDB2PQR server", "TREATMENT", 150, 168], ["the adaptive Poisson\u2013Boltzmann solver", "TREATMENT", 201, 238], ["SARS", "PROBLEM", 368, 372], ["SARS", "PROBLEM", 401, 405], ["CoV PLpro\u2013ChISG15", "TREATMENT", 406, 423]]], ["Source sequences for ISG15s were GenBank numbers AAH09507.1 for H. sapiens, AAB02697.1 for Mus musculus, AFH66859.1 for Tupaia belangeri, ELK23605.1 for Myotis davidii, and BAJ16365.1 for Oplegnathus fasciatus, and NCBI Reference Sequence XP_010997700.1 for Camelus dromedarius.", [["H. sapiens", "ORGANISM", 64, 74], ["Mus musculus", "ORGANISM", 91, 103], ["Tupaia belangeri", "ORGANISM", 120, 136], ["Myotis davidii", "ORGANISM", 153, 167], ["Oplegnathus fasciatus", "ORGANISM", 188, 209], ["Camelus dromedarius", "ORGANISM", 258, 277], ["ISG15s", "DNA", 21, 27], ["H. sapiens", "SPECIES", 64, 74], ["Mus musculus", "SPECIES", 91, 103], ["Tupaia belangeri", "SPECIES", 120, 136], ["Myotis davidii", "SPECIES", 153, 167], ["Oplegnathus fasciatus", "SPECIES", 188, 209], ["Camelus dromedarius", "SPECIES", 258, 277], ["H. sapiens", "SPECIES", 64, 74], ["Mus musculus", "SPECIES", 91, 103], ["Tupaia belangeri", "SPECIES", 120, 136], ["Myotis davidii", "SPECIES", 153, 167], ["Oplegnathus fasciatus", "SPECIES", 188, 209], ["Camelus dromedarius", "SPECIES", 258, 277], ["Source sequences", "TEST", 0, 16], ["ISG15s", "TEST", 21, 27], ["GenBank numbers", "TEST", 33, 48], ["H. sapiens", "PROBLEM", 64, 74], ["Mus musculus", "PROBLEM", 91, 103]]], ["Source sequences for PLPs were GenBank numbers AFS88944.1 for MERS CoV PLpro, AKP80587.1 for PEDV PLP2, and AHM88399.1 for PDCoV PLpro, and UniProtKB/Swiss-Prot numbers P0C6U8 for SARS CoV PLpro and P0C6V0 for MHV PLP2.", [["MHV", "ORGANISM", 210, 213], ["PLPs", "DNA", 21, 25], ["P0C6V0", "PROTEIN", 199, 205], ["MHV PLP2", "PROTEIN", 210, 218], ["MERS CoV", "SPECIES", 62, 70], ["PDCoV", "SPECIES", 123, 128], ["SARS CoV", "SPECIES", 180, 188], ["MHV", "SPECIES", 210, 213], ["PLPs", "TEST", 21, 25], ["GenBank numbers", "TEST", 31, 46], ["MERS CoV PLpro", "TEST", 62, 76], ["AKP", "TEST", 78, 81], ["PEDV PLP2", "TEST", 93, 102], ["AHM", "TEST", 108, 111], ["PDCoV PLpro", "TREATMENT", 123, 134], ["SARS CoV PLpro", "TREATMENT", 180, 194], ["P0C6V0", "TREATMENT", 199, 205], ["MHV PLP2", "TREATMENT", 210, 218]]]], "PMC7367001": [["Acupuncture ::: Regimen of the combination of acupuncture and medication #!start#[5]#!sep#bib0005#!sep#bibr#!end#Acupoint selection: Z\u00fas\u0101nl\u012d (\u8db3\u4e09\u91ccST36),S\u0101ny\u012bnji\u0101o (\u4e09\u9634\u4ea4SP6), T\u00e0ich\u014dng (\u592a\u51b2LR3), H\u00e9g\u016d (\u5408\u8c37LI4), Li\u00e8qu\u0113 (\u5217\u7f3aLU7), N\u00e8igu\u0101n (\u5185\u5173PC6) and Q\u016bch\u00ed (\u66f2\u6c60LI11).Acupuncture ::: Regimen of the combination of acupuncture and medication #!start#[5]#!sep#bib0005#!sep#bibr#!end#Operation: The patient was in recumbent.", [["patient", "ORGANISM", 383, 390], ["patient", "SPECIES", 383, 390], ["acupuncture", "TREATMENT", 46, 57], ["medication", "TREATMENT", 62, 72], ["Z\u00fas\u0101nl\u012d (\u8db3\u4e09\u91ccST36)", "TREATMENT", 133, 150], ["S\u0101ny\u012bnji\u0101o (\u4e09\u9634\u4ea4SP6)", "TREATMENT", 151, 170], ["T\u00e0ich\u014dng (\u592a\u51b2LR3)", "TREATMENT", 172, 188], ["H\u00e9g\u016d (\u5408\u8c37LI4)", "TREATMENT", 190, 202], ["Li\u00e8qu\u0113 (\u5217\u7f3aLU7)", "TREATMENT", 204, 218], ["N\u00e8igu\u0101n (\u5185\u5173PC6", "TREATMENT", 220, 234], ["acupuncture", "TREATMENT", 301, 312], ["medication", "TREATMENT", 317, 327]]], ["Each acupoint was sterilized strictly according to the requirements of disinfection and protection in the negative pressure ward.", [["Each acupoint", "TREATMENT", 0, 13], ["disinfection", "TREATMENT", 71, 83], ["protection", "TREATMENT", 88, 98]]], ["Hand sanitizer was used for hand hygiene.", [["hand", "ANATOMY", 28, 32], ["hand", "ORGANISM_SUBDIVISION", 28, 32], ["Hand sanitizer", "TREATMENT", 0, 14]]], ["One disinfection cotton ball was applied to each acupoint.", [["cotton", "SPECIES", 17, 23], ["One disinfection cotton ball", "TREATMENT", 0, 28], ["disinfection", "OBSERVATION", 4, 16], ["cotton ball", "OBSERVATION", 17, 28]]], ["After disinfection, the cotton balls were put into the infectious contaminant bucket in the inpatient ward buffer area.", [["cotton", "SPECIES", 24, 30], ["disinfection", "TREATMENT", 6, 18], ["the cotton balls", "TREATMENT", 20, 36], ["infectious", "OBSERVATION_MODIFIER", 55, 65]]], ["The needles were put into the sharp instrument box in the inpatient ward buffer area.", [["The needles", "TREATMENT", 0, 11], ["the sharp instrument box", "TREATMENT", 26, 50], ["sharp", "OBSERVATION_MODIFIER", 30, 35]]], ["Acupuncture manipulation: using disposable tube needles, 0.25 mm \u00d7 40 mm, at ST36, SP6, LR3, LI4, PC6 and LI11, the needles were inserted perpendicularly, 90 degrees, 25 to 35 mm in depth.", [["tube", "TISSUE", 43, 47], ["SP6", "DNA", 83, 86], ["LR3", "DNA", 88, 91], ["LI4", "DNA", 93, 96], ["PC6", "DNA", 98, 101], ["LI11", "DNA", 106, 110], ["Acupuncture manipulation", "TREATMENT", 0, 24], ["disposable tube needles", "TREATMENT", 32, 55], ["SP6", "TEST", 83, 86], ["the needles", "TREATMENT", 112, 123], ["tube needles", "OBSERVATION", 43, 55], ["PC6", "ANATOMY", 98, 101], ["35 mm", "OBSERVATION_MODIFIER", 173, 178]]], ["At LU7, the needle was inserted obliquely, 15 to 30 degrees, with the needle tip toward the elbow, 5 to 10 mm in depth.", [["elbow", "ANATOMY", 92, 97], ["elbow", "ORGANISM_SUBDIVISION", 92, 97], ["LU7", "DNA", 3, 6], ["the needle", "TREATMENT", 8, 18], ["the needle tip toward the elbow", "TREATMENT", 66, 97], ["needle", "ANATOMY", 12, 18], ["elbow", "ANATOMY", 92, 97], ["5 to 10 mm", "OBSERVATION_MODIFIER", 99, 109]]], ["The needles were manipulated with even needling technique.", [["The needles", "TREATMENT", 0, 11], ["needling technique", "TREATMENT", 39, 57]]], ["The depth of insertion at each acupoint was determined by deqi, meaning that the patient felt soreness, numbness and distention.", [["soreness", "DISEASE", 94, 102], ["numbness", "DISEASE", 104, 112], ["patient", "ORGANISM", 81, 88], ["patient", "SPECIES", 81, 88], ["insertion at each acupoint", "TREATMENT", 13, 39], ["soreness", "PROBLEM", 94, 102], ["numbness", "PROBLEM", 104, 112], ["distention", "PROBLEM", 117, 127], ["depth", "OBSERVATION_MODIFIER", 4, 9], ["insertion", "OBSERVATION_MODIFIER", 13, 22], ["numbness", "OBSERVATION", 104, 112], ["distention", "OBSERVATION", 117, 127]]], ["The acupoints on the unilateral side were stimulated and manipulated once every 10 min during the 30-min needle retaining every day.", [["acupoints", "ANATOMY", 4, 13], ["The acupoints on the unilateral side", "TREATMENT", 0, 36]]], ["The acupuncture therapy was given once daily.", [["The acupuncture therapy", "TREATMENT", 0, 23]]], ["The acupoints on the other side were stimulated in treatment on the second day.", [["acupoints", "ANATOMY", 4, 13], ["The acupoints", "TREATMENT", 0, 13], ["treatment", "TREATMENT", 51, 60]]], ["This therapy was given consecutively for 12 days till the patient was discharged.", [["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["This therapy", "TREATMENT", 0, 12]]], ["After every 12 treatments with acupuncture, at the interval of 3 days, the next course of treatment started.", [["acupuncture", "TREATMENT", 31, 42], ["treatment", "TREATMENT", 90, 99]]], ["Such treatment lasted till the patients were getting better and discharged.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["Such treatment", "TREATMENT", 0, 14]]], ["Besides, it was suggested that the patient could take a shower only 2 hours after the needles were removed each day.Chinese herbal decoction ::: Regimen of the combination of acupuncture and medication #!start#[5]#!sep#bib0005#!sep#bibr#!end#The modified Shanghai leishen No.1 formula [Hu\u00e1ngq\u00ed(\u751f\u9ec4\u82aaRadix Astragali) 15g, T\u00e0iz\u012d sh\u0113n (\u592a\u5b50\u53c2Radix Pseudostellariae) 15g, F\u00fal\u00edng (\u832f\u82d3Poria) 15g, Ch\u00e9np\u00ed (\u9648\u76aePericarpium Citri Reticulatae) 9g, P\u00e8il\u00e1n (\u4f69\u5170Herba Eupatorii) 9g, F\u00e1ngf\u0113ng (\u9632\u98ceRadix Saposhnikoviae) 9g, J\u012bny\u00ednhu\u0101 (\u91d1\u94f6\u82b1Flos Lonicerae Japonicae) 9g, Hu\u00e1ngq\u00edn (\u9ec4\u82a9Radix Scutellariae) 9g, fried B\u00e1ish\u00e1o (\u7092\u767d\u828dRadix Paeoniae Alba) 15g, Y\u00f9j\u012bn (\u90c1\u91d1Radix Curcumae) 12g, Ch\u00e1ih\u00fa (\u67f4\u80e1Radix Bupleuri) 9g and D\u0101nggu\u012b (\u5f53\u5f52Radix Angelicae Sinensis) 15g] was adopted, one dose a day.", [["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["the needles", "TREATMENT", 82, 93], ["acupuncture", "TREATMENT", 175, 186], ["medication", "TREATMENT", 191, 201], ["formula [Hu\u00e1ngq\u00ed", "TREATMENT", 277, 293], ["Radix Astragali)", "TREATMENT", 297, 313], ["T\u00e0iz\u012d sh\u0113n", "TREATMENT", 319, 329], ["Radix Pseudostellariae)", "TREATMENT", 334, 357], ["F\u00fal\u00edng (\u832f\u82d3Poria)", "TREATMENT", 363, 379], ["Ch\u00e9np\u00ed (\u9648\u76aePericarpium Citri Reticulatae)", "TREATMENT", 385, 425], ["P\u00e8il\u00e1n (\u4f69\u5170Herba Eupatorii)", "TREATMENT", 430, 456], ["F\u00e1ngf\u0113ng (\u9632\u98ceRadix Saposhnikoviae)", "TREATMENT", 461, 494], ["J\u012bny\u00ednhu\u0101 (\u91d1\u94f6\u82b1Flos Lonicerae Japonicae)", "TREATMENT", 499, 538], ["Hu\u00e1ngq\u00edn (\u9ec4\u82a9Radix Scutellariae)", "TREATMENT", 543, 574], ["Radix Paeoniae Alba)", "TREATMENT", 597, 617], ["Y\u00f9j\u012bn (\u90c1\u91d1Radix Curcumae)", "TREATMENT", 623, 647], ["Ch\u00e1ih\u00fa (\u67f4\u80e1Radix Bupleuri)", "TREATMENT", 653, 678], ["D\u0101nggu\u012b (\u5f53\u5f52Radix Angelicae Sinensis)", "TREATMENT", 686, 722]]], ["According to the concrete condition of illness, the formula was adjusted twice a week.", [["illness", "DISEASE", 39, 46], ["illness", "PROBLEM", 39, 46], ["the formula", "TREATMENT", 48, 59]]], ["For constipation, Ju\u00e9m\u00edngz\u012d (\u51b3\u660e\u5b50Semen Cassiae) 15g and Hu\u014fm\u00e1r\u00e9n (\u706b\u9ebb\u4ec1Fructus Cannabis) 30g were added.", [["constipation", "DISEASE", 4, 16], ["constipation", "PROBLEM", 4, 16], ["Ju\u00e9m\u00edngz\u012d (\u51b3\u660e\u5b50Semen Cassiae)", "TREATMENT", 18, 46], ["Hu\u014fm\u00e1r\u00e9n (\u706b\u9ebb\u4ec1Fructus Cannabis)", "TREATMENT", 55, 85]]], ["For tidal fever and sweating, Hu\u00e1ngb\u0103i (\u9ec4\u67cfCortex Phellodendri Chinensis) 15g and Zh\u012bm\u016d (\u77e5\u6bcdRhizoma Anemarrhenae) 15g were added.", [["tidal fever", "DISEASE", 4, 15], ["Hu\u00e1ngb\u0103i", "CHEMICAL", 30, 38], ["tidal fever", "PROBLEM", 4, 15], ["sweating", "PROBLEM", 20, 28], ["Hu\u00e1ngb\u0103i (\u9ec4\u67cfCortex Phellodendri Chinensis", "TREATMENT", 30, 71], ["Zh\u012bm\u016d (\u77e5\u6bcdRhizoma Anemarrhenae)", "TREATMENT", 81, 111]]], ["For loose stool, Sh\u0101ny\u00e0o (\u5c71\u836fRhizoma Dioscoreae) 30g and Bi\u0103nd\u00f2u (\u6241\u8c46Semen Lablab Album) 30g were added.", [["Sh\u0101ny\u00e0o", "CHEMICAL", 17, 24], ["stool", "ORGANISM_SUBSTANCE", 10, 15], ["loose stool", "PROBLEM", 4, 15], ["Sh\u0101ny\u00e0o (\u5c71\u836fRhizoma Dioscoreae", "TREATMENT", 17, 46], ["Bi\u0103nd\u00f2u (\u6241\u8c46Semen Lablab Album)", "TREATMENT", 56, 86]]], ["For abdominal distention, D\u00e0f\u00f9p\u00ed (\u5927\u8179\u76aePericarpium Arecae) 15g and M\u00f9xi\u0101ng (\u6728\u9999Radix Aucklandiae) 9g were added.", [["abdominal", "ANATOMY", 4, 13], ["abdominal distention", "DISEASE", 4, 24], ["abdominal", "ORGANISM_SUBDIVISION", 4, 13], ["abdominal distention", "PROBLEM", 4, 24], ["D\u00e0f\u00f9p\u00ed (\u5927\u8179\u76aePericarpium Arecae", "TREATMENT", 26, 55], ["M\u00f9xi\u0101ng (\u6728\u9999Radix Aucklandiae)", "TREATMENT", 65, 94], ["abdominal", "ANATOMY", 4, 13], ["distention", "OBSERVATION", 14, 24]]], ["For anorexia, fried G\u016dy\u00e1 (\u7092\u8c37\u82bdFructus Setariae Germinatus) 15g, fried M\u00e0iy\u00e1 (\u7092\u9ea6\u82bdFructus Hordei Germinatus) 15 g and J\u012bn\u00e8ij\u012bn (\u9e21\u5185\u91d1Endothelium Corneum Gigeriae Galli) 15 g were added.", [["anorexia", "DISEASE", 4, 12], ["anorexia", "PROBLEM", 4, 12], ["fried M\u00e0iy\u00e1 (\u7092\u9ea6\u82bdFructus Hordei Germinatus)", "TREATMENT", 63, 105], ["J\u012bn\u00e8ij\u012bn (\u9e21\u5185\u91d1Endothelium Corneum Gigeriae Galli)", "TREATMENT", 115, 163]]], ["For dark or purplish tongue, D\u0101nsh\u0113n (\u4e39\u53c2Radix et Rhizoma Salviae Miltiorrhizae) 15g and T\u00e1or\u00e9n (\u6843\u4ec1Semen Persicae) 9g were added.", [["purplish tongue", "ANATOMY", 12, 27], ["D\u0101nsh\u0113n", "CHEMICAL", 29, 36], ["tongue", "ORGANISM_SUBDIVISION", 21, 27], ["dark or purplish tongue", "PROBLEM", 4, 27], ["D\u0101nsh\u0113n (\u4e39\u53c2Radix et Rhizoma Salviae Miltiorrhizae)", "TREATMENT", 29, 79], ["T\u00e1or\u00e9n (\u6843\u4ec1Semen Persicae)", "TREATMENT", 88, 113], ["purplish", "OBSERVATION_MODIFIER", 12, 20], ["tongue", "ANATOMY", 21, 27]]], ["For red tongue with little coating, Pericarpium Citri Reticulata and Herba Eupatorii were omitted, N\u00e1nsh\u0101sh\u0113n (\u5357\u6c99\u53c2Radix Adenophorae) 30g, B\u0115ish\u0101sh\u0113n (\u5317\u6c99\u53c2Radix Glehniae) 30 g and M\u00e0id\u014dng (\u9ea6\u51acRadix Ophiopogonis) 15 g were added.", [["red tongue", "ANATOMY", 4, 14], ["tongue", "ORGAN", 8, 14], ["red tongue", "PROBLEM", 4, 14], ["little coating", "PROBLEM", 20, 34], ["Pericarpium Citri Reticulata", "TREATMENT", 36, 64], ["Herba Eupatorii", "TREATMENT", 69, 84], ["N\u00e1nsh\u0101sh\u0113n (\u5357\u6c99\u53c2Radix Adenophorae", "TREATMENT", 99, 131], ["B\u0115ish\u0101sh\u0113n (\u5317\u6c99\u53c2Radix Glehniae)", "TREATMENT", 138, 168], ["M\u00e0id\u014dng (\u9ea6\u51acRadix Ophiopogonis)", "TREATMENT", 178, 208], ["tongue", "ANATOMY", 8, 14], ["little", "OBSERVATION_MODIFIER", 20, 26], ["coating", "OBSERVATION_MODIFIER", 27, 34]]], ["For no improvement in lassitude, the dosage of Radix Astragali changed to be 30 g.", [["Radix Astragali", "CHEMICAL", 47, 62], ["lassitude", "TREATMENT", 22, 31], ["the dosage of Radix Astragali", "TREATMENT", 33, 62], ["no", "UNCERTAINTY", 4, 6], ["improvement", "OBSERVATION_MODIFIER", 7, 18]]], ["The herbal medication was taken orally consecutively till the patients were discharged.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["The herbal medication", "TREATMENT", 0, 21]]], ["When discharged, the herbal medication for 2-week dose was prescribed.Typical casesCase 1: Ms. WU, 81 years old, hospitalized on February 8, 2020 in Wuhan No. 672 Integrative Chinese and Western Medicine Orthopedics Hospital due to \u201crepeated fever and cough for several days\u201d.", [["fever", "DISEASE", 242, 247], ["cough", "DISEASE", 252, 257], ["the herbal medication", "TREATMENT", 17, 38], ["repeated fever", "PROBLEM", 233, 247], ["cough", "PROBLEM", 252, 257], ["fever", "OBSERVATION", 242, 247], ["cough", "OBSERVATION", 252, 257]]], ["The chest CT image suggested infectious lesions and the case was confirmed as COVID-19 and treated with the oral administration of arbidol and the injection of ribavirin for antivirus.", [["chest", "ANATOMY", 4, 9], ["lesions", "ANATOMY", 40, 47], ["oral", "ANATOMY", 108, 112], ["arbidol", "CHEMICAL", 131, 138], ["ribavirin", "CHEMICAL", 160, 169], ["arbidol", "CHEMICAL", 131, 138], ["ribavirin", "CHEMICAL", 160, 169], ["infectious lesions", "PATHOLOGICAL_FORMATION", 29, 47], ["oral", "ORGANISM_SUBDIVISION", 108, 112], ["arbidol", "SIMPLE_CHEMICAL", 131, 138], ["ribavirin", "SIMPLE_CHEMICAL", 160, 169], ["The chest CT image", "TEST", 0, 18], ["infectious lesions", "PROBLEM", 29, 47], ["COVID", "TEST", 78, 83], ["arbidol", "TREATMENT", 131, 138], ["ribavirin", "TREATMENT", 160, 169], ["antivirus", "TREATMENT", 174, 183], ["chest", "ANATOMY", 4, 9], ["infectious", "OBSERVATION_MODIFIER", 29, 39], ["lesions", "OBSERVATION", 40, 47]]], ["On February 13, 2020, the chest CT indicated the infectious lesions of the lungs and the lesion consolidation was shown as compared with the image on February 8, 2020.", [["chest", "ANATOMY", 26, 31], ["lesions", "ANATOMY", 60, 67], ["lungs", "ANATOMY", 75, 80], ["lesion", "ANATOMY", 89, 95], ["infectious lesions", "PATHOLOGICAL_FORMATION", 49, 67], ["lungs", "ORGAN", 75, 80], ["the chest CT", "TEST", 22, 34], ["the infectious lesions of the lungs", "PROBLEM", 45, 80], ["the lesion consolidation", "PROBLEM", 85, 109], ["chest", "ANATOMY", 26, 31], ["infectious", "OBSERVATION_MODIFIER", 49, 59], ["lesions", "OBSERVATION", 60, 67], ["lungs", "ANATOMY", 75, 80], ["lesion", "OBSERVATION_MODIFIER", 89, 95], ["consolidation", "OBSERVATION", 96, 109]]], ["The treatment for antivirus with the oral administration of arbidol and the injection of ribavirin was continued, but the therapeutic effect was not satisfactory.", [["oral", "ANATOMY", 37, 41], ["arbidol", "CHEMICAL", 60, 67], ["ribavirin", "CHEMICAL", 89, 98], ["arbidol", "CHEMICAL", 60, 67], ["ribavirin", "CHEMICAL", 89, 98], ["oral", "ORGANISM_SUBDIVISION", 37, 41], ["arbidol", "SIMPLE_CHEMICAL", 60, 67], ["ribavirin", "SIMPLE_CHEMICAL", 89, 98], ["antivirus", "SPECIES", 18, 27], ["The treatment", "TREATMENT", 0, 13], ["antivirus", "TREATMENT", 18, 27], ["arbidol", "TREATMENT", 60, 67], ["ribavirin", "TREATMENT", 89, 98]]], ["On February 19, 2020, because of \u201crepeated fever and cough for 4 weeks\u201d, the patient was shifted by stretcher to the Ward Seven, the Third Department of Infection, Wuhan Leishenshan Hospital.", [["fever", "DISEASE", 43, 48], ["cough", "DISEASE", 53, 58], ["Infection", "DISEASE", 153, 162], ["patient", "ORGANISM", 77, 84], ["patient", "SPECIES", 77, 84], ["\u201crepeated fever", "PROBLEM", 33, 48], ["cough", "PROBLEM", 53, 58], ["fever", "OBSERVATION", 43, 48], ["cough", "OBSERVATION", 53, 58], ["Infection", "OBSERVATION", 153, 162]]], ["On admission, the oxygen saturation of the patient was 69% and the symptoms were low spirits, fever, cough, chest oppression, shortness of breath, palpitation, dull pain in the chest, dull pain and discomforts in the epigastric region, poor appetite, constipation, lassitude, poor sleep (difficulty in falling into sleep, easy waking up), combined with obvious nervous and anxious emotions.", [["chest", "ANATOMY", 108, 113], ["chest", "ANATOMY", 177, 182], ["epigastric region", "ANATOMY", 217, 234], ["nervous", "ANATOMY", 361, 368], ["oxygen", "CHEMICAL", 18, 24], ["low spirits", "DISEASE", 81, 92], ["fever", "DISEASE", 94, 99], ["cough", "DISEASE", 101, 106], ["chest oppression", "DISEASE", 108, 124], ["shortness of breath", "DISEASE", 126, 145], ["palpitation", "DISEASE", 147, 158], ["pain", "DISEASE", 165, 169], ["pain", "DISEASE", 189, 193], ["discomforts", "DISEASE", 198, 209], ["constipation", "DISEASE", 251, 263], ["lassitude", "DISEASE", 265, 274], ["oxygen", "CHEMICAL", 18, 24], ["oxygen", "SIMPLE_CHEMICAL", 18, 24], ["patient", "ORGANISM", 43, 50], ["chest", "ORGANISM_SUBDIVISION", 108, 113], ["chest", "ORGANISM_SUBDIVISION", 177, 182], ["epigastric", "ORGANISM_SUBDIVISION", 217, 227], ["nervous", "ANATOMICAL_SYSTEM", 361, 368], ["patient", "SPECIES", 43, 50], ["the oxygen saturation", "TEST", 14, 35], ["the symptoms", "PROBLEM", 63, 75], ["low spirits", "PROBLEM", 81, 92], ["fever", "PROBLEM", 94, 99], ["cough", "PROBLEM", 101, 106], ["chest oppression", "PROBLEM", 108, 124], ["shortness of breath", "PROBLEM", 126, 145], ["palpitation", "PROBLEM", 147, 158], ["dull pain in the chest", "PROBLEM", 160, 182], ["dull pain", "PROBLEM", 184, 193], ["discomforts in the epigastric region", "PROBLEM", 198, 234], ["poor appetite", "PROBLEM", 236, 249], ["constipation", "PROBLEM", 251, 263], ["lassitude", "PROBLEM", 265, 274], ["poor sleep (difficulty in falling into sleep", "PROBLEM", 276, 320], ["obvious nervous and anxious emotions", "PROBLEM", 353, 389], ["chest", "ANATOMY", 108, 113], ["dull", "OBSERVATION_MODIFIER", 160, 164], ["pain", "OBSERVATION", 165, 169], ["chest", "ANATOMY", 177, 182], ["dull", "OBSERVATION_MODIFIER", 184, 188], ["pain", "OBSERVATION", 189, 193], ["discomforts", "OBSERVATION", 198, 209], ["epigastric", "ANATOMY", 217, 227], ["region", "ANATOMY_MODIFIER", 228, 234], ["poor", "OBSERVATION_MODIFIER", 236, 240], ["appetite", "OBSERVATION", 241, 249], ["constipation", "OBSERVATION", 251, 263], ["poor sleep", "OBSERVATION_MODIFIER", 276, 286]]], ["The tongue was pale and dark with thin, white and slightly sticky coating.", [["tongue", "ANATOMY", 4, 10], ["tongue", "ORGAN", 4, 10], ["thin, white and slightly sticky coating", "PROBLEM", 34, 73], ["tongue", "ANATOMY", 4, 10], ["pale", "OBSERVATION", 15, 19], ["dark", "OBSERVATION_MODIFIER", 24, 28], ["slightly", "OBSERVATION_MODIFIER", 50, 58], ["sticky coating", "OBSERVATION", 59, 73]]], ["The pulse was thready.Typical casesThis case was identified as severe type and differentiated as qi deficiency, liver stagnation and interaction of damp and stasis.", [["liver", "ANATOMY", 112, 117], ["liver stagnation", "DISEASE", 112, 128], ["stasis", "DISEASE", 157, 163], ["liver", "ORGAN", 112, 117], ["The pulse", "TEST", 0, 9], ["severe type and differentiated as qi deficiency", "PROBLEM", 63, 110], ["liver stagnation", "PROBLEM", 112, 128], ["damp", "PROBLEM", 148, 152], ["stasis", "PROBLEM", 157, 163], ["severe", "OBSERVATION_MODIFIER", 63, 69], ["qi deficiency", "OBSERVATION", 97, 110], ["liver", "ANATOMY", 112, 117], ["stagnation", "OBSERVATION", 118, 128], ["damp", "OBSERVATION", 148, 152], ["stasis", "OBSERVATION", 157, 163]]], ["On February 20, 0020, the decoction of the modified Shanghai leishen No.1 formula was taken, in which, the dose of Radix Astragali changed to be 30g, L\u00fag\u0113n (\u82a6\u6839Rhizoma Phragmitis) 30 g, P\u00edp\u00e1y\u00e8 (\u6787\u6777\u53f6Folium Eriobotryae) 12 g, fried Fructus Setariae Germinatus 15 g, fried Fructus Hordei Germinatus 15 g, Endothelium Corneum Gigeriae Galli 15 g, Hu\u014fm\u00e1r\u00e9n (\u706b\u9ebb\u4ec1Fructus Cannabis) 30g, Semen Persicae 9 g and Su\u0101nz\u0103or\u00e9n (\u9178\u67a3\u4ec1Semen Ziziphi Spinosae) 15g were added.", [["Radix Astragali", "CHEMICAL", 115, 130], ["fried", "SPECIES", 222, 227], ["fried", "SPECIES", 262, 267], ["Radix Astragali", "TREATMENT", 115, 130], ["L\u00fag\u0113n (\u82a6\u6839Rhizoma Phragmitis)", "TREATMENT", 150, 178], ["P\u00edp\u00e1y\u00e8 (\u6787\u6777\u53f6Folium Eriobotryae)", "TREATMENT", 185, 215], ["fried Fructus Setariae Germinatus", "TREATMENT", 222, 255], ["Endothelium Corneum Gigeriae Galli", "TREATMENT", 300, 334], ["Hu\u014fm\u00e1r\u00e9n (\u706b\u9ebb\u4ec1Fructus Cannabis)", "TREATMENT", 341, 371], ["Semen Persicae", "TREATMENT", 377, 391], ["Su\u0101nz\u0103or\u00e9n (\u9178\u67a3\u4ec1Semen Ziziphi Spinosae)", "TREATMENT", 400, 438]]], ["Besides, acupuncture was also applied in combination and the regimen was same as the above case.", [["acupuncture", "TREATMENT", 9, 20], ["the regimen", "TREATMENT", 57, 68]]], ["Simultaneously, the treatments such as antivirus, antiinfection, symptomatic treatment and nutritional support were provided.", [["the treatments", "TREATMENT", 16, 30], ["antivirus", "TREATMENT", 39, 48], ["antiinfection", "TREATMENT", 50, 63], ["symptomatic treatment", "TREATMENT", 65, 86], ["nutritional support", "TREATMENT", 91, 110]]], ["After the comprehensive treatment for 1 week, fever, cough and chest pain were relieved, but the patient still had chest oppression, palpitation and epigastric discomfort occasionally.", [["chest", "ANATOMY", 63, 68], ["chest", "ANATOMY", 115, 120], ["epigastric", "ANATOMY", 149, 159], ["fever", "DISEASE", 46, 51], ["cough", "DISEASE", 53, 58], ["chest pain", "DISEASE", 63, 73], ["chest oppression", "DISEASE", 115, 131], ["palpitation", "DISEASE", 133, 144], ["epigastric discomfort", "DISEASE", 149, 170], ["chest", "ORGANISM_SUBDIVISION", 63, 68], ["patient", "ORGANISM", 97, 104], ["chest", "ORGANISM_SUBDIVISION", 115, 120], ["epigastric", "ORGANISM_SUBDIVISION", 149, 159], ["patient", "SPECIES", 97, 104], ["the comprehensive treatment", "TREATMENT", 6, 33], ["fever", "PROBLEM", 46, 51], ["cough", "PROBLEM", 53, 58], ["chest pain", "PROBLEM", 63, 73], ["chest oppression", "PROBLEM", 115, 131], ["palpitation", "PROBLEM", 133, 144], ["epigastric discomfort", "PROBLEM", 149, 170], ["chest", "ANATOMY", 63, 68], ["chest", "ANATOMY", 115, 120], ["oppression", "OBSERVATION", 121, 131], ["epigastric", "ANATOMY", 149, 159], ["discomfort", "OBSERVATION", 160, 170]]], ["Lassitude was alleviated obviously, appetite fair, defecation and urination regular and sleep improved.", [["Lassitude", "TREATMENT", 0, 9], ["defecation", "PROBLEM", 51, 61], ["urination", "PROBLEM", 66, 75]]], ["The oxygen saturation was 99% (the flow of oxygen 5 L/min).Typical casesAfter treatment for 2 weeks, all of the symptoms were relieved, chest oppression was alleviated, palpitation appeared occasionally, shortness of breath and dull pain in epigastric region were presented on exertion, appetite was fair, defecation and urination regular and sleep normal at night.", [["chest", "ANATOMY", 136, 141], ["epigastric region", "ANATOMY", 241, 258], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 43, 49], ["chest oppression", "DISEASE", 136, 152], ["palpitation", "DISEASE", 169, 180], ["shortness of breath", "DISEASE", 204, 223], ["pain", "DISEASE", 233, 237], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["chest", "ORGANISM_SUBDIVISION", 136, 141], ["epigastric", "ORGANISM_SUBDIVISION", 241, 251], ["The oxygen saturation", "TEST", 0, 21], ["the flow of oxygen", "TREATMENT", 31, 49], ["treatment", "TREATMENT", 78, 87], ["the symptoms", "PROBLEM", 108, 120], ["chest oppression", "PROBLEM", 136, 152], ["palpitation", "PROBLEM", 169, 180], ["shortness of breath", "PROBLEM", 204, 223], ["dull pain in epigastric region", "PROBLEM", 228, 258], ["defecation and urination", "PROBLEM", 306, 330], ["oxygen", "OBSERVATION_MODIFIER", 4, 10], ["saturation", "OBSERVATION_MODIFIER", 11, 21], ["chest", "ANATOMY", 136, 141], ["dull", "OBSERVATION_MODIFIER", 228, 232], ["pain", "OBSERVATION", 233, 237], ["epigastric", "ANATOMY", 241, 251]]], ["The oxygen saturation was 99% (the flow of oxygen 3 L/min).", [["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "CHEMICAL", 4, 10], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["The oxygen saturation", "TEST", 0, 21], ["the flow of oxygen", "TREATMENT", 31, 49], ["oxygen", "OBSERVATION_MODIFIER", 4, 10], ["saturation", "OBSERVATION_MODIFIER", 11, 21]]], ["On March 4, 11 and 13, 2020, successively, RNA of COVID-19 was re-detected and the results were all negative.", [["COVID-19", "DNA", 50, 58], ["RNA of COVID", "TEST", 43, 55], ["negative", "OBSERVATION", 100, 108]]], ["The re-examiantion of the chest CT image showed that the multiple patchy ground glass density shadows of the lungs and the bilateral pleural effusion were all significantly absorbed.", [["lungs", "ANATOMY", 109, 114], ["pleural effusion", "ANATOMY", 133, 149], ["pleural effusion", "DISEASE", 133, 149], ["lungs", "ORGAN", 109, 114], ["pleural", "ORGAN", 133, 140], ["the chest CT image", "TEST", 22, 40], ["the multiple patchy ground glass density shadows of the lungs", "PROBLEM", 53, 114], ["the bilateral pleural effusion", "PROBLEM", 119, 149], ["chest", "ANATOMY", 26, 31], ["multiple", "OBSERVATION_MODIFIER", 57, 65], ["patchy", "OBSERVATION_MODIFIER", 66, 72], ["ground glass density", "OBSERVATION", 73, 93], ["shadows", "OBSERVATION", 94, 101], ["lungs", "ANATOMY", 109, 114], ["bilateral", "ANATOMY_MODIFIER", 123, 132], ["pleural", "ANATOMY", 133, 140], ["effusion", "OBSERVATION", 141, 149], ["significantly", "OBSERVATION_MODIFIER", 159, 172], ["absorbed", "OBSERVATION_MODIFIER", 173, 181]]], ["On March 13, the oxygen saturation was 98% in the condition of no oxygen inhalation.", [["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "CHEMICAL", 17, 23], ["oxygen", "CHEMICAL", 66, 72], ["oxygen", "SIMPLE_CHEMICAL", 17, 23], ["oxygen", "SIMPLE_CHEMICAL", 66, 72], ["the oxygen saturation", "TEST", 13, 34], ["oxygen inhalation", "TREATMENT", 66, 83], ["oxygen inhalation", "OBSERVATION", 66, 83]]], ["Hence, the patient was discharged.Typical casesCase 2: Ms. JIANG, 72 years old, considered to be suspected COVID-19 by the chest CT image on January 13, 2020 because of \u201classitude, repeated cough combined with poor appetite for 2 months\u201d.", [["lassitude", "DISEASE", 170, 179], ["cough", "DISEASE", 190, 195], ["patient", "ORGANISM", 11, 18], ["patient", "SPECIES", 11, 18], ["COVID", "TEST", 107, 112], ["the chest CT image", "TEST", 119, 137], ["repeated cough", "PROBLEM", 181, 195], ["poor appetite", "PROBLEM", 210, 223], ["chest", "ANATOMY", 123, 128]]], ["The patient was quarantined at home after the nucleic acid detection was turned to be negative and the body temperature was normal.", [["body", "ANATOMY", 103, 107], ["nucleic acid", "CHEMICAL", 46, 58], ["patient", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["patient", "SPECIES", 4, 11], ["the nucleic acid detection", "TEST", 42, 68], ["the body temperature", "TEST", 99, 119], ["normal", "OBSERVATION", 124, 130]]], ["On February 16, the patient visited the Eighth Hospital of Wuhan City due to diabetic ketoacidosis.", [["diabetic ketoacidosis", "DISEASE", 77, 98], ["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["diabetic ketoacidosis", "PROBLEM", 77, 98], ["diabetic", "OBSERVATION_MODIFIER", 77, 85], ["ketoacidosis", "OBSERVATION", 86, 98]]], ["The chest CT image suggested that COVID-19 was progressed.", [["chest", "ANATOMY", 4, 9], ["COVID-19", "CHEMICAL", 34, 42], ["COVID-19", "DNA", 34, 42], ["The chest CT image", "TEST", 0, 18], ["COVID", "TEST", 34, 39], ["chest", "ANATOMY", 4, 9]]], ["After the treatment with arbidol and chloroquine phosphate and the symptomatic treatment, the nucleic acid detection was negative, but the chest CT image indicated that the patchy shadows of the lungs had not been absorbed yet.", [["lungs", "ANATOMY", 195, 200], ["arbidol", "CHEMICAL", 25, 32], ["chloroquine phosphate", "CHEMICAL", 37, 58], ["nucleic acid", "CHEMICAL", 94, 106], ["arbidol", "CHEMICAL", 25, 32], ["chloroquine phosphate", "CHEMICAL", 37, 58], ["arbidol", "SIMPLE_CHEMICAL", 25, 32], ["chloroquine phosphate", "SIMPLE_CHEMICAL", 37, 58], ["lungs", "ORGAN", 195, 200], ["the treatment", "TREATMENT", 6, 19], ["arbidol", "TREATMENT", 25, 32], ["chloroquine phosphate", "TREATMENT", 37, 58], ["the symptomatic treatment", "TREATMENT", 63, 88], ["the nucleic acid detection", "TEST", 90, 116], ["the chest CT image", "TEST", 135, 153], ["the patchy shadows of the lungs", "PROBLEM", 169, 200], ["chest", "ANATOMY", 139, 144], ["patchy", "OBSERVATION_MODIFIER", 173, 179], ["shadows", "OBSERVATION", 180, 187], ["lungs", "ANATOMY", 195, 200]]], ["Besides, the patient felt weakness of the lower limbs and lost the self-care ability.", [["lower limbs", "ANATOMY", 42, 53], ["patient", "ORGANISM", 13, 20], ["lower limbs", "ORGANISM_SUBDIVISION", 42, 53], ["patient", "SPECIES", 13, 20], ["weakness of the lower limbs", "PROBLEM", 26, 53], ["weakness", "OBSERVATION", 26, 34], ["lower limbs", "ANATOMY", 42, 53]]], ["On March 11, 2020, the patient was shifted to C7 Inpatient Ward of Leishenshan Hospital by wheels for a further treatment with integrative Chinese and Western medicine.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["a further treatment", "TREATMENT", 102, 121], ["integrative Chinese", "TREATMENT", 127, 146], ["Western medicine", "TREATMENT", 151, 167]]], ["On admission, the patient had been lying on the bed for over 1 month and had cough, obvious lassitude, poor appetite, chest pain, mild chest oppression, dry stool and regular urination.Typical casesThis case was identified as ordinary type and differentiated as qi deficiency, liver stagnation and interaction of damp and stasis.", [["chest", "ANATOMY", 118, 123], ["chest", "ANATOMY", 135, 140], ["liver", "ANATOMY", 277, 282], ["cough", "DISEASE", 77, 82], ["lassitude", "DISEASE", 92, 101], ["chest pain", "DISEASE", 118, 128], ["chest oppression", "DISEASE", 135, 151], ["dry stool", "DISEASE", 153, 162], ["liver stagnation", "DISEASE", 277, 293], ["patient", "ORGANISM", 18, 25], ["chest", "ORGANISM_SUBDIVISION", 118, 123], ["chest", "ORGANISM_SUBDIVISION", 135, 140], ["liver", "ORGAN", 277, 282], ["patient", "SPECIES", 18, 25], ["cough", "PROBLEM", 77, 82], ["obvious lassitude", "PROBLEM", 84, 101], ["poor appetite", "PROBLEM", 103, 116], ["chest pain", "PROBLEM", 118, 128], ["mild chest oppression", "PROBLEM", 130, 151], ["dry stool", "PROBLEM", 153, 162], ["regular urination", "PROBLEM", 167, 184], ["qi deficiency", "PROBLEM", 262, 275], ["liver stagnation", "PROBLEM", 277, 293], ["damp", "PROBLEM", 313, 317], ["stasis", "PROBLEM", 322, 328], ["cough", "OBSERVATION", 77, 82], ["chest", "ANATOMY", 118, 123], ["mild", "OBSERVATION_MODIFIER", 130, 134], ["chest", "ANATOMY", 135, 140], ["oppression", "OBSERVATION", 141, 151], ["dry", "OBSERVATION_MODIFIER", 153, 156], ["stool", "OBSERVATION", 157, 162], ["qi deficiency", "OBSERVATION", 262, 275], ["liver", "ANATOMY", 277, 282], ["stagnation", "OBSERVATION", 283, 293], ["damp", "OBSERVATION", 313, 317], ["stasis", "OBSERVATION", 322, 328]]], ["On March 12, 2020, the decoction of the modified Shanghai leishen No.1 formula was taken, in which, the dose of Radix Astragali changed to be 30g, fried Fructus Setariae Germinatus 15g, fried Fructus Hordei Germinatus 15 g, Endothelium Corneum Gigeriae Galli 15 g, Ju\u00e9m\u00edngz\u012d (\u51b3\u660e\u5b50Semen Cassiae) 15 g, Fructus Cannabis 30g and Semen Persicae 9 g were added.", [["Radix Astragali", "CHEMICAL", 112, 127], ["fried Fructus Setariae Germinatus 15g, fried Fructus Hordei Germinatus", "CHEMICAL", 147, 217], ["fried", "SPECIES", 186, 191], ["Hordei Germinatus", "SPECIES", 200, 217], ["Fructus Cannabis 30g", "SPECIES", 300, 320], ["Radix Astragali", "TREATMENT", 112, 127], ["Endothelium Corneum Gigeriae Galli", "TREATMENT", 224, 258], ["Ju\u00e9m\u00edngz\u012d (\u51b3\u660e\u5b50Semen Cassiae)", "TREATMENT", 265, 293], ["Fructus Cannabis", "TREATMENT", 300, 316], ["Semen Persicae", "TREATMENT", 325, 339]]], ["Besides, acupuncture was applied in combination.", [["acupuncture", "TREATMENT", 9, 20]]], ["On the 2nd day of hospitalization, the patient caught a cold and had a fever, 38.4\u00b0c and the routine acupuncture was given at Q\u016bch\u00ed (\u66f2\u6c60 LI11) with strong stimulation.", [["fever", "DISEASE", 71, 76], ["patient", "ORGANISM", 39, 46], ["patient", "SPECIES", 39, 46], ["a cold", "PROBLEM", 54, 60], ["a fever", "PROBLEM", 69, 76], ["the routine acupuncture", "TREATMENT", 89, 112]]], ["With the symptomatic management combined, 3 days later, the body temperature was recovered to be normal and fever was not recurred till discharged.", [["body", "ANATOMY", 60, 64], ["fever", "DISEASE", 108, 113], ["body", "ORGANISM_SUBDIVISION", 60, 64], ["the symptomatic management", "TREATMENT", 5, 31], ["the body temperature", "TEST", 56, 76], ["fever", "PROBLEM", 108, 113], ["symptomatic", "OBSERVATION_MODIFIER", 9, 20], ["normal", "OBSERVATION", 97, 103]]], ["In 7 days of treatment, the patient could stand up and 9 days later, she could walk without help.", [["patient", "ORGANISM", 28, 35], ["patient", "SPECIES", 28, 35], ["treatment", "TREATMENT", 13, 22]]], ["Successively, on March 21, 25 and 27, 2020, the RNA of COVID-19 was re-detected and the results all indicated negative.", [["COVID-19", "DNA", 55, 63], ["the RNA", "TEST", 44, 51], ["COVID", "TEST", 55, 60], ["negative", "OBSERVATION", 110, 118]]], ["On March 26, RNA detection of COVID-19 with sputum was negative and on March 27, the chest CT image suggested that COVID-19 was absorbed as compared with before.", [["sputum", "ANATOMY", 44, 50], ["COVID-19", "CHEMICAL", 115, 123], ["COVID-19", "CHEMICAL", 115, 123], ["COVID-19", "GENE_OR_GENE_PRODUCT", 30, 38], ["sputum", "ORGANISM_SUBSTANCE", 44, 50], ["COVID-19", "DNA", 30, 38], ["COVID-19", "DNA", 115, 123], ["RNA detection", "TEST", 13, 26], ["COVID", "TEST", 30, 35], ["sputum", "TEST", 44, 50], ["the chest CT image", "TEST", 81, 99], ["COVID", "TEST", 115, 120], ["chest", "ANATOMY", 85, 90]]], ["On March 28, 2020, the patient was discharged.NoteAll of the cases were the elderly, of weak constitution and deficient in the antipathogenic qi.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["weak constitution and deficient", "PROBLEM", 88, 119]]], ["Hence, the retention of epidemic toxin resulted in the recurrence of illness.", [["illness", "DISEASE", 69, 76], ["epidemic toxin", "PROBLEM", 24, 38], ["illness", "PROBLEM", 69, 76], ["retention", "OBSERVATION_MODIFIER", 11, 20], ["illness", "OBSERVATION", 69, 76]]], ["On hospitalization, by the analysis of four diagnostic method, the cases were differentiated as qi deficiency, liver stagnation and interaction of damp and stasis and the patients had obvious lassitude and poor appetite.", [["liver", "ANATOMY", 111, 116], ["liver stagnation", "DISEASE", 111, 127], ["liver", "ORGAN", 111, 116], ["patients", "ORGANISM", 171, 179], ["patients", "SPECIES", 171, 179], ["qi deficiency", "PROBLEM", 96, 109], ["liver stagnation", "PROBLEM", 111, 127], ["damp", "PROBLEM", 147, 151], ["stasis", "PROBLEM", 156, 162], ["obvious lassitude", "PROBLEM", 184, 201], ["poor appetite", "PROBLEM", 206, 219], ["qi deficiency", "OBSERVATION", 96, 109], ["liver", "ANATOMY", 111, 116], ["stagnation", "OBSERVATION", 117, 127], ["stasis", "OBSERVATION", 156, 162]]], ["The treatment focused on strengthening the antipathoenic qi and benefiting qi, in which the lung and spleen were mainly considered.", [["lung", "ANATOMY", 92, 96], ["spleen", "ANATOMY", 101, 107], ["lung", "ORGAN", 92, 96], ["spleen", "ORGAN", 101, 107], ["The treatment", "TREATMENT", 0, 13], ["strengthening the antipathoenic qi", "TREATMENT", 25, 59], ["lung", "ANATOMY", 92, 96], ["spleen", "ANATOMY", 101, 107]]], ["In combination, for liver stagnation and damp and stasis, the treatment principle was smoothing liver qi, resolving damp and removing stasis.", [["liver", "ANATOMY", 20, 25], ["liver", "ANATOMY", 96, 101], ["liver stagnation", "DISEASE", 20, 36], ["liver", "ORGAN", 20, 25], ["liver", "ORGAN", 96, 101], ["liver stagnation", "PROBLEM", 20, 36], ["damp", "PROBLEM", 41, 45], ["stasis", "PROBLEM", 50, 56], ["the treatment principle", "TREATMENT", 58, 81], ["damp", "PROBLEM", 116, 120], ["removing stasis", "PROBLEM", 125, 140], ["liver", "ANATOMY", 20, 25], ["stagnation", "OBSERVATION", 26, 36], ["damp", "OBSERVATION", 41, 45], ["stasis", "OBSERVATION", 50, 56], ["liver", "ANATOMY", 96, 101], ["resolving", "OBSERVATION_MODIFIER", 106, 115], ["damp", "OBSERVATION", 116, 120], ["stasis", "OBSERVATION", 134, 140]]], ["Simultaneously, detoxification was given on the base of disease identification.", [["detoxification", "TREATMENT", 16, 30], ["disease identification", "TEST", 56, 78], ["disease", "OBSERVATION", 56, 63]]], ["It is said in the Chapter 72 of S\u00f9w\u00e8n (\u300a\u7d20\u95ee\u300bPlain Questions) that \u201cthe pathogenic factors may have no chance to invade the body if the antipathogenic qi is strong enough inside body\u201d.", [["body", "ANATOMY", 122, 126], ["body", "ANATOMY", 176, 180], ["body", "ORGANISM_SUBDIVISION", 122, 126], ["body", "ORGANISM_SUBDIVISION", 176, 180], ["the pathogenic factors", "PROBLEM", 66, 88]]], ["It indicates that the strength of the antipathogenic qi is the key for the human body consolidation and for the prevention from the invasion of exogenous pathogens.", [["body", "ANATOMY", 81, 85], ["human", "ORGANISM", 75, 80], ["body", "ORGANISM_SUBDIVISION", 81, 85], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["the human body consolidation", "PROBLEM", 71, 99], ["exogenous pathogens", "PROBLEM", 144, 163], ["consolidation", "OBSERVATION", 86, 99], ["exogenous pathogens", "OBSERVATION", 144, 163]]], ["You-ke WU(1582AD-1652AD), the famous epidemiologist of the Ming and Qing dynasties proposed that \u201cif the antipathogenic qi is abundant, the pathogens may not invade the body easily, but whenever it is insufficient, the pathogens may invade at a time of breathing\u201d \u201cwhenever the antipathogenic qi is slightly declined, the contagious disease may easily occur\u201d.", [["body", "ANATOMY", 169, 173], ["1582AD-1652AD", "CHEMICAL", 10, 23], ["body", "ORGANISM_SUBDIVISION", 169, 173], ["You-ke WU(1582AD-1652AD", "SPECIES", 0, 23], ["the pathogens", "PROBLEM", 136, 149], ["the pathogens", "PROBLEM", 215, 228], ["the contagious disease", "PROBLEM", 318, 340]]], ["These statements determine the close relationship between the strength of antipathogenic qi and the occurrence of epidemic disease and also emphasize the importance of treatment for strengthening the anitpathogenic qi and eliminating the pathogens.", [["epidemic disease", "PROBLEM", 114, 130], ["treatment", "TREATMENT", 168, 177], ["strengthening the anitpathogenic qi", "TREATMENT", 182, 217], ["the pathogens", "PROBLEM", 234, 247]]], ["The pathogenesis of COVID-19 is characterized as the mixture with damp.", [["COVID-19", "CHEMICAL", 20, 28], ["COVID-19", "CHEMICAL", 20, 28], ["COVID", "TEST", 20, 25], ["damp", "PROBLEM", 66, 70], ["damp", "OBSERVATION", 66, 70]]], ["Damp is lingering, resulting in the persistent retention of pathogen.", [["the persistent retention of pathogen", "PROBLEM", 32, 68], ["persistent", "OBSERVATION_MODIFIER", 36, 46], ["retention", "OBSERVATION_MODIFIER", 47, 56], ["pathogen", "OBSERVATION", 60, 68]]], ["Long-term illness leads to blood blockage and stasis and the interaction of damp and stasis.", [["blood", "ANATOMY", 27, 32], ["illness", "DISEASE", 10, 17], ["blood", "ORGANISM_SUBSTANCE", 27, 32], ["Long-term illness", "PROBLEM", 0, 17], ["blood blockage", "PROBLEM", 27, 41], ["stasis", "PROBLEM", 46, 52], ["damp and stasis", "PROBLEM", 76, 91], ["-term", "OBSERVATION_MODIFIER", 4, 9], ["illness", "OBSERVATION", 10, 17], ["blockage", "OBSERVATION", 33, 41], ["stasis", "OBSERVATION", 46, 52], ["damp", "OBSERVATION", 76, 80], ["stasis", "OBSERVATION", 85, 91]]], ["Because of long-term quarantine alone, the patient cannot communicate with the family and feel depressed.", [["depressed", "DISEASE", 95, 104], ["patient", "ORGANISM", 43, 50], ["patient", "SPECIES", 43, 50], ["depressed", "PROBLEM", 95, 104]]], ["Consequently, qi deficiency, liver stagnation and interaction of damp and stasis occur.", [["liver", "ANATOMY", 29, 34], ["liver stagnation", "DISEASE", 29, 45], ["stasis", "DISEASE", 74, 80], ["liver", "ORGAN", 29, 34], ["qi deficiency", "PROBLEM", 14, 27], ["liver stagnation", "PROBLEM", 29, 45], ["damp", "PROBLEM", 65, 69], ["stasis occur", "PROBLEM", 74, 86], ["qi deficiency", "OBSERVATION", 14, 27], ["liver", "ANATOMY", 29, 34], ["stagnation", "OBSERVATION", 35, 45], ["damp", "OBSERVATION", 65, 69], ["stasis", "OBSERVATION", 74, 80]]], ["Spleen is the postnatal foundation, dominating transportation and transformation of body fluids in physiology.", [["Spleen", "ANATOMY", 0, 6], ["body fluids", "ANATOMY", 84, 95], ["Spleen", "ORGAN", 0, 6], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["transformation of body fluids", "PROBLEM", 66, 95], ["postnatal", "OBSERVATION_MODIFIER", 14, 23], ["foundation", "OBSERVATION", 24, 34], ["transformation", "OBSERVATION_MODIFIER", 66, 80], ["body", "OBSERVATION_MODIFIER", 84, 88], ["fluids", "OBSERVATION", 89, 95]]], ["In the therapeutic regimens reported in this paper, ST36 is the key tonic points on the stomach meridian of foot-yangming, acting on strengthening the spleen, harmonizing the stomach, resolving phlegm and tranquilization.", [["stomach", "ANATOMY", 88, 95], ["spleen", "ANATOMY", 151, 157], ["stomach", "ANATOMY", 175, 182], ["phlegm", "DISEASE", 194, 200], ["stomach", "ORGAN", 88, 95], ["foot", "ORGANISM_SUBDIVISION", 108, 112], ["spleen", "ORGAN", 151, 157], ["stomach", "ORGAN", 175, 182], ["the therapeutic regimens", "TREATMENT", 3, 27], ["harmonizing the stomach", "PROBLEM", 159, 182], ["phlegm", "PROBLEM", 194, 200], ["stomach", "ANATOMY", 88, 95], ["foot", "ANATOMY", 108, 112], ["spleen", "ANATOMY", 151, 157], ["stomach", "ANATOMY", 175, 182], ["resolving", "OBSERVATION_MODIFIER", 184, 193], ["phlegm", "OBSERVATION", 194, 200]]], ["SP6 is on the spleen meridian of foot-taiyin.", [["spleen", "ANATOMY", 14, 20], ["SP6", "GENE_OR_GENE_PRODUCT", 0, 3], ["spleen", "ORGAN", 14, 20], ["foot", "ORGANISM_SUBDIVISION", 33, 37], ["SP6", "DNA", 0, 3], ["spleen", "ANATOMY", 14, 20], ["meridian", "ANATOMY_MODIFIER", 21, 29], ["foot", "ANATOMY", 33, 37]]], ["These two acupoints co-act on benefiting qi and strengthening the spleen for the transportation and transformation of body fluids.", [["spleen", "ANATOMY", 66, 72], ["body fluids", "ANATOMY", 118, 129], ["spleen", "ORGAN", 66, 72], ["body", "ORGANISM_SUBDIVISION", 118, 122], ["fluids", "ORGANISM_SUBSTANCE", 123, 129], ["benefiting qi", "TREATMENT", 30, 43], ["strengthening the spleen", "TREATMENT", 48, 72], ["transformation of body fluids", "TREATMENT", 100, 129], ["spleen", "ANATOMY", 66, 72]]], ["LI4 is on the large intestine meridian of hand-yangming, acting on dispersing wind, eliminating the exterior, clearing the lung, harmonizing the stomach and stopping pain.", [["intestine", "ANATOMY", 20, 29], ["hand", "ANATOMY", 42, 46], ["lung", "ANATOMY", 123, 127], ["stomach", "ANATOMY", 145, 152], ["pain", "DISEASE", 166, 170], ["intestine", "ORGAN", 20, 29], ["hand", "ORGANISM_SUBDIVISION", 42, 46], ["lung", "ORGAN", 123, 127], ["stomach", "ORGAN", 145, 152], ["stopping pain", "PROBLEM", 157, 170], ["large", "OBSERVATION_MODIFIER", 14, 19], ["intestine", "ANATOMY", 20, 29], ["meridian", "ANATOMY_MODIFIER", 30, 38], ["hand", "ANATOMY", 42, 46], ["clearing", "OBSERVATION", 110, 118], ["lung", "ANATOMY", 123, 127], ["stomach", "ANATOMY", 145, 152]]], ["LR3 is on the liver meridian of foot-jueyin, acting on smoothing liver qi, promoting collateral circulation, stopping pain and detoxification.", [["liver", "ANATOMY", 14, 19], ["liver", "ANATOMY", 65, 70], ["collateral", "ANATOMY", 85, 95], ["pain", "DISEASE", 118, 122], ["LR3", "GENE_OR_GENE_PRODUCT", 0, 3], ["liver", "ORGAN", 14, 19], ["foot", "ORGANISM_SUBDIVISION", 32, 36], ["liver", "ORGAN", 65, 70], ["collateral", "MULTI-TISSUE_STRUCTURE", 85, 95], ["LR3", "PROTEIN", 0, 3], ["stopping pain", "PROBLEM", 109, 122], ["detoxification", "TREATMENT", 127, 141], ["liver", "ANATOMY", 14, 19], ["meridian", "ANATOMY_MODIFIER", 20, 28], ["foot", "ANATOMY", 32, 36], ["liver", "ANATOMY", 65, 70], ["collateral circulation", "OBSERVATION", 85, 107]]], ["The combination of bilateral LI4 and LR3 is taken as four-gate points, acting on smoothing liver qi, activating blood circulation, tranquilizing the mind and stopping pain and it significantly relieves depression [6].", [["liver", "ANATOMY", 91, 96], ["blood", "ANATOMY", 112, 117], ["pain", "DISEASE", 167, 171], ["depression", "DISEASE", 202, 212], ["LI4", "GENE_OR_GENE_PRODUCT", 29, 32], ["LR3", "GENE_OR_GENE_PRODUCT", 37, 40], ["liver", "ORGAN", 91, 96], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["LI4", "PROTEIN", 29, 32], ["LR3", "PROTEIN", 37, 40], ["bilateral LI4 and LR3", "TREATMENT", 19, 40], ["activating blood circulation", "PROBLEM", 101, 129], ["pain", "PROBLEM", 167, 171], ["depression", "PROBLEM", 202, 212], ["bilateral", "ANATOMY_MODIFIER", 19, 28], ["LI4", "ANATOMY", 29, 32], ["liver", "ANATOMY", 91, 96]]], ["Acupuncture at LR3, in combination with LI11 and ST36 is the adjuvant therapy for anti-hypertension [7], [8], [9], [10].", [["LR3", "CHEMICAL", 15, 18], ["LI11", "CHEMICAL", 40, 44], ["LR3", "SIMPLE_CHEMICAL", 15, 18], ["LI11", "SIMPLE_CHEMICAL", 40, 44], ["anti-hypertension [7]", "SIMPLE_CHEMICAL", 82, 103], ["[8], [9]", "SIMPLE_CHEMICAL", 105, 113], ["[10]", "SIMPLE_CHEMICAL", 115, 119], ["Acupuncture at LR3", "TREATMENT", 0, 18], ["LI11", "TREATMENT", 40, 44], ["the adjuvant therapy", "TREATMENT", 57, 77], ["anti-hypertension", "TREATMENT", 82, 99]]], ["LI11 acts on promoting qi and blood circulation and LR3 on smoothing liver qi and regulating blood.", [["blood", "ANATOMY", 30, 35], ["liver", "ANATOMY", 69, 74], ["blood", "ANATOMY", 93, 98], ["LI11", "CHEMICAL", 0, 4], ["LI11", "SIMPLE_CHEMICAL", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["LR3", "SIMPLE_CHEMICAL", 52, 55], ["liver", "ORGAN", 69, 74], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["LI11", "PROTEIN", 0, 4], ["LR3", "PROTEIN", 52, 55], ["blood circulation", "TEST", 30, 47], ["blood", "TEST", 93, 98], ["liver", "ANATOMY", 69, 74], ["blood", "ANATOMY", 93, 98]]], ["These two acupoints represent zang and fu, yin and yang respectively, acting on eliminating the exterior syndrome, stopping pain and relieving depression, as well as controlling blood pressure.", [["blood", "ANATOMY", 178, 183], ["pain", "DISEASE", 124, 128], ["depression", "DISEASE", 143, 153], ["blood", "ORGANISM_SUBSTANCE", 178, 183], ["the exterior syndrome", "PROBLEM", 92, 113], ["stopping pain", "PROBLEM", 115, 128], ["relieving depression", "PROBLEM", 133, 153], ["blood pressure", "TEST", 178, 192], ["zang", "OBSERVATION", 30, 34]]], ["Acupuncture at LR3 and ST36 may bidirectionally regulate meridian system, increase angiotensin converting enzyme (ACE)expression, inhibit renin-angiotension-aldosterone system, up-regulate the expression of angiotension, dilate vessels and reduce peripheral resistance so as to control blood pressure.", [["vessels", "ANATOMY", 228, 235], ["blood", "ANATOMY", 286, 291], ["angiotensin", "CHEMICAL", 83, 94], ["aldosterone", "CHEMICAL", 157, 168], ["aldosterone", "CHEMICAL", 157, 168], ["LR3", "GENE_OR_GENE_PRODUCT", 15, 18], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 83, 112], ["ACE", "GENE_OR_GENE_PRODUCT", 114, 117], ["renin-angiotension-aldosterone", "GENE_OR_GENE_PRODUCT", 138, 168], ["angiotension", "SIMPLE_CHEMICAL", 207, 219], ["dilate vessels", "MULTI-TISSUE_STRUCTURE", 221, 235], ["blood", "ORGANISM_SUBSTANCE", 286, 291], ["angiotensin converting enzyme", "PROTEIN", 83, 112], ["ACE", "PROTEIN", 114, 117], ["renin", "PROTEIN", 138, 143], ["Acupuncture", "TREATMENT", 0, 11], ["angiotensin converting enzyme (ACE)expression", "TREATMENT", 83, 128], ["renin", "TEST", 138, 143], ["aldosterone system", "TREATMENT", 157, 175], ["angiotension", "TREATMENT", 207, 219], ["dilate vessels", "PROBLEM", 221, 235], ["peripheral resistance", "PROBLEM", 247, 268], ["blood pressure", "TEST", 286, 300], ["dilate", "OBSERVATION", 221, 227], ["vessels", "ANATOMY", 228, 235], ["peripheral resistance", "OBSERVATION", 247, 268]]], ["Both of the patients reported in the paper suffered from hypertension and their blood pressure kept stable during treatment.NoteAcupuncture is effective on fever due to exogenous pathogens.", [["blood", "ANATOMY", 80, 85], ["hypertension", "DISEASE", 57, 69], ["NoteAcupuncture", "CHEMICAL", 124, 139], ["fever", "DISEASE", 156, 161], ["patients", "ORGANISM", 12, 20], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["patients", "SPECIES", 12, 20], ["hypertension", "PROBLEM", 57, 69], ["their blood pressure", "TEST", 74, 94], ["treatment", "TREATMENT", 114, 123], ["NoteAcupuncture", "TREATMENT", 124, 139], ["fever", "PROBLEM", 156, 161], ["exogenous pathogens", "PROBLEM", 169, 188], ["hypertension", "OBSERVATION", 57, 69], ["stable", "OBSERVATION_MODIFIER", 100, 106], ["exogenous", "OBSERVATION_MODIFIER", 169, 178], ["pathogens", "OBSERVATION", 179, 188]]], ["In Case 2, for treatment of fever, the strong stimulation with acupuncture was given at LI11 daily.", [["fever", "DISEASE", 28, 33], ["LI11", "SIMPLE_CHEMICAL", 88, 92], ["treatment", "TREATMENT", 15, 24], ["fever", "PROBLEM", 28, 33], ["acupuncture", "TREATMENT", 63, 74]]], ["Acupuncture was applied mainly at LI11 and LI4.", [["Acupuncture", "TREATMENT", 0, 11]]], ["LI11 is the he-sea point of the hand-yangming meridian and is commonly used in clinic in combination with LI4 for reducing excess yang of yangming meridian.", [["hand", "ANATOMY", 32, 36], ["LI4", "CHEMICAL", 106, 109], ["LI11", "GENE_OR_GENE_PRODUCT", 0, 4], ["LI4", "SIMPLE_CHEMICAL", 106, 109], ["LI11", "DNA", 0, 4], ["LI4", "TREATMENT", 106, 109], ["hand", "ANATOMY", 32, 36]]], ["Animal experiment indicates that acupuncture at \u201cLI11\u201d reduces the levels of cyclic adenosine monophosphate (cAMP) and prostaglandin in cerebrospinal fluid and increases arginine vasopression (AVP).", [["cerebrospinal fluid", "ANATOMY", 136, 155], ["cyclic adenosine monophosphate", "CHEMICAL", 77, 107], ["cAMP", "CHEMICAL", 109, 113], ["prostaglandin", "CHEMICAL", 119, 132], ["arginine", "CHEMICAL", 170, 178], ["AVP", "CHEMICAL", 193, 196], ["cyclic adenosine monophosphate", "CHEMICAL", 77, 107], ["cAMP", "CHEMICAL", 109, 113], ["prostaglandin", "CHEMICAL", 119, 132], ["arginine", "CHEMICAL", 170, 178], ["cyclic adenosine monophosphate", "GENE_OR_GENE_PRODUCT", 77, 107], ["cAMP", "SIMPLE_CHEMICAL", 109, 113], ["prostaglandin", "SIMPLE_CHEMICAL", 119, 132], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 136, 155], ["arginine vasopression", "SIMPLE_CHEMICAL", 170, 191], ["AVP", "SIMPLE_CHEMICAL", 193, 196], ["acupuncture", "PROBLEM", 33, 44], ["cyclic adenosine monophosphate (cAMP)", "TREATMENT", 77, 114], ["prostaglandin in cerebrospinal fluid", "TREATMENT", 119, 155], ["increases arginine vasopression", "TREATMENT", 160, 191], ["cerebrospinal fluid", "OBSERVATION", 136, 155]]], ["It is deduced that acupuncture brings its role of defervescence by changing the levels of central febrile mediators [11].", [["febrile", "DISEASE", 98, 105], ["central febrile mediators", "TREATMENT", 90, 115]]], ["Taiyin and yangming are related externally and internally.", [["Taiyin", "CHEMICAL", 0, 6], ["Taiyin", "SIMPLE_CHEMICAL", 0, 6], ["Taiyin", "TREATMENT", 0, 6]]], ["Simultaneously stimulating LU7 and LI4 may eliminate the pathogens and the exterior syndrome.", [["LU7", "GENE_OR_GENE_PRODUCT", 27, 30], ["LI4", "GENE_OR_GENE_PRODUCT", 35, 38], ["LU7", "PROTEIN", 27, 30], ["LI4", "PROTEIN", 35, 38], ["Simultaneously stimulating LU7", "TEST", 0, 30], ["the pathogens", "PROBLEM", 53, 66], ["the exterior syndrome", "PROBLEM", 71, 92], ["pathogens", "OBSERVATION", 57, 66], ["exterior syndrome", "OBSERVATION", 75, 92]]], ["LU7 is the yuan-primary point of lung meridian and also one of the eight confluent points, acting on dispersing lung qi, eliminating pathogens, stopping cough, relieving asthma, benefiting water metabolism and regulating intestinal function.", [["lung", "ANATOMY", 33, 37], ["lung", "ANATOMY", 112, 116], ["intestinal", "ANATOMY", 221, 231], ["cough", "DISEASE", 153, 158], ["asthma", "DISEASE", 170, 176], ["LU7", "GENE_OR_GENE_PRODUCT", 0, 3], ["lung", "ORGAN", 33, 37], ["lung", "ORGAN", 112, 116], ["intestinal", "ORGAN", 221, 231], ["lung meridian", "PROBLEM", 33, 46], ["pathogens", "PROBLEM", 133, 142], ["cough", "PROBLEM", 153, 158], ["relieving asthma", "PROBLEM", 160, 176], ["lung", "ANATOMY", 33, 37], ["meridian", "ANATOMY_MODIFIER", 38, 46], ["confluent", "OBSERVATION_MODIFIER", 73, 82], ["lung", "ANATOMY", 112, 116], ["qi", "OBSERVATION", 117, 119], ["pathogens", "OBSERVATION_MODIFIER", 133, 142], ["relieving", "OBSERVATION_MODIFIER", 160, 169], ["asthma", "OBSERVATION", 170, 176], ["intestinal", "ANATOMY", 221, 231]]], ["In Zh\u0113nji\u016d D\u00e0ch\u00e9ng (\u300a\u9488\u7078\u5927\u6210\u300bThe Great Compendium of Acupuncture and Moxibustion), it is mentioned that LU7 and ST36 are applicable for asthmatic breathing.", [["asthmatic breathing", "DISEASE", 133, 152], ["LU7", "GENE_OR_GENE_PRODUCT", 101, 104], ["Zh\u0113nji\u016d D\u00e0ch\u00e9ng", "TREATMENT", 3, 18], ["Acupuncture", "TREATMENT", 50, 61], ["Moxibustion", "TREATMENT", 66, 77], ["asthmatic breathing", "PROBLEM", 133, 152]]], ["ECMO is prohibited in the patients aged over 70 years.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["ECMO", "TREATMENT", 0, 4]]], ["Pulmonary dysfunction in the elderly with severe case very easily progresses to be heart and lung failure.", [["Pulmonary", "ANATOMY", 0, 9], ["heart", "ANATOMY", 83, 88], ["lung", "ANATOMY", 93, 97], ["Pulmonary dysfunction", "DISEASE", 0, 21], ["heart and lung failure", "DISEASE", 83, 105], ["Pulmonary", "ORGAN", 0, 9], ["heart", "ORGAN", 83, 88], ["lung", "ORGAN", 93, 97], ["Pulmonary dysfunction", "PROBLEM", 0, 21], ["severe case", "PROBLEM", 42, 53], ["heart and lung failure", "PROBLEM", 83, 105], ["dysfunction", "OBSERVATION", 10, 21], ["heart", "ANATOMY", 83, 88], ["lung", "ANATOMY", 93, 97], ["failure", "OBSERVATION", 98, 105]]], ["The combination of acupuncture and medication may prevent from the further deterioration of disease, reduce the fatality rate and improve the curative rate.", [["acupuncture", "TREATMENT", 19, 30], ["medication", "TREATMENT", 35, 45], ["the further deterioration of disease", "PROBLEM", 63, 99], ["the fatality rate", "TEST", 108, 125], ["the curative rate", "TEST", 138, 155]]], ["In Case 1, the patient was aged 81 years old.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["Her digital oxygen saturation was 69% and she had obvious chest oppression and shortness of breath.", [["chest", "ANATOMY", 58, 63], ["oxygen", "CHEMICAL", 12, 18], ["chest oppression", "DISEASE", 58, 74], ["shortness of breath", "DISEASE", 79, 98], ["oxygen", "CHEMICAL", 12, 18], ["oxygen", "SIMPLE_CHEMICAL", 12, 18], ["chest", "ORGANISM_SUBDIVISION", 58, 63], ["Her digital oxygen saturation", "TEST", 0, 29], ["obvious chest oppression", "PROBLEM", 50, 74], ["shortness of breath", "PROBLEM", 79, 98], ["chest", "ANATOMY", 58, 63], ["oppression", "OBSERVATION", 64, 74]]], ["Immediately after the first acupuncture treatment, the patient could breathe smoothly.", [["patient", "ORGANISM", 55, 62], ["patient", "SPECIES", 55, 62], ["the first acupuncture treatment", "TREATMENT", 18, 49]]], ["For the other various symptoms, acupuncture focused on PC6, LI4 and ST36.", [["LI4", "GENE_OR_GENE_PRODUCT", 60, 63], ["the other various symptoms", "PROBLEM", 4, 30], ["acupuncture", "PROBLEM", 32, 43], ["PC6", "TEST", 55, 58], ["LI4", "TEST", 60, 63], ["ST36", "ANATOMY", 68, 72]]], ["After treated for 2 weeks, chest oppression was relieved and the flow of oxygen was reduced to be 3 L/min from 5 L/min.", [["chest", "ANATOMY", 27, 32], ["oxygen", "CHEMICAL", 73, 79], ["oxygen", "CHEMICAL", 73, 79], ["chest", "ORGANISM_SUBDIVISION", 27, 32], ["oxygen", "SIMPLE_CHEMICAL", 73, 79], ["chest oppression", "PROBLEM", 27, 43], ["the flow of oxygen", "TREATMENT", 61, 79], ["chest", "ANATOMY", 27, 32]]], ["After treated for 23 days, the patient could walk without help and discharged.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38]]], ["Besides, the imaging examination showed that the lesion foci were absorbed as compared with before.", [["lesion foci", "ANATOMY", 49, 60], ["the imaging examination", "TEST", 9, 32], ["the lesion foci", "PROBLEM", 45, 60], ["lesion", "OBSERVATION_MODIFIER", 49, 55], ["foci", "OBSERVATION", 56, 60]]], ["This case indicates the recovery of the lung for \u201cdominating qi and respiration\u201d.", [["lung", "ANATOMY", 40, 44], ["lung", "ORGAN", 40, 44], ["lung", "ANATOMY", 40, 44]]], ["On the base of acupuncture, the modified Shanghai leishen No.1 formula was administered orally for benefiting qi, strengthening the spleen and smoothing liver qi, activating blood circulation in collateral, resolving damp and detoxification, and the intravenous nutritional support was provided.", [["spleen", "ANATOMY", 132, 138], ["liver", "ANATOMY", 153, 158], ["blood", "ANATOMY", 174, 179], ["collateral", "ANATOMY", 195, 205], ["intravenous", "ANATOMY", 250, 261], ["spleen", "ORGAN", 132, 138], ["liver", "ORGAN", 153, 158], ["blood", "ORGANISM_SUBSTANCE", 174, 179], ["collateral", "MULTI-TISSUE_STRUCTURE", 195, 205], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 250, 261], ["acupuncture", "TREATMENT", 15, 26], ["the modified Shanghai leishen No.1 formula", "TREATMENT", 28, 70], ["activating blood circulation in collateral", "PROBLEM", 163, 205], ["damp and detoxification", "TREATMENT", 217, 240], ["the intravenous nutritional support", "TREATMENT", 246, 281], ["acupuncture", "OBSERVATION", 15, 26], ["spleen", "ANATOMY", 132, 138], ["liver", "ANATOMY", 153, 158], ["collateral", "OBSERVATION_MODIFIER", 195, 205]]], ["All of these three therapeutic methods co-achieve the quick recovery of the physical strength, the regaining of ant pathogenic qi and the elimination of epidemic toxin in these two patients.NoteTraditional Chinese medicine (TCM) has accumulated a large amount of clinical experiences in prevention and treatment of pestilence since the ancient time and it has played an important role in the battle against COVID-19.", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["ant pathogenic qi", "PROBLEM", 112, 129], ["epidemic toxin", "PROBLEM", 153, 167], ["treatment", "TREATMENT", 302, 311], ["pestilence", "TREATMENT", 315, 325], ["large", "OBSERVATION_MODIFIER", 247, 252], ["amount", "OBSERVATION_MODIFIER", 253, 259]]], ["Acupuncture is the feature of TCM in treatment.", [["Acupuncture", "TREATMENT", 0, 11], ["TCM in treatment", "TREATMENT", 30, 46]]], ["In the two cases reported in the paper, it shows that the combined regimen of acupuncture and medication displays the significant effect on the systematic symptoms in the bedridden patients with COVID-19.", [["bedridden", "DISEASE", 171, 180], ["COVID-19", "CHEMICAL", 195, 203], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["the combined regimen", "TREATMENT", 54, 74], ["acupuncture", "TREATMENT", 78, 89], ["medication", "TREATMENT", 94, 104], ["the systematic symptoms", "PROBLEM", 140, 163], ["COVID", "TEST", 195, 200], ["significant", "OBSERVATION_MODIFIER", 118, 129]]], ["The quicker and better therapeutic effect has been obtained by TCM with the combination of modern medicine.NoteThe combination of acupuncture and medication is feasible and effective in clinical treatment of COVID-19 and this therapy deserves to be promoted, under the premise of self-protection of medical staff, in the countries where COVID-19 outbreak has not been controlled yet.Uncited References:", [["modern medicine", "TREATMENT", 91, 106], ["acupuncture", "TREATMENT", 130, 141], ["medication", "TREATMENT", 146, 156], ["COVID", "TEST", 208, 213], ["this therapy", "TREATMENT", 221, 233], ["COVID", "TEST", 337, 342]]]], "183a9e7de4119399056f765fc55e5244dc17dc59": [["IntroductionThis paper is about the classification of flat connections on principal G-bundles with logarithmic singularities, where G is a connected complex reductive group.", [["flat connections", "PROBLEM", 54, 70], ["logarithmic singularities", "PROBLEM", 99, 124], ["a connected complex reductive group", "PROBLEM", 137, 172], ["logarithmic singularities", "OBSERVATION", 99, 124], ["reductive", "OBSERVATION", 157, 166]]], ["These connections are the differential geometric generalizations of linear ordinary differential equations with Fuchsian singularities.", [["Fuchsian singularities", "PROBLEM", 112, 134], ["linear", "OBSERVATION_MODIFIER", 68, 74], ["Fuchsian singularities", "OBSERVATION", 112, 134]]], ["In their most simple incarnation, these are differential equations of the form z ds dz = A(z)s(z).IntroductionIn this equation, A(z) is a matrix of holomorphic functions on the affine line, or more generally, a family of holomorphically varying elements of a Lie algebra.", [["the affine line", "TREATMENT", 173, 188], ["most simple", "OBSERVATION_MODIFIER", 9, 20]]], ["Two such equations are considered to be equivalent when they are related by a holomorphic gauge transformation.", [["a holomorphic gauge transformation", "TREATMENT", 76, 110]]], ["There has been much work in the past devoted to establishing standard normal forms for these differential equations and in describing their classification under holomorphic gauge transformations [20, 23, 35, 15, 1, 22, 2] .IntroductionIn the setting of complex vector bundles with logarithmic connections, there are classification results due to Deligne [13, Appendix C] and Simpson [33] , as well as Ogus [31] in the context of logarithmic geometry.", [["these differential equations", "PROBLEM", 87, 115], ["complex vector bundles", "PROBLEM", 253, 275], ["Deligne", "TEST", 346, 353], ["Appendix C", "TEST", 359, 369], ["logarithmic connections", "OBSERVATION", 281, 304], ["logarithmic geometry", "OBSERVATION", 429, 449]]], ["If we allow the gauge transformations to be meromorphic at the singularity locus, then we are in the setting of connections with regular singularities, and these have been much studied.", [["the gauge transformations", "TREATMENT", 12, 37]]], ["In this paper, we extend existing results by giving a completely functorial classification of logarithmic connections on principal G-bundles over arbitrary complex manifolds in terms of generalized monodromy data.", [["logarithmic connections", "PROBLEM", 94, 117], ["generalized monodromy data", "PROBLEM", 186, 212], ["logarithmic connections", "OBSERVATION", 94, 117], ["generalized", "OBSERVATION_MODIFIER", 186, 197], ["monodromy", "OBSERVATION", 198, 207]]], ["This allows us to give new proofs of known results which completely circumvent the use of power series, and which do not rely on results in analysis beyond the classic existence and uniqueness theorem for first order ordinary differential equations.", [["power series", "TEST", 90, 102]]], ["The starting point for our approach is the perspective, explained in [17] , that singular flat connections can be fruitfully studied as smooth flat algebroid connections for an appropriately chosen Lie algebroid.", [["singular flat connections", "PROBLEM", 81, 106], ["smooth flat algebroid connections", "PROBLEM", 136, 169]]], ["Such a Lie algebroid may be integrated to a Lie groupoid, which is a space on which the sections of the Lie algebroid are realized as vector fields tangent to a foliation.", [["sections", "ANATOMY", 88, 96], ["a Lie algebroid", "PROBLEM", 5, 20]]], ["If we then pull back a singular connection to the groupoid it becomes a smooth flat connection defined along the foliation.", [["a singular connection", "TREATMENT", 21, 42], ["a smooth flat connection", "PROBLEM", 70, 94], ["smooth", "OBSERVATION_MODIFIER", 72, 78], ["flat", "OBSERVATION", 79, 83]]], ["It may therefore be integrated using the basic existence and uniqueness results for ordinary differential equations.", [["ordinary differential equations", "TEST", 84, 115]]], ["The flat sections thus obtained are smooth and single-valued, and give rise to a representation of the Lie groupoid.", [["sections", "ANATOMY", 9, 17], ["flat sections", "CANCER", 4, 17], ["The flat sections", "TEST", 0, 17], ["smooth", "OBSERVATION_MODIFIER", 36, 42]]], ["This representation may in turn be used to recover the flat sections of the original singular connection, but these sections are typically singular and multivalued.", [["sections", "ANATOMY", 60, 68], ["sections", "ANATOMY", 116, 124], ["these sections", "TEST", 110, 124], ["singular connection", "OBSERVATION", 85, 104]]], ["In this way, the groupoid provides the natural domain of definition for the solutions to singular flat connections.", [["the solutions", "TREATMENT", 72, 85]]], ["From this vantage point, the fact that the solutions to singular differential equations are singular and multivalued is simply an indication that we are working on the wrong space.IntroductionThe passage from flat Lie algebroid connections to Lie groupoid representations, a special case of Lie's second theorem for Lie groupoids [27, 28] , gives an equivalence of categories.", [["The passage from flat Lie algebroid connections", "TREATMENT", 192, 239]]], ["Indeed, in the case of the tangent Lie algebroid to a manifold M , we get the equivalence between smooth flat connections and representations of the fundamental groupoid \u03a0(M ), obtained by taking the parallel transport.", [["tangent Lie algebroid", "CELL_LINE", 27, 48]]], ["The classical Riemann-Hilbert correspondence then follows from the observation that \u03a0(M ) and \u03c0 1 (M, x), the fundamental group based at the point x \u2208 M , are Morita equivalent, and so have equivalent categories of representations.", [["the observation", "TEST", 63, 78]]], ["In this paper, we are interested in flat connections on a complex manifold X with logarithmic singularities along a smooth hypersurface D. The relevant Lie algebroid in this case is the log tangent algebroid T X (\u2212logD), which integrates to the twisted fundamental groupoid \u03a0(X, D).", [["Lie algebroid", "PROTEIN", 152, 165], ["T X", "PROTEIN", 208, 211], ["logarithmic singularities", "PROBLEM", 82, 107]]], ["Our study of logarithmic connections therefore comes down to a study of the representations of this groupoid.IntroductionIn Section 3 of the paper, we study flat connections on the affine line which have a logarithmic singularity at the origin.", [["groupoid", "CANCER", 100, 108], ["Our study", "TEST", 0, 9], ["a study", "TEST", 61, 68], ["the affine line", "TREATMENT", 177, 192], ["a logarithmic singularity", "PROBLEM", 204, 229], ["logarithmic singularity", "OBSERVATION", 206, 229], ["origin", "ANATOMY_MODIFIER", 237, 243]]], ["The twisted fundamental groupoid, in this case, is simply given by an action groupoid C A. In Theorem 3.10, we construct an explicit pair of inverse functors between the category of C A representations and a category of generalized monodromy data F ((C, 0), G), which we describe below.", [["C A", "PROTEIN", 182, 185], ["generalized monodromy data F", "PROBLEM", 220, 248], ["twisted", "OBSERVATION_MODIFIER", 4, 11], ["fundamental", "OBSERVATION_MODIFIER", 12, 23], ["groupoid", "OBSERVATION", 24, 32]]], ["The objects of this category are tuples (M, K 1 , \u03bd 0 , K 0 , A), where K 1 and K 0 are right G-torsors, M \u2208 Aut G (K 1 ) is a monodromy element, A \u2208 aut G (K 0 ) is a residue element, and \u03bd 0 \u2282 Hom G (K 0 , K 1 ) is a torsor for a unipotent group which is determined by A and which is interpreted as a space of regularized parallel transport maps.", [["K", "CHEMICAL", 72, 73], ["K", "CHEMICAL", 116, 117], ["K", "CHEMICAL", 157, 158], ["tuples", "TEST", 33, 39], ["K", "TEST", 44, 45], ["K", "TEST", 56, 57], ["K", "TEST", 72, 73], ["K", "TEST", 80, 81], ["right G", "TEST", 88, 95], ["torsors", "TEST", 96, 103], ["K", "TEST", 116, 117], ["a monodromy element", "PROBLEM", 125, 144], ["A \u2208 aut G", "TEST", 146, 155], ["a residue element", "PROBLEM", 166, 183], ["K", "TEST", 202, 203], ["right", "ANATOMY_MODIFIER", 88, 93]]], ["Furthermore, we can substitute F ((C, 0), G) with an equivalent category E((C, 0), G), where \u03bd 0 is replaced by a torsor for the unipotent radical of a parabolic subgroup of Aut G (K 0 ).", [["Aut G", "CHEMICAL", 174, 179], ["(C, 0), G)", "SIMPLE_CHEMICAL", 75, 85], ["Aut G", "SIMPLE_CHEMICAL", 174, 179], ["an equivalent category E((C, 0)", "TREATMENT", 50, 81]]], ["A representation \u03a6 of C A has a canonical linear approximation L(\u03a6), which corresponds to a trivial connection of the formIntroductionfor constant R. Since such trivial connections are fully characterized by their residues, it is tempting to approach the classification problem by searching for a linearization isomorphism between \u03a6 and L(\u03a6).", [["C A", "PROTEIN", 22, 25], ["a trivial connection of the formIntroductionfor constant R.", "PROBLEM", 90, 149], ["a linearization isomorphism", "TEST", 295, 322], ["linear", "OBSERVATION_MODIFIER", 42, 48], ["trivial", "OBSERVATION_MODIFIER", 92, 99], ["connection", "OBSERVATION", 100, 110], ["trivial", "OBSERVATION", 161, 168]]], ["However, the phenomenon of resonance obstructs certain representations from admitting linearizations.", [["the phenomenon of resonance obstructs", "PROBLEM", 9, 46], ["admitting linearizations", "PROBLEM", 76, 100]]], ["There are several existing methods for getting around this problem, which involve abandoning linearizations in favor of less canonical normal forms.", [["abandoning linearizations", "PROBLEM", 82, 107], ["normal", "OBSERVATION", 135, 141]]], ["When the structure group is GL(n, C), it is possible to use a meromorphic gauge transformation to trivialize the connection so that the connection 1-form is constant and satisfies a normalization condition on its eigenvalues.", [["a meromorphic gauge transformation", "TREATMENT", 60, 94], ["a normalization condition", "PROBLEM", 180, 205]]], ["This leads to a classification of logarithmic connections given in terms of the data of a vector space V equipped with a filtration F and a compatible monodromy matrix M .", [["logarithmic connections", "TREATMENT", 34, 57], ["a filtration F", "TREATMENT", 119, 133], ["a compatible monodromy matrix M", "TREATMENT", 138, 169]]], ["The filtration F was first described by Levelt [24] and it encodes the asymptotic behavior of the meromorphic gauge transformation.", [["the meromorphic gauge transformation", "TREATMENT", 94, 130], ["meromorphic gauge transformation", "OBSERVATION", 98, 130]]], ["This approach to classification fails to generalize to the case of an arbitrary reductive structure group.", [["an arbitrary reductive structure group", "PROBLEM", 67, 105], ["reductive structure", "OBSERVATION", 80, 99]]], ["Note also that the trivial connection arising in this approach is in general not isomorphic to the linear approximation of the original connection.", [["the trivial connection", "PROBLEM", 15, 37], ["trivial", "OBSERVATION_MODIFIER", 19, 26], ["connection", "OBSERVATION", 27, 37], ["linear", "OBSERVATION_MODIFIER", 99, 105]]], ["Using a holomorphic gauge transformation, it is possible to trivialize a logarithmic connection so that it is in the Levelt normal formIntroductionwhere S is semisimple, and N i are nilpotent and satisfy [S, N i ] = iN i .", [["[S, N i ] = iN i", "SIMPLE_CHEMICAL", 204, 220], ["a holomorphic gauge transformation", "TREATMENT", 6, 40], ["a logarithmic connection", "PROBLEM", 71, 95]]], ["The Levelt normal form of a given connection is not unique, and the classification results of [1, 22] are obtained by analyzing the holomorphic equivalence of different Levelt normal forms.", [["normal", "OBSERVATION", 11, 17]]], ["The approach of [2] also works with the Levelt normal form, but gives a classification in terms of a monodromy element M contained in a parabolic subgroup P , generalizing the classification using the Levelt filtration.IntroductionIn this paper, we do not abandon linearizations, but rather circumvent the problem posed by resonance by using a functorial Jordan-Chevalley decomposition for representations.", [["monodromy element M", "DNA", 101, 120], ["a monodromy element M", "TREATMENT", 99, 120], ["the Levelt filtration", "TREATMENT", 197, 218], ["a functorial Jordan-Chevalley decomposition", "TREATMENT", 342, 385]]], ["Namely, in Theorem 3.9 we show that a given representation \u03a6 factors into a representation with semisimple monodromy \u03a6 s and a unipotent automorphism U .", [["\u03a6 factors", "PROTEIN", 59, 68], ["unipotent automorphism U", "CELL_LINE", 127, 151], ["semisimple monodromy", "TREATMENT", 96, 116]]], ["As a result, we obtain Theorem 3.10, in which a representation \u03a6 is classified by the data of its monodromy M , its residue A, and the space \u03bd 0 of strict linearizations of its semisimple component \u03a6 s .", [["semisimple", "OBSERVATION_MODIFIER", 177, 187], ["component", "OBSERVATION_MODIFIER", 188, 197]]], ["This provides a much cleaner approach to classification, and because it does not rely on arbitrary choices, it is completely functorial.", [["a much cleaner approach", "TREATMENT", 14, 37], ["functorial", "OBSERVATION", 125, 135]]], ["As a corollary, we also obtain a novel proof of the Levelt normal form, and consequently of the fact that logarithmic singularities are regular.IntroductionIn Section 5 of the paper, we turn to the general case of flat connections on a complex manifold X with logarithmic singularities along a smooth hypersurface D. The main tool here is Morita equivalence, which allows us to decompose the twisted fundamental groupoid \u03a0(X, D) into simple building blocks.", [["complex manifold X", "PROTEIN", 236, 254], ["logarithmic singularities", "PROBLEM", 106, 131], ["flat connections", "PROBLEM", 214, 230], ["logarithmic singularities", "PROBLEM", 260, 285], ["logarithmic singularities", "OBSERVATION", 106, 131], ["main", "OBSERVATION_MODIFIER", 321, 325]]], ["These building blocks consist of the fundamental group of the complement X \u00a0D, and certain action groupoids defined on the fibers of the normal bundle to D. In this way, the problem of classifying logarithmic connections is largely reduced to the 1-dimensional case, and hence we can readily apply the results from Section 3.IntroductionIn Theorem 5.7, we prove an equivalence between the category of flat connections on X with logarithmic singularities along D, and a category F ((X, D), G) of generalized monodromy data.", [["fibers", "ANATOMY", 123, 129], ["complement X \u00a0D", "GENE_OR_GENE_PRODUCT", 62, 77], ["fibers", "CELLULAR_COMPONENT", 123, 129], ["complement X \u00a0D", "PROTEIN", 62, 77], ["logarithmic singularities", "PROBLEM", 428, 453], ["generalized monodromy data", "PROBLEM", 495, 521], ["reduced", "OBSERVATION_MODIFIER", 232, 239]]], ["Very roughly, an object in this category consists of the data of a residue element for each component of D, a space of regularized parallel transport maps for each path p i , and a representation of \u03c0 1 (X \u00a0D, x 0 ).", [["\u03c0 1", "PROTEIN", 199, 202], ["a residue element", "PROBLEM", 65, 82], ["regularized parallel transport maps", "TREATMENT", 119, 154]]], ["Furthermore, the results on Morita equivalence may be understood both as an instance of Zung's linearization theorem [37, 36, 8] appropriately generalized to Lie groupoids in the holomorphic category, and as a generalization of the van Kampen theorem with several basepoints [4, 5] .IntroductionAcknowledgements.", [["the van Kampen theorem", "TREATMENT", 228, 250]]], ["In the end, it took the confinement imposed by the coronavirus pandemic to force me to finalize the details.", [["coronavirus", "ORGANISM", 51, 62]]], ["I would like to thank M. Gualtieri, P. Boalch, and B. Pym for many useful discussions.", [["B. Pym", "ORGANISM", 51, 57]]], ["I am supported by an NSERC postdoctoral fellowship.Lie groupoids and differential equationsIn this section, we explain how to recast the notion of flat logarithmic connections into the language of Lie groupoids.", [["Lie groupoids", "PROBLEM", 51, 64], ["differential equations", "TEST", 69, 91], ["differential equations", "OBSERVATION", 69, 91]]], ["For an introduction to Lie groupoids and Lie algebroids, we recommend [26, 7, 29] .Lie groupoids and differential equationsLet G be a complex Lie group, with Lie algebra g.", [["Let G", "GENE_OR_GENE_PRODUCT", 123, 128], ["Lie groupoids", "PROBLEM", 83, 96], ["differential equations", "TEST", 101, 123], ["differential equations", "OBSERVATION", 101, 123]]], ["The Atiyah algebroid of a principal Gbundle p : P \u2192 M is the Lie algebroid At(P ) = T P/G of G-invariant vector fields on P .", [["P", "DNA", 122, 123], ["G-invariant vector fields", "PROBLEM", 93, 118]]], ["It is a Lie algebroid over M and it sits in the following short exact sequenceLie groupoids and differential equationswhere Ad(P ) = P \u00d7 G g is the adjoint bundle, and the projection dp : At(P ) \u2192 T M is the anchor map.", [["adjoint bundle", "ANATOMY", 148, 162]]], ["Trivialising the bundle P \u223c = M \u00d7 G gives rise to a splitting of sequence 1.1.", [["P", "DNA", 24, 25], ["the bundle P \u223c", "TEST", 13, 27], ["a splitting of sequence", "PROBLEM", 50, 73], ["bundle", "ANATOMY_MODIFIER", 17, 23]]], ["This gives a concrete description of the Atiyah algebroid as At(P ) \u223c = T M \u2295 g, with bracketLie groupoids and differential equationswhere V, U are vector fields, and a, b are sections of g \u00d7 M .Lie groupoids and differential equationsOne of the Lie groupoids integrating the Atiyah algebroid is the gauge groupoid G(P ).", [["Atiyah algebroid", "DNA", 276, 292], ["gauge groupoid G(P )", "DNA", 300, 320], ["Lie groupoids", "PROBLEM", 195, 208], ["differential equations", "TEST", 213, 235]]], ["This is the groupoid over M whose space of arrows is given by (P \u00d7 P )/G, interpreted as the space of G-equivariant maps between the fibers of P .", [["fibers", "ANATOMY", 133, 139], ["fibers", "CELLULAR_COMPONENT", 133, 139], ["P", "DNA", 143, 144]]], ["A trivialization of P induces an isomorphism G(P ) \u223c = M \u00d7 G \u00d7 M , for which the target and source maps are given, respectively, by t(x, g, y) = x, s(x, g, y) = y, and the groupoid multiplication is given by (x, g, y) * (y, h, z) = (x, gh, z).Lie groupoids and differential equationsA G-representation of a Lie algebroid A \u2192 M is a Lie algebroid homomorphism \u2207 : A \u2192 At(P ) into the Atiyah algebroid of a principal G-bundle P .", [["P", "DNA", 20, 21], ["principal G-bundle P", "PROTEIN", 405, 425], ["source maps", "TEST", 92, 103], ["g", "TEST", 153, 154], ["y", "TEST", 161, 162], ["the groupoid multiplication", "TEST", 168, 195], ["z", "TEST", 227, 228], ["gh", "TEST", 236, 238], ["Lie groupoids", "PROBLEM", 243, 256]]], ["These form a category, which we denote Rep(A, G).", [["Rep", "GENE_OR_GENE_PRODUCT", 39, 42], ["Rep", "PROTEIN", 39, 42]]], ["For example, when the Lie algebroid is the tangent bundle T M , representations coincide with smooth flat connections over M .Lie groupoids and differential equationsLet X be a complex manifold with a smooth hypersurface D. The logarithmic tangent bundle T X (\u2212logD) is the Lie algebroid whose local sections are vector fields on X which are tangent to D. In the case of the affine line A with D given by the origin, the logarithmic tangent bundle T A (\u2212log 0) has a global non-vanishing section, whose image under the anchor map is the Euler vector field z\u2202 z .Lie groupoids and differential equationsA flat connection on X with logarithmic singularities along D is defined to be a representation of T X (\u2212logD).", [["sections", "ANATOMY", 300, 308], ["Let X", "GENE_OR_GENE_PRODUCT", 166, 171], ["T X", "GENE_OR_GENE_PRODUCT", 255, 258], ["T X", "GENE_OR_GENE_PRODUCT", 701, 704], ["Let X", "DNA", 166, 171], ["X", "DNA", 623, 624], ["T X", "PROTEIN", 701, 704], ["differential equations", "TEST", 144, 166], ["a complex manifold", "PROBLEM", 175, 193], ["a smooth hypersurface D.", "PROBLEM", 199, 223], ["a global non-vanishing section", "TREATMENT", 465, 495], ["differential equations", "TEST", 580, 602], ["A flat connection", "PROBLEM", 602, 619], ["logarithmic singularities", "PROBLEM", 630, 655], ["smooth", "OBSERVATION_MODIFIER", 94, 100], ["flat", "OBSERVATION_MODIFIER", 604, 608], ["connection", "OBSERVATION", 609, 619]]], ["More precisely, this is a principal bundle P and a homomorphism of Lie algebroidsLie groupoids and differential equationsThis agrees with the standard definition, as given in [12, Chapter 2] .", [["P", "DNA", 43, 44], ["a homomorphism of Lie algebroids", "PROBLEM", 49, 81], ["Lie groupoids", "PROBLEM", 81, 94], ["differential equations", "TEST", 99, 121], ["differential equations", "OBSERVATION", 99, 121]]], ["Logarithmic flat connections are a generalization of linear ordinary differential equations with Fuchsian singularities.", [["Fuchsian singularities", "PROBLEM", 97, 119], ["linear", "OBSERVATION_MODIFIER", 53, 59], ["Fuchsian singularities", "OBSERVATION", 97, 119]]], ["Indeed, a logarithmic connection on the trivial bundle over the affine line is given by a morphism \u2207 : T A (\u2212log 0) \u2192 T A \u2295 g, which is specified by its value on a global section as follows \u2207(z\u2202 z ) = (z\u2202 z , \u2212A(z)).Lie groupoids and differential equationsThis corresponds to the following ordinary differential equationLie groupoids and differential equationswhich has a Fuchsian singularity at the origin.", [["the trivial bundle over the affine line", "TREATMENT", 36, 75], ["a global section", "TEST", 162, 178], ["z", "TEST", 205, 206], ["Lie groupoids", "PROBLEM", 216, 229], ["differential equations", "TEST", 234, 256], ["a Fuchsian singularity", "PROBLEM", 370, 392], ["trivial", "OBSERVATION_MODIFIER", 40, 47], ["bundle", "OBSERVATION_MODIFIER", 48, 54], ["differential equations", "OBSERVATION", 234, 256], ["Fuchsian singularity", "OBSERVATION", 372, 392], ["origin", "ANATOMY_MODIFIER", 400, 406]]], ["In this equation, s is a G-valued function, which is a solution to the differential equation and a flat section of the logarithmic connection.", [["logarithmic connection", "OBSERVATION", 119, 141]]], ["Changing this equation using a gauge transformation is equivalent to changing the trivialization of the principal bundle.Lie groupoids and differential equationsA G-representation of a Lie groupoid G \u21d2 M is a homomorphism \u03a6 : G \u2192 G(P ) into the gauge groupoid of a principal G-bundle P .", [["principal G-bundle P", "PROTEIN", 265, 285], ["a gauge transformation", "TREATMENT", 29, 51], ["Lie groupoids", "PROBLEM", 121, 134], ["principal", "OBSERVATION_MODIFIER", 104, 113], ["bundle", "OBSERVATION_MODIFIER", 114, 120]]], ["These form a category, which we denote Rep(G, G).", [["Rep", "GENE_OR_GENE_PRODUCT", 39, 42], ["G, G", "GENE_OR_GENE_PRODUCT", 43, 47], ["Rep", "PROTEIN", 39, 42]]], ["Since the gauge groupoid of the trivial bundle is isomorphic to M \u00d7 G \u00d7 M , a representation of G on the trivial bundle is determined by a homomorphism \u03c6 : G \u2192 G.Lie groupoids and differential equationsLet A be the Lie algebroid of G. By differentiating a representation \u03a6 of G, we obtain a representation of A d\u03a6 : A \u2192 At(P ).Lie groupoids and differential equationsConversely, if G has connected and simply connected source fibers, then Lie's second theorem [27, 28] implies that a representation of A integrates in a unique way to a representation of G. It is worth noting that the analysis required for constructing this integration is limited to the classical existence and uniqueness result for first order ordinary differential equations (see [17, Theorem 3.8] ).", [["fibers", "CELLULAR_COMPONENT", 426, 432], ["Lie groupoids", "PROBLEM", 327, 340], ["the analysis", "TEST", 581, 593], ["trivial", "OBSERVATION", 32, 39], ["bundle", "OBSERVATION_MODIFIER", 40, 46], ["trivial", "OBSERVATION", 105, 112]]], ["This defines an equivalence between the categories of representationsLie groupoids and differential equationsFor example, the source simply connected Lie groupoid that integrates the tangent bundle T M of a manifold is the fundamental groupoid \u03a0(M ), consisting of homotopy classes of paths in M .", [["Lie groupoid", "PROTEIN", 150, 162], ["Lie groupoids", "PROBLEM", 69, 82], ["differential equations", "TEST", 87, 109], ["equivalence", "OBSERVATION_MODIFIER", 16, 27], ["differential equations", "OBSERVATION", 87, 109], ["paths", "OBSERVATION_MODIFIER", 285, 290]]], ["Hence, in this case, we recover the well-known fact that a flat connection on a principal bundle P is equivalent to a representation of the fundamental groupoid \u03a6 : \u03a0(M ) \u2192 G(P ).Lie groupoids and differential equationsIndeed, the G-equivariant map \u03a6(\u03b3) : P \u03b3(0) \u2192 P \u03b3(1) associated to a path \u03b3 in M is given by the parallel transport of the connection along this path.Lie groupoids and differential equationsThe logarithmic tangent bundle T X (\u2212logD) of a pair (X, D) admits an integrating Lie groupoid by results of [6, 9] .", [["principal bundle P", "PROTEIN", 80, 98], ["G(P )", "PROTEIN", 173, 178], ["T X", "PROTEIN", 440, 443], ["a flat connection", "PROBLEM", 57, 74], ["Lie groupoids", "PROBLEM", 179, 192], ["differential equations", "TEST", 197, 219], ["the G", "TEST", 227, 232], ["Lie groupoids", "PROBLEM", 369, 382], ["differential equations", "TEST", 387, 409], ["a pair (X, D)", "PROBLEM", 455, 468], ["differential equations", "OBSERVATION", 387, 409]]], ["The unique integration with connected and simply connected source fibers is the twisted fundamental groupoid and is denoted \u03a0(X, D).", [["fibers", "CELLULAR_COMPONENT", 66, 72]]], ["In this case, Lie's second theorem gives an equivalence between the category of flat connections on X with logarithmic singularities along D, and the category of representations of \u03a0(X, D)Lie groupoids and differential equationsThe upshot of this result is that the study of logarithmic connections is reduced to the representation theory of the twisted fundamental groupoid.Lie groupoids and differential equationsThe twisted fundamental groupoid \u03a0(A, 0) for the pair consisting of the affine line and the origin is given by the action groupoid C A, associated to the multiplicative action of C on A. The space of arrows is the product C \u00d7 A, the target and source maps are defined, respectively, to be t(\u03bb, z) = e \u03bb z, s(\u03bb, z) = z, and the multiplication is given by (\u03bb 1 , e \u03bb2 z) * (\u03bb 2 , z) = (\u03bb 1 + \u03bb 2 , z).Lie groupoids and differential equationsFor a general pair (X, D), the space of arrows of the twisted fundamental groupoid may fail to be Hausdorff.", [["groupoid", "CANCER", 366, 374], ["\u03a0(X, D)Lie groupoids", "PROBLEM", 181, 201], ["differential equations", "TEST", 206, 228], ["the study", "TEST", 262, 271], ["Lie groupoids", "PROBLEM", 375, 388], ["differential equations", "TEST", 393, 415], ["the affine line", "TREATMENT", 483, 498], ["z", "TEST", 709, 710], ["z", "TEST", 718, 719], ["z", "TEST", 726, 727], ["z", "TEST", 731, 732], ["the multiplication", "TEST", 738, 756], ["\u03bb", "TEST", 787, 788], ["z", "TEST", 793, 794], ["\u03bb", "TEST", 799, 800], ["\u03bb", "TEST", 805, 806], ["z", "TEST", 811, 812], ["Lie groupoids", "PROBLEM", 814, 827], ["differential equations", "PROBLEM", 832, 854], ["a general pair", "PROBLEM", 858, 872], ["differential equations", "OBSERVATION", 393, 415]]], ["This happens when the fundamental group of a tubular neighborhood of D in X \u00a0D does not embed into the fundamental group of X \u00a0D. By the results of [10] , there is a maximal Hausdorff Lie groupoid integrating T X (\u2212logD), and any representation factors through this groupoid.", [["tubular", "ANATOMY", 45, 52], ["tubular", "MULTI-TISSUE_STRUCTURE", 45, 52], ["X \u00a0D", "GENE_OR_GENE_PRODUCT", 74, 78], ["T X", "GENE_OR_GENE_PRODUCT", 209, 212], ["T X", "PROTEIN", 209, 212], ["\u2212logD", "PROTEIN", 214, 219]]], ["However, since this does not lead to any simplifications, in this paper we focus solely on representations of \u03a0(X, D).Refresher on reductive groupsIn this section, we review a portion of the theory of connected complex reductive groups, mainly following the reference [21] (see also [3] ).Refresher on reductive groupsAn endomorphism M of a vector space V is semisimple if it can be diagonalized, nilpotent if M k = 0 for some positive integer k, and unipotent if M \u2212 1 is nilpotent.", [["M \u2212 1", "GENE_OR_GENE_PRODUCT", 464, 469], ["reductive groups", "TREATMENT", 131, 147], ["reductive groups", "TREATMENT", 302, 318], ["nilpotent", "PROBLEM", 473, 482]]], ["These concepts carry over to the elements of a connected complex reductive group G and its Lie algebra g, and can be defined via faithful representations of G. An element g \u2208 G admits a unique multiplicative Jordan-Chevalley (JC) decomposition g = su, where s is semisimple, u is unipotent and su = us.Refresher on reductive groupsAn element x \u2208 g admits a unique additive JC decomposition x = s + n, where s is semisimple, n is nilpotent and [s, n] = 0.", [["a connected complex reductive group G", "TREATMENT", 45, 82], ["reductive groups", "TREATMENT", 315, 331], ["a unique additive JC decomposition", "TREATMENT", 355, 389]]], ["The JC decomposition is preserved by morphisms of reductive groups, the exponential map exp : g \u2192 G sends the additive JC decomposition to the multiplicative JC decomposition, and the exponential map defines a bijection between the set of nilpotent elements of g and the set of unipotent elements of G.Refresher on reductive groupsThere is a decomposition of semisimple elements of g into real and imaginary parts, corresponding to the decomposition of their eigenvalues in representations that are induced by representations of G. Combining this with the additive JC decomposition, an arbitrary element x \u2208 g admits a unique decomposition x = a + ib + n, where a and b are real semisimple, n is nilpotent, and all mutually commute.Refresher on reductive groupsLet T \u2282 G be a maximal torus, with Lie algebra t.", [["G.Refresher", "CHEMICAL", 300, 311], ["G.Refresher", "SIMPLE_CHEMICAL", 300, 311], ["Let T \u2282 G", "GENE_OR_GENE_PRODUCT", 761, 770], ["nilpotent elements", "DNA", 239, 257], ["unipotent elements", "DNA", 278, 296], ["semisimple elements", "DNA", 359, 378], ["Lie algebra t.", "SPECIES", 796, 810], ["The JC decomposition", "TREATMENT", 0, 20], ["the exponential map exp", "TEST", 68, 91], ["g \u2192 G", "TREATMENT", 94, 99], ["the additive JC decomposition", "TREATMENT", 106, 135], ["the multiplicative JC decomposition", "TREATMENT", 139, 174], ["the exponential map", "TEST", 180, 199], ["reductive groups", "TREATMENT", 315, 331], ["the additive JC decomposition", "TREATMENT", 552, 581], ["reductive groups", "TREATMENT", 745, 761], ["JC decomposition", "OBSERVATION", 4, 20], ["reductive groups", "OBSERVATION", 50, 66], ["JC decomposition", "OBSERVATION", 158, 174], ["semisimple elements", "OBSERVATION", 359, 378], ["JC decomposition", "OBSERVATION", 565, 581]]], ["Its adjoint action on g induces the root space decompositionRefresher on reductive groupswhere \u03a6 \u2282 t * is the set of roots, andRefresher on reductive groupsA parabolic subgroup of G is a subgroup that contains a Borel.", [["root space", "ANATOMY", 36, 46], ["roots", "ANATOMY", 117, 122], ["roots", "ORGAN", 117, 122], ["the root space decomposition", "PROBLEM", 32, 60], ["root space", "OBSERVATION", 36, 46], ["roots", "ANATOMY", 117, 122]]], ["The parabolics which contain B are called the standard parabolics.", [["B", "GENE_OR_GENE_PRODUCT", 29, 30]]], ["Let P I denote the standard parabolic associated to the subset I \u2286 \u2206.", [["Let P I", "GENE_OR_GENE_PRODUCT", 0, 7], ["P I", "DNA", 4, 7]]], ["It is generated by T , the positive root spaces U \u03b1 for \u03b1 \u2208 \u03a6 + , and the negative root spaces U \u03b1 for \u03b1 in the Z \u22650 -span of \u2212I. The unipotent radical of P I is the normal subgroup U I generated by the positive root spaces which are not in the Z-span of I. The quotient L I = P I /U I is a reductive group whose root system \u03a6(I) has a base given by I. A Levi subgroup is a lift of L I to P I , and it determines a Levi decomposition P I = L I U I .", [["root", "ANATOMY", 36, 40], ["root", "ANATOMY", 83, 87], ["root", "ANATOMY", 212, 216], ["U I", "GENE_OR_GENE_PRODUCT", 182, 185], ["U I", "GENE_OR_GENE_PRODUCT", 282, 285], ["\u03b1", "PROTEIN", 56, 57], ["\u03a6", "PROTEIN", 60, 61], ["\u03b1", "PROTEIN", 103, 104], ["\u2212I", "PROTEIN", 126, 128], ["P I", "PROTEIN", 155, 158], ["U I", "PROTEIN", 182, 185], ["P I", "PROTEIN", 277, 280], ["U I", "PROTEIN", 282, 285], ["L I", "PROTEIN", 382, 385], ["P I", "PROTEIN", 389, 392], ["I U I", "PROTEIN", 442, 447], ["\u03b1", "TEST", 56, 57], ["\u03b1", "TEST", 103, 104], ["the Z", "TEST", 108, 113], ["the positive root spaces", "PROBLEM", 199, 223], ["negative root", "ANATOMY", 74, 87], ["radical", "OBSERVATION_MODIFIER", 144, 151], ["positive root spaces", "OBSERVATION", 203, 223]]], ["All Levi subgroups of P I are conjugate, and there is a canonical choice generated by T and the root spaces in the Z-span of I.Refresher on reductive groupsFollowing [2, Section 2] and [30, page 55], a real semisimple element a \u2208 g defines a parabolic subgroup P (a) := {g \u2208 G | lim z\u21920 z a gz \u2212a exists in G along any ray},Refresher on reductive groupswhere z a = exp(log(z)a).", [["root", "ANATOMY", 96, 100], ["P I", "DNA", 22, 25], ["z\u21920 z", "PROTEIN", 283, 288], ["gz \u2212a", "PROTEIN", 291, 296], ["reductive groups", "TREATMENT", 140, 156], ["G", "TEST", 275, 276], ["lim", "TEST", 279, 282], ["z\u21920", "TEST", 283, 286], ["z", "TEST", 287, 288], ["\u2212a", "TEST", 294, 296], ["exists", "TEST", 297, 303], ["G", "TEST", 307, 308], ["any ray}", "TEST", 315, 323], ["reductive", "TEST", 337, 346], ["root", "ANATOMY", 96, 100]]], ["If a \u2208 t, and (\u03b1, a) \u2265 0 for all \u03b1 \u2208 \u03a6 + , then P (a) is the standard parabolic associated to the subset I(a) \u2286 \u2206, defined byRefresher on reductive groupsThe unipotent radical of P (a) is given byRefresher on reductive groupsz a gz \u2212a = 1 along any ray}, and a choice of Levi subgroup is given by C G (a), the centraliser of a in G. Therefore P (a) = C G (a) U (a).", [["C G", "SIMPLE_CHEMICAL", 297, 300], ["C G (a) U (a", "SIMPLE_CHEMICAL", 351, 363], ["\u03b1", "PROTEIN", 33, 34], ["\u03a6", "PROTEIN", 37, 38], ["reductive groups", "TREATMENT", 138, 154], ["Levi subgroup", "TREATMENT", 271, 284], ["radical", "OBSERVATION_MODIFIER", 168, 175]]], ["Note that the quotient map \u03c7 : P (a) \u2192 C G (a) can be defined by taking a limitRefresher on reductive groupsz a gz \u2212a along any ray.Logarithmic connections: Local theoryIn this section, we study the representation theory of \u03a0(A, 0) \u223c = C A. By Lie's second theorem, these representations are equivalent to logarithmic flat connections on the affine line, and hence to linear ordinary differential equations of the form 1.2.", [["gz", "PROTEIN", 112, 114], ["the quotient map", "TEST", 10, 26], ["the affine line", "TREATMENT", 338, 353]]], ["In this section, the structure group G is a connected complex reductive group.", [["a connected complex reductive group", "TREATMENT", 42, 77], ["complex", "OBSERVATION_MODIFIER", 54, 61], ["reductive", "OBSERVATION", 62, 71]]], ["We start by explaining how the invariants of a logarithmic connection arise out of the corresponding C A representation.", [["a logarithmic connection", "TREATMENT", 45, 69]]], ["There are two natural Lie groupoid homomorphismsLogarithmic connections: Local theorywith the property that p \u2022 \u03b9 = id C .", [["id C", "SIMPLE_CHEMICAL", 116, 120], ["groupoid homomorphisms", "OBSERVATION", 26, 48]]], ["These induce pullback functors between the categories of representationsLogarithmic connections: Local theoryGiven a representation \u03a6 of C A on a principal bundle P , the pullback \u03b9 * (\u03a6) has the formLogarithmic connections: Local theoryfor a unique Lie algebra element A 0 \u2208 aut G (P 0 ).", [["C A", "PROTEIN", 137, 140], ["principal bundle P", "PROTEIN", 146, 164], ["pullback functors", "OBSERVATION", 13, 30]]], ["For a representation which corresponds to a differential equation of the form 1.2, we have A 0 = A(0).", [["a differential equation", "TEST", 42, 65]]], ["Hence, A 0 is called the residue of the representation, and is denoted Res(\u03a6).", [["Res", "CHEMICAL", 71, 74], ["Res(\u03a6)", "PROTEIN", 71, 77]]], ["The representations in the image of p * are said to be trivial, because they are defined on trivial bundles K \u00d7 A, for G-torsors K, and have the formLogarithmic connections: Local theoryfor A \u2208 aut G (K).", [["G-torsors K", "CELL_LINE", 119, 130], ["G", "TEST", 119, 120], ["trivial", "OBSERVATION", 55, 62]]], ["These correspond to differential equations of the form 1.2 for which the connection 1-form A(z) is constant.Logarithmic connections: Local theoryThe monodromy of a representation (P, \u03a6) at a non-zero point z \u2208 A is the G-equivariant automorphism M (z) = \u03a6(2\u03c0i, z) : P z \u2192 P z .", [["P z", "DNA", 266, 269], ["P z", "DNA", 272, 275], ["differential equations", "TEST", 20, 42], ["the G", "TEST", 215, 220], ["differential", "OBSERVATION_MODIFIER", 20, 32], ["constant", "OBSERVATION_MODIFIER", 99, 107]]], ["This represents the failure of a solution to the corresponding differential equation 1.2 to be single-valued.", [["a solution", "TREATMENT", 31, 41], ["the corresponding differential equation", "TEST", 45, 84], ["failure", "OBSERVATION", 20, 27]]], ["If we let z vary over the affine line then we get a holomorphic automorphism M of (P, \u03a6).", [["the affine line", "TREATMENT", 22, 37]]], ["At the point z = 0, it is related to the residue via the exponential map M (0) = \u03a6(2\u03c0i, 0) = exp(2\u03c0iRes(\u03a6)).Logarithmic connections: Local theoryIf the bundle P is trivial, then the monodromy maps M (z) for different non-zero values of z are all conjugate.", [["P", "DNA", 159, 160], ["the residue", "PROBLEM", 37, 48], ["the exponential map M", "TEST", 53, 74], ["the monodromy maps M", "TEST", 178, 198], ["trivial", "OBSERVATION", 164, 171]]], ["The automorphism M (0) may fail to be conjugate to these maps, but it always lies in the closure of their conjugacy class.Logarithmic connections: Local theoryCombining the functors \u03b9 * and p * we get a linear approximation functorLogarithmic connections: Local theoryThis takes an arbitrary representation of C A and outputs the trivial representation determined by its residue.", [["C A", "GENE_OR_GENE_PRODUCT", 310, 313], ["C A", "PROTEIN", 310, 313], ["C A", "TREATMENT", 310, 313], ["closure", "OBSERVATION", 89, 96], ["trivial", "OBSERVATION", 330, 337]]], ["We highlight the following important definition.Logarithmic connections: Local theoryRemark 3.2.", [["Local theoryRemark", "TEST", 73, 91]]], ["The notion of a strict linearization is well-defined because i * L = i * .", [["a strict linearization", "PROBLEM", 14, 36]]], ["Furthermore, L 2 = L, so if T is a linearization of a representation, then T \u2022 L(T \u22121 ) defines a strict linearization.", [["a strict linearization", "TREATMENT", 96, 118]]], ["Hence, linearizations exist if and only if strict ones exist.Logarithmic connections: Local theoryRemark 3.3.", [["Local theoryRemark", "TEST", 86, 104]]], ["Let T be a linearization of a representation (P, \u03a6).", [["Let T", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["For every point z \u2208 A, this defines a G-equivariant map T z : P 0 \u2192 P z .", [["P 0", "DNA", 62, 65], ["P z", "DNA", 68, 71]]], ["Hence, a linearization may be interpreted as a regularized parallel transport out of the singularity.Logarithmic connections: Local theoryConsider a linearizable representation (P, \u03a6).", [["a linearization", "TREATMENT", 7, 22]]], ["It's linear approximation is given by (P 0 \u00d7 A, L(\u03a6)), where L(\u03a6)(\u03bb, z) = exp(\u03bbA), and where A \u2208 aut G (P 0 ) is its residue.", [["P 0", "PROTEIN", 104, 107], ["its residue", "PROBLEM", 113, 124]]], ["The space of linearizations, denoted \u03bd(\u03a6), is a right torsor for the group Aut(L(\u03a6)) of automorphisms of L(\u03a6).", [["right torsor", "ANATOMY", 48, 60], ["L(\u03a6)", "PROTEIN", 105, 109], ["right", "ANATOMY_MODIFIER", 48, 53]]], ["The space of strict linearizations, denoted \u03bd 0 (\u03a6), is a right torsor for the subgroup Aut 0 (L(\u03a6)) consisting of automorphisms of L(\u03a6) which are the identity at the point 0 \u2208 A.Logarithmic connections: Local theoryThe most important linearizable representations in this paper are those with semisimple monodromy, and it will be useful to have a description of the automorphism group of L(\u03a6) in this case.", [["right torsor", "ANATOMY", 58, 70], ["L(\u03a6)", "PROTEIN", 132, 136], ["L(\u03a6)", "PROTEIN", 388, 392], ["semisimple monodromy", "TREATMENT", 293, 313], ["strict linearizations", "OBSERVATION", 13, 34], ["right", "ANATOMY_MODIFIER", 58, 63], ["L", "ANATOMY_MODIFIER", 132, 133]]], ["For simplicity of presentation, we choose a trivialization of P , and write L(\u03a6)(\u03bb, z) = exp(\u03bbS) : C A \u2192 G, where S \u2208 g is semisimple.", [["semisimple", "OBSERVATION", 123, 133]]], ["An automorphism of L(\u03a6) is given by a holomorphic map g : A \u2192 G which satisfiesLogarithmic connections: Local theoryfor all (\u03bb, z) \u2208 C A. As a result of this equation, an automorphism is determined by its value at a single non-zero point of A. Hence, we can embed the automorphism group into G via the homomorphismLogarithmic connections: Local theoryWe can also restrict an automorphism to the point 0 \u2208 A to obtain an automorphism of the representation i * (\u03a6).", [["L(\u03a6)", "DNA", 19, 23], ["this equation", "TEST", 153, 166]]], ["This gives rise to the following short exact sequenceLogarithmic connections: Local theorywhich has a splitting given by the pullback functor p * .Logarithmic connections: Local theoryProposition 3.4.", [["Local theoryProposition", "TREATMENT", 172, 195]]], ["The automorphism groups of L(\u03a6) and \u03b9 * (\u03a6) are given byLogarithmic connections: Local theorywhere P (a) is the parabolic subgroup of G determined by the real semisimple element a \u2208 g, U (a) is it's unipotent radical, C G (S) is the centralizer of S, and C G (exp(2\u03c0iS)) is the centralizer of exp(2\u03c0iS), which is reductive but possibly disconnected.", [["C", "CHEMICAL", 218, 219], ["C", "CHEMICAL", 255, 256], ["2\u03c0iS", "CHEMICAL", 264, 268], ["2\u03c0iS", "CHEMICAL", 297, 301], ["C G", "SIMPLE_CHEMICAL", 218, 221], ["C G", "SIMPLE_CHEMICAL", 255, 258], ["C G", "PROTEIN", 255, 258], ["S", "TEST", 248, 249], ["exp", "TEST", 260, 263], ["exp", "OBSERVATION", 293, 296], ["reductive", "OBSERVATION_MODIFIER", 313, 322]]], ["Furthermore, Aut(L(\u03a6)) is the parabolic subgroup of C G (exp(2\u03c0iS)) determined by a, Aut 0 (L(\u03a6)) is its unipotent radical, and Aut(\u03b9 * (\u03a6)) is embedded as a Levi subgroup via p * .", [["C G", "CHEMICAL", 52, 55], ["C G", "SIMPLE_CHEMICAL", 52, 55], ["Aut", "SIMPLE_CHEMICAL", 128, 131], ["Furthermore", "TEST", 0, 11]]], ["Given the choice of a maximal torus of G whose Lie algebra contains S, we have the identificationLogarithmic connections: Local theorywhere U N (S) is the subgroup of G generated by the root spaces for roots that pair with S to give a positive integer.", [["root", "ANATOMY", 186, 190], ["roots", "ANATOMY", 202, 207], ["a positive integer", "PROBLEM", 233, 251], ["root", "ANATOMY", 186, 190]]], ["As a result, we have the identificationLogarithmic connections: Local theoryRemark 3.5.", [["Local theoryRemark", "TEST", 64, 82]]], ["The group U N (S) was also considered in [1, Section 8.5] in relation to their classification of logarithmic connections.Logarithmic connections: Local theoryProof.", [["The group U N (S)", "TEST", 0, 17], ["logarithmic connections", "OBSERVATION", 97, 120]]], ["An element g \u2208 Aut(L(\u03a6)) satisfiesLogarithmic connections: Local theoryfor z = 0.", [["An element g", "TEST", 0, 12]]], ["Conversely, letLogarithmic connections: Local theoryIt has a decomposition as g 1 = c j exp(n j ), where c \u2208 C G (S) and n j \u2208 g \u03b1 j , for a root \u03b1 j satisfying \u03b1 j (S) \u2208 N. We can therefore define an automorphism of L(\u03a6) by settingLogarithmic connections: Local theoryThe rest of the proof is straightforward and is left to the reader.Logarithmic connections: Local theoryCertain representations cannot be linearized.", [["\u03b1 j", "PROTEIN", 129, 132], ["a decomposition", "TEST", 59, 74], ["j", "TEST", 131, 132], ["left", "ANATOMY_MODIFIER", 317, 321]]], ["We can see this by observing that for trivial representations, the exponential of the residue is conjugate to the monodromy.", [["trivial representations", "PROBLEM", 38, 61], ["the residue", "PROBLEM", 82, 93]]], ["This is a property that is preserved by gauge transformations, and hence it holds for all linearizable representations.", [["all linearizable representations", "PROBLEM", 86, 118], ["gauge transformations", "OBSERVATION", 40, 61]]], ["This turns out to be the only obstruction to linearizability, as the following proposition shows.", [["obstruction", "DISEASE", 30, 41], ["obstruction to linearizability", "PROBLEM", 30, 60], ["obstruction", "OBSERVATION", 30, 41]]], ["A representation \u03a6 on a principal bundle P is linearizable if and only if its monodromy \u03a6(2\u03c0i, 1) is conjugate to exp(2\u03c0iRes(\u03a6)).", [["P", "DNA", 41, 42], ["monodromy \u03a6", "PROTEIN", 78, 89]]], ["In particular, since the conjugacy classes of semisimple elements are closed, representations with semisimple monodromy can always be linearized.Logarithmic connections: Local theoryProof.", [["semisimple elements", "DNA", 46, 65], ["semisimple monodromy", "TREATMENT", 99, 119], ["semisimple elements", "OBSERVATION", 46, 65]]], ["Let M (z) = \u03c6(2\u03c0i, z) be the monodromy, and let C \u2286 G be the conjugacy class of exp(2\u03c0iA), which is an embedded submanifold of G. By assumption, M : A \u2192 C. It is therefore possible to find a disc D(0, r) of radius r around 0 \u2208 A, and a holomorphic map h : D(0, r) \u2192 G such that h(0) = 1 and h(z)e 2\u03c0iA h(z) \u22121 = \u03c6(2\u03c0i, z).", [["C \u2286 G", "GENE_OR_GENE_PRODUCT", 48, 53], ["z", "TEST", 19, 20], ["the monodromy", "TEST", 25, 38], ["G", "TEST", 52, 53], ["a disc D", "TEST", 189, 197], ["radius", "TEST", 207, 213], ["A", "TEST", 227, 228], ["G", "TEST", 266, 267], ["exp", "OBSERVATION", 80, 83], ["disc", "OBSERVATION", 191, 195], ["radius", "ANATOMY_MODIFIER", 207, 213]]], ["As a result, the formulaLogarithmic connections: Local theorydefines a homomorphism \u03c8 : (C A)| D(0,r) \u2192 G such that \u03c8(2\u03c0i, z) = e 2\u03c0iA and \u03c8(\u03bb, 0) = e \u03bbA .", [["such", "TEST", 106, 110], ["\u03c8", "TEST", 116, 117], ["z", "TEST", 123, 124]]], ["In fact, because of the equation (\u03bb, z)(2\u03c0i, z) = (2\u03c0i, e \u03bb z)(\u03bb, z) in the groupoid, the image of \u03c8 is contained in C G (e 2\u03c0iA ), the centralizer of e 2\u03c0iA in G. This allows us to define an action of (C A)| D(0,r) on D(0, r) \u00d7 C G (e 2\u03c0iA ) via the formula (\u03bb, z) * (z, g) = (e \u03bb z, \u03c8(\u03bb, z)ge \u2212\u03bbA ).Logarithmic connections: Local theoryBut now note that (2\u03c0i, z) * (z, g) = (z, g), implying that this action descends to an action of (C * A)| D(0,r) .", [["C G", "CHEMICAL", 117, 120], ["2\u03c0iA", "CHEMICAL", 124, 128], ["C G", "SIMPLE_CHEMICAL", 117, 120], ["D(0, r", "SIMPLE_CHEMICAL", 219, 225], ["C G", "SIMPLE_CHEMICAL", 229, 232], ["e 2\u03c0iA", "SIMPLE_CHEMICAL", 234, 240], ["\u03c8", "PROTEIN", 99, 100], ["C G", "PROTEIN", 117, 120], ["the equation", "TEST", 20, 32], ["z", "TEST", 37, 38], ["z", "TEST", 45, 46], ["\u03c0i", "TEST", 52, 54], ["an action", "TEST", 189, 198], ["C", "TEST", 229, 230], ["G", "TEST", 231, 232], ["z", "TEST", 269, 270], ["z", "TEST", 282, 283]]], ["The point (0, 1) \u2208 D(0, r) \u00d7 C G (e 2\u03c0iA ) is a fixed point of the action.", [["C G (e 2\u03c0iA", "GENE_OR_GENE_PRODUCT", 29, 40], ["C G (e 2\u03c0iA", "TEST", 29, 40]]], ["We can hence use a Bochner linearization to find an equivariant identification between a neighbourhood of this fixed point and a neighbourhood of the origin in T (0,1) (D(0, r) \u00d7 C G (e 2\u03c0iA )).", [["a Bochner linearization", "TREATMENT", 17, 40]]], ["This identification can furthermore be chosen to be compatible with the projection to D(0, r).Logarithmic connections: Local theoryThe C * -action on T (0,1) (D(0, r) \u00d7 C G (e 2\u03c0iA )) is linear, and the Lie algebra of C G (e 2\u03c0iA ), which we denote c, is an invariant subspace.", [["C G", "GENE_OR_GENE_PRODUCT", 218, 221], ["C G", "PROTEIN", 218, 221], ["invariant subspace", "OBSERVATION", 258, 276]]], ["Therefore, we have a short exact sequence of representationsLogarithmic connections: Local theorywhere C = T 0 D(0, r) carries the standard weight 1 action.", [["Local theorywhere C", "TEST", 85, 104]]], ["Since C * -representations are completely reducible, we can split this sequence to produce a C * -invariant subspace.", [["a C * -invariant subspace", "PROBLEM", 91, 116], ["reducible", "OBSERVATION", 42, 51]]], ["Using the equivariant identification, and shrinking r as necessary, we therefore obtain a holomorphic map k : D(0, r) \u2192 C G (e 2\u03c0iA ) which satisfies (\u03bb, z) * (z, k(z)) = (e \u03bb z, k(e \u03bb z)),Logarithmic connections: Local theoryfor (\u03bb, z) \u2208 (C A)| D(0,r) .", [["a holomorphic map k", "TEST", 88, 107], ["G", "TEST", 122, 123], ["z)", "TEST", 154, 156], ["z", "TEST", 160, 161], ["k", "TEST", 163, 164], ["z", "TEST", 165, 166], ["z", "TEST", 176, 177], ["k", "TEST", 179, 180], ["z", "TEST", 185, 186], ["Logarithmic connections", "TEST", 189, 212], ["Local theoryfor", "TEST", 214, 229]]], ["The holomorphic map hk : D(0, r) \u2192 G provides the desired linearization.Jordan-Chevalley decompositionIn this section, we explain that representations of C A admit a Jordan-Chevalley decomposition.Jordan-Chevalley decompositionIn a sense, this is an integrated version of the result of [25] (generalized to arbitrary G in [1] ).", [["The holomorphic map hk", "TEST", 0, 22]]], ["We start by showing that the ordinary multiplicative JC decomposition can be applied to the monodromy of a representation.", [["the ordinary multiplicative JC decomposition", "TREATMENT", 25, 69]]], ["We start by trivializing the principal bundle P and choosing a faithful representation of G, so that we are working with a representation of the form \u03c6 : C A \u2192 GL(N, C).", [["P", "DNA", 46, 47], ["C A", "PROTEIN", 154, 157], ["GL", "PROTEIN", 160, 162]]], ["This is valid since the JC decomposition is preserved by morphisms of reductive groups.", [["the JC decomposition", "TREATMENT", 20, 40], ["reductive groups", "OBSERVATION", 70, 86]]], ["A 1-cocycle for C A, valued in a representation (P, \u03a6), is defined to be a holomorphic section \u03c3 of the bundle of groups t * Aut G (P ) over C A, which satisfies the following cocycle condition \u03c3(\u00b5, e \u03bb z)\u03a6(\u00b5, e \u03bb z)\u03c3(\u03bb, z) = \u03c3(\u00b5 + \u03bb, z)\u03a6(\u00b5, e \u03bb z), for all (\u00b5, \u03bb, z) \u2208 C \u00d7 C \u00d7 A. Given a representation (P, \u03a6), and a 1-cocycle \u03c3, then (P, \u03c3 \u2022 \u03a6) defines a new representation.Jordan-Chevalley decompositionProposition 3.8.", [["C A", "SIMPLE_CHEMICAL", 16, 19], ["C A", "SIMPLE_CHEMICAL", 141, 144], ["C A", "PROTEIN", 141, 144], ["\u03a6", "PROTEIN", 344, 345], ["a holomorphic section", "TEST", 73, 94], ["z", "TEST", 203, 204], ["\u03a6", "TEST", 205, 206], ["\u00b5", "TEST", 207, 208], ["z", "TEST", 214, 215], ["\u03c3", "TEST", 216, 217], ["z", "TEST", 221, 222], ["\u03c3", "TEST", 226, 227], ["\u00b5", "TEST", 228, 229], ["z", "TEST", 235, 236], ["\u03a6", "TEST", 237, 238], ["\u00b5", "TEST", 239, 240], ["z", "TEST", 246, 247], ["all", "TEST", 254, 257], ["z", "TEST", 265, 266]]], ["Let \u03a6 be a representation of C A on a principal bundle P .", [["Let \u03a6", "GENE_OR_GENE_PRODUCT", 0, 5], ["C A", "GENE_OR_GENE_PRODUCT", 29, 32], ["\u03a6", "DNA", 4, 5], ["C A", "PROTEIN", 29, 32], ["P", "DNA", 55, 56]]], ["Then the following formula defines a holomorphic groupoid 1-cocycleJordan-Chevalley decompositionlog(M u (e \u03bb z))).Jordan-Chevalley decompositionFurthermore, \u03c3 \u03a6 consists of unipotent automorphisms of P .Jordan-Chevalley decompositionProof.", [["\u03c3 \u03a6", "DNA", 158, 161], ["P", "DNA", 201, 202], ["a holomorphic groupoid", "TREATMENT", 35, 57]]], ["To see that \u03c3 \u03a6 is holomorphic, we first choose a trivialization of P and a faithful representation of G, so that M u is represented by a holomorphic family of unipotent matrices.", [["\u03c3 \u03a6", "GENE_OR_GENE_PRODUCT", 12, 15], ["\u03c3 \u03a6", "PROTEIN", 12, 15], ["P", "DNA", 68, 69]]], ["The holomorphicity of \u03c3 \u03a6 then follows from the fact that the matrix logarithm is well-defined for unipotent matrices and is given by a polynomial.Jordan-Chevalley decompositionTo check that \u03c3 \u03a6 satisfies the cocycle condition, we start with the fact that M u defines an automorphism of \u03a6, which is encoded by the equationJordan-Chevalley decompositionThen using the fact that both the exponential and the logarithm respect this equation, we getJordan-Chevalley decompositionProposition 3.8 leads to a Jordan-Chevalley decomposition for representations of C A. Indeed, given a representation \u03a6, the resulting representation \u03a6 s := \u03c3 \u03a6 \u2022 \u03a6 has semisimple monodromy given by M s , and the unipotent map M u is an automorphism of \u03a6 s .", [["matrix", "CELLULAR_COMPONENT", 62, 68], ["\u03c3 \u03a6", "SIMPLE_CHEMICAL", 191, 194], ["\u03a6", "GENE_OR_GENE_PRODUCT", 287, 288], ["\u03a6", "GENE_OR_GENE_PRODUCT", 727, 728], ["\u03c3 \u03a6", "PROTEIN", 22, 25], ["\u03c3 \u03a6", "PROTEIN", 191, 194], ["\u03a6", "DNA", 287, 288], ["\u03a6", "PROTEIN", 637, 638], ["C A.", "SPECIES", 556, 560], ["the matrix logarithm", "TEST", 58, 78], ["unipotent matrices", "TREATMENT", 99, 117], ["semisimple monodromy", "TREATMENT", 643, 663]]], ["This decomposition extends both the multiplicative Jordan-Chevalley decomposition of the monodromy, as well as the additive Jordan-Chevalley decomposition of the residue.", [["the monodromy", "TREATMENT", 85, 98], ["the residue", "PROBLEM", 158, 169], ["multiplicative", "OBSERVATION_MODIFIER", 36, 50], ["Jordan", "OBSERVATION_MODIFIER", 51, 57], ["monodromy", "OBSERVATION", 89, 98]]], ["We can make this JC decomposition functorial by introducing a category J C whose objects are tuples (P, \u03a8, U ), where \u03a8 is a representation of C A with semisimple monodromy on a principal bundle P , and U is a unipotent automorphism of (P, \u03a8).", [["C A", "SIMPLE_CHEMICAL", 143, 146], ["\u03a8", "PROTEIN", 118, 119], ["C A", "PROTEIN", 143, 146], ["a category J C", "TREATMENT", 60, 74]]], ["Theorem 3.9.", [["Theorem", "TEST", 0, 7]]], ["There is an isomorphism of categories D : Rep(C A, G) \u2192 J C defined on objects by sending a representation (P, \u03a6) to the tuple (P, \u03c3 \u03a6 \u2022 \u03a6, M u ), and defined on morphisms to be the identity.", [["Rep", "PROTEIN", 42, 45], ["J C", "PROTEIN", 56, 59], ["P", "DNA", 128, 129], ["\u03a6", "PROTEIN", 137, 138], ["P", "TEST", 128, 129], ["morphisms", "TEST", 162, 171]]], ["The inverse functor D \u22121 sends a tuple (P, \u03a8, U ) to the representation (P, \u03c4 U \u2022 \u03a8), where \u03c4 U is the 1-cocycle defined by the equationJordan-Chevalley decompositionlog(U (e \u03bb z))).Jordan-Chevalley decompositionGiven a representation (P, \u03a6), we call Aut 0 (L(\u03a6 s )) the resonance group of \u03a6.", [["inverse functor D \u22121", "DNA", 4, 24], ["P", "DNA", 73, 74], ["\u03c4 U", "DNA", 92, 95], ["1-cocycle", "DNA", 103, 112], ["The inverse functor", "TEST", 0, 19], ["cocycle", "TEST", 105, 112], ["the equationJordan", "TEST", 124, 142]]], ["By Proposition 3.4, this occurs when the semisimple part of the residue of \u03a6 pairs with a root to give a positive integer.", [["root", "ANATOMY", 90, 94], ["\u03a6 pairs", "PROTEIN", 75, 82], ["a positive integer", "PROBLEM", 103, 121]]], ["When the structure group is GL(n, C), this is equivalent to the condition that two eigenvalues of the residue differ by an integer.Jordan-Chevalley decompositionThe phenomenon of resonance is the main source of subtlety in the classification of logarithmic connections.", [["the residue", "PROBLEM", 98, 109], ["main", "OBSERVATION_MODIFIER", 196, 200], ["logarithmic connections", "OBSERVATION", 245, 268]]], ["Indeed, the failure of linearizability for some representations is often attributed to resonance.", [["the failure of linearizability", "PROBLEM", 8, 38], ["failure", "OBSERVATION", 12, 19]]], ["In fact, the failure of linearizability is due to the interaction between the resonance group and the unipotent part of the monodromy.Jordan-Chevalley decompositionTo see this, consider an object (P, \u03a6 s , U ) of J C corresponding to a representation \u03a6, and consider the following short exact sequence of groupsJordan-Chevalley decompositionBy Proposition 3.4, this sequence is isomorphic to the short exact sequence associated to a parabolic subgroup.", [["J C", "PROTEIN", 213, 216], ["short exact sequence", "DNA", 396, 416], ["the failure of linearizability", "PROBLEM", 9, 39], ["the resonance group", "TREATMENT", 74, 93], ["an object", "TEST", 186, 195], ["J C", "PROBLEM", 213, 216], ["failure", "OBSERVATION", 13, 20], ["monodromy", "OBSERVATION", 124, 133]]], ["This sequence has a canonical splitting given by the functor p * , and the image of this splitting is a Levi subgroup.", [["functor p *", "DNA", 53, 64]]], ["The linear approximation of \u03a6 can be expressed in the category J C as (P 0 \u00d7 A, L(\u03a6 s ), \u03b9 * (U )), where \u03b9 * (U ) is viewed as an element of the Levi subgroup.", [["\u03a6", "PROTEIN", 28, 29], ["linear", "OBSERVATION_MODIFIER", 4, 10]]], ["A linearization of \u03a6 is therefore equivalent to a linearization T of \u03a6 s , such that T \u22121 U T = \u03b9 * (U ).", [["\u03a6", "DNA", 19, 20], ["a linearization T of \u03a6 s", "TEST", 48, 72]]], ["By first choosing an arbitrary linearization of \u03a6 s , we can view U as an element of Aut(L(\u03a6 s )) which projects to i * (U ).", [["an arbitrary linearization of \u03a6 s", "TREATMENT", 18, 51]]], ["Then, a linearization is equivalent to an element of Aut(L(\u03a6 s )) which conjugates U to the element \u03b9 * (U ) in the Levi subgroup.", [["U", "GENE_OR_GENE_PRODUCT", 83, 84], ["a linearization", "TREATMENT", 6, 21]]], ["It is clear that a linearization exists if either U = 1 or the resonance group is trivial.", [["U = 1", "GENE_OR_GENE_PRODUCT", 50, 55], ["clear", "OBSERVATION", 6, 11], ["trivial", "OBSERVATION", 82, 89]]], ["Our approach to classification makes use of the JC decomposition of Theorem 3.9.", [["the JC decomposition", "TEST", 44, 64], ["Theorem", "TEST", 68, 75]]], ["Namely, we first apply the functor D from Theorem 3.9 to extract a representation \u03a6 s = \u03c3 \u03a6 \u2022 \u03a6 with semisimple monodromy.", [["semisimple monodromy", "TREATMENT", 101, 121], ["semisimple monodromy", "OBSERVATION", 101, 121]]], ["Then, we take the space of strict linearizations \u03bd 0 (\u03a6 s ) \u2282 Hom(L(\u03a6 s ), \u03a6 s ) \u2286 Hom G (P 0 , P 1 ), which is non-empty by Proposition 3.6, and which is a torsor for the resonance group Aut 0 (L(\u03a6 s )).", [["strict linearizations", "TREATMENT", 27, 48]]], ["The data that we use to classify the representation consists of (M (\u03a6), \u03bd 0 (\u03a6 s ), Res(\u03a6)), where M (\u03a6) = \u03a6(2\u03c0i, 1) is the monodromy at the point 1.The category of generalized monodromy dataWe define a category F ((C, 0), G) of generalized monodromy data, which we will use to classify representations of C A. To make sense of the definition, we start with a few simple observations.", [["Res", "CHEMICAL", 84, 87], ["C A.", "SPECIES", 306, 310], ["the monodromy", "TEST", 120, 133], ["generalized monodromy data", "PROBLEM", 229, 255]]], ["Let K 1 and K 0 be right G-torsors.", [["right G-torsors", "ANATOMY", 19, 34], ["Let K 1", "GENE_OR_GENE_PRODUCT", 0, 7], ["K 0", "GENE_OR_GENE_PRODUCT", 12, 15], ["K 0", "DNA", 12, 15], ["Let K", "TEST", 0, 5], ["K", "TEST", 12, 13], ["right", "ANATOMY_MODIFIER", 19, 24]]], ["The space of G-equivariant maps Hom G (K 0 , K 1 ) is then a bi-torsor for Aut G (K 1 ) acting on the left and Aut G (K 0 ) acting on the right.", [["left", "ANATOMY", 102, 106], ["K", "CHEMICAL", 82, 83], ["K", "CHEMICAL", 118, 119], ["K", "TEST", 39, 40], ["a bi-torsor", "TEST", 59, 70], ["left", "ANATOMY_MODIFIER", 102, 106], ["right", "ANATOMY_MODIFIER", 138, 143]]], ["Let A \u2208 aut G (K 0 ), which admits a JC decomposition A = S + N , for S semisimple and N nilpotent.", [["K", "CHEMICAL", 15, 16], ["S + N", "CHEMICAL", 58, 63], ["N", "CHEMICAL", 87, 88], ["S semisimple", "SIMPLE_CHEMICAL", 70, 82], ["N nilpotent", "SIMPLE_CHEMICAL", 87, 98]]], ["The element S defines two subgroupsThe category of generalized monodromy dataThese groups were identified in Proposition 3.4 with the automorphism groups of the trivial representation exp(\u03bbS) on K 0 \u00d7 A. In particular, U N (S) is the resonance group of exp(\u03bbS).", [["element S", "DNA", 4, 13], ["generalized monodromy dataThese groups", "TREATMENT", 51, 89], ["K", "TEST", 195, 196], ["generalized", "OBSERVATION_MODIFIER", 51, 62], ["trivial", "OBSERVATION", 161, 168]]], ["Next, let \u03bd 0 \u2282 Hom G (K 0 , K 1 ) be a reduction of structure to U N (S), which is acting on the right.", [["U N (S)", "GENE_OR_GENE_PRODUCT", 66, 73], ["K", "TEST", 23, 24], ["K", "TEST", 29, 30], ["a reduction of structure", "PROBLEM", 38, 62], ["right", "ANATOMY_MODIFIER", 98, 103]]], ["This extends to a right C Aut G (K0) (S) U N (S)-torsor denoted \u03bd \u2286 Hom G (K 0 , K 1 ).", [["N", "CHEMICAL", 43, 44], ["S", "CHEMICAL", 46, 47], ["K 1", "PROTEIN", 81, 84], ["torsor", "TEST", 49, 55], ["K", "TEST", 75, 76], ["K", "TEST", 81, 82], ["right", "ANATOMY_MODIFIER", 18, 23]]], ["By taking the stabilizers of \u03bd 0 and \u03bd for the left action, we obtain subgroups St(\u03bd 0 ) \u2282 St(\u03bd) of Aut G (K 1 ).", [["Aut G (K 1", "GENE_OR_GENE_PRODUCT", 100, 110], ["\u03bd 0 and \u03bd", "PROTEIN", 29, 38], ["Aut G", "PROTEIN", 100, 105], ["K 1", "PROTEIN", 107, 110], ["subgroups St", "TEST", 70, 82], ["Aut G (K", "TEST", 100, 108], ["left", "ANATOMY_MODIFIER", 47, 51]]], ["The groups St(\u03bd 0 ) and St(\u03bd) are non-canonically isomorphic to U N (S) and C Aut G (K0) (S) U N (S), respectively.", [["N", "CHEMICAL", 66, 67], ["The groups St", "TEST", 0, 13]]], ["Therefore, St(\u03bd 0 ) is normal in St(\u03bd), and there is a canonical short exact sequenceThe category of generalized monodromy dataThe objects of F ( (C, 0) , G) are defined to be tuples (M, K 1 , \u03bd 0 , K 0 , A), where K 1 , K 0 , \u03bd 0 and A are as above, and M \u2208 St(\u03bd) satisfies \u03c7(M ) = exp(2\u03c0iA).The category of generalized monodromy dataThe morphisms in F ((C, 0), G) are pairs of maps between the underlying G-torsors that preserve all the structure.Equivalence of categoriesThe preceding discussion, combined with Proposition 3.6 and Proposition 3.4, implies that we have a well-defined functorEquivalence of categoriesIn the opposite direction, we define a functorEquivalence of categorieswhich will provide an equivalence of categories.", [["K", "CHEMICAL", 215, 216], ["K", "CHEMICAL", 221, 222], ["K", "CHEMICAL", 187, 188], ["K", "CHEMICAL", 215, 216], ["K", "CHEMICAL", 221, 222], ["St(\u03bd 0 )", "GENE_OR_GENE_PRODUCT", 11, 19], ["St(\u03bd)", "GENE_OR_GENE_PRODUCT", 33, 38], ["St", "TEST", 11, 13], ["a canonical short exact sequence", "PROBLEM", 53, 85], ["generalized monodromy data", "PROBLEM", 101, 127], ["tuples", "TEST", 176, 182], ["K", "TEST", 187, 188], ["K", "TEST", 199, 200], ["K", "TEST", 215, 216], ["K", "TEST", 221, 222], ["generalized monodromy data", "PROBLEM", 309, 335], ["normal", "OBSERVATION", 23, 29]]], ["Again, we use the JC decomposition of Theorem 3.9.", [["the JC decomposition", "TEST", 14, 34], ["Theorem", "TEST", 38, 45]]], ["Given an object (M, K 1 , \u03bd 0 , K 0 , A) of F ((C, 0), G), we first construct a representation \u03a6 s with semisimple monodromy.", [["an object", "TEST", 6, 15], ["K", "TEST", 20, 21], ["K", "TEST", 32, 33], ["semisimple monodromy", "TREATMENT", 104, 124]]], ["The group U N (S) is identified with the resonance group of the trivial representation exp(\u03bbS), and therefore it acts on the trivial bundle K 0 \u00d7 A. We use this action to construct a principal bundleEquivalence of categoriesThe representation \u03a6 s is defined on this bundle via the formula \u03a6 s (\u03bb, z)(h, k, z) = (h, exp(\u03bbS)(k), e \u03bb z),Equivalence of categoriesfor (h, k, z) \u2208 \u03bd 0 \u00d7K 0 \u00d7A. It is clear that \u03a6 s has semisimple monodromy.", [["\u03bbS", "PROTEIN", 91, 93], ["The group U N (S)", "TEST", 0, 17], ["z", "TEST", 297, 298], ["k", "TEST", 303, 304], ["z", "TEST", 306, 307], ["exp", "TEST", 315, 318], ["k", "TEST", 323, 324], ["z", "TEST", 331, 332], ["Equivalence", "TEST", 334, 345], ["categoriesfor", "TEST", 349, 362], ["h", "TEST", 364, 365], ["k", "TEST", 367, 368], ["z)", "TEST", 370, 372], ["semisimple monodromy", "TREATMENT", 413, 433], ["trivial", "OBSERVATION_MODIFIER", 64, 71], ["representation exp", "OBSERVATION", 72, 90], ["clear", "OBSERVATION", 394, 399]]], ["Next, using the unipotent component M u of M and the nilpotent component N of A, we define an automorphism of \u03a6 sEquivalence of categoriesWe therefore have an object of J C, and so we define R(M,Equivalence of categoriesGiven a morphism in F ((C, 0), G)Equivalence of categoriesThis defines the functor R. Proof.", [["the nilpotent component", "TREATMENT", 49, 72]]], ["Given a representation (P, \u03a6), the representation RL(P, \u03a6) lives on the bundle (\u03bd 0 (\u03a6 s ) \u00d7 L(P ))/Aut 0 (L(\u03a6 s )).Equivalence of categoriesHence, using the fact that \u03bd 0 (\u03a6 s ) \u2282 Hom(L(P ), P ), we define \u03b7 (P,\u03a6) to be the evaluation map to P .", [["P", "DNA", 243, 244], ["the evaluation map", "TEST", 221, 239]]], ["The two G-torsors in the object LR(M, K 1 , \u03bd 0 , K 0 , A) are (\u03bd 0 \u2297 K 0 )| 1 and (\u03bd 0 \u2297 K 0 )| 0 .", [["K", "TEST", 38, 39], ["K", "TEST", 50, 51], ["K", "TEST", 70, 71], ["K", "TEST", 90, 91]]], ["Because the group U N (S) acts trivially on the fibre above 0 we haveEquivalence of categoriesAnd because \u03bd 0 \u2282 Hom G (K 0 , K 1 ), we get an evaluation mapEquivalence of categoriesThese two morphisms make up the component (M,K1,\u03bd0,K0,A) .Equivalence of categoriesAt the cost of a non-canonical equivalence, we can give a more explicit presentation of F ((C, 0), G) by taking the full subcategory generated by the objects whose underlying G-torsors are trivial.", [["K", "TEST", 119, 120], ["K", "TEST", 125, 126], ["an evaluation", "TEST", 139, 152], ["K1", "TEST", 226, 228], ["categories", "OBSERVATION", 254, 264], ["trivial", "OBSERVATION", 453, 460]]], ["Suppressing the trivial G-torsors from the notation, the set of objects of this subcategory is given by the set B of tuples (M, hU N (S), A = S + N ), where hU N (S) is a left coset, and such that M \u2208 h(C G (S) U N (S))h \u22121 , and \u03c7(h \u22121 M h) = exp(2\u03c0iA).", [["S + N", "CHEMICAL", 142, 147], ["N", "CHEMICAL", 160, 161], ["a left coset", "TREATMENT", 169, 181], ["h", "TEST", 219, 220], ["M h", "TEST", 237, 240], ["exp(2\u03c0iA", "TEST", 244, 252]]], ["The morphisms in this category with a fixed source object are given by G \u00d7 G, where a pair (k, g) corresponds to the morphism (T 1 , T 0 ) = (kg, g).", [["G \u00d7 G", "GENE_OR_GENE_PRODUCT", 71, 76]]], ["The pair (k, g) acts on an object as follows:Equivalence of categories(k, g) * (M, hU N (S), A) = ((kg)M (kg) \u22121 , k(ghg \u22121 )U N (Ad(g)(S)), Ad(g)(A)).Equivalence of categoriesTherefore we have the equivalenceEquivalence of categorieswhere the right-hand side is an action groupoid, and G G is the semi-direct product for the conjugation action of G on itself.Equivalence of categoriesNow consider the full subcategory where the residue is fixed to be A \u2208 g.", [["right-hand", "ANATOMY", 244, 254], ["N", "CHEMICAL", 127, 128], ["G G", "GENE_OR_GENE_PRODUCT", 287, 290], ["G", "SIMPLE_CHEMICAL", 348, 349], ["G G", "PROTEIN", 287, 290], ["U N", "TEST", 125, 128], ["G G", "TREATMENT", 287, 290], ["the residue", "PROBLEM", 425, 436], ["right", "ANATOMY_MODIFIER", 244, 249], ["hand", "ANATOMY", 250, 254]]], ["The objects of this subcategory can be taken to have the form (M, U N (S), A = S +N ), where only the element M is allowed to vary.", [["S +N", "CHEMICAL", 79, 83]]], ["There is a bijection between isomorphism classes of flat logarithmic G-connections on the affine line whose residue is conjugate to a fixed element A = S + N \u2208 g, and the set of elements M \u2208 C G (S) U N (S) such that \u03c7(M ) = exp(2\u03c0iA), modulo conjugation by (C G (A) U N (S)).Equivalence of categoriesRemark 3.12.", [["N", "CHEMICAL", 156, 157], ["C", "CHEMICAL", 191, 192], ["N", "CHEMICAL", 201, 202], ["2\u03c0iA", "CHEMICAL", 229, 233], ["N", "CHEMICAL", 269, 270], ["flat logarithmic G-connections", "TREATMENT", 52, 82], ["the affine line", "TREATMENT", 86, 101], ["such", "TEST", 207, 211], ["exp(2\u03c0iA", "TEST", 225, 233], ["modulo conjugation", "TEST", 236, 254]]], ["We can write an element M \u2208 T in its JC decomposition as exp(2\u03c0iS) exp(2\u03c0iN ), where N = i\u22650 N i is nilpotent, and [S, N i ] = iN i .", [["2\u03c0iN", "CHEMICAL", 71, 75], ["N", "CHEMICAL", 93, 94], ["[S, N i ] = iN", "CHEMICAL", 115, 129], ["nilpotent", "SIMPLE_CHEMICAL", 100, 109], ["[S, N i ] = iN i", "SIMPLE_CHEMICAL", 115, 131], ["nilpotent", "TEST", 100, 109]]], ["This recovers the result of [22] in the case G = GL(n, C), as well as the result [1, Theorem 8.5] for complex reductive G.Equivalence of categoriesThere is a redundancy in the definition of the category F ((C, 0) , G).", [["G = GL", "SIMPLE_CHEMICAL", 45, 51], ["Theorem", "TEST", 85, 92], ["complex reductive G.", "PROBLEM", 102, 122], ["a redundancy", "PROBLEM", 156, 168], ["redundancy", "OBSERVATION", 158, 168]]], ["Let E((C, 0) , G) be the category whose objects (M, K 1 , \u00b5 0 , K 0 , A) are defined in the same way as F ((C, 0) , G), except that \u00b5 0 is a right U (a)-torsor, where A = a + ib + N is the decomposition with a, b real semisimple, N nilpotent, and all mutually commuting.", [["N", "CHEMICAL", 180, 181], ["N", "CHEMICAL", 230, 231], ["+ ib + N", "SIMPLE_CHEMICAL", 173, 181], ["K", "TEST", 52, 53], ["K", "TEST", 64, 65], ["right", "ANATOMY_MODIFIER", 141, 146]]], ["There is an obvious functor from F ((C, 0), G) to E((C, 0), G), which replaces the U N (S)-torsor \u03bd 0 with its extension to a U (a)-torsor.", [["N (S)-torsor \u03bd 0", "CHEMICAL", 85, 101], ["E((C, 0), G)", "SIMPLE_CHEMICAL", 50, 62], ["an obvious functor", "PROBLEM", 9, 27]]], ["Conversely, given the U (a)-torsor \u00b5 0 from an object of E((C, 0), G), there is a natural way to reduce it to a U N (S)-torsor, for S = a + ib.", [["N", "CHEMICAL", 114, 115], ["S = a + ib", "SIMPLE_CHEMICAL", 132, 142]]], ["Hence, the categories F ( (C, 0) , G) and E((C, 0), G) are equivalent.Equivalence of categoriesBy looking at the isomorphism classes of objects in E((C, 0), G) we recover the classification result of [2, Theorem A].", [["E", "SIMPLE_CHEMICAL", 42, 43], ["(C, 0), G", "SIMPLE_CHEMICAL", 44, 53], ["the categories F", "TEST", 7, 23], ["G", "TEST", 35, 36], ["E", "TEST", 42, 43]]], ["Let C \u2286 C G (a) be the conjugacy class of exp(2\u03c0iA).", [["Let C \u2286 C G", "GENE_OR_GENE_PRODUCT", 0, 11], ["exp(2\u03c0iA)", "PROTEIN", 42, 51], ["exp", "OBSERVATION", 42, 45]]], ["By [2, Lemma 1], this canonically determines a conjugacy class in the reductive quotient of any parabolic subgroup of G conjugate to P (a).", [["G conjugate", "SIMPLE_CHEMICAL", 118, 129], ["G conjugate", "PROTEIN", 118, 129]]], ["[2, Theorem A]There is a bijection between isomorphism classes of flat logarithmic G-connections on the affine line whose residue is conjugate to a fixed element A = a+ib+N \u2208 g, and conjugacy classes of pairs (M, P ), where P is a parabolic conjugate to P (a), and M \u2208 P such that \u03c7(M ) \u2208 C.Corollary 3.13.", [["N", "CHEMICAL", 171, 172], ["P", "PROTEIN", 224, 225], ["flat logarithmic G-connections", "TREATMENT", 66, 96], ["the affine line", "TREATMENT", 100, 115]]], ["Let S be the collection of pairs (M, P ) as described above.", [["Let S", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["The group G acts on S by conjugation, and we can define an action groupoid G S. Let Q be the set of pairs (M, hU (a)) such that M \u2208 hP (a)h \u22121 and \u03c7(h \u22121 M h) = exp(2\u03c0iA).", [["Let Q", "GENE_OR_GENE_PRODUCT", 80, 85], ["exp(2\u03c0iA", "TEST", 161, 169]]], ["The group G C G (A) acts on Q, and the corresponding action groupoid is equivalent to the full subcategory of E((C, 0), G) consisting of elements whose residue is conjugate to A. By Theorem 3.10, this category is equivalent to the category of logarithmic connections with residue conjugate to A. Therefore, it suffices to provide an equivalence between G S and (G C G (A)) Q. There is a natural functor given as followsCorollary 3.13.", [["G C G (A)", "GENE_OR_GENE_PRODUCT", 10, 19], ["G S", "GENE_OR_GENE_PRODUCT", 353, 356], ["The group G C G (A) acts", "TREATMENT", 0, 24], ["residue conjugate", "PROBLEM", 272, 289], ["an equivalence between G S and (G C G (A))", "TREATMENT", 330, 372], ["a natural functor", "TREATMENT", 385, 402]]], ["To show that F is fully faithful, it suffices to show that it induces an isomorphism between stabilizer groups.", [["an isomorphism between stabilizer groups", "PROBLEM", 70, 110]]], ["But the stabilizer of (M, U (a)) is C G (M ) \u2229 (U (a) C G (A)), the stabilizer of (M, P (a)) is C G (M ) \u2229 P (a) = C G (M ) \u2229 (U (a) C G (a)), and these are equal.Corollary 3.13.", [["C G (M )", "SIMPLE_CHEMICAL", 36, 44], ["U (a) C G (A)", "SIMPLE_CHEMICAL", 48, 61], ["C G (M ) \u2229", "SIMPLE_CHEMICAL", 115, 125], ["U (a) C G (a)", "SIMPLE_CHEMICAL", 127, 140], ["G", "TEST", 56, 57], ["A", "TEST", 59, 60], ["the stabilizer", "TEST", 64, 78], ["G", "TEST", 98, 99], ["M", "TEST", 101, 102], ["P", "TEST", 107, 108], ["a", "TEST", 110, 111], ["C G", "TEST", 115, 118], ["U", "TEST", 127, 128], ["a", "TEST", 130, 131], ["C G", "TEST", 133, 136], ["equal", "OBSERVATION", 157, 162]]], ["Theorem 3.10, stated in terms of the category E( (C, 0) , G), can also be used to recover the equivalence between logarithmic connections and filtered local systems from [33, 2] .Morita equivalenceMorita equivalence is an equivalence relation between Lie groupoids that is weaker than isomorphism.", [["Theorem", "TEST", 0, 7], ["weaker", "OBSERVATION_MODIFIER", 273, 279]]], ["The approach that we take here, originally introduced in [19, 18, 32] , is based on the use of principal groupoid bibundles.Morita equivalenceLet G be a Lie groupoid over M , with target and source maps denoted by t and s respectively.", [["Let G", "GENE_OR_GENE_PRODUCT", 142, 147], ["source maps", "TEST", 191, 202]]], ["This can act on a manifold X equipped with a moment map \u03c6 : X \u2192 M .", [["X", "DNA", 27, 28]]], ["Namely, a left action of G on X is given by a map \u03b8 : G \u00d7 s,\u03c6 X \u2192 X,Morita equivalencesubject to the compatibility conditions that \u03c6(g.x) = t(g), g.(g .x) = (gg ).x where defined, and (\u03c6(x)).x = x, where : M \u2192 G is the embedding of identity arrows.", [["the compatibility conditions", "TEST", 97, 125], ["g.", "TEST", 146, 148], ["gg", "TEST", 158, 160], ["identity arrows", "PROBLEM", 232, 247], ["left", "ANATOMY_MODIFIER", 10, 14], ["identity arrows", "OBSERVATION", 232, 247]]], ["A representation of G on a principal G-bundle P \u2192 M is equivalent to a left action of G on P such that the action on the fibres is G-equivariant.Morita equivalenceA left G-bundle is defined by the data of a surjective submersion \u03c0 : Q \u2192 N and a left action of G on Q which preserves the fibers of \u03c0.", [["fibres", "ANATOMY", 121, 127], ["fibers", "ANATOMY", 287, 293], ["fibres", "CELLULAR_COMPONENT", 121, 127], ["fibers", "CELLULAR_COMPONENT", 287, 293], ["P", "DNA", 91, 92], ["left", "ANATOMY_MODIFIER", 71, 75], ["left", "ANATOMY_MODIFIER", 165, 169], ["left", "ANATOMY_MODIFIER", 245, 249]]], ["The bundle is principal if the action of G is free and fibrewise transitive, meaning that the following map is an isomorphismMorita equivalenceThe notions of right actions and right principal bundles are defined analogously.", [["right", "ANATOMY", 158, 163], ["right principal bundles", "ANATOMY", 176, 199], ["bundle", "OBSERVATION_MODIFIER", 4, 10], ["principal", "OBSERVATION_MODIFIER", 14, 23], ["right", "ANATOMY_MODIFIER", 158, 163], ["right", "ANATOMY_MODIFIER", 176, 181], ["principal", "ANATOMY_MODIFIER", 182, 191], ["bundles", "ANATOMY_MODIFIER", 192, 199]]], ["3. the actions of G and H are compatible in the sense that (g.z).h = g.(z.h), where z \u2208 Q, g \u2208 G, h \u2208 H and both actions are defined.Morita equivalenceWe say that the groupoids G and H are Morita equivalent.Morita equivalenceThe significance of Morita equivalences in this paper is that they provide a method for constructing equivalences between categories of groupoid representations.", [["H", "CHEMICAL", 24, 25], ["h \u2208 H", "CHEMICAL", 98, 103], ["z", "TEST", 84, 85], ["Morita equivalences", "PROBLEM", 245, 264], ["a method", "TREATMENT", 300, 308]]], ["The equivalence is given by a pull-push procedure.", [["a pull-push procedure", "TREATMENT", 28, 49]]], ["Consider a representation of H on the principal G-bundle P \u2192 N .", [["H", "CHEMICAL", 29, 30], ["principal G-bundle P \u2192 N", "PROTEIN", 38, 62]]], ["Pulling back along q we get the principal bundle q * P = Q \u00d7 N P over Q. This has a right H action given by Our main tool for constructing Morita equivalences is the following result, whose proof is left to the reader.", [["a right H action", "TREATMENT", 82, 98], ["right", "ANATOMY_MODIFIER", 84, 89], ["left", "ANATOMY_MODIFIER", 199, 203]]], ["First let A \u2192 M be the Lie algebroid of G, and denote its anchor \u03c1 : A \u2192 T M .", [["\u2192 T M", "GENE_OR_GENE_PRODUCT", 71, 76]]], ["We say that a submanifold N \u2286 M is transverse to A if T z M = T z N + im\u03c1 z for every point z \u2208 N .", [["N", "CHEMICAL", 96, 97], ["z", "TEST", 74, 75]]], ["Second, two points z 1 , z 2 \u2208 M lie in the same orbit of G if there is an arrow g \u2208 G such that s(g) = z 1 and t(g) = z 2 .", [["Second", "TEST", 0, 6], ["z", "TEST", 19, 20], ["z", "TEST", 25, 26], ["g", "TEST", 99, 100], ["z", "TEST", 104, 105], ["same orbit", "ANATOMY", 44, 54]]], ["This defines an equivalence relation on M , and M is partitioned into the orbits of G. Proposition 4.5 (Criterion for Morita equivalent subgroupoid).", [["Morita equivalent subgroupoid", "TREATMENT", 118, 147], ["equivalence", "OBSERVATION_MODIFIER", 16, 27], ["orbits", "ANATOMY", 74, 80]]], ["Let G \u21d2 M be a Lie groupoid with Lie algebroid A \u2192 M , and let N \u2286 M be an embedded submanifold.", [["Let G \u21d2 M", "GENE_OR_GENE_PRODUCT", 0, 9], ["embedded", "OBSERVATION", 75, 83]]], ["If N intersects every orbit of G and is transverse to A, then G| N is a Lie subgroupoid of G, which is Morita equivalent to G.Morita equivalenceProof.", [["G| N", "GENE_OR_GENE_PRODUCT", 62, 66]]], ["It suffices to check the condition of Lemma 4.4, namely that t| s \u22121 (N ) : s \u22121 (N ) \u2192 M is a surjective submersion.", [["Lemma", "TEST", 38, 43], ["a surjective submersion", "PROBLEM", 93, 116]]], ["That this map is surjective follows from the fact that N intersects every orbit.", [["orbit", "ANATOMY", 74, 79], ["orbit", "ORGAN", 74, 79], ["orbit", "ANATOMY", 74, 79]]], ["For n \u2208 N , we have the decomposition T (n) s \u22121 (N ) \u223c = A n \u2295 T n N , where (n) is the identity arrow at n.", [["the decomposition T", "TEST", 20, 39]]], ["The map dt (n) acts as the anchor on the first summand and the identity on the second.", [["The map", "TEST", 0, 7]]], ["Hence t| s \u22121 (N ) is a submersion along the identity bisection.", [["a submersion along the identity bisection", "PROBLEM", 22, 63], ["identity bisection", "OBSERVATION", 45, 63]]], ["Using left translation by local bisections, we can then show that t| s \u22121 (N ) is a submersion everywhere.Logarithmic connections: Global theoryLet X be a complex manifold with a smooth closed hypersurface D \u2282 X which is not necessarily connected, and let G be a connected complex reductive group.", [["Let X", "GENE_OR_GENE_PRODUCT", 144, 149], ["let G", "GENE_OR_GENE_PRODUCT", 252, 257], ["smooth closed hypersurface D \u2282 X", "DNA", 179, 211], ["a complex manifold", "PROBLEM", 153, 171], ["a smooth closed hypersurface D \u2282 X", "TREATMENT", 177, 211], ["a connected complex reductive group", "PROBLEM", 261, 296], ["left", "ANATOMY_MODIFIER", 6, 10], ["not necessarily", "UNCERTAINTY", 221, 236], ["reductive", "OBSERVATION", 281, 290]]], ["By Lie's second theorem, these representations are equivalent to principal G-bundles over X equipped with flat connections which have a logarithmic singularity along D. The goal of this section is to establish a general functorial Riemann-Hilbert correspondence for logarithmic flat connections.Logarithmic connections on line bundlesAs a warm-up, we will start by studying the special case where D is the zero section in the total space of a line bundle p : L \u2192 D. This will serve as a local model for the general case which we will consider later.Logarithmic connections on line bundlesWe start by describing in detail the structure of the twisted fundamental groupoid \u03a0(L, D).", [["line bundles", "ANATOMY", 322, 334], ["line bundles", "ANATOMY", 576, 588], ["a logarithmic singularity", "PROBLEM", 134, 159], ["this section", "TREATMENT", 181, 193], ["logarithmic flat connections", "PROBLEM", 266, 294], ["line bundles", "OBSERVATION_MODIFIER", 322, 334], ["line bundles", "OBSERVATION_MODIFIER", 576, 588]]], ["This groupoid has two orbits: the zero section D and its complement L \u00d7 .", [["complement L \u00d7", "GENE_OR_GENE_PRODUCT", 57, 71], ["complement L \u00d7", "PROTEIN", 57, 71], ["orbits", "ANATOMY", 22, 28]]], ["The restriction of the groupoid to the open orbit L \u00d7 is simply a fundamental groupoidLogarithmic connections on line bundlesTo determine the restriction of the groupoid to the orbit D, consider first the corresponding restriction of the Lie algebroid T L (\u2212logD)| D .", [["line bundles", "ANATOMY", 113, 125], ["\u2212logD)| D", "GENE_OR_GENE_PRODUCT", 257, 266], ["Lie algebroid T L (\u2212logD)| D", "PROTEIN", 238, 266], ["a fundamental groupoidLogarithmic connections on line bundles", "PROBLEM", 64, 125], ["orbit", "ANATOMY", 44, 49], ["bundles", "OBSERVATION_MODIFIER", 118, 125], ["orbit", "ANATOMY", 177, 182]]], ["To see this isomorphism, recall that the sections of At(L \u00d7 ) are defined to be the C * -invariant vector fields on L. Locally, these are spanned by C * -invariant lifts of vector fields on D, and the Euler vector field z\u2202 z , where z is a local linear coordinate on the fibers of L. These vector fields also define sections of T L (\u2212logD), and they are precisely the ones that survive when we restrict to the zero section.Logarithmic connections on line bundlesAs a result of the isomorphism T L (\u2212logD)| D \u223c = At(L \u00d7 ), we have an isomorphism between the restriction \u03a0(L, D)| D and the source simply connected integration of At(L \u00d7 ).", [["sections", "ANATOMY", 41, 49], ["fibers", "ANATOMY", 271, 277], ["sections", "ANATOMY", 316, 324], ["line bundles", "ANATOMY", 450, 462], ["T L", "GENE_OR_GENE_PRODUCT", 328, 331], ["T L", "PROTEIN", 328, 331], ["the zero section", "TREATMENT", 406, 422], ["the isomorphism", "TEST", 477, 492], ["line bundles", "OBSERVATION_MODIFIER", 450, 462]]], ["This is given by the quotient \u03a0(L \u00d7 )/C * , which is a groupoid over D. The composition of arrows is defined to be concatenation of paths, using the C * action to match up the endpoints as required.Logarithmic connections on line bundlesThere is a natural morphism of Lie algebroids p ! : T L (\u2212logD) \u2192 At(L \u00d7 ) which covers the projection map p : L \u2192 D. Over L \u00d7 this map is given by the quotient projection T L \u2192 T L/C * , and over D it is given by the isomorphism of Lie algebroids described above.", [["line bundles", "ANATOMY", 225, 237], ["T L", "GENE_OR_GENE_PRODUCT", 289, 292], ["the C * action", "TREATMENT", 145, 159], ["this map", "TREATMENT", 364, 372], ["line bundles", "OBSERVATION_MODIFIER", 225, 237]]], ["By Lie's second theorem, this map integrates to a morphism of Lie groupoids p : \u03a0(L, D) \u2192 \u03a0(L \u00d7 )/C * .Logarithmic connections on line bundlesCombining p with the source map s, we arrive at the following mapLogarithmic connections on line bundleswhich is an isomorphism.", [["line bundles", "ANATOMY", 130, 142], ["Logarithmic connections on line bundles", "PROBLEM", 103, 142], ["the source map s", "TEST", 159, 175], ["line", "ANATOMY", 130, 134], ["bundles", "ANATOMY_MODIFIER", 135, 142]]], ["This defines a linear left action of \u03a0(L \u00d7 )/C * on L, which is given by the following formulaLogarithmic connections on line bundleswhere g \u2208 \u03a0(L \u00d7 )/C * and v \u2208 L, such that s(g) = p(v).", [["line bundleswhere", "TEST", 121, 138], ["g", "TEST", 139, 140], ["linear", "OBSERVATION_MODIFIER", 15, 21], ["left", "ANATOMY_MODIFIER", 22, 26]]], ["As a result, \u03c6 defines an isomorphism between the twisted fundamental groupoid and the resulting action groupoid:Logarithmic connections on line bundlesGiven any point y \u2208 D, the fibre L y is transverse to the Lie algebroid T L (\u2212logD) and intersects both orbits of \u03a0(L, D).", [["line bundles", "ANATOMY", 140, 152], ["Lie algebroid T L", "PROTEIN", 210, 227], ["\u2212logD", "PROTEIN", 229, 234], ["an isomorphism between the twisted fundamental groupoid", "PROBLEM", 23, 78]]], ["In [34, Lemma 4.1.3] the isotropy group A(L y ) was shown to sit in the following short exact sequenceLogarithmic connections on line bundleswhere \u03c0(L \u00d7 , v) is the fundamental group of L \u00d7 based at a point v \u2208 L \u00d7 y .", [["Lemma", "TEST", 8, 13], ["line bundleswhere", "TEST", 129, 146]]], ["Let l denote the central element of \u03c0(L \u00d7 , v) which is represented by a counterclockwise loop contained in the fibre above y.", [["Let l", "GENE_OR_GENE_PRODUCT", 0, 5], ["a counterclockwise loop", "TREATMENT", 71, 94], ["central", "ANATOMY_MODIFIER", 17, 24], ["element", "OBSERVATION_MODIFIER", 25, 32], ["L", "ANATOMY_MODIFIER", 38, 39], ["counterclockwise loop", "OBSERVATION", 73, 94], ["fibre", "OBSERVATION_MODIFIER", 112, 117]]], ["The leftmost map in the sequence is defined by sending n \u2208 Z to (l \u2212n , 2\u03c0in) \u2208 \u03c0(L \u00d7 , v) \u00d7 C. This sequence can be upgraded to a short exact sequence of action groupoidsLogarithmic connections on line bundlesBy pulling back representations along the maps in the sequence, we obtain functors between the corresponding representation categories which go in the opposite direction.", [["The leftmost map", "TEST", 0, 16], ["line bundlesBy pulling back representations", "TREATMENT", 198, 241]]], ["The category Rep(A(L y ) L y , G) is thus embedded into Rep((\u03c0(L \u00d7 , v) \u00d7 C) L y , G) as the subcategory of representations which pullback to a trivial Z \u00d7 L y representation.Logarithmic connections on line bundlesThe representations of (\u03c0(L \u00d7 , v) \u00d7 C) L y are easy to describe.", [["line bundles", "ANATOMY", 202, 214], ["Rep", "GENE_OR_GENE_PRODUCT", 56, 59], ["Rep", "PROTEIN", 56, 59], ["a trivial Z \u00d7 L y representation", "TREATMENT", 142, 174], ["line bundles", "OBSERVATION_MODIFIER", 202, 214], ["L", "ANATOMY_MODIFIER", 254, 255]]], ["They are given by a pair of representations of C L y and \u03c0(L \u00d7 , v) on the same principal bundle P over L y .", [["principal bundle P", "PROTEIN", 80, 98], ["C L y", "TEST", 47, 52]]], ["Furthermore, because \u03c0(L \u00d7 , v) acts trivially on L y and commutes with C, it acts on P by automorphisms of the C L y -representation.", [["C", "CHEMICAL", 72, 73], ["C", "SIMPLE_CHEMICAL", 72, 73], ["P", "DNA", 86, 87], ["the C L y -representation", "TREATMENT", 108, 133]]], ["In terms of this description, the representations of A(L y ) L y are simply those for which the actions of 2\u03c0i \u2208 C and l \u2208 \u03c0(L \u00d7 , v) agree.", [["2\u03c0i \u2208 C", "CHEMICAL", 107, 114], ["2\u03c0i \u2208 C", "SIMPLE_CHEMICAL", 107, 114], ["l \u2208 \u03c0", "SIMPLE_CHEMICAL", 119, 124], ["A(L y )", "TREATMENT", 53, 60], ["C", "TEST", 113, 114]]], ["The category of representations Rep(A(L y ) L y , G) is isomorphic to a category consisting of tuples (P, \u03a6, \u03b3), where (P, \u03a6) is a representation of C L y , and \u03b3 : \u03c0(L \u00d7 , v) \u2192 Aut(P, \u03a6) is a homomorphism such that \u03b3(l) = \u03a6(2\u03c0i, z).Logarithmic connections on line bundlesWe can now apply the functors from Theorem 3.10 to give a description of the category of \u03a0(L, D) representations in terms of generalized monodromy data.", [["line bundles", "ANATOMY", 260, 272], ["Rep", "PROTEIN", 32, 35], ["\u03b3", "PROTEIN", 161, 162], ["Aut", "PROTEIN", 178, 181], ["P", "PROTEIN", 182, 183], ["\u03a6", "PROTEIN", 185, 186], ["Aut", "TEST", 178, 181], ["P", "TEST", 182, 183], ["a homomorphism such", "TEST", 191, 210], ["\u03a6", "TEST", 223, 224], ["z", "TEST", 230, 231], ["generalized monodromy data", "PROBLEM", 397, 423], ["line bundles", "OBSERVATION_MODIFIER", 260, 272], ["generalized", "OBSERVATION_MODIFIER", 397, 408], ["monodromy", "OBSERVATION", 409, 418]]], ["To this end, we define a category F ((L, D), G), which is similar to the one defined in Section 3.2.1.", [["a category F ((L, D), G)", "TEST", 23, 47]]], ["The objects of this category consist of tuples (\u03b3, K 1 , \u03bd 0 , K 0 , A), where K 1 and K 0 are right G-torsors, A \u2208 aut G (K 0 ) is an infinitesimal automorphism admitting the JC decomposition A = S + N , \u03bd 0 \u2282 Hom G (K 0 , K 1 ) is a right U N (S)-torsor, and finally, \u03b3 : \u03c0(L \u00d7 , v) \u2192 St(\u03bd) \u2286 Aut G (K 1 ) is a homomorphism.", [["K", "CHEMICAL", 79, 80], ["K", "CHEMICAL", 87, 88], ["K", "CHEMICAL", 123, 124], ["S + N", "CHEMICAL", 197, 202], ["N", "CHEMICAL", 243, 244], ["K 1", "GENE_OR_GENE_PRODUCT", 79, 82], ["Aut G (K 1", "GENE_OR_GENE_PRODUCT", 295, 305], ["K 0", "PROTEIN", 87, 90], ["\u03bd", "PROTEIN", 290, 291], ["tuples", "TEST", 40, 46], ["K", "TEST", 51, 52], ["K", "TEST", 63, 64], ["K", "TEST", 79, 80], ["K", "TEST", 87, 88], ["right G", "TEST", 95, 102], ["an infinitesimal automorphism", "PROBLEM", 132, 161], ["the JC decomposition", "TEST", 172, 192], ["G", "TEST", 215, 216], ["K", "TEST", 218, 219], ["K", "TEST", 224, 225], ["a right U N", "TEST", 233, 244], ["torsor", "TEST", 249, 255], ["v", "TEST", 282, 283], ["St", "TEST", 287, 289]]], ["The compatibility condition for this tuple is that \u03c7(\u03b3(l)) = exp(2\u03c0iA), where l is the central element represented by a counterclockwise loop in the fibre L \u00d7 y , and \u03c7 is the map defined by the sequence 3.5.", [["\u03c7", "PROTEIN", 167, 168], ["l", "ANATOMY_MODIFIER", 78, 79], ["central element", "OBSERVATION", 87, 102], ["counterclockwise loop", "OBSERVATION", 120, 141], ["fibre", "OBSERVATION_MODIFIER", 149, 154]]], ["The above discussion, Lemma 5.1, and Theorem 3.10 combine to give an equivalence between Rep(\u03a0 (L, D) , G) and a category consisting of tuples (\u03b3, M, K 1 , \u03bd 0 , K 0 , A), where (M, K 1 , \u03bd 0 , K 0 , A) is an object of F ((C, 0), G), and \u03b3 = (\u03b3 1 , \u03b3 0 ) : \u03c0(L \u00d7 , v) \u2192 Aut(M, K 1 , \u03bd 0 , K 0 , A) is a homomorphism such that \u03b3 1 (l) = M .", [["\u03b3 1 , \u03b3 0 )", "SIMPLE_CHEMICAL", 243, 254], ["\u03c0(L \u00d7", "SIMPLE_CHEMICAL", 257, 262], ["Rep", "PROTEIN", 89, 92], ["Lemma", "TEST", 22, 27], ["Theorem", "TEST", 37, 44], ["tuples", "TEST", 136, 142], ["K", "TEST", 150, 151], ["K", "TEST", 162, 163], ["K", "TEST", 182, 183], ["\u03bd", "TEST", 188, 189], ["K", "TEST", 194, 195], ["C", "TEST", 223, 224], ["G", "TEST", 230, 231], ["\u03c0", "TEST", 257, 258], ["\u00d7", "TEST", 261, 262], ["v)", "TEST", 265, 267], ["\u2192", "TEST", 268, 269], ["Aut", "TEST", 270, 273], ["M", "TEST", 274, 275], ["K", "TEST", 277, 278], ["\u03bd", "TEST", 283, 284], ["K", "TEST", 289, 290], ["a homomorphism", "TEST", 301, 315]]], ["The tuple (\u03b3 1 , K 1 , \u03bd 0 , K 0 , A) gives an object of F ((L, D), G).", [["The tuple", "TEST", 0, 9], ["K", "TEST", 17, 18], ["K", "TEST", 29, 30]]], ["Therefore, it suffices to show that we can reconstruct \u03b3 from \u03b3 1 alone.Logarithmic connections on line bundlesRecall from Section 3.2.1 that an automorphism of the object (M, K 1 , \u03bd 0 , K 0 , A) \u2208 F ((C, 0), G) consists of a pair of G-equivariant automorphisms T i : K i \u2192 K i , i = 0, 1, which preserve all of the structure.", [["line bundles", "ANATOMY", 99, 111], ["\u03b3 1", "GENE_OR_GENE_PRODUCT", 62, 65], ["\u03b3", "PROTEIN", 55, 56], ["\u03b3 1", "PROTEIN", 62, 65], ["K", "TEST", 176, 177], ["\u03bd", "TEST", 182, 183], ["K", "TEST", 188, 189], ["C", "TEST", 203, 204], ["K i", "TEST", 269, 272], ["K i", "TEST", 275, 278], ["line bundles", "OBSERVATION_MODIFIER", 99, 111]]], ["In particular, T 0 \u2208 C Aut G (K0) (A), and T 1 \u03bd 0 T \u22121 0 = \u03bd 0 .", [["T", "TEST", 15, 16], ["G", "TEST", 27, 28], ["T", "TEST", 43, 44]]], ["As a result, T 1 \u2208 St(\u03bd) \u2229 C Aut G (K1) (M ), and \u03c7(T 1 ) = T 0 .", [["T", "TEST", 13, 14], ["G", "TEST", 33, 34]]], ["This implies that the automorphism (T 1 , T 0 ) is completely determined by T 1 alone.", [["T 1", "GENE_OR_GENE_PRODUCT", 76, 79]]], ["Therefore, the homomorphism \u03b3 is fully determined by the componentLogarithmic connections on complex manifoldsIn this section, we deal with the fully general case of a smooth hypersurface D in a complex manifold X. The approach that we adopt for studying the representations of the twisted fundamental groupoid \u03a0(X, D) is to use a Morita equivalence to decompose the groupoid into more simple building blocks which can be analyzed using the methods of previous sections.", [["sections", "ANATOMY", 461, 469], ["homomorphism \u03b3", "DNA", 15, 29], ["a smooth hypersurface D", "PROBLEM", 166, 189], ["a Morita equivalence", "TREATMENT", 329, 349], ["previous sections", "TREATMENT", 452, 469]]], ["These building blocks consist of two types: the fundamental group of the complement X \u00a0D, and the twisted fundamental groupoid of the normal bundle \u03a0(N X,D , D), which was studied in Section 5.1.Construction of the Morita equivalenceWe construct a Morita equivalence relating \u03a0(X, D) to a groupoid which is defined over the normal bundle of D. The construction is inspired by Deligne's notion of tangential basepoints [11] .", [["complement X \u00a0D", "GENE_OR_GENE_PRODUCT", 73, 88], ["complement X \u00a0D", "PROTEIN", 73, 88], ["twisted fundamental groupoid", "PROTEIN", 98, 126], ["normal bundle \u03a0", "PROTEIN", 134, 149], ["N X", "PROTEIN", 150, 153], ["Morita equivalenceWe", "DNA", 215, 235]]], ["The intuition is to consider paths connecting points in X \u00a0D to points in D, but we only identify paths if they are related by a homotopy that fixes the normal direction of the paths at their endpoints lying in D. Hence, we are in effect considering paths that have an endpoint lying in the normal bundle to D. In order to make this precise, we will construct a larger space Z and a hypersurfac\u1ebd D, which contains both (X, D) and (N X,D , 0 D ), where 0 D is the zero section of the normal bundle N X,D .", [["hypersurfac\u1ebd D", "CHEMICAL", 383, 397], ["hypersurfac\u1ebd D", "SIMPLE_CHEMICAL", 383, 397], ["Z", "PROTEIN", 375, 376], ["hypersurfac\u1ebd D", "PROTEIN", 383, 397], ["normal bundle N X,D", "PROTEIN", 483, 502], ["normal", "OBSERVATION", 483, 489], ["bundle", "ANATOMY_MODIFIER", 490, 496]]], ["The twisted fundamental groupoid \u03a0(Z,D) of this larger pair of spaces will then allow us to consider paths going between N X,D , and X.Construction of the Morita equivalenceFirst, for each connected component D i of the hypersurface D, choose a tubular neighbourhood U i \u2282 X. These must be chosen so that they are pairwise disjoint.", [["tubular", "ANATOMY", 245, 252]]], ["Next, consider the deformation to the normal cone of (U i , D i ) (see [14] for a general account of this construction).", [["this construction", "TREATMENT", 101, 118], ["normal", "OBSERVATION", 38, 44]]], ["This is a family p : D i \u2192 C which interpolates between p \u22121 (t) = U i , for t = 0, and the normal bundle p \u22121 (0) = N X,Di .", [["D i \u2192 C", "CHEMICAL", 21, 28], ["N", "CHEMICAL", 117, 118], ["D i \u2192 C", "SIMPLE_CHEMICAL", 21, 28], ["U i", "TEST", 67, 70], ["Di", "PROBLEM", 121, 123], ["normal", "OBSERVATION", 92, 98], ["bundle", "ANATOMY_MODIFIER", 99, 105]]], ["The space D i can be constructed as followsConstruction of the Morita equivalenceThe map p is then given by the blow-down map followed by the projection to C.Construction of the Morita equivalenceThe deformation space D i contains a smooth hypersurface D i which is isomorphic to D i \u00d7C, and whose normal bundle is isomorphic to N X,Di \u00d7 C. This hypersurface intersects the non-zero fibres at D i , and the fibre over 0 at the zero section.", [["fibres", "ANATOMY", 383, 389], ["D i \u00d7C", "GENE_OR_GENE_PRODUCT", 280, 286], ["fibres", "CELLULAR_COMPONENT", 383, 389], ["N X", "PROTEIN", 329, 332], ["The map p", "TEST", 81, 90], ["the blow-down map", "TREATMENT", 108, 125], ["The deformation space D i", "PROBLEM", 196, 221], ["a smooth hypersurface D i", "PROBLEM", 231, 256], ["deformation", "OBSERVATION_MODIFIER", 200, 211], ["space D", "OBSERVATION", 212, 219], ["smooth", "OBSERVATION_MODIFIER", 233, 239], ["hypersurface D", "OBSERVATION", 240, 254], ["normal", "OBSERVATION", 298, 304], ["bundle", "OBSERVATION_MODIFIER", 305, 311], ["non-zero fibres", "OBSERVATION", 374, 389]]], ["Hence, the pair (D i , D i ) provides an interpolation between (U i , D i ) and (N X,D , 0 D ).", [["an interpolation", "TEST", 38, 54]]], ["Furthermore, because of the existence of tubular neighbourhood embeddings in the smooth category, (D i , D i ) is topologically equivalent to (N X,D \u00d7 C, 0 D \u00d7 C).Construction of the Morita equivalenceThe disjoint union i (D i \u00a0p \u22121 (0)) embeds holomorphically into X \u00d7 C * .", [["tubular", "ANATOMY", 41, 48], ["tubular neighbourhood embeddings", "PROBLEM", 41, 73], ["The disjoint union i (D i \u00a0p \u22121", "TREATMENT", 201, 232], ["tubular", "ANATOMY_MODIFIER", 41, 48], ["neighbourhood embeddings", "OBSERVATION", 49, 73], ["smooth category", "ANATOMY", 81, 96], ["disjoint", "OBSERVATION_MODIFIER", 205, 213], ["union", "OBSERVATION", 214, 219]]], ["We defineConstruction of the Morita equivalencewhere D(1, r) is a disc of radius 0 < r 1 centred at 1 \u2208 C. There is a natural map p : Z \u2192 C such that p \u22121 (0) = i N X,Di , and p \u22121 (1) = X. We also define the smooth hypersurface D = i D i .Construction of the Morita equivalenceThen D \u223c = D \u00d7 C, and it intersects p \u22121 (1) along D, and p \u22121 (0) along the disjoint union of the zero sections.Construction of the Morita equivalenceNext consider the twisted fundamental groupoid \u03a0(Z, D), which is the source simply connected integration of T Z (\u2212log D).", [["sections", "ANATOMY", 382, 390], ["N", "CHEMICAL", 163, 164], ["T Z", "GENE_OR_GENE_PRODUCT", 537, 540], ["\u2212log D", "GENE_OR_GENE_PRODUCT", 542, 548], ["T Z", "PROTEIN", 537, 540], ["\u2212log D", "PROTEIN", 542, 548], ["a disc of radius", "TREATMENT", 64, 80], ["Z", "TEST", 134, 135], ["Di", "TEST", 167, 169], ["disc", "ANATOMY", 66, 70], ["radius", "ANATOMY_MODIFIER", 74, 80], ["disjoint", "ANATOMY_MODIFIER", 355, 363], ["union", "OBSERVATION", 364, 369], ["zero sections", "OBSERVATION", 377, 390]]], ["The orbits of this groupoid consist of Z \u00a0D and the hypersurfaces D i .", [["groupoid", "ANATOMY", 19, 27], ["Z \u00a0D", "GENE_OR_GENE_PRODUCT", 39, 43], ["orbits", "ANATOMY", 4, 10]]], ["The fibre p \u22121 (1) = X intersects each orbit and is transverse to T Z (\u2212log D).", [["T Z", "GENE_OR_GENE_PRODUCT", 66, 69], ["\u2212log D", "GENE_OR_GENE_PRODUCT", 71, 77], ["fibre p \u22121 (1) = X", "DNA", 4, 22], ["T Z", "PROTEIN", 66, 69], ["\u2212log D", "PROTEIN", 71, 77], ["fibre", "OBSERVATION_MODIFIER", 4, 9], ["orbit", "ANATOMY", 39, 44], ["transverse", "OBSERVATION_MODIFIER", 52, 62]]], ["Therefore, by Proposition 4.5, \u03a0(Z, D) is Morita equivalent to \u03a0(Z, D)| X .Construction of the Morita equivalenceLemma 5.3.", [["Proposition", "TEST", 14, 25]]], ["The groupoid \u03a0(Z, D)| X is an integration of the Lie algebroid T Z (\u2212log D)| X = T X (\u2212logD).", [["T X", "GENE_OR_GENE_PRODUCT", 81, 84], ["Lie algebroid T Z", "PROTEIN", 49, 66], ["T X", "DNA", 81, 84]]], ["This map is an isomorphism when restricted to each component D i , since the normal bundle of D is isomorphic to N X,D \u00d7 C. Hence, to show that \u03c8 is an isomorphism, it suffices to check that it induces an isomorphism between the fundamental groups of X \u00a0D and Z \u00a0D. This fact follows from a combination of the van Kampen theorem, and the fact that each pair (D i , D i ) is homeomorphic to (N X,D \u00d7 C, 0 D \u00d7 C).Construction of the Morita equivalenceChoose a basepoint x 0 \u2208 X \u00a0D, and for each componentConstruction of the Morita equivalenceand let N = \u03a0(Z, D)| V .", [["\u03c8", "GENE_OR_GENE_PRODUCT", 144, 145], ["X \u00a0D", "GENE_OR_GENE_PRODUCT", 251, 255], ["\u03c8", "PROTEIN", 144, 145], ["the Morita", "TEST", 518, 528], ["normal", "OBSERVATION", 77, 83], ["bundle", "OBSERVATION_MODIFIER", 84, 90]]], ["The submanifold V satisfies the conditions of Proposition 4.5.", [["submanifold V", "PROTEIN", 4, 17]]], ["Therefore N is a Lie subgroupoid which is Morita equivalent to \u03a0(Z, D).", [["a Lie subgroupoid", "PROBLEM", 15, 32]]], ["The elements of N and Q may be interpreted as paths in X whose endpoints may lie in the normal bundle to D.Decomposing the groupoid of paths with tangential basepointsIn this section, we give a van Kampen style decomposition of the groupoid N into simple building blocks.", [["N", "CHEMICAL", 241, 242], ["a van Kampen style decomposition", "TREATMENT", 192, 224], ["simple building blocks", "TREATMENT", 248, 270]]], ["The groupoid \u03a0(X \u00a0D)v can be interpreted as the fundamental groupoid of X \u00a0D relative to the basepoint x 0 and the tangential basepoints v i .", [["X \u00a0D", "GENE_OR_GENE_PRODUCT", 72, 76], ["X \u00a0D", "PROTEIN", 72, 76]]], ["Recall from Section 5.1 the definition of the group A(N X,Di | di ) = \u03a0(N \u00d7 X,Di )/C * | di , which acts linearly on the fibre N X,Di | di of the normal bundle.", [["C * | di", "SIMPLE_CHEMICAL", 83, 91], ["fibre N X", "PROTEIN", 121, 130], ["Di", "TEST", 58, 60], ["Di", "TEST", 78, 80], ["di", "PROBLEM", 89, 91], ["normal", "OBSERVATION", 146, 152], ["bundle", "ANATOMY_MODIFIER", 153, 159]]], ["Let X be a complex manifold with a smooth closed hypersurface D \u2282 X. Choose a point x 0 \u2208 X \u00a0D, and for each connected component D i of D, choose a point d i \u2208 D i , and a non-zero normal vector v i \u2208 N X,Di | di .", [["Let X", "GENE_OR_GENE_PRODUCT", 0, 5], ["Let X", "DNA", 0, 5], ["a smooth closed hypersurface D \u2282 X.", "TREATMENT", 33, 68]]], ["Then \u03a0(X, D) is Morita equivalent to a Lie groupoid N whose base manifold is V = {x 0 } ( i N X,Di | di ).", [["N", "CHEMICAL", 52, 53], ["N", "CHEMICAL", 92, 93], ["a Lie groupoid N", "TREATMENT", 37, 53]]], ["For each component D i , we have N X,Di \u2282 Z, and restricting the log tangent algebroid, we get the identification T Z (\u2212log D)| N X,D i = T N X,D i (\u2212log 0 Di ).", [["T Z", "PROTEIN", 114, 117], ["Z", "TEST", 116, 117], ["D i", "TEST", 144, 147]]], ["Hence, by Lie's second theorem we have a morphism \u03a0(N X,Di , D i ) \u2192 \u03a0(Z, D).Decomposing the groupoid of paths with tangential basepointsUsing the results of Section 5.1, we see that this map can be restricted to the following morphismDecomposing the groupoid of paths with tangential basepointsIf we restrict \u03c6 i to the origin 0 di we get an isomorphism.", [["\u03c6", "DNA", 310, 311], ["tangential basepoints", "TREATMENT", 116, 137], ["tangential basepoints", "TREATMENT", 274, 295]]], ["If we restrict instead to the point v i , then we get the map \u03c0(N \u00d7 X,Di , v i ) \u2192 \u03a0(X \u00a0D)v, and this sits in the following commutative squareDecomposing the groupoid of paths with tangential basepointsEvery arrow in N is a product of arrows from \u03a0(X \u00a0D)v and arrows of the form \u03c6 i (u), for u \u2208 A(N X,Di | di ) N X,Di | di .", [["N X,Di | di ) N", "CHEMICAL", 298, 313], ["the map", "TEST", 54, 61], ["this sits", "PROBLEM", 97, 106], ["tangential basepoints", "TREATMENT", 181, 202]]], ["Furthermore, the non-uniqueness of the factorization arises precisely from elements \u03c6 i (\u03b3), for \u03b3 \u2208 \u03c0(N \u00d7 X,Di , v i ).", [["N", "CHEMICAL", 103, 104]]], ["For each point d i , choose a path p i : [0, 1] \u2192 X, such that p i (0) = d i , p i (0) = v i , p i (1) = x 0 , and p i ((0, 1]) \u2282 X \u00a0D. Let U i be a tubular neighbourhood of D i , and let \u03bb i denote the small loop in U i which rotates once around D i in the counterclockwise direction.", [["tubular", "ANATOMY", 149, 156], ["such", "TEST", 53, 57], ["i", "TEST", 117, 118], ["Let U i", "TEST", 136, 143], ["D i", "TEST", 174, 177], ["the small loop in U i", "PROBLEM", 199, 220], ["tubular", "ANATOMY", 149, 156], ["small loop", "OBSERVATION", 203, 213]]], ["The path p i induces a homomorphism from \u03c0(U i \u00a0D i ) to \u03c0(X \u00a0D, x 0 ).", [["\u03c0", "DNA", 57, 58]]], ["The objects of F ((X, D), G) are defined to be tuples (K, \u03a6, A, \u03bd 0 ), where K \u2192d \u222a {x 0 } is a principal G-bundle (i.e. a collection of right G-torsors), \u03a6 : \u03c0(X \u00a0D, x 0 ) \u2192 Aut G (K x0 ) is a homomorphism, A = (A 1 , ..., A n ) is a collection of infinitesimal symmetries A i \u2208 aut G (K di ) admitting JC decompositions A i = S i + N i , and \u03bd 0 = (\u03bd (1) 0 , ..., \u03bd (n) 0 ) is a collection of torsors, where \u03bd (i) 0 \u2282 Hom G (K di , K x0 ) is a right U N (S i )-torsor.", [["K", "CHEMICAL", 77, 78], ["K", "CHEMICAL", 55, 56], ["K", "CHEMICAL", 77, 78], ["N", "CHEMICAL", 334, 335], ["N", "CHEMICAL", 454, 455], ["K", "PROTEIN", 77, 78], ["G-bundle", "PROTEIN", 106, 114], ["right G", "PROTEIN", 137, 144], ["torsors", "PROTEIN", 145, 152], ["\u03a6", "PROTEIN", 155, 156], ["\u03c0", "PROTEIN", 159, 160], ["tuples", "TEST", 47, 53], ["K", "TEST", 55, 56], ["K", "TEST", 77, 78], ["infinitesimal symmetries", "TEST", 249, 273], ["G", "TEST", 284, 285], ["JC decompositions", "TEST", 304, 321], ["torsors", "TEST", 395, 402], ["G", "TEST", 424, 425], ["K di", "TEST", 427, 431], ["K", "TEST", 434, 435], ["a right U N", "TEST", 444, 455], ["right", "ANATOMY_MODIFIER", 137, 142], ["right", "ANATOMY_MODIFIER", 446, 451]]], ["These data satisfy the compatibility conditions that \u03a6| \u03c0i : \u03c0 i \u2192 St(\u03bd (i) ) and \u03c7 i (\u03a6(l i )) = exp(2\u03c0iA i ), for all i.", [["St", "TEST", 67, 69], ["exp(2\u03c0iA i", "TEST", 98, 108]]], ["Recall that the subgroups St(\u03bd (i) ) \u2286 Aut G (K x0 ) and the homormophisms \u03c7 i : St(\u03bd (i) ) \u2192 C Aut G (K d i ) (S i ) are defined in Section 3.2.1.", [["the homormophisms", "TEST", 57, 74], ["C Aut G", "TEST", 94, 101], ["K d i", "TEST", 103, 108]]], ["It thus remains for us to prove the equivalence between Rep(N , G) and F (\u03c0(X \u00a0D, x 0 ), G).", [["Rep", "PROTEIN", 56, 59]]], ["By Proposition 5.4 and Theorem 5.2, we get an equivalence between Rep(N , G) and a category C whose objects consist of the data of a principal bundle K overd \u222a {x 0 , v 1 , ..., v n }, a representation \u03a8 of \u03a0(X \u00a0X)v on this bundle, a collection of Lie algebra elements A i \u2208 aut G (K di ), and a collection of torsors \u00b5 (i) 0 \u2282 Hom G (K di , K vi ), all subject to appropriate compatibility conditions.", [["Rep", "PROTEIN", 66, 69], ["N , G)", "PROTEIN", 70, 76], ["\u03a8", "PROTEIN", 202, 203], ["\u03a0", "PROTEIN", 207, 208], ["X \u00a0X", "PROTEIN", 209, 213], ["Theorem", "TEST", 23, 30], ["\u03a0", "PROBLEM", 207, 208], ["this bundle", "PROBLEM", 219, 230], ["A i", "TEST", 269, 272], ["torsors", "TEST", 310, 317], ["Hom G", "TEST", 328, 333], ["K di", "TEST", 335, 339], ["K vi", "TEST", 342, 346]]], ["For each path p i , the path (p i (t), t) : [0, 1] \u2192 X \u00d7 C can be lifted to a pathp i \u2208 \u03a0(Z, D) going from v i \u2208 N X,Di | di to (x 0 , 1).", [["X \u00d7 C", "SIMPLE_CHEMICAL", 53, 58], ["N X", "PROTEIN", 113, 116], ["each path", "TEST", 4, 13], ["the path", "TEST", 20, 28], ["\u03a0", "TEST", 88, 89], ["Z", "TEST", 90, 91], ["D", "TEST", 93, 94], ["v i", "TEST", 107, 110], ["Di", "TEST", 117, 119]]], ["Hencep i \u2208 \u03a0(X \u00a0D)v. Conjugating by this path sends the image of \u03c0(N \u00d7 X,Di , v i ) in \u03a0(X \u00a0D)v onto the subgroup \u03c0 i \u2286 \u03c0(X \u00a0D, x 0 ), and the distinguished loop in the fibre N \u00d7 X,Di | di to the element l i \u2208 \u03c0 i .", [["N", "CHEMICAL", 175, 176], ["\u03a0", "PROTEIN", 87, 88], ["\u03c0", "PROTEIN", 120, 121], ["fibre N \u00d7 X", "PROTEIN", 169, 180], ["the image", "TEST", 52, 61], ["\u03c0", "TEST", 65, 66], ["Di", "TEST", 73, 75], ["v", "TEST", 94, 95], ["the subgroup", "TEST", 101, 113], ["D", "TEST", 125, 126], ["Di", "TEST", 181, 183], ["the element", "TEST", 192, 203], ["loop", "OBSERVATION", 157, 161], ["fibre", "ANATOMY_MODIFIER", 169, 174], ["l i", "ANATOMY_MODIFIER", 204, 207]]], ["Using these paths to identify K vi \u223c = K x0 we then get the desired equivalence between C and F ((X, D), G).", [["K", "CHEMICAL", 30, 31], ["C", "SIMPLE_CHEMICAL", 88, 89], ["K vi", "TEST", 30, 34]]]]}